<SEC-DOCUMENT>0001628280-20-002613.txt : 20200302
<SEC-HEADER>0001628280-20-002613.hdr.sgml : 20200302
<ACCEPTANCE-DATETIME>20200302090828
ACCESSION NUMBER:		0001628280-20-002613
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		113
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200302
DATE AS OF CHANGE:		20200302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Guardant Health, Inc.
		CENTRAL INDEX KEY:			0001576280
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				454139254
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38683
		FILM NUMBER:		20674449

	BUSINESS ADDRESS:	
		STREET 1:		505 PENOBSCOT DR.
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		855-698-8887

	MAIL ADDRESS:	
		STREET 1:		505 PENOBSCOT DR.
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gh-12312019x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:dc3342b48c9b4051abb75a151568fb02,x:0838dc1c2f684ecd836799af8bcfb5a9-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:gh="http://guardanthealth.com/20191231" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:AmendmentFlag" id="Fact-15972A11356727F6BB33A6258E3EB357-wk-Fact-15972A11356727F6BB33A6258E3EB357" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-61ABC39C7305E9F7B0FEA6258E385316-wk-Fact-61ABC39C7305E9F7B0FEA6258E385316">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-6DA9E62544E58D25B36BA6258E363422-wk-Fact-6DA9E62544E58D25B36BA6258E363422">FY</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalYearFocus" id="Fact-EA5A785CA08FF352020FA6258E39157E-wk-Fact-EA5A785CA08FF352020FA6258E39157E">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:EntityCentralIndexKey" id="Fact-3CC2E13DA20ED7F4FA6BA6258E37863A-wk-Fact-3CC2E13DA20ED7F4FA6BA6258E37863A">0001576280</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:TradingSymbol" id="Fact-7140260DEDB4A34C6CF891F8BEE6B0AC-wk-Fact-7140260DEDB4A34C6CF891F8BEE6B0AC">GH</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod" id="Fact-E263632CFEA0D88960DCA6258E81A39D-wk-Fact-E263632CFEA0D88960DCA6258E81A39D">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" id="Fact-69A944AAC1A5119DC9B877FFE6C6FDBE-wk-Fact-69A944AAC1A5119DC9B877FFE6C6FDBE">883000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" id="Fact-8109534AF13A6CE6EAFFA6258E5108FA-wk-Fact-8109534AF13A6CE6EAFFA6258E5108FA">4475000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" id="Fact-EE448B6E75B27D334D08AA058AC509E2-wk-Fact-EE448B6E75B27D334D08AA058AC509E2">723000</ix:nonFraction><ix:nonFraction decimals="0" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" id="Fact-61DA4A35953FCCE88DA57821615A244A-wk-Fact-61DA4A35953FCCE88DA57821615A244A">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-AFDA1D8DA22E78D612F3A6258E459D3B-wk-Fact-AFDA1D8DA22E78D612F3A6258E459D3B">0.0000001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-62A30F91F5DC63B38576A6258E387B8F-wk-Fact-62A30F91F5DC63B38576A6258E387B8F">0.0000001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-1084DC70F6DD649CC7F1A6258E5ED9D4-wk-Fact-1084DC70F6DD649CC7F1A6258E5ED9D4">350000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-67BCF8868EF08722AA8AA6258E2AD45A-wk-Fact-67BCF8868EF08722AA8AA6258E2AD45A">350000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-B1CACAF7AB7A40AA5D18A6258E81B216-wk-Fact-B1CACAF7AB7A40AA5D18A6258E81B216">85832454</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-71CA52211AE2B777AB14A6258E485B19-wk-Fact-71CA52211AE2B777AB14A6258E485B19">94261414</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-504816C04F8D786A5D0BA6258E6AC44B-wk-Fact-504816C04F8D786A5D0BA6258E6AC44B">85832454</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-E2A5B57D6C844DC8B805A6258E66BFB3-wk-Fact-E2A5B57D6C844DC8B805A6258E66BFB3">94261414</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" id="Fact-B924B24942AF1C5207EEF27610AA5EE2-wk-Fact-B924B24942AF1C5207EEF27610AA5EE2">1300000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2017Q4YTD" name="us-gaap:DefinedContributionPlanCostRecognized" id="Fact-76BBDE943DF797E827F978CEF6E6298F-wk-Fact-76BBDE943DF797E827F978CEF6E6298F">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2018Q4YTD" name="us-gaap:DefinedContributionPlanCostRecognized" id="Fact-D9D618D4C164013EB56278CEE95DFD5C-wk-Fact-D9D618D4C164013EB56278CEE95DFD5C">0</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-52D9E9FDC269CCD67D88784BD183FCF7-wk-Fact-52D9E9FDC269CCD67D88784BD183FCF7">P6Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember" name="us-gaap:LongTermDebt" id="Fact-E0816C9E1CBB7AF2EDECF297D58799C5-wk-Fact-E0816C9E1CBB7AF2EDECF297D58799C5">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-EEEC6D0A1304391F8163A6258E72D989-wk-Fact-EEEC6D0A1304391F8163A6258E72D989">0.0000001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-236F7AF67DD8A90AE4B4A6258E997A11-wk-Fact-236F7AF67DD8A90AE4B4A6258E997A11">0.0000001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-6C2D8FE7FF0C7194B61DA6258E8BFF4F-wk-Fact-6C2D8FE7FF0C7194B61DA6258E8BFF4F">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-0AB6E7656457DC0D7E16A6258E43235B-wk-Fact-0AB6E7656457DC0D7E16A6258E43235B">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-10F2B33FCCD468961D6EA6258E3AA083-wk-Fact-10F2B33FCCD468961D6EA6258E3AA083">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-FA08BF4F310A2C2DED81A6258E4289A1-wk-Fact-FA08BF4F310A2C2DED81A6258E4289A1">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-2E44BEAB699432CB8DBBA6258E6C9180-wk-Fact-2E44BEAB699432CB8DBBA6258E6C9180">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-9337DF82298BE0581FFAA6258EA62B21-wk-Fact-9337DF82298BE0581FFAA6258EA62B21">0</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-3A7669FDAFE69FB9463CA6258E80B579-wk-Fact-3A7669FDAFE69FB9463CA6258E80B579">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-A588C5498461F7CBB4FCA6258E7D5FC5-wk-Fact-A588C5498461F7CBB4FCA6258E7D5FC5">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gh_ComputerEquipmentandSoftwareMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-C41CC81AF102148FB148A6258E7E2E39-wk-Fact-C41CC81AF102148FB148A6258E7E2E39">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-14A8581EAB630E8727D6A6258E7E4212-wk-Fact-14A8581EAB630E8727D6A6258E7E4212">P7Y</ix:nonNumeric><ix:nonFraction decimals="0" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:RestrictedCash" id="Fact-C97BBE696C2ECAD63DE2781DCBA0F486-wk-Fact-C97BBE696C2ECAD63DE2781DCBA0F486">0</ix:nonFraction><ix:nonFraction decimals="0" unitRef="usd" contextRef="FI2019Q4" name="us-gaap:RestrictedCash" id="Fact-4082D3B7B2F7EEC6F4EB781DCB1C6DD1-wk-Fact-4082D3B7B2F7EEC6F4EB781DCB1C6DD1">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember" name="us-gaap:RevenueFromRelatedParties" id="Fact-D10DC2C1B94596BD67E791E862CB5D2B-wk-Fact-D10DC2C1B94596BD67E791E862CB5D2B">500000</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-FF4F0CB7FFD0DBBD8802F3136FE23487-wk-Fact-FF4F0CB7FFD0DBBD8802F3136FE23487">0.436</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-049EB0A70061DE1C48C8F3131A7FD60C-wk-Fact-049EB0A70061DE1C48C8F3131A7FD60C">0.603</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-2A704D969DD185097282F3131A8D6DE8-wk-Fact-2A704D969DD185097282F3131A8D6DE8">0.588</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-E433AECEEB20DD00A83EA6258E4A7BB2-wk-Fact-E433AECEEB20DD00A83EA6258E4A7BB2">0.751</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-C9046FC0C16BB9A3EB52A6258E56DD00-wk-Fact-C9046FC0C16BB9A3EB52A6258E56DD00">0.788</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" id="Fact-1C8E045C08ACA664A5C0F3026D4FC8D5-wk-Fact-1C8E045C08ACA664A5C0F3026D4FC8D5">0.687</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-EF39EAEE666457747390A6258E701AE0-wk-Fact-EF39EAEE666457747390A6258E701AE0">0.741</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-C8B21F5DEB8BEF1BB4A3A6258E69C839-wk-Fact-C8B21F5DEB8BEF1BB4A3A6258E69C839">0.687</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" id="Fact-1610E9DA0054DED5BD06F3026C57B4F0-wk-Fact-1610E9DA0054DED5BD06F3026C57B4F0">0.632</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-4D5D8F2D138E1E6A5161F31386240401-wk-Fact-4D5D8F2D138E1E6A5161F31386240401">0.024</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-1292E8670200F89FB53AF3131A776860-wk-Fact-1292E8670200F89FB53AF3131A776860">0.016</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-4BB386B2AB8D9AE72373A6258E481402-wk-Fact-4BB386B2AB8D9AE72373A6258E481402">0.022</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-E2835A45DE468419ED89A6258E4E2C89-wk-Fact-E2835A45DE468419ED89A6258E4E2C89">0.030</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-077932B4BD59055E9E33F3026EF8CD79-wk-Fact-077932B4BD59055E9E33F3026EF8CD79">0.027</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-9712D3BDE703B11A6173A6258E472A7B-wk-Fact-9712D3BDE703B11A6173A6258E472A7B">0.019</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-385A158D39B2D1ADFEBDA6258E754CA6-wk-Fact-385A158D39B2D1ADFEBDA6258E754CA6">0.025</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-5AAE0C6D5FE8045770B7F3026E030ED5-wk-Fact-5AAE0C6D5FE8045770B7F3026E030ED5">0.016</ix:nonFraction><ix:nonNumeric contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-3A627B61BCADC08438A5A6258E5E4A52-wk-Fact-3A627B61BCADC08438A5A6258E5E4A52">P6Y1M</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-0824CD1152BDD5DA97FDA6258E74E869-wk-Fact-0824CD1152BDD5DA97FDA6258E74E869">P6Y7D</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-221E2A732549F077B5E9A6258E57C958-wk-Fact-221E2A732549F077B5E9A6258E57C958">P6Y6M2D</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-23507DCF070D9524C008A6258E76C359-wk-Fact-23507DCF070D9524C008A6258E76C359">P5Y4D</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-053D95A092D93B039A7EF313575E35FB-wk-Fact-053D95A092D93B039A7EF313575E35FB">P3M29D</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-DCABCBB7B4D9CAA9AC2AF312041C16A5-wk-Fact-DCABCBB7B4D9CAA9AC2AF312041C16A5">P6M</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-4ABE8B486CF9D6589F8DF3026ACE6A41-wk-Fact-4ABE8B486CF9D6589F8DF3026ACE6A41">P6Y2M19D</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-51CF0AF71C00909F43EEF31202DE1B20-wk-Fact-51CF0AF71C00909F43EEF31202DE1B20">P3M15D</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-56CE46D68CBF3ED802CCF3026903064E-wk-Fact-56CE46D68CBF3ED802CCF3026903064E">P5Y6M</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="gh-20191231.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Feb14">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Jun28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">gh:AccountingStandardsUpdate201807Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">gh:AccountingStandardsUpdate201807Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">gh:AccountingStandardsUpdate201807Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2May31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-09</xbrli:startDate>
			<xbrli:endDate>2018-10-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep19">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-19</xbrli:startDate>
			<xbrli:endDate>2018-09-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct9_us-gaap_ClassOfWarrantOrRightAxis_gh_WarrantsPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gh:WarrantsPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-05-01</xbrli:startDate>
			<xbrli:endDate>2019-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct9_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Apr30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-05-01</xbrli:startDate>
			<xbrli:endDate>2019-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_gh_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerDMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-01-01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
					<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
				</xbrldi:typedMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gh_ComputerEquipmentandSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gh:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2May01-May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2May31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2May01-May31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_ContingentConsiderationByTypeAxis_gh_CommercializationMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">gh:CommercializationMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gh_CovenantsNotToCompeteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:CovenantsNotToCompeteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_ContingentConsiderationByTypeAxis_gh_EarnOutConsiderationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">gh:EarnOutConsiderationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gh_CovenantsNotToCompeteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:CovenantsNotToCompeteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec312019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-31</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Dec31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-31</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug01-Aug31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-01</xbrli:startDate>
			<xbrli:endDate>2017-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan31_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:CreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:CreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-31</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q4Jun01-Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:CreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierOneMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="gh:RoyaltyAgreementbyPaymentTierAxis">gh:TierOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-31</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:CreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2Jun30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierTwoMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="gh:RoyaltyAgreementbyPaymentTierAxis">gh:TierTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierOneMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="gh:RoyaltyAgreementbyPaymentTierAxis">gh:TierOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierTwoMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="gh:RoyaltyAgreementbyPaymentTierAxis">gh:TierTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-31</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Nov01-Nov30_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-01</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Jul01-Jul31_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q2May01-May31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-01</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Jul01-Jul31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct9">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-09</xbrli:startDate>
			<xbrli:endDate>2018-10-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep01-Sep30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct9_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-09</xbrli:startDate>
			<xbrli:endDate>2018-10-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-05-01</xbrli:startDate>
			<xbrli:endDate>2019-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct9_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-09</xbrli:startDate>
			<xbrli:endDate>2018-10-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-05-01</xbrli:startDate>
			<xbrli:endDate>2019-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_gh_SharesAvailableForFutureStockOptionGrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_gh_SharesAvailableForFutureStockOptionGrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2013Q3Sep30_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2012Q4Dec31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2014Q4Oct31_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesBConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gh:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct01-Oct31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Oct01-Oct31_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-01</xbrli:startDate>
			<xbrli:endDate>2017-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Oct31_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Apr30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-30</xbrli:startDate>
			<xbrli:endDate>2017-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Jul01-Jul31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:SoftBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:SoftBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-01</xbrli:startDate>
			<xbrli:endDate>2017-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2May01-May31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-01</xbrli:startDate>
			<xbrli:endDate>2017-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Dec31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-31</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:EmployeeStockPurchasePlanObligationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:EmployeeStockPurchasePlanObligationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:EmployeeStockPurchasePlanObligationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_AssetsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_AssetsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Jul01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="company">
		<xbrli:measure>gh:company</xbrli:measure>
	</xbrli:unit><xbrli:unit id="petition">
		<xbrli:measure>gh:petition</xbrli:measure>
	</xbrli:unit><xbrli:unit id="party">
		<xbrli:measure>gh:party</xbrli:measure>
	</xbrli:unit><xbrli:unit id="patent">
		<xbrli:measure>gh:patent</xbrli:measure>
	</xbrli:unit><xbrli:unit id="gbp">
		<xbrli:measure>iso4217:GBP</xbrli:measure>
	</xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d30009e1223-wk-Fact-37278A89EE20DFC9B188A6258E33CABC" toRefs="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d27497e1578-wk-Fact-4A43155C56BC426FCBE3A6258E2DF4E7" toRefs="TextSelection-6357B93E950236AB9E87A6258EB47973-0-wk-Footnote-6357B93E950236AB9E87A6258EB47973_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d27497e1578-wk-Fact-4A43155C56BC426FCBE3A6258E2DF4E7" toRefs="TextSelection-8658C3672FC3B51B14F877E26D4F91C5-0-wk-Footnote-8658C3672FC3B51B14F877E26D4F91C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d30009e1283-wk-Fact-4D2936D9D7A53B6DF502A6258E460D65" toRefs="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d30009e1203-wk-Fact-5B2DE63C41AB69886EC1A6258E3B0666" toRefs="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d27497e2067-wk-Fact-787E9732FDA1620CF163A6258E2DEF38" toRefs="TextSelection-6357B93E950236AB9E87A6258EB47973-0-wk-Footnote-6357B93E950236AB9E87A6258EB47973_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d27497e2067-wk-Fact-787E9732FDA1620CF163A6258E2DEF38" toRefs="TextSelection-8658C3672FC3B51B14F877E26D4F91C5-0-wk-Footnote-8658C3672FC3B51B14F877E26D4F91C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d30009e1245-wk-Fact-8B6729A9D18284EECA68A6258E3316AE d46357e2889-wk-Fact-8B6729A9D18284EECA68A6258E3316AE" toRefs="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d30009e1184-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF d46357e2840-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF" toRefs="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d27497e1597-wk-Fact-CCBF4B2DE891C350F87CA6258E343288" toRefs="TextSelection-6357B93E950236AB9E87A6258EB47973-0-wk-Footnote-6357B93E950236AB9E87A6258EB47973_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d27497e1597-wk-Fact-CCBF4B2DE891C350F87CA6258E343288" toRefs="TextSelection-8658C3672FC3B51B14F877E26D4F91C5-0-wk-Footnote-8658C3672FC3B51B14F877E26D4F91C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d27497e2048-wk-Fact-D9E58FA15C46A8F94757A6258E2ABF68" toRefs="TextSelection-6357B93E950236AB9E87A6258EB47973-0-wk-Footnote-6357B93E950236AB9E87A6258EB47973_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d27497e2048-wk-Fact-D9E58FA15C46A8F94757A6258E2ABF68" toRefs="TextSelection-8658C3672FC3B51B14F877E26D4F91C5-0-wk-Footnote-8658C3672FC3B51B14F877E26D4F91C5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d30009e1264-wk-Fact-E139CBAD9FD19C557986A6258E2D7893" toRefs="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"></ix:relationship></ix:resources></ix:header></div><div><a id="s92F066AC0B235D2F818655CDF2D1A910"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21259842519686%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, DC 20549</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_____________________</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d884e895-wk-Fact-2771A58601099553AAC5AB994851A54F" name="dei:DocumentType" contextRef="FD2019Q4YTD"><span style="font-size:18pt;font-weight:bold;">10-K</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_____________________</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span><ix:nonNumeric id="d884e908-wk-Fact-69318997CBC21EE5D0AAAB99D2314F99" name="dei:DocumentAnnualReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9746;</span></ix:nonNumeric></span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d884e917-wk-Fact-A7F73014D07516ABC15DF36E7B13E456" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q4YTD" format="ixt:datemonthdayyearen">December 31, 2019</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span><ix:nonNumeric id="d884e927-wk-Fact-AA4FF2FC26BA47BAF72EAB9B0053B7B5" name="dei:DocumentTransitionReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></ix:nonNumeric></span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: </span><span><ix:nonNumeric id="d884e939-wk-Fact-C7F2EB2D6EFA821A2A53AB9BF11B4B38" name="dei:EntityFileNumber" contextRef="FD2019Q4YTD"><span style="font-weight:bold;">001-38683</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_____________________</span></div><div style="line-height:120%;text-align:center;font-size:24pt;"><span><ix:nonNumeric id="d884e948-wk-Fact-28771D4B956C1C40924CAB9CCA66166E" name="dei:EntityRegistrantName" contextRef="FD2019Q4YTD"><span style="font-size:24pt;font-weight:bold;">GUARDANT HEALTH, INC.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:24pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_____________________</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21259842519686%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:21%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d884e973-wk-Fact-FE0B3E9ED1E56500DBA7ABA02507C561" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q4YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d884e983-wk-Fact-709CB4345A52F158AD85ABA146EFD3AE" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q4YTD">45-4139254</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d884e1008-wk-Fact-48A643C6E6B5799907F97E890DE78B78" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q4YTD"><span style="font-weight:bold;">505 Penobscot Dr.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d884e1014-wk-Fact-07A5CFF40B59734A00BF7E8956767DD7" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q4YTD"><span style="font-weight:bold;">Redwood City</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d884e1019-wk-Fact-777F7C3DA48A5D752D737E8997FB09BD" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q4YTD" format="ixt-sec:stateprovnameen"><span style="font-weight:bold;">California</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d884e1024-wk-Fact-3F52941B45D12F3C1F627E89E1B24350" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q4YTD"><span style="font-weight:bold;">94063</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:144%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Address of principal executive offices) (Zip Code)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</span><span><ix:nonNumeric id="d884e1036-wk-Fact-3868DA39C17FFF7571F9AF3311E375F2" name="dei:CityAreaCode" contextRef="FD2019Q4YTD"><span style="font-weight:bold;">855</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d884e1041-wk-Fact-2EBDBADBE7E565D596AEAF34A7223033" name="dei:LocalPhoneNumber" contextRef="FD2019Q4YTD"><span style="font-weight:bold;">698-8887</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21259842519686%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:21%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d884e1083-wk-Fact-E53AA6DEE1BBC27FF902ABA2B54E4E3B" name="dei:Security12bTitle" contextRef="FD2019Q4YTD">Common Stock, par value $0.00001</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d884e1093-wk-Fact-FE24D33EE96896A47084ABA34114625F" name="dei:SecurityExchangeName" contextRef="FD2019Q4YTD" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">None</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">___________________</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d884e1131-wk-Fact-312DF623356342D5A21777E65CA40AB4" name="dei:EntityWellKnownSeasonedIssuer" contextRef="FD2019Q4YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span><span style="font-family:inherit;font-size:10pt;">&#160; </span><span style="font-family:inherit;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d884e1152-wk-Fact-86C002F60CEA10FBCA82AF36826CA423" name="dei:EntityVoluntaryFilers" contextRef="FD2019Q4YTD">No</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d884e1163-wk-Fact-F512ABE94C298A779434AF37BD58BBEC" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q4YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div><br/></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d884e1176-wk-Fact-DAF63E8436AF288DC055AF3944A302FD" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q4YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.40944881889764%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:27%;"></td><td style="width:42%;"></td><td style="width:28%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d884e1204-wk-Fact-8FD104E387DA432F8237AF3B4D1723B7" name="dei:EntityFilerCategory" contextRef="FD2019Q4YTD" format="ixt-sec:entityfilercategoryen">Large Accelerated Filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated&#160;Filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-accelerated Filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d884e1261-wk-Fact-FA4EAE2934468FF36BD4AF3C8212BB23" name="dei:EntitySmallBusiness" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d884e1293-wk-Fact-06E9CA7FC82FBF9D4C60AF3CADBD73B8" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d884e1315-wk-Fact-7F3CB34B4D174D8DD15AAF44CED57D4E" name="dei:EntityShellCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate market value of the voting and non&#8209;voting common equity held by non&#8209;affiliates of the registrant, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d884e1328-wk-Fact-6A646C201020A1A8B3BE7E910E44CB51" name="dei:EntityPublicFloat" contextRef="I2019Q2Jun28" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> (based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Select Market on June&#160;28, 2019 of $86.33 per share).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of February&#160;14, 2020, the registrant had </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d884e1339-wk-Fact-8FE44DA58FFC49881D7FEE41F0474686" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q1Feb14" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">94,382,681</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, $0.00001 par value per share, outstanding.</span></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="TextSelection-9683F8C212F5DCF7AF55AF4786F56093-0-wk-Fact-463736903FF57BAD9CA2AF47987E241C" escape="true"><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portions of the registrant&#8217;s definitive proxy statement relating to its annual meeting of stockholders to be held in&#160;2020 (the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;</span><span style="font-family:inherit;font-size:10pt;">2020 Annual Meeting</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8221;</span><span style="font-family:inherit;font-size:10pt;">), to be filed with the Securities and Exchange Commission (the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;</span><span style="font-family:inherit;font-size:10pt;">SEC</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8221;</span><span style="font-family:inherit;font-size:10pt;">) within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates, are incorporated herein by reference where indicated. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, such proxy statement is not deemed to be filed as part hereof.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21259842519686%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sD3EA1D6538DD5817B839C0D8C5B7A2C8"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">GUARDANT HEALTH, INC.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 10-K</span></div><div style="line-height:174%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Fiscal Year Ended December 31, 2019</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:82%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s09F60FD840E35462BBB924AE43B6246B"><span style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART I</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Page</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s6BC78D0A698955EFA169CCD402AF2108"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item 1.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6BC78D0A698955EFA169CCD402AF2108">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sB7219C7CCF955064924FDCEFE0E976AB"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item 1A.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk Factors</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB7219C7CCF955064924FDCEFE0E976AB">35</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sC5F8C71D287454DC8C327305B04329DA"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item 1B.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unresolved Staff Comments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC5F8C71D287454DC8C327305B04329DA">80</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sD95200DBCA855F108FBBDA5C6C1067B7"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item 2.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Properties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD95200DBCA855F108FBBDA5C6C1067B7">80</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sF6B8118755505D64959C93E7254CEB73"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item 3.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal Proceedings</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF6B8118755505D64959C93E7254CEB73">80</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s82FD52279C085E528791A09F75AE7925"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item 4.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s82FD52279C085E528791A09F75AE7925">80</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s15A85F06C9CF5C00938F80A849C08A21"><span style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART </span></a><span style="font-family:inherit;font-size:10pt;font-weight:bold;">II</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1D70317D1F565576AE655B6DA5312D3D"><span style="font-family:inherit;font-size:10pt;">Item 5.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1D70317D1F565576AE655B6DA5312D3D">80</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sEC0ABDE860605BD184E8F6C42C794E98"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Item 6.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selected Financial Data</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEC0ABDE860605BD184E8F6C42C794E98">81</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4D722FEFA7CE5823AA22A986E1BF7E49"><span style="font-family:inherit;font-size:10pt;">Item 7.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4D722FEFA7CE5823AA22A986E1BF7E49">83</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF9C18E9E15BE5F39BFE20764D749D5E7"><span style="font-family:inherit;font-size:10pt;">Item 7A.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF9C18E9E15BE5F39BFE20764D749D5E7">102</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3FF4646FA9F65A34AECD9985CD62098A"><span style="font-family:inherit;font-size:10pt;">Item 8.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial Statements and Supplementary Data</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3FF4646FA9F65A34AECD9985CD62098A">103</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFDA8C48E37F95F1E99F541BBC28C4F39"><span style="font-family:inherit;font-size:10pt;">Item 9.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFDA8C48E37F95F1E99F541BBC28C4F39">149</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2740CD7E538E598E8BCB3F7E718BB282"><span style="font-family:inherit;font-size:10pt;">Item 9A.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Controls and Procedures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2740CD7E538E598E8BCB3F7E718BB282">149</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s46030965CE1E55C3BB30921CA9F49C23"><span style="font-family:inherit;font-size:10pt;">Item 9B.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other Information</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s46030965CE1E55C3BB30921CA9F49C23">150</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s15A85F06C9CF5C00938F80A849C08A21"><span style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART II</span></a><span style="font-family:inherit;font-size:10pt;font-weight:bold;">I</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s202ACDFD08365E10B2847C0D7FEF6E7C"><span style="font-family:inherit;font-size:10pt;">Item 10.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Directors, Executive Officers and Corporate Governance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s202ACDFD08365E10B2847C0D7FEF6E7C">152</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s057450DC44E8510AAD1965F1A957C4ED"><span style="font-family:inherit;font-size:10pt;">Item 11.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Executive Compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s057450DC44E8510AAD1965F1A957C4ED">152</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2BDE765875DA5948A11166A7F7A8AFD3"><span style="font-family:inherit;font-size:10pt;">Item 12.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2BDE765875DA5948A11166A7F7A8AFD3">152</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C17E3F0B0A65071934EE4FCF8C3BB7C"><span style="font-family:inherit;font-size:10pt;">Item 13.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C17E3F0B0A65071934EE4FCF8C3BB7C">152</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0F7F9E8B328A53F1841C4F3715C664CF"><span style="font-family:inherit;font-size:10pt;">Item 14.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal Accounting Fees and Services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0F7F9E8B328A53F1841C4F3715C664CF">152</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s15A85F06C9CF5C00938F80A849C08A21"><span style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART I</span></a><span style="font-family:inherit;font-size:10pt;font-weight:bold;">V</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0EE196BFDE695A489672FDF803F93C88"><span style="font-family:inherit;font-size:10pt;">Item 15.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exhibits, Financial Statement Schedules</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0EE196BFDE695A489672FDF803F93C88">152</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA180CB570FDC5DDFB928AE6FEEA1068F"><span style="font-family:inherit;font-size:10pt;">Item 16.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form 10-K Summary</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA180CB570FDC5DDFB928AE6FEEA1068F">155</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Signatures</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sABDA33F46CB252D081B58FDA9BE7089D"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">This Annual Report on Form 10-K, including the sections titled &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains forward-looking statements regarding future events and our future results that are based on our current expectations, estimates, forecasts and projections about our business, our results of operations, the industry in which we operate and the beliefs and assumptions of our management. Words such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;intend&#8221; and &#8220;expect,&#8221; variations of these words, and similar expressions are intended to identify forward-looking statements. These forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A,&#8220;Risk Factors,&#8221; of this Annual Report on Form 10-K and elsewhere herein, and in other reports we file with the U.S. Securities and Exchange Commission, or the SEC. While forward-looking statements are based on the reasonable expectations of our management at the time that they are made, you should not rely on them. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, whether as a result of new information, future events or otherwise, except as may be required by law.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Each of the terms the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar terms used herein refer collectively to Guardant Health, Inc., a Delaware corporation, and its consolidated subsidiaries, unless otherwise stated.&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s6BC78D0A698955EFA169CCD402AF2108"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Business</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood-based tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a routine blood draw, or liquid biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption of our tests, improve patient clinical outcomes, lower healthcare costs and accelerate drug development. In pursuit of our goal to manage cancer across all stages of the disease, we have launched our Guardant360 and GuardantOMNI tests for advanced stage cancer. Our Guardant360 test, launched in 2014, has been used by more than 7,000 oncologists, over 50 biopharmaceutical companies and all 28 National Comprehensive Cancer Network, or NCCN, Centers in the United States, and we believe it is the world&#8217;s market leading comprehensive liquid biopsy test based on public disclosure of the number of comprehensive liquid biopsy tests sold in 2018. Our GuardantOMNI test, launched in 2017, has been used by our biopharmaceutical customers as a comprehensive genomic profiling tool to help accelerate clinical development programs in both immuno-oncology and targeted therapy. These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Our LUNAR-1 assay was launched in 2018 for research use and in late 2019 for investigational use.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology, as it is practiced today, is primarily focused on matching cancer patients to personalized treatments based on the underlying molecular profile of their tumors. T</span><span style="font-family:inherit;font-size:10pt;color:#212121;">here is a critical need to expand the scope of precision oncology to enable precise detection, monitoring and selection of the appropriate intervention as early in the disease state as possible. We believe a</span><span style="font-family:inherit;font-size:10pt;"> major challenge to achieving this is the limited access to cancer&#8217;s molecular information. Traditionally, tissue tests that require physical access to tumor tissue through a biopsy or surgery have been used to gain access to this information. A tissue biopsy or surgery procedure, however, is often invasive, time-consuming and costly, which limits the utility of tissue tests. Tissue tests are also not feasible for certain applications such as screening for early detection of cancer.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our liquid biopsy tests address many of the challenges of tissue biopsies. We believe our tests can expand the scope of precision oncology to earlier stages of the disease, improve patient outcomes and lower healthcare costs. We estimate the market opportunity for our current commercial and pipeline products is over $35 billion in the United States, comprising applications for clinicians and biopharmaceutical customers to address early to late-stage disease, including: </span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Therapy selection in advanced stage cancer patients</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> - </span><span style="font-family:inherit;font-size:10pt;">We are pioneering the clinical comprehensive liquid biopsy market with our Guardant360 and GuardantOMNI tests. Based on SEER Cancer Registry statistics we estimate the total number of metastatic cancer patients in the United States to be approximately 700,000. Using publicly available pricing for tissue-based therapy selection tests, and assuming patients are testing an average of two times over the course of their disease, we estimate the potential market opportunity for therapy selection among these patients to be approximately $4 billion. Additionally, based on the number of targeted therapy and immuno-oncology therapy programs in the current clinical pipeline, prevalence data, and typical pricing for our tests when used by our biopharmaceutical company customers in connection with their clinical trials, we estimate that the potential market opportunity for our products in use by biopharmaceutical companies is approximately $2 billion. By combining these two, we estimate the aggregate market opportunity for therapy selection in late-stage cancer patients to be approximately $6 billion. Our Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes and our GuardantOMNI test has a broader 500-gene panel, both of which analyze circulating tumor DNA in blood. Our Guardant360 test has been used over 100,000 times by clinicians to help inform which therapy may be effective for advanced stage cancer patients with solid tumors. Our Guardant360 and GuardantOMNI tests are used by biopharmaceutical companies for a range of applications, including identifying target patient populations to accelerate translational science research, clinical trial enrollment, and drug development, and post-approval commercialization.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Neoadjuvant and adjuvant treatment selection in early stage cancer patients and surveillance in cancer survivors </span><span style="font-family:inherit;font-size:10pt;">-We are developing tests from our LUNAR program for neoadjuvant and adjuvant treatment selection in early stage cancer patients. The American Cancer Society estimated that in 2016 there were approximately 15 million solid tumor cancer survivors. We believe this reflects a potential market opportunity of approximately $15 billion. For early stage solid tumors, neoadjuvant and adjuvant treatment may be given as a first step in care to shrink the tumor or adjuvantly as a secondary treatment after the primary treatment to reduce the risk of recurrence. However, not all early stage cancer patients may benefit from neoadjuvant and adjuvant treatment. For instance, based on data published in 2007 from a randomized study of adjuvant chemotherapy versus observation in patients with colorectal cancer, the use of adjuvant treatment showed significant benefit for a subgroup of the patients who meet certain clinical criteria, but only marginal benefit for the patients who do not meet these criteria. We are currently investigating our LUNAR-1 assay&#8217;s ability to determine if the presence of ctDNA in early stage cancer could more accurately identify patients who may benefit from neoadjuvant and adjuvant treatment. We are also developing tests from our LUNAR program for minimal residual disease and recurrence detection in cancer survivors. Our LUNAR-1 assay leverages data and learnings from our Guardant360 and GuardantOMNI tests and is designed to enable clinicians to detect minimal residual disease and to detect cancer recurrence at a stage when intervention may have a higher chance of success. We believe our LUNAR-1 assay may also help biopharmaceutical companies identify new drug development opportunities. In return, these relationships could help us establish clinical utility for our tests and create new testing opportunities related to emerging therapies.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Early detection of cancer in asymptomatic individuals  eligible for cancer screening and individuals at a higher risk for developing cancer </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">-</span><span style="font-family:inherit;font-size:10pt;"> We are developing screening tests from our LUNAR program for individuals who are eligible for colorectal cancer screening annually based on the U.S. Preventive Services Task Force, or USPTF, guidelines for colorectal cancer screening. Recent data reported at the 2019 National Colorectal Cancer Roundtable, shows that amongst this population, approximately 31% are not up to date with the recommended colorectal cancer screening. Therefore, we believe there is a significant unmet need for non-invasive modalities such as our LUNAR-2 assay that, if successfully developed, we believe could increase compliance with the USPTF guidelines. Based on an estimated 30 million individuals who are eligible for colorectal cancer screening, we believe this represents a potential market opportunity of approximately $15 billion. We are also pursuing the development of screening tests from our LUNAR program for individuals at a higher risk of developing cancer due to multiple factors, including moderate to heavy smoking, hereditary risk and pre-existing infections and/or inflammatory conditions.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">Based on various industry sources, we estimate there are approximately 35 million individuals that satisfy one of three criteria for being susceptible to high risk cancer. We believe this represents a potential market opportunity of approximately $18 billion.&#160;We believe that developing a blood test for early detection of cancer requires a vast amount of molecular and clinical data across all stages of the disease in order to better understand the biology and clinical relevance of tumor-specific biomarkers in blood. We further believe that we can accelerate the collection of this data pool and the development of our LUNAR-2 assay for an early detection test in a capital-efficient manner by developing and commercializing our Guardant360 test, GuardantOMNI test and LUNAR-1 assay, while we are using our development-stage LUNAR-2 assay in exploratory studies. While we believe the benefits of early detection on clinical outcomes are widely known, early cancer or precancerous detection may also benefit biopharmaceutical companies by identifying a much larger at-risk population who may benefit from early therapeutic intervention or from preventative medicines.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that best-in-class technology is required to address these market opportunities, but is only one of many strengths required to create a market leading liquid biopsy platform. We believe our Guardant Health Oncology Platform has developed strengths across five critical layers, each of which facilitates success in the adjacent layers, and together the five layers form a barrier to entry and provide us a competitive advantage and a platform we can efficiently leverage across multiple products. These five layers include:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;"><img src="graphic3.jpg" alt="graphic3.jpg" style="height:262px;width:624px;"></img></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Technology</span><span style="font-family:inherit;font-size:10pt;"> - Our proprietary Guardant Health Digital Sequencing Technology combines cutting edge capabilities from multiple disciplines including biochemistry, next-generation sequencing, signal processing, bioinformatics, machine learning and process engineering to enable what we believe to be the world&#8217;s market leading comprehensive liquid biopsy test with a typical turnaround time of less than seven days after we receive the sample and enable our high performing liquid biopsy tests intended for different market segments. Furthermore, our machine learning capability enables performance improvement as we incorporate additional data.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical utility</span><span style="font-family:inherit;font-size:10pt;"> - We believe that success in the clinical utility layer requires both independent investments in clinical research and strategic relationships with market-leading biopharmaceutical companies. We have invested heavily in clinical studies, including more than 50 clinical outcomes studies demonstrating that overall biomarker detection rates of our non-invasive blood testing were in line with standard of care tissue testing. Our clinical research collaborations have resulted in more than 150 peer-reviewed publications. We also have relationships with over 50 biopharmaceutical customers that have provided rigorous clinical validation of our technology and early insights into test opportunities for emerging therapeutics.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory approval</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">- We believe Guardant360 test was the first comprehensive liquid biopsy approved by the New York State Department of Health, or NYSDOH. In addition, based on our review of publicly available records, we believe our facility was the first comprehensive liquid biopsy laboratory to be certified pursuant to the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, and NYSDOH-permitted. Our Guardant360 and GuardantOMNI tests have each been designated by the U.S. Food and Drug Administration, or the FDA, as a breakthrough device for use as a companion diagnostic in connection with certain specified therapeutic products of our biopharmaceutical customers. Among other things, designation as a breakthrough device provides for priority review by the FDA and more interactive communication with the FDA during the development process. In the fourth quarter of 2019, we submitted a premarket approval, or PMA, application to seek the FDA&#8217;s approval of our Guardant360 test to be used as a companion diagnostic, initially in connection with one therapeutic product of a biopharmaceutical customer, and to provide tumor mutation profiling for cancer patients with solid tumors. In February 2020, we submitted an additional module of the PMA application for our Guardant360 test to the FDA. We believe that FDA approval will become increasingly important for diagnostic tests to gain commercial adoption both in the United States and abroad.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Payer coverage and reimbursement</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">- The analytical and clinical data that we have generated in our efforts to establish clinical utility, combined with the support we have developed with key opinion leaders, or KOLs, in the oncology space have led to positive coverage decisions by a number of commercial payers. Our Guardant360 test is currently covered by Cigna, Priority Health, multiple regional Blue Cross Blue Shield plans as well as the health plans associated with eviCore for non-small cell lung cancer, or NSCLC, which we believe gives us a competitive advantage with these payers with respect to NSCLC patients. Payment from commercial payers differs depending on whether we have entered into a contract with the payers as a &#8220;participating provider.&#8221; Payers often reimburse non-participating providers, if at all, at a lower amount than participating providers. When we are not contracted with these payers, they determine the amount they are willing to reimburse us for tests. When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to Medicare, in July 2018, Palmetto GBA, the Medicare Administrative Contractor, or MAC, responsible for administering Medicare&#8217;s Molecular Diagnostic Services Program, or MolDx, issued a local coverage determination, or LCD, for our Guardant360 test with respect to NSCLC patients who meet certain clinical criteria. Shortly thereafter in 2018, Noridian Healthcare Solutions, the MAC responsible for adjudicating claims in California, where our laboratory is located, and a participant in MolDx, finalized an equivalent LCD for our Guardant360 test. Pursuant to this Noridian LCD, in September 2018, we began to submit claims for reimbursement for Guardant360 clinical testing performed for NSCLC patients covered under such LCD who meet certain clinical criteria, and in October 2018, we began to receive payments for these services from Medicare. In December 2019, replacing its prior NSCLC patient LCD, Palmetto GBA finalized a new LCD for our Guardant360 test that provides limited Medicare coverage for the Guardant360 test in patients diagnosed with solid cancers of non-central nervous system origin. The new LCD covers our Guardant360 test for fee-for-service Medicare patients with advanced cancers who meet its clinical criteria for complete genomic profiling with next-generation sequencing, or NGS, of tumor tissue to optimize treatment selection decisions but have insufficient or unavailable tissue for molecular profiling. The expanded coverage decision is in line with FDA approvals of several tumor-agnostic drugs that are based on a single genomic biomarker across all cancers or that are targetable across multiple cancer types. We expect Noridian Healthcare Solutions to issue a new LCD for our Guardant360 test equivalent to the new LCD issued by Palmetto GBA, though the timing and scope of the Noridian LCD are uncertain.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We anticipate approval by the FDA, if obtained, may support further improvements in coverage and reimbursement for our Guardant360 test. We estimate total current coverage in the United States for the Guardant360 test to be more than 170 million lives, including Medicare beneficiaries and members of several commercial health plans.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commercial adoption</span><span style="font-family:inherit;font-size:10pt;"> - Success in each of the layers above is important for commercial adoption of our tests by clinicians and biopharmaceutical companies. Additionally, for clinicians, endorsement by KOLs, utilization by academic centers and inclusion in national treatment guidelines are important, especially for adoption in the local community setting where 80% of cancer treatment occurs. Our relationships with key stakeholders across the oncology space, clinical data we believe to support use of Guardant360 test ahead of tissue based testing, as well as the inclusion of liquid biopsy as a potential alternative under certain circumstances to tissue biopsy in NCCN guidelines, have helped facilitate the use of our tests by 7,000 oncologists, who have collectively ordered our Guardant360 test over 100,000 times, and over 50 biopharmaceutical companies. We sold </span><span style="font-family:inherit;font-size:10pt;">49,926</span><span style="font-family:inherit;font-size:10pt;"> tests to clinical customers in the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, an increase from </span><span style="font-family:inherit;font-size:10pt;">29,238</span><span style="font-family:inherit;font-size:10pt;"> and 25,626 in the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. We sold </span><span style="font-family:inherit;font-size:10pt;">20,643</span><span style="font-family:inherit;font-size:10pt;"> tests to biopharmaceutical customers in the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, an increase from </span><span style="font-family:inherit;font-size:10pt;">10,370</span><span style="font-family:inherit;font-size:10pt;"> and 6,286 in the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the United States, we market our tests to clinical customers through our targeted sales organization, which is engaged in sales efforts and promotional activities primarily to oncologists and cancer centers. Outside the United States, we market our tests to clinical customers through distributors and direct contracts with healthcare institutions. We market our tests to biopharmaceutical customers globally through our business development team, which promotes the broad utility of our tests for drug development and commercialization. Additionally, we have established a joint venture with SoftBank to accelerate commercialization of our products including in Asia, the Middle East and Africa, with our initial focus being on Japan. Our products are currently marketed in approximately 40 countries.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generated total revenue of </span><span style="font-family:inherit;font-size:10pt;">$214.4 million</span><span style="font-family:inherit;font-size:10pt;"> in the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, an increase from </span><span style="font-family:inherit;font-size:10pt;">$90.6 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$49.8 million</span><span style="font-family:inherit;font-size:10pt;"> in the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. We also incurred net losses of </span><span style="font-family:inherit;font-size:10pt;">$67.9 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$84.3 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$83.2 million</span><span style="font-family:inherit;font-size:10pt;"> in the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE543230555315EE8A5181339D34C2DCD"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Summary of our product portfolio</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our product portfolio is built upon the same principle as our platform, in that success with each facilitates success for the next. Data and learnings from our Guardant360 test have benefited us in developing our GuardantOMNI test, both of which fuel development of our LUNAR program. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below illustrates our current products and development programs:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;"><img src="slide1a01.jpg" alt="slide1a01.jpg" style="height:468px;width:624px;"></img></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s3DB09192141A51CEB637180090961621"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Our strategy</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our objective is to be the leading provider of precision oncology products for cancer management across all stages of the disease and drive commercial adoption of our products. To achieve this, we intend to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase awareness of our products by:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">building awareness of liquid biopsy and pioneering a blood-first paradigm for genotyping cancer patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">educating biopharmaceutical companies, KOLs and advocacy groups;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Amplitude;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">advocating for inclusion of our tests in treatment guidelines; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expanding access to our products globally through direct investment and by leveraging our global network of partners.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expand clinical utility and increase reimbursement for our products by:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">working with private and public payers to establish coverage and reimbursement for our tests;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">investing in clinical evidence directly and through relationships with academia and biopharmaceutical companies to establish expanded indications for use;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">demonstrating improved clinical utility and health economics from use of our tests to patients, physicians and payers; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">pursuing FDA approval of our tests to facilitate reimbursement and global market access.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Strengthen our relationships with biopharmaceutical and academia customers by:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">demonstrating the utility of our products in connection with standard of care biopharmaceutical treatments thereby encouraging clinical adoption;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developing and seeking approval of our products as companion diagnostics for targeted therapies and immuno-oncology therapies; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">providing earlier insights into emerging clinically relevant biomarkers.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leverage our Guardant Health Oncology Platform to expand our product portfolio by:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">using our commercial engine as a force multiplier of returns on research and development investment to generate data and analytical insights to enable development of new products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">taking a disciplined and systematic approach to product and market development, by starting with therapy selection and then expanding sequentially towards early cancer detection;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">utilizing our data, sample biobank and insights into biology of circulating tumor-related biomarkers in blood to develop our LUNAR program;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">building on our regulatory and commercial infrastructure to accelerate new product launches and drive commercial efficiencies; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">using our strategic relationships, including our joint venture with SoftBank, to drive global commercialization of our products, with a near-term focus on Japan.</span></div></td></tr></table><div><a id="s7036D1B7D3D45F9D8D1B67768099530C"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Our industry</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite enormous investment in research and the introduction of new treatments, cancer remains a critical area of unmet medical need. According to the Centers for Disease Control and Prevention, or CDC, cancer is the second leading cause of death in the United States, exceeded only by heart disease. The American Cancer Society reported that in 2016 there were more than 15.5 million Americans with a history of cancer and that approximately 1.7 million new cancer cases would be diagnosed in 2018. Furthermore, approximately 600,000 Americans were expected to die of cancer in 2019. The International Agency for Research on Cancer predicted that the annual global burden of cancer would reach 22 million new cases and 13 million cancer deaths by 2030. The World Health Organization estimated that the total annual economic cost of cancer in 2010 was approximately $1.2 trillion.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The promise of precision oncology</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Traditionally, cancer has been classified by the specific organ in which it is located and treated independently of its molecular profile. However, cancer treatment is seeing a significant shift towards precision oncology, the practice of which seeks to match patients to personalized, targeted therapies based on the specific molecular profile of their tumors. Major cancer types, including lung, breast, colorectal and melanoma, for example, have become increasingly classified and treated on the basis of molecular profile.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discovery of new molecular biomarkers continues to result in further sub-classification of cancer patient populations, which increases complexity of diagnosing and treating the disease for clinicians. This has led to increasing clinical utility and adoption of comprehensive genomic profiling, or CGP. Unlike tests that focus on a single or limited set of biomarkers, commonly referred to as hotspot testing, CGP provides a more comprehensive view of the tumor&#8217;s molecular information. Specifically, a comprehensive genomic test must be able to identify all four classes of genetic alterations, namely single nucleotide variants, copy number variants, insertions/deletions and fusions, across multiple genes. The NCCN treatment guidelines now support multi-biomarker testing across several cancer types, which has led to increased adoption of CGP. For example, for NSCLC, NCCN treatment guidelines now include recommendations for testing across nine genes, as well as tumor mutational burden, or TMB, each associated with targeted therapies that are either FDA-approved or in late-stage development. </span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While precision oncology is improving clinical outcomes for patients across many cancer types, it is also benefiting oncology drug development. Biopharmaceutical companies are able to increase chances of a drug&#8217;s success in clinical trials by identifying and selecting patients whose cancer has the right molecular profile. This enables them to potentially require fewer patients for the trial and shorten the duration of late-stage clinical trials. According to GlobalData, approximately 66% of the solid tumor oncology clinical pipeline in 2018 was for targeted therapies and immuno-oncology therapy&#160;agents, many of which are targeting a cancer with a specific molecular profile or biomarker.  </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite improvements to clinical outcomes and oncology drug development, primarily in the advanced cancer setting, precision oncology has not significantly impacted earlier stage cancer care. For example, precision oncology has yet to fully impact neoadjuvant and adjuvant treatment management, minimal residual disease and recurrence detection in cancer survivors, or early cancer detection in screening eligible asymptomatic individuals and higher risk individuals. Many early stage cancer patients receive only non-targeted chemotherapy post-surgical resection of the tumor in the adjuvant setting and ad-hoc, symptomatic monitoring for recurrence. For early detection of cancer in screening eligible asymptomatic individuals, the current standard of care is comprised of single protein biomarker tests or radiographic imaging, which can have challenges with high false positive rates when used for screening. For example, according to the results from the national lung screening trial reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The New England Journal of Medicine </span><span style="font-family:inherit;font-size:10pt;">in November 2011, low-dose CT, or LDCT, imaging may identify lung nodules in heavy smokers, out of which 95% are benign. Furthermore, these tests are generally only applicable to specific cancers and incapable of broad screening for multi-cancer detection. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Limitations of tissue biopsies</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that precision oncology, as it is practiced currently, suffers from the major challenge of limited access to molecular information, largely resulting from a reliance on tissue biopsies. This has impeded progress on both early disease diagnosis and effective treatment selection. For a tissue biopsy to be performed, the patient typically must undergo an imaging procedure to locate the tumor, following which a biopsy of the tumor is taken using interventional procedures, such as a core needle biopsy or fine needle aspiration. As part of this procedure, the needle is placed into the tumor and cells are aspirated into a syringe. The cells are placed on a microscope slide, stained and examined by a pathologist to determine the diagnosis and classification of the disease. If genotyping is required, which could include testing with next-generation sequencing, additional slides with tumor tissue would need to be prepared for this analysis.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The tissue biopsy process holds significant challenges, including:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Adverse event risks - </span><span style="font-family:inherit;font-size:10pt;">Tissue biopsies require use of an invasive tool to access the tumor within the body and are frequently associated with morbidity and mortality. For instance, a study published in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Journal of Oncology Practice</span><span style="font-family:inherit;font-size:10pt;"> / </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical Lung Cancer </span><span style="font-family:inherit;font-size:10pt;">in March 2016 reported that, according to Medicare claims data from 2009 to 2011, a lung biopsy was associated with a 19.3% complication rate. Complications included pneumothorax, respiratory failure and hemorrhage. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Delay</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in care </span><span style="font-family:inherit;font-size:10pt;">- Collection of tissue biopsy often requires a medical imaging procedure to locate the cancer and coordination amongst an interventional radiologist, surgical oncologist and pathologist to interpret the imaging and collect and analyze the tissue. A traditional tissue biopsy can take several weeks to schedule and additional time to process the sample, which can be burdensome on the patient and delay the collection of critical molecular information. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost - </span><span style="font-family:inherit;font-size:10pt;">According to a study published in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Journal of Oncology Practice</span><span style="font-family:inherit;font-size:10pt;"> / </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical Lung Cancer </span><span style="font-family:inherit;font-size:10pt;">in March 2016, the average total cost of a lung biopsy is $14,670, due largely to the required imaging, biopsy or surgical procedure to obtain the tissue, and associated morbidity. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Limited tissue availability - </span><span style="font-family:inherit;font-size:10pt;">Tissue sampling has variable but significant failure rates due to procedural or sampling failure and may be exhausted by pathology tests for cancer diagnosis. In NSCLC, this has been documented across many institutions and happens as often as 60% of the time.</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span><span style="font-family:inherit;font-size:10pt;">In addition, tissue sampling is unavailable for a minority of patients due to medical contraindication, patient unwillingness or logistical concerns. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Limited to a small portion of a single tumor </span><span style="font-family:inherit;font-size:10pt;">- A tissue biopsy is often limited to a small portion of a single tumor site, which may not accurately represent the entire tumor or all clinically relevant biomarkers due to tumor heterogeneity. This could lead to tissue biopsy missing mutations targetable by therapy for patients with advanced solid tumors. This limitation has been demonstrated in many tumor types, including lung, breast, gastric, renal and cholangiocarcinoma. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inability to address applications for early stage cancer patients </span><span style="font-family:inherit;font-size:10pt;">- For disease recurrence detection or screening for early detection of cancer, tissue tests are impractical or not feasible.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The potential for our liquid biopsy technology</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our liquid biopsy technology can liberate molecular information across all stages of cancer and broaden the scope of precision oncology to earlier stages of the disease. Furthermore, we believe our liquid biopsy can potentially lead to dramatically greater rates of data generation and shorten cycles of learning, thereby accelerating progress in improving clinical outcomes. Relative to a tissue biopsy, a routine blood draw is:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">minimally invasive; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">rapidly administered;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cost effective; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">readily available.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we believe our liquid biopsy technology is: </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Able to provide timely insight into tumor genomic alterations </span><span style="font-family:inherit;font-size:10pt;">- Our liquid biopsy tests are convenient and fast. With a routine blood draw, and for example, typically seven days or less turn-around-time with our Guardant360 test, we believe our Guardant Health Oncology Platform can comprehensively genotype cancer patients and other populations to enable rapid initiation of effective treatment and potential clinical trial enrollment. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">More representative of the molecular profile of the tumor in its entirety </span><span style="font-family:inherit;font-size:10pt;">- Our test results could represent an overall summary of the entire molecular profile of the tumor or tumors and not just a subset of a single tumor that may be represented in a tissue sample. This may enable insight into potentially more targetable mutations than tissue testing. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Able to monitor response to therapy</span><span style="font-family:inherit;font-size:10pt;"> &#8211; We believe recent data suggests that changes in tumor burden can be monitored through the use of our liquid biopsy technology and successive blood draws to potentially provide quicker information as to the effectiveness of a chosen treatment than current approaches using radiographic imaging. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Able to address all stages of the disease</span><span style="font-family:inherit;font-size:10pt;"> &#8211; We believe ready access to molecular information and the ability to potentially detect cancer at early stages in blood enable our liquid biopsy technology to be used for applications, such as for minimal residual disease and recurrence detection or early cancer detection in screening eligible asymptomatic individuals and higher risk individuals. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Able to match standard-of-care tissue testing</span><span style="font-family:inherit;font-size:10pt;"> &#8211; In a recent head-to-head comparison of Guardant360 test to standard-of-care tissue testing for biomarker identification in first-line advanced NSCLC patients, our liquid biopsy technology produced biomarker detection rates in line with standard of care tissue testing.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">History of liquid biopsy and challenges</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The concept of a liquid biopsy is not new, and we believe that a minimally invasive tool, such as a liquid biopsy, has been an aspiration of the oncology field for many decades. Multiple modalities have been pursued to access a patient&#8217;s molecular information through blood, including ctDNA, circulating tumor cells, or CTCs, and exosomes. It has been shown that modalities using ctDNA may have distinct advantages over other known modalities. For example, ctDNA has a concentration in blood that may be over 100 times higher than CTCs, which can enable increased test sensitivity and accuracy. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">However, despite this promise of higher concentration and, therefore, higher theoretical sensitivity of a ctDNA test, these fragments are still found at very low concentrations which can make their analysis challenging by conventional methods. For example, circulating cell-free fetal DNA, which is the target for a variety of non-invasive prenatal testing applications for women during pregnancy, makes up a median of 10% of the total cell-free DNA in maternal blood. By contrast, the median concentration of ctDNA genomic alterations detected by us in blood of advanced cancer patients is 0.46% and can be present at levels below 0.01% in early stage cancer patients.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the sensitivity and specificity of conventional next-generation sequencing is sufficient for tissue biopsy based tumor profiling, this performance is inadequate for liquid biopsies due to the low concentrations of ctDNA in blood. Moreover, comprehensive genomic profiling for precision oncology requires detection across all four classes of genomic alterations below, which can be especially challenging with ctDNA: </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Single-nucleotide variants (SNVs)</span><span style="font-family:inherit;font-size:10pt;"> - variation(s) in a single nucleotide in a DNA molecule </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Insertions/deletions (Indels) -</span><span style="font-family:inherit;font-size:10pt;"> short nucleotide section(s) of a DNA molecule inserted or deleted </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Copy number amplifications (CNVs) - </span><span style="font-family:inherit;font-size:10pt;">regions(s), typically spanning one or more genes of the genome that are repeated </span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Genomic rearrangements </span><span style="font-family:inherit;font-size:10pt;">- involve gross alterations of chromosomes or large chromosomal regions and can take the form of deletions, duplications, insertions, inversions or translocations.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The market opportunity and our vision for the standard of cancer care</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that liquid biopsy tests can solve critical challenges of tissue-based tests, expand the scope of precision oncology across the cancer care continuum to earlier stage disease, and empower clinicians to make better decisions to improve clinical outcomes, lower healthcare costs and enable biopharmaceutical companies to advance new therapies. We believe liquid biopsy has application in the following areas, representing a market opportunity we estimate to be more than $50 billion in the United States:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Therapy selection in advanced cancers.</span><span style="font-family:inherit;font-size:10pt;"> Clinicians require genomic information in order to properly match advanced cancer patients with the appropriate treatment across multiple lines of therapy. Given the limitations of tissue biopsies, we believe a blood test that is capable of accessing the comprehensive genomic profile of the patient&#8217;s cancer represents a significant breakthrough, especially in the local community setting, where 80% of cancer patients are treated, infrastructure and expertise to access tissue may be especially limited. We also believe a comprehensive liquid biopsy test for therapy selection can benefit biopharmaceutical companies across a range of applications, including patient selection and recruitment for clinical trials and commercialization once the drug is approved, as well as identification of new molecular targets for drug development. For example, better access to molecular information can speed clinical trial enrollment and increase the probability of success of drug development in a target patient population. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate this is an up to $6 billion total market opportunity in the clinical and biopharmaceutical markets. This includes a near-term clinical opportunity of $2 billion, based on an estimated 700,000 metastatic patients in the United States and an assumed average reimbursement rate of $3,000, a similar amount covered by Medicare for a comprehensive genomic profiling test. We estimate the number of metastatic patients in the United States based on the number of deaths attributable to cancer annually in the United States as reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">A Cancer Journal for Clinicians</span><span style="font-family:inherit;font-size:10pt;"> and the number of patients who are diagnosed with advanced cancer in the United States and are alive a year after diagnosis as reported in the SEER Cancer Registry. We believe this opportunity may expand by up to an additional $2 billion, as metastatic patients may require multiple tests to inform subsequent lines of therapy.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate that the market opportunity with biopharmaceutical companies in the United States is over $2 billion including an opportunity of over 400,000 tests based on the industry&#8217;s current clinical pipeline of over 1,200 immuno-oncology and over 450 targeted therapy programs, involving more than 130,000 patients. These programs represent two distinct testing opportunities: (1) prospective screening to identify candidate patients for clinical trial enrollment and (2) retrospective analysis of patient samples. In addition, we estimate there is a market opportunity of $500 million in companion diagnostics development and other commercial opportunities. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The chart below represents the breakdown of the total estimated market opportunity across both the targeted therapy and immuno-oncology opportunities for the therapy selection markets:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;"><img src="marketopportunity.jpg" alt="marketopportunity.jpg" style="height:308px;width:484px;"></img></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Neoadjuvant and adjuvant treatment in early stage cancer patients and surveillance in cancer survivors. </span><span style="font-family:inherit;font-size:10pt;">We believe early stage cancer patients would benefit from tests that could more accurately identify patients to benefit from adjuvant treatment. A liquid biopsy test in this setting could help biopharmaceutical companies identify new opportunities in adjuvant drug development and therapies targeting earlier stage cancers. In addition, we believe cancer survivors would benefit from tests that could improve minimal residual disease and recurrence detection. Follow-up testing for surveillance in cancer survivors is often ad-hoc, leaving patients guessing as to if and when their cancer may recur. A portion of this market is currently served by prognostic and predictive molecular tests that can classify whether a patient may be at low-risk or high-risk of recurrence. We believe that a definitive diagnostic test for cancer would benefit this patient population both immediately following surgical resection of the tumor and as a monitoring tool in subsequent years. We estimate this is an approximately $15 billion market opportunity, based on an estimated 15 million solid tumor cancer survivors as of  2016, excluding survivors of blood cancers, including leukemia and Non-Hodgkin&#8217;s lymphoma, in the United States as reported by the American Cancer Society, and assuming an average price of $1,000 per test for each solid tumor cancer survivor, which is consistent with the cost to screen a patient for lung cancer as reported in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">New England Journal of Medicine</span><span style="font-family:inherit;font-size:10pt;"> in November 2011.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Early detection of cancer.</span><span style="font-family:inherit;font-size:10pt;"> Earlier detection of cancer is generally correlated with better clinical outcomes and a higher cure rate for many cancer types. We believe that a test that can accurately detect cancer at its earliest stages or even pre-cancer in a largely asymptomatic population will need to overcome high technological, clinical and regulatory challenges. However, such a test can have significant benefits on mortality and perhaps eventually reduce incidence rates of cancer, if the information provided can be effectively paired with the right preventative medicine or curative intervention. We believe this represents a potential market opportunity of approximately $15 billion for non-invasive modalities such as our LUNAR-2 assay that is under development, based on an estimated 30 million individuals who are eligible for colorectal cancer screening. In addition, we estimate this is an approximately $18 billion market opportunity with respect to individuals at a higher risk of developing cancer, based on an estimated 35 million individuals at higher risk for cancer in the United States and assuming an average price of $500 per test. The estimated 35 million individuals at higher risk for cancer in the United States consist of approximately 17 million individuals at moderate to high hereditary risk of developing breast, ovarian, colorectal, endometrial or prostate cancer, based on prevalence statistics reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Genetics in Medicine</span><span style="font-family:inherit;font-size:10pt;"> and U.S. Census Data; approximately 14.5 million people over the age of 50 who are moderate to heavy smokers, as reported by the Centers for Disease Control and Prevention; and approximately 3.5 million individuals in the United States at high risk of developing liver cancer due to Hepatitis C infection, based on the 2003-2010 data reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Hepatology</span><span style="font-family:inherit;font-size:10pt;"> in 2015.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The graphic below depicts the potential opportunities of liquid biopsy across the cancer continuum of care:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;"><img src="slide1a03.jpg" alt="slide1a03.jpg" style="height:468px;width:624px;"></img></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE6EF68EB3FE753629CADEA8B7629A1C2"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">The Guardant Health Oncology Platform</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Guardant Health Oncology Platform is comprised of strengths across five critical layers, each of which is tightly coupled with the others, and we believe success in each facilitates success in adjacent layers. We believe our platform and our position as a pioneer of comprehensive liquid biopsy provide us with a competitive advantage and form a barrier to entry. The following diagram depicts the five layers of our oncology platform:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;"><img src="guardantgraphic201910k.jpg" alt="guardantgraphic201910k.jpg" style="height:350px;width:624px;"></img></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Technology &#8211; Guardant Health Digital Sequencing</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Guardant Health Digital Sequencing combines state-of-the-art technology from multiple disciplines and is enabled by robust, high-efficiency biochemistry at the front-end, next-generation sequencing and a machine learning augmented bioinformatics pipeline. The combination of all of these technologies onto one platform has enabled our programs in liquid biopsy and what we believe is the highest performing clinical comprehensive liquid biopsy, with a turnaround time of typically less than seven days after we receive the sample. We believe our platform is able to detect all four classes of genomic alterations and microsatellite instability, or MSI, at sensitivity levels beyond comparable platforms.  </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Two specific enhancements we employ throughout the workflow include:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">High-efficiency chemistry</span><span style="font-family:inherit;font-size:10pt;"> - Our proprietary ctDNA sample preparation biochemistry is able to convert the vast majority of extracted ctDNA molecules into a sequencing library. This enables enhanced sensitivity to detect mutations present at ultra-low variant frequency and the ability to work with limited sample volumes. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Error suppression via proprietary bioinformatics engine</span><span style="font-family:inherit;font-size:10pt;"> - Our bioinformatics pipeline reduces the sequencing error rate by 1000-fold over conventional next-generation sequencing and by 30-fold over other sequencing assays relying on molecular barcoding alone. Furthermore, the machine learning capability enables performance improvement as we incorporate data from additional blood samples.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical utility </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that the measure of the clinical utility provided by a given diagnostic test or technology lies in the ability to enable the physician to match intervention with the patient to select the treatment likely to produce a more favorable outcome for the patient. We also believe that success in the clinical utility layer requires both independent, systematic investments in clinical research, and strategic relationships with market-leading biopharmaceutical companies. We aim to generate publications in independently peer-reviewed scientific journals to demonstrate clinical utility of our technology. For this reason, we have invested in directly sponsoring or participating in prospective, interventional clinical trials with leading academic cancer centers and biopharmaceutical companies, including over three dozen published clinical outcomes studies demonstrating that overall biomarker detection rates of our non-invasive blood testing were in line with tissue testing. We have built an internal clinical development team that can efficiently run clinical utility studies and continue to invest in such studies spanning many indications within the advanced cancer setting, including completed outcomes studies (27 in lung cancer, 15 in gastrointestinal cancers, 5 in breast cancer and 10 in other cancer types). We are also investing heavily in studies involving earlier stage disease.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The strength of our technology facilitates strategic relationships with academia and over 50 biopharmaceutical companies, to help them advance the development of their drug pipelines and expand the utilization of currently commercialized treatments. In return, these relationships provide rigorous clinical validation of our technology and early insights into emerging therapeutically relevant test targets. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory approval</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that Guardant360 test was the first comprehensive liquid biopsy approved by the NYSDOH. In addition, based on our review of publicly available records, we believe our facility was the first comprehensive liquid biopsy laboratory to become CLIA-certified, CAP-accredited and NYSDOH-permitted. Our Guardant360 and GuardantOMNI tests have each been designated by the FDA as a breakthrough device for use as a companion diagnostic in connection with certain specified therapeutic products of our biopharmaceutical customers. Among other things, designation as a breakthrough device provides for priority review by the FDA and more interactive communication with the FDA during the development process. In the fourth quarter of 2019, we submitted a PMA application to seek the FDA&#8217;s approval of our Guardant360 test to be used as a companion diagnostic, initially in connection with one therapeutic product of a biopharmaceutical customer, and to provide tumor mutation profiling for cancer patients with solid tumors. In February 2020, we submitted an additional module of the PMA application for our Guardant360 test to the FDA. Medicare&#8217;s National Coverage Determination, or NCD, for Next Generation Sequencing, or NGS, was established in 2018 and subsequently updated in 2020. The NCD provides coverage for molecular diagnostic tests such as our Guardant360 test, if, among other criteria, such tests are offered within their FDA-approved companion diagnostic labeling. We believe that this establishes a competitive advantage for tests receiving FDA approval and that FDA approval will be increasingly necessary for diagnostic tests to gain adoption, both in the United States and abroad, by clinicians, payers and biopharmaceutical companies.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Payer coverage</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Coverage from public and commercial payers is primarily influenced by clinical evidence, endorsement by KOLs and treatment guidelines. The analytical and clinical data that we have generated, combined with our support from KOLs, has led to a number of positive coverage decisions from commercial payers. Guardant360 test is currently covered by Cigna, Priority Health, multiple regional Blue Cross Blue Shield plans as well as the health plans associated with eviCore for NSCLC, which we believe gives us a competitive advantage with these payers. With respect to Medicare, in July 2018, Palmetto GBA, the MAC responsible for administering MolDx, issued an LCD for our Guardant360 test with respect to NSCLC patients who meet certain clinical criteria. Subsequently in 2018, Noridian Healthcare Solutions, the MAC responsible for adjudicating claims in California, where our laboratory is located, and a participant in MolDx, finalized an equivalent LCD for our Guardant360 test, and we have been billing Medicare pursuant to this Noridian LCD. In December 2019, replacing its prior NSCLC patient LCD, Palmetto GBA finalized a new LCD for our Guardant360 test that provides limited Medicare coverage for the Guardant360 test in patients diagnosed with solid cancers of non-central nervous system origin. The new LCD covers our Guardant360 test for fee-for-service Medicare patients with advanced cancers who meet its clinical criteria for complete genomic profiling with NGS of tumor tissue to optimize treatment selection decisions but have insufficient or unavailable tissue for molecular profiling. The expanded coverage decision is in line with FDA approvals of several tumor-agnostic drugs that are based on a single genomic biomarker across all cancers or that are targetable across multiple cancer types. We expect Noridian Healthcare Solutions to issue a new LCD for our Guardant360 test equivalent to the new LCD issued by Palmetto GBA, though the timing and scope of the Noridian LCD are uncertain. We anticipate FDA approval of our Guardant360 test, if obtained, may support further improvements in coverage and reimbursement, including Medicare according to the NGS NCD.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commercial adoption </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Success in each of the layers above is important for commercial adoption by clinicians and biopharmaceutical companies. Additionally, for clinicians, endorsement by KOLs traction at academic centers and inclusion in national treatment guidelines is important, especially for clinical adoption in the local community setting where 80% of cancer treatment occurs. Our relationships with key stakeholders across the oncology space, as well as the recent inclusion of liquid biopsy under certain circumstances as a potential alternative to tissue biopsy in NCCN treatment guidelines has helped facilitate adoption of our tests by 7,000 oncologists, who have collectively ordered our Guardant360 test over 100,000 times, and by over 50 biopharmaceutical companies.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Our products and development programs</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have launched our Guardant360 and GuardantOMNI tests and are developing additional tests under our LUNAR program, including having launched our LUNAR-1 assay for research or investigational use. We believe our product portfolio, once completed, will address the full continuum of care and has utility in both the clinical and biopharmaceutical markets.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Therapy Selection</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The increasing diversity of targeted therapies and associated molecular biomarkers has given rise to comprehensive genomic profiling, particularly in tumor types where multiple genomic targets can be found and treated effectively. For example, NSCLC, like other tumors, has multiple effective treatment options targeting different genomic mutations. There are nine targetable genes in NSCLC, which are comprised of alterations across all four genomic variant classes (SNVs, indels, CNVs, and fusions), as well as TMB. Five of these targets are on-label approved biomarkers for FDA-approved therapies. The NCCN treatment guidelines recently recommended testing for all of the genomic mutations or alterations across different cancer types, which demonstrates the requirement for broader genomic profiling.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite NCCN guidelines, data from a study of 800 NSCLC patients, published on </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical Lung Cancer</span><span style="font-family:inherit;font-size:10pt;"> in November 2017, reported that only a minority of patients actually were tested for the guideline-recommended targetable genomic mutations, and only 8% of patients were comprehensively genotyped. A retrospective review of data extracted from electronic medical records of 1,497 patients with pathologically confirmed metastatic colon cancer, or mCC, at 23 practices across the United States, published in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Journal of Clinical Oncology Precision Oncology</span><span style="font-family:inherit;font-size:10pt;"> in December 2019, showed that only 40% of such 1,497 patients were tested according to guidelines despite longstanding medical guidelines recommending biomarker testing for all patients with mCC. Such &#8220;undergenotyping&#8221; had multiple causes in the study, and primary reasons for not testing were lack of sufficient tissue, poor patient performance status or infeasibility to undergo a repeat biopsy for additional tissue.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Guardant360 Test</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe Guardant360 test is the market leading comprehensive liquid biopsy test, based on the number of tests ordered. Guardant360 test is a 74 gene test that supports treatment selection for advanced stage cancer patients with solid tumors. The testing process requires two 10 milliliter blood samples that are sent to our laboratory in Redwood City, California, where we process and analyze the samples using proprietary, next-generation sequencing-based Guardant Health Digital Sequencing Technology. Results are typically delivered in seven days following receipt of sample and delivered by a clinical report through fax, portal or mobile device.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since we launched our Guardant360 test in 2014, it has been ordered over 100,000 times by more than 7,000 oncologists across dozens of cancer types, by more than 50 biopharmaceutical companies and by all 28 NCCN centers. Guardant360 test is also currently being developed for use as a companion diagnostic.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Guardant360 clinical report</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A typical Guardant360 clinical report contains somatic mutations detected in patient blood samples, associated treatment options and available clinical trials in the vicinity of the patient&#8217;s location. Additionally, the report depicts a proprietary visual representation that shows the evolution of somatic mutations in longitudinal blood samples. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Analytical validation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe there are two key performance characteristics that are critical for a liquid biopsy test. The first is sensitivity, which refers to the level of ctDNA in circulation at which the technology reliably detects variants for a given input sample amount. The second is specificity, which is the probability that a given test result is accurate. These metrics are critical for effective treatment selection based on the results of liquid biopsy testing. It can be especially challenging to maintain high specificity at detection levels below 0.25% due to the high error rates of standard next-generation sequencing protocols at these levels and the broad genomic footprint tested simultaneously in a comprehensive liquid biopsy test. In order to assess these key performance characteristics for Guardant360 test, we conducted analytical validation studies against orthogonally validated methods. The results, as published in Clinical Cancer Research, demonstrated that Guardant360 test has a detection threshold of one to two molecules across multiple alteration types, including all four classes of genomic alterations and MSI, with very high specificity which results in accurate and sensitive detection of somatic mutations in patient samples.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical trials and publications</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The goal of our clinical development with Guardant360 test is to support its use for comprehensive genomic profiling across multiple tumor types, including as a preferred alternative to tissue testing to inform first line treatment right after diagnosis and at time of disease progression. We publish peer-reviewed studies in order to influence treatment guidelines, to educate clinicians and other oncology stakeholders about the value proposition of our test and to set the stage for reimbursement with private and public payers. We have over 50 approved, completed or active clinical outcomes studies, more than 150 peer-reviewed publications and more than 400 scientific abstracts. We are proactively pursuing studies to support the use of our Guardant360 test as a preferred alternative to tissue testing to inform first line treatment right after diagnosis, with the goal to provide evidence that our Guardant360 test detects genomic alterations at a similar rate compared to standard of care tissue testing in the United States, Europe and Asia. Such a strategy is predicated on the Guardant360 test&#8217;s ability to offer accurate, reliable and fast guideline-directed comprehensive genotyping for all adult solid tumors without exposing patients to invasive biopsy procedures&#8217; risks, delays or chance of failure. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summarizes the results of some of our Guardant360 test clinical studies:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Biomarker discovery rate</span><span style="font-family:inherit;font-size:10pt;">. In the first quarter of 2019, we announced results from our Noninvasive vs. Invasive Lung Evaluation, or NILE, study after it met its primary endpoint of demonstrating that Guardant360 test detected targetable genomic biomarkers in advanced, non-squamous NSCLC at a similar rate to standard of care tissue testing. Our Guardant360 test identified guideline-recommended biomarkers in 77 of the 282 patients enrolled in the study, while tissue testing identified such biomarkers in 60 of those patients. In the study, the median time to results for Guardant360 testing was much shorter than for tissue testing, as Guardant360 test results were reported in an average of 9 days, while tissue testing results were reported in an average of 15 days, and our Guardant360 test resulted in guideline-recommended testing for three times as many patients as standard-of-care tissue testing. We believe these data support the use of our testing ahead of tissue testing for all newly diagnosed advanced NSCLC patients. Findings from an 800-patient prospective clinical trial led by the Institute of Cancer Research London for treatment selection in advanced breast cancer, which we refer to as plasmaMATCH trial, as presented at the San Antonio Breast Cancer Symposium in December 2019, showed that our Guardant360 test accurately detected biomarkers that can guide targeted treatment for late stage breast cancer patients, many with bone metastases that are often difficult to biopsy and typically yield insufficient bone tissue for biomarker analysis.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Genotyping concordance with matched tumor tissue - </span><span style="font-family:inherit;font-size:10pt;">Results of a blinded retrospective study comprising 6,948 consecutive NSCLC samples to assess the concordance between Guardant360 test and tissue genotyping of samples received for clinical testing at our laboratory showed high positive predictive value, which is the probability that a variant detected by Guardant360 test in blood was in fact present in the corresponding tissue sample. A study published in Clinical Cancer Research in August 2019 concluded that microsatellite instability, or MSI, detection using the Guardant360 test was highly concordant with standard-of-care tissue testing, which enabled detection of MSI status concurrent with comprehensive genomic profiling and expanded access to immunotherapy for advanced cancer patients for whom current testing practices are inadequate.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Detection rate of ctDNA in patient samples - </span><span style="font-family:inherit;font-size:10pt;">We observed a test success rate of 99.6% in a study comprising 10,593 consecutive samples to provide insights into Guardant360 test performance in real-world clinical specimens. Overall detection rates of ctDNA were consistently high (85.9%), predominantly driven by NSCLC (87.7%), colorectal (85.0%) and breast (86.8%). We believe this cohort demonstrates the need for a highly sensitive liquid biopsy as the median variant allele frequency, or VAF, found was only 0.46%.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Prospective clinical response rate - </span><span style="font-family:inherit;font-size:10pt;">A prospective, interventional, multi-cancer clinical utility study of Guardant360 test across 193 patients with no tissue genotyping options showed an objective response rate of 87% (95% CI, 58%-98%) with disease control rate of 100% (95% CI, 75%-100%). In the NSCLC cohort, 73 patients were tested, 34 were matched with pre-specified therapy, of which 17 patients were treated with matched therapy, of which 15 patients were evaluable. Importantly, the response rate was independent of the VAF of mutations found in the blood.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical relevance of actionable mutations detected at ultra-low concentrations</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">- We analyzed the clinical response of a multi-center case series of Guardant360 test-detected targetable driver alterations in advanced NSCLC with VAFs of less than 0.2%. Twelve patients were selected who had targetable driver alterations in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">EGFR</span><span style="font-family:inherit;font-size:10pt;"> (n=7, VAF range 0.045%-0.14%), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">MET</span><span style="font-family:inherit;font-size:10pt;"> exon 14 skipping mutation (n=1, VAF = 0.06%), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">BRAF</span><span style="font-family:inherit;font-size:10pt;"> V600E (n=1, VAF = 0.1%), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">EML-ALK</span><span style="font-family:inherit;font-size:10pt;"> fusions (n=3, VAF range 0.07-0.16%). All patients responded to targeted therapy with median progression-free survival of 52 weeks. Of particular significance, 7 out of 12 patients were undergenotyped, largely due to tissue insufficiency. </span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GuardantConnect</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because metastatic cancer patients often exhaust standard of care treatment options as the disease progresses and guidelines recommend clinical trials for advanced cancer patients, clinical trial matching is an acute need in oncology. At the same time, biopharmaceutical companies need to fill clinical trials that require screening hundreds of thousands of patients. Despite these needs, clinical trial enrollment in oncology has severely lagged, with only 3-6% of cancer patients enrolling in clinical trials. GuardantConnect is our integrated software solution designed for our clinical and biopharmaceutical customers, seeking to connect patients in need tested with Guardant360 test with clinical trials. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">GuardantOMNI Test</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our GuardantOMNI test is built on Guardant Health Digital Sequencing Technology and learnings from our Guardant360 test. The GuardantOMNI test, launched in 2017, has a significantly larger genomic panel footprint than the Guardant360 test and has achieved comparable analytical performance in clinical studies, including for translational science applications in collaboration with several biopharmaceutical companies, including AstraZeneca, Bristol-Myers Squibb, Merck MSD, Merck KGaA of Darmstadt, Germany and Pfizer. It covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications, such as tumor mutational burden and microsatellite instability.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to preserve performance characteristics of our Guardant360 test across a broader gene panel, we implemented additional enhancements to the assay efficiency and bioinformatics analysis to improve the sensitivity of our GuardantOMNI test. These enhancements are critical in the context of using the GuardantOMNI test in the retrospective testing of clinical trial samples for translational science applications in collaboration with biopharmaceutical customers, as those samples are often available with only a limited volume of plasma.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Validation data indicates that the GuardantOMNI test exceeds the Guardant360 test&#8217;s sensitivity for detecting clinically actionable biomarkers. At the same time, broader panel-wide performance of small variants is roughly similar to that of Guardant360 test. The broad genomic footprint of our GuardantOMNI test enables accurate measurement of tumor mutational burden. The GuardantOMNI test received breakthrough device designation from the FDA in December 2018 and is currently being developed, including for use as a potential companion diagnostic, to identify patients who may benefit from immuno-oncology therapeutics, including patients that may more likely respond to immuno-oncology agents based on TMB.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">LUNAR Program</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#212121;">We believe that there is a critical need to develop products to expand precision oncology to post-cancer monitoring and earlier stage settings. Such products would enable clinicians to precisely detect, monitor and select the appropriate intervention at the right times in the disease&#8217;s evolution, key to significantly improving patient clinical outcomes. In order to systematically address this need, we launched our LUNAR program to develop tests to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and  asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;color:#212121;">Our research and development results to date indicate that somatic signatures alone may be insufficient for detection of early stage cancers with high sensitivity. For this reason, we have incorporated epigenomic signatures to enhance the performance of our LUNAR assays in these settings.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our LUNAR-1 assay is intended to address identification of those who are likely to benefit from adjuvant treatment,  detection of minimal residual disease in the blood of cancer patients after surgery, and surveillance of patients who have completed curative cancer treatment to potentially detect recurrence at an earlier stage. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our LUNAR-2 assay is being developed to address early cancer detection in screening eligible asymptomatic individuals and higher risk individuals. Early cancer detection is challenging, especially with respect to clinical specificity. There is a minimal amount of ctDNA in patients with low-disease burden. Additionally, naturally occurring genomic aberrations in blood as well as signals from non-cancer related diseases can add biological noise obfuscating detection of circulating tumor-related biomarkers. We believe we have the unique capability to overcome these challenges by leveraging our:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Vast data sets and deep insights:</span><span style="font-family:inherit;font-size:10pt;"> We have targeted deep sequencing data in combination with low coverage sequencing of whole genome from tens of thousands of cancer patients. This data has enabled discovery of novel epigenomic variations across multiple cancer types. We believe augmenting genomic with epigenomic signatures can enhance the clinical sensitivity and specificity of our tests significantly. Moreover, we developed a database of biological noise sources such as clonal hematopoiesis of indeterminate potential, which enables us to further enhance the sensitivity and specificity of our tests.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Extensive blood biobank:</span><span style="font-family:inherit;font-size:10pt;"> We have a biobank of tens of thousands of cancer samples that we use for discovery and, more importantly, biomarker verification and validation. For example, we are analyzing these samples with whole genome sequencing to identify and confirm tumor associated signatures. Also, we have been collecting additional samples through multiple on-going research collaborations.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Neoadjuvant and adjuvant treatment selection in early stage cancer patients</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neoadjuvant and adjuvant therapies may include chemotherapy, hormone therapy, radiation therapy, immunotherapy and targeted therapy. Neoadjuvant therapies are delivered before the main treatment to help reduce the size of a tumor or kill cancer cells that have spread. Adjuvant therapies are delivered after the primary treatment to destroy remaining cancer cells. Neoadjuvant and adjuvant therapies are often recommended when a patient with early-stage cancer undergoes surgery or radiation therapy and the oncologist believes the patient may benefit from additional systemic treatments. Neoadjuvant and adjuvant therapies benefit many, but not all, cancer patients. Our LUNAR-1 assay is intended to identify early stage cancer patients that may benefit from neoadjuvant and adjuvant treatment.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we believe there is an opportunity to evaluate clinical utility of our LUNAR-1 assay by partnering with biopharmaceutical companies to identify these patients for adjuvant trial enrollment and also monitor treatment effectiveness post-adjuvant treatment. In comparison to drug development in the metastatic setting, adjuvant drug development can cost significantly more, typically require more patients, last longer and have a lower probability of success. Identification of those most likely to benefit from adjuvant therapy is therefore an important clinical challenge. We believe that our LUNAR-1 assay could support ctDNA enrichment strategies that may reduce the cost of these development activities, lead to new therapeutic indications and potentially reduce the use of cytotoxic chemotherapy in patients unlikely to benefit. In June, 2019, results presented by us, together with the Massachusetts General Hospital Cancer Center, at the American Society of Clinical Oncology, or ASCO, annual meeting, provided evidence regarding our LUNAR-1 assay&#8217;s ability to identify early-stage colorectal cancer patients with post-operative molecular residual disease who may benefit from adjuvant therapy. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Minimal residual disease and recurrence detection in cancer survivors</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Minimal residual disease is a term generally used to describe the small number of cancer cells in the body after cancer treatment. After treating cancer, remaining cancer cells can become active and start to multiply, causing a relapse of the disease. Detecting minimal residual disease may indicate that the treatment was not completely effective or that the treatment was incomplete. The number of remaining cells may be so small that they do not cause any physical signs or symptoms and often cannot even be detected through traditional methods. Testing for minimal residual disease can help the treatment team distinguish between patients who need additional or different treatment from those who do not. This knowledge can also potentially guide treatment decisions and improve patient outcomes.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A recurrence occurs when the cancer comes back after treatment. This can happen weeks, months, or even years after the primary cancer was treated. Cancer survivors in general face a risk of developing another cancer, and fear of recurrence can negatively affect quality of life.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our LUNAR-1 assay is intended to provide cancer survivors with quantitative peace of mind through a test for minimal residual disease or recurrence and  help physicians determine those patients that may still have minimal residual disease or identify a risk of relapse much earlier than conventional methods and therefore finds candidates for earlier intervention. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To further pursue this potential market opportunity, we, in collaboration with a National Clinical Trials Network group, initiated a prospective multi-center randomized controlled trial, which we refer to as the COBRA study, in approximately 1,400 patients with resected stage II colon cancer to use our LUNAR-1 assay to evaluate recurrence-free survival in patients who receive ctDNA-directed therapy as compared to the current standard-of-care active surveillance.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Early cancer detection in screening eligible asymptomatic individuals</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Colorectal cancer may not cause symptoms until the cancer has spread and is difficult to treat, which makes screening for colorectal cancer in people who do not readily demonstrate symptoms appealing. It has the potential to find the cancer earlier when it may be easier to treat, and reduce disease-specific mortality. Based on the 2009-2015 cancer statistics from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, the average five-year survival rate for all U.S. colorectal cancer patients is 64.4% and is increased to 89.9% among those diagnosed at an early stage. </span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our LUNAR-2 assay is being developed to identify people who are likely to benefit from screening for colorectal cancer. In April 2019, at the American Association for Cancer Research, or AACR, annual meeting, we presented exploratory data around the use of our LUNAR-2 assay for potential screening applications in a cohort of 229 recently diagnosed colorectal cancer patients and aged-matched cancer-free controls. These data showed average LUNAR-2 assay sensitivity exceeding 80% with specificity of 94% for patients with stage I/II colorectal cancer in this cohort (76% in stage I and 87% in stage II). </span><span style="font-family:inherit;font-size:10pt;color:#212121;">To further pursue this potential market opportunity, we initiated a prospective screening study, which we refer to as the ECLIPSE trial, to evaluate the performance of our LUNAR-2 assay in detecting colorectal cancer in average-risk adults. We expect to recruit approximately 10,000 patients and enrolled the first patient in the study in the fourth quarter of 2019.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Early cancer detection in higher risk individuals</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although cancer is the second leading cause of death in the United States, it can be cured if detected and treated at its earliest stages.&#160;For example, the introduction of the Pap smear reduced cervical cancer mortality by more than 80% from 1950 to 2005. However, despite the benefit of screening, which is recommended by the U.S. Preventive Services Task Force for cervical, breast, lung and colorectal cancers, a significant number of people do not receive screening today. For example, greater than 30% of eligible Americans are not up to date on screening for colorectal cancer.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe some of the major challenges lie in the limited efficacy of existing screening modalities:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Protein testing - </span><span style="font-family:inherit;font-size:10pt;">Current screening tests using protein biomarkers for various cancers, including prostate (PSA), pancreatic (CA19-9) and ovarian (CA125), lack sensitivity and specificity.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Imaging - </span><span style="font-family:inherit;font-size:10pt;">While</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">radiographic imaging is sensitive, it lacks clinical specificity. For lung cancer screening, as an example, the landmark National Lung Cancer Screening Trial reported that low-dose computed tomography, or LDCT, lung cancer screening of heavy smokers significantly increased cancer diagnosis rate and decreased overall mortality. However, a recent practice survey reported that only 3.9% of the estimated 6.8 million eligible patients had received LDCT screening. An important barrier to adoption of LDCT screening has been its greater than 95% false positive rate, which results in many unnecessary biopsies or inaction on positive findings.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our goal is to develop an accurate, affordable test with potential for high compliance for use in higher risk individuals. To support this development, we have forged several clinical research collaborations, including with institutions such as  the University of San Francisco, the University of Colorado and the University of Pennsylvania, studying applications of our LUNAR-2 assay for different cancer types. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s51E3B8DDB91D5978A66F55DDA73E318B"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercialization </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. clinical commercial efforts</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We sell our tests to clinical customers in the United States through our targeted sales organization. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our clinician-focused sales organization in the United States is engaged in sales efforts and promotional activities primarily targeting oncologists and cancer centers.&#160;Our sales representatives typically have extensive backgrounds in laboratory testing, therapeutics and oncology.&#160;We have supplemented the team with clinical oncology specialists with extensive medical affairs experience for molecular information support in the field.&#160;&#160; </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our clinical commercial efforts are focused on driving adoption with academic research institutions and with community oncology practices, including through leading physician networks. As we continue to grow our sales organization, we are also expanding our reach to include large community practices, community oncology networks, integrated delivery/ payer-owned systems and government medical facilities that are looking for a reliable partner for comprehensive molecular information testing.&#160;</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">International clinical commercial efforts</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently offer our tests in countries outside the United States primarily through distributor relationships or direct contracts with hospitals. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currently, all customer samples are shipped globally to our laboratory in Redwood City, California. We are conducting studies in various jurisdictions in an effort to secure reimbursement. As these studies progress and we near commercial opportunities there, we may seek to establish an in-country laboratory and direct sales organization.&#160;Specifically, we have already demonstrated the ability to deploy our technology to partner laboratories such as cancer centers, for the development of liquid biopsy assays based on our technology platform. We believe that this capability will be important in accelerating adoption of our platform and the performance of liquid biopsy testing&#160;in certain countries.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Together with SoftBank, we formed a joint venture, Guardant Health AMEA, Inc., which we refer to as the Joint Venture, relating to the sale, marketing and distribution of our tests in all areas worldwide outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 2017, Iceland, Norway, Switzerland and Turkey, or the JV Territory. Depending on the market opportunity in a country, the Joint Venture may create direct operations or conduct its operations through either a distribution model or a licensing model. Direct operations would entail full operations including a laboratory, sales and marketing and regulatory among other functions. Under the distribution model, our tests would be marketed and sold by the Joint Venture or third-party distributors  in relevant countries within the JV Territory, and the tests would be performed by or on behalf of us or our affiliates outside of such countries on samples obtained by the Joint Venture  or third-party distributors in such countries. Under the license model, the Joint Venture, or an entity designated by the Joint Venture, would be licensed to market and sell the tests in relevant countries within the JV Territory, and the Joint Venture, or an entity designated by the Joint Venture, would perform the tests on samples obtained in such countries. Following a determination by the board of directors of the Joint Venture on the appropriate model for an individual country, we will enter into an agreement with the Joint Venture with respect to the individual country that is based on either the distribution or license model. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East, and Africa.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currently, we and the Joint Venture are primarily focused on expanding our commercial capabilities in Asia, with an initial focus on Japan. There are estimated to be over 400,000 deaths from solid tumor cancers annually in Japan with a significant portion relating to lung and gastric cancers. We are involved in several nationwide clinical programs that help establish clinical utility of our Guardant360 test in the Japanese population with the first patient tested in late 2018.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Biopharmaceutical commercial efforts</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business development team is focused on enterprise selling to biopharmaceutical companies in the United States and internationally. Our strategy with each biopharmaceutical customer is to demonstrate the value proposition of the Guardant Health Oncology Platform and expand its utilization across the organization from early stage research through clinical development to commercialization. Given the broad and differentiated utility of our platform, we believe we can support our biopharmaceutical customers across many applications, including:   </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">discovery of new targets and mechanisms of acquired resistance;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">retrospective sample analysis to rapidly identify biomarkers associated with response and lack of response; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">prospective screening and referral services to accelerate clinical trial enrollment; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">companion diagnostic development to support the approval and commercialization of therapeutics. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also expect to be able to capture other commercial opportunities from our genomic data, which can be used in combination with clinical outcomes or claims data for multiple applications, including novel target identification.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Payer coverage and reimbursement </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe our tests and services provide solutions that enhance the safety, efficacy and guide cost-effective treatment selection of cancer therapeutics, as evidenced by the adoption from key stakeholders in the healthcare ecosystem. Evidence-based analytical validity, clinical validity and clinical utility studies are key drivers of both clinical adoption and reimbursement from commercial and government payers. Peer-reviewed evidence of our products and services will continue to be a center piece of our reimbursement strategy.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe our products offer significant health economic value to payers in the following ways: </span></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;"><span style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">reduce undergenotyping, thereby matching health plan members to targeted therapies that are both less costly and more effective than potential alternatives such as immunotherapy; and </span></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;"><span style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</span><span style="font-family:inherit;font-size:10pt;">reduce the need for a repeat invasive biopsy, thereby avoiding the associated high costs and risks of tissue biopsy complications. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In sum, we believe our tests help payers reduce both diagnostic and treatment costs, while simultaneously and most importantly improving clinical outcomes.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate total lung cancer coverage in the United States for our Guardant360 test to be a total of more than 170 million lives, including Medicare beneficiaries and members of several commercial health plans.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commercial third-party payers and patient billing</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment from third-party payers differs depending on whether we have entered into a contract with the payers as a &#8220;participating provider&#8221; or do not have a contract and are considered a &#8220;non-participating provider.&#8221; Payers will often reimburse non-participating providers at a lower amount than participating providers or not at all. Where we are not reimbursed in full or at all, we may elect to appeal the insurer&#8217;s underpayment or denial of payment or seek payment from the patient. However, insurer appeal and patient collection efforts take a substantial amount of time and resources and are often unsuccessful. Additionally, there are several national third-party commercial payers that have adopted non-coverage policies that treat both tissue and liquid comprehensive genomic profiling, or CGP, testing, including our Guardant360 test, as experimental or investigational at this time.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have provided testing services to patients with many cancer types and indications, most of the time as a non-participating provider through 2019. We received reimbursement for tests across the spectrum of these patients, though for amounts that on average were significantly lower than for participating providers.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our test and, potentially, no reimbursement for non-covered uses identified under the payer&#8217;s policies or the contract. As a result, the potential for more favorable reimbursement associated with becoming a participating provider may be offset by a potential loss of reimbursement for non-covered uses of our tests. In addition, we have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and where commercial payers have determined that the amounts previously paid were too high and sought to recover those perceived excess payments by deducting such amounts from payments owed to us.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Coverage from commercial payers has been focused on NSCLC, which represented approximately 44% of our U.S. clinical testing volume in 2019 and approximately 46% of our U.S. clinical testing volume in both 2018 and 2017. To date, the benefit of increased reimbursement for covered NSCLC Guardant360 testing as a participating provider has been approximately offset by the loss of reimbursement on tests for non-covered indications previously received when we served as a non-participating provider. Therefore, the net result of receiving coverage for a particular indication, including NSCLC, may be little to no change in our average revenue per test for all our patients served by these insurance payers.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are actively engaged to expand coverage among existing contracted providers and to achieve coverage with the remaining key commercial payers, laboratory benefit managers and evidence review organizations.&#160;This includes addressing variable coverage requirements and evidence required, and the need for enhanced guideline support.&#160;Our existing contracted payers, which include Cigna, Priority Health and multiple Blue Cross Blue Shield regional plans, have determined that the analytical validity, clinical validity and clinical utility evidence requirements for medical policy inclusion of our Guardant360 test in NSCLC have been met.  In addition, as of July 1, 2019, our Guardant360 test is a covered benefit for the members of the health plans associated with eviCore, a technology assessment company, as being considered medically necessary to assist in selecting therapy for patients with advanced lung cancer.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we broaden our coverage amongst existing providers to include additional tests, we may begin to experience increases in average revenue per test performed; however, we cannot make any assurances that we will be successful in broadening our coverage on a timely basis or at all.&#160;Similarly, as we have experienced with our existing contracted payers, we cannot assure that the addition of new contracted payers will increase our average selling price or revenue.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to our existing contracted payers, various laboratory benefit managers and national expert opinion organizations who work with these plans have endorsed coverage of our Guardant360 test.&#160;The analytical validity, clinical validity and clinical utility evidence requirements for medical policy inclusion of our Guardant360 test in NSCLC have been met by multiple commercial payers and laboratory benefit managers.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Government payers</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare coverage is limited to items and services that are within the scope of a Medicare benefit category that are reasonable and necessary for the diagnosis or treatment of an illness or injury. National coverage determinations are made through an evidence-based process by CMS, with opportunities for public participation. Medicare&#8217;s NGS NCD (CAG-00450N) provides coverage for molecular diagnostic tests such as our Guardant360 test, if, among other criteria, such tests are offered within their FDA-approved companion diagnostic labeling.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2018, Palmetto GBA, or Palmetto, the MAC responsible for administering MolDx, issued an LCD for the Guardant360 test for NSCLC patients with a date of service on or after August 27, 2018 who meet certain clinical criteria. Noridian Healthcare Solutions, or Noridian, the MAC responsible for adjudicating claims in California, where our laboratory is located, is a participant in MolDx. Noridian published an equivalent LCD that adopts the positive coverage decision from Palmetto in the Noridian jurisdiction, effective as of October 20, 2018. In December 2019, replacing its prior NSCLC patient LCD, Palmetto finalized a new LCD for our Guardant360 test to provide limited Medicare coverage for use of the Guardant360 test for patients diagnosed with solid cancers of non-central nervous system origin. The new LCD requires that patients are recurrent, relapsed, refractory, metastatic, or advanced cancer patients who are seeking further treatment and are potential candidates for an FDA-approved or NCCN-recommended (for Category 1 or 2A level of evidence) biomarker targeted therapy. Additionally, the patient must not have had previous Guardant360 testing and must be untreated or not responding on the patient&#8217;s current therapy. A patient who has previously been tested with the Guardant360 test and has progressed with new malignant growth since the prior test is considered to have a new primary cancer diagnosis and thus is eligible to have another test. Finally, for qualifying cancers other than NSCLC, tissue-based comprehensive genomic profiling must be infeasible for coverage. NSCLC patients would be eligible for coverage if tissue-based testing is infeasible or if previous tissue-based comprehensive genomic profiling returned no actionable results. The new LCD covers our Guardant360 test for fee-for-service Medicare patients with advanced cancers who meet its clinical criteria for complete genomic profiling with next-generation sequencing, or NGS, of tumor tissue to optimize treatment selection decisions but have insufficient or unavailable tissue for molecular profiling. The expanded Medicare coverage decision is in line with FDA approvals of several tumor-agnostic drugs that are based on a single genomic biomarker across all cancers or that are targetable across multiple cancer types. We expect Noridian Healthcare Solutions to issue a new LCD for our Guardant360 test equivalent to the new LCD issued by Palmetto, though the timing and scope of the Noridian LCD are uncertain. We anticipate approval by the FDA, if obtained, may support further improvements in coverage and reimbursement for our Guardant360 test.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under Medicare, payment for laboratory tests like ours is generally made under the Clinical Laboratory Fee Schedule, or CLFS, with payment amounts assigned to specific procedure billing codes. In April 2014, Congress passed the Protecting Access to Medicare Act of 2014, or PAMA, which included substantial changes to the way in which clinical laboratory services are paid under Medicare. On June 23, 2016, CMS published the final rule implementing the reporting and rate-setting requirements under PAMA. Under PAMA, laboratories that receive the majority of their Medicare revenue from payments made under the CLFS were required to report to CMS, beginning in 2017 and every three years thereafter (or annually for &#8220;advanced diagnostic laboratory tests&#8221;), commercial payer payment rates and volumes for each test they perform. CMS uses this data to calculate a weighted median payment rate for each test, which is used to establish revised Medicare CLFS reimbursement rates for the test. As we have begun billing Medicare for our tests, we are subject to reporting requirements under PAMA and the Medicare rate for our tests will be calculated in the future based on our private payer rates. For tests furnished on or after January 1, 2018, Medicare payments for clinical diagnostic laboratory tests are based upon these reported commercial payer rates. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State Medicaid programs make individual coverage decisions for diagnostic tests and have taken steps to control the cost, utilization and delivery of healthcare services.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that additional state and federal health care reform measures may be adopted in the future, any of which could have a material adverse effect on the clinical laboratory industry and our ability to successfully commercialize our tests. Any of these or other changes could substantially impact our revenues and increase costs. We cannot predict how future healthcare policy changes, if any, will affect our business and financial success.  </span></div><div><a id="sEAAB65548EA15FF193E4DD0A888E66A2"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Operations</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We perform the Guardant360 and GuardantOMNI tests in our clinical laboratory located in Redwood City, California. Our laboratory is CAP-accredited, CLIA-certified, NYSDOH-permitted and also licensed in California, Florida, Maryland, Pennsylvania and Rhode Island.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The proprietary validated methods utilize robust semi-automated workflows designed for high throughput sample testing. This methodology allows for rapid scaling of testing volume without impacting performance metrics. These processes allow us to successfully deliver greater than 98% of results successfully. The workflows allow for rapid generation of reports delivering greater than 80% of results within seven calendar days from the day of sample receipt.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Guardant360 testing process includes blood collection, laboratory processing, analysis and reporting. All major processing steps utilize quality control to ensure consistent and reproducible results.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Guardant Health Digital Sequencing Technology</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Guardant Health Digital Sequencing Technology combines state-of-the-art technology from multiple disciplines and is enabled by robust, high-efficiency biochemistry at the front-end, next-generation sequencing and a machine learning augmented bioinformatics pipeline. The technology, through machine learning, has accrued performance improvements by incorporating learnings generated from the data collected from additional samples.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Two specific enhancements achieved by Guardant Health Digital Sequencing Technology are:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">High-efficiency chemistry</span><span style="font-family:inherit;font-size:10pt;">: Overall efficiency of Guardant Health Digital Sequencing in recovery of ctDNA molecules from starting input amount of ctDNA to the post-sequencing analysis of reconstructed molecules indicates the vast majority of extracted ctDNA molecules are converted into a sequencing library, which exceeds most other next-generation sequencing preparations by more than 100%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Error suppression via proprietary bioinformatics engine</span><span style="font-family:inherit;font-size:10pt;">: Error suppression through Guardant Health Digital Sequencing corresponds to a typical error rate of approximately one error per 3,000,000 reconstructed molecule nucleotides of high quality. This should be compared to the simplest single-end sequencing error rate of approximately one error per 1,000 sequenced nucleotides and approximately one error per 100,000 nucleotides that could be achieved by other assays relying on molecular barcoding alone.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Supply chain</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We utilize industry leading vendors for our supply chain. Most reagents and materials are sourced from a limited number of vendors and would require qualification to transition to a different vendor. To mitigate risk, we employ a multi-month, multi-lot safety stock strategy to ensure an uninterrupted supply of reagent and material to our laboratory. In the event that a latent defect is identified, the lot of material in use is expected to be timely quarantined and changed for a new vendor lot that has been previously qualified for use. The experience with our vendors during last five years has provided us confidence in their ability to produce consistent and quality instrumentation, reagents and materials.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2014, we entered into a supply agreement with Illumina, Inc., or Illumina, for Illumina to provide products and services that can be used for certain research and clinical activities, including certain sequencers, equipment and other materials that we use in our laboratory operations. Subsequently, we and Illumina amended the supply agreement to, among other things, update the specific products and services to be provided, and pricing terms therefor, and to extend the initial term of the supply agreement. During the term of the supply agreement, as amended, Illumina will supply us with sequencers, reagents, and other consumables for use with the Illumina sequencers, as well as service contracts for the maintenance and repair of the sequencers. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the term of the supply agreement, as amended, we are required to make a rolling, non-binding forecast of our expected needs for reagents and other consumables, and place purchase orders for reagents and other consumables, and Illumina may not unreasonably reject conforming purchase orders. Subject to discounts that vary depending on the volume of hardware and reagents and other consumables ordered, the price for sequencers and for service contracts is based on Illumina list prices, and the price for reagents and other consumables is based on contract prices that are fixed for a set period of time and may increase thereafter subject to limitations. The supply agreement does not require us to order minimum amounts of hardware, or to use exclusively the Illumina platform for conducting our sequencing. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The supply agreement contains negotiated use limitations, representations and warranties, indemnification, limitations of liability, and other provisions. The initial term of the supply agreement, as amended, continues until December 2021, and the supply agreement automatically renews for additional one-year terms thereafter unless either we or Illumina provide the other with notice of termination one year in advance of the date when such termination is to take effect. Either we or Illumina may terminate the supply agreement for the other&#8217;s uncured material breach, bankruptcy or insolvency-related events, or in the event a regulatory authority notifies such party that continued performance under the supply agreement would violate applicable laws or regulations. </span></div><div><a id="sA74002B830655DDBB5D9A8F5F6F9AB51"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Competition</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Growing understanding of the importance of biomarkers linked with therapy selection and response is leading to more companies offering services in genomic profiling. The promise of liquid biopsy is also leading to more companies attempting to enter the space and compete with us. Our main competition is from diagnostic companies with products and services to profile genes in cancers based on either single-marker or comprehensive genomic profile testing, based on next-generation sequencing in either blood or tissue. </span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our competitors within the liquid biopsy space include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in July 2018, Roche Molecular Systems, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Personal Genome Diagnostics, Inc., Qiagen N.V. and Sysmex Inostics. In addition, GRAIL, Inc. and Natera, Inc., among others, are our competitors in early cancer detection.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Competitors within the broader genomics profiling space based on tissue include laboratory companies such as Bio-Reference Laboratories, Inc., Laboratory Corporation of America and Quest Diagnostics, Inc., as well as companies such as Foundation Medicine, Inc., Caris Life Science and Myriad Genetics, Inc. that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with Guardant360 and GuardantOMNI tests. In addition, we aware that certain of our customers are also developing their own tests and may decide to enter our market or otherwise stop using our tests.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to developing kits, certain diagnostic companies also provide next-generation sequencing platforms that could be used for liquid biopsy testing. These include Illumina, Inc., Thermo Fisher Scientific Inc., and other companies developing next-generation sequencing platforms that are sold directly to biopharmaceutical companies, clinical laboratories and research centers. While many of the applications for these platforms are focused on research and development applications, each of these companies has launched and could continue to commercialize products focused on the clinical oncology market. These tests could include FDA-approved diagnostic kits, which can be sold to the clients who have purchased their platforms. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, many companies are developing information technology-based tools to support the integration of next-generation sequencing testing into the clinical setting. These companies may also use their own tests or others to develop an integrated system which could limit our access to certain networks.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe key competitive factors affecting our success are the price and performance of our products, evidence of clinical differentiation, support by KOLs, commercial competitiveness, turnaround time and scope and quality of payer contracts. Our Guardant Health Oncology Platform has developed strengths across five layers, which we believe form a barrier to entry and a competitive advantage. However, we cannot assure that we will continue to compete effectively on each of those layers.</span></div><div><a id="sB15C116DD4B7546EA91BD96581ECA0A8"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Intellectual property</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Protection of our intellectual property is fundamental to the long-term success of our business. We seek to ensure that investments made into the development of our technology are protected by relying on a combination of patents, trademarks, copyrights, trade secrets (such as know-how), license agreements, confidentiality agreements and procedures, non-disclosure agreements, invention disclosure and assignment agreements and</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">other</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">contractual rights.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our patent strategy is focused on seeking coverage for our core technology, our digital sequencing platform, and specific follow-on applications and implementations for detecting and monitoring cancer or other diseases by determining genetic variations in patient samples. In addition, we file for patent protection on our on-going research and development particularly into early stage cancer detection, including on pattern recognition based, for example, on analyzing our extensive patient blood sample database. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our patent portfolio includes owned and licensed patents and patent applications, generally falling into three broad categories:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Amplitude;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">applications and patents relating to our digital sequencing platform, including claims directed to methods for sequencing cell-free DNA, identifying CNVs, SNVs, indels and fusions in cell-free DNA and techniques for enriching nucleic acid samples;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">applications and patents relating to detecting and monitoring cancer and other diseases by determining genetic variations in biological samples; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">applications and patents relating to early-stage cancer detection.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issued U.S. patents and their international counterparts currently in our patent portfolio that relate to various aspects of our technology and products are expected to expire between 2026 and 2037.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our proprietary technology is also bolstered by our acquisition of, and procurement of licenses to, technologies developed by third parties. While we developed our digital sequencing platform internally, we believe the technologies underlying our licenses from third parties, which typically relate to improvements to next-generation sequencing technologies, are potentially valuable and of possible strategic importance to us or our competitors. Under some of these agreements, we are obligated to pay low single-digit percentage running royalties on net sales where the licensed technology is used in the product or service sold, subject to minimum annual royalties or fees in certain agreements.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our customers and partners recognize us as being a leader in the liquid biopsy field. Thus, just as patent and trade secret protection is essential to protecting our technology, we believe that it is equally as important for us to protect our brand and identity. We have filed for trademark protection in our name, logo and initial products in the United States.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We intend to pursue additional intellectual property protection to the extent we believe it would advance our business objectives. Despite our efforts to protect our intellectual property rights, they may not be respected in the future or may be invalidated, circumvented or challenged. In addition, laws of various foreign countries where our products are or expected to be sold may not protect our intellectual property rights to the same extent as laws in the United States.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also rely on trade secrets, including know-how, unpatented technology and other proprietary information, to maintain and strengthen our competitive position. We have determined that certain technologies, such as aspects of our sample preparation methods and some bioinformatic analysis techniques, are better kept as trade secrets. To mitigate the chance of trade secret misappropriation, it is our policy to</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">enter into nondisclosure and confidentiality agreements with parties who have access to our trade secrets, such as our employees, collaborators, outside scientific collaborators, consultants, advisors and other third parties. We also enter into invention disclosure and assignment agreements with our employees and consultants that obligate them to assign to us any inventions they have developed while working for us.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div><a id="sB3A3F5E82C2B5698A786708A7131BB90"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Government regulations</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Federal and state laboratory licensing requirements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under CLIA, a laboratory is any facility that performs laboratory testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease, or the impairment of or assessment of health. CLIA requires that a laboratory hold a certificate applicable to the type of laboratory examinations it performs and that it complies with, among other things, standards covering operations, personnel, facilities administration, quality systems and proficiency testing, which are intended to ensure, among other things, that clinical laboratory testing services are accurate, reliable and timely. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards. Because we are a CAP accredited laboratory, CMS does not perform this survey and inspection and relies on our CAP survey and inspection. We also may be subject to additional unannounced inspections. Laboratories performing high complexity testing are required to meet more stringent requirements than laboratories performing less complex tests. In addition, a laboratory that is certified as &#8220;high complexity&#8221; under CLIA may develop, manufacture, validate and use proprietary tests referred to as laboratory developed tests, or LDTs. CLIA requires analytical validation including accuracy, precision, specificity, sensitivity and establishment of a reference range for any LDT used in clinical testing. The regulatory and compliance standards applicable to any testing we perform may change over time and any such changes could have a material effect on our business. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory requirements. For example, state laws may require that nonresident laboratories, or out-of-state laboratories, maintain an in-state laboratory license to perform tests on samples from patients who reside in that state. As a condition of state licensure, these state laws may require that laboratory personnel meet certain qualifications, specify certain quality control procedures or facility requirements or prescribe record maintenance requirements. Because our laboratory is located in the State of California, we are required to and do maintain a California state laboratory license. We maintain a current license with NYSDOH for our laboratory. In addition, our laboratory is licensed in a few states where nonresident laboratories are required to obtain state laboratory licenses under certain circumstances, including Florida, Maryland, Pennsylvania and Rhode Island. Other states may currently have or adopt similar licensure requirements in the future, which may require us to modify, delay or stop its operations in those states. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to comply with CLIA certification and state clinical laboratory licensure requirements may result in a range of enforcement actions, including certificate or license suspension, limitation, or revocation, directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions, and revocation of the laboratory&#8217;s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CLIA and state laws and regulations, operating together, sometimes limit the ability of laboratories to offer consumer-initiated testing (also known as &#8220;direct access testing&#8221;). CLIA certified laboratories are permitted to perform testing only upon the order of an &#8220;authorized person,&#8221; defined as an individual authorized under state law to order tests or receive test results, or both. Many states do not permit persons other than licensed healthcare providers to order tests. We currently do not offer direct access testing and our CLIA tests may only be ordered by authorized healthcare providers.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory framework for medical devices in the United States</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to its authority under the Federal Food, Drug and Cosmetic Act, or the FDCA, the FDA has jurisdiction over medical devices, which are defined to include, among other things, in vitro diagnostic devices, or IVDs. The FDA regulates, among other things, the research, design, development, pre-clinical and clinical testing, manufacturing, safety, effectiveness, packaging, labeling, storage, recordkeeping, pre-market clearance or approval, adverse event reporting, marketing, promotion, sales, distribution and import and export of medical devices. Unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute in the United States will require either a premarket notification to the FDA requesting permission for commercial distribution under Section 510(k) of the FDCA, also referred to as a 510(k) clearance, or approval from the FDA of a PMA. Both the 510(k) clearance and PMA processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Device classification</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the FDCA, medical devices are classified into one of three classes-Class I, Class II or Class III-depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the FDA&#8217;s quality system regulation, or QSR, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I products are exempt from the premarket notification requirements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Class II devices are those that are subject to the General Controls, as well as special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification process.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Class III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those deemed novel and not substantially equivalent following the 510(k) process. The safety and effectiveness of Class III devices cannot be reasonably assured solely by the General Controls and special controls described above. Therefore, these devices are subject to the PMA process, which is generally more costly and time-consuming than the 510(k) process. As part of the PMA process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#8217;s satisfaction. Accordingly, a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies. A PMA application must also provide valid scientific evidence that demonstrates to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The investigational device exemption (IDE) process</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the United States, absent certain limited exceptions, human clinical trials intended to support medical device clearance or approval require an IDE application. Some types of studies deemed to present &#8220;non-significant risk&#8221; are deemed to have an approved IDE once certain requirements are addressed and institutional review board, or IRB, approval is obtained. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the sponsor must submit an IDE application to the FDA and obtain IDE approval prior to commencing the human clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. Generally, clinical trials for a significant risk device may begin only after the IDE application is approved by the FDA and the study protocol and informed consent are approved by appropriate IRBs at the clinical trial sites. There can be no assurance that submission of an IDE will result in the ability to commence clinical trials, and although the FDA&#8217;s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not bind the FDA to accept the results of the trial as sufficient to prove the product&#8217;s safety and efficacy, even if the trial meets its intended success criteria.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Such clinical trials must be conducted in accordance with the FDA&#8217;s IDE regulations that govern investigational device labeling, prohibit promotion and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Such clinical trials must also comply with the FDA&#8217;s good clinical practice regulations for IRB approval and for informed consent and other human subject protections. Required records and reports are subject to inspection by the FDA. The results of clinical testing may be unfavorable, or, even if the intended safety and efficacy success criteria are achieved, may not be considered sufficient for the FDA to grant marketing approval or clearance of a product. The commencement or completion of any clinical trial may be delayed or halted, or be inadequate to support approval of a PMA application, for numerous reasons, including, but not limited to, the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patients do not enroll in clinical trials at the rate expected;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patients do not comply with trial protocols;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patient follow-up is not at the rate expected;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patients experience adverse events;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patients die during a clinical trial, even though their death may not be related to the products that are part of the trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">device malfunctions occur with unexpected frequency or potential adverse consequences;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">side effects or device malfunctions of similar products already in the market that change the FDA&#8217;s view toward approval of new or similar PMAs or result in the imposition of new requirements or testing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">institutional review boards and third-party clinical investigators may delay or reject the trial protocol;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">third-party clinical investigators decline to participate in a trial or do not perform a trial on the anticipated schedule or consistent with the clinical trial protocol, investigator agreement, investigational plan, good clinical practices, the IDE regulations or other FDA or IRB requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">third-party investigators are disqualified by the FDA;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent with the clinical trial protocol or investigational or statistical plans, or otherwise fail to comply with the IDE regulations governing responsibilities, records and reports of sponsors of clinical investigations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">third-party clinical investigators have significant financial interests related to us or our study such that the FDA deems the study results unreliable, or the company or investigators fail to disclose such interests;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend or terminate our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in government regulations or administrative actions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the interim or final results of the clinical trial are inconclusive or unfavorable as to safety or efficacy; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA concludes that our trial designs are unreliable or inadequate to demonstrate safety and efficacy.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The 510(k) clearance process</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the 510(k) clearance process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#8220;substantially equivalent&#8221; to a legally marketed predicate device. A predicate device is a legally marketed device that is not subject to a PMA, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was previously found substantially equivalent through the 510(k) process. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After a 510(k) premarket notification is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute, the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the FDA determines that the device is not &#8220;substantially equivalent&#8221; to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous pre-marketing requirements of the PMA approval process, or seek reclassification of the device through the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">de novo</span><span style="font-family:inherit;font-size:10pt;"> process. The </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">de novo </span><span style="font-family:inherit;font-size:10pt;">classification process is an alternate pathway to classify medical devices that are automatically classified into Class III but which are low to moderate risk. A manufacturer can submit a petition for direct </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">de novo</span><span style="font-family:inherit;font-size:10pt;"> review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">De novo </span><span style="font-family:inherit;font-size:10pt;">classification may also be available after receipt of a &#8220;not substantially equivalent&#8221; letter following submission of a 510(k) to FDA. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application. The FDA requires each manufacturer to determine whether the proposed change requires a new submission in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. Many minor modifications are accomplished by a letter-to-file in which the manufacture documents the change in an internal letter-to-file. The letter-to-file is in lieu of submitting a new 510(k) to obtain clearance for such change. The FDA can always review these letters to file in an inspection. If the FDA disagrees with a manufacturer&#8217;s determination regarding whether a new premarket submission is required for the modification of an existing 510(k)-cleared device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA application is obtained. In addition, in these circumstances, the FDA can impose significant regulatory fines or penalties for failure to submit the requisite application(s).</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products.  For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals.  The FDA requested public feedback on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">More recently, in September 2019, the FDA finalized guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA intends to develop and maintain a list device types appropriate for the &#8220;safety and performance based&#8221; pathway and will continue to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The PMA process</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following receipt of a PMA application, the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit a substantive review. If it is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin the review. The FDA has 180 days to review a filed PMA application, although the review of an application more often occurs over a significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided and may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s response to deficiencies communicated by the FDA. </span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Before approving or denying a PMA, an FDA advisory committee may review the PMA at a public meeting and provide the FDA with the committee&#8217;s recommendation on whether the FDA should approve the submission, approve it with specific conditions, or not approve it. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to approval of a PMA, the FDA may conduct inspections of the clinical trial data and clinical trial sites, as well as inspections of the manufacturing facility and processes. Overall, the FDA review of a PMA application generally takes between one and three years but may take significantly longer. The FDA can delay, limit or deny approval of a PMA application for many reasons, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the device may not be shown safe or effective to the FDA&#8217;s satisfaction;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the manufacturing process or facilities may not meet applicable requirements; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in FDA approval policies or adoption of new regulations may require additional data.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. If the FDA&#8217;s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA may also determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the data are available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been sought by other companies have never been approved for marketing.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New PMA applications or PMA supplements are required for modification to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process. PMA supplements often require submission of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support changes from the device covered by a PMA and may or may not require as extensive technical or clinical data or the convening of an advisory panel, depending on the nature of the proposed change.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In approving a PMA application, as a condition of approval, the FDA may require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer term safety and effectiveness data for the device. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as restrictions on labeling, promotion, sale, distribution and use. New PMA applications or PMA supplements may also be required for modifications to approved diagnostic tests, including modifications to manufacturing processes, device labeling and device design, based on the findings of post-approval studies.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">FDA regulation of laboratory developed tests</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the FDA regulates medical devices, including IVDs, the FDA has historically exercised its enforcement discretion and not enforced applicable provisions of the FDCA and FDA regulations with respect to LDTs, which are a subset of IVDs that are intended for clinical use and are developed, validated and offered within a single laboratory for use only in that laboratory. We currently market our Guardant360 test as an LDT and therefore currently do not expect the FDA to enforce its medical device regulations and the applicable FDCA provisions on Guardant360 testing. </span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legislative and administrative proposals addressing oversight of LDTs were introduced in recent years and we expect that new legislative and administrative proposals will be introduced from time to time. It is possible that legislation could be enacted into law or regulations or guidance could be issued by the FDA which may result in new or increased regulatory requirements for us to continue to offer our LDTs or to develop and introduce new tests as LDTs. For example, in 2014 the FDA issued two draft guidance documents proposing a risk-based framework with respect to applying the FDA&#8217;s oversight over LDTs. The Framework Guidance stated that the FDA intended to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the existing classification of medical devices. Thus, we believe the FDA planned to begin to enforce its medical device requirements, including premarket submission requirements, on LDTs that have historically been marketed without FDA premarket review and oversight. In November 2016, the FDA announced its intention not to finalize the 2014 draft guidance to allow for further public discussion on an appropriate oversight approach to LDTs and to give congressional authorizing committees the opportunity to develop a legislative solution. In January 2017, the FDA issued a discussion paper on possible approaches to LDT regulation.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the FDA halted finalization of the guidance in November 2016 to allow for further public discussion on an appropriate oversight approach to LDTs and to give congressional authorizing committees the opportunity to develop a legislative solution, the FDA could ultimately modify its current approach to LDTs in a way that would subject our products marketed as LDTs to the enforcement of regulatory requirements. Moreover, legislative measures have recently been proposed in Congress that, if ultimately enacted, could provide the FDA with additional authority to require premarket review of and regulate LDTs.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research use only or investigational use only devices</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our GuardantOMNI test and LUNAR-1 assay are currently available for research use only, or RUO, or for investigational use only, or IUO, depending on the proposed application. An RUO device is an IVD that is in the laboratory research phase of development. RUO devices must bear prominent labeling stating: &#8220;For Research Use Only. Not for use in diagnostic procedures.&#8221; An IUO device is an IVD that in the product testing phase of development.  An IUO device must bear prominent labeling stating: &#8220;For Investigational Use Only. The performance characteristics of this product have not been established.&#8221; Neither RUO or IUO devices may be used in clinical practice, and such devices cannot be advertised or promoted for clinical or diagnostic purposes. Devices that are intended for RUO or IUO and are properly labeled as RUO or IUO are exempt from compliance with the FDA requirements discussed above, including the approval or clearance and QSR requirements. A device labeled RUO or IUO but intended to be used diagnostically may be viewed by the FDA as adulterated and misbranded under the FDCA and is subject to FDA enforcement activities. The FDA may consider the totality of the circumstances surrounding distribution and use of an RUO or IUO device, including how the device is marketed, when determining its intended use.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">EAP (Expedited Access Program)/Breakthrough Devices Program</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The EAP was a voluntary program for certain medical devices that demonstrate the potential to address unmet medical needs for life threatening or irreversibly debilitating diseases or conditions that are subject to premarket submissions. Under the EAP, the FDA worked with device sponsors to try to reduce the time and cost from development to marketing decision without changing the FDA&#8217;s PMA standard of reasonable assurance of safety and effectiveness or any other standards of valid scientific evidence. Components of the EAP include priority review, more interactive review, senior management involvement, and assignment of a case manager. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the 21st Century Cures Act, the Breakthrough Devices provisions were added to the FDCA. The Breakthrough Devices Program is a voluntary program intended to expedite the review, development, assessment and review of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions for which no approved or cleared treatment exists or that offer significant advantages over existing approved or cleared alternatives. For Breakthrough Devices, the FDA intends to provide interactive and timely communication with the sponsor during device development and throughout the review process. FDA also intends to assign staff to be available within a reasonable time to address questions by institutional review committees concerning the conditions and clinical testing expectations applicable to the investigational use of a Breakthrough Device. In addition, all submissions for devices designated as Breakthrough Devices will receive priority review, meaning that the review of the submission is placed at the top of the appropriate review queue and receives additional review resources, as needed. The Breakthrough Devices Program superseded the EAP and the previous priority review program for medical device submissions. The FDA has indicated that all participants previously granted EAP designation will have designation as breakthrough devices, and that no separate action will necessary for sponsors of EAP-designated devices to receive breakthrough device designation for such devices. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, we received EAP designation from the FDA for our Guardant360 test. In December 2018, we received breakthrough device designation from the FDA for our GuardantOMNI test.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Companion Diagnostics</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For certain of our tests, we are pursuing development as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> companion diagnostics for use in selecting the patients that may respond to our partners&#8217; pharmaceutical products. Companion diagnostics are regulated by the FDA as medical devices. The FDA issued a final guidance document in July 2014 addressing agency policy in relation to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> companion diagnostic tests. The guidance explains that for some drugs and therapeutic biologics, the use of a companion diagnostic test is essential for the safe and effective use of the product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test. According to the guidance, the FDA generally requires the therapeutic product and the companion diagnostic to be developed and approved or cleared contemporaneously. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> companion diagnostic device on issues related to co-development of the products, and in December 2018, FDA issued a draft guidance describing considerations for the development and labeling of in vitro companion diagnostic devices to support the indicated uses of multiple drug or biological oncology products.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pervasive and continuing FDA regulation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After a device enters commercial distribution, numerous regulatory requirements continue to apply. These include:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA&#8217;s QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, production, control, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures during all aspects of the manufacturing process;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">labeling regulations, unique device identification requirements and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">advertising and promotion requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">restrictions on sale, distribution or use of a device;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PMA annual reporting requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PMA approval of product modifications, or the potential for new 510(k) clearances for certain modifications to 510(k)-cleared devices;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">medical device correction and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">recall requirements, including a mandatory recall if there is a reasonable probability that the device would cause serious adverse health consequences or death;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an order of repair, replacement or refund;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">device tracking requirements; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has broad post-market and regulatory enforcement powers. Medical device manufacturers are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions such as: warning letters, fines, injunctions, consent decrees and civil penalties; unanticipated expenditures, repair, replacement, refunds, recall or seizure of our products; operating restrictions, partial suspension or total shutdown of production; the FDA&#8217;s refusal of our requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products; the FDA&#8217;s refusal to issue certificates to foreign governments needed to export products for sale in other countries; and withdrawing 510(k) clearance or premarket approvals that have already been granted and criminal prosecution.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Federal and state fraud and abuse laws</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to federal fraud and abuse laws such as the federal Anti-Kickback Statute, or AKS, the federal Eliminating Kickbacks in Recovery Act, or EKRA, the federal prohibition against physician self-referral, or Stark Law, and the federal false claims law, or the False Claims Act, or FCA. We are also subject to similar state and foreign fraud and abuse laws.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The AKS prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in return for or to induce such person to refer an individual, or to purchase, lease, order, arrange for, or recommend purchasing, leasing or ordering, any good, facility, item or service that is reimbursable, in whole or in part, under a federal healthcare program. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from an AKS violation constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The EKRA prohibits knowingly and willfully soliciting or receiving any remuneration (including any kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for referring a patient or patronage to a laboratory; or paying or offering any remuneration (including any kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, to induce a referral of an individual to a laboratory or in exchange for an individual using the services of that laboratory. The EKRA applies to all payers including commercial payers and government payers, and EKRA violations result in significant fines and/or up to 10 years in jail, separate and apart from existing AKS regulations.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Stark Law and similar state laws, including California&#8217;s Physician Ownership and Referral Act, generally prohibit, among other things, clinical laboratories and other entities from billing a patient or any governmental or commercial payer for any diagnostic services when the physician ordering the service, or any member of such physician&#8217;s immediate family, has a direct or indirect investment interest in or compensation arrangement with us, unless the arrangement meets an exception to the prohibition. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other federal fraud and abuse laws to which we are subject include but are not limited to the federal civil and criminal false claims laws including the FCA, which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government, and the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies. Under the FCA, private citizens can bring claims on behalf of the government through qui tam actions. We must also operate within the bounds of the fraud and abuse laws of the states in which we do business which may apply to items or services reimbursed by non-governmental third-party payers, including private insurers.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Efforts to ensure that our business arrangements with third parties comply with applicable laws and regulations will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Privacy and Security</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the administrative simplification provisions of the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, the U.S. Department of Health and Human Services, or HHS, issued regulations that establish uniform standards governing the conduct of certain electronic healthcare transactions and requirements for protecting the privacy and security of protected health information, or PHI, used or disclosed by covered entities. Covered entities and their business associates are subject to HIPAA and HITECH. Because we are a health care provider that electronically transmits health care information to payers, we are a covered entity under HIPAA. Our subcontractors that create, receive, maintain or transmit or otherwise process PHI on our behalf must also comply with HIPAA as business associates thereunder. </span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HIPAA and HITECH include the privacy and security rules, breach notification requirements and electronic transaction standards. The privacy rule covers the use and disclosure of PHI by covered entities and business associates. The privacy rule generally prohibits the use or disclosure of PHI except as permitted under the rule. The rule also sets forth individual patient rights, such as the right to access or amend certain records containing his or her PHI, or to request restrictions on the use or disclosure of his or her PHI. The security rule requires covered entities and business associates to safeguard the confidentiality, integrity, and availability of electronically transmitted or stored PHI by implementing administrative, physical and technical safeguards. Under HITECH&#8217;s breach notification rule, a covered entity must notify individuals, the Secretary of the HHS, and in some circumstances, the media of breaches of unsecured PHI. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If they are found to be in violation of HIPAA as the result of a breach of unsecured PHI, a complaint about their privacy practices or an audit by HHS, entities may be subject to significant civil and criminal fines and penalties and/or additional reporting and oversight obligations if such entities are required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we may be subject to state health information privacy, security and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. State laws may be more stringent, broader in scope or offer greater individual rights with respect to PHI than HIPAA. California, for example, has enacted the Confidentiality of Medical Information Act, which sets forth standards in addition to HIPAA and HITECH with which all California health care providers like us must abide. In addition, the California Consumer Privacy Act, or the CCPA, was signed into law on June 28, 2018, and went into effect January 1, 2020. The CCPA contains new disclosure obligations for businesses that collect personal information about California residents and affords those individuals new rights relating to their personal information that may affect our ability to use personal information. The CCPA authorizes private lawsuits to recover statutory damages for certain data breaches. Although the CCPA exempts protected health information regulated by HIPAA and certain data regarding clinical trials, the CCPA, to the extent applicable to our business and operations, may increase our compliance costs and potential liability with respect to other personal information we maintain about California residents. The CCPA has substantial penalties for non-compliance and we continue to assess its impact on our business. Complying with these various state laws and regulations, which may differ from state to state, requires significant resources and may complicate our compliance efforts.  Penalties for violation of any of these laws and regulations may include sanctions against a laboratory&#8217;s licensure, as well as civil and/or criminal penalties.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. healthcare reform </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the United States, there have been a number of legislative and regulatory changes at the federal and state levels which seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or the ACA, became law. The ACA substantially changed the way healthcare is financed by both commercial and government payers and contains a number of provisions expected to impact our business and operations, some of which in ways we cannot currently predict, including those governing enrollment in federal and state healthcare programs, reimbursement changes and fraud and abuse.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since its enactment, there have been efforts to repeal all or part of the ACA, and the current Presidential Administration and U.S. Congress have taken action to roll back certain provisions of the ACA. For example, the Tax Cuts and Jobs Act, among other things, removes penalties for not complying with the ACA&#8217;s individual mandate to carry health insurance. On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. It is unclear how these decisions, subsequent appeals, if any, and other efforts to challenge, repeal or replace the ACA will impact the ACA.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional Congressional action is taken. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial payers to reduce costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our tests, the coverage of or the amounts of reimbursement available for our tests from payers, including commercial and government payers.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAA84C3FCD60950FC807290E97AB11AE2"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Employees</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had 622 full-time employees, with 560 in technology, research and development, sales and business development, regulatory and medical affairs, reimbursement and client services, as well as laboratory operations, and 62 in general and administrative functions. Of these full-time employees, 171 work remotely and the remainder work in our headquarters in Redwood City, California. None of our employees is represented by a labor union with respect to his or her employment with us. We consider our relationship with our employees to be good</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Corporate information</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We were incorporated in Delaware in 2011 as Guardant Health, Inc.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Available information</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our website is located at </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">https://guardanthealth.com</span><span style="font-family:inherit;font-size:10pt;">. Our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K, including their exhibits, proxy and information statements, and amendments to those reports filed or furnished pursuant to Sections&#160;13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, are available through the &#8220;Investors&#8221; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form&#160;10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#8217;s Interactive Data Electronic Applications system at </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">http://www.sec.gov.</span><span style="font-family:inherit;font-size:10pt;"> All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB7219C7CCF955064924FDCEFE0E976AB"></a></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A. Risk Factors</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Our operations and financial results are subject to various risks and uncertainties including those described below. You should consider carefully the risks and uncertainties described below, in addition to other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. If any of the following risks or others not specified below materialize, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline.</span></div><div><a id="s12E29F6A39B35595B7836DB79230BD45"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to our business and strategy</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred significant losses since inception, we may continue to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have incurred significant losses since our inception. For the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, we incurred net losses of </span><span style="font-family:inherit;font-size:10pt;">67.9 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">84.3 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">83.2 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">352.8 million</span><span style="font-family:inherit;font-size:10pt;">. To date, we have financed our operations principally from the sale of stock and revenue from precision oncology testing and our development services. We have devoted substantially all of our resources to the development and commercialization of our current products and to research and development activities related to our LUNAR program, including clinical and regulatory initiatives to obtain marketing approval and sales and marketing activities. We will need to generate substantial revenue to achieve and then sustain profitability, and even if we achieve profitability, we cannot be sure that we will remain profitable for any period of time. Our failure to achieve or maintain profitability could negatively impact the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to generate sufficient revenue to achieve and maintain profitability and our current or future products may not achieve or maintain sufficient commercial market acceptance.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently not profitable. Even if we succeed in increasing adoption of our existing products and services by physicians, obtaining additional coverage decisions from commercial and government payers, maintaining and creating relationships with our existing and new biopharmaceutical partners, and developing and commercializing additional products and services, we may not be able to generate sufficient revenue to achieve or maintain profitability.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe our commercial success is dependent upon our ability to continue to successfully market and sell our current products, including our Guardant360 and GuardantOMNI tests, and our future products, to continue to expand our current relationships and develop new relationships with clinicians and biopharmaceutical customers and to develop and commercialize new products based on our Guardant Health Oncology Platform. Our ability to achieve and maintain sufficient commercial market acceptance of our existing and future products will depend on a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to increase awareness of our tests and the benefits of liquid biopsy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the rate of adoption and/or endorsement of our tests by clinicians, KOLs, advocacy groups and biopharmaceutical companies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing and scope of any approval by the FDA for our tests;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain positive coverage decisions for our tests from additional commercial payers and to broaden the scope of indications included in such coverage decisions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain reimbursement and expanded coverage from government payers, including Medicare;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of our investments in product innovation and commercial growth; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">negative publicity regarding ours or our competitors&#8217; products resulting from defects or errors; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to further validate our technology through clinical research and accompanying publications.</span></div></td></tr></table><div><br/></div><div><div style="line-height:144%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:144%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot assure that we will be successful in addressing each of these criteria or other criteria that might affect the market acceptance of our products. If we are unsuccessful in achieving and maintaining market acceptance of our products, our business and results of operations will suffer.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the level of demand for any of our products, which may vary significantly;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our products, which may change from time to time;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the volume and customer mix of our precision oncology testing; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the start and completion of projects in which our development services are utilized;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the introduction of new products or product enhancements by us or others in our industry;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">coverage and reimbursement policies with respect to our products and products that compete with our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expenditures that we may incur to acquire, develop or commercialize additional products and technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in governmental regulations or in the status of our regulatory approvals or applications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">future accounting pronouncements or changes in our accounting policies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developments or disruptions in the business and operations of our clinical, commercial and other partners; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of natural disasters, political and economic instability, including wars, terrorism, and political unrest, epidemics or pandemics, including the current outbreak of novel coronavirus (2019-nCoV), boycotts, curtailment of trade and other business restrictions; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, it is difficult to predict the amount we are able to collect for our tests from commercial payers. We receive reimbursement for our tests from several commercial payers for whom we are not a participating provider. Because we are not contracted with these payers, they determine the amount they are willing to reimburse us for tests. We have provided testing services to patients with many cancer types and indications, most of the time as a non-participating provider through 2019. When we have received payment as a non-participating provider, the amounts, on average, were significantly lower than for participating providers. Even when these payers have paid a claim, they may elect at any time to review previously paid claims and determine the amount they paid was too much. In these situations, the payer will typically notify us of their decision and then offset whatever amount they determine they overpaid against amounts they owe us on current claims. We have limited abilities to dispute these retroactive adjustments and we cannot predict when, or how often, a payer might engage in these reviews. A significant amount of these offsets by one or more payers in any given quarter could have a material effect on our results of operations and cause them to fall below expectations or guidance we may provide. We have sought to become a participating provider of a number of commercial payers; but that effort may not be successful and could be time-consuming and costly. Even when we have obtained positive coverage decisions for our tests from commercial payers&#160;and entered into agreements with them, such agreements typically are standard&#160;form contracts and may allow payers to terminate coverage on short notice, impose significant obligations on us and create additional regulatory and compliance risks and costs for us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of our reimbursement operations, we appeal denials from payers, and if successful, we receive payments from these appeals. However, due to the inherent variability of the insurance landscape, we cannot guarantee future success of, or any payments from, appeals of reimbursement denials by payers. Historic success and payments are not indicative of future success of and payments from such appeals.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cumulative effects of factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New product development and commercialization involve a lengthy and complex process and we may be unable to develop or commercialize new products on a timely basis, or at all.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We launched a CLIA-validated version of our LUNAR-1 assay for research or investigational use, depending on the proposed application of the assay. Products from our LUNAR program have taken time and considerable resources to develop, and we may not be able to complete the development and commercialization of the LUNAR assay or other products from our LUNAR program for clinical use on a timely basis, or at all. There can be no assurance that our LUNAR program will produce commercial products for recurrence detection of cancer or for early detection of cancer. Before we can commercialize any new products, we will need to expend significant funds in order to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conduct substantial research and development, including validation studies and clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">further develop and scale our laboratory processes to accommodate different products; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">further develop and scale our infrastructure to be able to analyze increasingly large amounts of data.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our product development process involves a high degree of risk, and product development efforts may fail for many reasons, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure of the product to perform as expected, including defects and errors; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lack of validation data; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure to demonstrate the clinical utility of the product.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our development plan involves using data and analytical insights generated from our current products as a force multiplier of returns on research and development investment in our LUNAR program. However, if we are unable to generate additional or compatible data and insights, then we may not be able to advance our LUNAR program as quickly, or at all, or without significant additional investment.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we develop products, we have made and will have to make significant investments in product development, marketing and selling resources, including investing heavily in clinical studies, which could adversely affect our future cash flows.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our current revenue is primarily generated from sales of our Guardant360 and GuardantOMNI tests and we are highly dependent on them for our success.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to execute our growth strategy and become profitable is highly dependent on the continued adoption and use of our Guardant360 test and our GuardantOMNI test, which accounted for almost all of our revenue in the years ended December 31, 2018 and 2019. Continued adoption and use of our tests will depend on several factors, including the prices we charge for our tests, the scope of coverage and amount of reimbursement available from third-party payers for our tests, the availability of clinical data that supports the value of our tests and the inclusion of our tests in industry treatment guidelines.&#160;In addition, many biopharmaceutical companies have existing relationships with companies that develop molecular diagnostic tests, including our competitors, and may continue to use their tests instead of ours. Despite our business development efforts, it could be difficult, expensive and/or time-consuming for biopharmaceutical companies to switch diagnostic tests for their products, and our tests may not be widely accepted by biopharmaceutical companies, if at all, which could in turn hinder the growth of sales of our tests. If we are unable to achieve commercial success for our Guardant360 and GuardantOMNI</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">tests, our business, results of operations and financial condition would be materially and adversely affected. We cannot assure that our tests will continue to maintain or gain market acceptance, and any failure to do so would materially harm our business and results of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our products, or our competitors&#8217; liquid biopsy-based products, do not meet the expectations of patients and our customers, our operating results, reputation and business could suffer.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success depends on the market&#8217;s confidence that we can provide reliable, high-quality precision oncology products that will improve clinical outcomes, lower healthcare costs and enable better biopharmaceutical development. We believe that patients, clinicians and biopharmaceutical companies are likely to be particularly sensitive to product defects and errors in the use of our products, including if our products fail to detect genomic alterations with high accuracy from samples or if we fail to list or inaccurately include certain treatment options and available clinical trials in our test reports, and there can be no guarantee that our products will meet their expectations. Furthermore, if our competitors&#8217; liquid-biopsy based products do not perform to expectations, it may result in lower confidence in liquid biopsy-based tests in general. As a result, the failure of our products or our competitors&#8217; products to perform as expected could significantly impair our operating results and our reputation. In addition, we may be subject to legal claims arising from any defects or errors in our products.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to support demand for our current and future products, including ensuring that we have adequate capacity to meet increased demand, or we are unable to successfully manage our anticipated growth, our business could suffer.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As our volume of test sales grows, we will need to continue to increase our workflow capacity for sample intake, customer service, billing and general process improvements, expand our internal quality assurance program and extend our platform to support comprehensive genomic analysis at a larger scale within expected turnaround times. We will need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our precision oncology products. Portions of our process are not automated and will require additional personnel to scale. We will also need to purchase additional equipment, some of which can take several months or more to procure, setup and validate, and increase our software and computing capacity to meet increased demand. There is no assurance that any of these increases in scale, expansion of personnel, equipment, software and computing capacities or process enhancements will be successfully implemented, if at all, or that we will have adequate space in our laboratory facility or be able to secure additional facility space to accommodate such required expansion.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we commercialize additional products, we will need to incorporate new equipment, implement new technology systems and laboratory processes, and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher product costs, declining product quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and could damage our reputation and the prospects for our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our revenue prospects could be reduced.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biopharmaceutical customers collaborate with us for analysis of whole blood or plasma samples for multiple applications primarily to support clinical trials, including patient identification, companion diagnostics and retrospective testing. In the years ended December&#160;31, 2019, 2018 and 2017, revenue from our top five biopharmaceutical customers, including their affiliated entities, accounted for 38.0%, 36.1% and 29.7% of our total revenue, respectively, with AstraZeneca PLC, including its affiliated entities, representing </span><span style="font-family:inherit;font-size:10pt;">26.0%</span><span style="font-family:inherit;font-size:10pt;">, 18.0% and 13.4% of our total revenue, respectively. The revenue attributable to our biopharmaceutical customers may also fluctuate in the future, which could have an adverse effect on our financial condition and results of operations. In addition, the termination of these relationships could result in a temporary or permanent loss of revenue. Adverse speculation about our existing or potential relationships with biopharmaceutical companies may be a catalyst for adverse speculation about us, our products and our technology, which can adversely affect our reputation and business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our future success depends in part on our ability to maintain relationships and to enter into new relationships with biopharmaceutical customers, including offering our platform to such customers for companion diagnostic development, novel target discovery and validation as well as clinical trial enrollment, and growing into other business opportunities. This can be difficult due to many factors, including the type of biomarker support required and our ability to deliver it and our biopharmaceutical customers&#8217; satisfaction with our products or services, internal and external constraints placed on these organizations and other factors that may be beyond our control. Furthermore, our biopharmaceutical customers may decide to decrease or discontinue their use of our current products, including our Guardant360 test and our GuardantOMNI test, or our future products due to changes in their research and product development plans, failures in their clinical trials, financial constraints, or utilization of internal testing resources or tests performed by other parties, or other circumstances outside of our control. Continued usage of our tests by particular biopharmaceutical customers may also depend on whether the partner obtains positive data in its clinical trials, is able to successfully obtain regulatory approval and subsequently commercializes&#160;a therapy for which we have partnered with them to develop a companion diagnostic, or other administrative factors that are outside our control. Some of our biopharmaceutical customers have contracted with us to provide testing for large numbers of samples, which could strain our testing capacity and restrict our ability to perform tests for other customers. Furthermore, biopharmaceutical companies may decline to do business with us or decrease or discontinue their use of our tests due to their broad strategic collaboration with any of our competitors. In addition to reducing our revenue, the loss of one or more of these relationships may reduce our exposure to research and clinical trials that facilitate the collection and incorporation of new information into our platform and tests. We engage in conversations with biopharmaceutical companies regarding potential commercial opportunities on an ongoing basis. There is no assurance that any of these conversations will result in a commercial agreement, that the resulting relationship will be successful, or that clinical trials conducted as part of the engagement will produce successful outcomes. If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our product development could be delayed and revenue and results of operations could be adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our payer concentration may materially adversely affect our financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We receive a substantial portion of our revenue from a limited number of third-party commercial payers, most of which have not contracted with us to be a participating provider.&#160;If one or more of these payers were to significantly reduce, or cease to pay, the amount such payer reimburses us for tests we perform, or if such payer does not reach or maintain favorable coverage and reimbursement decisions for our tests, it could have a material adverse effect on our business, financial condition and results of operations.&#160;We have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made.&#160;If commercial payers were to decide not to include us as a participating provider, cease paying us altogether, drastically reduce the amount they were willing to pay us or attempt to recover any amounts they had already paid, it could cause significant fluctuations in our quarterly results and could harm our business and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, we began to submit claims for Medicare reimbursement for Guardant360 clinical testing, and in October 2018, we began to receive payments from Medicare. Approximately 38.0% of our U.S. clinical tests were for Medicare beneficiaries in each of the years 2019, 2018 and 2017. Revenue attributable to Medicare accounted for more than 10% of our total revenue in the year ended December 31, 2019. Our Medicare reimbursement currently lacks the certainty afforded by a national coverage determination by CMS. In addition, pursuant to CMS regulations, we cannot bill Medicare directly for tests provided for Medicare beneficiaries in some situations. CMS adopted an exception to its laboratory date of service regulation, and if certain conditions are met, molecular testing laboratories such as us can rely on that exception to bill Medicare directly, instead of seeking payment from the hospital. If this exception is repealed or curtailed by CMS, or its laboratory date of service regulation is otherwise changed to adversely impact our ability to bill Medicare directly, our revenue could be materially reduced.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we fail to obtain or maintain coverage and adequate reimbursement from third-party payers, we may be unable to increase our testing volume and revenue as expected. Retrospective reimbursement adjustments, such as deductions from further payments and&#160;clawbacks, can also negatively impact our revenue and cause our financial results to fluctuate. In addition, as part of our reimbursement operations, we appeal denials from payers, and if successful, we receive payments from these appeals. However, due to the inherent variability of the insurance landscape, we cannot guarantee future success of, or any payments from, appeals of reimbursement denials by payers. Historic success and payments are not indicative of future success of and payments from such appeals.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue or to achieve and then sustain profitability.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Growing understanding of the importance of biomarkers linked with therapy selection and response is leading to more companies offering services in genomic profiling. The promise of liquid biopsy is also leading to more companies attempting to enter the space and compete with us. Our main competition is from diagnostic companies with products and services to profile genes in cancers based on either single-marker or comprehensive genomic profile testing, based on next-generation sequencing in either blood or tissue.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our competitors within the liquid biopsy space include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in July 2018, Roche Molecular Systems, Inc., Thermo Fisher Scientific Inc., Illumina, Inc., Personal Genome Diagnostics, Inc., Qiagen N.V. and Sysmex Inostics. In addition, GRAIL, Inc. and Natera Inc., among others, are developing and/or commercializing tests that are competitive with our LUNAR program for early cancer detection. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Competitors within the broader genomics profiling space based on tissue include laboratory companies such as Bio-Reference Laboratories, Inc., Laboratory Corporation of America and Quest Diagnostics, Inc., as well as companies such as Foundation Medicine, Inc., Caris Life Sciences, Inc. and Myriad Genetics, Inc., that sell molecular diagnostic tests for cancer to physicians and have or may develop tests which compete with our Guardant360 and GuardantOMNI tests. In addition, we are aware that certain of our customers are also developing their own tests and may decide to enter our market or otherwise stop using our tests.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of our competitors and potential competitors may have longer operating histories; larger customer bases; greater brand recognition and market penetration; substantially greater financial, technological and research and development resources and selling and marketing capabilities; and more experience dealing with third-party payers. As a result, they may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their tests than we do or sell their tests at prices designed to win significant levels of market share. We may not be able to compete effectively against these organizations. Increased competition and cost-saving initiatives on the part of governmental entities and other third-party payers are likely to result in pricing pressures, which could harm our sales, profitability or ability to gain market share. In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies. Certain of our competitors may be able to secure key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies and devote substantially more resources to product development than we can. In addition, companies or governments that control access to genetic testing through umbrella contracts or regional preferences could promote our competitors or prevent us from performing certain services. If we are unable to compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our tests, which could prevent us from increasing our revenue or achieving profitability and could cause our stock price to decline.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our competitors&#8217; tests could include FDA-approved diagnostic kits, which can be sold to their clients. In addition to developing kits, certain diagnostic companies also provide next-generation sequencing platforms that could be used for liquid biopsy testing. These include Illumina, Inc., Thermo Fisher Scientific Inc. and other companies developing next-generation sequencing platforms that are sold directly to biopharmaceutical companies, clinical laboratories and research centers. While many of the applications for these platforms are focused on research and development applications, each of these companies has launched and will continue to commercialize products and services focused on the clinical oncology market. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, many companies are developing information technology-based tools to support the integration of next-generation sequencing testing into the clinical setting. These companies may also use their own tests or others to develop an integrated system which could limit access for us to certain networks.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The sizes of the markets for our current and future products have not been established with precision, and may be smaller than we estimate.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our estimates of the annual total addressable markets for our current products and products under development in our LUNAR program are based on a number of internal and third-party estimates, including, without limitation, the number of patients with late-stage, solid tumor cancer, the number of individuals who are at a higher risk for developing cancer, and the assumed prices at which we can sell tests for markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current or future products may prove to be incorrect. If the actual number of patients who would benefit from our products, the price at which we can sell our products, or the annual total addressable market for our products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The precision oncology industry is subject to rapid change, which could make our Guardant Health Oncology Platform, our current products and any future products we may develop, obsolete.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements and evolving industry standards, all of which could make our current and future products obsolete. Our future success will depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer. There have also been advances in methods used to analyze very large amounts of molecular information. We must continuously enhance our Guardant Health Oncology Platform and develop new products to keep pace with evolving standards of care. If we do not update our product offerings to reflect new scientific knowledge about cancer biology, information about new cancer therapies or relevant clinical trials, our products could become obsolete and sales of our current products and any new products we may develop could decline or fail to grow as expected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since our inception, we have experienced rapid growth and anticipate further growth in our business operations. Our future growth could create strain on our organizational, administrative and operational infrastructure, including laboratory operations, quality control, customer service and sales organization management. We expect to continue to increase headcount and to hire more specialized personnel as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, laboratory personnel, client and account services personnel, as well as sales and marketing staff, and improve and maintain our technology to properly manage our growth. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in retaining our existing employees, our business may be harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we may not be able to maintain the quality or expected turnaround times of our products, or satisfy customer demand as it grows, and  our business may be harmed. Our ability to manage our growth properly will also require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain and could be demanding, and failure to complete this in a timely and efficient manner could adversely affect our operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have limited experience in marketing and selling our products, and if we are unable to expand our sales organization to adequately address our customers&#8217; needs, our business may be adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have limited experience in marketing and selling our current products, including our Guardant360 and GuardantOMNI tests, and other products we may develop. We may not be able to market, sell or distribute such tests or other products we may develop effectively enough to support our planned growth. We currently sell to clinicians in the United States through our own sales organization and to biopharmaceutical companies through our business development team. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each of our target markets is large, distinctive and diverse. As a result, we believe it is necessary for our sales representatives and business development managers to have established oncology-focused expertise. Competition for such employees within the precision oncology industry is intense. We may not be able to attract and retain personnel or be able to build an efficient and effective sales organization or business development team, which could negatively impact sales and market acceptance of our products and limit our revenue growth and potential profitability.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our expected future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Our future financial performance and our ability to commercialize our products, to increase our sales and to compete effectively will depend, in part, on our ability to manage this potential future growth effectively, without compromising quality.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outside the United States, we established the Joint Venture with SoftBank for sales of our products throughout Asia, the Middle East and Africa. We share a measure of control of the Joint Venture, and if its sales and marketing efforts for our products in those regions are not successful, our business would be materially and adversely affected. In other territories, such as Europe, we sell our tests primarily through distributor relationships or direct contracts with hospitals. Locating, qualifying, engaging and maintaining relationships with distribution partners and hospitals with local industry experience and knowledge will be necessary to effectively market and sell our products outside the United States. We may not be successful in finding, attracting and retaining distribution partners or local hospitals, or we may not be able to enter into such arrangements on favorable terms. Sales practices utilized by any such parties that are locally acceptable may not comply with sales practices standards required under U.S. laws that apply to us, which could create additional compliance risk. If our international sales and marketing efforts are not successful, we may not achieve market acceptance for our products outside the United States, which would materially and adversely impact our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on a limited number of suppliers or, in some cases, sole suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on a limited number of suppliers or, in some cases, sole suppliers, including Illumina Inc., or Illumina, for certain sequencers, reagents, blood tubes and other equipment, instruments and materials that we use in our laboratory operations. An interruption in our laboratory operations could occur if we encounter delays or difficulties in securing these laboratory equipment, instruments or materials, and if we cannot then obtain an acceptable substitute. Any such interruption could significantly and adversely affect our business, financial condition, results of operations and reputation. We rely on Illumina as the sole supplier of the sequencers and as the sole provider of maintenance and repair services for these sequencers. Any disruption in operations of Illumina or other sole or limited suppliers or termination or suspension of our relationships with them could materially and adversely impact our supply chain and laboratory operations of our precision oncology platform and thus our ability to conduct our business and generate revenue. These limited or sole suppliers could engage in diverse types of businesses, including selling products or providing services in competition with us, and there can be no assurance that we can continue to receive required equipment, instruments or materials from them.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that there are only a limited number of other manufacturers that are capable of supplying and servicing the equipment and materials necessary for our laboratory operations, including sequencers and various associated reagents, and potentially replacing our current suppliers. The use of equipment or materials furnished by these replacement suppliers would require us to alter our laboratory operations. Transitioning to a new supplier would be time-consuming and expensive, may result in interruptions in our laboratory operations, could affect the performance specifications of our laboratory operations or could require that we revalidate our tests. There can be no assurance that we will be able to secure alternative equipment, reagents and other materials, bring such equipment, reagents and materials online, and revalidate our tests without experiencing interruptions in our workflow. In the case of an alternative supplier for Illumina, for example, there can be no assurance that replacement sequencers and various associated reagents will be available or will meet our quality control and performance requirements for our laboratory operations. If we should encounter delays or difficulties in securing, reconfiguring or integrating the equipment and reagents we require for our products or in revalidating our products, our business, financial condition, results of operations and reputation could be materially and adversely affected.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our sole laboratory facility becomes damaged or inoperable or we are required to vacate our existing facility, our ability to perform our tests and pursue our research and development efforts may be jeopardized.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently derive the majority of our revenue from tests performed at a single laboratory facility located in Redwood City, California. Our facility and equipment could be harmed or rendered inoperable by natural or man-made disasters, including war, fire, earthquake, power loss, communications failure or terrorism, which may render it difficult or impossible for us to operate our Guardant Health Oncology Platform for some period of time. The inability to perform our tests or to reduce the backlog that could develop if our facility is inoperable, for even a short period of time, may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation. Furthermore, our facility and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facility, to locate and qualify a new facility or enable a third party to practice our proprietary technology, particularly in light of licensure and accreditation requirements. Even if we are able to find a third party with such qualifications to perform our tests, the parties may be unable to agree on commercially reasonable terms.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We carry insurance for damage to our property and disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our facility and business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The loss of any member of our senior management team or our inability to attract and retain highly skilled scientists, clinicians, sales representatives and business development managers could adversely affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success depends on the skills, experience and performance of key members of our senior management team, including Helmy Eltoukhy, our Chief Executive Officer, and AmirAli Talasaz, our President and Chief Operating Officer and the chairman of our board of directors. The individual and collective efforts of these employees will be important as we continue to develop our platform and additional products, and as we expand our commercial activities. The loss or incapacity of existing members of our executive management team could adversely affect our operations if we experience difficulties in hiring qualified successors. Our executive officers signed offer letters when first joining our company, but do not have employment agreements, and we cannot guarantee their retention for any period of time. We do not maintain &#8220;key person&#8221; insurance on any of our employees.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our research and development programs and laboratory operations depend on our ability to attract and retain highly skilled scientists and technicians. We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses, particularly near our headquarters in Redwood City, California. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. In addition, we may have difficulties locating, recruiting or retaining qualified sales representatives and business development managers. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we were to be sued for product liability or professional liability, we could face substantial liabilities that exceed our resources.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The marketing, sale and use of our products could lead to the filing of product liability claims were someone to allege that our products identified inaccurate or incomplete information regarding the genomic alterations of the tumor or malignancy analyzed, reported inaccurate or incomplete information concerning the available therapies for a certain type of cancer, or otherwise failed to perform as designed. We may also be subject to professional liability for errors in, a misunderstanding of, or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability or professional liability lawsuit could damage our reputation or cause current clinical customers to terminate existing agreements with us and potential clinical customers to seek other partners, any of which could adversely impact our results of operations. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are exposed to risks associated with our joint venture with SoftBank, and may not realize the advantages we expect from it.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a 50% ownership interest in the Joint Venture, Guardant Health AMEA, Inc., we formed with SoftBank in May 2018 to accelerate the commercialization of our products in Asia, the Middle East and Africa, with a near-term focus on Japan. However, the Joint Venture may not be successful in the timeframe we expect, or at all.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, SoftBank shares a measure of control over the operations of the Joint Venture. As a result, our investment in our joint venture involves risks that are different from the risks involved in owning facilities and operations independently. These risks include the possibility that our joint venture or SoftBank has economic or business interests or goals that are or become inconsistent with our economic or business interests or goals; is in a position to take action contrary to our instructions, requests, policies or objectives; subjects us to unexpected liabilities; takes actions that reduce our return on investment; or takes actions that harm our reputation or restrict our ability to run our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The joint venture agreement between us and SoftBank includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. SoftBank will have a put right to cause us to purchase all shares of the Joint Venture held by SoftBank and its affiliates, and we will have a call right to purchase all such shares in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#8217;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of our initial public offering, a change in control, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within 20 business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#8217;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which may result in the fair value of Softbank&#8217;s interest in the Joint Venture being determined to be materially different from what has been recorded in our consolidated financial statements, including those included elsewhere in this Annual Report on Form 10-K. We may pay the purchase price for those shares in cash (including in the form of a promissory note), in shares of our common stock, or in a combination thereof. In the event SoftBank exercises its put right, we will choose the form of consideration. In the event we exercise our call right, SoftBank will choose the form of consideration. If we are required or choose to purchase those shares from SoftBank, we could experience significant cash outflow, our other stockholders could see their holdings diluted, and our financial condition and the price of our common stock&#160;may be adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may acquire businesses, form joint ventures or make investments in companies or technologies that could negatively affect our operating results, distract management&#8217;s attention from other business concerns, dilute our stockholders&#8217; ownership, and significantly increase our debt, costs, expenses, liabilities and risks.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have made acquisitions of businesses, technologies and assets and may pursue additional acquisitions in the future. We also may pursue strategic alliances and additional joint ventures that leverage our Guardant Health Oncology Platform and industry experience to expand our product offerings or distribution. We have limited experience with acquisitions and forming strategic partnerships. We compete for those opportunities with others including our competitors, some of which have greater financial or operational resources than we do. We may not be able to identify suitable acquisition candidates or strategic partners, we may have inadequate access to information or insufficient time to complete due diligence, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Difficulties in assimilating acquired businesses include redeployment or loss of key employees and their severance, combination of teams and processes in various functional areas, reorganization or closures of facilities, relocation or disposition of excess equipment, and increased litigation, regulatory and compliance risks, any of which could be expensive and time consuming and adversely affect us. Integration of an acquired business also may disrupt our ongoing operations and require management resources that we would otherwise focus on developing our existing business. In addition, any acquisition could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our financial condition, results of operations and cash flows. We may also experience losses related to investments in other companies, which could have a material negative effect on our results of operations and financial condition. We may not realize the anticipated benefits of any acquisition, technology license, strategic alliance or joint venture.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To finance any acquisitions, joint ventures or investments, we may choose to issue shares of our common stock as consideration, which would dilute the ownership of our stockholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have limited international operations, but our business strategy incorporates potentially significant international expansion, including through the Joint Venture with SoftBank, which we formed to accelerate the commercialization of our products in Asia, the Middle East and Africa, with a near-term focus on Japan.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We plan to maintain distributor relationships, to conduct physician and patient association outreach activities, to extend laboratory capabilities and to expand payer relationships, outside of the United States, both directly and through our joint venture. Doing business internationally involves a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, economic sanctions and embargoes, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure by us, our distributors, our local partners or the Joint Venture with SoftBank to obtain regulatory approvals for the use of our products in various countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">additional potentially blocking or relevant third-party patent or other intellectual property rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">complexities and difficulties in obtaining intellectual property protection and enforcing our intellectual property;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">difficulties in staffing and managing foreign operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">complexities associated with managing multiple payer reimbursement regimes, government payers, or patient self-pay systems;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">logistics and regulations associated with shipping blood samples, including infrastructure conditions and transportation delays;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limits in our ability to penetrate international markets if we are not able to perform our tests locally;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations, currency controls and cash repatriation restrictions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">natural disasters, political and economic instability, including wars, terrorism, and political unrest, boycotts, curtailment of trade and other business restrictions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">public health or similar issues, such as epidemics or pandemics, including the current outbreak of novel coronavirus (2019-nCoV), for which the World Health Organization declared a global emergency on January 30, 2020, that could cause business disruption for the Joint Venture, including the Joint Venture&#8217;s offices in Japan and Singapore, and make it more difficult to sell our tests in the affected countries or regions, many of which are in the JV Territory, and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, or FCPA, its books and records provisions, or its anti-bribery provisions.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We could be adversely affected by violations of the FCPA and other anti-bribery laws.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International customers may currently order our Guardant360 and GuardantOMNI tests, either directly from us or through the Joint Venture with SoftBank, and we are subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. Our reliance on independent distributors to sell our Guardant360 and GuardantOMNI tests internationally demands a high degree of vigilance in maintaining our policy against participation in corrupt activity, because these distributors could be deemed to be our agents and we could be held responsible for their actions. Other U.S. companies in the medical device and biopharmaceutical field have faced criminal penalties under the FCPA for allowing their agents to deviate from appropriate practices in doing business with these individuals. We are also subject to similar anti-bribery laws in the jurisdictions in which we operate, including the United Kingdom&#8217;s Bribery Act of 2010, which also prohibits commercial bribery and makes it a crime for companies to fail to prevent bribery. These laws are complex and far-reaching in nature, and, as a result, we cannot assure that we would not be required in the future to alter one or more of our practices to be in compliance with these laws or any changes in these laws or the interpretation thereof. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, cause us to incur significant costs and expenses, including legal fees, and result in a material adverse effect on our business, prospects, financial condition and results of operations. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA, CMS and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We currently have a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and our code of conduct and the other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations, lawsuits or other actions stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, monetary fines, individual imprisonment, disgorgement of profits, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs or from coverage of commercial payers, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law and curtailment or restructuring of our operations, which could have a significantly adverse impact on our business. Whether or not we are successful in defending against such actions, we could incur substantial costs and expenses, including legal fees, and divert the attention of management from the operation of our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may need to raise additional capital to fund our existing operations, develop our platform, commercialize new products or expand our operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on our current business plan, we believe our current cash, cash equivalents and marketable securities and anticipated cash flow from operations, will be sufficient to meet our anticipated cash requirements over at least the next 12 months from the date of this Annual Report on Form 10-K. If our available cash balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements including because of lower demand for our products, lower than currently expected rates of reimbursement from commercial third-party payers and government payers or other risks described in this Annual Report on Form 10-K, we may seek to sell equity or convertible securities, enter into a credit facility or another form of third-party funding, or seek other debt financing.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may consider raising additional capital in the future to expand our business, to meet existing obligations, to pursue acquisitions or strategic investments, to take advantage of financing opportunities or for other reasons, including to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increase our sales and marketing efforts to drive market adoption of our current products, including our Guardant360 and GuardantOMNI tests, and address competitive developments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fund development and marketing efforts of products from our LUNAR program or any other future products we may develop;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expand our technologies into other types of cancer management and detection products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acquire, license or invest in technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acquire or invest in complementary businesses or assets; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">finance capital expenditures and general and administrative expenses.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our present and future funding requirements will depend on many factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to achieve revenue growth;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our rate of progress in establishing payer coverage and reimbursement arrangements with domestic and international commercial payers and government payers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of expanding our laboratory operations and product offerings, including our sales and marketing efforts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our rate of progress in, and costs of our sales and marketing activities associated with, establishing adoption of and reimbursement for our current products, including our Guardant360 and GuardantOMNI tests;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our rate of progress in, and costs of our research and development activities associated with, products in research and early development;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effect of competing technological and market developments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">costs related to our international expansion; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential costs of and delays in product development as a result of any existing or new regulatory oversight applicable to our products.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity or convertible securities, dilution to our stockholders could result. Any preferred equity securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products or grant licenses on terms that are not favorable to us. These alternatives of raising additional capital may not be available to us on acceptable or commercially reasonable terms, if at all, or in amounts sufficient to meet our needs. The failure to obtain any required future financing may require us to reduce or curtail existing operations and could contribute to negative market perceptions about us or our securities.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on third parties for the collection of blood samples for our tests.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on third-party phlebotomy providers, including physician offices, to collect blood samples for our tests. Our current third-party phlebotomy providers may refuse to continue to collect samples for us in the future, in particular if they have agreements or arrangements with one of our competitors to collect samples for their tests, or if the phlebotomy provider is owned or controlled by a laboratory that offers tests that compete with ours. There has been a trend towards consolidation of independent phlebotomy providers. Independent phlebotomy providers, once acquired by our competitors, may terminate their relationships with us. If our patients are unable to readily access a phlebotomy provider to collect a blood sample for our tests, we may be unable to compete effectively with other laboratories that have greater access to phlebotomy providers and our business, financial condition and results of operations may be harmed.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, if third-party phlebotomy providers fail to adequately and properly obtain and collect viable blood samples from patients and to properly package and ship the samples to us, our patients and their physicians may experience problems and delays in receiving test results, which could lead to dissatisfaction with our tests, therefore harming our reputation and adversely affecting our business, financial condition and results of operations. Similarly, our contracts with third-party phlebotomy providers to collect blood could be scrutinized under federal and state healthcare laws such as the federal Anti-Kickback Statute, or AKS, and the federal law prohibiting physician self-referral, or Stark Law, to the extent these services to us are deemed to provide a financial benefit to or relieve a financial burden for a potential referral source, or are subsequently found not to be for fair market value. If our operations are found to be in violation of any of these laws and regulations, we may be subject to administrative, civil and criminal penalties, damages, fines, individual imprisonment, exclusion from participation in federal healthcare programs or from coverage of commercial payers, refunding of payments received by us, and curtailment or cessation of our operations, any of which could harm our reputation and adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on commercial courier delivery services to transport samples to our laboratory facility in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business depends on our ability to quickly and reliably deliver test results to our customers. Blood samples are typically received within days from the United States and outside the United States for analysis at our Redwood City, California facility. Disruptions in delivery services to transport samples to that facility, whether due to labor disruptions, bad weather, natural disaster, terrorist acts or threats or for other reasons could adversely affect specimen integrity and our ability to process samples in a timely manner, delay our provision of test results to our customers, and ultimately our reputation and our business. In addition, if we are unable to continue to obtain expedited delivery services to transport samples to us on commercially reasonable terms, our operating results may be adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have incurred net losses since our inception and we may never achieve or sustain profitability. Generally, losses incurred will carry forward until such losses expire (for losses generated prior to January 1, 2018) or are used to offset future taxable income, if any. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the IRC, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss, or NOL, carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have not completed a study to assess whether an ownership change for purposes of Section 382 or 383 has occurred, or whether there have been multiple ownership changes since our inception. For purposes of Section 382 or 383, we may have experienced ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset such taxable income will be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. Therefore, if we attain profitability, we may be unable to use a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows. In addition, the Tax Cuts and Jobs Act of 2017 imposes a reduction to the maximum deduction allowed for NOLs generated in tax years beginning after December 31, 2017, but allow such NOLs to be carried forward indefinitely. These changes may adversely affect our future cash flow.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We depend on information technology systems, and any failure of these systems could harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We depend on information technology and telecommunications systems for significant elements of our operations, including our laboratory information management system, our computational biology system, our knowledge management system, our customer reporting and our GuardantConnect software platform. We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including for example, systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations. In addition to the aforementioned business systems, we intend to extend the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design and the automatic countermeasure operations of our technical systems. These information technology and telecommunications systems support a variety of functions, including laboratory operations, test validation, sample tracking, quality control, customer service support, billing and reimbursement, research and development activities, scientific and medical curation and general administrative activities. In addition, our third-party provider of billing and collections services for late-stage clinical testing in the United States depends upon technology and telecommunications systems provided by its outside vendors.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. For example, in the past year, we identified security incidents involving an unauthorized actor obtaining access to our email system and sending phishing messages.  Despite the precautionary measures we have taken in response to such incidents and to prevent other unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of our information technology or telecommunications systems or those used by our third-party service providers could prevent us from performing our comprehensive genomic analysis, preparing and providing reports to pathologists and oncologists, billing payers, processing reimbursement appeals, handling patient or physician inquiries, conducting research and development activities and managing the administrative aspects of our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and our reputation, and we may be unable to regain or repair our reputation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite the security and maintenance measures we and our vendors and distributors have in place to help protect against system failures, our systems, and those of our vendors and distributors, remain vulnerable to delays, disruptions, data corruption, programming and/or human errors or other similar events, such as those due to system updates, natural disasters, malicious attacks, accidents, power disruptions, telecommunications failures, acts of terrorism or war, computer viruses, physical or electronic break-ins or similar events. Such incidents may disrupt our operations, result in losses, damage our reputation, and expose us to the risks of litigation and liability (including regulatory liability); and may have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s6393C6B2C4DC5FAFBC2D135C44123DDF"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to our highly regulated industry</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We conduct business in a heavily regulated industry, and changes in regulations or violations of regulations may, directly or indirectly, reduce our revenue, adversely affect our results of operations and financial condition, and harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The clinical laboratory testing industry is highly regulated, and there can be no assurance that the regulatory environment in which we operate will not change significantly and adversely to us in the future. Areas of the regulatory environment that may affect our ability to conduct business include, without limitation:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal and state laws applicable to test ordering, documentation of tests ordered, billing practices and claims payment and/or regulatory agencies enforcing those laws and regulations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal and state health care fraud and abuse laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal and state laboratory anti-mark-up laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">coverage and reimbursement levels by Medicare, Medicaid, other governmental payers and private insurers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">restrictions on coverage of and reimbursement for tests;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal and state laws governing laboratory testing, including CLIA, and state licensing laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal and state laws and enforcement policies governing the development, use and distribution of diagnostic medical devices, including laboratory developed tests, or LDTs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal, state and local laws governing the handling and disposal of medical and hazardous waste; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal and state Occupational Safety and Health Administration rules and regulations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, and similar state data privacy and security laws.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In particular, the laws and regulations governing the marketing of clinical laboratory tests are extremely complex, and in many instances, there are no sufficient regulatory or judicial interpretations of these laws and regulations. For example, some of our clinical laboratory tests are, or may in the future be, actively regulated by the FDA pursuant to the medical device provisions of the Federal Food, Drug and Cosmetic Act, or FDCA. The FDA defines a medical device to include </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including a component, part or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease, in man or other animals. Our clinical laboratory tests are in vitro diagnostic products that are considered by the FDA to be medical devices. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, design, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion and sales and distribution of medical devices in the United States to ensure that medical devices distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the import and export of medical devices. If we do not comply with these requirements or later become subject to these requirements and fail to adequately comply, our business may be harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain of our tests are currently marketed as LDTs, and future changes in FDA enforcement discretion for LDTs could subject our operations to much more significant regulatory requirements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has a policy of enforcement discretion with respect to LDTs whereby the FDA does not actively enforce its regulatory requirements for such tests. However, the FDA has stated its intention to modify its enforcement discretion policy with respect to LDTs. If there are changes in FDA policy, or if the FDA disagrees that we are marketing our tests as LDTs within the scope of its policy of enforcement discretion, we may become subject to extensive regulatory requirements and may be required to stop selling our existing tests or launching any other tests we may develop and to conduct additional clinical trials or take other actions prior to continuing to market our tests. This could significantly increase the costs and expenses of conducting, or otherwise harm, our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently market our Guardant360 test as an LDT and may in the future market our other tests as LDTs. While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA, we cannot assure that the FDA will agree with our determination. A determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations and financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 31, 2014, the FDA notified Congress of its intent to modify, in a risk-based manner, its policy of enforcement discretion with respect to LDTs. On October 3, 2014, FDA issued two draft guidances, entitled &#8220;Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs),&#8221; or the Framework Guidance, and &#8220;FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs).&#8221; The Framework Guidance stated that the FDA intended to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the existing classification of medical devices. Thus, pursuant to the Framework Guidance, the FDA planned to begin to enforce its medical device requirements, including premarket submission requirements, on LDTs that have historically been marketed without FDA premarket review and oversight. Although the FDA halted finalization of the guidance in November 2016 to allow for further public discussion on an appropriate oversight approach to LDTs and to give congressional authorizing committees the opportunity to develop a legislative solution, the FDA could ultimately modify its current approach to LDTs in a way that would subject our products marketed as LDTs to the enforcement of regulatory requirements. If and when such changes to the regulatory framework occur, we could for the first time be subject to enforcement of regulatory requirements as a device manufacturer such as registration and listing requirements, medical device reporting requirements and the requirements of the FDA&#8217;s Quality System Regulation. Additionally, if and when the FDA begins to actively enforce its premarket submission regulations with respect to LDTs, we may be required to obtain premarket clearance or approval for our Guardant360 test and other products we plan to commercialize as LDTs. Moreover, legislative measures have recently been proposed in Congress that, if ultimately enacted, could provide the FDA with additional authority to require premarket review of and regulate LDTs.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">There is no guarantee that the FDA will grant 510(k) clearance or a premarket approval of our products and failure to obtain necessary clearances or approvals for our products would adversely affect our ability to grow our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Before we begin to label and market our products for use as clinical diagnostics in the United States, including as companion diagnostics, we may be required to obtain either 510(k) clearance or a premarket approval, or PMA, from the FDA, unless an exemption applies or FDA exercises its enforcement discretion and refrains from enforcing its medical device requirements. For example, the FDA has a policy of refraining from enforcing such requirements with respect to LDTs, which the FDA considers to be a type of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro </span><span style="font-family:inherit;font-size:10pt;">diagnostic test that is designed, manufactured and used within a single laboratory. Although we currently market Guardant360 test as an LDT pursuant to FDA&#8217;s policy of enforcement discretion, we could pursue clearances or approvals from the FDA for our Guardant360 and other tests, including future products we may develop. For example, in the fourth quarter of 2019, we submitted a premarket approval, or PMA, application to seek the FDA&#8217;s approval of our Guardant360 test to be used as a companion diagnostic, initially in connection with one therapeutic product of a biopharmaceutical customer, and to provide tumor mutation profiling for cancer patients with solid tumors. In February 2020, we submitted an additional module of the PMA application for our Guardant360 test to the FDA.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The process of obtaining a PMA is much more rigorous, costly, lengthy and uncertain than the 510(k) clearance process. In the PMA process, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. In the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, in order to clear the proposed device for marketing. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support a substantial equivalence determination.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA&#8217;s 510(k) clearance process usually takes from three to twelve&#160;months from submission, but may last longer. The process of obtaining a PMA generally takes from one to three years, or even longer, from the time the PMA is submitted to the FDA until an approval is obtained. Any delay or failure to obtain necessary regulatory approvals or clearances would have a material adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our inability to demonstrate to the satisfaction of the FDA that our products are safe or effective for their intended uses;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the disagreement of the FDA with the design, conduct or implementation of our clinical trials or the analysis or interpretation of data from our pre-clinical studies or clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">serious and unexpected adverse effects experienced by participants in our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our inability to demonstrate that the clinical and other benefits of any of our tests outweigh the risks;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an advisory committee, if convened by the FDA, may recommend against approval of our PMA or other application for any of our tests or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the FDA may still not approve the test;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA may identify deficiencies in our marketing application, and in our manufacturing processes, facilities or analytical methods or those of our third-party contract manufacturers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential for approval policies or regulations of the FDA to change significantly in a manner rendering our clinical data or regulatory filings insufficient for the clearance or approval; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA may audit our clinical trial data and conclude that the data is not sufficiently reliable to support a PMA application.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are unable to obtain clearance or approval for any tests for which we plan to seek clearance or approval, our business may be harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Modifications to our FDA-cleared or approved products may require new 510(k) clearances or premarket approvals, or may require us to cease marketing or recall the modified products until clearances are obtained.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For any product approved pursuant to a PMA, we are required to seek supplemental approval for many types of changes to the approved product, for which we will need to determine whether a PMA supplement or other regulatory filing is needed or whether the change may be reported via the PMA Annual Report. Similarly, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design, or manufacture, requires new 510(k) clearance or, possibly, approval of a new PMA. The FDA requires us to make this determination in the first instance, but the FDA may review and may not agree with our determination. If the FDA disagrees with our determination and requires us to seek approvals or clearances for modifications to our previously approved or cleared products, for which we concluded that new approvals or clearances are unnecessary, we may be required to cease marketing or distribution of our products or to recall the modified product until we obtain the approval or clearance, and we may be subject to significant regulatory fines or penalties.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If third-party payers, including commercial payers and government healthcare programs, do not provide coverage of, or adequate reimbursement for, our tests, our business and results of operations will be negatively affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our revenue and commercial success depend on achieving broad coverage and reimbursement for our tests from payers, including both commercial and government payers. If payers do not provide coverage of, or do not provide adequate reimbursement for, a substantial portion of our tests, we may need to seek payment from the patient, which may adversely affect demand for our tests. Coverage determinations by a payer may depend on a number of factors, including but not limited to a payer&#8217;s determination that a test is appropriate, medically necessary or cost-effective. If we are unable to provide payers with sufficient evidence of the clinical utility and validity of our test, they may not provide coverage, may provide limited coverage or may terminate coverage, which will adversely affect our revenues and our financial condition. To the extent that more competitors enter our markets, the availability of coverage and the reimbursement rate for our tests may decrease as we encounter pricing pressure from our competitors.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each payer makes its own decision as to whether to provide coverage for our tests, whether to enter into a contract with us and how much it will reimburse for a test. Negotiating with payers could be a time-consuming and costly process, and payers often insist on their standard form contracts, which typically contain requirements that apply to ordering physicians. There is no guarantee that a payer will provide adequate coverage or reimbursement for our tests or that we can reach an agreement with the payer on reasonable terms without being subject to additional regulatory and compliance risks. In addition, the determination by a payer to cover or not cover our tests and the amount it will reimburse for them are often made on an indication-by-indication basis. In cases where there is no coverage, or we do not have a contracted rate for reimbursement as a participating provider, with the payer, the patient is typically responsible for a greater share of the cost of the test, which may result in further delay of our revenue, increase our collection costs or decrease the likelihood of collection. We maintain a financial assistance program, the Guardant Access Fee Assistance Program, under which we provide tests without charge or at a significant discount to certain patients meeting income based eligibility standards. This may result in payers requiring us to prove eligibility of such patients to pay no or reduced test fees, and if the payers disagree with such eligibility, they may recoup amounts previously paid for such tests, terminate coverage or seek to renegotiate the rate for reimbursement.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our claims for reimbursement from payers may be denied upon submission, and we may need to take additional steps to receive payment, such as appealing the denials. Such appeals and other processes are time-consuming and expensive and may not result in payment. Payers may perform audits of historically paid claims and attempt to recoup funds years after the funds were initially distributed if the payers believe the funds were paid in error or determine that our tests were medically unnecessary. If a payer audits our claims and issues a negative audit finding, and we are not able to overturn the audit findings through appeal, the subsequent recoupment may result in a material adverse effect on our revenue. Additionally, in some cases commercial payers for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was excessive. In these situations, the payer typically notifies us of its decision and then offsets the amount it determines to be overpaid against amounts it owes us on current claims. We do not have a mechanism to dispute these retroactive adjustments, and we cannot predict when, or how often, a payer might engage in these reviews.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our test and, potentially, no reimbursement for non-covered uses identified under the payer&#8217;s policies or the contract. As a result, the potential for more favorable reimbursement associated with becoming a participating provider may be offset by a potential loss of reimbursement for non-covered uses of our tests.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we are a participating provider with some commercial payers, including Cigna, Priority Health, multiple Blue Cross Blue Shield regional plans as well as the health plans associated with eviCore, certain large, national commercial payers, including Anthem, Aetna and Humana, have issued non-coverage policies that treat both tissue and liquid CGP testing, including our Guardant360 test, as experimental or investigational. If we are not successful in obtaining coverage from such payers, including in reversing their existing non-coverage policies, or if other payers issue similar non-coverage policies, our business and results of operations could be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare&#8217;s National Coverage Determination, or NCD, for Next Generation Sequencing, or NGS, established in 2018 and subsequently updated in 2020 states that NGS tests, such as our Guardant360 test, are covered by Medicare nationally, when: (1) performed in a CLIA-certified laboratory, (2) ordered by a treating physician, (3) the patient meets certain clinical and treatment criteria, including having recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer, (4) the test is approved or cleared by the FDA as a companion in vitro diagnostic for an FDA approved or cleared indication for use in that patient&#8217;s cancer, and (5) results are provided to the treating physician for management of the patient using a report template to specify treatment options. The NGS NCD also states that each Medicare Administrative Contractor, or MAC, may provide local coverage of other next-generation sequencing tests for cancer patients only when the test is performed by a CLIA-certified laboratory, ordered by a treating physician and the patient meets the same clinical and treatment criteria required of nationally covered next-generation sequencing tests under the NGS NCD. An NGS test is not covered by Medicare when cancer patients do not have the above-noted indications for cancer under either national or local coverage criteria. In July 2018, Palmetto GBA, the MAC responsible for administering Medicare&#8217;s Molecular Diagnostic Services Program, or MolDx, issued a local coverage determination, or LCD, for our Guardant360 test for non-small cell lung cancer, or NSCLC, patients who meet certain clinical and treatment criteria. Noridian Healthcare Solutions, the MAC responsible for adjudicating claims in California, where our laboratory is located, and a participant in MolDx, recently finalized its LCD for our Guardant360 test. Pursuant to this Noridian LCD, in September 2018, we began to submit claims to Medicare for reimbursement for Guardant360 clinical testing performed for NSCLC patients covered under the LCD who meet certain clinical criteria, and in October 2018, we began to receive payments for these services from Medicare for these clinical tests. In December 2019, replacing its prior NSCLC patient LCD, Palmetto GBA finalized a new LCD for our Guardant360 test that provides limited Medicare coverage for the Guardant360 test in patients diagnosed with solid cancers of non-central nervous system origin. We expect Noridian Healthcare Solutions to issue a new LCD for our Guardant360 test equivalent to the new LCD issued by Palmetto GBA, though the timing and scope of the Noridian LCD are uncertain. We may not be able to obtain reimbursement under the expanded Noridian LCD until it is finalized and Noridian completes certain administrative steps.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under Medicare, payment for laboratory tests like ours is generally made under the Clinical Laboratory Fee Schedule, or CLFS, with payment amounts assigned to specific procedure billing codes. In April 2014, Congress passed the Protecting Access to Medicare Act of 2014, or PAMA, which included substantial changes to the way in which clinical laboratory services are paid under Medicare. Under PAMA, laboratories that receive the majority of their Medicare revenue from payments made under the CLFS are generally required to report to CMS, beginning in 2017 and every three years thereafter (or annually for &#8220;advanced diagnostic laboratory tests&#8221;), private payer payment rates and volumes for each test they perform. CMS uses this data to calculate a weighted median payment rate for each test, which is used to establish revised Medicare CLFS reimbursement rates for the test. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. As we have begun billing Medicare for our tests, we are subject to reporting requirements under PAMA and the Medicare rate for our tests will be calculated in the future based on our private payer rates. For clinical diagnostic laboratory tests furnished on or after January 1, 2018, their Medicare CLFS reimbursement rates are established upon these reported private payer rates. If we are unable to obtain and maintain favorable reimbursement rates from commercial payers for our tests, this may adversely affect the tests&#8217; Medicare reimbursement rates. We believe that our tests do not meet the current definition of advanced diagnostic laboratory tests, and we will be required to report private payer rates for our tests every three years; but this determination may change. It is unclear what impact new Medicare pricing structures, such as those adopted under PAMA, may have on our business, financial condition, results of operations or cash flows.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. federal government continues to show significant interest in pursuing health care reform and reducing health care costs. Similarly, private payers may seek to reduce costs by reducing coverage or reimbursement for our tests. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any government-adopted reform measures or changes to commercial payer coverage and policies could cause significant pricing pressure on reimbursement for health care products and services, including our tests, which could decrease demand for our tests, and adversely affect our sales, revenue and financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some payers have implemented, or are in the process of implementing, laboratory benefit management programs, often using third-party benefit managers to manage these programs. The stated goals of these programs are to help improve the quality of outpatient laboratory services, support evidence-based guidelines for patient care and lower costs. The impact on laboratories, such as us, of active laboratory benefit management by third parties is unclear, and we expect that it would have a negative impact on our revenue in the short term. Payers may resist reimbursement for our tests in favor of less expensive tests, require pre-authorization for our tests, or impose additional pricing pressure on and substantial administrative burden for reimbursement for our tests. We expect to continue to focus substantial resources on increasing adoption of, and coverage and reimbursement for, our current tests and any future tests we may develop. We believe it may take several years to achieve broad coverage and adequate contracted reimbursement with a majority of payers for our tests. However, we cannot predict whether, under what circumstances, or at what price levels payers will cover and reimburse our tests. If we fail to establish and maintain broad adoption of, and coverage and reimbursement for, our tests, our ability to generate revenue could be harmed and our business and prospects could suffer.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our products may in the future be subject to product recalls. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has the authority to require the recall of commercialized products that are subject to FDA regulation in the event of material deficiencies or defects in design or manufacture. The authority to require a recall must be based on an FDA finding that there is reasonable probability that the device would cause serious, adverse health consequences or death. We may also, on our own initiative, recall a product. The FDA requires that certain classifications of recalls be reported to the FDA within ten working days after the recall is initiated. If we obtain FDA approval for one of our tests, a government-mandated or voluntary recall by us or one of our distributors could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our products could divert managerial and financial resources and impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers&#8217; demands, which would have an adverse effect on our reputation, results of operations and financial condition. We may be subject to liability claims, may be required to bear costs or may take other actions that may have a negative impact on our future sales and our ability to generate profits. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, the FDA could require us to report those actions and take enforcement action for failing to report the recalls when they were conducted. A future recall announcement could harm our reputation with customers and negatively affect our sales and financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we initiate a correction or removal for one of our tests, issue a safety alert or undertake a field action or recall to reduce a risk to health imposed by the test, this could lead to increased scrutiny by the FDA and our customers regarding the quality and safety of our tests and to negative publicity, including FDA alerts, press releases or administrative or judicial actions. Furthermore, circulation of any such negative publicity could harm our reputation, be used by competitors against us in competitive situations and cause customers to delay purchase decisions or cancel orders.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ongoing research and development and clinical trial activities are subject to extensive regulation and review by numerous governmental authorities both in the United States and abroad. We are currently conducting pre-and post-market clinical studies of some of our tests. In the future we may conduct clinical trials to support approvals of new products. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the trial eligibility criteria. Clinical studies may need to be conducted in compliance with FDA regulations or the FDA may take enforcement action. The data collected from these clinical studies may ultimately be used to support marketing authorization for these products. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our marketing claims or that the FDA or foreign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and studies. The clinical trial process may fail to demonstrate that our tests are safe and effective for the proposed indicated uses, which could cause us to abandon or delay development of our tests. Any delay or termination of our clinical trials will delay the filing of our marketing applications. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval, and any such event may render us unable to commercialize our tests and generate revenue.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions and contract research organizations to perform the trials, and would control only certain aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties would not relieve us of our regulatory responsibilities. We and our third-party contractors are required to comply with good clinical practices, or GCPs, which are regulations and guidelines enforced by the FDA, and comparable regulations enforced by foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any third-party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory clearance or approval process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many of these factors would be beyond our control. We may not be able to undertake additional trials, repeat trials or enter into new arrangements with third parties without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the failure to perform by third parties, our research and development costs would increase, and we may not be able to obtain regulatory clearance or approval for our tests. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our tests, generate revenue or to achieve sustained profitability.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our &#8220;research use only&#8221; and &#8220;investigational use only&#8221; products could become subject to more onerous regulation by the FDA or other regulatory agencies in the future, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the United States, our GuardantOMNI test and our LUNAR-1 assay are currently available for research use only, or RUO, or for investigational use only, or IUO, depending on the proposed application. We make our RUO and IUO products available to a variety of parties, including biopharmaceutical companies and research institutes. Because RUO and IUO products are not intended for use in clinical practice and cannot be advertised or promoted for clinical or diagnostic claims, they are exempt from many regulatory requirements otherwise applicable to medical devices. In particular, while the FDA regulations require that RUO products be labeled &#8220;For Research Use Only. Not for use in diagnostic procedures,&#8221; and that IUO products be labeled &#8220;For Investigational Use Only. The performance characteristics of this product have not been established,&#8221; such products are not subject to the FDA&#8217;s pre- and post-market controls for medical devices.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant change in the laws governing RUO or IUO products or how they are enforced may require us to change our business model in order to maintain compliance. For instance, in November 2013 the FDA issued a guidance document entitled &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only,&#8221; or the RUO/IUO Guidance, which highlights the FDA&#8217;s interpretation that distribution of RUO or IUO products with any labeling, advertising or promotion that suggests that clinical laboratories can validate the test through their own procedures and subsequently offer it for clinical diagnostic use as an LDT is in conflict with the RUO or IUO status. The RUO/IUO Guidance further articulates the FDA&#8217;s position that any assistance offered in performing clinical validation or verification, or similar specialized technical support, to clinical laboratories, is in conflict with RUO or IUO status. If we engage in any activities that the FDA deems to be in conflict with the RUO or IUO status held by any of our products so labeled, we may be subject to immediate, severe and broad FDA enforcement action that would adversely affect our ability to continue operations. Accordingly, if the FDA finds that we are distributing our RUO or IUO products in a manner that is inconsistent with its RUO/IUO Guidance, we may be forced to stop distribution of our RUO/IUO tests until we are in compliance, which would reduce our revenue, increase our costs and adversely affect our business, prospects, results of operations and financial condition. In the event that the FDA requires, or we apply for, marketing authorization of our RUO or IUO products in the future, there can be no assurance that the FDA will grant any clearance or approval requested by us in a timely manner, or at all.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if we receive regulatory approval of our current products, including our Guardant360 and GuardantOMNI tests, or any of our other products, we will continue to be subject to extensive regulatory oversight.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical devices are subject to extensive regulation by the FDA in the United States and by regulatory agencies in other territories where we do business. If any of our products are approved by the FDA or other regulatory agencies, we will be required to timely file various reports. If these reports are not filed timely, regulators may impose sanctions and sales of our products may suffer, and we may be subject to product liability or regulatory enforcement actions, all of which could harm our business. In addition, as a condition of approving a PMA application, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional safety and effectiveness data for the device. The product labeling must be updated and submitted in a PMA supplement as results, including any adverse event data from the post-approval study, become available. Failure to conduct or timely complete post-approval studies in compliance with applicable regulations, update the product labeling, or comply with other post-approval requirements could result in withdrawal of approval of the PMA, which would harm our business and revenue.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA and the Federal Trade Commission, or FTC, also regulate the advertising and promotion of medical devices to ensure that their promotional claims made are consistent with the applicable marketing authorizations, that there are adequate and reasonable data to substantiate the claims, and that the promotional labeling and advertising is neither false nor misleading in any respect. If the FDA or FTC determines that any of our promotional claims are false, misleading, not substantiated or not permissible, we may be subject to enforcement actions and we may be required to revise our promotional claims and make other corrections or restitutions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA, state and foreign authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory agencies, which may include any of the following sanctions:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adverse publicity, warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizures of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">operating restrictions, partial suspension or total shutdown of production;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">customer notifications or repair, replacement or refunds;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refusing our requests for clearances or approvals of new products, new intended uses or modifications to existing products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">withdrawals of current clearances or approvals, resulting in prohibitions on sales of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refusal to issue certificates needed to export products for sale in other countries; and</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">criminal prosecution.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of these sanctions could also result in higher than anticipated costs or lower than anticipated sales of our products and have a material adverse effect on our reputation, business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our current or future products under development. For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals.  The FDA requested public feedback on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance, or restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">More recently, in September 2019, the FDA finalized guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA intends to develop and maintain a list device types appropriate for the &#8220;safety and performance based&#8221; pathway and will continue to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible.  The FDA may establish performance criteria for classes of devices for which we or our competitors seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our current or future products or make it more difficult to obtain clearance or approval for, manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional record keeping.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be promulgated that could prevent, limit or delay regulatory clearance or approval of our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. In particular, the Trump administration has taken several executive actions, including the issuance of a number of executive orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how these executive actions, will be implemented, and the extent to which they will affect the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in regulatory and oversight activities, including approving our applications, in the normal course, our business may be negatively impacted.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure to comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to the Clinical Laboratory Improvement Amendments, or CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations establish specific standards with respect to personnel qualifications, facility administration, proficiency testing, quality control, quality assurance and inspections. Any testing subject to CLIA regulation must be performed in a CLIA certified laboratory. CLIA certification is also required in order for us to be eligible to bill state and federal healthcare programs, as well as commercial payers, for our tests. We have a current CLIA certificate to perform our tests at our laboratory in Redwood City, California. To maintain this certificate, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our laboratory from time to time.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also required to maintain a California clinical laboratory license to perform testing in California. California laboratory laws establish standards for day-to-day operation of our clinical laboratory in Redwood City, California, including the training and skills required of personnel and quality control. In addition, some other states require our California laboratory to be licensed in the state in order to test specimens from those states. In addition to California, our laboratory is licensed in Florida, Maryland, Pennsylvania, Rhode Island and New York. Although we have obtained licenses from states where we believe we are required to be licensed, it is possible that other states we are not aware of currently require out-of-state laboratories to obtain licensure in order to test specimens from the state, and that other states may adopt similar requirements in the future.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also be subject to regulations in foreign jurisdictions as we seek to expand international utilization of our tests or as such jurisdictions adopt new licensure requirements, which may require review of our tests in order to offer them or may have other limitations such as restrictions on the transport of specimens necessary for us to perform our tests that may limit our ability to make our tests available outside of the United States. Complying with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to comply with applicable clinical laboratory licensure requirements may result in a range of enforcement actions, including suspension, limitation or revocation of our CLIA certificate and/or state licenses, imposition of a directed plan of action, on-site monitoring, civil monetary penalties, criminal sanctions, inability to receive reimbursement from Medicare, Medicaid and commercial payers, as well as significant adverse publicity. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing clinical laboratory licensure or our failure to renew our CLIA certificate, a state or foreign license or accreditation, could have a material adverse effect on our business, financial condition and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to test specimens from New York, LDTs must be approved by the New York State Department of Health, or NYSDOH, on a product-by-product basis before they are offered, and our Guardant360 test has been approved by NYSDOH. We will need to seek NYSDOH approval of any future LDTs we develop and want to offer for clinical testing to New York residents, and there can be no assurance that we will be able to obtain such approval. As a result, we are subject to periodic inspection by the NYSDOH and are required to demonstrate ongoing compliance with NYSDOH regulations and standards. To the extent NYSDOH identified any non-compliance and we are unable to implement satisfactory corrective actions to remedy such non-compliance, the State of New York could withdraw approval for our tests. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The College of American Pathologists, or CAP, maintains a clinical laboratory accreditation program. While not required to operate a CLIA-certified laboratory, many private insurers require CAP accreditation as a condition to contracting with clinical laboratories to cover their tests. In addition, some countries outside the United States require CAP accreditation as a condition to permitting clinical laboratories to test samples taken from their citizens. In 2014, we obtained CAP accreditation for our Redwood City, California laboratory, and in order to maintain such accreditation, we are subject to survey for compliance with CAP standards every two years. Failure to maintain CAP accreditation could have a material adverse effect on the sales of our tests and the results of our operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to numerous federal and state healthcare statutes and regulations; complying with such laws pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties and a material adverse effect to our business and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations are subject to other extensive federal, state, local and foreign laws and regulations, all of which are subject to change. These laws and regulations may include, among others:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the AKS, which prohibits knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind (e.g. provision of free or discounted goods, services or items), in return for or to induce such person to refer an individual, or to purchase, lease, order, arrange for or recommend purchasing, leasing or ordering, any good, facility, item or service that is reimbursable, in whole or in part, under a federal healthcare program. The term &#8216;&#8216;remuneration&#8217;&#8217; has been broadly interpreted to include anything of value, such as phlebotomy kits. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration that are alleged to be intended to induce referrals, purchases or recommendations of covered items or services may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">per se </span><span style="font-family:inherit;font-size:10pt;">illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have held that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the AKS has been violated. Moreover, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to significant civil monetary penalties, plus up to three times the remuneration involved. Violations of the AKS may also result in criminal penalties, including additional fines and imprisonment of up to ten years, and exclusion from Medicare, Medicaid or other governmental healthcare programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the EKRA, which prohibits knowingly and willfully soliciting or receiving any remuneration (including any kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for referring a patient or patronage to a laboratory; or paying or offering any remuneration (including any kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, to induce a referral of an individual to a laboratory or in exchange for an individual using the services of that laboratory. The EKRA applies to all payers including commercial payers and government payers. Violations of EKRA are subject to significant fines and/or up to 10 years in jail, separate and apart from existing AKS regulations and penalties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Stark Law, which prohibits a physician from making a referral for certain designated health services covered by the Medicare or Medicaid program, including laboratory and pathology services, if the physician or an immediate family member of the physician has a financial relationship with the entity providing the designated health services and prohibits that entity from billing, presenting or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral, unless an exception applies. Sanctions for violating the Stark Law include denial of payment, significant civil monetary penalties (on a per claim basis and additional penalties for a circumvention scheme), and exclusion from the federal health care programs; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies. Violations can result in significant civil monetary penalties for each wrongful act;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal and state &#8220;Anti-Markup&#8221; rules, which, among other things, typically prohibit a physician or supplier billing for clinical or diagnostic tests (with certain exceptions) from marking up the price of a purchased test performed by another physician or supplier that does not &#8220;share a practice&#8221; with the billing physician or supplier;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal Physician Payments&#160;Sunshine Act, which requires certain manufacturers of drugs, biologicals, and kits, medical devices or supplies that require premarket approval by or notification to the FDA, and for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to CMS, information related to (i) payments and other transfers of value to physicians, certain other health care professionals beginning in 2022, and teaching hospitals, and (ii) ownership and investment interests in such manufacturers held by physicians and their immediate family members. Failure to submit required information may result in significant civil monetary penalties for any payments, transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission, and may result in liability under other federal laws or regulations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal government may bring a lawsuit under the False Claims Act, or the FCA, against any party whom it believes has knowingly or recklessly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim for payment approved. The federal government and a number of courts have taken the position that claims presented in violation of certain other statutes, including the AKS or the Stark Law, can also be considered a violation of the FCA based on the theory that a provider impliedly certifies compliance with all applicable laws, regulations, and other rules when submitting claims for reimbursement. An FCA violation may provide the basis for the imposition of administrative penalties as well as exclusion from participation in governmental healthcare programs, including Medicare and Medicaid. A number of states including California have enacted laws that are similar to the federal FCA. Private individuals can bring FCA &#8220;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;">&#8221; actions, on behalf of the government and such individuals, commonly known as &#8220;whistleblowers,&#8221; may share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in federal healthcare programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the HIPAA fraud and abuse provisions, which created federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private insurers, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal and state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, unlawful trade practices, insurance fraud, kickbacks, patient inducement and statutory or common law fraud restrict the provision of products, services or items for free or at reduced charge to government or non-government healthcare program beneficiaries. These laws and regulations relating to the provision of items or services for free are complex and are subject to interpretation by the courts and by government agencies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">other federal and state fraud and abuse laws, such as state anti-kickback, self-referrals, false claims and anti-markup laws, any of which may extend to services reimbursable by any payer, including private insurers;  </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">state laws that prohibit other specified practices, such as billing physicians for tests that they order; providing tests at no or discounted cost to induce adoption; waiving co-insurance, co-payments, deductibles or other amounts owed by patients; billing a state healthcare program at a price that is higher than what is charged to other payers; or employing, exercising control over or splitting fees with licensed medical professionals; and   </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">similar foreign laws and regulations in the countries in which we operate or may operate in the future.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a clinical laboratory, our business practices may face additional scrutiny from various government agencies such as the Department of Justice, the U.S. Department of Health and Human Services Office of Inspector General, or OIG, and CMS. Certain arrangements between clinical laboratories and referring physicians have been identified in fraud alerts issued by the OIG as implicating the AKS. The OIG has stated that it is particularly concerned about these types of arrangements because the choice of laboratory and the decision to order laboratory tests typically are made or strongly influenced by the physician, with little or no patient input. Moreover, the provision of payments or other items of value by a clinical laboratory to a referral source could be prohibited under the Stark Law unless the arrangement meets all criteria of an exception. The government has been active in enforcement of these laws against clinical laboratories.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerous states have enacted laws prohibiting business corporations, such as us, from practicing medicine and from employing or engaging physicians and other medical professionals (generally referred to as the prohibition against the corporate practice of medicine), which could include physician laboratory directors. These laws are designed to prevent interference in the medical decision-making process by anyone who is not a licensed medical professional. For example, California&#8217;s Medical Board has indicated that determining the appropriate diagnostic tests for a particular condition and taking responsibility for the ultimate overall care of a patient, including making treatment options available to the patient, would constitute the unlicensed practice of medicine if performed by an unlicensed person. Violation of these laws may result in sanctions and civil or criminal penalties. It is possible that governmental authorities may conclude that our business practices, including our consulting and advisory board arrangements with physicians and other healthcare providers, some of whom receive stock or stock options as compensation for services provided, do not comply with current or future corporate practice of medicine statutes, regulations, agency guidance or case law.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The growth and international expansion of our business may increase the potential of violating applicable laws and regulations. The risk is further increased by the fact that many such laws and regulations have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our internal operations and business arrangements with third parties comply with applicable laws and regulations will involve substantial costs. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Any of the foregoing consequences could seriously harm our business and our financial results. To the extent our business operations are found to be in violation of any of these laws or  regulations, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, monetary fines, individual imprisonment, disgorgement of profits, possible exclusion from participation in Medicare, Medicaid and other healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and pursue our strategy. If any of the healthcare providers or other parties with whom we interact or may interact in the future, are found not to be in compliance with applicable laws and regulations, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in various healthcare programs, which could also negatively affect our business or revenue.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the validity of an informed consent from patients regarding our test was challenged, we could be forced to stop offering our products or using our resources, our business and results of operations would be negatively affected.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We offer our tests to physicians and to biopharmaceutical companies in connection with clinical trials. We have implemented measures to ensure that data and biological samples that we receive have been collected from subjects who have provided appropriate informed consent. We also act as a sponsor of clinical trials in connection with the development of our tests, which are frequently conducted in collaboration with different parties. We seek to receive approval from an ethical review board, or institutional review board, or IRB, for projects that meet the definition of &#8220;human subjects research,&#8221; which includes review and approval of processes for subject informed consent and authorization for use of personal information or waivers thereof. We and our biopharmaceutical partners could conduct clinical trials in a number of different countries. When we are acting as a vendor in connection with a clinical trial sponsored by our biopharmaceutical partners, we rely upon them to comply with the requirements to obtain the subject&#8217;s informed consent and to comply with applicable laws and regulations. The collection of data and samples in many different countries results in complex legal questions regarding the adequacy of informed consent and the status of genetic material under a large number of different legal systems. Those informed consents could be challenged and prove invalid, unlawful, or otherwise inadequate for our purposes. Any such findings against us, or our biopharmaceutical partners, could force us to stop accessing or using data and samples or servicing or conducting clinical trials, which would hinder our product offerings or development. We could also become involved in legal actions, which could consume our management and financial resources.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to fines, penalties, licensure requirements, or legal liability, if it is determined that through our test reports we are practicing medicine without a license.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our test reports delivered to physicians provide information regarding FDA-approved therapies and clinical trials that oncologists may use in making treatment decisions for their patients. We make members of our organization available to discuss the information provided in the reports. Certain state laws prohibit the practice of medicine without a license. Our customer service representatives and medical affairs team provide support to our customers, including assistance in interpreting the test report results. A governmental authority or other parties could allege that the identification of available therapies and clinical trials in our reports and the related customer service we provide constitute the practice of medicine. A state may seek to have us discontinue the inclusion of certain aspects of our test reports or the related services we provide, or subject us to fines, penalties, or licensure requirements. Any determination that we are practicing medicine without a license may result in significant liability to us, and our business and reputation would be harmed.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our billing and claim processing are complex and time-consuming, and any delay in submitting claims or failure to comply with applicable billing requirements could hinder collection and have an adverse effect on our revenue.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Billing for our tests is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, such as Medicare, Medicaid, health plans, insurance companies and patients, all of which may have different billing requirements. Several factors make the billing process complex, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">differences between the list prices for our tests and the reimbursement rates of payers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">compliance with complex federal and state regulations related to billing government healthcare programs, including Medicare and Medicaid, to the extent our tests are covered by such programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">differences in coverage among payers and the effect of patient co-payments or co-insurance; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">differences in information, pre-authorization and other billing requirements among payers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes to codes and coding instructions governing our tests;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">incorrect or missing billing information; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the resources required to manage the billing and claim appeals process.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These billing complexities and the related uncertainty in obtaining payment for our tests could negatively affect our revenue and cash flow, our ability to achieve profitability and the consistency and comparability of our results of operations. In addition, if claims for our tests are not submitted to payers on a timely basis, or if we fail to comply with applicable billing requirements, it could have an adverse effect on our revenue and our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the coding procedure used by third-party payers to identify various procedures, including our test, during the billing process is complex, does not adapt well to our tests and may not enable coverage and adequate reimbursement rates. Third-party payers usually require us to identify the test for which we are seeking reimbursement using a Current Procedural Terminology, or the CPT code. CPT coding plays a significant role in how our Guardant360 test is reimbursed both from commercial and governmental payers. The CPT code set is maintained by the American Medical Association, or AMA. In cases where there is not a specific CPT code to describe a test, such as Guardant360 test, the test may be billed under an unlisted molecular pathology procedure code or through the use of a combination of single gene CPT codes, depending on the payer. The Protecting Access to Medicare Act, or PAMA authorized the adoption of new, temporary billing codes and unique test identifiers for FDA-cleared or approved tests as well as advanced diagnostic laboratory tests. The AMA has created a new section of CPT codes, Proprietary Laboratory Analyses codes, to facilitate implementation of this section of PAMA. In addition, CMS maintains the Healthcare Common Procedure Coding System, or HCPCS, and may assign unique level II HCPCS code to tests that are not already described by a unique CPT code. If our Guardant360 test receives approval from the FDA, we may be required to obtain a new code to report the Guardant360 test on claims submitted to U.S. payers. New CPT codes are issued annually and new HCPCS codes are issued as frequently as quarterly. Payers&#8217; acceptance of the new code could be delayed, and transition to the new code could result in a decrease in reimbursement for our tests, both of which could potentially reduce revenue from commercial and government payers. Changes to the codes used to report the Guardant360 test to payers may result in significant changes in its reimbursement, which could negatively impact our revenue.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because the current coding for reporting our products does not describe a specific test, the claim must be examined to determine what test was provided, whether the test was appropriate and medically necessary, and whether payment should be rendered, which may require a letter of medical necessity from the ordering physician. This process can result in a delay in processing the claim, a lower reimbursement amount or denial of the claim. Because billing third-party </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">payers for our tests is an unpredictable, challenging, time-consuming and costly process, we may face long collection cycles and the risk that we may never collect at all, either of which could adversely affect our business, results of operations and financial condition, and we may have to increase collection efforts and incur additional costs.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in healthcare laws, regulations and policies could increase our costs, decrease our sales and revenues and negatively impact reimbursement for our tests.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or the ACA, became law. This law substantially changed the way health care is financed by both commercial payers and government payers, and significantly impacted our industry. The ACA contains a number of provisions expected to impact existing state and federal health care programs or result in the development of new programs, including those governing enrollments in state and federal health care programs, reimbursement changes and fraud and abuse. Our business and operations could be affected by the ACA, including in ways we cannot currently predict.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since its enactment, there have been efforts to repeal all or part of the ACA, and the current Presidential Administration and the U.S. Congress have taken action to roll back certain provisions of the ACA. For example, the Tax Cuts and Jobs Act, among other things, removes penalties for not complying with the ACA&#8217;s individual mandate to carry health insurance. On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. It is unclear how these decisions, subsequent appeals, if any, and other efforts to challenge, repeal or replace the ACA will impact the ACA or our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional Congressional action is taken.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial and government payers to reduce healthcare costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our tests, the coverage of or the amounts of reimbursement available for our tests from commercial and government payers.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our collection, use and disclosure of personally identifiable information, including patient and employee information, is subject to privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information in our possession could result in significant liability or reputational harm.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The privacy and security of personally identifiable information stored, maintained, received or transmitted, including electronically, is a major issue in the United States and abroad. We collect, process, maintain, retain, evaluate, utilize and distribute large amounts of personal health and financial information and other confidential and sensitive data about our customers and others in the ordinary course of our business.  While we strive to comply with all applicable privacy and security laws and regulations, as well as our own posted privacy policies, legal standards for privacy, including but not limited to &#8216;&#8216;unfairness&#8217;&#8217; and &#8216;&#8216;deception,&#8217;&#8217; as enforced by the FTC and state attorneys general, continue to evolve and any failure or perceived failure to comply may result in proceedings or actions against us by government entities or others, or could cause us to lose customers and payer coverage, which could have a material adverse effect on our business and results of operations. Recently, there has been an increase in public awareness of privacy issues in the wake of revelations about the various privacy-related government investigations and enforcement actions and civil lawsuits against healthcare companies. Concerns about and claims challenging our practices with regard to the collection, use, retention, disclosure or security of personally identifiable information or other privacy-related matters, even if unfounded and even if we are in compliance with applicable laws, could damage our reputation and harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerous federal, state and foreign laws and regulations govern collection, dissemination, use and confidentiality of personally identifiable information and protected health information, including HIPAA, state privacy and confidentiality laws (including state laws requiring disclosure of breaches); federal and state consumer protection and employment laws; and European and other foreign data protection laws. And new privacy legislation may create additional rights for consumers and impose additional requirements on businesses. As these laws and regulations increase in complexity and number, they may change frequently, sometimes conflict and increase our compliance efforts, costs and risks.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HIPAA, as amended by HITECH, establishes a set of national privacy and security standards for the protection of protected health information, or PHI, by health plans, certain healthcare providers and others that submit certain covered transactions electronically, or &#8216;&#8216;covered entities,&#8217;&#8217; and their &#8216;&#8216;business associates,&#8217;&#8217; which are persons or entities that perform certain services for, or on behalf of, a covered entity that involve creating, receiving, maintaining or transmitting PHI. We are a covered entity under HIPAA and therefore must comply with its requirements to protect the privacy and security of health information and must provide individuals with certain rights with respect to their health information. If we engage a&#160;business associate&#160;to help us carry out healthcare activities and functions, we must have a written business associate contract or other arrangement with the business associate that establishes specifically what the business associate has been engaged to do and requires the business associate to comply with the same requirements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 12, 2018, HHS issued a request for information, or RFI, seeking input from the public on how the HIPAA regulations, and the Privacy Rule in particular, could be modified to amend existing, or impose additional, obligations relating to the processing of PHI.  We will monitor this process and assess the impact of changes to the Privacy Rule or other HIPAA regulations to our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Penalties for violations of these laws vary. For instance, a single breach incident can result in findings of violations of multiple HIPAA provisions.  Penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include civil monetary penalties for each provision of HIPAA that is violated and, in certain circumstances, criminal penalties, including imprisonment and/or additional fines. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face additional fines and up to one-year imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer, or use identifiable health information for commercial advantage, personal gain, or malicious harm. In addition, responding to government investigations regarding alleged violations of these and other laws and regulations, even if ultimately concluded with no findings of violations or no penalties imposed, can consume company resources and impact our business and, if public, harm our reputation.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, various states, such as California and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information, and the California Consumer Privacy Act, which came into effect on January 1, 2020, and creates new data privacy rights for users,. These laws and regulations are not necessarily preempted by HIPAA, particularly if a state affords greater protection to individuals than HIPAA. Where state laws are more protective, we may have to comply with the stricter provisions. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and our clients, and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify. Changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as PHI, or personally identifiable information along with increased demands for enhanced data security infrastructure, could greatly increase our costs of providing our services, decrease demand for our services, reduce our revenue and/or subject us to additional risks.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the interpretation and application of consumer, health-related, and data protection laws, especially with respect to genetic samples and data, in the United States, the European Union, or the EU, and elsewhere are often uncertain, contradictory, and in flux. We and our joint ventures operate or may operate in a number of countries outside of the United States whose laws may in some cases be more stringent than the requirements in the United States. For example, EU member countries have specific requirements relating to cross-border transfers of personal data to certain jurisdictions, including to the United States where our laboratory resides. In addition, some countries have stricter consumer notice and/or consent requirements relating to personal data collection, use or sharing, more stringent requirements relating to organizations&#8217; privacy programs and provide stronger individual rights. Moreover, international privacy and data security regulations may become more complex and have greater consequences. For instance, the General Data Protection Regulation, or GDPR, went into effect in May 2018 and imposes stringent data protection requirements for controllers and processors of personal data of persons within the EU. The GDPR applies to any company established in the EU as well as to those outside the EU if they collect and use personal data in connection with the offering of goods or services to individuals in the EU or the monitoring of their behavior. The GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to health data, other special categories of personal data and pseudonymised (i.e., key-coded) data and additional obligations when we contract third-party processors in connection </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">with the processing of the personal data. The GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs could increase, and harm our business and financial condition. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU Member States may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. Failure to comply with the GDPR and other applicable privacy or data security-related laws, rules or regulations could result in material penalties imposed by regulators, affect our compliance with client contracts and have an adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">European data protection law also imposes strict rules on the transfer of personal data out of the EU to the United States. These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices. In addition, these rules are constantly under scrutiny. For example, both the EU-U.S. Privacy Shield Framework and EU Standard Contractual Clauses are the subject of legal challenges in European courts and may face additional challenges in the future, and the absence of successor safeguards for continued data transfer could require us to create duplicative, and potentially expensive, information technology infrastructure and business operations in Europe or limit our ability to collect and use personal information collected in Europe. In addition, the EU Commission has proposed a new ePrivacy Regulation that would address various matters, including provisions specifically aimed at the use of cookies to identify an individual&#8217;s online behavior, and any such ePrivacy Regulation may provide for new compliance obligations and significant penalties. Any of these changes to EU data protection law or its interpretation could disrupt and harm our business. We rely on a mixture of safeguards to transfer personal data from our EU business to the U.S., and could be impacted by changes in law as a result of a future review of these transfer mechanisms by European regulators or current challenges to these mechanisms in the European courts. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the United Kingdom leaving the EU could also lead to further legislative and regulatory changes. It remains unclear how the United Kingdom data protection laws or regulations will develop in the medium to longer term and how data transfer to the United Kingdom from the EU will be regulated, especially following the United Kingdom's departure from the EU on January 31, 2020 without a deal. However, the United Kingdom has transposed the GDPR into domestic law with the Data Protection Act 2018, which remains in force following the United Kingdom's departure from the EU.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that our current practices are challenged under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal, state and foreign enforcement bodies have increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cyber-based attacks, security breaches, loss of data and other disruptions in relation to our information systems and computer networks could compromise sensitive information related to our business, prevent us from accessing it and expose us to liability, which could adversely affect our business and reputation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cyber-attacks, security breaches, computer viruses, malware and other incidents could cause misappropriation, loss or other unauthorized disclosure of confidential data, materials or information, including those concerning our customers and employees. Increasingly complex methods have been used in cyber-attacks, including ransomware, phishing, structured query language injections and distributed denial-of-service attacks. A cyber-attack can also be in the form of unauthorized access or a blocking of authorized access. We can provide no assurance that we or our vendors will be able to detect, prevent or contain the effects of such attacks or other information security risks or threats in the future. The costs of attempting to protect against the foregoing risks and the costs of responding to a cyber-attack are significant. Large scale data breaches at other entities increase the challenge we and our vendors face in maintaining the security of our information technology systems and of our customers&#8217; sensitive information. Following a cyber-attack, our and/or our vendors&#8217; remediation efforts may not be successful, and a cyber-attack could result in interruptions, delays or cessation of service, and loss of existing or potential customers. In addition, breaches of our and/or our vendors&#8217; security measures and the unauthorized dissemination of sensitive personal information or proprietary information or confidential information about us, our customers or other third-parties, could expose our customers' private information and our customers to the risk of financial or medical identity theft, or expose us or other third parties to a risk of loss or misuse of this information, and result in investigations, regulatory enforcement actions, material fines and penalties, loss of customers, litigation or other actions which could have a material adverse effect on our business, prospects, reputation, results of operations and financial condition. In addition, if we fail to adhere to our privacy policy and other published statements or applicable laws concerning our processing, use, transmission and disclosure of protected </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">information, or if our statements or practices are found to be deceptive or misrepresentative, we could face regulatory actions, fines and other liability.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the ordinary course of our business, we collect and store sensitive data, including PHI, personally identifiable information, credit card and other financial information, intellectual property and proprietary business information owned or controlled by us or other parties such as customers and payers. We manage and maintain our applications and data utilizing a combination of on-site systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage parts of our data centers. We also communicate sensitive data, including patient data, through phone, Internet, facsimile, multiple third-party vendors and their subcontractors or integrations with third-party electronic medical records. These applications and data encompass a wide variety of information critical to our business, including research and development information, patient data, commercial information and business and financial information. We face a number of risks related to protecting this critical information, including loss of access, inappropriate use or disclosure, unauthorized access, inappropriate modification and our being unable to adequately monitor, audit or modify our controls over such critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data or otherwise process it on our behalf.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive data from unauthorized access, use, modification or disclosure, no security measures can be perfect and our information technology infrastructure could be vulnerable to hackers, phishing scams, malware, viruses, security flaws, employee errors, and other malfeasance or inadvertent disruptions. Any breach or interruption of our security measures or information technology infrastructure could compromise our networks, and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach, or other loss of information could result in legal claims or proceedings, and liability under federal, state or foreign laws that protect the privacy of personal information, such as HIPAA or HITECH, and regulatory penalties. Notice of breaches is required to be made to affected individuals, the Secretary of the Department of Health and Human Services or other state, federal or foreign regulators, and for extensive breaches, notice may need to be made to the media or State Attorneys General. Such a notice could harm our reputation and our ability to compete. Although we have implemented security measures and an enterprise security program to prevent unauthorized access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect all data from breach. Unauthorized access, loss or dissemination could disrupt our operations (including our ability to perform our analysis, provide test results, bill payers or patients, process claims and appeals, provide customer assistance, conduct research and development, develop intellectual property, collect, process and prepare financial information, provide information about our tests and continue other patient and physician education and outreach efforts, and manage our business) and damage our reputation, any of which could adversely affect our business and financial condition. We continue to prioritize security and the development of practices and controls to protect our systems. As cyber threats evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities, and these efforts may not be successful.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For example, in July 2018, we experienced security incidents involving an unauthorized actor obtaining access to our email system and sending phishing messages. We promptly engaged an independent cybersecurity firm to support our investigation, assess our systems and bolster security thereof. These incidents resulted in the unauthorized access of certain information relating to an aggregate of approximately 1,700 individuals. For approximately 1,100 of these individuals, the information accessed included PHI and primarily consisted of patients&#8217; names, contact information, birth dates, medical diagnosis codes and, in a very limited number of cases, Social Security numbers.  For the remaining individuals, information accessed did not include PHI and primarily consisted of Social Security numbers and certain other personal financial information, and credit card information in one of the incidents. We have provided timely notices to the U.S. Department of Health and Human Services, or the HHS, certain state regulators and certain credit agencies, as applicable, as well as to the individuals affected. We have offered credit monitoring and identity protection services to those who have been affected by this cyber-attack. While the cyber-attack did not have a material impact on our business, cash flows, financial condition and results of operations, we have incurred and may continue to incur internal and external costs, including those relating to mitigation of the incidents, and may be subject to penalties, such as those described above. We have implemented and continue to implement additional security measures as appropriate to help prevent future unauthorized access to our systems and the data we maintain, but we cannot guarantee that future incidents can be avoided. In addition, because the cybersecurity firm&#8217;s investigation only analyzed our email accounts dating back to February 2018 (the time period for which security logs were available in our email software), we cannot assure that no similar incidents took place before that time.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with a former employee&#8217;s complaints alleging non-compliance with applicable provisions of HIPAA, we received requests for information from the HHS Office for Civil Rights, or OCR, in August 2019. After we responded to these requests, we were informed by the OCR that it has closed this matter without further action.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have contingency plans and insurance coverage for certain potential claims, liabilities, and costs relating to security incidents that may arise from our business or operations; however, the coverage may not be sufficient to cover all claims, liabilities, and costs arising from the incidents, including fines and penalties. It could be difficult to predict the ultimate resolution of any such incidents or to estimate the amounts or ranges of potential loss, if any, that could result therefrom. If we cannot successfully resolve a security incident or contain any potential loss, it could materially impact our ability to operate our business as well as our results of operations and financial position.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s99EC47E2FBE658B994BBCFF444D2C40B"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to our intellectual property</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain sufficient intellectual property protection for our technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be impaired.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we have incurred and may continue to incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage of our competitors&#8217; products, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time-consuming and expensive.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As is the case with other biotechnology companies, our success depends in large part on our ability to obtain and maintain protection of the intellectual property we own solely and may own jointly with others or we have licensed and may continue to license from others, particularly patents, in the United States and other countries with respect to our products and technologies. We apply for patents covering our products and technologies and uses thereof, as we deem appropriate. However, obtaining and enforcing biotechnology patents is costly, time-consuming and complex, and we may fail to apply for patents on important products, services and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We own or license numerous U.S. patents and pending U.S. patent applications, with international counterparts in certain countries. It is possible that our or our licensors&#8217; pending patent applications will not result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is possible that others will design around our current or future patented technologies. Some of such patent rights are being challenged, including at the United States Patent and Trademark Office, or USPTO, in post-grant proceedings, at the European Patent Office, or EPO, in opposition proceedings, and some of such patent rights may be challenged in the future. We may not be successful in defending any such challenges made against our owned&#160;or licensed patents or patent applications. Any successful third-party challenge to such patent rights could result in their unenforceability or invalidity and increased competition to our business. We have challenged and may choose to challenge the patents or patent applications of third parties. The outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies&#8217; patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries, including opinions that may affect the patentability of methods for analyzing or comparing DNA sequences.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In particular, the patent positions of companies engaged in the development and commercialization of genomic diagnostic tests, like our current products, including our Guardant360 and GuardantOMNI tests, and our future products, are particularly uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to certain diagnostic tests and related methods. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature is uncertain, and it is possible that certain aspects of genetic diagnostics tests would be considered natural laws. Accordingly, the evolving legal and administrative standards around the world, including in the United States may adversely affect our ability to obtain patents and may facilitate third-party challenges to any owned or licensed patents. The laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. The legal systems of many foreign jurisdictions do not favor the enforcement of patent rights and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patent rights and other intellectual property rights thereunder. Proceedings to enforce our patent rights and other intellectual property protection in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary products, methods and technologies that are patentable.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assuming that other requirements for patentability are met, prior to March 16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On or after March 16, 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 16, 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO on or after March 16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution or post-grant proceedings, including post-grant review, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review and derivation proceedings, to attack the validity of a patent. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence might not be sufficient to invalidate the claim if presented in a district court action. Accordingly, third parties have used and may continue to use the USPTO proceedings to invalidate our patent claims that would not have been invalidated if first challenged by the third party in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding our or our licensors' prosecution of patent applications and enforcement or defense of issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Issued patents covering our products could be found invalid or unenforceable if challenged.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our owned or licensed patent rights have been, are being or may be challenged at a future point in time in opposition, derivation, re-examination, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review, post-grant review or interference. Any successful third-party challenge to our patent rights in this or any other proceeding could result in the unenforceability or invalidity of such patent rights, which may lead to increased competition to our business, which could harm our business. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize our current or future products.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not be aware of all third-party intellectual property rights potentially relating to our product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we have participated and may continue to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Our licensors may also license patent rights to others, and we may not be aware of such licenses before they are granted or such licenses may be subject to disputes or uncertainties that affect patent rights licensed by us or could limit our ability to enforce such patent rights. If third parties bring actions against our owned&#160;or licensed patent rights, we could experience significant costs and management distraction.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In patent litigation in the United States or abroad, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the patent office or made a misleading statement during prosecution. Similar claims may also be raised before patent offices in the United States or abroad, even outside the context of litigation, through mechanisms including re-examination, post-grant review and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patent rights in such a way that they no longer cover our products. The outcome of patent litigation or patent office proceedings following assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our products. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and some of our licensors have initiated, are currently involved in, and may in the future initiate or become involved in legal proceedings against a third party to enforce a patent covering one of our products. For example, we filed separate patent infringement suits against Foundation Medicine, Inc. (&#8220;Foundation Medicine&#8221;) and Personal Genome Diagnostics, Inc. (&#8220;Personal Genome Diagnostics&#8221;), alleging that each infringed patent related to our digital sequencing technology. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Defendants in such proceedings could counterclaim that the patents covering our product are invalid or unenforceable and could institute legal proceedings to challenge such patents both in court and before patent offices. For example, Foundation Medicine and Personal Genome Diagnostics have each asserted counterclaims of patent invalidity, unenforceability under the doctrine of inequitable conduct, and non-infringement. Personal Genome Diagnostics has also alleged antitrust violations related to the enforcement of our patent rights. In addition, Personal Genome Diagnostics and Foundation Medicine have each filed petition for post-grant review with the Patent Trial and Appeal Board at the USPTO, challenging the patentability of certain patents asserted by us.  If Foundation Medicine or Personal Genome Diagnostics were to prevail on their assertions of invalidity and/or unenforceability, we would lose at least part of the patent protection on our products. Such a loss of patent protection could have a material adverse impact on our business. A counterclaim, even if not successful, could be time-consuming and expensive to defend, damage our reputation in the marketplace and the prospects for our business, and divert our management&#8217;s attention.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on licenses from third parties, and if we lose these licenses then we may be subjected to future litigation. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are, and we may acquire companies that are, party to various royalty-bearing license agreements that grant us rights to use certain intellectual property, including patents and patent applications, typically in certain specified fields of use. We may need to obtain additional licenses from others to advance our research, development and commercialization activities. Our license agreements impose, and we expect that future license agreements will impose, various development, diligence, commercialization and other obligations on us, including obligations to making payments to our licensors upon achievement of milestones.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In spite of our efforts, our licensors have asserted and may in the future assert that we have materially breached our obligations under such license agreements and could therefore seek or threaten to terminate the license agreements. If these licenses are terminated, or if the underlying patent rights fail to provide the intended exclusivity, our ability to develop and commercialize products and technology covered by these license agreements would be limited or lost, and our competitors or other third parties might have the freedom to develop, produce, seek regulatory approval of, or to market, products identical or similar to ours and we may be required to cease our development and commercialization activities. Our actual or potential licensors could take action with respect to our licensed intellectual property that may decrease the value of such licensed intellectual property. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. Moreover, disputes could arise with respect to any aspect of our license agreements, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which our products or product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the licensing of patent and other rights controlled by our licensors or developed under our collaborative development relationships to others;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the inventorship and ownership of inventions and know-how licensed to us or resulting from the joint creation or use of intellectual property by our licensors, us and/or our partners; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the validity, enforceability or priority of licensed patent rights; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the amount of royalties and other payments we are obligated to pay under the license agreement.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we do not prevail in such disputes, we may lose any of such license agreements, the license agreements may not be meaningful for our business and operations, and we may be subject to unnecessary or additional payment obligations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements could be susceptible to multiple interpretations. The resolution of any such contract interpretation disagreement could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over licensed intellectual property impair our ability to enforce licensed intellectual property against third parties or use it to defend ourselves in litigation, the value of such licensed intellectual property may be diminished.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we fail to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects. If any of these license agreements is terminated, if the licensor fails to abide by the terms of the license agreement, if the licensor fails to prevent infringement by third parties, or if the licensed patent or other rights are found to be invalid or unenforceable, our may be unable to achieve our business goals and our results of operations and financial condition could be adversely affected. Absent the license agreements, we could infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs and be a distraction to management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys&#8217; fees, costs and expenses, royalties or, be enjoined from selling our products or services, including our Guardant360 and GuardantOMNI tests, which could adversely affect our ability to offer products or services, our ability to continue operations and our financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we cannot license and maintain rights to use third-party technology on reasonable terms, we may not be able to successfully commercialize our products. Our licensed or acquired technology may lose value or utility or over time.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we may identify third-party technology we may need, including to develop or commercialize new products or services. We may also need to negotiate licenses to patents or patent applications before or after introducing a commercial product, and we may not be able to obtain necessary licenses to such patents or patent applications. If we are unable to enter into the necessary licenses on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the licenses or fail to prevent infringement by third parties, or if the licensed patents or other rights are found to be invalid or unenforceable, our business may suffer. In addition, any technology licensed or acquired by us may lose value or utility, including as a result of a change of in the industry, in our business objectives, others' technology, our dispute with the licensor, and other circumstances outside our control. In return for the use of a third party&#8217;s technology, we may agree to pay the licensor royalties based on sales of our products or services. Royalties are a component of cost of products or services and affect the margins on our products or services.  If we are unable to negotiate reasonable royalties or if we have to pay royalties on technology that becomes less useful for us or ceases to provide value to us, our profit margin will be reduced and we may suffer losses.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to protect or enforce our intellectual property rights adequately throughout the world.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Filing, prosecuting and defending patents on our products and services in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some territories outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries and regions do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all jurisdictions, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our inventions in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products. Our patents or other intellectual property rights existing outside the United States may not be effective or sufficient to prevent them from competing. Similarly, intellectual property rights may be exhausted in certain situations, and others could import our products sold abroad and compete with us domestically.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries and regions do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized use or disclosure. If we are required to assert our rights against such party, it could result in significant cost and distraction.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Monitoring unauthorized use or disclosure is difficult, and we do not know whether the steps we have taken to prevent such use or disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also seek to preserve the integrity and confidentiality of our proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed trade secrets of their former employers.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have employed or engaged and expect to employ or engage individuals who were previously employed at or associated with universities or other companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we lose, in addition to paying monetary damages, we may be deprived of valuable intellectual property and face increased competition. A loss of key research personnel or work product could hamper or prevent our ability to commercialize potential products, which could harm our business. Even if we are successful in defending against these claims, litigation could result in damage to our reputation and substantial costs and be a distraction to management and affected individuals.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to protect and enforce our trademarks and we could infringe others&#8217; trademarks.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have not yet registered trademarks in all of our potential markets, although we have registered Guardant Health, Guardant360 and GuardantOMNI in the United States. If we apply to register additional trademarks in the United States and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. If we do not timely register and enforce marks used in connection with our products or services, we may encounter difficulty in enforcing them against third parties, and if these marks are registered by others, we could infringe such trademarks.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our owned&#160;or licensed intellectual property.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in or right to our owned&#160;or licensed patents, trade secrets or other intellectual property. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing such intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of our owned&#160;or licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending against any such claims, we may lose exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful in defending against such claims, litigation could result in damage to our reputation and substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are and may continue to be involved in litigation and other legal proceedings related to intellectual property, which could be time-intensive and costly and may adversely affect our business, operating results or financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have been, are currently in, and may also in the future be, involved with litigation or USPTO actions with various third parties. We expect that the number of such claims may increase as the number of our products or services grows, and the level of competition in our industry segments increases. Any infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time-consuming and costly litigation, diverting management&#8217;s time and attention from the development of our business, or requiring the payment of monetary damages (including treble damages, attorneys&#8217; fees, costs and expenses if we are found to have willfully infringed) and ongoing royalties.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Litigation may be necessary for us to enforce our intellectual property and proprietary rights or to determine the scope, coverage and validity of the intellectual property and proprietary rights of others. We are currently engaged in lawsuits against Foundation Medicine, Inc. and Personal Genome Diagnostics, Inc. for infringement over some of our patents and in proceedings before the USPTO in relation to certain such patents. The outcome of such lawsuits, as well as any other litigation or proceeding, is inherently uncertain and might not be favorable to us. Further, we could encounter delays in product introductions, or interruptions in sale of products or services, as we develop alternative products or services. In addition, if we resort to legal proceedings to enforce our intellectual property rights (as we have against Foundation Medicine, Inc. and Personal Genome Diagnostics, Inc.) or to determine the validity, scope and coverage of the intellectual property or other proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail. If we do not prevail in such legal proceedings, we may be required to pay damages, and we may lose significant intellectual property protection for our products or services, such that competitors could copy our products or services. Any litigation that may be necessary in the future could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we move into new markets and applications for our products or services, incumbent participants in such markets may assert their patents and other intellectual property or proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. As our business matures and our public profile grows, we may also be subject to an increased number of allegations of patent infringement, whether by our competitors or other patent owners, both in the United States and throughout the world wherever we seek to commercialize our products and services. Our competitors and others may have significantly larger and more mature patent portfolios than we have. In addition, while we can assert our own patents or other rights during litigation, our own patents may provide little or no deterrence or protection against patent holding companies or other patent owners who have no relevant product or service revenue. Therefore, our commercial success may depend in part on our non-infringement of the patents or other rights of third parties and on our success in defending ourselves in litigation.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">However, our research, development and commercialization activities are currently and may in the future be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation and other patent challenges, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology industry, including patent infringement lawsuits, interferences, oppositions and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review proceedings before the USPTO, and corresponding proceedings before foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products. As the precision oncology industry expands and more patents are issued, the risk increases that our products or services may be subject to claims of infringement of the patent rights of third parties. Numerous significant intellectual property issues have been litigated, are being litigated and will likely continue to be litigated, between existing and new participants in our existing and targeted markets, and our competitors have asserted and may in the future assert that our products or services infringe their intellectual property rights as part of a business strategy to impede our successful entry into or growth in those markets, and we may enforce our owned or licensed intellectual property rights against our competitors and other parties. For example, we have been or are currently involved in legal proceedings against Foundation Medicine and Personal Genome Diagnostics related to our patent rights both in court and before the USPTO.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third parties have asserted and may in the future assert that we are employing their proprietary technology or trade secrets without authorization. For instance, Foundation Medicine, Inc. filed a lawsuit for patent infringement against us in May 2016, which we settled in July 2018. We are also aware of issued U.S. patents and patent applications with claims related to our products and services, and there may be other related third-party patents or patent applications of which we are not aware. By interacting with us, our licensors may learn more about our business or technology and could assert additional patent rights against us, such as patent rights that are not currently licensed to us or patent rights that may be obtained by any such licensors in the future, which may occur if such patent rights are not available for licensing or if they are not offered on acceptable or commercially reasonable terms. Because patent applications can take many years to issue and are not publicly available until a certain period of time passes from filing, there may be currently pending patent applications which may later result in issued patents that our current or future products and services may infringe. In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may develop or obtain patents with our products or services in mind and claim that making, having made, using, selling, offering to sell or importing our products or services infringes these patents.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We could incur substantial costs and divert the attention of our management and technical personnel in defending against any of these claims. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can, for example, because they have substantially greater resources.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell certain products or services, and could result in the award of substantial damages against us, including treble damages, attorney&#8217;s fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in product or service introductions while we attempt to develop alternative products or services to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products or services, and the prohibition of sale of any of our products or services could materially affect our business and our ability to gain market acceptance for our products or services.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar requirements during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or forfeiture of the patent or patent application and thus loss of patent rights in the relevant jurisdiction. Such an event would allow our competitors to enter the unprotected market and have a material adverse effect on our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect our competitive position for an adequate amount of time.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our products or services are obtained, once the patent life has expired, we may be open to competition. Given the amount of time required for the development, testing and regulatory review of our new products or services, patents protecting them might expire before or shortly after they are commercialized. As a result, our owned and licensed patent portfolio may not provide us with a sufficient exclusivity period to exclude others from commercializing products or services similar or identical to ours.</span></div><div><a id="s86C62C116E555A7D9A4CC6C034B8B124"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to our common stock</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">An active trading market for our common stock may not be maintained.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We can provide no assurance that we will be able to maintain an active trading market for our common stock on the Nasdaq Global Select Market, or Nasdaq, or any other exchange in the future. If an active market for our common stock is not maintained, or if we fail to satisfy the continued listing standards of Nasdaq for any reason and our common stock is delisted, it may be difficult for our stockholders to sell shares without depressing the market price for the shares or at all. An inactive trading market may also impair our ability to both raise capital by selling shares of common stock and acquire other complementary products, technologies or businesses by using our shares of common stock as consideration.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The price of our common stock has fluctuated substantially and may do so in the future, and you may not be able to resell shares of our common stock at or above the price at which you purchased them.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The market price of our common stock has been volatile and may fluctuate substantially in the future due to many factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">volume and customer mix for our precision oncology testing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the introduction of new products or product enhancements by us or others in our industry;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disputes or other developments with respect to our or others&#8217; intellectual property rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to develop, obtain regulatory clearance or approval for, and market new and enhanced products on a timely basis;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">product liability claims or other litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">quarterly or annual variations in our results of operations or those of others in our industry;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">media exposure of our products or of those of others in our industry;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in governmental regulations or in the status of our regulatory approvals or applications;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in earnings estimates or recommendations by securities analysts; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual operating performance. In addition, in the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Securities litigation brought against us following volatility in our stock price, regardless of the merit or ultimate results of such litigation, could result in substantial costs, which would hurt our financial condition and operating results and divert management&#8217;s attention and resources from our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The trading market for our common stock is influenced to some extent by the research and reports that industry or financial analysts publish about us and our business. We do not control these analysts. The analysts who publish information about our common stock may have had relatively little experience with us or our industry, which could affect their ability to accurately forecast our results and could make it more likely that we fail to meet their estimates. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us provide inaccurate or unfavorable research or issue an adverse opinion regarding our stock price, our stock price could decline. If one or more of these analysts cease coverage of us or fail to publish reports covering us regularly, we could lose visibility in the market, which in turn could cause our stock price or trading volume to decline.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. In connection with adopting and implementing a new revenue recognition standard, FASB ASC Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">, management has made and will continue to make judgments and assumptions based on our interpretation of the new standard. The new revenue recognition standard is principle-based and interpretation of those principles may vary from company to company based on their unique circumstances. We also adopted a new lease accounting standard, FASB ASC Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, which involved significant judgment and assumptions, including the estimation of incremental borrowing rate used to discount our lease liabilities and the assessment of risks associated with the specific economic environment of our leased assets. It is possible that interpretation, industry practice and guidance may evolve as we work toward implementing these new accounting standards. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of analysts and investors, resulting in a decline in the market price of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">A significant portion of our total outstanding shares may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell their shares, could result in a decrease in the market price of our common stock. Moreover, holders of approximately 2.6 million&#160;shares of our common stock will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also registered shares of our common stock that have been issued or that we may issue under our current equity compensation plans, which shares can be freely sold in the public market, subject to volume limitations applicable to affiliates.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our executive officers, directors and principal stockholders have significant voting power and may take actions that may not be in the best interests of our other stockholders.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our executive officers and directors as well as entities affiliated with them collectively controlled approximately 37% of our outstanding common stock. As a result, these stockholders, if they act together, may be able to effectively control or exert significant influence over the management and affairs of our company and most matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change of control and might adversely affect the market price of our common stock. This concentration of ownership may not be in the best interests of our other stockholders.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We expect to incur significant additional costs as a result of being a public company, which may adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to incur costs associated with corporate governance requirements that are applicable to us as a public company, including rules and regulations of the SEC, under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, as well as the rules of Nasdaq. These rules and regulations, including those applicable to a large accelerated filer such as us, significantly increase our accounting, legal and financial compliance costs and make some activities more time-consuming. These rules and regulations also make it more expensive for us to maintain directors&#8217; and officers&#8217; liability insurance. Accordingly, increases in costs incurred as a result of being a publicly traded company may adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of becoming a public company, we are required, under Section 404 of the Sarbanes-Oxley Act, to furnish annual reports by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual and interim financial statements will not be detected or prevented on a timely basis.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. The effectiveness of our controls and procedures may be limited by a variety of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">faulty human judgment and simple errors, omissions or mistakes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fraudulent action of an individual or collusion of two or more people;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inappropriate management override of procedures; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the possibility that any enhancements to controls and procedures may still not be adequate to assure timely and accurate financial control.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the Sarbanes-Oxley Act and the rules and regulations promulgated by the SEC, we are required to furnish in this Annual Report on Form 10-K a report by our management regarding the effectiveness of our internal control over financial reporting. The report includes, among other things, an assessment of the effectiveness of our internal control over financial reporting as of the end of our fiscal year, including a statement as to whether or not our internal control over financial reporting is effective. This assessment must include disclosure of any material weaknesses in our internal control over financial reporting identified by management. While we believe our internal control over financial reporting is currently effective, the effectiveness of our internal controls in future periods is subject to the risk that our controls may become inadequate because of changes in conditions. Establishing, testing and maintaining an effective system of internal control over financial reporting requires significant resources and time commitments on the part of our management and our finance staff, may require additional staffing and infrastructure investments and would increase our costs of doing business. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, under the federal securities laws, our auditors are required to express an opinion on the effectiveness of our internal controls. If we are unable to confirm that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion on the effectiveness of our internal controls, we could lose investor confidence in the accuracy and completeness of our financial reports, which could cause the price of our common stock to decline.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated, communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Provisions in our corporate charter documents and under Delaware law could make a change in control of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may make it more difficult for our stockholders to replace current members of our board of directors or add new members thereto. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempts by our stockholders to change our management team. Among others, these provisions include that:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our board of directors has the exclusive right to expand its size and to elect directors to fill a vacancy created by the expansion of the board or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our stockholders may not act by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;  </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a special meeting of stockholders may be called only by our board of directors, its chairman, our chief executive officer or our president, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our amended and restated certificate of incorporation prohibits cumulative voting in the election of directors, which limits the ability of minority stockholders to elect their director candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our board of directors may alter our bylaws without obtaining stockholder approval; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors is required to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">stockholders must provide advance notice and additional disclosures in order to nominate candidates for election to the board of directors or to propose matters that can be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company; and</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our board of directors is authorized to issue shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror.  </span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. Furthermore, our amended and restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. We believe these provisions may benefit us by providing increased consistency in the application of Delaware law by Delaware courts, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits brought against us and our directors and officers by our stockholders. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in such action.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our amended and restated certificate of incorporation also provides that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. However, a Delaware court recently held that such an exclusive forum provision relating to federal courts was unenforceable under Delaware law, and unless and until the Delaware court decision&#160;is reversed on appeal or otherwise abrogated, we do not intend to enforce such a provision in the event of a complaint asserting a cause of action arising under the Securities Act against us or any of our directors, officers, employees or agents.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, future debt or other agreements we may enter into may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC5F8C71D287454DC8C327305B04329DA"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1B. Unresolved Staff Comments</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><a id="sD95200DBCA855F108FBBDA5C6C1067B7"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Properties</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our headquarters is located in Redwood City, California, where we lease approximately 163,000 square feet of space in several buildings. These leases currently have expiration dates ranging from 2025 to 2027. Our CLIA-certified laboratory is located in these facilities, where testing for both clinical and biopharmaceutical customers is performed. We also maintain leased office spaces in Spring City, Texas and Seattle, Washington. While we believe our existing facilities are adequate to meet our current requirements, we expect to expand our facilities as our operations grow over time. We believe we will be able to obtain such additional space on acceptable and commercially reasonable terms. </span></div><div><a id="sF6B8118755505D64959C93E7254CEB73"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Legal Proceedings</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may from time to time be involved in various legal proceedings and other matters arising in the normal course of business. For example, we have received, and may in the future continue to, receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. We have also instituted, and may in the future institute additional, legal proceedings to enforce our rights and seek remedies, such as monetary&#160;damages, injunctive relief and declaratory relief. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us because of diversion of management time and attention as well as the financial costs related to resolving such disputes.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information under the caption &#8220;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and Contingencies - Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;">&#8221; in Note 10 to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K, concerning certain legal proceedings in which we are involved, is hereby incorporated by reference. The resolution of any such legal proceeding is subject to inherent uncertainty and could have a material adverse effect on our financial condition, cash flows or results of operations.</span></div><div><a id="s82FD52279C085E528791A09F75AE7925"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Mine Safety Disclosures.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div><a id="s09F60FD840E35462BBB924AE43B6246B"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</span></div><div><a id="s1D70317D1F565576AE655B6DA5312D3D"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Market information for common stock</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our common stock is traded on the Nasdaq Global Select Market, or Nasdaq, under the symbol &#8220;GH.&#8221;</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Holders of record</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of&#160;February&#160;14, 2020, there were&#160;65 holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividend policy</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and any future earnings for the operation and expansion of our business. Accordingly, we do not anticipate declaring or paying dividends in the foreseeable future. The payment of any future dividends will be at the discretion of our board of directors and will depend on our results of operations, capital requirements, financial condition, prospects, contractual arrangements, including any limitations on payment of dividends, and other factors that the board may deem relevant.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unregistered sales of equity securities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchases of equity securities by the issuer and affiliated purchasers</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities authorized for issuance under equity compensation plans</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this item with respect to our equity compensation plans is incorporated by reference to our definitive proxy statement relating to our 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates (the &#8220;2020 Proxy Statement&#8221;).</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock performance graph</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The graph below shows a comparison, from October 4, 2018 (the date our common stock commenced trading on the Nasdaq)&#160;through&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">,&#160;of the cumulative total return to stockholders of our common stock relative to the Nasdaq Composite Index (&#8220;NBI&#8221;) and the Nasdaq Biotechnology Index (&#8220;IXIC&#8221;). The graph assumes that $100 was invested in each of our common stock, the Nasdaq Composite and the Nasdaq Biotechnology at their respective closing prices on October 4, 2018 and assumes reinvestment of gross dividends. The stock price performance shown in the graph represents past performance and should not be considered an indication of future stock price performance.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="stockchart.jpg" alt="stockchart.jpg" style="height:428px;width:624px;"></img></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">This graph is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference into any of our filings under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></div><div><a id="sEC0ABDE860605BD184E8F6C42C794E98"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6. Selected Financial Data</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following selected consolidated financial data should be read in conjunction with Part II, Item 7, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:inherit;font-size:10pt;">,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8221;</span><span style="font-family:inherit;font-size:10pt;">&#160;and the audited consolidated financial statements and related notes included in Part II, Item 8,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Financial Statements and Supplementary Data</span><span style="font-family:inherit;font-size:10pt;">,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8221;</span><span style="font-family:inherit;font-size:10pt;"> of this Annual Report on Form 10-K, including factors that may affect the comparability of such selected information. The consolidated statements of operations data for the years ended&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">,&#160;</span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and&#160;</span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, and the consolidated balance sheet data as of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively,&#160;are derived from our audited consolidated financial statements and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">related notes included elsewhere in this Annual Report on Form 10-K. The consolidated statements of operations data for the year ended&#160;December&#160;31, 2016 and the consolidated balance sheet data as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> and 2016, respectively, are&#160;derived from our audited consolidated financial statements that is not included in this Annual Report on Form 10-K. The selected consolidated financial data in this section are not intended to replace our consolidated financial statements and the related notes, and are qualified in their entirety by the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. Our historical results are not necessarily indicative of our results in any future period.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except per share data)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Statements of Operations Data:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology testing </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">180,462</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78,407</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42,088</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,496</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Development services </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,913</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,232</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,754</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">753</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">214,375</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90,639</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49,842</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,249</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs and operating expenses:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62,255</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,846</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28,883</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22,065</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of development services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,465</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,364</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,735</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86,292</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50,714</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,562</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,859</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and marketing expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78,335</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53,465</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32,497</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26,192</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61,399</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,192</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,777</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,921</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs and operating expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">296,746</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">183,581</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">126,454</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69,096</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(82,371</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(92,942</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(76,612</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(43,847</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,741</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,266</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,234</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">733</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,181</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,251</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,702</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3,018</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on debt extinguishment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(5,075</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,702</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,059</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before provision for income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(69,723</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(84,225</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(83,214</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(46,133</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for (Benefit from) income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,872</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(67,851</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(84,263</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(83,221</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(46,139</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment of redeemable noncontrolling interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(7,800</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(800</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(75,651</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(85,063</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(83,221</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(46,139</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deemed dividend related to repurchase of Series A convertible preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4,716</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deemed dividend related to change in conversion rate of Series D convertible preferred stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,058</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(75,651</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(85,063</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(88,995</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(46,139</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.84</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2.80</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(7.07</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3.53</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90,597</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30,403</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,582</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,053</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:24px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance Sheet Data:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and marketable securities </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">791,585</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">496,524</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">294,574</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">95,256</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Working capital </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1),(2),(3)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">524,624</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">422,047</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">223,308</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88,813</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1),(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">962,535</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">587,403</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">342,938</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">116,565</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">114,542</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62,451</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34,332</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,869</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable noncontrolling interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49,600</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41,800</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">798,393</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">483,152</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">308,606</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79,696</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:36px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(1)  Fiscal years 2018, 2017 and 2016 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:36px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(2) We define working capital as current assets less current liabilities. See our audited financial statements and related notes included elsewhere in this Annual Report on Form 10-K for further details regarding our current assets and current liabilities.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:36px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(3) Fiscal years 2018, 2017 and 2016 do not reflect the impact of adoption of the new leasing standard in fiscal year 2019.</span></div><div><a id="s4D722FEFA7CE5823AA22A986E1BF7E49"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">You should read the following discussion and analysis of financial condition and results of operations together with the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A&#8220;Risk Factors,&#8221; of this Annual Report on Form 10-K.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The following generally compares our results of operations for the years ended December 31, 2019 and 2018. A detailed discussion comparing our results of operations for the years ended December 31, 2018 and 2017 can be found in Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2018.</span></div><div><a id="s5F42BD2DC91059B584A5C547C39D31AF"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a routine blood draw, or liquid biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of our goal to manage cancer across all stages of the disease, we launched our Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. Our Guardant360 test, launched in 2014, has been used by more than 7,000 oncologists, over 50 biopharmaceutical companies and all 28 National Comprehensive Cancer Network, or NCCN, Centers. Our GuardantOMNI test, launched in 2017, has been used by our biopharmaceutical customers as a comprehensive genomic profiling tool to help accelerate clinical development programs in both immuno-oncology and targeted therapy. These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Our LUNAR-1 assay was launched in 2018 for research use and in late 2019 for investigational use.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since our inception, we have devoted substantially all of our resources to research and development activities related to our Guardant360 and GuardantOMNI tests and our LUNAR program, including clinical and regulatory initiatives to obtain approval by the U.S. Food and Drug Administration, or the FDA, as well as sales and marketing activities. We have over 50 approved, completed or active clinical outcomes studies, more than 150 peer-reviewed publications and more than 400 scientific abstracts. We are pioneering the clinical comprehensive liquid biopsy market with our Guardant360 and GuardantOMNI tests, both of which analyze circulating tumor DNA in blood. Our Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes and has been used by clinicians to help inform which therapy may be effective for advanced stage cancer patients with solid tumors and by biopharmaceutical companies </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">for a range of applications, including identifying target patient populations to accelerate translational science research, clinical trial enrollment, and drug development, and post-approval commercialization. Our GuardantOMNI test has a broader 500-gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications, such as tumor mutational burden and microsatellite instability, and has achieved comparable analytical performance in clinical studies, including for translational science applications in collaboration with several biopharmaceutical companies, including AstraZeneca, Bristol-Myers Squibb, Merck MSD, Merck KGaA of Darmstadt, Germany and Pfizer. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Guardant360 and GuardantOMNI tests have each been designated by the FDA as a breakthrough device for use as a companion diagnostic in connection with certain specified therapeutic products of our biopharmaceutical customers. Among other things, designation as a breakthrough device provides for priority review by the FDA and more interactive communication with the FDA during the development process. Our Guardant360 and GuardantOMNI tests are both being developed as companion diagnostics under collaborations with biopharmaceutical companies, including AstraZeneca and Amgen.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We perform our Guardant360, GuardantOMNI and other tests in our clinical laboratory located in Redwood City, California. Our laboratory is certified pursuant to the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, permitted by the New York State Department of Health, or NYSDOH, and licensed in California and four other states.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The analytical and clinical data that we have generated in our efforts to establish clinical utility, combined with the support we have developed with key opinion leaders, or KOLs, in the oncology space have led to positive coverage decisions by a number of commercial payers. Our Guardant360 test is currently covered by Cigna, Priority Health, multiple Blue Cross Blue Shield plans as well as the health plans associated with eviCore, which have adopted policies that specifically cover Guardant360 test for non-small cell lung cancer, or NSCLC, which we believe gives us a competitive advantage with these payers. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2018, Palmetto GBA, the Medicare Administrative Contractor, or MAC, responsible for administering Medicare&#8217;s Molecular Diagnostic Services Program, or MolDx, issued a local coverage determination, or LCD, for our Guardant360 test for NSCLC patients who meet certain clinical criteria. We worked with Palmetto GBA to obtain this positive coverage decision through the submission of a detailed dossier of analytical and clinical data to substantiate that the test meets Medicare&#8217;s medical necessity requirements. Subsequently in 2018, Noridian Healthcare Solutions, the MAC responsible for adjudicating claims in California, where our laboratory is located, and a participant in MolDx, also finalized its LCD for Guardant360 test. Pursuant to this Noridian LCD, in September 2018, we began to submit claims for reimbursement for Guardant360 clinical testing performed for NSCLC patients covered under the LCD who meet certain clinical criteria, and in October 2018, we began to receive payments for these services from Medicare.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate that approximately 75% of Medicare patients tested for NSCLC are covered by the LCDs for NSCLC patients. For the years ended December 31, 2019 and 2018, respectively, approximately 44% and 46% of our U.S. clinical tests&#160;were for patients tested for NSCLC.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, replacing its prior NSCLC patient LCD, Palmetto GBA finalized a new LCD for our Guardant360 test that provides limited Medicare&#160;coverage for the Guardant360 test in patients diagnosed with solid cancers of non-central nervous system origin. The new LCD requires that patients are recurrent, relapsed, refractory, metastatic, or advanced cancer patients who are seeking further treatment and are potential candidates for an FDA-approved or NCCN-recommended (for Category 1 or 2A level of evidence) biomarker targeted therapy. Additionally, the patient must not have had a previous Guardant360 testing and must be untreated or not responding on the patient&#8217;s current therapy. A patient who has previously been tested with the Guardant360 test and has progressed with new malignant growth since the patient&#8217;s prior test is considered to have a new primary cancer diagnosis and thus is eligible to have another test. Finally, for qualifying cancers other than NSCLC, tissue-based comprehensive genomic profiling must be infeasible for coverage. NSCLC patients would be eligible for coverage if tissue-based testing is infeasible or if previous tissue-based comprehensive genomic profiling returned no actionable results. The new LCD covers our Guardant360 test for fee-for-service&#160;Medicare&#160;patients with advanced cancers who meet its clinical criteria for complete genomic profiling with next-generation sequencing, or NGS, of tumor tissue to optimize treatment selection decisions but have insufficient or unavailable tissue for molecular profiling. The expanded Medicare coverage decision is in line with&#160;FDA&#160;approvals of several tumor-agnostic drugs that are based on a single genomic biomarker across all cancers or that are targetable across multiple cancer types. We expect Noridian Healthcare Solutions to issue a new LCD for our Guardant360 test equivalent to the new LCD issued by Palmetto GBA, though the timing and scope of the Noridian LCD are uncertain. Based on historic physician ordering patterns, we believe the new Noridian LCD, if issued, would significantly expand </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">coverage for use of the Guardant360 test for Medicare patients. We also anticipate approval by the FDA, if obtained, may support further improvements in coverage and reimbursement for our Guardant360 test.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the United States, we market our tests to clinical customers through our sales organization, which is engaged in sales efforts and promotional activities primarily targeting oncologists and cancer centers. Outside the United States, we market our tests to clinical customers through distributors and direct contracts with healthcare institutions. We also market our tests to biopharmaceutical customers globally through our business development team, which promotes the broad utility of our tests throughout drug development and commercialization. Additionally, we have established a joint venture with SoftBank to accelerate commercialization of our products including in Asia, the Middle East and Africa, with our initial focus being on Japan. Our products are currently marketed in approximately 40 countries.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generated total revenue of </span><span style="font-family:inherit;font-size:10pt;">$214.4 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$90.6 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$49.8 million</span><span style="font-family:inherit;font-size:10pt;"> for the years ended December&#160;31, 2019, 2018 and 2017, respectively. We also incurred net losses of </span><span style="font-family:inherit;font-size:10pt;">$67.9 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$84.3 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$83.2 million</span><span style="font-family:inherit;font-size:10pt;"> in the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. We have funded our operations to date principally from the sale of our stock and revenue from our precision oncology testing and development services. In 2017, we raised $320.4 million through the sale of our Series E convertible preferred stock. In October 2018, we completed our initial public offering, or the IPO, selling 14,375,000 shares of our common stock and raising $249.5 million net of underwriting discounts and commissions and other expenses payable by us. In May 2019, we completed an underwritten public offering of a total of 5,175,000&#160;shares of our common stock, through which we received net proceeds of&#160;approximately $349.7 million&#160;after deducting underwriting discounts and commissions and offering expenses payable by us. As of December&#160;31, 2019, we had cash, cash equivalents and marketable securities of $</span><span style="font-family:inherit;font-size:10pt;">791.6 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s683F298286AE50979971492FABDF642D"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Factors affecting our performance</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations, including:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Testing volume, pricing and customer mix. </span><span style="font-family:inherit;font-size:10pt;">Our revenue and costs are affected by the volume of testing and mix of customers from period to period. We evaluate both the volume of tests that we perform for patients on behalf of clinicians and the number of tests we perform for biopharmaceutical companies. Our performance depends on our ability to retain and broaden adoption with existing customers, as well as attract new customers. We believe that the test volume we receive from clinicians and biopharmaceutical companies are indicators of growth in each of these customer verticals. Customer mix for our tests has the potential to significantly affect our results of operations, as the average selling price for biopharmaceutical sample testing is currently higher than our average selling price for clinical tests because we are not a contracted provider for, or our tests are not covered by clinical patients&#8217; insurance for, the majority of the tests that we perform for patients on behalf of clinicians.  Approximately 38% of our U.S. clinical tests for the years ended December 31, 2019 and 2018 were for Medicare beneficiaries. Prior to the third quarter of 2018, Medicare did not cover our tests and we did not submit claims for reimbursement. In September 2018, we began to submit claims to Medicare for reimbursement for Guardant360 clinical tests for NSCLC patients covered under MolDx who meet certain clinical criteria, and in October 2018, we began to receive payments from Medicare for these clinical tests. In December 2019, Palmetto GBA expanded its LCD for our Guardant360 test to provide limited Medicare&#160;coverage for use of Guardant360 for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin. Noridian Healthcare Solutions, or Noridian, is the MAC responsible for adjudicating claims in California where our laboratory is located. Noridian is a participant in MolDx and recently issued a draft LCD for the Guardant360 test modeled on the expanded Palmetto LCD. We may not be able to obtain reimbursement under the expanded Noridian LCD until it is finalized and Noridian completes certain administrative steps. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory approval.</span><span style="font-family:inherit;font-size:10pt;"> Our Guardant360 test was the first comprehensive liquid biopsy test approved by NYSDOH. In addition, we believe our facility was the first comprehensive liquid biopsy laboratory to be CLIA-certified, CAP-accredited and NYSDOH-permitted. In the fourth quarter of 2019, we submitted a premarket approval, or PMA, application to seek the FDA&#8217;s approval of our Guardant360 test to be used as a companion diagnostic, initially in connection with one therapeutic product of a biopharmaceutical customer, and to provide tumor mutation profiling for cancer patients with solid tumors. In February 2020, we submitted an additional module of the PMA application for our Guardant360 test to the FDA. Medicare&#8217;s National Coverage Determination for Next Generation Sequencing established in 2018 and subsequently updated in 2020 provides coverage for molecular diagnostic tests such as our Guardant360 test, if, among other criteria, such tests are offered within their FDA-approved companion diagnostic labeling. We believe that this establishes a competitive advantage for tests receiving FDA approval and that FDA approval will be increasingly necessary for diagnostic tests to gain adoption, both in the United States and abroad. We believe FDA approval, if obtained, will help increase adoption of our tests and </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:24px;text-align:justify;"><span style="font-family:inherit;font-size:10pt;">facilitate favorable reimbursement decisions by Medicare and commercial payers. We also intend to pursue regulatory approvals in specific markets outside of the United States, including in Europe, Japan and China. Any negative regulatory decisions or changes in regulatory requirements affecting our business could adversely impact our operations and financial results.</span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Payer coverage and reimbursement</span><span style="font-family:inherit;font-size:10pt;">. Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payers, including both commercial and government payers. Payment from commercial payers can vary depending on whether we have entered into a contract with the payers as a &#8220;participating provider&#8221; or do not have a contract and are considered a &#8220;non-participating provider.&#8221; Payers often reimburse non-participating providers, if at all, at a lower amount than participating providers. We have received a substantial portion of our revenue from a limited number of commercial payers, most of which have not contracted with us to be a participating provider. We have received reimbursement for tests of patients with a variety of cancers, though for amounts that on average are significantly lower than for participating providers. We have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our test and, potentially, no reimbursement for non-covered uses identified under the payer&#8217;s policies or the contract. As a result, the potential for more favorable reimbursement associated with becoming a participating provider may be offset by a potential loss of reimbursement for non-covered uses of our tests. Current Procedural Terminology, or CPT, coding plays a significant role in how our Guardant360 test is reimbursed both from commercial and governmental payers. Changes to the codes used to report the Guardant360 test to payers may result in significant changes in its reimbursement. If our Guardant360 test receives approval from the FDA, we may be required to obtain a new code to report the Guardant360 test on claims submitted to U.S. payers. If a coding change were to occur, payments for certain uses of the Guardant360 test could be reduced or eliminated by such payers. Cigna, Priority Health, multiple Blue Cross Blue Shield plans as well as the health plans associated with eviCore adopted policies that cover our Guardant360 test for the majority of NSCLC patients we test. If their policies were to change in the future to cover additional cancer indications, we anticipate that our total reimbursement would increase. In September 2018, we began to submit claims for reimbursement with respect to Guardant360 clinical testing performed for NSCLC patients covered under the LCD who meet certain clinical criteria, and in October 2018, we began to receive payments from Medicare. We estimate total coverage in the United States for the Guardant360 test to be more than 170 million lives, including Medicare&#160;beneficiaries and members of&#160;several commercial health plans. If we fail to obtain or maintain coverage and adequate reimbursement from third-party payers, we may be unable to increase our testing volume and revenue as expected. Retrospective reimbursement adjustments, such as deductions from further payments and&#160;clawbacks, can also negatively impact our revenue and cause our financial results to fluctuate. Due to the inherent variability of the insurance landscape, historic success of, and payments from, appeals of reimbursement denials by payers are not indicative of future success of and payments from such appeals.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Biopharmaceutical customers. </span><span style="font-family:inherit;font-size:10pt;">Our revenue also depends on our ability to attract new, and to maintain and expand relationships with existing, biopharmaceutical customers, and we expect to increase our sales and marketing expense in furtherance of this goal. As we continue to develop these relationships, we expect to support a growing number of clinical trials both in the United States and internationally. If our relationships expand with biopharmaceutical customers, we believe we may continue to have opportunities to offer our platform to such customers for companion diagnostic development, novel target discovery and validation as well as clinical trial enrollment, and to grow into other business opportunities. For example, we believe that our genomic data, in combination with clinical outcomes or claims data, has revenue-generating potential, supporting novel drug development and companion diagnostic development.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and development. </span><span style="font-family:inherit;font-size:10pt;">A significant aspect of our business is our investment in research and development, including the development of new products, such as those being developed as part of our LUNAR program. In particular, we have invested heavily in clinical studies, including more than 50 clinical outcomes studies, the largest-ever liquid-to-tissue concordance study, and a prospective interventional clinical utility study demonstrating clinical overall response rates in line with tissue biopsy approaches. Our clinical research has resulted in over 150 peer-reviewed publications. With respect to our LUNAR program, we initiated a prospective screening study, which we refer to as the ECLIPSE trial, to recruit approximately 10,000 patients and evaluate the performance of our LUNAR-2 assay in detecting colorectal cancer in average-risk adults, and in collaboration with a National Clinical Trials Network group, initiated a prospective multi-center randomized controlled trial, which we refer to as the COBRA study, in approximately 1,400 patients with resected stage II colon cancer to use our LUNAR-1 assay to evaluate recurrence-free survival in patients who receive ctDNA-directed therapy as compared to the current standard-of-care active surveillance. Furthermore, we are collaborating with investigators from multiple academic cancer centers, including MD Anderson Cancer Center, the University of Colorado, Memorial Sloan Kettering Cancer Center, Massachusetts General Cancer Center, Wake Forest Cancer Center and the University of California San Francisco, as well as several international institutions. We believe these studies are critical to gaining physician adoption and driving favorable coverage decisions by payers, and expect our investments in clinical studies to increase. We expect to increase our research and development expense with the goal of fueling further innovation.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">International expansion. </span><span style="font-family:inherit;font-size:10pt;">A component of our long-term growth strategy is to expand our commercial footprint internationally, and we expect to increase our sales and marketing expense to execute on this strategy. We currently offer our tests in countries outside the United States primarily through distributor relationships or direct contracts with hospitals. In May 2018, we formed and capitalized a joint venture, Guardant Health AMEA, Inc., which we refer to as the Joint Venture, with SoftBank, relating to the sale, marketing and distribution of our tests generally outside the&#160;Americas&#160;and Europe. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East and Africa, with our initial focus being on Japan. The recent outbreak of novel coronavirus may disrupt operations for the Joint Venture and make it more difficult to sell our tests in the affected countries or regions, many of which are in the JV Territory. While the impact of this outbreak on the Joint Venture&#8217;s business is still uncertain and depends on many factors, including how long the outbreak goes uncontained, the Joint Venture&#8217;s revenue and results of operations could be adversely affected.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While each of these areas presents significant opportunities for us, they also pose significant risks and challenges that we must address. See Part I, Item 1A, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Risk Factors</span><span style="font-family:inherit;font-size:10pt;">&#8221; of this Annual Report on Form 10-K for more information.</span></div><div><a id="sAEA8500C2ACF571F80D880284EEE6420"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Components of results of operations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We derive our revenue from two sources: (i) precision oncology testing and (ii) development services.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, we adopted a new revenue recognition standard FASB ASC Topic 606,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">,&#160;or ASC 606, which primarily impacted our recognition of revenue related to patient claims paid by third-party commercial and governmental payors. We adopted ASC 606 using the modified retrospective method, which means that the cumulative effect of applying ASC 606 has been recognized to beginning accumulated deficit at January 1, 2019, the date of adoption of ASC 606, and prior comparative periods were not recast to reflect ASC 606. As a result, revenue for the&#160;year ended&#160;December&#160;31, 2018&#160;is presented in accordance with FASB ASC Topic 605,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">, or ASC 605, whereas revenue for the year ended&#160;December&#160;31, 2019&#160;is presented under ASC 606. ASC 606 provides a five-step model for recognizing revenue that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Precision oncology testing.</span><span style="font-family:inherit;font-size:10pt;">&#160;Precision oncology testing revenue is generated from sales of our Guardant 360 and GuardantOMNI tests to clinical and biopharmaceutical customers. In the United States, through&#160;December&#160;31, 2019, we generally performed tests as an out-of-network service provider without contracts with health insurance companies. We submit claims for payment for tests performed for patients covered by U.S. private payers. Prior to the third quarter of 2018, Medicare did not cover our tests and we did not submit claims for reimbursement for these tests. In September 2018, we began to submit claims to Medicare for reimbursement for Guardant360 clinical testing performed for NSCLC patients covered under Medicare&#8217;s Molecular Diagnostic Services Program who meet certain clinical criteria. Tests for </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">87</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patients covered by Medicare represented approximately 38% of our U.S. clinical tests in both </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.  Due to the historical general lack of contracts with U.S. private payers and variability in payments received for claims submitted to them, as well as the limited claims experience to date with Medicare, from our inception through the end of 2018 revenue had not been recognized by us at the time the service was performed as the price of the transaction was not fixed or determinable and collectability was not reasonably assured. As we provide precision oncology testing to biopharmaceutical customers under contracts for which all recognition criteria are met, we have recognized revenue on an accrual basis for those services.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Development services.</span><span style="font-family:inherit;font-size:10pt;"> Development services revenue represents services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions. It includes companion diagnostic development and regulatory approval services, clinical trial referrals and liquid biopsy testing development and support. We collaborate with biopharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, we provide services related to regulatory filings with the FDA to support companion diagnostic device submissions for our liquid biopsy panels. Under these arrangements, we generate revenue from progression of our collaboration efforts, as well as from provision of on-going support. Development services revenue can vary over time as different projects start and complete.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs and operating expenses</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of precision oncology testing. </span><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing generally consists of cost of materials, direct labor, including bonus, benefit and stock-based compensation; equipment and infrastructure expenses associated with processing liquid biopsy test samples, including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples; freight; curation of test results for physicians; and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing our tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to the tests. Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">While we do not believe the technologies underlying these licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of possible strategic importance to us or our competitors. Cost of precision oncology testing revenue included royalty expense of </span><span style="font-family:inherit;font-size:10pt;">$4.4 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$1.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect the cost of precision oncology testing to generally increase in line with the increase in the number of tests we perform, but the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of development services.</span><span style="font-family:inherit;font-size:10pt;"> Cost of development services includes costs incurred for the performance of development services requested by our customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of revenue. Cost of development services will vary depending on the nature, timing and scope of customer projects.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expense</span><span style="font-family:inherit;font-size:10pt;">. Research and development expenses consist of costs incurred to develop technology and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, other outside costs and costs to develop our technology capabilities. Research and development expenses also include costs related to activities performed under contracts with biopharmaceutical companies before technological feasibility has been achieved. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop our technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs. We expect that our research and development expenses will continue to increase in absolute dollars as we continue to innovate and develop additional products, expand our genomic and medical data management resources and conduct our ongoing and new clinical trials, with a particular focus on our LUNAR program.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales and marketing expense.</span><span style="font-family:inherit;font-size:10pt;">&#160;Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our direct sales force and sales management, client services, marketing and reimbursement, medical affairs, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel expenses </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses. We expect our sales and marketing expenses to increase in absolute dollars as we expand our sales force, increase our presence within and outside of the United States, and increase our marketing activities to drive further awareness and adoption of our Guardant360 and GuardantOMNI tests. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative expense</span><span style="font-family:inherit;font-size:10pt;">. Our general and administrative expenses include costs for our executive, accounting and finance, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel expenses and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses. We expect that our general and administrative expenses will continue to increase in absolute dollars, primarily due to increased headcount and costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and requirements of the SEC, director and officer insurance premiums and investor relations. These expenses, though expected to increase in absolute dollars, are expected to decrease modestly as a percentage of revenue in the long term, though they may fluctuate as a percentage of revenue from period to period due to the timing and extent of these expenses.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest income</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income consists of interest earned on our cash, cash equivalents and marketable securities.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest expense</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense consists primarily of interest from finance leases or capital leases and royalty obligations. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other income (expense), net</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2018, we settled a commercial legal dispute. In connection with the settlement, we received a payment of $4.25 million, which was recognized as one-time other income (expense), net for the year ended December&#160;31, 2018.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net also consists of foreign currency exchange gains and losses. We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Provision for (Benefit from) income tax</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes are recorded using an asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our tax positions are subject to income tax audits. We recognize the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. We recognize interest accrued and penalties related to unrecognized tax benefits in its tax provision. We evaluate uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for (benefit from) income taxes includes the effects of any accruals that we believe are appropriate, as well as the related net interest and penalties.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">89</span></div></div><hr style="page-break-after:always"></hr><div><a id="s56127A11C96656B28E8B4606D3DB1D20"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of operations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the significant components of our results of operations for the periods presented.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology testing </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">180,462</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78,407</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Development services </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,913</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,232</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">214,375</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90,639</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs and operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62,255</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,846</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of development services</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,465</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,364</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86,292</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50,714</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and marketing expense</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78,335</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53,465</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61,399</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,192</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs and operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">296,746</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">183,581</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(82,371</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(92,942</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,741</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,266</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,181</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,251</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,702</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(69,723</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(84,225</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for (benefit from) income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,872</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(67,851</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(84,263</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:7.5pt;">Fiscal year 2018 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts include stock-based compensation expense as follows:</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">863</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">512</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,907</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,684</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and marketing expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,716</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,727</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,468</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,928</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:50px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,954</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,851</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts include $157,000 of compensation expenses associated with repurchase of common stock for the year ended December 31, 2018. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0A466427C060533087671FCAAC121407"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of the Years Ended December 31, 2019 and 2018</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology testing   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">180,462</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78,407</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">102,055</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">130</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Development services   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,913</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,232</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,681</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">177</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">214,375</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90,639</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">123,736</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">137</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue was </span><span style="font-family:inherit;font-size:10pt;">$214.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$90.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$123.7 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">137%</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology testing revenue increased to </span><span style="font-family:inherit;font-size:10pt;">$180.5 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$78.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$102.1 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">130%</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology revenue from tests for clinical customers was&#160;</span><span style="font-family:inherit;font-size:10pt;">$101.0 million</span><span style="font-family:inherit;font-size:10pt;">&#160;for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, up 131.1% from $43.7 million&#160;for the year ended December&#160;31, 2018. This increase in clinical testing revenue was driven primarily by increases in test volume plus higher average revenue per test. Precision oncology revenue for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> included $6.8 million of payments received during that year from successful appeals of payers&#8217; denials of reimbursement for samples processed in 2018. Given the age of the samples associated with these successful appeals, we do not believe this appeals revenue is indicative of results in the ordinary course of our operations. Precision oncology tests for clinical customers increased to </span><span style="font-family:inherit;font-size:10pt;">49,926</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">29,238</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (excluding 354 tests in 2018 from a customer that in March 2018 began processing tests in-house). We believe this volume increase is due to a number of factors including increases in our commercial programs, additional clinical data including from the NILE study, and new drugs which continue to expand the need for comprehensive genomic profiling. Average revenue per test increased due to reimbursement for testing of most Medicare lung cancer patients starting in the fourth quarter of 2018, increases in commercial payer payments that we believe were beneficially affected by the Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;), and the $6.8 million from appeals of samples tested in 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology revenue from tests for biopharmaceutical customers was&#160;</span><span style="font-family:inherit;font-size:10pt;">$79.5 million</span><span style="font-family:inherit;font-size:10pt;">&#160;for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, up </span><span style="font-family:inherit;font-size:10pt;">129.1%</span><span style="font-family:inherit;font-size:10pt;"> from&#160;</span><span style="font-family:inherit;font-size:10pt;">$34.7 million</span><span style="font-family:inherit;font-size:10pt;">&#160;for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Precision oncology tests for biopharmaceutical customers increased to </span><span style="font-family:inherit;font-size:10pt;">20,643</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">10,370</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> due to an increase in the number of biopharmaceutical customers and their contracted projects. The average selling price of precision oncology tests for biopharmaceutical customers was $</span><span style="font-family:inherit;font-size:10pt;">3,850</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, up from </span><span style="font-family:inherit;font-size:10pt;">$3,347</span><span style="font-family:inherit;font-size:10pt;"> the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, due to a greater number of such tests being GuardantOMNI test, which has a higher selling price than the Guardant360 test. The change&#160;to accounting for revenue under ASC 606 increased precision oncology revenue from tests for pharmaceutical customers by $1.0 million since revenue under ASC 605 for precision oncology revenue from tests for pharmaceutical customers for the year ended December 31, 2019&#160;would have been approximately&#160;</span><span style="font-family:inherit;font-size:10pt;">$78.5 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Development services revenue increased to </span><span style="font-family:inherit;font-size:10pt;">$33.9 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$12.2 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$21.7 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">177%</span><span style="font-family:inherit;font-size:10pt;">. This increase in development services revenue was due to revenue received from new projects in 2019 and was mainly received from biopharmaceutical customers related to companion diagnostic development and regulatory approval services. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs and operating expenses</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of precision oncology testing</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62,255</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,846</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22,409</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing revenue was </span><span style="font-family:inherit;font-size:10pt;">$62.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$39.8 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$22.4 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">56%</span><span style="font-family:inherit;font-size:10pt;">. This increase in cost of precision oncology testing was primarily due to a </span><span style="font-family:inherit;font-size:10pt;">$11.2 million</span><span style="font-family:inherit;font-size:10pt;"> increase in material costs, a  </span><span style="font-family:inherit;font-size:10pt;">$5.2 million</span><span style="font-family:inherit;font-size:10pt;"> increase in labor and manufacturing overhead costs,&#160;and a </span><span style="font-family:inherit;font-size:10pt;">$2.9 million</span><span style="font-family:inherit;font-size:10pt;"> increase in royalties and  </span><span style="font-family:inherit;font-size:10pt;">$3.2 million</span><span style="font-family:inherit;font-size:10pt;"> increase in  other costs including costs related to freight, curation of test results for physicians. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of development services</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of development services   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,465</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,364</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,101</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">152</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of development services was </span><span style="font-family:inherit;font-size:10pt;">$8.5 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$3.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$5.1 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">152%</span><span style="font-family:inherit;font-size:10pt;">.  This increase in cost of development services was primarily due to an increase in labor costs related to companion diagnostic development and regulatory approval service contracts. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expense</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86,292</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50,714</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35,578</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses were </span><span style="font-family:inherit;font-size:10pt;">$86.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$50.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$35.6 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">70%</span><span style="font-family:inherit;font-size:10pt;">. This increase in research and development expense was primarily due to an increase of </span><span style="font-family:inherit;font-size:10pt;">$14.9 million</span><span style="font-family:inherit;font-size:10pt;"> in personnel-related costs, an increase of </span><span style="font-family:inherit;font-size:10pt;">$4.2 million</span><span style="font-family:inherit;font-size:10pt;"> in noncash stock-based compensation for employees in our research and development group, an increase of </span><span style="font-family:inherit;font-size:10pt;">$2.2 million</span><span style="font-family:inherit;font-size:10pt;"> related to allocated facilities and information technology infrastructure costs, and a </span><span style="font-family:inherit;font-size:10pt;">$0.9 million</span><span style="font-family:inherit;font-size:10pt;"> increase in office administrative costs as we increased our headcount to support continued investment in our technology. The increase is also attributable to an increase of </span><span style="font-family:inherit;font-size:10pt;">$7.9 million</span><span style="font-family:inherit;font-size:10pt;"> in material costs relating to the development of our LUNAR programs and the continuous improvement in our Guardant360 and GuardantOMNI liquid biopsy panels, and an increase of&#160;</span><span style="font-family:inherit;font-size:10pt;">$4.9 million</span><span style="font-family:inherit;font-size:10pt;">&#160;in development consulting fees.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales and marketing expense</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and marketing   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78,335</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53,465</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,870</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing expenses were </span><span style="font-family:inherit;font-size:10pt;">$78.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$53.5 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$24.9 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">47%</span><span style="font-family:inherit;font-size:10pt;">. This increase was primarily due to an increase of </span><span style="font-family:inherit;font-size:10pt;">$15.6 million</span><span style="font-family:inherit;font-size:10pt;"> in personnel-related costs and an increase of </span><span style="font-family:inherit;font-size:10pt;">$3.0 million</span><span style="font-family:inherit;font-size:10pt;"> in noncash stock-based compensation associated with the expansion of our commercial organization, an increase of </span><span style="font-family:inherit;font-size:10pt;">$2.9 million</span><span style="font-family:inherit;font-size:10pt;"> related to office administrative costs, an increase of&#160;</span><span style="font-family:inherit;font-size:10pt;">$2.3 million</span><span style="font-family:inherit;font-size:10pt;">&#160;in travel expenses, an increase of </span><span style="font-family:inherit;font-size:10pt;">$0.5 million</span><span style="font-family:inherit;font-size:10pt;"> related to allocated facilities and information technology infrastructure costs, and an increase of </span><span style="font-family:inherit;font-size:10pt;">$0.6 million</span><span style="font-family:inherit;font-size:10pt;"> in professional service expenses related to marketing activities. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">92</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative expense</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61,399</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,192</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,207</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses were </span><span style="font-family:inherit;font-size:10pt;">$61.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$36.2 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$25.2 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">70%</span><span style="font-family:inherit;font-size:10pt;">. This increase was primarily due to an increase of&#160;</span><span style="font-family:inherit;font-size:10pt;">$15.6 million</span><span style="font-family:inherit;font-size:10pt;">&#160;in personnel-related costs including an increase of </span><span style="font-family:inherit;font-size:10pt;">$2.5 million</span><span style="font-family:inherit;font-size:10pt;"> in noncash stock-based compensation expense and an increase of </span><span style="font-family:inherit;font-size:10pt;">$1.2 million</span><span style="font-family:inherit;font-size:10pt;"> in administration expenses as we increased our headcount, and an increase of&#160;</span><span style="font-family:inherit;font-size:10pt;">$11.9 million</span><span style="font-family:inherit;font-size:10pt;">&#160;in professional service expenses related to outside legal, accounting, consulting and IT services. This increase was offset by a $3.0 million reduction in legal costs due to settlements of a patent lawsuits and commercial legal disputes that were finalized and incurred in 2018. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest income</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,741</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,266</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,475</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">161</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income was </span><span style="font-family:inherit;font-size:10pt;">$13.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$5.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$8.5 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">161%</span><span style="font-family:inherit;font-size:10pt;">. The increase was primarily due to a higher cash, cash equivalents and marketable securities average balance year over year due to the timing of receipt of cash proceeds from our initial public offering and the follow-on offering that was completed in May 2019.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,181</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,251</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(70</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense was </span><span style="font-family:inherit;font-size:10pt;">$1.2 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$1.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, a decrease of </span><span style="font-family:inherit;font-size:10pt;">$0.1 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">6%</span><span style="font-family:inherit;font-size:10pt;">. This decrease was primarily due to reduced outstanding balance of an obligation related to a royalty in connection with a patent license agreement entered into in January 2017.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other income (expense), net</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,702</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4,614</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">*&#160;&#160;&#160;&#160;Not meaningful</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net included a gain of $4.3 million for settlement of a commercial legal dispute for the year ended December&#160;31, 2018. There was no similar charge or gain for the year ended December&#160;31, 2019.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net also included foreign currency exchange gains of </span><span style="font-family:inherit;font-size:10pt;">$0.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Foreign currency exchange gains/losses for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was immaterial. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">93</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Provision for (benefit from) income taxes</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for (benefit from) income taxes   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,872</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,910</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(5,026</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit from income taxes of $1.9 million for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to an expense of $38,000 for the year ended December 31, 2018 was primarily due to the release of valuation allowance of $1.6 million associated with nondeductible intangible assets recorded as part of the Bellwether Bio acquisition.&#160; Additionally, there was a benefit of $0.4 million associated with the utilization of tax losses from continuing operations against other comprehensive income gains.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">94</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2F8105CC550C5C958C28F9AD2B4296C1"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarterly results of operations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables set forth our unaudited quarterly consolidated statements of operations data for each of the eight quarters in the 24-month period ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. &#160;The information for each of these quarters has been prepared in accordance with generally accepted accounting principles in the United States of America and on the same basis as our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. In the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our results of operations. This data should be read in conjunction with our audited financial statements and related notes included elsewhere in this Annual Report on Form 10-K. These quarterly operating results are not necessarily indicative of our operating results for the full year or any future period.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">June 30, </span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">June 30, </span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">(unaudited)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Revenue:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Precision oncology testing </span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">57,414</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">52,147</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">42,064</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">28,837</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">28,096</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">18,298</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">17,822</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">14,191</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Development services </span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">5,483</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">8,701</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">11,911</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">7,818</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">4,777</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3,394</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">1,560</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2,501</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:30px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">62,897</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">60,848</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">53,975</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">36,655</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">32,873</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">21,692</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">19,382</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">16,692</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Costs and operating expenses:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Cost of precision oncology testing</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">20,004</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">16,578</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">14,650</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">11,023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">12,624</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">9,671</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">9,506</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">8,045</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Cost of development services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">1,834</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">1,936</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2,183</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2,512</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">1,323</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">380</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">453</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">1,208</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">25,875</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">24,569</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">19,532</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">16,316</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">16,652</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">14,253</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">11,554</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">8,255</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Sales and marketing expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">22,287</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">18,802</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">19,439</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">17,807</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">17,114</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">13,464</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">11,575</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">11,312</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">General and administrative expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">18,859</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">16,440</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">13,439</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">12,661</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">12,547</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">8,129</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">8,997</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">6,519</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:30px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total costs and operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">88,859</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">78,325</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">69,243</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">60,319</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">60,260</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">45,897</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">42,085</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">35,339</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(25,962</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(17,477</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(15,268</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(23,664</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(27,387</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(24,205</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(22,703</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(18,647</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3,871</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">4,286</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3,099</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2,485</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2,334</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">958</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">989</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">985</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(321</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(280</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(287</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(293</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(299</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(304</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(317</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(331</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(187</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">179</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(51</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">147</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">115</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">43</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">395</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">4,149</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Loss before provision for income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(22,599</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(13,292</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(12,507</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(21,325</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(25,237</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(23,508</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(21,636</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(13,844</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Provision for(benefit from) income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(489</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(202</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1,207</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">26</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">35</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(22,110</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(13,090</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(11,300</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(21,351</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(25,272</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(23,508</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(21,639</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(13,844</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Adjustment of redeemable noncontrolling interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(3,100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">300</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(300</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(4,700</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">150</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(950</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss attributable to Guardant Health, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(25,210</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(12,790</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(11,600</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(26,051</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(25,122</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(24,458</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(21,639</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(13,844</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss attributable to Guardant Health, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(25,210</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(12,790</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(11,600</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(26,051</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(25,122</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(24,458</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(21,639</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(13,844</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(0.27</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(0.14</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(0.13</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(0.30</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(0.30</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1.94</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1.75</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1.16</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">93,997</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">93,303</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">89,036</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">85,935</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">84,123</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">12,582</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">12,388</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">11,920</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Quarterly periods in 2018 do not reflect the adoption of the new revenue accounting standards in 2019.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">95</span></div></div><hr style="page-break-after:always"></hr><div><a id="s16688948C6965E11A5A2B88052B4BC68"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and capital resources</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have incurred losses and negative cash flows from operations since our inception, and as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$352.8 million</span><span style="font-family:inherit;font-size:10pt;">. We expect to incur additional operating losses in the near future and our operating expenses will increase as we continue to invest in clinical trials and develop new product offerings from our research programs, including our LUNAR program, expand our sales organization, and increase our marketing efforts to drive market adoption of our Guardant360 and GuardantOMNI tests. As demand for our Guardant360 and GuardantOMNI tests are expected to continue to increase from physicians and biopharmaceutical companies, we anticipate that our capital expenditure requirements will also increase in order to build additional capacity.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have funded our operations to date principally from the sale of stock and revenue from precision oncology testing and development services. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of </span><span style="font-family:inherit;font-size:10pt;">$143.2 million</span><span style="font-family:inherit;font-size:10pt;"> and marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$648.4 million</span><span style="font-family:inherit;font-size:10pt;">. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in marketable securities consisting of United States treasury securities and corporate bonds.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on our current business plan, we believe our current cash, cash equivalents and marketable securities and anticipated cash flow from operations will be sufficient to meet our anticipated cash requirements over at least the next 12 months from the date of this Annual Report on Form 10-K. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. As revenue from precision oncology testing and development service is expected to grow, we expect our accounts receivable and inventory balances to increase. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If our available cash, cash equivalents and marketable securities and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements including because of lower demand for our products as a result of lower than currently expected rates of reimbursement from our customers or other risks described in this Annual Report on Form 10-K, we may seek to sell additional common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products or grant licenses on terms that are not favorable to us. Additional capital may not be available to us on reasonable terms, or at all.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash flows</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our cash flows for the periods presented:</span></div><div style="line-height:120%;padding-bottom:16px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(47,134</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(72,185</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(317,570</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(153,028</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">367,304</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">293,161</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating activities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in operating activities during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$47.1 million</span><span style="font-family:inherit;font-size:10pt;">, which resulted from a net loss of </span><span style="font-family:inherit;font-size:10pt;">$67.9 million</span><span style="font-family:inherit;font-size:10pt;"> and net change in our operating assets and liabilities of </span><span style="font-family:inherit;font-size:10pt;">$6.1 million</span><span style="font-family:inherit;font-size:10pt;">, partially offset by non-cash charges of </span><span style="font-family:inherit;font-size:10pt;">$26.8 million</span><span style="font-family:inherit;font-size:10pt;">. Non-cash charges primarily consisted of </span><span style="font-family:inherit;font-size:10pt;">$11.4 million</span><span style="font-family:inherit;font-size:10pt;"> of depreciation and amortization and </span><span style="font-family:inherit;font-size:10pt;">$17.0 million</span><span style="font-family:inherit;font-size:10pt;"> of stock-based compensation, partially offset by </span><span style="font-family:inherit;font-size:10pt;">$2.3 million</span><span style="font-family:inherit;font-size:10pt;"> of amortization of discount on investment. The net change in our operating assets and liabilities was primarily the result of a </span><span style="font-family:inherit;font-size:10pt;">$7.4 million</span><span style="font-family:inherit;font-size:10pt;"> increase in accounts receivable driven by higher sales to biopharmaceutical customers and adoption of ASC 606, a </span><span style="font-family:inherit;font-size:10pt;">$6.2 million</span><span style="font-family:inherit;font-size:10pt;"> increase in prepaid expenses and other current assets, a </span><span style="font-family:inherit;font-size:10pt;">$6.0 million</span><span style="font-family:inherit;font-size:10pt;"> increase in inventory to support testing volumes, a  </span><span style="font-family:inherit;font-size:10pt;">$2.9 million</span><span style="font-family:inherit;font-size:10pt;"> increase in other assets for security deposits relating to new leases entered into in 2019 and a </span><span style="font-family:inherit;font-size:10pt;">$3.9 million</span><span style="font-family:inherit;font-size:10pt;"> decrease in deferred revenue partially offset by  a </span><span style="font-family:inherit;font-size:10pt;">$9.2 million</span><span style="font-family:inherit;font-size:10pt;"> increase in accrued expenses and other current liabilities, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">96</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a </span><span style="font-family:inherit;font-size:10pt;">$5.6 million</span><span style="font-family:inherit;font-size:10pt;"> increase in accrued compensation due to increased personnel, a </span><span style="font-family:inherit;font-size:10pt;">$4.3 million</span><span style="font-family:inherit;font-size:10pt;"> increase in accounts payable and a </span><span style="font-family:inherit;font-size:10pt;">$1.0 million</span><span style="font-family:inherit;font-size:10pt;"> increase in operating lease liabilities as a result of the adoption of ASC 842.         </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in operating activities during the year ended&#160;December&#160;31, 2018&#160;was&#160;$72.2 million, which resulted from a net loss of&#160;$84.3 million&#160;and net change in our operating assets and liabilities of&#160;$1.1 million, partially offset by non-cash charges of&#160;$13.2 million. Non-cash charges primarily consisted of&#160;$7.1 million&#160;of depreciation and amortization and&#160;$6.9 million&#160;of stock-based compensation, partially offset by&#160;$0.4 million&#160;of amortization of discount on investment. The net change in our operating assets and liabilities was primarily the result of a&#160;$22.9 million&#160;increase in accounts receivable driven by higher sales to biopharmaceutical customers, a&#160;$3.7 million&#160;increase in prepaid expenses and other current assets and a&#160;$1.8 million&#160;increase in inventory due to higher testing volumes, partially offset by a&#160;$13.0 million&#160;increase in deferred revenue, an&#160;$8.1 million&#160;increase in accrued compensation due to increased personnel, a&#160;$5.0 million&#160;increase in accounts payable and a&#160;$1.3 million&#160;increase in deferred rent.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investing activities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in investing activities during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$317.6 million</span><span style="font-family:inherit;font-size:10pt;">, which resulted primarily from purchases of marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$614.3 million</span><span style="font-family:inherit;font-size:10pt;">, purchases of property and equipment of </span><span style="font-family:inherit;font-size:10pt;">$18.7 million</span><span style="font-family:inherit;font-size:10pt;"> purchase of business of </span><span style="font-family:inherit;font-size:10pt;">$7.3 million</span><span style="font-family:inherit;font-size:10pt;"> and purchase of intangible assets of </span><span style="font-family:inherit;font-size:10pt;">$2.5 million</span><span style="font-family:inherit;font-size:10pt;">, partially offset by our proceeds from the maturities of marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$325.3 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in investing activities during the year ended&#160;December&#160;31, 2018&#160;was&#160;$153.0 million, which resulted primarily from purchases of marketable securities of&#160;$287.5 million&#160;and purchases of property and equipment of&#160;$20.2 million, partially offset by our proceeds from the maturities of marketable securities of&#160;$154.6 million.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financing activities</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by financing activities during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$367.3 million</span><span style="font-family:inherit;font-size:10pt;">  which was primarily due to proceeds of </span><span style="font-family:inherit;font-size:10pt;">$350.4 million</span><span style="font-family:inherit;font-size:10pt;"> from the follow-on offering completed in May 2019, and receipt of proceeds of </span><span style="font-family:inherit;font-size:10pt;">$18.0 million</span><span style="font-family:inherit;font-size:10pt;"> from issuance of common stock upon exercise of stock options and issuance of shares under our ESPP.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by financing activities during the year ended&#160;December&#160;31, 2018&#160;was&#160;$293.2 million, which was primarily due to proceeds from the IPO of $254.0 million, net of underwriting discounts and commissions, and net proceeds from sale of equity interests in noncontrolling interests of&#160;$41.0 million.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s37D25727F7F85B43BA30E0214A1C6838"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual obligations and commitments</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our contractual commitments will have an impact on our future liquidity. The following table summarizes our contractually committed future obligations as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments due by period</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;1 year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">1-3 years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">3-5 years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">More than 5 years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease obligations </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) (2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65,425</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,408</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18,630</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19,473</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18,914</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty obligation </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,775</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,402</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,084</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,364</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,925</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">77,200</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,810</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,714</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22,837</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22,839</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">We lease our office and laboratory space in Redwood City, California, and office space in Spring City, Texas and Seattle, Washington under operating leases that expire between January 2021 - November 2027. We also have operating leases for manufacturing and office equipment through March 2023. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Includes payments relating to a facility agreement entered into as of </span><span style="font-family:inherit;font-size:7.5pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:7.5pt;"> for a lease commencing in 2020 net of sublease income of $0.1 million. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">We have patent license agreements with four parties. Under these agreements, we have made one-time and milestone license fee payments that we have capitalized and are amortizing to expense ratably over the useful life of the applicable underlying patent rights. Under some of these agreements, we are obligated to pay low single-digit percentage running royalties on net sales where the patent right(s) are used in the product or service sold, subject to minimum annual royalties or fees in certain agreements.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">97</span></div></div><hr style="page-break-after:always"></hr><div><a id="s136A7B8FCBD655B3B4C81277A1A16995"></a></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-balance sheet arrangements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have not had any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</span></div><div><a id="s93CBB5E9EFC7543DB30324ACBCC76A94"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical accounting policies and estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have prepared our financial statements in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Our preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the financial statements, as well as revenue and expenses recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We derive revenue from the provision of precision oncology testing services provided to our ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to our biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from our platform. Development services include companion diagnostic development, information solutions and laboratory services. We currently receive payments from commercial third-party payors, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, we began recognizing revenue in accordance with ASC Topic 606,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">,&#160;or ASC 606. Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Precision oncology testing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue from the sale of our precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, we determine an implied contract exists with our clinical customers. We identify each sale of our liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with our clinical customers represents variable consideration. We estimate the variable consideration under the portfolio approach and consider the historical reimbursement data from third-party payers and patients, as well as known current or anticipated reimbursement trends not reflected in the historical data. We monitor the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. We identify our promise to </span></div><div><br/></div><div><div style="line-height:144%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:144%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Results of our precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by us or billed to customers.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Development services</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We perform development services for our biopharmaceutical customers utilizing our precision oncology information platform. Development services typically represent a single performance obligation as we perform a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage us for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We collaborate with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, we provide services related to regulatory filings with the FDA to support companion diagnostic device submissions for our liquid biopsy panels. Under these collaborations, we generate revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations. For development services performed, we are compensated through a combination of an upfront fee and performance-based non-refundable regulatory and other developmental milestone payments. The transaction price of our development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, we consider our historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than us. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. We recognize development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, we recognize revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in our consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contracts with multiple performance obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. We evaluate the terms and conditions included within our contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. We first identify material promises, in contrast to immaterial promises or administrative tasks, under the contract and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, we consider whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, we consider whether we provide a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Variable interest entity</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We review agreements we enter into with third party entities, pursuant to which we may have a variable interest in the entity, in order to determine if the entity is a variable interest entity, or VIE. If the entity is a VIE, we assess whether or not we are the primary beneficiary of that entity. In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If we determine we are the primary beneficiary of a VIE, we consolidate the statements of operations and financial condition of the VIE into our consolidated financial statements. Accounting for the consolidation is based on our determination if the VIE meets the definition of a business or and asset. Assets, liabilities and noncontrolling interests, excluding goodwill, of VIEs that are not determined to be businesses are recorded at fair value in our financial statements upon consolidation. Assets and liabilities that we have transferred to a VIE, after, or shortly before the date we became the primary beneficiary are recorded at the same amount at which the assets and liabilities would have been measured if they had not been transferred. Our determination about whether we should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2018, we and SoftBank formed and capitalized the Joint Venture for the sale, marketing and distribution of our tests in the JV Territory. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East and Africa, with an initial focus on Japan. As of March 31, 2018, the Joint Venture is deemed to be a VIE and we are identified as the primary beneficiary of the VIE. Consequently, we have consolidated the financial position, results of operations and cash flows of the Joint Venture in our financial statements and all intercompany balances have been eliminated in consolidation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The joint venture agreement also includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. SoftBank will have a put right to cause us to purchase all shares of the Joint Venture held by SoftBank and its affiliates, and we will have a call right to purchase all such shares in the event of (i) certain material disagreement relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#8217;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of our initial public offering, a change in control, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within&#160;20&#160;business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#8217;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank&#8217;s interest in the Joint Venture being determined to be materially different from what has been recorded in our consolidated financial statements, including those included elsewhere in this Annual Report on Form 10-K.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the event we exercise our call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a&#160;20%&#160;internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than&#160;40%&#160;of our fair value, we will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of&#160;40%&#160;of our fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may pay the purchase price for the shares of the Joint Venture in cash, in shares of our common stock, or in a combination thereof. In the event we exercise the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, we will choose the form of consideration. The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within our control and has been classified outside of permanent equity in our consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ownership in the Joint Venture to us on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the IPO and under certain other circumstances. We elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After the adoption of Accounting Standards Update 2018-07, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718):</span><span style="font-family:inherit;font-size:10pt;">&#160;Improvements to Nonemployee Share-Based Payment Accounting&#160;on January 1, 2019, we measure stock-based compensation expense for stock options granted to our employees, directors, and nonemployee consultants on the date of grant and recognize the corresponding compensation expense of those awards over the period that the related services are rendered, which is generally the vesting period of the respective award. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the fair value of stock options granted to our employees, directors, nonemployee consultants and purchase rights under our 2018 Employee Stock Purchase Plan on the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The assumptions used to calculate the fair value of our stock options were:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected term</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our expected term represents the period that our stock options are expected to be outstanding. After the adoption of Accounting Standards Update 2018-07, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(Topic 718):</span><span style="font-family:inherit;font-size:10pt;">&#160;Improvements to Nonemployee Share-Based Payment Accounting&#160;on January 1, 2019, the expected term of stock options issued to employees and nonemployee consultants is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term), as we do not have sufficient historical data to use any other method to estimate expected term. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected volatility</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the commencement of trading of our common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for our common stock. Due to limited historical data for the trading of our common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus our expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-free interest rate</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The risk-free interest rate is based on the U.S. treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the stock option grants. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected dividend yield</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we use an expected dividend yield of zero.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Black-Scholes assumptions</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted-average assumptions used in our Black-Scholes option-pricing model were as follows for stock option granted to our employees, directors and nonemployees for the periods presented:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:49%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 &#8211; 6.22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.01 &#8211; 6.51</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.02 &#8211; 6.08</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63.2% &#8211; 68.7%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68.7% &#8211; 78.8%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74.1% &#8211; 75.1%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.6% &#8211; 2.7%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.5% &#8211; 3.0%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.9% &#8211; 2.2%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize stock-based compensation expense net of forfeitures as they occur in accordance with Accounting Standards Update 2016-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718)</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We will continue to use judgment in evaluating the assumptions related to our stock-based compensation on a prospective basis. As we continue to accumulate additional data related to our common stock, we may have refinements to our estimates, which could materially impact our future stock-based compensation expense.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sBE60944BC75954E0853E91EAC877D399"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note 2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;">, to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information.</span></div><div><a id="sF9C18E9E15BE5F39BFE20764D749D5E7"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents, marketable securities and our indebtedness. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of </span><span style="font-family:inherit;font-size:10pt;">$143.2 million</span><span style="font-family:inherit;font-size:10pt;"> held primarily in cash deposits and money market funds. Our marketable securities are held in U.S. government debt securities, U.S. government agency bonds and corporate bonds. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we invested in short-term marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$379.6 million</span><span style="font-family:inherit;font-size:10pt;"> and long-term marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$268.8 million</span><span style="font-family:inherit;font-size:10pt;">. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of the interest rates in the United States. As of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, a hypothetical 100 basis point increase in interest rates would have resulted in an approximate&#160;$5.5 million&#160;decline of the fair value of our available-for-sale securities. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign currency risk</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of our revenue is generated in the United States. Through </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have generated an insignificant amount of revenues denominated in foreign currencies. As we expand our presence in the international market, our results of operations and cash flows are expected to increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. Our obligation related to a royalty denominated in Euros is subject to foreign currency risk. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the effect of a hypothetical 10% change in foreign currency exchange rates would result in a foreign exchange gains or losses of $1.3 million, on total cumulative balance of obligations. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">102</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3FF4646FA9F65A34AECD9985CD62098A"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8. Financial Statements and Supplementary Data</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Guardant Health, Inc.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Index to Consolidated Financial Statements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019 and 2018, and</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Years Ended December 31, 2019, 2018 and 2017</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:86%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Page</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3DC0560A7D29533AB6F978B5E87925B9"><span style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3DC0560A7D29533AB6F978B5E87925B9">104</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6553C79135DF5FD7B41646284FAF1252"><span style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6553C79135DF5FD7B41646284FAF1252">106</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC7B1FD537CD85A27AD4F8F21EB775432"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC7B1FD537CD85A27AD4F8F21EB775432">108</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAF3F77767A415562AF2A677C27AF794C"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Comprehensive Loss</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAF3F77767A415562AF2A677C27AF794C">109</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB0226247A2185664813B4873D2E3EB31"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of </span></a><a style="font-family:inherit;font-size:10pt;" href="#sB0226247A2185664813B4873D2E3EB31"><span style="font-family:inherit;font-size:10pt;">Redeemable Noncontrolling Interest and Stockholders' Equity</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB0226247A2185664813B4873D2E3EB31">110</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s75DE4AE5FD78550A979FFBAA92A8ED69"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s75DE4AE5FD78550A979FFBAA92A8ED69">112</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5B46EB9B1D095F189132C492B3C6520E"><span style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5B46EB9B1D095F189132C492B3C6520E">114</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The supplementary financial information required by this Item&#160;8 is included in Part II, Item&#160;7 under the caption&#160;&#8220;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Quarterly Results of Operations</span><span style="font-family:inherit;font-size:10pt;">&#8221;, which is incorporated herein by reference.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">103</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3DC0560A7D29533AB6F978B5E87925B9"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the Stockholders and the Board of Directors of</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Guardant Health, Inc.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Guardant Health, Inc. (the Company) as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive loss, redeemable noncontrolling interest and stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2019, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8220;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 2, 2020 expressed an unqualified opinion thereon.</span></div><div style="line-height:174%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> Adoption of ASU No. 2014-09</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in Note 2 to the consolidated financial statements, the Company changed its method for recognizing revenue as a result of the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), effective January 1, 2019.</span></div><div style="line-height:174%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="line-height:174%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Audit Matters</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Precision Oncology Revenue (testing services provided to ordering physicians) </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description of the Matter</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2019, revenue recognized from Precision Oncology was $180.5 million. As described in Note 2 to the consolidated financial statements, the Company recognizes revenue from the performance of precision oncology tests for clinical customers upon delivery of test results to the ordering physician. As most precision oncology tests requested by customers are sold based on a physician requisition form without further written terms and conditions, the Company determined an implied contract exists with its patients and estimates variable consideration to be received </span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">for these services. Management estimates variable consideration based on historical payment data from third-party payers and patients adjusted for known and forecasted changes in payment patterns and subject to a constraint such that revenue recognized is not expected to be reversed.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auditing the Company&#8217;s estimate of total consideration expected to be received for the precision oncology tests is complex and requires significant judgment to evaluate management&#8217;s estimate of payments to be received for the tests.  This estimate is affected by assumptions on coverage of the tests for the patient and experience with collection from third-party payors.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">How We Addressed the Matter in Our Audit</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of internal controls that address the risks of material misstatement relating to the measurement of precision oncology revenues based upon estimating variable consideration.  This included testing controls relating to management&#8217;s review of the significant assumptions described above and inputs used in the determination of the estimated amount that would be collected for tests performed during the period.  We also tested controls over the current and historical data used by management in determining this estimate of variable consideration, subject to a constraint, including the completeness and accuracy of the data.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our audit procedures over the Company&#8217;s precision oncology revenue included, among others, assessing assumptions and inputs described above, testing the completeness and accuracy of the underlying data used by the Company in its analysis, including the constraint applied. We agreed the terms and conditions of the type of test (i.e. lung, non-lung, etc.) to be performed to the requisition forms submitted by the physician. We compared the significant assumptions and inputs used by management to the Company&#8217;s third-party payor collection trends and other relevant factors. This included testing inputs to the calculation by comparing historical information to source documents and evaluating the historical accuracy of management's estimates by comparing such estimates to actual results.</span><span style="font-family:inherit;font-size:10pt;color:#24282d;">    </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation of Redeemable Non-Controlling Interest</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description of the Matter</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described in Note 3 to the consolidated financial statements, in May 2018, the Company entered into an agreement with an entity affiliated with SoftBank, a related party, to establish a Joint Venture to distribute the Company&#8217;s tests in certain markets outside the United States.   The Company is consolidating the Joint Venture and as part of the accounting for the redeemable noncontrolling interest (NCI) held by Softbank, management is carrying the NCI at its fair value as the agreement has a put feature which contractually allows Softbank to return the NCI interest back to the Company.  The fair value of the NCI was determined using two valuation models the income approach and the market approach. Determining the fair value of the NCI requires judgment and the use of significant estimates and assumptions, such as, discount rate and exit multiple rate. The discount rate is applied to calculate the present value the expected future cash flows of the Joint Venture.  The selection of exit multiple rate establishes an exit event (i.e. sale or initial public offering) of the Joint Venture. These significant estimates and assumptions are forward looking and could be affected by future economic and market conditions.  At December 31, 2019, the Company&#8217;s non-controlling interest was $49.6 million.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">How We Addressed the Matter in Our Audit</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We obtained an understanding, evaluated the design and tested the operating effectiveness of the Company&#8217;s controls over the fair value estimation of the NCI.  We tested controls over the selection and application of the valuation models and the underlying significant estimates and assumptions noted above.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To test the estimated fair value of the NCI, our audit procedures included, among others, involvement of our valuation specialist to assist us in the evaluation of the Company&#8217;s valuation methodology and testing of the significant estimates and assumptions. For example, we compared the discount rate to industry trends and market conditions and the exit multiple rate to the comparable public companies.  We also compared the revenue forecast to evidence of approval by the Joint Venture board of directors.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have served as the Company&#8217;s auditor since 2015.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redwood City, California</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">105</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6553C79135DF5FD7B41646284FAF1252"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Guardant Health, Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1068-wk-Fact-B3107E60B877A65B3F8DA6258E67A624" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">143,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1087-wk-Fact-94C37B74DA89F5960565A6258E2E90F1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1102-wk-Fact-DBF6C13215DB00C0E06AA6258E6AEF42" name="us-gaap:MarketableSecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">379,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1121-wk-Fact-4E6001699A1D52981298A6258E2C442E" name="us-gaap:MarketableSecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">278,417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1141-wk-Fact-932964D0A06B579D5FA9A6258E2C9EB4" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1160-wk-Fact-458877E932D5EBD4BD8CA6258E614976" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1180-wk-Fact-E190A32224F0C2ED41B1A6258E691196" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1199-wk-Fact-73EB6DD4D040B8E58FA4A6258E681AB5" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1219-wk-Fact-234F20EA2CCDC4F83668A6258E2C6FE7" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,389</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1238-wk-Fact-C1404E0FA5DD1E13F78BA6258E33FB32" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1258-wk-Fact-9CFF4FFE3BC02EA5FCFBA6258E6BEEAA" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">597,358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1277-wk-Fact-00E8A3950A32C9968A04A6258E63CD03" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">468,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1297-wk-Fact-3B1FA43F8C9DF451E37FA6258E2CD4EC" name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1316-wk-Fact-53678F51D29428BDCD16A6258E2DAFA7" name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,563</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1337-wk-Fact-70D2EDBA0CE7622F37B1A6258E2A47FB" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1356-wk-Fact-F2928BF2B06270B1745EA6258E2F72DD" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1376-wk-Fact-8C80AF6CC4A8BCD0FCDCEE6D1A15FBBC" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1415-wk-Fact-6D771168FBAEC197A7FCEE6DF63A7404" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1434-wk-Fact-8F972AC5CAC336F5E358EE6DF64C2E3A" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1454-wk-Fact-FE97572C8D1B2F96ECD4EE6E1A0CCB3E" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1473-wk-Fact-978B05E7243D87CCF76BEE6E1A087B24" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capitalized license fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1493-wk-Fact-7AB982A0A366416C7ECBA6258E6855F5" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1512-wk-Fact-0ABDE53C90E7BD355E30A6258E6239CD" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1532-wk-Fact-4BD1C4130DFD0EAC3A4FA6258E310079" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1551-wk-Fact-920DF56407E2DE37DC2CA6258E2AB586" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Assets</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1578-wk-Fact-4A43155C56BC426FCBE3A6258E2DF4E7" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">962,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1597-wk-Fact-CCBF4B2DE891C350F87CA6258E343288" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">587,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1699-wk-Fact-549F3227B6E38C4A3A53A6258E3057C0" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1718-wk-Fact-88ABD59BB60B02643A89A6258E3737BA" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,642</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1733-wk-Fact-A143034E4B9FB92D9FB3A6258E367FA7" name="us-gaap:DeferredCompensationLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,557</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1752-wk-Fact-0B82DFDAFDD85F4BC0FFA6258E63C82A" name="us-gaap:DeferredCompensationLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1773-wk-Fact-71CC6343C9567D0701CFA6258E2F8222" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1792-wk-Fact-B215684635F57C2B1BB6A6258E5F1626" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1812-wk-Fact-FC10FC77A02C712BEC01A6258E36079F" name="us-gaap:DeferredRevenueCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1831-wk-Fact-86E438AD1CC1914DEE39A6258E336EE4" name="us-gaap:DeferredRevenueCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1851-wk-Fact-38FB97B89C3C4B2E135FA6258E688B8C" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1870-wk-Fact-C9BA75F77CC595F33FFCA6258E3466D9" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1890-wk-Fact-6BDAA847E1388CB98902EE769A57661E" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred rent, net of current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1929-wk-Fact-97090656F47F8E27C3F0A6258E2C2E87" name="us-gaap:DeferredRentCreditNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1948-wk-Fact-61ECFFECABA92FA38684A6258E6A44EB" name="us-gaap:DeferredRentCreditNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,844</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obligation related to royalty</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1968-wk-Fact-97AFDFA53C0512E74784A6258E367455" name="gh:AccruedRoyaltiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,880</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e1987-wk-Fact-1BCA6BB19220D4943D39A6258E663F8B" name="gh:AccruedRoyaltiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2007-wk-Fact-3180396D5E94ED6882DCA6258E331915" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,672</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2026-wk-Fact-24C608AFFD17A2477C31A6258E605847" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Liabilities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2048-wk-Fact-D9E58FA15C46A8F94757A6258E2ABF68" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">114,542</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2067-wk-Fact-787E9732FDA1620CF163A6258E2DEF38" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commitments and contingencies (Note 10)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2087-wk-Fact-8B7360B8EF33839A7C33A6258E697AC9" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2105-wk-Fact-F78D811242E88740F26CA6258E69BB69" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2124-wk-Fact-ACD2A94D262935F8BC49A6258E33B156" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2143-wk-Fact-650B8E998CF3863DCAA5A6258E3807ED" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">106</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2019 and 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2220-wk-Fact-6A7F35AE585C2C21ECAEA6258E60DD29" name="us-gaap:PreferredStockValueOutstanding" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2239-wk-Fact-34424C986E7FFB80571BA6258E2BB23E" name="us-gaap:PreferredStockValueOutstanding" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock, par value of $0.00001 per share; 350,000,000 and 350,000,000 shares authorized as of December 31, 2019 and 2018, respectively; 94,261,414 and 85,832,454 shares issued and outstanding as of December 31, 2019 and 2018, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2259-wk-Fact-AC1D2E2EE2172E340DB2A6258E2FC305" name="us-gaap:CommonStockValueOutstanding" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2278-wk-Fact-F5C2C56EFBB695224069A6258E2A846A" name="us-gaap:CommonStockValueOutstanding" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2298-wk-Fact-F218BA73D777ACC507AAA6258E70EE86" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,150,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2317-wk-Fact-030E0C34DEF5054693A2A6258E353F5E" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">764,033</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive gain (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2337-wk-Fact-C14C877790BB8D9F4B75A6258E76EB22" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d27497e2356-wk-Fact-A935E69713932BF01599A6258E65463C" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d27497e2377-wk-Fact-BFC5FAAB703E313E049DA6258E318F4E" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">352,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d27497e2397-wk-Fact-6BABCF1E83F5B56BEB09A6258E34C8AB" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">280,799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Stockholders&#8217; Equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2418-wk-Fact-59A7633466DC3816626FA6258E32DB25" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">798,393</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2437-wk-Fact-2158FF91CAAC625B3D80A6258E2EC32E" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">483,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2462-wk-Fact-DABB7C98D261DC6E8FDBA6258E65EC6B" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">962,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d27497e2481-wk-Fact-CB529FF0DC7487D23733A6258E310B12" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">587,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1)<ix:footnote id="TextSelection-6357B93E950236AB9E87A6258EB47973-0-wk-Footnote-6357B93E950236AB9E87A6258EB47973_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-6357B93E950236AB9E87A6258EB47973-1"> As of&#160;</ix:footnote></span><ix:continuation id="TextSelection-6357B93E950236AB9E87A6258EB47973-1"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, includes&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d27497e2501-wk-Fact-C9B30A4D96217FC20AEA7E6D5E733780" name="us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d27497e2505-wk-Fact-C94CABE66DBAD6C4DBB377E239F32181" name="us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#8220;VIE&#8221;) and VIE&#8217;s subsidiaries, and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d27497e2509-wk-Fact-7D6DDEA18C7D528A30AA7E6D6D02DFBF" name="us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d27497e2514-wk-Fact-E51091D4C563EE19EFA877F339E8CAC1" name="us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of liabilities, respectively, of the consolidated VIE &#160;of liabilities of consolidated VIE and VIE&#8217;s subsidiaries for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investment in Joint Venture</span><span style="font-family:inherit;font-size:10pt;">.</span></ix:continuation></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2) <ix:footnote id="TextSelection-8658C3672FC3B51B14F877E26D4F91C5-0-wk-Footnote-8658C3672FC3B51B14F877E26D4F91C5_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Fiscal 2018 does not reflect the impact of the adoption of the new revenue accounting and lease accounting standards in fiscal year 2019.</ix:footnote></span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">107</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC7B1FD537CD85A27AD4F8F21EB775432"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Guardant Health, Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology testing </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1184-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF" name="gh:RevenuefromPrecisionOncologyTesting" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180,462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1203-wk-Fact-5B2DE63C41AB69886EC1A6258E3B0666" name="gh:RevenuefromPrecisionOncologyTesting" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1223-wk-Fact-37278A89EE20DFC9B188A6258E33CABC" name="gh:RevenuefromPrecisionOncologyTesting" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Development services</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1245-wk-Fact-8B6729A9D18284EECA68A6258E3316AE" name="gh:RevenuefromDevelopmentServices" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,913</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1264-wk-Fact-E139CBAD9FD19C557986A6258E2D7893" name="gh:RevenuefromDevelopmentServices" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,232</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1283-wk-Fact-4D2936D9D7A53B6DF502A6258E460D65" name="gh:RevenuefromDevelopmentServices" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,754</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1309-wk-Fact-4DE9547D7B5D2159A859A6258E3A1898" name="us-gaap:Revenues" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">214,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1328-wk-Fact-D1D5341DAF1488A2957EA6258E683A12" name="us-gaap:Revenues" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">90,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1347-wk-Fact-71C181FD76A4A1A34CB0A6258E9FCF29" name="us-gaap:Revenues" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs and operating expenses:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1440-wk-Fact-D776885A696B45EC18A7A6258E2FD195" name="gh:CostsofPrecisionOncologyTesting" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62,255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1459-wk-Fact-FC5F2158414C80AA7DA4A6258E4283FB" name="gh:CostsofPrecisionOncologyTesting" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,846</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1478-wk-Fact-B7EFBFBB082FE8085973A6258E301ECD" name="gh:CostsofPrecisionOncologyTesting" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of development services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1504-wk-Fact-624893A7D30D95177256A6258E39666F" name="gh:CostofDevelopmentServices" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1523-wk-Fact-22A4CDE99A64B5FC0099A6258E8705D7" name="gh:CostofDevelopmentServices" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1542-wk-Fact-71D6CFCE72A450B5C150A6258E676789" name="gh:CostofDevelopmentServices" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,735</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1568-wk-Fact-E4F9389B4D6CBB291C84A6258E2D3A8B" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1587-wk-Fact-F723EEEAA4F3220C47ACA6258E3FE220" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1606-wk-Fact-66A294FA7328F9F4B953A6258E2EC23F" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,562</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and marketing expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1633-wk-Fact-2C2223E877947D62403CA6258E3248D1" name="us-gaap:SellingAndMarketingExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78,335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1652-wk-Fact-083DF7C4B235810094E7A6258E363A46" name="us-gaap:SellingAndMarketingExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1671-wk-Fact-23B45AC22F4A6BFF5D6CA6258E34A620" name="us-gaap:SellingAndMarketingExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,497</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1697-wk-Fact-F0C0B87D8E21F5313043A6258E2E5884" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">61,399</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1716-wk-Fact-FD13D0A9D094DDCA3507A6258E32F402" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1735-wk-Fact-1A94BC50A606749A1ADCA6258E2BC2C0" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,777</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs and operating expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1761-wk-Fact-838BF008B4D0A88EB3A9A6258E40B668" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">296,746</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1780-wk-Fact-F97427327B186CEC1349A6258E33EA92" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">183,581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1799-wk-Fact-292C6B080F1A4188053FA6258E8F7A3A" name="us-gaap:CostsAndExpenses" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">126,454</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e1825-wk-Fact-126EDB351B5B224FBB25A6258E34C500" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">82,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e1845-wk-Fact-CFCEE5A46FE3701A17E0A6258EA6DE70" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">92,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e1865-wk-Fact-AE2F748415B13DDE756FA6258E437681" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">76,612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1892-wk-Fact-496CCEDD3A01D6AFD755A6258EA38C22" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1911-wk-Fact-36A785827904CDC46D4FA6258E2F2C08" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e1930-wk-Fact-C0A655E0A6BD7D06BB66A6258E4977F0" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e1956-wk-Fact-CCD8898096D567E0882FA6258E321E3E" name="us-gaap:InterestExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e1976-wk-Fact-F17B8B9C6B72F3A3BD01A6258EA2CFB4" name="us-gaap:InterestExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e1996-wk-Fact-C12A4C43DE5AE549875EA6258E47EA4E" name="us-gaap:InterestExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,702</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on debt extinguishment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2023-wk-Fact-043D7BA11E1A4E1E6280A6258E45617B" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2042-wk-Fact-136B8C09A698F74DEA31A6258E30FC6D" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2061-wk-Fact-63487DDF114014865E64A6258E356BB1" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2088-wk-Fact-2E6394D22E236EB7B233A6258EA4039F" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2107-wk-Fact-B037EB1E746BDCD793D7A6258E543A62" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,702</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2126-wk-Fact-F68A726106C5DF3128E5A6258E59E89A" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before provision for income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2153-wk-Fact-533D35D4131C9059CAE7A6258E46A63A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">69,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2173-wk-Fact-E8046E8FEE4F9385958AA6258E318575" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2193-wk-Fact-129FBB53D2772B0CEB01A6258E337EF0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2220-wk-Fact-0169B057D253E86D735EA6258E55D708" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,872</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2240-wk-Fact-E068EE171D06C4C2BD3DA6258E2D3C45" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2259-wk-Fact-29DDE49B36BBF8FF706BA6258E39EA9B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2285-wk-Fact-DD9CA72B1BBB5CC40BD8A6258E32F7EC" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2305-wk-Fact-4A8DB7FF4A717BAB2EA3A6258E443A47" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2325-wk-Fact-FF90E30B64F2C7FBE5B5A6258EA91FF9" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment of redeemable noncontrolling interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2353-wk-Fact-D077CEFD0B079FCF3D61A6258E2E6647" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2373-wk-Fact-31CADB87CCF74DD2F2C1A6258E34EF14" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2393-wk-Fact-418F0527488BE40C35CDA6258E2FA7B8" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2424-wk-Fact-0C6706E1876259798ED2A6258E385A17" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">75,651</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2444-wk-Fact-DA7C32E8FAD7508D2E32A6258E8265E9" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">85,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2465-wk-Fact-AFCDBD0520C9E2C5AB33A6258E29D834" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deemed dividend related to repurchase of Series A convertible preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2486-wk-Fact-E68A8C708E2097EC5946A6258E9E2226" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2505-wk-Fact-EBA109E0CAADBD273C7BA6258E32AF46" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2524-wk-Fact-1FF0D1ABEA05EF2C682AA6258E3BA553" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,716</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deemed dividend related to change in conversion rate of Series D convertible preferred stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2551-wk-Fact-26F1F32EB6B9B7D7D5A6A6258E3AC275" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2570-wk-Fact-E839DF2B5D3BDD98BBBDA6258E87AB93" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2589-wk-Fact-A468E27BF4939F5E8D3EA6258E447BE2" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,058</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2621-wk-Fact-1535B29FF0DAB4B154A2A6258E365584" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">75,651</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2641-wk-Fact-6133CF14439345C7338DA6258E9D2D95" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">85,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2662-wk-Fact-28A37E9521F9874504E6A6258E35A77C" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">88,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2688-wk-Fact-431CA7CCFD12D7D5971FA6258E4536C1" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2708-wk-Fact-67E566506F83BC6276A1A6258E62F4F5" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30009e2729-wk-Fact-08CC3E0BCEE177D04CA6A6258E311A4A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">7.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2750-wk-Fact-77260172BDC24CAE0417A6258E2DCB75" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">90,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2769-wk-Fact-C2FF126AE24D032B0278A6258E405B49" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">30,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30009e2788-wk-Fact-F37245EBF17027238E7AA6258E393BCD" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">12,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1) <ix:footnote id="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Fiscal year 2018 and 2017 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019. </ix:footnote></span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">108</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAF3F77767A415562AF2A677C27AF794C"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Guardant Health, Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Comprehensive Loss</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1115-wk-Fact-DD9CA72B1BBB5CC40BD8A6258E32F7EC" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1135-wk-Fact-4A8DB7FF4A717BAB2EA3A6258E443A47" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1156-wk-Fact-FF90E30B64F2C7FBE5B5A6258EA91FF9" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of tax impact:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on available-for-sale securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30310e1244-wk-Fact-431720F5631AE9EC0AA3A6258E5DF56D" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,110</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30310e1264-wk-Fact-9DDBB9CF92558B43AD3DA6258EA31002" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1283-wk-Fact-6AF17876E717FD91DE78A6258EA80FE8" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">446</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30310e1310-wk-Fact-E81D30CAB9FEB9A19AD5A6258E59CFB4" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30310e1329-wk-Fact-DDD8AED4C293E1923D8CA6258E9E4064" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30310e1348-wk-Fact-26E8492B95AC8A4AACF3A6258E7F8A3A" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30310e1374-wk-Fact-D825F1C00002D1476452A6258EA6AC45" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,194</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30310e1394-wk-Fact-6032CF74833A27BB2656A6258EA10F0B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1414-wk-Fact-2645F570754ED8CF2FA3A6258EA89EEE" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">446</ix:nonFraction>)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1446-wk-Fact-70D9E087B0785AB188A5A6258E5B8236" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">66,657</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1466-wk-Fact-E475CF877E4BE418F2EDA6258E492196" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1487-wk-Fact-23B1FA79DA408B2DA907A6258E5B9B1E" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss attributable to redeemable noncontrolling interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1508-wk-Fact-632373B76C7D4F306A7CA6258E615967" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1528-wk-Fact-B38BBC67C906DBBD5E09A6258E982ADB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d30310e1548-wk-Fact-44357517AF31A11CBC26A6258EA01EC4" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss attributable to Guardant Health, Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1579-wk-Fact-A01AA133C8DDDD269880A6258E96B77B" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">74,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1599-wk-Fact-30CA6E429CAC2B4C4DFCA6258E551015" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d30310e1620-wk-Fact-A9345E53687F4E4EF49BA6258E49ED20" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">109</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB0226247A2185664813B4873D2E3EB31"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Guardant Health, Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share data)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="34"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Redeemable Noncontrolling Interest</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Convertible <br/>Preferred Stock&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Common&#160;Stock&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional <br/>Paid-in <br/>Capital</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated </span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Other </span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Comprehensive Gain (Loss)</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated <br/>Deficit</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Total Stockholders&#8217; Equity</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Balance as of December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1279-wk-Fact-844359596E5A81188057A6258E64C56C" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1293-wk-Fact-EC5B6CF88ED198FF1543A6258E5F6694" name="us-gaap:SharesOutstanding" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">40,181,923</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1312-wk-Fact-99EFC2DD48BE27860015A6258E70DF87" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">179,997</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1327-wk-Fact-E3D4F63FB6C4CAF8F396A6258E57802D" name="us-gaap:SharesOutstanding" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,184,214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1346-wk-Fact-51A7E87E84947FE6BDC8A6258E56C5BA" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1365-wk-Fact-1A3057BA00C1FDB92DBFA6258E49610E" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,410</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e1385-wk-Fact-841BD83A559BF48A12F8A6258E5E435C" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e1405-wk-Fact-387AECF7D9986CE3E2D1A6258E57F216" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">107,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1425-wk-Fact-93D20B2CDD63F757F7D7A6258E5C0E0D" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Cumulative effect adjustment for ASU 2016-09 adoption</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1527-wk-Fact-883BD08D27B652702B72A650FAE9045A" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e1566-wk-Fact-ABF2382D144F73297812A6515D6E5367" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d38105e1586-wk-Fact-7C6968FAF086066164F0A65342EC458B" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of Series D convertible preferred stock in exchange for a technology license agreement</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1626-wk-Fact-91205F150B16F709D7ADA6258E909E9B" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">141,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1640-wk-Fact-CDBDC115FD78CFDB806FA6258E4A5711" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1751-wk-Fact-2CCB1E39EC48142BE2EEA6258E85D953" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of Series E convertible preferred stock, net of issuance cost of $883</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1791-wk-Fact-B6044D557E81640823D6A669A94E924D" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">38,970,592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1805-wk-Fact-6E7F37FAACB5B83F416FA66A80F3F8E5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">319,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e1916-wk-Fact-023408736869AEF995B5A66ADC294A90" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">319,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Repurchase of Series A convertible preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e1956-wk-Fact-1620020D7FE1E7D40ACCA66C3E81B6F7" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">666,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e1971-wk-Fact-C8B6786B36CF8837D421A66D3667032C" name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">619</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e2064-wk-Fact-B2077C8A8666D6CFC49CA66EA1BFAF47" name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,716</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e2084-wk-Fact-79F8BF82D03BF789CE2EA66EB3AB6CDF" name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e2159-wk-Fact-8B750B024F53AD6933E7A6258E739B0D" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">342,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e2192-wk-Fact-F3A31CB39EBD5E2B9CA4A6258E68F385" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e2250-wk-Fact-E76BABF6E56B3A3D959AA6258E4BDFA3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock upon exercise of warrants</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e2324-wk-Fact-E53379C9F058B6310E4BA6258E7733EF" name="gh:StockIssuedDuringPeriodSharesExerciseofWarrants" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">89,030</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e2357-wk-Fact-E1EAA2531418FA68EB13A6258E660D19" name="gh:StockIssuedDuringPeriodValueExerciseofWarrants" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e2415-wk-Fact-B33913FA4DAA79C63A0EA6258E57F9A6" name="gh:StockIssuedDuringPeriodValueExerciseofWarrants" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Vesting of common stock exercised early</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e2522-wk-Fact-7E3483D21BCDF6FE63A9A6258E66924B" name="gh:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e2580-wk-Fact-62AA337F1165EE48764DA6258E50E9E3" name="gh:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Repurchase of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e2654-wk-Fact-C0D77428FA4EE47EE729A6258E55A3B4" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,719,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e2688-wk-Fact-78F8E1AE90B2D5241002A6258E673330" name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e2747-wk-Fact-DC4FE97CD4564A276D2AA6258E608E5D" name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e2856-wk-Fact-B069381EB3919FA61FE7A6258E543679" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e2914-wk-Fact-B717513E3231A67304DCA6258E4CB48E" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive loss, net of tax impact</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e3041-wk-Fact-3EBC7F2943EE49B511FDA6258E714197" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">446</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e3080-wk-Fact-2645F570754ED8CF2FA3A6258EA89EEE" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">446</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e3227-wk-Fact-D0DFB23EA2E2C9444ED2A6258E6B0A19" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e3247-wk-Fact-34CE2134FBEFD23EE8C1A6258E71CA36" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Balance as of December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3269-wk-Fact-26A55D8A79EFC5CDAFE3A6258E600EED" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3288-wk-Fact-1C9C92E8245CF509A918A6258E68A0A0" name="us-gaap:SharesOutstanding" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">78,627,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3302-wk-Fact-EB182468A2F67BD0EFB5A6258E54906C" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">499,974</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3322-wk-Fact-C2E32A259D26C3F5FA0FA6258E4C294A" name="us-gaap:SharesOutstanding" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,896,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3336-wk-Fact-0FDDB1FDA68140134EE0A6258E51BDF8" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3355-wk-Fact-6BB87F447B7F9082895FA6258E4A7420" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e3375-wk-Fact-B41561B8858F7FB5E763A6258E5D2174" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e3395-wk-Fact-E5B3E6C9202EEE11E893A6258E844559" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">195,736</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3415-wk-Fact-AE041E9B471A7A5500CAA6258E8366F4" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">308,606</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Conversion of convertible preferred stock to common stock upon initial public offering</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e3456-wk-Fact-D7AF0F049A77A03801C8A6258E589335" name="gh:StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">78,627,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e3471-wk-Fact-722158C7214C8BB48B9FA6258E58BC14" name="gh:StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">499,974</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3492-wk-Fact-B448638235D53B379AD3A6708D8F3FF0" name="gh:StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">58,264,577</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3506-wk-Fact-F1AEBBCB6ED198A6414DA67092164D2E" name="gh:StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3525-wk-Fact-53B5CF9E5EB9D781D439A671D866270C" name="gh:StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">499,973</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock upon initial public offering, net of offering costs of $4,475 issuance of Series D convertible preferred stock in exchange for a technology license agreement</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3657-wk-Fact-AAEC892EEB6D5A46ABFDA67095A26E49" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,375,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3690-wk-Fact-96E3C9FDF6A59BE38CD2A671DB5AE9A7" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">249,531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3748-wk-Fact-72C9B53C70E53E24DA9BA6258E8D4994" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">249,531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3822-wk-Fact-9DF3038E96A65CECE02AA6258E685B6A" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">963,119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3855-wk-Fact-24460FAA09CDC664E0C8A6258E5B0BE7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3913-wk-Fact-E9BDC192EDBE399C903AA6258E8E2CAC" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock upon early exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e3987-wk-Fact-FAE829818E22E2491C3BAA1C6A61DC45" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">44,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock upon exercise of warrants</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e4152-wk-Fact-A892D4CDF35028AB6E0CA6258E4E112A" name="gh:StockIssuedDuringPeriodSharesExerciseofWarrants" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">320,289</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e4185-wk-Fact-BC4532F950FE1A327B01A6258E59D412" name="gh:StockIssuedDuringPeriodValueExerciseofWarrants" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e4243-wk-Fact-03EEFF6DFCDC76500CA1A6258E51B7B9" name="gh:StockIssuedDuringPeriodValueExerciseofWarrants" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Repurchase of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e4317-wk-Fact-5F712EAF4837136E3808A6258E67F9EF" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e4351-wk-Fact-AF0A8D659B245F5E4277A6258E75B3E0" name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e4410-wk-Fact-CD7503101B1D97FE7B4DA6258E5EE9AC" name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e4518-wk-Fact-68335CE4E8B46E32A99AA6258E8A7ADF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e4576-wk-Fact-C53E2344CDD99C9DA233A6258E8DF9C2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of equity interests in redeemable noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e4598-wk-Fact-8065A33FE3BC9958E75EA680101F62E9" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Adjustment of redeemable noncontrolling interest</span></div><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e4765-wk-Fact-553DDC56FBF0AF164694A67F1FA4044B" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e4890-wk-Fact-FEEC64875C7F5EF75C2DA6810FD7B4AA" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e4910-wk-Fact-31CADB87CCF74DD2F2C1A6258E34EF14" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive gain, net of tax impact</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5038-wk-Fact-619F4F9716FF443336C9A6258E571550" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5076-wk-Fact-6032CF74833A27BB2656A6258EA10F0B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e5222-wk-Fact-0EEDA505BA1872D2C1DEA6258E718592" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e5242-wk-Fact-368EB0132B0845EE0BB7A6258E609A48" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Balance as of December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5264-wk-Fact-784A6A47FC82D5112436A6258E4E73D5" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5283-wk-Fact-481479906A5715583CFEA6258E6F49EA" name="us-gaap:SharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5297-wk-Fact-650ECFF3F15E7AE0D47EA6258E500B6F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5317-wk-Fact-65E087CD13D7333D1BB5A6258E5AE2B8" name="us-gaap:SharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">85,832,454</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5331-wk-Fact-07B2592A318983B625E6A6258E867DBF" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5350-wk-Fact-9BDB2607EE37C81DBFD9A6258E678A4B" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">764,033</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e5370-wk-Fact-08B637DCD4DC1CFDB473A6258E6A5D60" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e5390-wk-Fact-8A4CBE8A184AFC9AB561A6258E7D298A" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">280,799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5410-wk-Fact-2158FF91CAAC625B3D80A6258E2EC32E" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">483,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Cumulative effect adjustment for Topic 606 adoption</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5556-wk-Fact-CD7118FBB5EA8B711AF5A65AE9E58BAD" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5575-wk-Fact-754623305367FB8670D2A65AEDEC3D9A" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Cumulative effect adjustment for ASU 2018-07 adoption </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5682-wk-Fact-1F4029FAFCD0176E373EA659259A0188" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e5721-wk-Fact-E771CE1D173C901BF9F1A6592EF355EB" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5741-wk-Fact-C5F55928FFEE1BB7F11EA65932BCB594" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock upon follow-on offering, net of offering costs of $723</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5817-wk-Fact-D334E916D5ED370DD485A678AF937CAF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,175,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5851-wk-Fact-71103611F9819B68397AA67A589AA9C5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">349,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5909-wk-Fact-D80DB7845EAEFC246118A67AA61D4D90" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">349,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e5983-wk-Fact-D0E866893B056217E1D1A6258E66948A" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,999,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e6016-wk-Fact-957E7A0D9BC623236B24A6258E8A0F22" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e6074-wk-Fact-958399E96E998909F666A6258E66306B" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Vesting of restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e6148-wk-Fact-6B8935B982091915B203EE9B7CC2DD25" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">22,208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock exercised early</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e6346-wk-Fact-9511BE589CD72311C692EE92B5B07E4D" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">95</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e6404-wk-Fact-2DF306F21BAA283704E5A6258E7E4D25" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">95</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Common stock issued under employee stock purchase plan </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e6479-wk-Fact-9ED3ED7A51B767BFA96FEE9FFA079A86" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">232,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e6512-wk-Fact-00E045273C28358CC750EEA03E663580" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,395</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e6570-wk-Fact-B5F5E09DEE0A04900E1DEEA03E5D796A" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,395</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e6677-wk-Fact-082023D26E2DFE75FFFFA6258E8996F6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e6735-wk-Fact-5CF7741B94AE9AAFA946A6258E8F921B" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e6756-wk-Fact-C0BBC3EE13E30CBD6160A6258E7137FD" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e6881-wk-Fact-2F21490BC6438412F38CA6258E6ED04A" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e6901-wk-Fact-D077CEFD0B079FCF3D61A6258E2E6647" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive gain, net of tax impact</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e7029-wk-Fact-8943A091ED1540BBFD48A6258E80104C" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,194</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e7067-wk-Fact-D825F1C00002D1476452A6258EA6AC45" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,194</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e7213-wk-Fact-9E797B007E634194BBFAA6258E4DDBF8" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e7233-wk-Fact-329F61DE9C9E18698163A6258E4D1211" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e7260-wk-Fact-96EC9E7A002824BC9591A6258E4F713F" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e7274-wk-Fact-534506779DFDA28AAC2AA6258E6D56B9" name="us-gaap:SharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e7293-wk-Fact-5531DC2F54D9594B534AA6258E71A99F" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e7308-wk-Fact-D1CCA7E55C89588405B9A6258E4C34E6" name="us-gaap:SharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">94,261,414</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e7327-wk-Fact-53A8E7D91DDA2DA6CAF2A6258E83CCAA" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e7346-wk-Fact-D86A2CD29D99DA7B9516A6258E750491" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,150,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e7366-wk-Fact-638F26B618BA52D4D793A6258E48CC94" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d38105e7385-wk-Fact-4FCD1090338F4CC86BA4A6258E5CC293" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">352,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d38105e7405-wk-Fact-59A7633466DC3816626FA6258E32DB25" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">798,393</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">110</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">111</span></div></div><hr style="page-break-after:always"></hr><div><a id="s75DE4AE5FD78550A979FFBAA92A8ED69"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Guardant Health, Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OPERATING ACTIVITIES:</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1155-wk-Fact-DD9CA72B1BBB5CC40BD8A6258E32F7EC" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1175-wk-Fact-4A8DB7FF4A717BAB2EA3A6258E443A47" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1195-wk-Fact-FF90E30B64F2C7FBE5B5A6258EA91FF9" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1274-wk-Fact-B062B1261FFB69270A54A6258EA99214" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,411</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1293-wk-Fact-40E17ABB23FA741F33BFA6258E6C0A28" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1312-wk-Fact-CAD88392C12F20B538C6A6258E75105B" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of ROU</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1333-wk-Fact-0B3BCC71E68BD5F32F1A78109DD1F67F" name="gh:AmortizationOfRightOfUseAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d42770e1352-wk-Fact-C5C1B42A526B522C49C078109DD9E088" name="gh:AmortizationOfRightOfUseAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1371-wk-Fact-2972B587F40F465D1C6D78109E9086DA" name="gh:AmortizationOfRightOfUseAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized translation (gains) losses on obligation related to royalty   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1392-wk-Fact-86374F05F8E990E78695A6258E7D1013" name="gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1412-wk-Fact-40A9A74353E7AE18F10FA6258E549B1B" name="gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1432-wk-Fact-8BD476A52310851068DDA6258E7CF785" name="gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">980</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Re-valuation of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1453-wk-Fact-695859C2BE5BB8EA621AEEA6A0A443E2" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1472-wk-Fact-8BB9D959B78CF48BACD4EEA6A0A9B9A3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1491-wk-Fact-5370DB297AF9F34F6E4EEEA6A0B0F3D9" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash stock-based compensation   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1512-wk-Fact-FC7ECE6A56FC09C182ACA6258E831498" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1531-wk-Fact-527730141B1277FED241A6258E96C5EF" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1550-wk-Fact-C2C0DA4A45BAACB4C262A6258E6E8710" name="us-gaap:ShareBasedCompensation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash interest expense   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1572-wk-Fact-0CB62532CD6C5BA241DAA6258E3FCCAD" name="gh:NoncashInterestExpensePaid" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1591-wk-Fact-4D1A9E807312EF139FC0A6258E68AF64" name="gh:NoncashInterestExpensePaid" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1611-wk-Fact-411719B4308F46D87844A6258E868D04" name="gh:NoncashInterestExpensePaid" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on debt extinguishment   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1632-wk-Fact-043D7BA11E1A4E1E6280A6258E45617B" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1651-wk-Fact-136B8C09A698F74DEA31A6258E30FC6D" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1670-wk-Fact-63487DDF114014865E64A6258E356BB1" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of premium (discount) on marketable securities   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1691-wk-Fact-81EAE14B5C7B6F8026F0A6258E8B0E60" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1711-wk-Fact-956F0156A20189804BC4A6258E826A4E" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">412</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1731-wk-Fact-84AF50A89D0884814503A6258E4150F9" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">359</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit from income tax differences</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1752-wk-Fact-EC17940722CD7D2CCE95EEA815E45409" name="us-gaap:IncomeTaxCreditsAndAdjustments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1772-wk-Fact-EC3A4084AFC1C09AC7C6EEA815C51D58" name="us-gaap:IncomeTaxCreditsAndAdjustments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e1791-wk-Fact-48181F3FD7293B94A331EEA8163FF273" name="us-gaap:IncomeTaxCreditsAndAdjustments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1874-wk-Fact-BD724D67BB1D74DCFC05A6258E7D9A13" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,389</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1894-wk-Fact-E6C1C7437164DD97D89AA6258E46B590" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1914-wk-Fact-596C6979C26601F79712A6258E2CE5B2" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1936-wk-Fact-68B5376A5DDABE50737EA6258E7E24B2" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1956-wk-Fact-00A9F8E342670D7EA588A6258E8CBE9B" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,849</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1976-wk-Fact-E8B8D0381436169FDB09A6258E2CD2C2" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e1998-wk-Fact-13336E8061F2583A108CA6258E5479FE" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2018-wk-Fact-06B1B732AE9F4644AA6BA6258E443FDA" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,663</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2038-wk-Fact-27DD4DB22970BCE258E1A6258E47D822" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2059-wk-Fact-B822674454A57012AA1AA6258E497E92" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,852</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2079-wk-Fact-32ABBFA802FFCAB03689A6258EA9892D" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2099-wk-Fact-7B07C42F635C4D9045A2A6258E8431CD" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2121-wk-Fact-E90F3AA8BFA95A2195E8A6258E7FE4B0" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2140-wk-Fact-AE1F388039D4B100EE00A6258E2B0371" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2159-wk-Fact-16FF9C55E2B14233B960A6258E77904D" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2180-wk-Fact-6A02953E27D10A17FB39A6258EA99831" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2199-wk-Fact-E71096B42E8E297DC0B0A6258E999015" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2218-wk-Fact-1668DED7F2EBCB14F71EA6258E74AEBC" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2240-wk-Fact-AFB9950F937E81E83CBBA6258E45A65B" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2259-wk-Fact-340276766C20FA9BF230A6258E8A3034" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2278-wk-Fact-C1A9ABE0A5BA0427CC40A6258E9D96D0" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,657</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term operating lease liabilities net of ROU</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2299-wk-Fact-A55C716DDA3FB8642F12780F9DD28110" name="gh:LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,039</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2318-wk-Fact-E4DAB43EC3A33FF53F78780F9E75B3C5" name="gh:LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2337-wk-Fact-3409BD0946A5376D93E3780F9DD8D641" name="gh:LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred rent   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2358-wk-Fact-EC4916E930B61507508CA6258E441B98" name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2377-wk-Fact-F32490393809CC104A3AA6258E78F795" name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2396-wk-Fact-D7C5895A691EEC6DB3D9A6258E7389BE" name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2417-wk-Fact-5799D84240BD9D651211A6258E69E034" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,861</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2437-wk-Fact-452C6E1983A6DD9D24DAA6258E2B71C1" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2456-wk-Fact-999941ACCD8F64EBD397A6258E762177" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2477-wk-Fact-C8AACBF5D48B3452C188EEAFE4AD111F" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2496-wk-Fact-AEB445FA8EA2483BF062EEAFE4EE5A6A" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2515-wk-Fact-0443D46A09D03CC89928EEAFE494F0E2" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2536-wk-Fact-0E5C3F5EA9B9988A74EFA6258E7E9EB3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">47,134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2556-wk-Fact-20C2084CBAC2D5ECD3A9A6258E5ABC01" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2576-wk-Fact-8DA04641D9F40BD79AE7A6258E79CEF3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72,235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INVESTING ACTIVITIES:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2722-wk-Fact-47C6BC2745BE353D99ECA6258E74CA75" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">614,290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2742-wk-Fact-6414296C0D4282375112A6258E6AFFC6" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">287,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2762-wk-Fact-FA5A6F380F28BB143DB4A6258E72BCC9" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturity of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2784-wk-Fact-F963FDC84A13C2386FC1A6258EA74692" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">325,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2803-wk-Fact-D313BD034AF3E952FFDAA6258E865272" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2822-wk-Fact-46BEF93CAAEEC73B275DA6258E909900" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">75,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business acquisition, net of cash acquired </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2843-wk-Fact-BF82F088BEAA78851BE1EECB5087CAC8" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,328</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2863-wk-Fact-9AA2BAA5814C47532FECEECB508C44F6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2882-wk-Fact-7E1D1546D2F1D1C8DCB1EECB5093CFD2" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase of property and equipment   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2904-wk-Fact-43799ED6A01FAA7A9CB2A6258E6EE0C4" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,717</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2924-wk-Fact-4825724AF3CE76175E8DA6258E70AB53" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2944-wk-Fact-9C0244D82DFBC6FCE01DA6258E9F3599" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase of intangible assets and capitalized license obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e2966-wk-Fact-8A32F24289B2A4A393EBEECBBBDC573A" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e2986-wk-Fact-9A8E8D724A0C38372EB6EECBBBE3E380" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3005-wk-Fact-0995C1C96C12279EC995EECBBBD77B32" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment in connection with a license agreement   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3026-wk-Fact-97C8CCA91535576E796FA6258E29D949" name="gh:PaymentsInConnectionWithLicenseAgreements" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3046-wk-Fact-B6B455A20F5BB55A3655A6258E7C087D" name="gh:PaymentsInConnectionWithLicenseAgreements" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3065-wk-Fact-6E8B228FB63B6B308ACEA6258E976EB9" name="gh:PaymentsInConnectionWithLicenseAgreements" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3087-wk-Fact-327AAE6B25258AD57064A6258E761269" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">317,570</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3107-wk-Fact-444CC6E07F59D0173BE4A6258E712693" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">153,028</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3127-wk-Fact-C957C19A88AE82D33A7DA6258E692500" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">170,416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCING ACTIVITIES:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment related to settlement of debt and buyout of royalty obligations   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3273-wk-Fact-364C680433E936E523B7A6258E91225D" name="gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3293-wk-Fact-BF5677E2461E53807183A6258E8CBFB0" name="gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3312-wk-Fact-A65AB8B729EE78CCB916A6258E7737E6" name="gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,844</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments made on capital lease obligations   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3334-wk-Fact-4F7238D6DE482E85DF22A6258E84FA8E" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3354-wk-Fact-2CE49154B582C1D315E3A6258E8E814A" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">443</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3374-wk-Fact-A80BB693DA87D2500EABA6258E8136DA" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of convertible preferred stock, net of issuance costs   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3396-wk-Fact-36BC709343FE2F62A35DA6258E46A74A" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3415-wk-Fact-322AE5F732A4DDF0CD63A6258E870DF9" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3434-wk-Fact-CBDA46C2C006472D6306A6258E83423A" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">319,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">112</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock under employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3475-wk-Fact-66CC9DCC2725E6EE0D72EED222F1163C" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,395</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3494-wk-Fact-21BE3C7D2442104A4144EED222904E2F" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3513-wk-Fact-F4D09867FE0F44CED433EED2226DE79D" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock upon exercise of stock options   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3534-wk-Fact-D5E294EDA3CAD38C5E2DA6258E6F291C" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3553-wk-Fact-C9610AA671969BD70C57A6258E6CB0C7" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3572-wk-Fact-98DA59601E9AB5CEE3D4A6258E6455FF" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock upon the exercise of warrants   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3593-wk-Fact-48822D392392C6C75C00A6258E7A7255" name="us-gaap:ProceedsFromWarrantExercises" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3612-wk-Fact-15B1DE2DED142F0EA092A6258E786734" name="us-gaap:ProceedsFromWarrantExercises" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3631-wk-Fact-EE9A3E73CF4865C3DF1DA6258E80D532" name="us-gaap:ProceedsFromWarrantExercises" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repurchase of convertible preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3652-wk-Fact-799468E3C03215130187A6258E88D309" name="us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3671-wk-Fact-4BDECA21E4F6B47914ECA6258E79E565" name="us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3690-wk-Fact-4D0755D9DCFCCD33CA32A6258E407DD3" name="us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repurchase of common stock   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3712-wk-Fact-B8947F769C147625B299A6258E9060B9" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3731-wk-Fact-A7A02ABDE893288E8B81A6258E2979F1" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3751-wk-Fact-49A0F4DCDB910BB4A20BA6258E885C75" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from public offerings of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3773-wk-Fact-0E1F20ACF630A31A34A8EECFFD719DCB" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">350,432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3792-wk-Fact-C98D0721C8F2F31FD34AA6258E8DDF1A" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">254,006</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3811-wk-Fact-F6DA493335109C59404BA6258E709B00" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment of offering costs related to public offerings of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3832-wk-Fact-D9EB8980E54E77B8771CEED0245AEDF4" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d42770e3852-wk-Fact-250821B5ADE1605E55B1A6258E31319B" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,386</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3872-wk-Fact-9AAA0DF72545A22C0C9BA6258E8C3494" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net proceeds from issuance of equity interests in redeemable noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3893-wk-Fact-F5DB2BC7D2979730E347A6258E6C43EF" name="us-gaap:ProceedsFromMinorityShareholders" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3912-wk-Fact-37642EDCB2E2680BA7B8A6258E64EE98" name="us-gaap:ProceedsFromMinorityShareholders" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3931-wk-Fact-6C00D544842BF44D9FB6A6258E8975F1" name="us-gaap:ProceedsFromMinorityShareholders" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3952-wk-Fact-7A19ED48037D49910E57A6258E7AE6BD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">367,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3971-wk-Fact-8B90ADD0424CE4381980A6258E435DB5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">293,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e3990-wk-Fact-1B53BC142360F8BA19C8A6258E3A8C2D" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">281,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4011-wk-Fact-68A445988AC1B0CEA8E2EEDBB9034ED0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4030-wk-Fact-5724F477FA6BCEA5195EEEDBB887EDB4" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4049-wk-Fact-D9E1D34F03294FFACB75EEDBB8ACB894" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net increase in cash, cash equivalents and restricted cash   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4070-wk-Fact-BACDB46B3A61CF8D88B7A6258E9EE8F1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4089-wk-Fact-444550461EBB1F7975B0A6258E8BDB96" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">67,948</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4108-wk-Fact-D1E56F5CE9D53FDB0D80A6258E6B2A44" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,005</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash - Beginning of period   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4130-wk-Fact-4DFB52891D1C2A2BF3B6A6258E2BA807" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4149-wk-Fact-2EA92269F4995E4107BDA6258E6D0295" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4168-wk-Fact-01D1C015B3460FF565A4A6258E96B037" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash - End of period   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4194-wk-Fact-E0E98295F85918915C83A6258E8552B4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">143,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4213-wk-Fact-4DFB52891D1C2A2BF3B6A6258E2BA807" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4232-wk-Fact-2EA92269F4995E4107BDA6258E6D0295" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental Disclosures of Cash Flow Information:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities arising from obtaining right-of-use assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d42770e4315-wk-Fact-DE8F9DD13CC53A32D020780DC9666B9F" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d42770e4334-wk-Fact-CECC9DB95DB392D79A5E780DC977C264" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d42770e4353-wk-Fact-BD2F9B865745932BA691780DC96B9B20" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for interest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4374-wk-Fact-EBDA9ACC7D4A511633DDA6258E7541BF" name="us-gaap:InterestPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4393-wk-Fact-8B291B4FD288FEEA1C4CA6258E739680" name="us-gaap:InterestPaidNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4412-wk-Fact-E07E556F81F890D4BDADA6258E48E1F3" name="us-gaap:InterestPaidNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4433-wk-Fact-911858A5574499D7E879A6258E8ECD16" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4452-wk-Fact-5BAE0DEAC219AC0A9E94A6258EA8557E" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4471-wk-Fact-A49D5AAA74624769A7F4A6258E6E1418" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental Disclosures of Noncash Investing and Financing Activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capitalized license fees financed through future royalty payment   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4554-wk-Fact-0CB3785580E45D59B29BA6258E5D94CD" name="gh:CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4573-wk-Fact-AF86E56277F0A7E21670A6258E7F4B77" name="gh:CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4592-wk-Fact-58B5EEDDA726BAC8B741A6258E8FB03B" name="gh:CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of Series D convertible preferred stock in exchange for a technology license agreement   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4613-wk-Fact-FF6217A3D0CAEA627C93A6258E6FD7F9" name="gh:ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4632-wk-Fact-2974C3D2DBD5D57C4113A6258E6D22FF" name="gh:ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4651-wk-Fact-1B429475A124591BB7B5A6258E6D5F3D" name="gh:ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increase in purchases of property and equipment included in accounts payable and accrued expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4672-wk-Fact-6A1353FD0C7582C33455A6258E8B206E" name="gh:IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4691-wk-Fact-6DD42BA88FBAEB9D097FA6258EA11A28" name="gh:IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4710-wk-Fact-3E4BCCDE23AB5F9B22F7A6258E880EA3" name="gh:IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vesting of common stock exercised early   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4731-wk-Fact-B70D11D0006DB0912E00A6258E8E6197" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">95</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4750-wk-Fact-5ED46B953A8D90E8D32EA6258E728452" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4769-wk-Fact-6049FA07A2AA1BB0B62BA6258E3D031A" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment acquired under capital leases   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4791-wk-Fact-5A937AF22FE1A08518ACA6258EA4D88C" name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4810-wk-Fact-448A23C1966023A8AF3DA6258EA74AA6" name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4829-wk-Fact-35854CB4A562CBD9391DA6258E8CFEA5" name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">346</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Conversion of convertible preferred stock to common stock upon initial public offering</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4850-wk-Fact-DFC28B95A79F22FB2A34A6258E2BF2F9" name="gh:ConversionofStockUponInitialPublicOffering" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4869-wk-Fact-1A3D9852821976386641A6258E7B0A01" name="gh:ConversionofStockUponInitialPublicOffering" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">499,974</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4888-wk-Fact-4A3E7735E42D490B1A4EA6258E79F946" name="gh:ConversionofStockUponInitialPublicOffering" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Initial fair value of contingent consideration at acquisition date </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4909-wk-Fact-3A3DA23C593B0141B1A4EEEDE8192884" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,065</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4928-wk-Fact-4FE428D8EA7AC7B7AE58EEEDE89F7AE7" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4947-wk-Fact-668D3026A3C296FCB53AEEEDE83E35D7" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:18px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred offering costs included in accounts payable and accrued expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4968-wk-Fact-59DF0DBD277CEB7C7D6CA6258E8F3E30" name="gh:OfferingCostsIncurredbutNotyetPaid" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e4987-wk-Fact-38BFD28FFD4341E8AA92A6258E899F67" name="gh:OfferingCostsIncurredbutNotyetPaid" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d42770e5006-wk-Fact-D2D03B7FEE0503F33914A6258E8B9CF6" name="gh:OfferingCostsIncurredbutNotyetPaid" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">113</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5B46EB9B1D095F189132C492B3C6520E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Guardant Health, Inc.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div><a id="sD61AE74E687A5256A39758CED15FB3FB"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">1. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="TextSelection-DBB1898643B7CE5D6759A6258EB4A5D6-0-wk-Fact-BB5AD0EA84DD4FAB7F0DA6258E6C1CCE" continuedAt="TextSelection-DBB1898643B7CE5D6759A6258EB4A5D6-1" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="TextSelection-DBB1898643B7CE5D6759A6258EB4A5D6-1"><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Guardant Health, Inc. (the &#8220;Company&#8221;) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which it enables by a routine blood draw, or liquid biopsy. The Guardant Health Oncology Platform is designed to leverage the Company&#8217;s capabilities in technology, clinical development, regulatory, reimbursement and commercial adoption to improve patient clinical outcomes, lower healthcare costs and accelerate biopharmaceutical drug development. In pursuit of its goal to manage cancer across all stages of the disease, the Company has launched its Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer patients, and is developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In April 2018, the Company established Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) in the United States with an entity affiliated with SoftBank. Under the terms of the joint venture agreement, the Company held a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43018e880-wk-Fact-71D9EEE1A0CD32387F70A6258E902245" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2018Q2Apr30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest in the Joint Venture. The Joint Venture has subsidiaries in Singapore and Japan (see Note 3,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Investment in Joint Venture</span><span style="font-family:inherit;font-size:10pt;">) and the Company has a subsidiary in Switzerland which was incorporated in 2019.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company&#8217;s Board of Directors and its stockholders approved a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43018e894-wk-Fact-ADE4A68992916C4D7D34A6258E8E969C" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="D2018Q3Sep19" unitRef="number" decimals="4" scale="0" format="ixt:numdotdecimal">0.7378</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">-for-one reverse stock split of the Company&#8217;s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the Company&#8217;s initial public offering (the &#8220;IPO&#8221;).  All share and per share amounts in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Approval of Amended and Restated Certificate of Incorporation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September&#160;2018, the Company&#8217;s Board of Directors and stockholders approved an amended and restated certificate of incorporation, which authorized </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43018e904-wk-Fact-B6A5E87AA10E1E450EB587A865675956" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2018Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">350,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43018e908-wk-Fact-A432DE2994BC4AD113D487A84B9CE174" name="us-gaap:PreferredStockSharesAuthorized" contextRef="FI2018Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock. The amended and restated certificate of incorporation became effective on October 9, 2018.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 9, 2018, the Company completed the IPO, in which it issued and sold </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43018e918-wk-Fact-A4903E7BDC376AB5D527A6258E90BAEF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,375,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at a public offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43018e922-wk-Fact-6D513932D4FBBB2C60FBA6258E6A82E0" name="us-gaap:SaleOfStockPricePerShare" contextRef="I2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">19.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. The Company received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43018e926-wk-Fact-05123C85F25836BFDC65A6258E8F0BDF" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="D2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">249.5</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million after deducting underwriting discounts and commissions and offering expenses payable by the Company. All then-outstanding warrants to purchase the Company&#8217;s common stock were exercised prior to the completion of the IPO. </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In addition, in connection with the IPO,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">all shares of the Company&#8217;s then-outstanding convertible preferred stock were automatically converted into </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43018e936-wk-Fact-E2D0FF8793DD041F4F6FCF4496FAB72B" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="I2018Q4Oct9_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">58,264,577</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock, and all then-outstanding warrants to purchase the Company&#8217;s convertible preferred stock were automatically converted into warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43018e941-wk-Fact-C3CF7ED03157D5A518FFCF44DE8F2817" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="I2018Q4Oct9_us-gaap_ClassOfWarrantOrRightAxis_gh_WarrantsPreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,636</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Follow-on Offering</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company completed an underwritten public offering, in which it issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43018e954-wk-Fact-24441838FD19FADE8E7EEF14FA2DAB4A" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q2May" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,175,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of its common stock (including the exercise in full of the underwriters&#8217; over-allotment option to purchase&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43018e958-wk-Fact-5459A2E6D8D84FC4A772EF16003CAF22" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q2May_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">675,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;additional shares) at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43018e962-wk-Fact-B100FE920B9098A1600CEF0EAEF7DD28" name="us-gaap:SharesIssuedPricePerShare" contextRef="I2019Q2May31" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">71.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company received net proceeds of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43018e966-wk-Fact-BFFF2C6D2159E772523EEF11FC1BD5AD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2019Q2May" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">349.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">114</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF05A4A516DF35197B7CB95C781CF47E9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">2. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-38F18625E00267BD0051A6258EB62A7E-0-wk-Fact-3A356495F14F6AE0DDD7A6258EA2A02A" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-1" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-25435946BBC3D479B38FA6258EB4C960-0-wk-Fact-36D3157E3F089B77229CA6258EA595A1" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#8217; interests in the Joint Venture are shown in the consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company believes that its existing cash and cash equivalents and marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:UseOfEstimates" id="TextSelection-ABF1DB6225C983D0ABF5A6258EB67068-0-wk-Fact-4D389012F41CD1A4724BA6258E9545CF" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations,&#160;goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="gh:JOBSActAccountingElectionPolicyTextBlock" id="TextSelection-FFC6327D42FFF21A80DCA6258EB523B7-0-wk-Fact-7F90C03F4D3331669FFFA6258E9C4E66" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">JOBS Act Accounting Election</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective December 31, 2019, we are no longer an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Prior to losing our status as an emerging growth company, the JOBS Act allowed us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements were made applicable to private companies, and we had elected to use this extended transition period.&#160;We can no longer take advantage of this extended transition period. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="TextSelection-D3152085D246544562EDA6258EB453AF-0-wk-Fact-B3BBFC398DEAE1B25BEEA6258EA30FCE" continuedAt="TextSelection-D3152085D246544562EDA6258EB453AF-1" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><ix:continuation id="TextSelection-D3152085D246544562EDA6258EB453AF-1" continuedAt="TextSelection-D3152085D246544562EDA6258EB453AF-2"><span style="font-family:inherit;font-size:10pt;">The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#8217; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the consolidated statements of operations. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-D3152085D246544562EDA6258EB453AF-2">, foreign currency translation adjustment was immaterial. </ix:continuation>For the year ended December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company did not have foreign currency translation adjustment as the foreign subsidiaries were established in 2018.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="TextSelection-B0FB0113A8286071EB11A6258EB48F4E-0-wk-Fact-70D87E20E84BBEB7CCE7A6258E942306" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company operates as one operating and reportable segment. The Company&#8217;s chief operating decision makers, the Chief Executive Officer, and the President and Chief Operating Officer, manage the Company&#8217;s operations on an aggregate basis for purposes of allocating resources.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">115</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-2" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="TextSelection-50290207811D8392D546A6258EB5880B-0-wk-Fact-5AAE5A4A22BF6DE9E12DA6258EA1A58F" continuedAt="TextSelection-50290207811D8392D546A6258EB5880B-1" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments with original maturities at the time of purchase of three months or less.&#160;Cash equivalents include bank demand deposits and money market accounts that invest primarily in U.S. government-backed securities and treasuries. Cash equivalents are carried at cost, which approximates their fair value.</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-50290207811D8392D546A6258EB5880B-1">In fiscal 2017, restricted cash consists of deposits related to the Company&#8217;s corporate credit card.</ix:continuation> The Company did not have any restricted cash as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:MarketableSecuritiesPolicy" id="TextSelection-7AA20F4AA6A01F35596FA6258EB7C0D5-0-wk-Fact-CAF885DC7B77C194C7F9A6258E994572" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities consist primarily of high-grade corporate bonds, commercial papers and certificates of deposit with third parties. Marketable securities with original maturities at the time of purchase between three and twelve months from balance sheet dates are classified as short-term marketable securities and those with maturities over twelve months from balance sheet dates are classified as long-term marketable securities. The Company classifies all marketable securities as available-for-sale, which are recorded at fair value. Unrealized gains and losses are included in accumulated other comprehensive loss in stockholders&#8217; equity. Any premium or discount arising at purchase is amortized or accreted to interest income or expense. Realized gains and losses and declines in value, if any, judged to be other than temporary on available&#8209;for&#8209;sale securities are reported in other income (expense), net. When securities are sold, any associated unrealized gain or loss initially recorded as a separate component of stockholders&#8217; equity is reclassified out of stockholders&#8217; equity on a specific&#8209;identification basis and recorded in earnings for the period.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not that it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and management&#8217;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ConcentrationRiskCreditRisk" id="TextSelection-458811539D1E0AA903E1A6258EB6AC5D-0-wk-Fact-F6822369679C11FF56A3A6258EA08AFC" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also invests in investment&#8209;grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after&#8209;tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="TextSelection-BFC253F18F7406671915A6258EB66166-0-wk-Fact-5D8A5889367A3CED68CFA6258EA7523A" continuedAt="TextSelection-BFC253F18F7406671915A6258EB66166-1" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective consolidated balance sheet date, are as follows:</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">116</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-3" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-4"><ix:continuation id="TextSelection-BFC253F18F7406671915A6258EB66166-1" continuedAt="TextSelection-BFC253F18F7406671915A6258EB66166-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:39%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Accounts Receivable</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer A   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e1377-wk-Fact-DAA0F8E88A8486A32675A6258E8A24B5" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_gh_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer B   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e1422-wk-Fact-0DA4B97C077E6E6DEDBFEF246E98DB68" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e1437-wk-Fact-FF3AC7BA5638D1E40650A6258E899A23" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e1452-wk-Fact-AE23964FA90CF67F44E6AA387E66ADC1" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e1467-wk-Fact-78320D385AE888A5740C781C6AFE258C" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e1483-wk-Fact-FF23F2397F29CB98C44CA6258E8C49F0" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer C   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e1541-wk-Fact-BBEDAC7B2E5B07C11B8CEF25661E7C18" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e1572-wk-Fact-FDA4BC74556D1126C68391CD066CA193" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-BFC253F18F7406671915A6258EB66166-2" continuedAt="TextSelection-BFC253F18F7406671915A6258EB66166-3"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-BFC253F18F7406671915A6258EB66166-3"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">less than 10%</span></div></ix:continuation></td></tr></table><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ReceivablesPolicyTextBlock" id="TextSelection-EAB0ED0129DEF5180BA7A6258EB5D42E-0-wk-Fact-53C8F2F4B5AD5A67F820A6258EA72B71" continuedAt="TextSelection-EAB0ED0129DEF5180BA7A6258EB5D42E-1" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-EAB0ED0129DEF5180BA7A6258EB5D42E-1">Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses.</ix:continuation> As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e1664-wk-Fact-4B1F04EC0A27BDA65F92A6258EA7A876" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="FI2019Q4" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> allowance for doubtful accounts.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InventoryPolicyTextBlock" id="TextSelection-498052C4C09176AA8A64A6258EB7F9CB-0-wk-Fact-B413DAE7EFBC65B03051A6258EA8617D" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory consisted entirely of supplies, which are consumed when providing liquid biopsy tests, and therefore the Company does not maintain any finished goods inventory.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by the Company, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Amounts written-down due to unmarketable inventory are recorded in cost of precision oncology testing.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="TextSelection-4268DE8F01DB20E2157AA6258EB72BC1-0-wk-Fact-F3B7E9A3CE8210058924A6258E967D4B" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost. Depreciation is computed over estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The Company periodically reviews the depreciable lives assigned to property and equipment placed in service and changes the estimates of useful lives, if necessary. Maintenance and repairs are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-64DFF5E6BD39A6BC70E0A6258EB5D05C-0-wk-Fact-8506191ED15D4E85BC1FA6258E91F782" continuedAt="TextSelection-0D3B7F065313444AC2DFA6258EB76C8F-0" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated useful lives for property and equipment are as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Property and Equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated&#160;Useful&#160;Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3 &#8211; 5 years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7 years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer hardware and computer software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3 years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lesser of estimated useful life or remaining lease term</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessCombinationsPolicy" id="TextSelection-FD68FCA0AB7CFFE96B35EF38AA0B4E31-0-wk-Fact-8F10849A834E574279A0EF3971169D3F" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company includes the results of operations of the businesses that are acquired as of the acquisition date. The Company allocates the purchase price of acquisitions to the assets acquired and liabilities assumed based on the estimated fair values. The excess of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition related costs are recognized separately from the business combination and are expensed as incurred.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">117</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-4" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-5"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="TextSelection-1107D69A7CFDBC6DFFD5EF39BE6AE556-0-wk-Fact-647C3FEDE7F1A0391814EF3A6C529912" continuedAt="TextSelection-1107D69A7CFDBC6DFFD5EF39BE6AE556-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Intangible Assets, net</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets related to in-process research and development costs (&#8220;IPR&amp;D&#8221;) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there has been&#160;no&#160;impairment of goodwill.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><ix:continuation id="TextSelection-1107D69A7CFDBC6DFFD5EF39BE6AE556-1" continuedAt="TextSelection-1107D69A7CFDBC6DFFD5EF39BE6AE556-2"><span style="font-family:inherit;font-size:10pt;">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6-</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d46357e1854-wk-Fact-2DC399A5A549CC34F9F3EF3D4378DC5F" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:duryear">10</ix:nonNumeric> years</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-1107D69A7CFDBC6DFFD5EF39BE6AE556-2">.</ix:continuation>  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="gh:ObligationRelatedtoRoyaltyPolicyTextBlock" id="TextSelection-4C79470F2DA3A2EE10E9A6258EB6F2C4-0-wk-Fact-38BE6A9F0C2F99D291C5A6258E99B163" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Obligation Related to Royalty</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of the Company&#8217;s asset acquisitions involve the potential for future payment of consideration that is contingent upon the royalty payments due on future product net sales, subject to annual minimums. The fair value of such liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="TextSelection-F43F9EF791C11130E338A6258EB57F8F-0-wk-Fact-B302DE4C92B78911B6B7A6258E9BA1FD" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment for Long-Lived Assets</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeLeasesPolicyTextBlock" id="TextSelection-A6E20FAF8E4F440E437C784CA0CEDB7F-0-wk-Fact-8E3B69F259C0B4BF341F784CF02CE585" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-7E6334ECD450BEE940B3A6258EB65E6D-0-wk-Fact-B8C76FA7F19A9E4B4A59A6258E997A5E" continuedAt="TextSelection-7E6334ECD450BEE940B3A6258EB65E6D-1" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition under ASC 606</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include companion diagnostic development, information solutions and laboratory services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">118</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-7E6334ECD450BEE940B3A6258EB65E6D-1" continuedAt="TextSelection-7E6334ECD450BEE940B3A6258EB65E6D-2"><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-5" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-6"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, we adopted the new revenue recognition standard FASB ASC Topic 606,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">,&#160;or ASC 606. Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Precision oncology testing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Development services</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations. The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">119</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-7E6334ECD450BEE940B3A6258EB65E6D-2"><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-6" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-7"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contracts with multiple performance obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated. For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contract assets</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable.&#160;Contract assets are presented under accounts receivable and other assets on the Company&#8217;s consolidated balance sheets. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had contract assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e1960-wk-Fact-2F1263100D85C236F7F0784F8E62FB0C" name="us-gaap:ContractWithCustomerAssetNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e1964-wk-Fact-521C42450508B3BB0CD2784FD96F4D41" name="us-gaap:ContractWithCustomerAssetNet" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is recorded in other assets in the consolidated balance sheet.  The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e1968-wk-Fact-9525492D58552333B8E77850FEBCEDDB" name="us-gaap:ContractWithCustomerAssetNet" contextRef="I2019Q1Jan1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of contract assets as of January 1, 2019. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred revenue </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company&#8217;s performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the deferred revenue balance was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e1992-wk-Fact-4CC8DCB50DBCFA2CF78BA6258E9DECD6" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e1996-wk-Fact-7B451599D3639134B38AA6258EA4983B" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which included </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e2000-wk-Fact-A5CAA86878EF6C31B11AA6258E96EBB3" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e2005-wk-Fact-60419A91375B78193646A6258EA8AB24" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the&#160;twelve months ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">&#160;that was included in the deferred revenue balance as of January 1, 2019 was&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e2013-wk-Fact-1E630130A5494378B71DEF5C99F22B33" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which primarily represented revenue from&#160;provision of development services under the collaboration agreement with our biopharmaceutical companies.&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Transaction price allocated to the remaining performance obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d46357e2028-wk-Fact-2A9E293824A505C50FCF7854B9267D91" name="us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" contextRef="FI2019Q4_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-01-01" format="ixt-sec:durmonth">12</ix:nonNumeric> months</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">120</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-7" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-8"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition under ASC 605</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include the development of new platforms and information solutions, including companion diagnostic development and laboratory services. The Company currently receives payments from commercial third-party payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when all of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Criterion (i) is satisfied when the Company has an arrangement or contract in place. Criterion (ii) is satisfied when the Company delivers a test report corresponding to each sample, without further commercial obligations. Determination of criteria (iii) and (iv) are based on management&#8217;s judgments regarding whether the fee is fixed or determinable, and whether the collectability of the fee is reasonably assured. The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians, if criteria (i) through (iv) above are met. The Company recognizes revenue on a cash basis when it cannot conclude that criteria (iii) and (iv) have been met. Most of precision oncology tests requested by clinical customers are sold without a contracted engagement with a third-party payer; therefore, the Company experiences significant variability in collections and does not have sufficient history to establish a predictable pattern of payment. Because the price is not fixed or determinable and collectability is not reasonably assured, the Company recognizes revenue on a cash basis for sales of its liquid biopsy tests to clinical customers where collection depends on a third-party payer or the individual patient. The Company uses judgment in its assessment of whether the fee is fixed or determinable and whether collectability is reasonably assured in determining when to recognize revenue. Accordingly, the Company expects to recognize revenue on a cash basis for these clinical customers until it has sufficient history to reliably estimate payment patterns. The Company&#8217;s precision oncology information services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from sales of the Company&#8217;s tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume, data access or biopharmaceutical research and development services over a defined period. The Company recognizes revenue upon delivery of the test results, or over the period in which biopharmaceutical research and development services are provided, as appropriate.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple-element arrangements.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Contracts with biopharmaceutical customers are primarily analyzed as multiple-element arrangements given the nature of the service deliverables. For development services performed, the Company is compensated in various ways, including (i) through non-refundable regulatory and other developmental milestone payments; and (ii) through royalty and sales milestone payments. The Company performs development services as part of its normal activities. The Company records these payments as development services revenue in the consolidated statements of operations using a proportional performance model over the period which the unit of accounting is delivered or based on the level of effort expended to date over the total expected effort, whichever is considered the most appropriate measure of performance. For development of new products or services under these arrangements, costs incurred before technological feasibility is assured are included as research and development expenses in the Company&#8217;s consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services. The Company collaborates with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations the Company generates revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For revenue arrangements with multiple deliverables, the Company evaluates each deliverable to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has stand-alone value to the customer and whether a general right of return exists. In assessing whether an item has standalone value, the Company considers factors such as the research, development and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the other party in the arrangement can use the other deliverables for their intended purpose without the receipt of the remaining elements, whether the value of the deliverable is dependent on the undelivered items and whether there are other vendors that can provide the </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">121</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-8" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-9"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">undelivered elements. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The Company allocates the arrangement consideration following a hierarchy to determine the relative selling price to be used for allocating revenue to deliverables: (i) vendor-specific objective evidence of fair value (&#8220;VSOE&#8221;), (ii) third-party evidence of selling price (&#8220;TPE&#8221;), and (iii) best estimate of the selling price (&#8220;BESP&#8221;) if neither VSOE nor TPE is available. The Company typically uses BESP to estimate the selling price, since it generally does not have VSOE or TPE of selling price for its units of accounting under multiple-element arrangements. In developing the BESP for a unit of accounting, the Company considers applicable market conditions and estimated costs. The Company validates the BESP for units of accounting by evaluating whether changes in the key assumptions used to determine the BESP will have a significant effect on the allocation of arrangement consideration between multiple units of accounting. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. The Company uses judgment in identifying the deliverables in its arrangements, assessing whether each deliverable is a separate unit of accounting and in determining the best estimate of selling price for certain deliverables. The Company also uses judgment in determining the period over which the deliverables are recognized in certain of its arrangements. Any amounts received that do not meet the criteria for revenue recognition are recorded as deferred revenue until such criteria are met. The Company performed laboratory installation and maintenance services for one of its customers as part of a multiple-element arrangement entered into in 2017. The Company recognized certain revenue from its construction service deliverables in a multiple-element collaboration arrangement based on the completed-contract method. This method was used as the Company determined that it did not have the basis for estimating performance under the contract. Other construction service deliverables under that contract were recognized under the percentage-of-completion method due to the Company&#8217;s ability to make reasonably dependable estimates of the extent of progress toward contract completion. All construction services under this arrangement were completed in March 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestones</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes payments that are contingent upon achievement of a substantive milestone in their entirety in the period in which the milestone is achieved. Milestones are defined as events that can only be achieved based on the Company&#8217;s performance and there is substantive uncertainty about whether the event will be achieved at the inception of the arrangement. Events that are contingent only on the passage of time or only on counterparty performance are not considered substantive milestones. Further, the amounts received must relate solely to prior performance, be reasonable relative to all of the deliverables and payment terms within the agreement and commensurate with the Company&#8217;s performance to achieve the milestone after commencement of the agreement. Any contingent payment that becomes payable upon achievement of events that are not considered substantive milestones are allocated to the units of accounting previously identified at the inception of an arrangement when the contingent payment is received and revenue is recognized based on the revenue recognition criteria for each unit of accounting. Revenue from commercial milestone payments are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="gh:CostsofPrecisionOncologyTestingPolicyTextBlock" id="TextSelection-26A4C6EB9917A93AD619A6258EB538E2-0-wk-Fact-7A347F07F774283E9EE5A6258EA314D4" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs of Precision Oncology Testing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="gh:CostofDevelopmentServicesPolicyTextBlock" id="TextSelection-72D73ED5151CF3D8F9AFA6258EB5E181-0-wk-Fact-EBDF08374808E7FCC123A6258E9C6E41" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Development Services</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of development service includes costs incurred for the performance of development services requested by the Company&#8217;s customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="TextSelection-0CB5436E0F1FEDB3F7CDA6258EB7EB7B-0-wk-Fact-D80E2A8F3952EF166DE1A6258E9EF73B" continuedAt="TextSelection-0CB5436E0F1FEDB3F7CDA6258EB7EB7B-1" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses are comprised of costs incurred to develop technology and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development expenses </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">122</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-9" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-10"><ix:continuation id="TextSelection-0CB5436E0F1FEDB3F7CDA6258EB7EB7B-1"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">also include costs related to activities performed under contracts with biopharmaceutical companies. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#8217;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="TextSelection-679E083033BBAA341A12A6258EB5FC0B-0-wk-Fact-F08CDB65B47F7115FDC8A6258EA8B91A" continuedAt="TextSelection-679E083033BBAA341A12A6258EB5FC0B-1" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-679E083033BBAA341A12A6258EB5FC0B-1">The Company expenses advertising costs as incurred.</ix:continuation> The Company incurred advertising costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e2152-wk-Fact-FF447140591007E81626A6258E95A48B" name="us-gaap:AdvertisingExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e2156-wk-Fact-6854C5E6363933A89AEBA6258E9B6ED2" name="us-gaap:AdvertisingExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e2160-wk-Fact-BD61C9ACCA11202D7941A6258E91C488" name="us-gaap:AdvertisingExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DeferredChargesPolicyTextBlock" id="TextSelection-7D99061816A04DF0038FA6258EB6ED0B-0-wk-Fact-29CE08ED0806B4D4D445A6258EA9CE46" continuedAt="TextSelection-7D99061816A04DF0038FA6258EB6ED0B-1" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Offering Costs</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-7D99061816A04DF0038FA6258EB6ED0B-1">Deferred offering costs consist of fees and expenses incurred in connection with the anticipated sale of the Company&#8217;s common stock in the IPO, including the legal, accounting, printing and other IPO-related costs.</ix:continuation> In October 2018, upon completion of the IPO, the Company reclassified deferred offering costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e2188-wk-Fact-6D3D12B968B75764DFC9A6258EA9CB02" name="us-gaap:DeferredOfferingCosts" contextRef="I2018Q4Oct31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> into additional paid-in capital as a reduction of the net proceeds received from the IPO. There were no deferred offering costs as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="TextSelection-BCA558D8919E80E6F25FA6258EB56644-0-wk-Fact-6143684B7852FD01825CA6258EA297FF" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock&#8209;Based Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock&#8209;based compensation related to stock options granted to the Company&#8217;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, the Company accounted for stock options issued to nonemployees consultants based on the estimated fair value at the grant date and re-measured at each reporting period. Starting January 1, 2019, upon adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2018-07,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718)</span><span style="font-family:inherit;font-size:10pt;">,&#160;Improvements to Nonemployee Share-Based Payment Accounting,&#160;the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the Black&#8209;Scholes option&#8209;pricing model to estimate the fair value of its stock options and purchase rights under its 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Starting January 1, 2017, forfeitures are accounted for as they occur.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for restricted stock units issued to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in the Company&#8217;s consolidated statement of operations on a straight-line basis over the requisite vesting period.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxPolicyTextBlock" id="TextSelection-590DB43CA205803F0E38A6258EB67EFE-0-wk-Fact-C9381ADDC3220418D364A6258E9F1ADC" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes are recorded using an asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">123</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-10" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-11"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EarningsPerSharePolicyTextBlock" id="TextSelection-16FBB4235DBB5751E9D1A6258EB5C70A-0-wk-Fact-7E5F235B4C5942862AE9A6258E971A44" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the closing of the Company&#8217;s IPO in October 2018 and the conversion of its convertible preferred stock into common stock, the Company calculated its basic and diluted net loss per share attributable to common stockholders of the Company in conformity with the two-class method required for companies with participating securities. The Company considered its convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on the Company&#8217;s common stock, holders of convertible preferred stock were entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock did not have a contractual obligation to share in the Company&#8217;s losses.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-9DA0AF7B64619413413EA6258EB63D1C-0-wk-Fact-C4157E84F500185022E0A6258EA5A6E9" continuedAt="TextSelection-9DA0AF7B64619413413EA6258EB63D1C-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Adopted </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2014-09,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)&#160;and all related amendments (collectively, &#8220;ASC 606&#8221;)</span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2019 utilizing the modified retrospective method. The cumulative effect of applying the standard to all contracts that were not completed as of the date of initial application was recognized to beginning accumulated deficit as of January 1, 2019. The Company identified certain differences in accounting for revenue recognition as a result of the adoption of ASC 606 which have impacted its financial position and results of operations.  For precision oncology testing revenue with certain clinical customers, the Company historically deferred revenue recognition until cash receipt when the price pursuant to the underlying customer arrangement became fixed and determinable and collectability became reasonably assured. Under the new standard, this is considered variable consideration and revenue is recognized at the estimated transaction price upon delivery. This results in earlier revenue recognition under the new standard as compared to previous revenue recognition. For development services revenue with certain biopharmaceutical customers, the Company historically limited revenue recognition based on the right to invoice the customer. Under the new standard, for these arrangements, the Company constrains revenue such that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For arrangements with regulatory and other developmental milestone payments, this results in a change to the timing and pattern of revenue recognition under the new standard as compared to previous revenue recognition.  Comparative information from prior periods has not been restated and&#160;continues to be reported under the accounting standards in effect for those periods. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="TextSelection-55C49623009BA29C67DBF1F8CAE5E3B9-0-wk-Fact-23A0191C29D9CC148576F1FAD87DF06A" continuedAt="TextSelection-55C49623009BA29C67DBF1F8CAE5E3B9-1" escape="true">The cumulative effect of changes made to the consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-55C49623009BA29C67DBF1F8CAE5E3B9-1" continuedAt="TextSelection-55C49623009BA29C67DBF1F8CAE5E3B9-2"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments due to ASC 606 </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of January 1, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e2465-wk-Fact-458877E932D5EBD4BD8CA6258E614976" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e2479-wk-Fact-21C4766D75BA87333B62F1FD981A765E" name="us-gaap:AccountsReceivableNetCurrent" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e2493-wk-Fact-5B3B135E1C0581457D83F1FD986A2547" name="us-gaap:AccountsReceivableNetCurrent" contextRef="I2019Q1Jan1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d46357e2564-wk-Fact-6BABCF1E83F5B56BEB09A6258E34C8AB" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">280,799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e2579-wk-Fact-120E4A1004C58F5480C4F1FE09E87E55" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d46357e2593-wk-Fact-AC015DFCD394626F2E4AF1FE0A8616B9" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="I2019Q1Jan1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">275,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC 606 requirements under the modified retrospective method of adoption, the impact of the adoption of ASC 606 on the Company&#8217;s consolidated statement of operations and consolidated balance sheet was as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">124</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9DA0AF7B64619413413EA6258EB63D1C-1" continuedAt="TextSelection-9DA0AF7B64619413413EA6258EB63D1C-2"><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-11" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-12"><ix:continuation id="TextSelection-55C49623009BA29C67DBF1F8CAE5E3B9-2"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the year ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported Under ASC 606</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology testing </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e2840-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF" name="gh:RevenuefromPrecisionOncologyTesting" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180,462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d46357e2854-wk-Fact-481AE1D70CF3C2A3683AF20ECBDB8D28" name="gh:RevenuefromPrecisionOncologyTesting" contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e2869-wk-Fact-D38896642B4E797B2ECAF20ECBBA34D0" name="gh:RevenuefromPrecisionOncologyTesting" contextRef="FD2019Q4YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180,115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Development services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e2889-wk-Fact-8B6729A9D18284EECA68A6258E3316AE" name="gh:RevenuefromDevelopmentServices" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,913</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e2903-wk-Fact-ABE309BC28661FD410CFF20F160C908E" name="gh:RevenuefromDevelopmentServices" contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e2917-wk-Fact-28D0F15716DF909D3CE7F20F15FF66DB" name="gh:RevenuefromDevelopmentServices" contextRef="FD2019Q4YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,913</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported Under ASC 606</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e3160-wk-Fact-932964D0A06B579D5FA9A6258E2C9EB4" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d46357e3174-wk-Fact-4E2CC39A2D75A32C2020F26AA60FB8A3" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d46357e3189-wk-Fact-5AAB289FB1273A355E80F26AA84BA3DD" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d46357e3260-wk-Fact-BFC5FAAB703E313E049DA6258E318F4E" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">352,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d46357e3275-wk-Fact-8BD49ABF515A94853454F26AAB03880E" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d46357e3290-wk-Fact-6CC9122B7F3514E4E1DDF26AAC384919" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">353,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 606 did not have an aggregate impact on the Company&#8217;s net cash used in operating activities but resulted in offsetting changes in certain assets presented within net cash used in operating activities in the Company&#8217;s consolidated statement of cash flows, as reflected in the above table. The the Company&#8217;s revenue is generated primarily from the sale of precision oncology testing and development services. Precision oncology testing revenue is generated from sales of the Company&#8217;s current products to clinical and biopharmaceutical customers. Total precision oncology testing revenues from sales to clinical customers for the years ended December 31, 2019, 2018 and 2017 were </span><span style="font-family:inherit;font-size:10pt;">$94.2 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$43.7 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$24.5 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. Total precision oncology testing revenues from sales to biopharmaceutical customers for the years ended December 31, 2019, 2018 and 2017 were </span><span style="font-family:inherit;font-size:10pt;">$79.5 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$34.7 million</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$17.6 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. Development services revenue represent services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted&#160;ASC 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">,  and its related amendments which requires the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for operating leases on the consolidated balance sheet on January 1, 2019 using a modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases in place as of January 1, 2019. The Company also elected the practical expedient to not separate lease and non-lease components for its facility leases, and to not recognize ROU assets and operating lease liabilities for short-term leases.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 842, the Company determines if an arrangement contains a lease and the classification of that lease, if applicable, at inception or upon modification of a contract. The Company has elected to not recognize a lease liability or ROU asset for short-term leases (leases with a term of twelve months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise). The Company has elected to not allocate the contract consideration for operating lease contracts with lease and non-lease components, and account for the lease and non-lease components as a single lease component. ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at lease commencement date. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. An option to extend the lease </span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">125</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9DA0AF7B64619413413EA6258EB63D1C-2" continuedAt="TextSelection-9DA0AF7B64619413413EA6258EB63D1C-3"><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-12" continuedAt="TextSelection-38F18625E00267BD0051A6258EB62A7E-13"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The primary impact of adopting&#160;Topic 842&#160;was the recognition of ROU assets and lease liabilities for operating leases of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e3357-wk-Fact-DE8847CD24AE38E25259785C5E7C7888" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Jan1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e3361-wk-Fact-DA726A1F20C742EE27DD785CF6D0BCEB" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Jan1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively, on January 1, 2019, which included reclassifying prepaid rent and deferred rent as a component of the ROU asset.&#160;Topic 842&#160;did not have a material impact on the Company's consolidated statements of operations and cash flows.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The short-term liabilities from the Company's operating leases are included in accrued expenses in the consolidated balance sheet. The Company's accounting for finance leases (formerly referred to as capital leases prior to the adoption of&#160;Topic 842) remains substantially unchanged. Finance leases are not material to the consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease expense for lease payments for the operating leases is recognized on a straight-line basis over the term of the lease.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718):</span><span style="font-family:inherit;font-size:10pt;"> Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, with certain exceptions. The Company early adopted this new guidance effective January 1, 2019. In accordance with the transition guidance, the Company assessed its outstanding nonemployee awards for which a measurement date had not been established. These outstanding awards were re-measured to fair value as of the January 1, 2019 adoption date. For nonemployee awards that contain performance condition, the measurement is based on the outcome that is probable as opposed to the lowest aggregate fair value within a range of possible outcomes. The adoption of ASU 2018-07 provided administrative relief by fixing the measurement date of nonemployee awards and eliminating the requirement of quarterly re-measurement. The Company adopted this standard on a modified retrospective basis and recorded a cumulative-effect adjustment of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d46357e3390-wk-Fact-D32D5958E516C669488FF2724486FA8A" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;as an increase to accumulated deficit and an equal increase to additional paid-in capital as of January 1, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;), which contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December&#160;31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No.&#160;118,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Tax Accounting Implications of the Tax Cuts and Jobs Act</span><span style="font-family:inherit;font-size:10pt;">&#160;(&#8220;SAB 118&#8221;) to address the accounting implications of the enacted U.S. federal tax reform. SAB 118 allows companies&#160;to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and no measurement period adjustments were recognized due to the full valuation allowance on the Company&#8217;s deferred tax assets.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13,&#160;Financial Instruments - Credit Losses:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">the FASB issued ASU 2017-04</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:10pt;">Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment which eliminates Step 2 from the goodwill impairment test and instead requires entities to perform its annual or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount</span><span style="font-family:Arial;font-size:9pt;">. </span><span style="font-family:inherit;font-size:10pt;">The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">126</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9DA0AF7B64619413413EA6258EB63D1C-3"><ix:continuation id="TextSelection-38F18625E00267BD0051A6258EB62A7E-13"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements in ASC 820, Fair Value Measurement, as part of its disclosure framework project. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted. The amendments in ASU 2018-13 on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments in ASU 2018-13 should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cloud Computing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15&#8212;Intangibles-Goodwill and Other-Internal&#8212;Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC Topic 350, Intangibles&#8212;Goodwill and Other, to determine which implementation costs to capitalize as assets or expense as incurred.  The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB amended ASC 808 and ASC 606 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The guidance is effective for us beginning January 1, 2020 and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU 2019-12, Income Taxes - Topic 740, which simplifies the accounting for income taxes.&#160; Amendments include removal of certain exceptions to the general principles of ASC 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes,</span><span style="font-family:inherit;font-size:10pt;"> related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences.&#160;ASU 2019-12 also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning January 1, 2021, and early adoption is permitted.&#160; The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sDB4B5B63CB165EA9B5511EAAE951B4A5"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">3. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="TextSelection-9A1DD23329CFFB0848D2A6258EB72347-0-wk-Fact-F552699B878982C62121A6258E85A76D" continuedAt="TextSelection-9A1DD23329CFFB0848D2A6258EB72347-1" escape="true">Investment in Joint Venture</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9A1DD23329CFFB0848D2A6258EB72347-1" continuedAt="TextSelection-9A1DD23329CFFB0848D2A6258EB72347-2"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with SoftBank&#8217;s purchase of its Series E convertible preferred stock, the Company entered into a joint venture agreement with an entity affiliated with SoftBank, a related party. In May 2018, the Company and SoftBank formed and capitalized Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) for the sale, marketing and distribution of the Company&#8217;s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the joint venture agreement, the Company paid </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43300e881-wk-Fact-8C26BBE8F0E3CBAD6438A6258E827D10" name="us-gaap:PaymentsToAcquireInterestInJointVenture" contextRef="D2018Q2May01-May31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43300e885-wk-Fact-D06192E4D1F1B8852F1CA6258E85544D" name="gh:EquityMethodInvestmentSharesPurchased" contextRef="D2018Q2May01-May31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">40,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, or </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43300e889-wk-Fact-B2EF8B21EE0B433FCF0CA6258E7F9FF0" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2018Q2May31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43300e893-wk-Fact-E40488D1537F276C8113A6258E7FFCC2" name="us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue" contextRef="I2018Q2May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43300e897-wk-Fact-7167E8B87C6540D682BBA6258E84B939" name="gh:EquityMethodInvestmentSharesPurchased" contextRef="D2018Q2May01-May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">40,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, or the other </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43300e902-wk-Fact-690C01940D851E2F6EC3A6258E817F00" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2018Q2May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest, of the Joint Venture. Neither party has the obligation to provide additional financial support to the Joint Venture. Each party holds two seats on the board of the Joint Venture and has to cast through its representatives on the board at least one vote for any board resolution of the Joint Venture to pass. The representatives of the Company on the Joint Venture&#8217;s board of directors have the right to appoint and remove a chief executive officer and a legal representative for the Joint Venture, in each case, subject to the approval of the full Joint Venture board of directors. The Joint Venture&#8217;s board of directors has the right to appoint and remove all other members of the Joint Venture&#8217;s senior management reporting to its chief executive officer and to approve the compensation of all foregoing individuals, including the compensation of the chief executive officer and legal representative.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the inception of the arrangement and at the end of each reporting period, the Company assesses whether the Joint Venture is a variable interest entity (&#8220;VIE&#8221;), and if so, who is the primary beneficiary of the VIE. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company and SoftBank had equal ownership interests and equal voting rights in the Joint Venture, and the Joint Venture&#8217;s board consisted of an equal number of directors representing the interest of the Company and SoftBank, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Joint Venture&#8217;s board had the right to vote on all critical matters that most significantly impact the Joint Venture&#8217;s economic performance, except that the Company had the unilateral right to make pricing decisions. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had responsibility for the Joint Venture&#8217;s daily operations, while SoftBank served as a financing partner. The Company also entered into various ancillary agreements with the Joint Venture necessary to operate its business. The Joint Venture is deemed to be a VIE, and considering the power and benefits criterion, the Company and SoftBank, collectively as a related party group, has the characteristics of the primary beneficiary of the Joint Venture, as the related party group has the power to direct the activities of the </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">127</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9A1DD23329CFFB0848D2A6258EB72347-2" continuedAt="TextSelection-9A1DD23329CFFB0848D2A6258EB72347-3"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VIE that most significantly impact the VIE&#8217;s economic performance and has the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Because the Company is most closely associated with the Joint Venture within the related party group, it has been identified as the VIE&#8217;s primary beneficiary.  As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation. The Company concluded the Joint Venture did not meet the definition of a business upon consolidation as it lacked the processes required to generate outputs. Upon consolidation no liabilities were assumed and other than cash, and any identifiable assets were related to intellectual property rights that the Company transferred to the Joint Venture shortly before it became its primary beneficiary and therefore such transfer was treated as a common control transaction.  Upon initial consolidation, the non-controlling interest of the affiliate of SoftBank was recorded at its estimated fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43300e924-wk-Fact-86B0F528337762C7E702A6258E84C93C" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which is equal to the original investment made by the affiliate of SoftBank. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Joint Venture had total assets of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43300e935-wk-Fact-C9B30A4D96217FC20AEA7E6D5E733780" name="us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was primarily comprised of cash and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company&#8217;s general credit or assets.&#160; Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Put-call arrangements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the &#8220;put right&#8221;), and the Company has a right to purchase all such shares (the &#8220;call right&#8221;).</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the Company&#8217;s business model were to change such that the sale, marketing and distribution of its tests in the territory covered by the joint venture agreement was no longer economical, SoftBank would have the right to cause the Company to purchase, or the Company would have the right to purchase, all of the shares of the Joint Venture held by SoftBank and its affiliates. In this instance, the Company would be required to repurchase the shares at an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43300e952-wk-Fact-D779310F226C8637F547A6258E805193" name="us-gaap:PaymentsToAcquireInterestInJointVenture" contextRef="D2018Q2May01-May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, the original purchase price paid by SoftBank to the Joint Venture for the shares.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, each of the Company and SoftBank may exercise its respective put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#8217;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of the Company&#8217;s initial public offering, a change in control of the Company, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d43300e959-wk-Fact-FA20312C610461BE4A15A6258E82ED6E" name="gh:VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" format="ixt-sec:durday">20</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#8217;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank&#8217;s interests in the Joint Venture being determined to be materially different from what has been recorded in the Company&#8217;s consolidated financial statements including those included elsewhere in this Annual Report on Form 10-K. As a result of the IPO, the put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank are exercisable on each subsequent anniversary of the IPO by the Company or SoftBank.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the event the Company exercises its call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43300e967-wk-Fact-63575D82AADF30660B02A6258E83496F" name="gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43300e974-wk-Fact-E0D29BA9909D45704FD7A6258E80A25A" name="gh:VariableInterestEntityThresholdPercentageofFairValue" contextRef="FD2019Q4YTD_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair value of the Company, the Company will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43300e978-wk-Fact-E0A72FF5D485E73CA2A0A6258E8345D5" name="gh:VariableInterestEntityPercentageoftheProduct" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its capital stock (which may be a non-voting security with senior preferences to all other classes of its equity or, if its common stock is publicly </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">128</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9A1DD23329CFFB0848D2A6258EB72347-3"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">traded on a national exchange, its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company&#8217;s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the IPO and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the redeemable noncontrolling interest held by SoftBank was determined using the combination of the income approach and the market approach. Determining the fair value of the redeemable noncontrolling interest requires judgment and the use of significant estimates and assumptions. Such estimates and assumptions include future revenue growth rates, gross profit margins, EBITDA margins, future capital expenditures, weighted average costs of capital and future market conditions, among others. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy. The change in the value of the redeemable noncontrolling interest consists of net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43300e998-wk-Fact-2C79E32DE5F23D21248E91DCF662B62E" name="us-gaap:NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and increase in fair value adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43300e1002-wk-Fact-1CC866EBE92622FEDF2591DFDB50C639" name="gh:RedeemableNoncontrollingInterestFairValueAdjustment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><a id="sE2FC6C0D15A95766984F191A2C59B302"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">4. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="TextSelection-BDD1E3D0403BB854D123A6258EB8E730-0-wk-Fact-F2CFF77A8024B4D85FD2A6258E704F39" continuedAt="TextSelection-BDD1E3D0403BB854D123A6258EB8E730-1" escape="true">Consolidated Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BDD1E3D0403BB854D123A6258EB8E730-1" continuedAt="TextSelection-BDD1E3D0403BB854D123A6258EB8E730-2"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</span></div><ix:continuation id="TextSelection-0D3B7F065313444AC2DFA6258EB76C8F-0"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1071-wk-Fact-52D54E66E81C1441C5F5A6258E5D6077" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1090-wk-Fact-115FB2A8AA00E62EDD36A6258E610A22" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer hardware   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1105-wk-Fact-F711530F834B36F48856A6258E62CE05" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1124-wk-Fact-44706A748E19E7A87FE4A6258E4C1BBE" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1144-wk-Fact-2B01B4B25D662CC8964BA6258E6816D2" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1163-wk-Fact-38CA83213AF601F25C3CA6258E4AA4DE" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,965</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1183-wk-Fact-B7F464BFB2AAD744578BA6258E5C8FA6" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,962</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1202-wk-Fact-64C1DDDC2C9DC13891B4A6258E5A615A" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,522</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer software   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1222-wk-Fact-90D21C93AA1DF503E312A6258E5FA3AC" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1241-wk-Fact-4712F28D05EBAA5E7AE3A6258E5C85AB" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">643</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1261-wk-Fact-72C0F336C062F9C18994A6258E55174A" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1280-wk-Fact-41D083013DB3817A6EACA6258E5A2090" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, gross   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1300-wk-Fact-F230E8CD3E5D2A9B6559A6258E60022A" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1319-wk-Fact-55629F1389A054638E9AA6258E5E8A3B" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,637</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d47727e1340-wk-Fact-E839D4CEDDC51DD9A3F5A6258E5F1B4B" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,923</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d47727e1360-wk-Fact-A3FDD2D982F93E24CE15A6258E5A66C0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,634</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1386-wk-Fact-70D2EDBA0CE7622F37B1A6258E2A47FB" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1405-wk-Fact-F2928BF2B06270B1745EA6258E2F72DD" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense related to property and equipment was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d47727e1417-wk-Fact-5EAE97E511CD0E1B5FABA6258E8956B9" name="us-gaap:Depreciation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d47727e1421-wk-Fact-25F6266F40468F52641AA6258E8241FF" name="us-gaap:Depreciation" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d47727e1425-wk-Fact-0F2A3C67E3D78BA79D7DA6258EA79485" name="us-gaap:Depreciation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">129</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-BDD1E3D0403BB854D123A6258EB8E730-2"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Expenses</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-EBD91A698FB77568D764A6258EB87142-0-wk-Fact-4BF089C4EDE02292C7D4A6258E86F976" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued royalty obligations   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1641-wk-Fact-5CC1574E79AA1DD6CDB0A6258E4BA54A" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1660-wk-Fact-BBD4DA70CA1AD667E84FA6258E39D829" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">707</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued legal expenses   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1675-wk-Fact-2A0893F7049639B3E9D7A6258E6DE3C8" name="gh:EstimatedLitigationLiabilityLegalFeesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1694-wk-Fact-4EF6D7FC5D6878531270A6258E9A2B5C" name="gh:EstimatedLitigationLiabilityLegalFeesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued tax liabilities   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1714-wk-Fact-55E66D800C11ED2E9CB9A6258E990A95" name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,050</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1733-wk-Fact-2466EFC06958272EBF30A6258E995832" name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,470</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional services   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1753-wk-Fact-851301F17DCF4F5B1313A6258E92A60F" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1772-wk-Fact-37207F5BDA967F66B36FA6258E8D17AE" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,791</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trials and studies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1792-wk-Fact-35DBE7E39C1C8CC48D177865EA77FE89" name="gh:AccruedClinicalTrialsandStudies" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,029</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1811-wk-Fact-7BB3265439D5592E22477865EA727D6C" name="gh:AccruedClinicalTrialsandStudies" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of property and equipment included in accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1831-wk-Fact-59E37DA604328A434D4BA6258E845813" name="gh:AccruedExpensesPropertyandEquipmentCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1850-wk-Fact-0C9887E8F147A0536405A6258E91291C" name="gh:AccruedExpensesPropertyandEquipmentCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">343</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1870-wk-Fact-FF8E6088F12AD6FD2D3F7866343D9311" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d47727e1889-wk-Fact-796558F200135C29D4C37866335DC6B9" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1910-wk-Fact-848C671FF5A12406BF83A6258E9A515B" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1929-wk-Fact-5C7059992575A367C8EBA6258E6D208F" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued expenses   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1954-wk-Fact-71CC6343C9567D0701CFA6258E2F8222" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d47727e1973-wk-Fact-B215684635F57C2B1BB6A6258E5F1626" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sCB2C7417D21E5D19B6C384315AC88A6A"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">5. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-B031BDC2A7A97D739FE9A6258EB8A6C1-0-wk-Fact-3D42AE7156F168E2858CA6258EA55D44" continuedAt="TextSelection-B031BDC2A7A97D739FE9A6258EB8A6C1-1" escape="true">Fair Value Measurements, Cash Equivalents and Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B031BDC2A7A97D739FE9A6258EB8A6C1-1" continuedAt="TextSelection-B031BDC2A7A97D739FE9A6258EB8A6C1-2"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments consist of cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">130</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-B031BDC2A7A97D739FE9A6258EB8A6C1-2" continuedAt="TextSelection-B031BDC2A7A97D739FE9A6258EB8A6C1-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="TextSelection-84C3E739ECA52D29FE6AA6258EB82078-0-wk-Fact-F359620A5FDABCE5295FA6258E64EE9D" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1341-wk-Fact-5FDE4566ED302958C89BA6258E9CFBBC" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1360-wk-Fact-695890ADCCAEB47E875FA6258E38124E" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1379-wk-Fact-8F5C52372BCD15E76044A6258E9B7511" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1399-wk-Fact-ACE53A88E3E08C24481DA6258E63C808" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1419-wk-Fact-54324F1796CE5431DB7AA6258E3A54BE" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1438-wk-Fact-2A1EA75C39E35D1543B2A6258E3BC9C5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1457-wk-Fact-1B93B01EE1F44A8C8966A6258EA19BCE" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1477-wk-Fact-FFD3447266770304BE61A6258E493FD1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bonds   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1579-wk-Fact-8219E78A61C9C0F73CB9A6258E9A5ED4" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1593-wk-Fact-73B22957B3288FE70C94A6258E3F65AD" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1617-wk-Fact-C4B705CBB1E57B02340BA6258E9CC1B9" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1632-wk-Fact-54567EF0AC14D808FB09A6258E5BFD31" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1652-wk-Fact-0D606E7F360093B1C2DFA6258E3D28CC" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">362,884</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1671-wk-Fact-3708C9AADA9CEDEEF4A4A6258E4DF262" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1690-wk-Fact-D5222568BEBF82F440E0A6258E553098" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">362,884</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1710-wk-Fact-5F8C8581753526B7E7F5A6258E9AD5F3" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term marketable securities   </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1735-wk-Fact-1E42CA33F0DEA22E31B5A6258E4A701F" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">379,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1754-wk-Fact-90A447B969B018AB55F3A6258EA6D3B3" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1773-wk-Fact-0F855BCCAE4E2AEC624EA6258E40A129" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">379,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1793-wk-Fact-26D3A160D33A35DE451FA6258E9A7BEC" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1896-wk-Fact-35D00E555F1463691ABFA6258E432C3F" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1910-wk-Fact-4303D814EB481C5E8FBBA6258EA58363" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1934-wk-Fact-95DC9BDDE03EAB584CFCA6258E641717" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1949-wk-Fact-6E78C1C5B0275787EBF1A6258E340219" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term marketable securities   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1969-wk-Fact-A95C2FA8C683E166B552A6258E4E4591" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e1988-wk-Fact-4BBDD2371514F5C75E39A6258E46D53E" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2007-wk-Fact-EB72A9473A9E0E3B3061A6258E4BCB73" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2027-wk-Fact-78A0C112C223D9E9E71CA6258E511F3A" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2052-wk-Fact-1A58A435DC345B7B8C19A6258E47482B" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">659,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2071-wk-Fact-C766AA606F511FB1ECD1A6258E3C92C7" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2090-wk-Fact-31B80E38E6BF22AF0C0AA6258E99A621" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">648,357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2110-wk-Fact-2D5C39D61C3B4F68D107A6258EA49D6D" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2294-wk-Fact-E837135145F568A3198CF27CECA7D7B7" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2308-wk-Fact-31217D07D044E6BE3B40F27CECD24A68" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2327-wk-Fact-7BC5FF0C39CAFCA2EDD4F27CECFE45A6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2352-wk-Fact-00DF04757C5656D0261AF27CECB0F636" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2372-wk-Fact-54FBE21D48EC6CAFA9F3F27A965AE6C2" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2391-wk-Fact-23D0D28A7923B26E5714F27A96675F06" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2410-wk-Fact-A6C3114C1DD853C66D02F27A965633BD" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2430-wk-Fact-C672075260B2DE9ADD91F27A965FD7C9" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2883-wk-Fact-4E004E536BD3989C6646A6258E815F75" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2902-wk-Fact-364307160ACFE121D855A6258E5EB3F4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2921-wk-Fact-78336598781D732D2B4DA6258E3C6ACD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2941-wk-Fact-1E209741A88526E41339A6258E417ADD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2961-wk-Fact-73FDED3F6891F2A79786A6258E935B8F" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2980-wk-Fact-FF053F08F4B6FA16A3ABA6258E413FF1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e2999-wk-Fact-8338EC7FC92B736D4F94A6258EA6F4F9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3019-wk-Fact-05EE7F61ECB01B362E90A6258E6E7DE7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bonds   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3121-wk-Fact-748EF9CC968EA75D3FABA6258E90E496" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3140-wk-Fact-7ABD543A369EE1537A5CA6258E35601F" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3159-wk-Fact-148A8EF3AF6D8AD887B4A6258E3B367D" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3179-wk-Fact-E61F44B0ABCA4E9F9999A6258EA671CF" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3194-wk-Fact-F74C3C0995BEC4F8E667A6258E3AB35C" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">235,016</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3213-wk-Fact-C26F04FBA487311506FDA6258E9F9653" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3232-wk-Fact-0AC0803268A5E8F7B9B2A6258E3A1DBC" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">235,016</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3252-wk-Fact-E4D9E1A771A2611A5511A6258EA9D418" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3272-wk-Fact-62ADCE60EECD55529741AACD1338F0DA" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,004</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3311-wk-Fact-6FB0A6261B84A1292F1CAACD1F360B60" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,004</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term marketable securities   </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3358-wk-Fact-1728BF5046D0D6C5A78AA6258E3B4969" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">278,417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3377-wk-Fact-94E0875163298A1A3681A6258E700F42" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3396-wk-Fact-459BCCC9B00A4DE5D36CA6258E78EFE0" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">278,417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3416-wk-Fact-1853E9B484E1365D243AA6258E30EE6D" name="us-gaap:DebtSecuritiesCurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bonds   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3518-wk-Fact-124DC59E9188223C1FE8A6258E5AF4B7" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3537-wk-Fact-F72DE1D47E33FDCA88EBA6258E4D8231" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3556-wk-Fact-3F93E08C6AB50DD1DE74A6258E301E82" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3576-wk-Fact-E749CF19F24947CEE40BA6258E9C456F" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3591-wk-Fact-27D67F8278EAEABE1659A6258E2FCC92" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3610-wk-Fact-D9D59285BDC08488B772A6258E94A3DB" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3629-wk-Fact-80200FE38C3ECAC1336DA6258E39D67D" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3649-wk-Fact-80BBA46E6A7E56D51463A6258E3E042C" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term marketable securities   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3674-wk-Fact-33B7F53BD83C58F43BC3A6258E98B4A0" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,563</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3693-wk-Fact-2E08D02AE1EBD1253937A6258E76182C" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3712-wk-Fact-72D6E850883BA7B2E1F2A6258E418CF6" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,563</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3732-wk-Fact-559EFF8BE02C0A563869A6258E46FC3B" name="us-gaap:DebtSecuritiesNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3752-wk-Fact-9F779335831D23274CD1A6258E6FBCB7" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,776</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3771-wk-Fact-DC7A3E77B62BC8DF9E76A6258E91ACE1" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3790-wk-Fact-7EB49472586F6F0DD166A6258E52CEE0" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">355,980</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e3810-wk-Fact-C6D39F28205536244908A6258EA497F7" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Corporate bonds, U.S. government debt securities and U.S. government agency bonds are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on  the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's contingent consideration was valued using the discounted cash flow method. Significant unobservable inputs used in the fair value measurement of the Company&#8217;s contingent consideration liability include the estimated amount and timing of projected cash flows, and the risk-adjusted discount rate used to present value the cash flows. The change in discount rate has an inverse relationship to the overall valuation of the contingent consideration.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">131</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-B031BDC2A7A97D739FE9A6258EB8A6C1-3"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The use of different inputs in the valuation of the contingent consideration liability could result in materially different fair value estimates.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="gh:DebtSecuritiesTableTextBlock" id="TextSelection-91A9300D95C3A58A943DA6258EB8DAB9-0-wk-Fact-5103A419498E6EE004ECA6258E803EF2" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarizes the Company&#8217;s cash equivalents and marketable securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market fund   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4204-wk-Fact-E0C30020ECE5EE6E6B83A6258E727E84" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4262-wk-Fact-72871018D9DA32A6B3EFA6258E9C3AE8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bond   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4277-wk-Fact-F61024AEB724DD91D03DA6258E427D7F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4296-wk-Fact-921481AEC20EDEFB6BB6A6258E379A45" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4315-wk-Fact-9D9C8CBF587295F0C4A5A6258E79AB0B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4335-wk-Fact-2131B05296ECE2B19F80A6258E721C3C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4355-wk-Fact-2D2B4CC95E369B68FBF4A6258E9F9B36" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">630,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4374-wk-Fact-61F220C4009A69E72450A6258EA123F3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d54325e4393-wk-Fact-8693BCC71AD7B5C868D8A6258E747635" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4414-wk-Fact-C3FA759084FF703B841AA6258E9FF9E9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">631,666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4439-wk-Fact-13247A7BC6986311BF0BA6258E8495F4" name="gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">657,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4458-wk-Fact-4764552C1891DC110518A6258E85B35E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d54325e4477-wk-Fact-29D4A04F0FD588A00EA1A6258E400C34" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4498-wk-Fact-91991EC1E12BFA12D261A6258E88E487" name="gh:CashCashEquivalentsandDebtSecuritiesFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">659,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market fund   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4868-wk-Fact-ED9C6356056B40D14124A6258E8A74FD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4926-wk-Fact-77E4E5823C167F1A71C3A6258E30E4DC" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bond   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e4941-wk-Fact-CDEC56DAB4B43C5BE703A6258E8A62FB" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d54325e4960-wk-Fact-5F8BBE8B529583277AD1A6258E2B9502" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d54325e4979-wk-Fact-6D3A476A1F87EE5AE561A6258E37A663" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e5000-wk-Fact-645E4F2FBB07C6D4E10EA6258E8B3333" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e5020-wk-Fact-9998E24FDF83884AE047A6258E3CF379" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">308,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e5039-wk-Fact-42701DFABF9BDB4BCD72A6258E3C709C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d54325e5058-wk-Fact-E10DA2264E34171D61C2A6258E356E6D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e5079-wk-Fact-A8BC26DE57CF45F8403EA6258E3415DE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">308,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency bonds................</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d54325e5099-wk-Fact-BF03DF1D47B3F7D4EA48AAD0D27EE6E7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d54325e5118-wk-Fact-E041D09997E99A9B54A4AAD0D62A1C80" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d54325e5137-wk-Fact-CA87E448A4493EADF99EAAD0D919A2EA" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d54325e5158-wk-Fact-16F8BBF3517B2F6D0A02AAD0DBEDBBD3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,004</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d54325e5183-wk-Fact-8A01D01700230EB517EDA6258E3579A3" name="gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e5202-wk-Fact-9049BB35EF9B8E9A36C6A6258E88FC69" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d54325e5221-wk-Fact-F653F0508C8C777674E1A6258E8E995D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54325e5242-wk-Fact-4AA6C026B4DB89BD75B0A6258E3B7ED2" name="gh:CashCashEquivalentsandDebtSecuritiesFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,776</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company&#8217;s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. The maturities of the Company&#8217;s long-term marketable securities range from&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d54325e5262-wk-Fact-CC1C182141095C66DAD9A6258E6F111D" name="gh:MarketableSecuritiesMaturityPeriod" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:duryear">1.04</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d54325e5266-wk-Fact-457182361D9E0A3F8B4EA6258EA16B26" name="gh:MarketableSecuritiesMaturityPeriod" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:duryear">1.75</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years from </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><a id="s79493fed7d4642a89406baf802ceb122"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">6. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-0-wk-Fact-F7F9ABE1B11AC48578A1F2842751A62E" continuedAt="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-1" escape="true">Acquisition of Bellwether Bio</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-1" continuedAt="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-2"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2019, the Company purchased of all of the outstanding shares of Bellwether Bio, Inc. (&#8220;Bellwether Bio&#8221;), a privately-held company developing a method for early blood-based cancer detection. The Company accounted for the acquisition as a business combination. The total purchase consideration was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d51364e874-wk-Fact-C1502677C50D96646BFCF2852FBCE9F0" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which consisted of i)&#160;&#160;&#160;&#160; </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d51364e880-wk-Fact-4B0E5F15CCA141FD0422F28561F7EAF1" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash paid upon closing; and ii) future contingent consideration liability with a fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d51364e884-wk-Fact-A2D8A99CFA7ADA3C8534F2859E1264B8" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> on the acquisition date. The contingent consideration is subject to the achievement of certain commercialization milestones with a maximum payout amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d51364e888-wk-Fact-E180F44349FCC1CB1333F285D15A47B4" name="gh:BusinessCombinationContingentConsiderationMaximumAmountPayable" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_ContingentConsiderationByTypeAxis_gh_CommercializationMilestonesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company will also pay additional earn-out consideration of up to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d51364e892-wk-Fact-F4C8D8761DBA71B2CD81F28608125EAA" name="gh:BusinessCombinationContingentConsiderationMaximumAmountPayable" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_ContingentConsiderationByTypeAxis_gh_EarnOutConsiderationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> subject to the achievement of certain commercialization milestones and&#160;the continued provision of services to the Company by certain former employees&#160;and consultants&#160;of Bellwether Bio. The contingent consideration and earn-out consideration may be paid, at the Company&#8217;s election, in cash or in the Company&#8217;s common stock. As of December&#160;31, 2019, the Company did not believe the earn-out consideration is probable to be achieved, and therefore, did not record any compensation expense. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The excess purchase consideration over the fair value of assets acquired and liabilities assumed was recorded as goodwill. Goodwill is attributable to future revenue opportunities that we expect to achieve from leveraging Bellwether Bio&#8217;s existing license and IPR&amp;D, as well as the assembled workforce. The valuation of the intangible assets acquired was determined using currently available information and reasonable assumptions. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="TextSelection-53EB3CB458C4C5F773F7F286D58F72A4-0-wk-Fact-4DA66A29ACF0A0CD66C1F286E59AD778" continuedAt="TextSelection-53EB3CB458C4C5F773F7F286D58F72A4-1" escape="true">The following table summarizes the allocation of the total consideration to the estimated fair values of assets acquired and liabilities assumed:</ix:nonNumeric></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">132</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-2" continuedAt="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-3"><ix:continuation id="TextSelection-53EB3CB458C4C5F773F7F286D58F72A4-1"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e984-wk-Fact-E996561590CD7F738C36F287FCCCB4A4" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identified intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1004-wk-Fact-96C37527A045B9FE51D6F28A5ADBEA52" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1029-wk-Fact-1EDAE73F9077AAEBCE21F288015A01E4" name="us-gaap:Goodwill" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,289</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net liabilities assumed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d51364e1054-wk-Fact-DC5AF06F6F7BAFBC24A2F288032158E6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,802</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1085-wk-Fact-E3A5D6739C58FE7958DBF28804E94921" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,708</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" id="TextSelection-C9AE7AC11A3B94DFD373F2871F120237-0-wk-Fact-4F8BC51626BBF364736EF28734F0ACF7" continuedAt="TextSelection-C9AE7AC11A3B94DFD373F2871F120237-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents details of the identified intangible assets acquired from the Bellwether Bio acquisition:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Useful Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired license</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1201-wk-Fact-123F807A326367F66AFAF28A55C4DC7F" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d51364e1215-wk-Fact-670887BC7775CDD44A9B5ABBBC5C8134" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" format="ixt-sec:duryear">10</ix:nonNumeric> years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1231-wk-Fact-23C22089F8D5C5AD85DAF28A58AC8E9D" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1271-wk-Fact-96C37527A045B9FE51D6F28A5ADBEA52" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-C9AE7AC11A3B94DFD373F2871F120237-1" continuedAt="TextSelection-C9AE7AC11A3B94DFD373F2871F120237-2"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-C9AE7AC11A3B94DFD373F2871F120237-2"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">IPR&amp;D assets are not subject to amortization.</span></div></ix:continuation></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the acquisition of Bellwether Bio, the Company also entered into non-compete agreements with certain key individuals based on their experience and importance to the operation of Bellwether Bio. The Company accounted for the covenants not to compete as purchases of intangible assets separate from the business combination as these non-compete agreements were initiated by the Company to protect its interests. The fair value of acquired covenants not to compete was estimated to be </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d51364e1298-wk-Fact-35CD9D0C8230E7C24D09F28BE9D8D19F" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gh_CovenantsNotToCompeteMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which is recorded within intangible assets on the consolidated balance sheet and will be amortized over an estimated useful life of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d51364e1302-wk-Fact-F001B1F6E8F257E41D70F28C2229A0BC" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gh_CovenantsNotToCompeteMember" format="ixt-sec:duryear">6</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> using the straight-line method.  </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="TextSelection-19EAD41277D51B6B414A5AB8A55B4AC6-0-wk-Fact-D4F391E15E30FF11D9935AB930E408B0" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents other intangible assets - net: </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Useful Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired license</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d51364e1576-wk-Fact-9146FC59F51913201EE15AB2D51C414D" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember" format="ixt-sec:duryear">9.5</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1591-wk-Fact-CF7634AF8A8EC576C02D5AB3527CAB25" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1610-wk-Fact-9E3C8B1123736E958F345AB37ACEA885" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1630-wk-Fact-1091955DDB6B0C2621805AB39E30B9E2" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,727</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-compete agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d51364e1650-wk-Fact-7A79770BE3F6871C27A55AB2D523E68F" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember" format="ixt-sec:duryear">5.5</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1660-wk-Fact-243F168C2DCBDA1AE74C5AB3528A214B" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1679-wk-Fact-C49166042AA2CAC809C75AB37A6D0561" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1699-wk-Fact-CFFCA65119F641C4EBE35AB39DB25CBD" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1739-wk-Fact-D3FD8B509F52276BE6455AB352812DCA" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1753-wk-Fact-BA6CA4CB0346BB1C85B35AB37A52F748" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">676</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1778-wk-Fact-2DC6157EF74A36F3BE2B5AB39DD1F0AF" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,924</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1890-wk-Fact-41F0ADCC00F7FDCC59975AB3D96E2A41" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1929-wk-Fact-41F0ADCC00F7FDCC59975AB3D96E2A41" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1959-wk-Fact-5D382625C755DDDD26485AB409737FD1" name="us-gaap:Goodwill" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e1998-wk-Fact-5D382625C755DDDD26485AB409737FD1" name="us-gaap:Goodwill" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e2038-wk-Fact-104BA2843BDFFE6F97C55AB5626DBAAA" name="gh:IntangibleAssetsGrossIncludingGoodwill" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e2057-wk-Fact-BA6CA4CB0346BB1C85B35AB37A52F748" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">676</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e2077-wk-Fact-4EB51FE98AD220A757925AB45C58EF8F" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no intangible assets as of December 31, 2018.  </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="TextSelection-8A790E949E50EB4F994F5AA82AD02163-0-wk-Fact-AE5C1BFFE1DAD61F1CC65AA8839BEBAB" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes estimated future amortization expense of finite-lived intangible assets&#8212;net:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:29%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e2158-wk-Fact-29134B8A119AB6FD14385AAD6B0859C1" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e2173-wk-Fact-8B834E49C670730882495AAD9F6AFAB4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e2193-wk-Fact-5560EDE0A2B4BE5579115AADE9C89574" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e2213-wk-Fact-03F53D9D516182CF6FEA5AAE124CDE35" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e2233-wk-Fact-B6DD73864B239E1A7C475AAE4EE77EF3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d51364e2258-wk-Fact-2DC6157EF74A36F3BE2B5AB39DD1F0AF" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,924</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration is measured at fair value on a quarterly basis based on additional information as it becomes available and change in estimated contingent consideration to be paid will be included in </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">133</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-3" continuedAt="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-4"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">operating expenses in the consolidated statements of operations. The fair value of acquisition-related contingent consideration is estimated using a multiple-outcome discounted cash flow valuation technique. Contingent consideration is classified within Level 3 of the fair value hierarchy, as it is based on a probability that includes significant unobservable inputs. The significant unobservable inputs include a probability-weighted estimate of achievement of certain commercialization milestones, continued services from certain former employees and consultants, resulting contingent payments, and discount rate to present value the expected payments. A significant change in any of these input factors in isolation could have a material impact to fair value measurement. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since initial valuation on the date of acquisition, contingent consideration liability increased by </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d51364e2276-wk-Fact-4EED99E2748C781EFD14F28E1E8BA1A8" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million due to change in estimate relating to inputs used to determine the fair value of contingent consideration. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, contingent consideration liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d51364e2284-wk-Fact-2F4C76650FBB2136C20D786E37E8B717" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded within other long-term liabilities on the consolidated balance sheet. </span></div></ix:continuation><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><ix:continuation id="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-4" continuedAt="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-5"><span style="font-family:inherit;font-size:10pt;">For the period ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company incurred acquisition-related transaction costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d51364e2295-wk-Fact-E397901871C88EABF94FF28D13EED02F" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-5"> million which are included in general and administrative expenses in the consolidated statements of operations.</ix:continuation> </span></div><div><a id="s26F1B4C709A25BBEBD5340C232C646CD"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">7. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="TextSelection-B234509F7B5DBE76E82FA6258EB88BA6-0-wk-Fact-5EAC17FD7264F978451DA6258E667586" continuedAt="TextSelection-B234509F7B5DBE76E82FA6258EB88BA6-1" escape="true">Patent License Agreement</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B234509F7B5DBE76E82FA6258EB88BA6-1"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the Company entered into a license agreement with a biotechnology company for an exclusive, non-transferable right to use proprietary technology related to high-throughput screening and identification of mutations in targeted gene sequences. The payment terms of the license agreement included (i) a one-time upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;<ix:nonFraction id="d54431e875-wk-Fact-15D7C009945783D64BDBA6258E6489DD" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="gbp" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">; (ii) issuance of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54431e879-wk-Fact-332A3EF2BB1C098D7F84A6258E63259C" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">141,774</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s Series D convertible preferred stock; (iii) a milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;<ix:nonFraction id="d54431e883-wk-Fact-1928F01DED1B914C0B58A6258E616F8F" name="gh:LicenseAgreementMilestonePaymentUponAchievement" contextRef="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="gbp" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the achievement of a specified milestone event; and (iv) future royalty payments at the minimum of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;<ix:nonFraction id="d54431e887-wk-Fact-BD11A21AD9D6963947C4A6258E60BAC6" name="gh:PaymentsforFutureRoyalties" contextRef="D2019Q4Dec312019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="gbp" decimals="-5" scale="6" format="ixt:numdotdecimal">13.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate based on annual net sales in which the licensed technology are used. The Company made a one-time upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54431e891-wk-Fact-B071CA0061686FC499F7A6258E61A1CE" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in January 2017 and a milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54431e896-wk-Fact-9AA53D45963C88D6686EA6258E650899" name="gh:LicenseAgreementMilestonePaymentUponAchievement" contextRef="D2017Q3Aug01-Aug31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in August 2017 upon achievement of the specified milestone event. The Series D convertible preferred stock issued under the license agreement had a fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54431e900-wk-Fact-2AD53EE00F74BBAD2C71A6258E632CC5" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> on the date of issuance. The transaction was treated as an acquisition of an asset and the Company capitalized the upfront payment, milestone payments and fair value of Series D convertible preferred stock in addition to license fees of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54431e904-wk-Fact-C24A642A9254C2F10DECA6258E622D56" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="I2018Q1Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the future minimum royalty payments discounted to the present value. The Company recorded the obligation at the estimated present value of the future payments using a discount rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54431e908-wk-Fact-C35E48B756427C1CF55DA6258E649E6F" name="us-gaap:DebtInstrumentMeasurementInput" contextRef="I2018Q1Jan31_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, the Company&#8217;s estimate of its effective borrowing rate for similar obligations.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, unamortized capitalized license fees plus one-time upfront and milestone payments totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54431e923-wk-Fact-DD68403CCE95177EA7DBA6258E650107" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54431e927-wk-Fact-371B9B676139BBF8E5A0A6258E62B6F0" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which will be amortized over the remaining useful life of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d54431e931-wk-Fact-B433439426327D3DF8F0A6258E648F46" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="D2019Q4Dec312019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" format="ixt-sec:duryear">7.0</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d54431e936-wk-Fact-6D52F56935119238FFE9A6258E62AF1D" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="D2018Q4Dec31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" format="ixt-sec:duryear">8.0</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years, respectively. Amortization of capitalized license fees plus one-time upfront and milestone payments totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54431e940-wk-Fact-B84287E7FC50804C00CCA6258E643FD5" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54431e944-wk-Fact-9C9A3818673C88289CAFA6258E6097E3" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q4QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div><a id="sE148A569EAC15A76A2520B09A3CB6E9D"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">8. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-362BC4A6CE9523FE4E6BA6258EB887A7-0-wk-Fact-C78D27BAAE100907D6B0A6258E651597" continuedAt="TextSelection-362BC4A6CE9523FE4E6BA6258EB887A7-1" escape="true">Senior Term Loan and Royalty Purchase Agreement</ix:nonNumeric></span></div><ix:continuation id="TextSelection-362BC4A6CE9523FE4E6BA6258EB887A7-1"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, the Company entered into a credit agreement with a financial institution for a senior term loan (the &#8220;Credit Agreement&#8221;). The Credit Agreement provided for up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54558e875-wk-Fact-83C7EBF893B0D2251CFAA6258E927528" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="I2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in borrowing capacity. The Company borrowed </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54558e879-wk-Fact-260EB182D3A360398D32A6258E9BA758" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="D2015Q4Jun01-Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> on the effective date of the Credit Agreement. The Credit Agreement provided for an interest rate equal to the greater of (i) three-month LIBOR or (ii) </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54558e883-wk-Fact-6E73027CF634E02AA38EA6258E947E86" name="gh:DebtInstrumentVariableRateBasisBaseRate" contextRef="I2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum plus </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54558e887-wk-Fact-002E1FCA0A64D835882EA6258E99F825" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">8.75</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> on the outstanding balance of the term loan not exceeding </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54558e891-wk-Fact-EB62A24435DDBC9FA67FA6258E65391F" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="I2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Concurrent with the Credit Agreement, the Company also entered into a Royalty Purchase Agreement (the &#8220;Royalty Agreement&#8221;) with the same financial institution, which obligated the Company to make quarterly royalty payments of (i) </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54558e898-wk-Fact-F2B236E3434C9673912CA6258E61730D" name="gh:RoyaltyPaymentsPercentageofRevenue" contextRef="D2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierOneMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> applied to total Company fiscal year revenues of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54558e902-wk-Fact-F8CCB5C59BB50D7BCC9AA6258E6533DD" name="gh:RoyaltyAgreementPaymentTierThreshold" contextRef="I2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierOneMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and (ii) </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54558e906-wk-Fact-437554D12857FCA6366BA6258E611746" name="gh:RoyaltyPaymentsPercentageofRevenue" contextRef="D2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierTwoMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.45</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> applied to fiscal year revenues in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54558e910-wk-Fact-D19C75002A5BD61F7A52A6258E97492C" name="gh:RoyaltyAgreementPaymentTierThreshold" contextRef="I2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierTwoMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Royalty Agreement included a buyout option, by which the Company had the right, exercisable in its sole discretion, to buy out the obligation to make future royalty payments. The price of this buyout option was calculated based on a table with axes of principal balance outstanding and time, less the cumulative sum of royalty payments at the time the buy-out option is exercised.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2017, the Company exercised its prepayment right under the Credit Agreement and repaid the outstanding principal balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54558e917-wk-Fact-4900BD8ECDA93AC6B5DDA6258E6389F7" name="us-gaap:RepaymentsOfDebt" contextRef="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">  and accrued interest of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54558e921-wk-Fact-8858AE3378C4935BB0FBA6258E9397DB" name="gh:PaymentofAccruedInterestDebt" contextRef="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The prepayment option also required the Company to pay a prepayment penalty of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54558e925-wk-Fact-618B317CEDEDEB9ADEC1A6258E96CBC8" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Concurrent with the prepayment of the senior term loan, the Company also excised its royalty buyout option for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54558e929-wk-Fact-EEBF1A79994CC8C9BABEA6258E6527E5" name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The transaction was accounted for as a debt extinguishment. The net carrying amount of the debt and royalty liabilities immediately before the extinguishment was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54558e933-wk-Fact-D92FC2FBFF677EA518C9A6258E973BCA" name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="I2017Q2Jun30" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. As a result, the difference between the reacquisition price and the net carrying amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d54558e938-wk-Fact-C4D4A0C2B8919F027465A6258E9BFBE0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as loss on debt extinguishment in the accompanying consolidated statements of operations. As of December&#160;31, 2019 and 2018, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d54558e942-wk-Fact-6268321BE3C2941A8C4DA6258E96B28F" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> outstanding balance under the senior term loan and its related royalty obligations.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">134</span></div></div><hr style="page-break-after:always"></hr><div><a id="s907629139fdb430ba4cbb21803cf433e"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">9. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-C02E51550F9A15757DFCF298FE7E3FB8-0-wk-Fact-B744833B42CD60954E7FF299A03031D7" continuedAt="TextSelection-C02E51550F9A15757DFCF298FE7E3FB8-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="TextSelection-C02E51550F9A15757DFCF298FE7E3FB8-1"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has&#160;entered into various operating lease agreements for office space,&#160;with remaining terms ranging from 1 year to 8 years some of which include one or more options to renew.  As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether we will renew the lease, as such, we do not include renewal options in our lease terms for calculating our lease liability, as the renewal options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these renewal options at the time of the lease commencement. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease expense for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d55254e882-wk-Fact-C93D5D7DB21104C226857E99085C2787" name="us-gaap:OperatingLeaseExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> which includes both lease and non-lease components (primarily common area maintenance charges and property taxes).</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rent expense for the facility leases was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d55254e889-wk-Fact-6D745D6F6B7836EF2C99A6258E94D8C1" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d55254e893-wk-Fact-ABD98A708A2256DA0A05A6258E4137EF" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the weighted-average remaining lease term and weighted-average discount rate for operating leases is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d55254e912-wk-Fact-D24531DBF6068DF3F947787468CE4FD1" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q4" format="ixt-sec:duryear">6.4</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e916-wk-Fact-83A7B31BA08DDD5160017874D71F3C4A" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q4" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">7.77</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> respectively. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-4A58E19D2F9E55D9D6E55A85EEBB9D91-0-wk-Fact-31836988BFA398424C075A860A4A7E74" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our future principal contractual obligations for operating lease commitments as of </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.57264957264957%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e996-wk-Fact-0E28E7299195E7C936349841277D13D2" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1011-wk-Fact-D4DDE1CC1C7C6452F5D0984127853353" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,534</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1031-wk-Fact-06FFBF6B3137991077A798412775FFD4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1051-wk-Fact-351600B3087615CFF05B984127489FAB" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1071-wk-Fact-46A4642330C6527A1AFA984127950AE6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,816</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1096-wk-Fact-897179A39FD3B5E6A6F29841278D1A6E" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less:  Imputed Interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d55254e1111-wk-Fact-686F874BBEAD8AE881C19841276CAB23" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,496</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1137-wk-Fact-93B195EFFEDB975235D398412764C7EE" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,396</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has additional future minimum lease payments relating to a facility agreement had not yet commenced amounting to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d55254e1152-wk-Fact-FF6BF00D10702DB3492E7889B6E7CACE" name="gh:LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (imputed interest of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d55254e1156-wk-Fact-BE4F102108E46B600541788B09A0C5D7" name="gh:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">) net of sublease income of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d55254e1160-wk-Fact-B0673ACF9D44530A1684788D0579B38F" name="gh:LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases are not material to the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">ASC 840 Disclosures</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">The Company elected</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">modified retrospective transition approach and is required to present previously disclosed information under the prior accounting standards for leases. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="TextSelection-1A8E40CC2D55919BDFB55A8685613CF8-0-wk-Fact-C5ADDF34168AD6341CFE5A86A4A5D656" continuedAt="TextSelection-1A8E40CC2D55919BDFB55A8685613CF8-1" escape="true">Total minimum lease payments as of </ix:nonNumeric></span><ix:continuation id="TextSelection-1A8E40CC2D55919BDFB55A8685613CF8-1" continuedAt="TextSelection-1A8E40CC2D55919BDFB55A8685613CF8-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></ix:continuation></div><ix:continuation id="TextSelection-1A8E40CC2D55919BDFB55A8685613CF8-2"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.57264957264957%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1251-wk-Fact-C79621EA0041B93E80985A8DB26F312C" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1266-wk-Fact-408647E97376652067C95A8DD82793D8" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1286-wk-Fact-111A610D43D8369BB5DA5A8E0199D994" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1306-wk-Fact-BE1B4607EDAAEE9322D55A8E2E074077" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,557</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1326-wk-Fact-46C5DC37EDEFA07426325A8E5868DB41" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1346-wk-Fact-99CAE67ED6985FDB1CCD5A8E80BE468E" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,786</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55254e1371-wk-Fact-DCF96958530CFD37ADB35A8EA8148B3D" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">135</span></div></div><hr style="page-break-after:always"></hr><div><a id="s23E2F6368DA35B73ACE43A206A8ED21E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">10. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-7C3B71F77517B8628BACA6258EB8D3E5-0-wk-Fact-B09938E3CF36D194AE2CA6258E9FA8BF" continuedAt="TextSelection-7C3B71F77517B8628BACA6258EB8D3E5-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="TextSelection-7C3B71F77517B8628BACA6258EB8D3E5-1" continuedAt="TextSelection-7C3B71F77517B8628BACA6258EB8D3E5-2"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has patent license agreements with </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e889-wk-Fact-3CDE37C6ECE0569A3EB2A6258E42C53C" name="gh:NumberofPartiesWithPatentLicenseAgreement" contextRef="FD2019Q4YTD" unitRef="party" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> different parties. Under these agreements, the Company has made one-time upfront and milestone payments, which it has capitalized and is amortizing to expense ratably over the useful life of the underlying patent right(s). Under some of these agreements, the Company is obligated to pay low single-digit percentage running royalties on net sales where the licensed patent right(s) are used in the product or service sold, subject to minimum annual royalties or fees in certain agreements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty expenses were included in cost of precision oncology testing on the accompanying consolidated statements of operations. The Company recognized royalty expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56022e896-wk-Fact-8BB6924A58929DE4E01BA6258E36F332" name="us-gaap:RoyaltyExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56022e900-wk-Fact-D0A2B97CF3B68326B885A6258EA07279" name="us-gaap:RoyaltyExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and  </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56022e904-wk-Fact-84BC5CDD1740120076DFA6258E386245" name="us-gaap:RoyaltyExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e908-wk-Fact-AC59761931AE5D39FE1DA6258E43F8AA" name="gh:RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e912-wk-Fact-8B641E9B913DDD437C69A6258E99763A" name="gh:RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e917-wk-Fact-2D2810C119BAB7719BF2A6258E45C820" name="gh:RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of precision oncology testing revenue in each period, for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="TextSelection-6D60B49139E78A262681F2A48FF71533-0-wk-Fact-9592D554F51464064E9BF2A4A158A857" continuedAt="TextSelection-6D60B49139E78A262681F2A48FF71533-1" escape="true">As of </ix:nonNumeric></span><ix:continuation id="TextSelection-6D60B49139E78A262681F2A48FF71533-1" continuedAt="TextSelection-6D60B49139E78A262681F2A48FF71533-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, future minimum royalty payments are due as follows regardless of sales amounts:</span></ix:continuation></div><ix:continuation id="TextSelection-6D60B49139E78A262681F2A48FF71533-2"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1008-wk-Fact-0160EB6A282421F139B6A6258E44BE7D" name="us-gaap:ContractualObligationDueInNextTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1023-wk-Fact-65C32A1B1AC48FB1BCF5A6258E3D1FF3" name="us-gaap:ContractualObligationDueInSecondYear" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1043-wk-Fact-20F11A80B7E701AF6408A6258E38D1B6" name="us-gaap:ContractualObligationDueInThirdYear" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,682</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1063-wk-Fact-FD491ACCDA5DE078ACDCA6258E3CFEF8" name="us-gaap:ContractualObligationDueInFourthYear" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,682</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1083-wk-Fact-1FBEC5268F94C073E751A6258E45BB9C" name="gh:ContractualObligationDueInFifthYearAndAfterFifthYear" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,607</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total future minimum royalty payments   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1103-wk-Fact-3BA602FF9746286C5040A6258E3B1613" name="us-gaap:ContractualObligation" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: amount representing interest   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d56022e1123-wk-Fact-8F8F536DE9A646721F26A6258E39707F" name="gh:ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of future minimum royalty payments   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1149-wk-Fact-118BD7BB49B67C5D0DB1A6258E428997" name="gh:ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,880</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnification Agreements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into indemnification agreements with certain directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no such matters have arisen and the Company does not believe that the outcome of any claims under indemnification arrangements will have a material adverse effect on its financial positions, results of operations or cash flows. Accordingly, the Company has not recorded a liability related to such indemnifications as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Security Incidents</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with a former employee&#8217;s complaints alleging non-compliance with applicable provisions of the Health Insurance Portability and Accountability Act of 1996, the Company received requests for information from the Office for Civil Rights, or OCR, of the U.S. Department of Health and Human Services in August 2019. After the Company responded to these requests, the Company was informed by the OCR that it has closed this matter without further action. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Patent Disputes</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2016, Foundation Medicine, Inc. (&#8220;Foundation Medicine&#8221;) filed a lawsuit for patent infringement against the Company in the United States District Court for the Eastern District of Texas, alleging that the Company infringed Foundation Medicine&#8217;s patent relating to its tissue biopsy assay technology and seeking compensatory damages and attorneys&#8217; fees. The Company filed </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1188-wk-Fact-BCA997D036EB0B362250A6258E3F2BA0" name="gh:NumberofPetitionsFiled" contextRef="D2016Q2May01-May31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" unitRef="patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> petitions for inter partes review (&#8220;IPR&#8221;) with the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) at the U.S. Patent and Trademark Office, challenging the patentability of Foundation Medicine&#8217;s patent. In July 2018, the Company reached an agreement with Foundation Medicine to settle the lawsuit and resolve the IPRs. As part of the settlement agreement, which was accepted by the PTAB and the United States District Court, </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">136</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-7C3B71F77517B8628BACA6258EB8D3E5-2"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Company made a one-time payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56022e1195-wk-Fact-CF983E1DD007041EE190A6258E3284A2" name="us-gaap:PaymentsForLegalSettlements" contextRef="D2018Q3Jul01-Jul31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to Foundation Medicine. The Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56022e1199-wk-Fact-90C0E48ACCE95196B72DA6258E926D34" name="us-gaap:LitigationSettlementExpense" contextRef="D2017Q4Dec31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as litigation settlement expense, a component of general and administrative expenses, at December 31, 2017.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2017, the Company filed separate lawsuits against Foundation Medicine and Personal Genome Diagnostics, Inc. (&#8220;Personal Genome Diagnostics&#8221;) in the United States District Court for the District of Delaware, alleging that each of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1206-wk-Fact-62742564CC4FBA21466AA6258E98D81F" name="gh:NumberofCompaniesthatInfringedonaPatent" contextRef="D2017Q4Nov01-Nov30_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" unitRef="company" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> companies has infringed a patent relating to the Company&#8217;s digital sequencing technology. The Company subsequently amended its original complaints in each case to assert infringement of three additional patents relating to its digital sequencing technology. In each lawsuit, the Company is seeking compensatory damages, injunctive relief and attorneys&#8217; fees. Personal Genome Diagnostics and Foundation Medicine have each asserted counterclaims of patent invalidity and non-infringement. In March 2018, Personal Genome Diagnostics filed </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1210-wk-Fact-0FE4EF63802AAB84963AA6258E9D3FA1" name="gh:NumberofPetitionsFiled" contextRef="D2017Q4Nov01-Nov30_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" unitRef="petition" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> petitions for post-grant review with the PTAB, challenging the patentability of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1214-wk-Fact-91421785F17B6BAC8B2AA6258E9E18F7" name="gh:NumberofAssertedPatents" contextRef="D2017Q4Nov01-Nov30_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" unitRef="patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of the patents asserted by the Company. Prior to reaching a decision on the merits, the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1218-wk-Fact-0FE4EF63802AAB84963AA6258E9D3FA1" name="gh:NumberofPetitionsFiled" contextRef="D2017Q4Nov01-Nov30_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" unitRef="petition" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> post-grant review petitions were dismissed with prejudice in July 2018. Subsequently,&#160;Foundation Medicine filed </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56022e1222-wk-Fact-F7F781115B71AC2B8AAEA6258E4388C4" name="gh:NumberofPetitionsFiled" contextRef="D2018Q3Jul01-Jul31_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" unitRef="petition" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> petitions for inter partes review with the PTAB, challenging the patentability of all four of the patents asserted by the Company, which actions are currently pending at the PTAB. The Company plans to vigorously defend its patent rights during such PTAB actions.&#160;At this time, the Company cannot reasonably ascertain the likelihood that any of the challenged patents will be found to be invalid or unenforceable.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License Dispute</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the Company filed a request for arbitration to the International Chamber of Commerce claiming that one of its licensors, KeyGene N.V. (&#8220;Licensor&#8221;), has breached its patent license agreement with the Company. In January 2019, Licensor responded with its answer and counterclaims and alleged that the Company has breached the patent license agreement. The Company subsequently followed up with supplemental claims, for which Licensor responded with its supplemental answer. The Company is seeking damages, declaratory relief and alternative forms of relief including recession and reformation to address Licensor&#8217;s alleged breaches of the patent license agreement. Licensor is seeking damages, recovery of costs and fees and declaratory relief in addition to the dismissal of the Company&#8217;s claims. The arbitration is in preliminary stages, and no date has been set for rendering a final decision. At this time, the Company cannot reasonably ascertain the likelihood that any of its claims or Licensor&#8217;s counterclaims will be heard by the arbitration panel or succeed on the merits.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Disputes</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2018, the Company settled a commercial dispute. In connection with the settlement, the Company received a payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56022e1238-wk-Fact-72CBA5AD8DBDA0C67DC6A6258E44D944" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" contextRef="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherIncomeMember" unitRef="usd" decimals="-4" scale="6" format="ixt:numdotdecimal">4.25</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was reported as other income in the consolidated statements of operations for the year ended December&#160;31, 2018.</span></div></ix:continuation><div><a id="s4F9B9399CA9F531CAF2034D061C5721F"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">11. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-39B4F28548148354383BA6258EB9FFFF-0-wk-Fact-322386941A47CEE3FF05A6258E4F9176" continuedAt="TextSelection-39B4F28548148354383BA6258EB9FFFF-1" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="TextSelection-39B4F28548148354383BA6258EB9FFFF-1" continuedAt="TextSelection-39B4F28548148354383BA6258EB9FFFF-2"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors (the &#8220;Board of Directors&#8221;). As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, no dividends on the Company&#8217;s common stock had been declared by the Board of Directors.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfStockByClassTextBlock" id="TextSelection-FB058028885B58EFF601A6258EB936C2-0-wk-Fact-C349C02373953CF012ACA6258E53E1BB" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares underlying outstanding stock options   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d55622e961-wk-Fact-185DBAA426AE4FF343CCF2AC2D659D66" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,494,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e975-wk-Fact-00698694BCDBE0E3A250A6258E3EFAD8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,588,405</ix:nonFraction></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares available for future stock option grants   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e986-wk-Fact-7C1953D0C05D7DB5789BF2AC2D512C49" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_gh_SharesAvailableForFutureStockOptionGrantsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,726,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e1000-wk-Fact-A5F533B9A5A00391DDF2A6258E3D50C1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_gh_SharesAvailableForFutureStockOptionGrantsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,556,507</ix:nonFraction></span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e1011-wk-Fact-67E9E290E5A5A3C7BF6D5ACABBBCDE68" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">689,917</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e1025-wk-Fact-7840158B91889CEA32E65ACABF4C9AE1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">922,250</ix:nonFraction></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e1036-wk-Fact-5343D12B2071A7DBAA06A6258E2D0232" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,911,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e1050-wk-Fact-EC281575EAB8E7AF6E06A6258E3D3DC4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,067,162</ix:nonFraction></span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Board of Directors and its stockholders approved a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e1063-wk-Fact-66B2F4323D6BD6FFE53BF2B2FEB63B25" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="D2018Q3Sep01-Sep30" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">0.7378</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">-for-one reverse stock split of the Company&#8217;s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the IPO. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">137</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-39B4F28548148354383BA6258EB9FFFF-2" continuedAt="TextSelection-0372C222EDBD58C1D2B9A6258EB9F7B8-0"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 9, 2018, the Company completed the IPO, in which it issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e1082-wk-Fact-62ADFC804E8296F676A5F2B33A4FCB14" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,375,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of its common stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d55622e1086-wk-Fact-6D513932D4FBBB2C60FBA6258E6A82E0" name="us-gaap:SaleOfStockPricePerShare" contextRef="I2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">19.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company received net proceeds of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d55622e1090-wk-Fact-BA0280F25241ED78C2F1F2B3A82C35B6" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="D2018Q4Oct9" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">249.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;after deducting underwriting discounts and commissions and offering expenses payable by the Company. All then-outstanding warrants to purchase the Company&#8217;s common stock were exercised prior to the completion of the IPO.&#160;In addition, in connection with the IPO,&#160;all shares of the Company&#8217;s then-outstanding convertible preferred stock were automatically converted into&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e1094-wk-Fact-753899F125885BECC4ECF2B3E5AA13CB" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="D2018Q4Oct9_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">58,264,577</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of its common stock, and all then-outstanding warrants to purchase the Company&#8217;s convertible preferred stock were automatically converted into warrants to purchase&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e1098-wk-Fact-B13F866F794BE51D627CF2B42DE714B8" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="D2018Q4Oct9_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,636</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of the Company&#8217;s common stock.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Follow-on Offering</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company completed an underwritten public offering, in which it issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d55622e1112-wk-Fact-1301C8E4E7E524C306B3F2B46A15C403" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q2May_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,175,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of its common stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d55622e1116-wk-Fact-F06F402A4E13A768B030F2B4DAB273DD" name="us-gaap:SharesIssuedPricePerShare" contextRef="I2019Q2May31" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">71.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company received net proceeds of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d55622e1120-wk-Fact-D464BB361B62C516613DF2B511F5A70E" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2019Q2May_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">349.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sE0817E1D703E5C6CA81FF226FEC490CB"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">12. <ix:continuation id="TextSelection-0372C222EDBD58C1D2B9A6258EB9F7B8-0" continuedAt="TextSelection-0372C222EDBD58C1D2B9A6258EB9F7B8-1">Warrants</ix:continuation></span></div><ix:continuation id="TextSelection-0372C222EDBD58C1D2B9A6258EB9F7B8-1"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with a bank loan agreement with a financial institution in September 2013, the Company issued warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56154e875-wk-Fact-0EC1AFAC94857AEE6E09A6258E95B9E7" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="I2013Q3Sep30_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,386</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series A convertible preferred stock at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56154e879-wk-Fact-34FDBACD8EF1C1EA3994A6258E95A11F" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I2013Q3Sep30_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.93</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. In October 2014, the Company issued additional warrants to the same financial institution to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56154e883-wk-Fact-775B4FBD10F5A384BAB0A6258E979811" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="I2014Q4Oct31_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesBConvertiblePreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,965</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series B convertible preferred stock at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56154e887-wk-Fact-332916907DF7E134E82EA6258E969675" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I2014Q4Oct31_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesBConvertiblePreferredStockMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">3.16</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. These preferred stock warrants were converted to warrants to purchase common stock upon the consummation of the IPO and were net exercised into </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56154e891-wk-Fact-C7083C5A034715F3A6C4A6258E95079C" name="gh:StockIssuedDuringPeriodSharesExerciseofWarrants" contextRef="D2018Q4Oct01-Oct31" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,548</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in October 2018. </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56154e896-wk-Fact-9717F86972FA0E75F170A6258E993B08" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> warrants remained outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2012, the Company issued to certain investors warrants to purchase&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56154e907-wk-Fact-3C3B6EDD32248B2B3329F2C0074C6118" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="I2012Q4Dec31" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">495,775</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock. The exercise price of the warrants is&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56154e911-wk-Fact-ECD3B8293DFE3C8BDA71F2C09092204D" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I2012Q4Dec31" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.14</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share and the warrants have a contractual term through September 2023.  For the year ended&#160;December&#160;31, 2018&#160;and&#160;2017,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56154e915-wk-Fact-D44CD555569EB47868C8F2C1181D3F6A" name="gh:StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">313,741</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56154e919-wk-Fact-F14074B09A9B1A615F51F2C12F056CA5" name="gh:StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">89,030</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares, respectively,&#160;were issued upon the exercise of these warrants. As of&#160;December&#160;31, 2017, warrants to purchase&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56154e923-wk-Fact-6EFC8C5A08CEDEB1F44AF2CA95976E13" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="FI2017Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">313,741</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock were outstanding, and these warrants were fully exercised prior to the consummation of the IPO in October 2018.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sE46D5E10B3525500AE3458F1A83ADD6A"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">13. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PreferredStockTextBlock" id="TextSelection-091DE5FB7AD0018EA8B1A6258EB942C7-0-wk-Fact-D677A8DF0369CD7432A3A6258E629D66" continuedAt="TextSelection-091DE5FB7AD0018EA8B1A6258EB942C7-1" escape="true">Convertible Preferred Stock</ix:nonNumeric></span></div><ix:continuation id="TextSelection-091DE5FB7AD0018EA8B1A6258EB942C7-1" continuedAt="TextSelection-091DE5FB7AD0018EA8B1A6258EB942C7-2"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company previously issued convertible preferred stock in one or more series, each with such designations, rights, qualifications, limitations, and restrictions as set forth in the Company&#8217;s certificate of incorporation, as in effect prior to the IPO. Immediately prior to the completion of the IPO, as described in Note 1,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Description of Business</span><span style="font-family:inherit;font-size:10pt;">, all shares of convertible preferred stock then outstanding were automatically converted to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e879-wk-Fact-1CF4CE1BEE8AE5801550AF7C04BAFEDC" name="gh:StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">58,264,577</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at the respective conversion ratios in October 2018.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, the Company entered into the Series E convertible preferred stock purchase agreement with SoftBank and certain of the Company&#8217;s existing stockholders. Pursuant to the purchase agreement, the Company issued and sold an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e890-wk-Fact-609BF8B2EC518E03972FA6258E50F012" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">38,174,246</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series E convertible preferred stock at a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56267e894-wk-Fact-E43B29BE3936C33B8BE3A6258E51B5C3" name="us-gaap:SaleOfStockPricePerShare" contextRef="I2017Q2May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">8.3936</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56267e898-wk-Fact-04460944FA670E5BD3B7A6258E62703E" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">320.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The purchase agreement also provided that the Company would issue additional shares of Series E convertible preferred stock to the Series E investors in such an amount as to cause SoftBank&#8217;s equity ownership in the Company to equal </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e902-wk-Fact-4A5C2537694FCF7DFD80A6258E6EF97E" name="gh:ThresholdPercentageofNewSharesIssued" contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s outstanding fully-diluted capital stock measured </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d56267e906-wk-Fact-FCE220F8398CFB595620A6258E4B5FE6" name="gh:ThresholdPeriodAfterInitialClosingtoIssueNewShares" contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember" format="ixt-sec:duryear">70</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> days after the initial closing. This gross-up was intended to enable the Company to engage in various repurchases of its equity from existing stockholders and still maintain SoftBank&#8217;s equity ownership at </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e911-wk-Fact-4A5C2537694FCF7DFD80A6258E6EF97E" name="gh:ThresholdPercentageofNewSharesIssued" contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">.&#160;As a result, in July 2017, the Company repurchased an aggregate of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e915-wk-Fact-B1FD96DE59E91446F626A6258E605914" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="D2017Q3Jul01-Jul31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,588,065</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock from certain of its directors and executive officers for a purchase price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56267e919-wk-Fact-187C53FA06B4AEFABBCCA6258E623271" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" contextRef="D2017Q3Jul01-Jul31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="5" scale="0" format="ixt:numdotdecimal">10.23887</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share, which represented a price equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e923-wk-Fact-E96893E4800EFD420309A6258E634923" name="gh:PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock" contextRef="D2017Q3Jul01-Jul31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">90</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the original price per shares for the Series E convertible preferred stock, as adjusted to reflect the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e927-wk-Fact-F00D389237F914004969A6258E6A529E" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="D2018Q3Sep19" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">0.7378</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">-for-one reverse stock split of the Company&#8217;s common stock effected on September 19, 2018. The Company also engaged in a tender offer pursuant to which it repurchased&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e931-wk-Fact-DF1107AF5C3C2F92A428A6258E5E8376" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="D2017Q3Aug01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">131,243</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock from certain employees at the same per share price paid for the Series E convertible preferred stock as adjusted to reflect the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e936-wk-Fact-F00D389237F914004969A6258E6A529E" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="D2018Q3Sep19" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">0.7378</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">-for-one reverse stock split of the Company&#8217;s common stock effected on September 19, 2018, and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e940-wk-Fact-C962A0B82E54C63AFD72A6258E5EB61F" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">666,920</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series A convertible preferred stock from existing stockholders at a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56267e944-wk-Fact-69676FBA403CC02D9BC3A6258E6F206A" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share of Series A convertible preferred stock. Following these repurchases, in October 2017, the Company issued an additional </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e948-wk-Fact-1756DBA8DC3F7224A13CA6258E5C5AEC" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="D2017Q4Oct01-Oct31_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">796,346</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series E convertible preferred stock to the Series E investors for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56267e952-wk-Fact-FA8C4F792E233B3E730EA6258E50D4F3" name="us-gaap:SharesIssuedPricePerShare" contextRef="I2017Q4Oct31_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember" unitRef="usdPerShare" decimals="5" scale="0" format="ixt:numdotdecimal">0.00001</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share pursuant to the terms of the gross up provision. The conversion price of Series E convertible preferred stock was adjusted as a result of the dilutive issuance of Series E convertible preferred stock under the gross up provision.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">138</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-091DE5FB7AD0018EA8B1A6258EB942C7-2"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, in accordance with its certificate of incorporation then in effect, the Company adjusted the conversion price of Series D convertible preferred stock from </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56267e959-wk-Fact-5C4A9F6B5FC59093646CA6258E56B84A" name="gh:ConvertiblePreferredStockConversionPrice" contextRef="D2017Q2Apr30" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">10.1338</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56267e963-wk-Fact-09B02A4261E4597F2624A6258E6C0D11" name="gh:ConvertiblePreferredStockConversionPrice" contextRef="D2017Q2May01-May31" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">9.8329</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. The Company accounted for the transaction as a modification. A deemed dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56267e967-wk-Fact-50C0567FC5367E4EA3ECA6258E661B35" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, calculated as the additional </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e971-wk-Fact-84DB369356091935B2EBA6258E58C9A0" name="us-gaap:PreferredStockDividendsShares" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">253,361</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock to be received upon the conversion of the Series D convertible preferred stock after the conversion ratio adjustment, multiplied by the then current fair value of the Company&#8217;s common stock, was reported as an increase to net loss attributable to common stockholders for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Repurchase of Series A Convertible Preferred Stock</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2017, the Company repurchased&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d56267e985-wk-Fact-87BCCBD138266C4F7015F2D31B5E1BAC" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">666,920</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of outstanding Series A convertible preferred stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56267e989-wk-Fact-2A7A7011EEC4F038AE9BF2D3708BFA27" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share for a total consideration of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56267e993-wk-Fact-0B8E6D8301748E7BF121F2D43280EE5F" name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The difference between the repurchase amount and the carrying value of these shares of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d56267e997-wk-Fact-818EFA0EDF4CDEAA4DBCF2D4B47F2A8F" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;was recorded as a deemed dividend in accumulated deficit on the accompanying consolidated statements of stockholders&#8217; equity.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s7A30B93832FA57F5955DF72AA5663EB7"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">14. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-0-wk-Fact-1E0C7E22D9846A1889DFA6258E564CF5" continuedAt="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-1" continuedAt="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-2"><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2012 Stock Plan and 2018 Incentive Award Plan</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2012 and September 2018, the Company&#8217;s Board of Directors adopted and its stockholders approved the Company&#8217;s 2012 Stock Plan (as amended and restated, the &#8220;2012 Plan&#8221;) and the Company&#8217;s 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;), respectively, under which the Company may grant cash and equity incentive awards such as stock options, restricted shares, stock units and stock appreciation rights to its employees and non-employees. Stock options granted may be either incentive stock options or nonstatutory stock options. Shares issued under the 2018 Plan may be authorized but unissued shares, or shares purchased in the open market or treasury shares. Upon effectiveness of the 2018 Plan in connection with the IPO in October 2018, the 2012 Plan was terminated and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e878-wk-Fact-2698E141E89E352BBA1F789BC55C3C23" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" contextRef="D2018Q4Oct01-Oct31" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">508,847</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares reserved under the 2012 Plan were forfeited. Any outstanding awards granted under the 2012 Plan remain outstanding, subject to the terms of the 2012 Plan and applicable award agreement, and further cancellation of awards granted under the 2012 Plan are not available for grant in the future. No further grants will be made under the 2012 Plan. </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">139</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-2" continuedAt="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-3"><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Activity</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-1237CF052B25A7DA5450A6258EBAA0FF-0-wk-Fact-699891A9F7F78899FA67A6258E58CACC" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:28%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Available for Grant&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Subject to Options Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Exercise Price&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Remaining Contractual Life (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1252-wk-Fact-32339A7F1B0D1B539C41A6258E43517B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2017Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,698,790</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1266-wk-Fact-EE72805FE1A89A9E899CA6258E44114A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2017Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,391,052</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1285-wk-Fact-664359953086E5BA1FCFA6258EA38310" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2017Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d61512e1300-wk-Fact-700E092FA0570D60F488A6258E91F04F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2017Q4YTD" format="ixt-sec:duryear">8.6</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1315-wk-Fact-A4F0AFD91904AA36107EA6258E455822" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1330-wk-Fact-190B103497FB59635A98A6258E928084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,658,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d61512e1410-wk-Fact-493E36020F48967BB2F7AF61C0E5F3BD" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">508,847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d61512e1491-wk-Fact-3DF7DDCEEC995EBF9E92A6258E41FFB0" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,088,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1506-wk-Fact-C02161AA2946C69E231FA6258E3E731E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,088,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1520-wk-Fact-3996820A5217681C704EA6258EA3F981" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1571-wk-Fact-7C4B7234CE8D520BB438AF67F3B74EE9" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d61512e1585-wk-Fact-FFEF43FE62B6E7F07529A6258EA79728" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,007,387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1600-wk-Fact-D61EE7F872BF2566795BA6258E3C585B" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.09</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1651-wk-Fact-06AD82A31CB1558C2436A6258E4303D1" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">795,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d61512e1665-wk-Fact-FD895EE10C8C6A0034B4A6258EA01EF5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">883,899</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1680-wk-Fact-5281B11E50C88227BF90A6258E3F5828" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repurchase of early exercised shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1731-wk-Fact-09AFA3AF4B8CD2F95A2BAF68DAAD7C97" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1812-wk-Fact-1F9C9555A99E00D8784BA6258EA2F955" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,556,507</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1826-wk-Fact-8B30EE4A348B5293AE8CA6258E2A7197" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,588,405</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1845-wk-Fact-9FB10817AF46E99A023BA6258E9C39A8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d61512e1860-wk-Fact-FC00A8D3F487ACA23C04A6258E421D5A" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD" format="ixt-sec:duryear">8.3</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1870-wk-Fact-4E5C350C939500AEEE94A6258E43E2BD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">250,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares authorized</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1890-wk-Fact-23EA3F1E547057B77979A6258E40EC93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e1970-wk-Fact-1747F80411D923907574A6258E4B8513" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d61512e2050-wk-Fact-2294A855D745208B9570A6258E9F39A7" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">324,579</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2065-wk-Fact-AB58A2276F83627210D1A6258EA890DF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">324,579</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2079-wk-Fact-F6C7A3E1416569BA0AD4A6258EA1E823" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">88.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2130-wk-Fact-BA88507F0AFF7D883CA8AF688D1171B8" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d61512e2144-wk-Fact-E1660D3408341BCD3F21A6258E40B6AE" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,999,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2159-wk-Fact-C7937BD4156EC8809635A6258E3FA894" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2210-wk-Fact-7CFD27023140FCAEC72CA6258E94C608" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d61512e2224-wk-Fact-9799F33F128332B19D57A6258E9E33ED" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">418,676</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2239-wk-Fact-CF9FC9790CB676E1B57BA6258E2A6B97" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repurchase of early exercised shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2290-wk-Fact-33A852BBBD00EA628175A6258E45EC67" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2370-wk-Fact-83C3AF72C8487BE15D12A6258E98640C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,244,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2384-wk-Fact-663A610EC22F88449182A6258E3EC19E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,494,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2403-wk-Fact-55C7B3C2046A1732EEBFA6258E3B190C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d61512e2418-wk-Fact-7399E8930D32E9556498A6258E4094F4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">7.7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2433-wk-Fact-04F1680A81A274CAD11BA6258E2A7A20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">306,392</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and Exercisable as of December 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2463-wk-Fact-7584C6B29E3F0EDCDF25A6258E421447" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,908,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2482-wk-Fact-D6D7B6A161830880879FA6258E3F6228" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d61512e2497-wk-Fact-65973B1803D33EFE2802A6258E91F1E7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">7.2</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2512-wk-Fact-6005C09258959E0D9F4BA6258E9ACE54" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">139,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e2524-wk-Fact-408531BF56E5C560A671A6258E527D30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">218.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e2528-wk-Fact-441D3DF9C7851F2CA9FFA6258E4D7DC9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e2532-wk-Fact-951BBD4B96D32F45C829A6258E4E8192" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted-average grant date fair value of options granted was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e2552-wk-Fact-761C6B71AC7596A8311CA6258E55FE60" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">52.37</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e2556-wk-Fact-64ABDD3EBE55E884F5C2A6258E5F7FC3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.17</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e2560-wk-Fact-B7F7F454C7C7099E4743A6258E596116" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.90</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future stock-based compensation for unvested options as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e2584-wk-Fact-E2AC45143992C94DCB02A6258E593E21" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d61512e2588-wk-Fact-D14E51B362696236CD3CA6258E4C0E69" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">2.7</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the Company modified one of the performance based awards issued to a nonemployee which resulted in reversal of expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e2595-wk-Fact-9EDCF03C8057AC444D4378A06F50380E" name="gh:ReversalOfStockBasedCompensationExpense" contextRef="D2019Q4Dec" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> due to options not vested.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="TextSelection-E59AD59F857DE810548FF2DA944D9F56-0-wk-Fact-B75C4CD9FA87B527E58CF2DAC88BF773" continuedAt="TextSelection-E59AD59F857DE810548FF2DA944D9F56-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s restricted stock unit activity under the 2012 Plan and the 2018 Plan and related information   is as follows: </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">140</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-3" continuedAt="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-4"><ix:continuation id="TextSelection-E59AD59F857DE810548FF2DA944D9F56-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:69%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Units Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2706-wk-Fact-E5C6422323F578581722F2E79C6D9203" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2725-wk-Fact-56FB989A468AA7428235F2E79E5451E9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2740-wk-Fact-933EA7D2392FA12493B57E9A9874D785" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">567,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2754-wk-Fact-D961FDED1AF43909B748F2E7A193AD86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">78.61</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d61512e2774-wk-Fact-E481F5B87E12EB53EB17F2E7A2F102C6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">22,208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2789-wk-Fact-CC58DD7068623337C82EF2E7A55622E0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">47.78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d61512e2809-wk-Fact-A5C94CE29D4AD57149E77E9A987D14B9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">49,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2824-wk-Fact-D45B0C2E21E92295A6ECF2E7A8016FA5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">57.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2844-wk-Fact-C0563BDA5A06C77A0A1AF2E7A8C63938" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">496,131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e2863-wk-Fact-225EFD4FD8E938E2155CF2E7A9E3099B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">82.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future stock-based compensation for unvested restricted stock units as of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e2916-wk-Fact-83BABE1758EF5BF3926EF2F9CAC38019" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d61512e2920-wk-Fact-EA64A3CFA7053C176DE4F2FB91E43C2D" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">3.5</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock&#8209;Based Compensation Expense</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="TextSelection-9E228F75D6C541CDE480A6258EBA0BAD-0-wk-Fact-C2D50DEF208FD27A0628A6258E73CD44" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the effect of employee and non&#8209;employee related stock&#8209;based compensation expense:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3214-wk-Fact-4FE09771B9BE5EBD17AFA6258E77546C" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3233-wk-Fact-397F7D70F83CF2C7B493A6258E870297" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">512</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3252-wk-Fact-334FAE2A5F9BF2D01D87A6258E77745F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3268-wk-Fact-830812F0A6471074EF67A6258E8C8F0F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3287-wk-Fact-D3AE418DDF1F46701067A6258E783DDC" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3306-wk-Fact-BB696C90052F1D431942A6258E6B95F2" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">507</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and marketing expense   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3327-wk-Fact-DB861C124E9F5B969FBFA6258E8C8E4C" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,716</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3346-wk-Fact-EA19E802EB7A329F9A5BA6258E756ECD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,727</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3365-wk-Fact-AA8C115C9B1413D24789A6258E86168A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3386-wk-Fact-442B1011B7CDD77ABBE0A6258E896D8A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3405-wk-Fact-5E3FAD61FA3E8BDB550EA6258E857106" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3424-wk-Fact-5C019454E9C59E70B521A6258E772DC3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3450-wk-Fact-C6C1619F66C53495E91BA6258E8ED626" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3469-wk-Fact-9874A7596968C66EB931A6258E8693AB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3488-wk-Fact-1F479EFDF42FA1FEFAA6A6258E9311FB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Valuation of Stock Options</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Starting January 1, 2019, the Company adopted ASU 2018-07 which aligns the accounting treatment of nonemployee awards with employee awards, and the fair value of stock options issued to employees and nonemployee consultants are both determined as of the grant date.&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-A3F8CC4F7D247A30B610A6258EB90DDA-0-wk-Fact-CC46C772C6AE792264B5A6258E5AF305" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The grant date fair value of employee and nonemployee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 &#8211; 6.22</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.01 &#8211; 6.51</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.02 &#8211; 6.08</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63.2% &#8211; 68.7%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68.7% &#8211; 78.8%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74.1% &#8211; 75.1%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.6% &#8211; 2.7%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.5% &#8211; 3.0%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.9% &#8211; 2.2%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3756-wk-Fact-0CF356A38BD7E01D9FE2A6258E594991" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3766-wk-Fact-D03B1DDD4BA510B37404884DEEC55D63" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3776-wk-Fact-956C1320747A057FA031884E00A7536F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company&#8217;s common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Common Stock</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the IPO, the grant date fair value of the Company&#8217;s common stock was determined by the Company&#8217;s Board of Directors with the assistance of management and an independent third-party valuation specialist. The grant date fair value of the Company&#8217;s common stock was determined using valuation methodologies which utilizes certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of the Company&#8217;s </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">141</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-4" continuedAt="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-5"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">common stock, the methodologies used to estimate the enterprise value of the Company were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="font-family:inherit;font-size:10pt;">. Subsequent to the IPO, the fair value of the Company&#8217;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Term</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the commencement of trading of the Company&#8217;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company&#8217;s common stock. Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-Free Interest Rate</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Dividend Yield</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3826-wk-Fact-0CF356A38BD7E01D9FE2A6258E594991" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Employee Stock Purchase Plan</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company&#8217;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). A total of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3840-wk-Fact-E95928C1BAAE5D2762FCA6258E55AA85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">922,250</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock are initially reserved for issuance under the ESPP. The number of shares may be increased in accordance with the terms of the ESPP. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3847-wk-Fact-9EE279C031A1DA097D7CF34AC676446E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3851-wk-Fact-A426AF1B3DE406E5CF49F34B09705DA8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the fair market value of the Company&#8217;s common stock on the first or last day of the offering period, whichever is lower. The initial offering period ran from October&#160;2, 2018 to January 31, 2019, the second offering period ran from February 1, 2019 to July 31, 2019, and the third offering period began on August 1, 2019 and ran to November 14, 2019. On a going forward basis, the ESPP will provide for separate&#160;six-month offering periods beginning on May 15 and November 15 of each year.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3862-wk-Fact-85EFBF03B988BDF96480F309DAFC9846" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">232,333</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares were purchased under the ESPP. </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e3866-wk-Fact-68CDA95A0B77A4D9ED06F349392875DB" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares were purchased under the ESPP during the year ended December 31, 2018. The total compensation expense related to the ESPP for year ended&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e3879-wk-Fact-FCD12B99A6871CC5CE4CF30842B06218" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e3883-wk-Fact-E6B8A1B4910532C168ABA6258E535A7C" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="TextSelection-1A0C193E689C3BCADC07F2DF991D5B2A-0-wk-Fact-EF16A07782C5C05BB775F2DFB572D8C2" continuedAt="TextSelection-1A0C193E689C3BCADC07F2DF991D5B2A-1" escape="true">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP: </ix:nonNumeric></span></div><ix:continuation id="TextSelection-1A0C193E689C3BCADC07F2DF991D5B2A-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.29 &#8211; 0.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.33</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58.8% &#8211; 60.3%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43.6%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.6% &#8211; 2.5%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.4%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e4106-wk-Fact-5125433A8B7400AAA5F0884F08E588A0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e4116-wk-Fact-4AA21D2F0C0D137B553B884F17D54257" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">142</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-5" continuedAt="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-6"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future stock-based compensation under the ESPP as of</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 was</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e4136-wk-Fact-A1F525057EA060EC7870F31AA4C7BDC7" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:10pt;">which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d61512e4142-wk-Fact-14F7869118B228979EE2F31AE3B1D93F" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:duryear">0.4</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities for Early Exercise of Employee Options</span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><ix:continuation id="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-6" continuedAt="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-7"><span style="font-family:inherit;font-size:10pt;">The Company allowed certain stock option holders to exercise unvested options to purchase shares of the Company&#8217;s common stock. Shares received from such early exercises are subject to repurchase in the event of the optionee&#8217;s employment termination, at the original issuance price, until the options are fully vested.  As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e4160-wk-Fact-5FA851AB369FD45882ACF31BD5AC6BCE" name="gh:CommonStockSubjecttoRepurchaseorCancellation" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">23,981</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d61512e4164-wk-Fact-C39E887E577F396D53B0A6258E52A389" name="gh:CommonStockSubjecttoRepurchaseorCancellation" contextRef="D2018Q4Dec31" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">44,268</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were subject to repurchase at weighted-average price of    </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e4168-wk-Fact-DB353BD528BE51A01D4DA6258E540256" name="gh:WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.66</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the cash proceeds received for unvested shares of common stock of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e4181-wk-Fact-26BBCCD31354E033B8A4F31E355BD2A4" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d61512e4185-wk-Fact-930EBED188B237767E3BF34838EECEC4" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-7"> million was recorded within other long-term liabilities on the consolidated balance sheet, respectively. The shares issued pursuant to unvested options have been included in shares issued and outstanding on the consolidated balance sheet and consolidated statement of redeemable noncontrolling interest and stockholders&#8217; equity as such shares are considered legally outstanding.</ix:continuation> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s7474BC16F46A5984A881287DD113A3F0"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">15. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-EE144B3EE32AC293DDC9A6258EBA515F-0-wk-Fact-60ED24339D1217751650A6258E6CF805" continuedAt="TextSelection-EE144B3EE32AC293DDC9A6258EBA515F-1" escape="true">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-748C48DDC853CD5D3B3AA6258EBA660A-0-wk-Fact-2B93B30838EC17A09AFDA6258E6B8A06" escape="true"><ix:continuation id="TextSelection-EE144B3EE32AC293DDC9A6258EBA515F-1" continuedAt="TextSelection-EE144B3EE32AC293DDC9A6258EBA515F-2"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except per share data)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1159-wk-Fact-DD9CA72B1BBB5CC40BD8A6258E32F7EC" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1179-wk-Fact-4A8DB7FF4A717BAB2EA3A6258E443A47" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1199-wk-Fact-FF90E30B64F2C7FBE5B5A6258EA91FF9" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1216-wk-Fact-D077CEFD0B079FCF3D61A6258E2E6647" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1236-wk-Fact-31CADB87CCF74DD2F2C1A6258E34EF14" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1256-wk-Fact-418F0527488BE40C35CDA6258E2FA7B8" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1277-wk-Fact-0C6706E1876259798ED2A6258E385A17" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">75,651</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1297-wk-Fact-DA7C32E8FAD7508D2E32A6258E8265E9" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">85,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1317-wk-Fact-AFCDBD0520C9E2C5AB33A6258E29D834" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deemed dividend related to repurchase of Series A convertible preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1339-wk-Fact-E68A8C708E2097EC5946A6258E9E2226" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1358-wk-Fact-EBA109E0CAADBD273C7BA6258E32AF46" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1377-wk-Fact-1FF0D1ABEA05EF2C682AA6258E3BA553" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,716</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deemed dividend related to change in conversion rate of Series D convertible preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1399-wk-Fact-26F1F32EB6B9B7D7D5A6A6258E3AC275" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1418-wk-Fact-E839DF2B5D3BDD98BBBDA6258E87AB93" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1437-wk-Fact-A468E27BF4939F5E8D3EA6258E447BE2" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,058</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1464-wk-Fact-1535B29FF0DAB4B154A2A6258E365584" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">75,651</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1484-wk-Fact-6133CF14439345C7338DA6258E9D2D95" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">85,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1504-wk-Fact-28A37E9521F9874504E6A6258E35A77C" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">88,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1526-wk-Fact-431CA7CCFD12D7D5971FA6258E4536C1" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1546-wk-Fact-67E566506F83BC6276A1A6258E62F4F5" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d58146e1566-wk-Fact-08CC3E0BCEE177D04CA6A6258E311A4A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">7.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1584-wk-Fact-77260172BDC24CAE0417A6258E2DCB75" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">90,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1603-wk-Fact-C2FF126AE24D032B0278A6258E405B49" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">30,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1622-wk-Fact-F37245EBF17027238E7AA6258E393BCD" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">12,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">143</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-EE144B3EE32AC293DDC9A6258EBA515F-2"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-9A06CAEDB8471CC725FFA6258EBADDD1-0-wk-Fact-25B27759EB637076E0C7A6258E46970F" continuedAt="TextSelection-9A06CAEDB8471CC725FFA6258EBADDD1-1" escape="true">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9A06CAEDB8471CC725FFA6258EBADDD1-1"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible preferred stock (on an as if converted basis)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1853-wk-Fact-88A66F16EFEC6F0EB52BA6258E7B224A" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1867-wk-Fact-39DD5FB2BC9FD042074AA6258E7B3E4E" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">43,898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1881-wk-Fact-FF6CF5FD501A49D5D07DA6258E750C22" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">44,818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options issued and outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1896-wk-Fact-7D11D7765B47A6FBFAD6A6258E775F9D" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,976</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1910-wk-Fact-1EF5130E5AC501C62A47A6258E7E6359" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">7,527</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1924-wk-Fact-D560DFAF49ECA821884FA6258E792E16" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ESPP obligation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1939-wk-Fact-0B512BB2B2F038A67C93A6258E8140BA" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1953-wk-Fact-67AE1003AC3ADF9211E4A6258E7C06C7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1967-wk-Fact-A0288CBABCA622C4AC3BA6258E7B31D5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock warrants (on an as if converted basis)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1982-wk-Fact-BFCB2A9D8A2E6BDD2506A6258E7645B9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e1996-wk-Fact-5D0DF66A78B90423E2B2A6258E7EA46B" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2010-wk-Fact-B0703BF47A93C9A4943FA6258E7C787A" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2025-wk-Fact-361B61D2AE0CD51A59B7A6258E7A92E7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2039-wk-Fact-AEF73A0E6D398C0E2FFFA6258E7B7FC8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2053-wk-Fact-408620BF81A6E27CEDCAA6258E7A486E" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2068-wk-Fact-E09C8BEADA143836BA75F3242E5355EC" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">252</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2082-wk-Fact-8612A650F57E21D6314EF3242E4A5643" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2096-wk-Fact-BAEBB45E797A34756D9D88514C7388EB" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock subject to repurchase</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2111-wk-Fact-EBDD8B82FFE9C27F7E63A6258E7842BF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2125-wk-Fact-8EC54D059B80054A3665A6258E7B5477" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2139-wk-Fact-350F30B88EF95FE237C7A6258E77BE9B" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2155-wk-Fact-82C3F8620404D6F4210BA6258E7C511A" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">6,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2169-wk-Fact-BA875E69B9AD16EFEFB8A6258E85352A" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">51,707</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d58146e2183-wk-Fact-7CFEE43E8546E70BF872A6258E78CEB6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">50,415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">144</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAC679BEA313658CDA8A143DC5611878E"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">16. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-0-wk-Fact-C284B1D80C6F5A900000A6258E9F5913" continuedAt="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-1" continuedAt="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="gh:ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock" id="TextSelection-3BDDD8D29B781A08D001A6258EBAFBF5-0-wk-Fact-6D05D647819F0D9472DAA6258E98FFB9" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of loss before provision for income taxes were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e1157-wk-Fact-094B10E9853787CDBAC9A6258E94DAF4" name="gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">69,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e1177-wk-Fact-86C23967F91E6226163FA6258E8BF5C3" name="gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e1197-wk-Fact-38065CA8E88DF1AC1843A6258E7B8EB6" name="gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1214-wk-Fact-5744A2E0CBE407B8139E885251F0386B" name="gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1233-wk-Fact-715F5C49FEE34B7C1A0AA6258E934F20" name="gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1252-wk-Fact-5B5DE80F8A81E4001A9DA6258E4A09CD" name="gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e1278-wk-Fact-533D35D4131C9059CAE7A6258E46A63A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">69,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e1298-wk-Fact-E8046E8FEE4F9385958AA6258E318575" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e1318-wk-Fact-129FBB53D2772B0CEB01A6258E337EF0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="TextSelection-90EA7E357A2B31F8CDFDA6258EBA76E1-0-wk-Fact-A2CABD8EAD0BFD91C43DA6258EA54027" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the provision for income taxes are as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1676-wk-Fact-8E1A219854B409D43717A6258E766136" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1695-wk-Fact-A4E4C4808CAB5466A2B1A6258E79EA7A" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1714-wk-Fact-1D83A40C28D0D43EEBCFA6258E99D368" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1730-wk-Fact-50B864E0A4E002D598C9A6258E7199C6" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1749-wk-Fact-3CDBA8B46A59A5CE6AE6A6258E95D4B0" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1768-wk-Fact-924450592E573B5AE2AFA6258E8F0905" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1794-wk-Fact-7180FA45AD20D10D5A5778AF9AC3F203" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1813-wk-Fact-BDC215B13A616FB08D4D78AF9AC76B23" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1832-wk-Fact-A9F8A0FC538AF082A24F78AF9B8D99AC" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal </span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e1915-wk-Fact-CF7FA2C22474B3A695B978B175C8B639" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,652</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1935-wk-Fact-9224CBB86D689799F29778B175C0D308" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1954-wk-Fact-AFB9E184F42284E7303B7E7B3958A598" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e1970-wk-Fact-155E83265833D498911978B1D7C9D8B4" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e1990-wk-Fact-1305B910200FBAA98DAB78B1D7925800" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2009-wk-Fact-683CF273D0AA00886B427E7B395FA2DB" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e2031-wk-Fact-65996545CE759E983D2E7E7BBFA9E371" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2051-wk-Fact-9E14B7920B1022957B497E7BBFB2C06A" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2070-wk-Fact-D02170DBF3D22F7E45007E7BBF2F9BAF" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e2096-wk-Fact-507ECC115A80FEBCFE7E78B2335E3BCF" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2116-wk-Fact-A92AE0C819AC1AC7403178B233561813" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2135-wk-Fact-EE963EE1308DD8CF1BCD78B2335149C7" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total provision for income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e2156-wk-Fact-0169B057D253E86D735EA6258E55D708" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,872</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2176-wk-Fact-E068EE171D06C4C2BD3DA6258E2D3C45" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2195-wk-Fact-29DDE49B36BBF8FF706BA6258E39EA9B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="TextSelection-64ECFD5030EF89AC3717A6258EBBE0A4-0-wk-Fact-F8F2A702BA84A9A33E5CA6258E94E3D6" continuedAt="TextSelection-64ECFD5030EF89AC3717A6258EBBE0A4-1" escape="true">Significant components of the Company&#8217;s deferred tax assets are as follows:</ix:nonNumeric></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">145</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-2" continuedAt="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-3"><ix:continuation id="TextSelection-64ECFD5030EF89AC3717A6258EBBE0A4-1"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating losses carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2443-wk-Fact-6EB7F72E6D0F675EB954A6258E803B41" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">90,534</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2462-wk-Fact-8B8F240683694FCB558AA6258E72206F" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2477-wk-Fact-B66C9F1C099FE6658F57A6258E7954D9" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2496-wk-Fact-25B214E7195360061CC8A6258E7C7FC9" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals and reserves</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2516-wk-Fact-4C419B8BE9BD4228F0E2A6258E847806" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,936</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2535-wk-Fact-0698849B28734B1CB3D7A6258E8101C3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2555-wk-Fact-3A8BE15D1EB34D71035EA6258E484E25" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2574-wk-Fact-2FF1CC406D0D9ADA7656A6258E74F3BB" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2594-wk-Fact-D00DA4A172E9C86CA045A6258E7F95F0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2613-wk-Fact-E7F2E16A1CF9450CD300A6258E7972A0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,289</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2633-wk-Fact-7D70FC7152D0F1A0587478B7EF15C499" name="gh:DeferredTaxAssetsLeaseLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2652-wk-Fact-6DE5BEB550931014075778B7EF11B6CC" name="gh:DeferredTaxAssetsLeaseLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2673-wk-Fact-F8C42848A434AB06E0DDA6258E89A3CB" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2692-wk-Fact-C3F0617DDD2DF5FD941BA6258E7EACE3" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">210</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax asset</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2717-wk-Fact-68508137C4F7DB73E8F2A6258E53B96E" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">134,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2736-wk-Fact-3453CCE80E02E5AF7064A6258E497073" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e2797-wk-Fact-BF6ECD0550E650B56788A6258E4A2932" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e2817-wk-Fact-8CA38608A4AF075DC32EA6258E803C18" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Section 481 (a) adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e2833-wk-Fact-89557B1C3C5432A1E5E078B91F33B458" name="gh:DeferredTaxLiabilitiesSection481aAdjustment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">914</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2853-wk-Fact-68F489F2C723BF0F7AA678B91F3844ED" name="gh:DeferredTaxLiabilitiesSection481aAdjustment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e2873-wk-Fact-A272C54FF37F5E9AD14278B9A9369683" name="gh:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2893-wk-Fact-1CDE9030DED035BCC13278B9A93B2DE6" name="gh:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain/loss on investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e2913-wk-Fact-FCF17067007869E3C79778BA4B00233B" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">346</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2933-wk-Fact-00AF5F59C9F68E05681778BA4B04D580" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e2953-wk-Fact-0A44FBA5B737C0B5A305A6258E8CCE07" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">125,245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e2973-wk-Fact-51E868CFF51C7E896CA6A6258E7D5F4C" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e2999-wk-Fact-0954F0696EC2C2BBC636A6258E7B7C99" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3018-wk-Fact-9DCA76308D33D27386EFA6258E4C0BE7" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-00119CC80BDB5F1E06D7A6258EBA2F14-0-wk-Fact-F33ACB006FF8568BDAD3A6258E9D0872" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents a reconciliation of the income tax expense computed at the statutory federal rate and the Company&#8217;s income tax expense for the periods presented:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax at the statutory federal rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3312-wk-Fact-65EEF7F6F552662C7968A6258E883819" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,642</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3332-wk-Fact-2368588343F70C95ED1CA6258E855CB5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">17,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3352-wk-Fact-96193225834255A0683EA6258E7DE555" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,293</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other nondeductible items</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3369-wk-Fact-EE43C5F7D86B59F2548DA6258E7D3974" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3388-wk-Fact-BB8DC0A5C674C8D138E0A6258E89B0EC" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">329</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3407-wk-Fact-29DD65E8F7D3CE81A32AA6258E86E749" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3428-wk-Fact-656C64B94BDF356AE0D4A6258E86A7DA" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">33,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3448-wk-Fact-F086AE66D4D552C22BFBA6258E7BCD02" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">497</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3467-wk-Fact-FD29CAD0D20A887688C2A6258E7AB74F" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,819</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3488-wk-Fact-FBD26BB32384609EB2B4A6258E8781FD" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3508-wk-Fact-87C3799CBC53C23CB08DA6258E7CD3AB" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,726</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3528-wk-Fact-76AE62184BE5373DC134A6258E82FDC8" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3550-wk-Fact-D172FCE180DCA2B5A2A7A6258E8C6D1E" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,049</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3569-wk-Fact-95D93E181AF87F834EE4A6258E716403" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3588-wk-Fact-456496FB51CCB6266916A6258E9250B3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State taxes, net of federal benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3609-wk-Fact-16B08C11B7DB0FBE7A8DA6258E80F948" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3629-wk-Fact-9D83B7CA391B1C9A598AA6258E81B05D" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3649-wk-Fact-7FCBA5D11106B20A61D1A6258E88E2FA" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,868</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in tax rate due to Tax Act</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3671-wk-Fact-417A25FB8F2536E03556A6258E878AFD" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3690-wk-Fact-1803CFBBC6C8152B2912A6258E724CB1" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3709-wk-Fact-253FABA05360AACBFF9AA6258E86FC22" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,346</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3731-wk-Fact-4F45FBA17B2D07EFA339A6258E74ECDC" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">605</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3751-wk-Fact-4644064BBD81ABCF2496A6258E94CFD9" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">343</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3770-wk-Fact-E59F2F1BC28E4181964FA6258E7DF80E" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d65609e3797-wk-Fact-0169B057D253E86D735EA6258E55D708" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,872</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3817-wk-Fact-E068EE171D06C4C2BD3DA6258E2D3C45" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3836-wk-Fact-29DDE49B36BBF8FF706BA6258E39EA9B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s actual tax expense differed from the statutory federal income tax expense using a tax rate of 21% for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> primarily due to state and foreign income taxes, nondeductible expenses, research and development tax credits, the acquisition of Bellwether Bio, and the change in valuation allowance.  The Company&#8217;s actual tax expense differed from the statutory federal income tax expense using a tax rate of 21% and 34% for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, primarily due to state income taxes, nondeductible expenses, research and development tax credits, and the change in valuation allowance.  The benefit from income taxes for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> included a release of a valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65609e3865-wk-Fact-B525FBF4712C88E29A4378C23F9345B5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with nondeductible intangible assets recorded as a result of the acquisition of Bellwether Bio.  In connection with the acquisition of Bellwether Bio, a deferred tax liability was established for the book-tax basis differences related to the non-goodwill intangible assets.  The net deferred tax liability from this acquisition creates an additional source of income to offset the Company&#8217;s deferred tax assets. The benefit from income taxes for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> also included a benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65609e3874-wk-Fact-78888B25FBB238F95A869843AA29189B" name="us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the utilization of tax losses from continuing operations against other comprehensive income gains in accordance with intra-period tax allocation under ASC Topic 740.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">146</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-3" continuedAt="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-4"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had a net operating loss carryforwards of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65609e3892-wk-Fact-7583165C9B4B84F19C7EA6258EA296BE" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">365.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3896-wk-Fact-B98A84B7676871CDBCB5A6258E9D6629" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">152.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for federal purposes, respectively, and $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3900-wk-Fact-A98118EF36D7AC23619478C8B6EA88CF" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">223.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3905-wk-Fact-7F992EDCD7AE2D9B2B9678C8C9A82599" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">73.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for state and local purposes, respectively, which may be subject to limitations as described below. If not utilized, these carryforwards will begin to expire in 2031 for federal, and 2020 for state and local purposes. Under the newly enacted federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the newly enacted federal income tax law.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had research and development tax credit carryforwards for federal tax purposes of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65609e3920-wk-Fact-75C45ABC684B3F6D311EA6258EA4D3B9" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3924-wk-Fact-1E5EE8BE9BADE443AE9F78C996D4D5AA" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and state research and development tax credit carryforwards of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65609e3928-wk-Fact-EE51105E0465E7DBA9B3A6258EA05A18" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e3933-wk-Fact-F9F36027EB64B21684BA78C9B9CDE4DE" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The federal research and development tax credit carryforwards will expire at various dates beginning in the year 2032. The Company&#8217;s state research and development tax credit carryforwards do not expire.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Utilization of the net operating loss (&#8220;NOL&#8221;) carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. Current laws impose substantial restrictions on the utilization of NOL carryforwards and credits in the event of an &#8220;ownership change&#8221; within a three-year period as defined by the Internal Revenue Code Section 382 (&#8220;Section 382&#8221;). If there should be an ownership change, the Company&#8217;s ability to utilize its NOL carryforwards and credits could be limited. The Company has not performed a Section 382 analysis. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Due to the Company&#8217;s history of U.S. operating losses, the Company believes that the recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not more likely than not to be realized and, accordingly, have provided a full valuation allowance against net U.S. deferred tax assets. The net change in total valuation allowance was an increase of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65609e3943-wk-Fact-A4A8F43B6455DE1B7E9BA6258E9AF97A" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and an increase of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65609e3947-wk-Fact-5F806FB0367CD4E9594278CA74506A62" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The SEC staff issued SAB 118 on December 23, 2017 regarding application of the Tax Act.  It provides a &#8220;measurement period,&#8221; lasting through December 22, 2018, to allow registrants time to obtain, prepare and analyze information to complete the accounting required under ASC 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;">.  The Company completed its analysis during the measurement period and there were no measurement period adjustments recognized during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has not recorded a provision for deferred U.S. tax expense that could result from the remittance of foreign undistributed earnings since the Company intends to reinvest the earnings in its foreign subsidiaries indefinitely.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has made an accounting policy election to treat Global Intangible Low-Taxed Income ("GILTI") taxes as a current period expense rather than including these amounts in the measurement of deferred taxes.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Uncertain Tax Positions</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records unrecognized tax benefits, where appropriate, for all uncertain income tax positions. The Company recorded unrecognized tax benefits for uncertain tax positions of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65609e3982-wk-Fact-3A641797B4FFDC6755E3A6258EA06016" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65609e3986-wk-Fact-635F750577B11A1FE41478CAF5BCFA77" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, none of which would impact the Company&#8217;s effective tax rate if recognized, because the benefit would be offset by an increase in the valuation allowance. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="TextSelection-13D863AA82A7AB66B23BA6258EBA93D7-0-wk-Fact-FBCC64A04C81757B95A4A6258E9AD2AC" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balance of total unrecognized tax benefits is as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits - Beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4283-wk-Fact-9E7D88DAA12579DDE467A6258E955F45" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,427</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4302-wk-Fact-DAD949776C6CB25E1689A6258E9542A8" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,712</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4321-wk-Fact-6CEAF32A104AC0677A3DA6258E9CF131" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">884</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to current year&#8217;s tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4337-wk-Fact-793F476162E8F20E2B1FA6258E9D6EB8" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4356-wk-Fact-118D90BB9BA0CB32306FA6258E9E761D" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,635</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4375-wk-Fact-0AEFFE5FF73E22E17DE7A6258E9BE5EE" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to prior years&#8217; tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4396-wk-Fact-D32A3660BE65918760C6A6258E9B1972" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4415-wk-Fact-3510187359E3E1CD7982A6258E9930BD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4434-wk-Fact-C6D1B59EDE6AC55C9AB1A6258E995DF3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits - End of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4460-wk-Fact-BDB89330966926D6A6A0A6258E96EC3D" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,543</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4479-wk-Fact-9E7D88DAA12579DDE467A6258E955F45" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,427</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65609e4498-wk-Fact-DAD949776C6CB25E1689A6258E9542A8" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,712</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. During the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized no interest and penalties associated with unrecognized tax benefits. There are no tax positions for which it is reasonably possible that </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">147</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-4" continuedAt="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-5"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-5">Due to the net operating loss carryforwards, all years remain open for income tax examination by tax authorities in the United States, various states and foreign tax jurisdictions in which the Company files tax returns.</ix:continuation> </span></div><div><a id="s3D7525DDFD445D7BAC5031D1C852DA3C"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">17. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="TextSelection-1AD9893B6FC4324EB371A6258EBB6A84-0-wk-Fact-9D270926AA9905CF49B4A6258E99335C" continuedAt="TextSelection-1AD9893B6FC4324EB371A6258EBB6A84-1" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><ix:continuation id="TextSelection-1AD9893B6FC4324EB371A6258EBB6A84-1" continuedAt="TextSelection-1AD9893B6FC4324EB371A6258EBB6A84-2"><span style="font-family:inherit;font-size:10pt;">The Company sponsors a 401(k) plan, and pursuant to its terms, eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65532e875-wk-Fact-12558B18F2DD647FBF66A6258EA01CE4" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="FD2019Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of eligible compensation on a pre-tax basis. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company contributed </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65532e883-wk-Fact-05CA6421C7E481C2C563F32AEDB62059" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-1AD9893B6FC4324EB371A6258EBB6A84-2"> to match employee contributions as permitted by the plan. For the years ended December 31, 2018 and 2017, the Company did not elect to match employee contributions as permitted by the plan. The Company pays the administrative costs for the plan.</ix:continuation> </span></div><div><a id="s013796CFA3AE5919BF8EEAF3B8012C9C"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">18. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SegmentReportingDisclosureTextBlock" id="TextSelection-74D169856C31CDD13E59A6258EBB82EC-0-wk-Fact-1604C86EB1790017E38DA6258E45AC0A" continuedAt="TextSelection-74D169856C31CDD13E59A6258EBB82EC-1" escape="true">Segment and Geographic Information</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="TextSelection-E150EFFEFFA2A46D1F1DA6258EBBF7D9-0-wk-Fact-FA4CAEBCA137B7A6E1F6A6258E470B84" escape="true"><ix:continuation id="TextSelection-74D169856C31CDD13E59A6258EBB82EC-1" continuedAt="TextSelection-74D169856C31CDD13E59A6258EBB82EC-2"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d66415e1159-wk-Fact-2DE8F73B9564A760CC76A6258E717869" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">194,312</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d66415e1178-wk-Fact-2B085F1AE228B69DF701A6258E86B388" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,916</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d66415e1197-wk-Fact-9C3491BECB8297B3D4A3AB6DB9A7C16E" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d66415e1219-wk-Fact-EDDE9BBC277C6333A5AEA6258E7EDBB5" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d66415e1238-wk-Fact-F7335247DEFCDC6BE3DEA6258E820F0E" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d66415e1257-wk-Fact-F5786265061FA6AEBE19AB6DB9B06563" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d66415e1283-wk-Fact-4DE9547D7B5D2159A859A6258E3A1898" name="us-gaap:Revenues" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">214,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d66415e1302-wk-Fact-D1D5341DAF1488A2957EA6258E683A12" name="us-gaap:Revenues" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">90,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d66415e1321-wk-Fact-71C181FD76A4A1A34CB0A6258E9FCF29" name="us-gaap:Revenues" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">No single country outside of the United States accounted for more than 10% of total revenue during each of the years ended </span><span style="font-family:inherit;font-size:7.5pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:7.5pt;">, </span><span style="font-family:inherit;font-size:7.5pt;">2018</span><span style="font-family:inherit;font-size:7.5pt;"> and </span><span style="font-family:inherit;font-size:7.5pt;">2017</span><span style="font-family:inherit;font-size:7.5pt;">. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:24px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(2)    Fiscal years 2018 and 2017 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019. </span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><ix:continuation id="TextSelection-74D169856C31CDD13E59A6258EBB82EC-2" continuedAt="TextSelection-74D169856C31CDD13E59A6258EBB82EC-3"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d66415e1365-wk-Fact-7F704507EFDA2E13E8B491E4D5CDDB2A" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_AssetsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">97</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d66415e1369-wk-Fact-5513AB697022AF9010B291E4D61C1924" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_AssetsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-74D169856C31CDD13E59A6258EBB82EC-3">, respectively, of the Company&#8217;s long-lived assets are located in the United States.</ix:continuation> </span></div><div><a id="sE29A12F992C954D19D5FE4A440BC7293"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">19. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="TextSelection-06542193A9644BDBC5E0A6258EBBEABD-0-wk-Fact-7C8CD47F3B565F0A4CE6A6258EA369CC" continuedAt="TextSelection-06542193A9644BDBC5E0A6258EBBEABD-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="TextSelection-06542193A9644BDBC5E0A6258EBBEABD-1"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in Note 3, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investment in Joint Venture</span><span style="font-family:inherit;font-size:10pt;">, and Note 13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Preferred Stock</span><span style="font-family:inherit;font-size:10pt;">, in connection with Softbank&#8217;s purchase of its Series E convertible preferred stock in 2017, the Company entered into a joint venture agreement with an entity affiliated with SoftBank. In May 2018, the Company and SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in Note 11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock</span><span style="font-family:inherit;font-size:10pt;">, in July and August 2017, the Company repurchased an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65814e890-wk-Fact-76E79E0F81A8FBFAAC1FA6258EA25CAE" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="D2018Q3Jul01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,640,901</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of outstanding common stock from certain executive officers for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65814e894-wk-Fact-67344EE60838DEE07AF4A6258EA2340D" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="D2018Q3Jul01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The difference between the repurchase amount and the fair value of repurchased shares of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65814e898-wk-Fact-31A39A4BC1533C0553EAA6258EA16EB9" name="gh:CommonStockCompensationExpense" contextRef="D2018Q3Jul01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> were recorded as cash-based compensation expense in the accompanying consolidated statements of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For each of the years ended December&#160;31, 2019 and 2017, the Company recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d65814e905-wk-Fact-BC2ED7A09B15F230BF1DF32EEC6E8DAC" name="us-gaap:RevenueFromRelatedParties" contextRef="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million from an entity affiliated with a member of the Company&#8217;s Board of Directors, who serves on the board of both the aforementioned entity and the Company. This individual was appointed to the Company&#8217;s board in January 2017. There was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d65814e909-wk-Fact-40F17908BE3982D5005B91E7F2023059" name="us-gaap:RevenueFromRelatedParties" contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember" unitRef="usd" decimals="-5" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> revenue recognized by the Company from that entity for the year ended December 31, 2018.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">148</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFDA8C48E37F95F1E99F541BBC28C4F39"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><a id="s2740CD7E538E598E8BCB3F7E718BB282"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9A. Controls and Procedures</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of disclosure controls and procedures</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management, with the participation of our chief executive officer, or CEO, and chief financial officer, or CFO, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or Exchange Act), as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our CEO and CFO have concluded that as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such required information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosures.</span></div><div style="line-height:174%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Management report on internal control over financial reporting</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in the Exchange Act Rules 13a-15(f). Under the supervision and with the participation of our management, including our CEO and CFO, we conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework in Internal Control Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the results of our assessment under the framework in the Internal Control&#8212;Integrated Framework (2013), our management concluded that our internal control over financial reporting was effective as of December&#160;31,&#160;2019.The effectiveness of our internal control over financial reporting as of December&#160;31,&#160;2019, has been audited by an independent registered public accounting firm, as stated in their report included in Part II, Item 8,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Financial Statements&#8221;</span><span style="font-family:inherit;font-size:10pt;"> of this Annual Report on Form 10-K.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in internal control</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Annual Report on Form 10-K that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inherent Limitations Over Internal Controls</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management, including our CEO and CFO, do not expect that our internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">149</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:174%;padding-top:12px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:174%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">To the Stockholders and the Board of Directors of Guardant Health, Inc.</span></div><div style="line-height:174%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Opinion on Internal Control </span><span style="font-family:inherit;font-size:9pt;color:#333333;font-weight:bold;">Over</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> Financial Reporting</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">We have audited Guardant Health, Inc.&#8217;s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Guardant Health, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018 and consolidated statements of operations, comprehensive loss, redeemable noncontrolling interest and stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and our report dated March 2, 2020 expressed an unqualified opinion thereon.</span></div><div style="line-height:174%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Basis for Opinion</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="line-height:174%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">/s/ Ernst &amp; Young LLP</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Redwood City, California</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;2, 2020</span></div><div style="line-height:174%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s46030965CE1E55C3BB30921CA9F49C23"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9B. Other Information.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We filed a Current Report on Form 8-K with the SEC on December 5, 2019 (the &#8220;Original 8-K Report&#8221;), which reported, among other things, that on December 2, 2019, Richard Lanman, M.D., notified us of his decision to retire as our Chief Medical Officer, effective as of December 31, 2019. This Item 9B disclosure intends to provide information called for under Item 5.02(e) of Form 8-K that had not been determined at the time of filing of the Original 8-K Report.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">150</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following Dr. Lanman&#8217;s retirement, we and Dr. Lanman, on February 28, 2020, entered into a part-time employment agreement for Dr. Lanman to continue with us as an advisor to facilitate a successful transition (the &#8220;Advisor Agreement&#8221;). Pursuant to the Advisor Agreement, Dr. Lanman will receive an hourly wage and will be entitled to a one-time bonus of $100,000 for his services provided to us in 2019 and the continued vesting of his equity awards previously granted by us during his part-time employment with us. The general terms and conditions of such equity awards are described in our definitive proxy statement filed on April 29, 2019 with the SEC. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This summary of the Advisor Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Advisor Agreement. The full text of the Advisor Agreement is included as Exhibit 10.21 to this Annual Report on Form 10-K and is incorporated herein by reference.</span></div><div><br/></div><div><div style="line-height:144%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:144%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">151</span></div></div><hr style="page-break-after:always"></hr><div><a id="s15A85F06C9CF5C00938F80A849C08A21"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</span></div><div><a id="s202ACDFD08365E10B2847C0D7FEF6E7C"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this Item 10 of Form 10-K will be included in our 2020 Proxy Statement to be filed with the SEC in connection with the solicitation of proxies for our 2020 Annual Meeting of Stockholders and is incorporated herein by reference. The 2020 Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates.</span></div><div><a id="s057450DC44E8510AAD1965F1A957C4ED"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 11. Executive Compensation</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this Item 11 of Form 10-K will be included in our 2020 Proxy Statement and is incorporated herein by reference.</span></div><div><a id="s2BDE765875DA5948A11166A7F7A8AFD3"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this Item 12 of Form 10-K will be included in our 2020 Proxy Statement and is incorporated herein by reference.</span></div><div><a id="s4C17E3F0B0A65071934EE4FCF8C3BB7C"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this Item 13 of Form 10-K will be included in our 2020 Proxy Statement and is incorporated herein by reference.</span></div><div><a id="s0F7F9E8B328A53F1841C4F3715C664CF"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 14. Principal Accounting Fees and Services</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this Item 14 of Form 10-K will be included in our 2020 Proxy Statement and is incorporated herein by reference.</span></div><div><a id="sE0C4F3B548D750A7887378224DB9D5A3"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</span></div><div><a id="s0EE196BFDE695A489672FDF803F93C88"></a></div><div style="line-height:120%;padding-bottom:10px;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 15. Exhibits, Financial Statement Schedules</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Documents filed as part of this report</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(1)</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All financial statements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Index to Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(2)</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statement Schedules</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All financial statement schedules have been omitted since the required information was not applicable or was not present in amounts sufficient to require submission of the schedules, or because the information required is included in the consolidated financial statements or the accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(3)</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibits required by Item 601 of Regulation S-K</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The exhibits listed in the following Index to Exhibits are filed, furnished or incorporated by reference as part of this Annual Report on Form 10-K.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">152</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">INDEX TO EXHIBITS</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Incorporated by Reference</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exhibit Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exhibit Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">File No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exhibit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Filed/Furnished Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012404/exhibit318-k.htm"><span style="font-family:inherit;font-size:9pt;">Amended and Restated Certificate of Incorporation</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8-K</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-38683</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10/9/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012404/exhibit328-k.htm"><span style="font-family:inherit;font-size:9pt;">Amended and Restated Bylaws</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-38683</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10/9/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="descriptionofregistran.htm"><span style="font-family:inherit;font-size:9pt;">Description of Registrant&#8217;s Securities Registered under Section 12 of the&#160;Exchange Act</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011647/exhibit101s-1.htm"><span style="font-family:inherit;font-size:9pt;">Amended and Restated Investors' Rights Agreement, dated May 9, 2017, by and among Guardant Health, Inc. and the investors listed therein</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/6/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.2#</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011647/exhibit103s-1.htm"><span style="font-family:inherit;font-size:9pt;">Amended and Restated 2012 Stock Plan</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/6/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.2(a)#</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011647/exhibit104s-1.htm"><span style="font-family:inherit;font-size:9pt;">Form of Notice of Stock Option Grant and Stock Option Agreement under the Amended and Restated 2012 Stock Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/6/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.3#</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012409/exhibit992as-8.htm"><span style="font-family:inherit;font-size:9pt;">2018 Incentive Award Plan</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227762</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">99.2(a)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10/10/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.3(a)#</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012029/exhibit109as-1a2.htm"><span style="font-family:inherit;font-size:9pt;">Form of Stock Option Agreement under the 2018 Incentive Award Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.9(a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/21/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.3(b)#</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012029/exhibit109bsa2.htm"><span style="font-family:inherit;font-size:9pt;">Form of Restricted Stock Award Agreement under the 2018 Incentive Award Plan</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.9(b)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/21/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.3(c)#</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012029/exhibit109cs-1a2.htm"><span style="font-family:inherit;font-size:9pt;">Form of Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.9(c)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/21/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.4#</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012409/exhibit993s-8.htm"><span style="font-family:inherit;font-size:9pt;">2018 Employee Stock Purchase Plan</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227762</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">99.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10/10/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.4(a)#</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828019003139/gh-12312018x10kxexhibit104a.htm"><span style="font-family:inherit;font-size:9pt;">First Amendment to 2018 Employee Stock Purchase Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-38683</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.4(a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3/29/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.5#</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012029/exhibit1013s-1a2.htm"><span style="font-family:inherit;font-size:9pt;">Executive Severance Plan</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.13</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/21/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.5(a)#</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828019003139/gh-12312018x10kxexhibit105a.htm"><span style="font-family:inherit;font-size:9pt;">First Amendment to Executive Severance Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-38683</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.5(a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3/29/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.6#</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828019006594/guardanthealth-directorcom.htm"><span style="font-family:inherit;font-size:9pt;">Non-Employee Director Compensation Program</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-Q</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-38683</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5/10/2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.7#</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018014499/gh-0930x2018x10qxexhibit109.htm"><span style="font-family:inherit;font-size:9pt;">Amended and Restated Offer Letter Agreement, dated September 16, 2018, by and between Guardant Health, Inc. and Ian Clark</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-38683</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.9</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11/19/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.8#</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018014499/gh-0930x2018x10qxexhibit10.htm"><span style="font-family:inherit;font-size:9pt;">Amended and Restated Offer Letter Agreement, dated September 16, 2018, by and between Guardant Health, Inc. and Stanley Meresman</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-Q</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-38683</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.10</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11/19/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.9</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011938/exhibit108s-1a1.htm"><span style="font-family:inherit;font-size:9pt;">Form of Indemnification Agreement between Guardant Health, Inc. and its directors and officers</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/18/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.10</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011647/exhibit102s-1.htm"><span style="font-family:inherit;font-size:9pt;">Lease, dated November 1, 2014, by and between the Registrant and Metropolitan Life Insurance Company</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/6/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.11</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011647/exhibit102as-1.htm"><span style="font-family:inherit;font-size:9pt;">First Amendment to Lease, dated October 17, 2017, by and between the Registrant and Metropolitan Life Insurance Company</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.2(a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/6/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.12&#167;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011647/exhibit105s-1.htm"><span style="font-family:inherit;font-size:9pt;">Joint Venture Agreement, dated May 9, 2017, by and between the Registrant and SoftBank Vision Fund (AIV M1) L.P., as assignee from SoftBank Group Capital Limited</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/6/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.13&#167;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011647/exhibit107s-1.htm"><span style="font-family:inherit;font-size:9pt;">Supply Agreement, dated September 15, 2014, by and between the Registrant and Illumina, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/6/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.14&#167;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011647/exhibit107as-1.htm"><span style="font-family:inherit;font-size:9pt;">Amendment to Supply Agreement, dated August 11, 2015, by and between the Registrant and Illumina, Inc.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.7(a)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/6/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.15&#167;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011647/exhibit107bs-1.htm"><span style="font-family:inherit;font-size:9pt;">Amendment #2 to Supply Agreement, dated December 24, 2016, by and between the Registrant and Illumina, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.7(b)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/6/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:144%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:144%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">153</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.16&#167;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011647/exhibit107cs-1.htm"><span style="font-family:inherit;font-size:9pt;">Amendment #3 to Supply Agreement, dated August 14, 2017, by and between the Registrant and Illumina, Inc.</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.7(c)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/6/2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.17&#167;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018011647/exhibit107ds-1.htm"><span style="font-family:inherit;font-size:9pt;">Amendment #4 to Supply Agreement, dated June 26, 2018, by and between the Registrant and Illumina, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-227206</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.7(d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9/6/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.18#</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828019003139/gh-12312018x10kxexhibit1019.htm"><span style="font-family:inherit;font-size:9pt;">Form of letter agreement relating to certain time-based equity awards held by Helmy Eltoukhy and AmirAli Talasaz</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-K</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-38683</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.19</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3/29/2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.19#</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828019006594/a10-qexhibitghlanmansigned.htm"><span style="font-family:inherit;font-size:9pt;">Offer Letter, dated July 29, 2014, by and between Guardant Health, Inc. and Richard Lanman</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-38683</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5/10/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.20#+</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828019006594/a10-qexhibitghleenasignedo.htm"><span style="font-family:inherit;font-size:9pt;">Offer Letter, dated May 13, 2018, by and between Guardant Health, Inc. and Leena Das-Young</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-Q</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-38683</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5/10/2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.21#+ </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a10-kexhibit1021lanman.htm"><span style="font-family:inherit;font-size:9pt;">Advisor Agreement, dated February 28, 2020, by and between Guardant Health, Inc. and Richard Lanman</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit211.htm"><span style="font-family:inherit;font-size:9pt;">List of Subsidiaries</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit231.htm"><span style="font-family:inherit;font-size:9pt;">Consent of Independent Registered Public Accounting Firm</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">24.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s6B2379F4C5EE5D168FD4E36EC4CE1C1A"><span style="font-family:inherit;font-size:9pt;">Power of Attorney (included on the signatures page of this Annual Report on Form 10-K)</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">31.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit311.htm"><span style="font-family:inherit;font-size:9pt;">Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">31.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit312.htm"><span style="font-family:inherit;font-size:9pt;">Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit321.htm"><span style="font-family:inherit;font-size:9pt;">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">**</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit322.htm"><span style="font-family:inherit;font-size:9pt;">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">**</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.SCH</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.DEF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.PRE</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">___________________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Filed herewith.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">**</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furnished herewith.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">#</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicates management contract or compensatory plan.</span></div></td></tr></table><div><br/></div><div><div style="line-height:144%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:144%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">154</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:144%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">&#167;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to, a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended, or Item 601(a)(5) of Regulation S-K.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">+              </span><span style="font-family:inherit;font-size:10pt;">Schedules and attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sA180CB570FDC5DDFB928AE6FEEA1068F"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 16. Form 10-K Summary</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div><div style="line-height:144%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:144%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">155</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6B2379F4C5EE5D168FD4E36EC4CE1C1A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD3EA1D6538DD5817B839C0D8C5B7A2C8"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:9%;"></td><td style="width:46%;"></td><td style="width:8%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">GUARDANT HEALTH, INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dated:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Helmy Eltoukhy</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Helmy Eltoukhy</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Executive Officer</span></div></td></tr></table></div></div><div style="line-height:174%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Power of Attorney</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Helmy Eltoukhy, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Signature</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Title</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Date</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Helmy Eltoukhy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Executive Officer and Director</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Helmy Eltoukhy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Derek Bertocci</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Accounting Officer and Principal Financial Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derek Bertocci</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ AmirAli Talasaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">President, Chief Operating Officer and Chairman of the Board of Directors</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AmirAli Talasaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Ian Clark</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ian Clark</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Bahija Jallal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bahija Jallal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Samir Kaul</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Samir Kaul</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Stanley Meresman</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stanley Meresman</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Dipchand Nishar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dipchand Nishar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">156</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>descriptionofregistran.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD5656DC2D124D180B41399CA85BD9358"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 4.1</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Description of the Registrant&#8217;s Securities Registered </font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Pursuant to Section 12 of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Except as otherwise indicated herein or as the context otherwise requires, references in this exhibit to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;our company&#8221; refer to Guardant Health, Inc.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following description of our common stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified in their entirety by reference to the full text of our amended and restated certificate of incorporation and amended and restated bylaws. We urge you to read those documents, each of which are incorporated by reference as exhibits to our filings with the Securities and Exchange Commission, for additional information.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">General</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our amended and restated certificate of incorporation authorizes 350,000,000 shares of common stock, all with a par value of $0.00001 per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. The election of directors by holders of our common stock is determined by a plurality of the votes cast by the stockholders entitled to vote on the election, subject to any preferential voting rights of any series of preferred stock that we may designate and issue in the future. Holders of our common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. Outstanding shares of our common stock are, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Anti-takeover Provisions</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the voting power of our shares of common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation and amended and restated bylaws provide that all stockholder actions must be effected at a duly called meeting of stockholders and not by consent in writing. A special meeting of stockholders may be called only by a majority of our board of directors, the chair of our board of directors or our chief executive officer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our amended and restated certificate of incorporation further provides that the affirmative vote of holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of voting stock, voting as a single class, is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to the size of the board, removal of directors, special meetings, actions by written consent and cumulative voting. The affirmative vote of holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of voting stock, voting as a single class, is required to amend or repeal our amended and restated bylaws, although our amended and restated bylaws may be amended by a simple majority vote of our board of directors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our amended and restated certificate of incorporation further provides that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finally, our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware is the sole and exclusive forum for: (i)&#160;any derivative action or proceeding brought on behalf of us; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees or agents to us or our stockholders; (iii)&#160;any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or amended and restated bylaws; or (iv)&#160;any action asserting a claim against us governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation also provides that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act of 1933, as amended, or the Securities Act. However, a Delaware court recently held that such an exclusive forum provision relating to federal courts was unenforceable under Delaware law, and unless and until the Delaware court decision is reversed on appeal or otherwise abrogated, we do not intend to enforce such a provision in the event of a complaint asserting a cause of action arising under the Securities Act against us or any of our directors, officers, employees or agents.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing provisions may make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of our company by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions may also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change the control of our company.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of our company. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy rights. However, these provisions may have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in control of our company or our management. As a consequence, these provisions also may inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Section&#160;203 of the Delaware General Corporation Law</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, Section&#160;203 defines business combination to include the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">upon closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least eight-five percent (85%) of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (i)&#160;persons who are directors and also officers and (ii)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least sixty-six and two-thirds percent (66 2/3%) of the outstanding voting stock that is not owned by the interested stockholder.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:76.92307692307693%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, Section&#160;203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, fifteen percent (15%) or more of the outstanding voting stock of the corporation.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any sale, transfer, pledge or other disposition of ten percent (10%) or more of the assets of the corporation involving the interested stockholder;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>3
<FILENAME>a10-kexhibit1021lanman.htm
<DESCRIPTION>EXHIBIT 10.21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA395D6EA65AD9098261199CFD8ECAE9C"></a></div><div><div style="line-height:120%;text-align:left;padding-left:42px;text-indent:624px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><img src="gh.jpg" alt="gh.jpg" style="height:44px;width:208px;"><font style="font-family:inherit;font-size:10pt;">Ex 10.21</font></div><div style="line-height:120%;text-align:left;padding-left:42px;text-indent:0px;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#0070c0;">GUARDANT HEALTH</font><font style="font-family:inherit;font-size:7pt;color:#0070c0;">&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:6.5pt;">505 Penobscot Drive, Redwood City, CA 94063 USA  </font><font style="font-family:inherit;font-size:6.5pt;color:#0070c0;">/</font><font style="font-family:inherit;font-size:6.5pt;">&#32;&#32;855.698.8887</font><font style="font-family:inherit;font-size:6.5pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:6.5pt;color:#114999;font-style:italic;">client services</font><font style="font-family:inherit;font-size:6.5pt;color:#003dba;font-style:italic;">&#32;&#32;</font><font style="font-family:inherit;font-size:6.5pt;color:#0070c0;">/ </font><font style="font-family:inherit;font-size:6.5pt;color:#003dba;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:6.5pt;">www.guardanthealth.com</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">December 31, 2019</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CONFIDENTIAL</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dr. Richard Lanman</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">556 Van Buren St.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Los Altos, CA 94022</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">Re:</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:left;font-size:11pt;text-indent:-96px;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Employment as Advisor</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dear Rick:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This letter will provide details regarding your employment as a part-time Advisor for Guardant Health, Inc. (the &#8220;Company&#8221;).  This letter constitutes the entire agreement between you and the Company with respect to the subject matter hereof and supersedes and replaces any and all prior agreements or representations relating to such subject matter including, but not limited to, your July 29, 2014 offer of employment with the Company which will become null and void upon your agreement to this letter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The details of your employment as an Advisor are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Start Date as Advisor</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;You will begin serving as an Advisor, effective January 3, 2020.  Although it is anticipated that your position as Advisor will last until December 31, 2020 (the &#8220;End Date&#8221;), you will remain an at-will employee during the entire term of your employment, as described below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Compensation</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The majority of your compensation for your services as an Advisor will be related to your continued vesting of your outstanding equity awards (see Stock Options/RSUs below).  Nevertheless, the Company will pay you an hourly rate of $22.00 per hour for compliance reasons. Your position is classified as non-exempt, meaning you are eligible for overtime pay.  You will be paid overtime as required by state and federal law.  As required by California law, I&#8217;ve provided detailed information about the terms of your wages in the enclosed Notice to Employee (Labor Code section 2810.5).  Please also sign and return one copy of the notice with this signed letter.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Sick Leave/Paid Time Off</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;As a part-time employee regularly scheduled to work fewer than 30 hours per week, you are not eligible to accrue vacation or to receive paid holidays.  As a part-time employee you will accrue sick time at one hour for every 30 hours worked. You may only use accrued sick leave beginning on the 90th day of employment. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Stock Options/RSUs</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">:  </font><font style="font-family:inherit;font-size:11pt;">The parties acknowledge that your seamless transition from Global Chief Medical Officer to part-time Advisor does not constitute a break in service for purposes of your outstanding stock options and restricted stock unit awards (together, the &#8220;Equity Awards&#8221;). In addition, the vesting schedule of your Equity Awards will continue in accordance with the same vesting schedule applicable while you were employed as Global Chief Medical Officer, and you will continue to vest in such awards so long as you continue to provide services as an Advisor to the Company.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">:  </font><font style="font-family:inherit;font-size:11pt;">Despite your transition from Global Chief Medical Officer, the Company will pay you a one-time bonus of $100,000 to recognize your efforts during 2019.  You will not be eligible for any other incentive compensation for past services or services under this Agreement. </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Benefits</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;In your role as Advisor, you are not eligible for any Company benefits (including any severance benefits that you may have had available to you when you were previously an executive of the Company), except as otherwise described in this letter and as otherwise required by state, federal, or local law.  As a result of your transition from Company executive to Advisor, the Company will reimburse your COBRA premiums during the term of your continued employment as an Advisor.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Expense Reimbursement</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">: </font><font style="font-family:inherit;font-size:11pt;">You must obtain prior approval from AmirAli Talasaz for any business-related travel, with any arrangements relating to transportation, lodging and meals to be mutually agreed between the parties in advance. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">At-Will Employment</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">:</font><font style="font-family:inherit;font-size:11pt;">&#32;Consistent with state law, your employment with the Company will be &#8220;at-will.&#8221;  This means that your employment with the Company will not last for any specific period of time, and either you or the Company can terminate your employment with 60 days&#8217; notice and for any reason or for no reason.  This letter will reflect the final, total and complete agreement between you and the Company regarding how your employment may be terminated.  The &#8220;at-will&#8221; nature of your employment may only be changed if the CEO of the Company signs a written contract which explicitly changes at-will status.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Offer Acceptance</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;In order to accept this agreement, you must sign this letter and the other document enclosed for your signature, and I must receive them back before close of business on February 28, 2020.  This letter, once accepted, constitutes the entire agreement between you and Guardant Health, Inc. with respect to the subject matter hereof and supersedes and replaces any and all prior agreements or representations relating to such subject matter including, but not limited to, your July 29, 2014 offer of employment.  If you have any questions about this letter, then before signing please contact me.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Sincerely,</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Amelia Merrill____</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Amelia Merrill</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VP, People</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Guardant Health, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">I, Dr. Richard Lanman, have read this letter and understand and agree to its terms.</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:37%;"></td><td style="width:63%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Signature:  </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Richard Lanman____</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date:  February 28, 2020                                                Dr. Richard Lanman</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;padding-left:12px;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>exhibit211.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE279B4C96A5C5D8795EF88DC71614D15"></a></div><div><div style="line-height:130%;padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 21.1</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsidiaries of Guardant Health, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.32478632478633%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:42%;"></td><td style="width:58%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Jurisdiction of Incorporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guardant Health AMEA, Inc.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guardant Health Pte. Ltd.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guardant Health Japan Corp.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guardant Holdings (Switzerland) GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Switzerland</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bellwether Bio, Inc.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Washington </font></div></td></tr></table></div></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exhibit231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9BFCE5F6AC5257009238CEE4C9283C8F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-227762) of Guardant Health, Inc. of our reports dated </font><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font><font style="font-family:inherit;font-size:10pt;">, with respect to the consolidated financial statements of Guardant Health, Inc. and the effectiveness of internal control over financial reporting of Guardant Health Inc., included in this Annual Report (Form 10-K) for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redwood City, California</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s69E50A20D4B8576393044168EE9E040A"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Helmy Eltoukhy, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Guardant Health, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;padding-left:1px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:42%;"></td><td style="width:7%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;padding-top:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font></div></td><td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Helmy Eltoukhy</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Helmy Eltoukhy</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s720B2CCBF9C05033ADFF14238A200CE2"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Derek Bertocci, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Guardant Health, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:96px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)   Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;padding-left:1px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:42%;"></td><td style="width:7%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;padding-top:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font></div></td><td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;padding-top:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Derek Bertocci</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derek Bertocci</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1F3FE47C3DBB5CEB9C167E98F2E2C994"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Annual Report of Guardant Health, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;padding-left:1px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:42%;"></td><td style="width:7%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font></div></td><td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;padding-top:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Helmy Eltoukhy</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Helmy Eltoukhy</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>exhibit322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s54B151263EA3500FBE9557451C98F06C"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Annual Report of Guardant Health, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;padding-left:1px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:42%;"></td><td style="width:7%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;padding-top:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font></div></td><td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;padding-top:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;2, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Derek Bertocci</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derek Bertocci</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;padding-top:1px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>gh-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://guardanthealth.com/20191231" xmlns:gh="http://guardanthealth.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AcquisitionOfBellwetherBio" roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBio">
        <link:definition>2106100 - Disclosure - Acquisition of Bellwether Bio</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails">
        <link:definition>2406403 - Disclosure - Acquisition of Bellwether Bio - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails" roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails">
        <link:definition>2406406 - Disclosure - Acquisition of Bellwether Bio - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails" roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails">
        <link:definition>2406404 - Disclosure - Acquisition of Bellwether Bio - Intangible Assets Acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionOfBellwetherBioNarrativeDetails" roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails">
        <link:definition>2406402 - Disclosure - Acquisition of Bellwether Bio - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails" roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails">
        <link:definition>2406405 - Disclosure - Acquisition of Bellwether Bio - Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionOfBellwetherBioOtherIntangibleAssetsDetailsCalc2" roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetailsCalc2">
        <link:definition>2406405 - Disclosure - Acquisition of Bellwether Bio - Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionOfBellwetherBioTables" roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables">
        <link:definition>2306301 - Disclosure - Acquisition of Bellwether Bio (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://guardanthealth.com/role/CommitmentsAndContingencies">
        <link:definition>2110100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2410402 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails" roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails">
        <link:definition>2410403 - Disclosure - Commitments and Contingencies - Schedule of Future Royalty Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetailsCalc2" roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetailsCalc2">
        <link:definition>2410403 - Disclosure - Commitments and Contingencies - Schedule of Future Royalty Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2310301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://guardanthealth.com/role/CommonStock">
        <link:definition>2111100 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://guardanthealth.com/role/CommonStockDetails">
        <link:definition>2411402 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetComponents" roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponents">
        <link:definition>2104100 - Disclosure - Consolidated Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetComponentsNarrativeDetails" roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsNarrativeDetails">
        <link:definition>2404403 - Disclosure - Consolidated Balance Sheet Components - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails">
        <link:definition>2404404 - Disclosure - Consolidated Balance Sheet Components - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails" roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails">
        <link:definition>2404402 - Disclosure - Consolidated Balance Sheet Components - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetComponentsTables" roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsTables">
        <link:definition>2304301 - Disclosure - Consolidated Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001001 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1003000 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperations" roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity" roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity">
        <link:definition>1004000 - Statement - Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical" roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical">
        <link:definition>1004001 - Statement - Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStock" roleURI="http://guardanthealth.com/role/ConvertiblePreferredStock">
        <link:definition>2113100 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockDetails" roleURI="http://guardanthealth.com/role/ConvertiblePreferredStockDetails">
        <link:definition>2413402 - Disclosure - Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://guardanthealth.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusiness" roleURI="http://guardanthealth.com/role/DescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessDetails" roleURI="http://guardanthealth.com/role/DescriptionOfBusinessDetails">
        <link:definition>2401401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://guardanthealth.com/role/EmployeeBenefitPlan">
        <link:definition>2117100 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://guardanthealth.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2417401 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsAndMarketableSecurities" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities">
        <link:definition>2105100 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails">
        <link:definition>2405403 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>2405402 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Fair Value Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails">
        <link:definition>2405404 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://guardanthealth.com/role/IncomeTaxes">
        <link:definition>2116100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveTaxRateReconciliationDetails" roleURI="http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails">
        <link:definition>2416405 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://guardanthealth.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2416406 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" roleURI="http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>2416407 - Disclosure - Income Taxes - Reconciliation of the Balance of Total Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2416404 - Disclosure - Income Taxes - Schedule of the Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails">
        <link:definition>2416403 - Disclosure - Income Taxes - Schedule of Components of the Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails" roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails">
        <link:definition>2416402 - Disclosure - Income Taxes - Schedule of Loss Before Components of the Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://guardanthealth.com/role/IncomeTaxesTables">
        <link:definition>2316301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentInJointVenture" roleURI="http://guardanthealth.com/role/InvestmentInJointVenture">
        <link:definition>2103100 - Disclosure - Investment in Joint Venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentInJointVentureDetails" roleURI="http://guardanthealth.com/role/InvestmentInJointVentureDetails">
        <link:definition>2403401 - Disclosure - Investment in Joint Venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://guardanthealth.com/role/Leases">
        <link:definition>2109100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails">
        <link:definition>2409402 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleOfFutureMinimalLeasePaymentsDetails" roleURI="http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails">
        <link:definition>2409404 - Disclosure - Leases - Schedule of Future Minimal Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleOfOperatingLiabilityMaturitiesDetails" roleURI="http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails">
        <link:definition>2409403 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleOfOperatingLiabilityMaturitiesDetailsCalc2" roleURI="http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetailsCalc2">
        <link:definition>2409403 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://guardanthealth.com/role/LeasesTables">
        <link:definition>2309301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributableToGuardantHealthIncCommonStockholders" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders">
        <link:definition>2115100 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails">
        <link:definition>2415403 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>2415402 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables">
        <link:definition>2315301 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PatentLicenseAgreement" roleURI="http://guardanthealth.com/role/PatentLicenseAgreement">
        <link:definition>2107100 - Disclosure - Patent License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PatentLicenseAgreementDetails" roleURI="http://guardanthealth.com/role/PatentLicenseAgreementDetails">
        <link:definition>2407401 - Disclosure - Patent License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://guardanthealth.com/role/RelatedPartyTransactions">
        <link:definition>2119100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://guardanthealth.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2419401 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentAndGeographicInformation" roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformation">
        <link:definition>2118100 - Disclosure - Segment and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentAndGeographicInformationDetails" roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformationDetails">
        <link:definition>2418402 - Disclosure - Segment and Geographic Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentAndGeographicInformationTables" roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformationTables">
        <link:definition>2318301 - Disclosure - Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeniorTermLoanAndRoyaltyPurchaseAgreement" roleURI="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreement">
        <link:definition>2108100 - Disclosure - Senior Term Loan and Royalty Purchase Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeniorTermLoanAndRoyaltyPurchaseAgreementDetails" roleURI="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails">
        <link:definition>2408401 - Disclosure - Senior Term Loan and Royalty Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://guardanthealth.com/role/StockBasedCompensation">
        <link:definition>2114100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2414402 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>2414404 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2414405 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2414403 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://guardanthealth.com/role/StockBasedCompensationTables">
        <link:definition>2314301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails">
        <link:definition>2414407 - Disclosure - Stock-Based Compensation - Valuation of Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationOfStockOptionsDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails">
        <link:definition>2414406 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details" roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details">
        <link:definition>2402407 - Disclosure - Summary of Significant Accounting Policies - Adoption of ASC 606 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails">
        <link:definition>2402406 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails" roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Useful Life of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Tables" roleURI="http://guardanthealth.com/role/Tables">
        <link:definition>2311301 - Disclosure - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://guardanthealth.com/role/Warrants">
        <link:definition>2112100 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsDetails" roleURI="http://guardanthealth.com/role/WarrantsDetails">
        <link:definition>2412401 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="gh_A2018EmployeeStockPurchasePlanMember" name="A2018EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_AccountingStandardsUpdate201807Member" name="AccountingStandardsUpdate201807Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_AccruedClinicalTrialsandStudies" name="AccruedClinicalTrialsandStudies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gh_AccruedExpensesPropertyandEquipmentCurrent" name="AccruedExpensesPropertyandEquipmentCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gh_AccruedRoyaltiesNoncurrent" name="AccruedRoyaltiesNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions" name="AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_AmortizationOfRightOfUseAssets" name="AmortizationOfRightOfUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_BellweatherBioInc.Member" name="BellweatherBioInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_BiopharmaceuticalCustomersMember" name="BiopharmaceuticalCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_BusinessCombinationContingentConsiderationMaximumAmountPayable" name="BusinessCombinationContingentConsiderationMaximumAmountPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment" name="CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_CashCashEquivalentsandDebtSecuritiesFairValue" name="CashCashEquivalentsandDebtSecuritiesFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gh_ClinicalCustomersMember" name="ClinicalCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_CommercializationMilestonesMember" name="CommercializationMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_CommonStockCompensationExpense" name="CommonStockCompensationExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gh_CommonStockSubjecttoRepurchaseorCancellation" name="CommonStockSubjecttoRepurchaseorCancellation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_ComputerEquipmentandSoftwareMember" name="ComputerEquipmentandSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_ContractualObligationDueInFifthYearAndAfterFifthYear" name="ContractualObligationDueInFifthYearAndAfterFifthYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments" name="ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments" name="ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gh_ConversionofStockUponInitialPublicOffering" name="ConversionofStockUponInitialPublicOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_ConvertiblePreferredStockConversionPrice" name="ConvertiblePreferredStockConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_CostofDevelopmentServices" name="CostofDevelopmentServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gh_CostofDevelopmentServicesPolicyTextBlock" name="CostofDevelopmentServicesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_CostsofPrecisionOncologyTesting" name="CostsofPrecisionOncologyTesting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gh_CostsofPrecisionOncologyTestingPolicyTextBlock" name="CostsofPrecisionOncologyTestingPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_CovenantsNotToCompeteMember" name="CovenantsNotToCompeteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_CreditAgreementMember" name="CreditAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_CustomerAMember" name="CustomerAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_CustomerBMember" name="CustomerBMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_CustomerCMember" name="CustomerCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_CustomerDMember" name="CustomerDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_DebtInstrumentVariableRateBasisBaseRate" name="DebtInstrumentVariableRateBasisBaseRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" name="DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gh_DebtSecuritiesTableTextBlock" name="DebtSecuritiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gh_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gh_DeferredTaxLiabilitiesSection481aAdjustment" name="DeferredTaxLiabilitiesSection481aAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gh_EarnOutConsiderationMember" name="EarnOutConsiderationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_EmployeeStockPurchasePlanObligationMember" name="EmployeeStockPurchasePlanObligationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_EquityMethodInvestmentSharesPurchased" name="EquityMethodInvestmentSharesPurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_EstimatedLitigationLiabilityLegalFeesCurrent" name="EstimatedLitigationLiabilityLegalFeesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" name="FoundationMedicineInc.vs.GuardantHealthInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_GuardantHealthAMEAIncMember" name="GuardantHealthAMEAIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest" name="IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest" name="IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_IncomeTaxesLineItems" name="IncomeTaxesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_IncomeTaxesTable" name="IncomeTaxesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid" name="IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_IntangibleAssetsGrossIncludingGoodwill" name="IntangibleAssetsGrossIncludingGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gh_JOBSActAccountingElectionPolicyTextBlock" name="JOBSActAccountingElectionPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability" name="LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome" name="LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount" name="LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gh_LicenseAgreementMilestonePaymentUponAchievement" name="LicenseAgreementMilestonePaymentUponAchievement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets" name="LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gh_MarketableSecuritiesMaturityPeriod" name="MarketableSecuritiesMaturityPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_NoncashInterestExpensePaid" name="NoncashInterestExpensePaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_NumberofAssertedPatents" name="NumberofAssertedPatents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_NumberofCompaniesthatInfringedonaPatent" name="NumberofCompaniesthatInfringedonaPatent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_NumberofPartiesWithPatentLicenseAgreement" name="NumberofPartiesWithPatentLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_NumberofPetitionsFiled" name="NumberofPetitionsFiled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_ObligationRelatedtoRoyaltyPolicyTextBlock" name="ObligationRelatedtoRoyaltyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_OfferingCostsIncurredbutNotyetPaid" name="OfferingCostsIncurredbutNotyetPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" name="PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_PaymentofAccruedInterestDebt" name="PaymentofAccruedInterestDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_PaymentsInConnectionWithLicenseAgreements" name="PaymentsInConnectionWithLicenseAgreements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_PaymentsforFutureRoyalties" name="PaymentsforFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock" name="PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" name="PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_PrecisionOncologyTestingMember" name="PrecisionOncologyTestingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_RedeemableNoncontrollingInterestFairValueAdjustment" name="RedeemableNoncontrollingInterestFairValueAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_RedeemableNoncontrollingInterestMember" name="RedeemableNoncontrollingInterestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_RevenuefromDevelopmentServices" name="RevenuefromDevelopmentServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_RevenuefromPrecisionOncologyTesting" name="RevenuefromPrecisionOncologyTesting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_ReversalOfStockBasedCompensationExpense" name="ReversalOfStockBasedCompensationExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_RoyaltyAgreementMember" name="RoyaltyAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_RoyaltyAgreementPaymentTierThreshold" name="RoyaltyAgreementPaymentTierThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gh_RoyaltyAgreementbyPaymentTierAxis" name="RoyaltyAgreementbyPaymentTierAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_RoyaltyAgreementbyPaymentTierDomain" name="RoyaltyAgreementbyPaymentTierDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue" name="RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_RoyaltyPaymentsPercentageofRevenue" name="RoyaltyPaymentsPercentageofRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock" name="ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_SeriesDConvertiblePreferredStockMember" name="SeriesDConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_SeriesEConvertiblePreferredStockMember" name="SeriesEConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares" name="SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" name="SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_SharesAvailableForFutureStockOptionGrantsMember" name="SharesAvailableForFutureStockOptionGrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_SoftBankMember" name="SoftBankMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" name="StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_StockIssuedDuringPeriodSharesExerciseofWarrants" name="StockIssuedDuringPeriodSharesExerciseofWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO" name="StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" name="StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_StockIssuedDuringPeriodValueExerciseofWarrants" name="StockIssuedDuringPeriodValueExerciseofWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" name="StockIssuedDuringPeriodValueStockOptionsExercisedEarly" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_ThresholdPercentageofNewSharesIssued" name="ThresholdPercentageofNewSharesIssued" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares" name="ThresholdPeriodAfterInitialClosingtoIssueNewShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_TierOneMember" name="TierOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_TierTwoMember" name="TierTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" name="UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement" name="ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gh_VariableInterestEntityPercentageoftheProduct" name="VariableInterestEntityPercentageoftheProduct" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_VariableInterestEntityThresholdPercentageofFairValue" name="VariableInterestEntityThresholdPercentageofFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" name="VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty" name="VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gh_WarrantsPreferredStockMember" name="WarrantsPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" name="WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>gh-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBio" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBio" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetailsCalc2" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioOtherIntangibleAssetsDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingencies" xlink:href="gh-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="gh-20191231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails" xlink:href="gh-20191231.xsd#CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetailsCalc2" xlink:href="gh-20191231.xsd#CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesTables" xlink:href="gh-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStock" xlink:href="gh-20191231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockDetails" xlink:href="gh-20191231.xsd#CommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponents" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsTables" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheets" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfOperations" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConvertiblePreferredStock" xlink:href="gh-20191231.xsd#ConvertiblePreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConvertiblePreferredStockDetails" xlink:href="gh-20191231.xsd#ConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CoverPage" xlink:href="gh-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionOfBusiness" xlink:href="gh-20191231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionOfBusinessDetails" xlink:href="gh-20191231.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/EmployeeBenefitPlan" xlink:href="gh-20191231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/EmployeeBenefitPlanDetails" xlink:href="gh-20191231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxes" xlink:href="gh-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:href="gh-20191231.xsd#IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesNarrativeDetails" xlink:href="gh-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" xlink:href="gh-20191231.xsd#IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="gh-20191231.xsd#IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:href="gh-20191231.xsd#IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails" xlink:href="gh-20191231.xsd#IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesTables" xlink:href="gh-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentInJointVenture" xlink:href="gh-20191231.xsd#InvestmentInJointVenture" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentInJointVentureDetails" xlink:href="gh-20191231.xsd#InvestmentInJointVentureDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/Leases" xlink:href="gh-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:href="gh-20191231.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails" xlink:href="gh-20191231.xsd#LeasesScheduleOfFutureMinimalLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails" xlink:href="gh-20191231.xsd#LeasesScheduleOfOperatingLiabilityMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetailsCalc2" xlink:href="gh-20191231.xsd#LeasesScheduleOfOperatingLiabilityMaturitiesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesTables" xlink:href="gh-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/PatentLicenseAgreement" xlink:href="gh-20191231.xsd#PatentLicenseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/PatentLicenseAgreementDetails" xlink:href="gh-20191231.xsd#PatentLicenseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:href="gh-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactionsDetails" xlink:href="gh-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformation" xlink:href="gh-20191231.xsd#SegmentAndGeographicInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformationDetails" xlink:href="gh-20191231.xsd#SegmentAndGeographicInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformationTables" xlink:href="gh-20191231.xsd#SegmentAndGeographicInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreement" xlink:href="gh-20191231.xsd#SeniorTermLoanAndRoyaltyPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails" xlink:href="gh-20191231.xsd#SeniorTermLoanAndRoyaltyPurchaseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensation" xlink:href="gh-20191231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:href="gh-20191231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationValuationOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/Tables" xlink:href="gh-20191231.xsd#Tables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/Warrants" xlink:href="gh-20191231.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/WarrantsDetails" xlink:href="gh-20191231.xsd#WarrantsDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBio" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_588b212f-0609-2b89-932f-cbe7e57377ff" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_588b212f-0609-2b89-932f-cbe7e57377ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_423e6bba-f43d-931c-5711-51d5522b2aaa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_423e6bba-f43d-931c-5711-51d5522b2aaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_28c91f3b-370e-e76f-4199-69e4166aabc6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_28c91f3b-370e-e76f-4199-69e4166aabc6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f7796428-4176-97fe-5145-79a026d8547a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f7796428-4176-97fe-5145-79a026d8547a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_71fd8e03-8eaf-f20c-786b-5e0492fb281b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_71fd8e03-8eaf-f20c-786b-5e0492fb281b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0e7343bd-e798-afc0-7fcc-ed296ae9f91c" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0e7343bd-e798-afc0-7fcc-ed296ae9f91c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_588b212f-0609-2b89-932f-cbe7e57377ff" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6558b51b-e5e6-31be-658a-d87768e28cf6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_588b212f-0609-2b89-932f-cbe7e57377ff" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6558b51b-e5e6-31be-658a-d87768e28cf6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_517e5230-eae7-c049-ebae-ce057eabc626" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_588b212f-0609-2b89-932f-cbe7e57377ff" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_517e5230-eae7-c049-ebae-ce057eabc626" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_cb59c411-be61-59fa-38c9-6346bc0b7f01" xlink:type="locator" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_0582AC26148D96797D0B5AB559EB1242" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_cb59c411-be61-59fa-38c9-6346bc0b7f01" xlink:to="loc_gh_IntangibleAssetsGrossIncludingGoodwill_0582AC26148D96797D0B5AB559EB1242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_cb59c411-be61-59fa-38c9-6346bc0b7f01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a49df76-38f6-6baa-87dd-2e9a7efd8303" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a49df76-38f6-6baa-87dd-2e9a7efd8303" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_CF5E71D978B08068404C983D5983DD5B_cb59c411-be61-59fa-38c9-6346bc0b7f01" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CF5E71D978B08068404C983D5983DD5B_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_CF5E71D978B08068404C983D5983DD5B_cb59c411-be61-59fa-38c9-6346bc0b7f01" xlink:to="loc_us-gaap_Goodwill_CF5E71D978B08068404C983D5983DD5B_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_CF5E71D978B08068404C983D5983DD5B_99bd5160-e32a-dcfc-e4fd-38dda5d465b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_CF5E71D978B08068404C983D5983DD5B_cb59c411-be61-59fa-38c9-6346bc0b7f01" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_CF5E71D978B08068404C983D5983DD5B_99bd5160-e32a-dcfc-e4fd-38dda5d465b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CF5E71D978B08068404C983D5983DD5B_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_CF5E71D978B08068404C983D5983DD5B_cb59c411-be61-59fa-38c9-6346bc0b7f01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CF5E71D978B08068404C983D5983DD5B_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_969c363d-ca7d-3828-00db-919559604b29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_1f6b2e56-1145-cf88-cf3d-6b29b64e51db" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_969c363d-ca7d-3828-00db-919559604b29" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_1f6b2e56-1145-cf88-cf3d-6b29b64e51db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_4534d2fe-37ac-e651-3737-accd5c658da4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_969c363d-ca7d-3828-00db-919559604b29" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_4534d2fe-37ac-e651-3737-accd5c658da4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_ed1eea2b-a48a-4242-eb9b-b8e39209496a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_969c363d-ca7d-3828-00db-919559604b29" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_ed1eea2b-a48a-4242-eb9b-b8e39209496a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_2a22a63a-481e-0a6f-f006-7a54404f656a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_969c363d-ca7d-3828-00db-919559604b29" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_2a22a63a-481e-0a6f-f006-7a54404f656a" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ContractualObligationDueInFifthYearAndAfterFifthYear" xlink:label="loc_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_65C15461700C724271D9F2A7DF7C6C5A" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_969c363d-ca7d-3828-00db-919559604b29" xlink:to="loc_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_65C15461700C724271D9F2A7DF7C6C5A" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_49190444C2503CEEC760F34786F7B58E_969c363d-ca7d-3828-00db-919559604b29" xlink:type="locator" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments" xlink:label="loc_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_49190444C2503CEEC760F34786F7B58E_293E6FAD94C1FC07A452D4C304CEBECD" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_49190444C2503CEEC760F34786F7B58E_969c363d-ca7d-3828-00db-919559604b29" xlink:to="loc_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_49190444C2503CEEC760F34786F7B58E_293E6FAD94C1FC07A452D4C304CEBECD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments" xlink:label="loc_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_49190444C2503CEEC760F34786F7B58E_246120a6-6e8f-bbd7-03c3-a625ad3bbeca" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_49190444C2503CEEC760F34786F7B58E_969c363d-ca7d-3828-00db-919559604b29" xlink:to="loc_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_49190444C2503CEEC760F34786F7B58E_246120a6-6e8f-bbd7-03c3-a625ad3bbeca" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommonStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommonStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_dd3f0ff4-453d-8a72-0356-517c43549266" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_dd3f0ff4-453d-8a72-0356-517c43549266" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:label="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_9370fd59-4f82-5a5e-54e1-a625aebcc24c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_9370fd59-4f82-5a5e-54e1-a625aebcc24c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_d1997c77-9fc6-cbee-b2e4-9f642058c98e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_d1997c77-9fc6-cbee-b2e4-9f642058c98e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AccruedClinicalTrialsandStudies" xlink:label="loc_gh_AccruedClinicalTrialsandStudies_5e77a6e0-fdd5-7db9-9267-f21d52025029" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_gh_AccruedClinicalTrialsandStudies_5e77a6e0-fdd5-7db9-9267-f21d52025029" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:label="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_c3fd0605-cddc-6ff1-ab21-a625ad891de0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_c3fd0605-cddc-6ff1-ab21-a625ad891de0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_50b1a6be-f082-bfa3-60b7-afefe9f63cb5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_50b1a6be-f082-bfa3-60b7-afefe9f63cb5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_ae96910d-f6c0-5dcf-e4f9-4ecf264ba7c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_ae96910d-f6c0-5dcf-e4f9-4ecf264ba7c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_84969fe3-08fd-b500-b7ad-ebd7bf4d768b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_84969fe3-08fd-b500-b7ad-ebd7bf4d768b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_55fda19b-3ba6-61b5-220d-6f7ed397180a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValueOutstanding_55fda19b-3ba6-61b5-220d-6f7ed397180a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_8c6cb868-c2c5-f73a-a7f6-65b98067e41e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_8c6cb868-c2c5-f73a-a7f6-65b98067e41e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_6a5e4e83-da70-0160-7819-0c9dfce0515e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_6a5e4e83-da70-0160-7819-0c9dfce0515e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_56ae2fbe-1d9b-2820-d3f0-88126fbd28ba" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_DeferredRevenueCurrent_56ae2fbe-1d9b-2820-d3f0-88126fbd28ba" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_2c8b0baf-771b-c301-80d6-9e2df7367293" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_2c8b0baf-771b-c301-80d6-9e2df7367293" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AccruedRoyaltiesNoncurrent" xlink:label="loc_gh_AccruedRoyaltiesNoncurrent_8f9e27d0-a87f-6a54-89e2-a625ae4301ca" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_gh_AccruedRoyaltiesNoncurrent_8f9e27d0-a87f-6a54-89e2-a625ae4301ca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AmortizationOfRightOfUseAssets" xlink:label="loc_gh_AmortizationOfRightOfUseAssets_690AE434505C917E4F3E78109593A044" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gh_AmortizationOfRightOfUseAssets_690AE434505C917E4F3E78109593A044" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" xlink:label="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_0a6b2f06-066d-1dfb-b579-a625aecce8df" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_0a6b2f06-066d-1dfb-b579-a625aecce8df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9dbcf839-4ba1-0e2b-8942-4c8a9981ac5b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9dbcf839-4ba1-0e2b-8942-4c8a9981ac5b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_NoncashInterestExpensePaid" xlink:label="loc_gh_NoncashInterestExpensePaid_54322a07-cbd3-d008-a66b-a625ae6380c3" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gh_NoncashInterestExpensePaid_54322a07-cbd3-d008-a66b-a625ae6380c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3832d5-e2fd-470b-5e04-ece38e7ab02d" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3832d5-e2fd-470b-5e04-ece38e7ab02d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_d484cea3-2847-d857-eadc-b0e28abf32ab" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_d484cea3-2847-d857-eadc-b0e28abf32ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_a7e5a9b0-da37-f993-db8e-55e01b78deb4" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_a7e5a9b0-da37-f993-db8e-55e01b78deb4" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets" xlink:label="loc_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_C8DACD932E2BDE84335F780F94821E1A" xlink:type="locator" />
    <link:calculationArc order="18" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_C8DACD932E2BDE84335F780F94821E1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_b298b57a-0a96-ddab-3fe3-9f644e58ca61" xlink:type="locator" />
    <link:calculationArc order="19" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_b298b57a-0a96-ddab-3fe3-9f644e58ca61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_f37803fe-8fc6-3fc4-e497-674e18f03ea5" xlink:type="locator" />
    <link:calculationArc order="20" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_f37803fe-8fc6-3fc4-e497-674e18f03ea5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="locator" />
    <link:calculationArc order="21" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ee3fb709-d548-2ee3-f8d1-e07a929829cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ee3fb709-d548-2ee3-f8d1-e07a929829cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_501ceb78-782e-aec9-eff2-2bd0a073c870" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_501ceb78-782e-aec9-eff2-2bd0a073c870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_80abba07-181c-6ed2-349d-9d7dfc078eab" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_80abba07-181c-6ed2-349d-9d7dfc078eab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1e99261d-1af1-2d77-636d-890a4a9c4511" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1e99261d-1af1-2d77-636d-890a4a9c4511" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentsInConnectionWithLicenseAgreements" xlink:label="loc_gh_PaymentsInConnectionWithLicenseAgreements_F5AC930EC3AEEF1C6687EECD68BF305C" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_gh_PaymentsInConnectionWithLicenseAgreements_F5AC930EC3AEEF1C6687EECD68BF305C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" xlink:label="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_f21b3c03-0492-8d39-f942-a625adf37cf1" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_f21b3c03-0492-8d39-f942-a625adf37cf1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_99289045-641b-e134-789c-dbf0b6bfb577" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_99289045-641b-e134-789c-dbf0b6bfb577" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7c2a31aa-de85-3d78-fe3c-7d70dce934c1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7c2a31aa-de85-3d78-fe3c-7d70dce934c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_696ef8d0-385f-266e-0f61-04b954a738e7" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_696ef8d0-385f-266e-0f61-04b954a738e7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_29fc0ccf-d68e-39c1-8f4d-25c014f2bb16" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_29fc0ccf-d68e-39c1-8f4d-25c014f2bb16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_3c9454ea-e360-6f27-b3ca-31b6fc832b0b" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_3c9454ea-e360-6f27-b3ca-31b6fc832b0b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_ea422513-12bd-029b-0166-7c34286633bc" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_ea422513-12bd-029b-0166-7c34286633bc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_a5dc819c-8eaf-e4c1-9f51-d9cf65264aae" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_a5dc819c-8eaf-e4c1-9f51-d9cf65264aae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_fef949b5-2828-00ed-cf5f-f47e165ae8a1" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_fef949b5-2828-00ed-cf5f-f47e165ae8a1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6df44786-4260-4fa4-e123-591abd5e882d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6df44786-4260-4fa4-e123-591abd5e882d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_7a8c75f6-aa6c-53a5-d989-5565dbb744c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_7a8c75f6-aa6c-53a5-d989-5565dbb744c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_b34bad75-b7e4-2e2c-e66a-587a358c2ddb" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_b34bad75-b7e4-2e2c-e66a-587a358c2ddb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromPrecisionOncologyTesting" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting_24281174-6253-4318-a4f3-a625ae9d4593" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:to="loc_gh_RevenuefromPrecisionOncologyTesting_24281174-6253-4318-a4f3-a625ae9d4593" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromDevelopmentServices" xlink:label="loc_gh_RevenuefromDevelopmentServices_6a71830b-c492-ba32-045a-a625ad795c95" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:to="loc_gh_RevenuefromDevelopmentServices_6a71830b-c492-ba32-045a-a625ad795c95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CostsofPrecisionOncologyTesting" xlink:label="loc_gh_CostsofPrecisionOncologyTesting_7ac3a9bf-d158-2c60-0b6d-a625ae14f3dd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_gh_CostsofPrecisionOncologyTesting_7ac3a9bf-d158-2c60-0b6d-a625ae14f3dd" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CostofDevelopmentServices" xlink:label="loc_gh_CostofDevelopmentServices_fee518a4-05e9-ec5f-21b0-a625ad794405" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_gh_CostofDevelopmentServices_fee518a4-05e9-ec5f-21b0-a625ad794405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_334a0036-49ae-85df-fa8d-a7de18d975ef" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_SellingAndMarketingExpense_334a0036-49ae-85df-fa8d-a7de18d975ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_c609831c-5373-b08c-75c9-bda79459b814" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_c609831c-5373-b08c-75c9-bda79459b814" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_63184a46-2bac-760c-5a30-fe8e316dca8f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_63184a46-2bac-760c-5a30-fe8e316dca8f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConvertiblePreferredStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/ConvertiblePreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/DescriptionOfBusinessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_afec7dd8-1b72-4a26-560d-a625ae7e0dd8" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_afec7dd8-1b72-4a26-560d-a625ae7e0dd8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_afec7dd8-1b72-4a26-560d-a625ae7e0dd8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_64d72b4b-2dc0-922d-29da-a625ad99e9cc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_afec7dd8-1b72-4a26-560d-a625ae7e0dd8" xlink:to="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_64d72b4b-2dc0-922d-29da-a625ad99e9cc" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_e0d96e45-d1fb-8409-6485-191ebc315350" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_e0d96e45-d1fb-8409-6485-191ebc315350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_a54b786a-47ac-0574-0fc0-e0d78ae648ed" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_a54b786a-47ac-0574-0fc0-e0d78ae648ed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_ec3339d2-b487-ee50-0e5d-912e3cb7fac1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eed137f7-f4cf-61e8-5dd4-67d3dd178f58" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_ec3339d2-b487-ee50-0e5d-912e3cb7fac1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eed137f7-f4cf-61e8-5dd4-67d3dd178f58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_46fd3e47-b379-3d5b-dad7-1fdc5e88b67f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_46fd3e47-b379-3d5b-dad7-1fdc5e88b67f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_debb22de-4eff-9a44-9569-2ec0efafa179" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_debb22de-4eff-9a44-9569-2ec0efafa179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2fc8d554-3ed0-9aae-a23b-3842180d9904" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2fc8d554-3ed0-9aae-a23b-3842180d9904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1c8f4a72-9556-38d6-3d32-089e2d1a35fe" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1c8f4a72-9556-38d6-3d32-089e2d1a35fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_403b8245-2a5c-b405-4865-11cfdebd2992" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_403b8245-2a5c-b405-4865-11cfdebd2992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_147896db-b2dd-402f-9f5b-8c57c745a45a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_147896db-b2dd-402f-9f5b-8c57c745a45a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_b8a6f67f-d570-db88-37fa-3568c826ebc5" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_b8a6f67f-d570-db88-37fa-3568c826ebc5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_7c88fa1f-0edb-d24c-9b87-0646da5010cf" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_7c88fa1f-0edb-d24c-9b87-0646da5010cf" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7f86d0ad-9065-5c14-f7d0-2ff3cc4df692" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7f86d0ad-9065-5c14-f7d0-2ff3cc4df692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_3e8259e4-f50c-f014-e08e-1363b80d4e32" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_3e8259e4-f50c-f014-e08e-1363b80d4e32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a38b9623-d40d-b02c-d37f-d84fb6a4eac7" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a38b9623-d40d-b02c-d37f-d84fb6a4eac7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187bb760-9cde-c4af-d9e1-306e7a6330eb" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187bb760-9cde-c4af-d9e1-306e7a6330eb" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_gh_DeferredTaxAssetsLeaseLiabilities_413EB85850D2A1C11D2178B7E642FE08" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_gh_DeferredTaxAssetsLeaseLiabilities_413EB85850D2A1C11D2178B7E642FE08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0cc13c2f-6b23-b741-4f28-07325c7e7169" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0cc13c2f-6b23-b741-4f28-07325c7e7169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4ed01819-014a-ce74-957e-ddc9b0c1d62e" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4ed01819-014a-ce74-957e-ddc9b0c1d62e" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DeferredTaxLiabilitiesSection481aAdjustment" xlink:label="loc_gh_DeferredTaxLiabilitiesSection481aAdjustment_21F99D3814EF5CC00D3578B917908FFD" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_gh_DeferredTaxLiabilitiesSection481aAdjustment_21F99D3814EF5CC00D3578B917908FFD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_gh_DeferredTaxLiabilitiesRightOfUseAssets_6720A5DBFDCB64C524B578B99C7BD222" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_gh_DeferredTaxLiabilitiesRightOfUseAssets_6720A5DBFDCB64C524B578B99C7BD222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_5c27ce1d-877f-aeaf-724c-f817c1dfc9b7" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_5c27ce1d-877f-aeaf-724c-f817c1dfc9b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bbb5a6cc-fe5e-18f1-e9f0-76884d58b714" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bbb5a6cc-fe5e-18f1-e9f0-76884d58b714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_840ca4a2-1542-fad2-992c-40136594b396" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_840ca4a2-1542-fad2-992c-40136594b396" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="locator" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest" xlink:label="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_6c94b42b-83de-98af-ea57-a625adc1b0e7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_6c94b42b-83de-98af-ea57-a625adc1b0e7" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest" xlink:label="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_afc0a0e8-89ce-f6a1-490e-a625ade9bfab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_afc0a0e8-89ce-f6a1-490e-a625ade9bfab" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/InvestmentInJointVenture" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/InvestmentInJointVentureDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5b651b24-1278-4eab-c840-7002c6d68546" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5b651b24-1278-4eab-c840-7002c6d68546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36c616b1-40de-90d4-3c05-7e224ce1169a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36c616b1-40de-90d4-3c05-7e224ce1169a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_198c3642-781c-a7d4-6f7d-8400ab29b18c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_198c3642-781c-a7d4-6f7d-8400ab29b18c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C7099340FE1C46528BFA983D592364B6_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_C7099340FE1C46528BFA983D592364B6_dba432e7-eec4-e0dc-718d-f46fe263fe47" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C7099340FE1C46528BFA983D592364B6_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_C7099340FE1C46528BFA983D592364B6_dba432e7-eec4-e0dc-718d-f46fe263fe47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_C7099340FE1C46528BFA983D592364B6_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C7099340FE1C46528BFA983D592364B6_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_OperatingLeaseLiability_C7099340FE1C46528BFA983D592364B6_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/PatentLicenseAgreement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/PatentLicenseAgreementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SegmentAndGeographicInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SegmentAndGeographicInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SegmentAndGeographicInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/Tables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/Warrants" xlink:type="extended" />
  <link:calculationLink xlink:role="http://guardanthealth.com/role/WarrantsDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>gh-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBio" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBio" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingencies" xlink:href="gh-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="gh-20191231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails" xlink:href="gh-20191231.xsd#CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesTables" xlink:href="gh-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStock" xlink:href="gh-20191231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockDetails" xlink:href="gh-20191231.xsd#CommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponents" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsTables" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheets" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfOperations" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConvertiblePreferredStock" xlink:href="gh-20191231.xsd#ConvertiblePreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConvertiblePreferredStockDetails" xlink:href="gh-20191231.xsd#ConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CoverPage" xlink:href="gh-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionOfBusiness" xlink:href="gh-20191231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionOfBusinessDetails" xlink:href="gh-20191231.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/EmployeeBenefitPlan" xlink:href="gh-20191231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/EmployeeBenefitPlanDetails" xlink:href="gh-20191231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxes" xlink:href="gh-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:href="gh-20191231.xsd#IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesNarrativeDetails" xlink:href="gh-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" xlink:href="gh-20191231.xsd#IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="gh-20191231.xsd#IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:href="gh-20191231.xsd#IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails" xlink:href="gh-20191231.xsd#IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesTables" xlink:href="gh-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentInJointVenture" xlink:href="gh-20191231.xsd#InvestmentInJointVenture" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentInJointVentureDetails" xlink:href="gh-20191231.xsd#InvestmentInJointVentureDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/Leases" xlink:href="gh-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:href="gh-20191231.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails" xlink:href="gh-20191231.xsd#LeasesScheduleOfFutureMinimalLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails" xlink:href="gh-20191231.xsd#LeasesScheduleOfOperatingLiabilityMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesTables" xlink:href="gh-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/PatentLicenseAgreement" xlink:href="gh-20191231.xsd#PatentLicenseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/PatentLicenseAgreementDetails" xlink:href="gh-20191231.xsd#PatentLicenseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:href="gh-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactionsDetails" xlink:href="gh-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformation" xlink:href="gh-20191231.xsd#SegmentAndGeographicInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformationDetails" xlink:href="gh-20191231.xsd#SegmentAndGeographicInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformationTables" xlink:href="gh-20191231.xsd#SegmentAndGeographicInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreement" xlink:href="gh-20191231.xsd#SeniorTermLoanAndRoyaltyPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails" xlink:href="gh-20191231.xsd#SeniorTermLoanAndRoyaltyPurchaseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensation" xlink:href="gh-20191231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:href="gh-20191231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationValuationOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/Tables" xlink:href="gh-20191231.xsd#Tables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/Warrants" xlink:href="gh-20191231.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/WarrantsDetails" xlink:href="gh-20191231.xsd#WarrantsDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBio" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D554C9C8A6F479955A1F282AC816B57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D554C9C8A6F479955A1F282AC816B57" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2DEB57B5F12A148C4D02F282AC8274C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D554C9C8A6F479955A1F282AC816B57" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2DEB57B5F12A148C4D02F282AC8274C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06457AADC9FC10D3698DF28942703724_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2DEB57B5F12A148C4D02F282AC8274C5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06457AADC9FC10D3698DF28942703724_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06457AADC9FC10D3698DF28942703724" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2DEB57B5F12A148C4D02F282AC8274C5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06457AADC9FC10D3698DF28942703724" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BellweatherBioInc.Member" xlink:label="loc_gh_BellweatherBioInc.Member_2B76389AAE935090E874F288E1016038" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06457AADC9FC10D3698DF28942703724" xlink:to="loc_gh_BellweatherBioInc.Member_2B76389AAE935090E874F288E1016038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7A3453CA7343B599559AF282AC8361B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7A3453CA7343B599559AF282AC8361B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_258D1B1C356176FD023CF282AC838F1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_258D1B1C356176FD023CF282AC838F1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3BD969067DEAF666D157F282AC832155" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:to="loc_us-gaap_Goodwill_3BD969067DEAF666D157F282AC832155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E91A4A67E35C84261CDFF282AC83160E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E91A4A67E35C84261CDFF282AC83160E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07BAB0768BE5C30DD953F282AC844FD2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07BAB0768BE5C30DD953F282AC844FD2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BellweatherBioInc.Member" xlink:label="loc_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16" xlink:to="loc_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9330F9407F0BB2E2373E77D8C7A5BF9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9330F9407F0BB2E2373E77D8C7A5BF9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_BADCA593FE433E1E8C6177D8C7A5D6AF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_BADCA593FE433E1E8C6177D8C7A5D6AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6FCE3B470CA839801EF577D8C7A5B71C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6FCE3B470CA839801EF577D8C7A5B71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7FF07A3A324BBCFAE17477D8C7A51F9D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7FF07A3A324BBCFAE17477D8C7A51F9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F61C4BA5FB151F082E0F77D8C7A5985A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F61C4BA5FB151F082E0F77D8C7A5985A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30F02F302A0F63E08E3777D8C7A5F1BC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30F02F302A0F63E08E3777D8C7A5F1BC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_17DACCDF3B0A180399C15EC872890380" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_17DACCDF3B0A180399C15EC872890380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F8207D678F03C2AB370D5EC872890B55_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17DACCDF3B0A180399C15EC872890380" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F8207D678F03C2AB370D5EC872890B55_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F8207D678F03C2AB370D5EC872890B55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17DACCDF3B0A180399C15EC872890380" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F8207D678F03C2AB370D5EC872890B55" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BellweatherBioInc.Member" xlink:label="loc_gh_BellweatherBioInc.Member_9A38069DE12B281598605EC8728A500D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F8207D678F03C2AB370D5EC872890B55" xlink:to="loc_gh_BellweatherBioInc.Member_9A38069DE12B281598605EC8728A500D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8B345B21C0E48A0716975EC8728A2A1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8B345B21C0E48A0716975EC8728A2A1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F655FB549F49EEE87865EC8728BB2AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F655FB549F49EEE87865EC8728BB2AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A07905DC90088B94E5D05EC8728B6723" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A07905DC90088B94E5D05EC8728B6723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_53FCA40CCB06E74A0F155EC8728BEF33" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_53FCA40CCB06E74A0F155EC8728BEF33" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CovenantsNotToCompeteMember" xlink:label="loc_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1" xlink:to="loc_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_76FE962BA79D261C4D1A77D8C82110C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_76FE962BA79D261C4D1A77D8C82110C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_90179661FDC703E491B877D8C821B2A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_90179661FDC703E491B877D8C821B2A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CommercializationMilestonesMember" xlink:label="loc_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:to="loc_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_EarnOutConsiderationMember" xlink:label="loc_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:to="loc_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6717FD54B1E1C5E5AAE277D8C8213C82" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6717FD54B1E1C5E5AAE277D8C8213C82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_270C45865B7CB442053A77D8C821273C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6717FD54B1E1C5E5AAE277D8C8213C82" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_270C45865B7CB442053A77D8C821273C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_270C45865B7CB442053A77D8C821273C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6717FD54B1E1C5E5AAE277D8C8213C82" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_270C45865B7CB442053A77D8C821273C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BellweatherBioInc.Member" xlink:label="loc_gh_BellweatherBioInc.Member_F3BFE269A29CFCFB160877D8C821EC2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_270C45865B7CB442053A77D8C821273C" xlink:to="loc_gh_BellweatherBioInc.Member_F3BFE269A29CFCFB160877D8C821EC2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C38F6D0E8CA52B2564BA77D8C8214B67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C38F6D0E8CA52B2564BA77D8C8214B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_713F2E4FC5D891CA56AA77D8C82153DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_713F2E4FC5D891CA56AA77D8C82153DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1590C5515448227C7C8C77D8C821CE60" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1590C5515448227C7C8C77D8C821CE60" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BusinessCombinationContingentConsiderationMaximumAmountPayable" xlink:label="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D9A1C5C68C3D33E36C5477D8C825B73D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D9A1C5C68C3D33E36C5477D8C825B73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_03FABBEDD20A4DA214D577D8C825CCBF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_03FABBEDD20A4DA214D577D8C825CCBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_336F6EA27789F12683B977D8C8254553" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_336F6EA27789F12683B977D8C8254553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2C38280CDFCD0F4505E677D8C8250ACF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2C38280CDFCD0F4505E677D8C8250ACF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C6E7D733361754D943C5983D598CFB5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C6E7D733361754D943C5983D598CFB5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E0448042DE894E76ACED983D598C0850_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C6E7D733361754D943C5983D598CFB5E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E0448042DE894E76ACED983D598C0850_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E0448042DE894E76ACED983D598C0850" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C6E7D733361754D943C5983D598CFB5E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E0448042DE894E76ACED983D598C0850" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BellweatherBioInc.Member" xlink:label="loc_gh_BellweatherBioInc.Member_677C5CACBE42EC7D7D7D983D598CAABB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E0448042DE894E76ACED983D598C0850" xlink:to="loc_gh_BellweatherBioInc.Member_677C5CACBE42EC7D7D7D983D598CAABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6265708456AF1FB6993B983D598D535A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6265708456AF1FB6993B983D598D535A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C6DBF630C9936684D9EF983D598DDB54_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6265708456AF1FB6993B983D598D535A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C6DBF630C9936684D9EF983D598DDB54_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C6DBF630C9936684D9EF983D598DDB54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6265708456AF1FB6993B983D598D535A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C6DBF630C9936684D9EF983D598DDB54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_32FE7EE707A8228FF4EA983D598DCB4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C6DBF630C9936684D9EF983D598DDB54" xlink:to="loc_us-gaap_LicenseMember_32FE7EE707A8228FF4EA983D598DCB4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_F2DBFB994A38E87AC6A0983D598D235A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C6DBF630C9936684D9EF983D598DDB54" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_F2DBFB994A38E87AC6A0983D598D235A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_84E60A8120943222BA32983D598D5401" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_84E60A8120943222BA32983D598D5401" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0AA77BABE118DD986A3A983D598E75E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0AA77BABE118DD986A3A983D598E75E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9401AEADEDF47B648A71983D598EBA43" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9401AEADEDF47B648A71983D598EBA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_E9C1E13379936A495065983D598EBB5F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_E9C1E13379936A495065983D598EBB5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1FEB2C1E46825035E49C983D598E17BA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1FEB2C1E46825035E49C983D598E17BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_033A5F5128CC29E534D5983D598E994E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_Goodwill_033A5F5128CC29E534D5983D598E994E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_95AB1B6257AD6E5373DA983D598F0047" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_95AB1B6257AD6E5373DA983D598F0047" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:to="loc_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:to="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:to="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" xlink:label="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:to="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:to="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AE952A85AE05489333B9F21FE3505A82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AE952A85AE05489333B9F21FE3505A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="loc_us-gaap_OtherIncomeMember_3A5E776BCCFD533479F4F21FE3519AC2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:to="loc_us-gaap_OtherIncomeMember_3A5E776BCCFD533479F4F21FE3519AC2" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofPartiesWithPatentLicenseAgreement" xlink:label="loc_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_EC64A4B3431D48F96B74F21FE3535560" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_us-gaap_RoyaltyExpense_EC64A4B3431D48F96B74F21FE3535560" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue" xlink:label="loc_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofPetitionsFiled" xlink:label="loc_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_22E03A4F950D3E83917DF21FE354585A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_22E03A4F950D3E83917DF21FE354585A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_6DDD68D07DE7E2C1E2DBF21FE3548BFA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_us-gaap_LitigationSettlementExpense_6DDD68D07DE7E2C1E2DBF21FE3548BFA" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofCompaniesthatInfringedonaPatent" xlink:label="loc_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofAssertedPatents" xlink:label="loc_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_DC41CF4C9FE06CB92D95F21FE3555AB5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_DC41CF4C9FE06CB92D95F21FE3555AB5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommonStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_75CE298790DFBE335B0777D8C75536E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_75CE298790DFBE335B0777D8C75536E3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75CE298790DFBE335B0777D8C75536E3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_68281E49B6915996E93777D8C7597187" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D" xlink:to="loc_us-gaap_IPOMember_68281E49B6915996E93777D8C7597187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3514630FF07DD25BECD077D8C759D210" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75CE298790DFBE335B0777D8C75536E3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3514630FF07DD25BECD077D8C759D210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3514630FF07DD25BECD077D8C759D210" xlink:to="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3514630FF07DD25BECD077D8C759D210" xlink:to="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_9A3B143D8B86F674503D77D8C7590ED9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503" xlink:to="loc_us-gaap_PreferredStockMember_9A3B143D8B86F674503D77D8C7590ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1926511A9F2F2AFDEFC277D8C759815C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503" xlink:to="loc_us-gaap_CommonStockMember_1926511A9F2F2AFDEFC277D8C759815C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6D86F422006789FA43D677D8C75997EE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6D86F422006789FA43D677D8C75997EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B4BC513FB4343780A18077D8C759081F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75CE298790DFBE335B0777D8C75536E3" xlink:to="loc_us-gaap_AwardTypeAxis_B4BC513FB4343780A18077D8C759081F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B4BC513FB4343780A18077D8C759081F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B4BC513FB4343780A18077D8C759081F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D3F3EB198D6C27C667CB77D8C759A247" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D3F3EB198D6C27C667CB77D8C759A247" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharesAvailableForFutureStockOptionGrantsMember" xlink:label="loc_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500" xlink:to="loc_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_D2AB68EFDF2695082D1977D8C75D2152" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500" xlink:to="loc_us-gaap_EmployeeStockMember_D2AB68EFDF2695082D1977D8C75D2152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1B962267A3A593789C8D77D8C75D7F6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1B962267A3A593789C8D77D8C75D7F6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B94C3B0803AF1B50C07877D8C75DF405" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B94C3B0803AF1B50C07877D8C75DF405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83D1684DCDA69EB7E42D77D8C75D9168" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83D1684DCDA69EB7E42D77D8C75D9168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_B7EEA816C9AEE2064BAD77D8C75DB644" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_B7EEA816C9AEE2064BAD77D8C75DB644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_D483FC07B999CECFADF777D8C75DC506" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_D483FC07B999CECFADF777D8C75DC506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7E5E2E3716B2406C783377D8C75DBE62" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7E5E2E3716B2406C783377D8C75DBE62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_CA33AFE2954359B456CB77D8C75D92AD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_CA33AFE2954359B456CB77D8C75D92AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9BDA1721D7AE95DD540477D8C75D720B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9BDA1721D7AE95DD540477D8C75D720B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03CB235E1EFA70FE459CF347877AA77B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_784855C01058888A0754F3478778B686" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03CB235E1EFA70FE459CF347877AA77B" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_784855C01058888A0754F3478778B686" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C699EEFA5AF3FAAE2364F3478779079D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_784855C01058888A0754F3478778B686" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C699EEFA5AF3FAAE2364F3478779079D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C699EEFA5AF3FAAE2364F3478779079D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C699EEFA5AF3FAAE2364F3478779079D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3480A5949D1FB8BD02E4F34787796B16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_3480A5949D1FB8BD02E4F34787796B16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_EAF433673D8FC07C9FDCF347877AC658" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_ComputerEquipmentMember_EAF433673D8FC07C9FDCF347877AC658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_B8A5F29DF42566D5C846F347877A6AAF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_B8A5F29DF42566D5C846F347877A6AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_E96D66D1C5194247BD4AF347877A61FD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_E96D66D1C5194247BD4AF347877A61FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9B029406BFFB33317C3FF347877A7105" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9B029406BFFB33317C3FF347877A7105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_1D9FE0DA7D3E0632EE41F347877A4CD2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_ConstructionInProgressMember_1D9FE0DA7D3E0632EE41F347877A4CD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_A11DB30A7986885E570DF347877B307D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03CB235E1EFA70FE459CF347877AA77B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_A11DB30A7986885E570DF347877B307D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BD9D740142A3340E7606F347877B941D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03CB235E1EFA70FE459CF347877AA77B" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BD9D740142A3340E7606F347877B941D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6B0747A20B1589335A93F347877BC904" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03CB235E1EFA70FE459CF347877AA77B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6B0747A20B1589335A93F347877BC904" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:to="loc_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:to="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:to="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_FC397500D3ED7C5E7B69983D44ABDBA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_FC397500D3ED7C5E7B69983D44ABDBA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_7336C3F2DCC0F8846F31983D44ACB771" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:to="loc_us-gaap_CommonStockMember_7336C3F2DCC0F8846F31983D44ACB771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_E3BC195EDE8623BCF5F0983D44AD0FD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:to="loc_us-gaap_ProfitLoss_E3BC195EDE8623BCF5F0983D44AD0FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9EE4D9ACAAC542A73590983D44AD9E76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9EE4D9ACAAC542A73590983D44AD9E76" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AmortizationOfRightOfUseAssets" xlink:label="loc_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" xlink:label="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_84408EC72C2733928836983D44AEE5CB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_84408EC72C2733928836983D44AEE5CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_48F94E26528D33212EC5983D44AEC9CD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_ShareBasedCompensation_48F94E26528D33212EC5983D44AEC9CD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_NoncashInterestExpensePaid" xlink:label="loc_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5CB6D2E5A897EE01A0F983D44AE9957" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5CB6D2E5A897EE01A0F983D44AE9957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_208EB62808C163F9149E983D44AF37E1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_208EB62808C163F9149E983D44AF37E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_409BC0F464675CCD5909983D44AF1C1A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_409BC0F464675CCD5909983D44AF1C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73F385DC68FEB63991E7983D44AF9AA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73F385DC68FEB63991E7983D44AF9AA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4F473823727057C1FE28983D44AFFD34" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4F473823727057C1FE28983D44AFFD34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D576EE1607EC86F8FE98983D44B05E8F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D576EE1607EC86F8FE98983D44B05E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7B2D8F92D24170CB165E983D44B0B2B7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7B2D8F92D24170CB165E983D44B0B2B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34AF78B59CA847ED9336983D44B00FFF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34AF78B59CA847ED9336983D44B00FFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0C4CD6D19F6629BF9F07983D44B09186" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0C4CD6D19F6629BF9F07983D44B09186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2508C9B47213468802CF983D44B0CBB2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2508C9B47213468802CF983D44B0CBB2" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets" xlink:label="loc_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_04782B15751F3C8CD0D5983D44B12746" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_04782B15751F3C8CD0D5983D44B12746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_BF1AEB30EDD2C774E446983D44B134B1" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_BF1AEB30EDD2C774E446983D44B134B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_AF901780CCB0F8A369BB983D44B1090F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_AF901780CCB0F8A369BB983D44B1090F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DC29E07C5961122C69F3983D44B19D26" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DC29E07C5961122C69F3983D44B19D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5D4A7CC9A5C0D32BE4F0983D44B2E65F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5D4A7CC9A5C0D32BE4F0983D44B2E65F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_904A0F36E74FBB8EC3E9983D44B20D32" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_904A0F36E74FBB8EC3E9983D44B20D32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9A52936F737047B485D6983D44B24E13" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9A52936F737047B485D6983D44B24E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99A263E2766936E7E120983D44B2DF92" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99A263E2766936E7E120983D44B2DF92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7DA34CB5B66A13F7870E983D44B2D0C7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7DA34CB5B66A13F7870E983D44B2D0C7" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentsInConnectionWithLicenseAgreements" xlink:label="loc_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_877165C7B1608D773C52983D44B3CE40" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_877165C7B1608D773C52983D44B3CE40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" xlink:label="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_33F7BD77213F72B211FC983D44B39269" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_33F7BD77213F72B211FC983D44B39269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7263B3FC1DF5D72F61FF983D44B3C296" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7263B3FC1DF5D72F61FF983D44B3C296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_8EA5643E78A03CA96B05983D44B47820" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_8EA5643E78A03CA96B05983D44B47820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_212D30DA03014E20970D983D44B4C773" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_212D30DA03014E20970D983D44B4C773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8640588B2B5E60545619983D44B45A93" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_8640588B2B5E60545619983D44B45A93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_9714F3BC5464E4A4C18E983D44B41E8F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_9714F3BC5464E4A4C18E983D44B41E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6E3D3B2734E9B6584A54983D44B4F3DA" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6E3D3B2734E9B6584A54983D44B4F3DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9AF96CDB98552A7EAA5B983D44B56193" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9AF96CDB98552A7EAA5B983D44B56193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4D375400A3109739E365983D44B51B08" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4D375400A3109739E365983D44B51B08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_B178B729D09E55717594983D44B5B0B9" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_B178B729D09E55717594983D44B5B0B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_292E6741495DFB73727A983D44B5F774" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_292E6741495DFB73727A983D44B5F774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_E8AD585409C99D29E53B983D44B590AC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_E8AD585409C99D29E53B983D44B590AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_919A78F575316DC90078983D44B5A5A0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_919A78F575316DC90078983D44B5A5A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A925A13952AA3D51B1E4983D44B650B1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A925A13952AA3D51B1E4983D44B650B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D47904643C71116D8428983D44B69384" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D47904643C71116D8428983D44B69384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_ACF72AA229373D403AC2983D44B650B3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:to="loc_us-gaap_InterestPaidNet_ACF72AA229373D403AC2983D44B650B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_DB632F7252C32CD94BAD983D44B70756" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_DB632F7252C32CD94BAD983D44B70756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment" xlink:label="loc_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement" xlink:label="loc_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_EF3BF0E8D071BA064020983D44B82DEC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_EF3BF0E8D071BA064020983D44B82DEC" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ConversionofStockUponInitialPublicOffering" xlink:label="loc_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FC645CCC6F1E533A7C0983D44B87447" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FC645CCC6F1E533A7C0983D44B87447" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_OfferingCostsIncurredbutNotyetPaid" xlink:label="loc_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FE9B84CE001A60614A2C77D8C928E76F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_StatementTable_FE9B84CE001A60614A2C77D8C928E76F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7A439688BD4F220CA62B77D8C928C340" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_FE9B84CE001A60614A2C77D8C928E76F" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7A439688BD4F220CA62B77D8C928C340" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_BB7B4AC6513849F334C177D8C9283FB5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7A439688BD4F220CA62B77D8C928C340" xlink:to="loc_us-gaap_ClassOfStockDomain_BB7B4AC6513849F334C177D8C9283FB5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_BB7B4AC6513849F334C177D8C9283FB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7A439688BD4F220CA62B77D8C928C340" xlink:to="loc_us-gaap_ClassOfStockDomain_BB7B4AC6513849F334C177D8C9283FB5" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesAConvertiblePreferredStockMember_F927F89CA394E4F1556F77D8C928C404" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_BB7B4AC6513849F334C177D8C9283FB5" xlink:to="loc_gh_SeriesAConvertiblePreferredStockMember_F927F89CA394E4F1556F77D8C928C404" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesDConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesDConvertiblePreferredStockMember_E6E4770AA3585E5D187077D8C9282CA1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_BB7B4AC6513849F334C177D8C9283FB5" xlink:to="loc_gh_SeriesDConvertiblePreferredStockMember_E6E4770AA3585E5D187077D8C9282CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromPrecisionOncologyTesting" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting_40AD5EF444B5DB9C8CA977D8C928C5BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:to="loc_gh_RevenuefromPrecisionOncologyTesting_40AD5EF444B5DB9C8CA977D8C928C5BE" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromDevelopmentServices" xlink:label="loc_gh_RevenuefromDevelopmentServices_FEE9598034DF3039C7AA77D8C928D802" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:to="loc_gh_RevenuefromDevelopmentServices_FEE9598034DF3039C7AA77D8C928D802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E544994C458D10B352C177D8C928C955" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:to="loc_us-gaap_Revenues_E544994C458D10B352C177D8C928C955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CostsofPrecisionOncologyTesting" xlink:label="loc_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CostofDevelopmentServices" xlink:label="loc_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7FC444B8A9781655BFB977D8C92843A8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7FC444B8A9781655BFB977D8C92843A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_7FBDFFCF718E6AF5A42377D8C9287A1D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_us-gaap_SellingAndMarketingExpense_7FBDFFCF718E6AF5A42377D8C9287A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3D92013C6509D7D1E70577D8C9288E76" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3D92013C6509D7D1E70577D8C9288E76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_590EA7EC8F3DF3443F1577D8C92899CC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_us-gaap_CostsAndExpenses_590EA7EC8F3DF3443F1577D8C92899CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_0793B8ECEACBE7E33D9677D8C92C5B39" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_OperatingIncomeLoss_0793B8ECEACBE7E33D9677D8C92C5B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_59EA801217DC3B350AEE77D8C92CC8E8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_59EA801217DC3B350AEE77D8C92CC8E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2D71F8DBCAD8895B025377D8C92C2BB9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_InterestExpense_2D71F8DBCAD8895B025377D8C92C2BB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_379F3E89CCD8F999FE6B77D8C92C7965" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_379F3E89CCD8F999FE6B77D8C92C7965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_A5641AD906C714E9641777D8C92CE07C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_A5641AD906C714E9641777D8C92CE07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4C99B8229DC525BBA75D77D8C92C2ADD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4C99B8229DC525BBA75D77D8C92C2ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_00C40839CAFAC354B1F277D8C92C8088" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_00C40839CAFAC354B1F277D8C92C8088" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_9AC9CF7A2505BC3B754477D8C92CEB66" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_ProfitLoss_9AC9CF7A2505BC3B754477D8C92CEB66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_08600CA3067A455FCCC977D8C92C3967" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_08600CA3067A455FCCC977D8C92C3967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5FDE85E6500E5D1A1A4C77D8C92C03CE" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_NetIncomeLoss_5FDE85E6500E5D1A1A4C77D8C92C03CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_98BEB72AAD3B1B84B86077D8C92C44A1" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_98BEB72AAD3B1B84B86077D8C92C44A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6E34E0E9C7CC0DCA170D77D8C92C7793" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6E34E0E9C7CC0DCA170D77D8C92C7793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_BF34EC48259F895BBAEB77D8C92C5456" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_BF34EC48259F895BBAEB77D8C92C5456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EA1055BFBA99665E3D4077D8C92C7D12" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EA1055BFBA99665E3D4077D8C92C7D12" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_69F3356B34EE26C7067588B6E8AAB0A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3B3F92880B63C5539E7E88B6E8A6AD80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_69F3356B34EE26C7067588B6E8AAB0A5" xlink:to="loc_us-gaap_StatementTable_3B3F92880B63C5539E7E88B6E8A6AD80" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_75EEC33341D1DA3178FE88B6E8A6B3D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3B3F92880B63C5539E7E88B6E8A6AD80" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_75EEC33341D1DA3178FE88B6E8A6B3D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75EEC33341D1DA3178FE88B6E8A6B3D0" xlink:to="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75EEC33341D1DA3178FE88B6E8A6B3D0" xlink:to="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RedeemableNoncontrollingInterestMember" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_4D6E0FB38219A5C2AEC188B6E8A74CB5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_us-gaap_PreferredStockMember_4D6E0FB38219A5C2AEC188B6E8A74CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FB3361B98E18AE5990DB88B6E8A72704" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_us-gaap_CommonStockMember_FB3361B98E18AE5990DB88B6E8A72704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B4B44F540E8257FBFF2E88B6E8A749AE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B4B44F540E8257FBFF2E88B6E8A749AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E1506E711CAB7DDCB50B88B6E8A7B7CD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E1506E711CAB7DDCB50B88B6E8A7B7CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A2D1011C35A06FCD6FF288B6E8A8CF37" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_us-gaap_RetainedEarningsMember_A2D1011C35A06FCD6FF288B6E8A8CF37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7431B1077665C5793C1088B6E8A81FA2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3B3F92880B63C5539E7E88B6E8A6AD80" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7431B1077665C5793C1088B6E8A81FA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7431B1077665C5793C1088B6E8A81FA2" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7431B1077665C5793C1088B6E8A81FA2" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_86813738CB525025119D88B6E8A8AFE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_86813738CB525025119D88B6E8A8AFE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_318BAEC67D82202AC7B088B6E8A8F944" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_318BAEC67D82202AC7B088B6E8A8F944" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AccountingStandardsUpdate201807Member" xlink:label="loc_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6" xlink:to="loc_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7AC3B2B326C98057749688B6E8A90F02" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3B3F92880B63C5539E7E88B6E8A6AD80" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7AC3B2B326C98057749688B6E8A90F02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7AC3B2B326C98057749688B6E8A90F02" xlink:to="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7AC3B2B326C98057749688B6E8A90F02" xlink:to="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesDConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21" xlink:to="loc_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesEConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21" xlink:to="loc_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesAConvertiblePreferredStockMember_FEB82E9651F38FE1545288B6E8AACBBC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21" xlink:to="loc_gh_SeriesAConvertiblePreferredStockMember_FEB82E9651F38FE1545288B6E8AACBBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69F3356B34EE26C7067588B6E8AAB0A5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_41B483BC070EE5F94D0788B6E8AA3516" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockholdersEquity_41B483BC070EE5F94D0788B6E8AA3516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_06BE039E59DECD8BEAE488B6E8AADDAE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_SharesOutstanding_06BE039E59DECD8BEAE488B6E8AADDAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AB67FB733F4959A94CEB88B6E8AB1F24" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AB67FB733F4959A94CEB88B6E8AB1F24" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" xlink:label="loc_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" xlink:label="loc_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AA197B13BE353E4DA39888B6E8ABA73B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AA197B13BE353E4DA39888B6E8ABA73B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_48BE5BC2FD012CC768D788B6E8AB1B43" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_48BE5BC2FD012CC768D788B6E8AB1B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829D5F9B37251EFD3A1088B6E8ACAB65" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829D5F9B37251EFD3A1088B6E8ACAB65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_F368F7E4659EC11D746A88B6E8AC9D76" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_F368F7E4659EC11D746A88B6E8AC9D76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_1D93E98C51296771D75588B6E8AC57E1" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_1D93E98C51296771D75588B6E8AC57E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_36C4F885AC24A300ED7F88B6E8AC65D6" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_36C4F885AC24A300ED7F88B6E8AC65D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36742BCE132C6462EFC288B6E8AC4EFB" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36742BCE132C6462EFC288B6E8AC4EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0E57AEA8EBE041181DA888B6E8AC3D9C" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0E57AEA8EBE041181DA888B6E8AC3D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_996726922F075BE846FB88B6E8ACD95B" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_996726922F075BE846FB88B6E8ACD95B" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_D8458A0C3EF830147E7C88B6E8AD9104" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_D8458A0C3EF830147E7C88B6E8AD9104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0854FC90483A33B8290988B6E8ADF354" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0854FC90483A33B8290988B6E8ADF354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_878E63CB9521F4D7212488B6E8ADEDBB" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_878E63CB9521F4D7212488B6E8ADEDBB" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_B1443ECD1D9E34C24E7288B6E8ADDE66" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_B1443ECD1D9E34C24E7288B6E8ADDE66" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueExerciseofWarrants" xlink:label="loc_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions" xlink:label="loc_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9B5E50593D7B99BCFB9088B6E8AE4A44" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9B5E50593D7B99BCFB9088B6E8AE4A44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_D9901D485160D0565E2F88B6E8AE0868" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_D9901D485160D0565E2F88B6E8AE0868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D7AF760685C3FBDE147488B6E8AEC8B5" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D7AF760685C3FBDE147488B6E8AEC8B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_75F5D5C7CE102FFC5EF488B6E8AE1F73" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_75F5D5C7CE102FFC5EF488B6E8AE1F73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69F3356B34EE26C7067588B6E8AAB0A5" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_C0591BBEFA93FD5B7A5088B6E8AF1CE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_C0591BBEFA93FD5B7A5088B6E8AF1CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22B3FE9BBA904971615688B6E8AF95A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22B3FE9BBA904971615688B6E8AF95A9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6F7AD1FE4F975B0524EB77D8C8FC3E4A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E13B4D533B68527DBD2977D8C8F83215" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6F7AD1FE4F975B0524EB77D8C8FC3E4A" xlink:to="loc_us-gaap_StatementTable_E13B4D533B68527DBD2977D8C8F83215" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E3A4C26B30B1BF0E81EC77D8C8F8F8AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E13B4D533B68527DBD2977D8C8F83215" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E3A4C26B30B1BF0E81EC77D8C8F8F8AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E3A4C26B30B1BF0E81EC77D8C8F8F8AA" xlink:to="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E3A4C26B30B1BF0E81EC77D8C8F8F8AA" xlink:to="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesDConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesDConvertiblePreferredStockMember_69C55AC290A43D9EF48A77D8C8F872B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77" xlink:to="loc_gh_SeriesDConvertiblePreferredStockMember_69C55AC290A43D9EF48A77D8C8F872B4" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesEConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesEConvertiblePreferredStockMember_D85399D9627A8E752CE177D8C8F82AB4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77" xlink:to="loc_gh_SeriesEConvertiblePreferredStockMember_D85399D9627A8E752CE177D8C8F82AB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C901CA1CBC670696F2B277D8C8FCED9E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77" xlink:to="loc_us-gaap_CommonStockMember_C901CA1CBC670696F2B277D8C8FCED9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FC798C49DB1F0C88B36177D8C8FC5CEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6F7AD1FE4F975B0524EB77D8C8FC3E4A" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FC798C49DB1F0C88B36177D8C8FC5CEF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConvertiblePreferredStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/ConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:to="loc_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SoftBankMember" xlink:label="loc_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6" xlink:to="loc_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C244986B5BE38D040A0677D8C7399CDA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_C244986B5BE38D040A0677D8C7399CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2E1BE8A7B5D940B9EFDB77D8C739581A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C244986B5BE38D040A0677D8C7399CDA" xlink:to="loc_us-gaap_EquityComponentDomain_2E1BE8A7B5D940B9EFDB77D8C739581A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2E1BE8A7B5D940B9EFDB77D8C739581A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C244986B5BE38D040A0677D8C7399CDA" xlink:to="loc_us-gaap_EquityComponentDomain_2E1BE8A7B5D940B9EFDB77D8C739581A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_38669F107A3145BB060977D8C73D2355" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2E1BE8A7B5D940B9EFDB77D8C739581A" xlink:to="loc_us-gaap_CommonStockMember_38669F107A3145BB060977D8C73D2355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A778968D584391F74AFB77D8C73D45AE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A778968D584391F74AFB77D8C73D45AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A778968D584391F74AFB77D8C73D45AE" xlink:to="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A778968D584391F74AFB77D8C73D45AE" xlink:to="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EF4B7D5C3F2928F142B877D8C73D329B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E" xlink:to="loc_us-gaap_CommonStockMember_EF4B7D5C3F2928F142B877D8C73D329B" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesEConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesEConvertiblePreferredStockMember_1015B056824D4926231F77D8C73DCDBA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E" xlink:to="loc_gh_SeriesEConvertiblePreferredStockMember_1015B056824D4926231F77D8C73DCDBA" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesAConvertiblePreferredStockMember_5F261E42CCB57674FF0277D8C73D411D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E" xlink:to="loc_gh_SeriesAConvertiblePreferredStockMember_5F261E42CCB57674FF0277D8C73D411D" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" xlink:label="loc_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_9B99345EBC65DB9F7A2477D8C73D4A37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_9B99345EBC65DB9F7A2477D8C73D4A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47C58A6040A1CA0D3F2177D8C73D0786" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47C58A6040A1CA0D3F2177D8C73D0786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_B5025D6BCF6F4FA43B0477D8C73D07BF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_B5025D6BCF6F4FA43B0477D8C73D07BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_145A7739F46555E55B2D77D8C73D06C4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_145A7739F46555E55B2D77D8C73D06C4" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ThresholdPercentageofNewSharesIssued" xlink:label="loc_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares" xlink:label="loc_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_3A080DC7A10ED5A4831077D8C73D9F73" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_3A080DC7A10ED5A4831077D8C73D9F73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_50D21BE6D60009C139D877D8C73D7EC6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_50D21BE6D60009C139D877D8C73D7EC6" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock" xlink:label="loc_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00174AF260115AE4137677D8C73D6D65" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00174AF260115AE4137677D8C73D6D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DD861292E893CE2E8F1077D8C73DDBB4" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DD861292E893CE2E8F1077D8C73DDBB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_F5D664059A8137CCFCD577D8C741EED2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_F5D664059A8137CCFCD577D8C741EED2" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_64B73D08942CB3FF03B077D8C741261B" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_64B73D08942CB3FF03B077D8C741261B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="loc_us-gaap_PreferredStockDividendsShares_E9468E3686588F8561B377D8C7412EC5" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_PreferredStockDividendsShares_E9468E3686588F8561B377D8C7412EC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_93B8302C7BC26E67783877D8C7410DE0" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_93B8302C7BC26E67783877D8C7410DE0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/DescriptionOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_18D4A0B7E9D5B047FCF787A8B233EB80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_18D4A0B7E9D5B047FCF787A8B233EB80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4835FAC2158B0ED891ED87A8B2332096_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_18D4A0B7E9D5B047FCF787A8B233EB80" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4835FAC2158B0ED891ED87A8B2332096_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4835FAC2158B0ED891ED87A8B2332096" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_18D4A0B7E9D5B047FCF787A8B233EB80" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4835FAC2158B0ED891ED87A8B2332096" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_WarrantsPreferredStockMember" xlink:label="loc_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4835FAC2158B0ED891ED87A8B2332096" xlink:to="loc_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_GuardantHealthAMEAIncMember" xlink:label="loc_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3" xlink:to="loc_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_47CE5DF2F4304BF3782287A8B2345FB5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:to="loc_us-gaap_StatementClassOfStockAxis_47CE5DF2F4304BF3782287A8B2345FB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_24CC62E5F134C188C0F487A8B2351490_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47CE5DF2F4304BF3782287A8B2345FB5" xlink:to="loc_us-gaap_ClassOfStockDomain_24CC62E5F134C188C0F487A8B2351490_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_24CC62E5F134C188C0F487A8B2351490" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47CE5DF2F4304BF3782287A8B2345FB5" xlink:to="loc_us-gaap_ClassOfStockDomain_24CC62E5F134C188C0F487A8B2351490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_ECE2DC36D3EE8072F3CC87A8B235747B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_24CC62E5F134C188C0F487A8B2351490" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_ECE2DC36D3EE8072F3CC87A8B235747B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_C4277F9206FCB5F9524A87A8B2355496" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_C4277F9206FCB5F9524A87A8B2355496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61C3CBCC27301EC9701E87A8B2350155_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_C4277F9206FCB5F9524A87A8B2355496" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61C3CBCC27301EC9701E87A8B2350155_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61C3CBCC27301EC9701E87A8B2350155" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_C4277F9206FCB5F9524A87A8B2355496" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61C3CBCC27301EC9701E87A8B2350155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_08E8195DC701364DD3F687A8B2369CBD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61C3CBCC27301EC9701E87A8B2350155" xlink:to="loc_us-gaap_IPOMember_08E8195DC701364DD3F687A8B2369CBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_45812379489641E0196887A8B236FD1F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61C3CBCC27301EC9701E87A8B2350155" xlink:to="loc_us-gaap_OverAllotmentOptionMember_45812379489641E0196887A8B236FD1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_51A3DE74CB69DF8C032A87A8B236C469" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_51A3DE74CB69DF8C032A87A8B236C469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00A8A497B89DE3EE2BD187A8B237E9AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00A8A497B89DE3EE2BD187A8B237E9AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_47DC2046BFCDCB7B4DFA87A8B237E487" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_47DC2046BFCDCB7B4DFA87A8B237E487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_EB8306B67D0DEC31EBAA87A8B237F388" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_EB8306B67D0DEC31EBAA87A8B237F388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0AA7718E546F8B57E79787A8B237AF72" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0AA7718E546F8B57E79787A8B237AF72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_916A8C8114EDBEE517DC87A8B2371B18" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_916A8C8114EDBEE517DC87A8B2371B18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_24DED18B3BD20C17F7C587A8B23753F0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_24DED18B3BD20C17F7C587A8B23753F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0E6BA1C36C580B097D1787A8B2371EEC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0E6BA1C36C580B097D1787A8B2371EEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53F6A9F5B552A98ACB2D87A8B238E1D0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53F6A9F5B552A98ACB2D87A8B238E1D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_DA1211BC3CCDF8D2942C87A8B2384DD5" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_DA1211BC3CCDF8D2942C87A8B2384DD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_654BDEA446A8DCB393A287A8B2380D0E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_654BDEA446A8DCB393A287A8B2380D0E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_606E5F32E03702513E59C97D00C56795" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_606E5F32E03702513E59C97D00C56795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_F8E9838876CBDCB5DC68C97D00C6AF62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_F8E9838876CBDCB5DC68C97D00C6AF62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_73C2B63EE3D9920C23FBC97D00C65A1A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_73C2B63EE3D9920C23FBC97D00C65A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CCE75E761AFA0BA0E0EAC97D00C65990" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CCE75E761AFA0BA0E0EAC97D00C65990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E549EBCB3E7A55C79DE0C97D00C7E6BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E549EBCB3E7A55C79DE0C97D00C7E6BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8391E5BE3BAB8190CA83C97D00C7B206" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8391E5BE3BAB8190CA83C97D00C7B206" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FE28E1DA4D14F4CDF0DAC97D00C7BAAF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FE28E1DA4D14F4CDF0DAC97D00C7BAAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C2C5D2852F2E7E3BF8DC97D00C72344" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C2C5D2852F2E7E3BF8DC97D00C72344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1C372FF43F1FCB711D47C97D00C840F1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1C372FF43F1FCB711D47C97D00C840F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F919B4123DE928932965C97D00C8E31F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F919B4123DE928932965C97D00C8E31F" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_A84AB4174DEF9D319C1E88B6E80EA74D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_A84AB4174DEF9D319C1E88B6E80EA74D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_05317BB52B02135EDC7988B6E80E13CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:to="loc_us-gaap_FinancialInstrumentAxis_05317BB52B02135EDC7988B6E80E13CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_05317BB52B02135EDC7988B6E80E13CA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_05317BB52B02135EDC7988B6E80E13CA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_D394186C44021E429C9688B6E80ED3A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_D394186C44021E429C9688B6E80ED3A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_FEB850B6A05FE021691588B6E80F2B36" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_FEB850B6A05FE021691588B6E80F2B36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C86EDDBE599C1F9748CA88B6E80FFAC0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C86EDDBE599C1F9748CA88B6E80FFAC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FE69A277146BA166445588B6E80FEC25" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FE69A277146BA166445588B6E80FEC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_D1636BBBEFC189DF602088B6E80F88EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FE69A277146BA166445588B6E80FEC25" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_D1636BBBEFC189DF602088B6E80F88EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_D1636BBBEFC189DF602088B6E80F88EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FE69A277146BA166445588B6E80FEC25" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_D1636BBBEFC189DF602088B6E80F88EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_957BAC594A730C621CAD88B6E80F8A44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_D1636BBBEFC189DF602088B6E80F88EA" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_957BAC594A730C621CAD88B6E80F8A44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B2554C061778FC46221888B6E80F8EC8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B2554C061778FC46221888B6E80F8EC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B2554C061778FC46221888B6E80F8EC8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B2554C061778FC46221888B6E80F8EC8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_A97187A3ADB0A89BB8B788B6E810D385" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_A97187A3ADB0A89BB8B788B6E810D385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ACD483CD75ED0363A6FE88B6E8107356" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ACD483CD75ED0363A6FE88B6E8107356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_05308E66C0DAB927361D88B6E810C76F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_05308E66C0DAB927361D88B6E810C76F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47295D87DA6E90CBC98E88B6E81185DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47295D87DA6E90CBC98E88B6E81185DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_4ED04ADA12504956E86388B6E8117A97" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_4ED04ADA12504956E86388B6E8117A97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_B5BAA0B41B56B72E2EFF88B6E811991C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_B5BAA0B41B56B72E2EFF88B6E811991C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3AB9C08221AFE29C441888B6E8116E91" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3AB9C08221AFE29C441888B6E8116E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A8DEE9BFA2F72542583888B991CEBF48" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A8DEE9BFA2F72542583888B991CEBF48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_F09A8C0D500B4CB11E2D88B6E812B4E0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_F09A8C0D500B4CB11E2D88B6E812B4E0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2186D0DA5B5C1B57942CA625E58DD34A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_368E93A61BFBFE12E34FA625E58C1766" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2186D0DA5B5C1B57942CA625E58DD34A" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_368E93A61BFBFE12E34FA625E58C1766" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9E6B81FB23B75ED4B255A625E58C482C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_368E93A61BFBFE12E34FA625E58C1766" xlink:to="loc_srt_RangeAxis_9E6B81FB23B75ED4B255A625E58C482C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7C0AFA8E6014E3F2F5F2A625E58C7C86_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9E6B81FB23B75ED4B255A625E58C482C" xlink:to="loc_srt_RangeMember_7C0AFA8E6014E3F2F5F2A625E58C7C86_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7C0AFA8E6014E3F2F5F2A625E58C7C86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9E6B81FB23B75ED4B255A625E58C482C" xlink:to="loc_srt_RangeMember_7C0AFA8E6014E3F2F5F2A625E58C7C86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_7920D988F268F6F3DE54A625E58D2431" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7C0AFA8E6014E3F2F5F2A625E58C7C86" xlink:to="loc_srt_MinimumMember_7920D988F268F6F3DE54A625E58D2431" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C68301CC8988E71928E1A625E58D7BDA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7C0AFA8E6014E3F2F5F2A625E58C7C86" xlink:to="loc_srt_MaximumMember_C68301CC8988E71928E1A625E58D7BDA" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_MarketableSecuritiesMaturityPeriod" xlink:label="loc_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2186D0DA5B5C1B57942CA625E58DD34A" xlink:to="loc_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeTaxesLineItems" xlink:label="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:type="locator" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeTaxesTable" xlink:label="loc_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_73345D37364AE6044A76983D583BBDC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:to="loc_us-gaap_DomesticCountryMember_73345D37364AE6044A76983D583BBDC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_63F8CF3B0F0ECAB7E9E6983D583B439C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_63F8CF3B0F0ECAB7E9E6983D583B439C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_CE3C006F969AAAA0E48D983D583C2206" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_CE3C006F969AAAA0E48D983D583C2206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_C06951897B59DE8C9887983D583C88E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_C06951897B59DE8C9887983D583C88E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_584DA3864F7C5318C9E2983D583C740B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_OperatingLossCarryforwards_584DA3864F7C5318C9E2983D583C740B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_E8CC0BFE06FAE77E4A1F983D583CA64C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_E8CC0BFE06FAE77E4A1F983D583CA64C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F859BAAFB8347D99AFD7983D583D83D2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F859BAAFB8347D99AFD7983D583D83D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8AA893505232586CFFEA983D583DCA57" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8AA893505232586CFFEA983D583DCA57" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/InvestmentInJointVenture" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/InvestmentInJointVentureDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:to="loc_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:to="loc_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:to="loc_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SoftBankMember" xlink:label="loc_gh_SoftBankMember_2990639116C75C39B3F191EAA8C88EE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D" xlink:to="loc_gh_SoftBankMember_2990639116C75C39B3F191EAA8C88EE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EA63FE9D40D9CE51D17C91EAA8C83534" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EA63FE9D40D9CE51D17C91EAA8C83534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_E20AA2EBB957C7A7584591EAA8C8BAFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EA63FE9D40D9CE51D17C91EAA8C83534" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_E20AA2EBB957C7A7584591EAA8C8BAFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_E20AA2EBB957C7A7584591EAA8C8BAFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EA63FE9D40D9CE51D17C91EAA8C83534" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_E20AA2EBB957C7A7584591EAA8C8BAFE" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_GuardantHealthAMEAIncMember" xlink:label="loc_gh_GuardantHealthAMEAIncMember_6D10D5108D1434D3F4AC91EAA8C8EFD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_E20AA2EBB957C7A7584591EAA8C8BAFE" xlink:to="loc_gh_GuardantHealthAMEAIncMember_6D10D5108D1434D3F4AC91EAA8C8EFD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_F54252EB534FB489505291EAA8C98D17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_F54252EB534FB489505291EAA8C98D17" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_EquityMethodInvestmentSharesPurchased" xlink:label="loc_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_86248E71DBE08F2598CA91EAA8C9B868" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_86248E71DBE08F2598CA91EAA8C9B868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_10DCB1F30A4B2CF57EB291EAA8C95F36" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_10DCB1F30A4B2CF57EB291EAA8C95F36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_F884403E335E1F3E2E8291EAA8CA6D31" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_F884403E335E1F3E2E8291EAA8CA6D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_50EF3B9DDC5BB15C0DCC91EAA8CAFEA7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_50EF3B9DDC5BB15C0DCC91EAA8CAFEA7" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty" xlink:label="loc_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityThresholdPercentageofFairValue" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityPercentageoftheProduct" xlink:label="loc_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable" xlink:label="loc_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable_698502EF81253AC5BDD491F62E6544B2" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable_698502EF81253AC5BDD491F62E6544B2" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RedeemableNoncontrollingInterestFairValueAdjustment" xlink:label="loc_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6AEE98371281182C1D8388B6E6D789CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6AEE98371281182C1D8388B6E6D789CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B04F9973A3A490E59B1E88B6E6D7859A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6AEE98371281182C1D8388B6E6D789CD" xlink:to="loc_us-gaap_ClassOfStockDomain_B04F9973A3A490E59B1E88B6E6D7859A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B04F9973A3A490E59B1E88B6E6D7859A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6AEE98371281182C1D8388B6E6D789CD" xlink:to="loc_us-gaap_ClassOfStockDomain_B04F9973A3A490E59B1E88B6E6D7859A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_76DD7A6B3F626BEA8B1188B6E6D84DC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B04F9973A3A490E59B1E88B6E6D7859A" xlink:to="loc_us-gaap_PreferredStockMember_76DD7A6B3F626BEA8B1188B6E6D84DC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_ED9D87394691006D27A988B6E6D89AA4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B04F9973A3A490E59B1E88B6E6D7859A" xlink:to="loc_us-gaap_CommonStockMember_ED9D87394691006D27A988B6E6D89AA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_C63C726358555CA6179088B6E6D87260" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_C63C726358555CA6179088B6E6D87260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7BB1454E325F28023E8C88B6E6D9F745" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7BB1454E325F28023E8C88B6E6D9F745" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_EmployeeStockPurchasePlanObligationMember" xlink:label="loc_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2C06239315353147AD5A88B6E6D9EBD7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_us-gaap_WarrantMember_2C06239315353147AD5A88B6E6D9EBD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_00EA638D75F2464FD28F88B90AA72B44" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_00EA638D75F2464FD28F88B90AA72B44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_C93D11ED92E3BF8880D788B6E6D96904" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_us-gaap_TreasuryStockCommonMember_C93D11ED92E3BF8880D788B6E6D96904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BEAE516D07C07A3CA1E888B6E6DAD147" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BEAE516D07C07A3CA1E888B6E6DAD147" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A82E7356D7CB537F6241983D58703123" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A82E7356D7CB537F6241983D58703123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B3CE3C47DE77DA03D9C0983D5871BD5E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A82E7356D7CB537F6241983D58703123" xlink:to="loc_us-gaap_ClassOfStockDomain_B3CE3C47DE77DA03D9C0983D5871BD5E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B3CE3C47DE77DA03D9C0983D5871BD5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A82E7356D7CB537F6241983D58703123" xlink:to="loc_us-gaap_ClassOfStockDomain_B3CE3C47DE77DA03D9C0983D5871BD5E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesAConvertiblePreferredStockMember_441DB5A240EC8C3F21A4983D5871F8BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B3CE3C47DE77DA03D9C0983D5871BD5E" xlink:to="loc_gh_SeriesAConvertiblePreferredStockMember_441DB5A240EC8C3F21A4983D5871F8BD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesDConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesDConvertiblePreferredStockMember_2ADE7ACB65F49E0B08FF983D587189C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B3CE3C47DE77DA03D9C0983D5871BD5E" xlink:to="loc_gh_SeriesDConvertiblePreferredStockMember_2ADE7ACB65F49E0B08FF983D587189C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_02F3FEACA10D5C8512C8983D5871A2FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_ProfitLoss_02F3FEACA10D5C8512C8983D5871A2FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_2F969D7CE0CB62AD0AE4983D58727AC5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_2F969D7CE0CB62AD0AE4983D58727AC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9E87242A74D1E1BE36C7983D5872CB4D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_NetIncomeLoss_9E87242A74D1E1BE36C7983D5872CB4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_A7E3E48ACFBEEFDD2D7D983D5872C2A3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_A7E3E48ACFBEEFDD2D7D983D5872C2A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_CAB7FF3CBCF57CA3CD05983D5872A1B1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_CAB7FF3CBCF57CA3CD05983D5872A1B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_272E6A962C27A028C893983D5872A3E7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_272E6A962C27A028C893983D5872A3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94CBC74E4D7D70D2FC8B983D5873C48A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94CBC74E4D7D70D2FC8B983D5873C48A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/PatentLicenseAgreement" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/PatentLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B323FB437AE7B9E74A7288B6E7C6A489" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B323FB437AE7B9E74A7288B6E7C6A489" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B323FB437AE7B9E74A7288B6E7C6A489" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_C1F00CF12FD75CE566CD88B6E7C77357" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_C1F00CF12FD75CE566CD88B6E7C77357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_309DDD72ACDE52DBC9A488B6E7C7416A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B323FB437AE7B9E74A7288B6E7C6A489" xlink:to="loc_us-gaap_StatementClassOfStockAxis_309DDD72ACDE52DBC9A488B6E7C7416A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_39A6A6176BB54A5B549B88B6E7C71800_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_309DDD72ACDE52DBC9A488B6E7C7416A" xlink:to="loc_us-gaap_ClassOfStockDomain_39A6A6176BB54A5B549B88B6E7C71800_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_39A6A6176BB54A5B549B88B6E7C71800" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_309DDD72ACDE52DBC9A488B6E7C7416A" xlink:to="loc_us-gaap_ClassOfStockDomain_39A6A6176BB54A5B549B88B6E7C71800" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesDConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesDConvertiblePreferredStockMember_03D5CD2EB897A6C1182088B6E7C7421F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_39A6A6176BB54A5B549B88B6E7C71800" xlink:to="loc_gh_SeriesDConvertiblePreferredStockMember_03D5CD2EB897A6C1182088B6E7C7421F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_AEB39AB8CA6E3634DEA988B6E7C731A4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B323FB437AE7B9E74A7288B6E7C6A489" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_AEB39AB8CA6E3634DEA988B6E7C731A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D143EF0B387C702889D088B6E7C8B1FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_AEB39AB8CA6E3634DEA988B6E7C731A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D143EF0B387C702889D088B6E7C8B1FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D143EF0B387C702889D088B6E7C8B1FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_AEB39AB8CA6E3634DEA988B6E7C731A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D143EF0B387C702889D088B6E7C8B1FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_7F44C0865EAABB9FCD2088B6E7C8F5F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D143EF0B387C702889D088B6E7C8B1FB" xlink:to="loc_us-gaap_LicensingAgreementsMember_7F44C0865EAABB9FCD2088B6E7C8F5F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3ABEB288BDB35F0AC41A88B6E7C859E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3ABEB288BDB35F0AC41A88B6E7C859E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2A288B358D7572B03EA488B6E7C9EDA2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2A288B358D7572B03EA488B6E7C9EDA2" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_LicenseAgreementMilestonePaymentUponAchievement" xlink:label="loc_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentsforFutureRoyalties" xlink:label="loc_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_17291C750C8653FC18B088B6E7C9682D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_17291C750C8653FC18B088B6E7C9682D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5E44E81C7D0418F6C6FE88B6E7C97F00" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5E44E81C7D0418F6C6FE88B6E7C97F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_18AF4BD120B1A2522EBD88B6E7C99F1C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_18AF4BD120B1A2522EBD88B6E7C99F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6606AAEEE63A8D766B9E88B6E7CA62AF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6606AAEEE63A8D766B9E88B6E7CA62AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_887CEB8C10D58D1205A288B6E7CA982D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_887CEB8C10D58D1205A288B6E7CA982D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:to="loc_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_5809A11025F24830D96291E039FFBD56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3" xlink:to="loc_us-gaap_ExecutiveOfficerMember_5809A11025F24830D96291E039FFBD56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_D62593647EADA0AE7B4B91E039FF1B30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_D62593647EADA0AE7B4B91E039FF1B30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_232C518B419672DE6E1D91E039FF173A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D62593647EADA0AE7B4B91E039FF1B30" xlink:to="loc_us-gaap_ClassOfStockDomain_232C518B419672DE6E1D91E039FF173A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_232C518B419672DE6E1D91E039FF173A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D62593647EADA0AE7B4B91E039FF1B30" xlink:to="loc_us-gaap_ClassOfStockDomain_232C518B419672DE6E1D91E039FF173A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_93DF60032DEDDF64DB0391E03A007357" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_232C518B419672DE6E1D91E039FF173A" xlink:to="loc_us-gaap_CommonStockMember_93DF60032DEDDF64DB0391E03A007357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:to="loc_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:to="loc_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srt_AffiliatedEntityMember_CF687FE8E998B2DEBF6991E03A00E232" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C" xlink:to="loc_srt_AffiliatedEntityMember_CF687FE8E998B2DEBF6991E03A00E232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_02577CB2FD985A02C78391E03A01F35D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_02577CB2FD985A02C78391E03A01F35D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_CF5B2E616D6BD95AFB3191E03A011788" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_CF5B2E616D6BD95AFB3191E03A011788" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CommonStockCompensationExpense" xlink:label="loc_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:to="loc_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_9F63F841660F2A76949291E03A014D50" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:to="loc_us-gaap_RevenueFromRelatedParties_9F63F841660F2A76949291E03A014D50" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SegmentAndGeographicInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SegmentAndGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsMember" xlink:label="loc_us-gaap_AssetsMember_9E0ECFB1EA7927FFD6C891FEC2FA7214" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79" xlink:to="loc_us-gaap_AssetsMember_9E0ECFB1EA7927FFD6C891FEC2FA7214" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_53814A68ADC3046C37B491FC497501C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_53814A68ADC3046C37B491FC497501C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:to="loc_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:to="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:to="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_AB15354AB48B695F3A7491EAA7711DA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:to="loc_country_US_AB15354AB48B695F3A7491EAA7711DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_6CEAC1DE94E8AD5D0D6591EAA7718AE9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:to="loc_us-gaap_NonUsMember_6CEAC1DE94E8AD5D0D6591EAA7718AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_32947E77E56461C5A01691EAA77100CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:to="loc_us-gaap_Revenues_32947E77E56461C5A01691EAA77100CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_F2486A5D21661A75AE8E91EAA772C144" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_F2486A5D21661A75AE8E91EAA772C144" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SegmentAndGeographicInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreement" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementbyPaymentTierAxis" xlink:label="loc_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:to="loc_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementbyPaymentTierDomain" xlink:label="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:to="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53_default" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementbyPaymentTierDomain" xlink:label="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:to="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_TierOneMember" xlink:label="loc_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:to="loc_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_TierTwoMember" xlink:label="loc_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:to="loc_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:to="loc_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CreditAgreementMember" xlink:label="loc_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:to="loc_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementMember" xlink:label="loc_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:to="loc_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:to="loc_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:to="loc_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:to="loc_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorLoansMember" xlink:label="loc_us-gaap_SeniorLoansMember_8EEF31F98D53609661B1F21FE36CCA32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674" xlink:to="loc_us-gaap_SeniorLoansMember_8EEF31F98D53609661B1F21FE36CCA32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81A5451D1FB027175816F21FE36C69B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81A5451D1FB027175816F21FE36C69B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_13F988D1C5934EE81050F21FE36D4EDB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_13F988D1C5934EE81050F21FE36D4EDB" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DebtInstrumentVariableRateBasisBaseRate" xlink:label="loc_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0DDBBCF7139CEB5ECEA7F21FE36D5B84" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0DDBBCF7139CEB5ECEA7F21FE36D5B84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53AA0BD27CDE104E86A7F21FE36DEEFE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53AA0BD27CDE104E86A7F21FE36DEEFE" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementPaymentTierThreshold" xlink:label="loc_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyPaymentsPercentageofRevenue" xlink:label="loc_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_2ADC4291B13BA2C94C5CF21FE36EC031" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_RepaymentsOfDebt_2ADC4291B13BA2C94C5CF21FE36EC031" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentofAccruedInterestDebt" xlink:label="loc_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_1BBF24202D6DE06F399CF21FE36E5B37" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_1BBF24202D6DE06F399CF21FE36E5B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_9446B0B4AE3CA9673BCFF21FE36E7160" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_9446B0B4AE3CA9673BCFF21FE36E7160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_8D8D8C863BE4A6985D67F21FE36E6BFD" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_8D8D8C863BE4A6985D67F21FE36E6BFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_265B2987106B44FF4340F21FE36EAB41" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_265B2987106B44FF4340F21FE36EAB41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_FC1662A75FD56C6BDBB5F21FE36F1318" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_LongTermDebt_FC1662A75FD56C6BDBB5F21FE36F1318" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B647B280890E3496FE2B77D8C7236214" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B647B280890E3496FE2B77D8C7236214" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B647B280890E3496FE2B77D8C7236214" xlink:to="loc_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:to="loc_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:to="loc_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_A2018EmployeeStockPurchasePlanMember" xlink:label="loc_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C" xlink:to="loc_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6F0D6F07E5460D59DB2877D8C72789E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B647B280890E3496FE2B77D8C7236214" xlink:to="loc_us-gaap_AwardTypeAxis_6F0D6F07E5460D59DB2877D8C72789E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6F0D6F07E5460D59DB2877D8C72789E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6F0D6F07E5460D59DB2877D8C72789E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A06C1F67AA710F05ECED77D8C727D872" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_A06C1F67AA710F05ECED77D8C727D872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7D86B626B5F73F7FE9BB77D8C727608D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7D86B626B5F73F7FE9BB77D8C727608D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1E385D4EFB72C062C84F77D8C7277D6C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B" xlink:to="loc_us-gaap_EmployeeStockMember_1E385D4EFB72C062C84F77D8C7277D6C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_642540B7A3EF308F036977D8C7275F31" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_642540B7A3EF308F036977D8C7275F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2C7A238F036D1BED983977D8C7271CF1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2C7A238F036D1BED983977D8C7271CF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9748368742DD91618B3777D8C727D0C9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9748368742DD91618B3777D8C727D0C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C74A240530DD3AFAE87677D8C727C1FD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C74A240530DD3AFAE87677D8C727C1FD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ReversalOfStockBasedCompensationExpense" xlink:label="loc_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A45AC792A283A025F6A077D8C7277470" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A45AC792A283A025F6A077D8C7277470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5F16D44B87D1CDA368AB77D8C72B207D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5F16D44B87D1CDA368AB77D8C72B207D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1DF9B2D252E17FE188EC78E6299192D9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1DF9B2D252E17FE188EC78E6299192D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_DB0BB48FD5871BBE189777D8C72B5D8F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_DB0BB48FD5871BBE189777D8C72B5D8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E13637F335E3281C79E877D8C72BA8CA" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E13637F335E3281C79E877D8C72BA8CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9D861A5BFE515060168A77D8C72B46CE" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9D861A5BFE515060168A77D8C72B46CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_794D0AC71D04B36F23FA77D8C72B3D55" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_794D0AC71D04B36F23FA77D8C72B3D55" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CommonStockSubjecttoRepurchaseorCancellation" xlink:label="loc_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" xlink:label="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_E00B1F03347718C0191977D8C72B4407" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_E00B1F03347718C0191977D8C72B4407" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:to="loc_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_505FC60AAFD5F09D609788B6E705070E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_505FC60AAFD5F09D609788B6E705070E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80126A9A121E92A905CB88B6E706EA31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80126A9A121E92A905CB88B6E706EA31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C2E333DD904C180FECCD88B6E7066778" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C2E333DD904C180FECCD88B6E7066778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_892D8C7C0D38D553118488B6E706D93D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_892D8C7C0D38D553118488B6E706D93D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355331D75890FF2F06D88B6E7062141" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355331D75890FF2F06D88B6E7062141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60D0C47AF85BF07071B188D443BFF0D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60D0C47AF85BF07071B188D443BFF0D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E94F37C450ED1243A5BF88D1070A9841" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E94F37C450ED1243A5BF88D1070A9841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30BDA54E64C9D5DB7C7888D10718440B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30BDA54E64C9D5DB7C7888D10718440B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2FD472C29ECCA28067DE88D1072716D3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2FD472C29ECCA28067DE88D1072716D3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4B003154F11D579E520D49BC42AF94E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D7D1060EA7E79E11CA1DD49BC428C130" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4B003154F11D579E520D49BC42AF94E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D7D1060EA7E79E11CA1DD49BC428C130" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B2555C577F9853BC845ED49BC428E6F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D7D1060EA7E79E11CA1DD49BC428C130" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B2555C577F9853BC845ED49BC428E6F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B2555C577F9853BC845ED49BC428E6F5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B2555C577F9853BC845ED49BC428E6F5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PrecisionOncologyTestingMember" xlink:label="loc_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:to="loc_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_921771769F7D408C8E06D49BC429463C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_921771769F7D408C8E06D49BC429463C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_83FFE9F3B5BA95B34CC1D49BC4294EEA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_83FFE9F3B5BA95B34CC1D49BC4294EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_02815E167CEBE3F6C27FD49BC4295243" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_02815E167CEBE3F6C27FD49BC4295243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_26DA9B1A2ACE0443957DD49BC42A7181" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4B003154F11D579E520D49BC42AF94E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_26DA9B1A2ACE0443957DD49BC42A7181" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CC6228EF2F990A50880F30F6CDA52AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CC6228EF2F990A50880F30F6CDA52AA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_45BD155AEEACA2D59DF1F30F6CDB655D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CC6228EF2F990A50880F30F6CDA52AA" xlink:to="loc_us-gaap_AwardTypeAxis_45BD155AEEACA2D59DF1F30F6CDB655D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6D61DAC11D4DE0F1A18CF30F6CDB6838_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_45BD155AEEACA2D59DF1F30F6CDB655D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6D61DAC11D4DE0F1A18CF30F6CDB6838_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6D61DAC11D4DE0F1A18CF30F6CDB6838" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_45BD155AEEACA2D59DF1F30F6CDB655D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6D61DAC11D4DE0F1A18CF30F6CDB6838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F30DF5E199C805BEC341F30F6CDBDFD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6D61DAC11D4DE0F1A18CF30F6CDB6838" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F30DF5E199C805BEC341F30F6CDBDFD8" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2E4C3F48B95DE2871EBAF30F6CDCF1E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2E4C3F48B95DE2871EBAF30F6CDCF1E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8E0B7DAF54DECC507E67F30F6CDC368D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8E0B7DAF54DECC507E67F30F6CDC368D" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_B8848473E59C253E6D65F30F6CDC039A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_B8848473E59C253E6D65F30F6CDC039A" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672C1F609E67873D54E5F30F6CDD7CFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672C1F609E67873D54E5F30F6CDD7CFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ECF9DCBD65614A1FB97F30F6CDE5F13" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ECF9DCBD65614A1FB97F30F6CDE5F13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11B260460BD772417390F30F6CDE68B1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11B260460BD772417390F30F6CDE68B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_342AC442107271B64C0BF30F6CDE20D8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_342AC442107271B64C0BF30F6CDE20D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03D9EB906B5646C74E25F30F6CDF1ADF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03D9EB906B5646C74E25F30F6CDF1ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26CEDBC478F5D8410941F30F6CDF182C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26CEDBC478F5D8410941F30F6CDF182C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3B9AEF7A4F7097C3FAC8F30F6CDFD7CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3B9AEF7A4F7097C3FAC8F30F6CDFD7CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F22C75C6A911F2B7E0B0F30F6CDF2CB7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F22C75C6A911F2B7E0B0F30F6CDF2CB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_C3343115CF9411A6C535F30F6CE0C851" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_C3343115CF9411A6C535F30F6CE0C851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9923499BF06DA596AA49F30F6CE0E649" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9923499BF06DA596AA49F30F6CE0E649" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_C8590AA99069DE479FF5F30F6CE07EF8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_C8590AA99069DE479FF5F30F6CE07EF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ED284325E1F9F75FDACF30F6CE0BA3A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ED284325E1F9F75FDACF30F6CE0BA3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_782B47BBA443B5127951F30F6CE01B68" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_782B47BBA443B5127951F30F6CE01B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D208E0654D340722B6A9F30F6CE1BBF4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D208E0654D340722B6A9F30F6CE1BBF4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_924D3E57A4D8CEEB4F8187BA55A11D67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_924D3E57A4D8CEEB4F8187BA55A11D67" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8E1FF74D5B2C3B31878C87BA55A185C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_924D3E57A4D8CEEB4F8187BA55A11D67" xlink:to="loc_us-gaap_AwardTypeAxis_8E1FF74D5B2C3B31878C87BA55A185C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93C7D6FBB8D65C17893287BA55A1CD1A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8E1FF74D5B2C3B31878C87BA55A185C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93C7D6FBB8D65C17893287BA55A1CD1A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93C7D6FBB8D65C17893287BA55A1CD1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8E1FF74D5B2C3B31878C87BA55A185C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93C7D6FBB8D65C17893287BA55A1CD1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_E731FA1F2C804D489B4B87BA55A22B76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93C7D6FBB8D65C17893287BA55A1CD1A" xlink:to="loc_us-gaap_EmployeeStockMember_E731FA1F2C804D489B4B87BA55A22B76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9E3289D8C94CD39A870587BA55A2F06E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_924D3E57A4D8CEEB4F8187BA55A11D67" xlink:to="loc_srt_RangeAxis_9E3289D8C94CD39A870587BA55A2F06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DA4976FA0D50C126563F87BA55A2AF4F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9E3289D8C94CD39A870587BA55A2F06E" xlink:to="loc_srt_RangeMember_DA4976FA0D50C126563F87BA55A2AF4F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DA4976FA0D50C126563F87BA55A2AF4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9E3289D8C94CD39A870587BA55A2F06E" xlink:to="loc_srt_RangeMember_DA4976FA0D50C126563F87BA55A2AF4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C773E5EDDE9F0258176787BA55A22143" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_DA4976FA0D50C126563F87BA55A2AF4F" xlink:to="loc_srt_MinimumMember_C773E5EDDE9F0258176787BA55A22143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C92AF6987724FC8BB25C87BA55A3D89A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_DA4976FA0D50C126563F87BA55A2AF4F" xlink:to="loc_srt_MaximumMember_C92AF6987724FC8BB25C87BA55A3D89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_09E0E359E0B45C56C23087BA55A34F16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_09E0E359E0B45C56C23087BA55A34F16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75E27C994FFD4438257587BA55A3A2A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75E27C994FFD4438257587BA55A3A2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A9794B0B90DC8EED9EB87BA55A385A0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A9794B0B90DC8EED9EB87BA55A385A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D2A32F396194A361D6B87BA55A3D67E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D2A32F396194A361D6B87BA55A3D67E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D33C7AC71FE30398EAAA87BA55B2007B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D33C7AC71FE30398EAAA87BA55B2007B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_0FDAD97D97916EF84BDE87BA55B28F5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D33C7AC71FE30398EAAA87BA55B2007B" xlink:to="loc_srt_RangeAxis_0FDAD97D97916EF84BDE87BA55B28F5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C5E467700BB61351050587BA55B3FCF0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0FDAD97D97916EF84BDE87BA55B28F5D" xlink:to="loc_srt_RangeMember_C5E467700BB61351050587BA55B3FCF0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C5E467700BB61351050587BA55B3FCF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0FDAD97D97916EF84BDE87BA55B28F5D" xlink:to="loc_srt_RangeMember_C5E467700BB61351050587BA55B3FCF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_105432715F6FA0CAA17E87BA55B33384" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_C5E467700BB61351050587BA55B3FCF0" xlink:to="loc_srt_MinimumMember_105432715F6FA0CAA17E87BA55B33384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_09D6BED58F9E4EE9F3E687BA55B3EFFE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_C5E467700BB61351050587BA55B3FCF0" xlink:to="loc_srt_MaximumMember_09D6BED58F9E4EE9F3E687BA55B3EFFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6EEBA1E38FD3CCBD10F287BA55B3F4A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D33C7AC71FE30398EAAA87BA55B2007B" xlink:to="loc_us-gaap_AwardTypeAxis_6EEBA1E38FD3CCBD10F287BA55B3F4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E8E0F2B1D36E8DC8BBF87BA55B4D71B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6EEBA1E38FD3CCBD10F287BA55B3F4A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E8E0F2B1D36E8DC8BBF87BA55B4D71B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E8E0F2B1D36E8DC8BBF87BA55B4D71B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6EEBA1E38FD3CCBD10F287BA55B3F4A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E8E0F2B1D36E8DC8BBF87BA55B4D71B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_DFF008156CD00E36BA7287BA55B42D3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E8E0F2B1D36E8DC8BBF87BA55B4D71B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_DFF008156CD00E36BA7287BA55B42D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0D3C8CBD596F4B03C74A87BA55B434AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0D3C8CBD596F4B03C74A87BA55B434AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_029B22A09317AB5DF4CA87BA55B53ADB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_029B22A09317AB5DF4CA87BA55B53ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6DE327D2C9CD150BD23087BA55B59CE3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6DE327D2C9CD150BD23087BA55B59CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D2F875BC0CBCA575089387BA55B5C1C3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D2F875BC0CBCA575089387BA55B5C1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2A3F526B39717377D35F87BA55B5F57A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2A3F526B39717377D35F87BA55B5F57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D947249A581CE2AF9AF287BA55B57E4F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D947249A581CE2AF9AF287BA55B57E4F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:to="loc_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:to="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:to="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ClinicalCustomersMember" xlink:label="loc_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:to="loc_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BiopharmaceuticalCustomersMember" xlink:label="loc_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:to="loc_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_49421ACCB184F61821E191EAA8D499B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_49421ACCB184F61821E191EAA8D499B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9CEBC81FB731E962B09D91EAA8D4F126" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9CEBC81FB731E962B09D91EAA8D4F126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_ED38C8357C2792EB51FF91EAA8D5A287" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_ED38C8357C2792EB51FF91EAA8D5A287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9E1622E32A5DE16B69C691EAA8D5FB89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9E1622E32A5DE16B69C691EAA8D5FB89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_376B03A6AA1CE6F6DEC791EAA8D52A14" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_376B03A6AA1CE6F6DEC791EAA8D52A14" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromPrecisionOncologyTesting" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:to="loc_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromDevelopmentServices" xlink:label="loc_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:to="loc_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_670424C64A727AB0D2D691CCCCFDD655" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_670424C64A727AB0D2D691CCCCFDD655" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_94A1410F24AAB761CD1691CCCCFE169E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_670424C64A727AB0D2D691CCCCFDD655" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_94A1410F24AAB761CD1691CCCCFE169E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_94A1410F24AAB761CD1691CCCCFE169E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_670424C64A727AB0D2D691CCCCFDD655" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_94A1410F24AAB761CD1691CCCCFE169E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_AEDEA7D05DEDE682586291CCCCFE36DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_94A1410F24AAB761CD1691CCCCFE169E" xlink:to="loc_us-gaap_OtherAssetsMember_AEDEA7D05DEDE682586291CCCCFE36DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8B87C76DF03787AB495791CCCCFEA2D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="loc_srt_RangeAxis_8B87C76DF03787AB495791CCCCFEA2D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_573F787C30EA44D2E02691CCCCFE1846_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8B87C76DF03787AB495791CCCCFEA2D7" xlink:to="loc_srt_RangeMember_573F787C30EA44D2E02691CCCCFE1846_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_573F787C30EA44D2E02691CCCCFE1846" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8B87C76DF03787AB495791CCCCFEA2D7" xlink:to="loc_srt_RangeMember_573F787C30EA44D2E02691CCCCFE1846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_BBCF5665DF48DCC1C37091CCCCFE9166" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_573F787C30EA44D2E02691CCCCFE1846" xlink:to="loc_srt_MinimumMember_BBCF5665DF48DCC1C37091CCCCFE9166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FAD0A78FA7ADEB2FF03791CCCD0495F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_573F787C30EA44D2E02691CCCCFE1846" xlink:to="loc_srt_MaximumMember_FAD0A78FA7ADEB2FF03791CCCD0495F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_78B0F541B4052F814B5B91CCCD055DF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168" xlink:to="loc_us-gaap_CollaborativeArrangementMember_78B0F541B4052F814B5B91CCCD055DF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68E2BA235AB7C15F192A91CCCD056047" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68E2BA235AB7C15F192A91CCCD056047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_319E13C2939622815F0891CCCD055610_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68E2BA235AB7C15F192A91CCCD056047" xlink:to="loc_us-gaap_TypeOfAdoptionMember_319E13C2939622815F0891CCCD055610_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_319E13C2939622815F0891CCCD055610" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68E2BA235AB7C15F192A91CCCD056047" xlink:to="loc_us-gaap_TypeOfAdoptionMember_319E13C2939622815F0891CCCD055610" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AccountingStandardsUpdate201807Member" xlink:label="loc_gh_AccountingStandardsUpdate201807Member_F86C199B0D0CAF69C56991CCCD05218F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_319E13C2939622815F0891CCCD055610" xlink:to="loc_gh_AccountingStandardsUpdate201807Member_F86C199B0D0CAF69C56991CCCD05218F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EC6B5830230BC87AE90091CCCD05F268" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_EC6B5830230BC87AE90091CCCD05F268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_41F674631901741CDF2891CCCD0667EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EC6B5830230BC87AE90091CCCD05F268" xlink:to="loc_us-gaap_EquityComponentDomain_41F674631901741CDF2891CCCD0667EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_41F674631901741CDF2891CCCD0667EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EC6B5830230BC87AE90091CCCD05F268" xlink:to="loc_us-gaap_EquityComponentDomain_41F674631901741CDF2891CCCD0667EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_D6D3C8E80165E000005B91CCCD06C95A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_41F674631901741CDF2891CCCD0667EF" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_D6D3C8E80165E000005B91CCCD06C95A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_111763676412976DEED591CCCD0682AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_41F674631901741CDF2891CCCD0667EF" xlink:to="loc_us-gaap_RetainedEarningsMember_111763676412976DEED591CCCD0682AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_F807002154CF6DF07AAB91CCCD071E06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_RestrictedCash_F807002154CF6DF07AAB91CCCD071E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9932F5096BB288BCE68591CCCD07529A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9932F5096BB288BCE68591CCCD07529A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_F6642C73CE6C17C4980D91CCCD07D9C5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_F6642C73CE6C17C4980D91CCCD07D9C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_6CFFE234AE0873759C7691CCCD071F3C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_AdvertisingExpense_6CFFE234AE0873759C7691CCCD071F3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5320F85A8C33FA3FEC0591CCCD07B1FE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5320F85A8C33FA3FEC0591CCCD07B1FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8C604EB7ABBF3B6CDBD591CCCD08FD5B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8C604EB7ABBF3B6CDBD591CCCD08FD5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2439493CD703F9DDC58D91CCCD084778" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2439493CD703F9DDC58D91CCCD084778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2DFF7A15F827A446A5A691CCCD08CB41" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2DFF7A15F827A446A5A691CCCD08CB41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_5535D212A9F49B55669B91CCCD08B5DF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_DeferredOfferingCosts_5535D212A9F49B55669B91CCCD08B5DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_28EBFC15D8335DB179E191CCCD082131" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_28EBFC15D8335DB179E191CCCD082131" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_2F461391F7E7510A17CB91CCCD085D03" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_OperatingLeaseLiability_2F461391F7E7510A17CB91CCCD085D03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D6EA4A91B45ACE263B0091CCCD08AF9A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D6EA4A91B45ACE263B0091CCCD08AF9A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_86EDB6CD2D7352E3512F78555394383B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_86EDB6CD2D7352E3512F78555394383B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_2B90C77941F02D58C320785439E86014" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_2B90C77941F02D58C320785439E86014" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_1ACDB1075B9E8D5CA4177854B6EA0A57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_1ACDB1075B9E8D5CA4177854B6EA0A57" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821" xlink:to="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_178431280B3B4EB3645791CCCCA625C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:to="loc_srt_MajorCustomersAxis_178431280B3B4EB3645791CCCCA625C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_178431280B3B4EB3645791CCCCA625C1" xlink:to="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_178431280B3B4EB3645791CCCCA625C1" xlink:to="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerAMember" xlink:label="loc_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:to="loc_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerBMember" xlink:label="loc_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:to="loc_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerCMember" xlink:label="loc_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:to="loc_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerDMember" xlink:label="loc_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:to="loc_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_CCDCB12EEECBD8AC2EF891CCCCA9D38E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_CCDCB12EEECBD8AC2EF891CCCCA9D38E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4DE79A263B8F12083B3491CCCCA9B81C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_CCDCB12EEECBD8AC2EF891CCCCA9D38E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4DE79A263B8F12083B3491CCCCA9B81C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4DE79A263B8F12083B3491CCCCA9B81C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_CCDCB12EEECBD8AC2EF891CCCCA9D38E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4DE79A263B8F12083B3491CCCCA9B81C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_C2F59F075B9FBA4F2A6491CCCCAA0FA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4DE79A263B8F12083B3491CCCCA9B81C" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_C2F59F075B9FBA4F2A6491CCCCAA0FA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_B7DDFCB64FF54414F4C291CCCCAA064B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:to="loc_us-gaap_SalesRevenueNetMember_B7DDFCB64FF54414F4C291CCCCAA064B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_6A2415853D93C0653C2291CCCCAB5560" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:to="loc_us-gaap_AccountsReceivableMember_6A2415853D93C0653C2291CCCCAB5560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_FC1657B19B6FB33A5FA791CCCCAB5929" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_FC1657B19B6FB33A5FA791CCCCAB5929" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_56A4709061792EC86C58A9FD95613F4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_56A4709061792EC86C58A9FD95613F4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6C9B885398938D1D1054A9FD9561A243" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6C9B885398938D1D1054A9FD9561A243" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ComputerEquipmentandSoftwareMember" xlink:label="loc_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:to="loc_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:to="loc_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:to="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:to="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_E588EE35EF8AC65ABA8BA9FD95628409" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:to="loc_srt_MinimumMember_E588EE35EF8AC65ABA8BA9FD95628409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_DEA2F184F458E1A3FD79A9FD95627AA5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:to="loc_srt_MaximumMember_DEA2F184F458E1A3FD79A9FD95627AA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C918A47ED619F22194CAA9FD95635041" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C918A47ED619F22194CAA9FD95635041" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/Tables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/Warrants" xlink:type="extended" />
  <link:definitionLink xlink:role="http://guardanthealth.com/role/WarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:to="loc_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:to="loc_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9C83113DC61F6379BAC777D8C74CE534" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933" xlink:to="loc_us-gaap_CommonStockMember_9C83113DC61F6379BAC777D8C74CE534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:to="loc_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesBConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:to="loc_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7032F04BEF587B9F6EA177D8C74CEF66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7032F04BEF587B9F6EA177D8C74CEF66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A15ABD1320A9DB0B8FF377D8C750BF67" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A15ABD1320A9DB0B8FF377D8C750BF67" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_B3A3A74517783EB5F5DA77D8C7505E24" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_B3A3A74517783EB5F5DA77D8C7505E24" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO" xlink:label="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>gh-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0053E0C94B9A2A211E645A2FE038309D_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0053E0C94B9A2A211E645A2FE038309D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0053E0C94B9A2A211E645A2FE038309D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0053E0C94B9A2A211E645A2FE038309D" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0053E0C94B9A2A211E645A2FE038309D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_41EF2E59DAF5B77638BD5A2FE0388E4A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_41EF2E59DAF5B77638BD5A2FE0388E4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_41EF2E59DAF5B77638BD5A2FE0388E4A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_41EF2E59DAF5B77638BD5A2FE0388E4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_41EF2E59DAF5B77638BD5A2FE0388E4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_41EF2E59DAF5B77638BD5A2FE0388E4A" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_41EF2E59DAF5B77638BD5A2FE0388E4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_BDC5C2F106312E3EB6AC5A2FE039EE8E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_BDC5C2F106312E3EB6AC5A2FE039EE8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_BDC5C2F106312E3EB6AC5A2FE039EE8E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_BDC5C2F106312E3EB6AC5A2FE039EE8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_BDC5C2F106312E3EB6AC5A2FE039EE8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_BDC5C2F106312E3EB6AC5A2FE039EE8E" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_BDC5C2F106312E3EB6AC5A2FE039EE8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_197077C5114C0EF07C505A2FE039ABBB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_197077C5114C0EF07C505A2FE039ABBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_197077C5114C0EF07C505A2FE039ABBB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_197077C5114C0EF07C505A2FE039ABBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_197077C5114C0EF07C505A2FE039ABBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_197077C5114C0EF07C505A2FE039ABBB" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_197077C5114C0EF07C505A2FE039ABBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C514D2A22CF78251CDC25A2FE0395E8C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C514D2A22CF78251CDC25A2FE0395E8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C514D2A22CF78251CDC25A2FE0395E8C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C514D2A22CF78251CDC25A2FE0395E8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C514D2A22CF78251CDC25A2FE0395E8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C514D2A22CF78251CDC25A2FE0395E8C" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C514D2A22CF78251CDC25A2FE0395E8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C03C9E073CD22A252A845A2FE039CC40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C03C9E073CD22A252A845A2FE039CC40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Purchase Plan Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C03C9E073CD22A252A845A2FE039CC40_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C03C9E073CD22A252A845A2FE039CC40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C03C9E073CD22A252A845A2FE039CC40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C03C9E073CD22A252A845A2FE039CC40" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C03C9E073CD22A252A845A2FE039CC40" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_271EAB18E2E84B935C8587BA56372072_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_271EAB18E2E84B935C8587BA56372072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_271EAB18E2E84B935C8587BA56372072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_271EAB18E2E84B935C8587BA56372072" xlink:to="lab_us-gaap_EquityAbstract_271EAB18E2E84B935C8587BA56372072" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9B996DF099BD899E488B87BA5637DAFC_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9B996DF099BD899E488B87BA5637DAFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9B996DF099BD899E488B87BA5637DAFC_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9B996DF099BD899E488B87BA5637DAFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9B996DF099BD899E488B87BA5637DAFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9B996DF099BD899E488B87BA5637DAFC" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9B996DF099BD899E488B87BA5637DAFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_F420056B99808E533DA0983D44A8094F_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_F420056B99808E533DA0983D44A8094F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_F420056B99808E533DA0983D44A8094F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_F420056B99808E533DA0983D44A8094F" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_F420056B99808E533DA0983D44A8094F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD_label_en-US" xlink:label="lab_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:to="lab_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:to="lab_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:to="lab_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_FC397500D3ED7C5E7B69983D44ABDBA3_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_FC397500D3ED7C5E7B69983D44ABDBA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_FC397500D3ED7C5E7B69983D44ABDBA3_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_FC397500D3ED7C5E7B69983D44ABDBA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_FC397500D3ED7C5E7B69983D44ABDBA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_FC397500D3ED7C5E7B69983D44ABDBA3" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_FC397500D3ED7C5E7B69983D44ABDBA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_7336C3F2DCC0F8846F31983D44ACB771_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_7336C3F2DCC0F8846F31983D44ACB771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_7336C3F2DCC0F8846F31983D44ACB771_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_7336C3F2DCC0F8846F31983D44ACB771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_7336C3F2DCC0F8846F31983D44ACB771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_7336C3F2DCC0F8846F31983D44ACB771" xlink:to="lab_us-gaap_CommonStockMember_7336C3F2DCC0F8846F31983D44ACB771" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="lab_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_E3BC195EDE8623BCF5F0983D44AD0FD6_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_E3BC195EDE8623BCF5F0983D44AD0FD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_E3BC195EDE8623BCF5F0983D44AD0FD6_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_E3BC195EDE8623BCF5F0983D44AD0FD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_E3BC195EDE8623BCF5F0983D44AD0FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_E3BC195EDE8623BCF5F0983D44AD0FD6" xlink:to="lab_us-gaap_ProfitLoss_E3BC195EDE8623BCF5F0983D44AD0FD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9EE4D9ACAAC542A73590983D44AD9E76_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_9EE4D9ACAAC542A73590983D44AD9E76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9EE4D9ACAAC542A73590983D44AD9E76_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_9EE4D9ACAAC542A73590983D44AD9E76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9EE4D9ACAAC542A73590983D44AD9E76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_9EE4D9ACAAC542A73590983D44AD9E76" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_9EE4D9ACAAC542A73590983D44AD9E76" xlink:type="arc" />
    <link:label id="lab_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765_terseLabel_en-US" xlink:label="lab_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of ROU</link:label>
    <link:label id="lab_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765_label_en-US" xlink:label="lab_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Right-Of-Use Assets</link:label>
    <link:label id="lab_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765_documentation_en-US" xlink:label="lab_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Of Right-Of-Use Assets</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_AmortizationOfRightOfUseAssets" xlink:label="loc_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765" xlink:to="lab_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765" xlink:type="arc" />
    <link:label id="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443_negatedTerseLabel_en-US" xlink:label="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized translation (gains) losses on obligation related to royalty</link:label>
    <link:label id="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443_label_en-US" xlink:label="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Translations Gain (Loss) On Obligation Related To Royalty</link:label>
    <link:label id="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443_documentation_en-US" xlink:label="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrealized Translations Gain (Loss) On Obligation Related To Royalty</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" xlink:label="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443" xlink:to="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_84408EC72C2733928836983D44AEE5CB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_84408EC72C2733928836983D44AEE5CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Re-valuation of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_84408EC72C2733928836983D44AEE5CB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_84408EC72C2733928836983D44AEE5CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_84408EC72C2733928836983D44AEE5CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_84408EC72C2733928836983D44AEE5CB" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_84408EC72C2733928836983D44AEE5CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_48F94E26528D33212EC5983D44AEC9CD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_48F94E26528D33212EC5983D44AEC9CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_48F94E26528D33212EC5983D44AEC9CD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_48F94E26528D33212EC5983D44AEC9CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_48F94E26528D33212EC5983D44AEC9CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_48F94E26528D33212EC5983D44AEC9CD" xlink:to="lab_us-gaap_ShareBasedCompensation_48F94E26528D33212EC5983D44AEC9CD" xlink:type="arc" />
    <link:label id="lab_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0_negatedTerseLabel_en-US" xlink:label="lab_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0_label_en-US" xlink:label="lab_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Interest Expense Paid</link:label>
    <link:label id="lab_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0_documentation_en-US" xlink:label="lab_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Interest Expense Paid</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_NoncashInterestExpensePaid" xlink:label="loc_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0" xlink:to="lab_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5CB6D2E5A897EE01A0F983D44AE9957_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5CB6D2E5A897EE01A0F983D44AE9957" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5CB6D2E5A897EE01A0F983D44AE9957_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5CB6D2E5A897EE01A0F983D44AE9957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5CB6D2E5A897EE01A0F983D44AE9957" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5CB6D2E5A897EE01A0F983D44AE9957" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5CB6D2E5A897EE01A0F983D44AE9957" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_208EB62808C163F9149E983D44AF37E1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_208EB62808C163F9149E983D44AF37E1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of premium (discount) on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_208EB62808C163F9149E983D44AF37E1_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_208EB62808C163F9149E983D44AF37E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_208EB62808C163F9149E983D44AF37E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_208EB62808C163F9149E983D44AF37E1" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_208EB62808C163F9149E983D44AF37E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_409BC0F464675CCD5909983D44AF1C1A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments_409BC0F464675CCD5909983D44AF1C1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit from income tax differences</link:label>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_409BC0F464675CCD5909983D44AF1C1A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments_409BC0F464675CCD5909983D44AF1C1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Credits and Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_409BC0F464675CCD5909983D44AF1C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxCreditsAndAdjustments_409BC0F464675CCD5909983D44AF1C1A" xlink:to="lab_us-gaap_IncomeTaxCreditsAndAdjustments_409BC0F464675CCD5909983D44AF1C1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_73F385DC68FEB63991E7983D44AF9AA8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_73F385DC68FEB63991E7983D44AF9AA8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_73F385DC68FEB63991E7983D44AF9AA8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_73F385DC68FEB63991E7983D44AF9AA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73F385DC68FEB63991E7983D44AF9AA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73F385DC68FEB63991E7983D44AF9AA8" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_73F385DC68FEB63991E7983D44AF9AA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4F473823727057C1FE28983D44AFFD34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4F473823727057C1FE28983D44AFFD34" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4F473823727057C1FE28983D44AFFD34_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4F473823727057C1FE28983D44AFFD34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4F473823727057C1FE28983D44AFFD34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_4F473823727057C1FE28983D44AFFD34" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_4F473823727057C1FE28983D44AFFD34" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D576EE1607EC86F8FE98983D44B05E8F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D576EE1607EC86F8FE98983D44B05E8F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D576EE1607EC86F8FE98983D44B05E8F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D576EE1607EC86F8FE98983D44B05E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D576EE1607EC86F8FE98983D44B05E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D576EE1607EC86F8FE98983D44B05E8F" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D576EE1607EC86F8FE98983D44B05E8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7B2D8F92D24170CB165E983D44B0B2B7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7B2D8F92D24170CB165E983D44B0B2B7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7B2D8F92D24170CB165E983D44B0B2B7_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7B2D8F92D24170CB165E983D44B0B2B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7B2D8F92D24170CB165E983D44B0B2B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7B2D8F92D24170CB165E983D44B0B2B7" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7B2D8F92D24170CB165E983D44B0B2B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_34AF78B59CA847ED9336983D44B00FFF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_34AF78B59CA847ED9336983D44B00FFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_34AF78B59CA847ED9336983D44B00FFF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_34AF78B59CA847ED9336983D44B00FFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34AF78B59CA847ED9336983D44B00FFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34AF78B59CA847ED9336983D44B00FFF" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_34AF78B59CA847ED9336983D44B00FFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0C4CD6D19F6629BF9F07983D44B09186_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0C4CD6D19F6629BF9F07983D44B09186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0C4CD6D19F6629BF9F07983D44B09186_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0C4CD6D19F6629BF9F07983D44B09186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0C4CD6D19F6629BF9F07983D44B09186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0C4CD6D19F6629BF9F07983D44B09186" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0C4CD6D19F6629BF9F07983D44B09186" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2508C9B47213468802CF983D44B0CBB2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2508C9B47213468802CF983D44B0CBB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2508C9B47213468802CF983D44B0CBB2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2508C9B47213468802CF983D44B0CBB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2508C9B47213468802CF983D44B0CBB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2508C9B47213468802CF983D44B0CBB2" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2508C9B47213468802CF983D44B0CBB2" xlink:type="arc" />
    <link:label id="lab_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658_terseLabel_en-US" xlink:label="lab_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities net of ROU</link:label>
    <link:label id="lab_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658_label_en-US" xlink:label="lab_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Operating Lease Liabilities Net Of Right Of Use Assets</link:label>
    <link:label id="lab_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658_documentation_en-US" xlink:label="lab_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Operating Lease Liabilities Net Of Right Of Use Assets</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets" xlink:label="loc_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658" xlink:to="lab_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_04782B15751F3C8CD0D5983D44B12746_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges_04782B15751F3C8CD0D5983D44B12746" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_04782B15751F3C8CD0D5983D44B12746_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges_04782B15751F3C8CD0D5983D44B12746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_04782B15751F3C8CD0D5983D44B12746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredCharges_04782B15751F3C8CD0D5983D44B12746" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredCharges_04782B15751F3C8CD0D5983D44B12746" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_BF1AEB30EDD2C774E446983D44B134B1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_BF1AEB30EDD2C774E446983D44B134B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_BF1AEB30EDD2C774E446983D44B134B1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_BF1AEB30EDD2C774E446983D44B134B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_BF1AEB30EDD2C774E446983D44B134B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_BF1AEB30EDD2C774E446983D44B134B1" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_BF1AEB30EDD2C774E446983D44B134B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_AF901780CCB0F8A369BB983D44B1090F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_AF901780CCB0F8A369BB983D44B1090F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_AF901780CCB0F8A369BB983D44B1090F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_AF901780CCB0F8A369BB983D44B1090F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_AF901780CCB0F8A369BB983D44B1090F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_AF901780CCB0F8A369BB983D44B1090F" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_AF901780CCB0F8A369BB983D44B1090F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DC29E07C5961122C69F3983D44B19D26_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DC29E07C5961122C69F3983D44B19D26" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DC29E07C5961122C69F3983D44B19D26_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DC29E07C5961122C69F3983D44B19D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DC29E07C5961122C69F3983D44B19D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DC29E07C5961122C69F3983D44B19D26" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DC29E07C5961122C69F3983D44B19D26" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_5D4A7CC9A5C0D32BE4F0983D44B2E65F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_5D4A7CC9A5C0D32BE4F0983D44B2E65F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_5D4A7CC9A5C0D32BE4F0983D44B2E65F_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_5D4A7CC9A5C0D32BE4F0983D44B2E65F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5D4A7CC9A5C0D32BE4F0983D44B2E65F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5D4A7CC9A5C0D32BE4F0983D44B2E65F" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_5D4A7CC9A5C0D32BE4F0983D44B2E65F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_904A0F36E74FBB8EC3E9983D44B20D32_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_904A0F36E74FBB8EC3E9983D44B20D32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_904A0F36E74FBB8EC3E9983D44B20D32_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_904A0F36E74FBB8EC3E9983D44B20D32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_904A0F36E74FBB8EC3E9983D44B20D32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_904A0F36E74FBB8EC3E9983D44B20D32" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_904A0F36E74FBB8EC3E9983D44B20D32" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9A52936F737047B485D6983D44B24E13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9A52936F737047B485D6983D44B24E13" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9A52936F737047B485D6983D44B24E13_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9A52936F737047B485D6983D44B24E13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9A52936F737047B485D6983D44B24E13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9A52936F737047B485D6983D44B24E13" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9A52936F737047B485D6983D44B24E13" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99A263E2766936E7E120983D44B2DF92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99A263E2766936E7E120983D44B2DF92" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99A263E2766936E7E120983D44B2DF92_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99A263E2766936E7E120983D44B2DF92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99A263E2766936E7E120983D44B2DF92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99A263E2766936E7E120983D44B2DF92" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99A263E2766936E7E120983D44B2DF92" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7DA34CB5B66A13F7870E983D44B2D0C7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7DA34CB5B66A13F7870E983D44B2D0C7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets and capitalized license obligations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7DA34CB5B66A13F7870E983D44B2D0C7_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7DA34CB5B66A13F7870E983D44B2D0C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7DA34CB5B66A13F7870E983D44B2D0C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7DA34CB5B66A13F7870E983D44B2D0C7" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7DA34CB5B66A13F7870E983D44B2D0C7" xlink:type="arc" />
    <link:label id="lab_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777_negatedLabel_en-US" xlink:label="lab_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment in connection with a license agreement</link:label>
    <link:label id="lab_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777_label_en-US" xlink:label="lab_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments In Connection With License Agreements</link:label>
    <link:label id="lab_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777_documentation_en-US" xlink:label="lab_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments In Connection With License Agreements</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentsInConnectionWithLicenseAgreements" xlink:label="loc_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777" xlink:to="lab_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_877165C7B1608D773C52983D44B3CE40_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_877165C7B1608D773C52983D44B3CE40" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_877165C7B1608D773C52983D44B3CE40_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_877165C7B1608D773C52983D44B3CE40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_877165C7B1608D773C52983D44B3CE40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_877165C7B1608D773C52983D44B3CE40" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_877165C7B1608D773C52983D44B3CE40" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:type="arc" />
    <link:label id="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92_negatedTerseLabel_en-US" xlink:label="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment related to settlement of debt and buyout of royalty obligations</link:label>
    <link:label id="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92_label_en-US" xlink:label="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Related to Settlement of Debt and Buyout of Royalty Obligations</link:label>
    <link:label id="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92_documentation_en-US" xlink:label="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Related to Settlement of Debt and Buyout of Royalty Obligations</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" xlink:label="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92" xlink:to="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_33F7BD77213F72B211FC983D44B39269_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_33F7BD77213F72B211FC983D44B39269" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments made on capital lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_33F7BD77213F72B211FC983D44B39269_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_33F7BD77213F72B211FC983D44B39269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_33F7BD77213F72B211FC983D44B39269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_33F7BD77213F72B211FC983D44B39269" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_33F7BD77213F72B211FC983D44B39269" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7263B3FC1DF5D72F61FF983D44B3C296_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7263B3FC1DF5D72F61FF983D44B3C296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7263B3FC1DF5D72F61FF983D44B3C296_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7263B3FC1DF5D72F61FF983D44B3C296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7263B3FC1DF5D72F61FF983D44B3C296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7263B3FC1DF5D72F61FF983D44B3C296" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7263B3FC1DF5D72F61FF983D44B3C296" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_8EA5643E78A03CA96B05983D44B47820_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_8EA5643E78A03CA96B05983D44B47820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_8EA5643E78A03CA96B05983D44B47820_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_8EA5643E78A03CA96B05983D44B47820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_8EA5643E78A03CA96B05983D44B47820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_8EA5643E78A03CA96B05983D44B47820" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_8EA5643E78A03CA96B05983D44B47820" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_212D30DA03014E20970D983D44B4C773_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_212D30DA03014E20970D983D44B4C773" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_212D30DA03014E20970D983D44B4C773_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_212D30DA03014E20970D983D44B4C773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_212D30DA03014E20970D983D44B4C773" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_212D30DA03014E20970D983D44B4C773" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_212D30DA03014E20970D983D44B4C773" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_8640588B2B5E60545619983D44B45A93_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_8640588B2B5E60545619983D44B45A93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock upon the exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_8640588B2B5E60545619983D44B45A93_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_8640588B2B5E60545619983D44B45A93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8640588B2B5E60545619983D44B45A93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_8640588B2B5E60545619983D44B45A93" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_8640588B2B5E60545619983D44B45A93" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_9714F3BC5464E4A4C18E983D44B41E8F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_9714F3BC5464E4A4C18E983D44B41E8F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_9714F3BC5464E4A4C18E983D44B41E8F_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_9714F3BC5464E4A4C18E983D44B41E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_9714F3BC5464E4A4C18E983D44B41E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_9714F3BC5464E4A4C18E983D44B41E8F" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_9714F3BC5464E4A4C18E983D44B41E8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6E3D3B2734E9B6584A54983D44B4F3DA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6E3D3B2734E9B6584A54983D44B4F3DA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6E3D3B2734E9B6584A54983D44B4F3DA_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6E3D3B2734E9B6584A54983D44B4F3DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6E3D3B2734E9B6584A54983D44B4F3DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6E3D3B2734E9B6584A54983D44B4F3DA" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6E3D3B2734E9B6584A54983D44B4F3DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9AF96CDB98552A7EAA5B983D44B56193_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9AF96CDB98552A7EAA5B983D44B56193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from public offerings of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9AF96CDB98552A7EAA5B983D44B56193_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9AF96CDB98552A7EAA5B983D44B56193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9AF96CDB98552A7EAA5B983D44B56193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9AF96CDB98552A7EAA5B983D44B56193" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9AF96CDB98552A7EAA5B983D44B56193" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_4D375400A3109739E365983D44B51B08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_4D375400A3109739E365983D44B51B08" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of offering costs related to public offerings of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_4D375400A3109739E365983D44B51B08_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_4D375400A3109739E365983D44B51B08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4D375400A3109739E365983D44B51B08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_4D375400A3109739E365983D44B51B08" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_4D375400A3109739E365983D44B51B08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_B178B729D09E55717594983D44B5B0B9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders_B178B729D09E55717594983D44B5B0B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of equity interests in redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_B178B729D09E55717594983D44B5B0B9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders_B178B729D09E55717594983D44B5B0B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_B178B729D09E55717594983D44B5B0B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders_B178B729D09E55717594983D44B5B0B9" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders_B178B729D09E55717594983D44B5B0B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_292E6741495DFB73727A983D44B5F774_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_292E6741495DFB73727A983D44B5F774" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_292E6741495DFB73727A983D44B5F774_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_292E6741495DFB73727A983D44B5F774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_292E6741495DFB73727A983D44B5F774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_292E6741495DFB73727A983D44B5F774" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_292E6741495DFB73727A983D44B5F774" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_E8AD585409C99D29E53B983D44B590AC_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_E8AD585409C99D29E53B983D44B590AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_E8AD585409C99D29E53B983D44B590AC_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_E8AD585409C99D29E53B983D44B590AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_E8AD585409C99D29E53B983D44B590AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_E8AD585409C99D29E53B983D44B590AC" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_E8AD585409C99D29E53B983D44B590AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_919A78F575316DC90078983D44B5A5A0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_919A78F575316DC90078983D44B5A5A0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_919A78F575316DC90078983D44B5A5A0_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_919A78F575316DC90078983D44B5A5A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_919A78F575316DC90078983D44B5A5A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_919A78F575316DC90078983D44B5A5A0" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_919A78F575316DC90078983D44B5A5A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A925A13952AA3D51B1E4983D44B650B1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A925A13952AA3D51B1E4983D44B650B1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash - Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A925A13952AA3D51B1E4983D44B650B1_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A925A13952AA3D51B1E4983D44B650B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A925A13952AA3D51B1E4983D44B650B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A925A13952AA3D51B1E4983D44B650B1" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A925A13952AA3D51B1E4983D44B650B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C86044CE86F2F4C4703A983D44B62BFE_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C86044CE86F2F4C4703A983D44B62BFE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash - End of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C86044CE86F2F4C4703A983D44B62BFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C86044CE86F2F4C4703A983D44B62BFE" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C86044CE86F2F4C4703A983D44B62BFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D47904643C71116D8428983D44B69384_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D47904643C71116D8428983D44B69384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D47904643C71116D8428983D44B69384_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D47904643C71116D8428983D44B69384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D47904643C71116D8428983D44B69384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D47904643C71116D8428983D44B69384" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D47904643C71116D8428983D44B69384" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_ACF72AA229373D403AC2983D44B650B3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_ACF72AA229373D403AC2983D44B650B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_ACF72AA229373D403AC2983D44B650B3_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_ACF72AA229373D403AC2983D44B650B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_ACF72AA229373D403AC2983D44B650B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_ACF72AA229373D403AC2983D44B650B3" xlink:to="lab_us-gaap_InterestPaidNet_ACF72AA229373D403AC2983D44B650B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_DB632F7252C32CD94BAD983D44B70756_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_DB632F7252C32CD94BAD983D44B70756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_DB632F7252C32CD94BAD983D44B70756_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_DB632F7252C32CD94BAD983D44B70756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_DB632F7252C32CD94BAD983D44B70756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_DB632F7252C32CD94BAD983D44B70756" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_DB632F7252C32CD94BAD983D44B70756" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosures of Noncash Investing and Financing Activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:type="arc" />
    <link:label id="lab_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598_terseLabel_en-US" xlink:label="lab_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized license fees financed through future royalty payment</link:label>
    <link:label id="lab_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598_label_en-US" xlink:label="lab_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized License Fees Financed Through Future Royalty Payment</link:label>
    <link:label id="lab_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598_documentation_en-US" xlink:label="lab_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capitalized License Fees Financed Through Future Royalty Payment</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment" xlink:label="loc_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598" xlink:to="lab_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598" xlink:type="arc" />
    <link:label id="lab_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254_terseLabel_en-US" xlink:label="lab_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series D convertible preferred stock in exchange for a technology license agreement</link:label>
    <link:label id="lab_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254_label_en-US" xlink:label="lab_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Of Convertible Preferred Stock Issued In Exchange For License Agreement</link:label>
    <link:label id="lab_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254_documentation_en-US" xlink:label="lab_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value Of Convertible Preferred Stock Issued In Exchange For License Agreement</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement" xlink:label="loc_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254" xlink:to="lab_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254" xlink:type="arc" />
    <link:label id="lab_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A_terseLabel_en-US" xlink:label="lab_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A_label_en-US" xlink:label="lab_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label id="lab_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A_documentation_en-US" xlink:label="lab_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A" xlink:to="lab_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A" xlink:type="arc" />
    <link:label id="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D_verboseLabel_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting of common stock exercised early</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D_label_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised Early</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D_documentation_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised Early</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D" xlink:to="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_EF3BF0E8D071BA064020983D44B82DEC_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred_EF3BF0E8D071BA064020983D44B82DEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment acquired under capital leases</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_EF3BF0E8D071BA064020983D44B82DEC_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred_EF3BF0E8D071BA064020983D44B82DEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_EF3BF0E8D071BA064020983D44B82DEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred_EF3BF0E8D071BA064020983D44B82DEC" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred_EF3BF0E8D071BA064020983D44B82DEC" xlink:type="arc" />
    <link:label id="lab_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994_terseLabel_en-US" xlink:label="lab_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering</link:label>
    <link:label id="lab_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994_label_en-US" xlink:label="lab_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock Upon Initial Public Offering</link:label>
    <link:label id="lab_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994_documentation_en-US" xlink:label="lab_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Stock Upon Initial Public Offering</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ConversionofStockUponInitialPublicOffering" xlink:label="loc_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994" xlink:to="lab_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7FC645CCC6F1E533A7C0983D44B87447_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7FC645CCC6F1E533A7C0983D44B87447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial fair value of contingent consideration at acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7FC645CCC6F1E533A7C0983D44B87447_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7FC645CCC6F1E533A7C0983D44B87447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FC645CCC6F1E533A7C0983D44B87447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FC645CCC6F1E533A7C0983D44B87447" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7FC645CCC6F1E533A7C0983D44B87447" xlink:type="arc" />
    <link:label id="lab_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E_terseLabel_en-US" xlink:label="lab_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E_label_en-US" xlink:label="lab_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Costs Incurred but Not yet Paid</link:label>
    <link:label id="lab_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E_documentation_en-US" xlink:label="lab_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offering Costs Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_OfferingCostsIncurredbutNotyetPaid" xlink:label="loc_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E" xlink:to="lab_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_80AC59CD0B4B58349E13C97D00C498C1_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_80AC59CD0B4B58349E13C97D00C498C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_80AC59CD0B4B58349E13C97D00C498C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_80AC59CD0B4B58349E13C97D00C498C1" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_80AC59CD0B4B58349E13C97D00C498C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:to="lab_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_606E5F32E03702513E59C97D00C56795_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_606E5F32E03702513E59C97D00C56795" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_606E5F32E03702513E59C97D00C56795_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_606E5F32E03702513E59C97D00C56795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_606E5F32E03702513E59C97D00C56795" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_606E5F32E03702513E59C97D00C56795" xlink:to="lab_us-gaap_MoneyMarketFundsMember_606E5F32E03702513E59C97D00C56795" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_F8E9838876CBDCB5DC68C97D00C6AF62_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_F8E9838876CBDCB5DC68C97D00C6AF62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_F8E9838876CBDCB5DC68C97D00C6AF62_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_F8E9838876CBDCB5DC68C97D00C6AF62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_F8E9838876CBDCB5DC68C97D00C6AF62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_F8E9838876CBDCB5DC68C97D00C6AF62" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_F8E9838876CBDCB5DC68C97D00C6AF62" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_73C2B63EE3D9920C23FBC97D00C65A1A_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_73C2B63EE3D9920C23FBC97D00C65A1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government debt securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_73C2B63EE3D9920C23FBC97D00C65A1A_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_73C2B63EE3D9920C23FBC97D00C65A1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_73C2B63EE3D9920C23FBC97D00C65A1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_73C2B63EE3D9920C23FBC97D00C65A1A" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_73C2B63EE3D9920C23FBC97D00C65A1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CCE75E761AFA0BA0E0EAC97D00C65990_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CCE75E761AFA0BA0E0EAC97D00C65990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CCE75E761AFA0BA0E0EAC97D00C65990_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CCE75E761AFA0BA0E0EAC97D00C65990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CCE75E761AFA0BA0E0EAC97D00C65990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CCE75E761AFA0BA0E0EAC97D00C65990" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CCE75E761AFA0BA0E0EAC97D00C65990" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E549EBCB3E7A55C79DE0C97D00C7E6BF_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E549EBCB3E7A55C79DE0C97D00C7E6BF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E549EBCB3E7A55C79DE0C97D00C7E6BF_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E549EBCB3E7A55C79DE0C97D00C7E6BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E549EBCB3E7A55C79DE0C97D00C7E6BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E549EBCB3E7A55C79DE0C97D00C7E6BF" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E549EBCB3E7A55C79DE0C97D00C7E6BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8391E5BE3BAB8190CA83C97D00C7B206_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8391E5BE3BAB8190CA83C97D00C7B206" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost, debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8391E5BE3BAB8190CA83C97D00C7B206_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8391E5BE3BAB8190CA83C97D00C7B206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8391E5BE3BAB8190CA83C97D00C7B206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8391E5BE3BAB8190CA83C97D00C7B206" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8391E5BE3BAB8190CA83C97D00C7B206" xlink:type="arc" />
    <link:label id="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6_totalLabel_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost, cash and cash equivalents and debt securities available-for-sale</link:label>
    <link:label id="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6_label_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost</link:label>
    <link:label id="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6_documentation_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6" xlink:to="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FE28E1DA4D14F4CDF0DAC97D00C7BAAF_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FE28E1DA4D14F4CDF0DAC97D00C7BAAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FE28E1DA4D14F4CDF0DAC97D00C7BAAF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FE28E1DA4D14F4CDF0DAC97D00C7BAAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FE28E1DA4D14F4CDF0DAC97D00C7BAAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FE28E1DA4D14F4CDF0DAC97D00C7BAAF" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FE28E1DA4D14F4CDF0DAC97D00C7BAAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C2C5D2852F2E7E3BF8DC97D00C72344_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C2C5D2852F2E7E3BF8DC97D00C72344" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C2C5D2852F2E7E3BF8DC97D00C72344_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C2C5D2852F2E7E3BF8DC97D00C72344" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C2C5D2852F2E7E3BF8DC97D00C72344" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C2C5D2852F2E7E3BF8DC97D00C72344" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C2C5D2852F2E7E3BF8DC97D00C72344" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1C372FF43F1FCB711D47C97D00C840F1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1C372FF43F1FCB711D47C97D00C840F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value, Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1C372FF43F1FCB711D47C97D00C840F1_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1C372FF43F1FCB711D47C97D00C840F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1C372FF43F1FCB711D47C97D00C840F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1C372FF43F1FCB711D47C97D00C840F1" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1C372FF43F1FCB711D47C97D00C840F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F919B4123DE928932965C97D00C8E31F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F919B4123DE928932965C97D00C8E31F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value, Debt Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F919B4123DE928932965C97D00C8E31F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F919B4123DE928932965C97D00C8E31F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F919B4123DE928932965C97D00C8E31F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F919B4123DE928932965C97D00C8E31F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F919B4123DE928932965C97D00C8E31F" xlink:type="arc" />
    <link:label id="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966_terseLabel_en-US" xlink:label="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value, Cash, Cash Equivalents and Debt Securities</link:label>
    <link:label id="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966_label_en-US" xlink:label="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Debt Securities, Fair Value</link:label>
    <link:label id="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966_documentation_en-US" xlink:label="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Debt Securities, Fair Value</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966" xlink:to="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0C26F198B4775C2647897E7C29E24013_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0C26F198B4775C2647897E7C29E24013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0C26F198B4775C2647897E7C29E24013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0C26F198B4775C2647897E7C29E24013" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0C26F198B4775C2647897E7C29E24013" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax impact:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CC027E8153A65366EA9B7E7C29E37266_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CC027E8153A65366EA9B7E7C29E37266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CC027E8153A65366EA9B7E7C29E37266_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CC027E8153A65366EA9B7E7C29E37266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CC027E8153A65366EA9B7E7C29E37266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CC027E8153A65366EA9B7E7C29E37266" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CC027E8153A65366EA9B7E7C29E37266" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_762354BB20CB42792CD57E7C29E3CA0D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_762354BB20CB42792CD57E7C29E3CA0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_762354BB20CB42792CD57E7C29E3CA0D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_762354BB20CB42792CD57E7C29E3CA0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_762354BB20CB42792CD57E7C29E3CA0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_762354BB20CB42792CD57E7C29E3CA0D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_762354BB20CB42792CD57E7C29E3CA0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5E2CB5D0789BC1E66C707E7C29E3E3D2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5E2CB5D0789BC1E66C707E7C29E3E3D2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5E2CB5D0789BC1E66C707E7C29E3E3D2_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5E2CB5D0789BC1E66C707E7C29E3E3D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5E2CB5D0789BC1E66C707E7C29E3E3D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5E2CB5D0789BC1E66C707E7C29E3E3D2" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5E2CB5D0789BC1E66C707E7C29E3E3D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_163BCAA74C98B931BAA77E7C29E4464F_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_163BCAA74C98B931BAA77E7C29E4464F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_163BCAA74C98B931BAA77E7C29E4464F_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_163BCAA74C98B931BAA77E7C29E4464F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_163BCAA74C98B931BAA77E7C29E4464F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_163BCAA74C98B931BAA77E7C29E4464F" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_163BCAA74C98B931BAA77E7C29E4464F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_18D8DC449BA17CA2EB127E7C29E430BC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_18D8DC449BA17CA2EB127E7C29E430BC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_18D8DC449BA17CA2EB127E7C29E430BC_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_18D8DC449BA17CA2EB127E7C29E430BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_18D8DC449BA17CA2EB127E7C29E430BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_18D8DC449BA17CA2EB127E7C29E430BC" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_18D8DC449BA17CA2EB127E7C29E430BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5EB2E4082CEEF5D8769E7E7C29E48FFE_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_5EB2E4082CEEF5D8769E7E7C29E48FFE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Guardant Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5EB2E4082CEEF5D8769E7E7C29E48FFE_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_5EB2E4082CEEF5D8769E7E7C29E48FFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5EB2E4082CEEF5D8769E7E7C29E48FFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5EB2E4082CEEF5D8769E7E7C29E48FFE" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_5EB2E4082CEEF5D8769E7E7C29E48FFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F7BF01E13D2FA7CA6C765A2FE0972AE4_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F7BF01E13D2FA7CA6C765A2FE0972AE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F7BF01E13D2FA7CA6C765A2FE0972AE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F7BF01E13D2FA7CA6C765A2FE0972AE4" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F7BF01E13D2FA7CA6C765A2FE0972AE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69C1F2B43F8D082D7FD15A2FE0979AC6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69C1F2B43F8D082D7FD15A2FE0979AC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69C1F2B43F8D082D7FD15A2FE0979AC6_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69C1F2B43F8D082D7FD15A2FE0979AC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69C1F2B43F8D082D7FD15A2FE0979AC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69C1F2B43F8D082D7FD15A2FE0979AC6" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69C1F2B43F8D082D7FD15A2FE0979AC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:to="lab_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_505FC60AAFD5F09D609788B6E705070E_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_505FC60AAFD5F09D609788B6E705070E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_505FC60AAFD5F09D609788B6E705070E_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_505FC60AAFD5F09D609788B6E705070E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_505FC60AAFD5F09D609788B6E705070E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_505FC60AAFD5F09D609788B6E705070E" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_505FC60AAFD5F09D609788B6E705070E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80126A9A121E92A905CB88B6E706EA31_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80126A9A121E92A905CB88B6E706EA31" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80126A9A121E92A905CB88B6E706EA31_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80126A9A121E92A905CB88B6E706EA31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80126A9A121E92A905CB88B6E706EA31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80126A9A121E92A905CB88B6E706EA31" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80126A9A121E92A905CB88B6E706EA31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C2E333DD904C180FECCD88B6E7066778_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C2E333DD904C180FECCD88B6E7066778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units outstanding, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C2E333DD904C180FECCD88B6E7066778_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C2E333DD904C180FECCD88B6E7066778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C2E333DD904C180FECCD88B6E7066778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C2E333DD904C180FECCD88B6E7066778" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C2E333DD904C180FECCD88B6E7066778" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_892D8C7C0D38D553118488B6E706D93D_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_892D8C7C0D38D553118488B6E706D93D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units outstanding, vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_892D8C7C0D38D553118488B6E706D93D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_892D8C7C0D38D553118488B6E706D93D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_892D8C7C0D38D553118488B6E706D93D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_892D8C7C0D38D553118488B6E706D93D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_892D8C7C0D38D553118488B6E706D93D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355331D75890FF2F06D88B6E7062141_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355331D75890FF2F06D88B6E7062141" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units outstanding, canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355331D75890FF2F06D88B6E7062141_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355331D75890FF2F06D88B6E7062141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355331D75890FF2F06D88B6E7062141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355331D75890FF2F06D88B6E7062141" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355331D75890FF2F06D88B6E7062141" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AD221141746209EC67E88B6E706EC61_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AD221141746209EC67E88B6E706EC61" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units outstanding, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AD221141746209EC67E88B6E706EC61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AD221141746209EC67E88B6E706EC61" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AD221141746209EC67E88B6E706EC61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60D0C47AF85BF07071B188D443BFF0D9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60D0C47AF85BF07071B188D443BFF0D9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60D0C47AF85BF07071B188D443BFF0D9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60D0C47AF85BF07071B188D443BFF0D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60D0C47AF85BF07071B188D443BFF0D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60D0C47AF85BF07071B188D443BFF0D9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60D0C47AF85BF07071B188D443BFF0D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E94F37C450ED1243A5BF88D1070A9841_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E94F37C450ED1243A5BF88D1070A9841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value, granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E94F37C450ED1243A5BF88D1070A9841_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E94F37C450ED1243A5BF88D1070A9841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E94F37C450ED1243A5BF88D1070A9841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E94F37C450ED1243A5BF88D1070A9841" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E94F37C450ED1243A5BF88D1070A9841" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30BDA54E64C9D5DB7C7888D10718440B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30BDA54E64C9D5DB7C7888D10718440B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value, vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30BDA54E64C9D5DB7C7888D10718440B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30BDA54E64C9D5DB7C7888D10718440B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30BDA54E64C9D5DB7C7888D10718440B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30BDA54E64C9D5DB7C7888D10718440B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30BDA54E64C9D5DB7C7888D10718440B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2FD472C29ECCA28067DE88D1072716D3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2FD472C29ECCA28067DE88D1072716D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value, canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2FD472C29ECCA28067DE88D1072716D3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2FD472C29ECCA28067DE88D1072716D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2FD472C29ECCA28067DE88D1072716D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2FD472C29ECCA28067DE88D1072716D3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2FD472C29ECCA28067DE88D1072716D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B70CFBF26619F8BC277B88CE2BDF02B2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B70CFBF26619F8BC277B88CE2BDF02B2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value, ending balance (in usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B70CFBF26619F8BC277B88CE2BDF02B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B70CFBF26619F8BC277B88CE2BDF02B2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B70CFBF26619F8BC277B88CE2BDF02B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C2C251290FE2135A2B8177D8C74C2BF7_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C2C251290FE2135A2B8177D8C74C2BF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C2C251290FE2135A2B8177D8C74C2BF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C2C251290FE2135A2B8177D8C74C2BF7" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C2C251290FE2135A2B8177D8C74C2BF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933" xlink:to="lab_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:type="arc" />
    <link:label id="lab_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B_terseLabel_en-US" xlink:label="lab_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B_label_en-US" xlink:label="lab_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B_documentation_en-US" xlink:label="lab_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B" xlink:to="lab_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B" xlink:type="arc" />
    <link:label id="lab_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D_terseLabel_en-US" xlink:label="lab_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D_label_en-US" xlink:label="lab_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D_documentation_en-US" xlink:label="lab_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesBConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D" xlink:to="lab_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7032F04BEF587B9F6EA177D8C74CEF66_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7032F04BEF587B9F6EA177D8C74CEF66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7032F04BEF587B9F6EA177D8C74CEF66_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7032F04BEF587B9F6EA177D8C74CEF66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7032F04BEF587B9F6EA177D8C74CEF66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7032F04BEF587B9F6EA177D8C74CEF66" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7032F04BEF587B9F6EA177D8C74CEF66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A15ABD1320A9DB0B8FF377D8C750BF67_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A15ABD1320A9DB0B8FF377D8C750BF67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A15ABD1320A9DB0B8FF377D8C750BF67_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A15ABD1320A9DB0B8FF377D8C750BF67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A15ABD1320A9DB0B8FF377D8C750BF67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A15ABD1320A9DB0B8FF377D8C750BF67" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A15ABD1320A9DB0B8FF377D8C750BF67" xlink:type="arc" />
    <link:label id="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B_terseLabel_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued from exercise of warrants (in shares)</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B_label_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Warrants</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B_documentation_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Warrants</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B" xlink:to="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_B3A3A74517783EB5F5DA77D8C7505E24_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_B3A3A74517783EB5F5DA77D8C7505E24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, outstanding</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_B3A3A74517783EB5F5DA77D8C7505E24_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_B3A3A74517783EB5F5DA77D8C7505E24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_B3A3A74517783EB5F5DA77D8C7505E24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_B3A3A74517783EB5F5DA77D8C7505E24" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_B3A3A74517783EB5F5DA77D8C7505E24" xlink:type="arc" />
    <link:label id="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA_terseLabel_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued during period, exercise of warrants prior to IPO</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA_label_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Warrants Prior to IPO</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA_documentation_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Warrants Prior to IPO</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO" xlink:label="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA" xlink:to="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_6351BBEAAC37CD5236737E7B595B5B1A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_6351BBEAAC37CD5236737E7B595B5B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6351BBEAAC37CD5236737E7B595B5B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6351BBEAAC37CD5236737E7B595B5B1A" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_6351BBEAAC37CD5236737E7B595B5B1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_733B333A16544D3FEC527E7B595C0AC7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_733B333A16544D3FEC527E7B595C0AC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_733B333A16544D3FEC527E7B595C0AC7_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_733B333A16544D3FEC527E7B595C0AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_733B333A16544D3FEC527E7B595C0AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_733B333A16544D3FEC527E7B595C0AC7" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_733B333A16544D3FEC527E7B595C0AC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_7F5D5587B9E58E39EB7D7E7B595DD170_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_7F5D5587B9E58E39EB7D7E7B595DD170" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_7F5D5587B9E58E39EB7D7E7B595DD170_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_7F5D5587B9E58E39EB7D7E7B595DD170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7F5D5587B9E58E39EB7D7E7B595DD170" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7F5D5587B9E58E39EB7D7E7B595DD170" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_7F5D5587B9E58E39EB7D7E7B595DD170" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_3BB2C91B3818C9A09DF77E7B595D018C_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_3BB2C91B3818C9A09DF77E7B595D018C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_3BB2C91B3818C9A09DF77E7B595D018C_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_3BB2C91B3818C9A09DF77E7B595D018C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3BB2C91B3818C9A09DF77E7B595D018C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3BB2C91B3818C9A09DF77E7B595D018C" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_3BB2C91B3818C9A09DF77E7B595D018C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_E0DCA4CEF0FA0C4AA1EA7E7B595DED33_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_E0DCA4CEF0FA0C4AA1EA7E7B595DED33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_E0DCA4CEF0FA0C4AA1EA7E7B595DED33_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_E0DCA4CEF0FA0C4AA1EA7E7B595DED33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_E0DCA4CEF0FA0C4AA1EA7E7B595DED33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_E0DCA4CEF0FA0C4AA1EA7E7B595DED33" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_E0DCA4CEF0FA0C4AA1EA7E7B595DED33" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3293974B8E1DC6C5732D7E7B595D2A9B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3293974B8E1DC6C5732D7E7B595D2A9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3293974B8E1DC6C5732D7E7B595D2A9B_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3293974B8E1DC6C5732D7E7B595D2A9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3293974B8E1DC6C5732D7E7B595D2A9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3293974B8E1DC6C5732D7E7B595D2A9B" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3293974B8E1DC6C5732D7E7B595D2A9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0ECD57E85307149931117E7BC235ADEC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0ECD57E85307149931117E7BC235ADEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0ECD57E85307149931117E7BC235ADEC_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0ECD57E85307149931117E7BC235ADEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0ECD57E85307149931117E7BC235ADEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0ECD57E85307149931117E7BC235ADEC" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0ECD57E85307149931117E7BC235ADEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7BD4643AACBD487DBC317E7B595DCB1C_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7BD4643AACBD487DBC317E7B595DCB1C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7BD4643AACBD487DBC317E7B595DCB1C_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7BD4643AACBD487DBC317E7B595DCB1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7BD4643AACBD487DBC317E7B595DCB1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7BD4643AACBD487DBC317E7B595DCB1C" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7BD4643AACBD487DBC317E7B595DCB1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6731CFFAEAC115FE48E47E7B595EC37B_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_6731CFFAEAC115FE48E47E7B595EC37B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6731CFFAEAC115FE48E47E7B595EC37B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_6731CFFAEAC115FE48E47E7B595EC37B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6731CFFAEAC115FE48E47E7B595EC37B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6731CFFAEAC115FE48E47E7B595EC37B" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_6731CFFAEAC115FE48E47E7B595EC37B" xlink:type="arc" />
    <link:label id="lab_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock_9DC4ACE970A75CDEFA3DA625E53701C8_terseLabel_en-US" xlink:label="lab_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock_9DC4ACE970A75CDEFA3DA625E53701C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of components of loss before provision for income taxes</link:label>
    <link:label id="lab_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock_9DC4ACE970A75CDEFA3DA625E53701C8_label_en-US" xlink:label="lab_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock_9DC4ACE970A75CDEFA3DA625E53701C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Components Before Income Tax Expense Benefit [Table Text Block]</link:label>
    <link:label id="lab_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock_9DC4ACE970A75CDEFA3DA625E53701C8_documentation_en-US" xlink:label="lab_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock_9DC4ACE970A75CDEFA3DA625E53701C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Components Before Income Tax Expense Benefit [Table Text Block]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock_9DC4ACE970A75CDEFA3DA625E53701C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock_9DC4ACE970A75CDEFA3DA625E53701C8" xlink:to="lab_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock_9DC4ACE970A75CDEFA3DA625E53701C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9925ED7E6832C0B20789A625E5372BE6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9925ED7E6832C0B20789A625E5372BE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of components of the provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9925ED7E6832C0B20789A625E5372BE6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9925ED7E6832C0B20789A625E5372BE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9925ED7E6832C0B20789A625E5372BE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9925ED7E6832C0B20789A625E5372BE6" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9925ED7E6832C0B20789A625E5372BE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_BEC1460D7967EBEF29A1A625E5378A82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_BEC1460D7967EBEF29A1A625E5378A82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_BEC1460D7967EBEF29A1A625E5378A82_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_BEC1460D7967EBEF29A1A625E5378A82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_BEC1460D7967EBEF29A1A625E5378A82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_BEC1460D7967EBEF29A1A625E5378A82" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_BEC1460D7967EBEF29A1A625E5378A82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_F9C12C45CF114DEF7458A625E537E91C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_F9C12C45CF114DEF7458A625E537E91C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_F9C12C45CF114DEF7458A625E537E91C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_F9C12C45CF114DEF7458A625E537E91C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_F9C12C45CF114DEF7458A625E537E91C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_F9C12C45CF114DEF7458A625E537E91C" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_F9C12C45CF114DEF7458A625E537E91C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5BE2395FFF112CABACACA625E5371A19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5BE2395FFF112CABACACA625E5371A19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the balance of total gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5BE2395FFF112CABACACA625E5371A19_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5BE2395FFF112CABACACA625E5371A19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5BE2395FFF112CABACACA625E5371A19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5BE2395FFF112CABACACA625E5371A19" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5BE2395FFF112CABACACA625E5371A19" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8E26F06E3EBD1D8AB7837853A960464E_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_8E26F06E3EBD1D8AB7837853A960464E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8E26F06E3EBD1D8AB7837853A960464E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8E26F06E3EBD1D8AB7837853A960464E" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_8E26F06E3EBD1D8AB7837853A960464E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_86EDB6CD2D7352E3512F78555394383B_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_86EDB6CD2D7352E3512F78555394383B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_86EDB6CD2D7352E3512F78555394383B_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_86EDB6CD2D7352E3512F78555394383B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_86EDB6CD2D7352E3512F78555394383B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_86EDB6CD2D7352E3512F78555394383B" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_86EDB6CD2D7352E3512F78555394383B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_2B90C77941F02D58C320785439E86014_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_2B90C77941F02D58C320785439E86014" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_2B90C77941F02D58C320785439E86014_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_2B90C77941F02D58C320785439E86014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_2B90C77941F02D58C320785439E86014" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_2B90C77941F02D58C320785439E86014" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_2B90C77941F02D58C320785439E86014" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_1ACDB1075B9E8D5CA4177854B6EA0A57_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_1ACDB1075B9E8D5CA4177854B6EA0A57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation, expected recognition period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_1ACDB1075B9E8D5CA4177854B6EA0A57_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_1ACDB1075B9E8D5CA4177854B6EA0A57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Optional Exemption, Remaining Duration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_1ACDB1075B9E8D5CA4177854B6EA0A57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_1ACDB1075B9E8D5CA4177854B6EA0A57" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_1ACDB1075B9E8D5CA4177854B6EA0A57" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:to="lab_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:to="lab_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:type="arc" />
    <link:label id="lab_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194_terseLabel_en-US" xlink:label="lab_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Customers</link:label>
    <link:label id="lab_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194_label_en-US" xlink:label="lab_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Customers [Member]</link:label>
    <link:label id="lab_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194_documentation_en-US" xlink:label="lab_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Customers [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ClinicalCustomersMember" xlink:label="loc_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194" xlink:to="lab_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194" xlink:type="arc" />
    <link:label id="lab_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A_terseLabel_en-US" xlink:label="lab_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biopharmaceutical Customers</link:label>
    <link:label id="lab_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A_label_en-US" xlink:label="lab_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharmaceutical Customers [Member]</link:label>
    <link:label id="lab_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A_documentation_en-US" xlink:label="lab_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biopharmaceutical Customers [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_BiopharmaceuticalCustomersMember" xlink:label="loc_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A" xlink:to="lab_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7" xlink:to="lab_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_49421ACCB184F61821E191EAA8D499B7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_49421ACCB184F61821E191EAA8D499B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Topic 606 adoption</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_49421ACCB184F61821E191EAA8D499B7_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_49421ACCB184F61821E191EAA8D499B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_49421ACCB184F61821E191EAA8D499B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_49421ACCB184F61821E191EAA8D499B7" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_49421ACCB184F61821E191EAA8D499B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9CEBC81FB731E962B09D91EAA8D4F126_terseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9CEBC81FB731E962B09D91EAA8D4F126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of Change</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9CEBC81FB731E962B09D91EAA8D4F126_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9CEBC81FB731E962B09D91EAA8D4F126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9CEBC81FB731E962B09D91EAA8D4F126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9CEBC81FB731E962B09D91EAA8D4F126" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9CEBC81FB731E962B09D91EAA8D4F126" xlink:type="arc" />
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_ED38C8357C2792EB51FF91EAA8D5A287_terseLabel_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_ED38C8357C2792EB51FF91EAA8D5A287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balances Without Adoption of ASC 606</link:label>
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_ED38C8357C2792EB51FF91EAA8D5A287_label_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_ED38C8357C2792EB51FF91EAA8D5A287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Calculated under Revenue Guidance in Effect before Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_ED38C8357C2792EB51FF91EAA8D5A287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_ED38C8357C2792EB51FF91EAA8D5A287" xlink:to="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_ED38C8357C2792EB51FF91EAA8D5A287" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9E1622E32A5DE16B69C691EAA8D5FB89_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_9E1622E32A5DE16B69C691EAA8D5FB89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9E1622E32A5DE16B69C691EAA8D5FB89_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_9E1622E32A5DE16B69C691EAA8D5FB89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9E1622E32A5DE16B69C691EAA8D5FB89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_9E1622E32A5DE16B69C691EAA8D5FB89" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_9E1622E32A5DE16B69C691EAA8D5FB89" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_376B03A6AA1CE6F6DEC791EAA8D52A14_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_376B03A6AA1CE6F6DEC791EAA8D52A14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_376B03A6AA1CE6F6DEC791EAA8D52A14_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_376B03A6AA1CE6F6DEC791EAA8D52A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_376B03A6AA1CE6F6DEC791EAA8D52A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_376B03A6AA1CE6F6DEC791EAA8D52A14" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_376B03A6AA1CE6F6DEC791EAA8D52A14" xlink:type="arc" />
    <link:label id="lab_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD_terseLabel_en-US" xlink:label="lab_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Precision oncology testing</link:label>
    <link:label id="lab_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD_label_en-US" xlink:label="lab_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Precision Oncology Testing</link:label>
    <link:label id="lab_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD_documentation_en-US" xlink:label="lab_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from Precision Oncology Testing</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromPrecisionOncologyTesting" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD" xlink:to="lab_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD" xlink:type="arc" />
    <link:label id="lab_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D_terseLabel_en-US" xlink:label="lab_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development services</link:label>
    <link:label id="lab_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D_label_en-US" xlink:label="lab_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Development Services</link:label>
    <link:label id="lab_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D_documentation_en-US" xlink:label="lab_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from Development Services</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromDevelopmentServices" xlink:label="loc_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D" xlink:to="lab_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FF7DC1915F45FCB746C55A2FE073C42F_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FF7DC1915F45FCB746C55A2FE073C42F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FF7DC1915F45FCB746C55A2FE073C42F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FF7DC1915F45FCB746C55A2FE073C42F" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FF7DC1915F45FCB746C55A2FE073C42F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_15375DB0CEC003D3D522A625E4D0CAB3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_15375DB0CEC003D3D522A625E4D0CAB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_15375DB0CEC003D3D522A625E4D0CAB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_15375DB0CEC003D3D522A625E4D0CAB3" xlink:to="lab_us-gaap_EarningsPerShareAbstract_15375DB0CEC003D3D522A625E4D0CAB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1543DC05F2EADF08AAE8A625E4D0628B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1543DC05F2EADF08AAE8A625E4D0628B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1543DC05F2EADF08AAE8A625E4D0628B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1543DC05F2EADF08AAE8A625E4D0628B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1543DC05F2EADF08AAE8A625E4D0628B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1543DC05F2EADF08AAE8A625E4D0628B" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1543DC05F2EADF08AAE8A625E4D0628B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_EE513DF37EC6994F817EA625E4D0D54B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_EE513DF37EC6994F817EA625E4D0D54B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_EE513DF37EC6994F817EA625E4D0D54B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_EE513DF37EC6994F817EA625E4D0D54B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_EE513DF37EC6994F817EA625E4D0D54B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_EE513DF37EC6994F817EA625E4D0D54B" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_EE513DF37EC6994F817EA625E4D0D54B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_56A4709061792EC86C58A9FD95613F4F_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_56A4709061792EC86C58A9FD95613F4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_56A4709061792EC86C58A9FD95613F4F_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_56A4709061792EC86C58A9FD95613F4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_56A4709061792EC86C58A9FD95613F4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_56A4709061792EC86C58A9FD95613F4F" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_56A4709061792EC86C58A9FD95613F4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6C9B885398938D1D1054A9FD9561A243_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_6C9B885398938D1D1054A9FD9561A243" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6C9B885398938D1D1054A9FD9561A243_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_6C9B885398938D1D1054A9FD9561A243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6C9B885398938D1D1054A9FD9561A243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_6C9B885398938D1D1054A9FD9561A243" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_6C9B885398938D1D1054A9FD9561A243" xlink:type="arc" />
    <link:label id="lab_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6_verboseLabel_en-US" xlink:label="lab_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer hardware and computer software</link:label>
    <link:label id="lab_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6_label_en-US" xlink:label="lab_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6_documentation_en-US" xlink:label="lab_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ComputerEquipmentandSoftwareMember" xlink:label="loc_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6" xlink:to="lab_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95_label_en-US" xlink:label="lab_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:to="lab_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58_terseLabel_en-US" xlink:label="lab_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58_label_en-US" xlink:label="lab_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:to="lab_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_E588EE35EF8AC65ABA8BA9FD95628409_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_E588EE35EF8AC65ABA8BA9FD95628409" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_E588EE35EF8AC65ABA8BA9FD95628409_label_en-US" xlink:label="lab_srt_MinimumMember_E588EE35EF8AC65ABA8BA9FD95628409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_E588EE35EF8AC65ABA8BA9FD95628409" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_E588EE35EF8AC65ABA8BA9FD95628409" xlink:to="lab_srt_MinimumMember_E588EE35EF8AC65ABA8BA9FD95628409" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_DEA2F184F458E1A3FD79A9FD95627AA5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_DEA2F184F458E1A3FD79A9FD95627AA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_DEA2F184F458E1A3FD79A9FD95627AA5_label_en-US" xlink:label="lab_srt_MaximumMember_DEA2F184F458E1A3FD79A9FD95627AA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_DEA2F184F458E1A3FD79A9FD95627AA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_DEA2F184F458E1A3FD79A9FD95627AA5" xlink:to="lab_srt_MaximumMember_DEA2F184F458E1A3FD79A9FD95627AA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_C918A47ED619F22194CAA9FD95635041_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_C918A47ED619F22194CAA9FD95635041" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_C918A47ED619F22194CAA9FD95635041_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_C918A47ED619F22194CAA9FD95635041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C918A47ED619F22194CAA9FD95635041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C918A47ED619F22194CAA9FD95635041" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_C918A47ED619F22194CAA9FD95635041" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D23E9919CAF700C5C771F3478778D742_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D23E9919CAF700C5C771F3478778D742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D23E9919CAF700C5C771F3478778D742" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D23E9919CAF700C5C771F3478778D742" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D23E9919CAF700C5C771F3478778D742" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_EAF433673D8FC07C9FDCF347877AC658_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_EAF433673D8FC07C9FDCF347877AC658" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_EAF433673D8FC07C9FDCF347877AC658_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_EAF433673D8FC07C9FDCF347877AC658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_EAF433673D8FC07C9FDCF347877AC658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_EAF433673D8FC07C9FDCF347877AC658" xlink:to="lab_us-gaap_ComputerEquipmentMember_EAF433673D8FC07C9FDCF347877AC658" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_B8A5F29DF42566D5C846F347877A6AAF_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_B8A5F29DF42566D5C846F347877A6AAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_B8A5F29DF42566D5C846F347877A6AAF_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_B8A5F29DF42566D5C846F347877A6AAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_B8A5F29DF42566D5C846F347877A6AAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_B8A5F29DF42566D5C846F347877A6AAF" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_B8A5F29DF42566D5C846F347877A6AAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9B029406BFFB33317C3FF347877A7105_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9B029406BFFB33317C3FF347877A7105" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9B029406BFFB33317C3FF347877A7105_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9B029406BFFB33317C3FF347877A7105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9B029406BFFB33317C3FF347877A7105" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9B029406BFFB33317C3FF347877A7105" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9B029406BFFB33317C3FF347877A7105" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_1D9FE0DA7D3E0632EE41F347877A4CD2_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_1D9FE0DA7D3E0632EE41F347877A4CD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_1D9FE0DA7D3E0632EE41F347877A4CD2_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_1D9FE0DA7D3E0632EE41F347877A4CD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_1D9FE0DA7D3E0632EE41F347877A4CD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_1D9FE0DA7D3E0632EE41F347877A4CD2" xlink:to="lab_us-gaap_ConstructionInProgressMember_1D9FE0DA7D3E0632EE41F347877A4CD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_A11DB30A7986885E570DF347877B307D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_A11DB30A7986885E570DF347877B307D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_A11DB30A7986885E570DF347877B307D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_A11DB30A7986885E570DF347877B307D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_A11DB30A7986885E570DF347877B307D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_A11DB30A7986885E570DF347877B307D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_A11DB30A7986885E570DF347877B307D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BD9D740142A3340E7606F347877B941D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BD9D740142A3340E7606F347877B941D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BD9D740142A3340E7606F347877B941D_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BD9D740142A3340E7606F347877B941D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BD9D740142A3340E7606F347877B941D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BD9D740142A3340E7606F347877B941D" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BD9D740142A3340E7606F347877B941D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6B0747A20B1589335A93F347877BC904_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_6B0747A20B1589335A93F347877BC904" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6B0747A20B1589335A93F347877BC904_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_6B0747A20B1589335A93F347877BC904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6B0747A20B1589335A93F347877BC904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6B0747A20B1589335A93F347877BC904" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_6B0747A20B1589335A93F347877BC904" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_00CD6A598D96C46AF80377D8C7A562B3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_00CD6A598D96C46AF80377D8C7A562B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_00CD6A598D96C46AF80377D8C7A562B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_00CD6A598D96C46AF80377D8C7A562B3" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_00CD6A598D96C46AF80377D8C7A562B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16" xlink:type="arc" />
    <link:label id="lab_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E_terseLabel_en-US" xlink:label="lab_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bellweather Bio, Inc.</link:label>
    <link:label id="lab_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E_label_en-US" xlink:label="lab_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bellweather Bio, Inc. [Member]</link:label>
    <link:label id="lab_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E_documentation_en-US" xlink:label="lab_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bellweather Bio, Inc. [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_BellweatherBioInc.Member" xlink:label="loc_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E" xlink:to="lab_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9330F9407F0BB2E2373E77D8C7A5BF9A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9330F9407F0BB2E2373E77D8C7A5BF9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9330F9407F0BB2E2373E77D8C7A5BF9A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9330F9407F0BB2E2373E77D8C7A5BF9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9330F9407F0BB2E2373E77D8C7A5BF9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9330F9407F0BB2E2373E77D8C7A5BF9A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9330F9407F0BB2E2373E77D8C7A5BF9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_BADCA593FE433E1E8C6177D8C7A5D6AF_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_BADCA593FE433E1E8C6177D8C7A5D6AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_BADCA593FE433E1E8C6177D8C7A5D6AF_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_BADCA593FE433E1E8C6177D8C7A5D6AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_BADCA593FE433E1E8C6177D8C7A5D6AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_BADCA593FE433E1E8C6177D8C7A5D6AF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_BADCA593FE433E1E8C6177D8C7A5D6AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6FCE3B470CA839801EF577D8C7A5B71C_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6FCE3B470CA839801EF577D8C7A5B71C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6FCE3B470CA839801EF577D8C7A5B71C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6FCE3B470CA839801EF577D8C7A5B71C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6FCE3B470CA839801EF577D8C7A5B71C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6FCE3B470CA839801EF577D8C7A5B71C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6FCE3B470CA839801EF577D8C7A5B71C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7FF07A3A324BBCFAE17477D8C7A51F9D_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7FF07A3A324BBCFAE17477D8C7A51F9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7FF07A3A324BBCFAE17477D8C7A51F9D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7FF07A3A324BBCFAE17477D8C7A51F9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7FF07A3A324BBCFAE17477D8C7A51F9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7FF07A3A324BBCFAE17477D8C7A51F9D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7FF07A3A324BBCFAE17477D8C7A51F9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F61C4BA5FB151F082E0F77D8C7A5985A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F61C4BA5FB151F082E0F77D8C7A5985A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F61C4BA5FB151F082E0F77D8C7A5985A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F61C4BA5FB151F082E0F77D8C7A5985A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F61C4BA5FB151F082E0F77D8C7A5985A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F61C4BA5FB151F082E0F77D8C7A5985A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F61C4BA5FB151F082E0F77D8C7A5985A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_30F02F302A0F63E08E3777D8C7A5F1BC_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_30F02F302A0F63E08E3777D8C7A5F1BC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_30F02F302A0F63E08E3777D8C7A5F1BC_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_30F02F302A0F63E08E3777D8C7A5F1BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30F02F302A0F63E08E3777D8C7A5F1BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30F02F302A0F63E08E3777D8C7A5F1BC" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_30F02F302A0F63E08E3777D8C7A5F1BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_6E103B95377765BCE48788B6E8DD89CA_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_6E103B95377765BCE48788B6E8DD89CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_6E103B95377765BCE48788B6E8DD89CA_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_6E103B95377765BCE48788B6E8DD89CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_6E103B95377765BCE48788B6E8DD89CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_6E103B95377765BCE48788B6E8DD89CA" xlink:to="lab_us-gaap_AssetsAbstract_6E103B95377765BCE48788B6E8DD89CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:to="lab_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18791FCE9F56E934DAF288B6E8DDF16E_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18791FCE9F56E934DAF288B6E8DDF16E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18791FCE9F56E934DAF288B6E8DDF16E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18791FCE9F56E934DAF288B6E8DDF16E" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18791FCE9F56E934DAF288B6E8DDF16E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_9BD193E6DEC6C30682FB88B6E8DE0649_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_9BD193E6DEC6C30682FB88B6E8DE0649" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_9BD193E6DEC6C30682FB88B6E8DE0649_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_9BD193E6DEC6C30682FB88B6E8DE0649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_9BD193E6DEC6C30682FB88B6E8DE0649" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_9BD193E6DEC6C30682FB88B6E8DE0649" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_9BD193E6DEC6C30682FB88B6E8DE0649" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_244C7908D33860DA6E9E88B6E8DEFDED_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_244C7908D33860DA6E9E88B6E8DEFDED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_244C7908D33860DA6E9E88B6E8DEFDED_label_en-US" xlink:label="lab_us-gaap_InventoryNet_244C7908D33860DA6E9E88B6E8DEFDED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_244C7908D33860DA6E9E88B6E8DEFDED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_244C7908D33860DA6E9E88B6E8DEFDED" xlink:to="lab_us-gaap_InventoryNet_244C7908D33860DA6E9E88B6E8DEFDED" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5A897B8645278AD36E2588B6E8DEDF8B_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5A897B8645278AD36E2588B6E8DEDF8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5A897B8645278AD36E2588B6E8DEDF8B_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5A897B8645278AD36E2588B6E8DEDF8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5A897B8645278AD36E2588B6E8DEDF8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5A897B8645278AD36E2588B6E8DEDF8B" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5A897B8645278AD36E2588B6E8DEDF8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_24B914E6E3F5AAAC310F88B6E8DE545A_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_24B914E6E3F5AAAC310F88B6E8DE545A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_24B914E6E3F5AAAC310F88B6E8DE545A_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_24B914E6E3F5AAAC310F88B6E8DE545A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_24B914E6E3F5AAAC310F88B6E8DE545A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_24B914E6E3F5AAAC310F88B6E8DE545A" xlink:to="lab_us-gaap_AssetsCurrent_24B914E6E3F5AAAC310F88B6E8DE545A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_8D663BE3C9691094326F88B6E8DFE6E0_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent_8D663BE3C9691094326F88B6E8DFE6E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_8D663BE3C9691094326F88B6E8DFE6E0_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent_8D663BE3C9691094326F88B6E8DFE6E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_8D663BE3C9691094326F88B6E8DFE6E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent_8D663BE3C9691094326F88B6E8DFE6E0" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent_8D663BE3C9691094326F88B6E8DFE6E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_29071BB6E8FFBAE2169F88B6E8DFC6E6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_29071BB6E8FFBAE2169F88B6E8DFC6E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_29071BB6E8FFBAE2169F88B6E8DFC6E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_29071BB6E8FFBAE2169F88B6E8DFC6E6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_29071BB6E8FFBAE2169F88B6E8DFC6E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0952989527B5C3A7B34E88B89675448A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0952989527B5C3A7B34E88B89675448A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0952989527B5C3A7B34E88B89675448A_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0952989527B5C3A7B34E88B89675448A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0952989527B5C3A7B34E88B89675448A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_0952989527B5C3A7B34E88B89675448A" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0952989527B5C3A7B34E88B89675448A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0A7EFFFCA1B5A648ABD788B6E8DFFA83_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0A7EFFFCA1B5A648ABD788B6E8DFFA83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0A7EFFFCA1B5A648ABD788B6E8DFFA83_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0A7EFFFCA1B5A648ABD788B6E8DFFA83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0A7EFFFCA1B5A648ABD788B6E8DFFA83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0A7EFFFCA1B5A648ABD788B6E8DFFA83" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0A7EFFFCA1B5A648ABD788B6E8DFFA83" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_6A2DDB83672B0E72001D88B6E8DFA2E8_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_6A2DDB83672B0E72001D88B6E8DFA2E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_6A2DDB83672B0E72001D88B6E8DFA2E8_label_en-US" xlink:label="lab_us-gaap_Goodwill_6A2DDB83672B0E72001D88B6E8DFA2E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_6A2DDB83672B0E72001D88B6E8DFA2E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_6A2DDB83672B0E72001D88B6E8DFA2E8" xlink:to="lab_us-gaap_Goodwill_6A2DDB83672B0E72001D88B6E8DFA2E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2A9093609ABB5BF7FA5088B6E8DF859F_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2A9093609ABB5BF7FA5088B6E8DF859F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized license fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2A9093609ABB5BF7FA5088B6E8DF859F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2A9093609ABB5BF7FA5088B6E8DF859F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2A9093609ABB5BF7FA5088B6E8DF859F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_CB34C7D012D6246D7BD688B6E8DFFDFE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_CB34C7D012D6246D7BD688B6E8DFFDFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_CB34C7D012D6246D7BD688B6E8DFFDFE_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_CB34C7D012D6246D7BD688B6E8DFFDFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_CB34C7D012D6246D7BD688B6E8DFFDFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_CB34C7D012D6246D7BD688B6E8DFFDFE" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_CB34C7D012D6246D7BD688B6E8DFFDFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_92A175D50219A78D27F588B6E8E0703E_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_92A175D50219A78D27F588B6E8E0703E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_92A175D50219A78D27F588B6E8E0703E_label_en-US" xlink:label="lab_us-gaap_Assets_92A175D50219A78D27F588B6E8E0703E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_92A175D50219A78D27F588B6E8E0703E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_92A175D50219A78D27F588B6E8E0703E" xlink:to="lab_us-gaap_Assets_92A175D50219A78D27F588B6E8E0703E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9B97B9FEB95A249B30CF88B6E8E078A3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9B97B9FEB95A249B30CF88B6E8E078A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9B97B9FEB95A249B30CF88B6E8E078A3_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9B97B9FEB95A249B30CF88B6E8E078A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9B97B9FEB95A249B30CF88B6E8E078A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9B97B9FEB95A249B30CF88B6E8E078A3" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9B97B9FEB95A249B30CF88B6E8E078A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_79630828627997AA399288B6E8E0EAE1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_79630828627997AA399288B6E8E0EAE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_79630828627997AA399288B6E8E0EAE1_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_79630828627997AA399288B6E8E0EAE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_79630828627997AA399288B6E8E0EAE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_79630828627997AA399288B6E8E0EAE1" xlink:to="lab_us-gaap_AccountsPayableCurrent_79630828627997AA399288B6E8E0EAE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_1F14FE9520893D22C26E88B6E8E08078_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent_1F14FE9520893D22C26E88B6E8E08078" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_1F14FE9520893D22C26E88B6E8E08078_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent_1F14FE9520893D22C26E88B6E8E08078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_1F14FE9520893D22C26E88B6E8E08078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrent_1F14FE9520893D22C26E88B6E8E08078" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrent_1F14FE9520893D22C26E88B6E8E08078" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9E44A5E3E492161D592188B6E8E1DFEC_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_9E44A5E3E492161D592188B6E8E1DFEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9E44A5E3E492161D592188B6E8E1DFEC_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_9E44A5E3E492161D592188B6E8E1DFEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9E44A5E3E492161D592188B6E8E1DFEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9E44A5E3E492161D592188B6E8E1DFEC" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_9E44A5E3E492161D592188B6E8E1DFEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_97BF368A34A74566788388B6E8E10B10_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_97BF368A34A74566788388B6E8E10B10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_97BF368A34A74566788388B6E8E10B10_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_97BF368A34A74566788388B6E8E10B10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_97BF368A34A74566788388B6E8E10B10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_97BF368A34A74566788388B6E8E10B10" xlink:to="lab_us-gaap_DeferredRevenueCurrent_97BF368A34A74566788388B6E8E10B10" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ED072A87C343F94F635088B6E8E1E749_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_ED072A87C343F94F635088B6E8E1E749" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ED072A87C343F94F635088B6E8E1E749_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_ED072A87C343F94F635088B6E8E1E749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_ED072A87C343F94F635088B6E8E1E749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_ED072A87C343F94F635088B6E8E1E749" xlink:to="lab_us-gaap_LiabilitiesCurrent_ED072A87C343F94F635088B6E8E1E749" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9F5D6632A937504C0CC488B6E8E17BD7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9F5D6632A937504C0CC488B6E8E17BD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9F5D6632A937504C0CC488B6E8E17BD7_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9F5D6632A937504C0CC488B6E8E17BD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9F5D6632A937504C0CC488B6E8E17BD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9F5D6632A937504C0CC488B6E8E17BD7" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9F5D6632A937504C0CC488B6E8E17BD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_37A24927680784433BA588B6E8E13D79_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_37A24927680784433BA588B6E8E13D79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_37A24927680784433BA588B6E8E13D79_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_37A24927680784433BA588B6E8E13D79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_37A24927680784433BA588B6E8E13D79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_37A24927680784433BA588B6E8E13D79" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_37A24927680784433BA588B6E8E13D79" xlink:type="arc" />
    <link:label id="lab_gh_AccruedRoyaltiesNoncurrent_C35DE25A3A1C0360AF4B88B6E8E145A6_terseLabel_en-US" xlink:label="lab_gh_AccruedRoyaltiesNoncurrent_C35DE25A3A1C0360AF4B88B6E8E145A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation related to royalty</link:label>
    <link:label id="lab_gh_AccruedRoyaltiesNoncurrent_C35DE25A3A1C0360AF4B88B6E8E145A6_label_en-US" xlink:label="lab_gh_AccruedRoyaltiesNoncurrent_C35DE25A3A1C0360AF4B88B6E8E145A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Noncurrent</link:label>
    <link:label id="lab_gh_AccruedRoyaltiesNoncurrent_C35DE25A3A1C0360AF4B88B6E8E145A6_documentation_en-US" xlink:label="lab_gh_AccruedRoyaltiesNoncurrent_C35DE25A3A1C0360AF4B88B6E8E145A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Noncurrent</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_AccruedRoyaltiesNoncurrent" xlink:label="loc_gh_AccruedRoyaltiesNoncurrent_C35DE25A3A1C0360AF4B88B6E8E145A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AccruedRoyaltiesNoncurrent_C35DE25A3A1C0360AF4B88B6E8E145A6" xlink:to="lab_gh_AccruedRoyaltiesNoncurrent_C35DE25A3A1C0360AF4B88B6E8E145A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_CB70DACA877B9C10F14B88B6E8E2877A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_CB70DACA877B9C10F14B88B6E8E2877A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_CB70DACA877B9C10F14B88B6E8E2877A_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_CB70DACA877B9C10F14B88B6E8E2877A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_CB70DACA877B9C10F14B88B6E8E2877A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_CB70DACA877B9C10F14B88B6E8E2877A" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_CB70DACA877B9C10F14B88B6E8E2877A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_BEA75CE4531290F9E75788B6E8E25C4C_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_BEA75CE4531290F9E75788B6E8E25C4C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_BEA75CE4531290F9E75788B6E8E25C4C_label_en-US" xlink:label="lab_us-gaap_Liabilities_BEA75CE4531290F9E75788B6E8E25C4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_BEA75CE4531290F9E75788B6E8E25C4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_BEA75CE4531290F9E75788B6E8E25C4C" xlink:to="lab_us-gaap_Liabilities_BEA75CE4531290F9E75788B6E8E25C4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_82003D98F6CDDE280BFA88B6E8E204AA_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_82003D98F6CDDE280BFA88B6E8E204AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_82003D98F6CDDE280BFA88B6E8E204AA_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_82003D98F6CDDE280BFA88B6E8E204AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_82003D98F6CDDE280BFA88B6E8E204AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_82003D98F6CDDE280BFA88B6E8E204AA" xlink:to="lab_us-gaap_CommitmentsAndContingencies_82003D98F6CDDE280BFA88B6E8E204AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_DCC6C9264DE28D3FC29788B6E8E209EB_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_DCC6C9264DE28D3FC29788B6E8E209EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_DCC6C9264DE28D3FC29788B6E8E209EB_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_DCC6C9264DE28D3FC29788B6E8E209EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_DCC6C9264DE28D3FC29788B6E8E209EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_DCC6C9264DE28D3FC29788B6E8E209EB" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_DCC6C9264DE28D3FC29788B6E8E209EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:to="lab_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_32308EA2F9DC9F82135E88B6E8E26D7D_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding_32308EA2F9DC9F82135E88B6E8E26D7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2019 and 2018</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_32308EA2F9DC9F82135E88B6E8E26D7D_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding_32308EA2F9DC9F82135E88B6E8E26D7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_32308EA2F9DC9F82135E88B6E8E26D7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding_32308EA2F9DC9F82135E88B6E8E26D7D" xlink:to="lab_us-gaap_PreferredStockValueOutstanding_32308EA2F9DC9F82135E88B6E8E26D7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_476DE09195C42D02684A88B6E8E3726C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding_476DE09195C42D02684A88B6E8E3726C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value of $0.00001 per share; 350,000,000 and 350,000,000 shares authorized as of December 31, 2019 and 2018, respectively; 94,261,414 and 85,832,454 shares issued and outstanding as of December 31, 2019 and 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_476DE09195C42D02684A88B6E8E3726C_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding_476DE09195C42D02684A88B6E8E3726C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_476DE09195C42D02684A88B6E8E3726C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding_476DE09195C42D02684A88B6E8E3726C" xlink:to="lab_us-gaap_CommonStockValueOutstanding_476DE09195C42D02684A88B6E8E3726C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_C9FCBFFEB23F8A0CA1EB88B6E8E3D98E_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_C9FCBFFEB23F8A0CA1EB88B6E8E3D98E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_C9FCBFFEB23F8A0CA1EB88B6E8E3D98E_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_C9FCBFFEB23F8A0CA1EB88B6E8E3D98E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C9FCBFFEB23F8A0CA1EB88B6E8E3D98E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_C9FCBFFEB23F8A0CA1EB88B6E8E3D98E" xlink:to="lab_us-gaap_AdditionalPaidInCapital_C9FCBFFEB23F8A0CA1EB88B6E8E3D98E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_697019B33294D3B0DDB288B6E8E34C7A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_697019B33294D3B0DDB288B6E8E34C7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive gain (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_697019B33294D3B0DDB288B6E8E34C7A_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_697019B33294D3B0DDB288B6E8E34C7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_697019B33294D3B0DDB288B6E8E34C7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_697019B33294D3B0DDB288B6E8E34C7A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_697019B33294D3B0DDB288B6E8E34C7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_582ACC47224A183CF0F988B6E8E3DABD_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_582ACC47224A183CF0F988B6E8E3DABD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_582ACC47224A183CF0F988B6E8E3DABD_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_582ACC47224A183CF0F988B6E8E3DABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_582ACC47224A183CF0F988B6E8E3DABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_582ACC47224A183CF0F988B6E8E3DABD" xlink:to="lab_us-gaap_StockholdersEquity_582ACC47224A183CF0F988B6E8E3DABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9B05401101A4ADD78C5388B6E8E3485A_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_9B05401101A4ADD78C5388B6E8E3485A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9B05401101A4ADD78C5388B6E8E3485A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_9B05401101A4ADD78C5388B6E8E3485A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9B05401101A4ADD78C5388B6E8E3485A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9B05401101A4ADD78C5388B6E8E3485A" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_9B05401101A4ADD78C5388B6E8E3485A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_130D563A52E7A73A6DD55A2FE0A5C445_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_130D563A52E7A73A6DD55A2FE0A5C445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_130D563A52E7A73A6DD55A2FE0A5C445" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_130D563A52E7A73A6DD55A2FE0A5C445" xlink:to="lab_us-gaap_LeasesAbstract_130D563A52E7A73A6DD55A2FE0A5C445" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6CF28EE1BCFB779430325A2FE0A51F19_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_6CF28EE1BCFB779430325A2FE0A51F19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6CF28EE1BCFB779430325A2FE0A51F19_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_6CF28EE1BCFB779430325A2FE0A51F19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6CF28EE1BCFB779430325A2FE0A51F19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_6CF28EE1BCFB779430325A2FE0A51F19" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_6CF28EE1BCFB779430325A2FE0A51F19" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1" xlink:type="arc" />
    <link:label id="lab_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE_terseLabel_en-US" xlink:label="lab_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Covenants Not To Compete</link:label>
    <link:label id="lab_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE_label_en-US" xlink:label="lab_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Covenants Not To Compete [Member]</link:label>
    <link:label id="lab_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE_documentation_en-US" xlink:label="lab_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Covenants Not To Compete [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CovenantsNotToCompeteMember" xlink:label="loc_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE" xlink:to="lab_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_76FE962BA79D261C4D1A77D8C82110C3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_76FE962BA79D261C4D1A77D8C82110C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, measurements, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_76FE962BA79D261C4D1A77D8C82110C3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_76FE962BA79D261C4D1A77D8C82110C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_76FE962BA79D261C4D1A77D8C82110C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_76FE962BA79D261C4D1A77D8C82110C3" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_76FE962BA79D261C4D1A77D8C82110C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_90179661FDC703E491B877D8C821B2A7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_90179661FDC703E491B877D8C821B2A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_90179661FDC703E491B877D8C821B2A7_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_90179661FDC703E491B877D8C821B2A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_90179661FDC703E491B877D8C821B2A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_90179661FDC703E491B877D8C821B2A7" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_90179661FDC703E491B877D8C821B2A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:type="arc" />
    <link:label id="lab_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA_terseLabel_en-US" xlink:label="lab_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercialization Milestones</link:label>
    <link:label id="lab_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA_label_en-US" xlink:label="lab_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercialization Milestones [Member]</link:label>
    <link:label id="lab_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA_documentation_en-US" xlink:label="lab_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercialization Milestones [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CommercializationMilestonesMember" xlink:label="loc_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA" xlink:to="lab_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA" xlink:type="arc" />
    <link:label id="lab_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA_terseLabel_en-US" xlink:label="lab_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earn-Out Consideration</link:label>
    <link:label id="lab_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA_label_en-US" xlink:label="lab_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earn-Out Consideration [Member]</link:label>
    <link:label id="lab_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA_documentation_en-US" xlink:label="lab_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earn-Out Consideration [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_EarnOutConsiderationMember" xlink:label="loc_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA" xlink:to="lab_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_C38F6D0E8CA52B2564BA77D8C8214B67_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_C38F6D0E8CA52B2564BA77D8C8214B67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_C38F6D0E8CA52B2564BA77D8C8214B67_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_C38F6D0E8CA52B2564BA77D8C8214B67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C38F6D0E8CA52B2564BA77D8C8214B67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C38F6D0E8CA52B2564BA77D8C8214B67" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_C38F6D0E8CA52B2564BA77D8C8214B67" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_713F2E4FC5D891CA56AA77D8C82153DD_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_713F2E4FC5D891CA56AA77D8C82153DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_713F2E4FC5D891CA56AA77D8C82153DD_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_713F2E4FC5D891CA56AA77D8C82153DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_713F2E4FC5D891CA56AA77D8C82153DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_713F2E4FC5D891CA56AA77D8C82153DD" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_713F2E4FC5D891CA56AA77D8C82153DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1590C5515448227C7C8C77D8C821CE60_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1590C5515448227C7C8C77D8C821CE60" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent liability from business acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1590C5515448227C7C8C77D8C821CE60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1590C5515448227C7C8C77D8C821CE60" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1590C5515448227C7C8C77D8C821CE60" xlink:type="arc" />
    <link:label id="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233_terseLabel_en-US" xlink:label="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contingent liability</link:label>
    <link:label id="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233_label_en-US" xlink:label="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Maximum Amount Payable</link:label>
    <link:label id="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233_documentation_en-US" xlink:label="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Maximum Amount Payable</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_BusinessCombinationContingentConsiderationMaximumAmountPayable" xlink:label="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233" xlink:to="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D9A1C5C68C3D33E36C5477D8C825B73D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D9A1C5C68C3D33E36C5477D8C825B73D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identified intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D9A1C5C68C3D33E36C5477D8C825B73D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D9A1C5C68C3D33E36C5477D8C825B73D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D9A1C5C68C3D33E36C5477D8C825B73D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D9A1C5C68C3D33E36C5477D8C825B73D" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D9A1C5C68C3D33E36C5477D8C825B73D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_03FABBEDD20A4DA214D577D8C825CCBF_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_03FABBEDD20A4DA214D577D8C825CCBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_03FABBEDD20A4DA214D577D8C825CCBF_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_03FABBEDD20A4DA214D577D8C825CCBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_03FABBEDD20A4DA214D577D8C825CCBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_03FABBEDD20A4DA214D577D8C825CCBF" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_03FABBEDD20A4DA214D577D8C825CCBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2C38280CDFCD0F4505E677D8C8250ACF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2C38280CDFCD0F4505E677D8C8250ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2C38280CDFCD0F4505E677D8C8250ACF_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2C38280CDFCD0F4505E677D8C8250ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2C38280CDFCD0F4505E677D8C8250ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2C38280CDFCD0F4505E677D8C8250ACF" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2C38280CDFCD0F4505E677D8C8250ACF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2B2368711248684AA1655A2FE107AAD3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2B2368711248684AA1655A2FE107AAD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2B2368711248684AA1655A2FE107AAD3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2B2368711248684AA1655A2FE107AAD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2B2368711248684AA1655A2FE107AAD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2B2368711248684AA1655A2FE107AAD3" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2B2368711248684AA1655A2FE107AAD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_E7FF4E8E38BA2400BA7A5A2FE1074FF0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_E7FF4E8E38BA2400BA7A5A2FE1074FF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_E7FF4E8E38BA2400BA7A5A2FE1074FF0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_E7FF4E8E38BA2400BA7A5A2FE1074FF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_E7FF4E8E38BA2400BA7A5A2FE1074FF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_E7FF4E8E38BA2400BA7A5A2FE1074FF0" xlink:to="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_E7FF4E8E38BA2400BA7A5A2FE1074FF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_07681E29C7A24AD163F05AB930C20743_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_07681E29C7A24AD163F05AB930C20743" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_07681E29C7A24AD163F05AB930C20743_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_07681E29C7A24AD163F05AB930C20743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_07681E29C7A24AD163F05AB930C20743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_07681E29C7A24AD163F05AB930C20743" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_07681E29C7A24AD163F05AB930C20743" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5A5704A5EAD806823D505AA8838FC6A6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5A5704A5EAD806823D505AA8838FC6A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5A5704A5EAD806823D505AA8838FC6A6_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5A5704A5EAD806823D505AA8838FC6A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5A5704A5EAD806823D505AA8838FC6A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5A5704A5EAD806823D505AA8838FC6A6" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5A5704A5EAD806823D505AA8838FC6A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_E4BEFA5EB4C4D8B636325A2FDF5248F8_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_E4BEFA5EB4C4D8B636325A2FDF5248F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_E4BEFA5EB4C4D8B636325A2FDF5248F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_E4BEFA5EB4C4D8B636325A2FDF5248F8" xlink:to="lab_us-gaap_SegmentReportingAbstract_E4BEFA5EB4C4D8B636325A2FDF5248F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_18E18F8B112FE08414435A2FDF523582_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_18E18F8B112FE08414435A2FDF523582" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment and Geographic Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_18E18F8B112FE08414435A2FDF523582_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_18E18F8B112FE08414435A2FDF523582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_18E18F8B112FE08414435A2FDF523582" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_18E18F8B112FE08414435A2FDF523582" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_18E18F8B112FE08414435A2FDF523582" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockTextBlock_B5517BA3D865A314F6A05A2FE05FC567_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock_B5517BA3D865A314F6A05A2FE05FC567" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_B5517BA3D865A314F6A05A2FE05FC567_label_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock_B5517BA3D865A314F6A05A2FE05FC567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_B5517BA3D865A314F6A05A2FE05FC567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock_B5517BA3D865A314F6A05A2FE05FC567" xlink:to="lab_us-gaap_PreferredStockTextBlock_B5517BA3D865A314F6A05A2FE05FC567" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_394B05E5F7A987DC8B7C77D8C62E0A22_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_394B05E5F7A987DC8B7C77D8C62E0A22" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits - Beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_394B05E5F7A987DC8B7C77D8C62E0A22_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_394B05E5F7A987DC8B7C77D8C62E0A22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_394B05E5F7A987DC8B7C77D8C62E0A22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_394B05E5F7A987DC8B7C77D8C62E0A22" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_394B05E5F7A987DC8B7C77D8C62E0A22" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7171C0EF2D6D89D0193877D8C62E1722_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7171C0EF2D6D89D0193877D8C62E1722" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases related to current year&#8217;s tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7171C0EF2D6D89D0193877D8C62E1722_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7171C0EF2D6D89D0193877D8C62E1722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7171C0EF2D6D89D0193877D8C62E1722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7171C0EF2D6D89D0193877D8C62E1722" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7171C0EF2D6D89D0193877D8C62E1722" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_F23432E2D3B65E89125677D8C62E52C8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_F23432E2D3B65E89125677D8C62E52C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases related to prior years&#8217; tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_F23432E2D3B65E89125677D8C62E52C8_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_F23432E2D3B65E89125677D8C62E52C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_F23432E2D3B65E89125677D8C62E52C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_F23432E2D3B65E89125677D8C62E52C8" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_F23432E2D3B65E89125677D8C62E52C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_A52D4E5971D6A47169C877D8C62EB97E_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_A52D4E5971D6A47169C877D8C62EB97E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits - End of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_A52D4E5971D6A47169C877D8C62EB97E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_A52D4E5971D6A47169C877D8C62EB97E" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_A52D4E5971D6A47169C877D8C62EB97E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_E995CADFB6EC4497C18277D8C85744E8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_E995CADFB6EC4497C18277D8C85744E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued royalty obligations</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_E995CADFB6EC4497C18277D8C85744E8_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_E995CADFB6EC4497C18277D8C85744E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_E995CADFB6EC4497C18277D8C85744E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_E995CADFB6EC4497C18277D8C85744E8" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_E995CADFB6EC4497C18277D8C85744E8" xlink:type="arc" />
    <link:label id="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_EC25C54149D47F9986E077D8C857C958_terseLabel_en-US" xlink:label="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_EC25C54149D47F9986E077D8C857C958" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal expenses</link:label>
    <link:label id="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_EC25C54149D47F9986E077D8C857C958_label_en-US" xlink:label="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_EC25C54149D47F9986E077D8C857C958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability, Legal Fees, Current</link:label>
    <link:label id="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_EC25C54149D47F9986E077D8C857C958_documentation_en-US" xlink:label="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_EC25C54149D47F9986E077D8C857C958" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability, Legal Fees, Current</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:label="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_EC25C54149D47F9986E077D8C857C958" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_EC25C54149D47F9986E077D8C857C958" xlink:to="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_EC25C54149D47F9986E077D8C857C958" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_F20C829BAEF36186886477D8C8571813_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent_F20C829BAEF36186886477D8C8571813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued tax liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_F20C829BAEF36186886477D8C8571813_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent_F20C829BAEF36186886477D8C8571813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_F20C829BAEF36186886477D8C8571813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent_F20C829BAEF36186886477D8C8571813" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent_F20C829BAEF36186886477D8C8571813" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_3BF8DEAFC2ED3064BE2277D8C857B8FD_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_3BF8DEAFC2ED3064BE2277D8C857B8FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_3BF8DEAFC2ED3064BE2277D8C857B8FD_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_3BF8DEAFC2ED3064BE2277D8C857B8FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3BF8DEAFC2ED3064BE2277D8C857B8FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_3BF8DEAFC2ED3064BE2277D8C857B8FD" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_3BF8DEAFC2ED3064BE2277D8C857B8FD" xlink:type="arc" />
    <link:label id="lab_gh_AccruedClinicalTrialsandStudies_FDE1F5E586115CD7AA427865EA5A4266_terseLabel_en-US" xlink:label="lab_gh_AccruedClinicalTrialsandStudies_FDE1F5E586115CD7AA427865EA5A4266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trials and studies</link:label>
    <link:label id="lab_gh_AccruedClinicalTrialsandStudies_FDE1F5E586115CD7AA427865EA5A4266_label_en-US" xlink:label="lab_gh_AccruedClinicalTrialsandStudies_FDE1F5E586115CD7AA427865EA5A4266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trials and Studies</link:label>
    <link:label id="lab_gh_AccruedClinicalTrialsandStudies_FDE1F5E586115CD7AA427865EA5A4266_documentation_en-US" xlink:label="lab_gh_AccruedClinicalTrialsandStudies_FDE1F5E586115CD7AA427865EA5A4266" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trials and Studies</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_AccruedClinicalTrialsandStudies" xlink:label="loc_gh_AccruedClinicalTrialsandStudies_FDE1F5E586115CD7AA427865EA5A4266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AccruedClinicalTrialsandStudies_FDE1F5E586115CD7AA427865EA5A4266" xlink:to="lab_gh_AccruedClinicalTrialsandStudies_FDE1F5E586115CD7AA427865EA5A4266" xlink:type="arc" />
    <link:label id="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_BE009ACCE66CD10CFAF177D8C85A9965_terseLabel_en-US" xlink:label="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_BE009ACCE66CD10CFAF177D8C85A9965" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accrued expenses</link:label>
    <link:label id="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_BE009ACCE66CD10CFAF177D8C85A9965_label_en-US" xlink:label="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_BE009ACCE66CD10CFAF177D8C85A9965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses, Property and Equipment, Current</link:label>
    <link:label id="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_BE009ACCE66CD10CFAF177D8C85A9965_documentation_en-US" xlink:label="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_BE009ACCE66CD10CFAF177D8C85A9965" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Expenses, Property and Equipment, Current</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:label="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_BE009ACCE66CD10CFAF177D8C85A9965" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_BE009ACCE66CD10CFAF177D8C85A9965" xlink:to="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_BE009ACCE66CD10CFAF177D8C85A9965" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5992F57FF67FAE9C702E78675386B77A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_5992F57FF67FAE9C702E78675386B77A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5992F57FF67FAE9C702E78675386B77A_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_5992F57FF67FAE9C702E78675386B77A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5992F57FF67FAE9C702E78675386B77A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_5992F57FF67FAE9C702E78675386B77A" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_5992F57FF67FAE9C702E78675386B77A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_56B50971DDA985EF4C9A77D8C85A1080_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_56B50971DDA985EF4C9A77D8C85A1080" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_56B50971DDA985EF4C9A77D8C85A1080_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_56B50971DDA985EF4C9A77D8C85A1080" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_56B50971DDA985EF4C9A77D8C85A1080" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_56B50971DDA985EF4C9A77D8C85A1080" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_56B50971DDA985EF4C9A77D8C85A1080" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_759459D02C2643601EDC77D8C85A4AA2_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_759459D02C2643601EDC77D8C85A4AA2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_759459D02C2643601EDC77D8C85A4AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_759459D02C2643601EDC77D8C85A4AA2" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_759459D02C2643601EDC77D8C85A4AA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:to="lab_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C" xlink:to="lab_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C" xlink:type="arc" />
    <link:label id="lab_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A_terseLabel_en-US" xlink:label="lab_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A_label_en-US" xlink:label="lab_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A_documentation_en-US" xlink:label="lab_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_A2018EmployeeStockPurchasePlanMember" xlink:label="loc_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A" xlink:to="lab_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_A06C1F67AA710F05ECED77D8C727D872_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_A06C1F67AA710F05ECED77D8C727D872" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_A06C1F67AA710F05ECED77D8C727D872_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_A06C1F67AA710F05ECED77D8C727D872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A06C1F67AA710F05ECED77D8C727D872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_A06C1F67AA710F05ECED77D8C727D872" xlink:to="lab_us-gaap_EmployeeStockOptionMember_A06C1F67AA710F05ECED77D8C727D872" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_1E385D4EFB72C062C84F77D8C7277D6C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_1E385D4EFB72C062C84F77D8C7277D6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_1E385D4EFB72C062C84F77D8C7277D6C_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_1E385D4EFB72C062C84F77D8C7277D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1E385D4EFB72C062C84F77D8C7277D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_1E385D4EFB72C062C84F77D8C7277D6C" xlink:to="lab_us-gaap_EmployeeStockMember_1E385D4EFB72C062C84F77D8C7277D6C" xlink:type="arc" />
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares canceled (in shares)</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_642540B7A3EF308F036977D8C7275F31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_642540B7A3EF308F036977D8C7275F31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_642540B7A3EF308F036977D8C7275F31_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_642540B7A3EF308F036977D8C7275F31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_642540B7A3EF308F036977D8C7275F31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_642540B7A3EF308F036977D8C7275F31" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_642540B7A3EF308F036977D8C7275F31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2C7A238F036D1BED983977D8C7271CF1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2C7A238F036D1BED983977D8C7271CF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, grants in period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2C7A238F036D1BED983977D8C7271CF1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2C7A238F036D1BED983977D8C7271CF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2C7A238F036D1BED983977D8C7271CF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2C7A238F036D1BED983977D8C7271CF1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2C7A238F036D1BED983977D8C7271CF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9748368742DD91618B3777D8C727D0C9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9748368742DD91618B3777D8C727D0C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation not recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9748368742DD91618B3777D8C727D0C9_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9748368742DD91618B3777D8C727D0C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9748368742DD91618B3777D8C727D0C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9748368742DD91618B3777D8C727D0C9" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9748368742DD91618B3777D8C727D0C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C74A240530DD3AFAE87677D8C727C1FD_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C74A240530DD3AFAE87677D8C727C1FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation not recognized, period for recognition (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C74A240530DD3AFAE87677D8C727C1FD_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C74A240530DD3AFAE87677D8C727C1FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C74A240530DD3AFAE87677D8C727C1FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C74A240530DD3AFAE87677D8C727C1FD" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C74A240530DD3AFAE87677D8C727C1FD" xlink:type="arc" />
    <link:label id="lab_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8_terseLabel_en-US" xlink:label="lab_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of stock based compensation expense</link:label>
    <link:label id="lab_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8_label_en-US" xlink:label="lab_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal Of Stock Based Compensation Expense</link:label>
    <link:label id="lab_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8_documentation_en-US" xlink:label="lab_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reversal Of Stock Based Compensation Expense</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ReversalOfStockBasedCompensationExpense" xlink:label="loc_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8" xlink:to="lab_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A45AC792A283A025F6A077D8C7277470_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A45AC792A283A025F6A077D8C7277470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation not recognized, restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A45AC792A283A025F6A077D8C7277470_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A45AC792A283A025F6A077D8C7277470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A45AC792A283A025F6A077D8C7277470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A45AC792A283A025F6A077D8C7277470" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A45AC792A283A025F6A077D8C7277470" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5F16D44B87D1CDA368AB77D8C72B207D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5F16D44B87D1CDA368AB77D8C72B207D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5F16D44B87D1CDA368AB77D8C72B207D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5F16D44B87D1CDA368AB77D8C72B207D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5F16D44B87D1CDA368AB77D8C72B207D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5F16D44B87D1CDA368AB77D8C72B207D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5F16D44B87D1CDA368AB77D8C72B207D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1DF9B2D252E17FE188EC78E6299192D9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1DF9B2D252E17FE188EC78E6299192D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1DF9B2D252E17FE188EC78E6299192D9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1DF9B2D252E17FE188EC78E6299192D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1DF9B2D252E17FE188EC78E6299192D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1DF9B2D252E17FE188EC78E6299192D9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1DF9B2D252E17FE188EC78E6299192D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_DB0BB48FD5871BBE189777D8C72B5D8F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_DB0BB48FD5871BBE189777D8C72B5D8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, maximum employee subscription rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_DB0BB48FD5871BBE189777D8C72B5D8F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_DB0BB48FD5871BBE189777D8C72B5D8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_DB0BB48FD5871BBE189777D8C72B5D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_DB0BB48FD5871BBE189777D8C72B5D8F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_DB0BB48FD5871BBE189777D8C72B5D8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E13637F335E3281C79E877D8C72BA8CA_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E13637F335E3281C79E877D8C72BA8CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, purchase price of common stock (percent of stock value)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E13637F335E3281C79E877D8C72BA8CA_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E13637F335E3281C79E877D8C72BA8CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E13637F335E3281C79E877D8C72BA8CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E13637F335E3281C79E877D8C72BA8CA" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E13637F335E3281C79E877D8C72BA8CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9D861A5BFE515060168A77D8C72B46CE_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9D861A5BFE515060168A77D8C72B46CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9D861A5BFE515060168A77D8C72B46CE_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9D861A5BFE515060168A77D8C72B46CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9D861A5BFE515060168A77D8C72B46CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9D861A5BFE515060168A77D8C72B46CE" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9D861A5BFE515060168A77D8C72B46CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_794D0AC71D04B36F23FA77D8C72B3D55_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_794D0AC71D04B36F23FA77D8C72B3D55" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_794D0AC71D04B36F23FA77D8C72B3D55_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_794D0AC71D04B36F23FA77D8C72B3D55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_794D0AC71D04B36F23FA77D8C72B3D55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_794D0AC71D04B36F23FA77D8C72B3D55" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_794D0AC71D04B36F23FA77D8C72B3D55" xlink:type="arc" />
    <link:label id="lab_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E_terseLabel_en-US" xlink:label="lab_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock subject to repurchase (in shares)</link:label>
    <link:label id="lab_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E_label_en-US" xlink:label="lab_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:label id="lab_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E_documentation_en-US" xlink:label="lab_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CommonStockSubjecttoRepurchaseorCancellation" xlink:label="loc_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E" xlink:to="lab_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E" xlink:type="arc" />
    <link:label id="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C_terseLabel_en-US" xlink:label="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock subject to repurchase, per share</link:label>
    <link:label id="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C_label_en-US" xlink:label="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share</link:label>
    <link:label id="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C_documentation_en-US" xlink:label="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" xlink:label="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C" xlink:to="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_E00B1F03347718C0191977D8C72B4407_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_E00B1F03347718C0191977D8C72B4407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds received for unvested shares</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_E00B1F03347718C0191977D8C72B4407_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_E00B1F03347718C0191977D8C72B4407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_E00B1F03347718C0191977D8C72B4407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_E00B1F03347718C0191977D8C72B4407" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_E00B1F03347718C0191977D8C72B4407" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_569D613F76C8419D55D65A2FE0BE27E2_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_569D613F76C8419D55D65A2FE0BE27E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_569D613F76C8419D55D65A2FE0BE27E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_569D613F76C8419D55D65A2FE0BE27E2" xlink:to="lab_us-gaap_DebtDisclosureAbstract_569D613F76C8419D55D65A2FE0BE27E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_B49CB8E6B98BEA102D945A2FE0BE6FFE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_B49CB8E6B98BEA102D945A2FE0BE6FFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Term Loan and Royalty Purchase Agreement</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_B49CB8E6B98BEA102D945A2FE0BE6FFE_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_B49CB8E6B98BEA102D945A2FE0BE6FFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_B49CB8E6B98BEA102D945A2FE0BE6FFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_B49CB8E6B98BEA102D945A2FE0BE6FFE" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_B49CB8E6B98BEA102D945A2FE0BE6FFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_67C4003D6A1961CEF0B288B6E8A6247A_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_67C4003D6A1961CEF0B288B6E8A6247A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_67C4003D6A1961CEF0B288B6E8A6247A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_67C4003D6A1961CEF0B288B6E8A6247A" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_67C4003D6A1961CEF0B288B6E8A6247A" xlink:type="arc" />
    <link:label id="lab_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14_terseLabel_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14_label_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14_documentation_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_RedeemableNoncontrollingInterestMember" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14" xlink:to="lab_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_4D6E0FB38219A5C2AEC188B6E8A74CB5_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_4D6E0FB38219A5C2AEC188B6E8A74CB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_4D6E0FB38219A5C2AEC188B6E8A74CB5_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_4D6E0FB38219A5C2AEC188B6E8A74CB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_4D6E0FB38219A5C2AEC188B6E8A74CB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_4D6E0FB38219A5C2AEC188B6E8A74CB5" xlink:to="lab_us-gaap_PreferredStockMember_4D6E0FB38219A5C2AEC188B6E8A74CB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B4B44F540E8257FBFF2E88B6E8A749AE_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B4B44F540E8257FBFF2E88B6E8A749AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B4B44F540E8257FBFF2E88B6E8A749AE_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B4B44F540E8257FBFF2E88B6E8A749AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B4B44F540E8257FBFF2E88B6E8A749AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_B4B44F540E8257FBFF2E88B6E8A749AE" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_B4B44F540E8257FBFF2E88B6E8A749AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E1506E711CAB7DDCB50B88B6E8A7B7CD_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E1506E711CAB7DDCB50B88B6E8A7B7CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E1506E711CAB7DDCB50B88B6E8A7B7CD_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E1506E711CAB7DDCB50B88B6E8A7B7CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E1506E711CAB7DDCB50B88B6E8A7B7CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E1506E711CAB7DDCB50B88B6E8A7B7CD" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E1506E711CAB7DDCB50B88B6E8A7B7CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_A2D1011C35A06FCD6FF288B6E8A8CF37_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_A2D1011C35A06FCD6FF288B6E8A8CF37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_A2D1011C35A06FCD6FF288B6E8A8CF37_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_A2D1011C35A06FCD6FF288B6E8A8CF37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A2D1011C35A06FCD6FF288B6E8A8CF37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_A2D1011C35A06FCD6FF288B6E8A8CF37" xlink:to="lab_us-gaap_RetainedEarningsMember_A2D1011C35A06FCD6FF288B6E8A8CF37" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_86813738CB525025119D88B6E8A8AFE6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member_86813738CB525025119D88B6E8A8AFE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2016-09 adoption</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_86813738CB525025119D88B6E8A8AFE6_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member_86813738CB525025119D88B6E8A8AFE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_86813738CB525025119D88B6E8A8AFE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201609Member_86813738CB525025119D88B6E8A8AFE6" xlink:to="lab_us-gaap_AccountingStandardsUpdate201609Member_86813738CB525025119D88B6E8A8AFE6" xlink:type="arc" />
    <link:label id="lab_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE_terseLabel_en-US" xlink:label="lab_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2018-07 adoption</link:label>
    <link:label id="lab_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE_label_en-US" xlink:label="lab_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2018-07 [Member]</link:label>
    <link:label id="lab_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE_documentation_en-US" xlink:label="lab_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2018-07 [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_AccountingStandardsUpdate201807Member" xlink:label="loc_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE" xlink:to="lab_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE" xlink:type="arc" />
    <link:label id="lab_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C_terseLabel_en-US" xlink:label="lab_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:label id="lab_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C_label_en-US" xlink:label="lab_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C_documentation_en-US" xlink:label="lab_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesDConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C" xlink:to="lab_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C" xlink:type="arc" />
    <link:label id="lab_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD_terseLabel_en-US" xlink:label="lab_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:label id="lab_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD_label_en-US" xlink:label="lab_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD_documentation_en-US" xlink:label="lab_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesEConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD" xlink:to="lab_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_41B483BC070EE5F94D0788B6E8AA3516_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_41B483BC070EE5F94D0788B6E8AA3516" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_41B483BC070EE5F94D0788B6E8AA3516" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_41B483BC070EE5F94D0788B6E8AA3516" xlink:to="lab_us-gaap_StockholdersEquity_41B483BC070EE5F94D0788B6E8AA3516" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_06BE039E59DECD8BEAE488B6E8AADDAE_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_06BE039E59DECD8BEAE488B6E8AADDAE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_06BE039E59DECD8BEAE488B6E8AADDAE_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_06BE039E59DECD8BEAE488B6E8AADDAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_06BE039E59DECD8BEAE488B6E8AADDAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_06BE039E59DECD8BEAE488B6E8AADDAE" xlink:to="lab_us-gaap_SharesOutstanding_06BE039E59DECD8BEAE488B6E8AADDAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AB67FB733F4959A94CEB88B6E8AB1F24_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AB67FB733F4959A94CEB88B6E8AB1F24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of new accounting principle</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AB67FB733F4959A94CEB88B6E8AB1F24_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AB67FB733F4959A94CEB88B6E8AB1F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AB67FB733F4959A94CEB88B6E8AB1F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AB67FB733F4959A94CEB88B6E8AB1F24" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AB67FB733F4959A94CEB88B6E8AB1F24" xlink:type="arc" />
    <link:label id="lab_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA_terseLabel_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering (in shares)</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA_label_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA_documentation_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" xlink:label="loc_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA" xlink:to="lab_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA" xlink:type="arc" />
    <link:label id="lab_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44_terseLabel_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44_label_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44_documentation_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" xlink:label="loc_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44" xlink:to="lab_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AA197B13BE353E4DA39888B6E8ABA73B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AA197B13BE353E4DA39888B6E8ABA73B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon follow-on offering, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AA197B13BE353E4DA39888B6E8ABA73B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AA197B13BE353E4DA39888B6E8ABA73B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AA197B13BE353E4DA39888B6E8ABA73B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AA197B13BE353E4DA39888B6E8ABA73B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AA197B13BE353E4DA39888B6E8ABA73B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_48BE5BC2FD012CC768D788B6E8AB1B43_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_48BE5BC2FD012CC768D788B6E8AB1B43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon follow-on offering, net of offering costs of $723</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_48BE5BC2FD012CC768D788B6E8AB1B43_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_48BE5BC2FD012CC768D788B6E8AB1B43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_48BE5BC2FD012CC768D788B6E8AB1B43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_48BE5BC2FD012CC768D788B6E8AB1B43" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_48BE5BC2FD012CC768D788B6E8AB1B43" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829D5F9B37251EFD3A1088B6E8ACAB65_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829D5F9B37251EFD3A1088B6E8ACAB65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829D5F9B37251EFD3A1088B6E8ACAB65_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829D5F9B37251EFD3A1088B6E8ACAB65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829D5F9B37251EFD3A1088B6E8ACAB65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829D5F9B37251EFD3A1088B6E8ACAB65" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829D5F9B37251EFD3A1088B6E8ACAB65" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_F368F7E4659EC11D746A88B6E8AC9D76_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_F368F7E4659EC11D746A88B6E8AC9D76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_F368F7E4659EC11D746A88B6E8AC9D76_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_F368F7E4659EC11D746A88B6E8AC9D76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_F368F7E4659EC11D746A88B6E8AC9D76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_F368F7E4659EC11D746A88B6E8AC9D76" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_F368F7E4659EC11D746A88B6E8AC9D76" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_1D93E98C51296771D75588B6E8AC57E1_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares_1D93E98C51296771D75588B6E8AC57E1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common and convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_1D93E98C51296771D75588B6E8AC57E1_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares_1D93E98C51296771D75588B6E8AC57E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_1D93E98C51296771D75588B6E8AC57E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares_1D93E98C51296771D75588B6E8AC57E1" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares_1D93E98C51296771D75588B6E8AC57E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_36C4F885AC24A300ED7F88B6E8AC65D6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue_36C4F885AC24A300ED7F88B6E8AC65D6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common and convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_36C4F885AC24A300ED7F88B6E8AC65D6_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue_36C4F885AC24A300ED7F88B6E8AC65D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_36C4F885AC24A300ED7F88B6E8AC65D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue_36C4F885AC24A300ED7F88B6E8AC65D6" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue_36C4F885AC24A300ED7F88B6E8AC65D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36742BCE132C6462EFC288B6E8AC4EFB_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36742BCE132C6462EFC288B6E8AC4EFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36742BCE132C6462EFC288B6E8AC4EFB_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36742BCE132C6462EFC288B6E8AC4EFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36742BCE132C6462EFC288B6E8AC4EFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36742BCE132C6462EFC288B6E8AC4EFB" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36742BCE132C6462EFC288B6E8AC4EFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0E57AEA8EBE041181DA888B6E8AC3D9C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0E57AEA8EBE041181DA888B6E8AC3D9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0E57AEA8EBE041181DA888B6E8AC3D9C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0E57AEA8EBE041181DA888B6E8AC3D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0E57AEA8EBE041181DA888B6E8AC3D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0E57AEA8EBE041181DA888B6E8AC3D9C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0E57AEA8EBE041181DA888B6E8AC3D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_996726922F075BE846FB88B6E8ACD95B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_996726922F075BE846FB88B6E8ACD95B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_996726922F075BE846FB88B6E8ACD95B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_996726922F075BE846FB88B6E8ACD95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_996726922F075BE846FB88B6E8ACD95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_996726922F075BE846FB88B6E8ACD95B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_996726922F075BE846FB88B6E8ACD95B" xlink:type="arc" />
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon early exercise of stock options (in shares)</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercises in Period</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercises in Period</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF" xlink:type="arc" />
    <link:label id="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_D8458A0C3EF830147E7C88B6E8AD9104_terseLabel_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_D8458A0C3EF830147E7C88B6E8AD9104" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon early exercise of stock options</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_D8458A0C3EF830147E7C88B6E8AD9104" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_D8458A0C3EF830147E7C88B6E8AD9104" xlink:to="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_D8458A0C3EF830147E7C88B6E8AD9104" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0854FC90483A33B8290988B6E8ADF354_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0854FC90483A33B8290988B6E8ADF354" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0854FC90483A33B8290988B6E8ADF354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0854FC90483A33B8290988B6E8ADF354" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0854FC90483A33B8290988B6E8ADF354" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_878E63CB9521F4D7212488B6E8ADEDBB_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_878E63CB9521F4D7212488B6E8ADEDBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_878E63CB9521F4D7212488B6E8ADEDBB_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_878E63CB9521F4D7212488B6E8ADEDBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_878E63CB9521F4D7212488B6E8ADEDBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_878E63CB9521F4D7212488B6E8ADEDBB" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_878E63CB9521F4D7212488B6E8ADEDBB" xlink:type="arc" />
    <link:label id="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_B1443ECD1D9E34C24E7288B6E8ADDE66_verboseLabel_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_B1443ECD1D9E34C24E7288B6E8ADDE66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_B1443ECD1D9E34C24E7288B6E8ADDE66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_B1443ECD1D9E34C24E7288B6E8ADDE66" xlink:to="lab_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_B1443ECD1D9E34C24E7288B6E8ADDE66" xlink:type="arc" />
    <link:label id="lab_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208_terseLabel_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208_label_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Exercise of Warrants</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208_documentation_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Exercise of Warrants</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueExerciseofWarrants" xlink:label="loc_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208" xlink:to="lab_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208" xlink:type="arc" />
    <link:label id="lab_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0_terseLabel_en-US" xlink:label="lab_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of common stock exercised early</link:label>
    <link:label id="lab_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0_label_en-US" xlink:label="lab_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation For Early Exercised Stock Options</link:label>
    <link:label id="lab_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0_documentation_en-US" xlink:label="lab_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation For Early Exercised Stock Options</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions" xlink:label="loc_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0" xlink:to="lab_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9B5E50593D7B99BCFB9088B6E8AE4A44_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9B5E50593D7B99BCFB9088B6E8AE4A44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9B5E50593D7B99BCFB9088B6E8AE4A44_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9B5E50593D7B99BCFB9088B6E8AE4A44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9B5E50593D7B99BCFB9088B6E8AE4A44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9B5E50593D7B99BCFB9088B6E8AE4A44" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9B5E50593D7B99BCFB9088B6E8AE4A44" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_D9901D485160D0565E2F88B6E8AE0868_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_D9901D485160D0565E2F88B6E8AE0868" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Adjustment of redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_D9901D485160D0565E2F88B6E8AE0868_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_D9901D485160D0565E2F88B6E8AE0868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_D9901D485160D0565E2F88B6E8AE0868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_D9901D485160D0565E2F88B6E8AE0868" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_D9901D485160D0565E2F88B6E8AE0868" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D7AF760685C3FBDE147488B6E8AEC8B5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D7AF760685C3FBDE147488B6E8AEC8B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) gain, net of tax impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D7AF760685C3FBDE147488B6E8AEC8B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D7AF760685C3FBDE147488B6E8AEC8B5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D7AF760685C3FBDE147488B6E8AEC8B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_75F5D5C7CE102FFC5EF488B6E8AE1F73_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_75F5D5C7CE102FFC5EF488B6E8AE1F73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_75F5D5C7CE102FFC5EF488B6E8AE1F73_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_75F5D5C7CE102FFC5EF488B6E8AE1F73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_75F5D5C7CE102FFC5EF488B6E8AE1F73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_75F5D5C7CE102FFC5EF488B6E8AE1F73" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_75F5D5C7CE102FFC5EF488B6E8AE1F73" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_F3FCFA74F34C2C19628088B6E8AE1005_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_F3FCFA74F34C2C19628088B6E8AE1005" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F3FCFA74F34C2C19628088B6E8AE1005" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_F3FCFA74F34C2C19628088B6E8AE1005" xlink:to="lab_us-gaap_SharesOutstanding_F3FCFA74F34C2C19628088B6E8AE1005" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_22F51327E302C1676DB488B6E8AFF263_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_22F51327E302C1676DB488B6E8AFF263" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22F51327E302C1676DB488B6E8AFF263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_22F51327E302C1676DB488B6E8AFF263" xlink:to="lab_us-gaap_StockholdersEquity_22F51327E302C1676DB488B6E8AFF263" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_C0591BBEFA93FD5B7A5088B6E8AF1CE9_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_C0591BBEFA93FD5B7A5088B6E8AF1CE9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_C0591BBEFA93FD5B7A5088B6E8AF1CE9_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_C0591BBEFA93FD5B7A5088B6E8AF1CE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_C0591BBEFA93FD5B7A5088B6E8AF1CE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_C0591BBEFA93FD5B7A5088B6E8AF1CE9" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_C0591BBEFA93FD5B7A5088B6E8AF1CE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22B3FE9BBA904971615688B6E8AF95A9_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22B3FE9BBA904971615688B6E8AF95A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of equity interests in redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22B3FE9BBA904971615688B6E8AF95A9_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22B3FE9BBA904971615688B6E8AF95A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22B3FE9BBA904971615688B6E8AF95A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22B3FE9BBA904971615688B6E8AF95A9" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22B3FE9BBA904971615688B6E8AF95A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4EF52A2D15C62910F33888B6E8AF22E6_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4EF52A2D15C62910F33888B6E8AF22E6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4EF52A2D15C62910F33888B6E8AF22E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4EF52A2D15C62910F33888B6E8AF22E6" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4EF52A2D15C62910F33888B6E8AF22E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_761C862E398D771AB6E75A2FDFD1A482_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_761C862E398D771AB6E75A2FDFD1A482" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_761C862E398D771AB6E75A2FDFD1A482_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_761C862E398D771AB6E75A2FDFD1A482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_761C862E398D771AB6E75A2FDFD1A482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_761C862E398D771AB6E75A2FDFD1A482" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_761C862E398D771AB6E75A2FDFD1A482" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_FEB850B6A05FE021691588B6E80F2B36_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember_FEB850B6A05FE021691588B6E80F2B36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_FEB850B6A05FE021691588B6E80F2B36_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember_FEB850B6A05FE021691588B6E80F2B36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_FEB850B6A05FE021691588B6E80F2B36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember_FEB850B6A05FE021691588B6E80F2B36" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember_FEB850B6A05FE021691588B6E80F2B36" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_A97187A3ADB0A89BB8B788B6E810D385_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_A97187A3ADB0A89BB8B788B6E810D385" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_A97187A3ADB0A89BB8B788B6E810D385_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_A97187A3ADB0A89BB8B788B6E810D385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_A97187A3ADB0A89BB8B788B6E810D385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_A97187A3ADB0A89BB8B788B6E810D385" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_A97187A3ADB0A89BB8B788B6E810D385" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_05308E66C0DAB927361D88B6E810C76F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_05308E66C0DAB927361D88B6E810C76F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_05308E66C0DAB927361D88B6E810C76F_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_05308E66C0DAB927361D88B6E810C76F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_05308E66C0DAB927361D88B6E810C76F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_05308E66C0DAB927361D88B6E810C76F" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_05308E66C0DAB927361D88B6E810C76F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47295D87DA6E90CBC98E88B6E81185DD_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47295D87DA6E90CBC98E88B6E81185DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47295D87DA6E90CBC98E88B6E81185DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47295D87DA6E90CBC98E88B6E81185DD" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47295D87DA6E90CBC98E88B6E81185DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_4ED04ADA12504956E86388B6E8117A97_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent_4ED04ADA12504956E86388B6E8117A97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, short-term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_4ED04ADA12504956E86388B6E8117A97_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent_4ED04ADA12504956E86388B6E8117A97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_4ED04ADA12504956E86388B6E8117A97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesCurrent_4ED04ADA12504956E86388B6E8117A97" xlink:to="lab_us-gaap_DebtSecuritiesCurrent_4ED04ADA12504956E86388B6E8117A97" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrent_B5BAA0B41B56B72E2EFF88B6E811991C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrent_B5BAA0B41B56B72E2EFF88B6E811991C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, long-term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrent_B5BAA0B41B56B72E2EFF88B6E811991C_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrent_B5BAA0B41B56B72E2EFF88B6E811991C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_B5BAA0B41B56B72E2EFF88B6E811991C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrent_B5BAA0B41B56B72E2EFF88B6E811991C" xlink:to="lab_us-gaap_DebtSecuritiesNoncurrent_B5BAA0B41B56B72E2EFF88B6E811991C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_3AB9C08221AFE29C441888B6E8116E91_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_3AB9C08221AFE29C441888B6E8116E91" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_3AB9C08221AFE29C441888B6E8116E91_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_3AB9C08221AFE29C441888B6E8116E91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3AB9C08221AFE29C441888B6E8116E91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3AB9C08221AFE29C441888B6E8116E91" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_3AB9C08221AFE29C441888B6E8116E91" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_F09A8C0D500B4CB11E2D88B6E812B4E0_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_F09A8C0D500B4CB11E2D88B6E812B4E0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_F09A8C0D500B4CB11E2D88B6E812B4E0_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_F09A8C0D500B4CB11E2D88B6E812B4E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_F09A8C0D500B4CB11E2D88B6E812B4E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_F09A8C0D500B4CB11E2D88B6E812B4E0" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_F09A8C0D500B4CB11E2D88B6E812B4E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsMember_9E0ECFB1EA7927FFD6C891FEC2FA7214_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsMember_9E0ECFB1EA7927FFD6C891FEC2FA7214" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsMember_9E0ECFB1EA7927FFD6C891FEC2FA7214_label_en-US" xlink:label="lab_us-gaap_AssetsMember_9E0ECFB1EA7927FFD6C891FEC2FA7214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsMember" xlink:label="loc_us-gaap_AssetsMember_9E0ECFB1EA7927FFD6C891FEC2FA7214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsMember_9E0ECFB1EA7927FFD6C891FEC2FA7214" xlink:to="lab_us-gaap_AssetsMember_9E0ECFB1EA7927FFD6C891FEC2FA7214" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_53814A68ADC3046C37B491FC497501C9_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_53814A68ADC3046C37B491FC497501C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_53814A68ADC3046C37B491FC497501C9_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_53814A68ADC3046C37B491FC497501C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_53814A68ADC3046C37B491FC497501C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember_53814A68ADC3046C37B491FC497501C9" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember_53814A68ADC3046C37B491FC497501C9" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:to="lab_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:to="lab_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:type="arc" />
    <link:label id="lab_country_US_AB15354AB48B695F3A7491EAA7711DA3_terseLabel_en-US" xlink:label="lab_country_US_AB15354AB48B695F3A7491EAA7711DA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_AB15354AB48B695F3A7491EAA7711DA3_label_en-US" xlink:label="lab_country_US_AB15354AB48B695F3A7491EAA7711DA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_AB15354AB48B695F3A7491EAA7711DA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_AB15354AB48B695F3A7491EAA7711DA3" xlink:to="lab_country_US_AB15354AB48B695F3A7491EAA7711DA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_6CEAC1DE94E8AD5D0D6591EAA7718AE9_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_6CEAC1DE94E8AD5D0D6591EAA7718AE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_6CEAC1DE94E8AD5D0D6591EAA7718AE9_label_en-US" xlink:label="lab_us-gaap_NonUsMember_6CEAC1DE94E8AD5D0D6591EAA7718AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_6CEAC1DE94E8AD5D0D6591EAA7718AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_6CEAC1DE94E8AD5D0D6591EAA7718AE9" xlink:to="lab_us-gaap_NonUsMember_6CEAC1DE94E8AD5D0D6591EAA7718AE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_32947E77E56461C5A01691EAA77100CF_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_32947E77E56461C5A01691EAA77100CF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_32947E77E56461C5A01691EAA77100CF_label_en-US" xlink:label="lab_us-gaap_Revenues_32947E77E56461C5A01691EAA77100CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_32947E77E56461C5A01691EAA77100CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_32947E77E56461C5A01691EAA77100CF" xlink:to="lab_us-gaap_Revenues_32947E77E56461C5A01691EAA77100CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_F2486A5D21661A75AE8E91EAA772C144_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_F2486A5D21661A75AE8E91EAA772C144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_F2486A5D21661A75AE8E91EAA772C144_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_F2486A5D21661A75AE8E91EAA772C144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_F2486A5D21661A75AE8E91EAA772C144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_F2486A5D21661A75AE8E91EAA772C144" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_F2486A5D21661A75AE8E91EAA772C144" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4B737706056B39A51D3F77D8C928F9B8_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_4B737706056B39A51D3F77D8C928F9B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_4B737706056B39A51D3F77D8C928F9B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_4B737706056B39A51D3F77D8C928F9B8" xlink:to="lab_us-gaap_IncomeStatementAbstract_4B737706056B39A51D3F77D8C928F9B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:to="lab_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:type="arc" />
    <link:label id="lab_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26_terseLabel_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of precision oncology testing</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26_label_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs of Precision Oncology Testing</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26_documentation_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs of Precision Oncology Testing</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CostsofPrecisionOncologyTesting" xlink:label="loc_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26" xlink:to="lab_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26" xlink:type="arc" />
    <link:label id="lab_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7_terseLabel_en-US" xlink:label="lab_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of development services</link:label>
    <link:label id="lab_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7_label_en-US" xlink:label="lab_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Development Services</link:label>
    <link:label id="lab_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7_documentation_en-US" xlink:label="lab_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost of Development Services</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CostofDevelopmentServices" xlink:label="loc_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7" xlink:to="lab_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7FC444B8A9781655BFB977D8C92843A8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_7FC444B8A9781655BFB977D8C92843A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7FC444B8A9781655BFB977D8C92843A8_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_7FC444B8A9781655BFB977D8C92843A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7FC444B8A9781655BFB977D8C92843A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_7FC444B8A9781655BFB977D8C92843A8" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_7FC444B8A9781655BFB977D8C92843A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_7FBDFFCF718E6AF5A42377D8C9287A1D_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense_7FBDFFCF718E6AF5A42377D8C9287A1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_7FBDFFCF718E6AF5A42377D8C9287A1D_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense_7FBDFFCF718E6AF5A42377D8C9287A1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_7FBDFFCF718E6AF5A42377D8C9287A1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense_7FBDFFCF718E6AF5A42377D8C9287A1D" xlink:to="lab_us-gaap_SellingAndMarketingExpense_7FBDFFCF718E6AF5A42377D8C9287A1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3D92013C6509D7D1E70577D8C9288E76_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_3D92013C6509D7D1E70577D8C9288E76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3D92013C6509D7D1E70577D8C9288E76_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_3D92013C6509D7D1E70577D8C9288E76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3D92013C6509D7D1E70577D8C9288E76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_3D92013C6509D7D1E70577D8C9288E76" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_3D92013C6509D7D1E70577D8C9288E76" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_590EA7EC8F3DF3443F1577D8C92899CC_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_590EA7EC8F3DF3443F1577D8C92899CC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_590EA7EC8F3DF3443F1577D8C92899CC_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_590EA7EC8F3DF3443F1577D8C92899CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_590EA7EC8F3DF3443F1577D8C92899CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_590EA7EC8F3DF3443F1577D8C92899CC" xlink:to="lab_us-gaap_CostsAndExpenses_590EA7EC8F3DF3443F1577D8C92899CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0793B8ECEACBE7E33D9677D8C92C5B39_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_0793B8ECEACBE7E33D9677D8C92C5B39" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0793B8ECEACBE7E33D9677D8C92C5B39_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_0793B8ECEACBE7E33D9677D8C92C5B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_0793B8ECEACBE7E33D9677D8C92C5B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_0793B8ECEACBE7E33D9677D8C92C5B39" xlink:to="lab_us-gaap_OperatingIncomeLoss_0793B8ECEACBE7E33D9677D8C92C5B39" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_59EA801217DC3B350AEE77D8C92CC8E8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_59EA801217DC3B350AEE77D8C92CC8E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_59EA801217DC3B350AEE77D8C92CC8E8_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_59EA801217DC3B350AEE77D8C92CC8E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_59EA801217DC3B350AEE77D8C92CC8E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_59EA801217DC3B350AEE77D8C92CC8E8" xlink:to="lab_us-gaap_InvestmentIncomeInterest_59EA801217DC3B350AEE77D8C92CC8E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_2D71F8DBCAD8895B025377D8C92C2BB9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_2D71F8DBCAD8895B025377D8C92C2BB9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_2D71F8DBCAD8895B025377D8C92C2BB9_label_en-US" xlink:label="lab_us-gaap_InterestExpense_2D71F8DBCAD8895B025377D8C92C2BB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2D71F8DBCAD8895B025377D8C92C2BB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_2D71F8DBCAD8895B025377D8C92C2BB9" xlink:to="lab_us-gaap_InterestExpense_2D71F8DBCAD8895B025377D8C92C2BB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_379F3E89CCD8F999FE6B77D8C92C7965_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_379F3E89CCD8F999FE6B77D8C92C7965" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_379F3E89CCD8F999FE6B77D8C92C7965" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_379F3E89CCD8F999FE6B77D8C92C7965" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_379F3E89CCD8F999FE6B77D8C92C7965" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_A5641AD906C714E9641777D8C92CE07C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_A5641AD906C714E9641777D8C92CE07C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_A5641AD906C714E9641777D8C92CE07C_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_A5641AD906C714E9641777D8C92CE07C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_A5641AD906C714E9641777D8C92CE07C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_A5641AD906C714E9641777D8C92CE07C" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_A5641AD906C714E9641777D8C92CE07C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4C99B8229DC525BBA75D77D8C92C2ADD_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4C99B8229DC525BBA75D77D8C92C2ADD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4C99B8229DC525BBA75D77D8C92C2ADD_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4C99B8229DC525BBA75D77D8C92C2ADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4C99B8229DC525BBA75D77D8C92C2ADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4C99B8229DC525BBA75D77D8C92C2ADD" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4C99B8229DC525BBA75D77D8C92C2ADD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_00C40839CAFAC354B1F277D8C92C8088_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_00C40839CAFAC354B1F277D8C92C8088" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_00C40839CAFAC354B1F277D8C92C8088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_00C40839CAFAC354B1F277D8C92C8088" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_00C40839CAFAC354B1F277D8C92C8088" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_9AC9CF7A2505BC3B754477D8C92CEB66_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_9AC9CF7A2505BC3B754477D8C92CEB66" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_9AC9CF7A2505BC3B754477D8C92CEB66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_9AC9CF7A2505BC3B754477D8C92CEB66" xlink:to="lab_us-gaap_ProfitLoss_9AC9CF7A2505BC3B754477D8C92CEB66" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_5FDE85E6500E5D1A1A4C77D8C92C03CE_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_5FDE85E6500E5D1A1A4C77D8C92C03CE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Guardant Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5FDE85E6500E5D1A1A4C77D8C92C03CE_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_5FDE85E6500E5D1A1A4C77D8C92C03CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5FDE85E6500E5D1A1A4C77D8C92C03CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_5FDE85E6500E5D1A1A4C77D8C92C03CE" xlink:to="lab_us-gaap_NetIncomeLoss_5FDE85E6500E5D1A1A4C77D8C92C03CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_98BEB72AAD3B1B84B86077D8C92C44A1_negatedLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_98BEB72AAD3B1B84B86077D8C92C44A1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend related to repurchase of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_98BEB72AAD3B1B84B86077D8C92C44A1_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_98BEB72AAD3B1B84B86077D8C92C44A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_98BEB72AAD3B1B84B86077D8C92C44A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_98BEB72AAD3B1B84B86077D8C92C44A1" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_98BEB72AAD3B1B84B86077D8C92C44A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6E34E0E9C7CC0DCA170D77D8C92C7793_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6E34E0E9C7CC0DCA170D77D8C92C7793" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Guardant Health, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6E34E0E9C7CC0DCA170D77D8C92C7793_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6E34E0E9C7CC0DCA170D77D8C92C7793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6E34E0E9C7CC0DCA170D77D8C92C7793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6E34E0E9C7CC0DCA170D77D8C92C7793" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6E34E0E9C7CC0DCA170D77D8C92C7793" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_BF34EC48259F895BBAEB77D8C92C5456_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_BF34EC48259F895BBAEB77D8C92C5456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to common stockholders, basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_BF34EC48259F895BBAEB77D8C92C5456_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_BF34EC48259F895BBAEB77D8C92C5456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_BF34EC48259F895BBAEB77D8C92C5456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_BF34EC48259F895BBAEB77D8C92C5456" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_BF34EC48259F895BBAEB77D8C92C5456" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EA1055BFBA99665E3D4077D8C92C7D12_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EA1055BFBA99665E3D4077D8C92C7D12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EA1055BFBA99665E3D4077D8C92C7D12_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EA1055BFBA99665E3D4077D8C92C7D12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EA1055BFBA99665E3D4077D8C92C7D12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EA1055BFBA99665E3D4077D8C92C7D12" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EA1055BFBA99665E3D4077D8C92C7D12" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_3DE149F3BEF00119E2795A2FDF444CCC_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_3DE149F3BEF00119E2795A2FDF444CCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_3DE149F3BEF00119E2795A2FDF444CCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_3DE149F3BEF00119E2795A2FDF444CCC" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_3DE149F3BEF00119E2795A2FDF444CCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_134FD3A28F133F21BCBC5A2FDF443576_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_134FD3A28F133F21BCBC5A2FDF443576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_134FD3A28F133F21BCBC5A2FDF443576_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_134FD3A28F133F21BCBC5A2FDF443576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_134FD3A28F133F21BCBC5A2FDF443576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_134FD3A28F133F21BCBC5A2FDF443576" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_134FD3A28F133F21BCBC5A2FDF443576" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseMember_32FE7EE707A8228FF4EA983D598DCB4B_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember_32FE7EE707A8228FF4EA983D598DCB4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired license</link:label>
    <link:label id="lab_us-gaap_LicenseMember_32FE7EE707A8228FF4EA983D598DCB4B_label_en-US" xlink:label="lab_us-gaap_LicenseMember_32FE7EE707A8228FF4EA983D598DCB4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_32FE7EE707A8228FF4EA983D598DCB4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_32FE7EE707A8228FF4EA983D598DCB4B" xlink:to="lab_us-gaap_LicenseMember_32FE7EE707A8228FF4EA983D598DCB4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_F2DBFB994A38E87AC6A0983D598D235A_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember_F2DBFB994A38E87AC6A0983D598D235A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-compete agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_F2DBFB994A38E87AC6A0983D598D235A_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember_F2DBFB994A38E87AC6A0983D598D235A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_F2DBFB994A38E87AC6A0983D598D235A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember_F2DBFB994A38E87AC6A0983D598D235A" xlink:to="lab_us-gaap_NoncompeteAgreementsMember_F2DBFB994A38E87AC6A0983D598D235A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0AA77BABE118DD986A3A983D598E75E0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0AA77BABE118DD986A3A983D598E75E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0AA77BABE118DD986A3A983D598E75E0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0AA77BABE118DD986A3A983D598E75E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0AA77BABE118DD986A3A983D598E75E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0AA77BABE118DD986A3A983D598E75E0" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0AA77BABE118DD986A3A983D598E75E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9401AEADEDF47B648A71983D598EBA43_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9401AEADEDF47B648A71983D598EBA43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9401AEADEDF47B648A71983D598EBA43_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9401AEADEDF47B648A71983D598EBA43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9401AEADEDF47B648A71983D598EBA43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9401AEADEDF47B648A71983D598EBA43" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9401AEADEDF47B648A71983D598EBA43" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1FEB2C1E46825035E49C983D598E17BA_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1FEB2C1E46825035E49C983D598E17BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1FEB2C1E46825035E49C983D598E17BA_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1FEB2C1E46825035E49C983D598E17BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1FEB2C1E46825035E49C983D598E17BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1FEB2C1E46825035E49C983D598E17BA" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1FEB2C1E46825035E49C983D598E17BA" xlink:type="arc" />
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741_terseLabel_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741_label_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741_documentation_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741" xlink:to="lab_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_95AB1B6257AD6E5373DA983D598F0047_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_95AB1B6257AD6E5373DA983D598F0047" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_95AB1B6257AD6E5373DA983D598F0047_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_95AB1B6257AD6E5373DA983D598F0047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_95AB1B6257AD6E5373DA983D598F0047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_95AB1B6257AD6E5373DA983D598F0047" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_95AB1B6257AD6E5373DA983D598F0047" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseExpense_4840A873DC579953E74D7E7C28D8CD34_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_4840A873DC579953E74D7E7C28D8CD34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_4840A873DC579953E74D7E7C28D8CD34_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_4840A873DC579953E74D7E7C28D8CD34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_4840A873DC579953E74D7E7C28D8CD34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_4840A873DC579953E74D7E7C28D8CD34" xlink:to="lab_us-gaap_OperatingLeaseExpense_4840A873DC579953E74D7E7C28D8CD34" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_088EFF42FE06B827071A7E7C28D80F8E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_088EFF42FE06B827071A7E7C28D80F8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense under Topic 840</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_088EFF42FE06B827071A7E7C28D80F8E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_088EFF42FE06B827071A7E7C28D80F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_088EFF42FE06B827071A7E7C28D80F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_088EFF42FE06B827071A7E7C28D80F8E" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_088EFF42FE06B827071A7E7C28D80F8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_70436A341AEBA9796DD97E7C28D8B56F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_70436A341AEBA9796DD97E7C28D8B56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_70436A341AEBA9796DD97E7C28D8B56F_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_70436A341AEBA9796DD97E7C28D8B56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_70436A341AEBA9796DD97E7C28D8B56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_70436A341AEBA9796DD97E7C28D8B56F" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_70436A341AEBA9796DD97E7C28D8B56F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_AF357508F9ECD705616C7E7C28D987E2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_AF357508F9ECD705616C7E7C28D987E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_AF357508F9ECD705616C7E7C28D987E2_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_AF357508F9ECD705616C7E7C28D987E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_AF357508F9ECD705616C7E7C28D987E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_AF357508F9ECD705616C7E7C28D987E2" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_AF357508F9ECD705616C7E7C28D987E2" xlink:type="arc" />
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability_153042D8D91A62A202977E7C28D9A520_terseLabel_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability_153042D8D91A62A202977E7C28D9A520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease not yet commenced, liability</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability_153042D8D91A62A202977E7C28D9A520_label_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability_153042D8D91A62A202977E7C28D9A520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Lease Liability</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability_153042D8D91A62A202977E7C28D9A520_documentation_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability_153042D8D91A62A202977E7C28D9A520" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Lease Liability</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability_153042D8D91A62A202977E7C28D9A520" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability_153042D8D91A62A202977E7C28D9A520" xlink:to="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability_153042D8D91A62A202977E7C28D9A520" xlink:type="arc" />
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount_5D10C9585A94FF9F17AA7E7C28D9D855_terseLabel_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount_5D10C9585A94FF9F17AA7E7C28D9D855" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease not yet commenced, imputed interest</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount_5D10C9585A94FF9F17AA7E7C28D9D855_label_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount_5D10C9585A94FF9F17AA7E7C28D9D855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Excess Amount</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount_5D10C9585A94FF9F17AA7E7C28D9D855_documentation_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount_5D10C9585A94FF9F17AA7E7C28D9D855" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount_5D10C9585A94FF9F17AA7E7C28D9D855" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount_5D10C9585A94FF9F17AA7E7C28D9D855" xlink:to="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount_5D10C9585A94FF9F17AA7E7C28D9D855" xlink:type="arc" />
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome_E5ACFFFCA5639B10A13F7E7C28D96029_terseLabel_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome_E5ACFFFCA5639B10A13F7E7C28D96029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease not yet commenced, sublease income</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome_E5ACFFFCA5639B10A13F7E7C28D96029_label_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome_E5ACFFFCA5639B10A13F7E7C28D96029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Sublease Income</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome_E5ACFFFCA5639B10A13F7E7C28D96029_documentation_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome_E5ACFFFCA5639B10A13F7E7C28D96029" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Sublease Income</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome_E5ACFFFCA5639B10A13F7E7C28D96029" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome_E5ACFFFCA5639B10A13F7E7C28D96029" xlink:to="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome_E5ACFFFCA5639B10A13F7E7C28D96029" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9871EAA358E9021B1F8BA625E5D014AF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9871EAA358E9021B1F8BA625E5D014AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9871EAA358E9021B1F8BA625E5D014AF_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9871EAA358E9021B1F8BA625E5D014AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9871EAA358E9021B1F8BA625E5D014AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9871EAA358E9021B1F8BA625E5D014AF" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9871EAA358E9021B1F8BA625E5D014AF" xlink:type="arc" />
    <link:label id="lab_gh_DebtSecuritiesTableTextBlock_1E910B68B7CDF08EB9A3A625E5D0D373_terseLabel_en-US" xlink:label="lab_gh_DebtSecuritiesTableTextBlock_1E910B68B7CDF08EB9A3A625E5D0D373" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_gh_DebtSecuritiesTableTextBlock_1E910B68B7CDF08EB9A3A625E5D0D373_label_en-US" xlink:label="lab_gh_DebtSecuritiesTableTextBlock_1E910B68B7CDF08EB9A3A625E5D0D373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Table Text Block]</link:label>
    <link:label id="lab_gh_DebtSecuritiesTableTextBlock_1E910B68B7CDF08EB9A3A625E5D0D373_documentation_en-US" xlink:label="lab_gh_DebtSecuritiesTableTextBlock_1E910B68B7CDF08EB9A3A625E5D0D373" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities [Table Text Block]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_DebtSecuritiesTableTextBlock" xlink:label="loc_gh_DebtSecuritiesTableTextBlock_1E910B68B7CDF08EB9A3A625E5D0D373" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtSecuritiesTableTextBlock_1E910B68B7CDF08EB9A3A625E5D0D373" xlink:to="lab_gh_DebtSecuritiesTableTextBlock_1E910B68B7CDF08EB9A3A625E5D0D373" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_DCF316A158B46DDF73415A2FE17D1696_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_DCF316A158B46DDF73415A2FE17D1696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_DCF316A158B46DDF73415A2FE17D1696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_DCF316A158B46DDF73415A2FE17D1696" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_DCF316A158B46DDF73415A2FE17D1696" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_F6E75C308091DA824BF05A2FE17D0028_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_F6E75C308091DA824BF05A2FE17D0028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Joint Venture</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_F6E75C308091DA824BF05A2FE17D0028_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_F6E75C308091DA824BF05A2FE17D0028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_F6E75C308091DA824BF05A2FE17D0028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_F6E75C308091DA824BF05A2FE17D0028" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_F6E75C308091DA824BF05A2FE17D0028" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_ADB82B6877DF4488C9A977D8C61D5AB7_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_ADB82B6877DF4488C9A977D8C61D5AB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ADB82B6877DF4488C9A977D8C61D5AB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ADB82B6877DF4488C9A977D8C61D5AB7" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_ADB82B6877DF4488C9A977D8C61D5AB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_91957B7C25BCAD9A541677D8C61D0643_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_91957B7C25BCAD9A541677D8C61D0643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, maximum annual employee contributions per employee, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_91957B7C25BCAD9A541677D8C61D0643_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_91957B7C25BCAD9A541677D8C61D0643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_91957B7C25BCAD9A541677D8C61D0643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_91957B7C25BCAD9A541677D8C61D0643" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_91957B7C25BCAD9A541677D8C61D0643" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_02BBCB974AF35E94922677D8C61D4BA9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_02BBCB974AF35E94922677D8C61D4BA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_02BBCB974AF35E94922677D8C61D4BA9_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_02BBCB974AF35E94922677D8C61D4BA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_02BBCB974AF35E94922677D8C61D4BA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_02BBCB974AF35E94922677D8C61D4BA9" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_02BBCB974AF35E94922677D8C61D4BA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AE481E0A9CD61CB278D077D8C660AACE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AE481E0A9CD61CB278D077D8C660AACE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AE481E0A9CD61CB278D077D8C660AACE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AE481E0A9CD61CB278D077D8C660AACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AE481E0A9CD61CB278D077D8C660AACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AE481E0A9CD61CB278D077D8C660AACE" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AE481E0A9CD61CB278D077D8C660AACE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F941C4453F02ADC7D4AB77D8C664B6C2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F941C4453F02ADC7D4AB77D8C664B6C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F941C4453F02ADC7D4AB77D8C664B6C2_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F941C4453F02ADC7D4AB77D8C664B6C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F941C4453F02ADC7D4AB77D8C664B6C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F941C4453F02ADC7D4AB77D8C664B6C2" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F941C4453F02ADC7D4AB77D8C664B6C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_B40EAC9028F39CF66D9477D8C6644CC6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_B40EAC9028F39CF66D9477D8C6644CC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_B40EAC9028F39CF66D9477D8C6644CC6_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_B40EAC9028F39CF66D9477D8C6644CC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_B40EAC9028F39CF66D9477D8C6644CC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_B40EAC9028F39CF66D9477D8C6644CC6" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_B40EAC9028F39CF66D9477D8C6644CC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9D0B353A239A44125AC577D8C6644456_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9D0B353A239A44125AC577D8C6644456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9D0B353A239A44125AC577D8C6644456_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9D0B353A239A44125AC577D8C6644456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9D0B353A239A44125AC577D8C6644456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9D0B353A239A44125AC577D8C6644456" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9D0B353A239A44125AC577D8C6644456" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_371024DDADCD5E3D450F77D8C664654A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_371024DDADCD5E3D450F77D8C664654A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_371024DDADCD5E3D450F77D8C664654A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_371024DDADCD5E3D450F77D8C664654A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_371024DDADCD5E3D450F77D8C664654A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_371024DDADCD5E3D450F77D8C664654A" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_371024DDADCD5E3D450F77D8C664654A" xlink:type="arc" />
    <link:label id="lab_gh_DeferredTaxAssetsLeaseLiabilities_4E6AEDDA8427B5C296F678B7F336CABF_terseLabel_en-US" xlink:label="lab_gh_DeferredTaxAssetsLeaseLiabilities_4E6AEDDA8427B5C296F678B7F336CABF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_gh_DeferredTaxAssetsLeaseLiabilities_4E6AEDDA8427B5C296F678B7F336CABF_label_en-US" xlink:label="lab_gh_DeferredTaxAssetsLeaseLiabilities_4E6AEDDA8427B5C296F678B7F336CABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_gh_DeferredTaxAssetsLeaseLiabilities_4E6AEDDA8427B5C296F678B7F336CABF_documentation_en-US" xlink:label="lab_gh_DeferredTaxAssetsLeaseLiabilities_4E6AEDDA8427B5C296F678B7F336CABF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_gh_DeferredTaxAssetsLeaseLiabilities_4E6AEDDA8427B5C296F678B7F336CABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DeferredTaxAssetsLeaseLiabilities_4E6AEDDA8427B5C296F678B7F336CABF" xlink:to="lab_gh_DeferredTaxAssetsLeaseLiabilities_4E6AEDDA8427B5C296F678B7F336CABF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_64952AA61725EFE95C9B77D8C6649D01_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_64952AA61725EFE95C9B77D8C6649D01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_64952AA61725EFE95C9B77D8C6649D01_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_64952AA61725EFE95C9B77D8C6649D01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_64952AA61725EFE95C9B77D8C6649D01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_64952AA61725EFE95C9B77D8C6649D01" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_64952AA61725EFE95C9B77D8C6649D01" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0AA89563CE746AD2CE4177D8C6643384_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0AA89563CE746AD2CE4177D8C6643384" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0AA89563CE746AD2CE4177D8C6643384_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0AA89563CE746AD2CE4177D8C6643384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0AA89563CE746AD2CE4177D8C6643384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0AA89563CE746AD2CE4177D8C6643384" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0AA89563CE746AD2CE4177D8C6643384" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_537E76F8B2AB4CD4BFFA77D8C664054E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_537E76F8B2AB4CD4BFFA77D8C664054E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_537E76F8B2AB4CD4BFFA77D8C664054E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_537E76F8B2AB4CD4BFFA77D8C664054E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_537E76F8B2AB4CD4BFFA77D8C664054E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_537E76F8B2AB4CD4BFFA77D8C664054E" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_537E76F8B2AB4CD4BFFA77D8C664054E" xlink:type="arc" />
    <link:label id="lab_gh_DeferredTaxLiabilitiesSection481aAdjustment_BCF2FA1A707D5E298A2078B91F25A7E5_negatedTerseLabel_en-US" xlink:label="lab_gh_DeferredTaxLiabilitiesSection481aAdjustment_BCF2FA1A707D5E298A2078B91F25A7E5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Section 481 (a) adjustment</link:label>
    <link:label id="lab_gh_DeferredTaxLiabilitiesSection481aAdjustment_BCF2FA1A707D5E298A2078B91F25A7E5_label_en-US" xlink:label="lab_gh_DeferredTaxLiabilitiesSection481aAdjustment_BCF2FA1A707D5E298A2078B91F25A7E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Section 481 (a) Adjustment</link:label>
    <link:label id="lab_gh_DeferredTaxLiabilitiesSection481aAdjustment_BCF2FA1A707D5E298A2078B91F25A7E5_documentation_en-US" xlink:label="lab_gh_DeferredTaxLiabilitiesSection481aAdjustment_BCF2FA1A707D5E298A2078B91F25A7E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Section 481 (a) Adjustment</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_DeferredTaxLiabilitiesSection481aAdjustment" xlink:label="loc_gh_DeferredTaxLiabilitiesSection481aAdjustment_BCF2FA1A707D5E298A2078B91F25A7E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DeferredTaxLiabilitiesSection481aAdjustment_BCF2FA1A707D5E298A2078B91F25A7E5" xlink:to="lab_gh_DeferredTaxLiabilitiesSection481aAdjustment_BCF2FA1A707D5E298A2078B91F25A7E5" xlink:type="arc" />
    <link:label id="lab_gh_DeferredTaxLiabilitiesRightOfUseAssets_B1A893EA6F0D54A68F8078B9A9274C17_negatedTerseLabel_en-US" xlink:label="lab_gh_DeferredTaxLiabilitiesRightOfUseAssets_B1A893EA6F0D54A68F8078B9A9274C17" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_gh_DeferredTaxLiabilitiesRightOfUseAssets_B1A893EA6F0D54A68F8078B9A9274C17_label_en-US" xlink:label="lab_gh_DeferredTaxLiabilitiesRightOfUseAssets_B1A893EA6F0D54A68F8078B9A9274C17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right-Of-Use Assets</link:label>
    <link:label id="lab_gh_DeferredTaxLiabilitiesRightOfUseAssets_B1A893EA6F0D54A68F8078B9A9274C17_documentation_en-US" xlink:label="lab_gh_DeferredTaxLiabilitiesRightOfUseAssets_B1A893EA6F0D54A68F8078B9A9274C17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right-Of-Use Assets</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_gh_DeferredTaxLiabilitiesRightOfUseAssets_B1A893EA6F0D54A68F8078B9A9274C17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DeferredTaxLiabilitiesRightOfUseAssets_B1A893EA6F0D54A68F8078B9A9274C17" xlink:to="lab_gh_DeferredTaxLiabilitiesRightOfUseAssets_B1A893EA6F0D54A68F8078B9A9274C17" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_011408AB4CCBE20A99AD78BA4AF1B4F0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_011408AB4CCBE20A99AD78BA4AF1B4F0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain/loss on investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_011408AB4CCBE20A99AD78BA4AF1B4F0_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_011408AB4CCBE20A99AD78BA4AF1B4F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Unrealized Gains on Trading Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_011408AB4CCBE20A99AD78BA4AF1B4F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_011408AB4CCBE20A99AD78BA4AF1B4F0" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_011408AB4CCBE20A99AD78BA4AF1B4F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D4443F9691F9D65DE32677D8C664C259_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D4443F9691F9D65DE32677D8C664C259" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D4443F9691F9D65DE32677D8C664C259_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D4443F9691F9D65DE32677D8C664C259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D4443F9691F9D65DE32677D8C664C259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D4443F9691F9D65DE32677D8C664C259" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D4443F9691F9D65DE32677D8C664C259" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_1FB7863C324B0AA20F2D77D8C6643411_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1FB7863C324B0AA20F2D77D8C6643411" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_1FB7863C324B0AA20F2D77D8C6643411_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1FB7863C324B0AA20F2D77D8C6643411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1FB7863C324B0AA20F2D77D8C6643411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1FB7863C324B0AA20F2D77D8C6643411" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1FB7863C324B0AA20F2D77D8C6643411" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_5573B78C68D01A95F9165A2FE167FDCC_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_5573B78C68D01A95F9165A2FE167FDCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_5573B78C68D01A95F9165A2FE167FDCC_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_5573B78C68D01A95F9165A2FE167FDCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_5573B78C68D01A95F9165A2FE167FDCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_5573B78C68D01A95F9165A2FE167FDCC" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_5573B78C68D01A95F9165A2FE167FDCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_34F2295619C95BDC5EFE5A2FE1098713_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_34F2295619C95BDC5EFE5A2FE1098713" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of Bellwether Bio</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_34F2295619C95BDC5EFE5A2FE1098713_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_34F2295619C95BDC5EFE5A2FE1098713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_34F2295619C95BDC5EFE5A2FE1098713" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_34F2295619C95BDC5EFE5A2FE1098713" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_34F2295619C95BDC5EFE5A2FE1098713" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_44E57E7CCAA5C22EA0907E6D011FAF4E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_44E57E7CCAA5C22EA0907E6D011FAF4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_44E57E7CCAA5C22EA0907E6D011FAF4E_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_44E57E7CCAA5C22EA0907E6D011FAF4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_44E57E7CCAA5C22EA0907E6D011FAF4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_44E57E7CCAA5C22EA0907E6D011FAF4E" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_44E57E7CCAA5C22EA0907E6D011FAF4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_27ADB43F08EF6241F7C07E6D011FEAA3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_27ADB43F08EF6241F7C07E6D011FEAA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_27ADB43F08EF6241F7C07E6D011FEAA3_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_27ADB43F08EF6241F7C07E6D011FEAA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_27ADB43F08EF6241F7C07E6D011FEAA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_27ADB43F08EF6241F7C07E6D011FEAA3" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_27ADB43F08EF6241F7C07E6D011FEAA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_620F2829962881372B487E6D011F0D2F_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_620F2829962881372B487E6D011F0D2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_620F2829962881372B487E6D011F0D2F_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_620F2829962881372B487E6D011F0D2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_620F2829962881372B487E6D011F0D2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_620F2829962881372B487E6D011F0D2F" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_620F2829962881372B487E6D011F0D2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2170DCFD2CE8EF612E317E6D011F9CFA_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_2170DCFD2CE8EF612E317E6D011F9CFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2170DCFD2CE8EF612E317E6D011F9CFA_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_2170DCFD2CE8EF612E317E6D011F9CFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2170DCFD2CE8EF612E317E6D011F9CFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_2170DCFD2CE8EF612E317E6D011F9CFA" xlink:to="lab_us-gaap_PreferredStockSharesIssued_2170DCFD2CE8EF612E317E6D011F9CFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_F1405367ED737DBBFE9A7E6D011F62D1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_F1405367ED737DBBFE9A7E6D011F62D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_F1405367ED737DBBFE9A7E6D011F62D1_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_F1405367ED737DBBFE9A7E6D011F62D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F1405367ED737DBBFE9A7E6D011F62D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_F1405367ED737DBBFE9A7E6D011F62D1" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_F1405367ED737DBBFE9A7E6D011F62D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_EA2C9204C1E2D2B2C0897E6D011F52D7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_EA2C9204C1E2D2B2C0897E6D011F52D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_EA2C9204C1E2D2B2C0897E6D011F52D7_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_EA2C9204C1E2D2B2C0897E6D011F52D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_EA2C9204C1E2D2B2C0897E6D011F52D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_EA2C9204C1E2D2B2C0897E6D011F52D7" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_EA2C9204C1E2D2B2C0897E6D011F52D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0476470814564BBF5BD97E6D0120C132_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0476470814564BBF5BD97E6D0120C132" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0476470814564BBF5BD97E6D0120C132_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0476470814564BBF5BD97E6D0120C132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0476470814564BBF5BD97E6D0120C132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_0476470814564BBF5BD97E6D0120C132" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0476470814564BBF5BD97E6D0120C132" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1E05833B47032930F8257E6D0120719F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_1E05833B47032930F8257E6D0120719F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1E05833B47032930F8257E6D0120719F_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_1E05833B47032930F8257E6D0120719F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1E05833B47032930F8257E6D0120719F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_1E05833B47032930F8257E6D0120719F" xlink:to="lab_us-gaap_CommonStockSharesIssued_1E05833B47032930F8257E6D0120719F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_EF3D20CDFDB4B3E213217E6D012077B1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_EF3D20CDFDB4B3E213217E6D012077B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable interest entity, assets</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_EF3D20CDFDB4B3E213217E6D012077B1_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_EF3D20CDFDB4B3E213217E6D012077B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Consolidated, Carrying Amount, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_EF3D20CDFDB4B3E213217E6D012077B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_EF3D20CDFDB4B3E213217E6D012077B1" xlink:to="lab_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_EF3D20CDFDB4B3E213217E6D012077B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_854838CAFF0B702B6A8A7E6D0120D780_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_854838CAFF0B702B6A8A7E6D0120D780" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable interest entity, liabilities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_854838CAFF0B702B6A8A7E6D0120D780_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_854838CAFF0B702B6A8A7E6D0120D780" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Consolidated, Carrying Amount, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_854838CAFF0B702B6A8A7E6D0120D780" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_854838CAFF0B702B6A8A7E6D0120D780" xlink:to="lab_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_854838CAFF0B702B6A8A7E6D0120D780" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_2F969D7CE0CB62AD0AE4983D58727AC5_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_2F969D7CE0CB62AD0AE4983D58727AC5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustment of redeemable noncontrolling interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_2F969D7CE0CB62AD0AE4983D58727AC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_2F969D7CE0CB62AD0AE4983D58727AC5" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_2F969D7CE0CB62AD0AE4983D58727AC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_9E87242A74D1E1BE36C7983D5872CB4D_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_9E87242A74D1E1BE36C7983D5872CB4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Guardant Health, Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9E87242A74D1E1BE36C7983D5872CB4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_9E87242A74D1E1BE36C7983D5872CB4D" xlink:to="lab_us-gaap_NetIncomeLoss_9E87242A74D1E1BE36C7983D5872CB4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_CAB7FF3CBCF57CA3CD05983D5872A1B1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_CAB7FF3CBCF57CA3CD05983D5872A1B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Guardant Health, Inc. common stockholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_CAB7FF3CBCF57CA3CD05983D5872A1B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_CAB7FF3CBCF57CA3CD05983D5872A1B1" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_CAB7FF3CBCF57CA3CD05983D5872A1B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_710F0FD1E3AF48A0740D77D8C8A45DE7_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_710F0FD1E3AF48A0740D77D8C8A45DE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_710F0FD1E3AF48A0740D77D8C8A45DE7_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_710F0FD1E3AF48A0740D77D8C8A45DE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_710F0FD1E3AF48A0740D77D8C8A45DE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_710F0FD1E3AF48A0740D77D8C8A45DE7" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_710F0FD1E3AF48A0740D77D8C8A45DE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_042C33F37D50999946E277D8C8A80C28_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_042C33F37D50999946E277D8C8A80C28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_042C33F37D50999946E277D8C8A80C28_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_042C33F37D50999946E277D8C8A80C28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_042C33F37D50999946E277D8C8A80C28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_042C33F37D50999946E277D8C8A80C28" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_042C33F37D50999946E277D8C8A80C28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_397EAD9A56B0E62ACBEF77D8C8A806DD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_397EAD9A56B0E62ACBEF77D8C8A806DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impact of Adoption of ASC 606</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_397EAD9A56B0E62ACBEF77D8C8A806DD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_397EAD9A56B0E62ACBEF77D8C8A806DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_397EAD9A56B0E62ACBEF77D8C8A806DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_397EAD9A56B0E62ACBEF77D8C8A806DD" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_397EAD9A56B0E62ACBEF77D8C8A806DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0D3C8CBD596F4B03C74A87BA55B434AE_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0D3C8CBD596F4B03C74A87BA55B434AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0D3C8CBD596F4B03C74A87BA55B434AE_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0D3C8CBD596F4B03C74A87BA55B434AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0D3C8CBD596F4B03C74A87BA55B434AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0D3C8CBD596F4B03C74A87BA55B434AE" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0D3C8CBD596F4B03C74A87BA55B434AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_029B22A09317AB5DF4CA87BA55B53ADB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_029B22A09317AB5DF4CA87BA55B53ADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_029B22A09317AB5DF4CA87BA55B53ADB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_029B22A09317AB5DF4CA87BA55B53ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_029B22A09317AB5DF4CA87BA55B53ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_029B22A09317AB5DF4CA87BA55B53ADB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_029B22A09317AB5DF4CA87BA55B53ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6DE327D2C9CD150BD23087BA55B59CE3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6DE327D2C9CD150BD23087BA55B59CE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6DE327D2C9CD150BD23087BA55B59CE3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6DE327D2C9CD150BD23087BA55B59CE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6DE327D2C9CD150BD23087BA55B59CE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6DE327D2C9CD150BD23087BA55B59CE3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6DE327D2C9CD150BD23087BA55B59CE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D2F875BC0CBCA575089387BA55B5C1C3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D2F875BC0CBCA575089387BA55B5C1C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D2F875BC0CBCA575089387BA55B5C1C3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D2F875BC0CBCA575089387BA55B5C1C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D2F875BC0CBCA575089387BA55B5C1C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D2F875BC0CBCA575089387BA55B5C1C3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D2F875BC0CBCA575089387BA55B5C1C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2A3F526B39717377D35F87BA55B5F57A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2A3F526B39717377D35F87BA55B5F57A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2A3F526B39717377D35F87BA55B5F57A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2A3F526B39717377D35F87BA55B5F57A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2A3F526B39717377D35F87BA55B5F57A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2A3F526B39717377D35F87BA55B5F57A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2A3F526B39717377D35F87BA55B5F57A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsMember_AEDEA7D05DEDE682586291CCCCFE36DA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember_AEDEA7D05DEDE682586291CCCCFE36DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_AEDEA7D05DEDE682586291CCCCFE36DA_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember_AEDEA7D05DEDE682586291CCCCFE36DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_AEDEA7D05DEDE682586291CCCCFE36DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember_AEDEA7D05DEDE682586291CCCCFE36DA" xlink:to="lab_us-gaap_OtherAssetsMember_AEDEA7D05DEDE682586291CCCCFE36DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:to="lab_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_78B0F541B4052F814B5B91CCCD055DF8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_78B0F541B4052F814B5B91CCCD055DF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_78B0F541B4052F814B5B91CCCD055DF8_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_78B0F541B4052F814B5B91CCCD055DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_78B0F541B4052F814B5B91CCCD055DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_78B0F541B4052F814B5B91CCCD055DF8" xlink:to="lab_us-gaap_CollaborativeArrangementMember_78B0F541B4052F814B5B91CCCD055DF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCash_F807002154CF6DF07AAB91CCCD071E06_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash_F807002154CF6DF07AAB91CCCD071E06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_F807002154CF6DF07AAB91CCCD071E06_label_en-US" xlink:label="lab_us-gaap_RestrictedCash_F807002154CF6DF07AAB91CCCD071E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_F807002154CF6DF07AAB91CCCD071E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash_F807002154CF6DF07AAB91CCCD071E06" xlink:to="lab_us-gaap_RestrictedCash_F807002154CF6DF07AAB91CCCD071E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9932F5096BB288BCE68591CCCD07529A_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9932F5096BB288BCE68591CCCD07529A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9932F5096BB288BCE68591CCCD07529A_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9932F5096BB288BCE68591CCCD07529A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9932F5096BB288BCE68591CCCD07529A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9932F5096BB288BCE68591CCCD07529A" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9932F5096BB288BCE68591CCCD07529A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_F6642C73CE6C17C4980D91CCCD07D9C5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet_F6642C73CE6C17C4980D91CCCD07D9C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_F6642C73CE6C17C4980D91CCCD07D9C5_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet_F6642C73CE6C17C4980D91CCCD07D9C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_F6642C73CE6C17C4980D91CCCD07D9C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_F6642C73CE6C17C4980D91CCCD07D9C5" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet_F6642C73CE6C17C4980D91CCCD07D9C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_6CFFE234AE0873759C7691CCCD071F3C_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_6CFFE234AE0873759C7691CCCD071F3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_6CFFE234AE0873759C7691CCCD071F3C_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_6CFFE234AE0873759C7691CCCD071F3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_6CFFE234AE0873759C7691CCCD071F3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_6CFFE234AE0873759C7691CCCD071F3C" xlink:to="lab_us-gaap_AdvertisingExpense_6CFFE234AE0873759C7691CCCD071F3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_5320F85A8C33FA3FEC0591CCCD07B1FE_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_5320F85A8C33FA3FEC0591CCCD07B1FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of offering costs related to initial public offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5320F85A8C33FA3FEC0591CCCD07B1FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_5320F85A8C33FA3FEC0591CCCD07B1FE" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_5320F85A8C33FA3FEC0591CCCD07B1FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8C604EB7ABBF3B6CDBD591CCCD08FD5B_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8C604EB7ABBF3B6CDBD591CCCD08FD5B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8C604EB7ABBF3B6CDBD591CCCD08FD5B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8C604EB7ABBF3B6CDBD591CCCD08FD5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8C604EB7ABBF3B6CDBD591CCCD08FD5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8C604EB7ABBF3B6CDBD591CCCD08FD5B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8C604EB7ABBF3B6CDBD591CCCD08FD5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_2439493CD703F9DDC58D91CCCD084778_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_2439493CD703F9DDC58D91CCCD084778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_2439493CD703F9DDC58D91CCCD084778_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_2439493CD703F9DDC58D91CCCD084778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2439493CD703F9DDC58D91CCCD084778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_2439493CD703F9DDC58D91CCCD084778" xlink:to="lab_us-gaap_ContractWithCustomerLiability_2439493CD703F9DDC58D91CCCD084778" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2DFF7A15F827A446A5A691CCCD08CB41_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2DFF7A15F827A446A5A691CCCD08CB41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2DFF7A15F827A446A5A691CCCD08CB41_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2DFF7A15F827A446A5A691CCCD08CB41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2DFF7A15F827A446A5A691CCCD08CB41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2DFF7A15F827A446A5A691CCCD08CB41" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2DFF7A15F827A446A5A691CCCD08CB41" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredOfferingCosts_5535D212A9F49B55669B91CCCD08B5DF_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_5535D212A9F49B55669B91CCCD08B5DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_5535D212A9F49B55669B91CCCD08B5DF_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_5535D212A9F49B55669B91CCCD08B5DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_5535D212A9F49B55669B91CCCD08B5DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts_5535D212A9F49B55669B91CCCD08B5DF" xlink:to="lab_us-gaap_DeferredOfferingCosts_5535D212A9F49B55669B91CCCD08B5DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2F461391F7E7510A17CB91CCCD085D03_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_2F461391F7E7510A17CB91CCCD085D03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2F461391F7E7510A17CB91CCCD085D03_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_2F461391F7E7510A17CB91CCCD085D03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_2F461391F7E7510A17CB91CCCD085D03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_2F461391F7E7510A17CB91CCCD085D03" xlink:to="lab_us-gaap_OperatingLeaseLiability_2F461391F7E7510A17CB91CCCD085D03" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_948F78C39FF81BED3632A625E65EF53F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_948F78C39FF81BED3632A625E65EF53F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_948F78C39FF81BED3632A625E65EF53F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_948F78C39FF81BED3632A625E65EF53F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_948F78C39FF81BED3632A625E65EF53F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_948F78C39FF81BED3632A625E65EF53F" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_948F78C39FF81BED3632A625E65EF53F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4B06DFCCAA22962CA3C6983D59265501_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4B06DFCCAA22962CA3C6983D59265501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4B06DFCCAA22962CA3C6983D59265501_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4B06DFCCAA22962CA3C6983D59265501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4B06DFCCAA22962CA3C6983D59265501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4B06DFCCAA22962CA3C6983D59265501" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4B06DFCCAA22962CA3C6983D59265501" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_43D58AAD6FE3DAE1E3A7983D5926961B_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_43D58AAD6FE3DAE1E3A7983D5926961B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_43D58AAD6FE3DAE1E3A7983D5926961B_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_43D58AAD6FE3DAE1E3A7983D5926961B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_43D58AAD6FE3DAE1E3A7983D5926961B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_43D58AAD6FE3DAE1E3A7983D5926961B" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_43D58AAD6FE3DAE1E3A7983D5926961B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_CF280F98A6114F9B9587983D59264EBB_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_CF280F98A6114F9B9587983D59264EBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_CF280F98A6114F9B9587983D59264EBB_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_CF280F98A6114F9B9587983D59264EBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_CF280F98A6114F9B9587983D59264EBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_CF280F98A6114F9B9587983D59264EBB" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_CF280F98A6114F9B9587983D59264EBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1129DE4AB9A195E78DA3983D592635A2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1129DE4AB9A195E78DA3983D592635A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1129DE4AB9A195E78DA3983D592635A2_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1129DE4AB9A195E78DA3983D592635A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1129DE4AB9A195E78DA3983D592635A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1129DE4AB9A195E78DA3983D592635A2" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1129DE4AB9A195E78DA3983D592635A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5D966A89165292A10053983D59261754_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5D966A89165292A10053983D59261754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5D966A89165292A10053983D59261754_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5D966A89165292A10053983D59261754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5D966A89165292A10053983D59261754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5D966A89165292A10053983D59261754" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5D966A89165292A10053983D59261754" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80D0C12DC7B9680BDE15983D5927426D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80D0C12DC7B9680BDE15983D5927426D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80D0C12DC7B9680BDE15983D5927426D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80D0C12DC7B9680BDE15983D5927426D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80D0C12DC7B9680BDE15983D5927426D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80D0C12DC7B9680BDE15983D5927426D" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80D0C12DC7B9680BDE15983D5927426D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5B1A131239FA42BA67C3983D5927A6D8_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5B1A131239FA42BA67C3983D5927A6D8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5B1A131239FA42BA67C3983D5927A6D8_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5B1A131239FA42BA67C3983D5927A6D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5B1A131239FA42BA67C3983D5927A6D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5B1A131239FA42BA67C3983D5927A6D8" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5B1A131239FA42BA67C3983D5927A6D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_C5F907B8F995C8F7B9B2983D5927FEAF_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_C5F907B8F995C8F7B9B2983D5927FEAF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_C5F907B8F995C8F7B9B2983D5927FEAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_C5F907B8F995C8F7B9B2983D5927FEAF" xlink:to="lab_us-gaap_OperatingLeaseLiability_C5F907B8F995C8F7B9B2983D5927FEAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1A96982AE40252D8B583F21FE361C303_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1A96982AE40252D8B583F21FE361C303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Royalty Payments</link:label>
    <link:label id="lab_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1A96982AE40252D8B583F21FE361C303_label_en-US" xlink:label="lab_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1A96982AE40252D8B583F21FE361C303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1A96982AE40252D8B583F21FE361C303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1A96982AE40252D8B583F21FE361C303" xlink:to="lab_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1A96982AE40252D8B583F21FE361C303" xlink:type="arc" />
    <link:label id="lab_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB_terseLabel_en-US" xlink:label="lab_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity period (years)</link:label>
    <link:label id="lab_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB_label_en-US" xlink:label="lab_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Maturity Period</link:label>
    <link:label id="lab_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB_documentation_en-US" xlink:label="lab_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Securities, Maturity Period</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_MarketableSecuritiesMaturityPeriod" xlink:label="loc_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB" xlink:to="lab_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1D365DED164D80D669465A2FDFA267D1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1D365DED164D80D669465A2FDFA267D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1D365DED164D80D669465A2FDFA267D1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1D365DED164D80D669465A2FDFA267D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1D365DED164D80D669465A2FDFA267D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_1D365DED164D80D669465A2FDFA267D1" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1D365DED164D80D669465A2FDFA267D1" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864_label_en-US" xlink:label="lab_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="lab_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_27611582B90EC2F1529B91EAAA43B3BE_terseLabel_en-US" xlink:label="lab_dei_DocumentType_27611582B90EC2F1529B91EAAA43B3BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_27611582B90EC2F1529B91EAAA43B3BE_label_en-US" xlink:label="lab_dei_DocumentType_27611582B90EC2F1529B91EAAA43B3BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_27611582B90EC2F1529B91EAAA43B3BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_27611582B90EC2F1529B91EAAA43B3BE" xlink:to="lab_dei_DocumentType_27611582B90EC2F1529B91EAAA43B3BE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentAnnualReport_41218A08D5C3FFEB591491EAAA433CE0_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport_41218A08D5C3FFEB591491EAAA433CE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_41218A08D5C3FFEB591491EAAA433CE0_label_en-US" xlink:label="lab_dei_DocumentAnnualReport_41218A08D5C3FFEB591491EAAA433CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_41218A08D5C3FFEB591491EAAA433CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_41218A08D5C3FFEB591491EAAA433CE0" xlink:to="lab_dei_DocumentAnnualReport_41218A08D5C3FFEB591491EAAA433CE0" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_C6939CCABD68D1938FD491EAAA437822_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_C6939CCABD68D1938FD491EAAA437822" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_C6939CCABD68D1938FD491EAAA437822_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_C6939CCABD68D1938FD491EAAA437822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_C6939CCABD68D1938FD491EAAA437822" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_C6939CCABD68D1938FD491EAAA437822" xlink:to="lab_dei_DocumentPeriodEndDate_C6939CCABD68D1938FD491EAAA437822" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_8E36B94CBDC945CA6DB091EAAA43FED4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_8E36B94CBDC945CA6DB091EAAA43FED4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_8E36B94CBDC945CA6DB091EAAA43FED4_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_8E36B94CBDC945CA6DB091EAAA43FED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_8E36B94CBDC945CA6DB091EAAA43FED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_8E36B94CBDC945CA6DB091EAAA43FED4" xlink:to="lab_dei_DocumentTransitionReport_8E36B94CBDC945CA6DB091EAAA43FED4" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_06C2E6ECACA2E51BED3891EAAA44DAD0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_06C2E6ECACA2E51BED3891EAAA44DAD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_06C2E6ECACA2E51BED3891EAAA44DAD0_label_en-US" xlink:label="lab_dei_EntityFileNumber_06C2E6ECACA2E51BED3891EAAA44DAD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_06C2E6ECACA2E51BED3891EAAA44DAD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_06C2E6ECACA2E51BED3891EAAA44DAD0" xlink:to="lab_dei_EntityFileNumber_06C2E6ECACA2E51BED3891EAAA44DAD0" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_7DFA03E0457929301D5491EAAA4458B6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_7DFA03E0457929301D5491EAAA4458B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_7DFA03E0457929301D5491EAAA4458B6_label_en-US" xlink:label="lab_dei_EntityRegistrantName_7DFA03E0457929301D5491EAAA4458B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_7DFA03E0457929301D5491EAAA4458B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_7DFA03E0457929301D5491EAAA4458B6" xlink:to="lab_dei_EntityRegistrantName_7DFA03E0457929301D5491EAAA4458B6" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_5B1D17AE17178EEEF23191EAAA443DDE_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_5B1D17AE17178EEEF23191EAAA443DDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_5B1D17AE17178EEEF23191EAAA443DDE_label_en-US" xlink:label="lab_dei_AmendmentFlag_5B1D17AE17178EEEF23191EAAA443DDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_5B1D17AE17178EEEF23191EAAA443DDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_5B1D17AE17178EEEF23191EAAA443DDE" xlink:to="lab_dei_AmendmentFlag_5B1D17AE17178EEEF23191EAAA443DDE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_40254C32C4CF3ACA7EF291EAAA447EB7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_40254C32C4CF3ACA7EF291EAAA447EB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_40254C32C4CF3ACA7EF291EAAA447EB7_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_40254C32C4CF3ACA7EF291EAAA447EB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_40254C32C4CF3ACA7EF291EAAA447EB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_40254C32C4CF3ACA7EF291EAAA447EB7" xlink:to="lab_dei_DocumentFiscalYearFocus_40254C32C4CF3ACA7EF291EAAA447EB7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9570E65BD821BB94DD4591EAAA446355_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_9570E65BD821BB94DD4591EAAA446355" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9570E65BD821BB94DD4591EAAA446355_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_9570E65BD821BB94DD4591EAAA446355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9570E65BD821BB94DD4591EAAA446355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_9570E65BD821BB94DD4591EAAA446355" xlink:to="lab_dei_DocumentFiscalPeriodFocus_9570E65BD821BB94DD4591EAAA446355" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_1FAA62541099CAF43C5691EAAA451047_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_1FAA62541099CAF43C5691EAAA451047" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_1FAA62541099CAF43C5691EAAA451047_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_1FAA62541099CAF43C5691EAAA451047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1FAA62541099CAF43C5691EAAA451047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_1FAA62541099CAF43C5691EAAA451047" xlink:to="lab_dei_EntityCentralIndexKey_1FAA62541099CAF43C5691EAAA451047" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_37297F34A9FBA7BCE42C91EAAA4538AC_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_37297F34A9FBA7BCE42C91EAAA4538AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_37297F34A9FBA7BCE42C91EAAA4538AC_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_37297F34A9FBA7BCE42C91EAAA4538AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_37297F34A9FBA7BCE42C91EAAA4538AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_37297F34A9FBA7BCE42C91EAAA4538AC" xlink:to="lab_dei_CurrentFiscalYearEndDate_37297F34A9FBA7BCE42C91EAAA4538AC" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_AC70C94ECA63094243C491EAAA4AC545_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_AC70C94ECA63094243C491EAAA4AC545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_AC70C94ECA63094243C491EAAA4AC545_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_AC70C94ECA63094243C491EAAA4AC545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_AC70C94ECA63094243C491EAAA4AC545" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_AC70C94ECA63094243C491EAAA4AC545" xlink:to="lab_dei_EntityIncorporationStateCountryCode_AC70C94ECA63094243C491EAAA4AC545" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0EC137D222611546921E91EAAA4AB4B4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_0EC137D222611546921E91EAAA4AB4B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0EC137D222611546921E91EAAA4AB4B4_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_0EC137D222611546921E91EAAA4AB4B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_0EC137D222611546921E91EAAA4AB4B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_0EC137D222611546921E91EAAA4AB4B4" xlink:to="lab_dei_EntityTaxIdentificationNumber_0EC137D222611546921E91EAAA4AB4B4" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_9F4AD29F5421A79D699B91EAAA4A9E89_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_9F4AD29F5421A79D699B91EAAA4A9E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_9F4AD29F5421A79D699B91EAAA4A9E89_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_9F4AD29F5421A79D699B91EAAA4A9E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_9F4AD29F5421A79D699B91EAAA4A9E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_9F4AD29F5421A79D699B91EAAA4A9E89" xlink:to="lab_dei_EntityAddressAddressLine1_9F4AD29F5421A79D699B91EAAA4A9E89" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_17D0CFCDACBAA4C3485A91EAAA4BF407_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_17D0CFCDACBAA4C3485A91EAAA4BF407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_17D0CFCDACBAA4C3485A91EAAA4BF407_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_17D0CFCDACBAA4C3485A91EAAA4BF407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_17D0CFCDACBAA4C3485A91EAAA4BF407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_17D0CFCDACBAA4C3485A91EAAA4BF407" xlink:to="lab_dei_EntityAddressCityOrTown_17D0CFCDACBAA4C3485A91EAAA4BF407" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_5EEDD19E3136EB417E9E91EAAA4B655F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_5EEDD19E3136EB417E9E91EAAA4B655F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5EEDD19E3136EB417E9E91EAAA4B655F_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_5EEDD19E3136EB417E9E91EAAA4B655F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_5EEDD19E3136EB417E9E91EAAA4B655F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_5EEDD19E3136EB417E9E91EAAA4B655F" xlink:to="lab_dei_EntityAddressStateOrProvince_5EEDD19E3136EB417E9E91EAAA4B655F" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_8E89D4B9F3823E35F4CB91EAAA4BE57A_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_8E89D4B9F3823E35F4CB91EAAA4BE57A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8E89D4B9F3823E35F4CB91EAAA4BE57A_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_8E89D4B9F3823E35F4CB91EAAA4BE57A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_8E89D4B9F3823E35F4CB91EAAA4BE57A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_8E89D4B9F3823E35F4CB91EAAA4BE57A" xlink:to="lab_dei_EntityAddressPostalZipCode_8E89D4B9F3823E35F4CB91EAAA4BE57A" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_4C2E49A8378C08F47BC191EAAA4B4B9B_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_4C2E49A8378C08F47BC191EAAA4B4B9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_4C2E49A8378C08F47BC191EAAA4B4B9B_label_en-US" xlink:label="lab_dei_CityAreaCode_4C2E49A8378C08F47BC191EAAA4B4B9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_4C2E49A8378C08F47BC191EAAA4B4B9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_4C2E49A8378C08F47BC191EAAA4B4B9B" xlink:to="lab_dei_CityAreaCode_4C2E49A8378C08F47BC191EAAA4B4B9B" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_A72EB935DA6E56A5FE9891EAAA4B2FB7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_A72EB935DA6E56A5FE9891EAAA4B2FB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_A72EB935DA6E56A5FE9891EAAA4B2FB7_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_A72EB935DA6E56A5FE9891EAAA4B2FB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_A72EB935DA6E56A5FE9891EAAA4B2FB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_A72EB935DA6E56A5FE9891EAAA4B2FB7" xlink:to="lab_dei_LocalPhoneNumber_A72EB935DA6E56A5FE9891EAAA4B2FB7" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_FF172879D85D0499AB6391EAAA4B9482_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_FF172879D85D0499AB6391EAAA4B9482" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_FF172879D85D0499AB6391EAAA4B9482_label_en-US" xlink:label="lab_dei_Security12bTitle_FF172879D85D0499AB6391EAAA4B9482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_FF172879D85D0499AB6391EAAA4B9482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_FF172879D85D0499AB6391EAAA4B9482" xlink:to="lab_dei_Security12bTitle_FF172879D85D0499AB6391EAAA4B9482" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_40AE5EACA7BE06ED427791EAAA4C4F97_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_40AE5EACA7BE06ED427791EAAA4C4F97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_40AE5EACA7BE06ED427791EAAA4C4F97_label_en-US" xlink:label="lab_dei_TradingSymbol_40AE5EACA7BE06ED427791EAAA4C4F97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_40AE5EACA7BE06ED427791EAAA4C4F97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_40AE5EACA7BE06ED427791EAAA4C4F97" xlink:to="lab_dei_TradingSymbol_40AE5EACA7BE06ED427791EAAA4C4F97" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_06614058F1D925D3D05591EAAA4C200D_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_06614058F1D925D3D05591EAAA4C200D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_06614058F1D925D3D05591EAAA4C200D_label_en-US" xlink:label="lab_dei_SecurityExchangeName_06614058F1D925D3D05591EAAA4C200D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_06614058F1D925D3D05591EAAA4C200D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_06614058F1D925D3D05591EAAA4C200D" xlink:to="lab_dei_SecurityExchangeName_06614058F1D925D3D05591EAAA4C200D" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_0120618A361354945A9E91EAAA4CB8CA_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0120618A361354945A9E91EAAA4CB8CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_0120618A361354945A9E91EAAA4CB8CA_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0120618A361354945A9E91EAAA4CB8CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0120618A361354945A9E91EAAA4CB8CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_0120618A361354945A9E91EAAA4CB8CA" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0120618A361354945A9E91EAAA4CB8CA" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_BCE676E0C8593E802AF491EAAA4CB1D4_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_BCE676E0C8593E802AF491EAAA4CB1D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_BCE676E0C8593E802AF491EAAA4CB1D4_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_BCE676E0C8593E802AF491EAAA4CB1D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_BCE676E0C8593E802AF491EAAA4CB1D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_BCE676E0C8593E802AF491EAAA4CB1D4" xlink:to="lab_dei_EntityVoluntaryFilers_BCE676E0C8593E802AF491EAAA4CB1D4" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_A08E6813E745F2B8A38891EAAA4CB8A4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_A08E6813E745F2B8A38891EAAA4CB8A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_A08E6813E745F2B8A38891EAAA4CB8A4_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_A08E6813E745F2B8A38891EAAA4CB8A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_A08E6813E745F2B8A38891EAAA4CB8A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_A08E6813E745F2B8A38891EAAA4CB8A4" xlink:to="lab_dei_EntityCurrentReportingStatus_A08E6813E745F2B8A38891EAAA4CB8A4" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_BDCFB9C0684D02AC8CD591EAAA4CF199_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_BDCFB9C0684D02AC8CD591EAAA4CF199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_BDCFB9C0684D02AC8CD591EAAA4CF199_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_BDCFB9C0684D02AC8CD591EAAA4CF199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_BDCFB9C0684D02AC8CD591EAAA4CF199" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_BDCFB9C0684D02AC8CD591EAAA4CF199" xlink:to="lab_dei_EntityInteractiveDataCurrent_BDCFB9C0684D02AC8CD591EAAA4CF199" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_0BBDAA8BCCC4ABA17D0891EAAA4CC92A_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_0BBDAA8BCCC4ABA17D0891EAAA4CC92A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_0BBDAA8BCCC4ABA17D0891EAAA4CC92A_label_en-US" xlink:label="lab_dei_EntityFilerCategory_0BBDAA8BCCC4ABA17D0891EAAA4CC92A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0BBDAA8BCCC4ABA17D0891EAAA4CC92A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_0BBDAA8BCCC4ABA17D0891EAAA4CC92A" xlink:to="lab_dei_EntityFilerCategory_0BBDAA8BCCC4ABA17D0891EAAA4CC92A" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_CA95899053A5CDE5D00C91EAAA4DFBE6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_CA95899053A5CDE5D00C91EAAA4DFBE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_CA95899053A5CDE5D00C91EAAA4DFBE6_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_CA95899053A5CDE5D00C91EAAA4DFBE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_CA95899053A5CDE5D00C91EAAA4DFBE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_CA95899053A5CDE5D00C91EAAA4DFBE6" xlink:to="lab_dei_EntitySmallBusiness_CA95899053A5CDE5D00C91EAAA4DFBE6" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_BC0F99DD08B73BBCB45591EAAA4D0E32_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_BC0F99DD08B73BBCB45591EAAA4D0E32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_BC0F99DD08B73BBCB45591EAAA4D0E32_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_BC0F99DD08B73BBCB45591EAAA4D0E32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_BC0F99DD08B73BBCB45591EAAA4D0E32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_BC0F99DD08B73BBCB45591EAAA4D0E32" xlink:to="lab_dei_EntityEmergingGrowthCompany_BC0F99DD08B73BBCB45591EAAA4D0E32" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_7D35FE4E6DFE80CECED391EAAA4DCB18_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_7D35FE4E6DFE80CECED391EAAA4DCB18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_7D35FE4E6DFE80CECED391EAAA4DCB18_label_en-US" xlink:label="lab_dei_EntityShellCompany_7D35FE4E6DFE80CECED391EAAA4DCB18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_7D35FE4E6DFE80CECED391EAAA4DCB18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_7D35FE4E6DFE80CECED391EAAA4DCB18" xlink:to="lab_dei_EntityShellCompany_7D35FE4E6DFE80CECED391EAAA4DCB18" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_1DE67C33FFA2DDA9E0A691EAAA4D41AD_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_1DE67C33FFA2DDA9E0A691EAAA4D41AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_1DE67C33FFA2DDA9E0A691EAAA4D41AD_label_en-US" xlink:label="lab_dei_EntityPublicFloat_1DE67C33FFA2DDA9E0A691EAAA4D41AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_1DE67C33FFA2DDA9E0A691EAAA4D41AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_1DE67C33FFA2DDA9E0A691EAAA4D41AD" xlink:to="lab_dei_EntityPublicFloat_1DE67C33FFA2DDA9E0A691EAAA4D41AD" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_BCE650188D557842EAFE91EAAA4D1624_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_BCE650188D557842EAFE91EAAA4D1624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_BCE650188D557842EAFE91EAAA4D1624_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_BCE650188D557842EAFE91EAAA4D1624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_BCE650188D557842EAFE91EAAA4D1624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_BCE650188D557842EAFE91EAAA4D1624" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_BCE650188D557842EAFE91EAAA4D1624" xlink:type="arc" />
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_0820A354CA66D368A95F91EAAA4DD7C6_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_0820A354CA66D368A95F91EAAA4DD7C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_0820A354CA66D368A95F91EAAA4DD7C6_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_0820A354CA66D368A95F91EAAA4DD7C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0820A354CA66D368A95F91EAAA4DD7C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0820A354CA66D368A95F91EAAA4DD7C6" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock_0820A354CA66D368A95F91EAAA4DD7C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3_label_en-US" xlink:label="lab_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:to="lab_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:to="lab_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:type="arc" />
    <link:label id="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423_terseLabel_en-US" xlink:label="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foundation Medicine, Inc. vs. Guardant Health, Inc..</link:label>
    <link:label id="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423_label_en-US" xlink:label="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member]</link:label>
    <link:label id="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423_documentation_en-US" xlink:label="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" xlink:label="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423" xlink:to="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423" xlink:type="arc" />
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C_terseLabel_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc.</link:label>
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C_label_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member]</link:label>
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C_documentation_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C" xlink:to="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_AE952A85AE05489333B9F21FE3505A82_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_AE952A85AE05489333B9F21FE3505A82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_AE952A85AE05489333B9F21FE3505A82_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_AE952A85AE05489333B9F21FE3505A82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AE952A85AE05489333B9F21FE3505A82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AE952A85AE05489333B9F21FE3505A82" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_AE952A85AE05489333B9F21FE3505A82" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeMember_3A5E776BCCFD533479F4F21FE3519AC2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeMember_3A5E776BCCFD533479F4F21FE3519AC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Income</link:label>
    <link:label id="lab_us-gaap_OtherIncomeMember_3A5E776BCCFD533479F4F21FE3519AC2_label_en-US" xlink:label="lab_us-gaap_OtherIncomeMember_3A5E776BCCFD533479F4F21FE3519AC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="loc_us-gaap_OtherIncomeMember_3A5E776BCCFD533479F4F21FE3519AC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeMember_3A5E776BCCFD533479F4F21FE3519AC2" xlink:to="lab_us-gaap_OtherIncomeMember_3A5E776BCCFD533479F4F21FE3519AC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:type="arc" />
    <link:label id="lab_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60_terseLabel_en-US" xlink:label="lab_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of parties with patent license agreement</link:label>
    <link:label id="lab_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60_label_en-US" xlink:label="lab_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Parties With Patent License Agreement</link:label>
    <link:label id="lab_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60_documentation_en-US" xlink:label="lab_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Parties With Patent License Agreement</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofPartiesWithPatentLicenseAgreement" xlink:label="loc_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60" xlink:to="lab_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_EC64A4B3431D48F96B74F21FE3535560_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_EC64A4B3431D48F96B74F21FE3535560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_EC64A4B3431D48F96B74F21FE3535560_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_EC64A4B3431D48F96B74F21FE3535560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_EC64A4B3431D48F96B74F21FE3535560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_EC64A4B3431D48F96B74F21FE3535560" xlink:to="lab_us-gaap_RoyaltyExpense_EC64A4B3431D48F96B74F21FE3535560" xlink:type="arc" />
    <link:label id="lab_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7_terseLabel_en-US" xlink:label="lab_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of precision oncology testing revenue</link:label>
    <link:label id="lab_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7_label_en-US" xlink:label="lab_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense, Percentage of Precision Oncology Testing Revenue</link:label>
    <link:label id="lab_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7_documentation_en-US" xlink:label="lab_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Expense, Percentage of Precision Oncology Testing Revenue</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue" xlink:label="loc_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7" xlink:to="lab_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7" xlink:type="arc" />
    <link:label id="lab_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B_terseLabel_en-US" xlink:label="lab_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of petitions filed</link:label>
    <link:label id="lab_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B_label_en-US" xlink:label="lab_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Petitions Filed</link:label>
    <link:label id="lab_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B_documentation_en-US" xlink:label="lab_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Petitions Filed</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofPetitionsFiled" xlink:label="loc_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B" xlink:to="lab_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_22E03A4F950D3E83917DF21FE354585A_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_22E03A4F950D3E83917DF21FE354585A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_22E03A4F950D3E83917DF21FE354585A_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_22E03A4F950D3E83917DF21FE354585A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_22E03A4F950D3E83917DF21FE354585A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_22E03A4F950D3E83917DF21FE354585A" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_22E03A4F950D3E83917DF21FE354585A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementExpense_6DDD68D07DE7E2C1E2DBF21FE3548BFA_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_6DDD68D07DE7E2C1E2DBF21FE3548BFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_6DDD68D07DE7E2C1E2DBF21FE3548BFA_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_6DDD68D07DE7E2C1E2DBF21FE3548BFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_6DDD68D07DE7E2C1E2DBF21FE3548BFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense_6DDD68D07DE7E2C1E2DBF21FE3548BFA" xlink:to="lab_us-gaap_LitigationSettlementExpense_6DDD68D07DE7E2C1E2DBF21FE3548BFA" xlink:type="arc" />
    <link:label id="lab_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65_terseLabel_en-US" xlink:label="lab_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of companies that infringed on a patent</link:label>
    <link:label id="lab_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65_label_en-US" xlink:label="lab_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Companies that Infringed on a Patent</link:label>
    <link:label id="lab_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65_documentation_en-US" xlink:label="lab_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Companies that Infringed on a Patent</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofCompaniesthatInfringedonaPatent" xlink:label="loc_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65" xlink:to="lab_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65" xlink:type="arc" />
    <link:label id="lab_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB_terseLabel_en-US" xlink:label="lab_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of asserted patents</link:label>
    <link:label id="lab_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB_label_en-US" xlink:label="lab_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Asserted Patents</link:label>
    <link:label id="lab_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB_documentation_en-US" xlink:label="lab_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Asserted Patents</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofAssertedPatents" xlink:label="loc_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB" xlink:to="lab_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_DC41CF4C9FE06CB92D95F21FE3555AB5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_DC41CF4C9FE06CB92D95F21FE3555AB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount awarded from other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_DC41CF4C9FE06CB92D95F21FE3555AB5_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_DC41CF4C9FE06CB92D95F21FE3555AB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_DC41CF4C9FE06CB92D95F21FE3555AB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_DC41CF4C9FE06CB92D95F21FE3555AB5" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_DC41CF4C9FE06CB92D95F21FE3555AB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_793F3754955EF8A1BDDF77D8C8AE1713_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_793F3754955EF8A1BDDF77D8C8AE1713" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_793F3754955EF8A1BDDF77D8C8AE1713_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_793F3754955EF8A1BDDF77D8C8AE1713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_793F3754955EF8A1BDDF77D8C8AE1713" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_793F3754955EF8A1BDDF77D8C8AE1713" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_793F3754955EF8A1BDDF77D8C8AE1713" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_13E4A8A7331BCD2E368477D8C8AEF046_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_13E4A8A7331BCD2E368477D8C8AEF046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_13E4A8A7331BCD2E368477D8C8AEF046_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_13E4A8A7331BCD2E368477D8C8AEF046" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_13E4A8A7331BCD2E368477D8C8AEF046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_13E4A8A7331BCD2E368477D8C8AEF046" xlink:to="lab_us-gaap_UseOfEstimates_13E4A8A7331BCD2E368477D8C8AEF046" xlink:type="arc" />
    <link:label id="lab_gh_JOBSActAccountingElectionPolicyTextBlock_C4F8618D2CC8E21D4A5777D8C8AE7759_terseLabel_en-US" xlink:label="lab_gh_JOBSActAccountingElectionPolicyTextBlock_C4F8618D2CC8E21D4A5777D8C8AE7759" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JOBS Act Accounting Election</link:label>
    <link:label id="lab_gh_JOBSActAccountingElectionPolicyTextBlock_C4F8618D2CC8E21D4A5777D8C8AE7759_label_en-US" xlink:label="lab_gh_JOBSActAccountingElectionPolicyTextBlock_C4F8618D2CC8E21D4A5777D8C8AE7759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JOBS Act Accounting Election [Policy Text Block]</link:label>
    <link:label id="lab_gh_JOBSActAccountingElectionPolicyTextBlock_C4F8618D2CC8E21D4A5777D8C8AE7759_documentation_en-US" xlink:label="lab_gh_JOBSActAccountingElectionPolicyTextBlock_C4F8618D2CC8E21D4A5777D8C8AE7759" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">JOBS Act Accounting Election [Policy Text Block]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_JOBSActAccountingElectionPolicyTextBlock" xlink:label="loc_gh_JOBSActAccountingElectionPolicyTextBlock_C4F8618D2CC8E21D4A5777D8C8AE7759" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_JOBSActAccountingElectionPolicyTextBlock_C4F8618D2CC8E21D4A5777D8C8AE7759" xlink:to="lab_gh_JOBSActAccountingElectionPolicyTextBlock_C4F8618D2CC8E21D4A5777D8C8AE7759" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_299148A23392B5056FB677D8C8AED152_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_299148A23392B5056FB677D8C8AED152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translations</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_299148A23392B5056FB677D8C8AED152_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_299148A23392B5056FB677D8C8AED152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_299148A23392B5056FB677D8C8AED152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_299148A23392B5056FB677D8C8AED152" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_299148A23392B5056FB677D8C8AED152" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_68006FD04B22F6A4BF5777D8C8AE2072_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_68006FD04B22F6A4BF5777D8C8AE2072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_68006FD04B22F6A4BF5777D8C8AE2072_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_68006FD04B22F6A4BF5777D8C8AE2072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_68006FD04B22F6A4BF5777D8C8AE2072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_68006FD04B22F6A4BF5777D8C8AE2072" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_68006FD04B22F6A4BF5777D8C8AE2072" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_13E46340D77CDE89BE6177D8C8AE57D8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_13E46340D77CDE89BE6177D8C8AE57D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_13E46340D77CDE89BE6177D8C8AE57D8_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_13E46340D77CDE89BE6177D8C8AE57D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_13E46340D77CDE89BE6177D8C8AE57D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_13E46340D77CDE89BE6177D8C8AE57D8" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_13E46340D77CDE89BE6177D8C8AE57D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_2AF468907036F945EAC277D8C8AECB4E_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_2AF468907036F945EAC277D8C8AECB4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_2AF468907036F945EAC277D8C8AECB4E_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_2AF468907036F945EAC277D8C8AECB4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_2AF468907036F945EAC277D8C8AECB4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_2AF468907036F945EAC277D8C8AECB4E" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_2AF468907036F945EAC277D8C8AECB4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_B4C69B1F8A91C424036877D8C8AE793C_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_B4C69B1F8A91C424036877D8C8AE793C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_B4C69B1F8A91C424036877D8C8AE793C_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_B4C69B1F8A91C424036877D8C8AE793C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_B4C69B1F8A91C424036877D8C8AE793C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_B4C69B1F8A91C424036877D8C8AE793C" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_B4C69B1F8A91C424036877D8C8AE793C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_D2BE20C0D31CE5C72E6F77D8C8AEEA4F_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_D2BE20C0D31CE5C72E6F77D8C8AEEA4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_D2BE20C0D31CE5C72E6F77D8C8AEEA4F_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_D2BE20C0D31CE5C72E6F77D8C8AEEA4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_D2BE20C0D31CE5C72E6F77D8C8AEEA4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock_D2BE20C0D31CE5C72E6F77D8C8AEEA4F" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock_D2BE20C0D31CE5C72E6F77D8C8AEEA4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_0260A470D520741DE7A177D8C8AEFFAA_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_0260A470D520741DE7A177D8C8AEFFAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_0260A470D520741DE7A177D8C8AEFFAA_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_0260A470D520741DE7A177D8C8AEFFAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_0260A470D520741DE7A177D8C8AEFFAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_0260A470D520741DE7A177D8C8AEFFAA" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_0260A470D520741DE7A177D8C8AEFFAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_D794C04E95FE0AF5E73177D8C8AE543F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_D794C04E95FE0AF5E73177D8C8AE543F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_D794C04E95FE0AF5E73177D8C8AE543F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_D794C04E95FE0AF5E73177D8C8AE543F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_D794C04E95FE0AF5E73177D8C8AE543F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_D794C04E95FE0AF5E73177D8C8AE543F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_D794C04E95FE0AF5E73177D8C8AE543F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_B4BA260FF1B964854C0977D8C8B20004_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_B4BA260FF1B964854C0977D8C8B20004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_B4BA260FF1B964854C0977D8C8B20004_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_B4BA260FF1B964854C0977D8C8B20004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_B4BA260FF1B964854C0977D8C8B20004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_B4BA260FF1B964854C0977D8C8B20004" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_B4BA260FF1B964854C0977D8C8B20004" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B297AC3591AD69A051E777D8C8B2DD01_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B297AC3591AD69A051E777D8C8B2DD01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B297AC3591AD69A051E777D8C8B2DD01_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B297AC3591AD69A051E777D8C8B2DD01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B297AC3591AD69A051E777D8C8B2DD01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B297AC3591AD69A051E777D8C8B2DD01" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B297AC3591AD69A051E777D8C8B2DD01" xlink:type="arc" />
    <link:label id="lab_gh_ObligationRelatedtoRoyaltyPolicyTextBlock_9F327EC4D9BC8039EB7877D8C8B21384_terseLabel_en-US" xlink:label="lab_gh_ObligationRelatedtoRoyaltyPolicyTextBlock_9F327EC4D9BC8039EB7877D8C8B21384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation Related to Royalty</link:label>
    <link:label id="lab_gh_ObligationRelatedtoRoyaltyPolicyTextBlock_9F327EC4D9BC8039EB7877D8C8B21384_label_en-US" xlink:label="lab_gh_ObligationRelatedtoRoyaltyPolicyTextBlock_9F327EC4D9BC8039EB7877D8C8B21384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligation Related to Royalty [Policy Text Block]</link:label>
    <link:label id="lab_gh_ObligationRelatedtoRoyaltyPolicyTextBlock_9F327EC4D9BC8039EB7877D8C8B21384_documentation_en-US" xlink:label="lab_gh_ObligationRelatedtoRoyaltyPolicyTextBlock_9F327EC4D9BC8039EB7877D8C8B21384" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Obligation Related to Royalty [Policy Text Block]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ObligationRelatedtoRoyaltyPolicyTextBlock" xlink:label="loc_gh_ObligationRelatedtoRoyaltyPolicyTextBlock_9F327EC4D9BC8039EB7877D8C8B21384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ObligationRelatedtoRoyaltyPolicyTextBlock_9F327EC4D9BC8039EB7877D8C8B21384" xlink:to="lab_gh_ObligationRelatedtoRoyaltyPolicyTextBlock_9F327EC4D9BC8039EB7877D8C8B21384" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E5120835EF459E141EC277D8C8B218EE_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E5120835EF459E141EC277D8C8B218EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment for Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E5120835EF459E141EC277D8C8B218EE_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E5120835EF459E141EC277D8C8B218EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E5120835EF459E141EC277D8C8B218EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E5120835EF459E141EC277D8C8B218EE" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E5120835EF459E141EC277D8C8B218EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_35D82424E57932BBBCEB784CEFEA1560_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_35D82424E57932BBBCEB784CEFEA1560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_35D82424E57932BBBCEB784CEFEA1560_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_35D82424E57932BBBCEB784CEFEA1560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_35D82424E57932BBBCEB784CEFEA1560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_35D82424E57932BBBCEB784CEFEA1560" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_35D82424E57932BBBCEB784CEFEA1560" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5B943E8708AB9C29241777D8C8B36326_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5B943E8708AB9C29241777D8C8B36326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5B943E8708AB9C29241777D8C8B36326_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5B943E8708AB9C29241777D8C8B36326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5B943E8708AB9C29241777D8C8B36326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5B943E8708AB9C29241777D8C8B36326" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5B943E8708AB9C29241777D8C8B36326" xlink:type="arc" />
    <link:label id="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_4C7401251720103F56B377D8C8B36834_terseLabel_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_4C7401251720103F56B377D8C8B36834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of Precision Oncology Testing</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_4C7401251720103F56B377D8C8B36834_label_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_4C7401251720103F56B377D8C8B36834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs of Precision Oncology Testing [Policy Text Block]</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_4C7401251720103F56B377D8C8B36834_documentation_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_4C7401251720103F56B377D8C8B36834" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs of Precision Oncology Testing [Policy Text Block]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:label="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_4C7401251720103F56B377D8C8B36834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_4C7401251720103F56B377D8C8B36834" xlink:to="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_4C7401251720103F56B377D8C8B36834" xlink:type="arc" />
    <link:label id="lab_gh_CostofDevelopmentServicesPolicyTextBlock_8B05850593D1E5EE12EC77D8C8B30874_terseLabel_en-US" xlink:label="lab_gh_CostofDevelopmentServicesPolicyTextBlock_8B05850593D1E5EE12EC77D8C8B30874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Development Services</link:label>
    <link:label id="lab_gh_CostofDevelopmentServicesPolicyTextBlock_8B05850593D1E5EE12EC77D8C8B30874_label_en-US" xlink:label="lab_gh_CostofDevelopmentServicesPolicyTextBlock_8B05850593D1E5EE12EC77D8C8B30874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Development Services [Policy Text Block]</link:label>
    <link:label id="lab_gh_CostofDevelopmentServicesPolicyTextBlock_8B05850593D1E5EE12EC77D8C8B30874_documentation_en-US" xlink:label="lab_gh_CostofDevelopmentServicesPolicyTextBlock_8B05850593D1E5EE12EC77D8C8B30874" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost of Development Services [Policy Text Block]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CostofDevelopmentServicesPolicyTextBlock" xlink:label="loc_gh_CostofDevelopmentServicesPolicyTextBlock_8B05850593D1E5EE12EC77D8C8B30874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostofDevelopmentServicesPolicyTextBlock_8B05850593D1E5EE12EC77D8C8B30874" xlink:to="lab_gh_CostofDevelopmentServicesPolicyTextBlock_8B05850593D1E5EE12EC77D8C8B30874" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D07DE1B46E22D4F03E8277D8C8B3A4E8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D07DE1B46E22D4F03E8277D8C8B3A4E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D07DE1B46E22D4F03E8277D8C8B3A4E8_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D07DE1B46E22D4F03E8277D8C8B3A4E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D07DE1B46E22D4F03E8277D8C8B3A4E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D07DE1B46E22D4F03E8277D8C8B3A4E8" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D07DE1B46E22D4F03E8277D8C8B3A4E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_4362F5D0554F1BDD2AED77D8C8B3FA6A_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_4362F5D0554F1BDD2AED77D8C8B3FA6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_4362F5D0554F1BDD2AED77D8C8B3FA6A_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_4362F5D0554F1BDD2AED77D8C8B3FA6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_4362F5D0554F1BDD2AED77D8C8B3FA6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock_4362F5D0554F1BDD2AED77D8C8B3FA6A" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock_4362F5D0554F1BDD2AED77D8C8B3FA6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_95549193E3DAF8835B4F77D8C8B3AA8C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock_95549193E3DAF8835B4F77D8C8B3AA8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_95549193E3DAF8835B4F77D8C8B3AA8C_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock_95549193E3DAF8835B4F77D8C8B3AA8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_95549193E3DAF8835B4F77D8C8B3AA8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock_95549193E3DAF8835B4F77D8C8B3AA8C" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock_95549193E3DAF8835B4F77D8C8B3AA8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0FD80DB24F72DE37011377D8C8B477B5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0FD80DB24F72DE37011377D8C8B477B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0FD80DB24F72DE37011377D8C8B477B5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0FD80DB24F72DE37011377D8C8B477B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0FD80DB24F72DE37011377D8C8B477B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0FD80DB24F72DE37011377D8C8B477B5" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0FD80DB24F72DE37011377D8C8B477B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5A788666C8E473C4340D77D8C8B4315C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_5A788666C8E473C4340D77D8C8B4315C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5A788666C8E473C4340D77D8C8B4315C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_5A788666C8E473C4340D77D8C8B4315C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5A788666C8E473C4340D77D8C8B4315C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_5A788666C8E473C4340D77D8C8B4315C" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_5A788666C8E473C4340D77D8C8B4315C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_62A1C110D456508B550B77D8C8B447A8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_62A1C110D456508B550B77D8C8B447A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share Attributable to Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_62A1C110D456508B550B77D8C8B447A8_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_62A1C110D456508B550B77D8C8B447A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_62A1C110D456508B550B77D8C8B447A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_62A1C110D456508B550B77D8C8B447A8" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_62A1C110D456508B550B77D8C8B447A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01E648E669995118571277D8C8B45D52_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01E648E669995118571277D8C8B45D52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01E648E669995118571277D8C8B45D52_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01E648E669995118571277D8C8B45D52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01E648E669995118571277D8C8B45D52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01E648E669995118571277D8C8B45D52" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01E648E669995118571277D8C8B45D52" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_B3A3521D63A4E76911A888B6E7C6D733_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_B3A3521D63A4E76911A888B6E7C6D733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_B3A3521D63A4E76911A888B6E7C6D733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_B3A3521D63A4E76911A888B6E7C6D733" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_B3A3521D63A4E76911A888B6E7C6D733" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_C1F00CF12FD75CE566CD88B6E7C77357_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_C1F00CF12FD75CE566CD88B6E7C77357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_C1F00CF12FD75CE566CD88B6E7C77357_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_C1F00CF12FD75CE566CD88B6E7C77357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_C1F00CF12FD75CE566CD88B6E7C77357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember_C1F00CF12FD75CE566CD88B6E7C77357" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember_C1F00CF12FD75CE566CD88B6E7C77357" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensingAgreementsMember_7F44C0865EAABB9FCD2088B6E7C8F5F5_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_7F44C0865EAABB9FCD2088B6E7C8F5F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Patent Licensing Agreement</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_7F44C0865EAABB9FCD2088B6E7C8F5F5_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_7F44C0865EAABB9FCD2088B6E7C8F5F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_7F44C0865EAABB9FCD2088B6E7C8F5F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember_7F44C0865EAABB9FCD2088B6E7C8F5F5" xlink:to="lab_us-gaap_LicensingAgreementsMember_7F44C0865EAABB9FCD2088B6E7C8F5F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_3ABEB288BDB35F0AC41A88B6E7C859E7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_3ABEB288BDB35F0AC41A88B6E7C859E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One-time upfront payment for finite-lived intangible asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3ABEB288BDB35F0AC41A88B6E7C859E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3ABEB288BDB35F0AC41A88B6E7C859E7" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_3ABEB288BDB35F0AC41A88B6E7C859E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2A288B358D7572B03EA488B6E7C9EDA2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2A288B358D7572B03EA488B6E7C9EDA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period for purchase of asset, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2A288B358D7572B03EA488B6E7C9EDA2_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2A288B358D7572B03EA488B6E7C9EDA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2A288B358D7572B03EA488B6E7C9EDA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2A288B358D7572B03EA488B6E7C9EDA2" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2A288B358D7572B03EA488B6E7C9EDA2" xlink:type="arc" />
    <link:label id="lab_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA_terseLabel_en-US" xlink:label="lab_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA_label_en-US" xlink:label="lab_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Milestone, Payment Upon Achievement</link:label>
    <link:label id="lab_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA_documentation_en-US" xlink:label="lab_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Milestone, Payment Upon Achievement</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_LicenseAgreementMilestonePaymentUponAchievement" xlink:label="loc_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA" xlink:to="lab_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA" xlink:type="arc" />
    <link:label id="lab_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40_terseLabel_en-US" xlink:label="lab_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future royalty payments</link:label>
    <link:label id="lab_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40_label_en-US" xlink:label="lab_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Future Royalties</link:label>
    <link:label id="lab_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40_documentation_en-US" xlink:label="lab_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Future Royalties</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentsforFutureRoyalties" xlink:label="loc_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40" xlink:to="lab_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_17291C750C8653FC18B088B6E7C9682D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_17291C750C8653FC18B088B6E7C9682D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of stock issued for purchase of license agreement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_17291C750C8653FC18B088B6E7C9682D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_17291C750C8653FC18B088B6E7C9682D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_17291C750C8653FC18B088B6E7C9682D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_17291C750C8653FC18B088B6E7C9682D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_17291C750C8653FC18B088B6E7C9682D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_18AF4BD120B1A2522EBD88B6E7C99F1C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput_18AF4BD120B1A2522EBD88B6E7C99F1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt security, measurement input</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_18AF4BD120B1A2522EBD88B6E7C99F1C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput_18AF4BD120B1A2522EBD88B6E7C99F1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_18AF4BD120B1A2522EBD88B6E7C99F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput_18AF4BD120B1A2522EBD88B6E7C99F1C" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput_18AF4BD120B1A2522EBD88B6E7C99F1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6606AAEEE63A8D766B9E88B6E7CA62AF_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6606AAEEE63A8D766B9E88B6E7CA62AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, useful life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6606AAEEE63A8D766B9E88B6E7CA62AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6606AAEEE63A8D766B9E88B6E7CA62AF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6606AAEEE63A8D766B9E88B6E7CA62AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_887CEB8C10D58D1205A288B6E7CA982D_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_887CEB8C10D58D1205A288B6E7CA982D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_887CEB8C10D58D1205A288B6E7CA982D_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_887CEB8C10D58D1205A288B6E7CA982D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_887CEB8C10D58D1205A288B6E7CA982D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_887CEB8C10D58D1205A288B6E7CA982D" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_887CEB8C10D58D1205A288B6E7CA982D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:to="lab_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:type="arc" />
    <link:label id="lab_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3_terseLabel_en-US" xlink:label="lab_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Agreement, by Payment Tier [Axis]</link:label>
    <link:label id="lab_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3_label_en-US" xlink:label="lab_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Agreement, by Payment Tier [Axis]</link:label>
    <link:label id="lab_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3_documentation_en-US" xlink:label="lab_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Agreement, by Payment Tier [Axis]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementbyPaymentTierAxis" xlink:label="loc_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:to="lab_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:type="arc" />
    <link:label id="lab_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53_terseLabel_en-US" xlink:label="lab_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Agreement, by Payment Tier [Domain]</link:label>
    <link:label id="lab_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53_label_en-US" xlink:label="lab_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Agreement, by Payment Tier [Domain]</link:label>
    <link:label id="lab_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53_documentation_en-US" xlink:label="lab_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Royalty Agreement, by Payment Tier [Axis]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementbyPaymentTierDomain" xlink:label="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:to="lab_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:type="arc" />
    <link:label id="lab_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C_terseLabel_en-US" xlink:label="lab_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tier One</link:label>
    <link:label id="lab_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C_label_en-US" xlink:label="lab_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tier One [Member]</link:label>
    <link:label id="lab_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C_documentation_en-US" xlink:label="lab_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tier One [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_TierOneMember" xlink:label="loc_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C" xlink:to="lab_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C" xlink:type="arc" />
    <link:label id="lab_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA_terseLabel_en-US" xlink:label="lab_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tier Two</link:label>
    <link:label id="lab_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA_label_en-US" xlink:label="lab_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tier Two [Member]</link:label>
    <link:label id="lab_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA_documentation_en-US" xlink:label="lab_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tier Two [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_TierTwoMember" xlink:label="loc_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA" xlink:to="lab_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:to="lab_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:type="arc" />
    <link:label id="lab_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6_terseLabel_en-US" xlink:label="lab_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6_label_en-US" xlink:label="lab_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6_documentation_en-US" xlink:label="lab_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CreditAgreementMember" xlink:label="loc_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6" xlink:to="lab_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6" xlink:type="arc" />
    <link:label id="lab_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C_terseLabel_en-US" xlink:label="lab_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Agreement</link:label>
    <link:label id="lab_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C_label_en-US" xlink:label="lab_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Agreement [Member]</link:label>
    <link:label id="lab_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C_documentation_en-US" xlink:label="lab_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Agreement [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementMember" xlink:label="loc_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C" xlink:to="lab_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:to="lab_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674" xlink:to="lab_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorLoansMember_8EEF31F98D53609661B1F21FE36CCA32_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLoansMember_8EEF31F98D53609661B1F21FE36CCA32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Term Loan</link:label>
    <link:label id="lab_us-gaap_SeniorLoansMember_8EEF31F98D53609661B1F21FE36CCA32_label_en-US" xlink:label="lab_us-gaap_SeniorLoansMember_8EEF31F98D53609661B1F21FE36CCA32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Loans [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorLoansMember" xlink:label="loc_us-gaap_SeniorLoansMember_8EEF31F98D53609661B1F21FE36CCA32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLoansMember_8EEF31F98D53609661B1F21FE36CCA32" xlink:to="lab_us-gaap_SeniorLoansMember_8EEF31F98D53609661B1F21FE36CCA32" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81A5451D1FB027175816F21FE36C69B2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81A5451D1FB027175816F21FE36C69B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity (up to)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81A5451D1FB027175816F21FE36C69B2_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81A5451D1FB027175816F21FE36C69B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81A5451D1FB027175816F21FE36C69B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81A5451D1FB027175816F21FE36C69B2" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81A5451D1FB027175816F21FE36C69B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_13F988D1C5934EE81050F21FE36D4EDB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit_13F988D1C5934EE81050F21FE36D4EDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowing</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_13F988D1C5934EE81050F21FE36D4EDB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit_13F988D1C5934EE81050F21FE36D4EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_13F988D1C5934EE81050F21FE36D4EDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit_13F988D1C5934EE81050F21FE36D4EDB" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit_13F988D1C5934EE81050F21FE36D4EDB" xlink:type="arc" />
    <link:label id="lab_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE_terseLabel_en-US" xlink:label="lab_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, stated interest rate</link:label>
    <link:label id="lab_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE_label_en-US" xlink:label="lab_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Rate Basis, Base Rate</link:label>
    <link:label id="lab_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE_documentation_en-US" xlink:label="lab_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Rate Basis, Base Rate</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_DebtInstrumentVariableRateBasisBaseRate" xlink:label="loc_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE" xlink:to="lab_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0DDBBCF7139CEB5ECEA7F21FE36D5B84_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0DDBBCF7139CEB5ECEA7F21FE36D5B84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0DDBBCF7139CEB5ECEA7F21FE36D5B84_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0DDBBCF7139CEB5ECEA7F21FE36D5B84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0DDBBCF7139CEB5ECEA7F21FE36D5B84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0DDBBCF7139CEB5ECEA7F21FE36D5B84" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0DDBBCF7139CEB5ECEA7F21FE36D5B84" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53AA0BD27CDE104E86A7F21FE36DEEFE_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53AA0BD27CDE104E86A7F21FE36DEEFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53AA0BD27CDE104E86A7F21FE36DEEFE_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53AA0BD27CDE104E86A7F21FE36DEEFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53AA0BD27CDE104E86A7F21FE36DEEFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53AA0BD27CDE104E86A7F21FE36DEEFE" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53AA0BD27CDE104E86A7F21FE36DEEFE" xlink:type="arc" />
    <link:label id="lab_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD_terseLabel_en-US" xlink:label="lab_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty agreement payment tier threshold</link:label>
    <link:label id="lab_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD_label_en-US" xlink:label="lab_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Agreement Payment Tier Threshold</link:label>
    <link:label id="lab_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD_documentation_en-US" xlink:label="lab_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Agreement Payment Tier Threshold</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementPaymentTierThreshold" xlink:label="loc_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD" xlink:to="lab_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD" xlink:type="arc" />
    <link:label id="lab_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A_terseLabel_en-US" xlink:label="lab_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly royalty payments, percentage of revenue</link:label>
    <link:label id="lab_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A_label_en-US" xlink:label="lab_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payments, Percentage of Revenue</link:label>
    <link:label id="lab_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A_documentation_en-US" xlink:label="lab_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Payments, Percentage of Revenue</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyPaymentsPercentageofRevenue" xlink:label="loc_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A" xlink:to="lab_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_2ADC4291B13BA2C94C5CF21FE36EC031_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_2ADC4291B13BA2C94C5CF21FE36EC031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_2ADC4291B13BA2C94C5CF21FE36EC031_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_2ADC4291B13BA2C94C5CF21FE36EC031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_2ADC4291B13BA2C94C5CF21FE36EC031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_2ADC4291B13BA2C94C5CF21FE36EC031" xlink:to="lab_us-gaap_RepaymentsOfDebt_2ADC4291B13BA2C94C5CF21FE36EC031" xlink:type="arc" />
    <link:label id="lab_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31_terseLabel_en-US" xlink:label="lab_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of accrued interest</link:label>
    <link:label id="lab_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31_label_en-US" xlink:label="lab_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Accrued Interest, Debt</link:label>
    <link:label id="lab_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31_documentation_en-US" xlink:label="lab_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment of Accrued Interest, Debt</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentofAccruedInterestDebt" xlink:label="loc_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31" xlink:to="lab_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_1BBF24202D6DE06F399CF21FE36E5B37_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_1BBF24202D6DE06F399CF21FE36E5B37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment penalty</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_1BBF24202D6DE06F399CF21FE36E5B37_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_1BBF24202D6DE06F399CF21FE36E5B37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_1BBF24202D6DE06F399CF21FE36E5B37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_1BBF24202D6DE06F399CF21FE36E5B37" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_1BBF24202D6DE06F399CF21FE36E5B37" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_9446B0B4AE3CA9673BCFF21FE36E7160_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_9446B0B4AE3CA9673BCFF21FE36E7160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_9446B0B4AE3CA9673BCFF21FE36E7160_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_9446B0B4AE3CA9673BCFF21FE36E7160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_9446B0B4AE3CA9673BCFF21FE36E7160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount_9446B0B4AE3CA9673BCFF21FE36E7160" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount_9446B0B4AE3CA9673BCFF21FE36E7160" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_8D8D8C863BE4A6985D67F21FE36E6BFD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount_8D8D8C863BE4A6985D67F21FE36E6BFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_8D8D8C863BE4A6985D67F21FE36E6BFD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount_8D8D8C863BE4A6985D67F21FE36E6BFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_8D8D8C863BE4A6985D67F21FE36E6BFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount_8D8D8C863BE4A6985D67F21FE36E6BFD" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount_8D8D8C863BE4A6985D67F21FE36E6BFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_265B2987106B44FF4340F21FE36EAB41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_265B2987106B44FF4340F21FE36EAB41" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_265B2987106B44FF4340F21FE36EAB41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_265B2987106B44FF4340F21FE36EAB41" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_265B2987106B44FF4340F21FE36EAB41" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_FC1662A75FD56C6BDBB5F21FE36F1318_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_FC1662A75FD56C6BDBB5F21FE36F1318" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_FC1662A75FD56C6BDBB5F21FE36F1318_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_FC1662A75FD56C6BDBB5F21FE36F1318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_FC1662A75FD56C6BDBB5F21FE36F1318" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_FC1662A75FD56C6BDBB5F21FE36F1318" xlink:to="lab_us-gaap_LongTermDebt_FC1662A75FD56C6BDBB5F21FE36F1318" xlink:type="arc" />
    <link:label id="lab_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE_terseLabel_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Precision oncology testing</link:label>
    <link:label id="lab_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE_label_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Precision Oncology Testing [Member]</link:label>
    <link:label id="lab_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE_documentation_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Precision Oncology Testing [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_PrecisionOncologyTestingMember" xlink:label="loc_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE" xlink:to="lab_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_921771769F7D408C8E06D49BC429463C_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_921771769F7D408C8E06D49BC429463C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_921771769F7D408C8E06D49BC429463C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_921771769F7D408C8E06D49BC429463C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_921771769F7D408C8E06D49BC429463C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_921771769F7D408C8E06D49BC429463C" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_921771769F7D408C8E06D49BC429463C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_83FFE9F3B5BA95B34CC1D49BC4294EEA_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember_83FFE9F3B5BA95B34CC1D49BC4294EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_83FFE9F3B5BA95B34CC1D49BC4294EEA_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember_83FFE9F3B5BA95B34CC1D49BC4294EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_83FFE9F3B5BA95B34CC1D49BC4294EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember_83FFE9F3B5BA95B34CC1D49BC4294EEA" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember_83FFE9F3B5BA95B34CC1D49BC4294EEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_26DA9B1A2ACE0443957DD49BC42A7181_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_26DA9B1A2ACE0443957DD49BC42A7181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_26DA9B1A2ACE0443957DD49BC42A7181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_26DA9B1A2ACE0443957DD49BC42A7181" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_26DA9B1A2ACE0443957DD49BC42A7181" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_369B890C6BC808309A8577D8C85C4CBF_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_369B890C6BC808309A8577D8C85C4CBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_369B890C6BC808309A8577D8C85C4CBF_label_en-US" xlink:label="lab_us-gaap_Depreciation_369B890C6BC808309A8577D8C85C4CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_369B890C6BC808309A8577D8C85C4CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_369B890C6BC808309A8577D8C85C4CBF" xlink:to="lab_us-gaap_Depreciation_369B890C6BC808309A8577D8C85C4CBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7A3453CA7343B599559AF282AC8361B6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7A3453CA7343B599559AF282AC8361B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7A3453CA7343B599559AF282AC8361B6_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7A3453CA7343B599559AF282AC8361B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7A3453CA7343B599559AF282AC8361B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7A3453CA7343B599559AF282AC8361B6" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7A3453CA7343B599559AF282AC8361B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E91A4A67E35C84261CDFF282AC83160E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E91A4A67E35C84261CDFF282AC83160E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E91A4A67E35C84261CDFF282AC83160E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E91A4A67E35C84261CDFF282AC83160E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E91A4A67E35C84261CDFF282AC83160E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E91A4A67E35C84261CDFF282AC83160E" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E91A4A67E35C84261CDFF282AC83160E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07BAB0768BE5C30DD953F282AC844FD2_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07BAB0768BE5C30DD953F282AC844FD2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07BAB0768BE5C30DD953F282AC844FD2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07BAB0768BE5C30DD953F282AC844FD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07BAB0768BE5C30DD953F282AC844FD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07BAB0768BE5C30DD953F282AC844FD2" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07BAB0768BE5C30DD953F282AC844FD2" xlink:type="arc" />
    <link:label id="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_94943A433066C0D2AE7DA625E504DBF1_terseLabel_en-US" xlink:label="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_94943A433066C0D2AE7DA625E504DBF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_94943A433066C0D2AE7DA625E504DBF1_label_en-US" xlink:label="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_94943A433066C0D2AE7DA625E504DBF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Federal, Income Taxes, Noncontrolling Interest</link:label>
    <link:label id="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_94943A433066C0D2AE7DA625E504DBF1_documentation_en-US" xlink:label="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_94943A433066C0D2AE7DA625E504DBF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Federal, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest" xlink:label="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_94943A433066C0D2AE7DA625E504DBF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_94943A433066C0D2AE7DA625E504DBF1" xlink:to="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_94943A433066C0D2AE7DA625E504DBF1" xlink:type="arc" />
    <link:label id="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_242AB9238034297AE576A625E505B47C_terseLabel_en-US" xlink:label="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_242AB9238034297AE576A625E505B47C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_242AB9238034297AE576A625E505B47C_label_en-US" xlink:label="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_242AB9238034297AE576A625E505B47C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Foreign, Income Taxes, Noncontrolling Interest</link:label>
    <link:label id="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_242AB9238034297AE576A625E505B47C_documentation_en-US" xlink:label="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_242AB9238034297AE576A625E505B47C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Foreign, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest" xlink:label="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_242AB9238034297AE576A625E505B47C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_242AB9238034297AE576A625E505B47C" xlink:to="lab_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_242AB9238034297AE576A625E505B47C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3A5194D41391A20F6656A625E709C069_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3A5194D41391A20F6656A625E709C069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3A5194D41391A20F6656A625E709C069_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3A5194D41391A20F6656A625E709C069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3A5194D41391A20F6656A625E709C069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3A5194D41391A20F6656A625E709C069" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3A5194D41391A20F6656A625E709C069" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EE5493BA92B5424A0D13A625E4F8E5E8_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EE5493BA92B5424A0D13A625E4F8E5E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EE5493BA92B5424A0D13A625E4F8E5E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EE5493BA92B5424A0D13A625E4F8E5E8" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EE5493BA92B5424A0D13A625E4F8E5E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CD2E6DF91C1FB68979FA625E4F9E35B_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CD2E6DF91C1FB68979FA625E4F9E35B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CD2E6DF91C1FB68979FA625E4F9E35B_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CD2E6DF91C1FB68979FA625E4F9E35B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CD2E6DF91C1FB68979FA625E4F9E35B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CD2E6DF91C1FB68979FA625E4F9E35B" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CD2E6DF91C1FB68979FA625E4F9E35B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_975D8CBCCD17E91B5E52F2AFCAFA8462_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_975D8CBCCD17E91B5E52F2AFCAFA8462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_975D8CBCCD17E91B5E52F2AFCAFA8462_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_975D8CBCCD17E91B5E52F2AFCAFA8462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_975D8CBCCD17E91B5E52F2AFCAFA8462" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock_975D8CBCCD17E91B5E52F2AFCAFA8462" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock_975D8CBCCD17E91B5E52F2AFCAFA8462" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_35A9F8BF3C5E0A6DFF45A625E5AB8A0A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_35A9F8BF3C5E0A6DFF45A625E5AB8A0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_35A9F8BF3C5E0A6DFF45A625E5AB8A0A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_35A9F8BF3C5E0A6DFF45A625E5AB8A0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_35A9F8BF3C5E0A6DFF45A625E5AB8A0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_35A9F8BF3C5E0A6DFF45A625E5AB8A0A" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_35A9F8BF3C5E0A6DFF45A625E5AB8A0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_35C922FE9F784360D0B85A8DB2279651_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_35C922FE9F784360D0B85A8DB2279651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_35C922FE9F784360D0B85A8DB2279651_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_35C922FE9F784360D0B85A8DB2279651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_35C922FE9F784360D0B85A8DB2279651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_35C922FE9F784360D0B85A8DB2279651" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_35C922FE9F784360D0B85A8DB2279651" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_901869CDCC0C5DEF12735A8DD81969EE_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_901869CDCC0C5DEF12735A8DD81969EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_901869CDCC0C5DEF12735A8DD81969EE_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_901869CDCC0C5DEF12735A8DD81969EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_901869CDCC0C5DEF12735A8DD81969EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_901869CDCC0C5DEF12735A8DD81969EE" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_901869CDCC0C5DEF12735A8DD81969EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D98583A607885F2EA7045A8E01817076_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D98583A607885F2EA7045A8E01817076" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D98583A607885F2EA7045A8E01817076_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D98583A607885F2EA7045A8E01817076" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D98583A607885F2EA7045A8E01817076" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D98583A607885F2EA7045A8E01817076" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D98583A607885F2EA7045A8E01817076" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B5EE1D303721827560755A8E2DFD3E06_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B5EE1D303721827560755A8E2DFD3E06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B5EE1D303721827560755A8E2DFD3E06_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B5EE1D303721827560755A8E2DFD3E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B5EE1D303721827560755A8E2DFD3E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B5EE1D303721827560755A8E2DFD3E06" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B5EE1D303721827560755A8E2DFD3E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8F15CC6F9B85352345665A8E584B13D0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8F15CC6F9B85352345665A8E584B13D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8F15CC6F9B85352345665A8E584B13D0_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8F15CC6F9B85352345665A8E584B13D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8F15CC6F9B85352345665A8E584B13D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8F15CC6F9B85352345665A8E584B13D0" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8F15CC6F9B85352345665A8E584B13D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2649D93C72AAB605DC235A8E80A9E367_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2649D93C72AAB605DC235A8E80A9E367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2649D93C72AAB605DC235A8E80A9E367_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2649D93C72AAB605DC235A8E80A9E367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2649D93C72AAB605DC235A8E80A9E367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2649D93C72AAB605DC235A8E80A9E367" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2649D93C72AAB605DC235A8E80A9E367" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_33AFD1E1FB1B7E6767ED5A8EA7FA23A6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_33AFD1E1FB1B7E6767ED5A8EA7FA23A6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_33AFD1E1FB1B7E6767ED5A8EA7FA23A6_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_33AFD1E1FB1B7E6767ED5A8EA7FA23A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_33AFD1E1FB1B7E6767ED5A8EA7FA23A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_33AFD1E1FB1B7E6767ED5A8EA7FA23A6" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_33AFD1E1FB1B7E6767ED5A8EA7FA23A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:to="lab_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExecutiveOfficerMember_5809A11025F24830D96291E039FFBD56_terseLabel_en-US" xlink:label="lab_us-gaap_ExecutiveOfficerMember_5809A11025F24830D96291E039FFBD56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Officer</link:label>
    <link:label id="lab_us-gaap_ExecutiveOfficerMember_5809A11025F24830D96291E039FFBD56_label_en-US" xlink:label="lab_us-gaap_ExecutiveOfficerMember_5809A11025F24830D96291E039FFBD56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_5809A11025F24830D96291E039FFBD56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExecutiveOfficerMember_5809A11025F24830D96291E039FFBD56" xlink:to="lab_us-gaap_ExecutiveOfficerMember_5809A11025F24830D96291E039FFBD56" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C" xlink:to="lab_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C" xlink:type="arc" />
    <link:label id="lab_srt_AffiliatedEntityMember_CF687FE8E998B2DEBF6991E03A00E232_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember_CF687FE8E998B2DEBF6991E03A00E232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_CF687FE8E998B2DEBF6991E03A00E232_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember_CF687FE8E998B2DEBF6991E03A00E232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srt_AffiliatedEntityMember_CF687FE8E998B2DEBF6991E03A00E232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember_CF687FE8E998B2DEBF6991E03A00E232" xlink:to="lab_srt_AffiliatedEntityMember_CF687FE8E998B2DEBF6991E03A00E232" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_02577CB2FD985A02C78391E03A01F35D_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares_02577CB2FD985A02C78391E03A01F35D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchased during period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_02577CB2FD985A02C78391E03A01F35D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares_02577CB2FD985A02C78391E03A01F35D" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares_02577CB2FD985A02C78391E03A01F35D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_CF5B2E616D6BD95AFB3191E03A011788_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_CF5B2E616D6BD95AFB3191E03A011788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchased during period, value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_CF5B2E616D6BD95AFB3191E03A011788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_CF5B2E616D6BD95AFB3191E03A011788" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_CF5B2E616D6BD95AFB3191E03A011788" xlink:type="arc" />
    <link:label id="lab_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5_verboseLabel_en-US" xlink:label="lab_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5_label_en-US" xlink:label="lab_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Compensation Expense</link:label>
    <link:label id="lab_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5_documentation_en-US" xlink:label="lab_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Compensation Expense</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CommonStockCompensationExpense" xlink:label="loc_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5" xlink:to="lab_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_9F63F841660F2A76949291E03A014D50_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_9F63F841660F2A76949291E03A014D50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_9F63F841660F2A76949291E03A014D50_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_9F63F841660F2A76949291E03A014D50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_9F63F841660F2A76949291E03A014D50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties_9F63F841660F2A76949291E03A014D50" xlink:to="lab_us-gaap_RevenueFromRelatedParties_9F63F841660F2A76949291E03A014D50" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:to="lab_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6" xlink:type="arc" />
    <link:label id="lab_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D_terseLabel_en-US" xlink:label="lab_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SoftBank</link:label>
    <link:label id="lab_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D_label_en-US" xlink:label="lab_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SoftBank [Member]</link:label>
    <link:label id="lab_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D_documentation_en-US" xlink:label="lab_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SoftBank [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SoftBankMember" xlink:label="loc_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D" xlink:to="lab_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="lab_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47C58A6040A1CA0D3F2177D8C73D0786_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47C58A6040A1CA0D3F2177D8C73D0786" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares purchased in joint venture (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47C58A6040A1CA0D3F2177D8C73D0786_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47C58A6040A1CA0D3F2177D8C73D0786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47C58A6040A1CA0D3F2177D8C73D0786" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47C58A6040A1CA0D3F2177D8C73D0786" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47C58A6040A1CA0D3F2177D8C73D0786" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_B5025D6BCF6F4FA43B0477D8C73D07BF_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_B5025D6BCF6F4FA43B0477D8C73D07BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_B5025D6BCF6F4FA43B0477D8C73D07BF_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_B5025D6BCF6F4FA43B0477D8C73D07BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_B5025D6BCF6F4FA43B0477D8C73D07BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_B5025D6BCF6F4FA43B0477D8C73D07BF" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_B5025D6BCF6F4FA43B0477D8C73D07BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_145A7739F46555E55B2D77D8C73D06C4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_145A7739F46555E55B2D77D8C73D06C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_145A7739F46555E55B2D77D8C73D06C4_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_145A7739F46555E55B2D77D8C73D06C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_145A7739F46555E55B2D77D8C73D06C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_145A7739F46555E55B2D77D8C73D06C4" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_145A7739F46555E55B2D77D8C73D06C4" xlink:type="arc" />
    <link:label id="lab_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6_terseLabel_en-US" xlink:label="lab_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of new shares issued</link:label>
    <link:label id="lab_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6_label_en-US" xlink:label="lab_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Percentage of New Shares Issued</link:label>
    <link:label id="lab_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6_documentation_en-US" xlink:label="lab_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold Percentage of New Shares Issued</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ThresholdPercentageofNewSharesIssued" xlink:label="loc_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6" xlink:to="lab_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6" xlink:type="arc" />
    <link:label id="lab_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808_terseLabel_en-US" xlink:label="lab_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold period after initial closing to issue new shares</link:label>
    <link:label id="lab_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808_label_en-US" xlink:label="lab_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Period After Initial Closing to Issue New Shares</link:label>
    <link:label id="lab_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808_documentation_en-US" xlink:label="lab_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold Period After Initial Closing to Issue New Shares</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares" xlink:label="loc_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808" xlink:to="lab_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_50D21BE6D60009C139D877D8C73D7EC6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_50D21BE6D60009C139D877D8C73D7EC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock acquired, average cost per share</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_50D21BE6D60009C139D877D8C73D7EC6_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_50D21BE6D60009C139D877D8C73D7EC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_50D21BE6D60009C139D877D8C73D7EC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_50D21BE6D60009C139D877D8C73D7EC6" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_50D21BE6D60009C139D877D8C73D7EC6" xlink:type="arc" />
    <link:label id="lab_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5_terseLabel_en-US" xlink:label="lab_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of the original price per share of Series E convertible preferred stock</link:label>
    <link:label id="lab_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5_label_en-US" xlink:label="lab_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of the Original Price per Share of the Convertible Preferred Stock</link:label>
    <link:label id="lab_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5_documentation_en-US" xlink:label="lab_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the Original Price per Share of the Convertible Preferred Stock</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock" xlink:label="loc_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5" xlink:to="lab_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00174AF260115AE4137677D8C73D6D65_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00174AF260115AE4137677D8C73D6D65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00174AF260115AE4137677D8C73D6D65_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00174AF260115AE4137677D8C73D6D65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00174AF260115AE4137677D8C73D6D65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00174AF260115AE4137677D8C73D6D65" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00174AF260115AE4137677D8C73D6D65" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_F5D664059A8137CCFCD577D8C741EED2_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_F5D664059A8137CCFCD577D8C741EED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price of stock issued (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_F5D664059A8137CCFCD577D8C741EED2_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_F5D664059A8137CCFCD577D8C741EED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_F5D664059A8137CCFCD577D8C741EED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_F5D664059A8137CCFCD577D8C741EED2" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_F5D664059A8137CCFCD577D8C741EED2" xlink:type="arc" />
    <link:label id="lab_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F_terseLabel_en-US" xlink:label="lab_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, convertible, conversion price</link:label>
    <link:label id="lab_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F_label_en-US" xlink:label="lab_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</link:label>
    <link:label id="lab_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F_documentation_en-US" xlink:label="lab_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F" xlink:to="lab_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_64B73D08942CB3FF03B077D8C741261B_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_64B73D08942CB3FF03B077D8C741261B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend related to repurchase of convertible preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_64B73D08942CB3FF03B077D8C741261B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_64B73D08942CB3FF03B077D8C741261B" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_64B73D08942CB3FF03B077D8C741261B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsShares_E9468E3686588F8561B377D8C7412EC5_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsShares_E9468E3686588F8561B377D8C7412EC5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Incremental common shares attributable to dilutive effect of conversion of preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsShares_E9468E3686588F8561B377D8C7412EC5_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsShares_E9468E3686588F8561B377D8C7412EC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="loc_us-gaap_PreferredStockDividendsShares_E9468E3686588F8561B377D8C7412EC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsShares_E9468E3686588F8561B377D8C7412EC5" xlink:to="lab_us-gaap_PreferredStockDividendsShares_E9468E3686588F8561B377D8C7412EC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_93B8302C7BC26E67783877D8C7410DE0_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue_93B8302C7BC26E67783877D8C7410DE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_93B8302C7BC26E67783877D8C7410DE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue_93B8302C7BC26E67783877D8C7410DE0" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue_93B8302C7BC26E67783877D8C7410DE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75E27C994FFD4438257587BA55A3A2A4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75E27C994FFD4438257587BA55A3A2A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75E27C994FFD4438257587BA55A3A2A4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75E27C994FFD4438257587BA55A3A2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75E27C994FFD4438257587BA55A3A2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75E27C994FFD4438257587BA55A3A2A4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75E27C994FFD4438257587BA55A3A2A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A9794B0B90DC8EED9EB87BA55A385A0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A9794B0B90DC8EED9EB87BA55A385A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A9794B0B90DC8EED9EB87BA55A385A0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A9794B0B90DC8EED9EB87BA55A385A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A9794B0B90DC8EED9EB87BA55A385A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A9794B0B90DC8EED9EB87BA55A385A0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A9794B0B90DC8EED9EB87BA55A385A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:to="lab_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:type="arc" />
    <link:label id="lab_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E_terseLabel_en-US" xlink:label="lab_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E_label_en-US" xlink:label="lab_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E_documentation_en-US" xlink:label="lab_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerAMember" xlink:label="loc_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E" xlink:to="lab_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E" xlink:type="arc" />
    <link:label id="lab_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42_terseLabel_en-US" xlink:label="lab_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42_label_en-US" xlink:label="lab_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42_documentation_en-US" xlink:label="lab_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer B</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerBMember" xlink:label="loc_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42" xlink:to="lab_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42" xlink:type="arc" />
    <link:label id="lab_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF_terseLabel_en-US" xlink:label="lab_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF_label_en-US" xlink:label="lab_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF_documentation_en-US" xlink:label="lab_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer C</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerCMember" xlink:label="loc_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF" xlink:to="lab_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF" xlink:type="arc" />
    <link:label id="lab_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900_terseLabel_en-US" xlink:label="lab_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer D</link:label>
    <link:label id="lab_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900_label_en-US" xlink:label="lab_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900_documentation_en-US" xlink:label="lab_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer D [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerDMember" xlink:label="loc_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900" xlink:to="lab_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_C2F59F075B9FBA4F2A6491CCCCAA0FA1_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_C2F59F075B9FBA4F2A6491CCCCAA0FA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_C2F59F075B9FBA4F2A6491CCCCAA0FA1_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_C2F59F075B9FBA4F2A6491CCCCAA0FA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_C2F59F075B9FBA4F2A6491CCCCAA0FA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_C2F59F075B9FBA4F2A6491CCCCAA0FA1" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_C2F59F075B9FBA4F2A6491CCCCAA0FA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNetMember_B7DDFCB64FF54414F4C291CCCCAA064B_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_B7DDFCB64FF54414F4C291CCCCAA064B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_B7DDFCB64FF54414F4C291CCCCAA064B_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_B7DDFCB64FF54414F4C291CCCCAA064B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_B7DDFCB64FF54414F4C291CCCCAA064B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_B7DDFCB64FF54414F4C291CCCCAA064B" xlink:to="lab_us-gaap_SalesRevenueNetMember_B7DDFCB64FF54414F4C291CCCCAA064B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_6A2415853D93C0653C2291CCCCAB5560_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_6A2415853D93C0653C2291CCCCAB5560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_6A2415853D93C0653C2291CCCCAB5560_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_6A2415853D93C0653C2291CCCCAB5560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_6A2415853D93C0653C2291CCCCAB5560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_6A2415853D93C0653C2291CCCCAB5560" xlink:to="lab_us-gaap_AccountsReceivableMember_6A2415853D93C0653C2291CCCCAB5560" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C594F20D111246DD321D5A8757213574_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C594F20D111246DD321D5A8757213574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Liability Maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C594F20D111246DD321D5A8757213574_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C594F20D111246DD321D5A8757213574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C594F20D111246DD321D5A8757213574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C594F20D111246DD321D5A8757213574" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C594F20D111246DD321D5A8757213574" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D874F0AA8DBB7CD09585A8491DD5C87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D874F0AA8DBB7CD09585A8491DD5C87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D874F0AA8DBB7CD09585A8491DD5C87_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D874F0AA8DBB7CD09585A8491DD5C87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D874F0AA8DBB7CD09585A8491DD5C87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D874F0AA8DBB7CD09585A8491DD5C87" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D874F0AA8DBB7CD09585A8491DD5C87" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8B345B21C0E48A0716975EC8728A2A1B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8B345B21C0E48A0716975EC8728A2A1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired license</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8B345B21C0E48A0716975EC8728A2A1B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8B345B21C0E48A0716975EC8728A2A1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8B345B21C0E48A0716975EC8728A2A1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8B345B21C0E48A0716975EC8728A2A1B" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8B345B21C0E48A0716975EC8728A2A1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F655FB549F49EEE87865EC8728BB2AE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F655FB549F49EEE87865EC8728BB2AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F655FB549F49EEE87865EC8728BB2AE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F655FB549F49EEE87865EC8728BB2AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F655FB549F49EEE87865EC8728BB2AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F655FB549F49EEE87865EC8728BB2AE" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F655FB549F49EEE87865EC8728BB2AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A07905DC90088B94E5D05EC8728B6723_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A07905DC90088B94E5D05EC8728B6723" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Identified intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A07905DC90088B94E5D05EC8728B6723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A07905DC90088B94E5D05EC8728B6723" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A07905DC90088B94E5D05EC8728B6723" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_76DD7A6B3F626BEA8B1188B6E6D84DC2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_76DD7A6B3F626BEA8B1188B6E6D84DC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_76DD7A6B3F626BEA8B1188B6E6D84DC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_76DD7A6B3F626BEA8B1188B6E6D84DC2" xlink:to="lab_us-gaap_PreferredStockMember_76DD7A6B3F626BEA8B1188B6E6D84DC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7BB1454E325F28023E8C88B6E6D9F745_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_7BB1454E325F28023E8C88B6E6D9F745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options issued and outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7BB1454E325F28023E8C88B6E6D9F745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_7BB1454E325F28023E8C88B6E6D9F745" xlink:to="lab_us-gaap_EmployeeStockOptionMember_7BB1454E325F28023E8C88B6E6D9F745" xlink:type="arc" />
    <link:label id="lab_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B_terseLabel_en-US" xlink:label="lab_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP obligation</link:label>
    <link:label id="lab_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B_label_en-US" xlink:label="lab_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Obligation [Member]</link:label>
    <link:label id="lab_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B_documentation_en-US" xlink:label="lab_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Obligation [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_EmployeeStockPurchasePlanObligationMember" xlink:label="loc_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B" xlink:to="lab_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_2C06239315353147AD5A88B6E6D9EBD7_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_2C06239315353147AD5A88B6E6D9EBD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_2C06239315353147AD5A88B6E6D9EBD7_label_en-US" xlink:label="lab_us-gaap_WarrantMember_2C06239315353147AD5A88B6E6D9EBD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2C06239315353147AD5A88B6E6D9EBD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_2C06239315353147AD5A88B6E6D9EBD7" xlink:to="lab_us-gaap_WarrantMember_2C06239315353147AD5A88B6E6D9EBD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_C93D11ED92E3BF8880D788B6E6D96904_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember_C93D11ED92E3BF8880D788B6E6D96904" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock subject to repurchase</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_C93D11ED92E3BF8880D788B6E6D96904_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember_C93D11ED92E3BF8880D788B6E6D96904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_C93D11ED92E3BF8880D788B6E6D96904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember_C93D11ED92E3BF8880D788B6E6D96904" xlink:to="lab_us-gaap_TreasuryStockCommonMember_C93D11ED92E3BF8880D788B6E6D96904" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BEAE516D07C07A3CA1E888B6E6DAD147_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BEAE516D07C07A3CA1E888B6E6DAD147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BEAE516D07C07A3CA1E888B6E6DAD147_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BEAE516D07C07A3CA1E888B6E6DAD147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BEAE516D07C07A3CA1E888B6E6DAD147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BEAE516D07C07A3CA1E888B6E6DAD147" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BEAE516D07C07A3CA1E888B6E6DAD147" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_68281E49B6915996E93777D8C7597187_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_68281E49B6915996E93777D8C7597187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_68281E49B6915996E93777D8C7597187_label_en-US" xlink:label="lab_us-gaap_IPOMember_68281E49B6915996E93777D8C7597187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_68281E49B6915996E93777D8C7597187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_68281E49B6915996E93777D8C7597187" xlink:to="lab_us-gaap_IPOMember_68281E49B6915996E93777D8C7597187" xlink:type="arc" />
    <link:label id="lab_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895_terseLabel_en-US" xlink:label="lab_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future stock option grants</link:label>
    <link:label id="lab_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895_label_en-US" xlink:label="lab_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Available For Future Stock Option Grants [Member]</link:label>
    <link:label id="lab_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895_documentation_en-US" xlink:label="lab_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Available For Future Stock Option Grants [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SharesAvailableForFutureStockOptionGrantsMember" xlink:label="loc_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895" xlink:to="lab_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_D2AB68EFDF2695082D1977D8C75D2152_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_D2AB68EFDF2695082D1977D8C75D2152" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2018 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_D2AB68EFDF2695082D1977D8C75D2152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_D2AB68EFDF2695082D1977D8C75D2152" xlink:to="lab_us-gaap_EmployeeStockMember_D2AB68EFDF2695082D1977D8C75D2152" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1B962267A3A593789C8D77D8C75D7F6C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1B962267A3A593789C8D77D8C75D7F6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1B962267A3A593789C8D77D8C75D7F6C_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1B962267A3A593789C8D77D8C75D7F6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1B962267A3A593789C8D77D8C75D7F6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1B962267A3A593789C8D77D8C75D7F6C" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1B962267A3A593789C8D77D8C75D7F6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83D1684DCDA69EB7E42D77D8C75D9168_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83D1684DCDA69EB7E42D77D8C75D9168" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon follow-on offering, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83D1684DCDA69EB7E42D77D8C75D9168" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83D1684DCDA69EB7E42D77D8C75D9168" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83D1684DCDA69EB7E42D77D8C75D9168" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_D483FC07B999CECFADF777D8C75DC506_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_D483FC07B999CECFADF777D8C75DC506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering and follow on offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_D483FC07B999CECFADF777D8C75DC506_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_D483FC07B999CECFADF777D8C75DC506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_D483FC07B999CECFADF777D8C75DC506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_D483FC07B999CECFADF777D8C75DC506" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_D483FC07B999CECFADF777D8C75DC506" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9BDA1721D7AE95DD540477D8C75D720B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9BDA1721D7AE95DD540477D8C75D720B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon follow-on offering, net of offering costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9BDA1721D7AE95DD540477D8C75D720B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9BDA1721D7AE95DD540477D8C75D720B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9BDA1721D7AE95DD540477D8C75D720B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_60E166B1C6AA280A23385A2FE2130282_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_60E166B1C6AA280A23385A2FE2130282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_60E166B1C6AA280A23385A2FE2130282_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_60E166B1C6AA280A23385A2FE2130282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_60E166B1C6AA280A23385A2FE2130282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_60E166B1C6AA280A23385A2FE2130282" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_60E166B1C6AA280A23385A2FE2130282" xlink:type="arc" />
    <link:label id="lab_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99_terseLabel_en-US" xlink:label="lab_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99_label_en-US" xlink:label="lab_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99_documentation_en-US" xlink:label="lab_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeTaxesTable" xlink:label="loc_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:to="lab_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_73345D37364AE6044A76983D583BBDC8_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_73345D37364AE6044A76983D583BBDC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_73345D37364AE6044A76983D583BBDC8_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_73345D37364AE6044A76983D583BBDC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_73345D37364AE6044A76983D583BBDC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_73345D37364AE6044A76983D583BBDC8" xlink:to="lab_us-gaap_DomesticCountryMember_73345D37364AE6044A76983D583BBDC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_63F8CF3B0F0ECAB7E9E6983D583B439C_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_63F8CF3B0F0ECAB7E9E6983D583B439C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_63F8CF3B0F0ECAB7E9E6983D583B439C_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_63F8CF3B0F0ECAB7E9E6983D583B439C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_63F8CF3B0F0ECAB7E9E6983D583B439C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_63F8CF3B0F0ECAB7E9E6983D583B439C" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_63F8CF3B0F0ECAB7E9E6983D583B439C" xlink:type="arc" />
    <link:label id="lab_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E_terseLabel_en-US" xlink:label="lab_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E_label_en-US" xlink:label="lab_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E_documentation_en-US" xlink:label="lab_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Income Taxes [Table]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeTaxesLineItems" xlink:label="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="lab_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_CE3C006F969AAAA0E48D983D583C2206_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_CE3C006F969AAAA0E48D983D583C2206" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Release from valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_CE3C006F969AAAA0E48D983D583C2206_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_CE3C006F969AAAA0E48D983D583C2206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_CE3C006F969AAAA0E48D983D583C2206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_CE3C006F969AAAA0E48D983D583C2206" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_CE3C006F969AAAA0E48D983D583C2206" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_C06951897B59DE8C9887983D583C88E6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_C06951897B59DE8C9887983D583C88E6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefit from intraperiod tax allocation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_C06951897B59DE8C9887983D583C88E6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_C06951897B59DE8C9887983D583C88E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Intraperiod Tax Allocation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_C06951897B59DE8C9887983D583C88E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_C06951897B59DE8C9887983D583C88E6" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_C06951897B59DE8C9887983D583C88E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_584DA3864F7C5318C9E2983D583C740B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_584DA3864F7C5318C9E2983D583C740B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_584DA3864F7C5318C9E2983D583C740B_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_584DA3864F7C5318C9E2983D583C740B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_584DA3864F7C5318C9E2983D583C740B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_584DA3864F7C5318C9E2983D583C740B" xlink:to="lab_us-gaap_OperatingLossCarryforwards_584DA3864F7C5318C9E2983D583C740B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_E8CC0BFE06FAE77E4A1F983D583CA64C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_E8CC0BFE06FAE77E4A1F983D583CA64C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards, research</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_E8CC0BFE06FAE77E4A1F983D583CA64C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_E8CC0BFE06FAE77E4A1F983D583CA64C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_E8CC0BFE06FAE77E4A1F983D583CA64C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_E8CC0BFE06FAE77E4A1F983D583CA64C" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_E8CC0BFE06FAE77E4A1F983D583CA64C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F859BAAFB8347D99AFD7983D583D83D2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F859BAAFB8347D99AFD7983D583D83D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F859BAAFB8347D99AFD7983D583D83D2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F859BAAFB8347D99AFD7983D583D83D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F859BAAFB8347D99AFD7983D583D83D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F859BAAFB8347D99AFD7983D583D83D2" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F859BAAFB8347D99AFD7983D583D83D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_8AA893505232586CFFEA983D583DCA57_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_8AA893505232586CFFEA983D583DCA57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8AA893505232586CFFEA983D583DCA57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_8AA893505232586CFFEA983D583DCA57" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_8AA893505232586CFFEA983D583DCA57" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ABFB156C0655F8E6953E5A2FE1429CB5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_ABFB156C0655F8E6953E5A2FE1429CB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements. Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ABFB156C0655F8E6953E5A2FE1429CB5_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_ABFB156C0655F8E6953E5A2FE1429CB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ABFB156C0655F8E6953E5A2FE1429CB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_ABFB156C0655F8E6953E5A2FE1429CB5" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_ABFB156C0655F8E6953E5A2FE1429CB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_54E402C7939B664127EBF34786FA0269_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_54E402C7939B664127EBF34786FA0269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_54E402C7939B664127EBF34786FA0269_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_54E402C7939B664127EBF34786FA0269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_54E402C7939B664127EBF34786FA0269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_54E402C7939B664127EBF34786FA0269" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_54E402C7939B664127EBF34786FA0269" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_EF3506FA44BDC4956ACEF34786FAA555_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear_EF3506FA44BDC4956ACEF34786FAA555" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_EF3506FA44BDC4956ACEF34786FAA555_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear_EF3506FA44BDC4956ACEF34786FAA555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Second Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_EF3506FA44BDC4956ACEF34786FAA555" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear_EF3506FA44BDC4956ACEF34786FAA555" xlink:to="lab_us-gaap_ContractualObligationDueInSecondYear_EF3506FA44BDC4956ACEF34786FAA555" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_750C7AA5DBBC9C623ED8F34786FAA6AC_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear_750C7AA5DBBC9C623ED8F34786FAA6AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_750C7AA5DBBC9C623ED8F34786FAA6AC_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear_750C7AA5DBBC9C623ED8F34786FAA6AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Third Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_750C7AA5DBBC9C623ED8F34786FAA6AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear_750C7AA5DBBC9C623ED8F34786FAA6AC" xlink:to="lab_us-gaap_ContractualObligationDueInThirdYear_750C7AA5DBBC9C623ED8F34786FAA6AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_3BE3E62DDFE6840B734EF34786FBE1F7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear_3BE3E62DDFE6840B734EF34786FBE1F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_3BE3E62DDFE6840B734EF34786FBE1F7_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear_3BE3E62DDFE6840B734EF34786FBE1F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Fourth Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_3BE3E62DDFE6840B734EF34786FBE1F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear_3BE3E62DDFE6840B734EF34786FBE1F7" xlink:to="lab_us-gaap_ContractualObligationDueInFourthYear_3BE3E62DDFE6840B734EF34786FBE1F7" xlink:type="arc" />
    <link:label id="lab_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_D9AE46F6E7431D777927F34786FB6585_terseLabel_en-US" xlink:label="lab_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_D9AE46F6E7431D777927F34786FB6585" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_D9AE46F6E7431D777927F34786FB6585_label_en-US" xlink:label="lab_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_D9AE46F6E7431D777927F34786FB6585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due In Fifth Year And After Fifth Year</link:label>
    <link:label id="lab_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_D9AE46F6E7431D777927F34786FB6585_documentation_en-US" xlink:label="lab_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_D9AE46F6E7431D777927F34786FB6585" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due In Fifth Year And After Fifth Year</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ContractualObligationDueInFifthYearAndAfterFifthYear" xlink:label="loc_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_D9AE46F6E7431D777927F34786FB6585" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_D9AE46F6E7431D777927F34786FB6585" xlink:to="lab_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_D9AE46F6E7431D777927F34786FB6585" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligation_B5883346A0FFC56D8BF4F34786FBE392_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation_B5883346A0FFC56D8BF4F34786FBE392" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum royalty payments</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_B5883346A0FFC56D8BF4F34786FBE392_label_en-US" xlink:label="lab_us-gaap_ContractualObligation_B5883346A0FFC56D8BF4F34786FBE392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_B5883346A0FFC56D8BF4F34786FBE392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation_B5883346A0FFC56D8BF4F34786FBE392" xlink:to="lab_us-gaap_ContractualObligation_B5883346A0FFC56D8BF4F34786FBE392" xlink:type="arc" />
    <link:label id="lab_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_801118FABB70B8E3EB56F34786FB7CF4_negatedTerseLabel_en-US" xlink:label="lab_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_801118FABB70B8E3EB56F34786FB7CF4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: amount representing interest</link:label>
    <link:label id="lab_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_801118FABB70B8E3EB56F34786FB7CF4_label_en-US" xlink:label="lab_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_801118FABB70B8E3EB56F34786FB7CF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Future Minimum Payments, Interest Amount Included in Payments</link:label>
    <link:label id="lab_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_801118FABB70B8E3EB56F34786FB7CF4_documentation_en-US" xlink:label="lab_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_801118FABB70B8E3EB56F34786FB7CF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Future Minimum Payments, Interest Amount Included in Payments</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments" xlink:label="loc_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_801118FABB70B8E3EB56F34786FB7CF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_801118FABB70B8E3EB56F34786FB7CF4" xlink:to="lab_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_801118FABB70B8E3EB56F34786FB7CF4" xlink:type="arc" />
    <link:label id="lab_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_9BB8422A9E6A33A8AB14F34786FB42C8_terseLabel_en-US" xlink:label="lab_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_9BB8422A9E6A33A8AB14F34786FB42C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of future minimum royalty payments</link:label>
    <link:label id="lab_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_9BB8422A9E6A33A8AB14F34786FB42C8_label_en-US" xlink:label="lab_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_9BB8422A9E6A33A8AB14F34786FB42C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
    <link:label id="lab_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_9BB8422A9E6A33A8AB14F34786FB42C8_documentation_en-US" xlink:label="lab_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_9BB8422A9E6A33A8AB14F34786FB42C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments" xlink:label="loc_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_9BB8422A9E6A33A8AB14F34786FB42C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_9BB8422A9E6A33A8AB14F34786FB42C8" xlink:to="lab_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_9BB8422A9E6A33A8AB14F34786FB42C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:type="arc" />
    <link:label id="lab_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59_terseLabel_en-US" xlink:label="lab_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Preferred Stock</link:label>
    <link:label id="lab_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59_label_en-US" xlink:label="lab_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Preferred Stock [Member]</link:label>
    <link:label id="lab_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59_documentation_en-US" xlink:label="lab_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Preferred Stock [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_WarrantsPreferredStockMember" xlink:label="loc_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59" xlink:to="lab_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3" xlink:type="arc" />
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85_terseLabel_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guardant Health AMEA, Inc</link:label>
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85_label_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guardant Health AMEA, Inc [Member]</link:label>
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85_documentation_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Guardant Health AMEA, Inc [Member]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_GuardantHealthAMEAIncMember" xlink:label="loc_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85" xlink:to="lab_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_45812379489641E0196887A8B236FD1F_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_45812379489641E0196887A8B236FD1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriters Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_45812379489641E0196887A8B236FD1F_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_45812379489641E0196887A8B236FD1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_45812379489641E0196887A8B236FD1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_45812379489641E0196887A8B236FD1F" xlink:to="lab_us-gaap_OverAllotmentOptionMember_45812379489641E0196887A8B236FD1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_51A3DE74CB69DF8C032A87A8B236C469_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_51A3DE74CB69DF8C032A87A8B236C469" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_51A3DE74CB69DF8C032A87A8B236C469_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_51A3DE74CB69DF8C032A87A8B236C469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_51A3DE74CB69DF8C032A87A8B236C469" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_51A3DE74CB69DF8C032A87A8B236C469" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_51A3DE74CB69DF8C032A87A8B236C469" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_47DC2046BFCDCB7B4DFA87A8B237E487_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_47DC2046BFCDCB7B4DFA87A8B237E487" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_47DC2046BFCDCB7B4DFA87A8B237E487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_47DC2046BFCDCB7B4DFA87A8B237E487" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_47DC2046BFCDCB7B4DFA87A8B237E487" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_EB8306B67D0DEC31EBAA87A8B237F388_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_EB8306B67D0DEC31EBAA87A8B237F388" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_EB8306B67D0DEC31EBAA87A8B237F388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_EB8306B67D0DEC31EBAA87A8B237F388" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_EB8306B67D0DEC31EBAA87A8B237F388" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0AA7718E546F8B57E79787A8B237AF72_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0AA7718E546F8B57E79787A8B237AF72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0AA7718E546F8B57E79787A8B237AF72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0AA7718E546F8B57E79787A8B237AF72" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0AA7718E546F8B57E79787A8B237AF72" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F28477166577B94F555577D8C654897B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F28477166577B94F555577D8C654897B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax at the statutory federal rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F28477166577B94F555577D8C654897B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F28477166577B94F555577D8C654897B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F28477166577B94F555577D8C654897B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F28477166577B94F555577D8C654897B" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F28477166577B94F555577D8C654897B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_2A8528FD3ABDA416A5F377D8C65411A5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_2A8528FD3ABDA416A5F377D8C65411A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other nondeductible items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_2A8528FD3ABDA416A5F377D8C65411A5_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_2A8528FD3ABDA416A5F377D8C65411A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_2A8528FD3ABDA416A5F377D8C65411A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_2A8528FD3ABDA416A5F377D8C65411A5" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_2A8528FD3ABDA416A5F377D8C65411A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_AD817E4F44CB731D904977D8C654A40D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_AD817E4F44CB731D904977D8C654A40D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_AD817E4F44CB731D904977D8C654A40D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_AD817E4F44CB731D904977D8C654A40D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_AD817E4F44CB731D904977D8C654A40D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_AD817E4F44CB731D904977D8C654A40D" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_AD817E4F44CB731D904977D8C654A40D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_447D45E89898F606B88177D8C654D696_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_447D45E89898F606B88177D8C654D696" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_447D45E89898F606B88177D8C654D696_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_447D45E89898F606B88177D8C654D696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_447D45E89898F606B88177D8C654D696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_447D45E89898F606B88177D8C654D696" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_447D45E89898F606B88177D8C654D696" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E5F83FDC723FA2928EA177D8C656EC0D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E5F83FDC723FA2928EA177D8C656EC0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes, net of federal benefits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E5F83FDC723FA2928EA177D8C656EC0D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E5F83FDC723FA2928EA177D8C656EC0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E5F83FDC723FA2928EA177D8C656EC0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E5F83FDC723FA2928EA177D8C656EC0D" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E5F83FDC723FA2928EA177D8C656EC0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_C0D908BC880B2E02E2FB77D8C65676D1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_C0D908BC880B2E02E2FB77D8C65676D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in tax rate due to Tax Act</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_C0D908BC880B2E02E2FB77D8C65676D1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_C0D908BC880B2E02E2FB77D8C65676D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_C0D908BC880B2E02E2FB77D8C65676D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_C0D908BC880B2E02E2FB77D8C65676D1" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_C0D908BC880B2E02E2FB77D8C65676D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_18E6285ABB2987EDEADF77D8C6565C70_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_18E6285ABB2987EDEADF77D8C6565C70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_18E6285ABB2987EDEADF77D8C6565C70_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_18E6285ABB2987EDEADF77D8C6565C70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_18E6285ABB2987EDEADF77D8C6565C70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_18E6285ABB2987EDEADF77D8C6565C70" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_18E6285ABB2987EDEADF77D8C6565C70" xlink:type="arc" />
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Available for Grant</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2E4C3F48B95DE2871EBAF30F6CDCF1E9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2E4C3F48B95DE2871EBAF30F6CDCF1E9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning number of shares, available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2E4C3F48B95DE2871EBAF30F6CDCF1E9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2E4C3F48B95DE2871EBAF30F6CDCF1E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2E4C3F48B95DE2871EBAF30F6CDCF1E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2E4C3F48B95DE2871EBAF30F6CDCF1E9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2E4C3F48B95DE2871EBAF30F6CDCF1E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8E0B7DAF54DECC507E67F30F6CDC368D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8E0B7DAF54DECC507E67F30F6CDC368D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8E0B7DAF54DECC507E67F30F6CDC368D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8E0B7DAF54DECC507E67F30F6CDC368D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8E0B7DAF54DECC507E67F30F6CDC368D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8E0B7DAF54DECC507E67F30F6CDC368D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8E0B7DAF54DECC507E67F30F6CDC368D" xlink:type="arc" />
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_B8848473E59C253E6D65F30F6CDC039A_negatedLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_B8848473E59C253E6D65F30F6CDC039A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares forfeited (in shares)</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_B8848473E59C253E6D65F30F6CDC039A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_B8848473E59C253E6D65F30F6CDC039A" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_B8848473E59C253E6D65F30F6CDC039A" xlink:type="arc" />
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1_negatedTerseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Grants in Period, Gross</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1" xlink:type="arc" />
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Exercised in Period, Gross</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Exercised in Period, Gross</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698" xlink:type="arc" />
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Cancellations in Period, Gross</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Cancellations in Period, Gross</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E" xlink:type="arc" />
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of early exercised shares</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available For Grant, Repurchase of Early Exercised Shares</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available For Grant, Repurchase of Early Exercised Shares</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ADD91490BDDC13665C32F30F6CDD48F1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ADD91490BDDC13665C32F30F6CDD48F1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending number of shares, available for grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ADD91490BDDC13665C32F30F6CDD48F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ADD91490BDDC13665C32F30F6CDD48F1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ADD91490BDDC13665C32F30F6CDD48F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Subject to Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672C1F609E67873D54E5F30F6CDD7CFA_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672C1F609E67873D54E5F30F6CDD7CFA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning number of shares, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672C1F609E67873D54E5F30F6CDD7CFA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672C1F609E67873D54E5F30F6CDD7CFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672C1F609E67873D54E5F30F6CDD7CFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672C1F609E67873D54E5F30F6CDD7CFA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672C1F609E67873D54E5F30F6CDD7CFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ECF9DCBD65614A1FB97F30F6CDE5F13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ECF9DCBD65614A1FB97F30F6CDE5F13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ECF9DCBD65614A1FB97F30F6CDE5F13_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ECF9DCBD65614A1FB97F30F6CDE5F13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ECF9DCBD65614A1FB97F30F6CDE5F13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ECF9DCBD65614A1FB97F30F6CDE5F13" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ECF9DCBD65614A1FB97F30F6CDE5F13" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11B260460BD772417390F30F6CDE68B1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11B260460BD772417390F30F6CDE68B1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11B260460BD772417390F30F6CDE68B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11B260460BD772417390F30F6CDE68B1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11B260460BD772417390F30F6CDE68B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_342AC442107271B64C0BF30F6CDE20D8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_342AC442107271B64C0BF30F6CDE20D8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_342AC442107271B64C0BF30F6CDE20D8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_342AC442107271B64C0BF30F6CDE20D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_342AC442107271B64C0BF30F6CDE20D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_342AC442107271B64C0BF30F6CDE20D8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_342AC442107271B64C0BF30F6CDE20D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9528BCF1417C784D64B5F30F6CDE9AC9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9528BCF1417C784D64B5F30F6CDE9AC9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending number of shares, outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9528BCF1417C784D64B5F30F6CDE9AC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9528BCF1417C784D64B5F30F6CDE9AC9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9528BCF1417C784D64B5F30F6CDE9AC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03D9EB906B5646C74E25F30F6CDF1ADF_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03D9EB906B5646C74E25F30F6CDF1ADF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance of options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03D9EB906B5646C74E25F30F6CDF1ADF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03D9EB906B5646C74E25F30F6CDF1ADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03D9EB906B5646C74E25F30F6CDF1ADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03D9EB906B5646C74E25F30F6CDF1ADF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03D9EB906B5646C74E25F30F6CDF1ADF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26CEDBC478F5D8410941F30F6CDF182C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26CEDBC478F5D8410941F30F6CDF182C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26CEDBC478F5D8410941F30F6CDF182C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26CEDBC478F5D8410941F30F6CDF182C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26CEDBC478F5D8410941F30F6CDF182C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26CEDBC478F5D8410941F30F6CDF182C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26CEDBC478F5D8410941F30F6CDF182C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3B9AEF7A4F7097C3FAC8F30F6CDFD7CC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3B9AEF7A4F7097C3FAC8F30F6CDFD7CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3B9AEF7A4F7097C3FAC8F30F6CDFD7CC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3B9AEF7A4F7097C3FAC8F30F6CDFD7CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3B9AEF7A4F7097C3FAC8F30F6CDFD7CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3B9AEF7A4F7097C3FAC8F30F6CDFD7CC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3B9AEF7A4F7097C3FAC8F30F6CDFD7CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F22C75C6A911F2B7E0B0F30F6CDF2CB7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F22C75C6A911F2B7E0B0F30F6CDF2CB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F22C75C6A911F2B7E0B0F30F6CDF2CB7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F22C75C6A911F2B7E0B0F30F6CDF2CB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F22C75C6A911F2B7E0B0F30F6CDF2CB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F22C75C6A911F2B7E0B0F30F6CDF2CB7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F22C75C6A911F2B7E0B0F30F6CDF2CB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EFE9E0780DFEFD880685F30F6CDFCF8F_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EFE9E0780DFEFD880685F30F6CDFCF8F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance of options outstanding (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EFE9E0780DFEFD880685F30F6CDFCF8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EFE9E0780DFEFD880685F30F6CDFCF8F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EFE9E0780DFEFD880685F30F6CDFCF8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_C3343115CF9411A6C535F30F6CE0C851_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_C3343115CF9411A6C535F30F6CE0C851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, Weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_C3343115CF9411A6C535F30F6CE0C851_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_C3343115CF9411A6C535F30F6CE0C851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_C3343115CF9411A6C535F30F6CE0C851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_C3343115CF9411A6C535F30F6CE0C851" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_C3343115CF9411A6C535F30F6CE0C851" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9923499BF06DA596AA49F30F6CE0E649_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9923499BF06DA596AA49F30F6CE0E649" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9923499BF06DA596AA49F30F6CE0E649_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9923499BF06DA596AA49F30F6CE0E649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9923499BF06DA596AA49F30F6CE0E649" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9923499BF06DA596AA49F30F6CE0E649" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9923499BF06DA596AA49F30F6CE0E649" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_C8590AA99069DE479FF5F30F6CE07EF8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_C8590AA99069DE479FF5F30F6CE07EF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable, Number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_C8590AA99069DE479FF5F30F6CE07EF8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_C8590AA99069DE479FF5F30F6CE07EF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_C8590AA99069DE479FF5F30F6CE07EF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_C8590AA99069DE479FF5F30F6CE07EF8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_C8590AA99069DE479FF5F30F6CE07EF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ED284325E1F9F75FDACF30F6CE0BA3A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ED284325E1F9F75FDACF30F6CE0BA3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable, Weighted average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ED284325E1F9F75FDACF30F6CE0BA3A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ED284325E1F9F75FDACF30F6CE0BA3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ED284325E1F9F75FDACF30F6CE0BA3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ED284325E1F9F75FDACF30F6CE0BA3A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ED284325E1F9F75FDACF30F6CE0BA3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_782B47BBA443B5127951F30F6CE01B68_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_782B47BBA443B5127951F30F6CE01B68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable, Weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_782B47BBA443B5127951F30F6CE01B68_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_782B47BBA443B5127951F30F6CE01B68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_782B47BBA443B5127951F30F6CE01B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_782B47BBA443B5127951F30F6CE01B68" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_782B47BBA443B5127951F30F6CE01B68" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D208E0654D340722B6A9F30F6CE1BBF4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D208E0654D340722B6A9F30F6CE1BBF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable, Aggregate intrinsic value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D208E0654D340722B6A9F30F6CE1BBF4_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D208E0654D340722B6A9F30F6CE1BBF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D208E0654D340722B6A9F30F6CE1BBF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D208E0654D340722B6A9F30F6CE1BBF4" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D208E0654D340722B6A9F30F6CE1BBF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C8E4BFB77B14AB1D00D75A2FE0D981C5_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C8E4BFB77B14AB1D00D75A2FE0D981C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent License Agreement</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C8E4BFB77B14AB1D00D75A2FE0D981C5_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C8E4BFB77B14AB1D00D75A2FE0D981C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C8E4BFB77B14AB1D00D75A2FE0D981C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C8E4BFB77B14AB1D00D75A2FE0D981C5" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C8E4BFB77B14AB1D00D75A2FE0D981C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7_label_en-US" xlink:label="lab_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:to="lab_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D_label_en-US" xlink:label="lab_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D" xlink:to="lab_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_F54252EB534FB489505291EAA8C98D17_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_F54252EB534FB489505291EAA8C98D17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire interest in joint venture</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_F54252EB534FB489505291EAA8C98D17_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_F54252EB534FB489505291EAA8C98D17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Interest in Joint Venture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_F54252EB534FB489505291EAA8C98D17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_F54252EB534FB489505291EAA8C98D17" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_F54252EB534FB489505291EAA8C98D17" xlink:type="arc" />
    <link:label id="lab_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825_terseLabel_en-US" xlink:label="lab_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, shares purchased</link:label>
    <link:label id="lab_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825_label_en-US" xlink:label="lab_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Shares Purchased</link:label>
    <link:label id="lab_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825_documentation_en-US" xlink:label="lab_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Shares Purchased</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_EquityMethodInvestmentSharesPurchased" xlink:label="loc_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825" xlink:to="lab_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825" xlink:type="arc" />
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_10DCB1F30A4B2CF57EB291EAA8C95F36_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_10DCB1F30A4B2CF57EB291EAA8C95F36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable noncontrolling interest, redemption value</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_10DCB1F30A4B2CF57EB291EAA8C95F36_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_10DCB1F30A4B2CF57EB291EAA8C95F36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Redemption Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_10DCB1F30A4B2CF57EB291EAA8C95F36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_10DCB1F30A4B2CF57EB291EAA8C95F36" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_10DCB1F30A4B2CF57EB291EAA8C95F36" xlink:type="arc" />
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_F884403E335E1F3E2E8291EAA8CA6D31_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_F884403E335E1F3E2E8291EAA8CA6D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable noncontrolling interest, fair value</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_F884403E335E1F3E2E8291EAA8CA6D31_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_F884403E335E1F3E2E8291EAA8CA6D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_F884403E335E1F3E2E8291EAA8CA6D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_F884403E335E1F3E2E8291EAA8CA6D31" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_F884403E335E1F3E2E8291EAA8CA6D31" xlink:type="arc" />
    <link:label id="lab_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376_terseLabel_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold period for unremedied material breach of the joint venture agreement by the other party</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376_label_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Threshold Period For Unremedied Material Breach of the Joint Venture Agreement By The Other Party</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376_documentation_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Threshold Period For Unremedied Material Breach of the Joint Venture Agreement By The Other Party</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty" xlink:label="loc_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376" xlink:to="lab_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376" xlink:type="arc" />
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D_terseLabel_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of fair value that is no less than internal rate of return</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D_label_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D_documentation_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D" xlink:to="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D" xlink:type="arc" />
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1_terseLabel_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of fair value (greater than)</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1_label_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Threshold Percentage of Fair Value</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1_documentation_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Threshold Percentage of Fair Value</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityThresholdPercentageofFairValue" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1" xlink:to="lab_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1" xlink:type="arc" />
    <link:label id="lab_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880_terseLabel_en-US" xlink:label="lab_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of the product</link:label>
    <link:label id="lab_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880_label_en-US" xlink:label="lab_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Percentage of the Product</link:label>
    <link:label id="lab_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880_documentation_en-US" xlink:label="lab_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Percentage of the Product</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityPercentageoftheProduct" xlink:label="loc_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880" xlink:to="lab_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable_698502EF81253AC5BDD491F62E6544B2_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable_698502EF81253AC5BDD491F62E6544B2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest in net loss joint venture</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable_698502EF81253AC5BDD491F62E6544B2_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable_698502EF81253AC5BDD491F62E6544B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest in Net Income (Loss) Joint Venture Partners, Redeemable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable" xlink:label="loc_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable_698502EF81253AC5BDD491F62E6544B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable_698502EF81253AC5BDD491F62E6544B2" xlink:to="lab_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable_698502EF81253AC5BDD491F62E6544B2" xlink:type="arc" />
    <link:label id="lab_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E_terseLabel_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable noncontrolling interest, fair value adjustment</link:label>
    <link:label id="lab_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E_label_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest, Fair Value Adjustment</link:label>
    <link:label id="lab_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E_documentation_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest, Fair Value Adjustment</link:label>
    <link:loc xlink:href="gh-20191231.xsd#gh_RedeemableNoncontrollingInterestFairValueAdjustment" xlink:label="loc_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E" xlink:to="lab_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FC798C49DB1F0C88B36177D8C8FC5CEF_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FC798C49DB1F0C88B36177D8C8FC5CEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FC798C49DB1F0C88B36177D8C8FC5CEF_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FC798C49DB1F0C88B36177D8C8FC5CEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FC798C49DB1F0C88B36177D8C8FC5CEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FC798C49DB1F0C88B36177D8C8FC5CEF" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FC798C49DB1F0C88B36177D8C8FC5CEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1151A63D7CE26F021E775A2FDF5C7E6D_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1151A63D7CE26F021E775A2FDF5C7E6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1151A63D7CE26F021E775A2FDF5C7E6D_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1151A63D7CE26F021E775A2FDF5C7E6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1151A63D7CE26F021E775A2FDF5C7E6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1151A63D7CE26F021E775A2FDF5C7E6D" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1151A63D7CE26F021E775A2FDF5C7E6D" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>gh-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBio" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBio" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables" xlink:href="gh-20191231.xsd#AcquisitionOfBellwetherBioTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingencies" xlink:href="gh-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="gh-20191231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails" xlink:href="gh-20191231.xsd#CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsAndContingenciesTables" xlink:href="gh-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStock" xlink:href="gh-20191231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockDetails" xlink:href="gh-20191231.xsd#CommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponents" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsTables" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheets" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="gh-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfOperations" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical" xlink:href="gh-20191231.xsd#ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConvertiblePreferredStock" xlink:href="gh-20191231.xsd#ConvertiblePreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/ConvertiblePreferredStockDetails" xlink:href="gh-20191231.xsd#ConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/CoverPage" xlink:href="gh-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionOfBusiness" xlink:href="gh-20191231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionOfBusinessDetails" xlink:href="gh-20191231.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/EmployeeBenefitPlan" xlink:href="gh-20191231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/EmployeeBenefitPlanDetails" xlink:href="gh-20191231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables" xlink:href="gh-20191231.xsd#FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxes" xlink:href="gh-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:href="gh-20191231.xsd#IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesNarrativeDetails" xlink:href="gh-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" xlink:href="gh-20191231.xsd#IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="gh-20191231.xsd#IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:href="gh-20191231.xsd#IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails" xlink:href="gh-20191231.xsd#IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesTables" xlink:href="gh-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentInJointVenture" xlink:href="gh-20191231.xsd#InvestmentInJointVenture" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentInJointVentureDetails" xlink:href="gh-20191231.xsd#InvestmentInJointVentureDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/Leases" xlink:href="gh-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:href="gh-20191231.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails" xlink:href="gh-20191231.xsd#LeasesScheduleOfFutureMinimalLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails" xlink:href="gh-20191231.xsd#LeasesScheduleOfOperatingLiabilityMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesTables" xlink:href="gh-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables" xlink:href="gh-20191231.xsd#NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/PatentLicenseAgreement" xlink:href="gh-20191231.xsd#PatentLicenseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/PatentLicenseAgreementDetails" xlink:href="gh-20191231.xsd#PatentLicenseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:href="gh-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactionsDetails" xlink:href="gh-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformation" xlink:href="gh-20191231.xsd#SegmentAndGeographicInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformationDetails" xlink:href="gh-20191231.xsd#SegmentAndGeographicInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentAndGeographicInformationTables" xlink:href="gh-20191231.xsd#SegmentAndGeographicInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreement" xlink:href="gh-20191231.xsd#SeniorTermLoanAndRoyaltyPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails" xlink:href="gh-20191231.xsd#SeniorTermLoanAndRoyaltyPurchaseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensation" xlink:href="gh-20191231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:href="gh-20191231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails" xlink:href="gh-20191231.xsd#StockBasedCompensationValuationOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails" xlink:href="gh-20191231.xsd#SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/Tables" xlink:href="gh-20191231.xsd#Tables" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/Warrants" xlink:href="gh-20191231.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://guardanthealth.com/role/WarrantsDetails" xlink:href="gh-20191231.xsd#WarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBio" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_26DC5324EAB120470C075A2FE1094CC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_34F2295619C95BDC5EFE5A2FE1098713" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_26DC5324EAB120470C075A2FE1094CC3" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_34F2295619C95BDC5EFE5A2FE1098713" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0CA15749BE6150534A70F282AC81086A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D554C9C8A6F479955A1F282AC816B57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0CA15749BE6150534A70F282AC81086A" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D554C9C8A6F479955A1F282AC816B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2DEB57B5F12A148C4D02F282AC8274C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D554C9C8A6F479955A1F282AC816B57" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2DEB57B5F12A148C4D02F282AC8274C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06457AADC9FC10D3698DF28942703724" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2DEB57B5F12A148C4D02F282AC8274C5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06457AADC9FC10D3698DF28942703724" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BellweatherBioInc.Member" xlink:label="loc_gh_BellweatherBioInc.Member_DE1314DBB6236636F367F282AC82E10F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06457AADC9FC10D3698DF28942703724" xlink:to="loc_gh_BellweatherBioInc.Member_DE1314DBB6236636F367F282AC82E10F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D554C9C8A6F479955A1F282AC816B57" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7A3453CA7343B599559AF282AC8361B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7A3453CA7343B599559AF282AC8361B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_258D1B1C356176FD023CF282AC838F1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_258D1B1C356176FD023CF282AC838F1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3BD969067DEAF666D157F282AC832155" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:to="loc_us-gaap_Goodwill_3BD969067DEAF666D157F282AC832155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E91A4A67E35C84261CDFF282AC83160E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E91A4A67E35C84261CDFF282AC83160E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07BAB0768BE5C30DD953F282AC844FD2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_18F0CC3147D40C997D6CF282AC823A51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07BAB0768BE5C30DD953F282AC844FD2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_00CD6A598D96C46AF80377D8C7A562B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_00CD6A598D96C46AF80377D8C7A562B3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C555BC1726B4D730CDBC78EFB0C509D0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BellweatherBioInc.Member" xlink:label="loc_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BD9FA9D63753B9EE960578EFB0C5CA16" xlink:to="loc_gh_BellweatherBioInc.Member_07CFEEA856B71FC4E4F278F02662D64E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B41AF4AEEF595022678678EFB0C4D0C4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9330F9407F0BB2E2373E77D8C7A5BF9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9330F9407F0BB2E2373E77D8C7A5BF9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_BADCA593FE433E1E8C6177D8C7A5D6AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_BADCA593FE433E1E8C6177D8C7A5D6AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6FCE3B470CA839801EF577D8C7A5B71C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6FCE3B470CA839801EF577D8C7A5B71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7FF07A3A324BBCFAE17477D8C7A51F9D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7FF07A3A324BBCFAE17477D8C7A51F9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F61C4BA5FB151F082E0F77D8C7A5985A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_F61C4BA5FB151F082E0F77D8C7A5985A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30F02F302A0F63E08E3777D8C7A5F1BC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0DBD79705C9D8C1DB51C78EFB0CB10B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30F02F302A0F63E08E3777D8C7A5F1BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C49BE801CE9BE6F274B45EC872895924" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C49BE801CE9BE6F274B45EC872895924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_17DACCDF3B0A180399C15EC872890380" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_17DACCDF3B0A180399C15EC872890380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F8207D678F03C2AB370D5EC872890B55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17DACCDF3B0A180399C15EC872890380" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F8207D678F03C2AB370D5EC872890B55" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BellweatherBioInc.Member" xlink:label="loc_gh_BellweatherBioInc.Member_9A38069DE12B281598605EC8728A500D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F8207D678F03C2AB370D5EC872890B55" xlink:to="loc_gh_BellweatherBioInc.Member_9A38069DE12B281598605EC8728A500D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3A0D581325201049DCF75EC87289F4D3" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8B345B21C0E48A0716975EC8728A2A1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8B345B21C0E48A0716975EC8728A2A1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F655FB549F49EEE87865EC8728BB2AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F655FB549F49EEE87865EC8728BB2AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A07905DC90088B94E5D05EC8728B6723" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A07905DC90088B94E5D05EC8728B6723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_53FCA40CCB06E74A0F155EC8728BEF33" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_F57B9F43858C76E6C0FB5EC8728A5DCD" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_53FCA40CCB06E74A0F155EC8728BEF33" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_43942EFF5C568DE81CFE77D8C81DB207" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_43942EFF5C568DE81CFE77D8C81DB207" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19FDF5BCA123C57C929D77D8C81D785B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CovenantsNotToCompeteMember" xlink:label="loc_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B3FA7EACEBA556C27A0677D8C81DECB1" xlink:to="loc_gh_CovenantsNotToCompeteMember_1BC11D410A22980259D777D8C81D3CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59067089D8F388FE071E77D8C81D68BC" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_76FE962BA79D261C4D1A77D8C82110C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4B29ABC91FA6E5E32E3F77D8C81D58FF" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_76FE962BA79D261C4D1A77D8C82110C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3645FD4DB51A2AC7A76677D8C821642C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_90179661FDC703E491B877D8C821B2A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3C5F2ED69F2DAA0A284777D8C821C0C8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_90179661FDC703E491B877D8C821B2A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_469B43536B1D125A49DE77D8C821EBBC" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CommercializationMilestonesMember" xlink:label="loc_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:to="loc_gh_CommercializationMilestonesMember_366DD2AEDB9907C8CD0D77D8C8212BEA" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_EarnOutConsiderationMember" xlink:label="loc_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0523F9BD58465CC0952277D8C821CC09" xlink:to="loc_gh_EarnOutConsiderationMember_94FCE0E1EB8F421AAA0B77D8C821E2CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6717FD54B1E1C5E5AAE277D8C8213C82" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6717FD54B1E1C5E5AAE277D8C8213C82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_270C45865B7CB442053A77D8C821273C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6717FD54B1E1C5E5AAE277D8C8213C82" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_270C45865B7CB442053A77D8C821273C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BellweatherBioInc.Member" xlink:label="loc_gh_BellweatherBioInc.Member_F3BFE269A29CFCFB160877D8C821EC2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_270C45865B7CB442053A77D8C821273C" xlink:to="loc_gh_BellweatherBioInc.Member_F3BFE269A29CFCFB160877D8C821EC2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B9F106AB8F2AA4F6304077D8C81DBAB1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C38F6D0E8CA52B2564BA77D8C8214B67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C38F6D0E8CA52B2564BA77D8C8214B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_713F2E4FC5D891CA56AA77D8C82153DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_713F2E4FC5D891CA56AA77D8C82153DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1590C5515448227C7C8C77D8C821CE60" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1590C5515448227C7C8C77D8C821CE60" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BusinessCombinationContingentConsiderationMaximumAmountPayable" xlink:label="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_6DB61EC487D557A3C3CD77D8C8219233" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D9A1C5C68C3D33E36C5477D8C825B73D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D9A1C5C68C3D33E36C5477D8C825B73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_03FABBEDD20A4DA214D577D8C825CCBF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_03FABBEDD20A4DA214D577D8C825CCBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_336F6EA27789F12683B977D8C8254553" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_336F6EA27789F12683B977D8C8254553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2C38280CDFCD0F4505E677D8C8250ACF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6964A5D654DFEA44EC6177D8C8216F0D" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2C38280CDFCD0F4505E677D8C8250ACF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8EADF2769DB7FC22F0E1983D598BEB27" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8EADF2769DB7FC22F0E1983D598BEB27" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C6E7D733361754D943C5983D598CFB5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C6E7D733361754D943C5983D598CFB5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E0448042DE894E76ACED983D598C0850" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C6E7D733361754D943C5983D598CFB5E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E0448042DE894E76ACED983D598C0850" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BellweatherBioInc.Member" xlink:label="loc_gh_BellweatherBioInc.Member_677C5CACBE42EC7D7D7D983D598CAABB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E0448042DE894E76ACED983D598C0850" xlink:to="loc_gh_BellweatherBioInc.Member_677C5CACBE42EC7D7D7D983D598CAABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6265708456AF1FB6993B983D598D535A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6265708456AF1FB6993B983D598D535A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C6DBF630C9936684D9EF983D598DDB54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6265708456AF1FB6993B983D598D535A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C6DBF630C9936684D9EF983D598DDB54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_32FE7EE707A8228FF4EA983D598DCB4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C6DBF630C9936684D9EF983D598DDB54" xlink:to="loc_us-gaap_LicenseMember_32FE7EE707A8228FF4EA983D598DCB4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_F2DBFB994A38E87AC6A0983D598D235A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C6DBF630C9936684D9EF983D598DDB54" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_F2DBFB994A38E87AC6A0983D598D235A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF0642CBACA5F5028844983D598B7F3A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_84E60A8120943222BA32983D598D5401" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_84E60A8120943222BA32983D598D5401" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0AA77BABE118DD986A3A983D598E75E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0AA77BABE118DD986A3A983D598E75E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9401AEADEDF47B648A71983D598EBA43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9401AEADEDF47B648A71983D598EBA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_E9C1E13379936A495065983D598EBB5F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_E9C1E13379936A495065983D598EBB5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1FEB2C1E46825035E49C983D598E17BA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1FEB2C1E46825035E49C983D598E17BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_033A5F5128CC29E534D5983D598E994E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_Goodwill_033A5F5128CC29E534D5983D598E994E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_gh_IntangibleAssetsGrossIncludingGoodwill_D4DC847FBC2FC0F65841983D598F4741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_95AB1B6257AD6E5373DA983D598F0047" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19733C6E1E952BF4C72B983D598DD794" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_95AB1B6257AD6E5373DA983D598F0047" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F9E905A01F0BB0DCDF635A2FE1075641" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2B2368711248684AA1655A2FE107AAD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F9E905A01F0BB0DCDF635A2FE1075641" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2B2368711248684AA1655A2FE107AAD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_E7FF4E8E38BA2400BA7A5A2FE1074FF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F9E905A01F0BB0DCDF635A2FE1075641" xlink:to="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_E7FF4E8E38BA2400BA7A5A2FE1074FF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_07681E29C7A24AD163F05AB930C20743" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F9E905A01F0BB0DCDF635A2FE1075641" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_07681E29C7A24AD163F05AB930C20743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5A5704A5EAD806823D505AA8838FC6A6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F9E905A01F0BB0DCDF635A2FE1075641" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5A5704A5EAD806823D505AA8838FC6A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F7BF01E13D2FA7CA6C765A2FE0972AE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69C1F2B43F8D082D7FD15A2FE0979AC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F7BF01E13D2FA7CA6C765A2FE0972AE4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69C1F2B43F8D082D7FD15A2FE0979AC6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4F3C2C2FC7D819A10EB2F21FE34EE861" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4F3C2C2FC7D819A10EB2F21FE34EE861" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:to="loc_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_C52D4CE5C585AA0EA693F21FE34FA0D3" xlink:to="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" xlink:label="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:to="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_BE393516C3A2C5DC9C68F21FE34FF423" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2E46CC9CD8EC9CC23170F21FE34F3D05" xlink:to="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_496971D6E28EEC1E6390F21FE34F5B9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C990585ECF3F603DABDAF21FE35058F5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AE952A85AE05489333B9F21FE3505A82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AE952A85AE05489333B9F21FE3505A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="loc_us-gaap_OtherIncomeMember_3A5E776BCCFD533479F4F21FE3519AC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C703229AE87912A1CC67F21FE35087CE" xlink:to="loc_us-gaap_OtherIncomeMember_3A5E776BCCFD533479F4F21FE3519AC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_97DDE3F114A38CE76992F21FE34E2C65" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofPartiesWithPatentLicenseAgreement" xlink:label="loc_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_gh_NumberofPartiesWithPatentLicenseAgreement_2D86EE42E418F920D300F21FE353DB60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_EC64A4B3431D48F96B74F21FE3535560" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_us-gaap_RoyaltyExpense_EC64A4B3431D48F96B74F21FE3535560" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue" xlink:label="loc_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue_0822D09EE430E70E3BBFF21FE3530BC7" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofPetitionsFiled" xlink:label="loc_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_gh_NumberofPetitionsFiled_9321E77F04117BC4F50EF21FE354931B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_22E03A4F950D3E83917DF21FE354585A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_22E03A4F950D3E83917DF21FE354585A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_6DDD68D07DE7E2C1E2DBF21FE3548BFA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_us-gaap_LitigationSettlementExpense_6DDD68D07DE7E2C1E2DBF21FE3548BFA" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofCompaniesthatInfringedonaPatent" xlink:label="loc_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_gh_NumberofCompaniesthatInfringedonaPatent_4959F7377F489925D4B2F21FE3540A65" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_NumberofAssertedPatents" xlink:label="loc_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_gh_NumberofAssertedPatents_45F2D99B3E1B9E542AF6F21FE355B3DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_DC41CF4C9FE06CB92D95F21FE3555AB5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_CFEB37BC33893E4D2ACDF21FE352BB76" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_DC41CF4C9FE06CB92D95F21FE3555AB5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41246D92BEFDA0343FA0F34786FACEB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_54E402C7939B664127EBF34786FA0269" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41246D92BEFDA0343FA0F34786FACEB2" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_54E402C7939B664127EBF34786FA0269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_EF3506FA44BDC4956ACEF34786FAA555" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41246D92BEFDA0343FA0F34786FACEB2" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_EF3506FA44BDC4956ACEF34786FAA555" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_750C7AA5DBBC9C623ED8F34786FAA6AC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41246D92BEFDA0343FA0F34786FACEB2" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_750C7AA5DBBC9C623ED8F34786FAA6AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_3BE3E62DDFE6840B734EF34786FBE1F7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41246D92BEFDA0343FA0F34786FACEB2" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_3BE3E62DDFE6840B734EF34786FBE1F7" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ContractualObligationDueInFifthYearAndAfterFifthYear" xlink:label="loc_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_D9AE46F6E7431D777927F34786FB6585" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41246D92BEFDA0343FA0F34786FACEB2" xlink:to="loc_gh_ContractualObligationDueInFifthYearAndAfterFifthYear_D9AE46F6E7431D777927F34786FB6585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_B5883346A0FFC56D8BF4F34786FBE392" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41246D92BEFDA0343FA0F34786FACEB2" xlink:to="loc_us-gaap_ContractualObligation_B5883346A0FFC56D8BF4F34786FBE392" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments" xlink:label="loc_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_801118FABB70B8E3EB56F34786FB7CF4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41246D92BEFDA0343FA0F34786FACEB2" xlink:to="loc_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments_801118FABB70B8E3EB56F34786FB7CF4" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments" xlink:label="loc_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_9BB8422A9E6A33A8AB14F34786FB42C8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41246D92BEFDA0343FA0F34786FACEB2" xlink:to="loc_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments_9BB8422A9E6A33A8AB14F34786FB42C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B016F099E17E0B89701BF21FE361B4D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1A96982AE40252D8B583F21FE361C303" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B016F099E17E0B89701BF21FE361B4D4" xlink:to="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1A96982AE40252D8B583F21FE361C303" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_271EAB18E2E84B935C8587BA56372072" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9B996DF099BD899E488B87BA5637DAFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_271EAB18E2E84B935C8587BA56372072" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9B996DF099BD899E488B87BA5637DAFC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1A602EC12B78802AEA0077D8C7554876" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_75CE298790DFBE335B0777D8C75536E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1A602EC12B78802AEA0077D8C7554876" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_75CE298790DFBE335B0777D8C75536E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75CE298790DFBE335B0777D8C75536E3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_88EE476C4A8C33AA656B77D8C759AE5A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_68281E49B6915996E93777D8C7597187" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48683C7DA819087121C877D8C759A40D" xlink:to="loc_us-gaap_IPOMember_68281E49B6915996E93777D8C7597187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3514630FF07DD25BECD077D8C759D210" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75CE298790DFBE335B0777D8C75536E3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3514630FF07DD25BECD077D8C759D210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3514630FF07DD25BECD077D8C759D210" xlink:to="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_9A3B143D8B86F674503D77D8C7590ED9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503" xlink:to="loc_us-gaap_PreferredStockMember_9A3B143D8B86F674503D77D8C7590ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1926511A9F2F2AFDEFC277D8C759815C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503" xlink:to="loc_us-gaap_CommonStockMember_1926511A9F2F2AFDEFC277D8C759815C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6D86F422006789FA43D677D8C75997EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7EB8DADD955665EFF28D77D8C759A503" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6D86F422006789FA43D677D8C75997EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B4BC513FB4343780A18077D8C759081F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75CE298790DFBE335B0777D8C75536E3" xlink:to="loc_us-gaap_AwardTypeAxis_B4BC513FB4343780A18077D8C759081F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B4BC513FB4343780A18077D8C759081F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D3F3EB198D6C27C667CB77D8C759A247" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D3F3EB198D6C27C667CB77D8C759A247" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharesAvailableForFutureStockOptionGrantsMember" xlink:label="loc_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500" xlink:to="loc_gh_SharesAvailableForFutureStockOptionGrantsMember_9E2B6F4F4E4558FC5535789548ADC895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_D2AB68EFDF2695082D1977D8C75D2152" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3C9D4422E7C2B415AC1F77D8C7591500" xlink:to="loc_us-gaap_EmployeeStockMember_D2AB68EFDF2695082D1977D8C75D2152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_75CE298790DFBE335B0777D8C75536E3" xlink:to="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1B962267A3A593789C8D77D8C75D7F6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1B962267A3A593789C8D77D8C75D7F6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B94C3B0803AF1B50C07877D8C75DF405" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B94C3B0803AF1B50C07877D8C75DF405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83D1684DCDA69EB7E42D77D8C75D9168" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83D1684DCDA69EB7E42D77D8C75D9168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_B7EEA816C9AEE2064BAD77D8C75DB644" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_B7EEA816C9AEE2064BAD77D8C75DB644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_D483FC07B999CECFADF777D8C75DC506" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_D483FC07B999CECFADF777D8C75DC506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7E5E2E3716B2406C783377D8C75DBE62" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7E5E2E3716B2406C783377D8C75DBE62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_CA33AFE2954359B456CB77D8C75D92AD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_CA33AFE2954359B456CB77D8C75D92AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9BDA1721D7AE95DD540477D8C75D720B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_965DCBB9D7B3FC63053577D8C75DA97A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9BDA1721D7AE95DD540477D8C75D720B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_F33457BB9D3EC40B9CD65A2FE1678098" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_5573B78C68D01A95F9165A2FE167FDCC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_F33457BB9D3EC40B9CD65A2FE1678098" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_5573B78C68D01A95F9165A2FE167FDCC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_659230B2C706E2D97B3177D8C85C671F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_369B890C6BC808309A8577D8C85C4CBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_659230B2C706E2D97B3177D8C85C671F" xlink:to="loc_us-gaap_Depreciation_369B890C6BC808309A8577D8C85C4CBF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_AD5F653A2F853E7C773877D8C8571FCB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_E995CADFB6EC4497C18277D8C85744E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_AD5F653A2F853E7C773877D8C8571FCB" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_E995CADFB6EC4497C18277D8C85744E8" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:label="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_EC25C54149D47F9986E077D8C857C958" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_AD5F653A2F853E7C773877D8C8571FCB" xlink:to="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_EC25C54149D47F9986E077D8C857C958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_F20C829BAEF36186886477D8C8571813" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_AD5F653A2F853E7C773877D8C8571FCB" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_F20C829BAEF36186886477D8C8571813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3BF8DEAFC2ED3064BE2277D8C857B8FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_AD5F653A2F853E7C773877D8C8571FCB" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3BF8DEAFC2ED3064BE2277D8C857B8FD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AccruedClinicalTrialsandStudies" xlink:label="loc_gh_AccruedClinicalTrialsandStudies_FDE1F5E586115CD7AA427865EA5A4266" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_AD5F653A2F853E7C773877D8C8571FCB" xlink:to="loc_gh_AccruedClinicalTrialsandStudies_FDE1F5E586115CD7AA427865EA5A4266" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:label="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_BE009ACCE66CD10CFAF177D8C85A9965" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_AD5F653A2F853E7C773877D8C8571FCB" xlink:to="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_BE009ACCE66CD10CFAF177D8C85A9965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5992F57FF67FAE9C702E78675386B77A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_AD5F653A2F853E7C773877D8C8571FCB" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5992F57FF67FAE9C702E78675386B77A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_56B50971DDA985EF4C9A77D8C85A1080" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_AD5F653A2F853E7C773877D8C8571FCB" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_56B50971DDA985EF4C9A77D8C85A1080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_759459D02C2643601EDC77D8C85A4AA2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_AD5F653A2F853E7C773877D8C8571FCB" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_759459D02C2643601EDC77D8C85A4AA2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D23E9919CAF700C5C771F3478778D742" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_784855C01058888A0754F3478778B686" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D23E9919CAF700C5C771F3478778D742" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_784855C01058888A0754F3478778B686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C699EEFA5AF3FAAE2364F3478779079D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_784855C01058888A0754F3478778B686" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C699EEFA5AF3FAAE2364F3478779079D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C699EEFA5AF3FAAE2364F3478779079D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3480A5949D1FB8BD02E4F34787796B16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_3480A5949D1FB8BD02E4F34787796B16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_EAF433673D8FC07C9FDCF347877AC658" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_ComputerEquipmentMember_EAF433673D8FC07C9FDCF347877AC658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_B8A5F29DF42566D5C846F347877A6AAF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_B8A5F29DF42566D5C846F347877A6AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_E96D66D1C5194247BD4AF347877A61FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_E96D66D1C5194247BD4AF347877A61FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9B029406BFFB33317C3FF347877A7105" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9B029406BFFB33317C3FF347877A7105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_1D9FE0DA7D3E0632EE41F347877A4CD2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5439FAF0B702CEA849F6F3478779D60C" xlink:to="loc_us-gaap_ConstructionInProgressMember_1D9FE0DA7D3E0632EE41F347877A4CD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03CB235E1EFA70FE459CF347877AA77B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_784855C01058888A0754F3478778B686" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03CB235E1EFA70FE459CF347877AA77B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_A11DB30A7986885E570DF347877B307D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03CB235E1EFA70FE459CF347877AA77B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_A11DB30A7986885E570DF347877B307D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BD9D740142A3340E7606F347877B941D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03CB235E1EFA70FE459CF347877AA77B" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BD9D740142A3340E7606F347877B941D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6B0747A20B1589335A93F347877BC904" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03CB235E1EFA70FE459CF347877AA77B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6B0747A20B1589335A93F347877BC904" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_04907047FF5B87C438A3A625E65E15C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C4B3550129A0505980C7A625E65E7C51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_04907047FF5B87C438A3A625E65E15C6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C4B3550129A0505980C7A625E65E7C51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_948F78C39FF81BED3632A625E65EF53F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_04907047FF5B87C438A3A625E65E15C6" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_948F78C39FF81BED3632A625E65EF53F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_6E103B95377765BCE48788B6E8DD89CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_AssetsAbstract_6E103B95377765BCE48788B6E8DD89CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6E103B95377765BCE48788B6E8DD89CA" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18791FCE9F56E934DAF288B6E8DDF16E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18791FCE9F56E934DAF288B6E8DDF16E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_9BD193E6DEC6C30682FB88B6E8DE0649" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_9BD193E6DEC6C30682FB88B6E8DE0649" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_BC96D825CE7FF9CB221988B6E8DEEAD3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_BC96D825CE7FF9CB221988B6E8DEEAD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_244C7908D33860DA6E9E88B6E8DEFDED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:to="loc_us-gaap_InventoryNet_244C7908D33860DA6E9E88B6E8DEFDED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5A897B8645278AD36E2588B6E8DEDF8B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5A897B8645278AD36E2588B6E8DEDF8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_24B914E6E3F5AAAC310F88B6E8DE545A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2E8DD178E848340C4F6A88B6E8DDD8E1" xlink:to="loc_us-gaap_AssetsCurrent_24B914E6E3F5AAAC310F88B6E8DE545A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_8D663BE3C9691094326F88B6E8DFE6E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_8D663BE3C9691094326F88B6E8DFE6E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_29071BB6E8FFBAE2169F88B6E8DFC6E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_29071BB6E8FFBAE2169F88B6E8DFC6E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0952989527B5C3A7B34E88B89675448A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0952989527B5C3A7B34E88B89675448A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0A7EFFFCA1B5A648ABD788B6E8DFFA83" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0A7EFFFCA1B5A648ABD788B6E8DFFA83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_6A2DDB83672B0E72001D88B6E8DFA2E8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_Goodwill_6A2DDB83672B0E72001D88B6E8DFA2E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2A9093609ABB5BF7FA5088B6E8DF859F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2A9093609ABB5BF7FA5088B6E8DF859F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_CB34C7D012D6246D7BD688B6E8DFFDFE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_CB34C7D012D6246D7BD688B6E8DFFDFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_92A175D50219A78D27F588B6E8E0703E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_Assets_92A175D50219A78D27F588B6E8E0703E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9B97B9FEB95A249B30CF88B6E8E078A3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9B97B9FEB95A249B30CF88B6E8E078A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9B97B9FEB95A249B30CF88B6E8E078A3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_79630828627997AA399288B6E8E0EAE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:to="loc_us-gaap_AccountsPayableCurrent_79630828627997AA399288B6E8E0EAE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_1F14FE9520893D22C26E88B6E8E08078" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_1F14FE9520893D22C26E88B6E8E08078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9E44A5E3E492161D592188B6E8E1DFEC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9E44A5E3E492161D592188B6E8E1DFEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_97BF368A34A74566788388B6E8E10B10" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:to="loc_us-gaap_DeferredRevenueCurrent_97BF368A34A74566788388B6E8E10B10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_ED072A87C343F94F635088B6E8E1E749" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6F4F33E4C11083D9BDB588B6E8E06675" xlink:to="loc_us-gaap_LiabilitiesCurrent_ED072A87C343F94F635088B6E8E1E749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9F5D6632A937504C0CC488B6E8E17BD7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9F5D6632A937504C0CC488B6E8E17BD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_37A24927680784433BA588B6E8E13D79" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_37A24927680784433BA588B6E8E13D79" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AccruedRoyaltiesNoncurrent" xlink:label="loc_gh_AccruedRoyaltiesNoncurrent_C35DE25A3A1C0360AF4B88B6E8E145A6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_gh_AccruedRoyaltiesNoncurrent_C35DE25A3A1C0360AF4B88B6E8E145A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_CB70DACA877B9C10F14B88B6E8E2877A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_CB70DACA877B9C10F14B88B6E8E2877A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_BEA75CE4531290F9E75788B6E8E25C4C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_Liabilities_BEA75CE4531290F9E75788B6E8E25C4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_82003D98F6CDDE280BFA88B6E8E204AA" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_CommitmentsAndContingencies_82003D98F6CDDE280BFA88B6E8E204AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_DCC6C9264DE28D3FC29788B6E8E209EB" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_DCC6C9264DE28D3FC29788B6E8E209EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_32308EA2F9DC9F82135E88B6E8E26D7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_32308EA2F9DC9F82135E88B6E8E26D7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_476DE09195C42D02684A88B6E8E3726C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:to="loc_us-gaap_CommonStockValueOutstanding_476DE09195C42D02684A88B6E8E3726C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C9FCBFFEB23F8A0CA1EB88B6E8E3D98E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:to="loc_us-gaap_AdditionalPaidInCapital_C9FCBFFEB23F8A0CA1EB88B6E8E3D98E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_697019B33294D3B0DDB288B6E8E34C7A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_697019B33294D3B0DDB288B6E8E34C7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99B2C6466F4DAFBDA50888B6E8E377AA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99B2C6466F4DAFBDA50888B6E8E377AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_582ACC47224A183CF0F988B6E8E3DABD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90313313C29F6F2A3DBD88B6E8E2AA03" xlink:to="loc_us-gaap_StockholdersEquity_582ACC47224A183CF0F988B6E8E3DABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9B05401101A4ADD78C5388B6E8E3485A" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76AC759A04504A9E95F788B6E8DD5A61" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9B05401101A4ADD78C5388B6E8E3485A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_39666504F6094861BFB57E6D011E464B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_44E57E7CCAA5C22EA0907E6D011FAF4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39666504F6094861BFB57E6D011E464B" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_44E57E7CCAA5C22EA0907E6D011FAF4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_27ADB43F08EF6241F7C07E6D011FEAA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39666504F6094861BFB57E6D011E464B" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_27ADB43F08EF6241F7C07E6D011FEAA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_620F2829962881372B487E6D011F0D2F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39666504F6094861BFB57E6D011E464B" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_620F2829962881372B487E6D011F0D2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2170DCFD2CE8EF612E317E6D011F9CFA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39666504F6094861BFB57E6D011E464B" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2170DCFD2CE8EF612E317E6D011F9CFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F1405367ED737DBBFE9A7E6D011F62D1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39666504F6094861BFB57E6D011E464B" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_F1405367ED737DBBFE9A7E6D011F62D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_EA2C9204C1E2D2B2C0897E6D011F52D7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39666504F6094861BFB57E6D011E464B" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_EA2C9204C1E2D2B2C0897E6D011F52D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0476470814564BBF5BD97E6D0120C132" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39666504F6094861BFB57E6D011E464B" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0476470814564BBF5BD97E6D0120C132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1E05833B47032930F8257E6D0120719F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39666504F6094861BFB57E6D011E464B" xlink:to="loc_us-gaap_CommonStockSharesIssued_1E05833B47032930F8257E6D0120719F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_EF3D20CDFDB4B3E213217E6D012077B1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39666504F6094861BFB57E6D011E464B" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_EF3D20CDFDB4B3E213217E6D012077B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_854838CAFF0B702B6A8A7E6D0120D780" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39666504F6094861BFB57E6D011E464B" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_854838CAFF0B702B6A8A7E6D0120D780" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_F420056B99808E533DA0983D44A8094F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_F420056B99808E533DA0983D44A8094F" xlink:to="loc_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:to="loc_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_924F8CE92B4AEB2412BE983D44AB7836" xlink:to="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_FC397500D3ED7C5E7B69983D44ABDBA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_FC397500D3ED7C5E7B69983D44ABDBA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_7336C3F2DCC0F8846F31983D44ACB771" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_036FD1CE7992B59E7D84983D44ABA039" xlink:to="loc_us-gaap_CommonStockMember_7336C3F2DCC0F8846F31983D44ACB771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_097F459C7A713B6E0652983D44AAD5DD" xlink:to="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_E3BC195EDE8623BCF5F0983D44AD0FD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:to="loc_us-gaap_ProfitLoss_E3BC195EDE8623BCF5F0983D44AD0FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9EE4D9ACAAC542A73590983D44AD9E76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9EE4D9ACAAC542A73590983D44AD9E76" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AmortizationOfRightOfUseAssets" xlink:label="loc_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_gh_AmortizationOfRightOfUseAssets_EBB58E152E0714DDA80F983D44AE1765" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" xlink:label="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3D1F86069D51B8EFD21D983D44AE5443" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_84408EC72C2733928836983D44AEE5CB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_84408EC72C2733928836983D44AEE5CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_48F94E26528D33212EC5983D44AEC9CD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_ShareBasedCompensation_48F94E26528D33212EC5983D44AEC9CD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_NoncashInterestExpensePaid" xlink:label="loc_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_gh_NoncashInterestExpensePaid_60AA4C11D5974159A044983D44AE2AE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5CB6D2E5A897EE01A0F983D44AE9957" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5CB6D2E5A897EE01A0F983D44AE9957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_208EB62808C163F9149E983D44AF37E1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_208EB62808C163F9149E983D44AF37E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_409BC0F464675CCD5909983D44AF1C1A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_409BC0F464675CCD5909983D44AF1C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49D04BD5D264F831D381983D44ADDAAF" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73F385DC68FEB63991E7983D44AF9AA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73F385DC68FEB63991E7983D44AF9AA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4F473823727057C1FE28983D44AFFD34" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4F473823727057C1FE28983D44AFFD34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D576EE1607EC86F8FE98983D44B05E8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D576EE1607EC86F8FE98983D44B05E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7B2D8F92D24170CB165E983D44B0B2B7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7B2D8F92D24170CB165E983D44B0B2B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34AF78B59CA847ED9336983D44B00FFF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34AF78B59CA847ED9336983D44B00FFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0C4CD6D19F6629BF9F07983D44B09186" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0C4CD6D19F6629BF9F07983D44B09186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2508C9B47213468802CF983D44B0CBB2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2508C9B47213468802CF983D44B0CBB2" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets" xlink:label="loc_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets_63718E0A8059154C8995983D44B0B658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_04782B15751F3C8CD0D5983D44B12746" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_04782B15751F3C8CD0D5983D44B12746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_BF1AEB30EDD2C774E446983D44B134B1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_BF1AEB30EDD2C774E446983D44B134B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_AF901780CCB0F8A369BB983D44B1090F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EEDE1D43AAF71E0DEE64983D44AF3051" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_AF901780CCB0F8A369BB983D44B1090F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DC29E07C5961122C69F3983D44B19D26" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45B6C350F01236F509B0983D44AC4E96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DC29E07C5961122C69F3983D44B19D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5D4A7CC9A5C0D32BE4F0983D44B2E65F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5D4A7CC9A5C0D32BE4F0983D44B2E65F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_904A0F36E74FBB8EC3E9983D44B20D32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_904A0F36E74FBB8EC3E9983D44B20D32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9A52936F737047B485D6983D44B24E13" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9A52936F737047B485D6983D44B24E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99A263E2766936E7E120983D44B2DF92" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99A263E2766936E7E120983D44B2DF92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7DA34CB5B66A13F7870E983D44B2D0C7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7DA34CB5B66A13F7870E983D44B2D0C7" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentsInConnectionWithLicenseAgreements" xlink:label="loc_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_gh_PaymentsInConnectionWithLicenseAgreements_63608A720A1253B1958E983D44B2A777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_877165C7B1608D773C52983D44B3CE40" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56F3EF909FC6C5EF4E02983D44B104DF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_877165C7B1608D773C52983D44B3CE40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" xlink:label="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_590BB4F793EA6D35950A983D44B34B92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_33F7BD77213F72B211FC983D44B39269" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_33F7BD77213F72B211FC983D44B39269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7263B3FC1DF5D72F61FF983D44B3C296" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7263B3FC1DF5D72F61FF983D44B3C296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_8EA5643E78A03CA96B05983D44B47820" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_8EA5643E78A03CA96B05983D44B47820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_212D30DA03014E20970D983D44B4C773" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_212D30DA03014E20970D983D44B4C773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8640588B2B5E60545619983D44B45A93" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_8640588B2B5E60545619983D44B45A93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_9714F3BC5464E4A4C18E983D44B41E8F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_9714F3BC5464E4A4C18E983D44B41E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6E3D3B2734E9B6584A54983D44B4F3DA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6E3D3B2734E9B6584A54983D44B4F3DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9AF96CDB98552A7EAA5B983D44B56193" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9AF96CDB98552A7EAA5B983D44B56193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4D375400A3109739E365983D44B51B08" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4D375400A3109739E365983D44B51B08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_B178B729D09E55717594983D44B5B0B9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_B178B729D09E55717594983D44B5B0B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_292E6741495DFB73727A983D44B5F774" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976B3F92A987A755650C983D44B35A3A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_292E6741495DFB73727A983D44B5F774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_E8AD585409C99D29E53B983D44B590AC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_E8AD585409C99D29E53B983D44B590AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_919A78F575316DC90078983D44B5A5A0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_919A78F575316DC90078983D44B5A5A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A925A13952AA3D51B1E4983D44B650B1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A925A13952AA3D51B1E4983D44B650B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C86044CE86F2F4C4703A983D44B62BFE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C86044CE86F2F4C4703A983D44B62BFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D47904643C71116D8428983D44B69384" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D47904643C71116D8428983D44B69384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_ACF72AA229373D403AC2983D44B650B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:to="loc_us-gaap_InterestPaidNet_ACF72AA229373D403AC2983D44B650B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_DB632F7252C32CD94BAD983D44B70756" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401D6BE6A933D9EF6419983D44B6AC50" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_DB632F7252C32CD94BAD983D44B70756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81B6B66140A0D62CAAF2983D44AC5F1C" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment" xlink:label="loc_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment_5C469FB405580FAD463D983D44B7A598" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement" xlink:label="loc_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement_F0B91A8AF3A70BBA3A22983D44B7A254" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid_1948F3E184CB76D0F180983D44B79F4A" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_9CBC87C9E2DBB195EB86983D44B7361D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_EF3BF0E8D071BA064020983D44B82DEC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_EF3BF0E8D071BA064020983D44B82DEC" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ConversionofStockUponInitialPublicOffering" xlink:label="loc_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_ConversionofStockUponInitialPublicOffering_3AAAA29BAD3E544D742E983D44B82994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FC645CCC6F1E533A7C0983D44B87447" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FC645CCC6F1E533A7C0983D44B87447" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_OfferingCostsIncurredbutNotyetPaid" xlink:label="loc_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_075DC94C169EE492BFAC983D44B7050B" xlink:to="loc_gh_OfferingCostsIncurredbutNotyetPaid_5DBF49552FC048F80B18983D44B8F01E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0C26F198B4775C2647897E7C29E24013" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_A601DF065F4E75E128FC7E7C29E39295" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0C26F198B4775C2647897E7C29E24013" xlink:to="loc_us-gaap_ProfitLoss_A601DF065F4E75E128FC7E7C29E39295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0C26F198B4775C2647897E7C29E24013" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CC027E8153A65366EA9B7E7C29E37266" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CC027E8153A65366EA9B7E7C29E37266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_762354BB20CB42792CD57E7C29E3CA0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_762354BB20CB42792CD57E7C29E3CA0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5E2CB5D0789BC1E66C707E7C29E3E3D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5F73EB8ABA5DD171B3077E7C29E3668B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5E2CB5D0789BC1E66C707E7C29E3E3D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_163BCAA74C98B931BAA77E7C29E4464F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0C26F198B4775C2647897E7C29E24013" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_163BCAA74C98B931BAA77E7C29E4464F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_18D8DC449BA17CA2EB127E7C29E430BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0C26F198B4775C2647897E7C29E24013" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_18D8DC449BA17CA2EB127E7C29E430BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5EB2E4082CEEF5D8769E7E7C29E48FFE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0C26F198B4775C2647897E7C29E24013" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5EB2E4082CEEF5D8769E7E7C29E48FFE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_4B737706056B39A51D3F77D8C928F9B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FE9B84CE001A60614A2C77D8C928E76F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4B737706056B39A51D3F77D8C928F9B8" xlink:to="loc_us-gaap_StatementTable_FE9B84CE001A60614A2C77D8C928E76F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7A439688BD4F220CA62B77D8C928C340" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FE9B84CE001A60614A2C77D8C928E76F" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7A439688BD4F220CA62B77D8C928C340" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_BB7B4AC6513849F334C177D8C9283FB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7A439688BD4F220CA62B77D8C928C340" xlink:to="loc_us-gaap_ClassOfStockDomain_BB7B4AC6513849F334C177D8C9283FB5" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesAConvertiblePreferredStockMember_F927F89CA394E4F1556F77D8C928C404" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_BB7B4AC6513849F334C177D8C9283FB5" xlink:to="loc_gh_SeriesAConvertiblePreferredStockMember_F927F89CA394E4F1556F77D8C928C404" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesDConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesDConvertiblePreferredStockMember_E6E4770AA3585E5D187077D8C9282CA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_BB7B4AC6513849F334C177D8C9283FB5" xlink:to="loc_gh_SeriesDConvertiblePreferredStockMember_E6E4770AA3585E5D187077D8C9282CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FE9B84CE001A60614A2C77D8C928E76F" xlink:to="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromPrecisionOncologyTesting" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting_40AD5EF444B5DB9C8CA977D8C928C5BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:to="loc_gh_RevenuefromPrecisionOncologyTesting_40AD5EF444B5DB9C8CA977D8C928C5BE" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromDevelopmentServices" xlink:label="loc_gh_RevenuefromDevelopmentServices_FEE9598034DF3039C7AA77D8C928D802" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:to="loc_gh_RevenuefromDevelopmentServices_FEE9598034DF3039C7AA77D8C928D802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E544994C458D10B352C177D8C928C955" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_DCB734A61E8F8BBE8FA677D8C928E06C" xlink:to="loc_us-gaap_Revenues_E544994C458D10B352C177D8C928C955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CostsofPrecisionOncologyTesting" xlink:label="loc_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_gh_CostsofPrecisionOncologyTesting_E353F0117CBAAA11F9C877D8C9282E26" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CostofDevelopmentServices" xlink:label="loc_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_gh_CostofDevelopmentServices_A8194D023011ED69067D77D8C928B9D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7FC444B8A9781655BFB977D8C92843A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7FC444B8A9781655BFB977D8C92843A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_7FBDFFCF718E6AF5A42377D8C9287A1D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_us-gaap_SellingAndMarketingExpense_7FBDFFCF718E6AF5A42377D8C9287A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3D92013C6509D7D1E70577D8C9288E76" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3D92013C6509D7D1E70577D8C9288E76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_590EA7EC8F3DF3443F1577D8C92899CC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5CC7DF81582AB5A89D7677D8C9282EB1" xlink:to="loc_us-gaap_CostsAndExpenses_590EA7EC8F3DF3443F1577D8C92899CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_0793B8ECEACBE7E33D9677D8C92C5B39" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_OperatingIncomeLoss_0793B8ECEACBE7E33D9677D8C92C5B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_59EA801217DC3B350AEE77D8C92CC8E8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_59EA801217DC3B350AEE77D8C92CC8E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2D71F8DBCAD8895B025377D8C92C2BB9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_InterestExpense_2D71F8DBCAD8895B025377D8C92C2BB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_379F3E89CCD8F999FE6B77D8C92C7965" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_379F3E89CCD8F999FE6B77D8C92C7965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_A5641AD906C714E9641777D8C92CE07C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_A5641AD906C714E9641777D8C92CE07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4C99B8229DC525BBA75D77D8C92C2ADD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4C99B8229DC525BBA75D77D8C92C2ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_00C40839CAFAC354B1F277D8C92C8088" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_00C40839CAFAC354B1F277D8C92C8088" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_9AC9CF7A2505BC3B754477D8C92CEB66" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_ProfitLoss_9AC9CF7A2505BC3B754477D8C92CEB66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_08600CA3067A455FCCC977D8C92C3967" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_08600CA3067A455FCCC977D8C92C3967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5FDE85E6500E5D1A1A4C77D8C92C03CE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_NetIncomeLoss_5FDE85E6500E5D1A1A4C77D8C92C03CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_98BEB72AAD3B1B84B86077D8C92C44A1" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_98BEB72AAD3B1B84B86077D8C92C44A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6E34E0E9C7CC0DCA170D77D8C92C7793" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6E34E0E9C7CC0DCA170D77D8C92C7793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_BF34EC48259F895BBAEB77D8C92C5456" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_BF34EC48259F895BBAEB77D8C92C5456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EA1055BFBA99665E3D4077D8C92C7D12" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16366DDBD7AA478BB5FD77D8C92825C8" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_EA1055BFBA99665E3D4077D8C92C7D12" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_67C4003D6A1961CEF0B288B6E8A6247A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3B3F92880B63C5539E7E88B6E8A6AD80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_67C4003D6A1961CEF0B288B6E8A6247A" xlink:to="loc_us-gaap_StatementTable_3B3F92880B63C5539E7E88B6E8A6AD80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_75EEC33341D1DA3178FE88B6E8A6B3D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3B3F92880B63C5539E7E88B6E8A6AD80" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_75EEC33341D1DA3178FE88B6E8A6B3D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75EEC33341D1DA3178FE88B6E8A6B3D0" xlink:to="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RedeemableNoncontrollingInterestMember" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_gh_RedeemableNoncontrollingInterestMember_8F8E225ED61461B2849F88B6E8A76F14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_4D6E0FB38219A5C2AEC188B6E8A74CB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_us-gaap_PreferredStockMember_4D6E0FB38219A5C2AEC188B6E8A74CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FB3361B98E18AE5990DB88B6E8A72704" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_us-gaap_CommonStockMember_FB3361B98E18AE5990DB88B6E8A72704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B4B44F540E8257FBFF2E88B6E8A749AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B4B44F540E8257FBFF2E88B6E8A749AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E1506E711CAB7DDCB50B88B6E8A7B7CD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E1506E711CAB7DDCB50B88B6E8A7B7CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A2D1011C35A06FCD6FF288B6E8A8CF37" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8DD88578D13B08FDBC1188B6E8A6373D" xlink:to="loc_us-gaap_RetainedEarningsMember_A2D1011C35A06FCD6FF288B6E8A8CF37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7431B1077665C5793C1088B6E8A81FA2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3B3F92880B63C5539E7E88B6E8A6AD80" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7431B1077665C5793C1088B6E8A81FA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7431B1077665C5793C1088B6E8A81FA2" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_86813738CB525025119D88B6E8A8AFE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_86813738CB525025119D88B6E8A8AFE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_318BAEC67D82202AC7B088B6E8A8F944" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_318BAEC67D82202AC7B088B6E8A8F944" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AccountingStandardsUpdate201807Member" xlink:label="loc_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A461BD4F8E216CE2F45188B6E8A806B6" xlink:to="loc_gh_AccountingStandardsUpdate201807Member_332E58F165F5E2C38DD288B6E8A86ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7AC3B2B326C98057749688B6E8A90F02" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3B3F92880B63C5539E7E88B6E8A6AD80" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7AC3B2B326C98057749688B6E8A90F02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7AC3B2B326C98057749688B6E8A90F02" xlink:to="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesDConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21" xlink:to="loc_gh_SeriesDConvertiblePreferredStockMember_4670F951827A6408DE9988B6E8A9182C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesEConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21" xlink:to="loc_gh_SeriesEConvertiblePreferredStockMember_CB8735123C956CD0F1F888B6E8A986FD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesAConvertiblePreferredStockMember_FEB82E9651F38FE1545288B6E8AACBBC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8CCEEB4A783DF881D6AA88B6E8A9DC21" xlink:to="loc_gh_SeriesAConvertiblePreferredStockMember_FEB82E9651F38FE1545288B6E8AACBBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_69F3356B34EE26C7067588B6E8AAB0A5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3B3F92880B63C5539E7E88B6E8A6AD80" xlink:to="loc_us-gaap_StatementLineItems_69F3356B34EE26C7067588B6E8AAB0A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69F3356B34EE26C7067588B6E8AAB0A5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_41B483BC070EE5F94D0788B6E8AA3516" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockholdersEquity_41B483BC070EE5F94D0788B6E8AA3516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_06BE039E59DECD8BEAE488B6E8AADDAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_SharesOutstanding_06BE039E59DECD8BEAE488B6E8AADDAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AB67FB733F4959A94CEB88B6E8AB1F24" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AB67FB733F4959A94CEB88B6E8AB1F24" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" xlink:label="loc_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_BD5C2F5C0B1382F622A588B6E8AB8ACA" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" xlink:label="loc_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_A7BAA8AB4B1AC788DF7288B6E8ABAE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AA197B13BE353E4DA39888B6E8ABA73B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AA197B13BE353E4DA39888B6E8ABA73B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_48BE5BC2FD012CC768D788B6E8AB1B43" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_48BE5BC2FD012CC768D788B6E8AB1B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829D5F9B37251EFD3A1088B6E8ACAB65" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829D5F9B37251EFD3A1088B6E8ACAB65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_F368F7E4659EC11D746A88B6E8AC9D76" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_F368F7E4659EC11D746A88B6E8AC9D76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_1D93E98C51296771D75588B6E8AC57E1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_1D93E98C51296771D75588B6E8AC57E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_36C4F885AC24A300ED7F88B6E8AC65D6" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_36C4F885AC24A300ED7F88B6E8AC65D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36742BCE132C6462EFC288B6E8AC4EFB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36742BCE132C6462EFC288B6E8AC4EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0E57AEA8EBE041181DA888B6E8AC3D9C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0E57AEA8EBE041181DA888B6E8AC3D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_996726922F075BE846FB88B6E8ACD95B" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_996726922F075BE846FB88B6E8ACD95B" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod_7C394048FA71EDDBE65B88B6E8AD89AF" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_D8458A0C3EF830147E7C88B6E8AD9104" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_D8458A0C3EF830147E7C88B6E8AD9104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0854FC90483A33B8290988B6E8ADF354" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0854FC90483A33B8290988B6E8ADF354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_878E63CB9521F4D7212488B6E8ADEDBB" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_878E63CB9521F4D7212488B6E8ADEDBB" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_B1443ECD1D9E34C24E7288B6E8ADDE66" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_B1443ECD1D9E34C24E7288B6E8ADDE66" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodValueExerciseofWarrants" xlink:label="loc_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_StockIssuedDuringPeriodValueExerciseofWarrants_A7A72A4A0A8CA169A62A88B6E8ADD208" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions" xlink:label="loc_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions_1322C18359E8398BFBC688DE31DE12C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9B5E50593D7B99BCFB9088B6E8AE4A44" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9B5E50593D7B99BCFB9088B6E8AE4A44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_D9901D485160D0565E2F88B6E8AE0868" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_D9901D485160D0565E2F88B6E8AE0868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D7AF760685C3FBDE147488B6E8AEC8B5" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D7AF760685C3FBDE147488B6E8AEC8B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_75F5D5C7CE102FFC5EF488B6E8AE1F73" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_75F5D5C7CE102FFC5EF488B6E8AE1F73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F3FCFA74F34C2C19628088B6E8AE1005" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_SharesOutstanding_F3FCFA74F34C2C19628088B6E8AE1005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22F51327E302C1676DB488B6E8AFF263" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A4488D86B50FBE58F4A288B6E8AAFB84" xlink:to="loc_us-gaap_StockholdersEquity_22F51327E302C1676DB488B6E8AFF263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69F3356B34EE26C7067588B6E8AAB0A5" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_C0591BBEFA93FD5B7A5088B6E8AF1CE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_C0591BBEFA93FD5B7A5088B6E8AF1CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22B3FE9BBA904971615688B6E8AF95A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22B3FE9BBA904971615688B6E8AF95A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4EF52A2D15C62910F33888B6E8AF22E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4305EA07B888F2AB077D88B6E8AF5195" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4EF52A2D15C62910F33888B6E8AF22E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_AD695AB04A050EE3207177D8C8F8DA76" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E13B4D533B68527DBD2977D8C8F83215" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_AD695AB04A050EE3207177D8C8F8DA76" xlink:to="loc_us-gaap_StatementTable_E13B4D533B68527DBD2977D8C8F83215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E3A4C26B30B1BF0E81EC77D8C8F8F8AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E13B4D533B68527DBD2977D8C8F83215" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E3A4C26B30B1BF0E81EC77D8C8F8F8AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E3A4C26B30B1BF0E81EC77D8C8F8F8AA" xlink:to="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesDConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesDConvertiblePreferredStockMember_69C55AC290A43D9EF48A77D8C8F872B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77" xlink:to="loc_gh_SeriesDConvertiblePreferredStockMember_69C55AC290A43D9EF48A77D8C8F872B4" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesEConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesEConvertiblePreferredStockMember_D85399D9627A8E752CE177D8C8F82AB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77" xlink:to="loc_gh_SeriesEConvertiblePreferredStockMember_D85399D9627A8E752CE177D8C8F82AB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C901CA1CBC670696F2B277D8C8FCED9E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A351AF47A92F9D6DB70777D8C8F8CC77" xlink:to="loc_us-gaap_CommonStockMember_C901CA1CBC670696F2B277D8C8FCED9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6F7AD1FE4F975B0524EB77D8C8FC3E4A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E13B4D533B68527DBD2977D8C8F83215" xlink:to="loc_us-gaap_StatementLineItems_6F7AD1FE4F975B0524EB77D8C8FC3E4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FC798C49DB1F0C88B36177D8C8FC5CEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6F7AD1FE4F975B0524EB77D8C8FC3E4A" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FC798C49DB1F0C88B36177D8C8FC5CEF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_EE987B046D1E8276332B5A2FE05F6F40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_B5517BA3D865A314F6A05A2FE05FC567" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_EE987B046D1E8276332B5A2FE05F6F40" xlink:to="loc_us-gaap_PreferredStockTextBlock_B5517BA3D865A314F6A05A2FE05FC567" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/ConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_3F51B158D555F7D0DCB377D8C7394699" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3F51B158D555F7D0DCB377D8C7394699" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:to="loc_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_50C58B1AA87C98ADFA4277D8C73957EF" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SoftBankMember" xlink:label="loc_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2DDEEC6EBAA82181D80077D8C739CAA6" xlink:to="loc_gh_SoftBankMember_C21D780C906B99B4E50677D8C739AD0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C244986B5BE38D040A0677D8C7399CDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_C244986B5BE38D040A0677D8C7399CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2E1BE8A7B5D940B9EFDB77D8C739581A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C244986B5BE38D040A0677D8C7399CDA" xlink:to="loc_us-gaap_EquityComponentDomain_2E1BE8A7B5D940B9EFDB77D8C739581A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_38669F107A3145BB060977D8C73D2355" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2E1BE8A7B5D940B9EFDB77D8C739581A" xlink:to="loc_us-gaap_CommonStockMember_38669F107A3145BB060977D8C73D2355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A778968D584391F74AFB77D8C73D45AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A778968D584391F74AFB77D8C73D45AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A778968D584391F74AFB77D8C73D45AE" xlink:to="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E" xlink:to="loc_us-gaap_CommonStockMember_38669F107A3145BB060977D8C73D2355" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesEConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesEConvertiblePreferredStockMember_1015B056824D4926231F77D8C73DCDBA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E" xlink:to="loc_gh_SeriesEConvertiblePreferredStockMember_1015B056824D4926231F77D8C73DCDBA" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesAConvertiblePreferredStockMember_5F261E42CCB57674FF0277D8C73D411D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_AF2393B9A06997A9413177D8C73D468E" xlink:to="loc_gh_SeriesAConvertiblePreferredStockMember_5F261E42CCB57674FF0277D8C73D411D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3DCE72BC1005FDE0FF6777D8C73945B5" xlink:to="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering" xlink:label="loc_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_9B99345EBC65DB9F7A2477D8C73D4A37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering_9B99345EBC65DB9F7A2477D8C73D4A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47C58A6040A1CA0D3F2177D8C73D0786" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47C58A6040A1CA0D3F2177D8C73D0786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_B5025D6BCF6F4FA43B0477D8C73D07BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_B5025D6BCF6F4FA43B0477D8C73D07BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_145A7739F46555E55B2D77D8C73D06C4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_145A7739F46555E55B2D77D8C73D06C4" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ThresholdPercentageofNewSharesIssued" xlink:label="loc_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_gh_ThresholdPercentageofNewSharesIssued_6D7D968167627B148CD777D8C73DF7B6" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares" xlink:label="loc_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares_92EDCD598156AE7E1C2077D8C73D3808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_3A080DC7A10ED5A4831077D8C73D9F73" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_3A080DC7A10ED5A4831077D8C73D9F73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_50D21BE6D60009C139D877D8C73D7EC6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_50D21BE6D60009C139D877D8C73D7EC6" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock" xlink:label="loc_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock_F1878A45151B80F9370777D8C73D10B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00174AF260115AE4137677D8C73D6D65" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00174AF260115AE4137677D8C73D6D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DD861292E893CE2E8F1077D8C73DDBB4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DD861292E893CE2E8F1077D8C73DDBB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_F5D664059A8137CCFCD577D8C741EED2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_F5D664059A8137CCFCD577D8C741EED2" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_gh_ConvertiblePreferredStockConversionPrice_6203202E8EC2220ED0D977D8C73D809F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_64B73D08942CB3FF03B077D8C741261B" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_64B73D08942CB3FF03B077D8C741261B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="loc_us-gaap_PreferredStockDividendsShares_E9468E3686588F8561B377D8C7412EC5" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_PreferredStockDividendsShares_E9468E3686588F8561B377D8C7412EC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_93B8302C7BC26E67783877D8C7410DE0" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BEBCE57D58732320E4F277D8C73D46CE" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_93B8302C7BC26E67783877D8C7410DE0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_27611582B90EC2F1529B91EAAA43B3BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_DocumentType_27611582B90EC2F1529B91EAAA43B3BE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_41218A08D5C3FFEB591491EAAA433CE0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_DocumentAnnualReport_41218A08D5C3FFEB591491EAAA433CE0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_C6939CCABD68D1938FD491EAAA437822" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_DocumentPeriodEndDate_C6939CCABD68D1938FD491EAAA437822" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_8E36B94CBDC945CA6DB091EAAA43FED4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_DocumentTransitionReport_8E36B94CBDC945CA6DB091EAAA43FED4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_06C2E6ECACA2E51BED3891EAAA44DAD0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityFileNumber_06C2E6ECACA2E51BED3891EAAA44DAD0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_7DFA03E0457929301D5491EAAA4458B6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityRegistrantName_7DFA03E0457929301D5491EAAA4458B6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_5B1D17AE17178EEEF23191EAAA443DDE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_AmendmentFlag_5B1D17AE17178EEEF23191EAAA443DDE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_40254C32C4CF3ACA7EF291EAAA447EB7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_DocumentFiscalYearFocus_40254C32C4CF3ACA7EF291EAAA447EB7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9570E65BD821BB94DD4591EAAA446355" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9570E65BD821BB94DD4591EAAA446355" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1FAA62541099CAF43C5691EAAA451047" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityCentralIndexKey_1FAA62541099CAF43C5691EAAA451047" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_37297F34A9FBA7BCE42C91EAAA4538AC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_CurrentFiscalYearEndDate_37297F34A9FBA7BCE42C91EAAA4538AC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_AC70C94ECA63094243C491EAAA4AC545" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityIncorporationStateCountryCode_AC70C94ECA63094243C491EAAA4AC545" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_0EC137D222611546921E91EAAA4AB4B4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityTaxIdentificationNumber_0EC137D222611546921E91EAAA4AB4B4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_9F4AD29F5421A79D699B91EAAA4A9E89" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityAddressAddressLine1_9F4AD29F5421A79D699B91EAAA4A9E89" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_17D0CFCDACBAA4C3485A91EAAA4BF407" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityAddressCityOrTown_17D0CFCDACBAA4C3485A91EAAA4BF407" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_5EEDD19E3136EB417E9E91EAAA4B655F" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityAddressStateOrProvince_5EEDD19E3136EB417E9E91EAAA4B655F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_8E89D4B9F3823E35F4CB91EAAA4BE57A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityAddressPostalZipCode_8E89D4B9F3823E35F4CB91EAAA4BE57A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_4C2E49A8378C08F47BC191EAAA4B4B9B" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_CityAreaCode_4C2E49A8378C08F47BC191EAAA4B4B9B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_A72EB935DA6E56A5FE9891EAAA4B2FB7" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_LocalPhoneNumber_A72EB935DA6E56A5FE9891EAAA4B2FB7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_FF172879D85D0499AB6391EAAA4B9482" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_Security12bTitle_FF172879D85D0499AB6391EAAA4B9482" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_40AE5EACA7BE06ED427791EAAA4C4F97" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_TradingSymbol_40AE5EACA7BE06ED427791EAAA4C4F97" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_06614058F1D925D3D05591EAAA4C200D" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_SecurityExchangeName_06614058F1D925D3D05591EAAA4C200D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0120618A361354945A9E91EAAA4CB8CA" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0120618A361354945A9E91EAAA4CB8CA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_BCE676E0C8593E802AF491EAAA4CB1D4" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityVoluntaryFilers_BCE676E0C8593E802AF491EAAA4CB1D4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_A08E6813E745F2B8A38891EAAA4CB8A4" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityCurrentReportingStatus_A08E6813E745F2B8A38891EAAA4CB8A4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_BDCFB9C0684D02AC8CD591EAAA4CF199" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityInteractiveDataCurrent_BDCFB9C0684D02AC8CD591EAAA4CF199" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0BBDAA8BCCC4ABA17D0891EAAA4CC92A" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityFilerCategory_0BBDAA8BCCC4ABA17D0891EAAA4CC92A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_CA95899053A5CDE5D00C91EAAA4DFBE6" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntitySmallBusiness_CA95899053A5CDE5D00C91EAAA4DFBE6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_BC0F99DD08B73BBCB45591EAAA4D0E32" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityEmergingGrowthCompany_BC0F99DD08B73BBCB45591EAAA4D0E32" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_7D35FE4E6DFE80CECED391EAAA4DCB18" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityShellCompany_7D35FE4E6DFE80CECED391EAAA4DCB18" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_1DE67C33FFA2DDA9E0A691EAAA4D41AD" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityPublicFloat_1DE67C33FFA2DDA9E0A691EAAA4D41AD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_BCE650188D557842EAFE91EAAA4D1624" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_BCE650188D557842EAFE91EAAA4D1624" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0820A354CA66D368A95F91EAAA4DD7C6" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E4FC009754E6C051B03391EAAA437864" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0820A354CA66D368A95F91EAAA4DD7C6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EE5493BA92B5424A0D13A625E4F8E5E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CD2E6DF91C1FB68979FA625E4F9E35B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EE5493BA92B5424A0D13A625E4F8E5E8" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CD2E6DF91C1FB68979FA625E4F9E35B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DescriptionOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21875B1E956EE548E05087A8B22E1A28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21875B1E956EE548E05087A8B22E1A28" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_18D4A0B7E9D5B047FCF787A8B233EB80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_18D4A0B7E9D5B047FCF787A8B233EB80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4835FAC2158B0ED891ED87A8B2332096" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_18D4A0B7E9D5B047FCF787A8B233EB80" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4835FAC2158B0ED891ED87A8B2332096" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_WarrantsPreferredStockMember" xlink:label="loc_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4835FAC2158B0ED891ED87A8B2332096" xlink:to="loc_gh_WarrantsPreferredStockMember_048C8FF213E661C749CB87A8B2335D59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4FDF72AA7381726817EA87A8B234EBCE" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_GuardantHealthAMEAIncMember" xlink:label="loc_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6748CC577463A9BC0B2687A8B23440D3" xlink:to="loc_gh_GuardantHealthAMEAIncMember_1C1BA87464FCB08879DE87A8B2345B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_47CE5DF2F4304BF3782287A8B2345FB5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:to="loc_us-gaap_StatementClassOfStockAxis_47CE5DF2F4304BF3782287A8B2345FB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_24CC62E5F134C188C0F487A8B2351490" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47CE5DF2F4304BF3782287A8B2345FB5" xlink:to="loc_us-gaap_ClassOfStockDomain_24CC62E5F134C188C0F487A8B2351490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_ECE2DC36D3EE8072F3CC87A8B235747B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_24CC62E5F134C188C0F487A8B2351490" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_ECE2DC36D3EE8072F3CC87A8B235747B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_C4277F9206FCB5F9524A87A8B2355496" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_C4277F9206FCB5F9524A87A8B2355496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61C3CBCC27301EC9701E87A8B2350155" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_C4277F9206FCB5F9524A87A8B2355496" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61C3CBCC27301EC9701E87A8B2350155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_08E8195DC701364DD3F687A8B2369CBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61C3CBCC27301EC9701E87A8B2350155" xlink:to="loc_us-gaap_IPOMember_08E8195DC701364DD3F687A8B2369CBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_45812379489641E0196887A8B236FD1F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61C3CBCC27301EC9701E87A8B2350155" xlink:to="loc_us-gaap_OverAllotmentOptionMember_45812379489641E0196887A8B236FD1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9FFED9F5B1901706235987A8B231DD14" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_51A3DE74CB69DF8C032A87A8B236C469" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_51A3DE74CB69DF8C032A87A8B236C469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00A8A497B89DE3EE2BD187A8B237E9AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00A8A497B89DE3EE2BD187A8B237E9AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_47DC2046BFCDCB7B4DFA87A8B237E487" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_47DC2046BFCDCB7B4DFA87A8B237E487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_EB8306B67D0DEC31EBAA87A8B237F388" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_EB8306B67D0DEC31EBAA87A8B237F388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0AA7718E546F8B57E79787A8B237AF72" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0AA7718E546F8B57E79787A8B237AF72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_916A8C8114EDBEE517DC87A8B2371B18" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_916A8C8114EDBEE517DC87A8B2371B18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_24DED18B3BD20C17F7C587A8B23753F0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_24DED18B3BD20C17F7C587A8B23753F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0E6BA1C36C580B097D1787A8B2371EEC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0E6BA1C36C580B097D1787A8B2371EEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53F6A9F5B552A98ACB2D87A8B238E1D0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53F6A9F5B552A98ACB2D87A8B238E1D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_DA1211BC3CCDF8D2942C87A8B2384DD5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_DA1211BC3CCDF8D2942C87A8B2384DD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_654BDEA446A8DCB393A287A8B2380D0E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_343515837FC5DC408A7F87A8B236CB8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_654BDEA446A8DCB393A287A8B2380D0E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_12A29CD10D537D2B079D5A2FDF5CD2CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1151A63D7CE26F021E775A2FDF5C7E6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_12A29CD10D537D2B079D5A2FDF5CD2CD" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1151A63D7CE26F021E775A2FDF5C7E6D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ADB82B6877DF4488C9A977D8C61D5AB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_91957B7C25BCAD9A541677D8C61D0643" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ADB82B6877DF4488C9A977D8C61D5AB7" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_91957B7C25BCAD9A541677D8C61D0643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_02BBCB974AF35E94922677D8C61D4BA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ADB82B6877DF4488C9A977D8C61D5AB7" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_02BBCB974AF35E94922677D8C61D4BA9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_058AE613C4D8690C92345A2FE142BC63" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ABFB156C0655F8E6953E5A2FE1429CB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_058AE613C4D8690C92345A2FE142BC63" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ABFB156C0655F8E6953E5A2FE1429CB5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_80AC59CD0B4B58349E13C97D00C498C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_80AC59CD0B4B58349E13C97D00C498C1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_657E50B37B5B49277B0AC97D00C56188" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_606E5F32E03702513E59C97D00C56795" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_606E5F32E03702513E59C97D00C56795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_F8E9838876CBDCB5DC68C97D00C6AF62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_F8E9838876CBDCB5DC68C97D00C6AF62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_73C2B63EE3D9920C23FBC97D00C65A1A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_73C2B63EE3D9920C23FBC97D00C65A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CCE75E761AFA0BA0E0EAC97D00C65990" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4F4108693B8A042EBCBCC97D00C5165D" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CCE75E761AFA0BA0E0EAC97D00C65990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D100737D5CA1FDD3AFEEC97D00C5A7C8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E549EBCB3E7A55C79DE0C97D00C7E6BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E549EBCB3E7A55C79DE0C97D00C7E6BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8391E5BE3BAB8190CA83C97D00C7B206" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8391E5BE3BAB8190CA83C97D00C7B206" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_C4DB0EAAE75C65FFF02BC97D00C7DCF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FE28E1DA4D14F4CDF0DAC97D00C7BAAF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FE28E1DA4D14F4CDF0DAC97D00C7BAAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C2C5D2852F2E7E3BF8DC97D00C72344" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C2C5D2852F2E7E3BF8DC97D00C72344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1C372FF43F1FCB711D47C97D00C840F1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1C372FF43F1FCB711D47C97D00C840F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F919B4123DE928932965C97D00C8E31F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F919B4123DE928932965C97D00C8E31F" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32CC2905A1D8C6DA1CA5C97D00C6014B" xlink:to="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_24E8B547F7160097BB3BC97D00C88966" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_127A29793309CDB0FF2688B6E80C0ECB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_127A29793309CDB0FF2688B6E80C0ECB" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3A3AA27970A9CC80DD3788B6E80D001A" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_A84AB4174DEF9D319C1E88B6E80EA74D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93B31EC528AB4DC6517888B6E80D769F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_A84AB4174DEF9D319C1E88B6E80EA74D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_05317BB52B02135EDC7988B6E80E13CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:to="loc_us-gaap_FinancialInstrumentAxis_05317BB52B02135EDC7988B6E80E13CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_05317BB52B02135EDC7988B6E80E13CA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_D394186C44021E429C9688B6E80ED3A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_D394186C44021E429C9688B6E80ED3A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_FEB850B6A05FE021691588B6E80F2B36" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_FEB850B6A05FE021691588B6E80F2B36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C86EDDBE599C1F9748CA88B6E80FFAC0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27CB1A8B4542DD55C04088B6E80EA591" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C86EDDBE599C1F9748CA88B6E80FFAC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FE69A277146BA166445588B6E80FEC25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FE69A277146BA166445588B6E80FEC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_D1636BBBEFC189DF602088B6E80F88EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FE69A277146BA166445588B6E80FEC25" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_D1636BBBEFC189DF602088B6E80F88EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_957BAC594A730C621CAD88B6E80F8A44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_D1636BBBEFC189DF602088B6E80F88EA" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_957BAC594A730C621CAD88B6E80F8A44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B2554C061778FC46221888B6E80F8EC8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B2554C061778FC46221888B6E80F8EC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B2554C061778FC46221888B6E80F8EC8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_A97187A3ADB0A89BB8B788B6E810D385" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_A97187A3ADB0A89BB8B788B6E810D385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ACD483CD75ED0363A6FE88B6E8107356" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ACD483CD75ED0363A6FE88B6E8107356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_05308E66C0DAB927361D88B6E810C76F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEA614C9DF25D6C1E93688B6E8107B41" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_05308E66C0DAB927361D88B6E810C76F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_628AE6E497EB5E10BB4D88B6E80D7064" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47295D87DA6E90CBC98E88B6E81185DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47295D87DA6E90CBC98E88B6E81185DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_4ED04ADA12504956E86388B6E8117A97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_4ED04ADA12504956E86388B6E8117A97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_B5BAA0B41B56B72E2EFF88B6E811991C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_B5BAA0B41B56B72E2EFF88B6E811991C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3AB9C08221AFE29C441888B6E8116E91" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3AB9C08221AFE29C441888B6E8116E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A8DEE9BFA2F72542583888B991CEBF48" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A8DEE9BFA2F72542583888B991CEBF48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_F09A8C0D500B4CB11E2D88B6E812B4E0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41A0B6C5ED1A458538FD88B6E8103AD6" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_F09A8C0D500B4CB11E2D88B6E812B4E0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_857BBF0FC9F23352849BA625E58C55F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_368E93A61BFBFE12E34FA625E58C1766" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_857BBF0FC9F23352849BA625E58C55F2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_368E93A61BFBFE12E34FA625E58C1766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9E6B81FB23B75ED4B255A625E58C482C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_368E93A61BFBFE12E34FA625E58C1766" xlink:to="loc_srt_RangeAxis_9E6B81FB23B75ED4B255A625E58C482C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7C0AFA8E6014E3F2F5F2A625E58C7C86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9E6B81FB23B75ED4B255A625E58C482C" xlink:to="loc_srt_RangeMember_7C0AFA8E6014E3F2F5F2A625E58C7C86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_7920D988F268F6F3DE54A625E58D2431" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7C0AFA8E6014E3F2F5F2A625E58C7C86" xlink:to="loc_srt_MinimumMember_7920D988F268F6F3DE54A625E58D2431" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C68301CC8988E71928E1A625E58D7BDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7C0AFA8E6014E3F2F5F2A625E58C7C86" xlink:to="loc_srt_MaximumMember_C68301CC8988E71928E1A625E58D7BDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2186D0DA5B5C1B57942CA625E58DD34A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_368E93A61BFBFE12E34FA625E58C1766" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2186D0DA5B5C1B57942CA625E58DD34A" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_MarketableSecuritiesMaturityPeriod" xlink:label="loc_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2186D0DA5B5C1B57942CA625E58DD34A" xlink:to="loc_gh_MarketableSecuritiesMaturityPeriod_BB2686047B74FC410914A625E58D57CB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4FDF1A5F3547E28C9841A625E5CF093B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9871EAA358E9021B1F8BA625E5D014AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4FDF1A5F3547E28C9841A625E5CF093B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9871EAA358E9021B1F8BA625E5D014AF" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DebtSecuritiesTableTextBlock" xlink:label="loc_gh_DebtSecuritiesTableTextBlock_1E910B68B7CDF08EB9A3A625E5D0D373" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4FDF1A5F3547E28C9841A625E5CF093B" xlink:to="loc_gh_DebtSecuritiesTableTextBlock_1E910B68B7CDF08EB9A3A625E5D0D373" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9604F109CCCEBC3F60455A2FDFA13D94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1D365DED164D80D669465A2FDFA267D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9604F109CCCEBC3F60455A2FDFA13D94" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1D365DED164D80D669465A2FDFA267D1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8042337F3E6A5B2AD0CB77D8C65366AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F28477166577B94F555577D8C654897B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8042337F3E6A5B2AD0CB77D8C65366AE" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F28477166577B94F555577D8C654897B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_2A8528FD3ABDA416A5F377D8C65411A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8042337F3E6A5B2AD0CB77D8C65366AE" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_2A8528FD3ABDA416A5F377D8C65411A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_AD817E4F44CB731D904977D8C654A40D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8042337F3E6A5B2AD0CB77D8C65366AE" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_AD817E4F44CB731D904977D8C654A40D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_447D45E89898F606B88177D8C654D696" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8042337F3E6A5B2AD0CB77D8C65366AE" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_447D45E89898F606B88177D8C654D696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_D8D3C243C39D70DCBA6C77D8C656043A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8042337F3E6A5B2AD0CB77D8C65366AE" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_D8D3C243C39D70DCBA6C77D8C656043A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E5F83FDC723FA2928EA177D8C656EC0D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8042337F3E6A5B2AD0CB77D8C65366AE" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E5F83FDC723FA2928EA177D8C656EC0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_C0D908BC880B2E02E2FB77D8C65676D1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8042337F3E6A5B2AD0CB77D8C65366AE" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_C0D908BC880B2E02E2FB77D8C65676D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_18E6285ABB2987EDEADF77D8C6565C70" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8042337F3E6A5B2AD0CB77D8C65366AE" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_18E6285ABB2987EDEADF77D8C6565C70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_559B9785A53B412EA5BF77D8C656F0FF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8042337F3E6A5B2AD0CB77D8C65366AE" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_559B9785A53B412EA5BF77D8C656F0FF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_25EBF653880142AD9623983D583A9A8F" xlink:type="locator" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeTaxesTable" xlink:label="loc_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25EBF653880142AD9623983D583A9A8F" xlink:to="loc_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_71232210EFEF1E4EEB0E983D583B8213" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_73345D37364AE6044A76983D583BBDC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:to="loc_us-gaap_DomesticCountryMember_73345D37364AE6044A76983D583BBDC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_63F8CF3B0F0ECAB7E9E6983D583B439C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3BF0369AFA980CC1F211983D583B4638" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_63F8CF3B0F0ECAB7E9E6983D583B439C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeTaxesLineItems" xlink:label="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_IncomeTaxesTable_B37320D7DDE389A79B77983D583AEE99" xlink:to="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_CE3C006F969AAAA0E48D983D583C2206" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_CE3C006F969AAAA0E48D983D583C2206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_C06951897B59DE8C9887983D583C88E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_C06951897B59DE8C9887983D583C88E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_584DA3864F7C5318C9E2983D583C740B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_OperatingLossCarryforwards_584DA3864F7C5318C9E2983D583C740B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_E8CC0BFE06FAE77E4A1F983D583CA64C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_E8CC0BFE06FAE77E4A1F983D583CA64C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F859BAAFB8347D99AFD7983D583D83D2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F859BAAFB8347D99AFD7983D583D83D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8AA893505232586CFFEA983D583DCA57" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_IncomeTaxesLineItems_37E7DEF06B11C3D2DB41983D583CD92E" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8AA893505232586CFFEA983D583DCA57" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7ACC156CBAF98ECD5E3477D8C62E1F93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ACC156CBAF98ECD5E3477D8C62E1F93" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_394B05E5F7A987DC8B7C77D8C62E0A22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_394B05E5F7A987DC8B7C77D8C62E0A22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7171C0EF2D6D89D0193877D8C62E1722" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7171C0EF2D6D89D0193877D8C62E1722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_F23432E2D3B65E89125677D8C62E52C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_F23432E2D3B65E89125677D8C62E52C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_A52D4E5971D6A47169C877D8C62EB97E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_DBC3B1E20F9E0DE05D8877D8C62EA02A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_A52D4E5971D6A47169C877D8C62EB97E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0B3AA958A5BC1F14E5D177D8C66002C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0B3AA958A5BC1F14E5D177D8C66002C3" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AE481E0A9CD61CB278D077D8C660AACE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AE481E0A9CD61CB278D077D8C660AACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F941C4453F02ADC7D4AB77D8C664B6C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F941C4453F02ADC7D4AB77D8C664B6C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_B40EAC9028F39CF66D9477D8C6644CC6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_B40EAC9028F39CF66D9477D8C6644CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9D0B353A239A44125AC577D8C6644456" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9D0B353A239A44125AC577D8C6644456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_371024DDADCD5E3D450F77D8C664654A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_371024DDADCD5E3D450F77D8C664654A" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_gh_DeferredTaxAssetsLeaseLiabilities_4E6AEDDA8427B5C296F678B7F336CABF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:to="loc_gh_DeferredTaxAssetsLeaseLiabilities_4E6AEDDA8427B5C296F678B7F336CABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_64952AA61725EFE95C9B77D8C6649D01" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_64952AA61725EFE95C9B77D8C6649D01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0AA89563CE746AD2CE4177D8C6643384" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17C68E99E2A667D57CD977D8C66087C7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0AA89563CE746AD2CE4177D8C6643384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0B3AA958A5BC1F14E5D177D8C66002C3" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_537E76F8B2AB4CD4BFFA77D8C664054E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_537E76F8B2AB4CD4BFFA77D8C664054E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DeferredTaxLiabilitiesSection481aAdjustment" xlink:label="loc_gh_DeferredTaxLiabilitiesSection481aAdjustment_BCF2FA1A707D5E298A2078B91F25A7E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45" xlink:to="loc_gh_DeferredTaxLiabilitiesSection481aAdjustment_BCF2FA1A707D5E298A2078B91F25A7E5" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_gh_DeferredTaxLiabilitiesRightOfUseAssets_B1A893EA6F0D54A68F8078B9A9274C17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45" xlink:to="loc_gh_DeferredTaxLiabilitiesRightOfUseAssets_B1A893EA6F0D54A68F8078B9A9274C17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_011408AB4CCBE20A99AD78BA4AF1B4F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5DE07F371B81800B8CD177D8C664BE45" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_011408AB4CCBE20A99AD78BA4AF1B4F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D4443F9691F9D65DE32677D8C664C259" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0B3AA958A5BC1F14E5D177D8C66002C3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D4443F9691F9D65DE32677D8C664C259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1FB7863C324B0AA20F2D77D8C6643411" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0B3AA958A5BC1F14E5D177D8C66002C3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1FB7863C324B0AA20F2D77D8C6643411" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6351BBEAAC37CD5236737E7B595B5B1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6351BBEAAC37CD5236737E7B595B5B1A" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_733B333A16544D3FEC527E7B595C0AC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_733B333A16544D3FEC527E7B595C0AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7F5D5587B9E58E39EB7D7E7B595DD170" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7F5D5587B9E58E39EB7D7E7B595DD170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3BB2C91B3818C9A09DF77E7B595D018C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3CB6965381113A1A668E7E7B595CDC7D" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3BB2C91B3818C9A09DF77E7B595D018C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6351BBEAAC37CD5236737E7B595B5B1A" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_E0DCA4CEF0FA0C4AA1EA7E7B595DED33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_E0DCA4CEF0FA0C4AA1EA7E7B595DED33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3293974B8E1DC6C5732D7E7B595D2A9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3293974B8E1DC6C5732D7E7B595D2A9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0ECD57E85307149931117E7BC235ADEC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0ECD57E85307149931117E7BC235ADEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7BD4643AACBD487DBC317E7B595DCB1C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_E7C0DC7DDBA8AA801E0D7E7B595D7A9B" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7BD4643AACBD487DBC317E7B595DCB1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6731CFFAEAC115FE48E47E7B595EC37B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6351BBEAAC37CD5236737E7B595B5B1A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6731CFFAEAC115FE48E47E7B595EC37B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C931EA340C2E47B00A4AA625E504A17D" xlink:type="locator" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest" xlink:label="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_94943A433066C0D2AE7DA625E504DBF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C931EA340C2E47B00A4AA625E504A17D" xlink:to="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest_94943A433066C0D2AE7DA625E504DBF1" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest" xlink:label="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_242AB9238034297AE576A625E505B47C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C931EA340C2E47B00A4AA625E504A17D" xlink:to="loc_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest_242AB9238034297AE576A625E505B47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_EEB264A45800D97404FFA625E505C418" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C931EA340C2E47B00A4AA625E504A17D" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_EEB264A45800D97404FFA625E505C418" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_41425189BE27BB8714E8A625E5366CEF" xlink:type="locator" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock_9DC4ACE970A75CDEFA3DA625E53701C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_41425189BE27BB8714E8A625E5366CEF" xlink:to="loc_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock_9DC4ACE970A75CDEFA3DA625E53701C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9925ED7E6832C0B20789A625E5372BE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_41425189BE27BB8714E8A625E5366CEF" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9925ED7E6832C0B20789A625E5372BE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_BEC1460D7967EBEF29A1A625E5378A82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_41425189BE27BB8714E8A625E5366CEF" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_BEC1460D7967EBEF29A1A625E5378A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_F9C12C45CF114DEF7458A625E537E91C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_41425189BE27BB8714E8A625E5366CEF" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_F9C12C45CF114DEF7458A625E537E91C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5BE2395FFF112CABACACA625E5371A19" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_41425189BE27BB8714E8A625E5366CEF" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5BE2395FFF112CABACACA625E5371A19" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/InvestmentInJointVenture" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_DCF316A158B46DDF73415A2FE17D1696" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_F6E75C308091DA824BF05A2FE17D0028" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_DCF316A158B46DDF73415A2FE17D1696" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_F6E75C308091DA824BF05A2FE17D0028" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/InvestmentInJointVentureDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_9F66376B249AC06E2F5C91EAA8C76A4C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_9F66376B249AC06E2F5C91EAA8C76A4C" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:to="loc_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_B559700A8E817B74503091EAA8C746F7" xlink:to="loc_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SoftBankMember" xlink:label="loc_gh_SoftBankMember_2990639116C75C39B3F191EAA8C88EE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6B5811E404635B5DD72591EAA8C7974D" xlink:to="loc_gh_SoftBankMember_2990639116C75C39B3F191EAA8C88EE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EA63FE9D40D9CE51D17C91EAA8C83534" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EA63FE9D40D9CE51D17C91EAA8C83534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_E20AA2EBB957C7A7584591EAA8C8BAFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EA63FE9D40D9CE51D17C91EAA8C83534" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_E20AA2EBB957C7A7584591EAA8C8BAFE" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_GuardantHealthAMEAIncMember" xlink:label="loc_gh_GuardantHealthAMEAIncMember_6D10D5108D1434D3F4AC91EAA8C8EFD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_E20AA2EBB957C7A7584591EAA8C8BAFE" xlink:to="loc_gh_GuardantHealthAMEAIncMember_6D10D5108D1434D3F4AC91EAA8C8EFD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3CA1C4AA1BEB28BF899191EAA8C71F57" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_F54252EB534FB489505291EAA8C98D17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_F54252EB534FB489505291EAA8C98D17" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_EquityMethodInvestmentSharesPurchased" xlink:label="loc_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_EquityMethodInvestmentSharesPurchased_83A087C1FFB18A4FA17B91EAA8C9E825" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_86248E71DBE08F2598CA91EAA8C9B868" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_86248E71DBE08F2598CA91EAA8C9B868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_10DCB1F30A4B2CF57EB291EAA8C95F36" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_10DCB1F30A4B2CF57EB291EAA8C95F36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_F884403E335E1F3E2E8291EAA8CA6D31" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_F884403E335E1F3E2E8291EAA8CA6D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_50EF3B9DDC5BB15C0DCC91EAA8CAFEA7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_50EF3B9DDC5BB15C0DCC91EAA8CAFEA7" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty" xlink:label="loc_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty_CADC5B32C7AF2DBE076991EAA8CA3376" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_D3AC14716543D1D475F891EAA8CAC56D" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityThresholdPercentageofFairValue" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageofFairValue_B6922AC9EB2629A181C591EAA8CA9CF1" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_VariableInterestEntityPercentageoftheProduct" xlink:label="loc_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_VariableInterestEntityPercentageoftheProduct_D2C71F28996F88432FC991EAA8CA5880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable" xlink:label="loc_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable_698502EF81253AC5BDD491F62E6544B2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable_698502EF81253AC5BDD491F62E6544B2" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RedeemableNoncontrollingInterestFairValueAdjustment" xlink:label="loc_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4570A588549CDBA6AEB091EAA8C9D949" xlink:to="loc_gh_RedeemableNoncontrollingInterestFairValueAdjustment_1D1C55B513A426A50CED91EAA8CB1B6E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_130D563A52E7A73A6DD55A2FE0A5C445" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6CF28EE1BCFB779430325A2FE0A51F19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_130D563A52E7A73A6DD55A2FE0A5C445" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_6CF28EE1BCFB779430325A2FE0A51F19" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_DEBC35DF5ADA55FE86B77E7C28D8105E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_4840A873DC579953E74D7E7C28D8CD34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_DEBC35DF5ADA55FE86B77E7C28D8105E" xlink:to="loc_us-gaap_OperatingLeaseExpense_4840A873DC579953E74D7E7C28D8CD34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_088EFF42FE06B827071A7E7C28D80F8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_DEBC35DF5ADA55FE86B77E7C28D8105E" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_088EFF42FE06B827071A7E7C28D80F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_70436A341AEBA9796DD97E7C28D8B56F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_DEBC35DF5ADA55FE86B77E7C28D8105E" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_70436A341AEBA9796DD97E7C28D8B56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_AF357508F9ECD705616C7E7C28D987E2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_DEBC35DF5ADA55FE86B77E7C28D8105E" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_AF357508F9ECD705616C7E7C28D987E2" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability_153042D8D91A62A202977E7C28D9A520" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_DEBC35DF5ADA55FE86B77E7C28D8105E" xlink:to="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability_153042D8D91A62A202977E7C28D9A520" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount_5D10C9585A94FF9F17AA7E7C28D9D855" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_DEBC35DF5ADA55FE86B77E7C28D8105E" xlink:to="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount_5D10C9585A94FF9F17AA7E7C28D9D855" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome_E5ACFFFCA5639B10A13F7E7C28D96029" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_DEBC35DF5ADA55FE86B77E7C28D8105E" xlink:to="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome_E5ACFFFCA5639B10A13F7E7C28D96029" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_EFC0439BBF2AFD4EB4A85A852AC361CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_35C922FE9F784360D0B85A8DB2279651" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EFC0439BBF2AFD4EB4A85A852AC361CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_35C922FE9F784360D0B85A8DB2279651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_901869CDCC0C5DEF12735A8DD81969EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EFC0439BBF2AFD4EB4A85A852AC361CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_901869CDCC0C5DEF12735A8DD81969EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D98583A607885F2EA7045A8E01817076" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EFC0439BBF2AFD4EB4A85A852AC361CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D98583A607885F2EA7045A8E01817076" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B5EE1D303721827560755A8E2DFD3E06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EFC0439BBF2AFD4EB4A85A852AC361CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B5EE1D303721827560755A8E2DFD3E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8F15CC6F9B85352345665A8E584B13D0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EFC0439BBF2AFD4EB4A85A852AC361CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8F15CC6F9B85352345665A8E584B13D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2649D93C72AAB605DC235A8E80A9E367" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EFC0439BBF2AFD4EB4A85A852AC361CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2649D93C72AAB605DC235A8E80A9E367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_33AFD1E1FB1B7E6767ED5A8EA7FA23A6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EFC0439BBF2AFD4EB4A85A852AC361CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_33AFD1E1FB1B7E6767ED5A8EA7FA23A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_3CA1A2A9B96DE84902B3983D59269877" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4B06DFCCAA22962CA3C6983D59265501" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3CA1A2A9B96DE84902B3983D59269877" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4B06DFCCAA22962CA3C6983D59265501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_43D58AAD6FE3DAE1E3A7983D5926961B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3CA1A2A9B96DE84902B3983D59269877" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_43D58AAD6FE3DAE1E3A7983D5926961B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_CF280F98A6114F9B9587983D59264EBB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3CA1A2A9B96DE84902B3983D59269877" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_CF280F98A6114F9B9587983D59264EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1129DE4AB9A195E78DA3983D592635A2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3CA1A2A9B96DE84902B3983D59269877" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1129DE4AB9A195E78DA3983D592635A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5D966A89165292A10053983D59261754" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3CA1A2A9B96DE84902B3983D59269877" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5D966A89165292A10053983D59261754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80D0C12DC7B9680BDE15983D5927426D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3CA1A2A9B96DE84902B3983D59269877" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80D0C12DC7B9680BDE15983D5927426D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5B1A131239FA42BA67C3983D5927A6D8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3CA1A2A9B96DE84902B3983D59269877" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5B1A131239FA42BA67C3983D5927A6D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_C5F907B8F995C8F7B9B2983D5927FEAF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3CA1A2A9B96DE84902B3983D59269877" xlink:to="loc_us-gaap_OperatingLeaseLiability_C5F907B8F995C8F7B9B2983D5927FEAF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_45E6C1CC7EFA0A0D174A5A8491D9ABF4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C594F20D111246DD321D5A8757213574" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45E6C1CC7EFA0A0D174A5A8491D9ABF4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C594F20D111246DD321D5A8757213574" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_D02800354E9E266D66685A82597BA4A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45E6C1CC7EFA0A0D174A5A8491D9ABF4" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_D02800354E9E266D66685A82597BA4A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_49D031C832E3B7AF9A195A2FDFD1382D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_761C862E398D771AB6E75A2FDFD1A482" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_49D031C832E3B7AF9A195A2FDFD1382D" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_761C862E398D771AB6E75A2FDFD1A482" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E813EEB33EF57D8503C588B6E6D63932" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E813EEB33EF57D8503C588B6E6D63932" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6AEE98371281182C1D8388B6E6D789CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6AEE98371281182C1D8388B6E6D789CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B04F9973A3A490E59B1E88B6E6D7859A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6AEE98371281182C1D8388B6E6D789CD" xlink:to="loc_us-gaap_ClassOfStockDomain_B04F9973A3A490E59B1E88B6E6D7859A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_76DD7A6B3F626BEA8B1188B6E6D84DC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B04F9973A3A490E59B1E88B6E6D7859A" xlink:to="loc_us-gaap_PreferredStockMember_76DD7A6B3F626BEA8B1188B6E6D84DC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_ED9D87394691006D27A988B6E6D89AA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B04F9973A3A490E59B1E88B6E6D7859A" xlink:to="loc_us-gaap_CommonStockMember_ED9D87394691006D27A988B6E6D89AA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D6D1AF1CEB40F24E01BE88B6E6D806FE" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_C63C726358555CA6179088B6E6D87260" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_C63C726358555CA6179088B6E6D87260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7BB1454E325F28023E8C88B6E6D9F745" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7BB1454E325F28023E8C88B6E6D9F745" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_EmployeeStockPurchasePlanObligationMember" xlink:label="loc_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_gh_EmployeeStockPurchasePlanObligationMember_CB60ECCB772E632C9FB088B6E6D9F18B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2C06239315353147AD5A88B6E6D9EBD7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_us-gaap_WarrantMember_2C06239315353147AD5A88B6E6D9EBD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_00EA638D75F2464FD28F88B90AA72B44" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_00EA638D75F2464FD28F88B90AA72B44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_C93D11ED92E3BF8880D788B6E6D96904" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_974BC991B0A6434A292F88B6E6D826A1" xlink:to="loc_us-gaap_TreasuryStockCommonMember_C93D11ED92E3BF8880D788B6E6D96904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_759156281BD1E7716A8988B6E6D67FD8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BEAE516D07C07A3CA1E888B6E6DAD147" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4960C53F1975355D8DE188B6E6DA6BF5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BEAE516D07C07A3CA1E888B6E6DAD147" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2819C595AEBB2E9DBB17983D58706007" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2819C595AEBB2E9DBB17983D58706007" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A82E7356D7CB537F6241983D58703123" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A82E7356D7CB537F6241983D58703123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B3CE3C47DE77DA03D9C0983D5871BD5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A82E7356D7CB537F6241983D58703123" xlink:to="loc_us-gaap_ClassOfStockDomain_B3CE3C47DE77DA03D9C0983D5871BD5E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesAConvertiblePreferredStockMember_441DB5A240EC8C3F21A4983D5871F8BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B3CE3C47DE77DA03D9C0983D5871BD5E" xlink:to="loc_gh_SeriesAConvertiblePreferredStockMember_441DB5A240EC8C3F21A4983D5871F8BD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesDConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesDConvertiblePreferredStockMember_2ADE7ACB65F49E0B08FF983D587189C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B3CE3C47DE77DA03D9C0983D5871BD5E" xlink:to="loc_gh_SeriesDConvertiblePreferredStockMember_2ADE7ACB65F49E0B08FF983D587189C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_94B5088014847D1087A5983D5870A1EC" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_02F3FEACA10D5C8512C8983D5871A2FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_ProfitLoss_02F3FEACA10D5C8512C8983D5871A2FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_2F969D7CE0CB62AD0AE4983D58727AC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_2F969D7CE0CB62AD0AE4983D58727AC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9E87242A74D1E1BE36C7983D5872CB4D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_NetIncomeLoss_9E87242A74D1E1BE36C7983D5872CB4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_A7E3E48ACFBEEFDD2D7D983D5872C2A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_A7E3E48ACFBEEFDD2D7D983D5872C2A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_CAB7FF3CBCF57CA3CD05983D5872A1B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_CAB7FF3CBCF57CA3CD05983D5872A1B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_272E6A962C27A028C893983D5872A3E7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_272E6A962C27A028C893983D5872A3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94CBC74E4D7D70D2FC8B983D5873C48A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_3CCDAFA4F78A72A40960983D5871537F" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94CBC74E4D7D70D2FC8B983D5873C48A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_15375DB0CEC003D3D522A625E4D0CAB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1543DC05F2EADF08AAE8A625E4D0628B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_15375DB0CEC003D3D522A625E4D0CAB3" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1543DC05F2EADF08AAE8A625E4D0628B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_EE513DF37EC6994F817EA625E4D0D54B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_15375DB0CEC003D3D522A625E4D0CAB3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_EE513DF37EC6994F817EA625E4D0D54B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/PatentLicenseAgreement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BB6FC22452FE0CF6C19D5A2FE0D999DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C8E4BFB77B14AB1D00D75A2FE0D981C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BB6FC22452FE0CF6C19D5A2FE0D999DB" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C8E4BFB77B14AB1D00D75A2FE0D981C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/PatentLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_B3A3521D63A4E76911A888B6E7C6D733" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B323FB437AE7B9E74A7288B6E7C6A489" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_B3A3521D63A4E76911A888B6E7C6D733" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B323FB437AE7B9E74A7288B6E7C6A489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B323FB437AE7B9E74A7288B6E7C6A489" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C295AE8952A97BF72DC488B6E7C64EDA" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_C1F00CF12FD75CE566CD88B6E7C77357" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_B40DF3003095ABD8586E88B6E7C64628" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_C1F00CF12FD75CE566CD88B6E7C77357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_309DDD72ACDE52DBC9A488B6E7C7416A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B323FB437AE7B9E74A7288B6E7C6A489" xlink:to="loc_us-gaap_StatementClassOfStockAxis_309DDD72ACDE52DBC9A488B6E7C7416A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_39A6A6176BB54A5B549B88B6E7C71800" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_309DDD72ACDE52DBC9A488B6E7C7416A" xlink:to="loc_us-gaap_ClassOfStockDomain_39A6A6176BB54A5B549B88B6E7C71800" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesDConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesDConvertiblePreferredStockMember_03D5CD2EB897A6C1182088B6E7C7421F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_39A6A6176BB54A5B549B88B6E7C71800" xlink:to="loc_gh_SeriesDConvertiblePreferredStockMember_03D5CD2EB897A6C1182088B6E7C7421F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_AEB39AB8CA6E3634DEA988B6E7C731A4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B323FB437AE7B9E74A7288B6E7C6A489" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_AEB39AB8CA6E3634DEA988B6E7C731A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D143EF0B387C702889D088B6E7C8B1FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_AEB39AB8CA6E3634DEA988B6E7C731A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D143EF0B387C702889D088B6E7C8B1FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_7F44C0865EAABB9FCD2088B6E7C8F5F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D143EF0B387C702889D088B6E7C8B1FB" xlink:to="loc_us-gaap_LicensingAgreementsMember_7F44C0865EAABB9FCD2088B6E7C8F5F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B323FB437AE7B9E74A7288B6E7C6A489" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3ABEB288BDB35F0AC41A88B6E7C859E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3ABEB288BDB35F0AC41A88B6E7C859E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2A288B358D7572B03EA488B6E7C9EDA2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2A288B358D7572B03EA488B6E7C9EDA2" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_LicenseAgreementMilestonePaymentUponAchievement" xlink:label="loc_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_gh_LicenseAgreementMilestonePaymentUponAchievement_A3F2FBA4B647820C6D8188B6E7C9E4CA" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentsforFutureRoyalties" xlink:label="loc_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_gh_PaymentsforFutureRoyalties_B017111A61454A944AE888B6E7C9AB40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_17291C750C8653FC18B088B6E7C9682D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_17291C750C8653FC18B088B6E7C9682D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5E44E81C7D0418F6C6FE88B6E7C97F00" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5E44E81C7D0418F6C6FE88B6E7C97F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_18AF4BD120B1A2522EBD88B6E7C99F1C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_18AF4BD120B1A2522EBD88B6E7C99F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6606AAEEE63A8D766B9E88B6E7CA62AF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6606AAEEE63A8D766B9E88B6E7CA62AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_887CEB8C10D58D1205A288B6E7CA982D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3B41E3CA5460150E3E0D88B6E7C8FB53" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_887CEB8C10D58D1205A288B6E7CA982D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_3DE149F3BEF00119E2795A2FDF444CCC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_134FD3A28F133F21BCBC5A2FDF443576" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_3DE149F3BEF00119E2795A2FDF444CCC" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_134FD3A28F133F21BCBC5A2FDF443576" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_86A6DF336C63170FBA7591E039FEEFC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_86A6DF336C63170FBA7591E039FEEFC9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:to="loc_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_F3859DD975E508F293DA91E039FEFDA8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_5809A11025F24830D96291E039FFBD56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8048C1DF2B7A0EA0896B91E039FEC6A3" xlink:to="loc_us-gaap_ExecutiveOfficerMember_5809A11025F24830D96291E039FFBD56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_D62593647EADA0AE7B4B91E039FF1B30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_D62593647EADA0AE7B4B91E039FF1B30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_232C518B419672DE6E1D91E039FF173A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D62593647EADA0AE7B4B91E039FF1B30" xlink:to="loc_us-gaap_ClassOfStockDomain_232C518B419672DE6E1D91E039FF173A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_93DF60032DEDDF64DB0391E03A007357" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_232C518B419672DE6E1D91E039FF173A" xlink:to="loc_us-gaap_CommonStockMember_93DF60032DEDDF64DB0391E03A007357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DA0284B9CD9608337F7E91E03A00587A" xlink:to="loc_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srt_AffiliatedEntityMember_CF687FE8E998B2DEBF6991E03A00E232" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7B92D1DB14B02E66BED791E03A00DF5C" xlink:to="loc_srt_AffiliatedEntityMember_CF687FE8E998B2DEBF6991E03A00E232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_A304A208641944321E5C91E039FE687D" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_02577CB2FD985A02C78391E03A01F35D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_02577CB2FD985A02C78391E03A01F35D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_CF5B2E616D6BD95AFB3191E03A011788" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_CF5B2E616D6BD95AFB3191E03A011788" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CommonStockCompensationExpense" xlink:label="loc_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:to="loc_gh_CommonStockCompensationExpense_C73A08BC3122F966EAED91E03A0131D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_9F63F841660F2A76949291E03A014D50" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47541F0D6D3D52028D2791E03A0146C0" xlink:to="loc_us-gaap_RevenueFromRelatedParties_9F63F841660F2A76949291E03A014D50" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentAndGeographicInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_E4BEFA5EB4C4D8B636325A2FDF5248F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_18E18F8B112FE08414435A2FDF523582" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_E4BEFA5EB4C4D8B636325A2FDF5248F8" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_18E18F8B112FE08414435A2FDF523582" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentAndGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_6E2BF072913883A0808391EAA76FEB1F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6E2BF072913883A0808391EAA76FEB1F" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_01F1D757C6ABB461BAB391FD90023941" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsMember" xlink:label="loc_us-gaap_AssetsMember_9E0ECFB1EA7927FFD6C891FEC2FA7214" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4C4A939BB520BEF5480891FD9009DD79" xlink:to="loc_us-gaap_AssetsMember_9E0ECFB1EA7927FFD6C891FEC2FA7214" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_C1D2A51B69ADCA17B5BF91EAA76FA7A5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_53814A68ADC3046C37B491FC497501C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_93038E01B687E752FD8C91EAA7707C42" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_53814A68ADC3046C37B491FC497501C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:to="loc_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_EFEF04669A78D5F0E3E491EAA770A6B3" xlink:to="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_AB15354AB48B695F3A7491EAA7711DA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:to="loc_country_US_AB15354AB48B695F3A7491EAA7711DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_6CEAC1DE94E8AD5D0D6591EAA7718AE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_B167D78276DAD3FC135291EAA770F1F5" xlink:to="loc_us-gaap_NonUsMember_6CEAC1DE94E8AD5D0D6591EAA7718AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6D1E54F5D1DC2422384091EAA76FCDC4" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_32947E77E56461C5A01691EAA77100CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:to="loc_us-gaap_Revenues_32947E77E56461C5A01691EAA77100CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_F2486A5D21661A75AE8E91EAA772C144" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_46065079B50BB43FB18791EAA771AC32" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_F2486A5D21661A75AE8E91EAA772C144" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentAndGeographicInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_47A165CED7DCA1A6EBB5A625E5ABFA48" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_35A9F8BF3C5E0A6DFF45A625E5AB8A0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_47A165CED7DCA1A6EBB5A625E5ABFA48" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_35A9F8BF3C5E0A6DFF45A625E5AB8A0A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_569D613F76C8419D55D65A2FE0BE27E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_B49CB8E6B98BEA102D945A2FE0BE6FFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_569D613F76C8419D55D65A2FE0BE27E2" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_B49CB8E6B98BEA102D945A2FE0BE6FFE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1072729B49459BA69411F21FE369D72A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1072729B49459BA69411F21FE369D72A" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementbyPaymentTierAxis" xlink:label="loc_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:to="loc_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementbyPaymentTierDomain" xlink:label="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_RoyaltyAgreementbyPaymentTierAxis_D5AA02DBA10F07881C64F21FE36AEED3" xlink:to="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_TierOneMember" xlink:label="loc_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:to="loc_gh_TierOneMember_854143613A7F9287A0B9F21FE36AA91C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_TierTwoMember" xlink:label="loc_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_RoyaltyAgreementbyPaymentTierDomain_3D092A18534DBA376A04F21FE36A6F53" xlink:to="loc_gh_TierTwoMember_AA6C1596472A7D0BC5D8F21FE36AB6BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:to="loc_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1AAE446C2A075C2C5A3CF21FE36BC3A3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CreditAgreementMember" xlink:label="loc_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:to="loc_gh_CreditAgreementMember_3EFB54CE7FCA0B0EF748F21FE36BD3B6" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementMember" xlink:label="loc_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65B7EB2C78A00D557DE7F21FE36BBB20" xlink:to="loc_gh_RoyaltyAgreementMember_0ADC8F8D200061B94BD5F21FE36BD44C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:to="loc_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_63DD6291722BE4B9B426F21FE36BDED1" xlink:to="loc_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorLoansMember" xlink:label="loc_us-gaap_SeniorLoansMember_8EEF31F98D53609661B1F21FE36CCA32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1A021E1C49633F1A73FBF21FE36C3674" xlink:to="loc_us-gaap_SeniorLoansMember_8EEF31F98D53609661B1F21FE36CCA32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_D78F337B091F8CAC3469F21FE369CA5E" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81A5451D1FB027175816F21FE36C69B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81A5451D1FB027175816F21FE36C69B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_13F988D1C5934EE81050F21FE36D4EDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_13F988D1C5934EE81050F21FE36D4EDB" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_DebtInstrumentVariableRateBasisBaseRate" xlink:label="loc_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_gh_DebtInstrumentVariableRateBasisBaseRate_C4C287E614A50A17EEADF21FE36D85DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0DDBBCF7139CEB5ECEA7F21FE36D5B84" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0DDBBCF7139CEB5ECEA7F21FE36D5B84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53AA0BD27CDE104E86A7F21FE36DEEFE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53AA0BD27CDE104E86A7F21FE36DEEFE" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyAgreementPaymentTierThreshold" xlink:label="loc_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_gh_RoyaltyAgreementPaymentTierThreshold_6D02548420F177B40AF5F21FE36D9ECD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RoyaltyPaymentsPercentageofRevenue" xlink:label="loc_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_gh_RoyaltyPaymentsPercentageofRevenue_3BCAAFA2E3F4CE9B130FF21FE36D1F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_2ADC4291B13BA2C94C5CF21FE36EC031" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_RepaymentsOfDebt_2ADC4291B13BA2C94C5CF21FE36EC031" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PaymentofAccruedInterestDebt" xlink:label="loc_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_gh_PaymentofAccruedInterestDebt_0BEA11F8323D8FDDBB8DF21FE36E4E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_1BBF24202D6DE06F399CF21FE36E5B37" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_1BBF24202D6DE06F399CF21FE36E5B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_9446B0B4AE3CA9673BCFF21FE36E7160" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_9446B0B4AE3CA9673BCFF21FE36E7160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_8D8D8C863BE4A6985D67F21FE36E6BFD" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_8D8D8C863BE4A6985D67F21FE36E6BFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_265B2987106B44FF4340F21FE36EAB41" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_265B2987106B44FF4340F21FE36EAB41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_FC1662A75FD56C6BDBB5F21FE36F1318" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_DB301EA6D8F15D7E8F5CF21FE36CD4CA" xlink:to="loc_us-gaap_LongTermDebt_FC1662A75FD56C6BDBB5F21FE36F1318" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0813272EB3D976079B94A625E7093D0B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3A5194D41391A20F6656A625E709C069" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0813272EB3D976079B94A625E7093D0B" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3A5194D41391A20F6656A625E709C069" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1E353881E185937A763A77D8C72359AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B647B280890E3496FE2B77D8C7236214" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1E353881E185937A763A77D8C72359AE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B647B280890E3496FE2B77D8C7236214" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B647B280890E3496FE2B77D8C7236214" xlink:to="loc_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_34B95DE3DF5C7E44C85477D8C7271D8A" xlink:to="loc_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_A2018EmployeeStockPurchasePlanMember" xlink:label="loc_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_C6D67F49DC3CF2393F1977D8C727E28C" xlink:to="loc_gh_A2018EmployeeStockPurchasePlanMember_49F16F700926B2DA37C877D8C727B28A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6F0D6F07E5460D59DB2877D8C72789E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B647B280890E3496FE2B77D8C7236214" xlink:to="loc_us-gaap_AwardTypeAxis_6F0D6F07E5460D59DB2877D8C72789E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6F0D6F07E5460D59DB2877D8C72789E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A06C1F67AA710F05ECED77D8C727D872" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_A06C1F67AA710F05ECED77D8C727D872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7D86B626B5F73F7FE9BB77D8C727608D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7D86B626B5F73F7FE9BB77D8C727608D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1E385D4EFB72C062C84F77D8C7277D6C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F110BC063C454058E76277D8C7278C8B" xlink:to="loc_us-gaap_EmployeeStockMember_1E385D4EFB72C062C84F77D8C7277D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B647B280890E3496FE2B77D8C7236214" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_132798C74688D050777B77D8C727D3CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_642540B7A3EF308F036977D8C7275F31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_642540B7A3EF308F036977D8C7275F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2C7A238F036D1BED983977D8C7271CF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2C7A238F036D1BED983977D8C7271CF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9748368742DD91618B3777D8C727D0C9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9748368742DD91618B3777D8C727D0C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C74A240530DD3AFAE87677D8C727C1FD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C74A240530DD3AFAE87677D8C727C1FD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ReversalOfStockBasedCompensationExpense" xlink:label="loc_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_gh_ReversalOfStockBasedCompensationExpense_082DE337779D03ADCA4D78A06E6783B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A45AC792A283A025F6A077D8C7277470" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A45AC792A283A025F6A077D8C7277470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5F16D44B87D1CDA368AB77D8C72B207D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5F16D44B87D1CDA368AB77D8C72B207D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1DF9B2D252E17FE188EC78E6299192D9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1DF9B2D252E17FE188EC78E6299192D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_DB0BB48FD5871BBE189777D8C72B5D8F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_DB0BB48FD5871BBE189777D8C72B5D8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E13637F335E3281C79E877D8C72BA8CA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E13637F335E3281C79E877D8C72BA8CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9D861A5BFE515060168A77D8C72B46CE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9D861A5BFE515060168A77D8C72B46CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_794D0AC71D04B36F23FA77D8C72B3D55" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_794D0AC71D04B36F23FA77D8C72B3D55" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CommonStockSubjecttoRepurchaseorCancellation" xlink:label="loc_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_gh_CommonStockSubjecttoRepurchaseorCancellation_70556CD744051B70754177D8C72BD39E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" xlink:label="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_F26267173AFD70D5305177D8C72B262C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_E00B1F03347718C0191977D8C72B4407" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3E0B8ABC792E3743FD277D8C72759F9" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_E00B1F03347718C0191977D8C72B4407" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E116B64B04CF88E0DBFB88B6E704FB4C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E116B64B04CF88E0DBFB88B6E704FB4C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:to="loc_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_AAC16BBA9E04DE81DEE588B6E704AA02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_505FC60AAFD5F09D609788B6E705070E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B7F9112602A55820B02388B6E704F664" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_505FC60AAFD5F09D609788B6E705070E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0AF0C3BA6C822704E97488B6E7046150" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80126A9A121E92A905CB88B6E706EA31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80126A9A121E92A905CB88B6E706EA31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C2E333DD904C180FECCD88B6E7066778" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C2E333DD904C180FECCD88B6E7066778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_892D8C7C0D38D553118488B6E706D93D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_892D8C7C0D38D553118488B6E706D93D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355331D75890FF2F06D88B6E7062141" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355331D75890FF2F06D88B6E7062141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AD221141746209EC67E88B6E706EC61" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856FC02B94AE28DA0CC888B6E705C723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AD221141746209EC67E88B6E706EC61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB181DE5D95A0A2CB31688B6E705BF29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60D0C47AF85BF07071B188D443BFF0D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60D0C47AF85BF07071B188D443BFF0D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E94F37C450ED1243A5BF88D1070A9841" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E94F37C450ED1243A5BF88D1070A9841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30BDA54E64C9D5DB7C7888D10718440B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30BDA54E64C9D5DB7C7888D10718440B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2FD472C29ECCA28067DE88D1072716D3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2FD472C29ECCA28067DE88D1072716D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B70CFBF26619F8BC277B88CE2BDF02B2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_E9BACC9920D6903F6D0088B6E7061B7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B70CFBF26619F8BC277B88CE2BDF02B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51B42E94617DF0200707D49BC4280BDC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D7D1060EA7E79E11CA1DD49BC428C130" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51B42E94617DF0200707D49BC4280BDC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D7D1060EA7E79E11CA1DD49BC428C130" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B2555C577F9853BC845ED49BC428E6F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D7D1060EA7E79E11CA1DD49BC428C130" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B2555C577F9853BC845ED49BC428E6F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B2555C577F9853BC845ED49BC428E6F5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_PrecisionOncologyTestingMember" xlink:label="loc_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:to="loc_gh_PrecisionOncologyTestingMember_D0AD8692CBF4C941BC52D49BC42927BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_921771769F7D408C8E06D49BC429463C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_921771769F7D408C8E06D49BC429463C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_83FFE9F3B5BA95B34CC1D49BC4294EEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_83FFE9F3B5BA95B34CC1D49BC4294EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_02815E167CEBE3F6C27FD49BC4295243" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EDD4CDE68D452993C48BD49BC429AD72" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_02815E167CEBE3F6C27FD49BC4295243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4B003154F11D579E520D49BC42AF94E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D7D1060EA7E79E11CA1DD49BC428C130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4B003154F11D579E520D49BC42AF94E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_26DA9B1A2ACE0443957DD49BC42A7181" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4B003154F11D579E520D49BC42AF94E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_26DA9B1A2ACE0443957DD49BC42A7181" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C897DD38277748EF9CD6F30F6CDA34B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CC6228EF2F990A50880F30F6CDA52AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C897DD38277748EF9CD6F30F6CDA34B4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CC6228EF2F990A50880F30F6CDA52AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_45BD155AEEACA2D59DF1F30F6CDB655D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CC6228EF2F990A50880F30F6CDA52AA" xlink:to="loc_us-gaap_AwardTypeAxis_45BD155AEEACA2D59DF1F30F6CDB655D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6D61DAC11D4DE0F1A18CF30F6CDB6838" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_45BD155AEEACA2D59DF1F30F6CDB655D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6D61DAC11D4DE0F1A18CF30F6CDB6838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F30DF5E199C805BEC341F30F6CDBDFD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6D61DAC11D4DE0F1A18CF30F6CDB6838" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F30DF5E199C805BEC341F30F6CDBDFD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CC6228EF2F990A50880F30F6CDA52AA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2E4C3F48B95DE2871EBAF30F6CDCF1E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2E4C3F48B95DE2871EBAF30F6CDCF1E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8E0B7DAF54DECC507E67F30F6CDC368D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8E0B7DAF54DECC507E67F30F6CDC368D" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_B8848473E59C253E6D65F30F6CDC039A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_B8848473E59C253E6D65F30F6CDC039A" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_67B230E7D4C30913938FF30F6CDC34D1" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross_61D283421B6EF020907FF30F6CDD7698" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross_33265516B8F867B272DEF30F6CDD177E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares_E4AC509AC6DAB3145A38F30F6CDD8116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ADD91490BDDC13665C32F30F6CDD48F1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_7626B8C6EC2C44E1D1F0F30F6CDCFD31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ADD91490BDDC13665C32F30F6CDD48F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672C1F609E67873D54E5F30F6CDD7CFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672C1F609E67873D54E5F30F6CDD7CFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ECF9DCBD65614A1FB97F30F6CDE5F13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ECF9DCBD65614A1FB97F30F6CDE5F13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11B260460BD772417390F30F6CDE68B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11B260460BD772417390F30F6CDE68B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_342AC442107271B64C0BF30F6CDE20D8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_342AC442107271B64C0BF30F6CDE20D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9528BCF1417C784D64B5F30F6CDE9AC9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ACEC831E453117CC162F30F6CDD7176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9528BCF1417C784D64B5F30F6CDE9AC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03D9EB906B5646C74E25F30F6CDF1ADF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03D9EB906B5646C74E25F30F6CDF1ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26CEDBC478F5D8410941F30F6CDF182C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26CEDBC478F5D8410941F30F6CDF182C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3B9AEF7A4F7097C3FAC8F30F6CDFD7CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3B9AEF7A4F7097C3FAC8F30F6CDFD7CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F22C75C6A911F2B7E0B0F30F6CDF2CB7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F22C75C6A911F2B7E0B0F30F6CDF2CB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EFE9E0780DFEFD880685F30F6CDFCF8F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1A8DEEF6A6B54C9F9026F30F6CDE813C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EFE9E0780DFEFD880685F30F6CDFCF8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2B200E3CD0EA014860EEF30F6CDBF259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_C3343115CF9411A6C535F30F6CE0C851" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_C3343115CF9411A6C535F30F6CE0C851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9923499BF06DA596AA49F30F6CE0E649" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9923499BF06DA596AA49F30F6CE0E649" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_C8590AA99069DE479FF5F30F6CE07EF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_C8590AA99069DE479FF5F30F6CE07EF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ED284325E1F9F75FDACF30F6CE0BA3A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ED284325E1F9F75FDACF30F6CE0BA3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_782B47BBA443B5127951F30F6CE01B68" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_782B47BBA443B5127951F30F6CE01B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D208E0654D340722B6A9F30F6CE1BBF4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B2E7078ADAA22563C2E1F30F6CDF8830" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D208E0654D340722B6A9F30F6CE1BBF4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0053E0C94B9A2A211E645A2FE038309D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_41EF2E59DAF5B77638BD5A2FE0388E4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0053E0C94B9A2A211E645A2FE038309D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_41EF2E59DAF5B77638BD5A2FE0388E4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_BDC5C2F106312E3EB6AC5A2FE039EE8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0053E0C94B9A2A211E645A2FE038309D" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_BDC5C2F106312E3EB6AC5A2FE039EE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_197077C5114C0EF07C505A2FE039ABBB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0053E0C94B9A2A211E645A2FE038309D" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_197077C5114C0EF07C505A2FE039ABBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C514D2A22CF78251CDC25A2FE0395E8C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0053E0C94B9A2A211E645A2FE038309D" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C514D2A22CF78251CDC25A2FE0395E8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C03C9E073CD22A252A845A2FE039CC40" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0053E0C94B9A2A211E645A2FE038309D" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C03C9E073CD22A252A845A2FE039CC40" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1870B7C9BF93DB7181F587BA55A190B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_924D3E57A4D8CEEB4F8187BA55A11D67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1870B7C9BF93DB7181F587BA55A190B2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_924D3E57A4D8CEEB4F8187BA55A11D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8E1FF74D5B2C3B31878C87BA55A185C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_924D3E57A4D8CEEB4F8187BA55A11D67" xlink:to="loc_us-gaap_AwardTypeAxis_8E1FF74D5B2C3B31878C87BA55A185C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93C7D6FBB8D65C17893287BA55A1CD1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8E1FF74D5B2C3B31878C87BA55A185C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93C7D6FBB8D65C17893287BA55A1CD1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_E731FA1F2C804D489B4B87BA55A22B76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93C7D6FBB8D65C17893287BA55A1CD1A" xlink:to="loc_us-gaap_EmployeeStockMember_E731FA1F2C804D489B4B87BA55A22B76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9E3289D8C94CD39A870587BA55A2F06E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_924D3E57A4D8CEEB4F8187BA55A11D67" xlink:to="loc_srt_RangeAxis_9E3289D8C94CD39A870587BA55A2F06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DA4976FA0D50C126563F87BA55A2AF4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9E3289D8C94CD39A870587BA55A2F06E" xlink:to="loc_srt_RangeMember_DA4976FA0D50C126563F87BA55A2AF4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C773E5EDDE9F0258176787BA55A22143" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_DA4976FA0D50C126563F87BA55A2AF4F" xlink:to="loc_srt_MinimumMember_C773E5EDDE9F0258176787BA55A22143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C92AF6987724FC8BB25C87BA55A3D89A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_DA4976FA0D50C126563F87BA55A2AF4F" xlink:to="loc_srt_MaximumMember_C92AF6987724FC8BB25C87BA55A3D89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_924D3E57A4D8CEEB4F8187BA55A11D67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_09E0E359E0B45C56C23087BA55A34F16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_09E0E359E0B45C56C23087BA55A34F16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75E27C994FFD4438257587BA55A3A2A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75E27C994FFD4438257587BA55A3A2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A9794B0B90DC8EED9EB87BA55A385A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2A9794B0B90DC8EED9EB87BA55A385A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D2A32F396194A361D6B87BA55A3D67E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C46123C124AFD717A67E87BA55A3A14C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D2A32F396194A361D6B87BA55A3D67E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8B442D88235674591ED687BA55B2AE65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D33C7AC71FE30398EAAA87BA55B2007B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8B442D88235674591ED687BA55B2AE65" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D33C7AC71FE30398EAAA87BA55B2007B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_0FDAD97D97916EF84BDE87BA55B28F5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D33C7AC71FE30398EAAA87BA55B2007B" xlink:to="loc_srt_RangeAxis_0FDAD97D97916EF84BDE87BA55B28F5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C5E467700BB61351050587BA55B3FCF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0FDAD97D97916EF84BDE87BA55B28F5D" xlink:to="loc_srt_RangeMember_C5E467700BB61351050587BA55B3FCF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_105432715F6FA0CAA17E87BA55B33384" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_C5E467700BB61351050587BA55B3FCF0" xlink:to="loc_srt_MinimumMember_105432715F6FA0CAA17E87BA55B33384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_09D6BED58F9E4EE9F3E687BA55B3EFFE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_C5E467700BB61351050587BA55B3FCF0" xlink:to="loc_srt_MaximumMember_09D6BED58F9E4EE9F3E687BA55B3EFFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6EEBA1E38FD3CCBD10F287BA55B3F4A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D33C7AC71FE30398EAAA87BA55B2007B" xlink:to="loc_us-gaap_AwardTypeAxis_6EEBA1E38FD3CCBD10F287BA55B3F4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E8E0F2B1D36E8DC8BBF87BA55B4D71B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6EEBA1E38FD3CCBD10F287BA55B3F4A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E8E0F2B1D36E8DC8BBF87BA55B4D71B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_DFF008156CD00E36BA7287BA55B42D3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E8E0F2B1D36E8DC8BBF87BA55B4D71B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_DFF008156CD00E36BA7287BA55B42D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D33C7AC71FE30398EAAA87BA55B2007B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0D3C8CBD596F4B03C74A87BA55B434AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0D3C8CBD596F4B03C74A87BA55B434AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_029B22A09317AB5DF4CA87BA55B53ADB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_029B22A09317AB5DF4CA87BA55B53ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6DE327D2C9CD150BD23087BA55B59CE3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6DE327D2C9CD150BD23087BA55B59CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D2F875BC0CBCA575089387BA55B5C1C3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D2F875BC0CBCA575089387BA55B5C1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2A3F526B39717377D35F87BA55B5F57A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2A3F526B39717377D35F87BA55B5F57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D947249A581CE2AF9AF287BA55B57E4F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_360E6D136FA7FEEC0E8C87BA55B48751" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D947249A581CE2AF9AF287BA55B57E4F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_16301A581A30F3BD7EBF5A2FE2131E90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_60E166B1C6AA280A23385A2FE2130282" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_16301A581A30F3BD7EBF5A2FE2131E90" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_60E166B1C6AA280A23385A2FE2130282" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_F8C3571D2955E0BB9FD391EAA8D2B922" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F8C3571D2955E0BB9FD391EAA8D2B922" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:to="loc_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6A6E744539D2B9225EB791EAA8D2DAD5" xlink:to="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ClinicalCustomersMember" xlink:label="loc_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:to="loc_gh_ClinicalCustomersMember_1B7B6DED6D60BC755A9891EAA8D39194" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_BiopharmaceuticalCustomersMember" xlink:label="loc_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_BB01C3BB13E1A5C513A091EAA8D26F3F" xlink:to="loc_gh_BiopharmaceuticalCustomersMember_4A40DC48D0466A77F1C191EAA8D3089A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5D5234083E5473E2C0FC91EAA8D36162" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_49421ACCB184F61821E191EAA8D499B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3876A208372F63F8B99991EAA8D345C7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_49421ACCB184F61821E191EAA8D499B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA996F2C4811CD6AD7C991EAA8D4A664" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9CEBC81FB731E962B09D91EAA8D4F126" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9CEBC81FB731E962B09D91EAA8D4F126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_ED38C8357C2792EB51FF91EAA8D5A287" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_4AF528FA6759DB6A5C2E91EAA8D4D7EF" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_ED38C8357C2792EB51FF91EAA8D5A287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_EE702720DAC4F6DB8F9C91EAA8D293E5" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9E1622E32A5DE16B69C691EAA8D5FB89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9E1622E32A5DE16B69C691EAA8D5FB89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_376B03A6AA1CE6F6DEC791EAA8D52A14" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_376B03A6AA1CE6F6DEC791EAA8D52A14" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromPrecisionOncologyTesting" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:to="loc_gh_RevenuefromPrecisionOncologyTesting_A81D9289E3E8274200B591EAA8D5CDAD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_RevenuefromDevelopmentServices" xlink:label="loc_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ED98C4357D46CD12D02E91EAA8D548E6" xlink:to="loc_gh_RevenuefromDevelopmentServices_D7585CD255E8DBA7842091EAA8D6E67D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E71FA07C08B5C6124FFF91CCCCFC0008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E71FA07C08B5C6124FFF91CCCCFC0008" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_670424C64A727AB0D2D691CCCCFDD655" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_670424C64A727AB0D2D691CCCCFDD655" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_94A1410F24AAB761CD1691CCCCFE169E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_670424C64A727AB0D2D691CCCCFDD655" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_94A1410F24AAB761CD1691CCCCFE169E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_AEDEA7D05DEDE682586291CCCCFE36DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_94A1410F24AAB761CD1691CCCCFE169E" xlink:to="loc_us-gaap_OtherAssetsMember_AEDEA7D05DEDE682586291CCCCFE36DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8B87C76DF03787AB495791CCCCFEA2D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="loc_srt_RangeAxis_8B87C76DF03787AB495791CCCCFEA2D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_573F787C30EA44D2E02691CCCCFE1846" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8B87C76DF03787AB495791CCCCFEA2D7" xlink:to="loc_srt_RangeMember_573F787C30EA44D2E02691CCCCFE1846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_BBCF5665DF48DCC1C37091CCCCFE9166" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_573F787C30EA44D2E02691CCCCFE1846" xlink:to="loc_srt_MinimumMember_BBCF5665DF48DCC1C37091CCCCFE9166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FAD0A78FA7ADEB2FF03791CCCD0495F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_573F787C30EA44D2E02691CCCCFE1846" xlink:to="loc_srt_MaximumMember_FAD0A78FA7ADEB2FF03791CCCD0495F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BF82E26F9C2F3E5D2F9191CCCD044D77" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_78B0F541B4052F814B5B91CCCD055DF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8F84F20DEC12A7CD78A391CCCD044168" xlink:to="loc_us-gaap_CollaborativeArrangementMember_78B0F541B4052F814B5B91CCCD055DF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68E2BA235AB7C15F192A91CCCD056047" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68E2BA235AB7C15F192A91CCCD056047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_319E13C2939622815F0891CCCD055610" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68E2BA235AB7C15F192A91CCCD056047" xlink:to="loc_us-gaap_TypeOfAdoptionMember_319E13C2939622815F0891CCCD055610" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_AccountingStandardsUpdate201807Member" xlink:label="loc_gh_AccountingStandardsUpdate201807Member_F86C199B0D0CAF69C56991CCCD05218F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_319E13C2939622815F0891CCCD055610" xlink:to="loc_gh_AccountingStandardsUpdate201807Member_F86C199B0D0CAF69C56991CCCD05218F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EC6B5830230BC87AE90091CCCD05F268" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_EC6B5830230BC87AE90091CCCD05F268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_41F674631901741CDF2891CCCD0667EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EC6B5830230BC87AE90091CCCD05F268" xlink:to="loc_us-gaap_EquityComponentDomain_41F674631901741CDF2891CCCD0667EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_D6D3C8E80165E000005B91CCCD06C95A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_41F674631901741CDF2891CCCD0667EF" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_D6D3C8E80165E000005B91CCCD06C95A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_111763676412976DEED591CCCD0682AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_41F674631901741CDF2891CCCD0667EF" xlink:to="loc_us-gaap_RetainedEarningsMember_111763676412976DEED591CCCD0682AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61CFD9FDBF958A1E955C91CCCCFD4C3E" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_F807002154CF6DF07AAB91CCCD071E06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_RestrictedCash_F807002154CF6DF07AAB91CCCD071E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9932F5096BB288BCE68591CCCD07529A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9932F5096BB288BCE68591CCCD07529A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_F6642C73CE6C17C4980D91CCCD07D9C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_F6642C73CE6C17C4980D91CCCD07D9C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_6CFFE234AE0873759C7691CCCD071F3C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_AdvertisingExpense_6CFFE234AE0873759C7691CCCD071F3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5320F85A8C33FA3FEC0591CCCD07B1FE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5320F85A8C33FA3FEC0591CCCD07B1FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8C604EB7ABBF3B6CDBD591CCCD08FD5B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8C604EB7ABBF3B6CDBD591CCCD08FD5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2439493CD703F9DDC58D91CCCD084778" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2439493CD703F9DDC58D91CCCD084778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2DFF7A15F827A446A5A691CCCD08CB41" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2DFF7A15F827A446A5A691CCCD08CB41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_5535D212A9F49B55669B91CCCD08B5DF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_DeferredOfferingCosts_5535D212A9F49B55669B91CCCD08B5DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_28EBFC15D8335DB179E191CCCD082131" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_28EBFC15D8335DB179E191CCCD082131" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_2F461391F7E7510A17CB91CCCD085D03" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_OperatingLeaseLiability_2F461391F7E7510A17CB91CCCD085D03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D6EA4A91B45ACE263B0091CCCD08AF9A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_49727B76317E76EBD22891CCCD064F4C" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D6EA4A91B45ACE263B0091CCCD08AF9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_793F3754955EF8A1BDDF77D8C8AE1713" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_793F3754955EF8A1BDDF77D8C8AE1713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_13E4A8A7331BCD2E368477D8C8AEF046" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_UseOfEstimates_13E4A8A7331BCD2E368477D8C8AEF046" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_JOBSActAccountingElectionPolicyTextBlock" xlink:label="loc_gh_JOBSActAccountingElectionPolicyTextBlock_C4F8618D2CC8E21D4A5777D8C8AE7759" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_gh_JOBSActAccountingElectionPolicyTextBlock_C4F8618D2CC8E21D4A5777D8C8AE7759" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_299148A23392B5056FB677D8C8AED152" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_299148A23392B5056FB677D8C8AED152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_68006FD04B22F6A4BF5777D8C8AE2072" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_68006FD04B22F6A4BF5777D8C8AE2072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_13E46340D77CDE89BE6177D8C8AE57D8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_13E46340D77CDE89BE6177D8C8AE57D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_2AF468907036F945EAC277D8C8AECB4E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_2AF468907036F945EAC277D8C8AECB4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_B4C69B1F8A91C424036877D8C8AE793C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_B4C69B1F8A91C424036877D8C8AE793C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_D2BE20C0D31CE5C72E6F77D8C8AEEA4F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_D2BE20C0D31CE5C72E6F77D8C8AEEA4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_0260A470D520741DE7A177D8C8AEFFAA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_0260A470D520741DE7A177D8C8AEFFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_D794C04E95FE0AF5E73177D8C8AE543F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_D794C04E95FE0AF5E73177D8C8AE543F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_B4BA260FF1B964854C0977D8C8B20004" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_B4BA260FF1B964854C0977D8C8B20004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B297AC3591AD69A051E777D8C8B2DD01" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B297AC3591AD69A051E777D8C8B2DD01" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ObligationRelatedtoRoyaltyPolicyTextBlock" xlink:label="loc_gh_ObligationRelatedtoRoyaltyPolicyTextBlock_9F327EC4D9BC8039EB7877D8C8B21384" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_gh_ObligationRelatedtoRoyaltyPolicyTextBlock_9F327EC4D9BC8039EB7877D8C8B21384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E5120835EF459E141EC277D8C8B218EE" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E5120835EF459E141EC277D8C8B218EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_35D82424E57932BBBCEB784CEFEA1560" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_35D82424E57932BBBCEB784CEFEA1560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5B943E8708AB9C29241777D8C8B36326" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5B943E8708AB9C29241777D8C8B36326" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:label="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_4C7401251720103F56B377D8C8B36834" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_4C7401251720103F56B377D8C8B36834" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CostofDevelopmentServicesPolicyTextBlock" xlink:label="loc_gh_CostofDevelopmentServicesPolicyTextBlock_8B05850593D1E5EE12EC77D8C8B30874" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_gh_CostofDevelopmentServicesPolicyTextBlock_8B05850593D1E5EE12EC77D8C8B30874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D07DE1B46E22D4F03E8277D8C8B3A4E8" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D07DE1B46E22D4F03E8277D8C8B3A4E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_4362F5D0554F1BDD2AED77D8C8B3FA6A" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_4362F5D0554F1BDD2AED77D8C8B3FA6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_95549193E3DAF8835B4F77D8C8B3AA8C" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_95549193E3DAF8835B4F77D8C8B3AA8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0FD80DB24F72DE37011377D8C8B477B5" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0FD80DB24F72DE37011377D8C8B477B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5A788666C8E473C4340D77D8C8B4315C" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5A788666C8E473C4340D77D8C8B4315C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_62A1C110D456508B550B77D8C8B447A8" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_62A1C110D456508B550B77D8C8B447A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01E648E669995118571277D8C8B45D52" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2133224F28DD911223CD77D8C8AEC49E" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01E648E669995118571277D8C8B45D52" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8E26F06E3EBD1D8AB7837853A960464E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8E26F06E3EBD1D8AB7837853A960464E" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_86EDB6CD2D7352E3512F78555394383B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_86EDB6CD2D7352E3512F78555394383B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9A4C89A62FEFEF74887D7855226B4079" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_2B90C77941F02D58C320785439E86014" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_2B90C77941F02D58C320785439E86014" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_1ACDB1075B9E8D5CA4177854B6EA0A57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2D6FC2F5EFE3401C03C27855226D3ECF" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_1ACDB1075B9E8D5CA4177854B6EA0A57" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_F2471F314B45BB0126B791CCCCA67D59" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F2471F314B45BB0126B791CCCCA67D59" xlink:to="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_178431280B3B4EB3645791CCCCA625C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:to="loc_srt_MajorCustomersAxis_178431280B3B4EB3645791CCCCA625C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_178431280B3B4EB3645791CCCCA625C1" xlink:to="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerAMember" xlink:label="loc_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:to="loc_gh_CustomerAMember_42CBCF7DC8BFB39016E891CCCCA70D4E" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerBMember" xlink:label="loc_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:to="loc_gh_CustomerBMember_B4AD685F446BDD4989A791CCCCA94C42" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerCMember" xlink:label="loc_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:to="loc_gh_CustomerCMember_3208B022A3E0BBF0C58591CCCCA97BBF" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_CustomerDMember" xlink:label="loc_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_549430F5387577BFE2A891CCCCA7CECD" xlink:to="loc_gh_CustomerDMember_129A9E3C48BC3564970691CD50B7E900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_CCDCB12EEECBD8AC2EF891CCCCA9D38E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_CCDCB12EEECBD8AC2EF891CCCCA9D38E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4DE79A263B8F12083B3491CCCCA9B81C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_CCDCB12EEECBD8AC2EF891CCCCA9D38E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4DE79A263B8F12083B3491CCCCA9B81C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_C2F59F075B9FBA4F2A6491CCCCAA0FA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4DE79A263B8F12083B3491CCCCA9B81C" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_C2F59F075B9FBA4F2A6491CCCCAA0FA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A7B74993D914FF7EBFBF91CCCCAAA037" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_B7DDFCB64FF54414F4C291CCCCAA064B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:to="loc_us-gaap_SalesRevenueNetMember_B7DDFCB64FF54414F4C291CCCCAA064B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_6A2415853D93C0653C2291CCCCAB5560" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_EA649AF735A65D5F54CF91CCCCAA36EE" xlink:to="loc_us-gaap_AccountsReceivableMember_6A2415853D93C0653C2291CCCCAB5560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3E0B787B0CA10CED2EFD91CCCCA60194" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_FC1657B19B6FB33A5FA791CCCCAB5929" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5F0147AF07BA318D619191CCCCAB0821" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_FC1657B19B6FB33A5FA791CCCCAB5929" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8923BC12B1F07A15D93977D8C8A45296" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_710F0FD1E3AF48A0740D77D8C8A45DE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8923BC12B1F07A15D93977D8C8A45296" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_710F0FD1E3AF48A0740D77D8C8A45DE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_042C33F37D50999946E277D8C8A80C28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8923BC12B1F07A15D93977D8C8A45296" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_042C33F37D50999946E277D8C8A80C28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_397EAD9A56B0E62ACBEF77D8C8A806DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8923BC12B1F07A15D93977D8C8A45296" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_397EAD9A56B0E62ACBEF77D8C8A806DD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_FAC9983896E64D904669A9FD956003C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FAC9983896E64D904669A9FD956003C3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4A3B0866A45586B6097DA9FD95619D0C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_56A4709061792EC86C58A9FD95613F4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_56A4709061792EC86C58A9FD95613F4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6C9B885398938D1D1054A9FD9561A243" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6C9B885398938D1D1054A9FD9561A243" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_ComputerEquipmentandSoftwareMember" xlink:label="loc_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_496FF0A29664AAA4EC3EA9FD9561BCD7" xlink:to="loc_gh_ComputerEquipmentandSoftwareMember_1F6CFF5EFD657A202D45A9FD95627AA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:to="loc_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_05980D977DFF81621F6FA9FD9562BA95" xlink:to="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_E588EE35EF8AC65ABA8BA9FD95628409" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:to="loc_srt_MinimumMember_E588EE35EF8AC65ABA8BA9FD95628409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_DEA2F184F458E1A3FD79A9FD95627AA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_62EB4E7F1E5D7BB9F7EFA9FD95624A58" xlink:to="loc_srt_MaximumMember_DEA2F184F458E1A3FD79A9FD95627AA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A433033B40AC2984CEF0A9FD95609A11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C918A47ED619F22194CAA9FD95635041" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D1A59419D334C32FE4DA9FD95633494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C918A47ED619F22194CAA9FD95635041" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/Tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_8CFAE112EBEC493582A6F2AFCAFA3338" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_975D8CBCCD17E91B5E52F2AFCAFA8462" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8CFAE112EBEC493582A6F2AFCAFA3338" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_975D8CBCCD17E91B5E52F2AFCAFA8462" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_BBECC70F80C672E0B3F55A2FE073BB99" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FF7DC1915F45FCB746C55A2FE073C42F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_BBECC70F80C672E0B3F55A2FE073BB99" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FF7DC1915F45FCB746C55A2FE073C42F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/WarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C2C251290FE2135A2B8177D8C74C2BF7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C2C251290FE2135A2B8177D8C74C2BF7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_774F71269ABEB641D38E77D8C74CD9F8" xlink:to="loc_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9C83113DC61F6379BAC777D8C74CE534" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_AB9CD69FE870796C055777D8C74C8933" xlink:to="loc_us-gaap_CommonStockMember_9C83113DC61F6379BAC777D8C74CE534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4F5DC2337E251F8DCB3377D8C74C070E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:to="loc_gh_SeriesAConvertiblePreferredStockMember_0A75BA304ACCCBA859B877D8C74C6D4B" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_SeriesBConvertiblePreferredStockMember" xlink:label="loc_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8A5CC3DE29FBDDBE7F4877D8C74CC1FD" xlink:to="loc_gh_SeriesBConvertiblePreferredStockMember_015DF7D5FE2D1968D15777D8C74C8A2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E5988F05EF32DFBCA43A77D8C74C0023" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7032F04BEF587B9F6EA177D8C74CEF66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7032F04BEF587B9F6EA177D8C74CEF66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A15ABD1320A9DB0B8FF377D8C750BF67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A15ABD1320A9DB0B8FF377D8C750BF67" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrants_3DC1128F699FBA135A1577D8C7500F8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_B3A3A74517783EB5F5DA77D8C7505E24" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_B3A3A74517783EB5F5DA77D8C7505E24" xlink:type="arc" />
    <link:loc xlink:href="gh-20191231.xsd#gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO" xlink:label="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2C1E85C75696CEF771F577D8C74C4BEF" xlink:to="loc_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO_7AB18CB44CDF54EF9D1B77D8C750DECA" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gh.jpg
<TEXT>
begin 644 gh.jpg
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ML3222'T55!)/TJ7)15WL-)MV0444G3K52G1QO-(L<:L\C$*JJ,DD] !7U?\
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M*** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ********
M"BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBB
MBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB
M@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HH
MHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHH
MHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH *
M******* "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH *****
M*** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ********
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M444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444
M%%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%
M%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%%
M !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11
M111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !111111
M10 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 4
M4444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444
M444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444
M%%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%
M%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%%
M !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11
M111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !111111
M10 44444444 %%%%%;?@[P;K/C_Q%::'H%A)J.IW38CACP.!R68GA5 Y)/ J
M+PIX5U7QOXBL=#T2S>^U2]D\N&"/J3@DDD\   DD\  D]*_3O]GO]G_2/@9X
M86*,1WOB*[13J&I8Y8]?+CSR(P>G<XR>P'QW$?$5'(:&GO59?#']7Y?GLNK7
MT.3Y14S2KV@MW^B\_P @IKN(U+,< 4K,%4DG %9-U=&X;T0=!_6J'[/'[,^B
M? _2ENI!'JGBNXCQ=:DRY$>1S%"#]U/?JW4X&%'LU%%?S/C,97S"O+$8F7-)
M]?ZV7D?LV'PU+"4E1HQM%#KJ\,_RKPG\ZK4445S_ (Y^('A_X;Z#)K'B34X=
M,L4X#2GYI&QG:BCEV]@,UYS^T#^T]X?^!]B;-0NL>*)DS#I<<F!%D</,1]Q?
M0?>;MQEA^='Q'^)_B/XK^()-8\2:C)>W!R(HONPVZ'^"-.BK^IZDD\U]IP]P
MAB<XMB*_N4>_67^'_-Z=KGSF;<04<OO2I>]4_!>O^7Y!4D4+SMA!GU]!4MK9
MM<?,3M3^=:<<:QKM48%>Z?&S]N+Q'XV:?3/!HF\+Z*V5-UD?;IQ_O#B(>R'/
M^USBOF.65YY7DD=I)')9G8Y+$\DD]S3**_H'+\LPF5TO8X2FHK\7ZO=GY3B\
M;B,=/VE>5W^"]%T(+>Q2'!;YV]^@JS1111117J'"%%%%%%%% !11111110 4
M444444O2@ HHHI**** "BBBBBBB@ HHHHHHHH ****6OH;X)_MG>+?AFUOIN
MNM)XJ\/*=OEW,A^U0+_TSE.<@?W6R.  5KYXHKSL=E^%S*DZ.+IJ4?/IZ/=/
MT.O#8NO@ZGM*$N5_UOW"J\]G'-D_=?\ O"K%%?KW\,_BOX8^+FAC5/#6I)>1
MJ )K=ODGMV(^[(AY!Z\\@XX)ZUUM?CIX+\;ZY\/=?@UKP]J,VF:C#TEA/#+D
M$JR]&4X&5((.*_0O]G/]K31OC#'#HNLB'1/%ZKQ;[L0WN!RT)/1NYC)SCD%@
M#C\"XBX.KY4GB<)>='K_ #1]>Z\U\UU/U3*.(J6.:HXCW:GX/T[/R^XQ9K=X
M&PP_$=*CK<90ZE6&1Z5G75BT673E/3N*^@*\$_:2_95TGXR6<VL:0L.E>,8T
M^6YQB.] '"38[] 'ZC@'(  ][HKX? X_$9;7CB<++EDOQ\GW7D?38K"T<92=
M&O&Z?]:%2K5K>F(A7.4_E56BOQI\1>'=3\):W=Z1K%E-IVI6C^7-;3KAD/7\
M00001P001P:S:_4#]I+]F_3/CEH)N;<1V'BRSC(LK_&%E'7R9<=4)S@]5)R.
M"P/YGZ]H.H^%]9O-)U:SEL-1M)#%/;S+AD8=OZ@C@@@BOZ9X>XAH9]0YE[M2
M/Q1_5>3_  V?G^,9ME-7*ZMGK![/]'YFZ"& (.12UEV=X83M;F/^5:88, 0<
M@UGT445]:>"+11111110 44444444 %%%%%%%% !11111110 44444444 %%
M%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%
M%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !
M11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !1111
M1110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110
M 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 444
M44444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 4444444
M4 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%
M%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%
M%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !
M11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !1111
M1110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110
M 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11114MM;37EQ
M%;V\3SSS.(XXHU+,[$X"@#J2>U15]I?L-_L^B3R_B/K]MD E=%MY5SSR&N"#
M^(3\6_NFO$SC-:.38.6*K=-$N[Z+_/LM3TLOP-3,,1&A3^;[+N%%%4M0N=J^
M4IY/7V]J]?\ V5?V<[?X,^&1J6JQ1R>+]2B!NI.&^R1G!$"'\BQ'4CN%!KW>
MBBOY3QV.KYCB)XK$2O*7]67DNA^Z87"TL'1C0HJR7]7(+VZ,S%%/R#]:JT44
M5\V?M1?M8VOPK@G\->%Y8KSQ@ZXEFP'BTX$=6!X:3'1>@SENP:U^U?\ M.1_
M"'2SX?\ #TL<WC"\CSN(#+81$']XPZ%S_"I_WCQ@-^<MS<S7EQ+<7$KSSRN9
M))9&+,[$Y+$GDDGO7Z5PCPFL=;,,?']W]F/\WF_[OY^F_P ;G^?/#7PF%?O]
M7V\EY_EZ[%7+.R\S$D@^7L/6BQM?-^=Q\@Z#UK2J75-4O-:U"XO]0N9KV]N'
M,DUQ.Y=Y&/4DGDFJM%%?O:2BK+8_+&VW=B4M%%%%%%4(******** "BBBBBB
MB@ HHHHHHHH ****]%_9[^')^*OQB\,>'7B\VSFNEFO1@X^SQ_O)03VRJE0?
M5A7?_MQ_"_\ X5W\<;^]M81%I7B%!J<&Q<*LA.)E^N\%_I(*]Q_X)N_"_P"R
MZ7XA\?7<1$MTW]EV#,"/W:D/,P]06\M<]C&P[UZ3^WI\+?\ A//@O+K5K 9=
M4\,R&^3:N6-N<+<+[ *%D/\ URKZ2G@>;+W.WO/WODO^!<_GO'<;*AQ[2P//
M^XBO8R[<\[._RERQ?:S$9MJDTV-MRCUILS=!386^;'K7Y@T445\V?T(3T444
M4444 %%%%%%%% !11111110 44445)!<2VL\<T,C0S1L'22-BK*P.001T(-1
MT4AA1117WK^RO^U]'XL%IX0\<WBQ:Z2L-AJLO"WO81R'H)?1CP_3[V-WUG7X
ML5]^_L@_M3-XZA@\%^+;H'Q#"FW3[^0X-\BC[CG_ )Z@#K_$!_>!+?AG%W"2
MPZEF.7Q]W>45T\UY=UTW6FWZ;D&?.JUA,6]?LOOY/S[/KZ[T+NQ_CB'U7_"J
M%;U9]]:;<R(./XA_6OJJOGG]K3]FN+XMZ"WB#0K=4\8:?%\JKQ]NB'/E-_MC
MG8?^ G@@CZ&HK\NR_,*^68F.*P[M*/W/NGY,^WQ>%I8VC*A65T_ZNBC5NQNO
M*;8Y^0]/:JE%?BU+$\$KQR(T<B$JR,,%2."".QIE?8_[</[/(TVXE^(WA^VQ
M;3N!K-O&O$<A.!< >C' ;_:(/\1(^.*_JO*,THYQA(XNCUW79]5_6ZU/PO'X
M&IE^(E0J=-GW7<WJ*IV-UYB^6Q^8=/<5<HHHHKVCS@HHHHHHHH ********
M"BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBB
MBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB
M@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HH
MHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHH
MHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH *
M******* "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH *****
M*** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ********
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M***FL[.XU"ZAM;6"2YN9G$<4,*%W=B<!54<DD]A2;25V,****AHKZ?\ A/\
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M"%:UN9)V]5<_/:U/V525.][-K[C>HJ.W_P!1'_NC^5244445TF(44444444
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M7Y/F''L<!BZN%^K<W(VK\UKV_P"W3[O"<+2Q6'A7]M;F2=N7_@A16=J$CI,
MK,HV]C5;SY/^>C?]]&OQBHK]G?['L/\ GQMO^_*_X4?V/8?\^-M_WY7_  KS
M_P#B)$?^@3_R?_[4Z_\ 4^7_ #__ /)?^";5%8OGR?\ /1O^^C1Y\G_/1O\
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M (B1'_H$_P#)_P#[4/\ 4^7_ #__ /)?^";5%8OGR?\ /1O^^C1Y\G_/1O\
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MP?W/U-!L(?[N/Q-?HS17P5I7_!1/Q9#C^T_"VC78[_99)8,]?[S/[5W>@_\
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M]GT?_!\C>HK-M;XQX63YE]>XK1!# $<BJ=%%%?3'C"T4444444 %%%%%%%%
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MOL,']S]31]A@_N?J:_3ZBOS!_P"&S/C%_P!#A_Y3+/\ ^,T?\-F?&+_H</\
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M?_L,7'_H$5?G17Z+_L"_\D-G_P"PQ<?^@15^<\>_\B?_ +>C^I]?PM_R,/\
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MBBBBB@ HHHHHHHH *****_1?]@7_ )(;/_V&+C_T"*OSHK]%_P!@7_DAL_\
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MAJG_ "S_ !_I5"K^J?\ +/\ '^E4*^?/VZO^2 WG_7_;?^A&OS:K])?VZO\
MD@-Y_P!?]M_Z$:_-JOUW@#_D4/\ QR_*)\!Q5_R,%_A7ZEO3?^/@_P"[_45I
MUF:;_P ?!_W?ZBM.BBBBOTH^."BBBBBBB@ HHHHHHHH ******** "BBBBBB
MB@ HHHHHHHH ******** "BBBOUZ^#NE_P!B?"7P98%=C0:-:(X_VO)7<?SS
M7756TJS&FZ79V@55$$*1;5Z#:H&!^56:_C"O4=:M.H^K;^]G]%T8>SIQAV21
MC7+%KB0D_P 1%14^5@TCD="2:97Q/_P4;U<M=>!M+5N%2[N9%]<F)5/3MM?\
MZ^+Z^H_^"A=Z9OB_H=L"I2'0XVXZAFGFR#^"K^=?+E?U!PE25'),/%=4W][;
M/Q//I^TS*L_-+[DD:.F+\CMZG'^?SJ[53301;D^K9%6Z****^O/ "BBBBBBB
M@ HHHHHHHH ******** "BBBBNS^#_PRU#XP?$71O"VG[D:\E_?W &1! OS2
M2'Z*#C/4X'4BN,K]'_\ @G[\%?\ A#? <_C?4[;9K'B!0MIO'S16((*X]/,8
M;O=5C->A@<-]:K*#V6K]#X7C3B./#.3U,8G^\?NP7]Y[/T6LGZ6ZA2,VT$FE
MJ&9N=OYU]/>&/#>G^#_#NFZ'I4 MM-TZW2VMX@<[410!D]SQR3R3DFM.BBOT
M1))61_GQ4J3JS=2H[R>K;W;?4C9BQ)-)1111113,PHHHHHHHH ******** "
MBBBBF30QW$+Q2HLL4BE71P"K C!!!ZBGT4#3MJ@HHHK\DOVJO@B_P/\ BI>:
M?;1,/#VH9O=*DP2!$Q.8LGJT;97J3MV$_>KQROUK_:N^":_&SX3WUE:0"3Q#
MIH-[I;#&YI5'S19XXD7*\G&[:3TK\EF4HQ5@58'!!'(KX#,L+]6K>[\,M5_D
M?WIX><3_ .LF41]M*]>E:,^[_EE_V\M_-,LHVY<TZJ\3;6YZ&K%-HHHKR3]0
M"BBBBBBB@ HHHHHHHH ******** "BBBBOJ'_@GSK'V/XOZO8,V([S1Y"JYZ
MR)+$1W_NE_\ .:^7J]U_8GOC:_M%>'H@6 NH;N(X]K>1^?\ OBOG.(Z7MLGQ
M4?[C?W*_Z'KY1/V>84'_ 'DOOT"JNHJ6M\_W3FK55[[_ (]7_#^8K],ZAOK.
M/4+&XM)AF*>-HG'JK @_SJ:BOY-3:=T?O+5U9F33D;8ZMUP<TVBOQ;N('M;B
M6&08DC8HWU!P:CKI/B5;+9_$;Q5;J2RQ:K=1@GJ0)G%<W7]H4I^TIQGW29_.
M4X\DG'L;U%)2T4445J0%%%%%%%% !11111110 4445O> _#9\8>./#^A#/\
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MHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBOI3]@/_ )+E=?\
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M?!7X;7'Q9^)FB>&X5;R+B8/=R+QY5NOS2MGL=H('^T5'>N'K[Z_8%^%)\/\
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MR.G^V/3I7Y1PGB'A\ZP\EU?+_P"!)H^[SZDJV6U5V5_N=RG6CIC?NW7T.?\
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M#V_]"%?E+7ZM?M.?\D#\;_\ 8/;_ -"%?E+7WGAW_N%;_'_[:CY;B[_>Z?\
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M_7Q_[P_G7Y&4445_9!_/!M44444444 %%%%%%%% !11111110 44445>T/\
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MI1O'H/A[2]$5A@27+O=R+[@_(N?JIKP#Q]\7/&'Q.N!+XF\07FJ*K;DMW8)
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M[K;U>PRGPQF:14'4FF5H:;#A6D/?@5\=>+O%%_XV\4:IKVIR>9?ZC</<S$=
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M?TJM7Y=_M*_L^7_P-\6$P+)=>%[]V;3KT\E>YAD]'7L?X@,C^(+XW7[$^/?
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M$%%%%%%%% !11117ZM?LQ_\ ) _!'_8/7_T(U^4M?JU^S'_R0/P1_P!@]?\
MT(U^4>(G^X4?\?\ [:S[KA'_ 'NI_A_5!61??\?3_A_*M>LB^_X^G_#^5>G5
M^=?[?G_)<K7_ + UO_Z,EK]%*_.O]OS_ )+E:_\ 8&M__1DM?#<!?\CC_MV7
MZ'T_%/\ R+_^WE^I!6M8_P#'JGX_SK)K6L?^/5/Q_G7S71117]('X\6*****
M*** "BBBBBBB@ HHHHHHHH ******** "BBBBOT#_P"">>DFU^%.O:@P(-WJ
M[1K[JD,?/YLP_"OS\K]5?V7?!Y\$_ GPE8R)LN+BU^WS9&&W3DR@'W"LJ_\
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M11117Z+_ + O_)#9_P#L,7'_ *!%7YT5^B_[ O\ R0V?_L,7'_H$5?G/'O\
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MI_N@FJU7],3AWQ[#_/Y5\-4445_6!^$%^BBBBBBB@ HHHHHHHH ********
M"BBBBOT/_8+^(T?B;X5S^&9Y<ZAX?G*HK'EK:4ET/X-YB^P"^HK\\*]0_9Q^
M+3?!SXI:=K$SN-(GS9ZBB\Y@<C+8[E6"O[[<=Z^3XHRMYMEE2C!7G'WH^JZ?
M-77S/=R7'+ 8V-23]UZ/T?\ D[,*S=2BVR"0#AN#]:TJBN(1/"R=^WUK]6*Y
M[XB>!K#XE>!]8\,ZED6FHP&(NHRT;9#)(/=6"L/<5OP3Q74$<T,BRPR*'21#
ME64C((/<&G5_+5.I.C4C4INTHNZ\FC]PG"-6#A)73T^1C5)!(895<=NM,8%2
M0>".*2OQN\6^%=1\$>)M2T'5H#;ZCI\[031GID'@@]U(P0>X(/>LBOO[]MO]
MGU_&>C?\)UH%KOUO38=NH6\2_-=6R]' '5X^?<KGGY5%? -?U=D.<4\ZP4<1
M'XEI)=G_ )/=>1^$YIE\\MQ+HRVW3[K^MS=5@RAAR",BEK/T^YV_NG.!_#_A
M6A11117T9Y 44444444 %%%%%%%% !11111110 44444444 %%%%%%%.56D8
M*H+,QP% R2: "BBBO>_V*?AZWC;XV6-_-$'T_0(SJ,I8<>8/EA'UWD./^N9K
M]*Z\6_9/^#+_  >^&42W\(C\0:NRWE^"/FB^7]W"3_L G/\ M,]>TU_+G%N:
MQS7,YSIN\(>['SMN_F[_ "L?MN08%X'!14U:4M7^B^[\2"]D\NW;U;Y1615F
M^F\Z; /RKP/ZU6I)IHX(7ED=8XT4LSL<  #))-?C[\2O%C>//B#XB\0DMMU*
M_FN(U?JL;.=B_@NT?A7Z,?M??$A?AW\%-62&79J>M#^R[4 \_O ?-;U&(P_/
M8E?6OS"K]!\.\ X4:V.DOB?*O1:O\;?<?*<78I2J4\-'[.K^>W]>8H!8@#DG
MBMM%\M%4= ,5F6$7F3ACT7FM6BOH;]A.\^R_'RUCW[/M&G7,6W'WL*'Q_P".
M9_"OGFO6_P!E#74\/?M">#+B23RXYKIK,\\$S1/$H_[Z=?QQ7Z-GM)ULKQ,%
MNX2_)GR&635/&T9/;F7YA5>^_P"/5_P_G5BHKI=UO(/;/Y<U^IM<U\4K ZM\
M,_%UB%W&YTB[AVYQG="XQ^M=+0\:R(R. R,-I4]"#7\E4JCI5(U%T:?W'[U4
MC[2#@^J,:I+?_7Q_[P_G4=*K%2"."*_%>BMKQKX;E\&^,-;T*?=YNFWLUH2P
MQNV.5W?0XS^-8M?V;3G&I!3B[IZG\Z2BX2<9;HW:*16#*&'((R*6BBBBM"0H
MHHHHHHH ******** "BBBBND^&MD^I?$;PK:1_ZRXU:UB7C/+3(!Q^-<W7K_
M .R7X7;Q5\?_  G%Y9>&SG;4)6QP@A4NI/\ P,(/J17G9C66&P5:M+:,9/[D
MSKPE-UL13IKJTOQ"D8X4D\"EJ*Z;9;R$^F/SXK]2:**'D6-&=R%11N+'H *_
MCH_H4QJ**506( &2>!7Y)_'FZ%Y\;/'D@7:/[;O$ZYSMF9<_CC/XUP=:?BC6
M#X@\2ZMJK?>OKN:Y/']]RW]:S*_LS"TW1P].D_LI+[D?SM6G[2K*:ZMLV8.(
M8P>/E'\JDHHJYHVD7GB#5[+2]/@:YOKV9+>"%>KR.P55'U)%?KM\+_ =G\,?
M .B>&;$[H=/MQ&\F,>;(26D?'^TY9L>]?%/[ WPJ_P"$B\;7WC6]B)L=#7R+
M0L/E>Z=<$^^R,GCUD0]J^_*_#./\V^L8J&74W[M/67^)[?<OS9^F\*8'V5&6
M+FM9Z+T7^;_(0D*"3P*QKB;SI6?MV^E:&H3>7#M'5N/PK+HKY0_:^_:@UWX6
M^)M+\-^#KVWMK]83<ZC+)"DQ4-_JH\," < L>^&7IW^GO%'B*Q\(^'-3UO49
M/*L-/MI+J=AR=B*6.!W/' [D@5^0_C[QE??$+QGK'B/46S=ZE<-.RYR$4\*@
M/HJA5'LHK@X(R6GF6+GB,3!2ITUL]4Y/;ULKOUL=7$N92P="-&C*TY=5NDO\
M_P#,*O65FDD9>09!/'-4XT,CJHZDXK:50BA1T Q7K/\ PVY\6_\ H.VO_@N@
M_P#B:/\ AMSXM_\ 0=M?_!=!_P#$UX/17[=_8&4_] L/_ 5_D?FO]J8__G_+
M_P "?^9#]A@_N?J:/L,']S]35BBO>/\ AMSXM_\ 0=M?_!=!_P#$T?\ #;GQ
M;_Z#MK_X+H/_ (FO!Z*/[ RG_H%A_P" K_(/[4Q__/\ E_X$_P#,K_88/[GZ
MFC[#!_<_4U8HKWC_ (;<^+?_ $';7_P70?\ Q-'_  VY\6_^@[:_^"Z#_P")
MKP>BC^P,I_Z!8?\ @*_R#^U,?_S_ )?^!/\ S*_V&#^Y^IH^PP?W/U-6**]X
M_P"&W/BW_P!!VU_\%T'_ ,370_#W]N3QY;^--';Q3J5O>^'6N%2^BCLHXV$3
M?*7!5<Y7.[ Z[<=Z^9J*RJ<.Y34A*'U:"NK744G\G;1EPS;'PDI>VD[=V[%?
M[#!_<_4TV2PB:,A5VMC@Y-6J*_:A'61%=&5E89#*<@CUHKY\_8J^+G_"P_A7
M'HU[-YFL^'=MG)N/S26^#Y+_ ) I_P  R>M?0=?R[F&!J9;BZF$J[P=O7L_F
MM3]NP>)AC*$*\-I+_AU\C"Y!P1@TE6]0A\N3>!\K=?K52OSC_;@^%?\ P@OQ
M6;7;.$II7B-6N\@?*ER#B9?Q)5_K(?2OG.OU/_:A^%0^+/PCU2PMX1+K%B/M
M^G8^\94!R@_WT++CIDJ>U?EA7]$\&YK_ &EED83?OTO=?I]E_=IZIGY%Q%@?
MJ>-<HKW9ZK]5]_YHUK&;SH0#]Y>#5BLFQF\J<<_*W!K6HHHHK[P^7"BBBOTE
M_85_Y(#9_P#7_<_^A"OH.OGS]A7_ )(#9_\ 7_<_^A"OH.OY*XA_Y&^*_P <
MOS/WG*/^1?0_PHS-2_X^!_N_U-5*MZE_Q\#_ '?ZFJE?*O\ P4/_ .27>'/^
MPR/_ $1+7P#7W]_P4/\ ^27>'/\ L,C_ -$2U\ U^Z\"_P#(EA_BE^9^8\3?
M\C*7HOR+^E_\M/P_K5^J&E_\M/P_K5^BO;?V6OC]-\%/&@AOY7?PKJC+'?PX
M+>2W19U'JN>0.JYX)"X\2HK[+&X.CF&'GA<0KQDK/_->:W1\[AL14PM6-:D[
M205#=6XN(\=&'0U-17[26MU#?6L-S;2QW%O,@DCEC8,KJ1D,".H(QS4E?%/[
M#_[1'EM!\./$5U\K9_L6ZF/0]3;$_F4S[K_=%?:U?RGG.4ULFQ<L+6]4^ZZ/
M_/LS]TR['T\QPZKT_FNS[?UT,)E*L0>".#25HZA;;E\U>H^][UG5\3?MP?L[
M?9Y)_B/X=M?W<A']M6T0^ZQX%R!Z'@/COAN[&OC"OVDN[2"^M9K:YACN+>9&
MCEAE4,CJ1@JP/!!!(Q7YC_M2?L_S?!/QEYNGQR2>%=39I+"8DMY)ZM Q/.5[
M$]5QR2&Q^N\$<1?6::RS%2]^*]Q]TNGJNGEZ'P'$N4>QD\;07NOXEV??T?Y^
MIHZ?=;E\INH'R^]7:PE)4@@X(YK7M;@7$>>C#@BO$Z***_73X$FHHHHHHHH
M*****_5K]F/_ )('X(_[!Z_^A&OREK]6OV8_^2!^"/\ L'K_ .A&ORCQ$_W"
MC_C_ /;6?=<(_P"]U/\ #^J"LB^_X^G_  _E6O61??\ 'T_X?RKTZOSK_;\_
MY+E:_P#8&M__ $9+7Z*5^=?[?G_)<K7_ + UO_Z,EKX;@+_D<?\ ;LOT/I^*
M?^1?_P!O+]2"M:Q_X]4_'^=9-:UC_P >J?C_ #KYKHHHK^D#\>+%%%%%%%%
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MS]31]A@_N?J:L45^A'['O[2NK_%J]UKP_P"++N&XUJ%1>6<L<*Q>9#PLB84
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M@_[O]16G69IO_'P?]W^HK3HHHHK]*/C@HHHHHHHH ******** "BBBBBBB@
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MT5JU-/E\R#;W7BLNK%C-Y4X!^ZW!K\L****_JD_#36HHHHHHHH ********
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M5_Y(#9_]?]S_ .A"OH.OY*XA_P"1OBO\<OS/WG*/^1?0_P *,S4O^/@?[O\
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MT^'S)-YZ+_.M.BBBBOV,_/0HHHHHHHH ******** "BBBBBBB@ HHHHK[_\
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MA0HHHHHHHH ******** "BBBOO#_ ()U?\B3XN_["$7_ *+KZXKY'_X)U?\
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MM',,/#%8=WC)?TGYK9GX5B</4PE65&JK21NT5#:W N(\]&'45-17ZM?LQ_\
M) _!'_8/7_T(U^4M?JU^S'_R0/P1_P!@]?\ T(U^;>(G^X4?\?\ [:S['A'_
M 'NI_A_5!61??\?3_A_*M>LB^_X^G_#^5>G5\Z_'[]D/_A>7CB+Q'_PEG]B;
M+..T^S?V;]HSM9VW;O-3KOZ8[5]%45^)8#,<5E=;ZQA)\L[6O9/1^J:/TO%8
M2AC:?LL1&\=]VORL05;M[_R8@FS=COFJE%?%?_#M_P#ZJ'_Y1/\ [HH_X=O_
M /50_P#RB?\ W17VI17TG^N>??\ 01_Y+#_Y$\;_ %=RO_GU_P"32_S+_P#:
MG_3+_P >_P#K4?VI_P!,O_'O_K50HKXK_P"';_\ U4/_ ,HG_P!T5>M_^"<>
MG+Y?G^.;J3&-_EZ:J9]<9D./UK[&HJ7QEGLM\1_Y+#_Y$:X=RM?\NOQE_F7_
M .U/^F7_ (]_]:C^U/\ IE_X]_\ 6JA17RG8_P#!._P7'C[9XDUZ?DY\@PQ<
M8XZQM76Z+^PS\*=)VFXT[4-7*_\ /[?N,_7RME>_T5PU>)LYK*TL3+Y.WY6.
MF&2Y=3U5%?/7\R\VJ-CB, ^YJ-M1E88&U?<"JM%<EX2^$?@KP(R2:#X7TO3)
MU&!<0VR^=CWD(+'\ZZVBBOGZM:K7ESU9.3[MW?XGK4Z<*4>6G%)>6A+)<RR?
M><X_*HJ****\^^(OQ^\!_"R.0:]X@MDO4_YA]L?.N2?0QKDK]6P/>OCCXS?M
MS>(_&L<^E^#X9/"VD/E6N]X-]*O^\.(OHN3Q][M7TF4\-9EF\DZ5/EA_-+1?
M+O\ (\?'9U@\ FIRO+LM7_P/F%%316DLW1<#U;@5>@L4AP6^=OTKZ#_:4_:P
MTKX2V=SH6@2PZGXR="NQ</%89_BE[%^XCZ]"V!C=^=&L:Q>^(-4NM2U*ZEO;
M^ZD,L]Q,Q9Y&)R235621I9&=V+NQRS,<DGU--K^A<CR#"Y%1Y*.LW\4GN_\
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MX_PK5K!K8M9O.A5C][H:\<K]%_V!?^2&S_\ 88N/_0(J_.BOT7_8%_Y(;/\
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M ,/"OAU_T!?%'_@+;?\ R11_P\*^'7_0%\4?^ MM_P#)%?GM11_J)DW\LO\
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MHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH
M******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ****
M**** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ********
M "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BB
MBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBB
MB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ H
MHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHH
MHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH
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M45^"9KG&,SFM[7%SO;9+9>B_7?S/U/ Y=A\NI\E"/J^K]?ZL6KC4 N5BY/\
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M+'^1;OU?3T6OH? YEQ3""=/ J[_F>WR77YZ>I%5BWLWFP3\J>IJY!IZ1\O\
M.WOTJU7??&'XY^*/C7K7VO7;O991,3::9;Y6WMQ[#^)O5FR3[# 'GM%%?MF'
MP]'"4HT:$5&*V2/S>K6J5YNI5E>3ZLCAA2%<(,>I[FI*******Z3$*******
M* "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "B
MBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBB
MBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@
MHHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHH
MHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH
M ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ***
M***** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH *******
M* "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "B
MBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBB
MBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@
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M110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110
M44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 4444
M4444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444
M %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%
M%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%
M% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !1
M1111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111
M110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110
M44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 4444
M4444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444
M %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%
M%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%
M% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !1
M1111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111
M110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110
M44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 4444
M4444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444
M %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%
M%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%
M% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !1
M1111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111
M110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110
M44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 4444
)4444 %%%%?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>graphic3.jpg
<TEXT>
begin 644 graphic3.jpg
M_]C_X  02D9)1@ ! 0( .P [  #_X1KB17AI9@  24DJ  @    % !H!!0 !
M    2@   !L!!0 !    4@   "@! P !     P   #$! @ ,    6@   #(!
M @ 4    9@   'H   "=!   %    )T$   4    1TE-4" R+C$P+C( ,C Q
M.#HP-SHP,B Q,#HT,CHS,  (   !!  !      $   $!!  !    :P    (!
M P #    X     ,! P !    !@    8! P !    !@   !4! P !     P
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M 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MV]PX_P#0]U0'2=.EBPEY=P-C 5T$BG\05(_(UV!\*6GFX6[=XPS*[C;\IW(
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MKJZ8=-J1K]V-?0"FR64GA_0=,\.,(Q+;1^?=[$ )N)/F(8@G<44JF<_PFJ5
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M3D=XI%>-BKJ<A@<$&@#EZ*Z/4=/348GNK:-4NT4M+$@P)5'5E'9AU(_$5SE
M&C9SV-[8R:'KD9FTFY;)(^_;2=!+&>Q'?U&00:\K\2>';[PMK4FF7_EM(J*Z
MRQ;C'*K#(9"0,CMG'4&O0ZK>--.36/!<>KB.1K[2)$MI9/,^4VKEMF0>ZR'
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M58$$<$'M24 8NH:<]DP8-YD#GY) .OL1V/M5*NI&QXW@F!,,@PX'4>A'N/\
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M  $  @(# 0$!            !@<%" ,$"0(!"O_$ !0! 0
M      #_V@ , P$  A #$    ??P                  PY717I 2'$/(L1
MHCYB3%'3. ZYV3G.\94RI(R2DI)@3(GY8989D@
M          #%%*E(%+%1%1E7D(/P            Y"?%H%NEO%U%X%R'=
M                        .H4&:WFN9K\4L=0                   R9
M>!L&;&&R!>)R@                      ^2B#4DU.-:"/
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MY!AR:&0.4[1WBS"'%;FQ)79EB9%0%"FVA6Y:A0I-"!G(:BESE0%RE9@H<
M    _3: ]%S=4[8           (V>=)YMD%         )<7<28RYEC)F0,,0
M@BQ^        ^R6DX,@8\Q9BS#$4*-(Z        "TCTR/0 R@         ,
M>>=1Y@$+       !W"^BP21$A,:56=,               &3+6.4CQ'2LRCC
MA       +-/5$WT.8        U./'TIH       L\O<E)G"J3!
M           DY9Q'2*&O1!       ;$'L4;#       PAY''GJ?(     !8I
ML0;W'P>?IS&,.X=PZYQ$V-ES5XPACS@/H^C+G3.F=PZQW2+G9,^=8^CB+_-8
MS? P!J0=4M BACRUB&$2!SGV=LCYVC*'7,49HQ1>!.RB34TAP     .T>G!Z
ME'<     *=/#<I$     ',;0EH'2*M/30KLQI8IDCIDW(@:"FYAH6;7%E$C/
MDZY\&5*Q)L=X[A/320^C; B9^G7.T><!ZK$:.V5T34E)Q&(,"9LJ4N I(V"(
M><9WS,F.)^5H9\P9HN9PX2H36T_     #9D]P"?@   &LQX6$3     .\;9E
ME%0F* -FC64VW/@V0-"#8L@YJ^6F;,%!FP9J8;!D1/L^S*G,7\8@Z1KH7.6N
M0P[)E3MFDIL.?A&BN"Q#$ D9*BEB^"ORAS8 C9T3X.8[Y8)5A\'8*T*N!(BS
MBIC54X@    68>\1=0  !K*>#I@P    ?1MB6H4P=<   ':)Z5P   #+%GDK
M,N9,R1DB2&,,08@Z)US@. YSG.P=XRYE@8XQQC3&&((H5B8@        R);Y
M2!K,    "<GON70  5$?SX$3    !;AM85*8D       ^RV"P20D@.T0@Q8
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M/2N#(GP9(Y2+GX6X:P&4+G).1@SA'2,$2+:*3)>24Q!UBF   =LGI S7,P8
M   ,F6::$'X   ; ']"YIP>%X   !O\ %0'     #(&SA-BNC\       !ER
M9%;    $X(. 2DBQ*R*        'Z6(0HUC,>    90F1I"   #^AXT&/-H
M  &VP,"    "\2]2N#X       !]$M)8=\[IVSMG,<YR'V?0/@^3B.$X#J'3
M.F8XAY%P       ?98Y1A1@   !."NC70   ]<S5,TX   )";QE)@   '.;;
MGT1L      &0+)) 90R)@S!'X        #[) 98QIBB-E;G5      )&?IJ,
M<    +T//HX   >BQ3AJ8   ;CD2/D   &1-S2!G"     #+EID@.\1 X@
M3<C!ES%F,,P8PX@?9F#" [1DCLG7.B=  '9):8LCI51T     #F)\:8F-
M,F<!JV  #T$,.:)@  &^I40   .4W9*^/P     L<GQWB(    %H'R=<LHPA
MFB'GV?)C#*'=(B9(GYB3)D)+&("=8J@  ^B8F)*X(*    #]+!-)CB   +*-
M'0  >G1-#R1   /0XHD   &UQU3K@    GY:)BC$     $X+'(\3X$?,D=8C
MI.C'&!(P7$1<R9]$?,@8PP95    ,^<Y4Q#@   #L'<-3P  "Y#0,  'MZ;
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M4Q0                  !E2F@ ":&OAB@"P36(K\%VFO!0);AZW&YI^@
M     P)YN'FN1 FYN"1$AH)B;9%>'& 7><AT  "Y#%@
M &4*; !FB,E3@Y"PS4XAI81DS3(DQZ='H2=\          $<//4\XRL#84O\
MK$P)VC:\RA#@"_3A,8 "S3E/D                  ^CC*Q ,X8<I<$Q,8:
MH$C)L:WGR>DAON9,            '4-.CSW-238\N<AI"2T#8<P)@@7&2LBH
M!REW$<                  )&4D<()@5X5<9PD!KP=,S13999Z$FUIR
M           %?FC)I&8 NXD)3)<A<IU"*DL+C,28H&6+;(\
M    2$J4Q!G3L%*G:.X58=4CI(C8(W=):                  5T:>&JAT#
M,&9,06\3$@!/2R#H&!.V6P?1B@              #*'X5.9L^BNS[,"<) "[
M25&V1,P                    #IFN9KJ=$J<^2V3'$H.T28D)%S/$[!AP
M           #, C1T3@,,<AW3JEL&6+P.8                        'R
M5*5\=4J\[1VS#DK,Z8,D1V3)G5,2          98RAECK',9,YB0G=.X9\_0
M                             8PZQU#$'?,294PA\G;,68PQ!AS%G&
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M3TGJD@C8SVD]ER>Q[/WLN)X'<:I8RT2KI62"S#J#-!9@<%)8VR]DB'OPO'(
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M&WF<*OL#T8UI43_>2*J?VML[*4Z"GY5R]63]4;RL/O7/;WYO'AL?K[''8O\
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MZMNSP&.A5'HU</C%6(#U>;[YS\<VR/J^"SE4-V:O)80'IQ%>*-3E]'BZE]3
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M+H1+AMB225>+;2QD94*6&8+S;(>;'/XO;'H8AICAG,4:YDZ4CLV%09L2QR4
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MC%2'$G/"@E!&0[H[U>-7+9K?EYGJT>LZ,VC$<]BFN*03\L>S<$Q2,(KR,OR
MX"N Q^Z)U&6YDYP&/<PBD0L, ^(C$]CN[<Y@:N_R\G*4(MF%,\$D(MT1N0"
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MIL=\Z1M1?2&S=%KHR.]@3(:TH@^>."423/A4+JLE) ]<1WH/]",[%9! "X0
M2N$')P54&#$ [69V:W>MBI@KG46%(:?]L?F2<<2EGY@*,V &X^U82@2H)!6
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MCL+_ &#<4#D(&\3TN@4#:TXO A@^\$SDQ10ER7I17&-O P#$C$&$><4&1LJ
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M*Z)<:[.G9,1OV5NHB<9BIJ4Y12D$AQI5FVR'#]9%!GA[\KL0['NSF@>,^C$
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M4#*5=[D%-XX"8G!\*3E5>90J[]73^(0#H#V1^<1* A4^*9M(*RI$&*XS"?-
MGQ5-RF3TYH97A *C;QM_*IL9/E^[=%KHPWD5V1)*%' \,Y9 TR 8-ZT5';/D
M'\5UV)_0S63,&<NFN"9R'TYP[%FV40Q.Q 1?6E9/D,I$HMBE_4H+. A@E E!
M*@<L9+F38$>AB$<HCZKU;\& 8&TB4@"Y(!0O* OHV>45YU#12NA<PY89)Y/=
M)[^JFCD9<&[!6C0"3@2@A]@@4T6?[5YV1WK)3B6()!CN?>T2<R?&6+[I6XBJ
MC;'@&A(*&!XB1C/*3X9"TGJ)PY4E*H>% C9A:KF8\$(X<(O!.8#R:BV CY7T
M^]69]<G!5%Q3*EP$@7"T+ ,I(@7[P1;&+OHB$$R2!B,L0-4-$"%SR5KQP/0%
M3@@M>+!KK!Z(!2LU$>I$>J 5P&;H28J$#!>%%'*B(H4)1M5;5;5WZD6# :9Q
MD0F&#D<@>7%!<H%J/B(+EK/"%J50P 7][&;MM=OH@P(OF5]4LTVGT8K7_P":
M,#6T0DB9?K:JIIDX+66X<Z'A@^%6_.9_CNKYC["E8T"R!H!<+#K&!ED.X\C>
MX*76+%9*CW<]J2'RI-<-MVC#$KL@!I,[[+T'"$;6]/0.)"<[$F$D\W0)CZ8%
M/CYF]7"JZ;&LZ=7@::XI@,I3C '(D2=$^\UGFH O1%>+ O*$$>Q-R&BRT2E&
M7-W.T]/U4P<C(EDH9AR,I@FAQ>G**BCX?")6PRZ.DCK.7H7 'W'HF+A-0")P
MC)@$D[,D.DV^8#)DLVBJWE0EF2@#M9>70D)U"2W7F9Z: B@0A"Q$L1L36;9Z
M0Y$\#39H)8'+155BH5+!(">@!:H+D3VP4ZPX/N#1'C@%CVE8\_$G%"FD6\&W
MT'(O9!4.!$3D T->B&G.LT(.24DC(?.XAR9;4KZ?&0J>,('+HB6DICL13]NB
MI<Q6,B):U$FSVK3.9?4F>"40]3;,)7B\0)9E+%US8DLI#9L93=$TBF,?;JB9
MC \E,01RL9JI@?%_B>%.E(V<PL0FM$\NA,T)5 !N8J:M441CRS$FR9@*!O8I
MVP;'WSV [ABB78);(B+()/3C!S!1*0+4@,9="B4GO@VX0I<S?ZG?!C^TB4B!
MQE9Q,S($A#F0\W4M";ICL!*5+AS!7"^BLL"O4-S$C))BDI,0T/N"@=2S#S"E
M>B46 2BD1I7HM5809%;' ]F<*_%((C4@4?H%,?#?(FP@(NS* &GWA=:2!@FY
M0N]@R)6V(!JXC@:D".3WH;-A$#T 01)^^+\W,3ZM50+UW]\7YP)WA[LJ F$9
MQ^$<Q/=2+Z1Z7-TBIC&@)@BJ)*_4%(N8,G"3$Y&46(!$&@R&>4!$_82L="P$
MXO11"2.\1@@*A<@E@D@FBO3*%GRUB)L6D08"]QTF EX+R+$E)U>=)9.%1Q "
M-)Z,S<?V%9VC8,#<<4:,;4K1A*X2OOCIKK-B5<($WU]S?R&(E0!C3"FB.6&0
MG1 A-[:55%5^E/>94JK1DPCHE/N+HJ*N-JB)*(._0*4+Z@[&PE1P#2]$Y((C
M+F'@G!:1<,K#=>\1/2B&7EJI5555657:O*\OZ&)BW^QEX/*AGG6([[Y5\M8(
M^TL^)^<V(\P?PV_QGROGPPF>;@XPX6[NO;1\Y#_2Y[RS\9PW>7S<#Q,Y+_:Y
M[0Q\X\K=57OL^,^%\^&0QQ</..R/$%\O_5GPWB_.&?$YXUB>^V=3L2?V>'1Y
M%/T"5QGA2N$+$$<CZ%*0!H!HPIO!F6Q[)@U-FJQCT8$8#,LV/NCF.F _<-%Z
MRK\(8 C$C[D71Z*T-HR/R@<I]*LB1T$5!0L!+ZZU^Y.=CB2E+^ZA:P2ME"4S
M,#FST&)J6FF5'E:RUP5Z);ADQ!O"] -XC <"%HHAD,$@8!% ]8M#.'QZ&IX#
M"Z?$S*[:*O\ _66<'R;W771/EFD/_8@9O(UUE,":]T1/S"\G8\[$'\&/$1G_
M -D4PE]3_P"P*80YU/T,/X,>(RC!=OF*!^(5FP;L7R"#P%=Y*JOL_P"4'3#[
MQN(Z]_6%A ;PZ/0Q/<]4V(Q50-^<&Q5,IKCE6N8XE!Z-I]"8Z5-T"=RXT;FC
M[W9;)I02XOVI!]HB5(Y&").2P/@(R)""M"F$NX*+GUL?/H;I%2@S'_=*G3*D
M+)5  L:=@P64_P#12"'P$^\%_)M-%'IDSR$/0<#_ ($!TJP E4#$@&4&GK=W
M-*Q]7:]="EE7)V);-&DSGG &&G$D%Y)<)P6:B0Z\'Q):,G-'_P"OJ_G],9.-
M?E]6(!$0Y<H?FR63W$2K7$J2\B3L$8'42@>1)3>-5MHG-4[],B B@F\$W;):
M$]#(F]T+J$KV6Z2YC?W32DU%)M+\VC49,]- E@.BZ21JH^H*@$K0&UZ, _$@
MPNB2#O0^V@/X$CZ&*! 0*)&2629H*0= S[9*:Z @R(<D/B*B BF/E23/8<#A
M&)]\"V+LS1W5Z#M"'T-ZI"'<&0&5(I#C0-X9[YR:*"BO3;W;"AO30:*8 "92
MTA'/\:?H$D38M[:?L?B#X/U@VFK-''X@IR95E1!.\*?M2")L(Q;5#WMPMD8*
M ])8>083_P!?,$B .#!'H0:G"2)*Z,0^\J<)=2%-L,PKAC[A%(H+SX+M62YB
MHF4H*"5&U6U;7[)9C/$, Z!0!3[X:@=[D*6.A')JV74!+(&LIF#[2C>D&0(3
MBX&-;@9L6KI2H-<"^[O?+S\;SPS]9P(] 1;HA$H;8IT2V?22J"Y$O:.M)4&P
M%'\D^#8.N8(3GW-LD'PCP8<'HF;K !R(0&P"=+CWA9B>!+%+K["^@=M)!A!H
MTH(7[2UJ?BMM2O2B2_4Z(6:3IV^37D<!;S6\41A]/.N(EHQQ4=_DG%JIAZ (
M$GOD9Y"[,5("S]W)OEP&UZ>AL"?M,3/N"""JN-+19A3(E%Q))-+O/#ZR4^>-
M5A()!03K)^0/#J(     !'H)^4$ 9E!B@1R12"EB[3L\6-]HB8FI%PEYL* 3
M\%UM>7U32R=7?OL)]*JP,.X+ =RXWW7I<?+)EAVM/O'$-7^!2(X3.UWZ,[@2
M^7?(8"3G)B**I]&N0 [8Y"P?4.!-'&0YU @)$$*(1B51#K(.ZMH9)4Q1A921
MD\XM1 !+-3W!UB&6H(14TX738<2A2 .&.'>5!Q75PQE47JEM?DM8ML70)0".
M<6?_ ';<E:!4YH=X%K4@YH)=U,#^A+($;0001=@X8IE@O)T,L*?CY/O+)B).
M!D-E$JJ!Y)(,(X18W:(7-K*-#Z[')SR%"7P38FVMU@HR".@EE *B748!\.*;
MU0#A$H;?0$3)STT.%14\)1&,?0Q=,ME B$IY_0!'#)YJ?]Q2AT. "WHLS0-)
M+:OY(5P*R).WC[&?\VU5@G8"=8!["Z^4R"Q$+K_J8?8&9PA78,H %<0V7(74
MDB9VT&2@     ( * "@#1QZ9 ,SATW%$R18B(!+M: '3DA)?] #.64$@0H)$
ML;,&^K'70+"UH7((WKS8A.U:!6?_ &1NDE:*$V1%,G??TK\N0DX5IH%[ ] W
M AN8B7W3HV@<GP-0R""[!\ ;2/4$$I&JG*P)0M+0P0-QH+O."02!)3B.!(LX
M$$I)KVY WJ\$=I4[<"$;',\0%/*R UVSPM3DJA4U/H+U55&%(-03,]0",@$@
M+'/=3XK9Q_\ ".>ZGQ6SC_X1PJ&DR21H"ANS*/\ (\I*V09AD/8]2^G6P)T1
MH;K%H%ZQCR&B)@Y&2O;D*H18@A"&(P$>0'-2\GD%D<6+@L/W)L[1E(Z[RVUI
M-3!T;2V-(?21@+@3HFW)YI[&*<.HUHE>$&GH)]Y4;W*F%6"$ZGS3]L;I&=#!
M<.HI^Q8NW5=5E""1K2FQ<T &$,*H").OUCB OH:&2PD6@3D)1F)>U#)R(='U
MLV#YFX0>4S)J@9%]30KP"I%#ZRJ)(F4(*"1"Q&Q+'!@#(N1 &;D&&OB2M!2,
M4A2 <#ZH\*OJA-,F4EB4 =BS+(0FY1I #[HKX9:YXDT[BK,'W@+L%)V7=0'F
M2IBJJLK:NU[?U*C SH "J-(!(TY7_C%Q-C93%T&.V'R<CIC+;B5!5,/0N9ZD
M#7P 30N7I:LI-.$<KL&\6;GO0@K[QB07\KPA&D;[Q]DW09"5TMAH(YCG$@2*
M#QLRWZX*!80Z<HX.@MT>>64HJ)ZB,)6?UAG".1'10G088@#MWYUO84(X _0)
M*Y,SA:L4=0@1RXD*1DL%-37@8>EL<1R%FP2CR:CZ&/5"V2")$#?'5F[;K&F0
ME0 #G[$FQ.+&B.(IWQ7E3@I!'(^R\SG,!:^R8\=9#W0(WT,<*N<ZF#\7$0HD
M^_5#V^K?!C]H"W'E!)XE1/Q]T4((%/-Z?< %=8KVW)M;EAOB%?8!3T05T)C)
M%!M9.8%\8H\D H+R^AH%0"5H#:]&-GK/X]'+8(FQL#WI$4!  -L?0/B[/G=$
MFQ-YH YQON(@*X@D2U/Z0@)(7.$M19>""@90^\LQ=0! K#39(Q;N7&^%"AOT
M@CI&!P+>VP1S8U<(7D#MRMF;%BRAJ)$(DZE-; /T20$%D0OI%VJ+"TA.H]W+
M$PG7K@1BU%V$1Y "$)/V2@0Q4U4.]#0YC'X49X>=$X3"Q/NWR]Y++H0;V_M&
MD70: ]Q[![_:>L)Y=ST6ZPZ@9+8>-<Q$"R>* ^K*5VHFPBO@!1@)R6JPNFFS
M8*BY6YXJHY3Y)U,M]"H?:X/61\ Y<$(DD]!!*UMD.&4H2CWH3$8":O1 $3XB
M-M.\4@1(=(P4Y@@+%$-C;,I=.Z]X;26BE7;^GT3B112121H,\.-R%5Y2@0B!
M.6A!&_A _MHLF./I1F"S880BH,=#'%(NE(=S.2I4#YF(I+,&)AU5ZR7]$U\H
M&E\6PDRNH!AB/CX&((XZG.@&:L;0CQ !?4/EW:&D+5;,HD9MUOXLW0:FRFQ@
M!]D98R8EYK0G_,(G+V"'0E <*$3O]F<D<Z4( ;50#EP^?-L@R&J#:BJ#ZHMM
M@-->H"=Y0P0?V'1.,G 6JS/UB2&(D512:R"!( 8+-)HGE\B,1Q2<;RP:7XFU
M.32<(C;H4X+A$E9T[9W XV&9SMRX;@GB)$46:A-AQ^^8Z(!L1)18LY.#S$+#
M,)D97%*O \JI:/-L<MLOZOWJRAK%P-.3*=77I1Z&.<*W+%6FFS3QPK10S0QJ
MR-GNYI 1UD#GH0PM$Y#*MY%!5@A'6RM\4@L!,A$I^[ [',2Z^B*^-M&OE$'%
M2&M'V.VA%4#JR6PNCCK:?B&-*2/JRWXML!>8MB(9Y?BS471E4D4' ?8G*%'!
M9K@0/)A)D%@%#N28RE9^S (!=9H.3 20HFA(2"^6S785]_KOV =T06)O")8
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M3_#Q7(K_ #)_#A"3X'_"&:=<X6[II_I3 "  -  ?@_;/_]H # ,!  (  P
M !                   "0 0 2 "  "0 0
M        "2"2             " 0                            022
M                   0"                        20
M           "2                    "2        ""  000   2" ""2
M    02                 0         "22222 0002202""0      2
M            "0          "202""""0" 00202       "20
M             2 "00       " 00 0         "          0
M 2 "                  "         0        0        "0
M             0"0      "0              "0  2 222" 02" 2  20 "
M002 22"0     ""     "       2 20 020002"202 " 2" 022 22 2"
M     0    "0     00 " 0"  "   20" 2"22   0  "" 2  2
M 0     "    "0    "" "00" 0""""0                   0    "2
M       ""             00        20      "0    20       0"  2
M"02"020 0 "00  "0      "     0 0    "       2"      0"0"00""
M "022  0"            0           20     2""""20  002  2   "0
M0    "2   "0                            0         "2    "0
M  0   "0              2"""" "2 202
M  "0      "02            "0      00       "         "0     "
M0"  "0" 0"0 "2  "2       0       "         0     "2     2 0
M02 "    22     20   0  "0       "0    "      "   0""2 "0
M"0        "       "         20               "0     2    "
M    0"            2         " "2 ""       ""    0       2
M   "    "      "0"2     """"      "   "      0 0  2   0   0
M    "            ""2         0  " "   0 "       "     "2
M          0    "      "0    "      0        0    "0 0  0
M 00   "   0    2   "   0 "0       0     2 0   "20
M2 "0 0     2 "0 "   0   2      2 2 2""2    "   "     0"
M  0 20 0  "    0            "0    0  "0 "0"0"0       00"  2
M 0                       0  " " 20"0        "  " 00 2
M               "  2 20 0            20 000    2
M     "0 0    0             "" ""0   "0                    ""
M"022               "0"20 "0 "                "  02  2
M             0" 2" 0               "2  022
M    "0"2  "0             "022"                          "0 2
M""00           20220                               "02"2"
M "2  2"                                    " ""222 02"
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M92H2 NA) (#1^JY;0/4;% "K[49" H/HE(JPF(=T@A5+?DV\ 1<*"]'!:0#
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MI:Q;"-.6>*#2,.14)H'M!]XESW9OR%;P'"?1L<:7-QBDX.X[;MG<1[YVN*P
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M4&(2)TIW73 <+ (@VS!%>1;.V9A [%KW639CTL5(.J@%!SG/![+"!!@F ?0
M OD-D8=%0M5F"VZ_"M*8I5BP/!9JT>B#X%8Q,B>+32MLQ19.$SJ25RI5,AU:
M[7,I;/<*+X#/"*/]IW0/[K!PPMM;TZ,6(71&X5F#ZN=JP^0X:2RD%E)U2] G
MH%$C5[!L,!IQ."$F.:Z)($!"VXV8$F6TO1TC*(4>@C6I4.! :6X9\$/U7?B8
M(B X<=1%$1%$2(FD1V(Z1X^A J *J !570 ;5>#'F."+Y H,$HU&LMN4D QZ
M[#T#FG.?U?/*FL&/#3 RBH>#:IVH)%U@>QB"0!&8<!N E!%L0[K'NS3P@^%F
M)--+(DV);BXK2V5+I&0-U!:'MU.NSRW9"$49*+('51*0(<W$DC4BW(^#"!7C
M3_0",\*UKX% <LRTK#]"5]&A$IF"\;45KRV#5;5 *CQ[EN(@V<0B84X/=5@%
M9MJ4OR498,44N#&.C7=*I40"UAD2L+7K>VHGZ6N!.4)C*QQ>C^(4S0H ;856
M*0ILHRT,%XD!/,92#BX\JQR1*QB(*TTN#(6\$$>,HP0%SO*2CAQ83IASPRA'
M1NRHEIM:!>C1*H(D1-D4UD@'VDX4.1-L2X4CIPP.FES00.QSZ N0R/TE.=")
M@(X#L$7WAI0*C212[WBV<52:(.0#Q-;RG."T#%<V%FL-YIK+-D--F(_M&D0>
M/"C'G8G/Y*+_ $-VK*3758+ (/6+?2@,;3=)U.Y\2/+Y%V-L1T)*@#*,^6RC
M'0H]Y  C,2S0LJ!$ZB$XLW3<FDA%2R7 A+Z6O[R;O/\ TT98_P!^R1,T(J$U
M YNH<7X;')2<;<",@E&5"S(#*#.'0?O' )FTL</86UW;H[14(4<B_*S, "^4
M*FO 2.>LEWE"P$;9TS,'*55@(++R8#<5;\ 2'%6ZS-/_  *4[+L-2$A+AF)_
M*/\ &B8"X#OFX63R5=R(-@1QN1JFE; E,6A.>$/A8RW!C3B#-+79$LT5@,89
M8C/EC:6B Z\024Q1(.\*M]-S"!H3L#10&I(C#03)S9X: B&%&=IHT!L6*V-4
M*,\0H0@44O4  *PE) %@(T._0[2.(O21R<$WE&7:D!8!Q8KAI,9$$ NJ2<&O
M VP2,4K,L&M:9M<%G_(BP(K_ "5V&4(=M ?4SD;L>!!?(RA$13&UW:UEIXBJ
M*LNF+A0F;91;4TSE8-0H/QES.A75!-070Y0L%"3L!A64DN% =LJJJAR&I464
M;T0X*#/C1-PPCB :/"!=.G.DH\]-*--H+56D6]C\J[+ 0?>1+(BT)XA8,4!?
M#32A%R.'25Q!>=YG+5)6PXLHH'+AH?!)J#8R *UNU!7<D9-T>M\?&><7HW>+
M&UO9UOC%*[ :]@+Y(XY XAU9R&Z*;9#%HDQRHS!:QP90U+R*SK%\[7V%;<:)
MC'>(C@[V"H8#G*1&2B05(/#5R 0CFD1% :%1A,^<TTKY*5%V#*.H'"##5C*J
MY#\_G?\ OZY#QB?YJX6UA7>IO?.29XHH3:SH -(QD9Y@8$21S#51+E885B18
M -T,%Q!>D-/U1=H\.=VH OU>E$HX-QY)CDEAS1-"X"#=Z*IS'M4-<[,Y V'0
M+P!-JJ >@!V8H4SBCB[0K^Z=!,('JZA3^E9XQ$*B6&5<NY9?I&&D*HYMUS6@
M<M+^#P1=X4,GG_NS<X<V!2;.\1U^TZ78FNSO%3_&(AQ@D_VW[97<5$P\_@T/
MX)5$1I4QW *[:)SHVB%PM >%#NU30/*SYRB@.;0>4.H/.%'??Y]&LJ.@! $!
M4AKXY)F&R/ #6>6;>0<E@%&%!;D70UTCDNR+MN67>3\_RG^ID.9OS_PF'@_C
MTGY_E])]W_'_ )Z(.@Y_T'_N,0_0('A5$_)B3RX!?RL?WAEK<^;[:?':?YR&
M%_I'?QB2HKX#1-!'Z"NW>;=%M[5M^P^TDU)G'(G$#>MI'GN:=FS*('^D5_&(
I!.-?Y/9Y[W_&(G*@X_"H_4PH9H(/P 'ZR?G^7_W)/_J_[R'@_CZ3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>guardantgraphic201910k.jpg
<TEXT>
begin 644 guardantgraphic201910k.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "J.M:U8>&])N]3U2[AL-/M8S+/<SN%2-1U))J]7Y[?
MMY?'"Y\2>,F\ Z9<NFBZ05-^J' N+HC.#ZJ@(&/[V[T!H VOC#_P4'U.ZO9]
M/^'EE%8V<;%1K&H1^9++_M1Q'Y4'^]N)&.%Z5\^ZM^TG\4M9=VN/'FN1ECD_
M9+MK<=<\"/;C\*\UHH [?_A>?Q(_Z*#XJ_\ !U<__%T?\+S^)'_10?%7_@ZN
M?_BZXBB@#M_^%Y_$C_HH/BK_ ,'5S_\ %T?\+S^)'_10?%7_ (.KG_XNN(HH
M [?_ (7G\2/^B@^*O_!U<_\ Q='_  O/XD?]%!\5?^#JY_\ BZPO#?@CQ'XR
M:9= T#5-<:'!E&FV<EP4STW;%./QK-U#3[K2;V:SOK::SNX6*2V]Q&4DC8=0
MRGD'V- '7_\ "\_B1_T4'Q5_X.KG_P"+H_X7G\2/^B@^*O\ P=7/_P 77$44
M =O_ ,+S^)'_ $4'Q5_X.KG_ .+H_P"%Y_$C_HH/BK_P=7/_ ,77$59T_3;O
M5KG[/8VLUY<;'D\JWC,C[54LS8 S@*"2>P!- '7?\+S^)'_10?%7_@ZN?_BZ
M/^%Y_$C_ **#XJ_\'5S_ /%USGA[PKK?BZ\>UT+1[_6KI%WM#I]J\[A<@9*H
M"<9(Y]Z2Q\,:SJ>M-H]GI-]=ZNK,AL(+9WG#+G<#&!NR,'(QQB@#I/\ A>?Q
M(_Z*#XJ_\'5S_P#%T?\ "\_B1_T4'Q5_X.KG_P"+KE-8T74/#VHS:?JMA<Z9
M?PG$MK>0M%+&2,X96 (X(ZBKOA_P7XA\61W#Z'H.IZREN,S-I]G).(N"?F**
M<< ]?0T ;W_"\_B1_P!%!\5?^#JY_P#BZ/\ A>?Q(_Z*#XJ_\'5S_P#%USOA
M_P *:WXLO'M-#T?4-9NT7>T&GVKSNJYQDJ@) R0/QIMCX8UG4]:;1[/2;Z[U
M=69#806SO.&7.X&,#=D8.1CC% '2?\+S^)'_ $4'Q5_X.KG_ .+H_P"%Y_$C
M_HH/BK_P=7/_ ,77*:QHNH>'M1FT_5;"YTR_A.);6\A:*6,D9PRL 1P1U%5%
M5I&"J"S,<!0,DF@#MO\ A>?Q(_Z*#XJ_\'5S_P#%T?\ "\_B1_T4'Q5_X.KG
M_P"+K*U[X<^+/"NGI?:WX7UK1[*1@J7-_I\T$;$C( 9U )-<[0!V_P#PO/XD
M?]%!\5?^#JY_^+H_X7G\2/\ HH/BK_P=7/\ \77$44 =O_PO/XD?]%!\5?\
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M>?Q(_P"B@^*O_!U<_P#Q=<14BVTS6[W B<P(ZQM*%.U68$JI/0$A6P/]D^E
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M/BK_ ,'5S_\ %UHZ7^TE\4M'96@\>:[(5.1]JO&N!USR)-V:\WHH ^Q_@_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@>0UVOBSXIW7BGPGI_AJ+1-'T/1;"Z>\@M],CE!$CHJL6>61V?.T'+$GMG
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MHHH **** "BBB@ HHHH **** "BBB@#]NZ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* ,6BBB@ HHHH **T_$GAV[\*ZJ=.O@@N5AAG(C;< )8DE49]=KC/OGK690
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M4=JJ7VOZGJ<,D5YJ-W=Q2W#7<B3SLZO.P :4@GER ,MU.* -[X1_\E6\&?\
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MO_R4G_\ B*/^%Y>"/^@W_P"2D_\ \10!WE%<'_PO+P1_T&__ "4G_P#B*/\
MA>7@C_H-_P#DI/\ _$4 =Y17!_\ "\O!'_0;_P#)2?\ ^(H_X7EX(_Z#?_DI
M/_\ $4 =Y17!_P#"\O!'_0;_ /)2?_XBC_A>7@C_ *#?_DI/_P#$4 =Y17!_
M\+R\$?\ 0;_\E)__ (BC_A>7@C_H-_\ DI/_ /$4 =Y17!_\+R\$?]!O_P E
M)_\ XBC_ (7EX(_Z#?\ Y*3_ /Q% '>45P?_  O+P1_T&_\ R4G_ /B*/^%Y
M>"/^@W_Y*3__ !% '>45P?\ PO+P1_T&_P#R4G_^(H_X7EX(_P"@W_Y*3_\
MQ% '>45P?_"\O!'_ $&__)2?_P"(H_X7EX(_Z#?_ )*3_P#Q% '>45P?_"\O
M!'_0;_\ )2?_ .(H_P"%Y>"/^@W_ .2D_P#\10!WE%<'_P +R\$?]!O_ ,E)
M_P#XBC_A>7@C_H-_^2D__P 10!WE%<'_ ,+R\$?]!O\ \E)__B*/^%Y>"/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '9^ _BI
MK/@6XC6*9KO3,_/8RM\N.Y4_PGZ<>H-?4_AGQ)8^+-%M]3T^3S+>8=#]Y&[J
MP[$5\2UZS^SOXLDTOQ2^C2/_ *)J*DJI/"RJ,@_BH(]^* /I6BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "OQ$K]NZ_$>>%[>:2*0;7C8JP]"#@T ,HHHH **U--\*ZWK&
MEWVI6&CW]]IU@ UW>6UJ\D-N#R#(X!"=#U(Z5ET %%%% !17J6M:#X"\'Z7X
M5&JZ5XCU&\U;28=2GN+/6;>".,N\BE5B:T<G&S/+\Y[5EZY\)KUO%.GZ?X9,
MFM6.JV"ZK87$P2W9;4[MQG+-LC,91U<EMH*YS@B@#@:*ZV\^%7B:QG:-K&&X
M7[%-J"3V=[!<P2P1?ZUHY8W9)"F#N5&+#!R*H:'X$U[Q)9P76F:;+>PSWJ:=
M%Y14M)<,I<(JYR?E!)(& ,9(R* ,&BO0--^$&JVWBSPS8ZW'$-*U758=-DO-
M)U"VO$1F=0Z>9"\B)(%;.UN>^"*CC^#?B#5KR]?2[: :<M_+8VDVHZC;6C73
MH^W9$)G0RMT!$8/) [XH X.BNPTCX2>*M:T^ZOHM.CM+&UNGL;FZU*\@LHH+
MA I:*1YW0(WS# 8C)R!G!QH6?PEU7[+KEA=:1?CQ%:WEA:6R13VXMLW)8)O8
MME@XV%'0E<$DG!!H \_HKKO$'PI\3^%]+N-0U&PAC@M76.[CAO8)IK1F.%$\
M*.TD.3P/,5><#J:NV_P/\9W=NTD6E0O)';&\ELQJ%M]J@A">9YDMOYGFQKMP
M<NHSD8ZC(!PE%*HRP'O7J'C_ . ^M^&_$&O1:7:BYTW3S)-'%/?VQOVMDY,W
MV8,)60 $[Q'MP">@S0!Y=17I&M?!Z\FU'3;?P]&UQ%)H-GJ][<ZA=0V\%N9H
MP6W32%(T7<<*&.3TR36%_P *K\4?\)-%H"Z8)-0EM_M:-'<1-;M;X)\\7 ?R
MO*P#^\W[1@\\4 <I1757WPO\36&K:3IW]G+>W&K$K8-IMU#>PW)!PP26%W0E
M3]X;OE[XKH;SX,WN@_#OQ'XAU<*)K"YM+>UDTZ_M[NU<R-()4=X6<;UVK\NX
M$9Y'(H \THKLOAKX";X@2>(;:!+B:^LM+:\M8H&50\@FB3#EA@(%D8DY&,9)
M !J*^^%/B>QO]*M!817SZH[QV<VFWL%[!,R8WJ)H7>,%006!;Y003@<T <E1
M75:O\,/$6CR:<C6MM?\ ]H7'V2V;2+^WU!9)_E_=;K>1P'.Y<*2"<\"CQ!\,
M?$?AN&&:ZLX;B*6X^R"33;V"^59STA<P.^R0\X1L,<' X- '*T5UOB3X5>)O
M">GSWFHV5NL-M(L5TMK?V]S):.V=JSQQ2,T))!&) O((Z\5U?@3]G_6]:UJV
MCURT:ST][*:]FCM[ZW-["BV[R1O);[FDC1F5!N= ,,.1D4 >3T45Z-<>%_"?
M@?1='D\4)JVLZUJMK'?C3])NX[)+.W<$QF262&7>[KAMH50JL/F).  ><T5Z
MKX?\"^"=:\3W\EKJ&J:IX>M]!NM9^RQR):WL,D08_9Y)#&Z$_+G>JD$,IP#D
M"A:>&?"/CK2-7_X1F#6=%UO3+234/L>JWL5[#=P1C,H62.&$I(JY8 JP8*W(
M.,@'G-%=-_PK7Q']N@M/[. >;3O[620W$0A-IM+&4R[M@7@CEL[OE^]Q7,T
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M&5GV*J@!07'W@"<]* ,3_A$]4^WRV9@1)(HA,\CSQK"(SC#^:6V;3D8.[!)
M%/C\+7RWES:26GF3I LRM'<QB,*S*%??RKK\P'RGOG/!K:AUZU::S6+4X;3;
MI4=M)]JM#/ SA]Q212K''<,%/('3K3;K5M&MYM56T:%&GTOR&:UCD6&6X\U&
M/EJPW*-H[@#(/ XH YD:/>>9?1^05>Q#-<!F \O#!3G)Z[B!@5;N?".J6EK)
M/+!&!&@DDB6XC::-3CYGB#;U'(Z@8R,]:V-9\36<^EV\UNS2:G>R1RZBK @
MQ#:HSC!#G+G'?%:&N^*+:XFU74+;5K,"\20QVL.E1I=+YF0R22>4!@ D%E<D
M_CP <[H&@QZMI]S-LEFN([NVMXX8Y%3S/,+@C)!P?E&#T&><TRT\'ZIJ*[[>
MW0*\C111RW,222L#@JBLP,A!X^4'FM#P7K=EI,++=S>43J-E/]QC\D;.7/ [
M CW]*MM<:7XANM(F?55L'LV\AX#%(9)%\YG#Q%5*Y(?HQ7!% ',:AH=[I*LU
MU!Y06XDM3\ZG]Y'MWKP>VY>>G-6'\.7MO'=QR64K7$,D,9\N52%,@)5=HR6+
M<8P>,<]:ZCQ4UAJ=]J^GW.IQ:9-:ZS=S[KB.1Q*CE5(78K?,#'T. =W6K'_"
M9Z38Z[J5Y#*]S U[8S0KL*O)'&C!SR, C(Z]Z ,%? \]KH^M7=]M62QB1D%O
M<Q2@.9%4K)M+;3ACP<'(]C5'1?#<NMZ/J%S ,S6LL*DO(D<2HPDRS,V .54
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M>W,4 )#$ ;G*@M@9('UQ5;_A#M66WN9Y+9+>&WD:&5[F>.("10"4&YAEL$$
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MTDTTC332,6>21BS,QY))/4U'110 4444 %%%% $DUQ+<LIFE>4JH12[$X4#
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MCF<%)HP>RR*0RCV!Q7B-]_P3S^&5W<-)%J'B.R0_\LH+R$J.?]N%C^M?3U%
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M3\-_^@WXJ_\  NV_^1Z/^'=/PW_Z#?BK_P "[;_Y'KZFHH ^6?\ AW3\-_\
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M/^PE;?\ HU: /M"BBB@ KRG]J3_DA/B;_MU_]*HJ]6KRG]J3_DA/B;_MU_\
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M4L4)B(:,R*K*P9OXP1@'GD5P%U9W%DR+<020-(BRH)4*ED895AGJ".0>]0T
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M6$+DD\8'TJUK?P9^+6K27D6IP7.J:A!!]KN=-DUJ"YOTC.&W/;><9AU!Y3-
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M#,?^V;X;]* /0:*;'(DJAD974C(*G(IU !1110 4444 %%%% !1110 4444
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M=2.><=#6@NH:+XJU;5]+M;R[*ZE$L%C!):*D<;PC$ W^:QZ K]WG>>E>944
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M\.?]A*V_]&K6#6]X!_Y'KPY_V$K;_P!&K0!]H4444 %>4_M2?\D)\3?]NO\
MZ515ZM7E/[4G_)"?$W_;K_Z514 ?G_1110 5M>"M/M]6\9:%8W<?FVMS?00R
MQY*[D:10PR.1P3TK%JSINH7&DZA:WUI)Y5U;2K-%)M#;74@J<'@\@=: /1FD
M\+0^'?$&H#PC:R3:7J,-E:K)>7.V9)!-S.!*"6 A_P"6909;ICBK\W@CP[I7
M]MZM.+"*V0V"VUGJCW9MXFN+?SVR;<&1MN"JY8<=2Q'/F#:Y>M8WMF9O]&O)
MTN9TV+\\B!PK9QD8\Q^!QS["M*U\?ZY:WEQ<+=QRM<016TT5Q:Q30RQQJJQA
MHG4H2H48)&1USDT =^WA+P?#I=WX@BN-+DA_T: 6MV-1%C%-()2Y0K&)V7$0
M*[B -S LVWEURWA_3/!7BT:396-['<V=G+*4^V".&5IBA6(R%&9!@.NX'EB"
M7 K@8_B)K\=_=W9O(YFNHEAF@GM89;=HU^XODLAC 7^$!?E[8IK?$#7)+C4)
MI+J*;[= MM/'-:PR1>6OW56-D*IMQ\NP#;VQ0!-\./#UEXD\3"#49!'96]M/
M>2ABX#B*)GVDHK, =O)4$XSCFN_\,6?AR34K:\TZ33(]21+R(PZ,M\8'B-E.
M<L;I<JZD ?*W(;H-N3Y'I.K7FA:E;W]A</:WENV^.:,\J?ZC'!!X(.*VI_B+
MKTTT$BW4%L(1+Y<-G906\0,B%';RXT52Q4D;B,XZ&@#JM6\.:)X7T)=;;2(M
M3)MM-B6SN)IA#YL]NTLDK['5R<H0 & RQ],5)JWAG0+B"6]M-(_L]'\++JBP
M>?(XCN#=",L"S9*[<@ YXQG)YKG_  WXZ:&:Y_M:_N8U>TAM$,=A;7D12+ 1
M9+>7"/@#A\AE(SSFG^-?B-/KFJ%M.EF2T&F1Z4TEQ$BR3Q*V\Y496,;^BH<*
MJJH.!0!V'B:QT+Q!\3O$OA^318[25A=3KJYN)?/29(GF+,I;RS&2I&-@(4@[
MLC)FT?PQIBV,6FBV_P!"U"?PZ]S%YC?O#*DADYSD9W'H1C/&*\^U+XH>)=7A
MO$NKZ*22\0Q3W*V<"7$D9/,9F5!)L[;=V, #&!BJD/C[7K=HC'?;3$;5D_<Q
MG!M@1!_#_""?KWS0!W.M7^B6OA_P1;:AHEL=,BOKR.=HI9Q*8A*JL1^\QD@[
MNG51T&0>9\4>$(O!>BW,%_&LNK3:E)!;R!V 6"'AI .A61G7!/\ SS;%9*>)
M[G4K&#2=4NL:2+EKAI([*&6>(L<N48[6P>NP.JDU-XZ\5'Q5JUN\;3-8V-I#
M86GVC D\J- H9@"0"QW,1DX+8R<4 7]/ATKP[X/T_5[S1K?7;G4;N:$)>33)
M% D0C)P(G0EF,G4D@ #CG-:FI6.@Z-X/FU$>&7-Y=ZG+;01ZI/,#;0F"*13A
M&3<P+Y5CP0>0V1CE-#\9:KX=M9;6SE@>UED65K>\M(;J,2#@.JRHP5L<;@ <
M<5%JGBK5=;A>*_O7ND>Z>\;S "QF=55FSC/15&.@QP* /3_&MCINE^%M9T&R
MTJUMX4\3"VBN&DF9XP8B0W,FTD#Y>1T]^:K>)O#/@_2[K7M%$VEQRZ<DT<-Q
M;?VB]^TT6<>:&C\C#$$-M"A<@AN/FX*\\=:SJ%OJD-U<Q7,>I3"XN?-M86)D
M QO0E,QG'&4VY'%37WQ%\0:E8R6EQ>QLLT2PS3K:PI<3(N,+),$$CC@<,QS@
M9Z4 =GXDT#P\VO\ C/2-/T"&TCT6SDDMYUN)WF>3SH5RV9"I WN  HX(SN(S
M2ZCX-TG^PO$EM+IVE:9JFDV0N%CMK^XNKU&66-&$[ FW.=Y!"A2#C X(KS^7
MQ?J\VH:I?/>$W>IH8[N01H#(I96(X&%^9%/RXZ5HWWQ.\1ZA;7\$MY J:@FR
M\:&Q@B>Y&0<RLJ!G.1G<Q)SDYR30!?\ @O>)8_$*RD>TAN_W-QM69I%"GR'.
M1L93GC'7N>^"+%RV@^'[70FN/#%MJ;:Q";Z4_:;A/(1I9(UB@VR<;0F<R;R2
M>>!SQ6DZM=Z'?QWMC+Y%S&&59-H; 92K<$$="1^-:VB_$#7- LH;6SN8/*@=
MI(#<6<,[V['J8GD1FC.>?D(YYZ\T =3X@\.Z+X)\/ZJKZ7%K.H1:[>:5%=74
MTJJD4:)AML;KEP3D9R.3D'C&+X3M-*A\'^(M7O\ 2X]4NK.>TCMHYI9$B'F>
M;NWB-E)&%'0@Y YQD'G+C7+ZZTT6$UPTMJ+A[O:P!)E<*&8MC))"CJ>U-@U:
M[MM+N]/CEVV=T\<DT>T'<R;MASC(QO;H>] 'I^J:/X8O-4GT>R\.0V!DT'^U
MQ>"ZG>6&8V@N=B!GV^7T7#*S8)^;.,)X>\%Z5>6L6F:CIFEV%Y-I<MTCR7]Q
M-J+.+=IDD"1GR44[0=DB@[3R2<&O//\ A+-5^W&\^U?Z2;/^S]_EI_J/)\G9
MC&/]6-N>O?.>:UK'XG^(+7R4%_'"! +1[J.PMVN3!MV;&D*!W&WC:S8P .PP
M =%JWAS1/#&@C6VTF+4BUKIL2V=Q-,L0EGMFEDF?8ZN3E,!0P')],5+9^'?#
MO[_6Y-&#6<WAY]5BTIKB41PSK="#&X-O,9VDX+9PV-V0&K!UKXARPZP7T*5C
MIXL+:P9-2M(9%N%BC50[P/YB Y!(Y8C/!K$O/&FLW]W?W,UYNEOK<6DP6)%3
MR05(C50H5%!1<!0,8H ]+\+_ -E:;I3:E#X?L=^I>'=1GFA:6Y,:[)W4*O[[
M<%VA1R2>.N<D\[HWA72M8M= UO[((])MXKC^V(5E<!I+<>80&))7S4>)1@CY
MBV,5S&F^-]9TDV7V>YCV6<$MK%'-;12Q^5(Q9T9'4JX)8GY@?T%7E\50:;X'
MOM'L)[I[G5YXIM0$D"10QK$6*I'M8[LLP8DA,;  "* *'@_1(?%7C#2]+D8V
MUO>W21,8^2JEN0N>^.!FN@A;0_$FDZY<VWAJVTF71XX[V/R[FX=;B/SHXC#-
MOD/)\S.Y-G0\<C'#V]Q+:SQSPR-#-&P=)(V*LK Y!!'0@UNZUX\UKQ!926EW
M/;B"6033+:V<%N9G X:0QHID/4Y8GDD]30!M_&B^@OOB9JA^Q16:1NB/]G:1
MB^%'S'>[<XXXP.!Q6GXG\-Z+J&GWC>';'2I+*WN(U%_:7ER+N")G" W,$YY)
M++EHU50W?! KSW5=9O-:U2;4;R8RWLK!WE"A22  #A0 .@Z5JZQ\0-<UZQGM
M;RZA:.X97N)(K2&*6Y*\@RR(@>7GGYR>>>O- '5W6CZ!=^(O$'A:#0H[-]-A
MN_)U87$S7#/;([EI59S&0_ED85%QN&#P<]!_PA=AXQFTZ&Z#).UOH-JD\;'<
MB2P/O"CH2=JXR#R*\VOOB)K^HZ=-9SW<3)-&L,TZVD*7$R+T62=4$CC@<,QS
M@9Z"JTGC36I;?R3?,J8ME'EHJL/LZE8<,!D%03R#D]\T =II.L:7J7@OQ\EC
MH$6C.EE!M-O--(&3[7",2>8[?/G'*[1][CIC.M[Z#_A2TEN=-M6E.MJOVHM+
MY@/E$[L!]N<?+]W&#TSS63J7Q*\0:KIU[8S75NEK>@"Z2VL+> W!#!@TC1QJ
M68,H.XDGD\\G.5:>)+^RT6[TB-XFT^Z=9)(I;>.0AP,!D9E+(<'&5()'!H [
M*Z\):7'X]\>Z<EH?L6EP7\EK'YCGRC&V$.<Y./<G/>MG3]&\*1:YINDW/AQ;
MF&;P^-3N+K[7,L_G+9F<[,/L"DI@@J3\S8(X XR;XH>)+BQN+5KV$)<V_P!E
MN94LH%FN(]H7;+*$WR< <LQ/&>M98\6:J+Z*\%U_I,=F;!'\M.(#$8=F,8^X
M2,]>^<\T =QI_AS0_$ECI.M_V3'IL(349+G3K&>4QSBUA250&D=W4MOVL0>@
MR #47A_2-#\:#2KP:'!I CURST^YM[.>=HKF*<N?^6DC,K*(R,AN0PX!&3Q=
MCXKU;2X]/2TO&@73YI+BVV*H*.X4.<XY!"*"#D8SQR:N7GQ UR\N-/F-Q;VY
MT^?[5;1V=E!;Q)+D'>8XT56;(')!X&.E '5V+>$KR[U>/^Q]'TZYMITM[.'5
M;B^^SS1@ON:22-\B;A.Z1XW<9Q7%^,-+.C^)+VU-B-.4,'2V6Y%PJHRAEVR#
MAU(((/H1UIVD^,M5T4W?V>6"2.[<2SP7=I#<PNX)(8QRHR[ADX.,C)'>L_5M
M6N]<U">^OIVN+J8Y>1L#H,  #@    #@  #B@"I7JW[+?_)=O#/_ &]?^DLM
M>4UT_P -?'$WPW\;:9XC@M4O9+(R?Z/(Q4.'C9",CIPY_&@#]+Z*\/\ !?[7
M7@KQ+Y<.J&X\.7;<$72^9#GVD4?JP6O9=,U:QUJS2[TZ\M[^U?[L]M*LB-]&
M4D4 6Z*** "BBB@ HHHH ***YGQO\2O"WPWT\WGB77;+1X<$JMQ*!))CJ$0?
M,Y]E!- '345\>_$;_@HEH6F^=;>#-"N-9F&56^U _9X,]F5!EV'L=AKYJ\>?
MM=?%'Q\TB3^(Y='LW/\ QZZ*/LJCU&\'S"/8N10!^EGC3XJ^$/AW;F7Q'XBT
M_23LWK#/./-<?[,8^9OP!KY_\:?\%#O VBM-%X>TG4_$DRGY)6 M+=Q_O-EQ
M^,=?GE-/)<S/+-(TLKG<SN268^I)ZTR@#Z>\8_\ !03XB:[YL>B6NE^&H"<H
M\4/VB=?8M)E#_P!\"O#_ !=\7/&OCSS!K_BC5-3BD.YK>:Y80Y]HP0@_ 5R-
M% !1110 4444 >N_LEW^G:;^T+X.FU1XX[?[1)&CRD!5F:)UBSG_ &RN/<BH
MM/\ AW\2+[XYZCI&FC4K'QG%=SSRZAYCVSQ EBT[2C[B,"?FS@[AC.:\GKI[
MOXH^,]0T8Z1=>+M=N=):,1&PFU*9X"@Z+Y9;;CVQ0![;?6O_  @/PQ^&VH>'
M_#>B^+M3\0:A=G5M0O\ 38M4-S<),$6W5Y%;8&7)^7#-USUKK]4\'^%/AYK7
M[0DND:#H^HIH=K82:='J-G%>)8S2_P"L""16 VLQ&T\?* <@8KY<\-_$/Q5X
M.MI;?0/$VL:';S-ODBTV_EMT=L8R0C $X[FJ,'B75[6WU*WAU6]A@U/'VZ*.
MX=5N\,6'F@'#X))^;/)S0!]GZ?I_A[Q%\1/ACX9N?!GA>+3O$W@[^U=4-OHM
MM%++</;R'<CJ@:+:8\CRRO+'VKCO <.CZ'\-?@BB^%_#M_<>(/$LUCJ-YJ.D
M6]S--;BY">66D0D</U'(VC! R#\UP^._$MO?6%]%XAU6*]L+<6=G<I>RB2V@
M ($4;;LHF"1M&!R:AC\6ZY#;Z;;QZSJ"0:9,;BQB6ZD"VDI;<7B&<(Q8 Y7!
MR,T ?8-CX-\(?$;6/B1H^L>'M#T;2O#_ (LTW3K&;3+&&SEB@:Z,$B-*BAG#
MJ.=Y."V1C PFGZ5X5U#XH>*O#>H>!)+[3M.U*"&**U\)65BFED7"K$SW2SEY
MXI 1N#AMX;( Z5\?R^+M=GAU2&36M1DBU643:A&UU(5O) VX/*,_O&#$G+9.
M3FM*^^*?C35+:VM[WQ?KUW;VLB2P13ZG.Z1.A!1E!;"E2!@CICB@#Z6^PZ1X
MA^.7Q3L4\)^'I1X1TZ^N- T"TT:WCCGGC"H#(L:!KC'+;'+#)X JO\&="N?B
M-X?OM7\2?#GP[!:KH&J)9:Q#IUO;?:YE"E3]G0!=R'.)508Z;J^78_%6MP^(
M#KT>L7\>N&0S'4UNG%SYAZOYN=VXY/.<\UI7GQ/\9:E>->7?BS7+J[:W>T:>
M;4IGD,+XWQ%BV=C8&5Z'% 'UCIOPVTO[9XX\(Z[I/AHW6C>%9)Y+#0_#P"6$
MPB5XI3J4H$[RG.<98')_NFO.?BYH,_BB^_9_TBUM[>[N+[PY86Z07;LD,A:4
MC:[(0P4]RO..G->.GXP^/6L19'QOXC-F(_*%O_:UQY>S&W;MWXQCC'I6%>>)
M=7U!M/:ZU6^N3IT:PV1FN'?[,BG*K'D_( >0%P!0!]9Z[X)T'6_AW\5TU*TT
M+[7X?N;6%;C0_#<>G0Z9,)]DL45R0)9\#.[S >QSR*[#X?QGP7^U9<^#-$\(
M:3:^%[/1B;6_@TR(W/E&W5A<M=[3(^]B4.7P=V,9KXUU7XM>.==T^:QU+QGX
M@U"RF3RY;:ZU2>6.1<@[65G((X'!]*73_BYXZTG3X+"Q\:>(;.QMT\N&UM]5
MGCBC7&-JJ'P!@G@4 ?1QT.Q\-_$#X1>$]%\%Z+KOAKQ!IMK/?WEWI,5U/>M,
MQ%R_VAE+IY0Y 1EV]Z3X@Z/8?#'X4^';CP;X0T/7C-XHU'3FU.^T:#49)H8[
MJ18(2SHV=X&,CYB%PI%?-6E_$KQ?H>CMI.F^*M;T_2VW!K&UU&:* [OO916"
M\Y.>.:[!?VA/$6E_"SPSX.\/WFI^&WT>>YEFU#3=3DA-V)7W!61 N-O/5CU[
M4 ?6FMZ%HO@^Q\6^'M'TW2ET=_%6AQSZ9)86\\<1N&C,T1W(<_>.-V2@;"E0
M !Y_\=]%L/A7=: _@KP1H&JG6=?U!+W[3HL%XIDCGV1V:*R$0KLS\J;2<9!Z
MU\LZ+\2/%OANXO9])\4:UI<]\_FW4MEJ$T+7#Y)W2%6!8\GDYZFI]-^*WC;1
MYKV:P\8:_8RWLIGNI+;4YXVGD/5W(8;F]SDT ?4?Q8\.^%_A#X#^(]WX:\.Z
M#=75OXIM[.VGU'38+XV2R6D4DL2>:K#"N74*<@9/&17B_P"U7X;TGPY\3+0Z
M/IMMI,&H:/9W\MK9Q^7"LLB9?8@X4$CH.*\MD\2ZO-I=QILFJWKZ=<7'VN:S
M:X<PR38QYK)G!?'\1&:9K&O:GXBN8[C5=1N]3N(XEA26\G:5UC485 6)(4=A
MT% %"BBB@ HHHH Z#PO\0O$_@F3=H'B#4M'R<LEG=/&C?[R@X;\17MWA#]O3
MXG^'=J:E-I_B2'(S]NM1')@=@T149]R#7SC10!^@'@__ (*,>%]198_$GAK4
M=%D8@>;92+=Q#U+9V,![!6_K7T!X%^.G@+XD>6OA[Q3I]]<2'"VC2>5<'_MD
M^'Q[XK\?Z 2#D<&@#]N@<\CD4M?DGX%_:8^)7P\\M-*\57DMHN!]CU!A=1;1
M_"!)DJ/]TBOI/X=_\%&8Y#';^-_#9B/0WVBME>O&87.0!W(<GVH ^V:*XCX>
M_&KP3\4H=_AKQ%9ZA+@LUKN,=PH'4F)L,![XQ7;T %%%% !1110 4V2188V=
MV5$499F. !ZDUR7CCXHZ)X%B9;N;[1?XREE 09#Z%O[H]S^ -?.?CKXK:WXZ
MD:.>7['IV?ELK<D)_P "/5C]>/0"@#UOQ]^T%8:/YEGX?5-2O!E3=-_J$/M_
M?/TX]S7@6N^(=1\37[7FIW<EY<-_%(>%'H!T ]A6=10 4M)10!T_C+X>:KX%
MBTZ343;LM\A>/R'+;2,95L@<C<.F1[US%6KW5+W4E@6[NY[I8$\N(32LXC4=
M%7)X'L*JT =[I_AZ1O">CWECX1_M^:X,WGS;+I]NU\*/W4B@<>HK.UKPG;KJ
MMX;:ZM]/L($A,SW$C2)!,Z F %%9G(.X< X"G)XS5"Y\1?\ $GT&"T::"\TU
MI7,R_+AF<,I4@YXQ[5NQ>.+0-J4<$^HZ-'?M%=/-IV T=PJD.H4.NZ-BQ(Y!
M'''% &,W@NXC\R6:^LX-/5$D34'9S#*&SM"@(7).UN-N1M.<8IO_  B,J27#
M2ZA8Q6,*H?MY=VA??G8%"J7R<-QMR,'.*TK[Q3I^L07.GW]UJTMH3')#>S$3
MS^8@8'*,X 5MY^4-Q@<GFGZ?XNT[3+6[TVQGU32;.3RI%OK1OW[RH&!+IO4;
M6#_=#<;5Z\Y *MMX&O)E>*.2QE25X!!>&20"02;PNS@<$H5.Y000!QS638>'
M+W4K=I84&[[3':)$V0\DK9PH&.V.<XQQ6QJGB^.ZL;Z".YU*YE=[8PW5[+OD
M_=^82Q^8[.7X4$X]:EOO'4"ZWH^H:?:-$+27[9/&YV^9<.092"#POR@#N,4
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MYO(M+6*!U"C<66+82.>F?>@#&T?1Y=8FE598K:&&/S9KBX)$<2Y R< D\D
M DD]*Z&Z\&H^BZ']BDM[BXNYKDO>1R,(C%&$.YMP!4+\^<J#]>*QO#^J6MG'
M?VE\LOV*^A$4DD"AI(RKJZL%) ;E<$$C@]:Z"P\9:7H,>E0:<=0DCMVNEN+A
M@L$I69$7='M9MK+MXY/0<\\ &0O@N:YMY+BQO[+488U<L]N9 =RJ7V;716W%
M0S#C!VGG(Q4>C^&[F\2UN-MLZ7'V@1Q7#.-PCC+,WR]AVYY(],UHWWC)H9+%
M[75=7U62WN!<%]3D*IQP%$8D<<@G)ST.,42>*M.B\30W-I;SPZ3:VLEK;PL
M9 &C<9;G&2\A)YZ4 4%\'R^3'YFHV,%[)#YZ6$KN)2I&Y>=NP$CD L#^8I8?
M!L\P@B-]9QZC/&)8M.=G\YP1E1D)L!8<@%@>1W(%6;C5]!U.:+4;^.]DO5@2
M.2R1%$,KH@16\W>&4$*"0%)ZX//&G)X^2XB@N'U77;:>.W6%M/M9BENS(@16
M#[\J#@$KL/.>>> #C]+TN?6+Y+6#:'8%F:1MJHJ@EF8]@ "3]*Z3_A#XI/##
M36<UOJM[+J4-I!-:M(!\R.2FUPI'(4Y(_'K6'X=U:/2-2:6XC::VFBDMYE0X
M?8Z%25]QG(^E;^G>*=)\+V<"Z4;V]N8]0AO3)=1+ K*BN-@"NQ!^;KGOVQR
M9\7@BXOI/*TZ_L=4F65(I([9W!C+-M!)=%!7<<;E)'(]1F./PVHU'3HK;4=-
MU7[1<K!LC>50&+  .&5'VG/5??G-:U[XPM67:-7\1ZE$\Z.8KFY\KRD5@V 0
M[[VX&&(7&,X]'W'C*Q^T:7))<7VKRVU_'=/>7MO&DZQJ>8PP=B^>N68<@<<D
MT 95MX-ENGA$U_8:=-=2,EM!</(#+ABN00C!5W @%R,X/UH_X0F:&&ZFN]1L
M;&"WO)+%I)FD.9$QG"JC,0<]<=N<<9Z+2]/3Q<^D7LEGJ#"UD,.ZUC1X6C$K
M./-??^X(WG)(/&#]<'Q5KUK?QWUK 6D+:O<W:R@?(T;[0N.^?E].XH I-X8D
MMM1O;2]OK+3S:D!Y9Y&96S]W8$5F8$<Y"X ZXK53P;!::3KLMW?6OVBUB@EM
MF4RE9%D((=<)_$#@;L8).0.M6/\ A,-.FOM4N%:ZL)[@P&&\BM8YI45$VL@#
M.-N3@[E;/RX[TNL>,-,UIM421]05+JRMH4FE59I3)#CE\N,AL?>SD9Z&@#*D
M\)S-B:>:QTRT2V@E:X=I2A,B;D& &8N0"2%&!@]!21>"+N:^F@6[L_)CM?MH
MO#(PA>'<%+J=N>"3P0#\I&,\5=NO$^F:M8C3[P7=O;""UVSPQ*[K+%$8S\A8
M J=QYW C X[5'-XHL8X;FSMX[@VBZ8;"V>15#LQF$I=P#A026X!...O6@#'U
MC0WTF.UF%S;WMK=*6BN+<MM;:<,,,JL"#ZCN,9KIM8\*62VNFVMC)IR_Z$E[
M=ZD[W ,8(ZL"-NTE@%"H6R*YO4-5BNM!TFR17$MH9B[,!M.]@1CGVK7_ .$H
ML+G_ $6X2X2RFTV&RFDC53(CQE6#JI8!AE>A(R#VH JP^";J\U"RM[2[L[J*
M\61H;N-V6(E%+.IW*&4@>H'4'H<UC:A:QV=TT45Y#?( /WUN'"'V&]5/Z5TM
MGXGTW2)+"VM1=3V5LMT[S31JDCRS0^7P@8@*-J_Q$]3[5R- !1110 5O> ?^
M1Z\.?]A*V_\ 1JU@UO> ?^1Z\.?]A*V_]&K0!]H4444 %>4_M2?\D)\3?]NO
M_I5%7JU>4_M2?\D)\3?]NO\ Z514 ?G_ %=TG1=0U^^6STNPN=2O&!*V]I"T
MLA &20J@G@52KJOAO\2-6^%OB0:UHZV\ESY30-'=QEXW1L9! (/4 \$=/3B@
M#F)8G@D>.1&CD0E61A@J1U!'8TRKVN:S<^(M:O\ 5;UE>[O9WN)F5=H+LQ8X
M'89-6/">F6NL>)=-L[^[BL+&6=1<7,SA%CC!RYR2!G:#@=S@4 ;.O?#V71/!
M^FZW]K$\TXC:[LQ$5:T64,T#%L\AU1FZ#''7-1^#/AQJ_B[4-+465[:Z3>W"
MV_\ :OV-W@0EMOWN%."0,;AR:[>U\=^&/&'B?7[.XLKS2[;Q%$;07%YJ,1M;
M0I@VS>6(4VA"B+R_"ELD\YN>'9$D^)7AGQ);^(M+T_1+6&U@<3ZC#');!(EC
MEA\DMN(+!_F"E2&W9ZD 'E>C^#]7UT--9Z;>W-A'*(I[R"V>2*'U+,!@8'/)
MZ5TEG\);W4_&4_AZQ-[=20ZC<63W:6#&'9%U?(8_-ZIVW+\W-:-NK:Y;^#[S
M2M<T_3(]'39<I=WT=N]M,)WD:949@T@960Y0,?EQC@5TZ>(])/C!)/[4L_*;
MQ=J,PD-P@7RY(D5)"<X"$_Q'CKSQ0!X]-X?NX845[._2^:[:S,#VA"^8 OR!
MLY,F6Y3;D<<\X"ZEX1UW1KVVL]0T74+&[NCM@M[FUDCDE.=N%4@%N>..]>A^
M#=1L_#_A^WTV[U*SM=1%_J,$<\=RDBV\DEFD<4V]"1LW\>8,@<G/%-\,-'X1
MAT.PU?5=/FF?Q%9WL2VU_%<QVL49<32-)&S(FXLG&<D1Y/ % 'G>I>%]9T>R
M@O+_ $F^L;2X.(;BYMGCCDXS\K$ 'CGBGW/A+7++28M4N=&U"WTN7:4O9;61
M86#?=(<C:<]N>:ZB'6X[[2/'HO=15I;ZYMY4:27<TI%P2749RQ"D].QKL-2_
MLC3K'QN$O--N%NK$QVNHW.MB\OM0(FB8,55]J?*N[:Z!AP!D@T >6^)?"\N@
M^+KW0;=GU&>"X^S1F.(AIFS@80$G))Z<U!J'A76M)L(;Z^T>_LK*<@17-Q:O
M''(2,@*Q&#QSQ7;7-Y!J'[0EO<VL\=S;R:] R30N'1AYJ\@C@BK=ZA\/)X[N
MM6UJPU*+5HV@MXK>^CN);B8SHZR-&&+1[%5CF0*03@<DB@#BT\!Z[%"[W>AZ
MS;AD;[.5TZ0K*X=4*DG& "V"1D@D#'/&-'IUW))<(EK,[VRL\ZK&28E!P2PQ
M\H!(!SZUZ?KWB2WNO''Q'O1J<,HN+%X[2<3@B0K-!L6-L\X5> .R^U4O%NM:
M9)X??4;.]A&I>*9(I-0@AP6M5CP90R]1YDV)![(* .-?P7X@CT^WOVT+4EL;
MDHL%RUG((I2YP@5MN&W'ICK5_P 3_#G6O#?BI?#YL+RZOY$1X8DM7#S;D#'8
MF,L =PR/[IZ=*]%U0:1I^G^. EWIMPMU8&.UU&YUL7M]J!$T3!BJOM3Y5W;7
M0,. ,D&FR:EIZ^,/$K>?H]V=<TB%+"2ZOPL#$"$O%*\4JM"S!'7#LO( ;@T
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M!DF<*HS!(!R?4D#\: 'VGP]NF\2ZMHMY.MK/I]G<7GF1KYB2K'$9%*G(RKJ
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MG5M?TG^RHD9DETZ_BN)[DX.Q4A4EU+''^L50!G..E '&4444 %%%% !1110
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M)2I+A02=J!/4X/ YYTDT5KZWTO[9J%GK6GQVM]%;R6PF5U,4!D"L71"0K,I
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M3XH4I8^*U8%6%KI8(/4?NUKG? -U%:R:T9+.&[_XELYQ,7&,#D?*R\'^G&*
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MRDWB#4 ING0Y6%1]V)3WQG)/<^P% '-ZQ^Q?X+O<M8W^K:<_91*DJ#\&7/\
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M'KP* />+KQYX0\-^./'WBZP\31ZVVLV,]M9::EE<)(9)MN?,+HJA%*]F)([
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M /!7!_\ $5U=% '*?\*G\#_]";X?_P#!7!_\11_PJ?P/_P!";X?_ /!7!_\
M$5U=% '*?\*G\#_]";X?_P#!7!_\11_PJ?P/_P!";X?_ /!7!_\ $5U=% '*
M?\*G\#_]";X?_P#!7!_\11_PJ?P/_P!";X?_ /!7!_\ $5U=% '*?\*G\#_]
M";X?_P#!7!_\11_PJ?P/_P!";X?_ /!7!_\ $5U=% '*?\*G\#_]";X?_P#!
M7!_\11_PJ?P/_P!";X?_ /!7!_\ $5U=% '*?\*G\#_]";X?_P#!7!_\11_P
MJ?P/_P!";X?_ /!7!_\ $5U=% '*?\*G\#_]";X?_P#!7!_\11_PJ?P/_P!"
M;X?_ /!7!_\ $5U=% '*?\*G\#_]";X?_P#!7!_\11_PJ?P/_P!";X?_ /!7
M!_\ $5U=% '*?\*G\#_]";X?_P#!7!_\11_PJ?P/_P!";X?_ /!7!_\ $5U=
M% '*?\*G\#_]";X?_P#!7!_\11_PJ?P/_P!";X?_ /!7!_\ $5U=% '*?\*G
M\#_]";X?_P#!7!_\11_PJ?P/_P!";X?_ /!7!_\ $5U=% '*?\*G\#_]";X?
M_P#!7!_\11_PJ?P/_P!";X?_ /!7!_\ $5U=% '*?\*G\#_]";X?_P#!7!_\
M11_PJ?P/_P!";X?_ /!7!_\ $5U=% &?H_A_2_#T!ATK3;/3(3UCLX$B4_@H
M%:%%% !61XN\6:7X&\-ZAKNM7:6.F6,1EFFD/0#H .[$X  Y)( Y-:Q.!D\"
MOS<_;2_:$;XG>+F\+Z+=;O#&CRE6>)LK>7(R&?/=5Y5>Q^8\@C !P/[0W[0>
ML?'?Q2UQ*9++P_:N1I^F%N$7IYCXX,A'Y9P.Y/DU%% !1110 445UG@KX=W?
MBQ'O9YUTG0H7V3:E,A8%L9\N)>LDF"/E! &06*@YH Y[2=)O=>U&"PTZTFOK
MV=ML5O;H7=SZ "O4-'^%^B^&=LWB>X&L:B.1H^FS_N8SZ3W"]?\ =BS_ -=%
M/%;D%]9^']-ETOPY:MIEA*NRXN'(:[O!_P!-9 !\O_3-<(,#(8C<<V@#3U'Q
M#=7]G%8HL-AI<)S#IUC&(;>,^NP=6X&7;+'')-9E%% !1110 4444 %%:.B^
M'M4\271M]*T^YU"8#+);1,Y4>IP.![GBNQL?@]=1X;6]7L=)7O!$_P!KN/P6
M,E ?9G4T >>TJJ68 #)/  KV"S\(^$-)QMTZ\UN4=9-1N#%$W_;*+##_ +^&
MMJUU^?2UVZ5!::*,8#:;;I#)CWD WG\6- 'E>F_#'Q7JL2RP:#>I;MTN+B/R
M(C_P-\+^M;5M\&[Q<'4M<T?3O[T:3M=2?AY*LA_%@/>NLN+J:\E,MQ-)/(>K
MR,6/YFO0?A3IL5[H_BZ4VMC/=V]FKVTE_'$R1OD\YE&T?CQ0!Y)#\,/#-M@W
M.NZE?'NEM8)"OX.TC'_QRM"'PKX-L_\ 5Z)?7I];_4<@_A$B8_,_6O6M>\+M
M=>&=#L+^ST^W\6ZA>@6AL(XHT>V88W.81Y9&[H1DXQ[U0U#X/S00ZLMI=7DM
MUIR[V%UIS6\,X'WO*D+G<1[@9[4 <#%'H5KS;>$]'A_WUFG_ /1LC5;CUZ6V
MQ]EL=*LL=#:Z7;1M_P!]"/)_$]Z[:R^$MA/XBE\/S^(6AUJ&V\^6)+'?"&"A
MC&'\P$D YSM KG+CP9Y.A^&=1^V;O[:EDB\ORO\ 4[) F<Y^;.<]!0!43QMK
MT/\ J=6NK;'3[/(8L>PVXQ4,WBS6[K)FUC4)23D[[IVS^9KT6^\ Z?H_A35=
M-N;FU2:WUR.V.K2VQW+&80Q&%W-CG[H/)IWA'X66']I:1J4\]Y<Z<^H"U:VO
M]-\@RG:65@#(<H<'GK[=< 'F$FM:A,NV2^N9%SG#3,1_.HO[0NO^?F;_ +[-
M=IJG@G3475]9N=2EL-(347L[=8[(/+)("2P">8 JJ.^[G'0=*NZI\([/0?#\
MNMW^O/\ V<S1FU:VLO,>X2105;#2+M/7()[=: //O[0NO^?F;_OLU)%K%_!G
MRKVXCSUVRL,_K791?"P7&K::D.J%M'O-/;46U)K? BC4'>&0.>5. ?F_BK$\
M.^&;+6XKAY+^Z$JR!(K2QL&N9Y ?XRNY551_O$^U &?%XGUB#_5ZM?1_[MRX
M_K5EO'/B&3_6ZU?3_P#7>=I/P^8FNJF^$<>GZCXCAU#6OLUMH\44[3I:EVE2
M0$@!-XPW08SU/6H+'X6+JU]X=^PZKYNF:UYBQW4EML>*1 2R-'O/IU#>OX@'
M*2>(KFX_X^;?3;P>EWIMM-_Z%&:J3'1[K_CZ\+:+/Z[('@S_ -^G3]*[:S^&
M5GK8N_['UQKTV-W%;70EL_*PCOL\Q/G.X YX.T\5+J'PQTS3I-;9]?G:TT9E
MCNY_[/',C<*D:^;\QSD'.T#'>@#SB?PWX/O/];X>GL_^P;J+I_Z-$M9\_P ,
M_"UT<V^L:MIWHL]I'<C\65T/_CIKU34/A2L?@V3Q'INK?VC:^6)DB:V\IR@;
M;(3\YP5;J!GCG-5KKX=VFFW\=E>ZS(M[]CCN9+2ULFFF$C\B)%# $@<DL5QD
M=: /(KCX.RODZ=XBTF\](IFDMI/_ !] G_C]9-]\*/%UBC2?V%<WD2C+2Z?M
MNXP/4M$6&/?-?2\GP[@\+^$O$\EPJWK2:=:W=K-=6HBG@W2,&4J22C<8.#7D
MT<KPR*\;M&Z\AE."/QH \7FADMY6BEC:*13AD<$$'T(IE>^R^);Z\B6+4&AU
M>%1@1ZG ET%'HID!*_@16/>>&_"6K?Z_0Y=,D/\ RUTFZ91GU*2[P?HI7\*
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M5'_"RM,_YX7?_?"__%4 ?+?_  @/B?\ Z%S5O_ &7_XFC_A ?$__ $+FK?\
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M?\+*TS_GA=_]\+_\50!\M_\ " ^)_P#H7-6_\ 9?_B:/^$!\3_\ 0N:M_P"
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M /$U]2?\+*TS_GA=_P#?"_\ Q5'_  LK3/\ GA=_]\+_ /%4 ?+?_" ^)_\
MH7-6_P# &7_XFC_A ?$__0N:M_X R_\ Q-?4G_"RM,_YX7?_ 'PO_P 51_PL
MK3/^>%W_ -\+_P#%4 ?+?_" ^)_^A<U;_P  9?\ XFC_ (0'Q/\ ]"YJW_@#
M+_\ $U]2?\+*TS_GA=_]\+_\51_PLK3/^>%W_P!\+_\ %4 ?+?\ P@/B?_H7
M-6_\ 9?_ (FC_A ?$_\ T+FK?^ ,O_Q-?4G_  LK3/\ GA=_]\+_ /%4?\+*
MTS_GA=_]\+_\50!\M_\ " ^)_P#H7-6_\ 9?_B:/^$!\3_\ 0N:M_P" ,O\
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M5%>A?$SP?;P01^)M&@6#2KJ7R;JSC'%C<D%MH_Z9N S)Z;77^'+>>T %%%%
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M)Y.3S5:BB@ HHHH ***7KP.30 E%=+8> M1G19;UHM)@89#7A(=A[1@%S['
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M R;RQGT^14G38S+O7Y@05/0Y!]JKUJZ_&L36,:N7VVJC<1CNQZ>G/'MBLJ@
MHHHH **** "BBB@ HHHH **** "BBB@ K0\/L5U[3B/^?B,?^/"L^K^@_P#(
M<T[_ *^8_P#T(4 >ST444 ?-/BS_ )&K6?\ K]F_]&-656KXL_Y&K6?^OV;_
M -&-650!N)XPU"/PN^@CROL3-N+;/GZ[L9SC&>>F?>L.BB@#<T+4O[-TV_E2
M15G66WDC4M@MM9B<#O[_ %K7:ZT_3Y?LEG<1FUDMKFY+;QPTD;!(S[A<#'JQ
MKC** .OAD1M:L-56]MX]/ABB#QM.H=550'C\O.XY(/08.[/K5>WU:VMY/##3
M2*]M;,SR1@[MF92<D#VP?PKF** .HU28VNGWZ%=+7[2ZC-K</.\N&W;L&1MO
MU8 \D>M9^C[9=(UB#S(DE=(V599%3<%?)P6(R<=NIK'HH ZR'4XSXCT=FNE\
MB&SCC+&0;4_=893Z<DY%3>'1:0MHMP\UO*L;AI9+N]VBV_>'(2($-TP<\@D^
MQKC:* .GN]059- C2Y41V\KN0D@Q&?/)SQTXQ^%4H;@1^*9Y8+R.TS-+Y=P5
M#H,[@/;!SC/;.:Q:* .O@U:33_LLFK7BWUQ%>Q2Q[9UN'2,9\SYU)P#\N%SU
M&<>M#[.FBV>K%[JVG^T1B" 0S+(7!D5MV 25&%_BP>17/T4 ;6EXN]%O;**>
M*"Y>6.7]]*L0D10P*[F(&02#@GG\*V--N(K-DBN-2AN9$N;,LWF#:@5GRH;/
MS!01DCCFN-HH Z>[U)?,T!4NEV0RN[!9!A"9R<GTXP?I5VVU&TC\Y1=11/)>
MW8BDW#$9>,*C\=!GO7%T4 =/IEC]C>"&[U9(LO(R6]K=IC.PC)E!*IN.%Y[$
MYK2MY[2TL[&,M96SI)=%HX;GS=H:#"DMN(R2.W'3O7#44 :GANXCMM2)>40,
M\,D<<S' C=D(5B>W)Z]JUM-FCT".R2]N89"-0AN%6"99O+1<[VRI(&<KQG)V
M_2N5HH Z1K%=,T76%EO+-Y)FC$4<%PDA<!\EOE)Q]#S[5<O)(YM2U-8[JW1[
MZUC%O-YZ;>-A96;/R$A2/FQ[]:X^B@#J;53;V4MA)J<!NYK8I$/.4QP_O%8I
MYH.T;@&[X'<\U/IMVFDR:7#+>0FZMUN9/,CF5UB5HL(F\'&=P)P#_%ZUQ]%
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M=)&C6S(RQJJ'*A=K C'UIR^$;8?ZS5E]_+MV;^9%._X1.P_Z"LG_ ("?_9T
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ME=2"?R_M \R.09Y5]F,?,1@KT_.@"XW@EX?-DE>[\E51U6&S+3[6W#+QEAM
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MAD:.12CJ2K*PP01U!IM=;X^LQ))9:N@YO$9)SZSI@,?^!*4;W):N2H ****
M)+>=K6XBF0X>-@ZGW!R*\X^)MK'8_$CQ9;1*%BAU:[C11T $S@5ZGX?L1J6N
M6%JQ"QRSHKL> JY&XGV R?PKQKQ1JY\0>)M6U0C!OKN:YQ_ON6_K0!F4444
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ML0B=EW?-C'/)Z_*.G'M4=QJ4UQ:VUNQ 2#.TKP3]?IT%5** -"XUA[A9"UO
M)Y!B2<*=[>IZX!/J *9;ZD8;=87MX9U1RZ&0-E2<9Z$9Z#KFJ5% %V^U6;4
MXD5!NE:8[01\Q ![].*?_;,CR3-+#%-'-MW0N&VY48!&""#^/>L^I;:W:ZN(
MH4(#2,$!;IDG% $M_J#Z@T1:..)8D\M%C! "Y)]?>I1JS+$0MO DK1^49U4A
MMN,'C.WIQG&:I2*8W93U4XIM &S<:XL;VK0PP22PP1JLS*VY&"C/< X/J#56
M+5W6*-)8(;DQ$^6\P8LN3G'! (SSSFJ%36]J]T9 F/W:-(<^@H M1ZPZJGFV
M\%P\9)1Y5.5R<XX(!&><$&D;6+AD*L$8F-XRQ!R0S;B>O7-4** - :Q(05DA
MAFB*(AC<''RC ;@@@_0]ZK7EX]Y(&95154(B1C"JH["H** "BBB@ HHHH **
MGLK1[ZZBMXRH>1MH+=*2WM7N6D"8_=HTC9/84 0T4YE"JI#JQ8<J,Y7GOQ_*
MFT %%%% !1110 4444 %%%% !1110 4444 %7]!_Y#FG?]?,?_H0JA5_0?\
MD.:=_P!?,?\ Z$* /9Z*** /FGQ9_P C5K/_ %^S?^C&K*K5\6?\C5K/_7[-
M_P"C&K*H **** 'K$S1/("NU2 06 //H,Y/3MTIE='X4M8+B)C+#'*?MUJGS
MJ#\I9LCZ'O1=31ZAINL;K6VA%K(A@\F%49 7*D%@,L,?WB>E &);V$]U"\L:
MKY:.J,[.J@%LXSD^QYZ"H&7:Q!ZCC@YKI?"<:36LD<B*\;7]FK*PR""SY!%6
M&FBL?[&BCLK-A<2.)FDMT<NOG,H'(XX[C!Z<\"@#D:*[ 6UCI%A+*H*NU]+
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M **** "NETNZ\[0=6G>"U:6W$7E,;6+(RV#_  \\>M<U5^SU3['IE_:>5O\
MM00;]V-NTYZ8YH UU\)RW36S3R21S72>8/)M,Q)GIN(( _ <54D\.Q6,,+ZC
M>&U::1D18XO,X4X+$Y&!GZT-K]O=+:O>:?\ :;BWC\H-YNU' ^[N7'./8BFK
MKD$UI;07ME]H%NY:(QR^6-I.2I&#D9H O0Z;8KX:O6FG3]W=A5N88@[,-HX&
M2./QJ-O"*0R7IFOMD%O$DPD6+)=6SCC(P>*I76O"XTZXM!:QPK+<"<>6<*H
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M?PKHG@/0;;2-%L;?2=,MEVQPP@*/<D]R>I)Y)Y-7)=:T^#_67UNA]#*N?YT
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MSZ]A0!&-#DVR2-<0);H%;SF+;6#9P1@9Z@C&,BFZ38PWCW0EF1!'"SJ6W8)
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MGJMAJF KBPN3_P LIF_=M_NN>GT;\S5FXMI;5]LL;1MC(W#J/4>HH BHHHH
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M* G+ G&#CL!U% &,\;1D!E*D@'YAC@C(--KH9%M9K[3[62T#F>&%6FWL&&5
M!7!QQ[@]ZI36,4<VF(!O\WAR"?G_ 'K+G\@.E &73MC;"^T[<XW8XSZ5MPVU
MBLDT?EP/,+AT\NYD=/E!X"L#C/7[Q]*CFQ!H,T#6RI(MWM)9F+*0#[XSVZ4
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M8;I.PE0-CZ>GX4 ?+]%?0+?"_P ,,Q)TP9]IY1_[-2?\*M\,?] S_P F)?\
MXJ@#Y_HKZ _X5;X8_P"@9_Y,2_\ Q5'_  JWPQ_T#/\ R8E_^*H ^?Z*^@/^
M%6^&/^@9_P"3$O\ \51_PJWPQ_T#/_)B7_XJ@#Y_HKZ _P"%6^&/^@9_Y,2_
M_%4?\*M\,?\ 0,_\F)?_ (J@#Y_HKZ _X5;X8_Z!G_DQ+_\ %4?\*M\,?] S
M_P F)?\ XJ@#Y_HKZ _X5;X8_P"@9_Y,2_\ Q5'_  JWPQ_T#/\ R8E_^*H
M^?Z*^@/^%6^&/^@9_P"3$O\ \51_PJWPQ_T#/_)B7_XJ@#Y_HKZ _P"%6^&/
M^@9_Y,2__%4?\*M\,?\ 0,_\F)?_ (J@#Y_HKZ _X5;X8_Z!G_DQ+_\ %4?\
M*M\,?] S_P F)?\ XJ@#Y_HKZ _X5;X8_P"@9_Y,2_\ Q5'_  JWPQ_T#/\
MR8E_^*H ^?Z*^@/^%6^&/^@9_P"3$O\ \51_PJWPQ_T#/_)B7_XJ@#Y_HKZ
M_P"%6^&/^@9_Y,2__%4?\*M\,?\ 0,_\F)?_ (J@#Y_HKZ _X5;X8_Z!G_DQ
M+_\ %4?\*M\,?] S_P F)?\ XJ@#Y_HKZ _X5;X8_P"@9_Y,2_\ Q5'_  JW
MPQ_T#/\ R8E_^*H ^?Z*^@/^%6^&/^@9_P"3$O\ \51_PJWPQ_T#/_)B7_XJ
M@#Y_HKZ _P"%6^&/^@9_Y,2__%4?\*M\,?\ 0,_\F)?_ (J@#Y_HKZ _X5;X
M8_Z!G_DQ+_\ %4?\*M\,?] S_P F)?\ XJ@#Y_HKZ _X5;X8_P"@9_Y,2_\
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MD?RH \XHKOI/AC&2=E^RC_:CS_44S_A5_P#U$_\ R7_^RH X2BN[_P"%7_\
M43_\E_\ [*G+\,5'WM0+?2+']30!P5%>BQ_#2R'^LNKAO]TJ/Z&KL/P_TB/&
MZ.27_?D/],4 >6U+;VLUTVV&&29O2-2Q_2O6H?"NFVZX2TAS_>9 3^9JV^DV
MTD?EM'N0=%;G'TS0!Y''I,K/M=XXW'6,-YD@_P" )EOTJ9-+DW%8+"XO)5ZB
M9EA _P" 9,C?D#7K7V"#*9C#!!A5(X'X4#3[=9!)Y*^:#D2$9;\Z /'+C3]2
MOK>56F<6RC,EOID(10/1RY$A'OM:J<?A.[^SI-8::'B8[?/6/[7(I_W)#"O_
M (XWX]_<U@C5=HC4+Z!1BI* /#;KX8>(=6:**\C:[@/SK]IN#)#'V_X]T, 0
M_1FJ:U^".O-YD3:M%I:=%DT]_*1O9DBCBE(^LY]*]LHH \ATG]F[0[&1)Y;E
MH[@\R_8;>--Y]1+*)9U/NLHKH[?X'>!UN!<7>@0ZU= Y6YUR1]1E7_=>X9RO
MX&N[HH AM;.WL84AMH([>%!M6.) JJ/0 =!4U%% !1110 4444 %%%% !111
M0 4444 %%%% !7GWQ,MV6\LKC'RM&8\^X.?ZUZ#61XHT7^W-)DA7'GJ=\1/]
MX=OQ'% 'D%%/EB>&1HY%*.IVLK#!!]*90 5+;7,EG,LL3;)%SAL ]1CO45%
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MPZ_I7K5% 'C']@ZG_P! Z[_[\-_A1_8.I_\ 0.N_^_#?X5[/10!XQ_8.I_\
M0.N_^_#?X4?V#J?_ $#KO_OPW^%>ST4 >,?V#J?_ $#KO_OPW^%']@ZG_P!
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M $#KO_OPW^%']@ZG_P! Z[_[\-_A7L]% 'C']@ZG_P! Z[_[\-_A1_8.I_\
M0.N_^_#?X5[/10!XQ_8.I_\ 0.N_^_#?X4?V#J?_ $#KO_OPW^%>ST4 >,?V
M#J?_ $#KO_OPW^%']@ZG_P! Z[_[\-_A7L]% 'C']@ZG_P! Z[_[\-_A1_8.
MI_\ 0.N_^_#?X5[/10!XQ_8.I_\ 0.N_^_#?X5-;^%M6NF"I83+[R+L'ZXKV
M&B@#B] ^'J6[I/J3+,XY$"\K^)[_ $_G79@!0 !@"EHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>marketopportunity.jpg
<TEXT>
begin 644 marketopportunity.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" &E I4# 1$  A$! Q$!_\0
M'@ !  $$ P$!              <%!@@) @0* P'_Q  < 0$  @,! 0$
M        !@<"! 4# 0C_V@ , P$  A #$    =_@
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MBX"CE$+F.X5 NTQS)0+=*82&0L9-'2.F4P%GDB'$BPO@F
M
M                                                %N_?FH[#[,^6
M.=/S+&_[C ^.50RQV+_,KD^@
M*(^:<,4G9,O?BW\L<7\<ZWECL<QRNCZ                            %
MA;FI9&YJ@   "ZM;8DK0W0(NZ&C;GOY #YGT  +^T]J]M39
M              &J*R8%K$L.$    #/&&2K=/4UE :+K?K##B4QX    ;9*V
MGFS2 30                           :HK)@6L2PX0.]]\\\X#8,>]7A\
M/'9M;:U;,V]:'^SR!GC#)5NGJ:R@-%UOUAAQ*8\    -LE;3S9I )H
M                     -45DP+6)8<(%2^8[7*IM&$^]'[/V<+^YO1Q[[W"
MQSDD?&>,,E6Z>IK* T76_6&'$ICP    VR5M/-FD F@
M  %J[.O&?0T@   !5O+TF#E]$#7!/(;K[F\1 [&.?7RP  &8\5D>URMIZ!HN
MM^L,.)3'@   !MDK:>;-(!-                    ,%9C%M*-MUH    )]
MXG5]#='6^        -%UOUAAQ*8\    -LE;3S9I )H
M  !@K,8MI1MNM -A<"FL(=GDUW4V/IZ8QYN:L"]_B"?>)U?0W1UO@
M#1=;]88<2F/    #;)6T\V:0":                    8*S&+:4;;K0#;'
M64^@+K:EVZ_K;GKA&G1Y^+4IC0GWB=7T-T=;X        T76_6&'$ICP
MVR5M/-FD F@                   &"LQBVE&VZT [?GGU/3   3[Q.KZ&Z
M.M\        :+K?K##B4QX    ;9*VGFS2 30            4GT\X<ZO.
M  '(G?C=4##^41W4_94"    $S\KH[N:BLX        :+K?K##B4QX    ;9
M*VGFS2 30            03V.5YW;TJ     =G'+U'_G6\@
M  -%UOUAAQ*8\    -LE;3S9I )H            ()['*\[MZ5 !FO#Y)9^S
MCT?3SO;2V;(V<,9Y/&QV<<O4?^=;R                T76_6&'$ICP
MVR5M/-FD F@            @GL<KSNWI4 &Q*"RVCX[5+V]*Q,W?9XBRZ)#L
MXY>H_P#.MY                :+K?K##B4QX    ;9*VGFS2 30
M    03V.5YW;TJ #L8_>OE\  '9QR]1_YUO(               #1=;]88<2
MF/    #;)6T\V:0":            "">QRO.[>E0    #LXY>H_\ZWD
M          !HNM^L,.)3'@   !MDK:>;-(!-     /PP6F,6     S%BTBN7
M7]Q&?0T=3EE0(    ?;Y]W4U-90               &BZWZPPXE,>    &V2
MMIYLT@$T     XOGEI_1E&     >BZB;BFKD](
M#1=;]88<2F/    #;)6T\V:0":     <7SRT_HRC!D%QNM+L=[T4]GE6MTN5
M)/#[,DZ70C;?T\5I5&!Z+J)N*:N3T@                      -%UOUAAQ
M*8\    -LE;3S9I )H    !Q?/+3^C*,$O\ .WLJX7+L7Y9&JE]\K[Y'5DW1
MW(DZ6KBM*XL/1=1-Q35R>D                      !HNM^L,.)3'@   !
MMDK:>;-(!-     .+YY:?T91@ '[\?GT !Z+J)N*:N3T@
M       -%UOUAAQ*8\    -LE;3S9I )H    !Q?/+3^C*,     ]%U$W%-7
M)Z0                      &BZWZPPXE,>    &V2MIYLT@$T     XOGE
MI_1E&     >BZB;BFKD](                      #1=;]88<2F/    #;
M)6T\V:0":     <7SRT_HRC     /1=1-Q35R>D
M !HNM^L,.)3'@   !MDK:>;-(!-     .+YY:?T91@    'HNHFXIJY/2
M                    T76_6&'$ICP    VR5M/-FD F@    '%\\M/Z,HP
M    #T743<4U<GI                       :+K?K##B4QX    ;9*VGFS
M2 30    #B^>6G]&48    !Z+J)N*:N3T@                      -%UO
MUAAQ*8\    -LE;3S9I )H    !Q?/+3^C*,     ]%U$W%-7)Z0
M              &BZWZPPXE,>    &V2MIYLT@$T     XOGEI_1E&     >
MBZB;BFKD](                      #1=;]88<2F/    #;)6T\V:0":
M   <7SRT_HRC     /1=1-Q35R>D                      !HNM^L,.)3
M'@   !MDK:>;-(!-     .+YY:?T91@    'HNHFXIJY/2
M         T76_6&'$ICP    VR5M/-FD F@    '%\\M/Z,HP    #T743<4
MU<GI                       :+K?K##B4QX    ;9*VGFS2 30    #B^
M>6G]&48    !Z+J)N*:N3T@                      -%UOUAAQ*8\
M-LE;3S9I )H    !Q?/+3^C*,     ]%U$W%-7)Z0
M   &BZWZPPXE,>    &V2MIYLT@$T     XOGEI_1E&     >BZB;BFKD](
M                     #1=;]88<2F/    #;)6T\V:0":    "F'P,5))P
M0    ,D.#V:WX^H                      $$=CEV9M:P    EOF]"3^?N
MU [0                                              ,!IM#Y5Y70
MJ?S.G^N'3SPK&O[?;#+H^_A:WOY9B123<GT :\9W"[_T-SN>>5Y>&Q3<OG<*
M)Z^5^:&[%O3YMVZFU>^IMS)R>H  !"?8Y-E;NI1?F-X^.QD5P>V   ('[/(Z
M'KYTO/#IYX?GQ^?7Z5SQ]J5Z>51PRR0X'>   X??F+DCC]4\O2VMGPN?6]LD
M.!W@     !;_ +>-P>/L+=]O&U]C7H^QXVAM:MU:VU]\/OVQRY??G6R^3!RN
MG^@ M/:U8SW]*Y-;WZ7KA\WRV]K7NC5V16O'TH7MY75K;-]:>V  !:>UK6?M
M:W6^_.]CE*_,Z(   C_>TK?]_'EC]NKP]J9]Q^6>/0R^=;/'[8?>\^RAS>B
M  +?]_".M[2X?58\\Y0YO1  M_V\;@\?8   8OR#B7?K>X
M   M78\+JU_<                 4CU\\B.'V
M([WM.1-'<
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M\/T$?;VE(.CN@           1OOZ4;;^E+/,Z%\:FT
M                                 /_$ #(0  $"! 0% P0" @,!
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M/P'_ /!I,Y1,_LB9VC_UG_S]G[ML\HB9^<LH'Y_W3^WP=,_LR*?FZ9Z/\_\
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MI'8[WR.\3>]8GLL_6\<\DW_LY?\ ;X&$4:<UXO7%OL"QF+5EJ3 2A7"8#<Q
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M!C*.@&"/1'[MNYO!O,_]1:_&V[F\&\S_ -1:_&V[F\&\S_U%K\;;N;P;S/\
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M3 W!(,66C5!!LM^+-&P:^"/A6DG=;IH%<8KI=NV3:(:L3GN4RR'9F$N9H6<
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M1(E9 "PW6YW8BI4 ([L)B,.6(J@76(8NT5R7YJEK7&MB3WNI)+TDIDJT@L(
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M*9)L?*F>O.' EEC" 2R.)2R=^FM1,&P$D._XVPUPPP-$&&H(+2)F$+Z1#9P
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M-6L29UH,R7DP\ATU]VL<!L8@.K"P1<"=2R:H;$VKDSK 1*>OE7Z)@H.%_)F
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MO/+5.9%)3)$13\Y%,Y_-$> 8@8B(_P"*/__$ %,1  ("  ,#!0D,!P4&!04
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M"2PZ%L<JY68^JV5B%ZCW:[=/6V-VLF@P9$V2 # %,E,Z0/DAA]C?UL1X6*R
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MR)5M9BX$$2BW1+48S,DJ2[K:UB;K<,$TUE[T:HGN%DO.*0L6C(=<@.E+(3D
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M-4%QD^((,D!14F$E,W-VLL(7)D)@<H&U1&)P>,<G0U-5=X*AML;_V@ ( 0$
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M-(]GZ%IT5_/2]_ES5JR('M6IZ+N]276D]/M9JR2S&F.FN">I;-5%-QT)*T:
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MU5ZHK7;$*V8D5K217F%J*Y&,Y;SV#)TE<C5*%T-V@M$7KE@J!*RS7Z!(=DD
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M><.#+<W(%KE\QZ(4^<P.4X9A'Q2S'.=F"5]O5OC4\;9$[!1J"N-TI;V) +/
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MLSL*5K:5U9$\LP!FP=63P:>-V^ LL$'S)8WXWQAOSC?C;&6K!);&0$9QU#0
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M5_< M_$-!Q<W=!<A-H(:!>=**;/!S.SXT3EK9=T$QUAY3UGN><,A65?_ )F
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M7,L+\FJS+<=Q!=L&HR:K5,$7B)#UF'=85+,OZ";T8)+X!#6<_P"$+B9X?;@
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M2)$B1(D2)$B2UW\@KI!=.O\ "&D$E>T@DDJZW#J+29'<E*FTX\29CNWE=G
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M1++O^J']#C5,!*09<9U_1C'SNV4IK;L:8-!)+ZI5'+__V@ , P$  @ #
M$                                              !  ! (()!)( !
M)(!(! (!)   )!())           !(  ( !! ((( )!)!(( (((!)(!)!!(
M          ()!) ! !) )  !! ) !! ()   (
M
M                                           !W.N0
M                         W>V*                            !K;
M;;;< &DDDDE                            $    !0!0    *
M                     @'8E@* *    !0
M  $!V1F!0!0    *                    *22223P K:+;;2 *    !0
M                 !     .        !0    *                    (
M "&4!P        *    !0                   ! !26P.        !0
M *                    ( .  !P        *    !0            -MMM
MMM0!4DDDDB        !0    *            !@    (
M*    !0            , )4L!                !0    *
M!@ D, (                *    !0            ,    !
M    !0    *            !@    (                *    !0    !$D
MDDDD0#MMMMMP               !0    *     &     ,
M         *    !0     P-MF@!@                      !0    *
M  &!,LKP,                       *    !0     P !@ !@
M             !0    *     &     ,                       *
M!0     P    !@                      !0    *     &     ,
M                  *    !0     P    !@                      !
M0    *     &     ,                       *    !0     P    !@
M                      !0    *     &     ,
M    *    !0     P    !@                      !0    *     &
M   ,                       *    !0     P    !@
M        !0    *     &     ,                       *    !0
M  P    !@                      !0    *     &     ,
M             *    !0     P    !@                      !0
M*     !)))))+))))))))))))))))))))))) VVVVW)
M                              ,Q!C+0 (+8*J2   !-P   -1RO(P
M F6P      &!$?.X8 !3OU:V@   D8    :>&+Z    /:  &   !K;;;;;;;
M;;;;;;;;;;?;;;;;;;;;;;;;;;;;:0                      0
M
M    =96QN+W60@. !"^\7VWM;J                   !?YYFKY:/V!< &<
MPH#C:^%0                    %8  ! "            (R
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M?4X;ZG#?4X;ZG#?4O*;&TPHP:=QOW !\"(;2\AD?/NP000:GF-OF-!;ZT![
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M86J#D&_JH6_1=7! 05,9VJ.#+\BB58?*98YL-2PM9-.>4C@$#&/&F\84>&9
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M'1-\)8&48?2Q[Z-LOF#&)K>^8-*IF?1#W]&#"C:78<P&*/\ ?6' >*\;P?Z
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M._\ ;ZU_;.L6B/;RS=.M$^?;<V?;<M((A)X2"7"GJ'16PLY^"R?'WG9X$S
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B\OW>9OO#*DXS!TB"[,[X7'ZD:2?YY5W&.Y%;;P3(63__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>slide1a01.jpg
<TEXT>
begin 644 slide1a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0 \ # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-']FXCLOO#^T*'F?IU17YB_\/._BE_T /"'_ (!W7_R31_P\[^*7_0 \(?\
M@'=?_)-']FXCLOO#^T*'F?IU17YB_P##SOXI?] #PA_X!W7_ ,DT?\/._BE_
MT /"'_@'=?\ R31_9N([+[P_M"AYGZ=45^8O_#SOXI?] #PA_P" =U_\DT?\
M/._BE_T /"'_ (!W7_R31_9N([+[P_M"AYGZ=45^8O\ P\[^*7_0 \(?^ =U
M_P#)-'_#SOXI?] #PA_X!W7_ ,DT?V;B.R^\/[0H>9^G5%?F+_P\[^*7_0 \
M(?\ @'=?_)-'_#SOXI?] #PA_P" =U_\DT?V;B.R^\/[0H>9^G5%?F7:_P#!
M3WXEI<(;GPYX4E@!^=(K:Y1B/9C.P'Y&OIK]FC]N#0/CQJZ^'-3TX^&?%+JS
M6]OYWFP7849(C? (< $[".@X)Y QJ8&O2CS26AI3QE&I+E3U/IJBBBN [0HK
MY(_:(_X* Z)\)?$EUX9\+Z2OBC6[-S%>SRS&*UMI!UC! )D8'@@8 /&2<@?/
MTG_!3SXGF1C'X?\ "*ID[5:TNB0.P)^T#/Y5Z%/ 5ZD>9+0X9XRC3?*V?IQ1
M7YB_\/._BE_T /"'_@'=?_)-'_#SOXI?] #PA_X!W7_R36O]FXCLOO(_M"AY
MGZ=45^8O_#SOXI?] #PA_P" =U_\DT?\/._BE_T /"'_ (!W7_R31_9N([+[
MP_M"AYGZ=45^8O\ P\[^*7_0 \(?^ =U_P#)-'_#SOXI?] #PA_X!W7_ ,DT
M?V;B.R^\/[0H>9^G5%?F+_P\[^*7_0 \(?\ @'=?_)-'_#SOXI?] #PA_P"
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M=?\ R31_9N([+[P_M"AYGZ=45^8O_#SOXI?] #PA_P" =U_\DT?\/._BE_T
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MZX#]H+_D@GQ*_P"Q9U+_ -)9*^ I_''U/M:GP,_$BBBBOOSXH**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(?S(/9S[,X"BN_\ ^&??BE_T37Q?_P""&Z_^-T?\,^_%+_HFOB__ ,$-U_\
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M .-T?\,^_%+_ *)KXO\ _!#=?_&Z/:0_F0>SGV9P%%=__P ,^_%+_HFOB_\
M\$-U_P#&Z/\ AGWXI?\ 1-?%_P#X(;K_ .-T>TA_,@]G/LS@**[_ /X9]^*7
M_1-?%_\ X(;K_P"-T?\ #/OQ2_Z)KXO_ /!#=?\ QNCVD/YD'LY]F<!17?\
M_#/OQ2_Z)KXO_P#!#=?_ !NC_AGWXI?]$U\7_P#@ANO_ (W1[2'\R#V<^S.
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MNI>!=(N/$OA6ZE:6"WL09+JS!.?*:/[S <@,N<@<X/7PW_AGWXI?]$U\7_\
M@ANO_C=?<T\12J14HR/D)T:E.7*XG 45W_\ PS[\4O\ HFOB_P#\$-U_\;H_
MX9]^*7_1-?%__@ANO_C=:>TA_,B/9S[,X"BN_P#^&??BE_T37Q?_ ."&Z_\
MC='_  S[\4O^B:^+_P#P0W7_ ,;H]I#^9![.?9G 45W_ /PS[\4O^B:^+_\
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M ,;H]I#^9![.?9G 45W_ /PS[\4O^B:^+_\ P0W7_P ;H_X9]^*7_1-?%_\
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MXB3\6= H_$U]^_L3_LAWOP1^U>+/%P@/BN]@\BWLX7$@L(3@N&8<&1B #MR
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M $'_ !?_ .!EK_\ (U'_  [$^%O_ $'_ !?_ .!EK_\ (U'L\+_._N#GQ/\
M(OO/HW_A</@+_H=_#G_@VM__ (NC_A</@+_H=_#G_@VM_P#XNOG+_AV)\+?^
M@_XO_P# RU_^1J/^'8GPM_Z#_B__ ,#+7_Y&H]GA?YW]P<^)_D7WGT;_ ,+A
M\!?]#OX<_P#!M;__ !='_"X? 7_0[^'/_!M;_P#Q=?.7_#L3X6_]!_Q?_P"!
MEK_\C4?\.Q/A;_T'_%__ (&6O_R-1[/"_P [^X.?$_R+[SZ-_P"%P^ O^AW\
M.?\ @VM__BZ/^%P^ O\ H=_#G_@VM_\ XNOG+_AV)\+?^@_XO_\  RU_^1J/
M^'8GPM_Z#_B__P #+7_Y&H]GA?YW]P<^)_D7WGT;_P +A\!?]#OX<_\ !M;_
M /Q='_"X? 7_ $._AS_P;6__ ,77SE_P[$^%O_0?\7_^!EK_ /(U'_#L3X6_
M]!_Q?_X&6O\ \C4>SPO\[^X.?$_R+[SZ-_X7#X"_Z'?PY_X-K?\ ^+H_X7#X
M"_Z'?PY_X-K?_P"+KYR_X=B?"W_H/^+_ /P,M?\ Y&H_X=B?"W_H/^+_ /P,
MM?\ Y&H]GA?YW]P<^)_D7WGT;_PN'P%_T._AS_P;6_\ \71_PN'P%_T._AS_
M ,&UO_\ %U\Y?\.Q/A;_ -!_Q?\ ^!EK_P#(U'_#L3X6_P#0?\7_ /@9:_\
MR-1[/"_SO[@Y\3_(OO/HW_A</@+_ *'?PY_X-K?_ .+H_P"%P^ O^AW\.?\
M@VM__BZ^<O\ AV)\+?\ H/\ B_\ \#+7_P"1J/\ AV)\+?\ H/\ B_\ \#+7
M_P"1J/9X7^=_<'/B?Y%]Y]&_\+A\!?\ 0[^'/_!M;_\ Q='_  N'P%_T._AS
M_P &UO\ _%U\Y?\ #L3X6_\ 0?\ %_\ X&6O_P C4?\ #L3X6_\ 0?\ %_\
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M+U7_ *+'>?\ @G?_ .2Z/^'9>J_]%CO/_!.__P ET>QP_P#S^_\ )6'M:_\
MSZ_%'W717PI_P[+U7_HL=Y_X)W_^2Z/^'9>J_P#18[S_ ,$[_P#R71['#_\
M/[_R5A[6O_SZ_%'W717PI_P[+U7_ *+'>?\ @G?_ .2Z/^'9>J_]%CO/_!._
M_P ET>QP_P#S^_\ )6'M:_\ SZ_%'W717PI_P[+U7_HL=Y_X)W_^2Z/^'9>J
M_P#18[S_ ,$[_P#R71['#_\ /[_R5A[6O_SZ_%'W717PI_P[+U7_ *+'>?\
M@G?_ .2Z/^'9>J_]%CO/_!.__P ET>QP_P#S^_\ )6'M:_\ SZ_%'W717PI_
MP[+U7_HL=Y_X)W_^2Z/^'9>J_P#18[S_ ,$[_P#R71['#_\ /[_R5A[6O_SZ
M_%'W717PI_P[+U7_ *+'>?\ @G?_ .2Z/^'9>J_]%CO/_!.__P ET>QP_P#S
M^_\ )6'M:_\ SZ_%'W717PI_P[+U7_HL=Y_X)W_^2Z/^'9>J_P#18[S_ ,$[
M_P#R71['#_\ /[_R5A[6O_SZ_%'W717PI_P[+U7_ *+'>?\ @G?_ .2Z/^'9
M>J_]%CO/_!.__P ET>QP_P#S^_\ )6'M:_\ SZ_%'W717PI_P[+U7_HL=Y_X
M)W_^2Z/^'9>J_P#18[S_ ,$[_P#R71['#_\ /[_R5A[6O_SZ_%'W717PI_P[
M+U7_ *+'>?\ @G?_ .2Z/^'9>J_]%CO/_!.__P ET>QP_P#S^_\ )6'M:_\
MSZ_%'W717PI_P[+U7_HL=Y_X)W_^2Z/^'9>J_P#18[S_ ,$[_P#R71['#_\
M/[_R5A[6O_SZ_%'W717PI_P[+U7_ *+'>?\ @G?_ .2Z/^'9>J_]%CO/_!._
M_P ET>QP_P#S^_\ )6'M:_\ SZ_%'W717PI_P[+U7_HL=Y_X)W_^2Z/^'9>J
M_P#18[S_ ,$[_P#R71['#_\ /[_R5A[6O_SZ_%'W717PI_P[+U7_ *+'>?\
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MTLAZ*B@EC^ !JQ7%?&Z1H?@OX^=&*.OA_4&5AU!%M)@UP17-)([).R;/A_\
M91\'O^U1^T/XL^*?B^W%[IFF3K+;6<PS&9F)%O'@\%8HTR1Z["<Y-?HK7Q]_
MP3#MT7X&^(IP/WC^(YD8^RVML1_Z$:^P:[L=)NLX](Z(Y,'&U)2ZO5A1117G
MG:%%%% !1110 4444 <SX8^)7AOQEX@\1:'H^IK>:KX?F6WU.V\J1&MW8$J,
MLH# [6Y4D<=:/"_Q(\.>,]=U_1]%U-;[4=!F6WU&)(I%$,A+ +O90K\HX.TG
M!4@X-?-E[KEY\*_$'BOXA:;83:E(?%&I^'[FSMUW/*9XX6LSCOBY1(_I<,>U
M:5K&OP93XDPRS7TTMGHVAI=WEG.MO(\TLEQYT[S%6\F,O([/*%+(A9EY KN>
M'C;3RM^%_P SC59]?G^A]3UC1^*K23QA/X;$<WVZ&PCU!I"H\KRWD>, '.=V
M4/;&,<U\IV?CS6+GPI\1K+2/$<D%E;WWA\V-_H_B>YUQ83<7BQ3F"^N8PSJ0
MF"F&C#!UYRZUTOQ0M-4\!_$*:WT6YU=/#$.@6S:_J,.H7%YK%O9&ZN"[V[RE
MW)!.6;=N2,-Y8W;=J^KV=F]?^&_S*]O=72_K7_(^H*JV.J66J&Y%G=P79MIF
MMY_(E5_*E7!9&P?E89&0>1D5\F>'O&VL:MXSW#QAH>G:T/$(CL(]8\>74#W&
MG><JPQQZ686AG6:V(V2[V9VD#[]PP)%F'@CPW\8X?#&K7Z^+K?Q"QN+&?7+J
M2>#39)+;S+KRG:4H/+9S]I6)F &03M H^K/9O47MUO8^N:P+#QE9:CXUUCPQ
M'%<+?Z7:6M[-(RKY3).TRH%.<D@P/G('48)YQ\VQ^+-6A\#>,Y]%\8:3<^'P
M^FK<GP]XUN?$EYI,3W(2\N1<S1K)"I@RP&XA#$[C;S7:? N;0KCXU?$*3PSK
M=WXAT0Z3I @OKF_EOT)$E[O6*YD+-,@;/S;W 8NN1MVK+H<L92?3_@?YE*MS
M-)=?^#_D>^T5XQ^T-XRM= NO#>F7EV=/@OS<2&XO?$TOAW3R8U7"R7L*-+YG
MS92)2%8!RV=H%>8P^-KK4OA#X"U37O&^GZ?+&=0BFT?6O%USH$VH+%.\44@O
M8PMQ(\00*5=,/YFY]K@4HT'**EW_ .#_ )#E649./;^OU/K6BO*O%WCR'2_V
M?XO$<=IKFFVTUC:E89[DQ7MLDA1?](N)/,:-5#?O)OF=5W.#N ->,Z%XXU:^
M\-_$JPTOQ%)#8VT^B/87VC^)KG7%A:>X$<S07US&&<'8 4PR*P<<Y<4H4)23
M?G;\O\QRK*+2/KNLO1?$NF^(9M4AT^Y^T2:9=M8W:^6R^7,$5ROS 9^5U.1D
M<]>M>>?#6"?PW\6_&_A>+4]4U#1[73M,U""/5M0FOI(I9C<I+MDF9G"L($.W
M.T'. ,UE?"GQ]X8T?QY\1- O_$>DV6NW?BN0V^EW%]%'=3;K:V"[(BVYLD$#
M YP:GV6]M;)/[Q^TVN=1IOQ^\$ZK<V<<5_J$$-Y<FSMK^]T:]M;*68,RB-;J
M6%82Q964#?\ ,PP,D@5+KGQQ\+>'->71KY/$":C)))%#%#X8U.83L@R_E,EN
M5E '.4)&.<UX=HGCSPQK/[,-YX&LM3L=<\8ZC#J&G6OAVQG2>]%Q)<3^6S1*
M2T:H2LA=@ H7<2*]9\7036OQ4^#L-Q)YUQ&-1223^\PLL$_B:VE2A&5FGU_#
MY&2J2DKJW3\?F=UJ7C;1]&L]%N;^XELX]8N8;.R6>UE21YI03&C(5W1DX.=X
M7&,'%;M>=_&;5+W2X?!9LKN>T-QXIT^WF\B5D\R)G8,C8/*GN#P:\LOY-4T^
MWF\6IXDUZ34HOB#'I45O)J<QLTLY-16W>#[.&$;+LD8@NK,IQM8!5 RC2YTF
MF:2J<K:/H/7?$VF^&5L#J5S]F%]>16%O^[9M\\APB?*#C)'4X [F@^)M-'B9
M?#YN?^)NUF;\6_EM_J X0ONQM^\0,9S[5P7[04AL?#OAS5Y(Y&T_1_$5AJ-_
M-&A;[/;)(?,F8#G:H.6/8 D\ FL;2_'&@^(OC%J_C#2=5MM6\*Z)X6:WO=8T
M]OM%JDOG^<8UDCRKNL:;F522 RY'S"B-/FCS#=2TN4[_ ,4?%+PWX-U:'3-3
MO+A;Z2#[4T5I87%UY$&[;YTQAC80QYS^\D*K\K<_*<=4K!E!!R#R"*^=_BUX
MUT&PO(_'7A'QS#H?C.;1(9+'2M0@+6_B.V8M+;P"W=5ED<LS*I@82(9,,#D+
M7LWA?QQ8>)+^]TD.8=?TV"VEU/3RCYM&GCWHN\J%;@-]TGISBE.GRQ4DO4(U
M+R:9T=%%%8&P4444 %%%% !1110!SWC[P'HOQ,\(ZEX;\06:WNEWT1CD1OO*
M?X74_P +*<$'L17Q-^POKFJ?!_X\>.?@QK%QYMN))IK7.0IN(2!O0=A)"0__
M &S6OOJO@IXQ;_\ !56+R_E$T9+@=_\ B2G_  %>EA7S4ZM-[6;^:.#$+EG3
MJ+>]OO/O6BBBO-.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@S]E7_ )/\^,W_ %RU
M;_TXV]?>=?!G[*O_ "?Y\9O^N6K?^G&WK[SKT,=_$7HOR.'!_ _5A1117GG<
M%%%% !1110 4444 %5;'2[/2UG%E:06@GF:XE$$2IYDK'+.V!RQ/4GDU:HH
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MXD?>=%%%>>=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGZF&%_@1] HHHKB.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4U?L)[?UT_S1'MH[_P!=?\CVJ+5;*?4KC3X[RWDO[>-)9K595,L2.6",R9R
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MT;^SB+OS3.+DQ?:O.V^3]H^?'E;L';N[UZU11[60>SB>2K\#KWS9=(/B*!O
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M?!EU_P I5;3_ *Y'_P!,K5Z&#_Y>?X6<6*_Y=_XD?>=%%%>>=H4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY!_PV_ZZZA_*VK[SKX'_ ."H]P+Z\^&.DPX>[=KY]F>0&-NJ\>Y#?E7H9?\
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M"A3?G++T7D$$<<UT_B#Q%IGA/1[G5=8OH=.TZV4-+<3MM5<D #W))  '))
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M/]HGB#HDB;0(V++E'XPS"I5!R5]O7Y?YC=91=MSZBU/5++1;&6]U"[@L+.(
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M^O%>C@_^7K_NLX<5_P NU_>1]]T445YQW!1110 4444 %%%% !1110 4444
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M??\ R/4?5J?_ #]7XE_6)_\ /MGW717PI_PS'^U9_P!%DL__  >7W_R/2/\
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MGPU:I;77F(6_<OL^?;C#<#!XIWPMK\C^\5L1MS+[CRC_ (>4?"3_ )]_$?\
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M?R/[Q\N)_F7W'B__  \H^$G_ #[^(_\ P C_ /CM'_#RCX2?\^_B/_P C_\
MCM>@?"[X6^ ?'W@^P\0ZC\'O!&BPZE%'=V5O#IUO<R&W= R-+FVCV/@\H-X'
M]XUUO_#/OPM_Z)KX0_\ !#:__&Z<GA8NS@_O0DL1)74E]QXE_P /*/A)_P ^
M_B/_ , (_P#X[3HO^"DOPCDD56B\0Q@G!=K!,#W.)"?TKVO_ (9]^%O_ $37
MPA_X(;7_ .-U6O\ ]FSX4:E#Y4OPX\+HOK;Z3!"W_?2*#^M+FPG\K^\?+B?Y
ME]Q#\+_VE/AO\8)DMO#/B>UN=19=W]G7 :WN>.N(W +8[E<CWKTZOB_XW_\
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M?['_ 'OP#_:O[OXFA_PVI\%/^A]L_P#P&N/_ (W1_P -J?!3_H?;/_P&N/\
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M'_#:GP4_Z'VS_P# :X_^-UG_ /#!WP+_ .A'_P#*O??_ !^C_A@[X%_]"/\
M^5>^_P#C]'^Q_P![\ _VK^[^)H?\-J?!3_H?;/\ \!KC_P"-T?\ #:GP4_Z'
MVS_\!KC_ .-UG_\ #!WP+_Z$?_RKWW_Q^C_A@[X%_P#0C_\ E7OO_C]'^Q_W
MOP#_ &K^[^)H?\-J?!3_ *'VS_\  :X_^-T?\-J?!3_H?;/_ ,!KC_XW6?\
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M[_X_1_L?][\ _P!J_N_B:'_#:GP4_P"A]L__  &N/_C='_#:GP4_Z'VS_P#
M:X_^-UG_ /#!WP+_ .A'_P#*O??_ !^C_A@[X%_]"/\ ^5>^_P#C]'^Q_P![
M\ _VK^[^)H?\-J?!3_H?;/\ \!KC_P"-T?\ #:GP4_Z'VS_\!KC_ .-UG_\
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M/^A]L_\ P&N/_C=9_P#PP=\"_P#H1_\ RKWW_P ?H_X8.^!?_0C_ /E7OO\
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MM>/O@G:W%M\7;JQ\(3)>VM[I9\-R6-I)&]LL5M: O8[ /+(*%6:'!_=@$X4
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M^GG=) T6%2%WD!$>X ,IX]QL]*7Q/\(;>PUKPM::;]JTE4G\.-&D\%NWEC$
M7;M(4@ #'8<5VM%9RJN5BXTU$^8-.^'^F^%_#?PG@U_P/-=^"8]#<ZKHUGH3
MW:QZN\5OLGNK**-G=MJW"[V1MKL,[20:7PG\*)]:USX=V?B/PU=77A:W3Q!+
M;:9JD+RPV=G)/ UC;W*-E1MC VQ29V^6H !C&WZ>HK3ZQ+^OG_F1["/]?+_(
M;'&L4:HBA$4855& !Z"G445R'2%?GQ^VKIR?!+]J+X>_$W21]D?49$GNUC)4
M2R6[HDQ/L\,B(<=>3WK]!Z^#/^"J7_'A\-?^NNH_RMJ]' /]^H]'=?@<.-_@
MN756_,^\ZHZ[J\/A_0]0U2YS]GL;>2YDQUVHI8_H*O5Q'QRS_P *5^(&#@_\
M(]J'3_KVDK@BN:21V2=DV?&__!/OPD_Q2^*'CCXM^(U%YJ,=R8[5I/F"7$Y9
MY7&>A1-J+Z"0^@K[_KY!_P""8<:CX$>('"C>WB2=2W<@6MK@?J?SKZ^KMQTF
MZ\ET6ARX.-J,7WU"BBBN [ HHHH **^6/@I\5M8\$^#O$[>(]3U#Q#-<6T^O
M:,;^X:::8_:9+5[2-F/(65;?"]OM(]JW_A;XLU[X;_#_ ,9/XAUA=?U'3?$7
MV274/$NM+:6D#-;V[,7GDW>5%YCL%6-&P74!<9(ZI8>4;J^WXG/&LG9GT117
MBVB_M&?\)+X:LY=&TK3=7\0WFO/X?M[6QUD2Z=+*D9F>9;Q8<M$(07)$6[<"
MNWO7'>'/C WPS_X6)J&O6&GZ9J^I^-UTY+>^U9(+"*;^S;5B\EXR?+%LC9@W
ME[SE1L#$J$L//56U&ZT-.Q]-45P7PB^+%E\5M,U26!M-:[TN\-G='1]274;-
MF*+(CPW"JF]2CKG*J0P92.,GG-?_ &@H/#GQ&LO#5W#H*QW.IQ:7]G7Q%$VL
M*TO$<IL%C/[HL5.3*&"-N*C[M9^RFY.-M47[2-E*^C/8**\NT_XV/?6^F6IT
M/RO$-UXCF\/RZ7]KR(#$7>2<R!.5^SH)0-HSO1<C.X4/#W[04&L?$RR\(W$6
M@I+?/<PQ0Z;XBBOM0M9(5+E+NV2/;#E5<9663# +WR'[&>NFPO:PTU/8**^=
M/!NJ_P!M:K\$+OSM0N-T^N+YFJWGVNY;:DJ_/+M7=]WCY1@8'.,UU7A_]H*#
M5_B79^$;B+04EOGNH8H=-\117VH6LD*EREW;)'MARJN,K+)A@%[Y%2HR6VMO
M\W_D)58O?^MO\SV&BOG_ ."/Q%U?P_X-^'6FZMX<BM- U@G3+#4X]1$EP9Q'
M)(IEMQ'A(W$4FUA*S?=W*N3MQ_ _QJLOA?\ "GP-ICOH\6H:M)J<D4WB'6%T
MJQCCBNY-Y><I(=Y+H%14).23@ FF\/*[2U_I_P"1*K1LF_ZV_P SZ8HKR^T^
M+$_C;X'ZQXO\,1V3:G;VMVJI]N66V2X@+I(4G6-Q(@*%D;9AQMR%R<97A;XL
M>+KKP[X)TV70=+U/QIKFE_VGM;5GAM/LL<<.^XEE%KE)&>9!Y21, 6/S8&:C
MV,]?(OVD=#V6BO*=6\<#X@? /QGJ+V#Z5?0:?JEA>V+R"7R+F!)8I460<.NY
M3M; R""0IR!B6WQ,U>U\-)H/B'0)- ^W^%[J_P!+NM,U<27+)!$@D60B("WF
M EC92AF4'/S':-S5&3#VB/<:*\>T7XIZW>:7H^C^$_#R^(]4M?#EEJU\VMZR
M;8JDR$0IYP@<S3.8I"251?ER6&[%267QRU3Q@^F)X+\)IJ_V[0X==5]6U,6"
M1QR/(GDMMCE/F90 8!0_-EEP-R]C,/:Q/7:*^>;7XFZKX@\>0^*_!_AR/6$U
M'P7:WY@U/4!8K#&)YV*%ECE)D)^4 +MX8EUXW=#XN_:*M]#\'^'O$5E!H-O9
MZSI2ZM /%'B*+23*K('$,*^7*TDH##(*JHW+\Q)(%>PG=)"]M&UV>RT5Y;IO
MQDU#Q1XLTK2?#GAR*\M+S0[+Q#)?ZAJ/V40V]P\B[-BQ2,TH" A>%/S NF!N
MYOPY^T)XK\30^#I;;X?6L4?BZVFETLRZ^!LDB57<7&+<^7&4WLK)YC'"AHT+
M$*O8S[?BA^U@>[45Y#-\?-OP]TGQ&UCHNC37=W<6%R/$GB"/3K*VN()'BEC%
MP8V:0EXWV;8OF526V< IH?QZG\::/X2/A?0[74M=U^WNKK[-<ZIY-G;Q6T@B
MG<W*12%U,C(J%8_G# G;2]C/>P>UAW/7Z*\6\=?M&#P7K%GH=S9^'])UXZ6F
MIWEMXH\31:9#'N9D6&&7RY/.<LC_ ,*J %)(+8KIO"OQDL?&<D,FFV3M87'A
MV#Q!#/)* Q61I%\IE (!'E\L&(Y]LD=&:7,UH"J0;Y;ZGH=%>%^"OBYXR\=?
M$;PH;32M-MO#&M>$[?7)+2;4F\V#S)(]S@BUR[KO*!-RJP^8E3Q3_ 'Q1O\
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MY5'S$L0#]-_''[=GP!^'=W):ZU\4]!^TQ@[XM-D?4&7'4$6ZR8/MUK.\.?\
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MUOQSJ-OXD\$>;!J^B'44U!IO#LEK:3S7)B@+JKRI,RQD;=R^6S!BP#%>S_\
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MXJW^$NB6WQ(OO&BO='4+RU:VDM#(OV4,PC5Y@H7=YK)%&A;=]U ,#DG$\*?
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M))[ 4 >$?!?]LK1/B-XV_P"%?^,/#6K_  K^)>PRQ^&_$:@"\0 DO:3C"3@
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M[8 Z_+7XV?\ !,SQW8?#_P#;)\$SZDR11:D+C28Y)6VJL\\+)""<'&Z38G_
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M;U#Q-/)=V6GZ790Z'+IKETC_ +37Y[UBA^5MC&.-6YZ/CK7M-87@KP?9>!=
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M ->:?#O]FW_A"?%&@ZO+?Z&9-(CD7[5HN@?8+_4F:,QDWUT9Y3< Y+L-J[I
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M**1T%=#12YI=Q\L>QD^(O"6A^,+:"WU[1M/UNW@E$\46HVL=PD<@! =0X(#
M$\CGDT^3PSH\MN;=])L7@-T+XQ-;(5-P'$@FQC'F!P&W==PSG-:=%+F>UQV1
MS.H_#'P=K'B*/7[_ ,)Z'>Z]$Z21ZI<:;#)=(R8V,)2I8%<#!SQ@8K1F\*:)
M<:3?:7+H^GR:9?/))=V3VJ&&X:1BTC2)C:Q8DDD@Y)R:U:*?-+N+E78X/6O@
MWX=F\)7.A:!I>E^%HIY;5V;3=.CC4K#<"<*53;D$[^_!=CW.=BQ\ Z-X;\/:
MGI?A;2=*\,"]20G^S]/CCB\YDVB1XTVAR..IY QFNDHI\\K6;#ECO8Y[X>^"
M[+X<^!]#\,Z<!]DTNTCMD8($WE1\SD#H6;+'W)J/6?AGX0\1:Q_:VK>%-$U3
M5?*\G[=>:=#-/Y>"-F]E+;<,PQG&"?6NEHI<TKN5]0Y5:UBI:Z396-U>7-M9
MV]O<WC*]S-%$JO.RJ$4N0,L0JJH)Z  =JP=#^%?@OPS?7-[H_A#0=)O+J)H9
M[BQTR"&26-B"R.RJ"RD@$@\' KJ:*.9K9CY5V.3TWX2^!M&L[JST_P &>'[&
MTNHI(+BWMM+@CCFC?;O1U" ,K;$R#P=JYZ"M'POX)\.^![6:V\.:!I?A^VF?
MS)8=+LX[9';&-S!% )P ,FMNBARD]V)1BMD%?!G_  52_P"0?\-O^NNH?RMJ
M^\Z^#/\ @JE_R#_AM_UUU#^5M7=E_P#O,/G^3./&_P"[R^7YGWG7$?'+_DBG
MQ _[%[4/_2:2NWKB/CE_R13X@?\ 8O:A_P"DTE<=/XUZG7/X6?/7_!,3_D@F
MO_\ 8S7'_I+:U]>5\A_\$Q/^2":__P!C-<?^DMK7UY73C/\ >)^IAA?X$?0*
M***XCJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O@RZ_Y2JVG_7(_P#I
ME:OO.O@RZ_Y2JVG_ %R/_IE:O0P?_+S_  LXL5_R[_Q(^\Z***\\[0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP
M?XM?L,_ [XU37%UXD^'VF+JDY+/J>EAK&Y9C_&SPE=[?[X:O>** /S/^(/\
MP1&\):A))-X)^(^KZ("=RVVM64=\O^Z'C,1 ^H8_7K7B^L?\$3?BS#)C2_&_
M@R\3/WKR2[MSC'7"P2=_?_"OV8HH _&71_\ @B;\6YK@C5?&O@NR@[/9S7=P
MW?\ A:WC]N_<_C]._ 7_ ((\_#/X<:E::OX[UBZ^(VH08=;"6 6FG;NOS1!F
M>3![,^T]U.<5]^T4 0VEI!I]K#:VL,=M;0HL<4,*!4C0# 50.     *FHHH
M^#/V5?\ D_SXS?\ 7+5O_3C;U]YU\%_LKL(_V_OC&K':6CU8*#W_ .)A ?Y"
MOO2O0QW\1>B_(X<'\#]6%%%%>>=P4444 %%%% !1110 4444 %%%% !1110
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MMEVL&D,94X52I?<<A>PF'MHGT'5:RU*TU)96M+J&Z6*5H)&AD#A)%.&0X/#
M\$=0:\3USX[:GI?CVQM;>YL-1T6;7HM$EMK/0M0D";W\K?\ VID6OF*Y!:'8
M2"&3<6&:S?ACX^U:]\=>)/!.A"RTVXAUK5=0NK[6;>1UGC-PZJEI&KQ^<58H
M9'#;4!5>6?Y7["7+=A[:-[(]^O-2M-/:W6ZNH;9KF400+-($,LA!(1<GYFPI
M.!S@'TJS7ROX<O/'&J?"SX;7E[K>FZSJ]QXJ*V4]W;3IY6/MJ,T[&:1I@,95
M5\OA0FX??'7S?&'QK%Y>AI'H,WB./QC_ ,(O-?M;3QVC1M9&Z6X6'S6<,H9
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MU^A8(8 @Y%>*?M4_LVV'[17@=+1)(['Q-INZ72[^3.Q6;&Z*3 )V/M&2!D$
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M_O\ PO'I_A7Q;(8M'U&+4O.NMS1-- ;BW\I1$)(XW(V22%3M# 9)'GB_M&?
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ME0K-_"W\F;1K4K?$OO1[=17B/_#:GP4_Z'VS_P# :X_^-T?\-J?!3_H?;/\
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M"3[5JMG:IN>-P,-,$'WXW7(D7GJ6.06V]]\%_P#@H)\/_'VFV]OXLND\&>(
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MOO\ X_5B/0_BYXC_ '\VH'3%?D(TRPX'^Z@)'X\U9_X5O\4/^ANA_P# V?\
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MUFO_ #O[V'L*7\B^Y&=_PP=\"_\ H1__ "KWW_Q^C_A@[X%_]"/_ .5>^_\
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M  P=\"_^A'_\J]]_\?H_X8.^!?\ T(__ )5[[_X_6C_PK?XH?]#=#_X&S_\
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M^T_&?_GUA_.U_P#BJ/M/QG_Y]8?SM?\ XJCZYB/YV'U6A_*>8?\ #L3X6_\
M0?\ %_\ X&6O_P C58L?^"9WPIL[E99=3\4WR#K#/?0!#SWV0*?R/>O1_M/Q
MG_Y]8OSM?_BJJR?$;XE>%?WVLZ&+FU7[[M;X '7.^,X'XTOKF(_G8?5:'\J/
M0?AG\%_!/P>L7M?"/AZTT<2#$LZ O/*/1Y7)=A[$X'85VU<+X!^+VC^.F6U
M;3]3QG[+,P._UV-_%^A]J[JN64G)WD[LZ8Q459*P4445(PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \@^._C2ZMUM/"VE%C>Z@!YWE_>V,=JQC_ 'CG/L/>NK^&OPUL
MO >EH2B3ZM*O^D76,G_<7T4?KU/MY[X?C_X27]HC4YY_WBV!D95/0>6!&/R)
MS]:]VH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M R54L>2!S5SQ9\1O"_@/PF?$_B+7]/T7PZHC)U2]G6.W D("?.3CYBPQZY%
M'1T5SW@7XA>&?B=X?CUWPEKVG^(]'D=HEOM-N%FB+J<,NY3C(/:NAH **XW1
M_C)X%\0>/-0\$Z;XLTF^\7:>K/=Z+!=(UU %VAB\8.1C<N?J*[*@ HK/USQ!
MIOAG3_MVK7L.GV7G0V_GW#A4$DLJQ1J2>A9W11[L*T* "BFR2)#&TDC*B*"S
M,QP !U)-<#_PT)\+/^BE^#__  ?6O_QR@#T"BN7\.?%/P7XPN3;Z#XOT'6[@
M=8M-U."X?\D8GN*ZB@ HHHH **** "BBB@ HJE'K>G3:M+I:7]J^IQ1B:2R6
M93,B' #E,[@O(YQCD5=H **** "BBB@#P[X8?\ET\7_[MU_Z41U[C7AWPP_Y
M+IXO_P!VZ_\ 2B.O<: "BBB@ HHHH \BT/\ :"CU3Q'\0M&N-">QN/"ZW$MF
M[709=5C@4>:R_+F,HS1A@=V/-0\YKJH_BUX9T_PCX=UWQ)K>D^%4UJTBNH(]
M4U"*$$O&KE%9RN\KN'0?@*\D\:?!7Q3JO@_QI>:1:1P>+8O$=_JFB+),@6[M
MIX$AEA9@V%$L>\88C#*A.,9J.\^%_C/0]4\/:I;Q>(7B/A&RT*[M?#3Z0]Q!
M+#DR)(-04QF-M_6)LDQ\@C:1W.G2EL[?,X^>I'=7/=/%'C[PSX(BMI?$7B/2
M= CNB5@?5+Z*V$I&"0I=ANQD=/44>*/'WAGP1%;2^(O$>DZ!'=$K ^J7T5L)
M2,$A2[#=C(Z>HKQ_1? ^N?#;5H;FQ\':KXSTFZ\*6>B06MY>V O;!H6E+0W.
M^1(BD@E0,T)<9A^XPVDX=]\,?B)X9\,Z)X9T^&[N[>W\+1Z0VH>'?[,5I+@;
MPT5W)?*S_95#+L\A"PS(2N=HJ%2A=>]^/]6_4MU)_P I[MXO^('A_P &0PIJ
MNO:5I=]>(_V"WU"\CA:Z< 86-68%SEE&%Y^8>M<I\._BU=^)-%\)WFLVNFV,
M.J>%8_$%Y?K?QQ+#(1&706[L9!$ Y;S"2JX )R:X32? /BWPS'8_:/"!\4G4
M?!%CX<EA>\M@FGW$0D$R3F1^8'\U2S1"4GRC\A^7-#0/ >JI-X4\%W:1V6M)
M\*[C2IT=PZP3%K>+YF3((# \C.<'&:M4Z=K7N3[2=[V/H'4O&.@:*JMJ&N:;
M8JUN;M3<W<<8, 95,HW$?(#(@W=,NH[BK%]XBTK2[@P7FIV=I.+:2\,<]PB-
MY$>/,EP3]Q=RY;H-PR>:\4T_P+X@^(7BK2/^$F\'3Z%X?C\'WWA^]6^O+:>1
MYIGM<[5AD<>65C?:Q(8E6W*GR[LW3?A_\1&\%^(]3U+2K:[\9+;V&B64-PUM
M/YUG:NK/=1!V,2S2.TLB"4X#)%O P16?LH=9?U_6Y?M)?RGMFD?$3PKX@T>;
M5]+\3:/J6E0S"WEOK._BE@24E0$:16*AB73@G/S#U%<_XD^/?@3PYX'U#Q8/
M$NEZMH]E,MM))I=_!-F9B,1 ^8%WX.[:3G )KR:'X6>-/$5G\1#K.F:I?Q:\
MVBK;Q>(YM,:YGC@N"9UE2T"P !.@^;<I').57H?B;\+?$6N7WQ4?2-+C>'6-
M"TJ#3U$T<8N;BWEN&DCP3\IV&)0S87D#. <6J=)2LY?CZ?YO[B?:5'&Z7]:_
MY?B>UZ+KFG>)-+M]2TF_M=4TZX&Z&\LIEFAD&2,JZD@C((X/:L_3?'WAC6O$
M%YH.G^(])OM<LPQN=,MKZ*2Y@"D*Q>)6++@D Y'!(J]I.H76JZ/#=3:9<:/=
MRH2;&_:)I(FY #F)W0^ORL>#Z\5\^>!_ _Q%E\>> KW7-,U*RLM$EO/MMN6T
MF'2[?S+>1%%C';#SS%N('[YMP!3*L=Q7&$(RYFW:WG_5S24W&UE>Y[EI'Q$\
M*>(-8;2=+\3:/J6JK"+@V-G?Q2SB(@$/L5BVW#+SC'S#UKE-<^-&EGQ_X3\-
M^'M9T369[[5IM.U:WM[I)Y[,):7$H!5'_=MO@V_.#P&&,\CD?#GPEUK1]!^#
MMM#I,>G7&AWEW-JK6[PJ;?SK.Y1GR&^<M+)&3MW$G!/0D97@GX>>++6]^#NG
M7G@I=/3P1/<1W^MO>6K+<![.>(RVZH[2,DDA1WWB-MS)\C?,4U5.FKN_?MY_
M\#[S/GJ.RM_6A[SXD\6:'X,TX:AX@UG3]"L"XC%UJ5TEO%O.<+N<@9.#Q[55
MU;XA^%=!T.RUO4_$VCZ=HU[M^RZC=W\45O/N7<NR1F"ME02,$Y S7'?&&Q\7
M3:WX<NO#ME?RV<"W*W5WH"::=5A9@FQ8VO\ ]T(6PV_;\Y*QXXS7G_@7X?\
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M[3J$,CN1++L1 X.<HP$4>"F"I4,,'FL^V^#?A*WTJ_L&T^XO(K^XM[FZGO\
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MH;5OL9T_SR[8\@N'*;<[?O '.,^^*70_$VF^)&U$:=<_:#I]X]A=?NV7RYT
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M_@D_^T\/@U\;F\#:U=B'PKXU>.V5I6PEMJ R+=_829,1]2T9)PM '[6>+/\
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MRI+$[1RHP970X*D<@@]C7[(?\$Q?VL+O]IGP/XE^$'Q-E'B35]/TYFBNK_\
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M_!7]CF\^$_[6GQ+^,DOBB#4K;Q?!<0II"6;1O;>9/#+DR%R&QY6/NC[U?3U
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MC2-<UG39O#VD)H:-&UN_VRT7852</"PSE =T>P\GG'%>BT4>TEW#DB<1X?\
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MBB@ HHHH **** "BBB@#P[X8?\ET\7_[MU_Z41U[C7AWPP_Y+IXO_P!VZ_\
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MPRK*PX(((((KY];2;RT^)GQROCXAOKF*#2;>5M+N+>SDMI0UI.45U,&XJF,
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M089()(VD5'*'9*Q5@C891QS7.^-_"/Q%\70:#.\NG((7N&O]"TWQ#?Z5$Q;
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M]:AS5$MCMK[XR>$-/\0:GHL^JN+[2UWZCLLYWAL4,(F#SS*ACB0H<JSL Q#
M$E2!J^$?'&F^-H9Y=-AU:*.':2VIZ/>:?N# D%/M$4>\<=5SCC/45RF@?#6]
M\-S?$)OLNFZW::X;<6>GWTS+'-''8Q6[1W!\I@H8QMG:KC:>G:D^$'@;Q'X-
MNM4_M.6.QT:6.&.RT.+7+K64MV0,'D6YNHTD4,"BB$#8OEY'+$5$HT^5M/73
M_@EJ4[JYZ91117.;!1110 4444 %>'?M.?ZCP[_O7'\HZ]QKP[]IS_4>'?\
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M\$_BI+/(DAT'42QRJ\>6QSQ[HW;KCZU[]9WD&H6L5S;2I/;RJ&22,Y5@>X-
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M/"OP]\>ZOXHU&]U>VUN*UG\(76BH_B&72E,=R[QE41-/7 AZX+%FX887C?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT),W_@#<5[;10!XE_P +8^(7_0DS?^ -Q1_PMCXA?]"3-_X W%>VT4 >)?\
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M W%'_"V/B%_T),W_ ( W%>VT4 >)?\+8^(7_ $),W_@#<4?\+8^(7_0DS?\
M@#<5[;10!XE_PMCXA?\ 0DS?^ -Q1_PMCXA?]"3-_P" -Q7MM% 'B7_"V/B%
M_P!"3-_X W%'_"V/B%_T),W_ ( W%>VT4 >)?\+8^(7_ $),W_@#<4?\+8^(
M7_0DS?\ @#<5[;10!XE_PMCXA?\ 0DS?^ -Q1_PMCXA?]"3-_P" -Q7MM% '
MB7_"V/B%_P!"3-_X W%'_"V/B%_T),W_ ( W%>VT4 >)?\+8^(7_ $),W_@#
M<4?\+8^(7_0DS?\ @#<5[;10!XE_PMCXA?\ 0DS?^ -Q1_PMCXA?]"3-_P"
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MINM0N$@B!P3C<Y Z G\#0!I45S/A/XG^#O'LCIX9\6:'XB>,$NNDZE#=%0"
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M >6_\%?OB-8_%?XA?#+X.>$+B/7/$]O>R/>6MHPD\JYN&CAMX"1G$G$A93R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLC;Y[<GH&1V8A?[C)[X_?"N5^)GPM\*?&/PA>>%_&>AVGB#0[KE[6[7.U@"
MZ,,,CC)PZD,,\&@#^8&O4?V>_CWK/[.OBC7/$OA[<FN7>B76E6<X/RP/,4'F
MD=]@!91_>"9XS7Z=>-/^")OP\U;4Y)_#/CW7_#UH[;A:7EO%?!.N0K9C..F,
MY/'4UZ#\#_\ @DI\'/A/K=OK6NOJ'Q"U*W??##K0C6Q0CH3;J,.>O$C,O3Y>
M* //_P#@CQ^S+J7P]\%ZW\5?$5G)8W_B>%+/2()EVN+!6#M,0>0)7";<]5B#
M<A@:_1RFHJQJJJH55& JC  ]*=0 4444 %%%% !1110 4444 %%%% !1110
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M'&UQ]D%K-IUVSS2F5T2.W!A5KEVV9VQ*Q7D'H:?LIVORA[2&USU.BN-'Q?\
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M^EV9T^S.AZK=Z9Y5N2I\H?9I8\KE%.#GH*J.(6\M]?Q^8G1>RVT_K8YOX_\
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M_74T@I+XF%%%%8FH5X=)_P G/1?[O_MF:]QKPZ3_ ).>B_W?_;,T >XT444
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M+C!&&(# +A^ATWX.ZM;Z+\*[&>ZLR?"UQ-)?M'(_[Q7L[B >4=G)W3*?FV\
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M%,$;H^\$ #)88P3[XK#\8_"*Y\:77Q&AGOHK.Q\4Z%;Z3#-&"\L#H+D,[(0
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M>/7M0![]17"6GQN\&W2 G5O(;&2DUO("/QVX_(U8_P"%Q>#?^@Y#_P!^Y/\
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M!Z<YGA?]H%;7_0/%=E/:7T)V/<11]2/[\?!4_3/T% 'M-%<3%\:/!DR[AK:
M?[4$JG]5I_\ PN+P;_T'(?\ OW)_\30!V=%<9_PN+P;_ -!R'_OW)_\ $T?\
M+B\&_P#0<A_[]R?_ !- '9T5QG_"XO!O_0<A_P"_<G_Q-'_"XO!O_0<A_P"_
M<G_Q- '9T5QG_"XO!O\ T'(?^_<G_P 31_PN+P;_ -!R'_OW)_\ $T =G17&
M?\+B\&_]!R'_ +]R?_$T?\+B\&_]!R'_ +]R?_$T =G17&?\+B\&_P#0<A_[
M]R?_ !-'_"XO!O\ T'(?^_<G_P 30!V=%<9_PN+P;_T'(?\ OW)_\31_PN+P
M;_T'(?\ OW)_\30!V=%<9_PN+P;_ -!R'_OW)_\ $T?\+B\&_P#0<A_[]R?_
M !- '9T5QG_"XO!O_0<A_P"_<G_Q-'_"XO!O_0<A_P"_<G_Q- '9T5QG_"XO
M!O\ T'(?^_<G_P 31_PN+P;_ -!R'_OW)_\ $T =G17&?\+B\&_]!R'_ +]R
M?_$T?\+B\&_]!R'_ +]R?_$T =G17&?\+B\&_P#0<A_[]R?_ !-'_"XO!O\
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MC_A1_@G_ * O_DU/_P#%UW5% '"_\*/\$_\ 0%_\FI__ (NC_A1_@G_H"_\
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M /%T?\*/\$_] 7_R:G_^+KNJ* .%_P"%'^"?^@+_ .34_P#\71_PH_P3_P!
M7_R:G_\ BZ[JB@#A?^%'^"?^@+_Y-3__ !='_"C_  3_ - 7_P FI_\ XNNZ
MHH X7_A1_@G_ * O_DU/_P#%T?\ "C_!/_0%_P#)J?\ ^+KNJ* .%_X4?X)_
MZ O_ )-3_P#Q='_"C_!/_0%_\FI__BZ[JB@#A?\ A1_@G_H"_P#DU/\ _%T?
M\*/\$_\ 0%_\FI__ (NNZHH X7_A1_@G_H"_^34__P 71_PH_P $_P#0%_\
M)J?_ .+KNJ* .%_X4?X)_P"@+_Y-3_\ Q='_  H_P3_T!?\ R:G_ /BZ[JB@
M#A?^%'^"?^@+_P"34_\ \71_PH_P3_T!?_)J?_XNNZHH X7_ (4?X)_Z O\
MY-3_ /Q='_"C_!/_ $!?_)J?_P"+KNJ* .%_X4?X)_Z O_DU/_\ %T?\*/\
M!/\ T!?_ ":G_P#BZ[JB@#A?^%'^"?\ H"_^34__ ,71_P */\$_] 7_ ,FI
M_P#XNNZHH X7_A1_@G_H"_\ DU/_ /%U);_!?P9:R!TT1"P_YZ3RN/R9B*[:
MB@"O8Z?:Z7;+;V=M#:6Z_=BA0(H_ 58HHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>slide1a03.jpg
<TEXT>
begin 644 slide1a03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0 \ # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHK@OCK\4D^"WPG\0>,VL3J1TR.,
MI:^9L$CR2I$@+8.!ND!/'0&JC%SDHQW9,I**<GLCO:*_/RP_X*+_ !(U6TCN
MK+X60WEM)G9-;BY=&P2#A@N#R"/PJQ_P\&^*7_1(_P#R%=?_ !-=_P#9]?LO
MO1Q_7:/?\&??=%? G_#P;XI?]$C_ /(5U_\ $T?\/!OBE_T2/_R%=?\ Q-'U
M"OV7WH/KM'N_N9]]T5\"?\/!OBE_T2/_ ,A77_Q-'_#P;XI?]$C_ /(5U_\
M$T?4*_9?>@^NT>[^YGWW17P)_P /!OBE_P!$C_\ (5U_\31_P\&^*7_1(_\
MR%=?_$T?4*_9?>@^NT>[^YGWW17P)_P\&^*7_1(__(5U_P#$T?\ #P;XI?\
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M_P 31_P\&^*7_1(__(5U_P#$T?4*_9?>@^NT>[^YGWW17P)_P\&^*7_1(_\
MR%=?_$T?\/!OBE_T2/\ \A77_P 31]0K]E]Z#Z[1[O[F??=%? G_  \&^*7_
M $2/_P A77_Q-'_#P;XI?]$C_P#(5U_\31]0K]E]Z#Z[1[O[F??=%? G_#P;
MXI?]$C_\A77_ ,31_P /!OBE_P!$C_\ (5U_\31]0K]E]Z#Z[1[O[F??=%?
MG_#P;XI?]$C_ /(5U_\ $T?\/!OBE_T2/_R%=?\ Q-'U"OV7WH/KM'N_N9]]
MT5\!2?\ !0KXGPQL[_"541069FCN@ !U).VOHG]DW]I"X_:0\(ZOJ5[HL6BW
MNF78MG2WF,D<BL@96&0"#U!'/3.><#*IA*M*//):>II3Q5*I+EB]3W2BBBN,
MZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^8/VV_B)X9U[
M]GOXF>&M/UVQO-?TM;!KS3HI@9H0;^VY*^V0#Z$@'&17T_7YE_\ !0KX$W7@
M'QW)X\T@2C0/$[[+]4)VPW8PQ5O]F38'&?XE;IA:]# PC4K)2=FM5\CBQDI0
MI-Q5^Y]*?L4_$7PQX;_9V^&/A[5->L+#7-5-\+&PGG59I_\ 3[@#:ON>!ZD8
M&37U!7YA?L _ N[^)OQ M/&>L^<WASPC(OV(.3MDNPQE1$]%1F,IQ_$R_P!X
MU^GM&.A&G6:B[MZOYA@YRG23:LMD%%%%>>=H4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S_Q!_P"1!\2_]@RY
M_P#135\A_P#!+?\ Y$'QO_V$X?\ T57UY\0?^1!\2_\ 8,N?_135\A_\$M_^
M1!\;_P#83A_]%5Z-+_=:GJCAJ?[S3^9]N4445YQW!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!YQX@^.VA>&]:N],N['4_M%K(8W
M,<494^A&9!P1@].]9_\ PTEX9_Y\=6_[\Q?_ !RN'_:,T+[#XLM-31<1W\&&
M/K(G!_\ '2E>34 ?2/\ PTEX9_Y\=6_[\Q?_ !RC_AI+PS_SXZM_WYB_^.5\
MW44 ?2/_  TEX9_Y\=6_[\Q?_'*/^&DO#/\ SXZM_P!^8O\ XY7S=10!](_\
M-)>&?^?'5O\ OS%_\<H_X:2\,_\ /CJW_?F+_P".5\W44 ?2/_#27AG_ )\=
M6_[\Q?\ QRC_ (:2\,_\^.K?]^8O_CE?-U% 'TC_ ,-)>&?^?'5O^_,7_P <
MH_X:2\,_\^.K?]^8O_CE?-U% 'TC_P -)>&?^?'5O^_,7_QRC_AI+PS_ ,^.
MK?\ ?F+_ ..5\W44 ?2/_#27AG_GQU;_ +\Q?_'*/^&DO#/_ #XZM_WYB_\
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M/]5\N[/[P_UZSG^:/_@)]X?\-X^ /^@1XD_\!K?_ ./T?\-X^ /^@1XD_P#
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M  WCX _Z!'B3_P !K?\ ^/U\'T5]]_JOEW9_>?DO^O6<_P T?_ 3[P_X;Q\
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M*OC>'LLPN,S*6 QR>S2L[>\O^!<_6N(,UQ6%RJ&8Y>U9\K=U?W9+3\6CU_\
MX;X^'_\ T!_$O_@+;_\ Q^C_ (;X^'__ $!_$O\ X"V__P ?KX(HK]4_U)RC
M^67_ ($?E7^O&<?S1_\  3[W_P"&^/A__P! ?Q+_ . MO_\ 'Z/^&^/A_P#]
M ?Q+_P" MO\ _'Z^"**/]2<H_EE_X$'^O&<?S1_\!/O?_AOCX?\ _0'\2_\
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M^.OV@-9T%_ _AS3]'T.RU*V@MX;%7,VQU59)B^0[C:<-@$;B*S_"][X<\#_
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MEE;6UB_G! ()(]A=&!V\!R01DXYKXYU#7-1U;5'U.^U"ZO=2=@[7EQ,TDS,
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M]G;<_-+QMXCD\7>+M8UJ3.;ZZDG56_A4L=J_@,#\*Q:_2'_A5/@G_H3M _\
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MJ?\ 7S/S]HK] O[)^$/_ #Y^"?\ OU9_X4?V3\(?^?/P3_WZL_\ "C_6Z/\
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M - \CG_U%G_T&0/S3HK]+/[%^"7_ #X> /\ OS8_X4?V+\$O^?#P!_WYL?\
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M_OS8_P"%:_ZTQ_Z!Y&'^HL_^@R!^:=%?I9_8OP2_Y\/ '_?FQ_PH_L7X)?\
M/AX _P"_-C_A1_K3'_H'D'^HL_\ H,@?FG17Z6?V+\$O^?#P!_WYL?\ "C^Q
M?@E_SX> /^_-C_A1_K3'_H'D'^HL_P#H,@?FG17Z6?V+\$O^?#P!_P!^;'_"
MC^Q?@E_SX> /^_-C_A1_K3'_ *!Y!_J+/_H,@?FG17Z6?V+\$O\ GP\ ?]^;
M'_"C^Q?@E_SX> /^_-C_ (4?ZTQ_Z!Y!_J+/_H,@?FG17Z6?V+\$O^?#P!_W
MYL?\*EM?#?P9O91%;Z5X$GE/1(K>R8_D!1_K5%:O#R!<"3;LL7 _,ZG11//*
MD<:EY'(5549))Z 5^IH^#G@ \CP/X;(_[!-O_P#$5);_  C\"VEQ'/!X+\/0
MS1L'22/2H%9&!R""$X(/>L'QA0Z4G]Z.I>'6*OKB(_<RU\.?"B>!_ >@Z"@
M-A9QPN1T:0*-[?BQ8_C7PK^VQXR_X23XS2Z;$^ZVT6UCM  <CS&'F.?K\ZJ?
M]ROT-KE=0^%/@G5KZ>\OO!V@7EY.YDEN+C2X'DD8\EF8IDD^IKY?(LWI97CI
M8W$0<VT[6[MZO\_O/TG/,FJ9E@(8##34(IK?LEHOR^X_)ZBOU9_X4S\/_P#H
M1?#7_@HM_P#XBL&[\+_!?3Y3%=:3X#MI!P4FMK)3QP>"*_1X<>4*CM##2?I8
M_-I\ UZ:O/$Q7JF?F)17Z:?V+\#O^?#X??\ ?FQ_PH_L7X'?\^'P^_[\V/\
MA6W^NT?^@29E_J//_H+@?F717Z:?V+\#O^?#X??]^;'_  H_L7X'?\^'P^_[
M\V/^%'^NT?\ H$F'^H\_^@N!^9=%?II_8OP._P"?#X??]^;'_"C^Q?@=_P ^
M'P^_[\V/^%'^NT?^@28?ZCS_ .@N!^9=%?II_8OP._Y\/A]_WYL?\*/[%^!W
M_/A\/O\ OS8_X4?Z[1_Z!)A_J//_ *"X'YET5^FG]B_ [_GP^'W_ 'YL?\*/
M[%^!W_/A\/O^_-C_ (4?Z[1_Z!)A_J//_H+@?F717Z:?V+\#O^?#X??]^;'_
M  J_I?@?X0ZY)Y>F^'_!.H2?W+6RLY3Q[*IJ9<<4XJ\L+-(<>!:DG:.*@V?E
MY7N?[&O@[_A*OC9874B;[;1H)-0?/3< $C_'<X;_ (#7W-_PIGX?_P#0B^&O
M_!1;_P#Q%:_A_P #^'/"4DTFA^']+T628!97T^RC@+@= Q11D#WKQ\QXXI8O
M"5</1I.,I)J]UI?1_@>UEO M7"8REB*U92C!IV2>MM5^)'X^\60^!?!&O>(;
MC:8M,LIKK:QQO*(2J_4G _&OQGO;R;4;R>[N9&FN)Y&EDD;JS,<DGZDU^U>L
M:-I_B'39].U6QMM3T^< 2VMY"LL4@!! 9&!!Y /([5R?_"B_AM_T3WPK_P""
M6V_^(KY+(LZH91"ISTW*4K;=E_PY];G^1U\XG3Y*BC&-][[O_AC\>:*_7W4/
M@[\*])MS<7W@CP?9P @&6XTFT1<GH,E,5S[:#\ 58@Z=\-P1P08-/_PKZV/%
M].>L:$F?'RX-JPTGB(H_**BOU<_L+X ?] [X;?\ ?C3_ /"C^PO@!_T#OAM_
MWXT__"K_ -;(_P#0-,C_ %0E_P!!,#\HZ*_5S^PO@!_T#OAM_P!^-/\ \*/[
M"^ '_0.^&W_?C3_\*/\ 6R/_ $#3#_5"7_03 _*.BOU<_L+X ?\ 0.^&W_?C
M3_\ "C^PO@!_T#OAM_WXT_\ PH_ULC_T#3#_ %0E_P!!,#\HZ*_5S^PO@!_T
M#OAM_P!^-/\ \*/["^ '_0.^&W_?C3_\*/\ 6R/_ $#3#_5"7_03 _*.BOU<
M_L+X ?\ 0.^&W_?C3_\ "C^PO@!_T#OAM_WXT_\ PH_ULC_T#3#_ %0E_P!!
M,#\HZ*_5S^PO@!_T#OAM_P!^-/\ \*V])^%?PCUZ(RZ9X/\ !6HQC!+VFF6<
MH&>G*J:F7%U."O+#R14>#JDW:.(BS\B*^\?^"</@?[+X?\5>+9H_FNYTTVW8
MC^&,;Y"/8ET'U2OI7_A1?PV_Z)[X5_\ !+;?_$5T^@^'=)\*Z<FGZ+I=GI%@
MC%EM;"W2"($G)(50!DFO!S;B>&8826&I4W'FM=M]%J?09/PM/+L9'%5:BERW
MLDNKT-&BBBOS\_1 HHHH **** "O!?VQ/VBKC]GKX=6]UI,$5QXCU:<VMA]H
M7='#M&9)6&1NV@@ >K#/ (/O5? O_!50G'PP&>/^)I_[:5V8.G&K7C"6QRXJ
M<J=&4H[GR?JW[37Q9UJ\:YN/B-XECD;DK::G+;)^"1,JC\!5+_AH+XI?]%*\
M7_\ @^NO_CE<!2JI=@JC+$X K[+V5/\ E7W'ROM)]V=]_P -!?%+_HI7B_\
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MO_A@?X?_ /08\2_^!5O_ /&*/^&!_A__ -!CQ+_X%6__ ,8KZ4HKD_UDS?\
MZ")'9_JSD_\ T#1/FO\ X8'^'_\ T&/$O_@5;_\ QBC_ (8'^'__ $&/$O\
MX%6__P 8KZ4HH_UDS?\ Z")!_JSD_P#T#1/FO_A@?X?_ /08\2_^!5O_ /&*
M/^&!_A__ -!CQ+_X%6__ ,8KZ4HH_P!9,W_Z")!_JSD__0-$^:_^&!_A_P#]
M!CQ+_P"!5O\ _&*/^&!_A_\ ]!CQ+_X%6_\ \8KZ4HH_UDS?_H(D'^K.3_\
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M^P,K_P"?$3Y8_P"'<_PV_P"@WXJ_\"[;_P"1Z/\ AW/\-O\ H-^*O_ NV_\
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M9/M_P[Y\#6Q&7XQ9;B9N<9)NG)[Z;Q?=K>__  R^FZ***^6/K HHHH ****
M"O@3_@JI_P TO_[BG_MI7WW7P)_P54_YI?\ ]Q3_ -M*]'+_ />8?/\ )G#C
MO]WE\OS1\"5);J6N(PK;26 ##MSUJ.GP[/.3S/N;AN^F>:^R/E3] /C=I/QY
MT7P3K6EV>B^&=:T"'3&:Y\9VL%O:ZC-"T*FYW*TY(9E3:Q5<L%&.U?GY7WYX
MB\5?"J3P'XRT_3[#X<VUKI6GSV]O(;=6U*X5[.,VLD+Y/F2>:SJYZ@@=".?@
M.O.P=^5IJWRL=V+MS)IW^=PK]X?%5PUIX7UB=.'CLYG'U"$U^#U?NYXT_P"1
M-U[_ *\+C_T6U>=F_P#R[^?Z'=EGV_E^IYU^S59JGA;5;H ;Y+WRB>^%12/_
M $,UZ_7E'[-O_(C7W_81D_\ 145>KU\\>X%%%% '.:A\1/#^E^.-+\'W6H>5
MXCU2WDNK2R\F0^;%'G>V\+L&,'@L#Z5T=?./Q _Y/@^%W_8O:C_)Z^<?[=^(
MD/P)MOB1#\5?%4>L6OBQM)L[-KH26B0M,0?.C8$SL&.1YA("X7&!7?'"^T46
MG:]OO;?^1Q2Q'(VFKVO^%O\ ,_1RBOCVW\2:]\$?C!\1O#&J^/\ Q-XAT&/P
M/+XC-YJ,B7-U:7"OL+6ZE0J]253A1D YQFN%^!OQ"\?:+\>/ ,-YJ/BN+PQX
MPT^[NXX_%WB6'5A=0K \L<Z1QHOV7E5X/.,C. :/JC:<E+2U_72X_K*32:ZV
M_0^_*YOPS\1?#WC'7/$&CZ/J'VS4= N%M=2A\F1/(D()"[F4!N >5)%?"7PK
M_P"%F?&[Q!X1O4\0_%BWFO\ 5);K7-5CO&L_#OV%9&Q]B(P-Q 5=FT@G=QU-
M=QXQ^(/BFU\)_M330^)-7BFT;4[6/3)$OI0UBI896$AOW8/<+BK>#Y7R<UWI
M^:1*Q7,N:VG_  +GVS17Q]X8NO&'PS^.?PIBO?B'KWBFW\<:-=W.J6VM3J;2
M*6.V\U6@B VPJ"1PO/!R3G%>7_"O_A9GQN\0>$;U/$/Q8MYK_5);K7-5CO&L
M_#OV%9&Q]B(P-Q 5=FT@G=QU-2L)IS<RM_P_^0WB=;<NO_#?YGZ(T5FZ=XDT
MC6-1U#3[#5;*]O\ 3G5+VUM[A));5F&5610<H2 2 V,UI5P;;G:%%%%(#POX
MD1_V?\=O"UQ$,-<&UW^Y,S(?TQ4G[8-X]M\)$C4\7&HPQ-] KM_-12?%?_DM
M7@S_ 'K7_P!*6J']LK_DE5E_V%H?_14M>[D23S.A?^9'RG%<G'(\6U_(ST+X
M*Z>FE_"7PE#& JMIL,YV^LBB0_JQKM:Y7X4_\DN\'?\ 8&L__1"5U5>=C).6
M)JM]9/\ ,]G+8J&!H1CLH1_)!1117&>D%%%% !1110 4444 %%%% !1110 4
M444 ?+7[/$0TC]HKX@Z7" MLBWFU5Z )=H%_1C6+^U?#_;W[0WPTT.8!K:8V
MJE6Y4^;=E&X^BBM[X'?\G3?$/_<O_P#TLBK&_:0_Y.P^%7_733O_ $O>OTV;
M_P"%A3Z^RO\ /D/PZA%?ZNRI?9^L-6\O:;'UU1117YD?N(4444 %%%% !111
M0 4444 %%%% !1110 5Q/QNTV/5O@_XTMY &']D7,B[NFY(V=3_WTHKMJY7X
ML?\ )+?&/_8&O/\ T0]=.%;C7IM=U^9Q8Z*EA:L7LXR_)GD'["]X]S\&[V-_
MNV^LSQ)]#%"_\W-<3\&X?[>_;2\<WDX#26'VYHRW)&V6. 8_X"V/I77_ +!W
M_)(=7_[#LW_I/;URO[/O_)X/Q._ZYZC_ .EL-?;5?=Q.9-?R_FU<_,J'OX+)
M8RVYE^"=CZZHHHKX _6CG-0^(GA_2_'&E^#[K4/*\1ZI;R75I9>3(?-BCSO;
M>%V#&#P6!]*Z.OG+Q]_R?%\+?^Q>U'^3UR'[6/B;7M6^*$'A/PE?>-9=7L]"
M;5I['PYXBM]#M881(X,\LTB,93]W*9   (.2<=D</SN*3W5_Q9RRK<JDVMG8
M^JM8\3:1X=:Q75M5L=,:^N%M+1;RX2$W$S?=BCW$;G/91DFM*OSH\63:Q\8?
M@O\ LZ^)O$7BO7(]4O\ Q+'HTTUG=B$*!<S(MTHV\7*J@ E^N0<UZ+^T'K'Q
M!M?BAX.^$?A"^\4ZO:VV@"^D>P\2P:5JNHR*[)YDE[+&=Q4)DJH^;<Q/3C7Z
MGJH\VNM_D9_6M'+ETTM\S[2HKP[]E>]\?0_#G6;#X@R8U32M1FMK:2\U6WU"
MX2 1HZI<S0L0TBECDL%8C!(Z5XM\'=1\8:/\4M'TGXB^,/&EOK'BH7T=I=V^
MJP7V@:K$8W*O9[,&U=0T;J0#TY"[L5BL/=R7,O=_'T-76TB[;_@?9&B>)M(\
M3+=MI&JV.JK9W#6ERUC<),(9EQNB?:3M<9&5/(S6E7PS^S)X?@^'_@GXW^,)
M_&7BI(]"U36+%H%O%G1MB(PO&A9=KW61_K&(![C%9/P-^(7C[1?CQX!AO-1\
M5Q>&/&&GW=W''XN\2PZL+J%8'ECG2.-%^R\JO!YQD9P#6TL)K+EEM_E<RCB=
M(\RW_P ['WY17YW?"O\ X69\;O$'A&]3Q#\6+>:_U26ZUS58[QK/P[]A61L?
M8B,#<0%79M()W<=35OQ7XJ^-'Q<^(GQ&NO"Y\2F+PUJTVGV:Z-XNM-)LK!8B
M0IN;65-TX.TL69@#\RYP,!_4FI<KFM-_R%]:TORL_0:BO$?#L.L>)/%'PF\0
M:[\0H=$UDZ(SWO@ZTO(FAUF9X?GF0)+M=4)W JK@8&"!R?;JX9QY-+G9&7-T
M"OFG]O+38Y_A?HEZ0/.M]72-6/7:\,NX?FB_E7TM7SK^W5_R1RP_[#,/_HJ:
MO7R1M9C1MW/FN)XJ638E/^4[ZSUJ=?V:X-6R?M(\)+=9SSN^Q[NOUKRG]@'2
MXX?ASXCU$*OFW&J_9V;')$<*,!_Y%/YFO1K7_DTR+_L2!_Z05P_[ _\ R1_6
M/^P]-_Z3V]>['W<FQUNM2*_%GDKW\WR]RZ4I/YV1]*4445\.??!7.6?Q$\/Z
MAX[U#P;;ZAYGB2PM$OKFR\F0;(7("MO*[#DD<!B?:NCKY+\07D^G_M/_ !MN
MK6>2VN8/A\)(IH7*/&X4$,K#D$$ @BMZ5-5.:_1?JC&I-PMYL^M**_/O1V^(
M<?A_X$:['\7?%G]I>.+C^R[U9ITEMH("-JF.%E(,H7.97W,6^;@UTJ_$C5_A
M/H/Q_P##.M>-_%FK:9X7NM-73=6:Y2;5E^U'+1K,ZX&>%W$849*@'@]+P;V4
MK_?WM^9@L4MW&W_#7/M^BO@7X7?$KXE?#OQA\2M"UG4M<TY;/P3<:_:6WB[7
MX==FMITVB*7SD10H(8_NMOID'(K1_9RT+X@^.OB5X,UBXUGXMVNAVUC_ &EK
MTGBB^>#3[NZ(#1I:)TE@8DY4C[N.1Q1+!N*;<E9!'%*3247=GV+X%^(GA[XE
MZ7=:CX;U#^TK.VNI+*63R9(MLT9PZX=5)QGJ!CT-=)7P+/\ $?QM)^S2=1M/
M&.L6NN-\23I\6IM=R2RQP[\+&=S?-&./W9^4XP178_\ "0^+?@;\5/B7X7C\
M?:SXCLX/ D_B6VNO%%P+DVMXC;05^7"IG)" 8Y P<9HEA'=\K_I6_P PCB=%
M='V317PM^SEH7Q!\=?$KP9K%QK/Q;M=#MK'^TM>D\47SP:?=W1 :-+1.DL#$
MG*D?=QR.*^U]#\2:1XFAN)M'U6RU:&WG:VFDL;A)ECE7[T;%2<,,C*GD9KGK
M4?8RY;W-J57VBO:QI4445SFX5\=_'R$:+^V5\.;VW 5[UM.$F."2;IXB3_P#
M _"OL2OC_P#:4_Y.V^%'_733?_2]Z^PX7_WV<>CIS_(^-XJ_W*G+JJD/_2BC
M_P %*+^2/P_X%L@3Y4UU=3,,]T2,#_T8:^OO#^DQZ!H.FZ9"JK#96T5LBJ,
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M2G_)VWPH_P"NFF_^E[U]@5\?_M*?\G;?"C_KIIO_ *7O7U_"_P#OTO\ !/\
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M/]#[8HHHKYD^I"BBB@ HHHH *^!/^"JG_-+_ /N*?^VE??=? G_!53_FE_\
MW%/_ &TKT<O_ -YA\_R9PX[_ '>7R_-'P)3XI#%(CCJI!'X4RNU^%?Q('PSU
MV>_;PUX>\3K/#Y!M_$=C]KACRP.]5W##<8SZ$U]A)M*Z5SY>-F]6>Y:_^TA\
M.;Z'Q/XNM-(\4-\1?$6BOI-U:75S$=)B,D2Q/(F/WAP%#!2,9].M?+%?HK\0
MM#M8_#WC74Y?AU\--/\ ALWAR2;1_%MC:6XGFNGA78$ ?<&+LZJ-HP0/F..?
MSJKBPLHR3Y5^-_E\CKQ,91:YG^%@K]W/&QQX-UXG@?8+C_T6U?A'7[L^//\
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M(?\ D9T/\2/DN+/^1%B_\#/3?A3_ ,DN\'?]@:S_ /1"5U5<K\*?^27>#O\
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M77AWXA-JTDC^'X? "WNL37!FW*\5^I60[C\P_>*.O48)_5JU1X[:)9',LBH
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M_:PY4?('CCQ]%\%M6^&WQKTRVU&30/$?A(Z-?+J,ADN#,L EM&E('S.S* 7
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M#P0"?_ "N'_8'_Y(_K'_ &'IO_2>WKLG_P"30&_[$7_W'UQO[ __ "1_6/\
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MFMZN6O6]M9^OYG11I>RNO0****Y3H"OC_P#:4_Y.V^%'_733?_2]Z^P*^/\
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MZI_Z7P5]-E/^ZXS_  ?JCY;./][P7^/]#[8HHHKYD^I"BBB@ HHHH *^!/\
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MYX;^-0UG0=1MIY(=1NX8_#=B\4@+2PR.A!0 9")RV2H;O76?V1XNT/XX?9_
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M?^27>#O^P-9_^B$KJJY7X4_\DN\'?]@:S_\ 1"5U5>7B_P#>*G^)_F>[E_\
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M?_D^#XM_]<]4_P#2^"OILI_W7&?X/U1\MG'^]X+_ !_H?;%%%%?,GU(4444
M%%%% !7P)_P54_YI?_W%/_;2OONO@3_@JI_S2_\ [BG_ +:5Z.7_ .\P^?Y,
MX<=_N\OE^:/@2N@\!^"]9^(7BW3O#_A^V%WJ]Y)M@A,B1Y(!8_,Y & ">3VK
MGZ[WX%^#=*^('Q4T+P_K-_+IME?2/&)H95B<R>6QB178$*6<*N2/XJ^OG+EB
MV?,07-)(^S/'7@GXO^%[/XH?V[%X<M/"TFFSW2>)IK6)IC+]ECB=($\\O"TX
M4*Q((R,@#-?GM7V1X@^#_A&Q\/ZWX9\91:AJOQ5A\.W/B+5?$;ZNTXTV1,&W
MM7&XI(67:"3D_,,=1CXWKCPFS_RM^K_KH=6*W7^=PK]V?'G_ "(WB+_L'7'_
M **:OPFK]V?'G_(C>(O^P=<?^BFKS,W_ .7?S_0[\L^W\OU.#_9M<'P3?KGY
MAJ+DCZQ1_P"!KUFO /V;?$D=MJ&I:),^UKD"X@SW900P^N,'_@)KW^OGCW H
MHHH ^5OA3I]SI?Q(_:2\!B'_ (F>H3OK-C'O ^T)=0.,J3Z,4!). 6[5T/PH
MT/XJ_"OX3?"'PQIWAC3YI(9VM_$RWUTA>PMC*S;XV27:S88GY=_88[CW9?#6
MD+X@;7AI5B-<:W^R'4Q;I]I,.[=Y1EQNV9YVYQGFM*NN5?FZ=OO2L<T:/+U[
M_B[GP?XL_9+UC3OB5XSN[KX/6'Q3L]<U.74=/UD^*7THV*RL6,4T0=2X5CG*
MC)&>>0!]+^&;+QYX)U[X?>%-+\-:+'X"M=&\G5[V"ZD9K.X2,A(X/,D\QTR%
M +*QP<E@1SZS11/$SJ)*2O;U_P _R"&'C3;<?T_R/G'XX?L[#XT?M!>";_7_
M  __ &QX$L]*NH+^3[;Y&R8EFB&$D64\X^[QZUVOB;PIJ/PE\ Z?HWPK^'NB
MZ[I4<S+>^'I[M;0SPLA!*R2 JSEMNXR9R!CZ>LT5'MI-1B]ETZ%^RBFY+=]3
MXBL_@#\3M*\&?%J_\/>#+'PA>>-TMM.M/!VGZG"\5A#]VXG:7*QY*E\*G]\X
M' %:WQ _8Y\0^!?#_A/6_AWXI\6>+O$WA:^MIK#1=<UB%K-(E($BPJZHL0P%
MXW8V@C!.*^QZ*V^N5+WT_I6,?JL+6_KN?-GBPMXV_;8^'MK;HZ-X3\/W>J7Z
MD@B$W \E(R1D;N5/7IR*^DZSK3P[I.GZQ?:M:Z99VVJWX1;N^AMT6>X"#""1
MP-S[1P,DX'2M&N>I/GY4NBL=$(<MV^K"BBBL30\'^,5Y'9_&'PI._*P+;2.!
MUP+AC_2G?MD*6^%-F0,@:K"3_P!^Y:X7XM>*4U[XA7=Y:N)(+0K!"XZ'9U/T
MW;OPKUS]H30SXV^"FJ26@,DD44>HQ*HSE5PS?^.%J]C)ZD:.8T)RVYD?-<2T
M9XC)L53@KMPE^"N=1\)9%E^%O@\J<C^Q[1?Q$*@_J*ZRO'?V5_&</B?X66=@
M9 ;[1V-I,G?9DM&WTVG'U4U[%6.9498?&5J4UJI/\]#JR3$PQF68>O3=TX1_
M*S7R>@4445YI[84444 %%%% !1110 4444 %%%% !1169XD\06?A30+_ %C4
M)/*L[.%II&]@.@]R< >Y%5&,IR48J[9%2I&E!U)NR6K?9(^</@6PD_:C^(CK
M\R[;\9[?\?D7^%<]^TE(L/[7'PRD<[40:8S'T OY:Z;]C_2[K6=;\7^,;M<-
M=R>0K ?*SNYEEQ]/D_.O-?VWM0FTGXX>';ZW.V>VTBWFC;T9;F<C]17Z?RJ>
M>.@GK&GR_/E1^&0FZ?"T<7):2K<Z].=_Y'W/16)X+\667CGPII6O:>^^TOX%
MF7G)4D?,I]U.5/N#6W7YC.,J<G"2LT?N5.I&K!5(.Z:NGY,****@T"BBB@ H
MHHH **** "BBB@ HHHH *Y/XN2+#\*?&;N=JKHMX2?\ M@]=97BW[7'CNW\'
M?!O5+0RJNH:T/L%O'W96(\T_0)NY]67UKNP-*5?%4J<%JVOS/+S7$0PN KUJ
MCLE%_E^KT.._8*U".3X9Z_8@'SH=7:9O3:\,0'ZQM7._ %A#^V)\2U?Y6D34
M0H/?_3(C_(9JM^P#K2K=>,=(8C>Z6]U&N><*75S_ ./)4'B:^7X+?MGIJUZ3
M#HVME6>9A@!)DV,Q/HLJY/L*^YKTF\PQ^'6\H77GHF?EN%KI93E6+E\-.I:7
MEK)79]F4445^<'[,%>,?M2?#'Q#\1O"&@77A2.WN_$'AO6[;7+6PNY/+BO#%
MNS$6) !.[@MQQC(SFO9Z*N$W3DI+H1.*G%Q9\P?%GPK\6?C?\+8KN]\%Z?X:
M\1:'KUGJ^E^'SJ\=R]T(0V]9)UQ&NXO\HR,;>35;PY\/OBAXH^+WC?QKXH\(
MV?AZ+6_!DFE6=E:ZI%=-%-N 6&1\KER0S;E&P!E&[(-?5%%="Q#C'E45^/\
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M4>&,S2,68EF/4DY-)0 5]2_ _P 21^(O =O;2,KW&G_Z+*AY^4?<./3;@?\
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M_P#)_P#[4_72BOR+_MK4/^?ZY_[_ #?XT?VUJ'_/]<_]_F_QH_U.E_S_ /\
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M_)/_ +8/^(B1_P"@7_R?_P"U/U_HK\@/[:U#_G^N?^_S?XT?VUJ'_/\ 7/\
MW^;_ !H_XA[+_H*_\D_^V#_B(D?^@7_R?_[4_7^LW7/$FD^&;1KK5]3L]+ME
MY,MY.L2_FQ%?DE_;6H?\_P!<_P#?YO\ &JLDCS2,\C,[L<EF.2:TAX?>][^)
MT\H__;&<_$3W?<PNOG+_ .U/L3]H;]LBSO-+N_#?@&:25KA3%<ZW@H%4\%8
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M "G(/[0S7_H _P#*D#[1HKXN_P"'=NI?]%7NO_!2W_R31_P[MU+_ **O=?\
M@I;_ .2:/J&5_P#0=_Y3D']H9K_T ?\ E2!]HT5\7?\ #NW4O^BKW7_@I;_Y
M)H_X=VZE_P!%7NO_  4M_P#)-'U#*_\ H._\IR#^T,U_Z /_ "I ^T:*^+O^
M'=NI?]%7NO\ P4M_\DT?\.[=2_Z*O=?^"EO_ ))H^H97_P!!W_E.0?VAFO\
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MTL+B5B(O2S1\:445ZK\.?@;=^*+>+4=7DDT[37PT<:C]],OJ,_='N0<^G>N
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M4?ZX4/\ GT_O17_$.L5_T$1^YGY7T5^J'_"F_ '_ $(_AO\ \%%O_P#$4?\
M"F_ '_0C^&__  46_P#\11_KA0_Y]/[T'_$.L5_T$1^YGY7T5^J'_"F_ '_0
MC^&__!1;_P#Q%'_"F_ '_0C^&_\ P46__P 11_KA0_Y]/[T'_$.L5_T$1^YG
MY7T5^J'_  IOP!_T(_AO_P %%O\ _$4?\*;\ ?\ 0C^&_P#P46__ ,11_KA0
M_P"?3^]!_P 0ZQ7_ $$1^YGY7T5^J'_"F_ '_0C^&_\ P46__P 11_PIOP!_
MT(_AO_P46_\ \11_KA0_Y]/[T'_$.L5_T$1^YGY7T5^J'_"F_ '_ $(_AO\
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M (4WX _Z$?PW_P""BW_^(H]MD_\ SYG_ .!+_(/J_$7_ $$4_P#P!_YGE?\
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M>XK_ )_Q^YGY345^K/\ PIGX?_\ 0B^&O_!1;_\ Q%><^*+?X?\ AOXT>#/
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M  #3_P".5ZJGP:^'[*K?\(+X:&1G_D$6_P#\12_\*9^'_P#T(OAK_P %%O\
M_$5/UCA__GQ4_P# E_D/ZOQ#_P!!%/\ \ ?^9Y3_ ,-U?#C_ )X:Y_X!I_\
M'*/^&ZOAQ_SPUS_P#3_XY6AXHM_A_P"&_C1X,\ ?\*O\-7/_  D5K=7/]H?8
M;=?L_DJ6V^7Y)W;O7<,>]='X&\&_#_QQ8WUS_P *GM?#_P!DO9+/R=<\.6]M
M)-LQ^]C&#NB;/RMWP>*MU,A24GAZEO\ &O\ (E4<_;LL13_\ ?\ F<9_PW5\
M./\ GAKG_@&G_P <H_X;J^''_/#7/_ -/_CE>K?\*9^'_P#T(OAK_P %%O\
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M"FW9-?CZ=O\ @">*@E=I_A_F?<7C'QEHOP_\-WVO^(=0BTO1[)-\]U-DA1G
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M6@W-E<?:K74_#]\;2[@?:5.UP",%6(((/6N*C_9'\"'X:ZEX-NFU;4(]0O\
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MW]IH-O\ :;U?LUQ%)&A( ;RWC#LNX@;E4@$C-8'PB_;,\#_$KX9ZGXKU*?\
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M +:S[ HHHKY ^Q"BBB@ HHHH *^!/^"JG_-+_P#N*?\ MI7WW7P)_P %5/\
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M6!7,;1,?)*R;BFU3GCH.:,595(2?Y^GF/#W<))?UOY'YYU^[GC3_ )$W7O\
MKPN/_1;5^$=?NYXT_P"1-U[_ *\+C_T6U>?F_P#R[^?Z'9EGV_E^IP7[-O\
MR(U]_P!A&3_T5%7J]>4?LV_\B-??]A&3_P!%15ZO7SQ[@4444 >6?M.>-8/A
M_P#!/Q%K$^HZKI0C6&);G1"@NPSRHH6-G!5"<X+$?*"2,D 5\Q_!CQC\3_#O
MQ$\>^#=2UG5]$E;P?-JUBOC7Q)!K#65SN1(9VN50+&GSY*%>, D'BOM7QCX-
MT7X@>&[[0/$.G1:IH]ZFR>UFR PSD$$$%2" 0P(((!!%<%X3_97^%?@=KLZ+
MX/MK7[9I\NEW*O<3S">VD<.Z.)'8-D@?,<L   0!BNZC6IPI.$E=O_@>9QU:
M52=12B]$?/WP@M_%]W=>)_AYXB\6_$#0_B%J7AJ6ZCM]8U:.\MFFW*([NQNH
MB#$H<,#'SPWWB5J3X0_&;Q'\<O&'PA\+Q:KJEA=^'+&XOO%ZQW+Q23S6[>1'
M'/M(+;W4.RMUW\BOH[X8?L[_  [^#5_=WW@_PS!I%[=)Y4MR9Y9Y"F0=@:5V
M*J2 2%P#@9Z"N8^ OP%O/AIXZ^)/BW6?[,_M/Q5JC3P0Z6SM'!:[F95)=5.]
MF<E@!C*C![#:5>E)3:7IZ[/O^?0RC1J1<5?U]-SY0_MWXB0_ FV^)$/Q5\51
MZQ:^+&TFSLVNA):)"TQ!\Z-@3.P8Y'F$@+A<8%>M6]]XK^%OQ=^)7@E_'7B'
MQ/8/X#N/$$5SK%T'FM;L$INA90/+7DD*F ..I ->^?\ #//P_P#^$)'A#^P/
M^*=&H?VH+/[;<?\ 'SNW>9O\S?\ >YVYQ[5-XW^#VB^([KQ)K]G91Q>,=4\/
MSZ FHS7$H00N"51D!*@;R"6"[OY42Q5.3:MIKT7E;]0CAYQUOKIU?G<^/_#W
MBKQGX5\$?!#XB0_%+7_$VK^(M7M]'O="O+Q9;*2!F9&40CDRJ%"M(Q9RS D@
MUV7P)^'7]D_M4?&:]7Q7XHN9/#L]I<+:R:GE-3\VWE.V[&S]ZL>0$Z;>.M>H
M_ []D/P9\-=,\*ZMJ_AS2[GQ[I5JL<VJ6DDK0M*"<2*C;5+8(^<H&R,YKT*\
M^!W@>_\ B=:_$.;0(SXQME"QZFD\J'A#&"R!PC'82N64G&/08JIB:?O1CU36
MR[W7R_JPJ="?NRETMU?;\SXN?QEXRO\ ]G2Z^/3_ !8\06_BR/5"L7AZ&\4:
M2G^DB,6S6N,%O+)?GM@D$\UWWB\^+_B-\:OBAIJ^/O$_A/2M*\+6>L)IVBWC
M0[;G[.& #')C3<6WJFTOD9/%>YK^R;\)%\:'Q6/!%A_;7G_:=^^7R/,SG=Y&
M_P K.>?N=>>M=>WPK\+MXF\0>(#I?_$WUZR73]2N/M$O[^!5VA-N[:O'=0#[
MU,L53O>*_!::K3Y6>I4<//:3_%Z[Z_,^-_"?BGQ]H_AWX#?$6^^(WB'6;SQ5
MKMOHM_I-S*BV!MG=XQ^Z5<&3"<R-EB3G((S7+_&KXM>-[37O%WCCP=K7C<Z3
MH/B)M-?4+SQ#;PZ5',LN/LZZ8$W2I@@!BQR.6'!K[=7X#^!D\.^%-"&AXTKP
MM>)J&CV_VN?_ $6=&9E?=OW/@L>'+#GI7.>(OV0OA!XKU_5=;U3P5:W&IZHQ
M>ZF6YN(@S%@Q=520*C$KDLH!.6R?F.;CBJ/-S2C^"VOZKH1+#U>7EC+\7O;_
M #/%Y/AJ-8_;XN-WB[Q/9,WAR+7!]DU+RR2+I/\ 0_NG_13C)B^O-4O%7QD\
M8^"]!_::U33]9OI[O1]:L[33#=3-/'IT<K;&,2.2J !LX QG!P<5]-^,_@7X
M&^(/BC0_$>OZ!'?ZWHC(UA>>?+$\6Q]Z [' <!N0'!')]35NU^$'@^SD\6,F
MAPR#Q7)YFM1W$CS)>-M*\H[%5X)X4 5E]8AIS*]DE]S7YHU]A/7E=M7^*.5^
M!_@&7P*2\GQ-UOQS_:NGPW9MM<OENBC=YX#]Y(FW ;>1P.:\!\8_$'Q3:^$_
MVIIH?$FKQ3:-J=K'IDB7TH:Q4L,K"0W[L'N%Q7TS\+O@)X"^"\E_)X-\.PZ-
M+?!1<2^?+.[@<A=TKL0N3T! IU]\"/ VI6?C"TN=#\RW\73)/K2?:YQ]K=#E
M3D/E,?[&VHC6A&;D]=NBZ-%2I3<$EIOU?8^>?#M]XQ^%OQN^%BWGCWQ!XP@\
M;:+>7>IV.JS*;99HK;SE-O$JXA&<#"\\'DYQ7B7C";7_ !]^S#'\2]>^).KW
M^HZWXBC@G\-7%RC6$82X.V*&$C,<BA1)E#]W@KU-?H+<?"OPO=^(O"^NRZ7O
MU7PS!);Z3<?:)1]FC>,1NNT-M?*@#+AC^-<3??L@?![4-4U349_ UDUYJ4@E
MN)%FF3#AP^Z,!P(B6'/EA<C(.02*WIXJG%J36NG1=&_TM]QC/#SDFD]/5]E_
MP?O/.?$DGBGQE^T#\6/!^F>)=8TY?^$*@FTR*UOY8DM;LE"LD85@$8M@$C!(
M)!ZUR_P?^,7B'XZ>)O@KH%OK6H6DVC:;<:GXK$%U)')<20.;>))RI&X.Z;RK
M9SOY%?5EC\._#VF^.K_QC;Z?Y?B.^M$L;B]\Z0[X4(*IL+;!@@<A0?>LOP+\
M$_!/PU\1:[KOAK0H],U77',E_<+/+)YI+LYPKN50;F)P@ Z>@K'ZQ3Y6K:V5
MO6UF:^QGS)WTOK]]T?'7_"VO&9^ 5I:+XOU2PNM?^(\V@3^()KMWGL;,GD1R
M,24 QQ@C !QUK3AT34/AY\=OC%I]IXQUCQ-?Z9\-YS:ZG?7(DU&W< .J/,@!
M9U)W!B V&7T!/U,W[/GP^?P+J7@V3PW#-X;U&[>_N+*:>9\W#D%I%<N71LC^
M%ACMC--\!_L[_#KX8Z@][X8\+VNE7,EB=-E>.25_-@+[RL@=B')/\; M@ 9P
M *U^M4[.RWOT7D9_5ZEU=[>I\\2_$S6I/AU^RXT?BN_;4=:U>T346747,U]&
M %E$WS9D7<0&W9&2,UYA\:OBUXWM->\7>./!VM>-SI.@^(FTU]0O/$-O#I4<
MRRX^SKI@3=*F" &+'(Y8<&OK[0/V2?A'X7U2VU+2_!=K9W]M?IJ4%REQ.7BG
M0DJ5)D.$!/\ JQ\AP,KP,1^(OV0OA!XKU_5=;U3P5:W&IZHQ>ZF6YN(@S%@Q
M=520*C$KDLH!.6R?F.:AB:$97LVO1=[]_P"NQ,J%:4;7U]?+T/+[Z\U&']J;
MXO7&E:A::1JW_"!PM:7U\ZI!;S';L=V8$!0V#R"..<TG[*VL^(/#_P 2)_"?
MC?6_&T?BZ?1OMT^D^)K^+4K&XQ(H^TV4Z']VN=X\OD88?,2M?0-Y\'_!^H>(
M=;UNZT2*ZU+6M.&DZA)-+(Z7%J,8C,9;8!P.0 ?>LOX8?L[_  [^#5_=WW@_
MPS!I%[=)Y4MR9Y9Y"F0=@:5V*J2 2%P#@9Z"L'7INFXVULNG;^NWW&RHS4U*
M_5GHU%%%>>=H4444 >'?##_DNGB__=NO_2B.O-OVD/\ D[#X5?\ 733O_2]Z
M])^&'_)=/%_^[=?^E$=>;?M(?\G8?"K_ *Z:=_Z7O7TF0_[W+_!+\CXSBS_<
M(?\ 7R'_ *4CZZHHI#R".E?-GV8M%?%?BKX0ZOI/[2'@[P%!\7OBA_8VMZ9=
MW]Q,WB9_/1X]Q4(0FT+P,@J3[U'#XG\0_!_]J#X@6OAKPMK'Q*U"U\-:;$[7
M.H1Q2F*&)-\UQ<./FD8#. I+L3@5W?55)>[*^E^W6W4X_K#7Q1ZV_"Y]L45\
MZ^(/VT?#VE_"GP9XMLM):[U+Q89([#2;S48+)$>)BLQFN9#Y<:*PQN/4E>!D
MXK^&_P!LZRU_X8^/O$3>'(HM=\'QQS7>CVNLPWEO,DAQ&T5Y"K(P.&SA3@C%
M9_5JUK\O6WXV_,T^L4[VOY_J?25%>#)^T9XK;X8W/C27X675A:RRPG3(=1UZ
MTMEN;:1&?[1/(Y"VRC &'R3O7'4XY[P]^VO;:U\+_B!XED\+1Q:QX-\@W6EV
MNM0WEM.LS;4:.\B5D;HV<*<8QD]E]6JO9>6Z#V]/J_P9]-45\\^&_P!JS5-3
M\;:+H&M?#;4O#">)K*2[\-75]?Q,=09(_,$<J(#]G)&.I8C<,@9HMOVNX-0^
M$OA;Q3:>&&E\0:]KB^'D\-M?;7ANO,9'#2^6>%4!ON?Q <4?5ZO;\OZZ#]O3
M[_U_3/H:BO'OCU^T$_P:O_"^D6'AT>)-?\0R3):6LVJ0Z;;@1*I8O<2_*"=P
M"C'S'C(. <CXB?M41_#7P)X8U+5_"MQ8^*_$$LD%OX=U/48+)87B)$C2W4A$
M:1#C;)T;>F!@\3&A4DDTM]ARK0BVF]CWBBOCSQY^T99?';]F7XO6C:9%HNNZ
M)9(MW9VNIPZE;E)'!C>*YA^20':P..A&*Z?Q#^U#8_!GP9\.?#=EI-MKOB.^
M\.VEY]GOM:MM(MH8!"J[GN)SM#$@[4 R=IZ<9U^JU-K:WV^5]S/ZQ#?I_2V/
MIRBOG2Q_;2T&^^#P\8Q:%=7&LMJX\/IX?L[F.X:74&&5CCG7Y'C*\B0#![ G
MBN7^/W[1'Q9\*_ ^_P!;@\ W7@#7K;4(;>YNIM0M;Z.VA8H4DC)0K-O+&,@#
M*'DTHX6K*2BU;6VK'+$4U'F6NESZSHKYP\<?$CQ ^H?!5_$^AZWX.UG6?$#6
MLNDZ5XCC,( P%-P8XF6XC88;RP4QG&:3Q1^UQJMOJGBV3PC\--0\8>%_"-P]
MMK>NQZG#;+"\?,WE1,I:;8 2<$=.P(-+ZO-VM^:[VW'[>"W_ %]3Z0HKY\\2
M?M92Q^(O"6D>#O U_P"-+CQ3H(UK35@O([9LEC^[FWKMC4*&S)N." -ISFN\
M^!'QDB^-O@^ZU8Z1/X?U'3[^;2]0TR>993;W$6-RAP!N&&'.!WX[F)4:D8\T
MEH5&M"4N5/4]'HKY*\&_M*)\.?@C>^+)-,\1>)HW\93:,UMJ>M?;;M0S<F%_
M)7*C'R0X'7&_O7I_PH_:!U+QQ\1]7\#^)_ ]WX'\06E@NJV\%Q?Q78N+5G"A
MR4 "-EAE?FQR"01BJEAZD;NVB)C7A*ROJSV:BOGCX[_M6:C\$_$ES9MX)M]1
MTNUB662_O/$UG82S*5#-]GMGS+/MR1\HY8$>]6_$_P"U0_\ ;WA#0_ O@J^\
M<ZQX@TB/7S:K>Q61M;%QE7=G!7?U^4D#I\W(H6'J-)I:/S7]+YC=>FFTWJO4
M]\HKX>_9X^.A^%?P[FU6\\/SOH_B#XBW>GWD]Q/Y$NE>=Y95I(]C;L?,&&Y<
M%>IS7O6K?M$7$/C+XA:'H_A.778O!UG;2W%U%?QP^=<S$8AQ(H1%52S-(7X"
MGY:J>&G&32U_JQ,,1"44V>ST5\V_#/\ ;(C\<7GB[3-1\+VVEZWH6BS:W'#I
MOB"VU:VN88Q\RFX@!5'R5&W!.#GV-?PA^V7?Z_>^!+K5?AIJ6@>%/%US'I]E
MKD^HQ/\ Z6W&P0A0QCW9 D)7<!D+VI?5:JOIMYK^F/ZQ3=M?S/IJBO!XOVEM
M9\0?$'5]&\)?#?4_$_AS0]372M7\00WL47V>;<%?RK=ANF"9R=I!P,XQ@GDO
MB-^W5I_@_P 7Z]I6D>&K77-/T"<VVI7MUXDL]/F\Q?\ 6"VMI#YEQMY'RXRP
M(]Z4<-5D[)?B@>(IQ5V_S/J6BO!/%/[5)_X2#PEH?@'P=>>/M5U_24U[[/'>
MQV7V:Q;H[-("-_4;"5YP,Y(K$_8.OCJ7PY\97AMYK0W'B[4)3;W*;)8MWEG8
MZ]F&<$>HH>'E&FYRT!5HRFH1U/I:OG7]NK_DCEA_V&8?_14U?15?.O[=7_)'
M+#_L,P_^BIJ]')?^1C1_Q'@\3?\ (GQ/^%G76O\ R:9%_P!B0/\ T@KA_P!@
M?_DC^L?]AZ;_ -)[>NXM?^33(O\ L2!_Z05P_P"P/_R1_6/^P]-_Z3V]>\O^
M1/C?^OL?U/'I_P#(VP'_ %Y?Y(^E****^'/O@HHHH ***:S"-69CM51DD]J
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MKS\UU5-OS_0[,MT<_E^IP7[-O_(C7W_81D_]%15ZO7E'[-O_ "(U]_V$9/\
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M];_B)481M;R_ ^0OC)^R%XP\<?$CQYK6D3>"[[3O%EI%']I\26<LU_I;QP[
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ME^IJ**QK5G7GSR7]?.[-:5-4H\J"BBBL#4**** "OC_]GG_D\;XH?]<]1_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q_\
ML\_\GC?%#_KGJ/\ Z70U]@5\?_L\_P#)XWQ0_P"N>H_^ET-?7Y)_N>/_ .O?
M_MR/CL\_WW+_ /KY_P"VL^P****^0/L0HHHH **** "JVHZ;::Q87%C?VL-[
M97"&.:WN(Q)'(IX*LIX(/H:LT4 >$7G[#/P/OKJ2>3P+$KR')$.HWD2?@JS!
M1^ J#_A@[X%_]"/_ .5>^_\ C]>_45T?6*W\[^]F'L*7\B^Y'@/_  P=\"_^
MA'_\J]]_\?H_X8.^!?\ T(__ )5[[_X_7OU%'UFO_._O8>PI?R+[D>>?#/\
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M&^%'B+P?XATW3+2W2;5=+CAG8+*A>"TC;+2!$#LK8!!QA0V*\U^%W@/Q1/\
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MP_[#,/\ Z*FKVLE_Y&-'_$?,\3?\B?$_X6==:_\ )ID7_8D#_P!(*X?]@?\
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MF_%7C7_A%=4T"R_L'6]7_M:Z^R_:-*L_/ALN,^9<-N'EQ_[7-$:E7X8R?W]
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M-6O_ $ )O_ H?_$T >VT5XE_PTU:_P#0 F_\"A_\31_PTU:_] ";_P "A_\
M$T >VT5XE_PTU:_] ";_ ,"A_P#$T?\ #35K_P! ";_P*'_Q- 'MM%>)?\--
M6O\ T )O_ H?_$T?\--6O_0 F_\  H?_ !- 'MM%>)?\--6O_0 F_P# H?\
MQ-'_  TU:_\ 0 F_\"A_\30![;17B7_#35K_ - ";_P*'_Q-'_#35K_T )O_
M  *'_P 30![;17B7_#35K_T )O\ P*'_ ,31_P --6O_ $ )O_ H?_$T >VT
M5XE_PTU:_P#0 F_\"A_\31_PTU:_] ";_P "A_\ $T >VT5XE_PTU:_] ";_
M ,"A_P#$T?\ #35K_P! ";_P*'_Q- 'MM%>)?\--6O\ T )O_ H?_$T?\--6
MO_0 F_\  H?_ !- 'MM%>)?\--6O_0 F_P# H?\ Q-'_  TU:_\ 0 F_\"A_
M\30![;17B7_#35K_ - ";_P*'_Q-'_#35K_T )O_  *'_P 30![;17B7_#35
MK_T )O\ P*'_ ,339/VFHMH$/AV1W)QAKL#^2&@#V^O(/C9\1DALW\+Z0QN=
M3O"(I_)^8QJ3_J^.K-TQZ$^HK!N/'/Q$^(JFVT;2Y-*M)#@SPJR''?,K8'_?
M.#7:_#;X.6O@V4:EJ,BZCK1R1)R4ASUVYY)_VC^G< U_A7X*_P"$'\)PVLP'
MV^<^?=$'.'(^[]  !]<GO65\?/A6GQ<^'%]H\84:G"?M6GR,<!9U!P"?1@64
M_P"]GM7HU%;T*T\/5C6INTHNZ.7%8:GC*$\/65XR5G\SY:_9-^. @MU^&WBM
MCIVMZ:[6UBUT=AD ./L[9Z.IX [C ZCGZEKPWX]_LP:7\67;6=)FCT7Q4H'^
ME8/E7.!@"4#D$8&''.."#QCR*Q^*GQR^!,8L/$WA^;Q)I,!V+=W"/-\O;%S'
MGK_TT!/TKZ>MA*&;R^L8*2C4?Q0;MKU<7U3_ *['PV'S#%<.Q6#S*$ITHZ1J
MQ5_=Z*:6J:_J^Y]GT5\C6_[?\*ADN_ \L4JG!$>I \]^#$,<]JE_X> :?_T)
MES_X,%_^-UR?ZNYI_P ^?QC_ )GHKC#(W_S$?^2R_P#D3ZTHKY+_ .'@&G_]
M"9<_^#!?_C='_#P#3_\ H3+G_P &"_\ QNE_J]FG_/G\8_YC_P!<,C_Z"/\
MR67_ ,B?6E%?)?\ P\ T_P#Z$RY_\&"__&Z/^'@&G_\ 0F7/_@P7_P"-T?ZO
M9I_SY_&/^8?ZX9'_ -!'_DLO_D3ZTHKY+_X> :?_ -"9<_\ @P7_ .-T?\/
M-/\ ^A,N?_!@O_QNC_5[-/\ GS^,?\P_UPR/_H(_\EE_\B?6E%?)?_#P#3_^
MA,N?_!@O_P ;H_X> :?_ -"9<_\ @P7_ .-T?ZO9I_SY_&/^8?ZX9'_T$?\
MDLO_ )$^M**^2_\ AX!I_P#T)ES_ .#!?_C='_#P#3_^A,N?_!@O_P ;H_U>
MS3_GS^,?\P_UPR/_ *"/_)9?_(GUI17R7_P\ T__ *$RY_\ !@O_ ,;H_P"'
M@&G_ /0F7/\ X,%_^-T?ZO9I_P ^?QC_ )A_KAD?_01_Y++_ .1/K2BODO\
MX> :?_T)ES_X,%_^-T?\/ -/_P"A,N?_  8+_P#&Z/\ 5[-/^?/XQ_S#_7#(
M_P#H(_\ )9?_ ")]:45\E_\ #P#3_P#H3+G_ ,&"_P#QNC_AX!I__0F7/_@P
M7_XW1_J]FG_/G\8_YA_KAD?_ $$?^2R_^1/K2BODO_AX!I__ $)ES_X,%_\
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MS1MCE''\+#/(-;U?&&N?L\_$WX"^()];^%NIW&JZ5(V6L593-M[++$WRR@=
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M9N ?XCZU!XF_;$\">-I[:;Q%\)+#7IK8$02:F8+EH@3D[2\)V\^E7_J]G/\
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M+9'TS17X+:MK>H^(+QKO5+^ZU*Z;EI[N9I7/U9B35*O<_LG^_P#A_P $\?\
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M *#D/_?N3_XFH/\ A1_@G_H"_P#DU/\ _%T?\*/\$_\ 0%_\FI__ (N@"?\
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M/^%Q>#?^@Y#_ -^Y/_B:@_X4?X)_Z O_ )-3_P#Q='_"C_!/_0%_\FI__BZ
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M^I_D7/\ AJ+X6_\ 0WVW_?B;_P"(H_X:B^%O_0WVW_?B;_XBJ?\ PR/\)O\
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M^I_D7/\ AJ+X6_\ 0WVW_?B;_P"(H_X:B^%O_0WVW_?B;_XBJ?\ PR/\)O\
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MQ)67/&E2@GTDY-KU<="[_P -4?"O_H<+;_OQ/_\ $4?\-4?"O_H<+;_OQ/\
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M7?\ \=H_XQOO7^ZG_F%^)>U#[ZG^1<_X:H^%?_0X6W_?B?\ ^(H_X:H^%?\
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M]V=OFD9F.68GD]ZZ"O/J2C*<I16C9V4TXP2EN%%%%9F@4444 %%%% !1110
M5'<6\=W;RP3()(95*.C=&4C!!_"I** /"_@3OT'QYXI\/ABT,6\C=ZQ2[ ?Q
M#_RKS;]M":X\5?$KX?>"DE,<%TRN0O=YYA$#CO@(<?[QKTSX8?\ )=/%_P#N
MW7_I1'7FW[2'_)V'PJ_ZZ:=_Z7O7TG#^F-Y^L8R:];,^,XM][+/9])3@GZ.2
M/J_2=+M=#TNTTZQA6WLK2)8(84'"(H  'X"K=%%?.-N3NS[*,5%*,59(****
M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>U<&"DI1=G>W]?UT[';BXM25U8*_=SQI_P B;KW_ %X7'_HMJ_".OW<\:?\
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M][E_@E^1\9Q9_N$/^OD/_2D?75%%%?-GV84444 %%%% !1110 4444 %%%%
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M9X>\%_!'2+G4-&>Y\$:Y/J>HM%/,4EC>9G A)B!9L,,A@HSWK7FHRLWNDO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX5O\4/\ H;H?_ V?_P"-T?\ "M_BA_T-T/\ X&S_ /QNC_A;'Q"_Z$F;_P
M;BC_ (6Q\0O^A)F_\ ;B@ _X5O\ %#_H;H?_  -G_P#C='_"M_BA_P!#=#_X
M&S__ !NC_A;'Q"_Z$F;_ , ;BC_A;'Q"_P"A)F_\ ;B@ _X5O\4/^ANA_P#
MV?\ ^-T?\*W^*'_0W0_^!L__ ,;H_P"%L?$+_H29O_ &XH_X6Q\0O^A)F_\
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M]%,MO_!M=_\ QFC_ (4/^T)_T4RV_P#!M=__ !FC_AI+XV_]$FN?_!1?4?\
M#27QM_Z)-<_^"B^HMF?\M+_R0.;(_P"?$?\ E0/^%#_M"?\ 13+;_P &UW_\
M9H_X4/\ M"?]%,MO_!M=_P#QFC_AI+XV_P#1)KG_ ,%%]1_PTE\;?^B37/\
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M[98'_O(W53^AZ$$5U-<]XY\?:%\-]!EUCQ#J$>GV4?R@MR\C=D11RS'T'UZ
MFOG<,ZZK1>&OSWTMO?RL?:XE4'1FL3;DMK?:WG<^7KS]BWQKX/OYI?A_\06L
M(93]V:>>RD [!GAW;^.^!]*L#X!_M#CC_A9]M_X-[O\ ^,TW5OVY=7U[4Y+3
MP/X&FU)5R0]UOEE8>IBB'R_]]&G+^TQ\<&4$?"2Y(/((T>^_QK]4_P",B<4\
M3&ES?W_9\WS/R>_#:DUA95>7^Y[3E^0O_"@_VB/^BGVW_@WN_P#XS1_PH/\
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MAS9)_/B/_*@?\*#_ &B/^BGVW_@WN_\ XS1_PH/]HC_HI]M_X-[O_P",T?\
M#2WQQ_Z)'<_^">^H_P"&EOCC_P!$CN?_  3WU%LZ_DH?^4PYLD_GQ'_E0/\
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MO;71-2TK3?!L6A-!]FCO+>&%('FQY12%HBY8$ELC'W<'X8KS\''EBURM>O\
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ME[U])D/^]R_P2_(^,XL_W"'_ %\A_P"E(^NJ***^;/LPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KYU_;J_Y(Y8?]AF'_P!%35]%5\Z_MU?\D<L/^PS#_P"BIJ]K)?\ D8T?
M\1\SQ-_R)\3_ (6==:_\FF1?]B0/_2"N'_8'_P"2/ZQ_V'IO_2>WKN+7_DTR
M+_L2!_Z05P_[ _\ R1_6/^P]-_Z3V]>\O^1/C?\ K[']3QZ?_(VP'_7E_DCZ
M4HHHKX<^^"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "OC_P#9Y_Y/&^*'_7/4?_2Z&OL"OC_]
MGG_D\;XH?]<]1_\ 2Z&OK\D_W/'_ /7O_P!N1\=GG^^Y?_U\_P#;6?8%%%%?
M('V(4444 %%%% !7P)_P54_YI?\ ]Q3_ -M*^^Z^!/\ @JI_S2__ +BG_MI7
MHY?_ +S#Y_DSAQW^[R^7YH^!*[SX+ZAKD/C%]*T/Q+I?A.37;.?2KO4M:DCB
MM%MI$)D221T?9N"@!@,Y(P1FN#I5(# D9&>:^PE'F31\O%\K3/T4^,7B#QEX
M8C^(NE^(OC[X?N?"T6CW5O::##/IQUN:9H0(X9HELUX8L0=A#!2"".37YU5]
M[^)OVP/">K>!/&VB6WC.2UTQ+"ZL=(T&WT,A+RWGL8HX85E\L&$V\PER6X8-
MP6&W'P17GX*,HQ:E&WRM^B.W%RC)KE=_Q_4*_=SQI_R)NO?]>%Q_Z+:OPCK]
MW/&G_(FZ]_UX7'_HMJ\_-_\ EW\_T.W+/M_+]3@OV;?^1&OO^PC)_P"BHJ]7
MKRC]FW_D1K[_ +",G_HJ*O5Z^>/<"BBB@ HHHH **** "BBB@ KA?BU\7])^
M#^CV-[J-AJNL7-_="TL]+T.U^TWES)M9CLCW#(559CST%=U5*]T73]2N[*ZO
M+"VNKFQD,MI--"KO;N5*EHV(RI*DC(QP2*N#BI)S5T3+F:]UZG!?#?\ :"\(
M?%GQ'+I'A:ZDU0PZ7#JDUY$$,,(E8JL#_-N68;22A48'?M61\2OCUJ?AWQRO
M@GP3X(O/B!XKCM%O[RUBOHK&WM(&)"F2>0%0[8X7'([UZ9H?A/1/#,E])H^C
M:?I,E],;B[>QM4A-Q*>KR%0-[<GDY-?#WQN\/?#O0?VI/'-Y\9;'4V\,Z]IE
MI-HMS;?:A#+<1Q+&8_W&-T@*G:&RH[XW"O0P].C6JRM%V2T6[;T[6_-''6G4
MITU=J[>^W^9]!_$3]H+Q7X#T'P#CX:O>^+?%5S)9_P#".R:W%";:55)V^?L9
M'R!G/RC^5=]\+?%7C'Q7I=Y/XR\#?\()>13;(+3^UX=1\Z/:#OWQ !><C!YX
MS7R=X7L? ^D_LV?#RP_:+TK6GL5DNYM-N[R.]*V<9<"&*9K=MZLR'**PQM4C
MC%=Y^PKIUW9Q?$&?2$U2+X83ZFI\*KJID#&(;_,:-7Y\LYCP>Y!S\P:MJV'I
MQHR:6J>^MGKT=[?*WS,J=:<JL4WHUMI=:==/U^1]#:U\2O"/AJ6]BU?Q5HFE
M26/E_:DO=1AA-OY@)C\P,PV[@#MSC.#BI[?QYX9NM:M]&@\1:3-J]S +F#3X
M[Z)KB6$C<)%C#;F4CG<!C%?)_BSP'X=\:?M/_&^;7M&L]8?3_!\,MI]MB$JP
MR& ?.H/ 88&&QD=B*\V\,^!] \,_!_\ 9C\3:7I%I8^(=0\86J7>IQ1 7$ZO
M/(&5WZD85< \#'&*4<'3E%>\[NW3O&_Z#>*FI/165_P=CZC\?_'_ %KP[X)^
M+.J6.CZ3%=^#2J6C-JT5^MT21S/!"RR6Y_V'()Z]J33OCIKUY\6/A9X7>TTX
M6'BKPT^LWLBQ2>;',(M^V([\!,]F#'WKP/Q/_P BG^V)_P!A"#^M=OH?_)QW
M[/7_ &(DG_I/6CP].,'IT?\ Z0G^9G[:;DM>W_I31[W\-_BE_P )EX3U77=9
MMM,\/VUA>SVKO!KEO?P".,C]X\T1V1DYY1N5[UNZ%\1?"GBC3;W4=&\3Z-J^
MGV0)NKNQU"*>*  ;B7=6(7 YY/2OS_-A=W7[,B7,MC>:GX5L/B;/=^(K6S0L
M6L48%RP')4''L#@]J[+0YO"GC+XJ?$'Q/\)=(33OA];^ +RRU"[L=/>QL[B\
M(9E58RBY<+C/RC[A/U4\##WFG;5^BM;3U?0<<7+1-=O7^D?9FF_$GPCK.K6V
MEZ?XIT6^U.Z@6Z@LK;489)I82NX2(@8LR%>0P&,<UT=?GEI/@/P[X3^$W[,'
MB/2-&L[#7]0\5V(N]3AB'VB<2.^]7?JP^48!X';%?H;7#B:$:+7([K7\'8ZZ
M%:55/F7;\5<****XCJ"BBB@ HHHH **** "BBB@#P[X8?\ET\7_[MU_Z41UY
MM^TA_P G8?"K_KIIW_I>]>D_##_DNGB__=NO_2B.O-OVD/\ D[#X5?\ 733O
M_2]Z^DR'_>Y?X)?D?&<6?[A#_KY#_P!*1]=4445\V?9A1110 4444 %%%% !
M1110!RWQ,^(VE?"KP?=^(M7CNKBV@:.)+6QB\VXN)9'"1Q1)D;G9F  R*X[P
M+^TYX.^(GB70_#^D#4#K>HP74UQI]Q$D<^E&W(62.\C+[HG+'  # X/..:]-
MU31=/UR".'4K"VU"&.5+A([J%9561&#(X# X92 0>H(R*KV/A/1-,UR^UJST
M;3[36+Y56[U""U1+BX Z"20#<P&!C)/2MXRI<C4D^;U,I*IS73T/-?BU\>[S
MP/XTTCP5X5\(W'CKQIJ-L]\-,AO8[*.&V4D&22:0$+D@@#'..H) .S\#?C/:
M_&KPO>7ZZ9<:#J^F7LFFZII%TX=[2Y3&Y-P W+R,-@9YXXKQCXK>++'X'_M?
MZ;X^\5QW%GX.U3PLVD?VPEI)/%;W*S&38WEAF!(4 <?Q>@)&5\%OB59?!_P)
M\0/BGXBTO6DT'QCXRDGTRUAM<W#0RL1'*8V9<!CGOD[1@'(SUN@G23C'5VL^
M[ZKL<JK-5&I/373LNYZM\5/C+\2_A]J.MS:=\($U[PKIL/V@Z])XJM+-7C6,
M/(QB=2R[3N'/7;D=:[#X'_$NZ^,'PQT;Q?=Z$_AQM35Y$L9+CSR(P[*K[]B9
M# !A\HX/XUY!^V%KUYXUNO!WP8T*Y:#5?&5VLFHM&,M;Z=&=TC-Z9*GZB-AW
MKZ-T?1[/P[HMEI6G6Z6NGV,"6UO!&,+'&BA54>P %85%%48OELWZ[??U9M!R
M=67O72]-_NZ&);_%3P5=W>GVL'B_09KG47:.RACU.!GNF5BC+&H;+D,"I"YP
M014D?Q"T+5=)URZT'6-*U^?28Y#<06FHPD12*I(CE<,1%G:>6QCD]J_.JX^'
M7AFX_9'F\02Z)9OKMUXY^S2ZDT8^T&(S%#&)/O*NW^$$#//7FO<;OPCHGP]_
M:B\>Z-X:TJTT+2I?AC/.]G8PK%&T@DVAR!_%@#)[]3S73+"PC>S>E_PM_F81
MQ$W:Z[?C_P ,>DZQ^T3K\4/P:N;?2=(M%\;:N;&^@2_74T@C!QF&Y@<1N?\
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M7O)7\K_J%?NYXT_Y$W7O^O"X_P#1;5^$=?NYXT_Y$W7O^O"X_P#1;5Y>;_\
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M265Q'%&I=W8X"@#))H \1^&'_)=/%_\ NW7_ *41UYM^TA_R=A\*O^NFG?\
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M&1[M)Q_NGTKW<CBYYE12[W^X^5XIJ1IY-B7)[QM\VTD>F6O_ ":9%_V) _\
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M_0<A_P"_<G_Q-0?\*/\ !/\ T!?_ ":G_P#BZ/\ A1_@G_H"_P#DU/\ _%T
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MN/C5X-MXRQUE9#V6."1B?_'?YUYOXN^)NJ_%.?\ X1SPM8S):SG$TK\/(O\
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M<_X:B^%O_0WVW_?B;_XBC_AJ+X6_]#?;?]^)O_B*I_\ #(_PF_Z%3_RHW?\
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M )(%^)^U#[ZG^1<_X:B^%O\ T-]M_P!^)O\ XBC_ (:B^%O_ $-]M_WXF_\
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M -#A;?\ ?B?_ .(H_P"&J/A7_P!#A;?]^)__ (BJ?_#(/PD_Z%/_ ,J5W_\
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M:Y_\%%]1_P -)?&W_HDUS_X*+ZOK2BC^T\)_T"1^]A_8F8?]#&?W1_R/DO\
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MIL$@?0'Z4_[2PG_0)'[W_F+^Q,P_Z&,_NC_D?*7_  TE\;?^B37/_@HOJ/\
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MH]]_C7U)X7\)Z-X+TB+2]"TVWTNPC^[#;H%!/J3U8GN3DFM:O0EFV54WRT,
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M\-+?''_HD=S_ .">^H_X:6^./_1([G_P3WU?7-%']LX'_H A]\O\P_L7'_\
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M1_\ 2Z&OL,D_W+'KI[-?^E'QN>?[]E[Z^T?_ *2?8%%%%?'GV04444 %%%%
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M''[;E]X0_;:\-_ 5/"=O=6FK)"[:XU\RR1^9$\G$6P@XV8^]WK._;Q_;QO\
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MP/UV:)QE9(]4#*P]01;\U[=_P5@_Y,E\7_\ 7[IW_I7%7H'[ ?\ R9M\)_\
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M&^K/3V"BBBD 4444 %?.O[=7_)'+#_L,P_\ HJ:OHJOG7]NK_DCEA_V&8?\
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M_P B-??]A&3_ -%15ZO7E'[-O_(C7W_81D_]%15ZO7SQ[@4444 %?EK\%?\
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M110 5\L_MG_MW>&OV6]+&AZ9%'XI^)NH(%T[P[ 2_E%^$EN-O*KDC"#YWZ#
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M_P"Q('_I!7#_ + __)']8_[#TW_I/;UW%K_R:9%_V) _](*X?]@?_DC^L?\
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M_P"ET-?7Y)_N>/\ ^O?_ +<CX[//]]R__KY_[:S[ HHHKY ^Q"BBB@ HHHH
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MQM:-U#*P]"#UK'TWP-X;T:^:]T_P_I=C>,<FXMK*..0D]3N50:W** "BBB@
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MC6+X5^'/A/P))<R>&O"^C>'GN0JSMI6GPVIE"YVAC&HW8R<9]37144 %%%%
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M/#>OWSZGXL^'_B"]\):G?R8W7OV:0I%<G'=XPNX]W1SWKZ"H **** "BBB@
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M*** "BBB@ KX_P#V>?\ D\;XH?\ 7/4?_2Z&OL"OC_\ 9Y_Y/&^*'_7/4?\
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MHZE_:%WX+\.W5_EF^U3:5 \N6^\=Y3/.3GGG-=5#"EO$D42+'$BA51!@*!P
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MO^_$W_Q%'_#47PM_Z&^V_P"_$W_Q%']GXW_GS+_P%_Y!_;&6_P#03#_P./\
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M\#C_ )G6V?PO\&Z=X9@\.VGA+0K7P_!-'<Q:3#IL*6D<L;J\<BQ!=H9616#
M9!4$<@5T]>5_\-1?"W_H;[;_ +\3?_$4?\-1?"W_ *&^V_[\3?\ Q%']GXW_
M )\R_P# 7_D']L9;_P!!,/\ P./^9VEK\/?"MCJD.I6WAK1[?48;NXOX[R*P
MB69+F==L\ZN%R))%^5W!RPX)-:^H:;::O9O:7UK#>VLF"\%Q&)$;!!&5(P<$
M _4"O-/^&HOA;_T-]M_WXF_^(H_X:B^%O_0WVW_?B;_XBC^S\;_SYE_X"_\
M(/[8RW_H)A_X''_,]$U;P]I6O2:?)J>F6>HR:==+>V37=NDIMKA595FC+ ['
M"NZAEP0&89Y-:%>5_P##47PM_P"AOMO^_$W_ ,11_P -1?"W_H;[;_OQ-_\
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MZ!Y_^ R_R#^U\N_Z"8?^!Q_S/5Z*\H_X:H^%?_0X6W_?B?\ ^(H_X:H^%?\
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MY1_PU1\*_P#H<+;_ +\3_P#Q%'_#5'PK_P"APMO^_$__ ,11_9.8_P#0//\
M\!E_D']KY=_T$P_\#C_F>KT5Y1_PU1\*_P#H<+;_ +\3_P#Q%'_#5'PK_P"A
MPMO^_$__ ,11_9.8_P#0//\ \!E_D']KY=_T$P_\#C_F>KT5Y1_PU1\*_P#H
M<+;_ +\3_P#Q%'_#5'PK_P"APMO^_$__ ,11_9.8_P#0//\ \!E_D']KY=_T
M$P_\#C_F>KT5Y1_PU1\*_P#H<+;_ +\3_P#Q%'_#5'PK_P"APMO^_$__ ,11
M_9.8_P#0//\ \!E_D']KY=_T$P_\#C_F>KT5Y1_PU1\*_P#H<+;_ +\3_P#Q
M%'_#5'PK_P"APMO^_$__ ,11_9.8_P#0//\ \!E_D']KY=_T$P_\#C_F>KT5
MY1_PU1\*_P#H<+;_ +\3_P#Q%'_#5'PK_P"APMO^_$__ ,11_9.8_P#0//\
M\!E_D']KY=_T$P_\#C_F>KT5Y1_PU1\*_P#H<+;_ +\3_P#Q%'_#5'PK_P"A
MPMO^_$__ ,11_9.8_P#0//\ \!E_D']KY=_T$P_\#C_F>KT5Y1_PU1\*_P#H
M<+;_ +\3_P#Q%5[[]K7X4V,)D/BI)S@XC@L[AV/M_J\#\2*:RC,6[+#3_P#
M9?Y"><9;%7>)A_X''_,]9N[N&PM9KFYE6&WA1I))'.%10,DD^@ KX_\ V/6D
M\8_'+XC>,XHV%C<";!;L;BY$JK^"Q']*R_B=^T'XC_:-O/\ A _ASH]W#I]X
M=MU<2866>//.\CB*+UR23P.,E3]-? _X1V?P9\"V^AP2"YO)&^T7UV!CSIB
M#C_9   'H,]2:^FEAWD.65J>)TKU[)1ZQBG=M]K[)?\ !M\Q'$+/\THU,+K0
MH7;ETE)JR2[VW;_X%_0****^#/O@HHHH **** "BBB@ HHHH **** "BBB@
MKE]9^&/A;7IFFO=%MVE8Y:2+=$S'U)0C)^M=110!PO\ PH_P3_T!?_)J?_XN
MC_A1_@G_ * O_DU/_P#%UW5% '"_\*/\$_\ 0%_\FI__ (NC_A1_@G_H"_\
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ME%>3:_(\_$9?@\7+FQ%&,W_>BG^:/'_^&1_A-_T*G_E1N_\ X[1_PR/\)O\
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M,J_Z!:?_ (!'_(\?_P"&1_A-_P!"I_Y4;O\ ^.T?\,C_  F_Z%3_ ,J-W_\
M':]@HH_M/'?\_P"?_@3_ ,P_L3*O^@6G_P" 1_R/'_\ AD?X3?\ 0J?^5&[_
M /CM'_#(_P )O^A4_P#*C=__ !VO8**/[3QW_/\ G_X$_P#,/[$RK_H%I_\
M@$?\CQ__ (9'^$W_ $*G_E1N_P#X[1_PR/\ ";_H5/\ RHW?_P =KV"BC^T\
M=_S_ )_^!/\ S#^Q,J_Z!:?_ (!'_(\?_P"&1_A-_P!"I_Y4;O\ ^.T?\,C_
M  F_Z%3_ ,J-W_\ ':]@HH_M/'?\_P"?_@3_ ,P_L3*O^@6G_P" 1_R/'_\
MAD?X3?\ 0J?^5&[_ /CM'_#(_P )O^A4_P#*C=__ !VO8**/[3QW_/\ G_X$
M_P#,/[$RK_H%I_\ @$?\CQ__ (9'^$W_ $*G_E1N_P#X[1_PR/\ ";_H5/\
MRHW?_P =KV"BC^T\=_S_ )_^!/\ S#^Q,J_Z!:?_ (!'_(\Z\,_L[_#GP?=K
M=:9X3LEN%.Y)+HO<LA[%?-9L'W%>BT45R5:]6N^:K-R?FV_S/1P^%H86/)AZ
M:@NR27Y!1116!TGG?BK]GGX<^-+M[K5O"=C)<N=SS6V^V=SZL8F4L?<U@?\
M#(/PD_Z%/_RI7?\ \=KV.BO5IYMF%**A3Q$TET4I+]3RJF4Y=5DYU,/!M]7"
M+?Y'CG_#(/PD_P"A3_\ *E=__':/^&0?A)_T*?\ Y4KO_P".U['15_VSF?\
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M_#(/PD_Z%/\ \J5W_P#':/\ AD'X2?\ 0I_^5*[_ /CM>QT4?VSF?_054_\
M Y?YA_8N5_\ 0+3_ / (_P"1XY_PR#\)/^A3_P#*E=__ !VC_AD'X2?]"G_Y
M4KO_ ..U['11_;.9_P#054_\#E_F']BY7_T"T_\ P"/^1XY_PR#\)/\ H4__
M "I7?_QVC_AD'X2?]"G_ .5*[_\ CM>QT4?VSF?_ $%5/_ Y?YA_8N5_] M/
M_P  C_D>.?\ #(/PD_Z%/_RI7?\ \=H_X9!^$G_0I_\ E2N__CM>QT4?VSF?
M_054_P# Y?YA_8N5_P#0+3_\ C_D>.?\,@_"3_H4_P#RI7?_ ,=H_P"&0?A)
M_P!"G_Y4KO\ ^.U['11_;.9_]!53_P #E_F']BY7_P! M/\ \ C_ )'CG_#(
M/PD_Z%/_ ,J5W_\ ':/^&0?A)_T*?_E2N_\ X[7L=%']LYG_ -!53_P.7^8?
MV+E?_0+3_P# (_Y'CG_#(/PD_P"A3_\ *E=__':/^&0?A)_T*?\ Y4KO_P".
MU['11_;.9_\ 054_\#E_F']BY7_T"T__  "/^1XY_P ,@_"3_H4__*E=_P#Q
MVC_AD'X2?]"G_P"5*[_^.U['11_;.9_]!53_ ,#E_F']BY7_ - M/_P"/^1X
MY_PR#\)/^A3_ /*E=_\ QVC_ (9!^$G_ $*?_E2N_P#X[7L=%']LYG_T%5/_
M  .7^8?V+E?_ $"T_P#P"/\ D>.?\,@_"3_H4_\ RI7?_P =IT?[(OPEBD5U
M\)*2IR-VH7;#\C+@U[#11_;.9_\ 034_\#E_F']BY7_T"T__  "/^1C^&?!^
MA^"[#[%H.DV>D6I.6CLX5C#'U; ^8^YYK8HHKRISE4DYS=V^K/6A"-.*A!62
,Z(****@L**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>stockchart.jpg
<TEXT>
begin 644 stockchart.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $-H:71R82!3
M86UU   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,Q-P  DI(
M @    ,Q-P  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    ,C R,#HP,CHR." Q,CHS.3HU,@ R,#(P.C R.C(X
M(#$R.C,Y.C4R    0P!H &D = !R &$ ( !3 &$ ;0!U    _^$+'FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2?ON[\G
M(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX-"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB
M:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S
M9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q
M.#)F,6(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+R(^/'AM<#I#<F5A=&5$871E/C(P,C M,#(M,CA4,3(Z,SDZ-3(N,3<Q/"]X
M;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP=&EO;CX\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD
M,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D9CI397$@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX\
M<F1F.FQI/D-H:71R82!386UU/"]R9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D
M8SIC<F5A=&]R/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP
M;65T83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG
M=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>
M)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@("@D*% L+%"H<
M&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*O_  !$( 8T"0@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M<X!8]@,$GZ?C5";5]9TK6[#3]5DL9DU-7C@N;>W=/)F52V&0NVY3Z@KT/UH
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M% !1110 5%:?\></_7-?Y5+45I_QYP_]<U_E0!+1110 4444 %%%% !1110
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M1>2__/S+^2_X4>2__/S+^2_X4 2T5%Y+_P#/S+^2_P"%'DO_ ,_,OY+_ (4
M2T5%Y+_\_,OY+_A1Y+_\_,OY+_A0!+147DO_ ,_,OY+_ (4>2_\ S\R_DO\
MA0!+147DO_S\R_DO^%'DO_S\R_DO^% $M%1>2_\ S\R_DO\ A1Y+_P#/S+^2
M_P"% $M%1>2__/S+^2_X4>2__/S+^2_X4 2T5%Y+_P#/S+^2_P"%'DO_ ,_,
MOY+_ (4 2T5%Y+_\_,OY+_A1Y+_\_,OY+_A0!+147DO_ ,_,OY+_ (4>2_\
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MO_S\R_DO^%'DO_S\R_DO^%2T4 1>2_\ S\R_DO\ A1Y+_P#/S+^2_P"%2T4
M1>2__/S+^2_X4>2__/S+^2_X5+10!%Y+_P#/S+^2_P"%'DO_ ,_,OY+_ (5+
M10!%Y+_\_,OY+_A1Y+_\_,OY+_A4M% $7DO_ ,_,OY+_ (4>2_\ S\R_DO\
MA4M% $7DO_S\R_DO^%'DO_S\R_DO^%2T4 1>2_\ S\R_DO\ A1Y+_P#/S+^2
M_P"%2T4 1>2__/S+^2_X5BOK\:^*DT0/<&0CYI?DPIV[@,;>>.];]>;W,VSX
MK*__ $\(GYJ%KBQE:5%0<>LDOD=V"H1K.:ETBVO4]#\E_P#GYE_)?\*/)?\
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MK?XT 2T5%]FC]9/^_K?XT?9H_63_ +^M_C0!+147V:/UD_[^M_C1]FC]9/\
MOZW^- $M1W%Q%:V[SW$BQQ1C+,QX I/LT?K)_P!_6_QKE_'W^C^'42,O^^G5
M&S(QXP3W/J!6->I[*E*?8WP]+VU6-/NSIK.\M]0M$N;.42PO]U@.OYU/7&>%
M$.FZUJ&@7+N?+;S8"'*Y7CT/H0?SKKOLT?K)_P!_6_QI8>JZM-2>CV?JAXBD
MJ-1Q6JW7H]B6BHOLT?K)_P!_6_QH^S1^LG_?UO\ &MSG):*B^S1^LG_?UO\
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M,H]QU%<6#J1C'V$G[T=/\G]QWXVE*4OK$5[LM?\ -?>7**,T9KO/."BC-&:
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MP<%>6Q@].U=710!RMOX=U..XMK21K3^S;349+Y)ED8S/N9W"%-N!AI#\VXY
M''-=5110 QX(I&W21(Q]2H--^RV__/"/_O@5+10!%]EM_P#GA'_WP*/LMO\
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M 1?9;?\ YX1_]\"C[+;_ //"/_O@5+10!%]EM_\ GA'_ -\"C[+;_P#/"/\
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M?_GA'_WP*EHKL.$B^RV__/"/_O@4?9;?_GA'_P!\"G331V\+S3N$CC4LS,>
M!7)W'Q&TU(V^S6US+(#P& 0'\<G^585<12H_Q)6-Z.'JU_X<;G42PVL,+RR0
MQ*B*68[!P!7GFDZ)J^MV]SJ5A>+:BXG=61R1D<'(P#ZX[=*TK_6;[Q5<?V/H
MZ+!#)"DEQ*[<A2%)'ZX]_I77:981:7IL%G!RD*XSC[Q[G\3S7')1QE32_+&^
MNUW_ , [HN6"I.]N>5M-[+S]3@9-'\4V5P-5FCCE:V0Y4LK J!CE1UR.?7\:
MZ[1-5TS6+*!U%JMS(F7@^7<I'!XZXK:(R,'D5QD_@#R;B2ZTG47MYQ(7A&W
M0?W<@Y_'T[4>QJX:5Z-Y)[IO\4'MZ.*CRUK1:V:7X,UO$M_8:3I,WF;(KB:)
MUM]L?);'!]L$CFJG@?3(H_#J7,R"26Z=I&,BY( ) _EG\:Q;"WUG5/&EM!KZ
M^9]A!D;*#:!CCIP<G'Z^E>A55!O$576:LEHD]_-_H3B$L/15!.[E9MK;K9?J
M<CI^A:QHWB"0V26DNGW$^]F?[T2YSQWSCCC(Z5UU%%==&C&BG&+T_(XZU:59
MJ4DK_GZA1116Q@13?ZVW_P"NA_\ 06J6HIO];;_]=#_Z"U2T %%%% !1110
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MES1FHOLMO_SPC_[X%'V6W_YX1_\ ? H ES1FHOLMO_SPC_[X%'V6W_YX1_\
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M[(0W#F5MH+#TSCC/>MVB@#G8/"\T5Y"K:@KZ;;WKWL-L+?#AV+-@R;N5#.Q
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M***ZCD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4G2Q\/=IU9<O]Z*E+[TTK>OR#ZU1>LJ3OY;?J;:^+;4Q M!-YF.5&" ?K_\
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M,<!0.I-8L'B_0)I8E@OMS7#JHQ"_!. NX[?DSD ;L9XQ0!K^<_\ S[2_FO\
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M7[3<K%-*]OYXBC*L=Q3OR%7)X&[/:MBL[5].T^^6*34&,+Q$B&=)C$\9/7#
MCT''0XH RM(?4+/Q%%I=Q80V\8M9I9;BT@"0W#!XA&P[JV#)E2??D8KIJYVU
MEOK758+*TUNWU..0&0Q72_OEC4J&82(,$C>O#+D^O4UT5 !7)7,.L76J7U[+
M96EU!:3>5'8S6?SR1  [XYB<%CD\8QV.#S76UQM[)I.FWT\>CW^IV4T+'SQ9
M6LMS;QL1GYUVLHX_NX- &]X;N[F^\.VES?*RSR*Q97CV$?,<97C'&*U*SM$N
M;N[L1/=36=S'( T%Q:;@LJ$=2ISM/XFM&@""^EFAT^XEM(O.G2)FBC/\; '
M_$UQKG6M)T^"]:TM[N>[:+_2H-/$4UNS.N]70Y)4J6&[@@]1WKLKVUMKVRD@
MOHUDMV'SJ_3 YS^&,USMPJZ-%YVE>(PL095%M>M]ICR2%4 @^8.2.Y ]* .I
MHJ*V,YMHS=K&D^T>8L3%E!]B0#C\*EH Y_Q<?.M++3Q8VEVU[<^6GVTE8HR$
M9LY )#';@8[FJ'AN6UM/$LFF0Z/'IMT;5I;H9+LQ5U"E7/WD(8X]P1P0:Z#4
M=-DO7CEMM0NK&:,$*T+ JW^\C J?Y^]4K>YUBUU*&UOX;*^+C_CXMG$4JID
MLT3$\9(R5;\.E &Y45S+Y%I-+Y;2^6C-L49+8&<"I:BNK<7=J\#22Q!QC?"Y
M1E]P1TH \Y#6NEZ7;ZS=^'=-0SE)K.:U=Y(4=B,*RG 5N3@CC/'!QGTNN4-]
M<V7E);:[IFL03OY<,%[*D<LC#^%9%X9NG!7/J:Z:UEEFM8Y)[=K:1A\T3,&*
M'TR"0: ):P?%Q\S3;:S^Q6EXU[=+ JWA(B0[68,2.0?EP,<Y(K>JCJ6G27WE
MO!?W5E+%G8\##:<X^\K JPX[C/7!&: .>\/-:V'B8:9'H\6GWTEI++=D,TA8
M(\80I(?O(=[^A!7D#OU]8<,^M6>H06U]%9:B),A9X'$,RID!F,;$@@97)5O3
MCI6Y0 5PE_!!J.M:E>7?AVUNK2UF^SW#12,+H@*#YC(!AUP>!G)'3/2N[KD]
M0O8]"OO)@\66D,K'=]BU:57'//#9#J/3)8>U &OX8O5U'PS9744444;H0B0C
M"*H) P/3 %:M4-)N+F>V/VNQCM"I&PPS+)'(#SN4C!Q]0*OT 5[^<6NFW-P8
MC.(H7<Q#J^ 3M_'I7G\?V71;2RU*Z\/Z='+.\3V5Q:N\L"L[*"NTXV,%)((X
M..QXKT*[MA>6CP-+-"'Q\\,A1UYSP16+/'K6DPES>6NJ6@(&R^Q!(.<*/,4;
M2<XQE1SWYH Z"BHK:22:VCDF@:WD906B=@2A],@D'\*EH Y?Q5&U_J5AIL6E
MV5[*R27"M>2-'C:5!6-E!(8[OI@=Z7PC<VGVS4K"PTU=.6V\II8BI\P2MNW!
MCGYONC![@YJSX@\FQ87\GB(Z,Y7:/.D5H7Q_TS?J?]T@TNB:K>7TH9H]/OK=
M\@ZCIUP&3(Z!D/(/T+=>U &[1110!P5W!:W^J:EJ%_X>M)[""X:WN7BD;[0
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MX4TY+.8S0B$;7*;,^HV_PX.1CMC%:]9?A^?3&TU;71V816@$;12JRR1G_:#
M,">>O7FM2@"OJ!@&FW1NY&CMQ"_FNI(*K@Y((Y''I7G%O;^')[2UMQ_;)N$D
M@$M[-]H\N)S("GFH\FT%L#MCY@>.*]&U*":YTV>"W$)>1"FVX4E&!X((!!Y&
M17-%8+*W%OKFB7%K")(I'N+61KF*0Q ;-Y'SX&U?O+CCD]: .NHJ*VN8;RVC
MN+61989%#(Z'(85+0!R'B^_32-:L-1BGC6ZB@E4I-;/*BQ%DW.2G*<A1GONQ
M4O@V:2[O-6N[Z,VU_,\?G6OV<P^6H4[&P2=Q;)Y]L=JMZ[I]W<7HN%TVUU*
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M>1)%.5'F)&^Y5;N <#(_"I:* "JFJI=R:->IIK!+QK>06[$])-IVG\\5;HH
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M/.'_ *YK_*@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M**W-#/T"UFLO#>F6MTFR:"TBCD7(.UE0 C(XZBM"BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH BF_UMO_ -=#_P"@M4M13?ZV
MW_ZZ'_T%JEH **** "BBB@ HHHH *@CBGCB5%ECPH &8S_\ %5/10!%MN/\
MGK%_WZ/_ ,51MN/^>L7_ 'Z/_P 54M% $6VX_P">L7_?H_\ Q5&VX_YZQ?\
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M4;;C_GK%_P!^C_\ %5+10!%MN/\ GK%_WZ/_ ,51MN/^>L7_ 'Z/_P 54M%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6854619088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 09, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 19, 2018</div></th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,911,031<span></span>
</td>
<td class="nump">12,067,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon follow-on offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering and follow on offering | $</a></td>
<td class="nump">$ 249,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price of stock issued (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon follow-on offering, net of offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,494,889<span></span>
</td>
<td class="nump">7,588,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_SharesAvailableForFutureStockOptionGrantsMember', window );">Shares available for future stock option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,726,225<span></span>
</td>
<td class="nump">3,556,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">689,917<span></span>
</td>
<td class="nump">922,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="nump">58,264,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon follow-on offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="nump">7,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon follow-on offering, net of offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon follow-on offering, shares</a></td>
<td class="nump">14,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price (usd per share) | $ / shares</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering and follow on offering | $</a></td>
<td class="nump">$ 249,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_SharesAvailableForFutureStockOptionGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_SharesAvailableForFutureStockOptionGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6674186864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Liability Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 7,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">7,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">7,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">8,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2024 and thereafter</a></td>
<td class="nump">20,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed Interest</a></td>
<td class="num">(11,496)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">51,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 40,396<span></span>
</td>
<td class="nump">$ 22,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6854471024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning number of shares, available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,556,507<span></span>
</td>
<td class="nump">1,698,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,658,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross', window );">Shares forfeited (in shares)</a></td>
<td class="num">(508,847)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(508,847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(324,579)<span></span>
</td>
<td class="num">(2,088,639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross', window );">Canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,636<span></span>
</td>
<td class="nump">795,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares', window );">Repurchase of early exercised shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending number of shares, available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,244,564<span></span>
</td>
<td class="nump">3,556,507<span></span>
</td>
<td class="nump">1,698,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning number of shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,588,405<span></span>
</td>
<td class="nump">7,391,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,579<span></span>
</td>
<td class="nump">2,088,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,999,419)<span></span>
</td>
<td class="num">(1,007,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(418,676)<span></span>
</td>
<td class="num">(883,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending number of shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,494,889<span></span>
</td>
<td class="nump">7,588,405<span></span>
</td>
<td class="nump">7,391,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance of options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.58<span></span>
</td>
<td class="nump">$ 3.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.18<span></span>
</td>
<td class="nump">7.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.87<span></span>
</td>
<td class="nump">3.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.64<span></span>
</td>
<td class="nump">4.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance of options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.90<span></span>
</td>
<td class="nump">$ 4.58<span></span>
</td>
<td class="nump">$ 3.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average remaining contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,392<span></span>
</td>
<td class="nump">$ 250,495<span></span>
</td>
<td class="nump">$ 3,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, Number of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,908,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, Weighted average exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable, Weighted average remaining contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable, Aggregate intrinsic value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Cancellations in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Exercised in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Available For Grant, Repurchase of Early Exercised Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6881107200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) - Credit Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerAMember', window );">Customer A | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerBMember', window );">Customer B | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerBMember', window );">Customer B | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerCMember', window );">Customer C | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerDMember', window );">Customer D | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6883456560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Joint Venture (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets', window );">Variable interest entity, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.1<span></span>
</td>
<td class="nump">$ 48.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable', window );">Noncontrolling interest in net loss joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RedeemableNoncontrollingInterestFairValueAdjustment', window );">Redeemable noncontrolling interest, fair value adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Payments to acquire interest in joint venture</a></td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_EquityMethodInvestmentSharesPurchased', window );">Equity method investment, shares purchased</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interest, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty', window );">Threshold period for unremedied material breach of the joint venture agreement by the other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn', window );">Threshold percentage of fair value that is no less than internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_VariableInterestEntityPercentageoftheProduct', window );">Percentage of the product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gh_SoftBankMember', window );">SoftBank | Guardant Health AMEA, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Payments to acquire interest in joint venture</a></td>
<td class="nump">$ 41.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_EquityMethodInvestmentSharesPurchased', window );">Equity method investment, shares purchased</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue', window );">Redeemable noncontrolling interest, redemption value</a></td>
<td class="nump">$ 41.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_VariableInterestEntityThresholdPercentageofFairValue', window );">Threshold percentage of fair value (greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EquityMethodInvestmentSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EquityMethodInvestmentSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RedeemableNoncontrollingInterestFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Fair Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RedeemableNoncontrollingInterestFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_VariableInterestEntityPercentageoftheProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Percentage of the Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_VariableInterestEntityPercentageoftheProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_VariableInterestEntityThresholdPercentageofFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Threshold Percentage of Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_VariableInterestEntityThresholdPercentageofFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Threshold Period For Unremedied Material Breach of the Joint Venture Agreement By The Other Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) attributable to redeemable noncontrolling shareholder, unit holder, partner, or other equity holder of a joint venture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 24(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the consolidated Variable Interest Entity's assets included in the reporting entity's statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=108788376&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gh_SoftBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gh_SoftBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>28
<FILENAME>0001628280-20-002613-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-002613-xbrl.zip
M4$L#!!0    (  Q)8E#H=QDZ^ P  *(\   :    83$P+6ME>&AI8FET,3 R
M,6QA;FUA;BYH=&W=6VMSV[82_=S^"E2Y[:0S>E#R(Y;L>$:1W,8=U_;83C/]
M= <D(1$Q2+  *%G]]7<7("GJ$2>2U6NGF:DKDB"P6.S9/;L 3WX87@WN_KP^
M(Y&)!;G^\.[B?$!JC5;KX]Z@U1K>#<G[N]\OR'[3:Y,[11/-#9<)%:W6V66-
MU")CTEZK-9U.F].]IE3CUMU-"[O:;PDI-6N&)JR=?G^"MTZ__^XD8C2$_W]W
M\D.C088RR&*6&!(H1@T+2:9Y,B8?0Z;O29LT&F7+@4QGBH\C0SI>QR,?I;KG
M$UJT,-P(=GKV$'&?FY.6NX3!6OEH)[X,9Z<G(9\0;6:"O:V-9&(:(QIS,>O=
M\9AI<LFFY$;&-#FVSS3_F_7:7FJ.47IX\_2$DH3&\*[N[W4/AH=G_<.#_K#K
M=8\ZA^UVMSOX97AT-NB?=0>UTY,6A?_L6\6?8F3!$]:(&,ZEU^YX/QX;]F :
M5/!QTA-L9(Y3&H:@A09>]/8[Z8-KP9,0--4[[.S#G1413_#.NLGQ)&**FS5O
MM/#6Z0F/QT2KX&UM'#4_I>,:H<+,+_(><WGW<>PI#TW4ZWA'\'N;@<\>2-MK
M=MJ% *T=:\A;T,]A\V!3!96O^.KTZX3TOB1DN[,@U-&F(N$+@112]5YYWALO
M\.#U7S_T;X;]RSOR_JQ_<?>^D/3K.WVSIM.?7NUUCN=_-N^T4-Z!=T"N62)]
M'4A#AHI/6)W<L' J94@&W,SJ9- GW7WO<(]\N.T3LNU0RS-H;2_S?-Y'!P?-
MP^Y1\^CHZ,VV_;EK;-_C!@PC*$9XXDS;[?UNM[NV^T!P]*::J0D/F'ZR2O="
MGWY^'KN8S'S9GFX CTN[O5E@;!MG5(4T,1!0A(F:@8P7/4/%UUNOL;%/J[C)
M]L8>O;VAOWH1 A0.TI?&R+BW5_IQ)U0 ELS4+L0:LH#%/E-DKUT'^M#N;J6D
MW<DSN+K\Y7QX=GEWWK]X9E&>W62&JDEN>! !NL@%38!^/:LX!P>'Y ^:D'>9
M8@FY-<UGE>9":M(71NHB5G8ZB_(8Z@M& B9$#J:W-:]FKW5*@^(Z'[+ FY%I
MKWT(8%L"H+WW&"\FJQS2@/F8L!C!,</]G!BV3(@/\Q\MVW2A^80IPP,J<JV!
M7+7'5;RDH 6&U3W<F(XZ)=^PWI(K=W)_7LKU S_!-JKLM;'E1&P?(0NDHIB?
M]3+H3J$@R+CC5,B93;0H6%0XX5JJ-9.V:]2R1K61Z[:64YGCITP;/IKMQG=3
MA0[BOK=U8/F<=%6M6YO=@;AW$==$, /NF4RY$"15<L)#1D)F*!>:*#8&5X=)
M[DQFBK"%E:$DI<HT#."N6"7 G"*_YN2#O+?LHT[.DZ!)7@,9(3^].NITO..!
MC%.:S.Q5^_CG)B%520*9P)1-9@#.^!(,QQ4C=*P8LV/[S$P9.#R0B= DM(WR
M+F$:)@*Q=<H"0XRTSW3F?\++F-K^01E,CNR;.DN9T@P2>'NI6"IH8"]F]@:U
M.N$PJ7)T3> *&L(8<&6M%_4DX!>H"4;461 M#\F30&2HQSKQ,T,2R#$$CSG6
M$(RL.^7^EHD9Z71MS-\G<C2"]T#,BL[MW!8F&T$L<BOG Y9@'9(,?J/D$\E#
MDJ4R<9W/E6=U4BI[@XCQK'8Z-TE0R3I;3$H3I&@K&BQ1"#G5WP(0[>742>)+
M$3[J'6\-@(X,J6%KO.-3!ZZ=]K;LJIID_0FXS(URS!.7WP$V%I:I3AA8>& @
MT2:_T01<QHSLU6VY#-P!T(A(9N.(<$,XO@8QC:>VYF8B:IP%I-(5]RIZ<,,*
MJ@W)X!U!ELATQUOP0V< %-1DX8@L$ET?BL449 >!*:@([SB#8V")F;)0G[LF
M %*\QC#K*!GXED!Q'R3W&1CDMP"XC>P1?1%+M'WPLLP0O49,/TEH-BM7)ZB(
M:Z.5O5N4()9<26[$SKU;7UUT NN>9'!GPK3U^T7W,C/:@/_%>^RO#$>F4PB'
MFKS68#JW1@;WY"JU4:-U<_M!.ZO $'C)D+M%3# -#'HQIF$8HK,\X!& AH)8
MH= 'P,#_Z72:GD=2#&TH \X*IRDX30(4GFH8K4G^7  -P"H H&@^XC /F'<B
MDP9[ .L%NXT93?*H;_TI XOC2-ZQ;VDY)@0;$ GDKJ =[D#4*9]3#(R@!(7&
M/X-5M$X+,#>"B*LH G6*8%]L-@#SAF$23O$YL =$9_O-,3B*G)Z$>3" 'SR!
MIK%;3>J#]JWB$(_S2#&E8UA9 +-#;" D1'QR*<&G,%S2LP+8KR^@"P5J!P:D
MT3=!IYVCMM<\P/6Y%J!(D%]HB/$ P)PQF$PE1":0U\C4FAF.DKC.\X -JL87
M8-"-@^[+P_LML%MRP>B$M:YQM3'M(E>CT<O"?G^1GI:^&PAM)BBB1P<1"S/A
M4#V5ZAZL<@H0@OB2D#W/0DE;4 '7O*^74$#N5L(!7J5!H#)&)C1P5@@&!'<5
MQ!T,;180D10\I#/M;'VM7&7<R;O3J&4'(F.MJT0V>HG97$"4G(46W.#LP  3
MF%N&=FH["EU/ M?+A6.+:^G T/7 /D,Z6^293?+"[/.)I;H7&CA78\$.(;3-
M!D6%;*.%<@R'P7TBIP"2,:L0+\UHC%&*F'*#E8R4C,FO0OK@U@<19R/R.PNQ
M$(&^ 7RA1<5JOAA*IBVDYDD? ,2'F'5/"NH8N+"39@J"%]-K8ZVVRI1.F;EG
MUD;Q ,.V>Y@E0":+8&SDF $"E NT!1UT ;MOV\R3TW-P]6!0V+5K7@3]PH64
M$BUTX/!<4 6<#4!28F8\CPP =!JOZ9"F$+T#6RZ#'$_D_H&ITF/8B/V8NNM6
M":5;*<6 5<#1K'(Q4<T5 C%-2,?1\9UJ\Z(F\!F.E.?8.5=ID@V<Q[>!TW<R
MR5X(-(=,I]PP9VR;@.\Q/HGAQ8'2QYE:1MGVO+H'G-)%,CE.0(@\NQD!%HTN
MDB#<GZAR0(2RO\07<4B)8,,R"&9,$[9*PU/,V4H3DQ5*;M?"L:A^4<58$Z*6
M=K*^.FS98QI557<V-BGWQA-.".Q@]-4(Z?Y&:EY0'[.&]:P-.@(6VJ-B"J2D
MML69CW]0W@WV)+\1]\$2-N)FEQYD!_SX/*\+*BFJ=:3/T-P"Q84#\?,YD==E
M8=,^UTA.;7PK6Q2LP9+3"%EH1"%X32!]HSF#MD$JRNNY-LBEBDVXS+3 *BR!
MI#3(K-?(LZM<C)_K\"A@J2T 6@<SY9I5"BXVY9O7E6U!M]IR)3FM%YEI'3V0
MD$$U1Z5(*3)ARFB_[( +[<SEA<F5BEUQP(KQV <*GSO6P=6[FS[./.99K*M%
MIH7JTKST\+D"Z+^NPG3V@*&"D9M"83CG70;DK?%DDRY0$I&^P6IAOE60(F4"
MT[%6T8^YZ@M.[JB@FOY=8LG'PX- HAME<4D!.L#R+#6T&Q *#&R<;SI4=QBL
MX:40AJGCI$*&8P?!$"LW0F,CB,)Q9C(J$$08-\-RW\14&#[2TG""F-TD[?LV
M#*=O&A\1:?,-Q1?CA >0IG!MRET=5QNS]:[EW8W579^\V)9G+7E]NIDG+/E>
M&E;P="5G^V*'=D\*25AAH+B%QH$]8@V$R] Z7V")+K%@W!(Z]-B8 U0Z"\ 3
MH<?B"2V8ZO+8AQX6'71>URN*9;8PF(_M:I8DWU!,9'YC::,P=Z,C8??Z0(81
M# H(,M)0MPMFRZ#,?.WFX7R[,Y+3%=DQ@OEL/KG0BK.\#L4R0(M,L77;5669
M!CH+(H0XA*H\LIU=+04Y6SG$X#,%8P)[L0% 49BPV_QC#Y@I<@/=N;YTN6&!
M-I7I?V%&=F7W1OL!QG[T7"\&U06U@BS?%3RHE=&QD-($'<FR<</6D9<Y"JZ^
MRY?"XL!Y6;6>[UC F];"'![/77]%V1'>CHE/@WNP,7@%[ Q?1],JP@Z6 ']A
MOK(;;YVC<N>M@B\@04CEW!Q86-]\8W[]28!_\18]*/#< MY1793QKPR+.[8J
ME>]/5!1LD/;F2X0KBO*E;I\!<8XPC]GVA&[YD.(Z_':.=E2CO<7L'K0\JS^I
M?+QP6FE'PCWF3%JZ!1P-4AU*?F=*@>/\+_Q[<5, -K,@Y L4\(_K.KEF$NSW
M!0JWUA4]2<X="+7U>=9GD^$K'<P.Y#JOD]73MG7G5X$-ABMATX+:;@BXN(#1
M )V]K4+@AO &R[TJ?Z7U@H%Z:S[GJ7:7X/:T.%XXS>JY(Y,;'8>MZNP+7X"Y
M<ZWV*Q_?,I%&((6@J6:]XL=*16]^.!::P/#)VUJG.!2[YBRL&V+OS8^5D[.+
MSP[WYL^^?)C6F=,2]"MG?E%MU>O<_*JW;!W7WEE<+3R-,!)RVHMX""NTBV_1
M?GK5/O2.EZJ7FQW#W='D_AGHW1;<<ON]BB]%W$58KT;<U0.^2T7B_[.7Q%-B
MH(T5QDPV_/?"/B!X]@\JU@KPU5LYFW[(^&93*=\\ME?Q77%A/]?]_L1^1WSZ
M/U!+ P04    "  ,26)09^_0;M\0  #,:0  &@   &1E<V-R:7!T:6]N;V9R
M96=I<W1R86XN:'1M[5U;<]LV%GYN?P7J;COIC&Q='+N)Y7HFL;-M9KI-)DTG
MLX\0"8IH*((A0,G:7[_G E"D+D[L.&/'Y4,2B00!G(-SOG.E<OK=Q:OSM_]]
M_4*D;I:)UW\]__WEN=C;[_??'9[W^Q=O+\1O;__SNWA\,!B*MZ7,K7;:Y#+K
M]U_\L2?V4N>*DWY_L5@<+ X/3#GMOWW3QZD>]S-CK#J(7;QW]NTI7CK[]IO3
M5,D8_OWF]+O]?7%AHFJF<B>B4DFG8E%9G4_%NUC9]V(H]O?KD>>F6)9ZFCHQ
M&HP&XITIW^NY#".<=IDZ>W&9ZHEVIWW^"HOU_6JG$Q,OSTYC/1?6+3/URUYB
M<K>?R)G.EB=O]4Q9\8=:B#=F)O,QW;/Z?^ID."C<&'</3YZ=2I'+&3QK+XZ.
MCXXOSD<7P]'CB^&3P?/'P\.G3\^?/3EZ?O'T\.C)WMEI7\(?>HK^:GR<E(VO
M83N9SM5^JI# D^%H\,/8J4NW+S,]S4^([.:F1K2I4[RRC1R=IZK4&T_0UP4O
M,3%9#%-XAL'9#D_[>/^:.\M4TEKF\;4WYI\@GMQ@ Q'(CBH_?PM;>'.A;%3J
M F5=F$2X5(DW:JJM Q5P/W[_9#3\>6S%GRJJ8#X-\L-W50E2?-]H>5V5MH)M
M"V=PQT33<!3(:M#PXC)*93Y5XEGD\/;PZ>'C6Y&,XVN3<OQYDO%W99U.EI^G
M-H/ 3AI^HAW,'9'>1*IP0EIA@('E0ELE=![KB# ,KB@-0E/B &1P!%/ SAJ#
M2_6ATJ6R/?B4P/ \ N;#,R[55BBOE7!8*&>CP7BA>O1I. Y7*KM^Q51EN"+S
MN'$5EI\5,E^&N[0B3OYK)<L8I>(W)3.7]L3+/#H(S/Y\</GQ^\/1^ ;3[6+Z
M6^!D8K+,+-!$Q&WU]'3.X)MU)GI//(A4Z21PM2C-7%L8:<-0@/$\AJ/"47 ,
MCLX-A^N$#A''Z3PR96%*26O@R*U/39:97%@A2R5L-9O)$O6(1L.5#Q5L/M$P
MC Y7Z5* EL/)NR4\N#I\/ Z4E*3*,L&R\H4V>B#>*5&5H.)+4^&R8'AC6!LL
MM8B]-0:Q5#)*<>Y%JN$#DK):A>9J[%W6(FMQ0MQVHD$WIU8LM$O7,08W5>/,
M.9R9MG@V/3A<H#>.O7L!"\*%&1%U<%L0,+@1!-PU#.U0L%]5KDJ9W>V^;I<W
M-SV?5^OJ#S!:KNQQ!=I07M_R]5"TO2[U$,_QF>;  _'J9CI:@<*5L'\K#H\&
MO<& _@B;@J(11C5I@5T *) F25'(4LQE5M&D_QH<P&/@EA= '3U\('X#V5"E
MW8Z)H,8(/^ <QZ2IN1)SXQ1I'FD\30(&+(L%;A/6!05T.)^M)C/M'#\H^3%8
M@R9._9K(@-B(W#B1RCG8O6I694#QG)9!U"97%C (L5QE_CQ@FA@@,7(&Y@!D
M2:\@ <XU5K"A&<@5P1"P)*M "S0@JC]5W)L5D;0.!^"5UBZ;'& R")KK_?20
MUK_A,U&:+\%\,-0Y#:C4(@17Q!%6$>K#-QZ+,L?[=:ET8J& C4LT62#V*!#(
M*$"]2GFS +COJNN>'G!,(6O!NH%@$6@ZE2UI0Z"!.@:IM"C!N/8$T%U%F2R9
M:SCYQ(#Y;S'_:LK#G%^(]KN&D/L 8R^]),XQ)/8RD&EP%6/&#5#3&'AGLHH%
M%0=?I2V?*C+X8*[0H;4*3E;.I<[D)&-@B#'FT1-:$B=IJWSB%.-B(9<SOVW$
MC5A-'",">;U AIR 4U![  U)HZ=+#4NU)<M4#L 4W&K0MS79NEI3"'QR@P^I
M68'X0Y)=.XSH=<=TAWD*_OD<YL)O :!>-=9>P?(V!O? 1U(YBS3;@$+J&#G7
M0Z36,?"7;_;(O5OR?1R8 _^!X]8BKQD4>?U>K7F19Q?P9ZXS->5]?.S,6VH<
M!P"0,5))$)$D<)NAP-6K!OQLS+XB_3ZJ^GWP6&[-FWL&>KKOY'MEX)3$ZSID
M>4C,NADN;@:#V]C7<,+>!"?LO.V$O=P(E+8^]9P"I;NV!7?/][VSYRJ2%02&
M"#(MV/\4+Z^W^1C^BP,D ,7?X "W?#:">;, X?>PMMT=;IF%A093@]"&Q@K0
MCGPXLC]^CMJWN;&K_I&XGW(+L6($Q(4;! M)#B5X8!7ZHF"+ ^[B6!%7 ,41
M/ ,79DH1 [:YU,AI &JP4A8-+&#I H.6?'H@G@E;J B]LUT3>.SWRY@\6[+7
MW#R 7=X@Y:Y2J<O=@]!\D@E*M4J$NH2 BB3!),!0579>G0].KR]X2562X^0%
MS+*$X9& ]=:4&)FK.@YKV&P8E2D,?JR^=$O8R26MZA9FWZ6ZA)@ PD5,-HM'
MQ\?[H_[A#S_MTD*O2'C+H9-CMGI%_BD?K/IO&#D++.: 8D+<84&<*":GO"<'
MD<B2V\S1]?!K5GE_L9ZN5(A.<,V[FG@T@2H2:'0'9P9\M?5@J*U:<"7H,V@0
MJJ #E@2MI'SC.A*R3_>@S@N]=%4H9-:N,V)DQ+2%2TTU33\VLO9/_1#")ZMG
M1:96,!48MQV&.IRY99S9@?:8?J$T ":T29\@Q&)YP6+&.7X0+^L/+VD?X0M<
MIRP699KH&8PHYBR+<CJE5!WF=KKCQ"?^K7/0YV7OAG6 UGGV1)5G$&ABC+;I
M1]3(V$S)2<S_P6GD#%P0SU:S7K-. ;L @^]PJ@(3<LX'E*#2[#J<P\8I'W">
M2@ADR]K9^]/Y'5\ -"^HN,"%,FLRCAK5)0"YK=?%OT_$(_W3C]\/CP=CRG !
MT^:\-1F%0!YHCI0BN)N4"#T.DWL3E<HLP?4J.X99FM/X9U%^2\9!E$P]P]&3
M,E1!I$AT7($Q !KB"IVFA<>IO':@&H;#.S_L')%R*0 SLU2*+LDIUEB0E57M
M/S5]-MKC)VU23L%TPC%46'_2U#I1-$J]G,+SAC PO^:Y+Q_ ,:V$YG>Y"#NZ
MOL29*U%^C/<?Z?DUZ9IB.)RO4A4Z)YG,T*J"9XJA2.1*T,AQD/C82SQETM;D
M:,4-BAS0LY9% 3XQYK4J+& %N<%@ @M06-^"K8;TU9)R<"@"H6/%[ZM9%J!:
M 8D&'3[3A*DTKJ:1 JF8F!^ACE@.I%:;_;N"TXPUL6?L\S^>M@#73*-..,6&
M;KU.KJMUL;98?*,4TQ+HQTH?'PEN-I,8;"5U,HDK :V]]5H/>3,>.*@Q>&(.
M6%ZZ;),--M[1L?OLT,8&;QRS9=9L\9O#XIS0!(H\\SU__LHUSDR[H(O/9H Q
MD:R#S&T"E?BJ$&S,9V5#L@RK[G#PN6O+-\?322W[*TD/,K,33GI;881+S:S\
M7.=:JVRM"EJ'6PM:[:&865THT#D8NY(4/B],'^<.1(T*1,17/O_\"D5KNM]K
M4K^ W52Y5S,*X9F >EDR)4B@MU[\T>FLC62\NQB\=5J1_%9*=7(5JV!WM6ST
M7T@0TBD*4@\MHL]F(+3D<5/SF;H&,7HM02\_]9@_=D"?+0>=RU2WB)1J:M9B
M0(2FF7P/Y@-PS!#T(3.KS)$&(Z/5)<!"'1>%^(R*)G# D=KE$DMTJ@ @X%]J
M8/"05\C2D5DQ$XIOL0>H-'5>RO?D<",%SD^YF^VQC?A3Y[O73WV3$0>!M%]:
MD(JQVH)5PF8/?'@E/S#>JG7^$&I>P:3M#-I&,J>Y4 W8)&JT#3G(*1:(#L3+
MO&[S8"L=RN$RX">JB2\BQ!NU!MRBQ3T6QEH=JE0[N .[X0K$^BP4B?C8MW;3
M0AVD;-5?".@ 8P#S("A5,5L"P(8(,<G#/1K'64%^@Z<Z='YMGGJGJZRK;1GD
M)B/'QIY F!P8XF.FWZM,I\;$G X&&Y!7=);!+?/(C!PVW*%\1=*2"E-PT(7)
M=!0JDK DZ@L\ I):YZ7<LF!O /L^;4@ D4B@TNA\;C*,07*$^HKM#$;%(+KH
MM<KH0Z7;^PE"(+9R@+20I3_4;"'R8 6>5QFZ[)YB<O!!52P1X=86HQ*O13]Y
M-VE(3=0@!GR<RG*O&CQ^N:RKH;5+L!4XR'DEL\AZ3ZSVJY%ZH6X!.I9FALI+
MOH B0PB(1'="$,0IJE"RW#8O]GZ4.$-J0!(QZ>\K9J2U,7@$2[S+*D@ME3N
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M9HI,<M:&H]7Z+B:R=:0!\EV[U;7NE:>,6G@/"7-&";X:@Z_)9$M\'X"KGDP
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MU%9QM?"S2YR=FE=<B.WZQ4U=\!502P,$%     @ #$EB4#"==/ ! P  O0P
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MF^%CI>ZG^^-3764WU@-WD]],W"=&]P=02P,$%     @ #$EB4!$]%6UT"
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M*\9*,E!1KAQI^X=^ST.!;:Q?,"V$F\CUB]@V"&Y&PP_#07\TO+HD5Q_(Z&-
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M"GFG!"I"#\^0XR@"Y6-!-]@+1 ;1<4^XER=<N!N$"R94YBX:(!IY%$&-(R:
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M0H$YT,#C"M0-F,70'3SQF2*3D'LAT2G^6O2?0 S-!\$%1%P+T"VHA";<A+!
MG3#/.HCC)N":]&&9\'!@4X;3Y6TX4N;%*5,]<,HP$O 80(GX7H"P"'P!<[BM
MEN[S.( H35'QPV=/I#Z,"4!?0EP12,*5F)($<(H40^H)L>!0#E^]-C70U+>E
M1!$M4@$&0!P)Z+;3:>N/1W5( B$G>L8JQ49<&X6I@N+%S&_PLKA$#CUS9L/;
M(S]>G!_GA\&/P0J8?O[QG5NYJ.N< ;F*Q1 L@X!#\T2?6J3U"%7,8AHPRA$K
M@#W"-.*&ZQ![H%D$&0BS$+9]KCTA=0K],#<I*3)P)TIZS(?+FIP EGT&Y,@
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M7IELMNK+"G[[UF1V5KL70?*Z-CM%VY(ZJ \=-9MGC@?)E)<)T 48 6J^F E
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MQF,_FI_MV$^&0<2FYT^SN/@AH1.BOSP%_6STR3 ^B(*H&+HL*H*AZNI__OQ
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MB;Z*XI,\!HRGTTD?-=-D"M=[%$7+\$'/;<0A;!67H.((I2KH)C_')ZXD(D]
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M*%XC,!\$DQRH'8"AY)%ECH%$N<8ODCB5H\0X7AF!)I_I ^Z?8/E@]/XNN2S
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M[J?0?R'H+9!\5PO+_X,3$="O4S._D';3Y#4PO_^'3_WGXDX6<0_97B <05_
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M-L\;YP.J^&J C1:,G-6L9R.J<I-0,9.2O?34N7G6YDU<6$K(FHY7R0\B:2_
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M(?<IK+FGY+;WN+E_>#_^G(79.CPR O1D'[\?O_S5T?]J_N0;9)I\;\B\SF\
MI"^5Q4:[.N,NXOL1\CAVOWIG?^ZU):H1C'GQ=BJC5!IT$G".%B+4+(=K#PY<
MH.SI?;#Y>)'Z!B+;R2K\*/<NS,T47-S_K'P-7S??'WKSQ0QKTN2TPEV0-B"2
M :(&.*F6=?H*B+U!\C:)* [[=A8^)[X&5%\7GB?QCQAXV@O)]+#$'@0M)HF<
ME&N)-6.>PK+Z&C-M=LQT(3S.F1+<=9R-KG^!M*.Z( '*_#5T^K,;NC:':=9&
MI5L)V#9-6X>7M+OP?,:R8:J-2R+F)<%@3C'YDUPKQ5_#K3_[>HQD+HB!,&?E
M^N@(#CB>II=?4,!4L<2SMI/WBSSG7U/I7Q>@\_P DZ$U1U3#.7B!+-FP9Q56
MTU7<J?K,PDC-?/7TOGIZG_R"KU32XF%R'[0Z.9_>"[3]ZNW]Z8U;4'<R(#U6
MG!#]99)35 *@G,&"K#=*JC8Q3;^%SYHZ(M'-2N-;D((U'*#>G 9UBQ;FF"B
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M#E8W!V[U>:1*'U@)934?_<5H<W>MNBJ*%7T;&[DF7Q-(R:?4.!J1H&M5EV#
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M:FF<,IK*5H>P3PZX,1IM[1T\8QO/X8*//1<0<Z7>^(QF=;0UVGY&EUV#.=C
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MFL2_@J\Y]#VX6(5&.+-RSF#(+-LW+P7^CA,X9>"RM)J/T]B]I<\+H5S;_(E
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MEK+#L>8L;))T[\GUE/*732!Q"*6U7;"A\L*[/JNY(Q#0IBQ[C\H)\3="FI<
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M!U@@\LOJRD6F$Y3063.N<R2'QE4]B3A XEG3 VFE>*7F6EA.PPU$)'S9)=H
M&LIF(LP75OG5&<XC\Q65\],IQ7'*C/4>D-;B;0K6O^=5#*-]ZK;&K>X SF"M
M6I"==V/-K)5OH=HP7I 4J;8&99 HV?/13/J#M]PORT\-8^EK@]K&Q7:C82'W
ML%#CQ=&2WV OT2Y<3A_/JHE;A@F1N*?HN$=/%2G:!9>5KU7I'MA08_LBS0L
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MQ4$GKLR&HM)R2?/!A F"QLR472^[+U[*O X:A3-]K[_.XBL2]!NE6S0Y),=
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MF=L!K+??AFKT8.0/_S$JV4__"RO9WRL>\4KD-<6Z1 "C##N&=T9\^P!UAL-
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MJ%8L=1'<T7EX') G6*>495>X!*@5753<G46CG;U"*35-M%H;(6J,=<=%(<7
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M@GM1DI (?$>@2WC//%(ER^0>Z=">1HJA=@-E$&Z^N07AM _=9(O<TL'J>
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MA%+8^8 29X/B HIIVX&-#:_5!"O/UT+R(GC9C$PB[9G2PM6PTGT%BT%Z-[@
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MTJ!6(+4I+MPO 5PS%F\-),]/C%_;E)RX3MHM4/L@0[#_-A)TR1\Y+8B&;X!
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M9$G[GX/DN^#?D?Z"ML:,6Z8W9I .<M,)OW*<&]&KZ:65 4JM2,%C'C:U(@U
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M>7+', J9('5(D\8:&2C:8L ?._OYLL##AYO1T;!DTO0)T4/E#Y[C0I/8Q@V
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MR03^U2KS/X9$7N9R'P4JVZ@#<UI7IW65F</[[1'32Z6V3O+;Q+5A?3LNMCJ
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M!;9QW=UR[T"]X_5A$\&Q)2[Z>/%3==4%.P)? 3^7I<^^*3<[U9OJC+S,4=5
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MGSU2C7LVJ]@^26(Q?.F31TG^B%(9@VWOI%<DJG4LPYS0HO%+/&QA)I 4-[B
M[,@6U"@@K%KR4VVJ74G#1"P^*/%!T@2B9825>/GR)?WYY7\+P4YXPD\?66;*
M:B%9^=GQV6>D07,:((P]XF_/7,PE^A+5DW*GHV2K3I^1AN?CSQ[97I,J)YES
M8UB8CKY"1L*+^]Y9G8IQX'.381H+BJ,;:>@F%@2";SL!E:VH-!%(@99>6.R+
MLAFZ9$TBJ6L+S$O !?M[(0X JJO]XL?SBZQN [U"K_K+UJFE'7X5=]-@N\FA
MNW*Z)+AA1@2J<QL7-Q;L'8O[GH5MJ=]T71LORST+.T(.PEO&?6C;]-Y7CDZ7
MS 719YA)4#SGW*['F.2CY>-(!*N7X9=GX4^9#^M&FI] 2&GL? Z?9].HKXS8
M&OS?9.J"6U$V8:N&M?;=-^?L!88%,<THRQ+B@L7$*O_8-15TT1;/X_9['8(!
MB+]8<I966]<\?U>H#U#F3[F:&/,?U)C/TF*IASAL"/=!6.I%,])I+1N6K/SK
MBQ\N"D?@==UAE3S4^#U>_!3\KA4MMN\CMN&UT!L/=XT9%-A*I<:FS @QO89#
M,GS<DEGE0(3>S D;A45#HP+"5QS5OB&9KB!C:&2R0B,M$AQAP Z.U^/%JX1Y
M.]S*7@X#7=,AN=T9Z_07A?!""E03=#+Z,N$/MIQG<J9=>O\(A6;GS1F!M4Y3
MG"5S^6V#T7L=GKMX5$G_BE+)3U\BR[H.6AVB;),N63AYR<OQ%Y*7X-+0\W Y
M':XO:5:"]3822(XQDW?C@?;;SDT@H]#NFD(YH-A6#Q;QVK,F15=?.;$+^(J&
MG);J]S.O'6\>>))P/BLZ+PBSV-]0,_W ],]AW5S57,GAQOJ[]PET]MB7O_\=
M(X^7GJKZ$S$<P9+FALL(UG>U);Y-TP46VJUTP4O(,I)R%*?%J5:<(IO3=1U7
M9'CM$H#$Y,J,,ZMA_-W$MNYKK.](I[6NXS(]HE$A.$J'_%>\O:ZV(H)QNGXJ
MSD;E/YI@"FGRQ$X<1F,?<Z((5-Y[+=D=6/&+'UZ\+JRRGR16J&1X)0H![# Q
M%V3P-J% 6;.BSK);B8#8>=B5C0A,&._V-ER&M4?HO-I5T*71:J.W=*)ZRC\/
M3_;J'!AB5!QKA4%Z9%,&#[YE^1?^P9RPG1FA4BL=8S+HCQ<\"7QC^Z%%SVK?
MF)/O+YPTX#U0QZL8Y$QK6VP+\[D)PYZEY3Q*4UW6;G'Q8Y@>\ >W$@B' ?HC
M5Y^"0=I[_C*NH'--Z&/XZ"USK=$B$EX_BQ></Y^O+Z'X>U2PMNQ.TXBZ0'HX
MQ, R!2NT$=@K?&.QI)75N1[3&W""B2&^U(Y#->"R63(_>KE@J"1I8538QOX^
MZ:5M/0S,<$I(%XTSD:(?O,G&($_Q178PR=']PV2F565.I^':86CUX6KBI]VP
M^SH#:/7KM+ZIB9^T#9%;OW=85DH4JDA/F.*QM3V5G) I; _L4O%&!Z0'1EO)
MYLG'!3K%6"FTTV9EE<O-HB0O%;%T56!(F1-WAK5Z:KS68_#1D!;H($O)Z_5/
M90N>5];.^:+(=]7!N83"K\LUH'"L-1O!Y\\^\!TM-US-%13%H4RM+"7:Y?/5
M/S=O.P4M3$!XN@P'\?F]'9G<#>=IHE45IU!"''AQ2$=+-0WZO+%__P';WXIF
MNBIF+-/,B&9+:F*=OA+D_@3G3^/"MCQ,"H[WX$" M/06#-6;+95$R%&QL5'8
M'ZF_HC_!)8FX/[I<A8C>_%PVZ70C;+8),>(,ZO&0(A4BQ&!MUDTW5PX\ E>"
M,AB_/G[]>*&:]@YW++)S?&H.5/WT(!V0@ZDK2P$-$E.<T)8UR=@%I$57XS+_
M'&BEI.DE62B\!R*HA? V@G"ZW,<K/A!R]_BX=:4_^^14C'T?B[%$TQIWS)D:
M$EGZICMC;51#JETC)C'!.5L5AJL&RW(<4A'5"8RYRZ,C6OE^IR72&^K9YG4;
MPP7#)<:]#48X!]PO9DL8^!PRQD723_&^Z/*]IDJ@V!\NE"EY(F6"NEZUKG<I
MB;!7GB[\(2EL3S[S'#MR& 0[2J$J=ORD/^JE\8W^6YP5O01GH$6&[JI#H]<Z
M^P[CT;JP()HM/:?1U/Q5E*10R]UI8F0F!BJLY5U[%D2.CF32B(M'SG.]!-8<
MBH7=;=6KG:<GE>.Y:Y.(*1['(P9%Q*GN&4:4(<*8<6*N&IPO8$Z)Y$18O&*7
M$B$;G"P^E$-PZ1R'8P_E  I.'# O;#V"I-^%\59OD%X(8B<1 "C[QZE"G:G2
M6ZI H#U7X/!D3\41*4W-@-;,-)K(,AKA4</T'4@3NJ,R9I.B^"S6T+I;CD-R
MAW#S\$/T/K>*2T;B9\5%$K0D,?3\KAXI+J6J&QH!Y01ODZAB3F(W\7%K1NL!
MZ#F01QD>3T+=3EJVJKF&+8?>CTCQY $%8>/C^#G7W2DSSZ+(*.*.X&CJV:W[
MY;AA]+3(JN[X$YI<XO8/;SG$!J)&DO3I&/H'X#A%0](8[B9!"H_![YHAUP3H
M)9:X.!/3&5;P9IH :QA*:N5&,&YBXD2E?X2GPH.:-G].=1!S=>$TXM=V6&Z5
MI>!>NV:SEMI"BTJ4/ FSU]?-7M8)0,G!?$Q(II',X6IA=$V\(EVA*"3@[!%Z
M$=A=:%JE4UQ@M];J')]HZ:VH=TP4$AL-ZGB\08]J/3$Z>$:KCQ,Y.BF)WJ C
M9>"FH#3-PFWKRI&D"X&V!I*6!B%.^," GV8FW+J5QOJLKY[/T-F'+?51H:IQ
MZ7(P4GL7Z/-"J6ZX><;U%(4WNK0M;7PX3#!PZSU17B:%S;8ZFB'>Y<*LODRY
MN[:</A7'"SUBJ7&-<>=T*A7ZZ*6.ZDSS/U,<6+W)*]P*9 T;*2%:<&(+JC!/
MR,FN?\L2+GL/B9=GJ =],H(>LC65/$]$,*AJ95LE.#A"!;M8@#QF^&5=W+U[
MO4]P7D8,D[N( ? [:YF#M"FC+ 3@"-)02D(ME]66R:RHDXL=/(:D46$C7+;=
MJ6X$:9"6S3HX1U(L32GE@-\?"K?FHLZ-K$BCOTB6;$3G/U[\(A.0DIK:-I%X
MHB9,OKJUVND<0X/H3.#2P8S4?7[6\"6K]/) YZ0]N9S*K#?0N&7R,2]T@]07
M^QPL2&4Y-8YU+!+R/F-[$/6_%=VJWRI-KOLC/1Z(:XI?F(N\Q1PYPR4EO:SC
MRSP?(?5<2KT/[;>:RCKH],HAA;C-#NNY QZR7-RT#="/Y%3]<YF;H=N5NBGZ
ME=^FA5%R(ONOJ#_>N9I>E;UK0Z3[<K*9:/K#WVXTD/6KPIW VG 9>R D"VJ4
M/EX\/)ZGOXD#Q(D^\9)/*7^L1@!??AG7!J;.J]B)=@14IDLFFLEK#/SN"NO9
M<Y>-T/Y#0D;?7.UK\$>IVBJY/5[6_29;P?QBMBM8[B@G<8A1_GL5W+,]MX5$
M)J,W!XH&87.'<=>ZN?A'X>5[\ +!G^?NLC 0A/DMW169"L7REV5FK26N,U"=
M]O?7:C)#.(M=I2V?5$[OQQ"0[1,<GFS9.&W!_RC[E3:O::B/^%"8@#S%KVCQ
MF75@07.XBC%)A!O16T,<B+SXOFHJ=#0Y<)*$FN$O -[ R"\%+O>"NUHWC&JF
MX*>QW4:G!M( TX<XO%@+DR^\W"<$ ]H\- ZL6<B?H*IOO4P<],"IB>,&.BCJ
MN=V&@^B:<U_<R239_+"!&CY&CKV_Y]-32OG]2RD_*-:,4G&<!I$:,QV"Z)3T
M4HXQZZ3I2LYFM$[DL1MWU$M=Y!#VX&$T-36P.RD%IZ @0!W)<&#7K^VT[<6A
MHVL=Y6%  7O77G5<#A_"NRZOI4DR#NI4/(*3DTR[G,5]48C217\\I&C,##:J
M'8.5H2A[-C*G:Z+A8DZ\F7-5R-W )T()S51TY=R7A. 9%Q(&BD+ 13AE7%]S
MTTO2R*.*EC*'DFM3):%<1,-3H4:>L36*K^J#<2C'!.I+ UX?D.. X:5R,R<;
M$^9?S2U7;=\US<8Q#=6@:Y?@AN-K2AI.>8&0S@T+((=^;[NM3!8[;\&3&R-?
M0WB37;?LI$DX_.L=@?TD!QB9 >( USI7C$.'.J.C%8B(UHM\3GR[^J5SY?0(
M$^8.[-\TQV!]9<IS=\"?Y.D K$9X( CX*11.'EGI'XDZG"AGT>SMM'53[PC,
M)REL*T3(6OA6O/XY^:E2*(((D@<U8FJ* B5_S*72H$1=VIW /M1@(3^JCY5R
MJPM65FE77*:,5-<IZO5;D!F04EI )M=C/R#QK39@!(!AI4+X(04:,J7[R4NO
MNHK!Z<%N6(S2@#0D_ZKB*V)K5-ZOC _U(B#^P(7\[PD7RZJC'$*8I6>(K$X%
M>8G\[+)_4PNH!PDM#DTU3]1/G'.I$G=3>5_94NP""[9>6@S32B2[:1Q$E9?A
M0NQ?LZOF#79JSQ(530\C.:"!AD'B'\ .<N E7YZEZ@\W^5$2'O@%FYT8=_.#
M4TY%'/E2KB\F/C6-O6X!><8Y0XD^$[<G]<+VGLQ4P>&VL?\<H/;5&@MSD]Q$
MQ@,4*<;!P9V2#&@6.^0%@*,\\"6/0)E0JA5%/C=08*&#WWJJS2'H^JNR%9O&
M%#!"R>&-J)[SIIT7:4%**7',+S@C_P&-@-'Z[)0GR#B;JG>>!*YG)A*76W7L
M>':+V&.)@U#X-T".2@RO,01Z^$O;D::X+R6-W8536;J]%4P=7YS-=/2;B"B,
M$H'750- U:UFF)'A2OLW8!@M<0UL9S(*"T3*[J LEY1MB@?ECAE&:;]*FEN.
M<PAG%XN,(6N NP'TLO$(%19?@P8>FTAA@VD)FE^#DTI<E!QMZMV-["5%OX/]
M.;G'G$H'0MHLSX9UL>>7O")R)YOX+?VDUI+B=Q>O;)WQ-:+7@+T;B_CB,*22
M0KH&2\4UQI_[[^M!ZL?3G:G ![C$W'(FA*$L\NR/Y3XRY/1""V5PH;;B+BQL
M6M;;:AE%*7!289BQ^L,!UU+S3K8M8DC#CIOE_(4P?78N<.@-^1RX1<9#OO,G
M)\R%FLE5,@*Y$UQM $4TR0'U)<5C<7-QSYA/*<>-3RC""/+'N"3HDBAL".<O
M'Q>:7CUT#)Y[F6H_,(JOC>MF^F#!,:%N\P/F\5;02'HNWW>NJ8>2T=O5!HV1
M[2H)X.A2D?TJ>ZJ'CNI=ZK033_=J5+6=[K*1YG7.OE,UP90M5^%$QH;2QG*7
M@BO,R44=G!Z::CSETER(=,D@LRL5*)@Z O!L %V7,(G=#AOY<L7\>%UZWJC=
M&\3I-3IST;*>\X:L;L#Q",+;%7GD&J@YI^I86]>C;S9$[\Q.F\MJWVGJE ^Q
M0UU(+LL;]XZN4EF]44C7,6J"AKOO"?S':'O9$\FQ(91XX2:CA,&<;:1#@F"Y
M]!!(Y(1;4T%/:Q(]IP'D%ZAP#LK4G<H2Q @]JR9FRT<M1(ZN*N0,.Y GX3H4
MCZNZ,2D-VX&FKGLV<H:O2;;S_)4CY@55L5H90,7V7-?;P9LEG8+.8_?!KPE[
M0<7])BR*;\7QX!])OFRPXJ DIEW%3/(NKGXP <ETO0<F#6'1@_%&:FQRK2/<
M50^&PT@7D2T:1$+!1Y26(2P/^4[&!S+Y:E9(!M%-DGL#3T[7<G+-I=]<D<09
MO7A<7D4YMICY2F//C&U38QZ)MY@]V"(COFN(<KM>6(W[ZG)_'_&'GJWW<XD<
MX7KXZ.N7,^G*(FDJ_?G'GUX:R1(^^>'7G\Y_.7M*C8/E/DMF"@]THQW-V?K!
ML?K+KS\7>I8=6CWXPDOZ(H='&&;#[G+6P>LWL>WG=DFZ 1XV_-X!J.W)$,K?
M!!^ITF2@V$E'1%YW6[(-Y;(:69EO&:OF/,'\8AJ2D6'_IN*4P?SMI5)N*AR.
M,V/B_DM]2W-#6',[> [LBV_ :+#VK5B4/8B]/@H^L")]]0[TDD@8(LN:Q#2N
MHPS[[+8>DM +J(N5.OT4G\"@<U\]\19@VS65;5CO,D945C#)O_@QN:P8KU*9
M,:'NLE]T;'\-#_%S6 O$(+#SX^5>U/I4A\+;)MSKY?WW>IDMOWA+2I[)B8JC
MC3AO"6#:$QW14H)CHN(0/""\+9ZOJO6=:O9<S'F4KP=G"&7P(O-87YTM)N4
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MHG4\+V>&Y,3@PI4\N R'X(K" !M4#4Z.\M2!>D$PRKMJ>2V%*"Z*%4FA,NW
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M']]W]R);U^J!,I510F7+B.24;2!:+_/LM9W4$@PTY_&IB6R0$B'4^1I"#V)
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M__UK@W#B'13WGANJ7UZ\+ S_#MVJ"$23T*=KM0(B^V62E@+,0';!+R.CVZ.
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M,"JXK0 G$T=/'P;VQX+T<(V^5%&B2N,4&(C&J<P9BMQ@P-81K1D-AR_G^QJ
M(GY#@"19@_D?)L2O26)X-F5Z!"?NI.L\W<L<:FU%%%JF7@X3):W4*@_OS+E<
M.N7N*/;GP#]+A:AB@@H"Z$6*V;HZ/Z3E\L-G$@#CS[_R,U3!+^5>9U;MI-2&
M\3&HI!>!E;O>PHS%NAG?)5H>?^G"6)"XQ@[:,H?%U3VZ/"I-=...0,&*64S1
M ;= >9A9I9P:;7)NT[Z4W4['3=BN[8Y/LEVNMC$W/ADX^-M?A2O;/1A.-VO#
MRSR4&)DO^VX8P@J$X+;Z\"GJ '--7Q5C\)>P'0<:USI3K))X/!\#FB$::=?<
MS$CJG'2"!R=[ SV,K0H4O KB@Y;-J!H=!U\P?8T<.43;.;C-G)U,9^/@%3T/
MN374&BA!6P:DM,8$WU HAV*EH<[XH/>RXZFFIL]3IG;0VW(^K2='AQ1';RKS
MG[Q.89XY0"\L8Q$6S^E6KOGD%[L9]M]WSU_]0@X4*PJ;,TF:>^%)*)OE*F&#
M&\W<8"2C*Z4T H4VABO@+% WMQCM#YQRE1WR[:_LY= SLC7CDYN"*0VJ8J+2
M2.'#YG%8$ZSA#L<(;VSY"H?)^]A<1G'W4&4/=D#@*>J$K8.?U*V<'HHZ%]'#
MBX\E]DZ28_)[=OHH#Q]<S-Z]L9R:PV2H?5).=)IT9*5\:P.?CW2B[KCV)N<Z
M+%\B<$]*+Y'^)E%;2[SUSO)[F?O*]\,J[KM+2EO'D&DR2#BP:'E5[56X#L.&
M;6]A!,23#KNEWH0''JZ[?H<O@J(&_CL],[XK*3,R+4IW#U62!-)I (HH$A2+
MY.+&),MZRP93S(:$?/R:'.C)<;D@\>NKCL^3?*UC+PS5N.K:?7#FPST^KA]7
MCXO%VVI_1JWMJT?QB\X9\;-^*Y)2EN5/N&7B<DB7[W'7?C\]U7[?Q]JOV<2T
M'("_^'7O#)N<HE*EC+X.9XUP!"K#><U 016(G@W3L*M=D.:>XI#M4^^U('FL
M344N"1GG9$=[W!MND3-W:2*(_(W\W,C =C&$23MDBWG0TZ&VY'#.'T(?9SYF
M>'<^-26IY(!8YI#,N?PZ=6%2?N1)>1TG):DYL&GC3'7PF3[Y_-.OGCTIGCS!
M_Y RQD>?_F^]Y*XCHJ3;KF]6MW0.,P?*(GCI+;E+MFBHO,P,%38 W..!"4%#
M>#W(<>5[?0X)&M\Y:#9(<HTILE5/%/76#!PGK="CJ*&EB8,4P&UXR6ENZ7(?
M$Q>4)(FMZQ/:[488B=GD#]$E/$BD%KO?9Q;3'>C,8XQX+7:<6;:<>/,^*O6.
M\\RP\Z6!T(SK.>[<HI^+>#0MZ@]@2:IYB7D+N=D3)91L.'E[JV;5K9'YB1O5
MM542>[%O*RNQ918E0WMA#?!GZ4[O4^AH%H)QQHG'@G&IB!(HP<(8C&'9C\%Z
M[K,(U)IYOOWU##V*FH)^?5U3&^*+$!-583._99#>KS16<!RY&4R4MR\:,G]\
M9V1B)=,2!IPAWM:5!U_%YMBE(><J9>FOT'*DRL]J[RZ'2KB01(B>'/1R';::
M.;>:#91PS):([E[/8B>@P=4H*96;:C:AR1HD19(="^OTFKGJLH07IPEG).%M
M)%AR:.;H.1BT^!M'05R[X'1QT-01MU?-K2?7S-(CO8&H&516CC<+QVOZ5F@W
M5FB-UM*/889=,T[L!$VP)&5-2IF")Q'2N&77O94PSY@# 0G76,"Z7;N6K)$%
M3E%K!RG,N:>FI:01/+JG07AE5M;O[S+E+/"GR;E)F+LFLO"X82#G3!,%YDCZ
M)/DYP4'70S]N=P>0SY34@I K>#@W]3MM;G;KF.R5KMO4KK&%"=<+SV6+3,U;
MV-!2'%)HB%$R7.X](Q:,ZP @  XST/KQ9EN(AJ^-A3W(IJ(KU,,&)07;U*[Y
MCW:?TE'%O<Q/1U)8\0(:/*>6X?$TECF"(VJRM^08^:]P^U68C:8J;]1/#;/B
MI$W#)P#EF)_KFU.CNTN9-ID<-$ES7^JD4SJ_[[RCE[HL0.T("88..I%DC1MN
M$T&VBQJ^>;%VMYG13 ].O;-AF<+K:LNDW)42SRZ]O [&"J"+F<O\'VIMI]AV
M[*ODDJ[D^8G4/)VPVBIX\X\7WW>WU8V@J_/'(VN'-V![9PXA,F'A"Y5P.-Y&
MAS%/IU'+,V.^.%[0*:E;T=7]/2]VE Z84I*)LT2A^(K)_C+4.WW:EGT? C=I
MV.% KGHG'59B7H,5(ZMW"<>7%6"I";)F-<)2F]G83,36&'@Q44N9O1ARI2C#
MW_5ZYE]+.P!%G<.2#M.\H2=\#TFB] V8>$!5!>DY8^&4!!)7BLZ73:(/6+4W
M=2\H(\,# ,X)8.LF^%>'FT7\8UUV*TN6QSP4#Z$Z:YRP"MM1D<BJ]C37@<0[
M=@;SK&N6MD$CJ$!7$TG1-FB!I"!(_A6\IYO:M401EJ-)*QSNGD;R<WPK^V%L
M6/LP*&>7F(K@X)3+MX0#T 2^=KL4U$\W).+F[+'+0:_>75^I']4)!9+K=F5!
M<3F=-]N1DOUMF-[@:T<U^DV8#$H>NOIM*OAJXDMI'+A%Z1.E3MB;*/5=2[/T
M.X!AI#LPBC0_F&E-SJO?@5?ZYY@MGKF[YLQ&.6Q@BE8(UM[<*N,63Z!B+X<D
MK1-F(')6XM3G^5?(ZM@Z4N(4+Y2T\TJF7+($N,"!GBTN93A@PK3A5]O=$0G"
M?#"442M)FRI<9.7)0,"D2JGB=*CB7>F([#:WT#[<7M?#-<H'%LBL%G\=JYY@
M6FUP2V$:_U(YTQ!;H5?"=GG6K<]4*E;N1Q!,_P" T(GNNT5YU,U 62<_KKR$
MT1:[N&RZY5O)_4V^P@W=I:D($W2O'%2Q46D')9X.NV1%GFI.]$"L-]P/SAM)
MXLA2GI#S+X.=0?)R<4DD6]T*@("!,(MVB#.SJ%8@GXJ H/AJL[5JJ'1": NJ
M#%-UU6'B<&$]E.T2*<"R3,<=C.PQ]'F\^ 'MZT2V4OGB2@72#^'9T;X3 VW@
M?GI*HT-4RO,ZL(CID1N++21($;@6CMPVNE#:FTGYIFT#+>'.VD;*<ZA'EKZY
M2#-P&=H]JEZ.,BXK(=A38B$ET ? "JML/382BF;+.<L)XOC60Z%@$ED.C A>
MIU4IV21\13U<C.R.:G^&);+7SX)\FRT9IL,O:$._"5.((IVNG-R0Q8[5%$,T
MFX?@"J61F&<?)88P016A6YKDCE,;9ULIUKP8FH8!EO,K^<G_,3#>!)Z97%EB
M&+"0$I[.<J;D60J$E!\5S5'5FDD6XY&9/IJ)<6./Z57UA& <GU&S3Z"@?J6D
M?I@+!F?ZT^,Y,H=IC!Z*$R4/)[Q<W74++;72^'N[_]EAA"IWX1R"W\C$.I4Q
M<>(CY8J5$3I)@3H:B;V'WXZ*$(#G;7G3K#L]/U9C*4D:[J6]C3-E4PAP[$H\
M[D+K9Z="ZS^NT/K/$O)*V\1J-MWI\DU#8A S"$N7<)G<5&)HPNX+FX[E( 0O
MS3L:A["S)V9#HNF0U@G#W/ZK_?DCE9-']F_W_[/W[LUM(TF^Z%=!>,Z<XXZ
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M&FM.2(M)[N?0O34!\R@]): /.Y)*^J[*=D1$'K5(<Z'FP:$%3N84^2Y]BI%
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M,1/!(ZU+X!:TQAT#U[6L]F!W.U=WRU%<]7X8<=_B^L4C;>""BM,P-<[6C*L
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M]4Y[.]W'X2MC/A-^G?*O:$]BDD?09]T'<60Z4&28;I/O333E*(XINU'9*C[
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MQ5+*D$LK;7GJ"7(@S8N<INN0AWZ/[&*7*7#[VNE#;(.Z6RUUT*<)A@Q[^OP
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MVR"W/LK8I.6:J08& '0"(%J6=9O]L*(D F+= ,6]NML+24^J\N/N&:R]P:_
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M2 4+[5\B5"ZDS;1[9,9)4YG>K067' N6D3+DQNX1!F10,BD2Q2^G0 K8WV[
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M.SS/B>%?,_CPM2!]QL'D(];K(+#5Q56&Y@9PR5NI)AN4+*V)J<9E.H*(R:B
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M_T*[.5^@JS(S[3EU:RF!\,A_3*O/'=2%CDQMGKJ]DRH[99BM02@-I8OQ*I;
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MB!YL,Y"KSZF;M_-*F4K#%[S=RB;KJ%:HJJQA,LF>6A<Z_YW"&%7XWT/:[GD
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M; X\G8A>,@Z5A-U3F)C0APOH*287##3[=D(.*&9T/WN1AA6./%MLR-<Q20&
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M;Y@6B60%!ILE]J1">)MAOPP<U6.+@R]QZ%L6$-EJA$&->[($T[;*O-;1OLX
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MWN!%!%8I5>G")L#&;.#B8OT5WLHYR#I6SR4E<WXEZ>0N"X:6E"_@]O(/#4[
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M%$=5,YZ!KE7?@X6R6FR1);G]0#'ZESW!Z15\V/RUL/_F%82'I=AL$G[<BOX
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M_I*_._6G!=5,:L+G'HH_/X%JHQO$\U%Q\(M\ B]$R%6!LE90<83YVQ<FS@3
M&0BY\AR)'"L@I!*Z*(\SFTC$:FA1I'G^.;@B%4$R1UE!5&Q'&,GX^\MP1D]
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M4\NIIQI>(W'*:%-K=)%2>@5$!#9FFG@N>GWRA&-8%EE]T4S5LS6YDJ(D0N6
MKSJV0A__</N87]04;$7K@GMR0RG=47QF_2N*M/)+EQSC/3FOSSG&>-]M*Q#;
M#+H2]<EF8*$!#,QCA;GNQ9]5-0 J,X_J;.XODS+DT-Z6#FMK9)6"2:\JX*HN
M RHK@7HZ2K5)>DFW3,,&-G334-=&/Y0:3J7**(12:<)V>08Z&=PE3")^TO"#
ME,I[)T\$HZBR;NCJ]-K<0BZ32]%P4T7;@E9&_%P=7>8"9;L%FGH6RI0*/#.I
M79YJP2<;&^E^=@8\5M4L68L5EBJ5AQ%6%5*5TBF%!$1)EJ<&FQX+%ZFZQ-I
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M7F]2).&WF$[MR,?H-E!J;+=\C,&PT70,[VEQ1#$LRA[EB8@[9  Y360 F:O
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MFV5%6;QYG_#@6C;9=Z")91KP?#<((H]^F+F>'_AY>7<_G"$"G):<"F\>RE8
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M]''*7U)8$<@,JH0L?C2?IPE$\3**<=&W$7REE=K@G8O($!195(22-J#0P/#
MG5L&;D@B<2L"'\2W]!1*AKTN'YMYDPR77/]."\-GS>XAA7L++V<SM"#P:["]
M"R&DPEX;I,14>,^W0+4'L"NI.L2_IY8#<@>KGR>%/B--1U<D8,2K,,R 6SX+
MV+,4*?(ABA>6T[GX*]D."_=1,@$J_=@%/8=JK:3SB=M@GL:YJREIX^^769R
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M:J^G\SC*[N;6;V[LS7'@WJ7UE,"PD-00DNZQ",G'T NRJ:"6/[+XGMD!T[6
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M^Y_1*,LN+@Y.]-R5_/8XJ_Z%=J%'HD=G\(\MU?,S]L>A[\.0F-L1$( Z\H8
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M4"9_;NRHS&ZY]F]J>.Q%IN*7&PHA5B-VC_/<*\+GNXE&*+46]1? ?-A%V$\
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M2WXEYTZ]U>\I5/-4E;*C3EDG256I\\U >$GTV8U.1NP6V$D%8"(UIPTI2@,
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MM<^4+,KYO[GD4\X_Y*M%D6U]#&?-.:ZH<0>HIL,WS@-Z.J>$AX@R5><9$!
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M(!)U/-!$,"P0II9BC;E4%BO&@; BP4D"HF*RT\P8*L:(D3'E_!#FUAP!'1R
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MX$R2X 12QY4#EO :^10 S;:&1Y?0O%C._?T5%9C? OI//N@C[(<"^V<L2M0
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M1CW^T\O)[Z.U/Y>\*,P]"[WS?RV]D'N1/A^/%MDJO+EYPG^J6)4]G_^+(WR
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M)H01HA33M8N8X*0=5]<[&/L;N3-F+/J,(QB'"\8'L8A;+")N+;$:(<F!-BZ
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M%QH&:0H$-\IL=:[;LFV;]:X[289$L/J5Z4[++\<8]3G=9W\,W.A>V@\(/HA
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M/UL!]D%R06SA$>$>X7XOW(GLIHQ"BTD",)(D2931G%9P]W^*[7R:0<)]H'&
MP<%]6'[^-[0W9HM)GH46'[/[#(J[[(D?TP!D^)8#;[4%K8S7"9C&BD&3""N$
MKL,!TCFQ'>1[%5%\\%>\G)[4>VFSZG\W]-&EI(JF=FDEH#'KUU#82WO@F/2
MPP2S:'4!0@BE@##HM(8)EYSJ.F @M-62#0[,O04=&!]+(B*:(YKW&\T0B%:S
MAXZRA!HG+<6)U< VX3^FD2);FOT/1W-O<0<LQP#TVMIOD&B.887N)\S3U?IW
M(YV=SQ:+D/FS/!M=E;(;YPENLPGN=OI,-$5"0@L-4D@GN,GF0UH)L#6][%5L
M<HL<3JJCOH_.9@2,*7D3__Y@#_GHTSM(K'9\>L@IB1"3"9&2.J\4<-W,_K0
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M/==5/%YTRO]6A"H9#X_+0+EWG>9*)]!Z90)1(P6VP#^FC8;! 1.=TYQ8+"2
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MBTG_>]1>-%>^2]!%#UUZU%]:3NA7_7OQPYRU]T.<M;(%_U"*8,^^G"_[=TL
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M9MBPBM=%K*4@D]-8DPU:LM8HB205VB4.#9KUY^1:*(2HPR(#2K^N@171D<
MMUF%3]=]4+3570L#52K([84-Q)DFMSG,3#)0-+ 'N.#\#@=FC2PI8'_AA.YH
M/V"<&]B$O* )\5'.EG"ZL-UBY:10YGC$O&OP^O42."RJT/!=Z\B:6P#V<=[<
MA^[B<5:XLV5*VRG>(S8<,PUI3C!@OJ*M0NI"PEXD,R2X>S$OEGUB+$'._TP-
M(%J=6%MDV2';\B8OJ@NP^V[%L&?!@+^HTXR(T6D&!A@PN%LP#:",!1F418&&
M'LE[-+S!T(.]UTZ5V$ /C<$MI(<&-!#?/3#%!G@],R!^D8=2&!L@!<$2ZM\G
M]#(DKR8)W@"9*@IL4T?2(H-['%Z13#]%&#^)_U(OH\2@KW !=^D2VQ3!+&Y*
M' =472:Z>0Y/XXMA%<O-G,QND54#,UIO"C"-2[8VZ?8S\^(IT+;H^YTA2T_*
M? 5[<Z\L:1@G_9H6H"RE/^]=/W*$&=XTP9!IUX@S@Q[%C8_Z>+AZ5"Q]]SWE
M^YBPPUWI]'ON-G93,I#G+U.C]>6E?I5KM5';FG\K66[A,C?TENYV-N>!1W=I
M_-KA!-N&SZ_@8B7RX&Z3SW*@=7+?[F)%7UP:[UM[V.)'^EN3(JU)<RZ%DMJ&
MVU2$-%A.727H&Q%254[W2[+<D)!I30L!")UUOUNIRRN%Y9YQFC=_4PKE <B:
MNW@!6[_*BR*_(\NO,\MLQ3Y1DJ=?DFQ).>KRVG?7R(3<IL+Z>I)T$7<*M_->
M3A?.3\T8?4EJ(<A&5BBQ052/Q-5I.DS@E)6<X\O*-[7D*U:E*$0*@[=-WB%Q
MUK%^K<6S]:8?TJGK=73F\LZ=N;YY9R[[:9VYG#?'Z<RU>QK[?^^\>0GU)2N5
M=&-O+_QMQ7-F4=;F@QJ/Z5@X]Z!KI[![U191?(=:^G*IY#&+<&8,+1Y1<Y'F
M##<KTAVVOJ*C%- +4;1K+Y6<ZZS!2NN=O?3W6L=([A:YNF9#G@)^J.'R7[&W
M8X]MW);@!YJ_BR9B[Y&!V7_=%9B%?]5E5"=AZ :CL>W&$R><V)[M14'HC;Q)
M, K",&P'9I6>0MK0'W@<[Q=_EBFEQCZF0ZRG@J+^[AJF[N7> J8/=Y4+)^;3
M_*&';+EOU5L>![8?6U/;' 6N/9G8P7B,6S[UQ^9P-.ETEV]N^:^2O3SG9MOV
MI=O9[+;']]&;KOM]!SWN'.FE$)H5>G.$'4@:.JEM&7ZZJD1L;)$612H_*<G&
M$^: 5-O4;;SLO</-:">H[,!RT;73&^O\MVW!P[*O*:P*)CZ P7Y/W%0WC'7N
M)P.@FMG49H9HZ2@BR*A!< $*!?F$5F4=VMWN+&S8N/"*1 &[B/TN0*KBL])B
MQRN!AB#&?)FDT!,(QYVLT>4JGP,!@;I]WNXDW"*MGV&86W)KE)LK=,&AMQ &
MWZPXQCV_-*;-">""D0P5_8EW-!;(D\9O:\(["^]*>L,E== !M^Q;:=9W*(WT
M)V52HT" %Q<)N;=Q\FB@9II]K)PYRJI[Z;6?P 'T!2@^5OGL,UU .!-BB^>-
M>DO=SO^V ;+"X#1[2Z;QQR&088G\+?[X)WUS80:#)ZF#?2>BGX4H ]L]).,G
MYF*!%?[\R^,E_;M;C+H*V0B\['>0R;?K97Z?IL;'&^!V%T-R_'S@"VK4N%NI
M \!EQG(S#)69P;W%6Z?FAF-*_TM)X[$C25QX#HVP^L*7/YEA, LO_G6>SUE"
MJV SB:15/<5RP%:?-*?2K\*YW [@)"@R1*P/XRDE!5U4,"8EL"#&?SI!D)ZN
M]UM".DV?&JHR)8&>4.G85!3@P65ITS<2C-WPND78Q[@%7K4I-/?@3<**SU4*
MMBK&K*Z6&4C..:T06*<^MAB/(!2PU6(LDI&+)"N$-S!1V*)VE$Y)2G;:87/;
MGNF2T2H" ACO(C45=P<^F].>\%;H2X$=;W@08=:@ 0J3.D.!G5^Q$Q&UC'5>
M\JR)>^=WL&P-WJ8M1431$H,B%124RT$-)>\.OT%00M*H?J4NK\0<S.$!]!J@
M2"$Z*-)EEBXP!KG(ODIG0N=L8+">_4&2A9^30T#^5,1H)8#M'[#ME=!C+K1A
M6T$WG6!5Z)-DWY8X*@M!G  *RX(69LP4HO:""1T&EIC[;V/.:CCCL6./O<@+
M)Y[ECWP_<L-P.K4#VW5#?QJ'<=NV:L.!WR]:*0+ 7;+U,GTGX,/O%[+0V5;S
MZY&I!]<W.[,.0C-HU2#_*)4_SE,=J>A( \C<!E+O!2DW3,1#0,K69;=R\;%,
M128>M.A6'#V@J$2./+.=T\=A).!A0/S+YL-S9AL(0 .[\0+]>D*?[P]-O[1R
M\$ -I07,MLRF1_]9U;MW*^*SGY*O#T'_?*L9O_GK^Y6"!#(MV38=<L RY,_+
MCY?&(L5HYA(T M#N5\2VTE6BH BP-F.T$5Z\O^57)6@IE?$3?B4 +_@$?"9!
M+U)UD4'M02_< J\6!:8Q_"T@SXB[R(MU3B&Q*OF:L+1C#8=1D@C*59'PM/DX
MA])(BTE@K+7!-9=A:840)X[W%[H1Q@+NCOK4MO["EA$,P6#*JQ1^1UYNBLRT
M]E!@*V$/40Q5B3ZAN9HACDA!M=K6RLN25QF:?R&@M0 ;4WM[7"]*UHQ)JB'F
M>/SN: Q3P:0&V-$,!"4Q1,8"P;R!)'(VHV%EY7T)_'(@Q)=4 ]'7 ZP6GKL'
MT9=>5-DM[R6\DJ@COULQV@:E=W:U(0L\+X":5ZCX$5.E,4'6+U ;^[R"GQC"
M)ZPI<C HZ7L*HLI;^'$R0N&[6$CE_R/]I98%QG"S7*;P)]">A?/* J/AZ'9!
M?97UEX,&+[%-2J_KO1%/Y/$2//8Q'AJP/ 4@8_Y=8)B#G"WUS+*>F<E[V[C7
M=#,P4^?VTA##,]BIK&&?/ EX&2LVK+B5+#3@]E*UN/E&4HRFJ#&BBU3H.IA[
ME=[G&/]=,3BY,;M:O=.6!NPA)Z-$F@R$?X%Y9QB-78,6)M9)"BUZB=#)04M5
M+HD5O-RP; $LZ8([I+JGMH# %7V+J?4WI>PKU\A\DTK->0%T28JRB-3CEM+D
MMV2&*#<M+HPC(P\0M2\GY>B35B'0F@R;JAS<T<KXGU34PTWGKV%];_XZ51[%
M=RO@<AM>RNG-O>$W\;?Z3?P+RQ'\L7]E%\8(Z!!TQE])(CW6P=&WE8^/(OVF
M743$#N@SQ"O5NY0:T)E*+PF&++*"A@$S+EVBE5G+.Q2/Y'^7X">)\;Q8YOEG
MXF\*(2LM:L5K:@&.X'IT4ALSGN9235/%GN_7G&54NZLS?=ZU4@,R<IYJM3A9
MKM3 'T+789;4/+U"^"=H#;0$9G&*98)E6CM:I*-7,L!:H6DH^[;)/A?-@X.L
M3*%L+XT&&\U4?A0\G0K6)TSP.E@L0;=J9FBO5N51G?@OR2W^,\_G!"0XO>DR
M@Q G3/K525SM+7PJN##=(\[O"6E%[\!265VC8ZL4+F%UR'@7WY/E(ES"CF?^
M_(OQD=2OA8+/8Q]5NG7JA^]J/B1<N4*;APO^L4K7AEW' *_ECS3F59%;#K,3
M@&VDB53:$8^O\3#A(*0+EJQ6:/LC[AO5I@R4_:T# U-D8+Y<@.;V(Y1P0:T3
M\%MTE3";H%N,%@?Q25(+]VUYC/:'MN$1[??EXX_JS/->1$-"ZO@OH@Y-3K<;
MLKYBK&:[6\,9J_G\6,UC@2U?!BP)DC;>7,-X^X*8H(P;_?='BI301I$RSLH9
MZ)'PG3$M0*&]RXO/0AJ-:@<9OD9[\H\Z\L&1KOXW#3HR:(#&-ZN:(MI1*MUU
M7H]?M,?7Y(1F.A,4A?)>;'/;:JF8 $@<8IC('+77+.2"T?/POZE,3GEF1D^A
MJSK?CY:@#HV4^;H6PV8%MW])/H!K3M5928. SYYC9/@IV\H8'/J2%B*;37=W
M;E;Y%09=A;MOC:ZDC0C)B3H'QJ_X7\/9MMT#E2&TPCPBVI9Y6LZ*3,7A=,<&
MVN=TM-4]XI$V2_31<.X0567(:T :PS)7\ >*R>4EY0%1D)&5"M0OA*8A_"5U
M78I,)C!P8N BPU"*\@')([@T8M!(V!V\??N[\VP$XW""G*4HD@JU:5#B$PP/
M6U=3#0==)TUBR!HIA6OZI-RP!%_HT[D\4:7@)"(PWTH+&2WSS9P.88/;?=ZE
M!XDA3P@3S=BYZ)HY%^_PFJ^2I7CZSS(U/N:+Z@Z]KC]]W%Q5T@JZ<%%JC40]
M"N7FC)L0PW<R*L'R?00,I33>K>CZ,*C1:!VK$6N9D9_0X?L.(:VB%2XI*AAG
M';3SLQ-5&X.'G=&P,S6LGG I@1&)1+_4^7V(YLC1ERM8&>\&97B7<A]JN<12
M3UF& ^,04W+ G%XDA$JT;W.C9K11E(E,L5I*PRPEHAXV5L+\$DK!HNT4ILN/
M:1Z=Q!U_21MMA$UCKW*A#6B7Z"0CT^\PGO=%10)USD4Z ;$NT"=-CM3(LEQ4
M+"DI8!("*"7=K3K2[8J[RI.RF<TRF!JK%XB+U_=(YPB:NL$,C..<(E-5OIY2
MFCCPO*'0%+SAGAF)9#[[--=-N>/J4=1WNXIRJEK(ZX-@/!M1Z^'M:*LXCBXL
M&V5%/77C0L(Z75.*MI*=C%G:"?Y2<0?^=86_%H%Q(];5:<:%@@F0?T&WX*('
MR"DM2BZ1AA6J!."KE(TL:3K/$F8'P^DI.32,?I))"#)HPQL#W$#8)A1KY3Q^
M#3E9W>1S+I.$S\]$L4N*JFN;2BQCI>P>'K&VO%KY;HWP;B?/#6P\++[$"$(P
MM^%9S.&6!Z>1!:=K:T>?D,FC8OSM% Y@8;,;2F6D.1,'$3  S7RE225WI#D4
MY(.FY!QBI5OHJ\%2B=ERQ4+FI&65KB\V:VGRX?@B1V"AO,Z2*I^NE%B#O:Q1
M>]?+,,@#W9\OSD2W*37HE$3W6SD>ND-OZ#NCH>5[DS@:>IYE3>)X$GG6T(V]
M-[IW\ @K:M0R=I63-P/)NZI^N:!/M#78#UZU+7E1$\4 1KW U?Z^ <$-O+=1
M4G?,)77_YU.GJ0\C3G\C-O)N]2458)':+8<>S"$PG<]O^ORBL34>VXYC1Z/I
M=&B&;CBVA4,SL!TWN*CAO%//L_TH&H9!&(7VR =S0O@^0R\._/'N9/=][['>
M&&D)Y@6LK"HV*?)FN1:\UG_+@?,9_P5_@Q5)B*O8J1;U'. ,/F R3UF+O<<'
M?%+PF?\"KDO./[*U,1PWP9#>O2HA]E_O)A(!=GI*&*DY[<H Z"(8)JO/R@V@
MRO4(9R^8[RAG)OA+JLV,ZU^K/,,24W":.1X4W2$? 4$V_Y?(\0N3HY%<%RDK
M[EQ>:,5141 .BP4(WD16R543&U!,DY4&TMH)C/A;<J]9'RHS $2-_!U!O]&7
M2[FLTA2?&_\)TFF.WMS_DR9+>$_\VR0FC>ZR@8UM7"*%ZI-B#V$= X2I?D[K
M2K<2:*FA2MM0,@SALGJ";@5$>AMW>;$$H3N'\:2R 3_^/2]P;G1GDX$Q2E$U
M6M8??(1GM>\)$PPJ#:SO_\)\YODMU443OMI;5FQ) "IU9+(I\G4*^P^_RU<"
M42ZV-8 -F<&>KT!K^AUA-O?P1CB5?Z;%DN'J<^/3!A9_WTHH^LH:#^$1E_<2
M4-?82P&#!PY!,%XJBE.@@,[^J0"S&15-%H5\T5539F*1OV7S.=#?)!$Q]GC!
M&R")27FP<S#K.$4;9G:"%I&L.2:3,M6Y;+DN34*G//+GR4UQ'--,P[!.^P]'
MMC\<3L*I.0'-(A[[KA,*668'8\ML"UF1$U=^RF-*6DLELWRW(D(0=-#,0T&9
M'?Y_-M"?:5W OQWK[V51_?WC[":=;Y;I^T6_Z.Y^FJ:_PVQD9HJ\['S7\:K#
M17]8*LF.#)+HTGR^8@/(:IYXPCL/N.YM,C9]*[(G[MB:6D/XPIY:(ZFL>*ZK
MM*CKFRT*%&5$EA^$X)B?T,E2;F6I'^Z[WZ?J=,W=K1#-@6EV#_C)!\MS(K,>
M>%^^DB+TF<^[;H4YM"?3<&A;DXDYA&^GHZDISCN81M-IYT+W']#[NU5:E#?9
M^@.P;_1^7Z?=U#(^^&]ZY'"*]$%]Y+8Z<*PRM>/$O>YI_^7)QYW+?6)_!*QJ
MH/),=;E8^R>4)H3/*76&XAPBC^,Y.7_D*$*9N*8;AF/+<X*I'?BCT+(<22C3
MT<CN-C^9@["B7JE8SAKFFP,O7%U+ < 'C$_=DA^ D 8[B&:>9G__-;U.EJQE
M2SJ06R+R"D]?3KC6*Q8445US*;#\8!*"43OR/=<<^Z$]' I!X0XC)SJZH#@U
M GAEXH0RRLD">#[ZB$R[;I84F2/3BH T0L^:V%-_,A+\(K2"J?DL@N742.2U
MBI]+X_<T(UKAT-B-2 1LEH25O0BTU&3-P;I9(_18NO9;PT_0RR_&SI>8\W&7
M&V6:5*IT^E5.>?P]DR/12#/"L'J),( BWUS?B +P D!$L<'6:*+X:D4Y;5_R
MBCW7Y+&F[^&7^;)ALG>,U752BI2-SIL:1GZOM:LL?[6X.5A$LRHO2J[910$)
M6=4W@0W,1'$P"O]@GLOL!DLNI%_3V89<[SFH!S-$8*$A#JN[QCS9QLR4FZ*E
M8& $"4]A1D6HR\T5 O8:D1@1;U)9<LW-Z*Z!]^4!*R[W+[CEMBA[#T:]!1:-
M-:UNDU4B L(U !Z+K& \8,<&\AR*_(LL%JV5DD'DVW))2;.<Y9BMYAF0_P:N
M=2,/J.>']-F.]_8=VTEZ*>)*ED!.U_KB]! \46(E4D7IR(G,ZH.0$;B>2C#8
MK2$5">;MRT?A^2_2YRKYEW08]OA<68?.%D:98R@VQQ%P6%D8\RI=4=$%_+-8
M!_SZTHB)R![-9'NSS*,G-+?8ZM/$JC=<**++UT4(D;X%3D=I]T@QJMK<%G-C
MU^VEFJTEI>LNZB(5+..:5UN1LHK3R>-J<4E]/>U6.J=X#KNV!X^CP<](PG!.
ML3'#;#^$T8*\KY"/42B6@+D:J'BIRK5N?UD*QY#?9C.]JM! @ &,3JU<.2E0
M2=!KCFYC-3\JZ0ZW88:G-!>]A\K3W'A]/4@F2(JB0'&O?*OSM1-L5%>7LR14
MQC*M;Q%"!S$R@.Q%J"_(I$ W64D84+/!AQ[00'Z4;_"RS<" 0TZB?+1E70BK
MR<A6L#]EB<_" #RQE$33%3: 2<L^.8J\"\UIQDH@O EY%5];64I9E;7/[X1<
M80Z'0@]V%KGN:CLW&1"J2J&R:3L:D18#.VZN!TIL@]6&BBD,"^)EI@3S#N[:
M9CFRX'#G)>H=O!2$61)K$?@&U1-1C'M "\R3S%8*SME*1\]6VA]A?E* >E^2
MTK=3Q>#Z'R)#A#ZT57+4QE3'O$NNRKRX4DGQ15.X<:9[6O,8E0:K9C8C+.8Z
MQS/FFK' N/04&F%LD-8U3&?)IFQT(46F1ZM#/ 8SI3*?:5'A+F_5.D;U,J^L
MHL52G< ,@2E<($ZL7]^L'CYV::!HW,+DVF*JA3PB(TH9Q^N\%#4 &8RUN^1R
MOS&:,;ZI#]+$.CCF"R.SFDE4%I<4%J8FETJ4B62R3X"8,*7WZ)(/OA(%C+L3
MD56G;]-4=!:#/:D1=8F2:YR:TW@+X=[!*D]FGU7/K'S&IH!("2"))YN_8E0<
M,ZTNC3^[8ZWR!F*/BKX R6QDX%]KM8B;*WKV()T)2A#%%0F;+TK&*'PB;B7)
M1TJ9PF@YDI70J3MJ%Z'NZN++W4VC>M)T(]"BQ#VX@@MPFXIH=U>&"@6]X.?+
M#9A4\B4&U>X'05%)/48X_X377<<  @W3SLG0>&,'F8:Q5Y'FK^_H[OT1B;ND
MU.HI5K0.65]CWLI+?\:(162[=:S:'YI3SPX=)PA\>Q1, M.6'NI1Y(P>%['
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M'X*WDV7K73IE8_J]V. 386H?ZM;;RY+F6=O_9=[.T!-W8XY51]/KC:B<C.L
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MI^%H)\X?.853.8HQ&"M,?5<:F#1^4Q[;OD-)ANHW#:KHZ8:XA?S6X2Q(6(1
M%8$J E4$J@A4$2HD'#14_M6-O5.UYX9@L@G)VKA>:@"PE-($$H:9A"JN339W
MK<8/')G^M)B/SSX! #$QX@*_HL$6W%I#B(![3=1[1720G4 X@@$V A(;$P$U
MM2*)ZS1G105F#YPM/@<=AGJ\>+JQ< %KSL>%'K2J ^(F[L1D4*-E;(P%V*J8
M"J(37?=J(Y!#/AS</*?DA:"HG1)X!D6-M(7SF.5".PTM!HA3+KB-D[I>.28
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MJ6-/GGL>@@T]>PZ!3HE5S1E3B@&6>"TPAE:;Y@Q/2Z1W@@9Z@+=3\FMM=X0
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M&C%OH9:2)+8(&B*L9DYW53+!#FJ59%19IM$VU*Z/4CLGJ2>177A8+#R:B,2
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M]E^KZ;=TYJ->'A>[(SJQ._N?LQ%?4U+SCR4Q)YZ6AQ^J@^B(2W;6*8PA9SS
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M :QE0TGT# 4*CQJFWS2DYAC*2YW8O,]IKF&/3W^N88]/?ZYGN<='>'9\@J4
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M3/QQ*83XYH]HLEAY[GE)QNJ=JUF_K>P)^/K9BL_R^3VT/B]Q"CYO.5Y/X".
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M&9^I\$6P95F $XJ--!0R*)!.6&*58UD+$='&XB<U+]W/LLEBE9\!QPZ?,4]
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MYL'N1?OUFN-(F?8USVVRZ+'*<$\@[_4I2UYS+F&*,((P!I$I"E)0I<IQKJ1
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MF[*V!UO]Y^K01AX[P=_78?T$A+2!MYFR, 4@AH #%(>82)1P(63($AZI*&E
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MD:QK 2,.!(ZH IAP2%.L6%2I-,!EU.@5LC.L5!+<K**UQ^+< +ZSA-96<=^
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MW\MM[W/:?NS=VI[+*@)P):LHC7B((P0(4Y!CE"1AZF55"&6+YLK1_4!DF_U
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MCZ(/X9HV6D8?.JFH?:)P7U._< WNJ!T;V7TTE^] E+&[99*]@?S94E70))O
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M&K*]3F)T+=P#HN4\)O-. SOC#'39TN[):R_8\ZA-T==3@@&J=:WP &.N'WA
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M6GT^PW:>9J-WLXF-ZD$:'<NXLWMBSW2GYOW';XAN6\&M%C]B#-D*@)#T7*2
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M(K2:)7J@H]IY5/NX0X/* V\CG]=?P/2E*NZQ>U>JUT2*C]J^KFM/UZ(#Z,I
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M"94G<W6^043COS*^R-!DA^F!Q3?.)#6KM=K*I2LE9PL+M4 G]8 7V+;#N!2
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M $H<;-NTB*)0PBZQH.5$<$.:3/3JX*:#F[.%FUK0%E,08""5G10(&O@(LV(
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M912.9\YXX!<,=,1LUI/H&:N2> B1NWFD9W(8=X!T4D#B-1\-=QW,;< =X@2
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MV+2*<TZ+M2\:TB4L;+R5N6QUR85K'5T!YE4&&79L IE@D@2!Y]J,4K_TP]L
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MRI#.6SRZ0%9'[2Z0U9%\H0@)M'W5';E;8:%U-+^TA5]<**MS';6$=BVRPZ#
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MDSAN4"+)L7<Q.Y2IX.^L<$;;CKWHI JG,DG5&TF=K)M(3_)8B@39&H,=#.
M!SC  0YP@!<7?-4"; V3-4YY(>&S[FZ[1C*FO*B,:49AHN91("5S0@48"+V^
MPFBB-Q$+CYUGW4"ZK.&Z=(/KJ1:.9=Q'Q@5\X ,?^, '/O 5*1Q^4\!?;*WC
M5) ",19\?NTPAZE' N%#4CMRROL'QY5FM=VNMNQ:_;A5:9=K[6:EV;:;=F,!
M+SJ/;D2L)$.#V.)0#-FV#-T@\T@N1/E,T>J%&IYFL4B86LU.'9SZ,F&-,,QX
M0/IB$,6I.EC/[*;FP_J$[(G!O@EP@ ,<X  '.,"+"VZ6F"H$87FQ86/K[K;K
MDSTI+SP(K*EJID=UH\J0:QS!FKX4/=:^%6Z6RK\%^]&C(T@O#;(XR=3++&G$
M+K* E)%=YB6[LLT_Z5=:[*HWVM(P^EP=.@E=6-+![5O7YR%)J8:KTS7V0;FR
MPWC"N!<-U.LTD^>GW^DBE2UG7*P.C[L\%$GIQVU BFUT%L>R'.1RP <^\($/
M?. #7Y&"\PW.Y9 N<4R7FR;YLUG67I&2<9:O9(YER$-7\F!ME0QN"8 #'.
M!SC  0[PXFBX0A"6':203+'=:H27\^XI)+O._MCM[#9W[R227:Y:+^JH ZN&
MC)!!_@H^\($/?. #WR;R+5]-;')*R$%*R%CPGZ5,WCTE9* R@8<#'.  !SC
M 0YP@!=(DQ4"T;;LW9.SCB&JVB37+83Y3D*EK]C_'EV<LI,P24G>"-:*W$PM
M6,-*6I7(\??>^'LO$@D+HY3QP4#PF([0!YZ$J5":3*5N6CSEI)<"P;K"Y5E"
MITF3_#HIOR)%% LF^EWAJ<D3;F3JWYWCOD#CZQE2^>ON7. #'_C !S[P;2*?
M60.\BJU\E"SH-+^:KOA,<NEB&WPR;K_DMU$8]8>L?9N*,%%)CH[KBSZ_4Q:F
M5\_&^@7  0YP@ ,<X  O+KA96J80A$JR-!NGAHA1DSRW$.9[08 T>>!F03ZF
MZU2&UUV>B+?($=@<?. #'_C !S[P%2\H+[8>4=%ZJWULN@XSR:6+;? 7XON6
MZ,E0+BV\AY, '.  !SC  0YP@!='V!2"4.F7T\:1(<K4),\MA/E>4".GO"L"
MY!G !S[P@0]\X -?<:.=#<\SG%^T35=@)KETL0W^0F1_'HN$(OGE#22"FP <
MX  '., !#G" %T?:%(+0MBJ&Z%*3O+80IFNJ&F/G_&K6W$K;O2CN\U1-+<L3
M)B>DBYI224W/%!!ZEXY,QU)&W$D9&>:_5I]=NC*G'WMJ+J=V/H5NPDC\?C*D
M;M?==\ '/O"!#WS@VT2^]POL]U(5$-U]K_].%$2%4"5?Z&+:CO7QU]DE6[CF
M_V_VO^E2ZZ(R5P3!J/X^;UE;>IN.<L?;3USZ4O9%PL[$#;N(^CS\E3TN];3
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ML*@P4SR34TA[EHI0O?)AH9848F/Z^BFA#1M%R,L8L$=NNG'2G0W]]-6R_Z0
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M3@X/G7WGA(1NP,*(8_BC@,QAOI.C<P#?+P=E+"7\48B]*_JK^EW640*<-#$
MEKIS:[CU/J,%2QZF)NADF&D88A&J]QQ[4^J=$W1/ B*]#=Y!=.B=8(%($/9A
M0@MJ)F._/GS[^O"5E;'E>T7<2:D[B'I.@;Z3,.#\F+#P?SL' <6=1@+4.UW
MU$[^4EQ"3HEIB'MTBT8:C<[PUM898I).D::3$-TYP)IQSD F.B/W 5[OO3W:
MOXE$H_E?VYH_IU@9%G;6+YKF$G$.S#WTV=TK.!OM^]+6OAF)G3G75'\E_U_N
M;CV:UHB_T<QO;,VLR&DZ\\[H;8UR#*R__-:6CXGLS+\=\]\A4$TOO3O!9#+D
MJ\.WKPXG=H;\,<8[)FL=L\6""+E9'D(6=,RH('2&J4ML#&5"8LR5)X>:7+F
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M-;TDQ>(D:-3NP;A-8-U###C,\_7/FOZA-<@H>\<I(OQW%$3X B.I')4ZR#5
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M(I9KA6P1O]1S[\+#Q.[J?/QJY_?588?U+[R+LUF,3Z&_)[.9@Z%I%Q4/5+H
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M\M@KY1!F%5@2<-GG^:B&Z51=L>%[C[1C\'J,7!P Y-B=&&>TSH(]++WR0'.
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M/%[=K69QD\7F]_%J@<T5-?G]+%_K9#Y1=T6YG/[W^O<'93S"H:Y>D6DK+2<
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MJI%CM,4RU_-,U(F"7YZ@30!ACT>I=_>LQ@MYP[+_;K2,8WZXNCZ72N?VE4E
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MD8<^BT(U7[&&"G2_A ^2;;]+'?SNZVFMJB_/6V0 & ($ED9Y93 E&GI4R2>
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MO+RZ?K$O,IV/I_>S@-/FTO?'8-@Q-[!QIYG2C'O-,8Y7K$HEB7%5[D4L!C+
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M:HOD5B*!$6QNQ?1PPV9=91R_8?,\!$:OXH;-3NJ;.JR(0<$V!!IJ#YR SE3
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M7D)#K\M6+[)(OCV[!D3T%].*U&,ND6#G(=;Z,"U=N=@<IRV.>D7VM@G<$V*
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M])4RD&FMI /$NB0-1QL TI7U([+M3$GZK2EP,$G_-!R+.06Y@$QGS;V$$#&
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M7U4UV^PQOSU,;R;QM^]FZ^'HZK:>IUP3=;NLYE_J[]-TX'Q4I1OB]4$:IXV
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M3IED407G''H:U0-A.#%$M[LR<<01'RW5L+=1W .E$![$/1 CZ[6)!HAJ1@H
MZE&:==@3P:$$]C+L8"ADBC[_RW-%,>?$<XB85-II1F#*-V@ LM*/J?&?%A\]
M@,Q/NFKX-*#&TE>&N5Q6:6DLD]X)#GB<>X#&>;<9FY 8EVFZ#RRW5K?,=D/J
M;;&A*"= B20X5U3C_7VJOEA?M\BF>OELD$9@"+$U#'J&N=3*;,?D*"ZP+F%/
MV;P*7>R'R&A2WK7O'4N2VM<F$$^M01ASARCTPAH=?VZV2@[*S;D>?O<?"J2S
M$N%XCLO^5D$H:@RV#DFOK=6.>R*:<1KH"ZW^-*#\VC"B%U9OEQM%Z@1E46*
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M6%[?#],-'V8D>;'/1>U  Q4%ZT!I,^;8;-IYZO>25CU8B9\_LT[WRA<' AL
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M>AB*.<BF+*.G)-18=&8BI^;\>RVMAIE4+C:[%^[:#42\)&[_9;U@$N]"+TR
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MMTW)DT>L?::\F5[=76Y7^6/*QPOYXU.1/J3;,ON:MM_M+LRUL1LF#HQB'X"
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M.TG<A 'O/' =WYE+\I5'/HO\N^+3SIMY9F"%QC!U$C;4"F:>AWNO_WBI^$U
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MX/)G-S%&;F2'@-#&.1<X(9G)Q6]:79I)J?)BC_\\BQ6]+6GJ2F6R1C37,N6
MD'^T"D6F+4QYMD!O8_VCUR9F2!O[1(*)F$]?E4BL:<7 QDF<N&'HP"2*L0M
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M)4#K>#7[ 1K9\ER%Z1E7XDKNB!3=ZCSIKZ]9X9\757[Y^6H!4.Q$./9]3)+
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MD+KOQSG!W*G:2BOS\U RS3Z]>X&./L;$'W.3W9I2%W0801@F+ALH.PXF(2(
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M=/4)7WVZ^7+U\>/EIY^LRT\W] N]OK'0)V)=WUSA__O?KSX2^N7Z__JGR'7
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M5W2Z!"9.3/TP<2C&%G8"#_48B$6"T96?LN59E5#;C'<$\R.JP4E(UZF,BYD
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MY\'+ 6Q8Y!HO*K!.V8.WS3;@EWP'JN;?_B8\VUL.6=?GXLO!:DZ3&P=^;3P
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MU,($V=3R(M=/'#<Y&'<IA'+7 &@R*C/TU>X$.*DGU4_YZZ9:3&]GX%A.7@\
M+QXFE#UZKNFV2R'B!F13,_/+4$G=3KV]%-,$9P)O.IT4RM_V=_^5K>NZ^)KU
M%5=1DJ9[];9]YP-9$/J$(L^SH!TA"T'/[JU3-Q3M *[5YB2'PJL6)J@+4!Z
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M$].J,X8=:EO,E NQY2>$^DR*.V,!25RIXUB*)B:4/9K=Y^M<<O]0E3DQ+9N
M--E%P!80Z!'-)%?GB1G0II%,+D.(QCI1:'VZI.NO8K^KF9UO=;K;\&;_?SQO
MV,!C$?:ML%\#\P/;16[ =,V!E@-M.Z2];9S$OF3MI<&B:0'Z]@?@>'ZU0I!N
MBF?Q=^<T$RM<7$W,J61A=< '#@!!B_! \VP%UG7FAHLKC<PO0\\T^_2^J-+.
MF,"&[)#9P$*=6==U8A@DM@\3&#O$#2@]B*R/(]%7M?48FT;CV*A DAJGC\ZK
M^Z_3,ZE5V1IRI?=?-9$KO/TZ/<EJNZ]:R+Z^_2I$Q_G=5[U,SK[YJMF=PM 3
M)YP$OF5EGE7T9 _R_*Z,CZPDA';@(.Q[5D#C,.SLANP?1=^0UF3-<!IH40(*
M1N_,:B3X:EZ8@5NYQ"!"JWQFT,6O<&J8@6>UW*"'[^O)08R0\]E!,YFSIP?=
M_A2F'CO)!!%?LTNB +F0/18DY-T^K,1.@MYNX"=">U'ZK$V3(&*-"6(\P8()
M8E)NE1+$(*VJ"6(\OY()8E*>1R6(D7R+)HAKA PE"&UD+B1!Z//G;8+0S)3H
MHOF'W;K,TBJC6?O?#[OWKQ9\+;;;I"AYD^T5]KP@H($?02N)^(S&P_T\!B=1
M('3*WY1MP\FCAPM^Z0'_#>2["R_E<-R@ RXH><9"(K;P/F<TY-*-@4 869"7
M9'1@:=Y4;):Q2&_,NV*:)USAOH!7-E>>'7F!&Q$+67$,$][A%?6&F.3[J^>V
M/W:=EK68M"H8D1FO;_$(#]TH>\AW?"L8W*5;WCUHA@;QKV@9&'0C.%S&N!KC
MP+F.[6.XD+IBJOJ\KRN^F,H>E)7E1['EAC$,:4PH?]$X]GH[E.)887!(VYAG
M;(RXZ$*>1;$BP2QUDK/.KD/>"9H9[BXZ)6-(3)2)6XB6J.,_=\'/""9$E82T
MQ^[R[UE\?Y^MZ\_WG[*_CILU7\I\M\Z?MZP*:&^?^'R/NYWC%8Y\E$3(=1,O
MA"$./1+W1R C.W&D)CD&81B>[QR1@ZR!SEL0[+*_0'K<NWSNX<OID\G8B G9
M0L(BIW@G$8D/$6&XP<EN\@$YGQ*UV/FG\+53$4844IWE 2F=('3+T-PI'"TF
M'Q;B&QA#MP2UJV45,US<7UPYJXN3#J9_/!>[#[N\SM/ME_W=-E]_9A[RKUU%
M%!(G@<2*;#=P$M]Q,.R1!UCL[M$EX36=%PZNM%>,'I>@GP]+T.VU;77Q^@;2
M/7.)R5+C$WANG&)?T7JE=)?&8B@7V,19"E2#!;G ;7&O'YZA_0OV\+SJ?<T]
M!IW+H/49]$[_A ^,^*[44B!/L*^UO =(8)-LHOA<V&9;VM,Q_T;=XA@IECN6
MQQ9C?^<WB.L$CE&$,0/I138F* AH@OHU]PC'GF@7L:7 _2E+L;'9=/J'0K7Z
M6O3SH*_X:MQ<:NTU_=,RMO1:]%.CO_*:Y^E1+KQT1T>J[IKMT5AJV34?(5>K
MKIEC)75>X%+-^"G[J_E1M<+8#A&K]J+8A6[L4>R&P<$X<B.9/0M-)DV?QV(H
MFFW2IO1Y6]O<%]MM\=>OC5JU\;D!NZQ9,3\L.:V+JJY&[+)JBHS@UNOT0=&_
M_,,W*UJ@,QS\N$K>M<,@^MA?Q@:#;J?.'1K1S=E(V6Q$_VC;"Z(81FRJ3"W;
M(03Y 46'38O(<S6HIJ3%GT0TV;_\W\AQM0BF;$Q&Z:7!<&B?L"U,+5]3)R^6
MBM0O6BM5?1*3RE&,:2DPC_7QY]/Z^%NV9A^M<P8J<$(*DS!RD0/M.*$NMJT.
M%,&1#[45GN.A3*JM%]?B#I*:]Y\W68=J"*"&^G3:V$VY;7ET81$:+4BW:J6K
M+XZ+5G7MSLI4QKHYUE$Q7\>4N'Z0H-CS81@3VZ;(\W&/*:1(JJ^:622+S@+Z
M"FH-(1M?:$\;K0EW3!8F^V)D*Y;L^H*X:-'7[:M$B:^;82G)/][H?B89K6P:
MNG$8$&@[H8\0LPS[DP0$HMA>[;('WMQ60MG'&102A+ 5A%-LPKIPA'>R2,)O
M!!W:7Q]7O(\,@81.3\#]"#$^07>^$I]!; <9NZ:H>NA>D&QJ<NB<-NKD2H<
M-LJ\<GWB)4$ ,7$\[%I63%%_9Q;Q(?5[_;N5+&]'&570P%OY2E9%"/6)GR#]
MX[5/(^5FI*\!N!SE:^ H"I\<U\O7/4E_)&1/A2DM*[[-#S\W[_14\8^L7.<,
M&0."/"<BL>TZQ/=\)TY(?[:!>'&B[WB!FOE9=\VR#B;_:?O/[2M1II9T%2.D
M81G7?' DI9.C^O6N$4U^HTFVJYIS;P"7)?M<>W'VW0LX_=R7]*7Y9\Q[?-R
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MCLO,Q=0/+7Y4KC,5L>0A(=]J!B82[LT1&J@Z;%)2HTB?D%B;9TY>ICEI)ZC
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M;EA=V^)H5]3@):N;EGH-R!NP[1$*[\::HO_J[O<"F)?3V!;P#7BGM6TT&&S
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ML6,$L;%4X7W]6)3-+2@.PC3R7'[W>>([GIT@<C :8RQ5!XXT-;4 -E)7@?2
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M@'_1C/0UJ^HR7S=WA56/JR2PD&4Y-O1(XM/$0ACW:0_9L>7+Y!3)KS9]^.V
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MOM=5]MCN/G&F8B*#RJ0DGDHEU4FF73J_?@ ^,E-2B@F  $EWGQ-E69)SK[T
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M:>81Y DSF4=X1<25-((N;?,+QF@/+B01QK&A+B)M^K.UE<#(92'$-/8]C!-
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M%!$9,VI9DWJ<36[Y"/+&^2V7O+?!/,MRJC4+P6HJUD/D(B9 OJ9X*<HFR^2
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M]E"='QRKTX.=7_/4V!PL6;32+,M01EO.O2EMM,BA1$J6E%5=O?\L[6O[@$3
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M<CIST.D\O'&$C\U/S[R<5ISMMMB W"^DJRQC ED*&>4BA_-\D]S9=U8L\1!
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M61\A69%8%;Z-*JPEJJT*[+?K;3&GNI[@C1=7C>;YJ;15QS\]:=5FTK"RKH(
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MA]];ZT_%M>RL\(_=GB.ZWQ7_W5CO<A#5*D8H3@+H0C_P81R2-&6HMT805+H
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M>EZ<ZD[]K\Q&:7"?DD[K*2>W9=P\/)!8C\IF@!'*E;)&>@.!Q4P*&V26!'&
M.2+G1;%DS3=@4@J^^SGU=#?GZCI;VR2C;;K#\=]^SV^^YM4+O-CQ=&8=Q)!8
MK1G"C&'F,>,U!L$ \^?/A",U5[:-[0E'EF <Y^\6^<V!L]6V6 :%!V$A  FW
M!!@IN66FEA0K"A-8A(;'HE-.6<=BWC>['IB(G[9'#=]- KK%93%ZEI;UQ654
M/+.[\2)LCNT>MGAI\<495YA0;!3'!&L:52C5!FW,H&9G/TX>0;S]VP&GT]!;
M[ ]/L^6N4NA^N1[-?BO+R5_%=-I3]]C;C@Q18:&&!E,&.?/!KL(U1;#PT)[7
M?##XWM*VPOKJ/ UXO94 :RN9!(Q;ISQCS$):&UL809JR:L8_".6.Q/(M#J4/
MONEIT'SP3>8D5$0Q[C U@B &C?4UOI !E\!5TIBK^WR<;X*RP]#06^P!'_(#
M70$I;\H UTH#SH1VU&!@K:1X@R<AWJ($QM.#1^=G?NP?CNJ'J^3D;K?#KBQY
MZ\XV8"Q35(HP#QO"E!< <VZ%X8HRI$_H?C^ELTT3J#Q1SGDJ*4"(<1'^Y[P&
M<>O6G.FN=1I!4IUMAV'^]IQMAE*J#>2(:6(Y#K!JLY&/ FG!>7&J._4W=+8=
M!O=Y.-O"8LHK:1GF%&OIG&2 UC(;!<]_Z_ PS1_L;#L,WU,ZVP WWCDE*-,<
M>D,<\8@'<Q QABPC*>N^-\*$(S77P-EV&+9OV=D&K+9<<D"-#!,^M)K"NB=I
M"'3*E#7 S=533EG'8MX7NWPQ*Q;Y^^+;\RW>%Q9*'\*BZ,M?^?1;_GL95EZ[
M^)=6<28Q!EX2P#W0&CF$.7:U=:J];!0K^*;'N2.(4YY0 \/DZW_FH^K+7V5K
M--W4EVEE35@Z8>\(Q@XZ81BLL0F+JI20EP&.GP-@YW' #YB4X?6[-C:.K#%C
MWCBL8WR]$E@* ,,4MNVT')H?R(75(S&/@'ZXU/3E\J5%25J%&?<><(451D1K
MXY6#G-3H0"]3W/G-_54_&C&/0'Z8O%2706<KB4*!ULCYJ-;,,VB(5M1K&' !
M CG@:YRDH"D6Y^'^I1^!H2GP#X"FN[V?NPMFP;0&R&. %/ ,.R <YK6T'NJ4
M>9J],6=F!V0['.&3^R:?]9>-[_4<79,FGO *!I)Q\:271YQH0IT1' E)9;.C
M(_W/2K4S/-[\NKC?2GH@X3YO90NU9U@!2P7$B 81 )'6>%YCYXG]D<X4-Z;1
M ;-4-VIX>SY-R*TRQGJL@8("8"D-K.4#6)R93[-71C1T<QZF@?-P<WJ! +<L
M^ERP04IC'C"M9=9) ;@#9%VRY@]V<QZ&[RG=G%(%09FT#B*-! PK  8V+544
M@)3M@C?"A",UU\#->1BV?8TL]4"[8RQNXO8\I)K,4Z[#X(P%#<L"YI@!7F^1
ML.;,SIB<<I;K4"UO,7+Z7O:^S@X\>&,F-"94(VB (T(!#IFLE:B0@OJ\!M=N
MJ-?+4:M#5?4VN\(DOWQ=-;UUCYVMR(AGE 8JD$ .Z9P37+"-'K1&*B7L:H S
MQ1OL,FVJ[VUVH[=RL#>,8A($8D@ A-"2.&IK\U,SCE)VL YW47>^]?T&NU*[
M"AS0^N&?>7%UO0AR?\NKT55^GW$Z;3WQ:K49Q=XH HS1@#E.%/"0UD@YCU.H
M/D"G=R]4[U$?)_<)[;Z=X8T[@0B6!#GOJ:%,6">@\>OP0@&M1J!1VL,S/)\F
M/01,:>&14L%JP8" +2I*IV1!&N#2K!V"))]/.PCS 40>Z+O?1_^OK,QT%&3;
M[=\YH)8,2F\]U49!A WE1B)I:QRXH&>V+= =39J[&Q-5,  JWK?_P^AFOPOH
MP)HRC;WB3AFG%:7,(*X J_%PYMR&PTZ8TIR-+6C@*)>1*;_ELWBQR(=RL;JL
M^C9?Y+N\1CL*9% ;""V!0"$D!4 TPK)I+S;ZS,['=:;-L@.P>QNN1D45;]G+
M0Z?)1S%1?+P_R%?Y?RWSV?ANWXRYOW1&8V(C(*05'@OA'>!P:YHPD12]-\#=
MP/YFRM:A[YUR+[5[_ZRXOW1&-))*&PF]8HXZC!SVM=Q4^#-+LMLJ$UYC66MH
MGY)E\T_Y>%E5Q>SJU1GSD.(99]Y)AK3BTL:<5<1"M98<00B:W=KR!GG6!A<:
M\"P1[A/,H-N/_U'D57C_]=W[_%L^;3Z)[J@@PXQ0;TD,^59(&:XX8[7TC* S
M.ZUVBGFT/?1/.L@]%^.H2?75>K*PAO+(628]LDH%>U807F-A@!%G.NRU1) F
M(U]+T/=.PW>SV^5BO@(%-9]BGY?*)(!<,@:]-1Q@1R34HI93(W5F]_QTQ('7
MF):,=U^\,N7JUMN 1O@T+X+Z5LK4=U]",_;,JGO+9H1)33#%3$,+$55$6E?+
M['32PG2 #L?>)M2V@3\QV6*K]\Z?>\MF@"+LI0Y&,&'4&" I0MM.&WX]KP&M
M10XT8]?12!^Y"7MSDU?C8C3='-+]O9CF\T49>M7NK=@]Q8(1P:Q%REDM)>!&
M& MLW7:DW9DE\FE1EV5G(!]%$#>J9A?+QV+M8L;KSV>2>.. "YU">(*@"C.^
MWG849%(H,<#MTTXHT1JZ;^]H(N.0>TN)A@X:ZJA2;HL6#O\DL&> >1IZLW':
M@?L\SB$B#@RA@E'-C28$ 8JWNW*(XQ0S>H!S5K+F#SZ'>!B^ISR'Z+'V#C&I
MD#3>> T9V"XBG4G:H7PC3#A2<PW.(1Z&[0E'EO>IZ5:99"3FIZ/$>J<(<776
MNKB1YI-.LQZ>[>6LIZQC,3_AD8_'5F$UFLW7VH0-V-:DFLQ@X9D%3AA%D4:4
M$;WMLT2S,]MX;(<4^P]8M(5W7\S[.+I;[<%^*3=#>BU3/O^M*N>[QK9]13,.
ML4<NK#NH%1(&L9G:2DRQ/;-SU)TPK&6,3SN>O;3>K4\:W1T\K.VL+8-4 D,I
MI(2(L&PV<?=CNWAV+"53S<$^Y&]Y];5\B^SK'OCCC/C&S?I]]+VX6=ZHFW(Y
M6X2^],JYC.0Z,V8U"]8I$=Q2RA4VV&QWVB0ZMR-=K9*M;_#_^QAOEZ= K530
M4,.$P19CAYFA9*.+L#C$*7/^ +?A^AIU!Z.P'_G8+L!>:>VL14 1JX+5;FF-
ME#$Z)=9V@,OU3JC=(_[#,W55%9:#5^N0%W,=/[Z;K2>RB\M]9M7AJ_[66Y!A
MS#QS"G$NI(>(":QEC3^A-,7&X3\(_X>IJA-VE0?H?LJG\;IH4\X/3>_S2B49
M,E@@ 8SUQ@)/**"N#E2D0)F4 5O\N(1M!^V39U%864)/)Y]SS*@@G+(><2:M
MYMX@Y(&#4F!+I=!.HT%D5-AA#S3/I;"ODLQY$..3M3**>@J0$(342'"/SRSF
MJ!U2O)I%H66TWU[ B6&.6X[#5 MY&%8EP89NY#,Q:<UYL:D+Q3>]V?<@H,\C
MU,0!0@0@R#HAB>-,&6=KF8&@9Y9H/5GS!X>:'(;O*4--@@T5KZPUVA'D3( C
M_+=NJ0KKX?-GPI&::Q!J<ABV \BKTE&*'X88Y4 0RI2'7C,IPWIQC8.E..F.
MJP$Z:GN8RKH#?P D[#BYCV%6QV ?$X!@3(1AW_D:#ZMIHVN WLZ UPE3$I/[
M'*:!OACYOAC'Z^'V'K9\]%R&D7?<.0ZX$@@)[XE3M2Q&DS.;/CO3=-D>QGWQ
MY4,Y&Z_3$JFK8#ZL=E+WDN?U0IE' 2LM)5%8.,&580K44J*SFR3[8E)K@ ]@
M8MQNMQXW&][OUD(9%CUA\0.=I$A[8CC:#O26RY0I<- ),$YACQV+^H_L"1?$
M,: $1" LR1%"6F&T-40(^''R+QY!GC8]XH?I80 CY+Z0XGU%,Q"C6[72#L*
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MJDJJ-X-*,BEBFA2 * JF A6XQLM@<"9G=SOF4A.KK".-]#C,E+//BP=4['U
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M4M9;;W?CN3$U7DT/VRKJ/08.O]QH?=<@^4B#TIEA4CKGPQK38Z^40YC5<DO
MY;EE^VR=#L_CAUN&_.14B^W>FX2D0>F,$BS#FA3HL'PP3@DB/:OEM@R<6?A,
MJTQHRK*CT>Z+9;^/ FRSO+I[V.J])^EWE,HP$4 %TT]:Z+70P?YS6PR9AF<V
M7;:J^;(KE'L\\GR[#* W9](K)3*G/,&8<6Q%/-1AI+=F(Y\R[-S<MEVRJ!V$
M^V+0:K\K'GU]=W-;E=_6*2GVLFA'J4P+13V2UA-$&;/4"%+CIIA29Y;CK4LF
MM8=R7VSRRVI6Q(/Z 0E??(^?]I/I]4*9D\P&Z:"A4!)$N+9$;:6$Y^:>[9)+
MK8'<VRF7\G+QUVC5WOJCS;_ETW+M\BGG#8:IQG5D4@,D"6#:>XTQAMQ@7V/
M85+VA 'Z>+LD6E>8]V=2S>:+:KFZV.#=+"!U%=2ZGVJ[BF702N^ 5=QB!QA&
MSI%Z\T818\_L\&>WQE5K,)]\7^%]@[Q6^PMG !N-,'4PK*,Y\(Y0N;4K%><I
M!_4&:+F?;@/K6,1/SK/?JG)^%,=6!3,%H=48*"YC,"!UE .[D39\S<]L@[1-
M]3=EUC$X]^@)7MXLUVZ)!R=7PN=IOM+F;*)NRFI1_&OU_:LR[G8<M_**3%MI
M.0&0((4Q 8XS4$\J6A*8PM3F(V'?=]UW2-@3*>;D ^:'?!===Q7+F :<<(6
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MBS5VHXYXKB6?S1_?3+*?0TV*9]!#XL.PCH"0V**8T=35DHO0"<_+6=(!HSI
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MO-4A;W)Y;V+-F7/604MP0)Q#!ZQSC&S[+:!)-[,.\"C"T*C<H^Y.Q_7Z\MJ
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M-BJ?44L4-T8J:H#%2#M2G_G7R#&:-#4/=KG2)4>>IE?H0 L]YN@8Y_ED[@.
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M8.;U$,90M^KB<NT""&I\U+K-MPW"&0ZK*0,&A=XNA2:<T_"9<"&YX_%6"T1
MLY30G1UEN2P6#]7R\J&5S4.98@!:#QCUQ''J(!+>;"3!$DEZ7ANRG>GY^=&4
MXP#NRZ)971+T@N2QR:NDVU]&WS^6U4JCBT55A/$JYH?_4GY<X=R@2[7TAHQZ
MCL.Z5FE%K85AP8$!K_%C3*3XI0:X*]L704^CG5.S^X]9E:]=(_]13F,$]&^C
M8A9%OIC=WWR@JF(>CQD\V(>I$3F"[JFOS(P!B#L!*5:,!DR=DKI&F".6$BHP
MP &Z=UXV[!<]J_'4'<6755Y<S4RT56?CNR_5:#8?K5)(A_%H]=MT1:8:A7;[
M3(MOSSA#F!*M$3":("Z1L;3&W2B0LGL]P.ECJ-WG=!H]=4]ZB'RBM911AXRF
M-A[)T08ZQ@P'M>0.VY1$O0.\N7"H7$Y026\>F.>MKEN\/?SU(G1Q7Z2<+8*6
M0INNZEC,71Z;=M^408:U48H3$VQ:B:$.GS=X$L)(2@*L 5*\+VO_M%H:TA#<
M#NM;?E,&A176$"*U@MPHY.(]Y1L\,=#]G#/O.R7-X)>ZK2AK $/^<<-WF-HT
M<@0(9)SSU K.I*OE%#[IU."0CVR?;B@^$/$3NP&>Y_#H??]_#=^V40TV)5\I
MD<5X&<X! Y1I+!6%%GO.K3 2"2]UH[#DCGT<7^*@U,2%L7HP\RXTFQ@' %0,
M,$@4,K5$CK-^[OCM;=V;K->GIR]3P.SM%&_=2#,=S>MT:^I[L<OS\VJ9C"N"
M)1-"6^)16%LKAG0MH\%)]U\-D##'*O@UGB3"V9N5\*"9MKP9%;-=QL&SAS.M
MN2;*, JQ(-)C3 RLI<)>GZNW\'CM/IW]4R$]+H@XK^+N]*MA][_G-U_SZI6@
MX49E,R\1]T(:A25QQ$-*V7:@-02<V?'J%#66W4*;0!";0)!]93/'7+"4@5*8
M"NJHA8*#6@ID5$JRG 'NP[=)D):A[=TZ>5^?L&QBEFP?CGM,C%FK+5<J+*ZT
MIMYNI:(FY:3@  G3MCUR+(Z])0C)O^6S9:,;,Y\^FED3K'JB6,R_'^0)_RJV
M!0>PE-VR <XU*2I]=L];$I)'32V;=T:YPN U+F(4^$58K4W+J[LOZ^#+E^>5
M!@4S I2--]'&['162R.,DMNID>J4+:H!,N%X]94=HIK*"AL^3LO;R/ PWWTK
MQB_F/=Y;)@R93E(I ";68X"EX=$IL6ZU%2#%.3K ^:)E+J0#VO?$T6#"R.()
M$BF)(518"#2FZ-[D,I*FK%8'Z$Q,ID0B?OUY.N:+N9I-5N=SYXU,B->*9-08
M;KV 5""EJ1+2\BU$T;%S7H-&BZ9$2X@>>38PO+N\/,R<V%,H<YAB#R#D1BNE
M(/1AWKMO-SJS,,MT]94=(7LT(^*%V@TMB5<?SY2 DEB <&BOLTP"QK?=00<L
MSFL\:)L%;6#:GQTQS\.[8O;6!XW>(+'3N-A1+IX%C&:S" :S@(Q2[?76="98
MI6Q:##%=1UO\Z0+<WO:Y\E5X2&CR[Z/JSWRQRJN^CT6O%PI2:NN]\1P*QY2G
MBB!<2\E5O^DVWB"%6D.V+_[\EL_R:C0-#5:3FV)61/GC5=#[2;2G9(:M#._$
MAE$0T+/0<4!K>>,N8J\!/&^/2>W">ZK5T0&KHHQ*X!1W1G@<EOR$8 ^W$DEI
M4C96#\^$T?EZN77").+96YALG9?Y/@QR5ZCK\Z<SP"76PAFGC';<Q62M-4"&
M:IQRI=T ]U5:7#6G@]D72=:9$:+4ZZ8V"(I^K4CH!DX) !'DUF"-*5#.U1(:
MX5*,X@%:-"W2I25$^^/,NGG[+9<G3V;(<NB%U499(235 -':,C-()]V1V=Q2
M.5G\>QM$2<&S-TMW5,SF<<S+YQ<S]SV.@\MB?KT.NK;YUUV#R]ZR&>;28R?"
MM&J%EU)ZQ^J0+,,E2]GL'V :KQ;)TS:TO1[W^5#.RL>3ZO[19W?!3%%&H+(2
M,,,A<3+\QFMI'> I5O  4VVU:=VTB6M_DU9MB<5KA-?)OI:A[??'&W1^65;Y
M@SL&ZKN&ZU$WF/R/:XD70"WN?L\7U_'RO7H.WV5E]]B*C!@IM4!(6D,1U5IQ
M:K>3@[(I&TR'9_QZ2];[<)74;V<)DFWZM,YG^671Z.Z3QR4R  P! DNCO#+Q
M.#_TJ)9/ )&R)G@;MTVDD3 5T+X(<V@V,JF,-#[F<0=4AZ4-IX1LYPB=ENP&
MG/7@=#2(?5'A0[ZX'_H>'[3]E$_R_"9^/O@D=D*M&1 L]!J% >.*4.J-,;4_
MR6#)4IR]L+G/_PTO._L#_R0D;4J[+,#E!'6, A##[Q54I([6-@";I##4P\,&
MWM*HE8)C?W/8PS,7MOA63/+99/[DR.F[F]O=,6B'5)-)H9V.]]Y9K*$61(?>
M4B-!2-)I&=A\B_WQT/16.-4AT*>9*[^-BNEZ5#7ES4TY6\EU74Z#.N=Z-"_&
MC>?'O35ES&'B@).&&P.L49"#[;J#<YERF24\?+/^S0YEK2/=%_/<J)J%:7K^
M,:\^7P<(5VV-X3C%=+G8>7?'GI*9]D%>0P*&TL<]::W<=A.1DJ0K+^$ PQ%:
M9%:[R/;%I'_F\8[@?**^Y=7H*O^PC&<5+RY7$EPL%_/%:!;33C4GV'$59DY!
ML(H54U(R1EV\1';;SRQ,.1<"S]LQT O@)\YBLV^=$N1Z.'2OM^L>2W":A/?/
M6W58FOO7RV>,&Q*(9YF"DD'C/-!(",V<4 P1WNC.N8[E/S 9#M;8QZ@LH!DV
ME.*85JF62%EQKKE-VM'R[M0XAT';^^'SM= QZ58YBSV^:7J<E\IEG#IG,,8$
M6F@5AESXK:P:VW.ET8&*?HTO+4#:FQ7\N*E[,^6\^'PFK!6"<F$AUD!XJPV$
MM6SQ,OLSI4N:GI_:OBT@>^0)Y=V&P:Z4*,W*9L(+AQ!UED'"8!A]2;#?UU)P
MYN&9Y<Q)U&39+;JGV4Q\E42['L^(90YXC06"4E&#E#,U9IR8I"1<!^\V]W$A
M:SO,:1'2_F+YMUM'>YGR[-DLB(,#\:5P4"A'I016US(AGI22:X!GT=HE22J:
M?3%$329%U,UH&N^1VUY=O9<M.\MEFFA"/"7 "42YU]XCM^T-4J7XLP88L-TN
M<]I$MC<6C<?+F^4T[HV\EBQ[/Z.:UI$Y2 %S'$*C-+<VC*Y@VY,T-REF\0#W
M@5MF5T<H]W?J>A'$7UU?OMK2WDNKEPMD"ED(@FR8*L"\L2QTI(UTPGB<$KHQ
MP#W==CG4"J3]37#_;[F)B?1E]2'_*_2 <KFZD?=C5<["Q_%Z*W?/QLY!]62<
M8*@AX)PQ:BB7V$!08P&].K-<4BUM]'0)<5]T^Q+>=G&I)N5M5-O>T>FEQS,5
MEYN6Q.4G9,8A3VC=+P5@^LPRR72D];)UH'LTIC;R?XX.LE$UF?]Q&_U.X7D&
M9!-#:G_Y3# !PR OPKR.*$ 40FEKV95W9T:R-/4_MZ%:!W@(Y"*)Y-J6SS 4
M6CG#N!4( :0,U]M>ZB5)V3D8X/37&[F.!?BH_>M=#1& []J^;E0TPQ@Y*CQD
MU,=+\' P1[?V(E-)N5<'N+W4"DDZPK9WIVI+]XT8K)'&B!DI8N84LKI0(<HH
M@4_*USI _K3M3$V$L[<=[,3[1H0QSFFBN,#6"P$M4ZJ6RAJ4% <]8)(<K]W]
M]XT<!NE1<T\/UTD0QH&78;A%7#$"A'52UE*$+\\L!WR*&@^^3N(P:!,(XA((
MLJ]L9K3@F(:7&DF9L<##@-)&"L'\F=W[W29!6H8V@2#=WECDM$!.,@H]%MY!
M2FAM8RFCD^Y<':#]T29!6H:V=_/U_7$7TK!X:4^\1Y XA^(]WXS36BH-5$K8
MQ0"]HFT;K,?BV&-J@RH?S7.;KW^^FSV/G?U43J>^K/X*J[8=U#FPIK"*)$)8
MP30%7L=E'U';WN*U.+,PL!1"/$^%T"'0_0U+KQTO>'%8>OIP1J F FL#.'".
M^IAJF]=2A5FZUYW@VS _E/%\1;7HE$2=:?[9Z)4(=V\DBF=RY@\.Y>SBT--G
M,\"T V%(I](Z8X5VRI%:)FN3XGT.MI7/CD*):/>V4[..*XGYC2\O\_'BXO*)
M+Z^8C8O;:<#IXTI#]YNANW9TCJXT4YIQKSG&GD@JE23&U?$K,;7-F44O]L7&
MWA1RW*HOROQN/E_F$[NL8GO6@\&J"ZT7'?&"D?+RU07(XN%QZS]NR]F[6;$H
M1M./RZ_38GP19*Y>O2&FK[=GVE*#/#5 0RR09PBIVM[10IE&Y^O>SD*B:VH/
M5W-M]H%_C*;+_%1=H.V79XIKI0)F1$-E@OED/:]UK,-LF#*X#S $]'0]X,2*
MZW4)]5K_#Q/<ZD^[=WN:5) I!24/75_'*ZT<L0I+L96>8WU>4:>]+K+:!O_$
MU%MUO 3F/2Z?D;!*H#I,/19 9 QGPO*M[:5)2E:> :8D/C'QDK ?Q)!W/^)?
M/!SQ/^?C\.BB.'XHW%MQ)I"TU$N-.:+0>8O5-L#3A!5$RB;YX<F%SYVIW2AE
M"$-G!PQN5F_F,1.>.\*H= 9"RPFKO6(F7@240. !)B8>PE#;MDYZY>^G_'99
MC:\#="_TS'TDW5DX@U9B)X6A$,4;@8+8M%YL&LI=4NQ3\US(/>: [)6,;6(_
M!,:MNM*1A%N5S3 SQ M!E4%$80"<Y77"!,.H37(D#3<=\A!(=PS^@S T5W^\
M6.T/S]WWO!H7\YTI_ ZO+*#""=+&08P,(PPY;VJ\#7$^9<U]1&[E\Z)CEYH8
M@A79$CU?KRL#CG+EE'#: 0*A@%;5FQ(&6YD4AOH#NZFZ5L0@!L]/^7Q1%>/%
M9@=61<1^JW;GG3^NPDP&(P8QB9 'G&HG"/.U[\Y829,&T1_0Y=2K-H[S(L4F
M?(UV1LP:D,_F&[55H]G5*OKJZ]W](Q]'=_&K50OKCC6JIG=U[YH7&V_P*TZC
M3MZ5<8,E 41XQ:&S5CM&:Y2LD,JG</8'=1(-05&M.T5?G ]633W<Q_EZ79D5
MA H%#'9>8  )=]S44DJ8E$UKB&FD3^RS;$T1@YCIW<WMM+S+UU)]W*P /TY'
MLZ.G^M=KS("@Q!L9.B16&&N!)*B/[UB/:1)1#W86]9$><!"S?6L*&<*ZZ55A
MCEP[O5I?)KAP#!LM*8*>6(X@JF,AK;,ZR3#];W]1I\IH/\*O'NC+RW^.HE'R
MXHVIAU>2:4@(=L9"*QTF!A&W#5JQUJ5=*GBP3^<<1L3.=="ZD9A(K5?JR!17
M'"FB@!)&02850VHK%0(IMYBBPZ^K?//#5]<*."Z1RGV"JT7Y.+MG46?W?'EE
M%6!XM&2:/+1J7^9?1R_+($;(0(&I= )+H;TV+*C&86@=1";EY@(TP$-F/1!U
M&)KJ+>_4O;1?RE=2W+XL[:<\H#TO%OGGO/I6C/-U?_Z4C\NKV:J6?8[+KE^=
M24T=!51BR[64VG@MZ^@81U1:MJL?V,,T,+WUU5.&=\VQE1) 2P2%#%A &76H
M]BL[(%B2D7+L7:+GX]?O3S-],?BUQ-)1P"#MQ>67T?<=5&U2/+-<><X $]1@
MK\/,1GB]U'1&I%UA\0,[I#K _B3C9O@T7<;#LA_+:J7>1_TJ]*:JI:$T^449
MIYY::KAQ$"#O#75^BR;T/"4T'_V ;JI!:.EMG-KWV!NO./%Q/\5 R9#8VC\0
M@*0Q]&"/U/K8OIN=281H(MAO)7<(0IZ&!2=W& 2A&&=6U]W">\22!J^#?45G
M1J%4M$^7^.A+?G-;5J/J+BWKT>O59 0#ZA3@6@CAD=*K^X$W2% H>[W![(VG
M/&H-Y;[X]J3!9E15=V&$53<Q!\7>F?Z%R7V7$[W]EV4&4 FU=EY)["W57-%Z
M)O#0.)GB37H[R7+:H-W3.QY.K:L3]8#4(\3'5!?F(HV]DUHK"8CDD$%:)Q3V
MDJH4%@]P!#X%?[O0PW^/T<WZ/7&>HGBA%34,20C"9%M'@WN$DFY'.3@J_U1F
M[=L8H0_3U#W___W79TH*UM6?JS^]^)=-/8] OUH&-$:SQ74^FBZN_S8N;]8J
M,^5L7DZ+>"W#9&N\S2\N]VWHJMGDN=G_<:6_ZWQ1C$?3Q^+DWQ?Y;))/?NXQ
M^>TF!_"C)JJO\T4U&N_:-6M4/E.6A4%+ Z( !<YA!#B,W#+""ZN:'9[N6/Y5
M.MLF@J[SWCJ(-;$48\T$1=QJBV0M$48P9:4R0+]YRUI^+1?P,=#VMZ72YB4G
M#BMB4%CG 0VU!TY 9VH9?5CKG2E]#E1PXTM.#H.SM]29B9><Q+RQRA.N)/+2
M,JMYF) W4ID@WYF2Y'CM[K_DY#!(CPLW[/Z2$R8-C<?!)5 $6QE]%JJ6@B-]
M9IG!4]1X\"4GAT&;0)!.+SFQ@F(IK62(*^$X1<9M9^)@UY_917UM$J1E:'N;
M:NZ3-.Z]Z_'9LYF1 !H%C3:, R:91QIM9#(N=((^E\5O@BYM0=F[\?K^R"M.
M/%<6>D>\Y%0#BHC3M538D11S=8#C2=OFZK$X#BJ(]W[7,OX[FHUS4^[>OTNI
M-O.&2V&(M!IZ$,]Q8E8/LX8:EW3*>\",.X(JQX37MH-Z?[MN+\_()]LT:[P[
M]F2#Q#DIN :$6>@$X@QCI*E"W@'JF2>-3EMT(]%C8+\$+/7T <(OB/9*B4Q3
M"KE6V I&%8;$,P5J&0UE9[9H/5;!91=@GKH_VGPQ*J;S-]<ML:=00RHLI=1S
M"ZS1>#7J<2P)DXU\GAW9;>/K?+*<YAMK5=^M;->]6]6OE\JP-2ZL8TV,3?/6
M >\9W\I*DP*LA]\]&ROZJ277&J!'FG3S:O& -.&WIX0)7X7%R#+ZFP(RB[L/
MHYO\E<WIUQ[-*#!4:*B4X$;&' 2*H%H2RL_.Y&I#IV6KD'9)COL,D^JJRM?[
MK$]:_.H6]4'E,V2M<X:Y>"$$B@G7! "US$:I7N^=ZXY&Z2HONP?WN.W)\G*A
M1[/=VY"/GLD,@I8+8"1@\<0=<12PNE4J#+/GH_(.-%6V@VKO6TF;6(_RYK:<
MQ=5F4U_H2^6"K(3(&$RM'186$*#N997&GML&4XMS3Q?X]L6E)TW=ZR-]\?D,
M.:B=4%Q3*PG0TGFKMR.N@.?J2T_3<]D^LF_#UX'%_\_>EVVWL2/9_E$WYN$1
MXVG?:UM>MD_5ZON"14LIF5TTTTU2/D?U]1<@F=1@#DDB)Z7=U:O*EA,08L<&
M$!$(!!B3'@*>_&FJ-6! ;F6R"--1.D 7Z_7D<<=Y:+[.7!W%N9 L.HV"8 D]
M)\I7:%E"LU[!'>#I6*M[4R:VKR9QQR,LL99Q\962*TD@ACNIF,AAS #7F :T
M6R-QYRQ(?R;*ZX$S1_C.U^M^TEL@@.E(C E$+)&(Q=_N*RF,U2/S%AH@1%O0
M9A!$91#D5-M /6+0$62,IIQQXCU .WP@S E(#'#+;I(@#4/;QX[]MD:.R][O
M@W;:.,KC?L4QP@@XXA]E8R9GWQY@\9DV++TF<+UL43E6=W0\3\1++24F-.+)
MJ-72<X7(#DF%1W:ZGLFF'AZ"/T\_G?G#D]TL?W^?5O'XE[7HVQR@^>?%9+Z<
M7"=&''.1S^@F$&ZH4"R%H*!1P&*/=CL0X"+G&.AL&ZV+VLK-<+4#J'L@W8?%
MIEKC6H1Z!'O6)&@*$+5,FY1%XQ7!&I!'"77.T?3 [;E&J90#:@^T2==MIU%)
MV^*?U\7T1W$3AW_V:E6CHQ#=8<6C=>,)HY0Z2C6R.S28R;DR,4#;KS6*-0_U
M1>;@Y_@ORW1+-?[JZZ22NZ*\?5_\]701W6_*U6D9F.56,I%J-2&N(1'&5N:Q
M]5SG;&X#K.W7F!G6 K;9[(AFH+J-&&[M.3,KE]&06Y7KT>S&=IHK]?H)$CEK
M+)4"4J8<=]"@*BW 8I'U,L  7XMJA3FM(-W=T539ZN/@6 $!K.$* F>I(@+#
MG=0RK^SHV87[7@N_6H.WL[(\J;3+_6)36DA=_^_]-*I(1:\G+K#I8D<-T[MN
M%X$"BZ!VS#( @#002RLJ!+@S.5O? !]F:I9@+8%\T1[X= M>?2VN%M.[:;HG
ME%R$[]MQK/_EY/6;YWMB?K_!0\&%(A12J 7P$E>W,:/T$&3EJ)_]+--KH5@?
MR'>Z9SXK.?.^7&W>*?OT?39=/0;P/B9]PU,[Z!E=!0!@.K9&#$!(E2,0\RJA
MRL;IF94N-,"7G%K84-M#NU/^G8X>7SV-'G\JKN.GJ^EI>^[BCH.U@D$4[5PA
ML7'Q?_RC,6)U7AF0T9X&]()]9TQ]XDC7#KH>:A,\M8P10*42<2(:XZ,[M9&1
M0.<LRN'7P/,L&N!70[!>9-P=W.$?B;T>TWX3KF[KP!"(B$3R.X-0A,8"N\LF
M$D!FW1@;;5R^/8"[6F5>W/J=_IC>%/.;Y>9=CETVX)MOWX_?PCVGF\"(3M%A
M(0DR&GL/L ;5I$$,9CT(//KX?(M(]\RYDR&SH^V"DRD9"C/!J!!>T"@>WLGJ
M3)9U?W8@__6=4C<)[A "L*>>G#S9-DBL17K%@VN#F(N^B\"BDAE8E_.>*AQM
M?+\M>#NKAQ%G[H?)7?'\M]<N?+&L2+TLKO_CKOSQGS?%-/%9IC^L3;LG-(X_
M"NM?>*3,Q4_?A*@! X#DE#AF (4:8"RA4TH1S 6KY2DV,G1;7M^O*VO%7W1@
MY$\_"8@S"*E 6H)H GE(D=35P#76([E)D:&PLA'@ZBV^%VM;S>?WDUF<V>7B
M$%_W?1KB/@&% L*F%PF]TU1"4@D1O>ZLUZG'JOT, %MFP8?JP0,;#<X3-'CV
M;3!,8FF,TI8)"R46WI)'/%!.(&) ;F:S/,A!L&4BK'.!IIL$H1I+PLO/0S(J
MM21&6R,)-8I9#2IAO+,C2=5J>%/( [$E1KCY:KIZ\--9L<ER/<"$EY\%P QR
MS!EE%'(1"&>QV Z>6&5S-H8!Y5\UPX!,\%K5_,?B;II$FZ]2Y92CVG_^:>#6
M*X =()1+)#& EE8+&J$B*P-O0'Y6DPS( K E%JBX--VDY<G/)ONNUOST3: :
M6LB5@QQRX9SS",-JV-C:'(=@0/E-S>@]![F630 _75Y/9O]=3!8^_F1? ._(
MUX$ 1(G!R!#C<5S&>!2F$H4[G7,+:D Y2,T: 'D8=D*'C<E:GQ!/O@^2<N 8
MU58@J*-=8RVAE3@LKZS+@'*&VJ#$Y2BV:AJ8.,#%9/9F?E/\_7^+?>]7'_PV
M0*\4B_2&0$JC/,&&LJT8% *2=4MR0$D[35H'>1"VQ 1SOU@\6[J.!P\.?1XP
M1Y)[3)3T6G%MTO7U2A@LE!E)HDPS?&@(Q587AW1RN4A/3B9MK \PUU48%P^F
MO#GN1AQM&93A(+K#T3=B&$B"(NTKHU@92K+. T<7<6P>T%8Y\WGR]YN;",KT
M=GJ]'FR-D,.!-@$X S&W"*$492=,(N@JL33)R[P;742R22A;98BZN8DZ66[_
MY^UT7NQ+)3[Z?9">*(NDIP1!Q:5E<G?NHJ036:_ CRXXV12,7;#"Q#]>+3Z7
M?^V[<WSDZP"Y!2G'3QD=1V\P$51M1=&>@"QC=*3!REP0N^##>JN[6GQ8E#^F
M\[V9E*>:!.J<M5 Z##%SFD#N9+7T:49I5OKD2(.8C2#9!3T^E,O59/;_IM]/
M6J3[&@01USA+M/18(.PP]<14ZY]VE&?5-!Y=G+,Q'-MR8]/H%L7D"!6>?A*(
M08Y():+ !@A/HJ]516JC122S<EU'%]_,0*XE=;\M4U3M:SD_?JCY\K.@.'):
M8FH5<Y0IZIVLSN4T\EE1;3BZ&&8F>BVI?GM!Z &B+Y^GJ[V/-.W[+'@/.1+1
MSA74 B*ETJQ"0$LB<A)<T.@"EIGHM:3ZSXO)S71^]^GAVY=R=D#OS[X)!"A'
M73IZT0XP9],[,=MAF_3J8X[21Q>5S(&NY<GN_K[^.IG?%4=2&/9]&@!CD  J
M/+0248LMH-5ABXGXYA2I1:,+-C: 8*MF_S^+V>S_SJ.K^JF8+..NM'Y8]41T
M\4"; " "# J%&<242!)=W<J;,5J8K/+6(XTN-@-EJPSY1SF[CPI9K%.Q%H=.
MN/=^&[1QC#,'C* 2.P&0\F0G!LS*>$0CC2KF0=CNT?;FA&V3B)DVM:B4@RD/
MQYH$!81C F+'"?5(1YX+\4AOE<6+D<86&T&RY</-B&0JE?BCL)/59#O@$Z>:
M^YH$;8W7T@ FB(V$-R+50]L*Y6&]AVT/T6.D <9&D&P]6WIA)JOBKEP<3XMY
M]F4 6ENEA#;&$*55BJCO&&XDRK(J1AI2S &P50Y\^C:9S?3]<CHOEL<WCF=?
M!J,D%5("BA4UUD5W&50I'-9KEU64>W21Q7P 6^6 ^U8L[N(&]L>B_&OU-3WQ
M-ID?7P_VMHB&$?!2VDAFS;'61I.=$V6!PUFQI]&%'9L#LMWUX6OTA^I0XNF'
M@5M,O8MH6!\-9..,LQ4@-MK(.;5I\>BBD-GXM4J S;,4?E9.CAN.3[X+T$8/
MR6#LO4+61D<9J"KETQ*HLAY-&ET\,A>^=AW,QZ=*-K4XKNY7R]5D?K/_ 9MZ
M#=<>- 50"$LI%P0YY:M8BH4,Y3B;>'3QRL;Q;/D&QO(QC[.XT0\?DRZ*^77Q
MN?A[I6?[J[V>U3X @8#"E!C%F,5,1$O*5^):GE4X&(\NJMD6K(\L:K4DBBV6
MUXOI]]6Z@.)+/^7,\BCY)7^N%G>3^?3?:TG2^Q3E;'JSH=#\YL,3*:]N_70^
MF5]/)[-=4:SED3HKC?8?G*-$8JTDTI0@HH"%.%W!B/01CKI:UM< \;/3Y?6L
M7-XOCBXE;?VJ (Q%R2"3T$"OF9!<^BVJTF&:E4LSG$6G)R:6@U)>GVN;+5:3
MZ>SW$G><6 @*3C5TDK+$,>$ !8(KH1%R4*$>E[A/]U^6TYOI9/%PM=A4JGY7
MK+Z6-V_F/XKEJBB>O'"D'W[^N/IL_7CF$1B;_#5!>N^L]!%0"2 '#&$J-VAB
M:"W,NH0RUJ6M-@-?EJ;K3W'U#/_\*;"MY??/R2+5B+A:?)S>?5VE9]R/\/E@
MFP"%C1N'YDY:FMZ5\\;SK8S8:9%5"'%XY.R''OO?WLU61J^$V[Q??2[EMJ]>
M$X&I5P9!*C1P-IW.V$I.!&2.BSE TC6@[SH,N@C;TQS:4[5\^WN7S\O*'GL.
M_EB+ (@PPGL$L6,,&DZDT=6(J:595_%>"1O.U5W9!K(7KB?+Q>K)6A+_]G(=
MB3]Z\H;YS\MNVOGW+<8I=?# OI;;92#>>HZ4XEA CEC\+Z>VR)!4%3?G,&UX
MG.MUV^M85VVR^- P#VZ&IQL%QN,D-91SPK"2V@ =1=Q*1X#->0AP0*M?=R0H
M6T+^HIWRCVULXK_6L0GUSJDW\^MC&^61!@$:J*/,A!%O-!#I(H6KQDNUR"IZ
M,2RF-*6XL@5<N[*Z=T[QT]KM)]R\@VW2T_..6H\\P8!HOZXENY/19SW5-Z S
MG4'L=TTKHV,W;_-$1$WO[LG' 1%C&'+40TP,%,( 3[9244CDV"()^=K=[]1=
M#FEG1#GT*M+!C:UFR^",0]9@9K%S G#DL3&5O)SPD1T"Y2C\)7<:!;:S+6ZW
M\CY9D$]M<8?:!),N%WJ) (O;./62(E)9B)22K*#2@*[>#&N+:T@9G1'N<93)
MG+RZ75=;3[<(ROG)+>]TX\"@P48;@S@&T!G)XW]74@.85=QT@.M7 ]I_R:>F
M(>Z*6&\^7)W<_';?!""<@)):$P>/&;$6^\I_8=+HG 3.(=*D0:66S4#:%2VN
M4GK9;%:NPQM7ZU2$DS0YV"80*B#"7!(A&8$.0,E$):.W,*<,U1!CENW1IBF(
M>[63WE;/N)UK+.T:!DRB54D%YM[$F4. 4-Q7TAHM<@@UH$NIP[>8+M5(5_S;
M'ZZ]^FL>=?9U^OU#L;A.%+@[EE%3NX] H<+6<6(TD]9'%P@CM<. L)$=!S9%
MB+(;N+N+?D88OI:SJ+;E1I;WY:K8).A_GTU7CP\P?TQ*WE?_]=*N @!**"*Y
M%M*ZZ# C;>$6$>ZD&NW98*,$;!GU[F)=+RZ&J/LXI1;3?Q<W1RAWI%4@W!H$
M"-/>6*.Y)M:KG9Q$Y%23.CL2W\5+QBWQJSF(NZ+2\\#<&6PZWC"X]-0NTXQ;
M8)W!T&FUD]9CD7,;].RXURLF5*,H]Q'06I=7C']9CWQ=5BGN_$^<IIJAK5/=
M!* 4YU X2I@7FG+'996TQI7G.??0!^TU-+L]MH=X#]S[L)A>%]&F7(M0CV?/
MF@0)F1)&0$B<U<Y1&%?P2D*8=Z-]0/5ONN-4#KK=[8?E=5'<+'W$)[%^,K\N
MWLRGJ^EDMKFN?74;M;;_)O39?01$K(L&I<;:(F @]]S0"@.*?<[I]("*ZK2^
M1[8#=P_6O)E\GZXFL\VB^S'J=?&CN/'EPM^O[A=%)5P]&[]>7P$XIA4T$6(J
M@ :26[A;QJ%S.:];#:BF3W=V?RNP=QK@V&SV]CY-F<WS?AMAWA=_K?_I>*Y7
MG0Y"G&Q,I4 EI4A)H8Q&54JY<##K!>8!%0WJ(IC1--:=,>V)75G;4#O4)E@%
M$83:8&.L%Q9)@BI;0A!KLXZX!U1[J&U"-81OSZO5/R:S^R)CL7K>/C!*M'7I
M"5,EK-%88E5ES@E@04[@=4C//_:S6&5AW=&5???M^ZQ\* I=S(O;Z>K#;#)_
M/HX.;^JG8F%%=,&W5Y<_%JOI8IWP^5@ H<9]_#-Z"1 I)(V%P-+TT)X&7%JJ
MD+>>&HM,K;203K#8HZ9EG:(AYW03(*10,6RY<8AY@*#CO$*#.S:R))E6>/*S
MZ=P6_/VM#WT7].A^F5!6"Z29X-QZ0H0P4LGX9V$8C#2H]_Q0.UC8J)1Y<6/*
M^6HQ_7*?A$DJ>C?Y>_KM_IN:S^\GLZ?_N(P[4Z72[8GT$8P:Z#U(*"G7W""J
MC;)240)9A1U@9"27[5IE5=FW5KJR>0](9LKEZF-Q7=[-3QS;U6H? $H5:"4G
MRF/J))$([60G6F65?O_-R*9P[VA_\Y/I8FVGORLF"8MU31PS67Y-&10_HI.0
M2N3,;]Y-%O^*V]Z76;%];6=:]+<![L;\J,(ZA:J.-0N "N48Q(98P20P,EV=
MBL:'@P1IPVHMT]U)6\?T/=HN*.TUI,R ] :J<$Q2["IYI<FZG3G ;:D9U9?M
M 3S\V5[OJ[YMXS:6!@&4H='[ 9IH*C"1+G)%\E3?GTAA8)_6[Y?5(_;J1X0^
MJ<.7BQ3>.55QKD;K$%T^P*/+1XV"WEJLO'-;V:GB)N>4_+4M$[5I\)-QT#3,
M79FCNVIY;^81@W71X1-7)0^T"(QR1X'&7%,=[1[.=01S*Q^#60EC Z11HQI_
MN>DT@G!7#%JG%$7=I.WB4['X,;V>SN^>E&%\%&+Y.0YLN?^?3MZ3;/+7!.()
M!-$0P%HH0)#3Z;[/%DG(Z,BB@-E\*@>CBJY(_:Z<%P\;X\??SV^6)^_7[6\0
M&&".>HP<P!P@"J-]*'<0<SDR$[P?8I0M:**[U*%M=?_G^TF-DA='VH7HBTB!
MA>#,:!O]$&N8V,K*E&=9;SK]9MV!4Y#F%-(5^?[\]'FQ]A$?SF#>X4:!8X,T
MP\YA*R4"!F&O*RFI@CE/# ZP&M0@:->8-KKCW!_I=93YV@BY*R(<*:!PUMI7
MMXM@C./4<0:55T KX(!3.P1D5NFH 99N&0@?6]%-9PE)NUJ2+SVZ1P'>UKDA
M?TX_ 2-CD 1Q4J:# JN@4;3" D"24Y]J@-MUFYYSF[AW9A).EE_C%'X9BUV9
MR6+Q$*?T.GAUS#2LTSZD-U[2K,:.*TI-*DX)MK)SQW1.D8;S'9-R-9FUFQ/7
M#B]>VH M(-\5ZU[B\F*6?DNOI?\['7\N5WJR/!H@/+>K(-)[:%0[K)464 *C
M1!5UY1J!K&>)?U4NMJR$T[3<4[;XP,I_6RZ6<823S<R9_#R!G@YV#^\:ZCD8
M8G6T0E0T3*(-XKT'J#*8N34^ZX7"7XV&_>AD((OE]?7]M_M9>K+QCT6Y7/XY
MCR[:+(GT1S2M=4(@FCE_7[Z"UNL_>(?2_9#TG&@TYXWUP*K=C%8J9XL?H/LS
MB&6U%<T,G=5OX]_:9/6S_@,TR%"+!$4>.1ZW*R]LA5TJU)[!ZOIU N2&U?/B
M+HWW\R].[AP%]>M5[4D&.-NSVM-'Q !SY#W!'GJC.826\"T&@@!?*YVDJ<(#
MG11/Z=&_RL>_KP7V:4K5TYEVQAIZJ(O@)92:1.O;.HF$Q$BR"F/A<%95SR$6
M)NAE?6P(_(M\J30)7DR$:$L_'\=N9NQWFL[J(B#BA*:$>PY9>LY<:UQ9XD)(
MEN,=#;',0-O>49O@#S_1=-=4+9?%^JNWT\F7Z6Q[0K#N[N9J_C$U2'=-UR&*
M,>:=0L05DEQB#*2)KJ[WB FAF1/  &=JA?Y;EK:FBN('[\MH$C[5V*GLU,9^
M1V HY7<[(KG3U$&@-;%;'"T';&2/(3=#J4.I[ATKH^=SE1,O'!]L%+#"2B$N
M.5#2F"B:Q;R2$H"L;(<A4ZX[=M0[73E?%5T1[F,19^3T.OK+^X>^_Z<GTQ]R
MN@T2:PR=H5$'$7;#*(Q 5> SV>VQ7_OW AN@3-D;^J\MUU4)$L6"G%CGI<50
M&NBVTCD5?SHN;G5#A'JYK><A__JNE@"*8?1Y*-( 04R=-5Q6\D%L<K;: 2;(
M]+_5-J.'WQ=0#N?7(6XT5$(32I"UE!I P&[&4ID3(![@6IG-IS8OH)RGBM=]
M,<!B2:!@AI!4>B==4I:5;^@L5CE!O '2KA^:G'4QX#R%])&DG9&<O?\JA-."
M LT4H-Y%H9F$="NQ1QIWF^SU:U"P89V,\JJ 8,Y:[:B,MK.7Z25X52'@E<FY
M*C#VJRM-L+)!W73FW516NGYX<O[A%\7_WD=9'DYY.J=;QUG)I$*<0Y(J33-&
M"-W-2F=0SMW1 7)R %Y/XSKIG(O[QGW2L:G1.EC(,--:.V^@D-8S@*I)[H5P
M8PUV-\&$0RQK#.T^6;;<S<>3>W&=YB%5[$LE6(CB&!B&H%%V)[G*RNX;,L^:
MX$(-GF7"W</6NOOC?TV+1?S]7Q_>%C^*6?W=]4@'02-*B0$,<BZ\(0PA*';2
MNZS"1P-,D![4!MN<6GI=_7X6XZ+=]F _P3G%(#%QWB-JF8%.XFU\  *NR=CB
MA T3I,Z2V!#TG=/PS?S[_6JY!@76WWM_;A64Y.E%5*RL!DI(K87FE9P6BY&5
MJ&F) X>8EHUWG[Q"%_$*57(:2P0VEE-G 698,>]VV&$ZLD!??[RZ#.\^>84O
MXM6V53HT L(Q9H!56B*.&;25G(:SG!26(8=%.N?597AWSJL,:_9MC4H>C?Z>
M0* "FIDX0Z$B5% L_ [+N"'DK(D#?.1V0!Y'#]H;Y\TVPI&D5G"KF)/ :"-%
MM<M 0>W(DKQZXL_%]][.TTY7#'U^JF,B-L6))UGV?!](-&N(2@_944 DC3(Q
M7,G&HU$]4GNR5^8UH8E^6!;!N#Z3:(]-@J9:1<0(U)1ICAQRWE<22@ESWM0=
MLHTY(*Y=K(S.+O.NL3IOFSW8)N!H6AL@$(+*.R0-(55("\*XE.?$^<X/1;=>
M>V88A&M*&UTQ3M\OH\S+I2F_?9G.UVI.KQ%%0"+D\4_+:=3W]B;G!LV'(UR\
MH+>@A'5.:J^0YX@21%--6Z'3)'3:DYP#DY&Z+_DL;5]/G=\'> +C>>MGS1Z"
M!U() RP%<=LP&D*'*JR1)BXGF^OL\AN_RFK:CFZ&?Y7]_621IM^/8HS7TP7E
M6GO@C?0(8XH$D5HQ1!T5AE)?JY#\<.-_W5U/QTPXB16#VFOO('*8^ I'R+.*
M9PPY:I)%J=:NIY^GC MWQ^5B]83,\6\OB1Q_%#Y.XBY^()?EV;\'Z9@6T&N$
M=3K?(>D(O!HS$2C'(1TR@;K3=9F/>NM,.7AL]N*+P U07@F7BL\X[)&/\ZH:
M-S=B),O-A;IZJ>F+,&M3U^^F\_3(\5%M/_LF<(F E4*D2A^>>6P=)=NQ6T3P
M2+*$+M98V0QNK>I\\[#U<9T__288)C" QH@X?L>A3!5%J[%S;4=R)[H1G6?@
M]OLX^YBOB*!@%EA%-3504RX),A66%I.1<+!_JV0(VCL]$_94*=SG,+^;K-*?
M'CX4BVFY[Z7[6NV"UG'19H!PS8DW! ()=VLWY?4JIPU_S^M9\V5[&AE^9&<]
M5\<5SR'>>JBHQY1PAX21@FPW/^.!Q,,I-WBH!N3N[?7Z>]S)KH(4'#JE,(VK
M,D!00R^V(0D;S8RL0OE#7DJR"')\9VH:\XLVG^<'RNO9?(P^)UH$Z"0$F@G-
M4\%^X;14N!JQQ1R/U-AI@B7-0MO1SO%F'O^8*MKWN ?LQO"HA1I;P)%60<8-
MVL>MV1CCM,$^_I52A:)"%<16UKI@V9FL=5;[8\T"M)A1ZRQDQ I@&9.$;:5%
MC-N1!$8:U7O9&KS=SUMW>UM<I[.Y^+>/DU41-Z-R?AVMYG7'?1_8-3^Y!2 (
M8^ZQ8]&V1\H"HSE/-<DI9DRY 4SNYRK8_=C]_;V8+PM=S(O;Z4JM?)&R&F:?
M(@7NXQ@?'MM'-=9!IXG?$SP2A'/(&.5<2^)I_+\MGD1(/C(?LQ%F'5H^>M!'
M5[&[ S)&_SNN(_=Q_8FVSE;.J[A:';OW=&Y7 2E!D? 6*VT5@2P9914B,)IH
MXS)*.V1H4Y /D(2?OD:PHSN6GMC[EGZR32K;^[ABH_T'907DCGA"HG(PM!(0
M66&G",BY/3+ O.J>Z=J8'GKF</R!B4J=IO(ERR)==SR?IS_W$0CAEE G9/Q/
M-(>9%A&3+0:6R9Q#\OHIUUT_)-<A);,A[YEVYFLZ=WP3W82-(N,'F^!6"HML
M-#Z;E7]-YM<7&*1G=!ZLL-@@@@V6E@-KM&)FBUKTXG#.*=L LZX[9&A[2NB9
MNLE\+M(94>3";$\<JSY/#_44'/4">YN>=(S.?CI%5]549LYD[>3GIUB/B90-
M(3Z0Q=/-)^F)A(L=]_W]A"BN!$(;(8!&#B"'?(4YXRPKKC? UPU[6!*S\.Z9
M>VLW3=W\S_URM3[M/9]U+WL(4#B&!%5:(RFXLTY97\E/#<^Y4#+ QP\[Y%LF
MTITS[7F\J@ZSGK<(E$HM>120XO1"J(L@[N3SP.><-<OA74UJE4E9R'9_&#&8
MBT+-GSL@ZK2/:HO; R11DY(A+ 6V5& EE:A%ZAH'^D_ /'1U9\]706..$;#<
M6H>%5%Q&FE6C<T[*7R>*7UM/95-H=KY J_O5US(EI9TH$;N_0>"1;PA!X+SS
MT!'G-'!;Z;1 ,"?)8T!<R=+KH>4X!\C^:'*R7NNA)@%K#S"3RBLI@#'0(P@K
M"0G#.9?A!T25IM1\DC47H=I9;9DXV.5J>FW*^_EJ\7"R?N'>[P/'F-"4S\2(
M<@P0HCBK9-,VJ][TJV#,N2I^62"F 5"[(LRS*,[_N5],ES?3ZZ2SD]0YT3(P
M[(7Q6 ,/G%&:.^EV\A(L<VZ"#OG$MRD2-0OO17FI3[;>MT>N[!SX,F#NN'4>
M, VAP1;9Z.UL1VBL1+62?(9/@"9,E&80[&K)^/G0X>6Y1!6<4]_2"GAD#3FW
MJV <-@ P+^.,BO\''!&V0@0AT,V%X:[.0K-I47:*=L\QKC=QKYU\7]_P2>+,
MULJ/PIX?^SK44S" 20I3 A>5UJ5T<E'-:R.$ZZ92^&ME7[M@=T6^J^_K(E;S
MN[?E<FDFB\7#;;GX:[*X.>;#'VX4J"!68<&(YX9B&,5TJ)*2$Y"3N3F@1*.F
MN=08H)WY92]/[G=))\]&7R-OZ,R>0IPY!FCOXC*N'.>.*.@K/!0C.6;X@-X.
M:II@[:(\D#/OWA.&O*!2*^6UP(1;&9TD6RWQ-OY_K:I=PT\8:FTC[0KXKNCZ
M9[H'7M[-I_]>CWYK(!S;6 ^T"$(I(3$%%&%$!3/>.U7)9Q3-*<$]H*2?IHG5
M#)K='UB^.*F_U9-98OG5[>=T;OS'(MH(!T0;WPDG5\9 RHQ6<?]QQE(79_CZ
M<!FYN"75.A=J1]:76CJ@$O?W]>S^)E6&6/N@RP_%(NIH'G_PN71_3[Y%EJ^S
M?8K5_6*^_%C.9GZS&1\!K.U?':PV6$.'@)<.6 >HC<[*%G4%T,A>G6V$?^6@
M5?3ZMCPLB0;44<_CVLRM27?4*_F 0CFVU-D4W+CSGU:3Q:I5(@Z'-#5WTO.4
MU#,)XS1?%)-EVE^7][/D;?NH@>W;&A^JB,V'<CE-Z%_ V3-_0>"00P.<1Y99
M(2V $N^T 7D6Q0=TH/!:R=VN-@<Y%SY$H1;MS80#W0>/,,'((8LU2Y>4(**L
M0HZBK./Y <4,QS4/FM'EZS-+%$66."HYM$P1#IDT.W"UY#F'P&>''S=FB9O?
M_.;KY2KJWKW_=/VUN+F?17\^70\NYRG]_NKVIS#7\U*#X_/L@<9*22H4U09Z
M&#5FM]>J& #(].C9'U?+::EKM0^0FU2-5#JD&..I4*.5E?PBFM&_CH]=FPDO
MGV=L >?>#M N.H@]HY>@'!$P>F726 :-1EQ84.&@E,G9N0;(MX:Y<>HXK3'<
M>^/?'V5Y\]=T-HO;SINHX?E=*FBQ^:=S"'BDF^ E@880BGW<U:WAEJCMQ2-&
M-#,C\W<[9F!SP/>90U#];)M3D\ZC%S^*9 NIZ^O%_61V%AEK=1@T 4X9"9#P
M6!K/F)6D0H<8DY,%-4#WLV-:MJ&"@26YY">W!&FC#42Q0E@J0J+/K S=R4]H
M-R5Q1DS!?,P'M"@^+2H5)U'E]UY47:R-7Q<PAP 1:^-6D\[++*' 5\BF.E?C
M2(,9S(+:MH(NNFOQT[C?IACBDX#&_HL7)YL%XIAR<>B"(*ZI09)YQH7F'F-F
ME,ZYQS^@5)AVR=4"T/WYS2<J>^YO$!B1%"G%($?4>2>ID3N3.!W>9-!H@(5L
MNO:&+X"X/\<WY5.=Y>*F!@&D)#+*L'&<,&61<:0*6A&,1:UZ[HU5IFF]GDC7
MSNP%$'=%H -0/%DZ+P\1[^DD4.M 7'0YU (* +0PN^@HT8[\0I6&&XX3YX/=
MPYKU9- ?%N7W8K%Z^#";S%?1\$L/*WU/Q9SJ+69U>@HTY=XR+S12FAA+M/>J
MP@-0TDW0N.M:K6WPY?"*UX(><BWV)T/Z5*PO:1,!)X_5PD[:[J<Z"-IXY!54
M',1M(EUH4@A$XU)"'_UP[KI9U$;$JU;A;Y!.'Z=W7U=7MW\N#Q\MU&X;-$QY
M_$XQ#VQZ/U9XL99"2<2)@3DGJ/4#M[\"B3*1[W>;3&DBDUE*$OEC,ITOK^:?
M%Y.4I_+X*-;9^^7I+@. D "1%FNC'0)*2F4C0HHH#S7Q.84KAUODO+>-LW&%
M].:-GG5EL5;];$((3A4/H)<V/1J%$:N -HCF%.$;[B+9AA?1/-B]D>Q]<=:9
M0/P\0*^YB*XX1D1'OQP!C^S.%R<P)UYV_@E5K^53&^//^; .)5<Q^BD_ILO8
MLR\73SX>7XXBPQ1J[90RF!M+$68\.6*:2JII-()ZS%'<W$,X4(3$E//5='X?
M=\!M8E(YKQ65NKC3@(UF,E4XA1#BZ%DP)MP6*9,R3L:57=8(9UY&J;H"O[-
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MALVE70:B ;/>&*40D@P9A0VK4*(4C#ND59LB-5(-6T"[JYVFKCC)4/O\5]D
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M<4B,I-! GB(/L.$B!"\Z+5-)Z>[;]UGY4!1KHZ<J Y7&<NS>8)V6@4@/F><
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M=4OT[$Y;&@GU4A3EUPR\AYP"'7Y;B(:"E]9HRRB#1$&O976>%0&&.;=/I[2
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M@][7$G,PPWA6)OAGUR@),CA5 ;44R/@GI>39CEH @[)N2_\65&L=X]YVW;L
MTR-W;U,-J6^I6O7JW6)/)>G5.3-@.U\4HEB<LE)1IH%C2!GM_ Y-9G.BH4;H
M>^QP<AQ$'J,RJ?Y8%;</=^_GMQ&+2H^?J_"'8CVY6&MEI!182.88L1(0QJ22
M<7\6M^  FUJEM;N>CPY/J2>BK^N^(BB",<!8$Z ,DIL\OJ!"02HXL3.Q-NAP
M< YI%>G!K:I:P1\U6@>B<-RE,A:G8BJ8CH/E=CMN*"V8V!E^^W2H:V4UAGQP
MJM4*$ZG1.A#)?$0QKOB,**6(,]A5X];&3FRWV"H3:MOR3='NBV7_GD78%L7R
M%_/EY&'(D5:!LE0<30(&N43."&:HJ,:)?5;=PDMB51/)OZJCVA;*?;')/RP7
M\_7#LH@]]O-_TD^KDV0ZW"@P([40%$LAL;#00D!)-4J%2"VC\W*<#%URJ360
MFT5/E_??'R* NQ'-%C>?R]OUWQ&7HP'5)]L%Z)GQZ:*P990K!) E=-M[Q)7*
M*2EQ]J[^1['\L[Q DG2!=)<WY#XE_\*1JY*[WP= I0 V>3>\%Y"A. 9?]5DK
MF95V=GP32&?6= ZHG1/AX 3RXHG D-/$<0\=M5QKZ;G;]9LHFN.R'I%ETE!6
M+R7="+-.+TK/%_/[A_NCTO[EF>"H$,ZE"EY"&4:55D)7?1<$3.1$O+'$RG9P
MZ_9R_#^G9?[\F6"=0AX*X@D5#BKL+9?/%JF)3/BMR#P#M\%](.]K1%N=;ARH
MA8I*$O?V&!.#D7>DVN_'#[+2:XSP2&@X9UM3Q ?GV=-!3Q.B/;4.1D(1=^PN
M12-YA* D1E7CIH!,[."@32+4Y5ACL'LZ61PX#"OAM/Y9XPSPUP>#,%XY".,"
MD])P8RJ08AXI;Y17&.-:1G/7YWZ?U^7U7_JGN9NMS@PLV-LR2$ZM,-H8"[F3
M4%-'435F05A.UH41*FM3@1\\V6L#U)Z4\G]FRV7\>#BUK#H09[)/\Z_?UJL/
MY;JP\]7U7;E*WKK3^EKS#4%'>1H.O "&<>2 QI[2:/0YP'$T&0=,EK;AR[?R
M+BK(ZI&,OPZAEDK7?4?P*<T+E)!&4]<;S0DS.QP,0;V>3_3A,&R='R_UOB/D
M>YX!AH[7Z6\B,,@@"I$$WB&(HP"T@)NX*TX,TK[6L6]'UR+2BG%UNQW(U7(S
MC).9$P\V"HY*(3R@SF-DO39Q7Z.JD0* <HZ/1KB.MR[_E_<CV@*ZMT#5*+5-
M4.+CM)2..,K%)D;Q>)C.T7:!<^(Y1$PJ[30C,*63J,9JI9^(%[E-H;]:,-J#
MMR\JO>CJR?";O<^'5(/=,NE3078NF0&4\FIL0N*)S4<MR?EEC;$6D.WOFM_]
M?:J $8V?T]E87CX;I!$80FP-@YYA+K4RNS$YFE?E?GQLR93KJ[M\>6CVQI!]
MT^NI)"N'V@3BJ34(8^[B N^%-1KCW8S,P=02B+6_-+4%[:#T.9U5Y7"K(!0U
M!EN'I-?6:L<]$=4X#?0321G<HKSK,*@1MHT"K3X7RQ2E;\K%INIYU(6/%>3'
MEZ':;0-0G&J% 5'&&*T$E7HW"F8GERZE#7F6W6*<P12=P913;0. U'IN:=QG
M6BB9L/#9XJU0SEQR*<M1+E-:QGC0=>E]G0PI1QL&9* 3U'#*HBV8;@M"3ZO1
M$NTFDB^Y;P.G*;Z#LNG#0^+_U>WGXOIA.5]'73&SN[OB1O^L_&#;!\^F6_TW
M!PXP\B A0P77TC.G=JXTYUE.\/&EK(4-R%.'DYT)85#2NG^*Y?5\%:?R^76Q
M^^5N*$=S_S1Y7U"0*FTA1D!)JX$6WF_-6 JT9Q,K0-8G05N&OID-EPR!=ZO5
M0W%CHY9LRIW-RYO/WR):JZJ#Y:YO!XRY\UX2L#40(N&93$EKTP$"I-6X@!<Y
M]O^EK,'-*=4YWH-.;U</ZU6Z.!('=>Y,]JQIT%A%:X;05'(/.TWC5EQ5(Z8.
MY3@^QY@+K\=)JSG*?<Q/<2HME^ORW<>K5F:JI]<%KC041A-BK*?$>6FAKL9J
MG5$9C**39U2/R->(^=C^(OWUYVQ5_)__^E]02P,$%     @ #$EB4+2A?@"R
M(0$ :"D!  P   !G<F%P:&EC,RYJ<&>DNP547<NV)KPV[@0-[D$"!'</P2VX
MNWN X!H(;D&#NVMPM^#N[N[!"4YO<LZ[]Y[7;_SC[^YBU-ZSJF9]LZ:4K;5Y
MGGM> UY)BDJ( B 0!, #_@.>U_$V1%S,30! 0N(M  <  #2 !X(&0&!*$ISQ
M_Z85P)D:!/F'A@1G)C  $OA; YR9P30F^!L, KB!<RH4\*?\7]]B$C(?29C?
M,3&^8P:8&9DXN1DYN!F929@8N5F9N5D87Z2"H/X@OWR _J8MP1D"+/%%VMJ+
MU+^EP[SD_Z"Q_F-4((B_^NZ\]/V;OL %_B2X/W_/_VF#%WG@C^=%0!B @X&!
MA8&&@X6%A8>'0T#"1$9"1$3"1<= Q23$(R8BQ",@(*%X1T5"1D=.0$#-04/'
MR,3*RDI,Q<7'R<S[CH65^04$! \/CX2(A(.,C,-,2D#*_'^<GML!-#C $@16
ME@R 0 -!HH&>NP!B\#BA07\2\'<"04!"0</ PL$C(((9:EZ]6 H2 @H2&AH*
M;'20)[@=@$*#1B=E$H+!D->');/#9/X2E0E'_KZB TMA_)2"Q<#>%QX!^S4.
M+MX;2BIJFK>L;.P<G%S<PA]$1,7$)205E9155-74-0R-C$U,S<PM'#X[.CF[
MN+KY??4/" P*#HF.B8V+_YZ0F)25G9.;EU]06%1955U36U??T/BSLZN[I[>O
M?V!B<FIZ9G9N?F%]8W-K>V=W;__@[/SB\NKZ]\WMW8M>+WK^5_H?]4(#ZP4!
M!04)!?NB%PC"^84!#0J:E D&74@>5M\.@XSY"QSF^ZC,B@YX<A:%4RP#^W$$
M; K6]3=G+ZK]T>S_GV*^_U>:_4NQ?^NU "!!@L#.@T0#!(#;IQ#J#(@_>7;<
M@[[L)O@L9]^9@R8Z3UF[@@;2#IGT9SE1CB-1S:R:!_<D/7F [2O+Y!P;G4$I
M>5IJVAYC 1+21A\<NXY='U3N4D*!SKN14D29O/W7OZ-HK4UK:UTQV4$=;U$Y
MR2_*5:N31<89AG<#FP6L#3]A9LFQEMN10<[B]W^TZW':A0H[-VN;N>*3?Z^S
M*L=J&(5K17)'O>:E!.KW_EDXHU\GP88L)_(CKJIQQ;WR/)^ORV+9[>I$0R4-
MXK2T1.",9>8*<7]>Z7CR>(9"M'>(0V(0Z9)'3#;ES#X$^(Q'[&MUO/#F]''Y
MTC\80V?U!WE$L@$"T^IL6G7M)[-:C.J9%=P)YSC:^ZMX1\C(];@YTXCZ8>8:
M7AY#F-PRS86E7TRMFS6:YO:8WS*N^P$O5A!]6_ 5/HX&,I=5"8G)BD%U9< ;
M>A^6GU?M!/>*Q-UXF]&RQ9]9'F<7!"3W,#I.5TJJ>%GV(PHR2P?A>:.5DX=B
MJ*C3WS&Z]M\IK9[ZF8\R1!%EV[\A(!Q_M^0?/,IU&0OZA0S8]W:YS>,\S;;V
MUG1ZAW/<>ZL_ QDMS\ 35-O-K#+QE\^'Q>F4JXKU"F60N 8Z8HD41DA$N5F<
M=R$!NM#SPI]K=W:NMER-X4*!I4$""5(M(N?4=<']C@P4*Q<_=>*+UVW/0/OW
M9P#/^8'";?41^B1RQDE@IG'0&Q#Y_*WL,$$"/= TS :)P'\I,U+/S>Y Q#3?
MO]265R')2E0MXYZ I4$WP7<@D?<9J%ZNNK4'F W/=)K0^J9V#9\!&3COW:2(
M7=WDCXDF4Y>/5/)Q2F0M*ZF(/^1CPA<=(N1VM8UT@&I-0\SO+,U#>]#MD?"_
M4S!U7&UCH(B^AA2LP-5J2C4%U#=#$*3F80T)OG_3U?R0?^.5\Q'VE14O%_V@
MC-VZ.\Q*=XH(6Y=A3!H08Q&IQ\A'$^-BV/':&9FF8L8*J^*^V+(KZK4/YTIR
MP^$@4<W>K!?L#PX#6@>G B)ILKQ;+4@<*(A/@BN:_'[G/=,>]);Y^QA+8AX7
M6D(U*5!$FH5QF_BR#@^X#V:0 <TWCAE+)97F1)0N^-OGI34\"GPLB89+?.*W
MGK MA@?$2,UBYFA)(SS:.J\R$ZO[NX9R4@P'UR_&3NL[KCD/J#-0&=LF&2Z+
MO]@6S"W-#ZFZ1&Q0AH=LA:W[<*X]*:NT](QV<R^'4-A9H%=+_#9,1J>^!E5%
M_JQBJ#Y!L$33>BP6E.'_901Z=SEKC,8("=M/I4]@#\,R^MY!D$A8Q+G.&^E=
MWKE<H*.4M7I.._M)J/ITP^C <4T@Y*\*WLM-MA[=_;H[Y?:Z*:LRJQW:>C$[
M#-$NHQ?1?0)Q@')6"#7P5SY\(%_K*,Z<9ON>-/I!EJ. ]LW@JS4X"872@(_X
MO$AW8S!$P>O+NEVJ## Q^O2#)$-AC(4X'5S.G,H$1#FF6'LJ_*BGLX$YOI8-
MB]I3!IZCZ _Q@IN_4L(G?.9_9839A?D5.A:25N,Y)9IC)^=F#BPLGA*L(4\0
M5;(#M\D357L0QR.%CG8V\1DYV':[@S6U0I@TT1(_W\$JN!XJ%>1W8\8,5 CC
M]Y-_*O*C>(0&F$,6 CN/B? _-DAYL6R37%#<O>(D#NZ[+/O>6<M-8+\T2)\B
M8IUY ?7=.'?05GX@#+*#$^=!!K##KGWM//1S9D&]]GSQU;?LI>OB_?7#;\EE
M[^BM+\8UM(^\H48$"%0]*:.L"WLHI>8G5LS/('B,E5B8RPEA2=UW83,.Y7O7
M0V&MVVR^17'ZAY2]__&V!)7 *";LFO >L!O,-J_H3;3Y91IS7]&#YGV2)?$,
M]%J867^NY\)&9G&ZV#6 ?3RKK:M^Y!\QKP$1(#M2((4BH4M4U],'V'XG%)"^
M4 D,K+[ 3=/\'L!"":^J*C+DSP[S2_"V:O]V#);;)(C+J+)&^NIQY>'1&2,I
MCHTVZ#9,"/<J8H5-($%C.;*3W9@*74<@$2D4XPCD8UTDMQY/0FPAOYY,@S5O
M8_3A-03)B%#?!01&^V8AGW>/#V-$:4$:__(GV*P^P0=_CGNYCR->RPYI;8>:
M#Y9>MD@:(E#1-5UG/[X8G\_;]XD;7@#<'AE.3W'8,>OU#$>ENTGKF\Q]&<<]
M[/&T-T1\WBB7H/#'P@+46Z^&9Z!M^(DU6V5*[*%-*]V0AJSN^($G/\[UH3\W
M<F"E0!R?!4U/+=(+AJ91Y7ONDIDYQ1[>+Y&4@D$;ZPQ#8D9(W%&2'1]&786&
M6 -=2IUGH/D+_FT(\CU;0UWTROS:.R.F6R$A Z;T[X0^98F\-/FAB20<-IT6
M^GV]ZA"_%,=\X:_R%ET<I%V2C-V#VQRCT$C8->@W<0Y$F6[&8*GHW#QN*/O7
M]<<6ESB?@;'?2K 2D[FA\*[.D(8@;:@0[U=*D7VS>AXTYCOK-LN;2 ._V!_R
M[8'\523ODR0C+[R*>@/RIF@V]2'IB34DF,5>'(I']\L300)A%[>U3$OW8HF^
M@RR9\&<@\DMZ)]O[0]GF"@2;4N-@S5]5A:#6P,QR47["R>P 5XJ&AB']!$J(
M;UCR05R0Z0D1Z>LJ9*>7V'-*4[\PV3I%5W2725C>H5JM"^W.^/!FA5R&VXJ,
MBR9?YU>;4SI)]R/2B2AG(S%C6H](X/9REDGJH@9_LGH7K2!V5]CF='L)^RM]
MB-@"Z"H5*AVT,V)]U%@A5)7;?20Z<[9>"\M^W"+!\$7%+;G-B%]1Q#SC54 I
M.%"*;)_Z#$KV/MWHE:]1YZ7U9%GQR:Q>_"WB3)&2L'VKW.21 SD[IYJ^,C^:
MOZJEKBUJV% 7EQ4'#VM9V(%+\$FH7&%?M5RGLZN6>/Z)--+!']&VB RFOK:#
M L*M+R6ED.^&9,.'UR!D\8S!WY$!4;L3ZS1$W(8<77-9L\+,1.=>[4L?%=0K
MN,LM4W0?[A/(&PFV_ORI*P%F>NSV8NEUENO )8%/^9]($QWZ1L;[#V@;IZ_<
M2RUNR\H2/B]$E2^'>P)Y_<94@9>$+)UAY.B+8KO+1X+P]3$[I$%4=B)O$T=/
MDW(%H3%5GA+S>BTA=%9$*>*%&N$([")&.NLO">_2N'U4*\;QQ.-WKH9;F@!Y
MP:'HL&< [DA@@=?--->BI-\60]@8??%#>\""_2^!!9O\_?;K/"FZF(&)@>WE
M""FBRP& .JN:_G/PKA"=O][7L "O$H%Y0KG9_!9 T=?5VE0B(RH[#D7Y>T$A
M275CB[U^@(0$EPDD^8&<Q6+ R, <\3MBKK;=G$V!Z$OB" M7RNB/D UOLQ%:
M?*X)"R#?TB,HP-?7^Q)XP_',/;*?W4:I&$Q8&?;'2P5'ZM6'H3XB"N2J9_E0
M//5&P$%W3%R@=:"2,Q%<[@GFBIVGL*J<BO;9(P@V*%[U6"H@VY&)QY5VH 6=
MBH(,6H)[R=LJL,S9BEU)&\T)-TU4$!(I^F,1./3T-HE:A@'#Y-#YQ-RE(WE7
M*_MLSJ=JQ%)!RC.^=L%%9Q@2TXGJ1>TZ*K(%6?74@+.I1@[8)PAO;GS=,!\H
M!P"."P4T\K/A[I)\Z2.,>EL;>7*Q+VQ)N+1E\?<^5^U'88>'0W7'@IWZ<"-Z
MK ;3"S]TC^ZWKU-0-'V]\HKG#_9M71WLZ*1[3/H6YMI'Y;R?:@"3W1DX38&5
M+W(7F+,!"_+W@W X=T6QX)DK7GHU8ST[$.G19!AXXO=;<V#1?S/"6\<\VL6'
MM^B#/9E^Q]P-29TH\;'CPS#@D"\]N2QN9AK>A+.UY@5%\.2(Z.+.>%NQ[*_=
M+91$EI%6W[<\RC:1ZHCS,)/A=>^E_,/)E'.T[)=%:W9AKSM*5WCL;7(_U:._
M[N-W@7# /GK_]3BI-TF?7_$'X<W#B/1P>7)8F$8?<2XHOP,:8Z,&JN./.;<X
M2YO(SX GBG<N8#^E,G1'9\.A/AS0>U<8!/6(G_E@I\XB3-]<BCE>;<^@K.]+
M#=JQHR-#+)C9 1@+J92> <?&\O7> K9$]\R'2+M\%AGT[21*XN8P+V(7]\@N
MA"99,9<<U?"0QI0 6"@\8'NO+%)^<E(^^%=IME*3"#V=..,;^>E8)_VIR"Y5
M+D$\=H>YE;G^S,.HQ.KD^'[RDT6),2G<(S%O^6]"Y;1G5(&VS?2E$GFZM]9D
M68V#V)L$19VDW[XQ\Y@2"I4+%ZVP3L:HG6JYU4>(MDY02)D;7? K6FS7&A$=
MDK;WFNZ2( '6-\&A+M^5J)Z\<HEOSDH6)F:IZEJG8 I-[H_9J&?.R<0I;.\'
M/HE#JS%'I2$D#6<@$V*/\#0]C(#JODA7^MK5HX3>1,-N:F)(7PR=]]D/V7N/
MYBJ/18G&% P^&*B!SY$^W[:>BFKX ,R]35<CM4U19T-_95R*24MOJ=I[^H1Z
MX\?+M2.!9=FOCQ*C:WQ[H)DD#W8<<XCASWRNXJ-UOR/;Y,HU4E-30WFP#:=B
M8B1$ $RE'YK]G^X-M3:CY03YALVZ+:%;4: F('\G>&3O\3R!#T6FG99\O7<%
M_;@]OWP\)39**9,RTKG7D)S"; 3&O+EK1T;#A\0)8?4O\\8@T6?&8>_ROCT#
MM0]>PL0CN<&O7=2LL^C<4.FX'AUD"DM-L2].WJI+QI$0$*!%4(-&WL5PJ482
M"FIGS]:(4B9L!5-LE@]9+.B*H%?FV%:'(0_'_%;SUD@Y.)A\S5BUE0+A;J,8
M.?8$7IQWAUPNC)Z!UG!:*6XFE6C!]C7?WI!6ABFZU<;4L-"P)M,:,>0[,0?>
M2(PHBBQ!4 ^CQ%,U2).%"(_QP70WC -GQ)4H#K$#VUG"G)B/DS:]+V3,6D+C
MC4*$N$QS^C6N=YF%7;$8.?8GP8]#1;TDM?9MY?N".#+&9KM^=+I!WI.1NQ_Y
M$ZGXE:+Z8*V.!:*>$HMSX@TD^GEC) 1QT47/V.?1HEIP]"8M;5UI*MJCN*WM
MHF[<O+ TM/DH=N;B;&^W>LO'G@%A\!'2FEONW08:\H!K5&2C0X#<;SG;?$E1
MA1+E+U"?A(XE!'$: U*NI7$X$B'3HP6Y[]'F[I7?'HCVAJ\E8"#YH<#*[XG5
M/P-\EBF-=>Y2A20Q)^2&_-D5=T35( )[7@6ZJ I5Q3CRBI(6IVG2)JD@96S\
MN NLUUD<HKHVKD1=*G$B)62U_M:D]_WV!WP=RJ-/O@+<P&YQY8VUL7F1Y:R&
M4Z8EUG3*=>"PKQ%2>,U8F-^>B%V-EXS%[Y_\R%..B[AOZEKKDVCQN<:Q?"OX
MC1*1>]CSN(F;^3,@7[>[=>'-!CX#ZZ\;HSG+2PGS)BFBQJ$RYVSJ<#OHU'[I
M-%!$< Y7PE&@^7*'G">8Q*^X[/J*A9C-<8N'*<=]Z2.)^$IT=7@G%TS/3\(9
M(;Y1=<;#XG7 IH]\X$\?1\5# !K9].L8D:6&%.Z<L(G?&:I%.MN&-3CL(XY?
MXQO6+O,H[0Y?P9& [F(8\RT)$X@JBS*)5*CC^%&@2GQV]NH)ANH$]5IN3Y:/
M&43HZ$ 2'LVVK<#ZT?-3=M(V;6Y=E,WG&TJMZ"*R;]Z.L7I>>I"W=Q\AB\1)
M+8/C*0Z61P5YDB+*]T,$)HAOXAEA:]4<'@7P@+JO$4Q(@D&]Y2K\>='@JT-^
M+\; HJ%"[V*-E+7USO92% [G9B&_;]D6]%S&6^_/'Z&-*B!AU($K)5R!=+E=
M13I&*O$Z[]:N9X!.L2 #L(8E)8>=AY:X#JZ(9&N_1++HPCZ3@S@5CJ?]YC!F
MFLMEI22>F3CWNA>QAR5"SE 0BW??>S?[&5@5_7Z,84ADN3EI5RQ@\+[DIV@/
M<QN#;FR:ZW7N/4)$F2ML0?LH0:3\,*# :1@=)%<H)&VFY_7#_[<H^>U.M6@:
M4K)S*XJ 7U0_0=CE1K$,$(SEA]&43UCQQ.N%"1(Y4MH=^/X$L4E<_@P4%4M@
M?JNE4,@Y9UFI-G<XC]/#157FHX9\&U+E8$5.9&24T-^#JLRFX8/O +NP08&Z
MFM$GL I9\;M7;G"BDM8:I[@8)<.7]MTY6\#=!L5],/G;1U &'"V#ULX!^$ Z
M5B8W%D><@542-,&=%59%@- Y;:.P\SBD=OX-;BQBS2Z]:^N)%2199'D.%3 R
MQ*ZNG/=)X&LKH\!)G.(S %&*?*:N^5B[!^&S01VIGCSY.+[T1"BCWPV]4^?)
MV_W%QJ0^304ABD'A5Z^_O"#:?J-C3[$W5FJ13;3PU*7\4KH@+%O7@]"L%9NG
MSL*L6.+V1/6]8\#K-SYQH\,4R6H0.3%^O1\(*S2)F,[\2^-2G@A.IYZ,%)"3
M G*:\=/5-OFRK@1ZGTYTN?X\-$(5FN"GH!]NG+^I77&_$L0F? ^1M?,&,8R1
M$SWLR^\@<OK^?>TP=E7V<<J*S)7N@CF_[N',I=<^3@.I2FMAQ2@WY<C%"[)5
MA6:J^YZY.J.F]FWG$Z_)R4G6KLE)C C\5GSX1A9V9I4 H5#W9@=(XKC1>ZAG
M8(\J_;W%<MQ2DO5@252%Z*UQ<#V%]WO:$=;5H&N.3SG\E!,:ZK_9C\7D:#"_
M$HGN_4"+<!E1C53@.K[45EA4JZN3X5"JFH%<5QEQQOX=M>Z,];'W&VRFX]IF
M+N"8(!9LXM_UK4Z4,#*3,+)&SI"[P^XBFMRNHN^(SQO2[T8%ZMTU!X4P^<*(
MIJ7&*E6LFI< +6H7L<649H)Z<]-72YJSWV]@#8D-W+P$4@&;1DR#?%RB0)))
MBVH.>@@Z5?$>.J_CV114P[&06L6ME3 BYD^$KL2/MCT^K#^_AKQ1[.D6",85
M&(G.K(F5P/EZ>OC;>X$H72/)!X$ZR^<UQ6?*\-ZINPEY0<3ZNR1F3YDWF" *
MAWZT-_A08::X><WAE,N]/**P/_+&P>=>>4'0#@UH3[[J!ND9D!PL14S\P%1M
M^&B(1'PM=C,-2P/ V OQ!O6NV)[>I<_X8'+_#'"^+QSS=FU"O5BH\'$U:D?Z
MU7L@H]X4M_V-;EX:J=<6[[N7Y^NINQ05SZ$8"6N[JM_8%;XF3-^&JU$3^DE)
MT411A/0O64'8F1X_LM47TIE=^24(N2 ?XZY&'6Y4>$>A_:#J5=*.*RHG6$;D
M9+8^/P.?'2X/E1SE7M\XBZ#1)55&4='#1 PZ\$_ W>93D%WNY:2)03EHL6>?
MB5YJ/B9W-GIPDS''1:\3CS18^:*\(;'&(?_E(X0+X\,C8Z-I38TLUEV7MYQ
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MV-<B'R5&$>  =] 7M3KG[QK^D\LZ2\,.GVY6Z4:T%R$A*<Y= / :?Q50OB&
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M5H\EGI$U=^<:835$+<_ Z0A':4:!M=4C\:%(X*_1PWX!FD<7C!/=PP+O-\_
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M5*_>L1[:WAF>&AVNSI8;_G9U]+ 2KIZ>?!6C?:.JL]2Y+C4*:]N!6?DES;F
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M<KSZ[5,BC9Y&_>2QZ1X.[1^0ODO6>GNMWBM[%JE*3OMO+\FF/RCF\QTB'F<
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MY]YCD-NQ36(\8PQAIDPO'(5Q.E(GYLK8SE1/4D<J+[-B9*]W<7$W_+T-6*8
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M,*8XTD+KK>3%HY^0C.>FNW/++/PQ+=>7=O$#?N-9>.5+F &H!+)"ZZV;&5L
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M;6"'12-1R4VCBN/4[%J2LVO Z,DLD%3)H=,@65LX-*$ @IJDXV9=QD3O@J(
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M74E'!4D;3;]X#72'$JN7[,\'KC+1(?\ [P5(AS[-9R+70,^&^J9]6BU.WP&
M7G?78CIC#[9)S?M.'$TW=_I3K$EGZIAMNYA(;E4PVUB#+[<0LBNI/M PTY>H
M,<O2^!M;]8_"),%W?E5,.J/TQG>#+74J+GZ4-0Z+-DY$#N9K)$MA1:Q*_*9;
M5N4RRMX#/DL:#GIBB0+'$G1(U51T^#&*8C,F"8".9Q&VO?L_0P^MRDM.W17&
M47I:6D=#'L]#=*GY.B9=%C%ILI,9O9=2T_\ !HR>8BAR"GO)P22NQ9F+,Q+,
MS$EF)YDDGF2?$G]X@*"2>@ S)^H;>9PJ^P/1C6E1/]Y(JI_:VSLI3H*?E7+U
M9/U1O*P^]<]O?F\>&Q^OL<=B_P#X!%GMYW&,1L_ZM12#/ZNT,^W*IC-K_6+5
M>'/_ *.NWF]V8S[9L2N2Y_6IY?=MYK=O!A_.Q//_ (VV\U@V 0_S6%QC^]C[
M?TG;NPX>OV:%?_P[=UJR^K32J\OJ\UMW;:K]FK4_\C;G:1CZS5J9_P# VY]D
M8>HTJV7_  ]N]7PY_M4*_P"CT1RV\[@F[\WMDPN//](8<^OZ=O.;MX2?YI9(
M/\#<MO.;MA/I08I<0C^@>[MSAQRJ?Y">K,H_WZZLMO-8Y=K?ZSAW'R^OL[K^
MK;WGO#A,OJ%KC42?N=).?W[:H:\%Q!\NI<K2C^J9$<_<FQ[1A=^(#Y;59N'_
M +P*4_M?O$,I*LI!5E.1!'0@CF"/ [)0WMI^4H5717Q6'*/&:(/BEC^$(#WC
M%-F&/>DXV078XIADZXW@)YC$*J^<JCYF(UN<E9UZ,_Q7HZC$SB/X*#$:XXB#
M.*W5;XJ[2EY6*DRG-625.FI6"2!),B4&U;%<%SEW7WBC>]@TO^;'/WUA4W71
M-0E;0%8EN#H!9Y8YLO=[QX46_<>)5;ZJ?5B%9H&T^S/#1GER!8?.YWDSS[-A
MV%P]?1U519R]G[HSR]N?C\!0PFBG$MXC:AJ5U/)>),X0,YYZ8TSUR/T2-68\
MAMA^Z&#MG@^ZL+4A(.7;L58ZL4Q"3+D6DLZU'55(D,9X<F7P210QO++*RI''
M&I>21V.2HB*"S,QY*H!)/(;17]Z(TQ#&742U-W0P->KGS27&'7,,>A%-<U(Y
M2<4,W"XUR75I&F&%!HKUX_"."$=V-  !XLV0+LQY_#Z*M:>R_P V"&29OT1J
MQV$EI:N&0G\KB-J.'^PIDE!]C(NWO[&K%U_&'"ZP0#ZK%G5&X^H+M[VP'M+>
M$N(VY9/TUT\SMIHP4,-7IE1I0Q<OK8.?OY;>=O6W'S3/)I_J!@OZMLSS_>>:
MDJ?6#D?TC;S5^T,ODF9W3^HY9?U;98A2PS$O6;=&(R?<\8CTGVY;>?P6Q28]
M9,.NL?T0V/-+]0V_:['NSMX08M7,?]:W#YH?=&=N)%62_#^>PZ:.TI^R@(G/
M^ZV,=B&6"0=4FC>-Q]:N ?U?#<>E+HU#3+$W?@L1^,<\1[LB$9CYRYYHRGGM
M+>W8C3#L:53+:W=+!:US(9O+A#MD$?Q-,Y)ER3A! 97AFC>*6)VCDBD4I)&Z
M')D=& 964\F4@$'D?@<5W"MLHEN:L5W8GDZ5<=J1,W U'T(L0@#PN>BYR%5,
MLHVDAE1HY8G:.2-QDR2(Q5T8>#*P((\#[O>"OG\;@L<V7KX%Z%,_N[2?ZVV-
ML<\IH,(D7V 812AY>H:HF/CS)^ WDWYE UX%2&'8-J'7&\8#5TF7P/8JO$:5
M>7F[&8Z;%F)))S)/,DGJ2?$GX&&G3ADL6K$@BAAB&IY';H /UDG)54%F(4$[
M%83!?WME0K9NC*6K@889-6I:AIDNY=V:<CN<XQDNM'>65VDDD8N\CL6=V/,L
MS'F2?$GX7A4JL]J3Q$,;/I]KL.ZB_2<@>W;5C6*TL-^=6B]_71]%HH3H3/P;
MB./T;>]L-GQ24?E\5ERBS]E2#*-U]DO/V[<*&5*, ]&"A$E6-?L\,<3^WMKD
M=I&/5G8LQ^]LS[L2)0?21F-<D$39?S<LJ./J*Y[=FFA>*?4%X;C2<V.2]>1!
M\&STGKGEM!4EKZ;%GXB/C0-KYY>DLI1>?SV78U[4?"F 5BFM'Y-S'>C9UY_7
M^)H:<7&D6,RE=<<>2!E4G.5T7TG499Y\^G79XW&3QLR..1R93I89C,'(CP.7
MXU1>;,0JCUDG(=>779$N0\%I%UH.)%)FH.6><3N!S]?/\:Q01O+(_)412S'[
MAX>L] .9VDI00Z[,7$UQ\2)=/";1)WG=4.EN7)N?AGM8KUZ_$FJ,4L)Q8%X;
M!F0C4\BJW>1AW"PY>K+:>W!#KKU@YGDXD2Z B<1NZ[J[9)S[BMGT'/EM+96%
MS7@T\6;+S:ZW5%&H\BQ9U[HS;GGEEF?<ZX99(7^=$[1M^E2#MP;@KXG!^9Q"
MO'87^L0),_:6.WG*MS!IC^4I2=JJY^MX)N^J_0AR^O8O@]^EBZ 9\*-^S7<O
M6:LY'ZI2QZ!=C#:KS5I1UCGC:)_KR< Y>H]#X?")+$[1R1L'21&*NC+S#*PY
M@@]"-A'.T-#>R)--6^0(JV-A1DE6]IY);^3#8 Y^AD1IC$]*["]>U6D,4\,@
MR='7P]1!ZJP)5U(925(/P%6]6;18J3Q687^;+"XD0^T9KS'B.6U?>"@FC#M[
M\/AQZ)!TANS=S%*Y/C*EM3/+ET:SEX>[QF7GI3=R:,CPSDQ/#&&?M\TV7W[5
MK?Y/$<$J29_RM>>U6=/;I2.%O]H!\!N?A*=V7&Y\0WIQ#PU%V[#AI]97L2^/
MRES'L^ 6.-6>1V5$1 6=W8Y*JJ.;,Q.0 YD\AMH&E][L0KCM=CDWD*K, 13K
MGF.VRISGE'-.B'3H=\SS)YDGJ?A!9,:4:/4W;[]G@T^M WG)<_DE$*$\BXV[
MPGQZTORGSIX<&^C&N<TN1ZAR8W'JV[/ 8Z%4>C5P^,58@/5YOOG/QS;(^KX+
M.50W9J\EA >G$5XHU.7T>+J7U, >HVL<*U+ E:Q+%%%$V4>43E,Y$]&4MIU'
MBAP"2!RVP\O5BA>"2,&169G?4Z9CHH":@652&*Y\F]+5@M>==<4JE)%S9=2F
M0\LT*L/N(.WD_L_O/LO$X7&G]/AZL^)Q>+U\->7LVGPD03O:422<0RS!(\SK
MX,9$HU&%&7TXWS [TCOJVQ##K:=HAK13F/OR(<TL0+&Q,31G5PW.H>CF3RY
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MIM,X,LLC&,2-#DRM+(JL2T4O=Z*3SRVJVI8=6(W2O"DXLW=1V,H/##B,Y5P
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MERBJTK*EPYY>K>ZU:E]$Y$;W8ME;9-_=<*P@L*3>,WU7B/3,>.:8Q0B$K @
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MC8Z0>#JF&"^?9)-2W2P/$<YFZ_47J:$T+XRGASW4&5X2>D($[])C07NJ<*'
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MQ3V&VSJHX^VBMHR,3(S\=&;X59\.L6&V2E!O=8^2\-:YDZ\AB\30&[N0?@C
MP8MTP*0ZUWLE"([$S$)^HW)W?G,".V='F7@J%F:DE9G$:Y.W^O9E\<A=E[-Q
M;^HV\D )HT$^%U4/9&%@\7@/3SX^T/WFN$WC<_%3*P<97:@R!,BY'(P@&0SK
M:/5!^ST0Y@C<SGRJ.&._\9S ISOM")=(WR]:*3=O2T'%"C=>3+R6II-FZ;\>
MH!,"2*#VB3X>_:JUEQVH(MU?U_F.^"W^*&)A:TJ0X4)W6 &;X-S"E<Z\C1+/
MZ<?/H+&Y<JD.8F2Q676:R5Q/]!1H,:('M6R4[5:.^"PK5YPTUPNB\5M*-.7)
ME$P&X^GC*EG9(=)<HC 0;\<$V3OB9F_.N^.DG63X<?I,+]^CF'=KI,P=S8-^
M2Z&/VPV>#5(1A.'I.86NZHYLO7'WLUQ\-A]K7V6TKWV^FI6H/1+!\T*1'(VO
M2#2\]?"8BN8'8#_F3G7^YZWGG*'B#8BSADUO]^[ XHI*+@"^]Q0D2^9IGBIQ
M!SO'.=S^9ED8HIOH*E_QX!OS@\0Y%2(I4F&VN^<D/>::Q0'[G!IA $AS_)5P
M7O(PE</2><GR=&QQV)5#@Z._6U@ZK=K_V4ND:RZ;OJU2F1I!JG#RPO;:4K'4
M&I=B,*5"@/RV"=.9Z[<VA9*X("'8E,&+ROO?21,2DS#=@^YU/9/OCE\1DQ<.
M#FWB?P D;]$@,M9O];'<L=GPV;WSQ02 !D@#.",^3/U8 E"!@0 0 /RS?2(
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M- OIY=5<,BR7KO#-@.EL(F;%&-IRWNXX9Z55'D'4*OP1:><?X)6[(7L87]K
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M!41+[.&XB_ 0REJ,F>Z73"J>%6"Z%R\S'D0O+0X0'KBF,+1&";J#Y/8%S!;
MH6R45-,80F$5&-A"F[!2>9/1:Y, >26P&A!-R[")(T2H5"8)GE5T*NH?QZP!
M+Z25EJ%_Q &G0<FLU](YAJQMYO2KW][=^C:(>I $'[Z"J[BZ$+5<KF25@4E2
MIDO93L9#*V5Y"PWQ#!/>];5,/&U!/((#5Z %B%-_$M0%XM4/X2@@=:-+&^OH
MGDZK(* 9ZK/H,'7,;W(?(E :&J>HY7B$@ OD3Z :X2E] (3_ (4.0S#X*>$B
M[VU4ATY*^O*"0GQ5[ -!L<8@)R!4>0UW;O,8'.+\@1.CH47H,&B%:"$1=K
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MF5(L8#?XA2!PL $1!PWM%=T50*0N$82=L>T5G</L*,<%?[&@R!4@#<MY,H#
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M0[]#M(XB])')P3>49=J0%@'%BN&DQD00"ZI)P:\#;!(Q2LRP:UIFUP6?\B+
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M!X4.[5- \K/G** YM!Y0Z@\X4=]_GT:RHZ $ 0%2&OCDF8;(\ -9Y9MY!R6
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MC]YD:Q.< Z%JX 6.HP<GI$C(6+6!71= V%=;9U4B7P,E Y"F <0R^SG(LGL
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M6QGOV*10*2JID  '%3S)4/HQPF0]Z#*W5'\(KPEU#;;LV)N8;A.R:1DH-VR
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MW<57]S(&W0HH>=[Z]8'<NTC+>7]VA;4.).=S.]L[;JV^IC27"WFAG_<H[P>
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MVXGN ;FNVT_9]T!XWAU%:I#,OM@]D)AT#R!(4=8TC1EN^?G1 [X[WP-L'/<
MC/,O:_ZRYK_,FIF93D[D&^TO%DT+CG@QW0;Z0]G.GQ\!AW;YNGBYGX+RK8B^
M3W__?WPN>!7Q0,7ZK&K@#N\>^&@XI/MP#Q2_\3AW%'"*LZ$3S7[*OZ:9W,.[
M(++U3])]#8F[^>).XFRMKI3MUX^=1G8:7$N"BV)C'L'79R5XH@FTK]R#4ZS,
M8.-*9WN;<;<\N*H/+=1W]FP?^GAF-@U?"%V5&(C]V?PEND=W,:OG709-[\O&
MI>CQP=^-*3<YRJ)3OK2O%(8;T@A3-*%*?#$5:TAU9^812&I#8@]XFA)_Y_DI
M\Q@L9*_Y^:>44;\T]9S'=]>!]@7B9G4DFE/<86B@M/6\Q_IQILUUW]A%YZ@K
M*[W-:EMCC?$6R)9LW<COR93SI>T9O"@R;6N@#+>YP0CC!FTL(=6.?%\M<?V)
MQIIN[_I +#@.X:$N$P,IWE+T9M#XHJ-ME6CU#L6T!W*6/2B#?>R4.PTB@TFI
M#Q ;J>#O-J=IPVV+!@]?1+SK>7JBD6P?T8T11)"H@<64?\LVPU=XMI8: ),X
M;E>"<3)G]4[S/AU_U^E.]L$F?0RO+9S!34+TA&J/T7M@KCW%2["'<YGGM>:@
M>Q !OO^3S2\@,^<2*#D#_O[482=&T."B]=QVO4'*JK7LPG)5.+^-SIJ&#FO<
M6^!#RLKZ,V00#:Z_KU:4ZI<3X>$3*R.#?$K;CQ+80RN5^  D@%R:;,6/?[:<
MA6*DS'ZA\8!';&IH)T[(XHNY]<C2OKYKEDY"Z].R6C\ZT3L^!'LFI*+'^BO4
M6TOUCP6,6+3,\5')8];V:*-'@1=!*AHX=$T1#28RVLADF#/Z45W!@XC!%:WO
M_)39ZG^]K,C\^9K%=C3I3PH6$L,!.J.>U$_/@:S;4#9<XW^\<DCNU>BBRIS;
MYNL!242W\$SM+_ADN_M#=H0Y$!2G?1806@F2]"U%N@]HK:N^U:GT^&/3(WP3
M&O-%&\1DFVR-\MG:"Q,MXS$.M5XV_JW8I@HOCY\)K*U"R"A+?#=E5'4ZY?>[
MY%G!J#![6-_F!ZY())WW;X?R=1S(Y*-]K^OUR.,3$$]CKO2 =9EA_9M#$@JS
MU7RUAD:,E7%VT9CFPVX] X3J9E>$-"OTY!X8Z"29.FE7RH4&F37)>Q7TS[#5
M^%%$NF&=&% F2U[%BA%(Y.#Y8VT8WS&W(:PS4SK,?;WSEN5=+7CN 5_R8NL>
MY:GS1Q+RO=43QTQ VI9'U:-,U=[WC//CDY\\OO#FW<BD9HM-V)IU9*?22!&X
M+[7=F-#YX6^:A:?XO*^CS_6R)/]TZFOADO"PF,]D<7E]RGO>-KN1/+Q%U@5C
MG_%[<V8[<"<R\TIT@;I@(IN\HG HY$;JO#UD6^$>R'(+;O<1^]P1 D!M4@O6
MCM(^DE-#,@?^_(37<H/UTU18G15TT)-^EJ5-?H2L$QS6'/@T1A7;IWU*]S18
M,QS!&V_>=(E&D9 2WVU3#SIR]<:*KA]GNH)F:TR-45N4.29:[O7/R!,-_]GJ
MKP1HJU?R*@FMST;5%D"X,$*\16BOBO#>>8/"5+U12TCF9<%8X[*6\7#8\1%K
M^G.*+2@?!8, <$YGV2W-<7:2:VW^$&?=&?ZJ<",C\"B518J;,J!8GM/$2B T
M4M".#(#%/)L8/#_M\^FH*+B-(BOHGR?.]R)8AUA:-+OYHB29'FVN2A_U_**G
MGN:_9:B$0OC;S8J,94&J)>5)OT>8B%70F9?8N72"VK]PJ:?.QHI_OO1=U3K:
MLETZ*6B].%[R]MM=;7TQ"P\2F(3@=?N@*@!NG8)()9@9)K)VH:_._EG(8)X7
MGJ#1BQ2MLHE)8DE6!T7C$HLBNMFS9[J\]T"0GT+!D;Q2QW<152GC06MJ_X&,
M" G9@BAO:R_+1T/B^SAP,[F^PA'GK2J2WZVZ!5+KX7Y/+-)(]%=X\U,WY&WW
M"NI/8LL'R&6?EQ&C,6YOC&Q\<;I] N-'M3N'>FF?=>RD7@W $\&&D>,!J"+I
MV][/L:,UOU"XG=!6NXE+,-+C,O3> U2CY0%6'!\A"W/M']ROR&9LA'Z_V%#9
M@:_69XE9DDV:&DP6K:J!(>@I"T];8O5MGL=&$SRJ!@416IKFG15*Z?6;4B-T
MTSKI6Q$%,:OC%0,GF06K()_*RPM/=7IBM7W<9K^\0!.<(<->Y%Q^9=36(CRT
MP+]$Y<K(YI.#6X13A='(J^671WT@8R9&PK9H5&R EI=44Q;C/P"&)H]__B<!
MJ:;R&)FJ0#=MHAU:+#(9P3RS>?*I5C J4]$ORM=X2[I\+5+&-&MK9Y($VJ>'
M"-ELF7-F;9%@8YE@B5O4R[F#@&&$D06(U"C^!HYWO9,[RU6_+-Z$,,S>)!GO
M_'/]__GP?(^&+"E'DL-$(FW:9H0N?GQ;YY-,ENE]G^$3;/8&:=N?(LTSY7@I
M):TNN&;^_<^VTV%?#1F"UV?R^!0V(MQ%VAG#<@]\=>!Z60+B*14DA.7$O>=$
M.S#D_-].)/ZK<?NB:KGU5BF+HBE-.9_&5)2K[WMPL"S>WX]^&X37'QWY#*;Z
ME^C;_?JU! G$]_)V=#B7=R)D'-YXG$FH]4S7Y)]\H5<"-B0,;&<H0&H[M.J%
M7]*,&ZF$:67!)@V:@L1'VR-U+,!*'#1"HQ=9<ZF5?NP=SJ0'UP&AK]+F8LO>
MME:$]/?P+CJ^A@^ZC=<*42GIL34&M4Q@YQ!@1AXY2Y-!TP8]8\K-F\UJU(I9
MK[RJC7MXB (J['9B%EF?!+=H1N'11N;F(DE,$6P9%(8VZ;S'0FN%F12?M.M3
M\0IZN?8X=M 3,8%!Y>$</&KN[\+K'ZDKFJ) 0I850X^G&TQTZ415QSDT&MM?
MV$ (LJSXF5D_&$D:92&9\^(VUL-%P*,+T_ <:K?U44M[T;SB94.1F3SXXN,O
MW[^MHA %CZ!U<J(%?VW#9]GDB&RHD#Z\YGTFJ4IC5%33TCI;Q5@;B?OQD>$3
M>B_9F L\3!8.1ELL:O( '(A9[5$*A:$"$D%6L1-24*L@U=PX/O(V_4>COO@/
MS>_)/:P9C^W0)O<KV_H9'OFI;_KS;6G,OF.*Q=73/]D*O<(IK+<1UP1QPEDE
M0(0">AD$A97+MX2(S-4V%?)DW!&ZFO:4,0?R=8>@QUFV7WB[ONP.MKFX'0HE
MQ.8QTK*1E@IV^RX40^^!#>FFS:['X"E[SZ][:C-C24JDOZX&_U0D)8DM!N,8
M .BG1/!NCIQQP!M"=D"]T',TTD GNMXWU="O92?JTP&?R(7@MY/OVO4XSBAK
M"9L,/:+<_CDB$G(//*H:8#A+4LCA^\PZR]9T8RCL12329K21#3+&.F\O1[L9
MOU$D!&E@/5& Z*WCWJJ9E]D_\[IR6UMQZ*\(MF_26.MSD^M#3Z'P8%-?H^DT
M15:&7FR,GP2?G?:_9YKKC2CG<^2%6\U4P4_@QL/3.)IKY*X=GE6CS4192@]K
MA^G(XTYJ)$XGHPJ,QHX8!C[BY:WBM?B0+#_,'O%T)Q05(R%"@G)0!:".O-E4
MCSAV_EDF9TYV<1B+6!PO7.OQ11_[O/;5SF0+0P[C@_.GQZ^QA%%&-$UTJ\[Z
M^@U!:6XB%0WWP%7(T")ONG)7TRRYRIW9JE-30K=[BTM^D'MW7C\#GI_29K-Y
MVN$$37A!\PUCDEI'T&]=]VF*IY+'\1<?WPGT=&]\Q^)6@'2R(G5@SC@'%VL.
MHKI'^/519--+Z\LK(W;PS#*0J_(X#BM1!.HY]M$ Y#WZG^S+#K!A8YQQ/5A*
MZKBP(TW2]\C=]Q%OVPC-B'-+?@Q5,N:>[-.^A 19>G4%LOT%>HJS[ \_3>C5
M2=DKRH\,*\J]MM2GG;9J526]T >M4I2MUTZ:'7.UN:I_1X@#].X*/E5AM[@;
MF>#^7^>&A]2%)9M'_IA'!C<\;FP5QX(O*/]DJ> Y?;QM62N5PRL"MA^19U&=
MQ<76QYC=$7T6R:0PFN%EG94>*ET;\,5?(8K^1JZ\^3$_LN7MH^JW%</BPU@9
M4R9BM]QF1']:<=6/-^@=)6\,6,6(L-4*IP??\,$_0%E2)DY33UV-Q_^=5/NR
MU"2H>)0D$ -XO_H_CTEU9:(K\8L^BHP,Z9?;NL;9_9@?>(N\N7MA]B#A?HCN
MW0,*(H"?V8/:P9P,!S&40W5X&71J?$7:U 6)QXI<MKYGT"MA98&I&T7N 8HC
M>L[8<1&C W[B*5"S? B-$GV@U9F$!$A7"G"&>O5=I354_%R@Z)4P;TRSJ_BJ
M9;+XN%%_ZU&[S_857=_/5?+!(R6#Y8FT7[\2A9DU*4YFT)-7/LJ@U(4.WQT,
MB;0+%<L5K9B)]&<9CEBZ/G)Y;9+'I$2?/T?9(#G,L]T0>0*%6TE R16QAV)?
M[F'EW!:C*0VDN/)'BZ@:X=K$"G@B%%#]AB3#4631NN0B'7\%7YI(2YT;#7%>
MH/,T+A!-#.]]K<TCSO_9,P2"%.ZG7?Q I@WIM-L[C0FQ)@J)[KTE+#F-3:[)
M'\^#ZFE%:9B8-.C&[HK%TBAOQVWCI]B#!M#$]TFS?#?<4.)*'MZ8=DSS#?\J
MP!*^_=1X0" F3G:3\I/,J64NF=<=V6Y'IY5H D^\N["C%[9=ZLV)V([>G[P/
M003>9.QP,;GI2ZNFN;PYMLZ8M['BYLFBG FL?#>S>+>?>T\.O2_K2J&AW[;T
M$?[]7FQY7<&CC8[EH+Z]%S\.AKY5+-!QHC&!:,I&WE^Y+O/4L<K8\=(BZFUX
M/K2+.Q;(@>)=GKI_WWC0HY)ZX&55?;@NS*C!)G!YG+:$4T,5 V*1'^TFE#W1
MZD]P/JHUL[9:>1L2)@OE2!VU8':'-%M9LIJGBD^B7X*TG[UN*82^7U>OI@XR
MQ5X[@1D56\8KQK!UI82W?1*00., W*2$9&FOH3):"05HQ^8L;V.$S);#58GB
MOSZ_,:B9154^U4OM;DJT<W3=^9-UQ;W0D.E4%(O]'?UYEU"\&/%0%Z.KKK"4
MV^JM$&;&0B,U9*!A+/%DE@?CV\O8QWY%HV[ECSRZT8DFR2@B00J8%7GAQ(C*
M0J-=%T,4 LO'@^&>Q4M8P[)H\1B E?RF_VOP:-L;IVI5.U>)YF0FY0D7%"\F
M1?77WO"T+!F,(V(5MZ]SJ,L?[:W!X?-L>NAYWB&-R>+B;UUGLA0\+J"5O>>.
M-DO<RT;FKFSM9ZNFB]X( >5&03*!MB>_FYE\B;[OUEU6$2VO[/N$A,^2P^^!
M*2T2LIRFF" J@RNN8A0YUU^!'%*<:"1W1%)OX.>+GXE8(YF$AB\&J\,GGM[9
M.Z:_5B0X)I8E1=[R^C6EBB8:>B?EXPK6>PF$]]9QZJU_:[WM]BOJ=.^I*(8<
MZ::-6\QNUB\7*#ER+%7@G0F%K6@I< W1]6& /LQ4B![I3E7LSNE.Y2IFJYY3
M55@FF*=LC2M*&SY("KL38!A$P(GVA5IJ[XL_0[S.L;Q(MPW::!^&Q,A1\X</
MNB=^+*6&AB.@:D5T.]9$MN:8PIC7TK;AHI>TL3F6+%)@2P.$2,:U2?O\\;2#
M5ZT2W]=R;*!?M'CBJ7Q&RY"?;F@;+ K\(&"?+^O6H2)8!9;Z"A1357>M!%4X
M/F$"K.1ZK'<@P+T5,YB^HFAEO-:@DJ6ML2F6<EO[ M2[$1WO\EXS^+MMQ@PO
MB*'4@;MS;16U/894<]2=6(4;+:BXO'M8;FL'*^W[F6F3=7[OJ)?8I]=YUC(K
MEN>*$\9GDJA2?[B6C>W?,[5.L_OKO*,?;P\+'&!*5+CXTM>O\W([;'_ 10%P
MIPX-\\TO$YFEUS"*X%6?*/J5 %]KIU].S<J8"SO;@;=[N8Y8<QO+LPID\^DP
MO0I,-LECBW*-IA>8-#P$:<]39UY5%:T<NMHG&1Z)N9\TQRH1YR5K45@TC>'Y
M$Z"LSI<']-KF_SAJ3=X6[!C#][44YJXN&Z&UZYED :)C._;1,/P(I2KC*DS6
M'0UX+!3EG-U)<R02M,O351W%+7MZAJ]$E!3.5EK7XHJ-NX5$RJM+^)D?&L 1
M'!L/E- !$I]M-5<HWP.U'B:$9J&\;I*_G<UC&$,I;8QAVLX9M8$TP,_AH\E7
MLV>7 Q^SZ.>%C]HNJ]-VE>DI$L6L),62VNQ8"91DO5EB\P'MI#Z]1D%3!7>[
ML;.E/_F@-[EJ(9]PT/ B*#+\BDJ.>KX>]5Q79&:D"BX/D@L3JU"O*,XH%N5"
M@YTU9XHIARM#_%2*[.<M>B4+VHU,!"JF76E*)[F->0KT6)ADMWBPY ^Y)&/D
M7S;-BSAZ\FHZ&9Y+QO%U*S!^,;2V9AHQ^6RRO2TP@44?2(E ,A@D4N8;:8]-
MX6R&K[Q@2WYT@L'"VX*\VY?"/L27!V]*O;X:Y_L:*I7(HD+K[$JMRESI-D+U
M]E@<%.C#(&_BN'[E&-NR.:Y[I*N/GYF<,6F_HVSM'UZ.;O7$%+KSQ<4=.3=S
M.2YXOD8^Y\Q35&?V=,3<U>8>L(^FL%G&*^Z0=A(3!Y(&GP6Z1>6LB\R%M/:T
M@B]U&W4@TF]MN"0FL!AC?2S3A%<Q?^DF0IJ4KY:C1Q^2J&:1.)7GV_:LC(NE
M5C5"K5 &S%63,>RVF4SX\>?HX*L0QCC'#R9#;?.Z<:ZVD)RU SV]B"+)2;I9
M/>*\^G<Z)B]%N\?$_8*#9YH,@; [(CH]>-)R0[NK,':M"D\343Z3T4FV</5S
MPG?TOMH)2 []%-5/Y(BO#RG))G&7-9P[2+.]M^=E!NU3<1#>.;=GG_[TL<?R
M.//RFX_$YE^<&W"90,3/PO B8V@$^2=$,ULV]JA@^.!^SU_/Z',M1##: GYJ
M?QRPX]UZ&ZKK'UD*:!C[;^!,O@0*[_"A'JN8^Z2M29K-=C'M8O$G,H(A.ML;
M&1F)V%14OSKN 6QC\FNZ3Z>.(CN7^U\2Q44D/<YUQ.C?@(7>/F&];1Y\-FOX
MNJ)HP';3WKHC]HGP\OE%]PB3?^@+QXT0+ED D7&C$V5&;#^U8H^W0*G/W&5
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MCVBYX:Y62;&[N>C"WY(%?U>30LS&ON([9E.\_+4,BN%-L4'OR%F31!ZY34L
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M6?D>6JI7O]8J<?=HT.)O/T_4L]!'L!IBZ6@7),EVE'VZ5!+V7(LE;!0"P6L
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M:I+I<I>9J;PI0K>@\_&*.CLD,X9QJ).,8SULM8CLUW0-3.EG[H"9A=7U<*2
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M_AUCGJ^K]2('74-]@FQ(7910P(?T(,$3UG%B^BKK1X*_$3D2^YE+211WGN$
M49S"=9$SF^/),K.9:5<4E[#CG&9AD[M9*6-308]5]O+* CSAT3O-UT;%FWWH
MA%B0X"N,==.F!(.-^\T;1<"3,61]^/2Y1\28=$.0E*^C )3@UE:'0@!43';K
MR10#\+95(GBG*A#RWGE[7FXM%8HF@4X4<A[Y,J  -U;!.1FLFG[GB7+#P_$#
M<9)R5XK(M!?D1@OA'!7NY:ATTIS-,FRR0_+F(N?>,S$YY/ Z*6]<5K7)XTIV
M2%G+S\V6CHAI<QVL9P5:\4E&=C.4A#+.491_, @*/8QT9BH+&B;K(P_OOV4-
M)U#H6<2/5P]886%B8"WYU_JRK 8A.-I98&:9T<[N#\F);\/M#%\P)1"0A;^.
M4U[>-ZB*\%&V<LWU&&(%*PGN-((9,4UUWM@;,O\TCT,9+HF7LJ#J$K7Y#C?Q
MM"^"3PQYEVPV!!HWHLNGLT1UT5)FJ4H@+)&NL_#MTGJ;&R(]A1;&BN:7##WC
MJWXDE#N2$97\&FH.D/)Z(\#K)(Z\U\"U__S0\%6*8L<T;<P.W<N U 72+7&Z
M9#66^ .WO,TEF %&S^H+J]28L.*!LA5IBS(K+]YCR/>+1B-(%X@C%R>S,J:S
MJ+0.?_V3POIMU>;DI<<1Y!3_H)V*($_98D.>7;[.)%:(-\9^)>3W!@YEG).8
M[1\,^D(X(W[-ZH%0?QE5:+R5DVU(7[KQ_DDA95*(._-GC!'MVLIG6PEH1A./
MU/N9=#,\:;[TO3;.-CX3>9[7W:QE;G+#B#//Z"1:'.XF*N\HS>BS/ZTZN0>Z
MU.'>X*(T*O.=FX^QJC_T"OK*<[3L4[=8FF_E_#UD) _C([+6'V,+/63[,VF\
MCYV5A=(3E'?9^!U%*^K-T=57!>PYG;GVRB4 TR!'"6K_]67DTS[RZ<H4X^=+
M2WPH<HN?)%#KN(ZRD>4OT:&+W>UDS21\=^Z1Y(KO2.<GCV>0%V;6B@>U=[@3
M,('CE?!,#-2->I'7^5E(\-"9)T"_:1(OQ2%16^F:O*#B*+[\3ZL9HM',HCOT
MM\1Q3#Y6;CL G<STSM SFO"OS94Q35'JB-CP3@RN47W),%4S<->G@NX<\QVI
M_Y_8N55AK1KE<*6+8UV^$O="Y>5C<]/E(PF16),^LT\2-._@G-<C,+'86IKG
M<XLV9W@X@Y&>CTV?ZA_X8BN\5X.> *L.)/CP<-1!UAPT^@G@N,M^?G%TR^Q_
M6G[_GPUWBX@&16Q =K4R/4[-Z4&BDD6S.V'!CXP>19U.K):ZR\M!*(G([7MZ
MAQ1FRMN&IVNKB\9W\ZHT1):.*\QKRU85VQU3_0.H#UBQUL#=1FO1QL Q[QIG
M\"&;4'LY)Z_I$_!#,R.\4MBA1T )S\_IK1&%C\M#I=@K^.8QL9 ZMX>RA&V4
MU3E)8Y+_XH_/Q9NY(0>2[$;<;XF-1^1!6XDK 6+I\()[;X_%?C%P5NB7R&XA
M&\>=]^]G[;AB3.FQ,SM8MOP]9D>;&VK\JZP)5ZW=H>311P/<^LM#$[]VI^H(
ME3<U_NGS>3T]G=-*^J %,@ZFN&.Y7-61@3](@]G/BBL?!]:,HLPU$IX 167\
M=YX7O(M?:VV]OFV]DGD" DHJ6I2_^I%/.KCZ$\L7_Q+JRIZKH[N^*.**OR*
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MUW .C09T@E$00>OX"2@C@3M%25[\-67BH7:]"GI&Q[<K;#UA&TL+[<V&M+'
MK_([[Q%.M28.9"@!CL<R)1O"#\9H0>OKVAJ(,8Z5%8&7684[!*4G B=.GN5#
M_WL>7UFU;IC!6 3#EXS@95/=9Q(X>G[*] 105:JV?WW(]$'A2+/G_'::RS7L
ME&F0^V9+QI,3OF8R1Z,+7)?^UP*U<RI&#I=2;;2)[,#:2U&#KB2#A4A,KAB<
M#1B(D(;\NXO.Q!\PVVG^QD5]&H0TS5D) O\)>&<?]@2<:6'\H_QO\&^Q?XO]
M6^S_HUA6'MQ?X>P2G8I5L6Z23M2D+O"5&ISY9<X_-KUE(UMU"N 4/5ZA+14&
M!3$_30B2K?)%@3W@I'<-$ 0%"/*6*Z$K(W?PBX,Y%PC:F3R:6CESE^W.^F-?
M:WJDL7HZ<9-=+&LE&0[LB 2]0>I\_+-:3UT#6^UC=WR=,-QS72F354B\3E+T
M [[V2W8['6_KEO>_0-C+&0_6]>752()3BPR7#"R2>;X";F*TFBP.AD/0#_IM
M5*0X[6+!;#QO^0E[UV,9;%RA"9O#^45;S>L]@Z4[@'6*QS_DCC/4;73#.[#<
MFCX^;[_N<>?MOFCWU1/@QO8$S$J+:&Z1S/C13)I-( 2M%\R^EM5NK/^R:>EZ
M A1- 9^.RU&'8!2Z;TO.EBC*GV"XTP_IFLS5<U8.Z3U%VOUTT*B[(RJ]P!3;
MF@'0C-E_K]A8[K533XO(NX O*\1V57[@U.J]_ZWNE8Z'T;310D$3//MI'=)F
M."!O>/;^";!I1!!SJ]"8N_(@[=:7%OP N)4!K&ML\6=P*?G^9:$+O>^NB9\:
MN=ZO7@^QO7D".D(;*EQO+R&+!9)6N5&?^=+LX@9C/8$5?V(>I&TO^QZ:EP<U
M;-66_"5VRQP<].>OQ,_XNQ\A$/"9'<S!E=U9=K*CC5QI5M6/^D,M35_ 367M
MQH'-X$?H"WF1L+)??;$[-G_\B/9K#/<>.;XOS(VYVYM7@1D0CMPRMR([G^K]
M1%0P$J3.>GKXYOB%3@I\O L@0>\Z@NNC_&%#?\*ZVW'KG@"M7"/#++T'6=I'
M@E<F%^*Z5Q7>W<>NZQEXW8]CRE"878X76DYU#//X\0\3YQ^RR3(G7TTWJ:^D
M5.#B/,\/AJU</=EGTEOF#*Q&[7'6?$]9WNTZ4J]90  '+MD<W0OPNB@US<V,
MU1-P:1NMN3E;T# P;^M2QN;"UVQ0#WX"?)^=^[]8:;'A_-KP AYAA#^V01RF
M&[HXE@RJ67WV.2?J"Z)3'M@5EJATVNS*5/J;ELL>IW4T%"1P<@X] 6JU$C]_
M^]GNBJ(!ZLH4-G^>@)+IRHJ:R:-STIHCOLV7."ML,R>UYC.\F/*"PB<9=;>I
MEWJGP/Z=> BO =_.SC0C=):^0:B^8<"I_PN.#(FS258S/F/&.DU(,LV"KDR!
MR$V*D/,!\G1%U>4J[9!;LB;PRRD,([-]V0%IA]!&]^MP@\+A3Q+!GH^]_D*1
M]^\.'_W,GX#V4;?4HB"7*0,CG::I@NJ)%Y^\A5UC?HG4RF&R(7L&L!2?MJ2[
M4+&<E)S%C$F>(9J7'UN?@/F1\33-AMH+ZG60BD;U!,?D+&WFLB7*6$<]1\?N
MCOW]T52\#<F9Q5!;8ZRHVU"/>(7;)Q\V$O*&U+B#D'KO45$(\53J*C+S%-5Z
MG."V$M)M1T2-B/!Z&KL=:UC"X]Z'6M2(B?ZN2HLXFDW6)@UU_U9E"&#1M^%K
MC'_E!;GT/UEJ?(28M3IOD(G/'&I-_G4SSP7EGAW&YI)V@H&B S'Z,)69]E%P
M7A_1L9!NBI6JA!P2?Q2_9-25J#4V34ADF9&'^Y%055JAC:'Q@"M#PT#$>]1:
M'N^Q(I65CF\8KYF^5=J);^ZL*K92IWB!ZU?OB,Q+/[IX5\'OSAHBQ2M_4>,\
M :M%RA,M-N*AFEYS+8\#L^27<\M]8!>&NO/JF'N1WMO?:W@>PLHO.7+.!CY.
MYL_,7]TN3,J8Q9SX'\%&HKOS;780 X(8PA(#7L!%.()_[7[LJITZ<^RQJSFR
MZ#&:<,;G"<!!L+LXVY=;+[CGCEE1_4+H&. _"ME,\^*'L-($F\*HT\K\+1=N
MC4W#*UJ+F"ELOR)VT?2*R3;3IVVJPMQ2P0@WK>:12.]K@1/3>DBM52&A^"N0
M2B<A!JA&W]0U&_]5(UR8=6M_Y=6$O>BKG_D-B4\ C406_,%TU8<9YAK!DS6G
MQ1_//*Q0=-P2A:\Z3DQZ,^K+R=33*,*YSOEBT*',:\)J!NI69Z#[K2C8)8KL
M0\('?E(!WJWQH;-?513U=JVA:D'BY #,,R=A13-">^$UT7I\%RK-N]=)I[7P
MY+MSAD@52U</]<^R)9TIDK*Y/Y%8X03:-YD49\D5CQU2*1_CGH!A \;][Q93
M^2U==Z^-N@-$K",N;4Z_LCHFC_,>*O0L+'ZB,?EQ;YI(LF%*\V'+]0EX9F-(
M8DI>^=/9M.JQ4N?YK9-_\^:V?6<J,/ ?F6/5OA?[2@W'L&5MWJG<$LN#HKL7
MTU=VGHQ:.;%))\&5GI [_$,)RO;PM<4*!5LH&00JLAWV>U7RKURJ78I]_N(M
MWV -YC#E5LT5KW5N4VO0;W%N3U6BQXMJ(B3VE\/68F+UT*$%F5GVA\WS*OAC
M4N@*;U/SQ7I'D'"%V+I($S@^E7'Q(.'U4KFHDVPQ/6V 2SL=["1D/:#[7B7:
MW.C6/>HT<;_>!>%H:+;!N8#NR2^=.\?&^D?? #%ZA25 $\X[ZC&YGF?%EW H
M1'ENO4 89\:1K3]/Z(!Z(&RZ)M?Q^M?O";=93 GRYMT(5WM"^0[5CM3#]*_F
MW?BY,1AKK"S_2)LGUSG[,MS75B./KX[QG,CD]-(TF8::(T7R8K>\@D<=750P
MCI2[C2)2^?LYT73@L=(I;X;/E>UZ/9,G8MLH8GI-?251':3=-&YE[[D1;LUP
M*A@R14FFO(BPGR:NTKR\.*-'DNQ-HN -19A/[+0"]J&O:O_*^83E"=B.7L<X
ME1$G)HJ;E&#JN26RJ)Y<W6S];;G]\<3!S!?(9IR#[T-LX[XAVB;^_)AJ[<_=
ML\OA8KT7\>"WJ$F^@>*L?DF7,HZ#:YH,-U&7:<3,LV(V,67/EN\N'RQ1MNYC
MP\1>-\3EP=W50/YCPEJ.M\6O\IZ KQB]?X,WA_4J'(7S"7AAI KMC6;70Z8H
MO'G6@=!@0K!5O'WT,/CKP]A/0)\*QK#_60 \ZS%D5.\) ,R>@ W+_QL5_MU#
MD^*[(:L/9W]5T)S5UH_=KKL_ 3Y__WTI0</^!'2C;/C?D?#:(Y#^41/,>WQ.
M\^()^--4YK^&TX%0])5_ K!9/SX!F23^-]U/ $S]GQ0"/M!_]$L)?P+V]*<[
MSM"-'AECX1(^RG]SJ)V*)R" ^^\5O%?_,O-/_ZH2Z7P502OV%PSE.&L^ 9UD
M_O!4\74DF/@#=BKT$1A^ GIGI[+^>>JR_S;&OXWQ;V/\VQC_1XUAO9)U!NU+
M31^FU$6[-(OAUW__Y1.\'<WW[?_S SE0(SUD&D^>O&J'@6J6?X4YS?6-?+Y>
M6>V[1*'>TH*P?%4I12XF!?#0G/YE1II@A&^^OH!FLISSRGN!A[<25%0O7[:-
M:#F45\O5]B^3X4DK_.>V^\N,*IN&3,I)L[96WQHF)*U383<549L^$5F8L,XL
M@VNHV^2Q%YOFD93)0^&!\I9H,<HJ<U4R8V/R>AU;+-V5&V->-G[I7E42\__O
M?E+872E:B#6A3:G+*3D1[_+]-%;@LAO;VU&#]N4U+1 F:C]QC\S=^YZK1W4D
MO>LV>!M3M_U7K=@OXHF5UJ/7V(PR/0.-A.<Q3GS% J(_JBK\=&8G.Z WL;(1
M8NS:E@T7GLFZ[$&?W2[,D66^'*D-(LIV6/XG : %/TP,*[:/!,J?&BF/%UP8
MDG N!_?$?E&+*LK?A)$Y5#DG["#!!L?OY+).WM2;&8G;L]RF#WW;H+=/0A;S
M%L'"S2]NNV8*,_A=4*I0PL.B*NRMYW)>4<$^:_J&T1E"4CT(2DR0!R7(\Z06
MYM\5=#I3NIW)Y#*SYY#&/!M8CL;X+,XMSP1*5-_[7S7"9AIL.(TJS/#V,\&"
M%8QOWO[D1SZSU_%O3/,!877BTRBM/,L[QO!U-KX,^X>"8DY$+^39]V/QRR%J
M#?\5\&B_S,IWI&ZX_WIF7:7>@">W;+Y5 D[%2?9'R\T97J UZPR-?BKBZ/+T
M&5Q/LHLXT2-HWW^[(;N?^>U!=<Z2_YJ2Y$E;Z=7V=G^.P\6R,D/OB=/$A[X?
M#_+%EL@/,TV>KM8-[<9=ID6L%M:1.-@G]!(D8O!1E?\ZQ"WW;"RR8YUJ_.J>
MIM8W[UYS3N\VTWR5%35]$\/=,%U+6!IP;?;O?7TD(EZH_?!=P;/ \*&R'Y;U
MH,+$3J;OE'\QI0:));,BF3C0<FNGT@-_N$7T9]I4\=+:;J>"YEKD1<Z5WNJ'
M$"&=-/-_<_'PD73>B/Y4/^[.F.Z^K&M=NB&/A=:]2$3(^C=17W,V],[W.!_"
MI9&NGN9QGY*)=[A8:.7WDZ#[P25+0>&P]#8^5KF*3!KPRB@:8*R;LN>8?:_%
M3QZ[> T96Z;62E:GRO ^>6"!Q/8=^C+^GL$VH-Z1B50Q>"=_ZDHC)*^-_(QI
MF"H&HU!X%MMF_4'UUMF^<$4?7SO;[?%=52P 3X'74\F(W^U;[V<52HP"-DL>
M]TKMU>V3=I<VX9>#I[@(.<Z@49Q\'[@_*YIRCJ&HM?U+'W7[%QZF>\$?]12T
MM[\M@G] $XFLZNF&$ ,ER_&7Y5_.;GHQ*K.JO5K'BQ'#:AWK!H>K%X<8C^B2
M?^/7'PSU%19_? 358U_"R0SXW;F;7!XT@\&#7<^F?>/K\=(26$ DZT/GV1,0
MLS:!X+BC6LER=+2=-3YJRSB=3U5.0:/9 @\/U)1FG55>G=Y>!3\!*+1_8^!^
MQ=E%+TI!0.**X*;C'5<VWN/8!F/2!JL_A;504KK;OJL%&,MJ%8QUGL3@[];G
M%8._+-"G<J85:[L+,_I:KLE\:8"O8/6#HBQNJR7/SCTNA#*QLY-REG@%"49[
MWTQUV7'5CYX(NY7<7"E9]C#1J4%=LN*?67/E7A3:O"!"FI.%L0ST7%ACYEJ.
M6D-3:L8<02F9=O#-1(<8\3@PZHUP#*ZJ_;=!5\\-2>]"BNBW^G&*#*7ZM@E,
MN$EFB59;WE6\?=Q)QN7/:->"Y26HPPH1NH\#4SSQ%OFE>\V^K0VK\Q-CK2,@
M0:<3+=1D++\3@=*9#B+0O6RXX?6$E4SCP2E#P6P\CZ1V7.D]!6ML"NF^/CL1
MTC[Y;M^<JR+6J0)T'#?_K7:?<90=HCN2(AG'3[(Q?;.JS;/M?]:VM&QY(Y>Y
M3!5L0N5,-^24R 4Q\NB&JJ]IIUF8D9ICPQ!O-W#21IGWM?ZNH)Q>@L^:KBPI
MML3?<\URX?>TV"B^,^*[.9XI76UA#N7>G [<^PLB= \LLY^MA[)JOY.))/H@
MH$&*7.M*0V+5[*?U^_Y],)SNML,PJ<75HN!0UW_.5<$3V?1[2[UOG8SO5$8M
MOCG9I5DE2A\-7A5"W.YF9J*P(A]E=+N:MB\Q@$%JQ (JJ.K%E?T,0D-MN+0-
MC@>KS9[R[W@\L&8T-B4?2($F6BO]P^<2/_TG[8NX?OG#KGRS7IJ.2),$BP=.
M>?Z7I.]G0Y*T):C/Y5XU=5# \18_U37.MHK:;SU3'RRVXMJZ16G]LYM(4GJE
M[+KM5MH7?7D'WM+2K*U_V^]4V;$;)XM*_8P':4-=*\?GXYEOZW/9#3 Y6O"'
MYI3!YKHH1Q,G27#>X\]&G,%]R"S<:<7[/U=!OY#'+G$R\770&=K?K 6B5[[B
MX8+)GJFU7;XH0'GNTX#JC2YIE)ETZ7^DMWZ[#1-KJPP'16![2YJ%"!"2D7)A
M3"&1;BZI8"Q2,\-<[J9&<=C&=5YW2G;YNST!6+N6_\P$^#\]./?NEE?"'1@:
MX@(1G[*:5S\95N4<OCE,QG3&Q\@K<K';:#5O]@^[R],Y?+?4\*J)0NX)L'3"
MOZ")!KQ\_SX[-07,V=!7H3>T3X]O1NKSIS]-0,VCU%DE.03Q>4?YY2'HZMXT
M[]R)]54 %HO_T7U535I'G>*UXJ+($\!VM+S?4FB-!3!7^))("$UGYK",;0_:
M!B:(_KQ0PNQW'L#R=9;/V</0AG;\++H7<:NN#SA:WGFCVB44Y5#N?"Q!QJ-1
M/V&?7\=O9>8P$YE@H?TC>\ HC;2P\J<G0YE^1?ZQ;1[[F^@(I'33=)-B^K-L
MK"F-LE'&>^5H4'-=8T,T7#.546(9#G)6F[/4T@U-\_4F4A71S%$ 1U4+BIP+
M?7:R1!&*F&X_V]XN?\VCHNP(W@*-";U;?.$4VB42\U8#[))VN&=H8\,:^2TQ
M-('Y9Y+'& A/(!OKN\:P+_7CN3CW2O^.!ZS%Q:$.Q_FWQ'X7(II?H>9Q8HK]
M&'IK+(N41;8@G.[>.0IHY-;[]5BY\A#?^?;U]?5.L'TQ#S2A3,>3@OJXE=CQ
M>-O7&<A;>,TJVP2SU LCJ7:YTRTY<<NJ"$4 @[E%=35-4PSG%>#MIA2*_\'7
M6P7$U31;PYM@27!W22"0X!+<(;@3?" $U\%MD&!! X.[N[L[!'>7,+A+</>?
MYSWG_-][SB<7?;,OIKIF=U>MU7MU59VH_ZB +=UAFS]]C[VI5F;<FRS_TH<H
MHZ&CW1RH!*_+F 4PE%76E;6RA&3I3E*8K:2PZ1\.1$;[_/6B4F;,EK8AR9([
MI@[@>"44DX(.;QJWDR<@8/:J%<_Z0+JM*HG;FJ&,,DX!F\? V&2']!7/=@GL
MQOED);=T$4>3O8_ZUXZH:FH1R-MN+^3%2BHIF"$D*'<)BJ=J%+U+-](;[F7*
MKZ1H;(<ZF2))&LE6G;+A+<D_CBA#IPDV;5C:$J-.ED(VB/95 !X4\;R^GFP=
M)1>C"?T]E[4=S,4S (]%IL<X<?-0^ /&$^HPZ3;9GAI+>O]F:W5X'&0A\5[S
M:O/XN&LAT[A)UR/.H[,T3HQ04^Y>.ZC9JUJ\+'ZNXD3^RMSE>%B[S9\5/C=3
MPCTEK3V7IFC>!6U%QX'KGZSLL7>K2HC:=%MEX5Z>VX]IO=L;@]S1@_[)^A?<
MI(X<WT@@UB92^F%;L:,S8;AQM.-PPE@3V@M> 4XH(]\8!65!O\Q3;.BI&1N8
MKRNAL:D<.5>W;%W4PCRAQZ*"^J'E KV2Y!=P>'@69$Q7ZUNEZS5I('^24&D<
M O@RN]"-I'K/C+9T4AHQ5@ACVWA_Q3-0S#>HW[AJ-S?M$P(,9I4.Y*R(F=6K
M:"U*6LS#V+]THKOI5X8PO2P]/L>T]='UUT;W4=(X='42KM0./8#J_T&F";^M
MMY#]^Y-AF?G3.W^I>[=; N3ZA)!7%#VN+XQ&X^?<8CKV#[(_#S(3E%/E3"8U
MFJ8$;Z@I<2)*&G@.SW_XMEA^?8PZQJ%5.$7%<6.<:9:\*[39$B:'$W>#%MYS
MWJPH#@1,SBG#MY8.AD]<)6U>"@6TT4^<63\(%/06S\PNI0H=YR+\J($; \&&
M7.QP,7LG1^@1I,:-_A%57M*T;FA,K9^4AN7[@XF^,3+;-L>Q1]JY>LU)IZU)
M814^_?U^::BCT?'XN6L#E&K@.AB._D>VT-_.M_I5)2S]-T3?)BMIA;J2.B4)
MD/FO<':A^/9!P'=YF4RV6[E?79BZ?G*FCK\(@O%I/\@=[IQE$XS 6K_:_KIO
M[5Z3PU,!,5DE\4N=<S33E@\&/7OA?K=]D6LOX:7V8I(Y$PW$V#E.PV#XR%XS
M+2=MVYNFI2WJY,M/:B71YG?U_J_$L2\7BKCA+VFCHT?4__^VP?'E\-'";\0=
MZ\A?39N*QUUF37[7CYC[&:A_2(@X5ME!?EEOF;'+:_/0/%(\]'A?QRI^\Y[T
MR>9&"?F-C27'YA!:BXHBO6UE;V["(U#FN[)V5'/#I=271^O@1=?=]03\<+AA
M=$J'<;'^'H>Q:<+J-:TV, OO#N%=-I*RA7'U3S@3D;G<ID:[;JS TE^?@5<1
MA137 \45NT]D-?=)QCUKERU-W$(_]5EOTTM?P(,)7[*LWLW5Q,60E_SL;P,A
M(I>9@@?IPJZGK#-9O;NK;KV[UWCMF?V.>J^6]Z\LB@M:YVL)"(?$R!>C&G<5
MY<*U_:1/\;-+=/:4ON7#5$CF0Y8'2R;S-#V:S\?O2,>1!3B+W1V&Y^*QTZ^V
M#!]&U,JE9FL^3UMS\% W-4EMSJG_R9!F)2<A C?<+UZ6+(G]UI8XQA0QNBX4
MC&I^&-B4T&*Q[8(3H=!) M;-RD5/3?VM'#6WIIU(4L64U*.XWWWEO?UYJQ]L
M2N<*[\VJZ4Q,GEBH]XWD\W1Y*578M\]A*FPE;L'4/&KPR"DO68)T!&^OVM69
M N/&4/>>CR=D__>R9Y14%>Z'?BI[;T*[:8U/7('@[(D6/F=R/7;EN"\QV"R9
M.A]A?:3DMQGHSB5B!;H@PX'&) ;'/^\H!IL?A:2G+GA:3(W>ISG6U74X1XKA
M<6_P<?,<WZGGA>7<"E)\9+:A.'1V!C=N#02R;6"E>&0X9V!P"=+,Z(H.>/'O
M<Z/P0?S.K&8@S)F-ZSNR4]8"(TD27I_?>FE?V&#-[ZDW"926KK6X>M7FA,CF
MI<KE5SI_X-FH/]!9KEQM:!'*W[\F"&,QLXY;Z/\$2$<V.]CUPZ )V]X\/([M
M&$MV--#9MBLNZ_8[]N&BKZ[TD@T#=3/68%"5+@A)^05$2XP]\6E\S$#E"P],
M*ABH=M=5]MJ;M&MXI/(L\SI.ZOR'#S0.<]55:\OQ]O$;DYR];RYJ1J]T0247
MB1^M>P;2W?VQ>YX!#Q:JBPP,YJQ6] /9\4NYVSMW\[/T6YO\1GC!/$YJBJS8
M$LOVP&MP_.21_DQ\C?+3D5=^W(KK_3L+8,LL?P0U[JS%/EOR?0H;-Z7?KCC;
M?^S;M-$K]S<_*Z0,/?#X7Q$I(DKQ8[[@,#01<<#8-;Q#_0>U1N/X*H@,=,R9
ME+YO+>"1\CCW#.1Y8O!)<8MM34J<]/?O]^\[5U5T(C@A:%2KO5 78P\GK*@/
M:J?8S$>;>U>K0C[/P%[^->BF;6^@$R 7$>>)S38H>5N5@BGQ^O/"O[;O]+@-
M(U62.Z.\MCR)<M""GD0V[9 !Z_OPXVS$2*\%$1C'Q@^ZDZVYGQZ2!;MSR=KK
M@R;!J3P:\$=-:?M=J!BVXF[^)@]FE01W0O[\7Y"/37SEZ;:::^)@G*S/0!W;
M;[^GQB3@;/ ?9^])KECKU6Z<2G0PVFF*=G_\0OWBM2O1QE->]0P8"MU^N,M_
M#/CP#$Q@*B&WJHWP2;;,A&9-(B7T-B<CH&+T%LZ,\&FT3&J+F?.)&NF6>J-+
M;CSLOLI5S/]3^[AH2X^P%*7Y AI]HKP -!'UFN:>RE9I7=F^ $GEZ>)7&+MF
MKYS"Y1H,L4F"2)"MSGEC:>M4F8GN4M2$JF3OPZ,?78<]H!#ZA\Y23T&0 *_2
MB(NEDP6)@^AL<J[^7IP<1F<1'P3,1* 8!<JMO_^T<%K%:D(R]*J!\(G!7E(&
MR,6/=F"7>I5EY<50$T6'MNQ=":3G,E^)S\4SA!'W1C:&+4CCL705G4$$9SRM
M&1+S(XU\:"P##<Z[1V5P>B=\V>?*^%0LB5-;.QU0;KV7/W<Z1\:^LX/-CR.H
M)Z&6;B?[SQ?"#]4:J>R+1G$Q2</O(ZKITNQEGHLR<4*2Y4)(RW4.1_\:IL7F
M,#'$75V=? O5D62:=Q8\&<9 Z^5-Z[XJ9#AF8)2IDD6PNT64N668C/\H,H3E
MS>;U\^(%2'K-UZ=IM\<T&)WC>?0L#H5N,MF[7I#7Z)KGK<C7-BWG#(/HJ%4D
M6*%P8Z6@<"4?)\M/H>E-4%P)*_+7<EBW,Z!@@V3I&A&Z8'U3-"QD:NS7E!N$
M#V9PZ8:*?\-KC5O&A ;[K,!C.XI/(VSS?P9>FZ9!J.5;#+=@X=L6EKK:LHR$
M738.# 1H=BU!B3&Q,&CV<AG(<BVS^EZM.UJFS9ZO']4?O@!X6,2:>X$$8)H]
M;0ZLDC1]NE+<D(/( 81"2KLQ@<;"PPO3^R_F@OR%^*+EJ"&KL2IV$5(7#_L+
MRR"/B$4=V!B608]^_=D&*JX_H[\Z?]I2D?%TJ4' $EHW0_\4_MF[CQF?W24$
ME10%7@"I+OPCVR@V[.&&6$[R?>4B7A"I*13Y0&M.V^/*K/Q]H<0',<GW#?W[
M;#FK]^HQ&K-[ J%/;F%Q(SAELXNEM=Z'4&DR-.7[+U[SVV@KK>?7AYU[]409
MR'NS=9-:RSHZ#%6OG?4-(FA<L'D^R,LT>;;^_<21)-]=C!MWQAMWV[:'YLW3
M20K]U&04P>%_V5+_QGKRUIU8W #]#>V1GSK#4:EC):ZL?3V2;-!FW!>)UR$Y
M*:C>TCM3M8!*H&13TS;W-))!03E=,2M9##;*#SS!],S6F4$QNEN]5M>EX2(D
M5=0"Y/;V]EIMU5\JZ8I>W+_56FK%2'!H2%/RD#!T["4Y:*]B:WA]5C["V6P[
M4V*_B@#XO62 OD#9AG2(,J$:.'G!2(UQES"%XG>J7?YC6K<TI7&*PDD5N1]
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MJL;(0$0_TA9\9)2[^_B+7S5-X, %AD/-12)KP]!;GW@+=KCP>-+0=&6%<+$
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M6Q=I_N%LX7F!T">3_COR"UUY\LR\ Y)2<"9^U3N_ 7_E" (ZD>]L713+M+F
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M&=YY9\V:;^[,M^;^N>O>N_+C^=%=:U575^_:O6M7U=XLQ.Y#W&L--2=KQJV
MY2P;D@+1@07)__H;.L7R@1YS:WM-13\ 6SV[L[N=_]DI\K=/O&%H%7GO:&DH
M5-70HLXK.H]QWU^EO,.)_63,D:V]I*\E3,'38HPA#6L *P1:FA,F@G]U,:GH
MU?8A+5MS/\G=9##4P] _CNR);;TW*(JI2XAW)52A32!I<?N3'$1D-(R-F%9B
M@AR%<<>F[Q?5U#ZK#M;+!JN5S3WH$F5PJL/$9,I=:)&,K)>YF9XD=>DF!PM/
M;_3XK_FP[XK(;744C>F7-^;J%0)(#?/V\$!'N!;OG6!?]SK]O4N/U[PC#0/K
M%TM[>"W$<G^]LC:PJA>]1VGX^KD+4AUKD.ZOYO#;9YO:IH&4(5P5O?-Z]2PJ
M'N]IUE)=7QCLZT RW!4GW(5#L3HUOB0-QN8<2#8NF[)^\5[]HARA#KY?]1>#
MX>$F ;_=Z5=VH:@+,CW!#D9\:'8F+U[0*@UO7JK9^9&%I*9%>(@35$Q4+.=M
MVU9V?GVAK4D!J8<N16#Z%Y-F&(2)@?JX&D7ECH+\#K.SZV+V>T<MO7WN/.(X
M9'[<SW!2<*BX*IM>3^8MDRMEE\?),E4,V';MMJ,?1U&CLZW&ZH<Q@,9W.GU/
M9XU."1U_KP^A!6(WHO#GDQ &<4&)&"1-[>6TSBJ2Y*I.*-4R#8ZAYV1W1)M/
M]N>3SPFQG@YP:,+\,<B"5/S'28#3MX8^]PO,X@.0RIH=[\W>:$HNDRU7USRD
MM&+9]NO;)/+V P41F!Z!F\?T K(XEC%Y^+CM,^0R]DX;\^HXV[OL7AAB0CNU
MET/W8?66JX\D(/G7X;5T"RJ6/-N""_RJDIN,K]>?\SZDUY&D_H X8FHQMO+F
M.A AWGT$G<UOR_U#7M!_"A2-8\!7Y%!/>C)1>7: ^8 Z)BW: &EV'E/8%!1_
M]#+3\^6$JNB9A1.#;O9)T&!Q: 5#=N1:G!F-(VUB&3]]WK:"-N:(:P;O1"A@
MQRV<R=XS1-N1*IG,M*' ([*"I:#LBC 7P92IS3+B"FX.Y^:=T3\>\/SHJ?XB
M:)^H!X8I["*: CB?U^8/KC!K:):\SD^F42QYR=?2EGN-;C>W=I'[><3AV0,P
M,3W77-<Q?:^R_RY="@\0!K+2L.C&;G'S%P8*:,LU)2<RHT&@:9/H_:L(_D(K
M?'?!(Z^@*G5-]=8LT\.JK:6D==F^Z>[$5UH^TS0 GZ(,N2QOK1*84GCV?O :
M_@!T=^7H$][9+3P @Y*69J+ED I>[-[<766M-DP-(JKCWO,YM:/+3Q5*8 K1
M%:R9',DCAW$.\VM8[OGD4E$QU'"DU<(R)_<-8W<R>BGM#V)CNKCN\P^73F;A
MO/)UC=VW%PT1)O>73#K-DH"M)\ZETC+ED\6L\\ T#?5%Z0$GR?=E7:Y&ZKV,
M'JWX\/X"7;G[LO,5A8LL@[N_-@84=H:I17G(T?[;5@(-5WK_@\J-9$VB5E\G
M2O;2Y%-06&6B<JL#=YX!^JBX&L2*.6C-E<PQ#64(&2F%#,(53/+*Y#/^1R>Z
MQ$]</SK&?C]M?V42JM;%AK(8'@/5<[EE>+)1F@-OQZG\^0#D1>^-Z477MMPL
MA@]>J;A4./D:4II^S0DQVI\(.SLC9Y,Y11R?K%M];==I'7FE7');^A7/GRQO
M"?WD&O>MC8L^S8EV_L 4#LX*'?"2GY_>FI_*D0@/ 7U60KP,9&<Y)L5QB"0X
M-6[[5S5C!Q7\S!AME1U8-&A-,L.E5(8(,/9;B4;F"1A4*)[PA8G91C]* A#0
MG3>'*4/N]U2X4M"EDO3"YB5\_I5V7UK=;>O7+FL7I05OQO:L00YX64P'/(!F
MU50G\QHU3AA_HUW"!G'$KDGE]1,]'%O4;\.X+<*,<P*#E='J1<VSJ&_*J'NL
MPR0NM'!]1+.X*P,N.C .,OA4F3?*]PV7O%6<*%S.*&(0$AW,J]9YAO#;?O68
M!JY.^R!0QLI99246B8Q>/(>W-W37B<_,>[L""EZCF1-6/QO4\-$&7YJX'TOE
M#B7K/7^V'99YD;=,,)@FQ:*A]@",:EIT?'T ?&U1:+P$@.)9H=)>AB2U]"#A
MYJ;/[WB68[L0Z*E38X[2WU:])5E!K 87;;)#"DGYJ$'"8D1=DIH45%(X;65:
MLV)5W$$R6# >EI$:0Q/^LY4"'?,\&RL;@IO X(3S7D%+>LN]S521"[$DH-0M
MLZT4W@F">^6I9]71R2,<V++[R+2 N.6XU(UK?/BR_%02V-^J!"C$&'Z+0!%5
M6LBZ'_=1F)<I0Z&8>>&HB,;T"IG*)#)RYY7^^'X1R0+?]Q+TS\K:XTC&]O Q
M>D#/Z2P-)5X*@S#E?%<?.7$]4/Z6H(6O:^YB-VSQG>P@CB8WU/ZP]S6B2ZG4
M6\/>+KL0"IDM!8WO\R_&#*K;K=23Q-WT?"E'"P?S)6AA>73=3/:VWJLWR[6;
MPXJ(S%G8Z,7Q;.^/&$S">&AR>\AM*I8BAY/B-L7CIF%^*\_H?)V$& ;46(MM
MPMU-N&T];&?2&V465OM3>+J!4&6^6N0TH=,N:\;,I$R%W,6YIQ[Q*#L9(*K4
MQ UO:FWR<Y;= .J4:.>O"?[4Q&2KIC1V/J;ATI'G]%#4.9GZJ/E@*WYB\E_/
MR /S#!M^U46RT*LGZ1.I^H*G.QB  QAXR2:\J[ Z #&8+-3!@[10'Z-!(: 7
M!/C-M_#!V,'$/#S[=K;4*E*":BOBX.6W^Z<%I<Z>ZAI<-W)U_33B1J$)/I^(
M839?NUQ3)S[(U6D*EC+Y,95.K>_V18BF:)!DZGX)TRZIA+A_:X']9LAV/7TT
M9ED"7X^!(X;0=WGVRU[IU2I%82ZAK)*7#H*D7(0RGG;PHAX7TF8P?S<8XP>6
M3GJ&WE6GSW>,:H#[NOM/YF\,B:Y!NZVY^PY,<MQ*5)SOBH1L>T:IE/$QP0![
M[V:Q) ">Y5>-=IBOD:F)>M\T8>FI6]^[=-JS6L0!H5-35<4B"PB@0?\>L27/
MBRE(4=OU:GA!C(:7X(+BLR2-CXKS.#LZ!YL8-37RY*/D^ GVZP53JW<2^W[3
M$\S 45OE0][@(]YC>()RFJAM8.R\*A4.,[:U#DY^8BV8ZFTX'IC>RZ)._W4)
M.U%H[Y?6$Q"FE"T'7_<8-Q?)2K>'X]*@%6+/2U7OY565KCE;SA9BXK.?$'T2
M_@Q.;:T#[RZ:FB\IG3&GO2TM9US T*7T7(#C/)P_V?@YFK'\-"4KV=')YS1_
M60[I1YV$41M_I]&GR0SC;*%"/X(Q:GK(,UARY:'6$F1@>?-?S=1L#@>5(]4T
M&U6''I1 0H#B?N,K0ZTHT0"(T&IZ&FI_6A\!*X\S\X(J0V2/IHU>I\P2F:U
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MQ ] -,[?"5:*#KOO0*+'GW7O&;U%O'XV>3\ OIK+X==(7FL=_YJ6IL#]\7W
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M.P&"NSL\<L[<J9ES9N;>?^Y]K^JO]YJNS:*7])+^NG<7_;KP^@. +"TN)0X
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MW6QM*W78[+6)CBX@/?HH=(I+*W+8/]C/83O2Q+[I(-2I3X^G"5'^PR!F,1)
MYRA"H3&84HZ=2AL,WUWY32[VONQ<.9YV] [QD/N81[&JM7JEC8")S3T;AJ*F
MG+TI+5/8\B\6@%K\(2ZKH\-!7P3B-TK]XBJ%QQ>9HX<_Y/#$'@6L-L;7IP8
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MBR,K,@ $%/SMH@@.^G9__#4("0[Q=I6$ L' 8H9&X^!21,;FQ"1F$4)G8S=
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M"H10:SLK+G7T74;[6S6,N\\B<KAM@6EK[M_U')43:3".%KNGPSYE9(A>*LJ
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M-SZ>Z^ NPL*<.ISLJ5&5>U;DJ,57@'%)*@FQ^P%.V;33*$Q8OI)*;*-RUSL
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MYW-@TW3O_L:=ZTNNQM:.(^4):%34&%5DV5=2(,H%6LZ5/46IR+YA^,[C\NA
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MQ_QDR.XW($ZNQJS^0S,$[W86'^.63WG(G!KI%5=MNX/EQ$.:Y)7*-%,#7]C
M!']'G_KC].)O"*J\+:ZW<_B1::ISJF#V&Y* :UGCOV'6OD/@=TBM>WG_#M[.
MJYO? %CNNW_T9S,VSGB]-H9<4Y'7"W.DH@!I5_0#PK"]9X4_;>1^P.%7 (-A
MEY6^MV"$_FKVU7WDOY!I'SS7V7*I>:",N-2MP:RMFN_TV=1<U1;"")"&2%*K
M(D-EBB+>J.)K:M!DB3 &C^)!>4\[4"6((@)\O"L(W@@M.-E&Z4J[-5)7#2&O
M3^Y'@W%$X@6>>TOUTP6=+0PXC$E:MA?&T@N4IO69R7EWN*&?K^>*)EM]$SK>
M.4YHT:Y=$6YS3.B?E0CH/FBRTRSD],GARX,%58A)AD:/KOXXT8:G1Z6>1Y 4
M;HQQ9%@;J5Y0ME!.V>PP>/P,YQ1?\VDE(5Z&X@Q"UZQ65BPP*U4W$&OOOQ+Q
M]CLQDU#DOMNKVQ1PPWG5$)P2.,P2[ &ZMPT"1$!TLV^&I,QT/!A=AWQ8S7>I
MD42C5*]V^)'3431@648G<KKOY^R)/R&I@Q :OJI\@&&%64VU"P!4DSF399L@
M@[>PW[ MUP])>40AS/9JHY 3MX%+!;$P7433&GYL5)T"N9;_6AQ^SHDE17C+
MW6D-@W+\I$,LK%7\.DS $QVM\E#W_5ZP-38- #%DS8[S"#?/8J6Z;Y-FP)&G
M43<)W2RHDIYN. .ZI<H;Z$!#DXD#E.U=A7F&.I=YK'_)9OGST35W+[A=P74L
M<_N)U+&@7]85Q)(Z*%K:H%$L\<I*1P@;;0,2D/)3!(WP[H7&W\U_>H=1PA-%
MSV]HQ[U3S^.(:USS>O9AG>JI,>2YU/?HGXJL>\9&^9H2#=K7'X_Y&!]2O[#Y
M9ML9;Q%I29RG'STZ$V$_C A&K9LOI]P-S2D]F3V^6QD:?%<7N\6U>+/SCN4Z
MT1^G<Q+(<AY;D7\W?N/;\J^,:5>,N.FKM9HF+4CSP*02O.>13TW!27E@"WLA
M*H9M:-6,YI.;I1,9" 5!H2H27 V/"\_>8@&^8_8O[[BCO8EN.?_X_.&T1Z/!
M=C**Z.#4#[8CW\['X!6@X7VF=HSGO 7UT+8>5&VQG(TM.+OVA.$MOG+7\U)U
M^Z-\B7-W$.G:O0M"[_L_L&:C"^S9H>1R;S4R[B]?>F?TIZ/MPP7?CL!VAL)Q
M[/7N+N*?\T=VM36O'[IQZ.N,@<="SYMN$Y_[7;RR6%80.6D,&7L^ "7. G74
M-_&G,IZ3W%VN1OC:P $^(QDS9?_I@1%'+5=5![> SJ;<0ZHVFD?\H?BQU&=1
M<#:XKK#%09:R+W$8D)D^&.'%'7+A"GAZHYIBAJ1\PSZ@Z7EFAC@G>6:B8;5X
M6'3S"87*#$"RJ,)#4:H?(V(#[7L&(-T'FF,X$J*R+HELF.V=TH8+%29N%=,]
M,;.IZH6SD5O:])N0P4@N,,G#PAHHJ2G0(!(]8\:G?9&8:_KB@NHA<">Y.F5)
MU2$-"AN'WVSF4D5(QYZX)3.8W]O#L!)SBW+A]1$%LZ&VEB>=XY$)+PF7S; S
M=,"[ZN&,#B<+911I\'A ]?2_(Z64!+LR7M/J?UEX!>CY.?R#Q K*4V(-P]#S
M8@[1;IN]*S<UPBJYM08JZ/PO=MXJ*LYOZ1MLW GN[NZNP=W=I:%Q C0.@>#6
MN#O!W5T2I'%H@CL$=X(F)$'F_YXS<W%FWM&K^=;ZKI_Z2=6NJKWVS0/T;77D
ML=-( _ @\>F)O?]-&[.VNP+U-Z[_5)-@Y!/GZ@(EN[2&]?["%8W]IJMAMHJJ
M H)/W.?C:3+8FZ+PO44V<%\Z_'/!KZUY<SKOS#$6R_G=?4V'- ="%="HRE]8
MO>W.K'N+AZ1;YQ]%.,%'TH=K$IUXOIZ!"&G%TJ-3%%OYN/J7;H;MS,L,H6R$
MLXMG?M#,.<*T&T-.MIUMF]3C0O^<+^XZR;D57VSO]C/HF?!IFMMQ1 FA_A)Y
MAWB1<+2SOG,YR. PW8J7T$BL5W/$UJ+/$=UF.LZT:MO59$W5S68TIC)J$-I"
M1)[E8E^;T%Q;4]9'SQ0FN# ,1%3$1\'Q,*L)/1WO;XM[:7GM?]Z;^$''/K?V
M#/LU/4<9_;N.JK?OT&\F:%JD>)/Z8@Y&\7^X3[\H!?]/\/\@X/NN#.HNI;OV
MEV)WW[N(GZ>OAL5M5[ =[9!MZJG%?Y;IYM2[S;+?IB%S7>(!,G^]0]FUUG^>
M?&"1=D\^<OIG$5\=H5S-/S=(.VP6]I>\]$IG5OVSL/^O*8M^;H!=)3IZQM1M
M[.BKI\"Y"[P(U,-T]"?H_J^<,:7L^AV]RJD$R/L]#QG'>C7Q?&?%N\]")R#I
MOW[_ML'[!MC\^B]OZ\FOV_\FGPG]^>/?@L W0%?HOURT4;_T_=M9SAO@:O=?
M=B_'WP#N;X!_)?'?,#;M9[>(FEB&_-%#PBC<R*Y\Q\I-T#PGR;LW]RL4RNMV
MVF9JE6A((8$;\^/F.#-FR'"/_4?=K";)@OS@,HY8*4V"X0U&;]2W$495(.D'
M'3T0W1.\/GQ*'^?[SY[L-OF7./5TFC(^);]&A>B_?R;@N9"SG)H\E:$L%R7B
M7,'?-S!U-23<$6#J1OI*6-/QBA3&*_8K8;W;GFS(?D4OCHD@KY+0OGK%K7F3
M?8)K5%>M;H*)@L@P49J2%'>L(3-BR8L91]_$WD35CHVPMN,2*UIJ"A/[(!.5
M(1EU#"WJX]D/_8%O9T#:-3>VOK]<0JW-2)+;=NOUAB()J;8VV.T5 PAH\;ZH
M2?@-J3U/C&K,OJG#OT1J.'WS<6-H:W=X>:9FV9<R!E>',WBBJD@EM0N/3)SM
MK=W2+/J%.,PH%W/402P;PB3;6]?@A:7U5-5E0*D2C@*95Q+6"1[]5JQU>SP[
M=/J[>YBH;])/JI+*K'RZ8ER39JPV'GC,3A>Q6QQY%@3&7R&/F.U^IZL0]WZ:
M""SS/8BX0H.]83^EV^3R=^5"TE@X,43(/@/TI,3#N:I[!P-?.'(7*V%)OT""
MPC6^9*II:C36_#UA&E&EM7*4[*+5L$<W\,(&Q\:V'T8>,AM3_\TNF/W#S-@/
MKX8+DE&[&N&DR.N+F8*DO^[O4&.6ZH/]"_=,$FC/>,N%>ME&C(81MUCBB*6]
M?4J1\C,O!">+>UCBHP,Y1,\5REHW5EP$G(T;I^'00JC8V#URM[D->AQ9;+ZM
MQ<'E9.T].1 #L=6W$]C5$GU-EZ883V5,& H]ZS$_L<"K2W%H*E7TU5@".V9P
M":,W^IH_"J3.9NU^9FU>?C^=07"@D>ER_120U5%13AN'!>[MLL*LG18X=O<T
M$.1R_4 HN.W$"'^8&$)%5J$^(J.5CUD Q5R&!P.@-I=\YA_.EG@/;\3WV)6A
M&R.QX4,9^I9FA>^G2=4]4:!\WFK$:!7A([:V2RUNR%OIRGE99A 1&E=Y\B_8
M6"L;M6=.1&=F^?*VDR18+6S*]81YA6K9'Z(R39P;QEC2V2=3SIOA53V$!(8J
M%#G,@+U8*%)O@'=\=9HO#\D_RUL+[=J4L[&(NM/M4\/Q%M;V%##L[-EW4[&5
M2F*P^[P>ZP7<9#:W@"3N1F;Y9*G :;&QLS@ZE)D/ !)PI;99]T2RG2WQAYT\
M8=/ICDO>/7;W+%600@IWHSRBP=37Q"=.!!H\E!LP;VOS1DQ,4!U'L*$R91 :
M)&XTSIX\54]8O*1V>W_#;H)>.0'_ICZ3]%?DFALFKWNU63XQEZF:&[=(,UIM
M'@A5+X3/)L9Q[4P]C@].5JG<3@B/P\@'B(,7M:R1UA;@^5)Y8Q3_!Y>?EUW\
MO9:J?T1<JM[@;G\DE(S%9L60:,R=K7ITKSW-F>S6S;3"33S[YLPD*C7.,NU]
M&H29CX4GQX"#MBT*BG0K8= 7B]9EZ:^R7]DNDAR6Q* )0B>&,].\' \,+)7]
M0AF-.]]@W2AWM=S\<\!-\;B]O $:#$>G,<]KI ,=$),OM:X:(FRNS1X2<AG-
M6 W_2D1P83 [2I!N,-+CO5J?F7[\K=:O5+:@HJ=M]-+8@'*?8?8QP^<6>0 7
ME'F!GL>ZBX: VVL&#\7YA "'@H6<5(.%F64TE.9HYG^SG\&],Y(&5/@ N?AA
M-!1GSD+)%7):=XBYU8B5D"Z@@X&NTN%[.7S*$N4D]D@P<#2MP_>W0>4S.@E"
MZBZ:X*Q$)%31VMT W1&:UG\H^+V!4MVLW'96V"1EMY)6\U/6:0P;K5M8!,D4
ML!]-.0-G)@YS"$U)'@H]P<=_@#X)@7CC_V;J%)V:[?"]TK5)WIX+-GXA4H/G
MN$]! X-0)-IL-"W$*3$E7,U&QMQN,Q8=X\=N)?BM9!3_JL3_#7/.IHMIX,['
M*O1H93@3_61/9LC!DZYYV2 20N!5L5:?>=&BVB?<R54HTV1L$\+OWR/N&[O!
MUYV&VZ//6H:G>I^R&M[NP^N>FB"P#9(+R8D2@S<KI:B.ZD3&!+(FO0%L^YP'
M.@IQ.%6FUG%Y=!"EJ').BP^H*Z[9,7<H,(FB4, %BBK:+,'\DGRT^))2%'=3
M8D*&- \MF"3FU^R9)B:84[L6D>NV16)EQJT4<F)V3.)I:$00?L=1B)^+A:I+
M+> V3UL(#2N?A^Y88-WZ"I^)J!"%2-&@Q_)"R:>:MSK^0Z.!LVQK8\;\HEW=
M5%<GU5V61EP;5C99$BETR(^'-F7,3)-G8=;>,%=OJP9!5N'6Q#:+7":!MEGH
M\]]QB;A[6^.@GW&3'.U*O0U+$VR/FG4$&3=\7&2#J+D,4P\B'!B N)@O^XR5
MFM[M<X$>"G'-<0O*#6P^O&6$#[UXD0@$1]?>O>3(V,I=9F230(;)S5G[G/T5
M: L"Y590.?*[1'XZL4?,/#!K"N@L29Y@TJZJ.YBQ@)G(68%ZO;9S5":UQJUT
M_Z/_3%R@+97@.@M?6A.WG)]>)7T/ /=7FUN;O>_?'.?*_F@=,7 ]!M(,=.;D
MV^>TL[."9]SY=B!G./*LJH(-WV2-==C=5(JBJW&U?^(T<DO!K"6C%J,=;JT\
M/!TOTZB/T3:='WIK5*]-WZE"PT.'!5:4\D5 LYI/?\24X(0SFB+'4F+PQ3+X
M#)HHKD6,?Z%8(S@XV(^S)H>:D\3(M9UQ1(U,A]-O4H=31%9CJDMJX1=/#8U?
MX\ \1AY< 0+(WF.Y@45(J')321.Z87>SE:L-AB3?Q(8"X0Y<H@6O'6BS;_:'
M%1VS/6ZNMF!*2&*=[FQC(R#G)7(APMZ/WU \.4G#H@F&).H0K!#2MVHO@-;K
MN<'L@OQ$+DAM@N>)^>A;4C<)W=G<M!'+^<?=^9'>/76-6(Z3Y]*1=OFWR)+B
MN:H(@@MFF+2]ZX,,*1&<;CP1V^IHIP"\!?Y*#/W4 Z%->]_\7ALD=YP5&?'L
M\I)?WV[#X_B:QWBO16@Y?T\;L;-@"35J?%*-0JV-_(#FU(2UV.];>*&^L]J]
MYM&!;+>.BP3X!)$_^7%N9B]K%UM3<C1E&1-]RZ6?4I0.@9;1 WAL9]U,(#@D
ML)WS9O0N+-,*A>7VNO#RA%@S&_Z\V>-?/9?SN:C8#^\1Y^0Q<PFRV,7,",]T
M*C]$$$G"66]_+I7]AM !@AV3,,AZY9@HST0W\//2QJ^AZGXW$%PU/I]5B?:X
M,@LT=R-QI>AIF(3.6^,($/9NA^O#[;!;BIW;@W7=#)PPT#MR[.I-)>&/\$RS
M&7O!\(SM-F%B9BCP9!]7V[!4PK^5?U8R9P44H[%XV]NX(MAT%&B"N6S:"QG+
MHTK5],/V75.06 GK:(@=:=%BE%7,+<^NZ8,*#EP_?8*DV[TWY*'%;3)M$E4O
M&8J:M!EC@GQO927'=Z;-)7!.W%/WX\.O*I/XXWNPW:_G95G^>7F\IZ"<$NJ2
MEFA%_E?EB#?#&]M35-.GA7E9=P&^3%MH&LT5+S783%7[L)=F7+<<A\S:FX1Z
M&&TH5IF* 0Q ;S)M-:Q3(V PHRT<W%[S)"\XR5=& N)II.+J0F61F=!$VG19
M8 -&4B4I>IU[3E+-,Y.(B!A1F%L\<9G'PY2LHHGXY>\5_'/C_7U7ZNS)VZ//
MOCTE*HLS55XH1 J12)@->[<"/MW1Y,:R=,3U;O%H"&8/D)4&1:7=Q\N.EM&N
MTHCI3FB^IQ,CJ"]%1TWN)XQ@FZKC$6__,AI64&5>&+5B,J09X!1;.\"+@(_/
M7 #SA/=OTR33,RTW#03U-0T*N?&">#IA\OOUG%ZEAB=<W2*#Z[GG-JE!];IX
MG0OE1VE.-9\\7?VB9/@MZR8RW4!<B+@L7?(=)#.3;&J]&RM,%QY# BN6#\YQ
MUT1J,%8,(DB,^:<S-5I10.RI;FLL"YUT8.V5?W\VZ:C=].8B;H7':)W(W(C8
M!FZ&]\/)][@?PI+37ZVOB9@%85".M;3RGZJ;O:BN+F@+.OWA.3DWT/'I+I0H
MGYE J57W+2K"5=[3OQ9]'OY&YN-E5[Y70WL68*KDCLW_&?+?A[3Q!,8W)KB.
M9A*ZN<3/Q&>AKJFRHLBP'W#[FBB"^>OTU=W^_^CZ?Y"0VB@VO_"!]<Z_\0:>
ML;5+LJM$A#;E\I-3X*U8>24MG^+)>W#C!\?YJDI@A+A]G53XOHK"/#53X=;)
MP\D;8!Y3J"(HF=&DOU[2HU0$+&><*@,8WA=LJK0N;UO^CG:ZB7.X["J!(6'#
MT<$6O5I#>.=6J$#7;6B([>"O0X</;S+CK3A;Y88(.._4=2O(X)0S5"_8YT.E
MC1.%V?)1_ $)L77*:?;^H'1E1*[@\6D'T62))GL/I9'00*:8;)G$@*#%SD+=
M\TX#N"KS#BS+Q(]P==ICA7K?1(_J#M?.-W2'ZNL?:WK<-YRL.7/'/$LFK+5$
MSA+Y1<<U5V^"NCV6F1M#.RHT*&FV5C3B<AJW7;"$@*Q+U<N\&9=_5ER4$_-^
M-#&20B05:UC^*&(JB;S<=JB3S8:UNZ,LH3_Y%,C8;<R$M:#.BS>G9XXIH13=
M^!SAWF*XTF,TQ*4VK*55=_EG?@8U[!DS32K*W-2=A8=1]-4?'@S-YWIIMIM;
MP(VE^<8>:O :[1'P6B2OR$%?X'$SSFY319_3-CJU:=P;'R*"33K4C=N.KE''
M:'JE(#_MS=B,13MVVMLX-XVSX-<+',@PHQ';DG(6^><76PQ:Z4 &.S35YLUQ
MZF'FPJ,J&4DRF&^ Q>6LKS_!ZQE7%1XG!JT51*:F4 $BDR<^/A+2N<.I0-_O
M[F?\WZ\<C8>:GWS/X')@J-.*LOR4O/R\I-Z7YY]ZVRV[\$W H36\%I_1,GG>
MTYA:S,:!/HIW/_$E\A? @J0Z\A;H07T7DXK =SJUJE*I$;@PZ6#7\ZR+V/SS
MM??44&'&!/S3N1YZDO#3L]/?TLIQ%(.QDP1/B+8@AZ/3V+,;[[];]!B_#%;P
ML;?<63MW&G;N#4^7R/A6R, [#G6BT]P)H@]LA>-G&<NMIY*ZY.6">=^9Z5._
M\=?)/Q!9$06+$YK)-OPV]"_3CWY*FS#LYN0CGZ0D*^G+I;@//[VY(FC$24U4
M8X#O]J2@;:4KC4MU(L#6;HW-C2@ZMF6R#102Z\QB8S+TQ[C;PJT(YYKCZ-*C
MQYFYA[0[%'D^7(U\U4/PVG;"$XJ^?&1!X50<FN;!A0GBRLL[D%X*N.=,(HG+
MT[4XX:RZQE:7VIGPPV5PE#+)G_3DQ.44):8;SA::2_JMS6<4'7&XQQ;<I7UC
MK)*HXGB-VQR:EZ+\/_^\[E/?-6H$%N^V&JJ>VV,>_'+HT%><$B+P0J[A G]-
MD7+:4H"]K^]Q><P?NZU\ 0-6TFNINQY*]5SO9'W.=?@\+5BD][V0&5=44V\Q
M:SYF@]C0(%*J"6^Y&FO"6OZ"EE(.!:Y)L[J@-'1,:"!*JI$1B"4O=(%;5L$B
M2H>GNUGGC3<<2WDH_S 3\EI8.A#GAX7JO3:GN4\0=&7B4.63U7]W-JT9X'TU
MN).H(W"EF)O#?7EU#:(7#;\68Z*OM W&;6=M[?'F3/O,R; &OSWD[<<7X!1^
MEA17\ =X]KOB8M>K&'71(9IVZ/T@5%?QX_+GS+H0#BQY1#W^/M%YE REL009
M:Z?O-X\;"%1Z.L577?!7<6CI"Z[6\@ '_JURP??8>OC;KOVF)E,+%K]05VLW
M'2N02O M^@:V2-4GCC5P:6<FON"FT%<*#-;%*1*<CEVO=M$G?*/G/)60X??]
M?#B7 -\Z48B>&HNH-1IVC4(,7-8B%T?C(AI4PKPPSN&5GU@6K'I7FT'*\G@*
MBDA99L?/\F,(,@)J/!?V./VI*2++C&L=/"VPR9PNC];J;7;9K5<OJ0I@Z-^+
MP14F%9R/B68+UP_J,BDQNF6T:*5%9C@>K!$3H:5\[^&:N%-?SI<)[3">(&;-
M]_SF[^)QL:CL5^+)VRNJ7N&Y4*T+DAWS(%^9H!X)]A^6J(L.G6$-_<V^;O7[
M=G<X]"H:,;1QB4MCAH!COW$WOD?)T.[2G@X#UD*@[HW)8M,PP_>-/8V$DA>W
MD\O=0L*COKRR(A-JY-.OXJ92I# 25*RC+&KB\FT6A;;6D)GC6OGG6-,FAQ'&
M"/PJEG8$)OVUOMQ =@+2:#T(0SZ\/0SV@V>FC([C1\U!C%>LI;"Z'SVKVZ;!
M+G;4Q6SF^2JNA2!DL!B*!P(R IQ3\2@,>5TE+[RQ<?+H1Z$]UAVPLW+YH]2A
M5$VU%%?LE-@W $@XS<!,WFIR<=8Z@B.$9=(/GL]WF!WB/(6LPL]NG!T9^SZH
MA[*I=31P"7Y#X=TOY[;:(M;XJ*PXN+ATAKI2:Y9Q59C=*XJY>J3B#]=@2V-#
MIFD) [RL4F',SH3V1N5N.U#1O3CK:>)E_'"5HFF6-B?."T5:@10O^LU\U_A%
M6P\-HX*Q$?+,7JHT!L?TQZRB$\G=UZM&&#4G-5CQ&[T?6>EA=>[ 4L#$5%\A
MF8!]L6:#%9/E?>H;X&E+Z57KPWWME>I1WIH50UITVC",Z5M(49RU(CU]7^X;
MP.-S174P_OR#F^WFSHZQ(=CN6SQ^MXH]30_9Y?4GAWU8?6RE!'.E0R4*VR\W
M;/[)7MG]^(8AHC$FO@4'03>BTE,8B*FW'?81EKN807IN,;8Y1 KZ6]%FE1%+
M"Y1^R$8QK^)HC86+[J*=IL7+(8F-C0TA=2+NT8@M>(?A@-S+(FG#,"G ,$V#
MEQYF7AT96P*>L0/'G2I,RT#NW'/ZQ^H\#'ACDV,=!%UA96^ 0%OM!M%G"_XJ
M3H<:9ZA9])(1\T9%8;#N+RITVR6@A)F(7D@36:J\/(GFKT#RS]\FS ?W5WY+
MDWRA%7*B7&>J8UII8[.TC4I0HJ'%D[RD:OVM)?$'G%M*D@G!Q\2$&^QDNDJ#
M(I)T""@7*1A?3MH/:)?2D9#R!XJW;+<2TY%4G"I(:7_%]H8CHM4(.C_"36<D
M_'R'*'TU$Q>6<B3V" OL]36;7,7Q&(28GC"P$PKS&?(8YG+Q33'W[. S8-K"
MVP+,MD[CXM2WZ_S2AY(W:A6QNF6K3GW*G?5D.#[F,&$.]8%["BT0:<7*T\RZ
M,54'S"*213"+XVWN8] Z7'.MM] \5V)S&=F,*F4LQBYI>VH\%!I7?E=-J7:;
M# )1G%,/,0GZSQ54Y<@[23']\+EAUM%&3>6EQCAF-^3T%EDN=1E(D[_EU^C-
MT:_4X]!S=!CPK@Y_M ]FG)):1U]"E1O7AV^>L;JNHJ*36%F[AT)^"F-:=!0(
M1O /L U;V^]-)I 4'--497R'<'68XS5!F;_BABKJW4 $E]'."GXY+_7,C:#K
M'.%+4@OJ=C]++32LY! S@92TAR!#F&%QF$_6@[$.'/'\,\JJ-*77PJ"K$#SV
MA0I3LZ^VCD9;&/E9VFXS,%5;^K/8@AA]S4^+.RT8U] "[F .==WR8)P42'P9
M;6XX_775B*2HP_?8I.25YF>%)Y>XB2BJ6\48UHOHBDE)/C7K!\W<5-)K98<R
M=5@N;?H15IL/?_Q:X*)2$$MI[X:33+>Z1F3AL=W'K118?^3?;LC$HV7OL^RB
MVSH+4R=0DK=<$=%:'C%$!C<V]F;FV3:--:WXJ>P-"C## <##P\$AP:.BHB,C
MHR"A 1 0X9'@D &X>/@$*$*$M#P"&5GS"W3TVMX^;>W+.$0T#+R",I[I^ZA\
M[W5T;1CYP;ZMP\1,LM9>81WRMA[^X\QR>@9^X9\[Q_[7__\C2\._ ?I<G-FP
MQP//C1BN":1?:'79%G%E5K2%T=T-([)%>3[;BA3L1X=@EAO+29@Y;:)O\[IV
M:'0_BKB3M-'5BE=R>6^G./?C RWB\I32KV17<&Q _%%MYA(49IO/FW#'R84Y
MM];FGL<@Z7VH\*W'&Z#H:A-D5V"#>A!<(6K+FR3]E0]V":3^ZFS$4Q7IZ5/;
MWIE+10.#PPWA-Z\Q6 6+*ATKB/!G>:".4VHJX8##PL'C7#K(FF@@_.\%#D,2
M(3G3,:)[6=*NX(/-]%EJ<3]B]B0)&/6MQX?][=>@+K<#&.]?B=#=ETUE8P8^
M8R!ISJW(L>=8J*(]UK/Q6"@(G$RU94,SC?5['.>$=#Q$6E.DK. @1-I=&K1(
M@2XZ$WI!2SJF%_,J<B!^\%_&FZD<?Z\G$R&-4X& KQQRH<3O?E]OM]/)8N,Q
M^2N1PG@G&5^^C8&_F+P!6'X\HPRTX"OJ^-8NY2Q\ HU3=M3J7TSQ6E]@9 E1
MX[XKR,>+O^6(P4O'(5BKR^2UT17S+K;2]I%)(6GA;VK<EM+=CH;77[%@METE
M&)ZA2FD)TS _7"!0%24B;^/=]YS9@[Q"IDCF"/Q>9Y_^V[SK#..]]&[U#/@K
M3D2ID2_L!A0$FTPHK.4.%8V[!T5))\&0"(;CD]PA+/;UA,S%8^=>D&M&WX4"
M(*QY:B3=TNZ80TU2WT4#T(+LWSIO:,HVE\L7;UH(97;U6F,U,C- YBNR=$MR
MFB057NB)BNY%[]V*8XPCM<.U^CYSDP67FV*;C@.)%DT3R6ACV3?G&?,#!8R]
M ?Z*;(K"/"' \8*3T3XWZ3K$@HN]CZ88V+'1"7A&C+MQ,<4D&,A09E);QB.,
M)/&*U&31[]#_OK0;?>J:S#=1A9RCIV@D"17A&4GS)3-8$MG((TB"?]),<>!0
M>*/Z4TI31A$$_LX@R:<:7XML(L9F&QC$T/,,34OL(Z JH*5$9GF2R(IF@?O(
MU;3/L*?>.57,QI+E3C>89N7V+[&  I(CZUA(:[QHU6^2]<S8$U1[UJH$-RB0
MF5 XPT(-E@%\]&R]43E\B0V">4AI/PV$T;1$TPP%+V5E[?@RRE[T$*.,/_/R
MR&@B4H7*[W%HDF[OP\Z41,?\'%QC<J3<Z<=3/<=S_[G3$WAV1V/_-1)RB#3C
M:6J1_@4'%#"KO1@BSU'NN_'D&V=3P>@9TX69%;;?&C@VP*F-"I>HRHRQ(649
M!5 )W^&^F8B$"BXT JK&63;+,C[.(2LQ.4:A-W<:Z=^6>#=WF201I&\4G=-@
M\*6BI;@O0N;3V8;2T"NV_N0<Q;&G&Y'E=Q&''I75?22*FQ4F/!-:_$&$CB]5
M,-+84O6VJ@^NWG\CDQ"!2BF@"VQ[QMSOZ;HVN?+P4S94,"<-UA*4.F8K&:W
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MLG#1&)&4J=EJ%4 6Y'#3,\GNP NLU\CQ#6,6=2J91AG35R=E<?S_T Z=[]X
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M)UB6!CI;=,N044O[JRR1IA<]&^+VO#+ ,IF.6G!+F[ _M95&&Y -]\9].][
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MWX'_+<65J]3OL5KG9$:;\!,/J,AK[IQT&\GF@(_T6'9/5^!Y:"(WV/UQZ0U
M9GF\?5'S*C PV[>J]^P4E._76/6T\$OHAX76;<6UVTYO\8':UG_B7(%DC54A
MX#YJ2N[%XC> PR$<F1U)B[NP4TL*)Q6=-8_!DWI^U\'W,?EH_E>OL>VEKE=D
MR9>^F@_/F$%__71WGTA^_;RN^'K#^^-J6RWT.W!WL_>?= ?'OW;Y<+X!PI)#
MW<_-W@ (5*__B70:OQ0X2HNKL\'C&5* 8,H=I5/HS1$GD-\G7W[X2&WTTSQ
MTNA^JJG&[Z]E_1_*Y-_!.5\WY%XY@B/_8\!".\[G/J^] ;+O:*L%:3@OP4XF
MM3-PJT?6-:8#_SR/R45S1IC WB:*]@T4;82W),<.N+345*7-H3H=-I6U<\8#
MEBSWEFH)LIO<RX,!DR>9"-^']FV;F9&!]+*>D?+J7KY-A>EY)7F!]UJ< 08+
M9>;BH\>+> 2&+?@.>&F1M@ASU:;FC ?("G$8$NMGZ%,8Y*-7'>J]DZPAZ*_V
M[L6#QE*NZY0!]A"</603%?>RV$%(S[80&.M75J#0V,/8HJZI+_L.$LOH YE#
MV6B47?HV[R#S7N[[K8""\&%SXP(PYBM<:'O,L_%OM!]EYZ_3R<RUKP$&CUQO
M )?E8KF6-P#WH7K>![WZ/I/*I=]?%U>)5&2TUV/Q9P4'<8-%D%UZ*" F'5\\
M*&)0^5G1^3[MML\;+7683M7$1V"J]D>!<ILYZ@+\%!9;@XW1[,FIN'!Q<[@4
M J#?N?D3W."_E'27^\(0U,EVCH0,$V5LQ=%P;-A+#ZNR%"R2"EL3<!$Q1$;P
MM[%)''3-J:-[ZL0908[7,P2-GD(UBUDBX (O//W!W1P':0*.*0F3%[$IK:WY
M+]O[M?,ZX47++JPB7UR)/N:K#,FF5V@!](,+.DB(Y+/9(X-U3D+^[_)5HZ-%
MRL4,SU(2E>/#M4G-\)H!)QZP'+'@D3[Q1X-)@2)S1PDOY=+[XQ-:_\];*+@I
MWYG[O=8/SOY-G4#XT "WXXV$;_A_IS\(+5E^*MXQ"^@L?4!\O=N<[2 N8?Z5
MM>-6/0 GW=]Y[Z9PBO9RU/7?@YW_1MX8U]E5FUNA0*Q=4>>A>^&*_ Q R?7;
M _PLZ3GIZ+M<CFC.M1*#L"Q&%A3$HJNMR3'$#.#+;RAC\=TFS/M75<\O]QUP
MU8#D7)_O?:'DV?7'S:Z"LQ]:X.OM_A.MP*!BWZL3L:#%K;]='T07=XI.MOL"
M8$4/OZ2N_O?@R%98T3;IV/_"SEN&Q;5L:Z.-N[NF<6NT<4D:=X)+X^X>"! @
MN+N[NWOPX.ZNP9V@"0%B'UE[K_6LM=<^YSOW.>?'/?>Y8\[9LVJ\-6J,M[IF
M=8WYHW6^?9]>S?X)^*%[@_>7-?DF_?L'-5D?./W/. ^B?QGX!X4?E_W62,IT
M V=E=JS8!7AJ2EKL[$!TZ]O M,9^8N*H?9LI$%Y\E+2WQPXULKR\PH:ILJ0N
M<;3E6*!ZJ(:++T<4"2$\%YMWLG51T.VBF=H+1!21IC?<F%-+A"-K))4Z-4\)
M2J6.K+<%,H^ HG9MN[PI\9# "B56]K<WS"5Y;<G:]+MPV,! !Z5Y>AN:# [F
MAEAQ:E/^4'7]JV?@6'=73/)3.;4:=_6RE&(>?=*+5Q_U2?,#=N2,^0VH3<S@
MZ002A*5'4FGK][9 5N>'&>.BE#=CB[:H?%DLTE>*8NG>=V,>,DZ>=A-.S*W]
M 2,/G8403\SS^G+R^5?1UD>?!@@\/'CJSPM=U2V!X8<CJS&"O,NC$)]Q)=%4
M+M'-7/\7_47=_C6/8=_R_CJ72MZ^WO%Y<X>F0Z\RQ50;&(J2(6^4)@5'"PL.
M'\$=@C=P"<+@M'!*08IRQG=0]C#L3S%=6*DS)%9/(\RM'E2'E;M_[B$-.EAB
M0&S@,=,([NT7D(B+,L^W37[!.6;&%FC&II(_']^1V(1\/86#X]'+F.A!KR#]
M%OW>LIN_S$"3RUX".M]B#^:Q@*V%,V:!BQJ3DN*6:3W:([QX?1PC&7[?L@P:
MVUC87BA<0%.WT5@T"ZY.7*IW<W?!V64+4JP1]@M";A^\T;8DSQ[(XI[C)8U;
MVPEV(]-D:V=<F>#!OU1K5!BS 5OB-"R,AW)] 2KWW0.+T7<1IDEX9%AX2!\3
M^E4Q;-J/RP+'7_%@.['7+4;EZ/OJTI_TD=-W1HZS<0K(Q&^-?B.5/R:]+(L=
MP_K+ SIF^<57\]O];2ZE:^Y\[MB<(6391\)7^2_;\&ZU%QUCUNQYMMT%+QC_
MN@]ERMT\X$Z=X=E2>99$^?B\]KSUQJOV*-E0]3)I^N(FXS]RZ:E(]PGC]8+T
M =)?=F4'X*^=)0F/B!VG-#>!_P^>%:;_<$HD_2\D)'R(8>1\[1!*#=[<?4J,
MS:._WN[]!-RO3SL?SWRY^ZZ5J]3Z==EQT?/366R7^_] U9R%9:4'%P*GH7SC
MV5D7(<P1RC%$9=E!_*.>@<GR[DC(\T*$E/+'AS>Q4J'OW^7LS>9??CQJ_63U
MYNO_#_P)$+)M]AH>X42U/%IA[X:)!5R/:?90#Z-[ZUYC/'QOF]JJN#U9?N'U
M\;'V>;;KEYK_3G4R\J5T7N \#LF0R[C>*!)>V&W7T,H$OY/L?7Y_U.6][A=3
M1Y'A0O&M=6?YR:?]X)F3T9OZW6N'(=<?GEL_WG[Q?92STLI9L.A<ZD(LK UF
MM56IBRGK[,.(^+1DN\(RBTM%'AL_SND'1F;K\1"3)TBE0''6=U4K@4C!GT=]
MSRX6H0&[144GBV5HF#?P^+?1F"V-Q_;:AI1=#_KK55K)Z*S*JH,J#2J*F]*\
M*82";!Q&IG(1LI,3Z0L"\QL.RHW)5VL<9$R:%C@9H,FF[>:W74XW\$T!FK"H
MM@S*0B23F\]UK5:*S0C!W+*:@S$8PK*OS9.#!:*<YS'N^;72G7/(_-76WFM[
M!<_(7E2I,VI33K&9U<9TRZ5, T(5)F/TMA-&">2"4W1L$SN<4:!=*G9=LLSE
MQMIBN@Q*9SQWP:>E;M H_,198MTK?^#72EHFH2+8<3?&#&C#(#UR16RR4))I
MB6..2E3ECE^\C!F 8U)[-O= -U@>AU=CWD_O38V"N*R^X&%>!:Z*:=918)6A
MY@[Q9,O*81.-4H;H;EI;8QMQ8;A+,0CJQ*[%^^E2HG 1;=9&Z^B-%>F"G4.P
MCD/6837DB(\^FG]#:::-T6B\D9@DABKJ)^!M[/#N] ^/[[F)%:S1JWM+6)76
M-6LQI3*OT#(SNHNZXL@HDAP0RI:./1"YN/!=S+<[]ULG.I&&[A>8-0?FX6H@
M.U>8>6Y=T)M%C4MH77:SY:-@CM)G3P2CB."4.YH0D@/FGET1!V<>0S.J4U8J
M71W-;3M-8G,?UN=YUR&=U.?*V ON'J[Q>GJ<YNG0;:H06:ANB20KM]7)'HXU
MZ_8Z $^Y+@_QK%7YIIOQ6#(MA\=&L5YWS*Y*EP8BST$[T!1DLW9:FEYX)<-F
MPYJ4_-&M74-QLLB->X. <2O48$94=K9E)U8?:*$\KI*&5$X23&]3;TOW4A6!
M;# UD-.9.6H5<\G]5@V1G ]JT:WA,@J#0K> 46 B7E:/'+2H,1FG00%=>ZUB
M,HA/;B+/:O;FVT12Z<GMJ,4$OX:&EB%HT)9^K,SIN\9-8?$D17V E88"!NJF
ME]0U6\J89C<NM;0C7,)EO=9VG@E5>B+>@!DV"[8I5TU7&\5[JQ]H44D-B"YR
MF;IAKS@/#3BCHMNJDUGVA*\6B^DTAE62BURC%@)TFJ8U($8M/7H@KX_&5@2,
MEGX,70DU&8#&AD8IZL J$S>6,N71!"7>4>T!$ 8CL$_S=%YOEFV#HE^9R[6V
M-9,V,(S@N3$RTBI*BJ?"%9MV LFW+KY24@8$Q2*V['HD$ND=.PT$?M@,%_*=
M@4:2^LR/M>_YK;W::K0G5<$H-K@+BE!JD<)FR*U$C$1"BID^,A&A6#5Y"$A
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M-@R!8_OI"./-!+JLC;,R5)(>EN[LU\%1%MB4 L[F<P/\.[MASLA3$CE<LOJ
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MR[8(0U$]Z@,'G"=$>?8K#SE?08E>4F;-3M&SWDX\)SP?KF=I5B5FU5^&H+7
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M_F'R&Y3W+T$#^ $P/?\H_X*4_T!XGP9C 495EC8!^ _%7XD3_^;Z3_)7XNB
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MG? SFA*%X,7DWU)T,0R='^NE?(A^$[W5:AQ2D;H"8X*X>=>ZF8WVBZ)SQT\
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M)E9![0I08&$,8A(%O=:2E!5')DZP:E5 .5P<>_C#6^N+*3[A5'1$E !EB.C
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M(W8"O ! 1D'VQP'\MX/L'(G'"Y14%ZEI2!?47 ;.D9&3GSM/_CO7I+-!I//
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M\;L[8[Z#=SQO:<I3D[$S>SZS"ES4:RX/_C 28;3A&AAH^6'_5S^KXV-:9BD
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M8^<JOE?EW:GTBW].C%SD_>.$YPJ'CF1J?B2B(PAFQ(\,'(((G)<#X]WB_S)
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M8GFG/K638IZB0S[:E5=OLB#=%5W5@(BZGO<F["H+Q\L;]S\ M/B!35$Q7HZ
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M&I7=SI8;$TV<*)W=RQ V!J3SH4DW.H![Z@(P/&KV,LD=$+1+$'NACV3K\)O
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M']Y4H+$90L&YS/R3"$=:EY[._/HFGC_Y:R\^4SU;Y4=C?Y@;>=!XH%>4<<$
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M!,>,Y,O1Z2RA4C>TKKU-T<N7[QX'SQR,"E_LFY>.B$?/Q)4U<?IX78B0MK&
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MCJPCIPE?M]G<8M<5[&5*H,U!4^(@N?B3Z--E#>25D;EB<>_:*JF3]/%"9[W
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M?Z<?74-EI5\,R1-_#5'81ZJC5^.#[\O3#"*)<! 7O8?$DEB/GQ9/[S#P5=1
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M^;=\S,_> FGEFL%['XOZ.#9C6]=][W&S!4-(8SU$.W&JWD<ZW0)07YYW2-_
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MQ&>UBLJ,S=KAIH'Q=M 9 9#!UBK;I4BA+L\8DW&'&@Y)>KB0EC\^UWER^Y&
M*FQ.BN:& F*]<M7;F'IN2)4F_3!_P4C-.=@-S]2M\<EP[8MMSJ%BE]9P9?\,
MN_]0[-=*Q[6=/4]L="XE2!7 C1J,%U.%$MEH)_D7A1Y4_E[1=FT4<EW>&*]I
M*4?;*[1^?88=&_SE8=\;3(R50Q#$./Z)4SAPASLF.DQ*9+$>UG^NB985(3U)
M W_##LHFF[-3>(PL-?X.J&D_+-V>Q.*CPN).G,3I E+_9M6GD2]HR"WW]XF3
M_4KB"W_,ECA()Y'17Z"D[R*@,M*$O*'"LJ"K/GMU$HEM'IAXA:?A* 6 VC2#
M2P9_!NU;YR]J4GB?.[=%X:9D93YP$D]R7G8H.Y^NTUS9\)=<%BWW"!+"^.9!
M=LO?SU8<!4U;F\'-%U:U;=V>N$%G-' *#M\]VERN/Z3%Q:%57$L+??K;\Y!I
M6C508%0SVSF&O&AER5C3Z51$-)\[[\M[)>O#KP8$L83O #(9PW=I)5(!P7PS
M=0N(<LW[<1U]KB&(^?9BT_=*^&JA62;?!5NQBAN=PEU4,$FQ3K\7:^Z,D @/
M4%M;P/*6FYCO_>5192?=HTN9[>L/I1K.VGA6O1%+S>H(OX"48G50$\_1WGF@
MX$"BPX8\,%ZCQABG7LMTL3 9_:@C_T9<^K-GE%& DT>.*]+H*NQ3G1W^<X6&
M8">G<YCAWU7!D=-O"2)'W]>!/K%_HR?_,S=],LSF*7.7RW5O 6&^B/,FXR,^
M(NSJHKV2SPQGTLZHG2H_0[:-1'J2E/THD[N6I@<U$,>3D;,GZ&DUZJQM<L\O
M/$$\&>QQ!S<-.^VC"FQ5O_SPI>/ZQ)R2@+/)P(#_Y^<HF-RQ#&F%./6X2Y4>
M=N#^QM35/9S/@JWT06@<V@DHUW@@S9+-+ ,X(@@'HJ(R:5^?]MIWY51=6FED
M.-B#SPTNC33B[VVF0@O?T+PD28%<*DNGH)1CF$J9\AN,VA*T;H:-9>>1\Q_
M@O0U,R29].U[P?B8T!NRK$?S^C=C,Z()"CY_F<IPOW@PS?&>_M 2B8WW>^)L
M$J7E<_%-6;@A$E$ICX]1=V:DFZ.7.13S]&>?=MF:@CJ/TD[-/H<3:!*6LD6*
MA^#4>4SH:KH:8SA5:UNNU%^(-JIH:_)7"@C\R%!I?-G_-GTIU:6.;"-5:B-C
M.3_Y>_9!0(TI:WP]1@4!DM_N-:3REJ#2@WB/>5Y+'7H1?(LV%5A2Y%C$_9[#
MDE5[3$M[Y SNMZ"<PCKG+3G\':N"BUZ.I,6JHJMMWXV,["BR\@*ZOX8\?D!J
M,J.[E7+\83.NPB9\^@8?HZ@9H1\O)[WE/4NW>%S</E-9:=_L[+.*YVO[)2LZ
M^W/C\Y]!;P"3\_*T&/N^Y'T/)Q.398UR^ M[OS&^C\,,A,?$2T(+0U,BN*^%
M)*5&8KTH]/XKO1S:I*"">X'$$.HW,V)$3",.9XS*D@5M[2WMV4?(#66S@?=)
M]M[N'3: ON1&IVW\7"]]'=V-C:-%-:XRYOQH;L+_?7CY/\/"$+VO.2UZ"R"P
MA(0[GM65\[DM[#;X!4="B>1Y,YLM1QMC!\'2W/RL)?RQZZ5=Z[.\66C.3P>R
MAA48#YW.5$1G=27L+VR6]I6@5%R!82)HF(MQ9.U3<O)W0D<MLUK-+V)C] S!
ML8)0<"BP+K74BRK/K=RYA?CSX75>(*N9FEC/X*_*<36KSJWMZG[?P;YE>X/K
M[#5J/Z;&\GTB?P1('>EP5J$,4KQ^MLCB<)1B:T<:.X)(E2MQSQ'$81HMAQ '
M4T"J##*-V_P3")9W!M7H6+1N]%=LA#.,#3_2N\[HMGWJS'Y.VV+8=<U#<T1N
M,2<63(LGVCA9<+,$P0L9ZR)3SGZE\[YC9NFP>;S_LMWOJ2[IG,G%Z2T@7.@K
M.S]K,7C_U\E$5,MXQ95<E\ ?.;#Q'-U%#RRE;W+?)!86\=>V]M7D,L_(+U;:
ME%X^_S>;\A:/I$LH;T@"7J+Z6_8M6.;^M-LHMR7KA/S=.S9(WVX\,79EB;R,
M+8QZ;Z"JS[UT%P.C5@I*03U<YO,\-,YRX*4F_Q^'6T CT_UW=1\>?"G^0F$L
M")60<?6H"0*;KA!AWN*&>3F(R;0'&Z.5\YQMKW-LW2I$'U;P#^L.9;\6WJAY
MM73</-Y]ZC7J]734OBI8?O4#CWO[+:!H]?A9!R76OA$35>HL+FCSTW3"N=0,
M#J]O>7A=;O$: M_2$'U!I:7UIK;QBJ424H 4;R2)$6R30B@0FV!"]:?+66?
MG?5B(E9D;.7[A&[5X;HG4M%:>?H/:5W=S,,3$%<D)-?U1B\V AOV-!9OO$&G
M\A(2;.N2#,1R96EHPYYOLDI(;C$XR9/](*I9 ;Z!'%_Y&#:<PP^\(BQ-&=R
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M9!RY/G[J=R,!7@WN$O4+_G:G9#NC IV%DG4G 7Y-$!@JUO&WD2UPAD2NW_[
MK<<M-AO%K=.R)2VP7#T*A.\^YR<!Y["D MJE1:_?0;)(XDL,;NIDZ<;74]K
M:7Y@L[1B6MV^UQWY%@TYMR?Q36\&>:H'F4QZEOX39<@ZL95OR795>4XT%Y(
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M;Q8C])]%D^]_I&G_,8?+_\:PP_]9]!VFQ,AA/'-DQXHI(2CPHZU( -VT41*
M*FN)D&Q  M12H:T$Y:$)F2^N=\Q5.;PZCH\0/ZG7.3Z!7SGI(J?#.>U!['07
M T.8 @;=TX0"6<\93#A2OO?F.;]*B];=W Z5B#0I"F/&')W:X&;/*JYBRW',
MUGAV!-,=K-0"F^J[UNMYW:OI,M_\[!":M(=<# 3FLNX(^:G\'^V2!$.HU=[H
M,.^'";MA0>RWO!5N=<BSZ9GV<W@(D@2(YF.OPQQ%^_VL:Y/X&?:U1]XJV2)
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M+#H<;T,"W)GNY,=?K2<!5OQM?]Y/A00U^>@,M:]TP9%K_-0ZOY:Z(/AS_"0
M;P&1SQ233@PGD!_^@I$$P,X>:#"<(W#_4$QFV90CR&!F.Y!S93E&]6"&&>_
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M\_-$Z-R E/;.X_=57 *8JE-:DG" \_*Z)M0$9FU.,*7:5&(O0<AWR6A-NMH
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M@2=,#C8T@VBY2ND=4&7QOKU*E%OB2_KJ*YTFRVJ4RH"S9),M"/Z\_735(8S
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MDPQ_'LD3:,'L%LS/+KV[5GL%0-M!G:"\!*N+W"L W8'+O.^*3C>O&&>"RQ4
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M_A=.\G&-^"G8;0OPM+BCKANS"V*:ZCM ]T?%0L:+@%) X&16#0*)$>;;OV0
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M1\F-X=.FZ7X&)!5!ZOPFP0XOA@%2.L(]H*+6/\-^98J\LS-@P=7P(G+Z2=O
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M\8\+7W9N9/M&M=N$P&&'(VIAS-#W':"1.@4K"S7$9TL+$*J?@]E6B>GQ,N?
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M=+D^R2ZQP%>[J?K7F9ZP=Q*GPE+\ZE/]I@#@TC61);[K'X2!)H<]KA-EQQ6
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M<0-R_E'BY.V9.?9@DC4$2SA+1$JHO@W_Q_O:MTKX":O1W]"E\G?\358;FQ\
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M4+G+(,2V_T1W=1"N62R&]%*P%W]M.8LC>!M$)3GVYC_+"R6UV'+?,^%N50+
MO.%_RUAY;"D'1*U_P@-@$M_=._P4Q/HHB"_R2$#1XK8X6G@'\)SY!\&6GB;H
MG#G(<=C" .[$:N<^C/TB)O6?Y-8T J.+<3RPH3D@[L;@GX3<!&1 #A1QP1LP
MM 2,8)I/..(!,A=3[V^9=[>LV/X]17$TYM6^/^PW!QZP:G:!!T1/1&/Y8&&@
MWY($S>Q?^2<1.7C)&/N"\$0#"$N>_B?]YW$R'D#H'UM;XJ%0/>/"/\O5>9R)
M!]Q:0(5<D@\1K%B"AX!UCL;HX0$TX WG$ +S;/_D/_=]#3^"-X>496/#]Y2]
M_I:BDS"D8(H_Y]P5P#C=?3CFTHZ@.&LQ!(8INH,QS. _J<W_SD2082EV?]_B
M?WGXOSS\7Q[^+P__VSQ,!>UPH$6D:+O\_7E=)1UJV_WN# ;JXP%_8]P8-50%
M-1'UK.9\X2102$9[0QY&H@/$ W3_TM<-'!%&?7$AF&X7&.0CGK/Q/M&JSQ%
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M#5D-34+T7RG>GSG\/+8AL0O:AAS=T]-K@I=N=35IF91D4Y1"T/OZ&JXGO7B
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M+;DTEO;\"3:B["R 5=$Z(8YO5C'Z=O]^PAG1P@#K<3^ 7=2:GVNQOH^$>B&
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MD5,9E!.3FP_C*7GY_8]%S(> VP\>L['B >^6SU3,ELU8+Y[#\M#[%Y.@7FG
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MLY +:=PY<\@89Q2C:Y&_]CV#4T&=[MT/I&^%8TZ%=D@O'CJ *PA8W,Z!&IM
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M(UW^RC;Z27+PQ&%<_X+3<)+6*<TA.-![)_AUWQ\^&1;3$5.M"Y$;P,]HOQN
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M&@X0+$B5H]&.,I8&L8?FW= 3^?XX9"H)4/[B[T)7+3Q 0(GQJO/*R6W1[>]
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MQ$O-3$F!Q,1$H&#M3Q5;3?&VC[B1(.HGM>]5:/@WE**JI::5%4"7Y[UZD?/
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M8TN;&'I+ ]BE1SQ69KD"=[;L%BN^,AH)[RCT)0__7GPKVT+J@PJW'8'=>-9
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MZ]6E7D\UK1E6U\IU8E(/5?3^/'EQ9: ($WIXK*1C=2=N1OSF*Q4>F2$6TZ'
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M%EP&:O6/>]F2)#<C];YMH:',+\_1J)N]^9Z*K9WR@"YD#X+ATY[?&[Z&X &
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M8)4UU]PI07*J^D!N>.HZ2UKRT@2%, 3]$L06 [%8:#CX0),,V.,8)P/8+,F
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M?2J^^1\Y^,^Q/+T)_W[B97<<\_]Z,/Z%+4HZ-=K;Z=]E/MQ4)-E3&"RR"?Q
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M;T*@Q0._96)Q,2'S!S0X$](Y<_B>&O!OWP>X&X#M2$7+Z9ES,(W3V12OF)D
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M#<)AQ)V;H,>L,9W(7_CA!00^%)O9825PBT=GFHY&<>V& 5(0?Z^((+9$!DP
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M@5-G#^,Q\NT,T^E TT&"/*80LGBF%_3NAV/2WJ,\XW?-P7.30I$++YE3TT[
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M"^*1NR'O:SE\[=,?V_N/EIF-9G+Y@-JZO)8CC8JPFGJ]+(^\N<)KSN*K]C:
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MQ;Q&84D1<X8X(/[P"8ZX]_\-HN+S_/@(BF%GT(;$O5?R>_S?)QZ::_HOM5S
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M^+T#&4!)BRKG]AJU0#EL%M>+(M7L!%Q@^ XG)"-!SPD?K:0!X 1'@6Q_?(R
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M0 V"#I$,H-A4@]FV>;$1=-(&-(E3 BAJ%(D.V0-33>?Q_]GC1<Y-;>RKX][
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MC6^T[R8N"O-,A*.1R4N)M74C-MU,G4Q*A 25G7]$BW#_JLW^<DKR4O'U7A!
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M;*W#ML6(R?<$.5%#-I#NZ?20;+XH%P1Z&_$R0\IR;*:H\_K'<.FW\T=V"=N
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M4!< ]UKP(PSRDUF@%8#12CJ3,IE5#GBJ]=8678[)D",9 :"KH1:._R/. B&
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M(_3(OS6USV,1[FV\G++H$*\R(A$4LKA7A.V_%<$<1 !=U/OO)2QX-[H."_V
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M3@IH06SOJV.!>KQQ[09@BSK26+'=)X?DRP\63\1][C(2;!!G>X.ACG*CL^D
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MAU- \[B;2$M,Y!*&<@A+=Z^]^]>B87^M'!>?B$JKI@GB:#Z0#SJ<C6[A1GR
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M]6/_KD=@Q-MT&##^!!H0_SK^+F :KP&<JC/,?QY#!KLA-IC_VWOGE+!'Z2)
MQ9&>X"/C%'B#&76[IN1*F@,C4,AG\NRHY&\QJ6_6Z,<*(XH$R*/L<E&$+Q]@
M3D4C$ YG#?S5:6IH0CYI[3KB*+)*J$-'O^)D<779D?^'M.^,:JIMUXRBHM)%
M>HD*"$CO51"1)D( :=*B(C726X! I/<F @H*(KU&I"DMTD% I$LH(:%)"234
M "%,WG>^,W.^[YQ99\[,C[U8*V21>^]]/U?)L[FOG>_(W?X(IC<\R=[*3Q/M
M-Y#_=<TB/P:AS:)#0L&TYIP&'DU-(6-W;1HC=E7+D9.27]^6-/P<\G?>R2.Z
M(V* NYTV%)B2I6#;&WBG'TR1@AV<J^1S%+#E1IC_)\VJ0MR'4%Y:2.F<AE%
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MJV[3<L1C?PJ_"\:'6[B0@2LAW8M #F>*]%$(01!CC!+T1S;388>/7T1Q? <
M]*_IGKO'_QIP*1\/3*D#QLVSU1'8HOTN3LA"6CNX,I(69\WB/Z/6V1DUN,/
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MT;+='V9D>C;M5<T]HD-O$8-[E%=C94. 1B>.!1]MQ*J+&-)O!5YCU+4=_*@
MV"F,1[B8S<U1J&J&#/@F7"$"U\46GF:W2 E&D('0EVA7]#.\=OZEHA+=VPE#
MF;IQ=VZKV7$8+J;F@[XBLMS5SI-"1DEF6(%?-Z?JGNSSN"\:1YB-PAPN5D?F
MOLPY;,A;?F>=S*"DZM6K'C*E@,F+;>,E)'_#T@%UQM6F2_^PT4#*-)?Z<A]$
M7F/S$:+[KEIVJ[XDMHRF&3S^L^BJ]Y?61'@<^LK+4&F8+/PR]-,Q[N97QKM#
MDV]-A#EUI\$BW]@!3X+L\RO!\>#:E!BU.Y F\];;90BH?5?VR]LH'DAGP!G
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MP)\K3,C"41'LVX^=XOR2E."8J^%NTB+61\_UK;\85:9%/65*>'I-4I>?MWZ
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M+=?=F9*M3:5X5;]&D65NWTQ@Z\<QN-':3Y'\>:J;MX$D'E*C!=O ,LSH=*+
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M?N%.<R[6IT[J!NZ>M'_N>R=P^3@*A?;(.)0Y[E)8.Q5+*1%"?!"%NXE=.EG
M$Q*M6"9ZOJ"^XH^AH3]75**SC)YE)"M-+4%_[/!347\6C%\FJX>. %DII*1V
M!K".^*Y@!YBJJK_LMN5>/"[F4= 0%7_]M;11Y<P >Q^54*!L052%L%"]FUL%
M=\WU\<#,)IOCG_%'G;W :ZKWCF/:+0AJ,55$E2>3L'N37]:4+6(7)5])7I]E
MQSI\38KF&K@H]=XQO1M8WU/A40YM %TFR8ZK/L/ +\_>;6BL[BWK?/FY!3:T
M_."'E=NK:YXZAM\C]-=W_1M7FF>\3J!BE(7W>.VJR.KPM=!)DUZLQ!477GJ\
MW!D@25SU\<<DB(&E!%_#RTSUYIP@7-+]Z,&<Y,M4+C\A+40FPFN)I#:&IHGD
M-/68?1XULIN$T9C@.P?Y0R9[[QB ._NSG]2A*F\S.--29#.CM.L$Q$WW[_+&
M'XFT(^L^P92(?,'8?MEA)FBV N$-2L;:-6AJQGU<QOL97,"[ ,BOR..%; V"
M=Z2@J$T(O5TAX.]D0?Q==!A)P^5I4U4+&QO!-B'!W#.__]YY>4N'T)?>5RX\
M+[<,2FMNB'T[%5F)J+B;'7^TN(C$/2DE,1,$AG*@M]'&H[CG3UX@6PAR'R)K
MA8V&#H*=!FMQ_4"AY3#>?8^N,T"]YAG  ZJIB9<(1[3X5$(C=%/ \A7!+&GU
M-5X9 4X7 _:/]*A*AOKRGZW+9ENIRYU*O)T+<JF;KQ@__"&"V9Y>7,PG6N"W
MW,QW.W?;4O[Z8B H9.F0^>C:FEU IEEABKU[[R"[NPW+NH_=?D7H"!LC<0#+
M&E- -+3UEZ!^,J/OY<="\CR:DF&*];H5J64F.G0S]'Q>9CG4I<= #%[!3/M
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M6CISZM=SC]\T0#>9?X8&./V$W.8J8]>4A"*U)<\Q[.ZYE?D/ZJE:E7^4%W(
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M8]UX\5*4N53YDJ\NO3HJ/R]7VCI;3.KE%EGLD%'-GJ<*Y^/1MM1\(@(.'^:
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MF)'IZ\1"1+=P)8,H.U2 8V^$,TVR4UD,<S#I>B%CR,ACN^1@[=\O)#!#SMD
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MIFQ7P?5EUYSXOB[^=:HMZ"LJ#?'4YK75"E6.T/K3R<.M.':K"\XJT@W7"I<
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M$:$;,@MICA:S40:U)3]-Z42130U:QY&C1I=@S\D1>-&PA%%\SREDL;LL\[=
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MQCD(N\-84]HI''2C5,4_JTZ4=#SIE*NVD93=7)V(S;6?JCK1L>MXYL3UT<7
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MJ^?"_77#]U:5,ZW39[,X-5\9&'<Q==KT!X]KGC\SHR9;]AG*X?@"".<[H^4
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MA 3?.0)#^G:E_GC3"!4\SMA@1U\NNL?<D];^;<^QC_F89K3,J%?>8F[Z)%G
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M$I!0;#>@+_QXC4']^>M,IWJ6_93D@^4":+:G?'15XZ@WQN(P]?/Q1PDE'HL
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M@ P^):T9P1(T&'0#6Y5!9H185K>7-IQVLFB](@$%N5DG_W((&6@\B[[_)6@
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MO>^.:FK;]HZBH@BB=*5$I2E5>B<B @(""E*D1021(J @/1!! >D""@)"$$1
M2N@!A 0!*2*]@Y2$WA-J2/WBN?>]=\\YM[U[O_&-][YQ_MAC)&LG>[6YYIIS
M[?F;OZ,*?EPL;;!Z(^.<5UZM4K9H6T?1D^;TIGU%12.[WG.!;WF\&=N8>0S/
MF4>35&&.H5&72C3K_V56QX7-">268C"KL_Q<O+R;HW1AYN/2KB1"?#?RQ;!<
M(3/S<H7+N8RU<T$Q_$]3.*6/:/'-C7Q%RHV4H%Q[8@,,(]ZW*>,U=04Z/#7
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MS5VOAMW4(!>H>OGCDMM,/!A7QQ]\&!?O0HR_D/ZAP])J3VY5N,&0\;X\!ZG
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M["U 6C0.*[FN-+/Y,E.PEP3ZP'1U-2"&T\3:>?^,@->R]H^P1)7VSHW(3AX
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M2'*Y=Y<L[TP=TYVK* V['_F!\\;G;R$Q,XR99".Y7;G'0Z'/K3_+>96\^S&
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M:[&9-P,A_VH.DS^EG)Y>ZSK>CW)ECASW1K+TF=\2Y>*B<UNSTYGABB*R_)5
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MK?>K+X,!?2/9Q^G= X?X.XQ%:AH<I!$$](L%:*X#0E,,X#I?RINOMB'$0U1
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M=_!)>'SE,T*E>@UPY2I=3":HS6SZG*H,]K4?:^LYV N($IH+;:-NQ&K@>7/
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M3Y/WRAB]IICOZ"?7=FW_)2Z82^Y]I6G3ET;)TA?>/3C.SP5A^H#] A5;H,N
M8MC0!RI=-(&)E+!")"OQWAT51263#A\SI>_[=16+3W@]J&#*4_4^\CBR$8"3
MOI/MB-L60RJZ4/3/:FKW,_R[CP2%(YJ/OC,5C0YLG.E WE,:2)R+THO"\M/>
MHWUA9$],3#!*!72$MC_ )-IG4'( 5>\)>[1<JP7O[&Z="KO2 GL0Z-)<X'?0
M;^BB\TC[W.@7U32N1+7$%+]2?>A36QQ@KU(VULQ-E>LY*/N8H"EF_MH21#OB
M6[OF/Z-=!ZP"O3I.P X'F N+/^%'R9.?OI%PUFG\P$N_B.)U3*I^]SU18F?R
M15T'UV?2".TEAN1*R]E:/SS<E+Z<INH[<OY68L'(;/>0ZYCD+^W)E!.3ZCL7
M*<+T03@SG8.<9T-.)WJ;$3$I**7)\79MOP1OQ,U]CZ^7&/>/Y9WL2L\ZII%X
M;,KC \LHKABZXCI]CSB+7]U#G+97MXK7_ES>E?PDZ"XML_ CK_:FO2'R[>'I
MHS/K-S!A=G508!<7#=U40.J#*A64 L)IN\G-/PS5[[R>)%6_3T\@5-")B(Y3
MIC?F+I"P(2$:XTV2R?&PN+B&^Z)I^NOZ8F("0$ =.A$MB@M0H"&:)D2)HNA]
M=)YO+N493Z\L]DXL[3Z5XZAK/^4S4Z>0:50G>Y4[QG4S)X&B!U]DE4<GX'C*
M1>($ S!A;QTJ&@(SK0_5J_5LWSA^:EE?'&?D1HXX@^MSXQDG)US TYV$@N3>
M9YXG2;7%']WJ^1)Q>[W\MWPQ?S1R,Y;_*'7!MD-'STP?B@,*Z&QY4S#!T+39
ME4TER0ZK3Y]S3F7;GMU[\^$[UM,F!G [=.,WF-?DKL@6-Y7WY\6%*LAN:?.)
MLARAP3[^TO)G=7)+EHWPIQC@S/#%:G:B[?&ZMJJ,!($>B</Y]33N6?@EI#QH
MVS%(;O+PS*ILO0L_46R6CGOWA'=HPO_8M$!D:G4B>]4^Z+$3WTG8:+V#Y$E0
MR&A;U-<<=6 ]J8S3,"!&7.Z14M$OOEP;0*M4>2$Q+?C3V8PATQ\?^7)N,$%0
MS7:S!50!K5BJ^O;*VB>1>T/?DQF0C8,I5(5E$)U-Y:-+KVG+?VUM6C8[TGJP
MM6!")/KFLS 72R+^+20"0$P'L#LC)H%+*:,#C?"#95BNR44T6[6 4L7H\D+%
M7<ZRUT%)WWA?^[Y&?RP\E]NC8R8AC@-C;]G/&WM3<(I0+#VM!WZ&>H7V=#-@
M))UDW$L5>OM@=;T[SCOHU9+B)PV[A.NU3CF?+<]]6"L<!TQZH("CU8Z$RS[P
M03]&+RIN;=LU!.P<17&"#UPIB_[@'(2,H[-B**8(!1J6HH,\K^).9*I7)(V$
MCVOV!'KSC+@RT^;NN?M"PR5?>1Q1GT<#9BH[*KBR !H*]&GY=D$3H!F;H[V=
M \QJ^Q@07UC,GD)DR!0^.=)NI2/S4UG*6K=UY,S!+Q]AX9*!#1!D ?U 39'Y
M=$ <1E0];L;T]==#W:LS*3HVK[)GVX166%]P%Z*G7N+*I=&EL#J=F=?.82XG
MB9+MKWW>)<7>RZ!MX2L?%1Z 3?I0^. ]E!/!BDVE?&E6E^$6] E,F32L+&35
MK'"RZXT% W+ *^DF+>'UZ6=NERJ*M7BMA ]=6)7:2>,H^<[/G A&HBYM_(K@
MM-S/WYMQ!Y9WO4IOO-R/KW:-/#;:_7U&S[.0(/%]2RX^3RAP*.K4.ODH?-44
MQT371#>(%4V$Z1TD/C7QZ9*:UG$$;@;(]^@/GS@QLYXKRPHOA%944K-AS>N4
M0P&XS<MV<PS(*I@7,W?UUW*196:F0QH<$SI2.(=7TB_UR3P<4R^4I;NX9NED
M'P]>LVV'9(Z7'=2+ 516A6 _2UV8R\D)[_PJ]\XT"\O&JFSZ.W=XSF;*J::+
M[Z1I&,OF^I,7]:'RJ/:J^=4[A)3AVIDK9-U,5:K.P%QUE5SOL,4M#X,J_^(V
MCN10@K[6PCX?J@* 664!5<FRM#6^5M:W8F)?[Q9_,HB>DN6O!HK;&I7?%^R2
M/L36?UQH\FZ] ,F;RBM"/S]J"2K*( -"CRG_@6^Q8 '12[0[?:@/:0VT/#V]
M7H\3[NQ=RO9_T^"H5K$C<;'A%_G.#_.0)"+ ) RAJ9'=@64CL@G @.@# ;$O
M-$8T$GPR@]M:%0V3G5."W3-E/[DA"K!'R'"*(U*2W,6/!F+)\Q9#UT>^C5<\
MYW$-$W7-,-=E9A7<]T@4&[YEH6E=.J3$N]0RI_#9%^*1+<A1>(#YH$DQ]#G$
M VE(G$L"</7:^ 3=,S=(V3(IU_ AZ:U\INW"6T>L>5%1=IU0@,0]7$F/H9T!
MSS8+3;U>^X[H?6\S12PTX") Q[ERO<WS.UY>,_YLZE&VVJ"C6%(HEGH<NO*#
M 3F+:61 MA<9$/([R!8#$ENKVU<K%RIK1/2.+1)?/SNDE+G6'2;I,SQS_=XO
M$)/>^ 6$; .*KU^7G5"CT[B[[YZV2U*!804I\\9>WL.M1DXD@?=@&N('&HX*
M[OLBSB^ PH&A*5=C^]]1P9..AJ/;!U!?)TE"L%WG,'UHOO6_O;UE0'Y*(YM$
M/$/_M 3^ES/R#AQ*[X%MA$[RPY9S\D"#[,7COV/60AF0W6T&I%)JIK1G>PQ'
MKT6O%E+ =!3[4*_IWWAS_C9OC-S^=0%;7P<#,N'Z@_JD$71O(5D=/TSJ,@)-
M^]>#NBX--5J6?OP:4"3-TXA \)DK%EJQO7F1*=O+5N!20-&DGNNE\U.-(P.:
MF&P=!0>*"C-G#*]TK5:GM5PPYTG-L,F2Y<PYS1F)'$UTC/^LYR9_SDS3(SR@
MU1?%[(00;AH(U9FVNZ-K?_2AQJZ:;X5V9-IYR5&1,N9U:Z\]3P.<BD6S=U"U
MK\B?B!%364WK^WPK-.W0 NK.Z#.EGQ,LOF[%*7JFA1UU6U#.5^Q>P$9I3-V7
MYL!W!/7$5-W/1JOYD>:J*ML4M@-;,!LRRY-;A)\%FR.@!_C5)]6)DW1G*@-R
M9N!W4K9+91]8RPU]G>09US*4]%7UPZ;$5F&D9MV$2!\V>]L*H&>YA[;*3(]\
M.?5=>DLGP^#]E[_B8L9=Y^2^2!1<22*ZM)K;IA'+1.(,917;#_.:O@@YRA.C
M,X=[%D]_ZQDGDS23>LAT3,##]6'=%G.X'0&S.@ZJ]C+1K@XFZ)<C!UBF!&&1
M:M4919((N1'?VTE-Z1Q?5"<<-NVU#M>YB;QA:1K<59N"CS@']9"E>YJ@G*%%
M1!7UTPH7[C8Z:#MKJ5KQIYTY>8SU^^,,;XE@TPO!V&Z_7162(RV%+D<?M-L-
M3GKE,+&(VAM#+%+>&OTV?,T_89^]^/&;\^=LU9W?IC>L'5/U8=K$T0\,YBTY
M!*QDO7&:^$7I=>YT1,=3L<9UPR.5<0](/R0?15KCQP<[J"KD@%PDE!SY@JS6
M:-LR<+;/WW9H1$/+C45Q)>+S"2_WL6+UKQ?V19ZQ*A\L]"JMK8C9Z Z25ZII
M<C/]?OFK:FKTZ20WLAVAYQZ5]6AGCC!0FT28_\166I%1T.CGR?X\-]%/TUU6
M:$N][]]1D] N/G83Q^N@5(1]/;R4^6[:@'.%574_)&KT"L\SOIY/A59D:SKH
M,',U0>LG*]P%T5-143QD%D:X3(;2[TUR@[&^B)LN654E][_[TDP()4_4>#*%
MY5BJE1@JZF\TZ7_O65-=E:[C%G-2>>5F#QOK3#8 9R//D*+(S:]DXY%:^603
M0FO,&BXRWS='N;BJ=E!Y:MZC<J_0M/G5&8Z#88E[A$ZG!%$N(T\/ZBF@>L3U
M@*('<<K8-XNWE%ZIBBKV%XFYN2_,&D*WWTTV6B6,:+:JQ*KYB?,-NO>KIY24
M"6K87=S_N7==XZ#;IPJW?!?-I:2HT=!3$KTL/.^H?N2G4_"[4/Z@26&RB%5_
MM=G4N.3,I;+:XFJ*<4KA2HR9P$N1S%#@,K=(E+'QX?GD@6GO9J4S]=#2E =T
M20<'1ZNWBSE"3QV3A_PGS,]EMEQ(BA:Y;GQ*JS5\IZ Y1X(<1]0T(.],C0:(
MVB,M@:(G4YSGAOS/F/5)E5FMMKL%'/NB:29ZKD.X^,:K5=66 L[F<):6E <N
MXJ!Q,16Z^#J\K\@7?$"5/)ETU-^#]_3L:M>':)'0KZ)EKTW8+MPZH,6T/^JT
MPDQLR[ >#Y7[:3-I-X2$>U!$J"SONWWEKAI\R4[DTL2X-;)5N>ZAUDAAA#4)
M3.T5J184C7&J+3#F>W,/,-M2[N\?^$RQN&[-]='> PJ2JL?%V+*)W"*+Z(/T
MX\C@?D4]<1>R\VW,O1/- LVM<:O7E:^M!7U.<#MP-N;LT=75<=.CM;95NAY[
MM<;UH(>1@@"NE3NF5N^I43J=-X43@5(!J+7BT3XGMX)C#-Z,G$W7*1%(G<9<
MGX;U2TM!KD*"\7#Q6E4RE+ _E8AH%O:^$P1GUL,@?O'+U#9W<5@Z-%1:>,U%
M(S5'2_B$S'2L2/1#+M.BES^F35JX!:G.Y%0"FDDV6NEV#ZN%^_64Z0,JXHC8
MG"\ZB9GQ^I!]7V@3.>5@-&J$W@_.X:TFG\/P51M,!QRBJA"]4E[IQ>Y__]YR
MU^MI(;O/L&+1^^T#W^,-F?2=_+ER[%GD$ NP>^'=F'QZ/[Q,=0+NZ*#FYR!O
MD^-I:$(Z+YJ8#1DA(XB?FS2A/'-D?Z)LHVWM8>)3^]K\U\Z^(?Y!KQ&V;Y9*
M3E<G/VB7]AQ *FM"ZN]($,]<H;U5O(T923]/OC!R+>EUCX_$)SR ?*SNZXY(
M0/"&[X_P\4K_FOF JWP>+8S2"CVW/F,2B[3+6SJXO*O9$*E@-T0]\\;WNDR,
MEK+2_?*BG)(BZQZU8E?Q6[KEW:H*426TQV &7Q,X-??65^\]L-OJ1-Q?J(LX
MB=<0;+4M&^QX1=SWD>]!1NZ)UKW3IW/Y#DL\BXH4I!C2!QS0*\O3V-B*W3F,
M>FLLTNQF6 #ZC6.>SN(O'.:R(_;Z6G'&,T?H OMP]^[V48/)[V\"K00=,NYL
M<H^UU]>33WV00RH<J<[@D^J<RA5JL+0W/=4F9A3JV=J$4$F&\<(\K7C-W#Z(
M65#/<.7G.\D%E#J]SE*TLRV17RZQ23UP^N:Z$WSU"&$\@A0&<%,E-(*S''H:
MDB*:PD5"PPEJTCG"'RW<NKT_/,JQR#NF=7\W5_SB5(L/TQ!=E7J>/ ,,-$WP
M5Y3!N(O*)@7(N<C3!6%#61-!5>T"37WM)_@@34=K17Q$*T7M9"FAH8A6%TE:
M=.W147() V+@?&O, -GU4OJ#0[L_9R<OOUZ@6L 1>.[W^TSOPZ&KH(>4$ERA
M,"">&B#$L!A)@I$ ,KR(ZDY+1QT)M6N\T![T?LRA,= ?P;-3Q"'(8^DF7MC!
M PF19H/L")+$B':KK%.3WRH;?E!/D@->(8:&JHIRI3-'5N8F_,_U?6E+=]#,
MOBMYYJ1W^#,"6WJW7BHY@A+D,\D'II1Q>K#R?FE@.P')ZAX<A&%?>E4Z/-',
M5W:S0J-4JDJ A>U6T8%]B.>T3 ;D^OI=*-!=*WBW24^EC\I92/8^=]?L:QGG
MI0#):5:E&1X>_K/[,RR[ZB3<U,HV#F 3J49$\SJT>"&H)CNUO$OX(90F.9VD
M$%H-+7KL;[$0O:(SYM!Y13I%48(!R2OFW9_:L//D,(3&_G,M1)+:#'JE3$^!
M?*=P\TG98V4<03*^\WA,OZ.GRI$+G9W\S27Z['RQ3#+55O4,"' !>R@43Q(D
M9Q&+!HQZWU.M"$D(BMZH99I0]M>& 8<'G?$R7%VS8\\R@O9EG6**WYF?SJJ#
MB8+!M0Y3&A*][1 J.W-2^"Q>D">1EK 2O_]E6S@OLB*59I,:UF5-)"6X UD@
MDL #6,M*1TX%BZ\G+>S.EY[9:.;8OI'&\L$VZ@++0N5*$L4F-)!43'9FB3OY
M/%-[L&@T$F'DW9FI>7AQR?T:;]*81^3L5;T;4%#8!YKP4K&"IE]46'TTM3O(
MNU9L'5=?NA\L-0\[ZCN([)HS&DZ/UK_0:<R?&C>-C4;)DZ%3*3&3997UCBJ:
MSF5 Q9.?'3WNNWYI+OJ6<"4Q[?Y%>KD^ARGS\]P6>U-T9B'5()";RM=:OSOT
M_.20(!RH/K3$ZGY-]_PUKZL&8J VD]XUEV-6[8=6KW4_CSUAQD50F1#ACS8E
M!*:/I48IV-9&TA)1*I-44P :IZN)G=0KF.Z)I4O4 )D%:!E-%UJV8:K3LY#0
MAK73XZ+;V!=O_JB]GPC5KH 4H:#)PIWBV SGUI6?]K?KN((:+_3)Q >N.*TZ
M;QRYQO&,8\KK P-"2*\]@.X3(:,9D'LU*0R(,-;F990NI1%6BFO ,B]G5N%C
M44*A.@9#_N8BD2;G>Y64BHXHYE]Y%7?8\TLIT]TVZ9"B@F87[EYDR,NN/'*Z
MT0#5X%777:7DMWY9Q_6T>9/9GD4JN,5#@#:T*R;JH!_4'WX/=4C-6\>EWD&%
M0D)9]=>DZ .D#,)I<;Q9W\F.T]!SY5;*$ZU6E:82]]%5#Z*.I5Q5,(R'S.OZ
M Y,-<+Z39$4DG. OV!RLL;$#C"+"D9JIK3)LZS895_;72TD]XW.LR'SH2_HP
M,M(H5EXF5]S,(2<@I7]<0'\* H&P9<=#DJ<G%#K"KN9(Y[!:OTIMR\WXFGC0
M8"I:QRY[G H%"AJM]I+;Z:*ALOI 3FEDOF7\!+3_14G8]RN8+QQN1DHQU]4&
M9 46OUY@V< .W*U_63L&)FD/48U5\W68![NMR53U_*X(8-2I*J)'>TBUXU6/
ME.?4HST;)A\Q2E57[W>;P'AZ698T5_@HY] -5A0!Y"V .VDM:>WY% /".6[N
MM<VE>?H>:>!(.?/6R')Y( -R.L.$;9\SN(:\#V(:SD*]UE_^7G72&FA>7GQH
MAHC<VQ5PHUGY7G')\6.-OBD2R3-#.!T4SP(*1HX+B@"6ZVP%1\I;XUY5"@9K
MG/C>^?"3QP_'EV>+"-^*V=C>RLX*4&8IA^F=%9@23-VX6@.[;DC5V(;8&?N:
MA#6+T*7<: ^F8@$;P5-MYQ^R2D:=1C2('P#F&\>%;J>P^PC#8\HR@E.OG8R0
M6Y7@F@R[=_.-4\Z\Z-<).>!UPDS2_A]GB%SIGD4^VW$ETXT7[GC'V'3?:*N[
M&[V')"$\".I7("%E!0V$3/7$RQ %[^JRN^<B^/1)/3<Y!DZ=T%%0O1;BR217
M<*?E%-9A8'/40F;0O]#?M;32Q58DM,E'+XK#)ONO^JZ=),,IIY#:Y!/36('0
M]/H)<7KK4/5%S1'U"$S%6 _IB6YKNHYG:H:>KRAA;W(D!&O^5^S59 :$%,:
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M7C:^592H6LB=RVR]131I1"?GR-"R [COT"46MNV$;3Y#2WI8]YL^S"E.,^R
MWE ]T Y=20D; (&DROWP>P8X@IQC<)V,3H)6+[9RK)[*^K[87D/Y'@,2Q'+J
M=+[ ;7S;7-U-&28!R\&E8S:'TA(G%:S>#>%/A\=OX/Z62O WS( *L128" .B
MY\F 1.$V3ENM)E;2HT$X?Z>5VF/]LAK[=XD)8:5$W(\Y.)F= 9&@?^M +\A
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MP2% "!;<W=WAK>Q[=[+/.[E_N>?<>^[[7BI?DYJ>6E5=W34UO^Z>F?MO]PO
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M-,B*NX(20Z &=65'Q"W JO'P(E*W_*!#D+HYJ&.2K6A$72SB<00>/^83*W9
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M*1!3A-?YWI[UEGP" VU?/QR29#>GQ$]M%N/48?8Z5_0,T3'#G&L)JY*CWJS
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MZ,B*:0@21[P']E]_!YQ>"?-WKN+W@">R8#^D:_@I[X$6N.\(_4S+YW*1[/:
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MNW )ZB*A5D2D\S;NUE[!//?J24>NW$KJK DE&1YAS*I[X5('?VPD]9"_T-K
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M\;#OWM:P+;WXQ,8X+1PVPWII)/_RE4?4-S*=3YEW(X?-J^/7UEQ\1F%69BL
M_<,;#</82,/+L3I#ZD,#ZB,_O91[@,V[6L1:^O@>\+6X!VPL"BGYDY0N*6EL
MNF Q2H2R!85P/D%=RV0-K\=//3=R/P;WT"]?&'_T<!OUO"151[OK-KQS_]H)
MF<=5%&JY!DO5^:V*$1B(!)'6&; (\<;+$<C< TV]/F"DTD_M5W,D-X[%QY8W
M VD7T@P^Z_'=MT="74DMCQJCG[=G#FYX;T/+BM\>J_<OW_+U3PN&VR7HMSJT
M8?M'&OIB?$ER]*8]9"IJ.Y%!4D2KQ["3)4M-C\D\(,AIJ:<IH8%<7'ZMRUXP
MV^IZE2@W\QN6DD5;7U]I;3(3[!FI4EXBA\VZ^BW&>U97D\R\D/5)D5?W=/&B
M[)G 3;+#AV:@A]GC-KQ,"KN@41LE&AKGO$3=ZHQZ@4)'IM#3_05*;BM^RU/%
M0BCY52N<3X^>MO1"5HO/@49^K2Z);>S=#=D=1>',<WM8-/N\[1@M+/L8$B6!
M(-?N596)Q1D\+/Z&ED(WMR<?T1&5(KVF*Y5$#Y9%(U1</.I59*7X_=%V[-+O
MJN;4A@Z/A31C;F&VX^\^8UTR'['8\(OFAF++Y.OI\*X$!?$7I!E\QMA463E4
M'F*C#F@(6SB=D:KQ E!!G>XR0>]-<[1"&!B_(G8;$Z?E;_D05DH:<3 6FE_U
M0P() =PI!,EOV&Y&[@/C'QRV;]_G6< A0&GO*6QYJQ9:/LZE0]RY><(=R\/L
M/ BZM,+9Q%:-.V*@TIF2&Z.YG)'##(VIS+M3U8O^M''.ZSOV"GS\*2SF,IWS
M$Y[Z,ME<6P\W\>EZ+>>L@JC[6RM&?@YM\ZS22>I+2D'S_N78[[L[:O+_V%.@
M?YP&I=+S1K$0N>T75YV*68:>G(@G/$4-1*&'UN2WZ1%6/]E,RH5,Y@*;QVJR
M;)E;R[R[42.=#$E:9E<CUIVB\*:K\B]%R$U\>:_H(T:JK56UPDGOM-:2T!2/
M+)TK6,G5XQC"LB5T)DGUJ&+0Y: ;"0':O#ECL39TN6M:N2/LM!_?"_AC6>47
MWPOX8U7E[[\7\,>2S:^^%P D%,Y_T[)0=="<>U'Q8AD6<V3&G<S=YR\2@G]J
M4S3G-"%Z2VC[FL.:=V5@M=?9WK=62T>\A45(<]I?IKR:IZ:B-F!=J#%4+4T7
M3O*'Z<B?&##9; 1< 7[,JG A^<M65M-^7T+Z^X\C_/.<_:W^7Z@^W%3U%71O
M[#81QJ;B/^=E8:C8H@OW:<W4*<F55&9ZA_Z5EX<$&:] 1-CZ7<ZIH"\1:VF@
MQ5W>W67VSB<1+ 4UV_84;8'7Z1WXCV!@_)H+9<' YZJ#O43C/*^:J<D8JT9:
M=CXJXT'UC(?5DGO*,+VGG+F_>!_YOZ'\,Y[7% 6>NYV]UK<_>Q"TWF=+)30[
M'YDH.-D)TH3/.6.=S2EU*1AP?$,<JSDSY1;3\5D=5XY:PFR0>SJJCH=_P7&"
MZU!74\;:(=6(G5*<XN%Y7!CF)>&'##,6L^%&MTH='2D@8<M-5]P.B8[MLP2,
M %2W]PE4)FHA/Q(= @I%$-273$#,31$*X5L8V.M[-B709H6>>SXDKY8V_OW#
M)<=I=U[9-Q,W9G\R%IKY^18UFJ(5,Q;L(8:FB+GF!I\] "@:7[D%,^@7=::B
M3K5QA:C^\9N7(TWK$#QI[L-Y#Q!FYFQ/J68[C"<Y]<0O/VNW8%&5=XXI$L.'
M:6OCYLP5QG0;N@<$O]Y9WG&,V+5]\DK5Z<""5TN_\=IR[ZX_% NU]&!LFO"=
M^>C,84[4:+2\*I^^QU\BW$NR 2,WZ'-YEGBL=YCY)Y-5U>AW-4A?* E;]O+#
M<+>=SY!4TD\_S#,6WY;A'JW*8M"W=7EY;6D82^B[F3A)#$NSLWZ4YXU5+W-M
M%4Y23T#9';#;RGS0"KO M%R[,BA,5)[**DQX![H'AJI:D^Z!<-*?K+0H('R.
M&C(X?A2H$./0+,3KDGP/'.\RK[4NRS355U=5N]FN@Q%YV3\OXJ6!)$WS-+98
MWCE>US%E(L MQ''?M*4C7/YP_T='<#)B0P%U)@QP3?5*_GT']FEZ[C_5JEB?
MICQ>.MPM=J+GL0$=BY)\JEPG]5VOUDM'_$NG\_]D$S+J&_P&X5/W7!="O4]B
MZE3(%,V@\NT&P=NV3U0)$.A'CG-_6L8)O V\(:KJ;_3(BT5IF%.Q$ZA T_P;
MS>9UKQ8%AYB6D&#HOW@+G@HH-(QSO.?K]#M7J*RMIT0AKBRH1_B6?):.(OC+
M#I-"%Q.G  -O_ARRG#=!!A^U^N.Y^4L1"$[/\[?"2RJS9F>;FQ.R306Z'(9%
M>2M/3A $X "-7X0C+31\G1&!I9MP#XE:/O?I7_VXO8U(0XQ5:JRM#DLE=%.!
MHDS-&JV94#V/0BI:CUAZO$DE2R"W1 O\4BG,W\3AYMS/UJO6C3N^EQZK;1PM
M6FCHPGUBJN)M_RWY2F7KIT,_@C'?C :&YK7P \9V[K[I/C&)K6:1[F*^/\\6
MC+MWQ;KQ:7VS4'7!\I.,(!C[YL(/D]3\U^MA_*_.Y6\5WWW0S^THS9_3FNKJ
M7K4,_<.I+[ MO^QGQN;/>'9%XY7B_#+GNERHN8<XU(#HNM#-M?1EZ<6(3#L"
MTIF;RP,) EW_P_/\;?3MSBNTG'3K/6;G 2(.JT\$!,H1ZG@H58;$QUVT,'I_
M[QOF^ NU<']ZU,(G/93C"7^YQOXFL+):6FM&K.:VKHR#L+O6!;,64-$EJ9:A
M\S9U*;]R:LC4I(#>/<!<E7S8\8V8& %(MO_JR^'YZQ@& P$S.%T75/(2!-2N
MO=V&2JJZY4LD-*+(G%II#/%LUNIS8LBY^P_2HZ#V7 N="0-+<JW/WA $E._1
M2<#B4.:1'V&4IZ-P0++M7UX(M/B;_=X_WC[Z443-[P%2.\A)SCL5QK\<*$,Q
M_BFB?]&HTC)\\@B4@YCPW![;EG]\GU<KDP6-4BR '1! /*4!QE<-7%OVMMK;
ME6:_;=6X*T=5L&O/+?=/U]EHIT)1^GK9=P*@%MQ#[]K"BYBI"04)2NF0'#>&
MA$'UU>H7=)3Q*4.S45C/XF%M8*@*U3RT28-]'I<O]>-5'8;7E.(4.51W9HB5
M"8[+XYQ%:(!F#GM*CGR1VP\51I9'=G-'JPVS\&U@1!R+THO>$]@?0Z,KU[7A
MU*N3,C7@3GF]M:WHHFX.AQN8U">IAWK+,R6R]4&<,@%(EH<7#S3Z$AR243-<
M7<_Y""TN8^Z!2L(4.Y7Q47N,1LVR0-R$M79+M ]U-UAU:N]<=LP$/"@F74A-
MJZ]XN$KB4G99ED4,F5,M-8 !>K\QLG;GAM7VVC>";2[8NVS/=)"G!]LM:Y!7
M5EW;J%"3G9:;2QBV0(_K"WNM"\RF^$2Y)1\UB9FF6:!*S#?)IZ^\\G6%H5K&
MAFI<%*NR1?Z6PK,2,]W/1Y5(E!:;P+T<&]M=;#DN%[@J><-JR*'Z:<PHTBY4
M/8I-DNKA(-**!^%X.O(46*L_>U;<<YHQ"4_C;;(^<DJWT,N)U.KN($JSFU;<
M?L\1&>@AZ+>3)<]X0Q)]N0*7J5Y%)Z\U8\@G3YLG*A4)NH'Q[/'.#[)V;]S5
MT'"S>C,V#[DR,[9P0;W03.^LB"4RW1<HW<(DE?S]TO7M/Z9CB&2 :6&2#M]K
MBMCJNSCY&)I35[>YBJ5G?XB+,R;W%>E!E1 (*6I%D,Q"<Z!U+)9%V4R4\ZGB
M+/ -\UR8.>YZ&I4YPC\ALD04'UJU[5@NW9^_USTY+AE&%P'6L[=#PD=V!=:Y
MN]@5S"= O4MRE!HC"[6CBI^K0%K:! I+3$_1523X:D[)P@%;9;Q^HLUS)/X@
MVJ3'&.3<4RP./LBI&?7O&(L?I\I+B87M +WDJ$G 46?=E\Q*?<'FK'X.!1%K
MLP9'+;V5.!9/W.M[X'FW $BW7%N]N2ZX_8&D6_I4CC]M2$A&JVD"E0F<+#(@
M)G7SH6Z#_6NC%$"?<OBN)E*FLKZAI;*2Z]R22NS2Y3GECGVU+V4YE3L.? -=
M]R'UITY;4[QO"4<>;ZJD'=V:HBJ 0?PZV!)H4M_8D68 -(?U7ER0O";RY>BN
MK4U+I\/YXP&6@*J-9?X#['H5TG>;X#U+^*ZC-3E,4=OBS;,#/<:L4MCQB<?*
M9N==Q*\*XGF.KOR3B4FKFX7AW,9NDDAJP301$!3V%6M&SZO$;%7NQ/?:^6V_
M*9$/>K+'1,8$.]KN35)-+I-_EB:ON%"\/77G]HN1GCS!K8!7O*]CPWP%\J#7
M_:=H#B)2K;/-/V ND@2Q09&[\#L3GW1:JYH&FU;7'YQF37G"SR$]J.C0HD:7
M%7, #;H5\P*%!>+84P(K+NQN#YK0*Z1O.^D<YGW7FL;IBU$IFJ;6XAFGJI-Q
M\W,ZJUX33\[ZS;L&4?K[LH\W<]TM\0GPKJTY,6.S<D2DF]H!,:S:I=-,UB?T
M(OEFSOD9$E_HJ#3]):G(&W:HL %?J0,B7^X!P/E[,K.?X[*D92ZVH1GCF):<
MFE.'=8_!4XQ08ZJC1.5ZO8<FN5#/D=,\:CAL&W.$OUBCYOIQ2IWRB95_/TG3
MX3>G8C2++9$2=<W-LP>S%A1/3,'2;_R17Z3#6445:?$%]X?98>##IV7H$(6K
M*4KW(^YRT@9(VQDD]\4\QO\ ^_IN A;F-!VM@#;#EW]M309^NB-6--\R2;@Z
MXDHZW\#Q'I!@ZNLS-*$A$EN>3H>9:]A'XA4*X*C$+F7S>@?=LPSGBW\J]'D,
MD?D4H64T]TN5A]AK)DV>*8^UT+5H0/%9@+&NKU%T,O+XP4U-[(5SEP[70[BB
MJ$+QA\1Q"#5NZ6B$F<7M:-W!IX@VN=<<6)H],7+W '_<![A6J '=@H;B455>
M@=79S]Y6+,)'O:3LS2J2E*0+\@BIFKIF,3HB5$F#L9S7L]\Z;7'?X\Y^>-PE
M3%.(A&@K2G*H^U[[;7U35?G(PIBCI<1);>H<MV>*2$X,[C%>'Q4.D:]7,_X"
M^E)#'T //FS]9C!J$+.L,L*PEO15VI TD\".TK _![$=U5OP6\EX&:='?NLB
M>57-",<%DQ/^[LH[D[HZEBP)"45!%8-)[F7\!3(IH'!ALZK>YE0D8XYQK*&*
MO.J5%0,E4".R&C'G2A;NQ!F>H8.2(JZ$ATMOFO?BL'@H\6E2#%K],R*8\DU?
M2Q-?Y$72XW95PIV,[?_5WG<&10%L:PX9E2@@.0]!<H8A@Y)%$$4RBHB$888<
M!D0&D,P,<88@(#E(S@P@2!AR$(8@43("DC,B/-VW;ZONUM;6K7JW:O?'_7%^
M?1VJJ\_I^KK.^;JQ3TC+=@M3G8'W(^P#MCGY&+DW I,NIWPLY9V..CU*+&>V
M9MC07,U)>HZ>,6;]&=ES%R'0Q>RPB0V.0P>"POV]Z1O $OU8:]=KF>^VX7T2
M*S#]$.A/MW1;Z=QG4O<0+:""VGO=8Y*.U'KN.N+D(;=&%#VO!'X#7ONFF :^
MJMGRZ31 @FP3%'*T=O.>$U&"2.+DE,"9HRZ**B(-A5AP>:#3EJB;X@[07]G>
MH5(/#U%2IPKPP4+/6Y<@5]+BOMF>\2N1:8OQ+&KIE.)1<:J6&QPQ+]WE)R$%
MN< %?ES9[@FYJ*D03\)]H;CNTQ['BX@C%CJ.G;X>H%<617T4?Q;% ^SW;YM%
ME WG$0Y'EC,?8'$_E3T),XD77=TMXK=-KL1]<A?FG6H<3(B7):5LYK7OQ]_E
MO^V_3ZRS(6WQXK/OU5,PH:PWT^L!I^'DY"C31N$0IO)CDMU@=P-;Y(E]Q]1'
M:.(SU/6 U(#[7;T!B07C;FY+JEMR'&_S\&&L#@19_X*RL?^$!3\<C$QW!]$,
MGNFX)L?5?9SFO-L+)4# N=_F>0UK,_3U=H/S2C]2;<K*?TYR,[=L)\!R]><L
M?Q]&I&H+:).5DG)0&0<1PT%6=Z^VE$5P/)/2H'+19;T(V^KKD7L(9ZQQ2G]^
M*E(=D<=:F#A"Z$?D=C WK*C#.MRP- #.T!PBXS8<*S!+HWWG>E _3<76B-=C
M#2[7%,*\?@WB)D?V5+!]=L";B%U6:>ASA$ *=E[4SI4^U3V]]HV2*/6AW>LU
M[EN$CCA]*]UY\1BWA[XO32S6\C#"7B?&@%')]4NL6L^#*$#_&+MAS0&MN17V
MO<Q!M%D^>GD,$#<GYOO>6:'D91^*[WM\U&9)1AWZ<LHXN!]GT3"^$L=(9J+W
M:PVA&V;#1797MH(,H_Q9W_,9P(3'@Z+*Z],+ZP$[1R^BO(5GWI)F5X</ 0HK
M*>GW0(JVK$A*Z<DI9G_>Q(+O!FRQ@<73^G?8%<W,!SQ<F*D_9GA7(U6:0U29
M%YB;,:W[._E#A]4C7%5VOJ?41RQVOCT,9;K#HR+0W9\/SYZ:S?5PD!-A"Q:K
MLUEUTW=4(LN8 ,&79MFX79[:Z.$,KC=1DE?.>%^N]-W*O<KX#()/RH1W-YH=
MVL:R<%U/+6KD]TP>)#PKMFD.IGRRT"PX:P&>O<_1BGC=8'-4<OQE0R5,TG*G
MHQQ!GY'O&R.DAM*HVPXH4$R@4^6X"$E0B%/B)RC.R:F7_. P--.=N,/VJ@N;
MQ/Y*5>Y*P!RP<67Y=EM/6-%TQJIN9P3]$<+S*N;]FV%5H/AL$'*]R!=J86%P
MMZ_@06Y/P3SS<_2/U\WB)H;YEK]7.9%*[2Q4X*QQSVE1:Q"D[DX)8RZAH/J7
MDL"6F-L?-_:>E>UZ15OI,EN<.U=$QYZ?U[O1?DH%U#SL.DB0,&ZC2,+#/+$<
M6#77%T6/73@,56GJO;3'SR\J+\/.EWP9TZ-R0^QC-%^X:ND"CN(FFZR374KG
MSWWT'X!T2M?K?!)HO;EO][O28>2X8P[^7,!%, \"/.S6>.J;"\!4CZ\MQ:S[
MXP>X*9?,Z,.@Z70CQ>5IDV9OZI Z.S,SFNQ2C]JCV!\%JV7= I-@>P9QD-)K
MK*/O5(,>?MD2%U#!+.0NB&3M2P^(J^$3,K]0)V"MA?[LN1$V(Y: O%#N5_^7
M$@J%F)-VQBP*_\XAL,VR38%6+K;PNXZC4,-K26U3[FZJO/ ]SH7K]W2K%+\#
M;#J5Z^R+U" !=.@<8*_9HAM9?RI>2G=7,+$)CP4.B<*H$KDF[ZL5;9NCUKZ'
M0Z!EPF]^*75J<-_)P0]9E\ +MV0C=M=Z=%R^BU%2/U6Z_:LO!(N.Z^_Q^5;G
M:-RCN#]-D8OC":\#@,]?G7BQDTU;:= ^T?RA#N0F_72+@  '>%YF. 85L:]7
M 5<AOQ8SDTD*Q?=2*B3%L 2HEASC65^[@0OFYAABEOFM!A^4+-(T'&Q:![)/
M>UKH">MN=UYZN@\?**&P)2V5@@K\@K4KMD3 8#FYG[X5ZLWU].A8 CTISH.C
M3DXM:X]VNFA%O\G$6QXP\"=S?.*!GVH<&[<5L<PZP^(HEK-UN/QM 4%'8-H,
MB#>H;-6.*,>;,/NX%\C>D9]%\0+[I.XZWZ8 FS]MW=_'TU&WBF"301'9VA&&
M*;2FL&Z^Y?9P/!W2[>C4MP)!6@K07(6#=^MWVI'O7)K$_$/2:I8I>;&A5YE<
M\I*H&<5-NNRW@3C9K<!YCK$?:65KQ]EI2LJ7\X<4N866Q(^007&'E%\;K,?Q
MFC5H#4F(?(C*KHN+G>BOV6HS.^Z$-6!\\UQJ 8V_5[J)&?U7RN?8_$R,EYKW
M=D3)3:UA;@]Y0TVU2#OX?P*.L2;RS\M>Z3G*-S_*>#=45)&F'*P6SH[<:LBU
MUO>W:P7+[<#E8CKE!UBB?Z_:()6S#(E#GTV4:Z"C_3V_!F2IN0##6.P'.Q(;
M#KH%YM7\G40A; 127Z$]>QQQN>44OMR;Y\=9%'<7F*W(C[>C/Y,81"TOK\\+
ME0NSKH6<)0A4 E9L"=]P5_60U/G1>1SQ-N1K,LR;;TVV)PE8O[I5K7V;(*@J
MI5X<99EYTGRG!7W0$B\ETG]'L^MN.$NPIA;;G"'!-NK@(:0(+&/NZ:>/^!E]
M9RZL&97S"@^0YYR5?C0"32W_5"E]&OXX<>?0-_87ZQSDCNO6?JO*Y@>?&X!G
MB"J5K_KNT-JX<^T.R/.\S$JVXUDD80SFY=6ANYQ2MX*)OFD:;R',GW>3J[(Y
MJ/T&$!F6X<HFPUUS?Y4]VVDV"Q]#PU;&LS99#+,%P\AD);1.9:J[EGF<!7LX
M?ZW&R(B'I..3EC=ANL>$?C(@:,PAPDF+[>N1-B/9B)&!8Z-:O.*L.<OY<P_]
MQK;>IK0QO@^"M7O\=]QFTP],ME4>-C6UCN4T-?L[/ORB0U;?/O$: 1>8M4#Q
M*4F\J\M69<SD1%\*L[;5T$CJ -V2#V-:S27A(Y4!/_$?"S+U.OD91$C]EK=0
M"!1Y$RAQ.CRNF<B!B*  ?6NO^DZBZ$-@VT7MJ*4ON6W_FDK,#F6&&HWMETFZ
MJ-;I)C'OPITP5[VM3[,N5AQT[[,O-^LC0\(/C8P^&2PS7'XE>?'7V13*U3YM
M,8T_]PZ>$+9MD(0VU4CV"'VHJDQ'I-M^SSPO5I2&P3QD<LGG(RN1,\^0@@%P
M@2MX_1C)8'ZUVMG.6/YX;8:,7C=&MGJSH9S8OJ'Q<!J^:/?8N,F')%]6L[D5
M?>WO*'U'2??.6\'!^)0U30XQ0K)<5[^8 'X"Z'_[):/_@LO!/9--2F>A:5,O
MJCX8ACFN:$,@H^8ZO/.'1!3J-)GO I,!&U&;8$ILT].M2T%U$:&E2-($@WI-
M+ 6(Q+U)RIFTUPM$D@98OF9W\,YD/_#J';\2)HX/]&>0H2D++;7(U6">\J18
M>A%G^C:[4IMNBV[#FB'9H'I">?S2#ON[R\F&"9%9(U+#PAG1VX6TBY5CO)VR
MDHCU8Y+7QB!0<![W0L608!5\<56*4G;Z\KA+XZ;MKSIN]#/QV4A^Q74)?N$S
M,7>9\!%628L)5-G,PO!DPK3%S-QO] N%@323R 8\N/&4W&(E1S"%OX<J(QNK
M"_E(A= E&]KSHG6 #\5E+D0]WV$EL:5Z 1=H'!9C+I2>-!$O^+YI^,(LH*!_
M0Z]1FPCQ25?V06W\85Z4[EW=HM7513<K)0!=^_<M'=O2A=D?3>ABEL0YF6T'
MJ9-TQ5DU#V8Q@J!@-2!^P('5FOOZPM&CUH2M;0V+SV.*.1N/DY+5^VD_\HP0
MPB5KTT^P *=S-^>I3O2#1S!@_6&09O)>^J&/'\L&]V3MMFCGT2:BH*P<.<A5
MBR\396R7('G]]24#S8AURV0^0.TM)-D (_OK73^7K<Q2? V)=T!5VB+D:3L$
M#+8GCI9Z9]%1]M9S#;'SK?&P*[:6ZC%]ICO#7=B03UH2C>5F33N44Y2+=M8U
M+Y>@G1"?DIL+DU-I9A$=X/&PL>Z]#FVL&YC;$LL90?ZA]V)?IF+!TJUO6Y75
MBXZN;E 6/3IGWEO=R16F]2#N[T'OTAUB !;D+-:',=!SHH05.\8 MUP?OF:!
MD'EDBE$JD5/>>9 K&\FTHJ.OCN\\W-7BR&*I.9RG&_-SSE5N98_ PF\'M3:(
M'IN9F9DO:Z87UQ/LNN"HZ-^.[Z_!SWMY.:&D?/:H84(8.X^:3/9?%4ZGMBP^
M/ W)B-A. LGM)0:ILO*HO8W7*;3,[\JTU*<A<?W[3$Z@0&96*]*Q] URMD]"
M'H7O)10^3D4JAP7 ('4M^!TZ1'.ND=QP/98T"XOFV>[M:FTUJ.E!XRHRG3Q7
MN<8R=$[L!F"G5G">K)8A#/&^,)%)D.[G7;A@;WD2:Z@IQ]M48E$D"K'%U*+L
MPM22O$"$AH1UP^>CSA^U&ZS4P8WC\YP("&'H*H>XX'O.B&\LZ6SBF1.CSY\W
M@/T5S/7L7, >IV9O]T0<K7GGB/%,+%>"OP23@G:& "_/WRB17^DFRTLX47VL
MZN>6=1','[=;^;WJ_-.72,LF8_'2Q-YR*'3]@V/1=/Y:Z&2B%PM^]PQH/"4X
M0?F95_]?UPQVE2M/@]\^FAUZLZ(]6:>G3\W="AY \]X7 GH[RB!^,%"5?P*!
MNB61X*\ER3)G:7;'R2;F O.[\6OT\IYY3?<,\RY$?(%X&7D;Y?P$6AU5L]@E
M?9#0NJ0Z)[-EP> EHJTS)![Y#0N>?!&^@6/6M[!B3=%P((30?AH VO_.^B+&
ME_D95J8+J"AB(/[@"5UUV.D276]*N%U.H<T=WY,/PWYN"^>KK6M@G^5= L+U
M_&5G%!O3>V_#B@XA1)4*MNLD2,'1.GY>#,X^>$[=^N']^B4=39)@4D(V30T/
MC9?5#?<NUR/=P*0)]]F6)S4Q40^HF&7CCQ8A+UH:5Q(GX?); H+@%!?AW,:Z
M>+LP#3)D.&>HGBI+>/0>3GNR5)JA$ '-"3:^+UW3'TW]>FZU\'[OD\Q?54;G
M,HXB>]+@YA]#=5<C[!G@4P]*=/;C[G8^-^?,@*J9LNVF@'GLCT8KF2DCN/HH
M0\P06;-I<*>*5_M,(0E#C[EW<M%F1:DE =U$9CXL>']!TSB%X\MMF!&@[T)G
M2Q\ _9O:W&BP[?P^.Q.1(5VFN6R!GB:OF1,A96\A->ZH+F8Y;G?VP'JU,H0M
M?.^8\?1^^B':*^@M1KO=KEM3R]9,?>%(KS'!?XC6$NK(ON/WNM2,#$ZL_#0]
MV#NVR2+3;;)>BADAH2^B &&\ ;@Y$"I;" KV!(VBX"_?M7PE1CV;0#3]:"BX
M- G[9M'[)OX6663M+@=2C4 :^LFI?FS!4?;>5R$*'*=Z,EZ41"8#:QZ;IJ:_
M?9LN8%'HY?XQHK CNC3@$W.)B\RN2RW,42S>%!AQ2%5Z3I!-X!<_\UD (XMF
MUIY4\M?"U")$N#'^'WS *:\3I U+!Y7?R? M/#G3U/<2&V(=:O'XL@TT*O+T
M I'EO:8^_\-3D =O<M)D(X2]&'AC=W2<MC:E2_HC&6V.H(\-T1U(S+!@57F@
M.6YW?9R\=VRGCE^Q0G" IE82TOL*I,!BI\8X&VN- 50L]K&MZS_?/2#_?(4K
M;JS[!7JO\9[Y\2W@JD>SXC7=^'.V^,""UF+W$M:A@ESOMWV<+8CX;_RW93;6
M./"N@,C6D[\4_:E*2,Y$'=YO^&7&7(.$0N&I4[]9<J098[@  \NA:P^R;F&*
MEQLS]MJMR.':,47_&I4_.-@YR)G'Q:N0S*/6 =W(7(?+'IONO/HJ=7Z\X2@T
M-BD=].UP-)19YTK<!*SR$(,K',N)U7H[:QX$+3).ZJD%T(:U$Y*Y@M7AXE=/
M3]6R:ZP'W.Y-YSA83\OV\U#(0"Q9,KZMT 5E.U%O97)5H\^>M+5\JPZ(7*LR
MY8P_7=K7XH'/B;G*N>AN2L\JE,Q*Z6F7%=P7Z+5M]'F$4D@J*110(TAGZHTZ
M>ER%J878/L*,64_D'9H=GB[EJ4C"HN,3$\^JQ@]468UIGZBR)$>]Z*0&>Q]M
MG[YP:HR:;GWJN%'0\<YP^FFPJ8T?2X+"Q/?;/7E%;0%LW?J@-"_Z>^[J50PI
M7"ND<H!R"MBPH[3_G9X)IKU? M^?PKNKWNO,W(>3L;RFJ=KOY.9QNQB?D;Y.
MN0P=-RS#UF=[KL.R6A )#^#T,?O/ "3]VNP9 ,CHORHY_C\:C/@N]$_^ZLQV
MJ?CI;"0846@R#I#9[6T/UK[%2!AKW:A4DOTI#9UJ7VI:EYF//T(@43^FW7F?
MK)1TE4KU3T#0XG7\\-@\LU;"V5_C]K>MA&L/L,1AV6EJ[_D& ^;X;XLU;B-]
ML7["1O(RF2X[>QIY8#=(X\,?,CMS8G,4E&QUWO#;V /-5.5B&VBE1:=OI65I
M]8P!Y\-&U5(9FI#Y$'<QW9C)B3?@)@%PO?ALG^)7TG4S#]J8#U43C\<H2(%>
MQTI%!-QJ8S,C70AYQ^=^+*). Z=ZL*0/87,?6_BS^&_AE )A(TY;)30&^_EA
MJ#*M(E.I'\\7M!EY&A,@LZG,',TLMO90S&E9$T P,[ES!C5<#)-JY1I_61_?
M:8%U/D"$L!23,^Y]W6BK-WA@>=Q*AMOUTAL8Z(.NTU.PVEKTY5*SO RJ^]*^
MC4,&5.)Y=,H$OMQ?RZ_"(']T,\!&ZQ=O .*@(:<)<AH]*WK-!MQ*7'\E/D'E
MZFKB5H#3;X!: "UN\XQJ5F]U"/BHJE\E*()#=A%6KGO4<2;_+AR:%K U2^Q+
MM"I+__A DL3(C/'B.="VTOEX6+"R,10*R0]6;^=1CWE2'T?:0^@I/1 ;?NF+
MRXXL%TG;XD4@.JT>M?=7.J<,AL)Z<.EP>4,2LS^<F]BZ*6V@'2K%N!1F 'K8
M;=HRJ.D+)!_ A<0<#X,6)W"E7N>*ZCP3TOQ[SM?]_8I%BB@SV6)&JYU$.&SG
M?/*$%O#,A\VM+OGG[,-92K1%P4^WC\[C288D]#(?EZ-%*;LA+B)[?!DT.U26
MVIG.E/&87*\O/88F?,CPJIV_0J^^ Z+R7)B+(T6JFW0E./XT\J4 J^W,'&(N
M8">557L(_">R)D-L2Z>=*NMSO;Q<^:HDK"^JB:,4@@="8[P!L!""&*)R]%_2
M+8B]IPS$W_MY&?H;6]99$<^:ID[&+K84I-[E=1$2H"E8EP/GJH]<;-!>R]1+
M?A(BE/U %C,#N((7.^3 !;:BW6<TEC<OZ-^04+T,.MI1\#N88@6GWEO@:HX_
M852>MY>Z.\OS.=> K8]&@$>D:)#"_2HQ#M M6/F?<C50VSUR=[D9"+5]JO6P
M@V(CJW%N?%12(IFF'_669'RFD\&=3G_:Y#)%D_UI!;[IW'&HXG00(!RX^PI/
M[@O?5 $XZW\.XZ\O^4)'%+I3!^)&5? *@OT4OUDK;;P!S:7[L?B;:#GA/N?I
MP^YJ@)ZL UTPQLUP5PF5O__:"!1\2G9WF"HNJ-3K;HBSJ%("SGA_'*&#1@$6
MA2$MJDV($BGYF6XHYR^5C][E7!%BDA>S%F3:\PV@G1B30 U:@ G?"H.7CKV:
M0U/NK'1M- ..E[IZ[JY,,H@$JG0P)3WY1)6AE;5A_.<U#E*L QSE0]LDF"QT
M)1%U[^81#]_:."S[Q)^%W^A?03XL(MIU38\[@4%%@&C!S7+\QN>OC'4$S+R#
M2?K]\!::HS94EF[A\EM;&EO0AQYNXBC5SYDJHDHF:Z[BZ?%?NMUFX-+'G@['
M@H0)FRZ,D%QR][+&1^JQZ6P7VQ_],,92'_#R'>K-_?K6H_5\%RDT92&&F!XH
M"@J7/!E0F/W-Y2#5/%7=)"?>GT>A-GR+8Y$MM;VG3;?/@%+?<9E<9-WJW>%/
M#6!*\*7V]2M;FT,BC3[&OM,A,#C-<+(VLC3FT"*YW>S5&Z,\%N3[NTJ:6FP9
M3J%M(;7;PM8CAE7@B(7I=!1ZW2PD3+VM>Y4"TTN+U_8W=NX5+ZV4@*OFYO7Y
MZZ*^Y:DS)T<N)7O[(%K8Q$";R'#>Q$ZT3WWR9<,I:H[>J'9T:5E%9I0);A48
M&@&(QS4NCJ<UA$&\,HSN-&/*\35H-+_VN &=+D#DAQ*+R !WRJ^14@:4LPZ2
MUA]DX[!>7+UW=9C44PS;8)%\!0X$YO^R"^L_*08+"(043'^>.!X@$T>:GBG!
M"1(,5$F ^_SX6+ID^HCC/JW+Z1P7$.>T4FV5\H:< 2J)Y2ZE7 ])IL!/D_JC
M!4MS#=[-G?K4IX[,/F052I0$=0"#_U592F?TZUDMSIP3QJF9'(B^)^,^2]7\
MDE^E(^_7Z3I<>-3,_3Q9)XI&<H%2R/S.6'_,%_7'!/L*IZR/*5F8O+.7R64?
M-1Z*; 3*VL1/\EL_90J$G1)4!<P2A/QP(-"-4GW +Z!&^)IZX;\DI@5]7%B:
M/LX.+K0M$FY(4%0ZJT*UZ1?Z.6G21UU[[P_-[M5DGGYPCY#Z,(ZZ:25? [*<
MP;N[V$EVN/M[?=+?[ G[@%Q :3]=1/LBS=>OQ)_IZ,K&9>M=Y\U;S^T1KQ&5
MFFLV<:ZP'T[_F(SXO]E_7Q7[?_R5ZG^S_BFI#Y^-.2V4C (4NW5LJ524W:8(
M/:_K2C0>+C'%KZ&QN/3B/EV%].0K+J:VW^0^;8DW@ //P [.DC]\8LK_0N4&
M0&\%H1LZ$6#]N' #&-RZ/'FWO1M[P?(/';R$%T*+9QWOO3/&;4W)F QXW_/^
M9F>8[XVOT[[!S<=X7)X3-9;)A+KOH0'>N@$\MW]*][P4]N;X6.]0BT8YM0*,
MM]R&O '\#+Z>-$4OFW*G23WG56?"%R-AV/"AJ\K^,9(/;FJ)JF$&!U$F L^$
M)<6-.3'>PNU*-X#;"SE-%"]+=[3T,9]3K<G5+8R-VY\-4[81/D?0A?K1'E"=
M>LF<@ ]K1&B2>(9H*'\1_[H.\6$_/[L!T&F=DI_])MY5.=B[%FC@KU#YQ4QT
M57$#(/AX P"ZG#3-3\VU]79>M[?> ++F>Z[_S(5]YA>6$<"Z$*UXB^>B$I:7
ME&S\9E"$]FT/AB-0_@=_>;HR 6588@9P]WC2*/##&R_!X9S:-J K];F%<?7^
M:4-ACW-B:['+*;RW-^=^WT46HXJKO8 ?Y8<"V+SOB;!@ESEJHCZ5-Y?\\F'O
MJ!X3['%T WC/YO 89'FBZ'?\S,0M(D1!<Q&OAX-E O)XS&)'!@SV+Q9:BP/4
M])PEIA_T7AI_NB^55D,S8;IR U@BGU3Y 6V]^K,6Y),; "FTZ@;PP.ML]09P
MY=Y\6_#C5FWS.]&KP=])*@7#*M=4\[;78=M[?3> \S4KW)5"T>;! G.&TX;1
M4=F,5)0EG.%L+19W4(Z,*EK:Q,Z_<W9*?]HD9R78R9296N+KMARDD>=6VM"W
M+GJIN.TT>I<81HXB85SS6,C&O54H[G1S0<COWGJ%WA]2/ ,#15DR;8R1*N+U
M5;R2<25?-T ;7_G+ALA^XT^"1<DWT0TZU0["7$B-7@4S0WP)N2U!]7_^L/IG
M\X.DRYERJ'NF^UEX*2-_W.#IJ"HUI/$&D%D5^#WWSR8_J5^Y]L/> -[%_@&-
M_@W^&_PW^/\8I+HPJHT8TW[/.4Q'.D+H]VM\_,D_5A'^?V;L-]/_ 5!+ 0(4
M Q0    (  Q)8E#H=QDZ^ P  *(\   :              "  0    !A,3 M
M:V5X:&EB:70Q,#(Q;&%N;6%N+FAT;5!+ 0(4 Q0    (  Q)8E!G[]!NWQ
M ,QI   :              "  3 -  !D97-C<FEP=&EO;F]F<F5G:7-T<F%N
M+FAT;5!+ 0(4 Q0    (  Q)8E $+@"J80,   0<   .              "
M 4<>  !E>&AI8FET,C$Q+FAT;5!+ 0(4 Q0    (  Q)8E PG73P 0,  +T,
M   .              "  =0A  !E>&AI8FET,C,Q+FAT;5!+ 0(4 Q0    (
M  Q)8E 1/15M= @  -LR   .              "  0$E  !E>&AI8FET,S$Q
M+FAT;5!+ 0(4 Q0    (  Q)8E!:#HKZ>0@  *XQ   .              "
M :$M  !E>&AI8FET,S$R+FAT;5!+ 0(4 Q0    (  Q)8E 9B>S!GP4  !$:
M   .              "  48V  !E>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    (
M  Q)8E [G_!QFP4  (H9   .              "  1$\  !E>&AI8FET,S(R
M+FAT;5!+ 0(4 Q0    (  Q)8E :Y.<?K0\% +<X-0 3              "
M =A!  !G:"TQ,C,Q,C Q.7@Q,&LN:'1M4$L! A0#%     @ #$EB4!4:B&<S
M&   W!\!  \              ( !ME$% &=H+3(P,3DQ,C,Q+GAS9%!+ 0(4
M Q0    (  Q)8E Y7FAW.#0  -!) @ 3              "  19J!0!G:"TR
M,#$Y,3(S,5]C86PN>&UL4$L! A0#%     @ #$EB4,0%KQ "D@  D5 ' !,
M             ( !?YX% &=H+3(P,3DQ,C,Q7V1E9BYX;6Q02P$"% ,4
M"  ,26)0RGRNSL4S 0!-7Q  $P              @ &R, 8 9V@M,C Q.3$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    (  Q)8E!E_W9"-\H  -<^"@ 3
M      "  :AD!P!G:"TR,#$Y,3(S,5]P<F4N>&UL4$L! A0#%     @ #$EB
M4+2A?@"R(0$ :"D!  P              ( !$"\( &=R87!H:6,S+FIP9U!+
M 0(4 Q0    (  Q)8E!LBCK"""0! +)A 0 :              "  >Q0"0!G
M=6%R9&%N=&=R87!H:6,R,#$Y,3!K+FIP9U!+ 0(4 Q0    (  Q)8E O$W7,
MOM@  ,SZ   5              "  2QU"@!M87)K971O<'!O<G1U;FET>2YJ
M<&=02P$"% ,4    "  ,26)0X$ HSXG  0!@&0( #0              @ $=
M3@L <VQI9&4Q83 Q+FIP9U!+ 0(4 Q0    (  Q)8E")&ASY)O<! )]J @ -
M              "  =$.#0!S;&ED93%A,#,N:G!G4$L! A0#%     @ #$EB
M4*!72=K>7@  GY0   X              ( !(@8/ '-T;V-K8VAA<G0N:G!G
64$L%!@     4 !0 \00  "QE#P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>29
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gh-12312019x10k.htm": {
   "axisCustom": 1,
   "axisStandard": 36,
   "contextCount": 305,
   "dts": {
    "calculationLink": {
     "local": [
      "gh-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gh-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "gh-12312019x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gh-20191231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gh-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "gh-20191231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 744,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 58,
    "http://guardanthealth.com/20191231": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 65
   },
   "keyCustom": 79,
   "keyStandard": 469,
   "memberCustom": 28,
   "memberStandard": 57,
   "nsprefix": "gh",
   "nsuri": "http://guardanthealth.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://guardanthealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Investment in Joint Venture",
     "role": "http://guardanthealth.com/role/InvestmentInJointVenture",
     "shortName": "Investment in Joint Venture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Consolidated Balance Sheet Components",
     "role": "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponents",
     "shortName": "Consolidated Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities",
     "shortName": "Fair Value Measurements. Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Acquisition of Bellwether Bio",
     "role": "http://guardanthealth.com/role/AcquisitionOfBellwetherBio",
     "shortName": "Acquisition of Bellwether Bio",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Patent License Agreement",
     "role": "http://guardanthealth.com/role/PatentLicenseAgreement",
     "shortName": "Patent License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Senior Term Loan and Royalty Purchase Agreement",
     "role": "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreement",
     "shortName": "Senior Term Loan and Royalty Purchase Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Leases",
     "role": "http://guardanthealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Commitments and Contingencies",
     "role": "http://guardanthealth.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Common Stock",
     "role": "http://guardanthealth.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Consolidated Balance Sheets",
     "role": "http://guardanthealth.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Warrants",
     "role": "http://guardanthealth.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Convertible Preferred Stock",
     "role": "http://guardanthealth.com/role/ConvertiblePreferredStock",
     "shortName": "Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Stock-Based Compensation",
     "role": "http://guardanthealth.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115100 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - Income Taxes",
     "role": "http://guardanthealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117100 - Disclosure - Employee Benefit Plan",
     "role": "http://guardanthealth.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118100 - Disclosure - Segment and Geographic Information",
     "role": "http://guardanthealth.com/role/SegmentAndGeographicInformation",
     "shortName": "Segment and Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119100 - Disclosure - Related Party Transactions",
     "role": "http://guardanthealth.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001001 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Consolidated Balance Sheet Components (Tables)",
     "role": "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsTables",
     "shortName": "Consolidated Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities (Tables)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables",
     "shortName": "Fair Value Measurements. Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Acquisition of Bellwether Bio (Tables)",
     "role": "http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables",
     "shortName": "Acquisition of Bellwether Bio (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Leases (Tables)",
     "role": "http://guardanthealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://guardanthealth.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - (Tables)",
     "role": "http://guardanthealth.com/role/Tables",
     "shortName": "(Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314301 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315301 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gh:ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316301 - Disclosure - Income Taxes (Tables)",
     "role": "http://guardanthealth.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gh:ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318301 - Disclosure - Segment and Geographic Information (Tables)",
     "role": "http://guardanthealth.com/role/SegmentAndGeographicInformationTables",
     "shortName": "Segment and Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "gh:RevenuefromPrecisionOncologyTesting",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Consolidated Statements of Operations",
     "role": "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "gh:CostsofPrecisionOncologyTesting",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "D2018Q3Sep19",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401401 - Disclosure - Description of Business (Details)",
     "role": "http://guardanthealth.com/role/DescriptionOfBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2018Q3",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2017Q4YTD_srt_MajorCustomersAxis_gh_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)",
     "role": "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2017Q4YTD_srt_MajorCustomersAxis_gh_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Summary of Significant Accounting Policies - Useful Life of Property and Equipment, Net (Details)",
     "role": "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails",
     "shortName": "Summary of Significant Accounting Policies - Useful Life of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-01-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402406 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligation (Details)",
     "role": "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails",
     "shortName": "Summary of Significant Accounting Policies - Remaining Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-01-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402407 - Disclosure - Summary of Significant Accounting Policies - Adoption of ASC 606 (Details)",
     "role": "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details",
     "shortName": "Summary of Significant Accounting Policies - Adoption of ASC 606 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "I2019Q1Jan1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Investment in Joint Venture (Details)",
     "role": "http://guardanthealth.com/role/InvestmentInJointVentureDetails",
     "shortName": "Investment in Joint Venture (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Consolidated Balance Sheet Components - Schedule of Property, Plant and Equipment (Details)",
     "role": "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails",
     "shortName": "Consolidated Balance Sheet Components - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2018Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Consolidated Balance Sheet Components - Narrative (Details)",
     "role": "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsNarrativeDetails",
     "shortName": "Consolidated Balance Sheet Components - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2018Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Consolidated Balance Sheet Components - Schedule of Accrued Expenses (Details)",
     "role": "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails",
     "shortName": "Consolidated Balance Sheet Components - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Fair Value Assets and Liabilities Measured on Recurring Basis (Details)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements. Cash Equivalents and Marketable Securities - Fair Value Assets and Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405403 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements. Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "gh:DebtSecuritiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "lang": null,
      "name": "gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gh:MarketableSecuritiesMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405404 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Narrative (Details)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails",
     "shortName": "Fair Value Measurements. Cash Equivalents and Marketable Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gh:MarketableSecuritiesMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Acquisition of Bellwether Bio - Narrative (Details)",
     "role": "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
     "shortName": "Acquisition of Bellwether Bio - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Acquisition of Bellwether Bio - Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails",
     "shortName": "Acquisition of Bellwether Bio - Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406404 - Disclosure - Acquisition of Bellwether Bio - Intangible Assets Acquired (Details)",
     "role": "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails",
     "shortName": "Acquisition of Bellwether Bio - Intangible Assets Acquired (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406405 - Disclosure - Acquisition of Bellwether Bio - Other Intangible Assets (Details)",
     "role": "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails",
     "shortName": "Acquisition of Bellwether Bio - Other Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406406 - Disclosure - Acquisition of Bellwether Bio - Future Amortization Expense (Details)",
     "role": "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails",
     "shortName": "Acquisition of Bellwether Bio - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407401 - Disclosure - Patent License Agreement (Details)",
     "role": "http://guardanthealth.com/role/PatentLicenseAgreementDetails",
     "shortName": "Patent License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "I2017Q2Jun30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentRepurchaseAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408401 - Disclosure - Senior Term Loan and Royalty Purchase Agreement (Details)",
     "role": "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails",
     "shortName": "Senior Term Loan and Royalty Purchase Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "I2017Q2Jun30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentRepurchaseAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2016Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity",
     "role": "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
     "shortName": "Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2016Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Leases - Narrative (Details)",
     "role": "http://guardanthealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)",
     "role": "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails",
     "shortName": "Leases - Schedule of Operating Liability Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Leases - Schedule of Future Minimal Lease Payments (Details)",
     "role": "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails",
     "shortName": "Leases - Schedule of Future Minimal Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gh:NumberofPartiesWithPatentLicenseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "party",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gh:NumberofPartiesWithPatentLicenseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "party",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Commitments and Contingencies - Schedule of Future Royalty Payments (Details)",
     "role": "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Royalty Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Common Stock (Details)",
     "role": "http://guardanthealth.com/role/CommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "I2012Q4Dec31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412401 - Disclosure - Warrants (Details)",
     "role": "http://guardanthealth.com/role/WarrantsDetails",
     "shortName": "Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "I2012Q4Dec31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "D2018Q3Sep19",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413402 - Disclosure - Convertible Preferred Stock (Details)",
     "role": "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
     "shortName": "Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "D2017Q2Apr30",
      "decimals": "INF",
      "lang": null,
      "name": "gh:ConvertiblePreferredStockConversionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "D2018Q4Oct01-Oct31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414402 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "D2019Q4Dec",
      "decimals": "-5",
      "lang": null,
      "name": "gh:ReversalOfStockBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414403 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004001 - Statement - Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity (Parenthetical)",
     "role": "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414404 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Valuation of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Stock-Based Compensation - Valuation of Employee Stock Purchase Plan (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails",
     "shortName": "Stock-Based Compensation - Valuation of Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415402 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415403 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "gh:ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416402 - Disclosure - Income Taxes - Schedule of Loss Before Components of the Provision for Income Taxes (Details)",
     "role": "http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Loss Before Components of the Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "gh:ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416403 - Disclosure - Income Taxes - Schedule of Components of the Provision for Income Taxes (Details)",
     "role": "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Components of the Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416404 - Disclosure - Income Taxes - Schedule of the Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of the Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416405 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)",
     "role": "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Effective Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Income Taxes - Reconciliation of the Balance of Total Gross Unrecognized Tax Benefits (Details)",
     "role": "http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of the Balance of Total Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417401 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://guardanthealth.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418402 - Disclosure - Segment and Geographic Information (Details)",
     "role": "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails",
     "shortName": "Segment and Geographic Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_srt_StatementGeographicalAxis_country_US",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419401 - Disclosure - Related Party Transactions (Details)",
     "role": "http://guardanthealth.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Description of Business",
     "role": "http://guardanthealth.com/role/DescriptionOfBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-12312019x10k.htm",
      "contextRef": "I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - gh-12312019x10k.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - gh-12312019x10k.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 93,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gh_A2018EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 Employee Stock Purchase Plan [Member]",
        "label": "2018 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2018EmployeeStockPurchasePlanMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_AccountingStandardsUpdate201807Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2018-07 [Member]",
        "label": "Accounting Standards Update 2018-07 [Member]",
        "terseLabel": "ASU 2018-07 adoption"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201807Member",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_AccruedClinicalTrialsandStudies": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Clinical Trials and Studies",
        "label": "Accrued Clinical Trials and Studies",
        "terseLabel": "Accrued clinical trials and studies"
       }
      }
     },
     "localname": "AccruedClinicalTrialsandStudies",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AccruedExpensesPropertyandEquipmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Expenses, Property and Equipment, Current",
        "label": "Accrued Expenses, Property and Equipment, Current",
        "terseLabel": "Purchases of property and equipment included in accrued expenses"
       }
      }
     },
     "localname": "AccruedExpensesPropertyandEquipmentCurrent",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AccruedRoyaltiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Royalties, Noncurrent",
        "label": "Accrued Royalties, Noncurrent",
        "terseLabel": "Obligation related to royalty"
       }
      }
     },
     "localname": "AccruedRoyaltiesNoncurrent",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Share-based Compensation For Early Exercised Stock Options",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation For Early Exercised Stock Options",
        "terseLabel": "Vesting of common stock exercised early"
       }
      }
     },
     "localname": "AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AmortizationOfRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization Of Right-Of-Use Assets",
        "label": "Amortization Of Right-Of-Use Assets",
        "terseLabel": "Amortization of ROU"
       }
      }
     },
     "localname": "AmortizationOfRightOfUseAssets",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_BellweatherBioInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bellweather Bio, Inc. [Member]",
        "label": "Bellweather Bio, Inc. [Member]",
        "terseLabel": "Bellweather Bio, Inc."
       }
      }
     },
     "localname": "BellweatherBioInc.Member",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_BiopharmaceuticalCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biopharmaceutical Customers [Member]",
        "label": "Biopharmaceutical Customers [Member]",
        "terseLabel": "Biopharmaceutical Customers"
       }
      }
     },
     "localname": "BiopharmaceuticalCustomersMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_BusinessCombinationContingentConsiderationMaximumAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Maximum Amount Payable",
        "label": "Business Combination, Contingent Consideration, Maximum Amount Payable",
        "terseLabel": "Maximum contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationMaximumAmountPayable",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Capitalized License Fees Financed Through Future Royalty Payment",
        "label": "Capitalized License Fees Financed Through Future Royalty Payment",
        "terseLabel": "Capitalized license fees financed through future royalty payment"
       }
      }
     },
     "localname": "CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CashCashEquivalentsandDebtSecuritiesFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents and Debt Securities, Fair Value",
        "label": "Cash, Cash Equivalents and Debt Securities, Fair Value",
        "terseLabel": "Estimated Fair Value, Cash, Cash Equivalents and Debt Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsandDebtSecuritiesFairValue",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ClinicalCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical Customers [Member]",
        "label": "Clinical Customers [Member]",
        "terseLabel": "Clinical Customers"
       }
      }
     },
     "localname": "ClinicalCustomersMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CommercializationMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercialization Milestones [Member]",
        "label": "Commercialization Milestones [Member]",
        "terseLabel": "Commercialization Milestones"
       }
      }
     },
     "localname": "CommercializationMilestonesMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CommonStockCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Compensation Expense",
        "label": "Common Stock, Compensation Expense",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "CommonStockCompensationExpense",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CommonStockSubjecttoRepurchaseorCancellation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Subject to Repurchase or Cancellation",
        "label": "Common Stock Subject to Repurchase or Cancellation",
        "terseLabel": "Stock subject to repurchase (in shares)"
       }
      }
     },
     "localname": "CommonStockSubjecttoRepurchaseorCancellation",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_ComputerEquipmentandSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Computer Equipment and Software [Member]",
        "label": "Computer Equipment and Software [Member]",
        "verboseLabel": "Computer hardware and computer software"
       }
      }
     },
     "localname": "ComputerEquipmentandSoftwareMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ContractualObligationDueInFifthYearAndAfterFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual Obligation, Due In Fifth Year And After Fifth Year",
        "label": "Contractual Obligation, Due In Fifth Year And After Fifth Year",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "ContractualObligationDueInFifthYearAndAfterFifthYear",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual Obligation, Future Minimum Payments, Interest Amount Included in Payments",
        "label": "Contractual Obligation, Future Minimum Payments, Interest Amount Included in Payments",
        "negatedTerseLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual Obligation, Future Minimum Payments, Present Value of Net Minimum Payments",
        "label": "Contractual Obligation, Future Minimum Payments, Present Value of Net Minimum Payments",
        "terseLabel": "Present value of future minimum royalty payments"
       }
      }
     },
     "localname": "ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ConversionofStockUponInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Conversion of Stock Upon Initial Public Offering",
        "label": "Conversion of Stock Upon Initial Public Offering",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "ConversionofStockUponInitialPublicOffering",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ConvertiblePreferredStockConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Preferred Stock, Conversion Price",
        "label": "Convertible Preferred Stock, Conversion Price",
        "terseLabel": "Preferred stock, convertible, conversion price"
       }
      }
     },
     "localname": "ConvertiblePreferredStockConversionPrice",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "gh_CostofDevelopmentServices": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of Development Services",
        "label": "Cost of Development Services",
        "terseLabel": "Cost of development services"
       }
      }
     },
     "localname": "CostofDevelopmentServices",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CostofDevelopmentServicesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of Development Services [Policy Text Block]",
        "label": "Cost of Development Services [Policy Text Block]",
        "terseLabel": "Cost of Development Services"
       }
      }
     },
     "localname": "CostofDevelopmentServicesPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_CostsofPrecisionOncologyTesting": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs of Precision Oncology Testing",
        "label": "Costs of Precision Oncology Testing",
        "terseLabel": "Cost of precision oncology testing"
       }
      }
     },
     "localname": "CostsofPrecisionOncologyTesting",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CostsofPrecisionOncologyTestingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs of Precision Oncology Testing [Policy Text Block]",
        "label": "Costs of Precision Oncology Testing [Policy Text Block]",
        "terseLabel": "Costs of Precision Oncology Testing"
       }
      }
     },
     "localname": "CostsofPrecisionOncologyTestingPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_CovenantsNotToCompeteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Covenants Not To Compete [Member]",
        "label": "Covenants Not To Compete [Member]",
        "terseLabel": "Covenants Not To Compete"
       }
      }
     },
     "localname": "CovenantsNotToCompeteMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer A [Member]",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer B",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer C",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer D [Member]",
        "label": "Customer D [Member]",
        "terseLabel": "Customer D"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_DebtInstrumentVariableRateBasisBaseRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Variable Rate Basis, Base Rate",
        "label": "Debt Instrument, Variable Rate Basis, Base Rate",
        "terseLabel": "Debt instrument, stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentVariableRateBasisBaseRate",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost",
        "label": "Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost",
        "totalLabel": "Amortized cost, cash and cash equivalents and debt securities available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_DebtSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities [Table Text Block]",
        "label": "Debt Securities [Table Text Block]",
        "terseLabel": "Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesTableTextBlock",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right-Of-Use Assets",
        "label": "Deferred Tax Liabilities, Right-Of-Use Assets",
        "negatedTerseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_DeferredTaxLiabilitiesSection481aAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Section 481 (a) Adjustment",
        "label": "Deferred Tax Liabilities, Section 481 (a) Adjustment",
        "negatedTerseLabel": "Section 481 (a) adjustment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesSection481aAdjustment",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_EarnOutConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earn-Out Consideration [Member]",
        "label": "Earn-Out Consideration [Member]",
        "terseLabel": "Earn-Out Consideration"
       }
      }
     },
     "localname": "EarnOutConsiderationMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_EmployeeStockPurchasePlanObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan Obligation [Member]",
        "label": "Employee Stock Purchase Plan Obligation [Member]",
        "terseLabel": "ESPP obligation"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanObligationMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_EquityMethodInvestmentSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Shares Purchased",
        "label": "Equity Method Investment, Shares Purchased",
        "terseLabel": "Equity method investment, shares purchased"
       }
      }
     },
     "localname": "EquityMethodInvestmentSharesPurchased",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_EstimatedLitigationLiabilityLegalFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated Litigation Liability, Legal Fees, Current",
        "label": "Estimated Litigation Liability, Legal Fees, Current",
        "terseLabel": "Accrued legal expenses"
       }
      }
     },
     "localname": "EstimatedLitigationLiabilityLegalFeesCurrent",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_FoundationMedicineInc.vs.GuardantHealthInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member]",
        "label": "Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member]",
        "terseLabel": "Foundation Medicine, Inc. vs. Guardant Health, Inc.."
       }
      }
     },
     "localname": "FoundationMedicineInc.vs.GuardantHealthInc.Member",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_GuardantHealthAMEAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Guardant Health AMEA, Inc [Member]",
        "label": "Guardant Health AMEA, Inc [Member]",
        "terseLabel": "Guardant Health AMEA, Inc"
       }
      }
     },
     "localname": "GuardantHealthAMEAIncMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails",
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income (Loss) from Continuing Operations before Equity Method Investments, Federal, Income Taxes, Noncontrolling Interest",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Federal, Income Taxes, Noncontrolling Interest",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income (Loss) from Continuing Operations before Equity Method Investments, Foreign, Income Taxes, Noncontrolling Interest",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Foreign, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Income Taxes [Table]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gh_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Capital Expenditures Incurred But Not Yet Paid",
        "label": "Increase (Decrease) In Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Increase in purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_IntangibleAssetsGrossIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible Assets, Gross (Including Goodwill)",
        "label": "Intangible Assets, Gross (Including Goodwill)",
        "terseLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossIncludingGoodwill",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_JOBSActAccountingElectionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "JOBS Act Accounting Election [Policy Text Block]",
        "label": "JOBS Act Accounting Election [Policy Text Block]",
        "terseLabel": "JOBS Act Accounting Election"
       }
      }
     },
     "localname": "JOBSActAccountingElectionPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Lease Liability",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Lease Liability",
        "terseLabel": "Lease not yet commenced, liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Sublease Income",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Sublease Income",
        "terseLabel": "Lease not yet commenced, sublease income"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Excess Amount",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Excess Amount",
        "terseLabel": "Lease not yet commenced, imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_LicenseAgreementMilestonePaymentUponAchievement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement Milestone, Payment Upon Achievement",
        "label": "License Agreement Milestone, Payment Upon Achievement",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentUponAchievement",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-Term Operating Lease Liabilities Net Of Right Of Use Assets",
        "label": "Long-Term Operating Lease Liabilities Net Of Right Of Use Assets",
        "terseLabel": "Long-term operating lease liabilities net of ROU"
       }
      }
     },
     "localname": "LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_MarketableSecuritiesMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Marketable Securities, Maturity Period",
        "label": "Marketable Securities, Maturity Period",
        "terseLabel": "Maturity period (years)"
       }
      }
     },
     "localname": "MarketableSecuritiesMaturityPeriod",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_NoncashInterestExpensePaid": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash Interest Expense Paid",
        "label": "Noncash Interest Expense Paid",
        "negatedTerseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NoncashInterestExpensePaid",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_NumberofAssertedPatents": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Asserted Patents",
        "label": "Number of Asserted Patents",
        "terseLabel": "Number of asserted patents"
       }
      }
     },
     "localname": "NumberofAssertedPatents",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_NumberofCompaniesthatInfringedonaPatent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Companies that Infringed on a Patent",
        "label": "Number of Companies that Infringed on a Patent",
        "terseLabel": "Number of companies that infringed on a patent"
       }
      }
     },
     "localname": "NumberofCompaniesthatInfringedonaPatent",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_NumberofPartiesWithPatentLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Parties With Patent License Agreement",
        "label": "Number of Parties With Patent License Agreement",
        "terseLabel": "Number of parties with patent license agreement"
       }
      }
     },
     "localname": "NumberofPartiesWithPatentLicenseAgreement",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_NumberofPetitionsFiled": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Petitions Filed",
        "label": "Number of Petitions Filed",
        "terseLabel": "Number of petitions filed"
       }
      }
     },
     "localname": "NumberofPetitionsFiled",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_ObligationRelatedtoRoyaltyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Obligation Related to Royalty [Policy Text Block]",
        "label": "Obligation Related to Royalty [Policy Text Block]",
        "terseLabel": "Obligation Related to Royalty"
       }
      }
     },
     "localname": "ObligationRelatedtoRoyaltyPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_OfferingCostsIncurredbutNotyetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Offering Costs Incurred but Not yet Paid",
        "label": "Offering Costs Incurred but Not yet Paid",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "OfferingCostsIncurredbutNotyetPaid",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Related to Settlement of Debt and Buyout of Royalty Obligations",
        "label": "Payment Related to Settlement of Debt and Buyout of Royalty Obligations",
        "negatedTerseLabel": "Payment related to settlement of debt and buyout of royalty obligations"
       }
      }
     },
     "localname": "PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_PaymentofAccruedInterestDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment of Accrued Interest, Debt",
        "label": "Payment of Accrued Interest, Debt",
        "terseLabel": "Payment of accrued interest"
       }
      }
     },
     "localname": "PaymentofAccruedInterestDebt",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_PaymentsInConnectionWithLicenseAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments In Connection With License Agreements",
        "label": "Payments In Connection With License Agreements",
        "negatedLabel": "Payment in connection with a license agreement"
       }
      }
     },
     "localname": "PaymentsInConnectionWithLicenseAgreements",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_PaymentsforFutureRoyalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Future Royalties",
        "label": "Payments for Future Royalties",
        "terseLabel": "Future royalty payments"
       }
      }
     },
     "localname": "PaymentsforFutureRoyalties",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the Original Price per Share of the Convertible Preferred Stock",
        "label": "Percentage of the Original Price per Share of the Convertible Preferred Stock",
        "terseLabel": "Percentage of the original price per share of Series E convertible preferred stock"
       }
      }
     },
     "localname": "PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member]",
        "label": "Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member]",
        "terseLabel": "Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc."
       }
      }
     },
     "localname": "PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_PrecisionOncologyTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Precision Oncology Testing [Member]",
        "label": "Precision Oncology Testing [Member]",
        "terseLabel": "Precision oncology testing"
       }
      }
     },
     "localname": "PrecisionOncologyTestingMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_RedeemableNoncontrollingInterestFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Fair Value Adjustment",
        "label": "Redeemable Noncontrolling Interest, Fair Value Adjustment",
        "terseLabel": "Redeemable noncontrolling interest, fair value adjustment"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestFairValueAdjustment",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_RedeemableNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Member]",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "terseLabel": "Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_RevenuefromDevelopmentServices": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from Development Services",
        "label": "Revenue from Development Services",
        "terseLabel": "Development services"
       }
      }
     },
     "localname": "RevenuefromDevelopmentServices",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_RevenuefromPrecisionOncologyTesting": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from Precision Oncology Testing",
        "label": "Revenue from Precision Oncology Testing",
        "terseLabel": "Precision oncology testing"
       }
      }
     },
     "localname": "RevenuefromPrecisionOncologyTesting",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ReversalOfStockBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reversal Of Stock Based Compensation Expense",
        "label": "Reversal Of Stock Based Compensation Expense",
        "terseLabel": "Reversal of stock based compensation expense"
       }
      }
     },
     "localname": "ReversalOfStockBasedCompensationExpense",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_RoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Agreement [Member]",
        "label": "Royalty Agreement [Member]",
        "terseLabel": "Royalty Agreement"
       }
      }
     },
     "localname": "RoyaltyAgreementMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_RoyaltyAgreementPaymentTierThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Agreement Payment Tier Threshold",
        "label": "Royalty Agreement Payment Tier Threshold",
        "terseLabel": "Royalty agreement payment tier threshold"
       }
      }
     },
     "localname": "RoyaltyAgreementPaymentTierThreshold",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_RoyaltyAgreementbyPaymentTierAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Agreement, by Payment Tier [Axis]",
        "label": "Royalty Agreement, by Payment Tier [Axis]",
        "terseLabel": "Royalty Agreement, by Payment Tier [Axis]"
       }
      }
     },
     "localname": "RoyaltyAgreementbyPaymentTierAxis",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gh_RoyaltyAgreementbyPaymentTierDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Royalty Agreement, by Payment Tier [Axis]",
        "label": "Royalty Agreement, by Payment Tier [Domain]",
        "terseLabel": "Royalty Agreement, by Payment Tier [Domain]"
       }
      }
     },
     "localname": "RoyaltyAgreementbyPaymentTierDomain",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Expense, Percentage of Precision Oncology Testing Revenue",
        "label": "Royalty Expense, Percentage of Precision Oncology Testing Revenue",
        "terseLabel": "Percentage of precision oncology testing revenue"
       }
      }
     },
     "localname": "RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_RoyaltyPaymentsPercentageofRevenue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Payments, Percentage of Revenue",
        "label": "Royalty Payments, Percentage of Revenue",
        "terseLabel": "Quarterly royalty payments, percentage of revenue"
       }
      }
     },
     "localname": "RoyaltyPaymentsPercentageofRevenue",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Components Before Income Tax Expense Benefit [Table Text Block]",
        "label": "Schedule Of Components Before Income Tax Expense Benefit [Table Text Block]",
        "terseLabel": "Schedule of components of loss before provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series B Convertible Preferred Stock [Member]",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series D Convertible Preferred Stock [Member]",
        "label": "Series D Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_SeriesEConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series E Convertible Preferred Stock [Member]",
        "label": "Series E Convertible Preferred Stock [Member]",
        "terseLabel": "Series E Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Cancellations in Period, Gross",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Cancellations in Period, Gross",
        "terseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Exercised in Period, Gross",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Exercised in Period, Gross",
        "terseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross",
        "negatedLabel": "Shares forfeited (in shares)",
        "terseLabel": "Shares canceled (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Grants in Period, Gross",
        "negatedTerseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercises in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercises in Period",
        "terseLabel": "Issuance of common stock upon early exercise of stock options (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available For Grant, Repurchase of Early Exercised Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available For Grant, Repurchase of Early Exercised Shares",
        "terseLabel": "Repurchase of early exercised shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]",
        "terseLabel": "Shares Available for Grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gh_SharesAvailableForFutureStockOptionGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares Available For Future Stock Option Grants [Member]",
        "label": "Shares Available For Future Stock Option Grants [Member]",
        "terseLabel": "Shares available for future stock option grants"
       }
      }
     },
     "localname": "SharesAvailableForFutureStockOptionGrantsMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_SoftBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SoftBank [Member]",
        "label": "SoftBank [Member]",
        "terseLabel": "SoftBank"
       }
      }
     },
     "localname": "SoftBankMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_StockIssuedDuringPeriodSharesExerciseofWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Exercise of Warrants",
        "label": "Stock Issued During Period, Shares, Exercise of Warrants",
        "terseLabel": "Stock issued from exercise of warrants (in shares)",
        "verboseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseofWarrants",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Exercise of Warrants Prior to IPO",
        "label": "Stock Issued During Period, Shares, Exercise of Warrants Prior to IPO",
        "terseLabel": "Shares issued during period, exercise of warrants prior to IPO"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_StockIssuedDuringPeriodValueExerciseofWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Exercise of Warrants",
        "label": "Stock Issued During Period, Value, Exercise of Warrants",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseofWarrants",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Stock Options Exercised Early",
        "label": "Stock Issued During Period, Value, Stock Options Exercised Early",
        "terseLabel": "Issuance of common stock upon early exercise of stock options",
        "verboseLabel": "Vesting of common stock exercised early"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedEarly",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ThresholdPercentageofNewSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold Percentage of New Shares Issued",
        "label": "Threshold Percentage of New Shares Issued",
        "terseLabel": "Threshold percentage of new shares issued"
       }
      }
     },
     "localname": "ThresholdPercentageofNewSharesIssued",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold Period After Initial Closing to Issue New Shares",
        "label": "Threshold Period After Initial Closing to Issue New Shares",
        "terseLabel": "Threshold period after initial closing to issue new shares"
       }
      }
     },
     "localname": "ThresholdPeriodAfterInitialClosingtoIssueNewShares",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_TierOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tier One [Member]",
        "label": "Tier One [Member]",
        "terseLabel": "Tier One"
       }
      }
     },
     "localname": "TierOneMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_TierTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tier Two [Member]",
        "label": "Tier Two [Member]",
        "terseLabel": "Tier Two"
       }
      }
     },
     "localname": "TierTwoMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrealized Translations Gain (Loss) On Obligation Related To Royalty",
        "label": "Unrealized Translations Gain (Loss) On Obligation Related To Royalty",
        "negatedTerseLabel": "Unrealized translation (gains) losses on obligation related to royalty"
       }
      }
     },
     "localname": "UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value Of Convertible Preferred Stock Issued In Exchange For License Agreement",
        "label": "Value Of Convertible Preferred Stock Issued In Exchange For License Agreement",
        "terseLabel": "Issuance of Series D convertible preferred stock in exchange for a technology license agreement"
       }
      }
     },
     "localname": "ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_VariableInterestEntityPercentageoftheProduct": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entity, Percentage of the Product",
        "label": "Variable Interest Entity, Percentage of the Product",
        "terseLabel": "Percentage of the product"
       }
      }
     },
     "localname": "VariableInterestEntityPercentageoftheProduct",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_VariableInterestEntityThresholdPercentageofFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entity, Threshold Percentage of Fair Value",
        "label": "Variable Interest Entity, Threshold Percentage of Fair Value",
        "terseLabel": "Threshold percentage of fair value (greater than)"
       }
      }
     },
     "localname": "VariableInterestEntityThresholdPercentageofFairValue",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return",
        "label": "Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return",
        "terseLabel": "Threshold percentage of fair value that is no less than internal rate of return"
       }
      }
     },
     "localname": "VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entity, Threshold Period For Unremedied Material Breach of the Joint Venture Agreement By The Other Party",
        "label": "Variable Interest Entity, Threshold Period For Unremedied Material Breach of the Joint Venture Agreement By The Other Party",
        "terseLabel": "Threshold period for unremedied material breach of the joint venture agreement by the other party"
       }
      }
     },
     "localname": "VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_WarrantsPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants, Preferred Stock [Member]",
        "label": "Warrants, Preferred Stock [Member]",
        "terseLabel": "Warrants, Preferred Stock"
       }
      }
     },
     "localname": "WarrantsPreferredStockMember",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share",
        "terseLabel": "Stock subject to repurchase, per share"
       }
      }
     },
     "localname": "WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare",
     "nsuri": "http://guardanthealth.com/20191231",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r266",
      "r426",
      "r428",
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r56",
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails",
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r168",
      "r251",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails",
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r167",
      "r251",
      "r255",
      "r477",
      "r479"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Topic 606 adoption"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201609Member": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.",
        "label": "Accounting Standards Update 2016-09 [Member]",
        "terseLabel": "ASU 2016-09 adoption"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201609Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r20",
      "r252"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premium (discount) on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r15",
      "r454",
      "r466"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Accrued tax liabilities"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails",
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r39"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r39"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalty obligations"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r33",
      "r211"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r60",
      "r61",
      "r62"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive gain (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r59",
      "r62",
      "r63",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted Average Useful Life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Consolidated Balance Sheet Components"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r270",
      "r272",
      "r316",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r232",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r189",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.",
        "label": "Advertising Costs, Policy [Policy Text Block]",
        "terseLabel": "Advertising"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r272",
      "r300",
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r51",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.",
        "label": "Allowance for Doubtful Accounts Receivable",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r98",
      "r195",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r162",
      "r452",
      "r465"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r55"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Member]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost, debt securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r175",
      "r178"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value, Debt Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r273",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r365",
      "r366",
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total purchase consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r97",
      "r371"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Re-valuation of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r364",
      "r367",
      "r370"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Initial fair value of contingent consideration at acquisition date",
        "verboseLabel": "Contingent liability from business acquisition"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisition of Bellwether Bio"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBio"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Identified intangible assets",
        "totalLabel": "Identified intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Acquired license"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedTerseLabel": "Net liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r106",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Calculated under guidance for revenue recognition in effect prior to change to new guidance for revenue from contract with customer when using transition method for cumulative effect in period including initial date of application.",
        "label": "Calculated under Revenue Guidance in Effect before Topic 606 [Member]",
        "terseLabel": "Balances Without Adoption of ASC 606"
       }
      }
     },
     "localname": "CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r103",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase during the period in capital lease obligations due to entering into new capital leases.",
        "label": "Capital Lease Obligations Incurred",
        "terseLabel": "Property and equipment acquired under capital leases"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r29",
      "r100"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "verboseLabel": "Estimated Fair Value, Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r11",
      "r101",
      "r106",
      "r170",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r93",
      "r100",
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - End of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r93",
      "r403"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosures of Noncash Investing and Financing Activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails",
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r121",
      "r242",
      "r243",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails",
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails",
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of securities called by warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants, outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r111",
      "r242",
      "r243",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r216",
      "r458",
      "r473"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r215",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails",
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, par value of $0.00001 per share; 350,000,000 and 350,000,000 shares authorized as of December 31, 2019 and 2018, respectively; 94,261,414 and 85,832,454 shares issued and outstanding as of December 31, 2019 and 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r262",
      "r263",
      "r269",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r66",
      "r68",
      "r69"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Guardant Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r68",
      "r374",
      "r383"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r399",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r399",
      "r400",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r399",
      "r400",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r143",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r149",
      "r150",
      "r399",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r146",
      "r149",
      "r150",
      "r151",
      "r399",
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r399",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r246",
      "r248",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Net",
        "terseLabel": "Contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r246",
      "r247",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Deferred revenue, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "totalLabel": "Total future minimum royalty payments"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Fourth Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "ContractualObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Next Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Second Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "ContractualObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Third Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "ContractualObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.",
        "label": "Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Royalty Payments"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r264",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Cumulative effect of new accounting principle"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r348"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r346",
      "r350"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r346",
      "r350"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Senior Term Loan and Royalty Purchase Agreement"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r453",
      "r455",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Debt security, measurement input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as current.",
        "label": "Debt Securities, Current",
        "terseLabel": "Debt securities, short-term"
       }
      }
     },
     "localname": "DebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Noncurrent",
        "terseLabel": "Debt securities, long-term"
       }
      }
     },
     "localname": "DebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "auth_ref": [
      "r260",
      "r261"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Cash proceeds received for unvested shares"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r347",
      "r350"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r347",
      "r350"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r110",
      "r347",
      "r350"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r54",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r44",
      "r411"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r347",
      "r350"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r321",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r323",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r343",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r343",
      "r344",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Tax credit carryforwards, research"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r321",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r322",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r323",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": {
     "auth_ref": [
      "r323",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.",
        "label": "Deferred Tax Liabilities, Unrealized Gains on Trading Securities",
        "negatedTerseLabel": "Unrealized gain/loss on investments"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, employer contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution plan, maximum annual employee contributions per employee, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r98",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r98",
      "r160"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.",
        "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]",
        "terseLabel": "Effect of Change"
       }
      }
     },
     "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r244",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r132",
      "r133",
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Net effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock based compensation not recognized, period for recognition (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Stock based compensation not recognized, restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested options awarded to employees as compensation.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Stock based compensation not recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock",
        "verboseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock options issued and outstanding",
        "verboseLabel": "Stock option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails",
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investment in Joint Venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVenture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ExecutiveOfficerMember": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One of the ranking officers of the entity, appointed to the position by the board of directors.",
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Extinguishment of debt"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r392",
      "r396",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r267",
      "r391",
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements. Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r264",
      "r265",
      "r267",
      "r391",
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r264",
      "r265",
      "r267",
      "r391",
      "r435"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r264",
      "r265",
      "r267",
      "r391",
      "r436"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [
      "r389",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r389",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Fair value, measurements, recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.",
        "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets Acquired"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets, useful life",
        "verboseLabel": "Intangible assets, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Depreciation"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed.",
        "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]",
        "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r196",
      "r198",
      "r202",
      "r206",
      "r438"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails",
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r202",
      "r438"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails",
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r196",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails",
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetailsCalc2": {
       "order": 3.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Capitalized license fees",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails",
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets",
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r402",
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translations"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r98",
      "r219",
      "r220"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on debt extinguishment",
        "negatedTerseLabel": "Loss on debt extinguishment",
        "terseLabel": "Loss on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails",
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r193",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r208",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment for Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.",
        "label": "Income Tax Credits and Adjustments",
        "terseLabel": "Benefit from income tax differences"
       }
      }
     },
     "localname": "IncomeTaxCreditsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r161",
      "r351"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes",
        "totalLabel": "Total provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
      "http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) for continuing operations, discontinued operations, other comprehensive income, and items charged (credited) directly to shareholders' equity.",
        "label": "Income Tax Expense (Benefit), Intraperiod Tax Allocation",
        "negatedTerseLabel": "Benefit from intraperiod tax allocation"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitIntraperiodTaxAllocation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r327",
      "r328",
      "r336",
      "r337",
      "r342",
      "r353",
      "r478"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r326",
      "r329",
      "r330"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r325",
      "r329",
      "r330"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Change in tax rate due to Tax Act"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r109",
      "r329",
      "r330"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at the statutory federal rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Other nondeductible items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r109",
      "r329",
      "r330"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes, net of federal benefits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedTerseLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredCharges": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.",
        "label": "Increase (Decrease) in Deferred Charges",
        "negatedTerseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Axis]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Domain]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Patent License Agreement"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r194",
      "r200"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r71",
      "r159",
      "r408",
      "r409",
      "r461"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r91",
      "r94",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r52",
      "r185"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r53",
      "r106",
      "r139",
      "r186",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r80",
      "r158"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liability Maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Imputed Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r456",
      "r470"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities, Redeemable Noncontrolling Interest and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Acquired license"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Patent Licensing Agreement"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity (up to)"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r36",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Amount awarded from other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement, expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r218",
      "r455",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Outstanding balance"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r3",
      "r38"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r93",
      "r96",
      "r99"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r64",
      "r67",
      "r72",
      "r99",
      "r133",
      "r460",
      "r474"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Guardant Health, Inc.",
        "totalLabel": "Net loss attributable to Guardant Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "negatedLabel": "Adjustment of redeemable noncontrolling interest",
        "negatedTerseLabel": "Adjustment of redeemable noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r124",
      "r127"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to Guardant Health, Inc. common stockholders",
        "totalLabel": "Net loss attributable to Guardant Health, Inc. common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r226",
      "r377",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Non-compete agreements"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) attributable to redeemable noncontrolling shareholder, unit holder, partner, or other equity holder of a joint venture.",
        "label": "Noncontrolling Interest in Net Income (Loss) Joint Venture Partners, Redeemable",
        "negatedLabel": "Noncontrolling interest in net loss joint venture"
       }
      }
     },
     "localname": "NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r422",
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r421",
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r410",
      "r413"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r410",
      "r413"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r410",
      "r413"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r410",
      "r413"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r410",
      "r413"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r410",
      "r413"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r410",
      "r413"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense under Topic 840"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r384"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r9",
      "r39"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r385",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r57",
      "r60",
      "r404",
      "r405",
      "r406",
      "r407"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r65",
      "r68",
      "r70",
      "r232"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive (loss) gain, net of tax impact",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r68",
      "r374",
      "r375",
      "r379"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive loss attributable to redeemable noncontrolling interest"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax impact:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r58",
      "r60"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeMember": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other revenue.",
        "label": "Other Income [Member]",
        "terseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase of common stock",
        "terseLabel": "Stock repurchased during period, value"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.",
        "label": "Payments for Repurchase of Convertible Preferred Stock",
        "negatedTerseLabel": "Repurchase of convertible preferred stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Prepayment penalty"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of offering costs related to public offerings of common stock",
        "terseLabel": "Payment of offering costs related to initial public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r82",
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Business acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Purchase of intangible assets and capitalized license obligations",
        "terseLabel": "One-time upfront payment for finite-lived intangible asset"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.",
        "label": "Payments to Acquire Interest in Joint Venture",
        "terseLabel": "Payments to acquire interest in joint venture"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r273",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name pertaining to equity-based compensation arrangements.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the equity-based compensation arrangement plan.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Deemed dividend related to repurchase of convertible preferred stock",
        "terseLabel": "Deemed dividend related to repurchase of convertible preferred stock"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendsShares": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.",
        "label": "Preferred Stock Dividends, Shares",
        "verboseLabel": "Incremental common shares attributable to dilutive effect of conversion of preferred stock"
       }
      }
     },
     "localname": "PreferredStockDividendsShares",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock",
        "verboseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2019 and 2018"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering and follow on offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offerings of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r84",
      "r303"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based compensation arrangement, excluding stock option exercises.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r85",
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from borrowing"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Net proceeds from issuance of equity interests in redeemable noncontrolling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturity of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r84",
      "r303"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from issuance of common stock upon the exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r64",
      "r67",
      "r92",
      "r162",
      "r166",
      "r374",
      "r376",
      "r378",
      "r382",
      "r383"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r33",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r32",
      "r210"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r212",
      "r472"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails",
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r106",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsTables",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r20",
      "r26",
      "r106",
      "r171",
      "r174",
      "r471"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.",
        "label": "Receivables, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r224",
      "r225",
      "r227",
      "r228"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "terseLabel": "Redeemable noncontrolling interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": {
     "auth_ref": [
      "r224",
      "r225",
      "r227",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Fair Value",
        "terseLabel": "Redeemable noncontrolling interest, fair value"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date.",
        "label": "Redeemable Noncontrolling Interest, Equity, Redemption Value",
        "terseLabel": "Redeemable noncontrolling interest, redemption value"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r266",
      "r426",
      "r428",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedTerseLabel": "Payments made on capital lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r320",
      "r481"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r106",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r105",
      "r451",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r239",
      "r469"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r75",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining duration of performance obligation for which optional exemption was applied not to disclose amount of transaction price allocated to and timing of revenue recognition for remaining performance obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Optional Exemption, Remaining Duration",
        "terseLabel": "Remaining performance obligation, expected recognition period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Remaining performance obligation, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r76",
      "r156",
      "r157",
      "r165"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r420",
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "verboseLabel": "Shares purchased in joint venture (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price (usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of goods and services rendered, in the normal course of business, after sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Sales Revenue, Net [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails",
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.",
        "label": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of the provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of the components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r128",
      "r129",
      "r131",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Effective tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r196",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails",
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r123",
      "r125",
      "r126",
      "r137",
      "r138",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]",
        "terseLabel": "Schedule of Impact of Adoption of ASC 606"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r33",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r112",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r155",
      "r162",
      "r163",
      "r164",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r155",
      "r162",
      "r163",
      "r164",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r273",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r277",
      "r288",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Employee Stock Purchase Plan Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r46",
      "r114",
      "r222",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r108",
      "r223",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Stock by Class"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/Tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r335",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of the balance of total gross unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r146",
      "r149",
      "r150",
      "r151",
      "r399",
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Concentration of Risk, by Risk Factor"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentAndGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing expense"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing expense"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A senior loan takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors.",
        "label": "Senior Loans [Member]",
        "terseLabel": "Senior Term Loan"
       }
      }
     },
     "localname": "SeniorLoansMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Restricted stock units outstanding, canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value, canceled (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units outstanding, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value, granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Restricted stock units outstanding, ending balance (in shares)",
        "periodStartLabel": "Restricted stock units outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average grant date fair value, ending balance (in usd per share)",
        "periodStartLabel": "Weighted-average grant date fair value, beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted stock units outstanding, vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value, vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Employee stock purchase plan, maximum employee subscription rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under an established share-based compensation plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Ending number of shares, available for grant",
        "periodStartLabel": "Beginning number of shares, available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable, Weighted average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercises in period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, grants in period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r279",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending number of shares, outstanding",
        "periodStartLabel": "Beginning number of shares, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Subject to Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance of options outstanding (in dollars per share)",
        "periodStartLabel": "Beginning balance of options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options vested and exercisable, Number of options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r106",
      "r273",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r295",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options vested and exercisable, Aggregate intrinsic value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and exercisable, Weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, Weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Employee stock purchase plan, purchase price of common stock (percent of stock value)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price of stock issued (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails",
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r49",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://guardanthealth.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r48",
      "r232",
      "r233",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of convertible preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued under employee stock purchase plan (in shares)",
        "verboseLabel": "Common stock issued under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon follow-on offering, net of offering costs (in shares)",
        "verboseLabel": "Issuance of common stock upon follow-on offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Stock issued during period for purchase of asset, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r232",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r239",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r49",
      "r232",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issued under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon follow-on offering, net of offering costs of $723",
        "verboseLabel": "Issuance of common stock upon follow-on offering, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Fair value of stock issued for purchase of license agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r232",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of common and convertible preferred stock (in shares)",
        "terseLabel": "Stock repurchased during period (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchase of common and convertible preferred stock",
        "terseLabel": "Repurchase of shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r173"
     ],
     "calculation": {
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets",
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStock",
      "http://guardanthealth.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of equity interests in redeemable noncontrolling interest"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Relationship to Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury stock acquired, average cost per share"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r50",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Common stock subject to repurchase"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details",
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r264",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agency bonds"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government debt securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r264",
      "r267",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. government debt securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r324",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits - End of period",
        "periodStartLabel": "Unrecognized tax benefits - Beginning of period",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails",
      "http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year\u2019s tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to prior years\u2019 tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r141",
      "r142",
      "r144",
      "r145",
      "r152",
      "r153",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Release from valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the consolidated Variable Interest Entity's assets included in the reporting entity's statement of financial position.",
        "label": "Variable Interest Entity, Consolidated, Carrying Amount, Assets",
        "terseLabel": "Variable interest entity, assets"
       }
      }
     },
     "localname": "VariableInterestEntityConsolidatedCarryingAmountAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://guardanthealth.com/role/InvestmentInJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the consolidated Variable Interest Entity's liabilities included in the reporting entity's statement of financial position.",
        "label": "Variable Interest Entity, Consolidated, Carrying Amount, Liabilities",
        "terseLabel": "Variable interest entity, liabilities"
       }
      }
     },
     "localname": "VariableInterestEntityConsolidatedCarryingAmountLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://guardanthealth.com/role/ConsolidatedStatementsOfOperations",
      "http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1278-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e543-108305"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(b)(6))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "305",
   "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e4975-111524"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=84159346&loc=d3e8275-108329"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68054294&loc=d3e8384-108330"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12317-112629"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12355-112629"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "24(b)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130558-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79507997-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79507997-165333"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508013-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508013-165333"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508029-165333"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508029-165333"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508043-165333"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508043-165333"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508057-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508057-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32059-109318"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238393&loc=d3e36027-109320"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e1043-128460"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108788376&loc=d3e5710-111685"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624186-113959"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109975725&loc=SL5629052-113961"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32022-110900"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32157-110900"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=114873854&loc=SL114874292-224272"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r484": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r485": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r486": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r487": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r488": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "5"
  },
  "r489": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6637493632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in Note 3, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investment in Joint Venture</span><span style="font-family:inherit;font-size:10pt;">, and Note 13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Preferred Stock</span><span style="font-family:inherit;font-size:10pt;">, in connection with Softbank&#8217;s purchase of its Series E convertible preferred stock in 2017, the Company entered into a joint venture agreement with an entity affiliated with SoftBank. In May 2018, the Company and SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in Note 11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock</span><span style="font-family:inherit;font-size:10pt;">, in July and August 2017, the Company repurchased an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>1,640,901</span></span><span style="font-family:inherit;font-size:10pt;"> shares of outstanding common stock from certain executive officers for </span><span style="font-family:inherit;font-size:10pt;"><span>$16.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. The difference between the repurchase amount and the fair value of repurchased shares of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> were recorded as cash-based compensation expense in the accompanying consolidated statements of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For each of the years ended December&#160;31, 2019 and 2017, the Company recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5</span></span><span style="font-family:inherit;font-size:10pt;"> million from an entity affiliated with a member of the Company&#8217;s Board of Directors, who serves on the board of both the aforementioned entity and the Company. This individual was appointed to the Company&#8217;s board in January 2017. There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> revenue recognized by the Company from that entity for the year ended December 31, 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863998944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</a></td>
<td class="text">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders<div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except per share data)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(67,851</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84,263</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,221</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85,063</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,221</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deemed dividend related to repurchase of Series A convertible preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,716</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deemed dividend related to change in conversion rate of Series D convertible preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,058</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85,063</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(88,995</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,597</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,582</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible preferred stock (on an as if converted basis)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,818</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options issued and outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,179</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ESPP obligation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock warrants (on an as if converted basis)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock subject to repurchase</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,311</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,415</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6631520512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Bellwether Bio (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following table summarizes the allocation of the total consideration to the estimated fair values of assets acquired and liabilities assumed:<div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>521</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identified intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net liabilities assumed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,802</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,708</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Schedule of Intangible Assets Acquired</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents details of the identified intangible assets acquired from the Bellwether Bio acquisition:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Useful Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired license</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">IPR&amp;D assets are not subject to amortization.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents other intangible assets - net: </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Useful Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired license</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-compete agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,290</span></span></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,490</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>676</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,814</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes estimated future amortization expense of finite-lived intangible assets&#8212;net:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:29%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,924</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6860131024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:28%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Available for Grant&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Subject to Options Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Exercise Price&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Remaining Contractual Life (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,698,790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,391,052</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,658,602</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(508,847</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,088,639</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,088,639</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,007,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>795,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(883,899</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repurchase of early exercised shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,230</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,556,507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,588,405</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares authorized</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(324,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>324,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,999,419</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,636</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(418,676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repurchase of early exercised shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,244,564</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,494,889</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306,392</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and Exercisable as of December 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,908,216</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s restricted stock unit activity under the 2012 Plan and the 2018 Plan and related information   is as follows: </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Units Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49,086</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57.51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,131</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock Based Compensation Expense</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the effect of employee and non&#8209;employee related stock&#8209;based compensation expense:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>863</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>512</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and marketing expense   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,716</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,954</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,851</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options Valuation Assumptions</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The grant date fair value of employee and nonemployee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 &#8211; 6.22</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.01 &#8211; 6.51</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.02 &#8211; 6.08</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63.2% &#8211; 68.7%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68.7% &#8211; 78.8%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74.1% &#8211; 75.1%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.6% &#8211; 2.7%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.5% &#8211; 3.0%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.9% &#8211; 2.2%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Employee Stock Purchase Plan Valuation Assumptions</a></td>
<td class="text">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP: <div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.29 &#8211; 0.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.33</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58.8% &#8211; 60.3%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43.6%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.6% &#8211; 2.5%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.4%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608827328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patent License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Patent License Agreement</a></td>
<td class="text">Patent License Agreement<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the Company entered into a license agreement with a biotechnology company for an exclusive, non-transferable right to use proprietary technology related to high-throughput screening and identification of mutations in targeted gene sequences. The payment terms of the license agreement included (i) a one-time upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">; (ii) issuance of </span><span style="font-family:inherit;font-size:10pt;"><span>141,774</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s Series D convertible preferred stock; (iii) a milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the achievement of a specified milestone event; and (iv) future royalty payments at the minimum of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;13.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate based on annual net sales in which the licensed technology are used. The Company made a one-time upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in January 2017 and a milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in August 2017 upon achievement of the specified milestone event. The Series D convertible preferred stock issued under the license agreement had a fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the date of issuance. The transaction was treated as an acquisition of an asset and the Company capitalized the upfront payment, milestone payments and fair value of Series D convertible preferred stock in addition to license fees of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the future minimum royalty payments discounted to the present value. The Company recorded the obligation at the estimated present value of the future payments using a discount rate of </span><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span><span style="font-family:inherit;font-size:10pt;">, the Company&#8217;s estimate of its effective borrowing rate for similar obligations.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, unamortized capitalized license fees plus one-time upfront and milestone payments totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$6.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which will be amortized over the remaining useful life of </span><span style="font-family:inherit;font-size:10pt;"><span>7.0</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>8.0</span></span><span style="font-family:inherit;font-size:10pt;"> years, respectively. Amortization of capitalized license fees plus one-time upfront and milestone payments totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6591998480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Joint Venture<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investment in Joint Venture</a></td>
<td class="text">Investment in Joint Venture<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with SoftBank&#8217;s purchase of its Series E convertible preferred stock, the Company entered into a joint venture agreement with an entity affiliated with SoftBank, a related party. In May 2018, the Company and SoftBank formed and capitalized Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) for the sale, marketing and distribution of the Company&#8217;s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the joint venture agreement, the Company paid </span><span style="font-family:inherit;font-size:10pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;"><span>40,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, or </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed </span><span style="font-family:inherit;font-size:10pt;"><span>$41.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;"><span>40,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, or the other </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest, of the Joint Venture. Neither party has the obligation to provide additional financial support to the Joint Venture. Each party holds two seats on the board of the Joint Venture and has to cast through its representatives on the board at least one vote for any board resolution of the Joint Venture to pass. The representatives of the Company on the Joint Venture&#8217;s board of directors have the right to appoint and remove a chief executive officer and a legal representative for the Joint Venture, in each case, subject to the approval of the full Joint Venture board of directors. The Joint Venture&#8217;s board of directors has the right to appoint and remove all other members of the Joint Venture&#8217;s senior management reporting to its chief executive officer and to approve the compensation of all foregoing individuals, including the compensation of the chief executive officer and legal representative.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the inception of the arrangement and at the end of each reporting period, the Company assesses whether the Joint Venture is a variable interest entity (&#8220;VIE&#8221;), and if so, who is the primary beneficiary of the VIE. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company and SoftBank had equal ownership interests and equal voting rights in the Joint Venture, and the Joint Venture&#8217;s board consisted of an equal number of directors representing the interest of the Company and SoftBank, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Joint Venture&#8217;s board had the right to vote on all critical matters that most significantly impact the Joint Venture&#8217;s economic performance, except that the Company had the unilateral right to make pricing decisions. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had responsibility for the Joint Venture&#8217;s daily operations, while SoftBank served as a financing partner. The Company also entered into various ancillary agreements with the Joint Venture necessary to operate its business. The Joint Venture is deemed to be a VIE, and considering the power and benefits criterion, the Company and SoftBank, collectively as a related party group, has the characteristics of the primary beneficiary of the Joint Venture, as the related party group has the power to direct the activities of the </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VIE that most significantly impact the VIE&#8217;s economic performance and has the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Because the Company is most closely associated with the Joint Venture within the related party group, it has been identified as the VIE&#8217;s primary beneficiary.  As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation. The Company concluded the Joint Venture did not meet the definition of a business upon consolidation as it lacked the processes required to generate outputs. Upon consolidation no liabilities were assumed and other than cash, and any identifiable assets were related to intellectual property rights that the Company transferred to the Joint Venture shortly before it became its primary beneficiary and therefore such transfer was treated as a common control transaction.  Upon initial consolidation, the non-controlling interest of the affiliate of SoftBank was recorded at its estimated fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$41.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is equal to the original investment made by the affiliate of SoftBank. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Joint Venture had total assets of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$45.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was primarily comprised of cash and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company&#8217;s general credit or assets.&#160; Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Put-call arrangements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the &#8220;put right&#8221;), and the Company has a right to purchase all such shares (the &#8220;call right&#8221;).</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the Company&#8217;s business model were to change such that the sale, marketing and distribution of its tests in the territory covered by the joint venture agreement was no longer economical, SoftBank would have the right to cause the Company to purchase, or the Company would have the right to purchase, all of the shares of the Joint Venture held by SoftBank and its affiliates. In this instance, the Company would be required to repurchase the shares at an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$41.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, the original purchase price paid by SoftBank to the Joint Venture for the shares.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, each of the Company and SoftBank may exercise its respective put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#8217;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of the Company&#8217;s initial public offering, a change in control of the Company, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#8217;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank&#8217;s interests in the Joint Venture being determined to be materially different from what has been recorded in the Company&#8217;s consolidated financial statements including those included elsewhere in this Annual Report on Form 10-K. As a result of the IPO, the put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank are exercisable on each subsequent anniversary of the IPO by the Company or SoftBank.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the event the Company exercises its call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;"> internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair value of the Company, the Company will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its capital stock (which may be a non-voting security with senior preferences to all other classes of its equity or, if its common stock is publicly </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">traded on a national exchange, its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company&#8217;s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the IPO and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the redeemable noncontrolling interest held by SoftBank was determined using the combination of the income approach and the market approach. Determining the fair value of the redeemable noncontrolling interest requires judgment and the use of significant estimates and assumptions. Such estimates and assumptions include future revenue growth rates, gross profit margins, EBITDA margins, future capital expenditures, weighted average costs of capital and future market conditions, among others. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy. The change in the value of the redeemable noncontrolling interest consists of net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and increase in fair value adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843174784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors (the &#8220;Board of Directors&#8221;). As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, no dividends on the Company&#8217;s common stock had been declared by the Board of Directors.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares underlying outstanding stock options   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,494,889</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,588,405</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares available for future stock option grants   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,726,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,556,507</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>689,917</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922,250</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,911,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,067,162</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Board of Directors and its stockholders approved a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>0.7378</span></span><span style="font-family:inherit;font-size:10pt;">-for-one reverse stock split of the Company&#8217;s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the IPO. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 9, 2018, the Company completed the IPO, in which it issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>14,375,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of its common stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$19.00</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company received net proceeds of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$249.5 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;after deducting underwriting discounts and commissions and offering expenses payable by the Company. All then-outstanding warrants to purchase the Company&#8217;s common stock were exercised prior to the completion of the IPO.&#160;In addition, in connection with the IPO,&#160;all shares of the Company&#8217;s then-outstanding convertible preferred stock were automatically converted into&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>58,264,577</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of its common stock, and all then-outstanding warrants to purchase the Company&#8217;s convertible preferred stock were automatically converted into warrants to purchase&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>7,636</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of the Company&#8217;s common stock.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Follow-on Offering</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company completed an underwritten public offering, in which it issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>5,175,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of its common stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$71.00</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company received net proceeds of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$349.7 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div>Warrants<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with a bank loan agreement with a financial institution in September 2013, the Company issued warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>5,386</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series A convertible preferred stock at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.93</span></span><span style="font-family:inherit;font-size:10pt;"> per share. In October 2014, the Company issued additional warrants to the same financial institution to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>4,965</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series B convertible preferred stock at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.16</span></span><span style="font-family:inherit;font-size:10pt;"> per share. These preferred stock warrants were converted to warrants to purchase common stock upon the consummation of the IPO and were net exercised into </span><span style="font-family:inherit;font-size:10pt;"><span>6,548</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in October 2018. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> warrants remained outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2012, the Company issued to certain investors warrants to purchase&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>495,775</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock. The exercise price of the warrants is&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$0.14</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share and the warrants have a contractual term through September 2023.  For the year ended&#160;December&#160;31, 2018&#160;and&#160;2017,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>313,741</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>89,030</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares, respectively,&#160;were issued upon the exercise of these warrants. As of&#160;December&#160;31, 2017, warrants to purchase&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>313,741</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock were outstanding, and these warrants were fully exercised prior to the consummation of the IPO in October 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6881104656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 14, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GUARDANT HEALTH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001576280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-4139254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">505 Penobscot Dr.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">698-8887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,382,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portions of the registrant&#8217;s definitive proxy statement relating to its annual meeting of stockholders to be held in&#160;2020 (the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;</span><span style="font-family:inherit;font-size:10pt;">2020 Annual Meeting</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8221;</span><span style="font-family:inherit;font-size:10pt;">), to be filed with the Securities and Exchange Commission (the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;</span><span style="font-family:inherit;font-size:10pt;">SEC</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8221;</span><span style="font-family:inherit;font-size:10pt;">) within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates, are incorporated herein by reference where indicated. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, such proxy statement is not deemed to be filed as part hereof.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608825168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of the Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses carryforwards</a></td>
<td class="nump">$ 90,534<span></span>
</td>
<td class="nump">$ 36,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">14,165<span></span>
</td>
<td class="nump">17,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">4,936<span></span>
</td>
<td class="nump">5,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research and development credits</a></td>
<td class="nump">11,031<span></span>
</td>
<td class="nump">5,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,143<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">10,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">134,164<span></span>
</td>
<td class="nump">66,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DeferredTaxLiabilitiesSection481aAdjustment', window );">Section 481 (a) adjustment</a></td>
<td class="num">(914)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use asset</a></td>
<td class="num">(7,363)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities', window );">Unrealized gain/loss on investments</a></td>
<td class="num">(346)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(125,245)<span></span>
</td>
<td class="num">(66,196)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DeferredTaxLiabilitiesSection481aAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Section 481 (a) Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DeferredTaxLiabilitiesSection481aAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6858854848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (67,851)<span></span>
</td>
<td class="num">$ (84,263)<span></span>
</td>
<td class="num">$ (83,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax impact:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="num">(446)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="num">(446)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(66,657)<span></span>
</td>
<td class="num">(83,814)<span></span>
</td>
<td class="num">(83,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to redeemable noncontrolling interest</a></td>
<td class="num">(7,800)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Guardant Health, Inc.</a></td>
<td class="num">$ (74,457)<span></span>
</td>
<td class="num">$ (84,614)<span></span>
</td>
<td class="num">$ (83,667)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32157-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32022-110900<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6661538912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Unit Activity (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units outstanding, granted (in shares) | shares</a></td>
<td class="nump">567,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units outstanding, vested (in shares) | shares</a></td>
<td class="num">(22,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units outstanding, canceled (in shares) | shares</a></td>
<td class="num">(49,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">496,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, granted (in usd per share) | $ / shares</a></td>
<td class="nump">78.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, vested (in usd per share) | $ / shares</a></td>
<td class="nump">47.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, canceled (in usd per share) | $ / shares</a></td>
<td class="nump">57.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 82.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6866350688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Release from valuation allowance</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation', window );">Benefit from intraperiod tax allocation</a></td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">59,049<span></span>
</td>
<td class="nump">$ 22,516<span></span>
</td>
<td class="nump">$ 5,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">6,543<span></span>
</td>
<td class="nump">3,427<span></span>
</td>
<td class="nump">$ 1,712<span></span>
</td>
<td class="nump">$ 884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">365,300<span></span>
</td>
<td class="nump">152,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards, research</a></td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">223,200<span></span>
</td>
<td class="nump">73,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards, research</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Income Taxes [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) for continuing operations, discontinued operations, other comprehensive income, and items charged (credited) directly to shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871079232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Stock repurchased during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 7,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period (in shares)</a></td>
<td class="nump">131,243<span></span>
</td>
<td class="nump">1,588,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember', window );">Executive Officer | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,640,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Stock repurchased during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CommonStockCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CommonStockCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Compensation Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CommonStockCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873854&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6838072032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Guardant Health, Inc. (the &#8220;Company&#8221;) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which it enables by a routine blood draw, or liquid biopsy. The Guardant Health Oncology Platform is designed to leverage the Company&#8217;s capabilities in technology, clinical development, regulatory, reimbursement and commercial adoption to improve patient clinical outcomes, lower healthcare costs and accelerate biopharmaceutical drug development. In pursuit of its goal to manage cancer across all stages of the disease, the Company has launched its Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer patients, and is developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In April 2018, the Company established Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) in the United States with an entity affiliated with SoftBank. Under the terms of the joint venture agreement, the Company held a </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest in the Joint Venture. The Joint Venture has subsidiaries in Singapore and Japan (see Note 3,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Investment in Joint Venture</span><span style="font-family:inherit;font-size:10pt;">) and the Company has a subsidiary in Switzerland which was incorporated in 2019.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company&#8217;s Board of Directors and its stockholders approved a </span><span style="font-family:inherit;font-size:10pt;"><span>0.7378</span></span><span style="font-family:inherit;font-size:10pt;">-for-one reverse stock split of the Company&#8217;s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the Company&#8217;s initial public offering (the &#8220;IPO&#8221;).  All share and per share amounts in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Approval of Amended and Restated Certificate of Incorporation</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September&#160;2018, the Company&#8217;s Board of Directors and stockholders approved an amended and restated certificate of incorporation, which authorized </span><span style="font-family:inherit;font-size:10pt;"><span>350,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock and </span><span style="font-family:inherit;font-size:10pt;"><span>10,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock. The amended and restated certificate of incorporation became effective on October 9, 2018.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 9, 2018, the Company completed the IPO, in which it issued and sold </span><span style="font-family:inherit;font-size:10pt;"><span>14,375,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at a public offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>$19.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The Company received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$249.5</span></span><span style="font-family:inherit;font-size:10pt;"> million after deducting underwriting discounts and commissions and offering expenses payable by the Company. All then-outstanding warrants to purchase the Company&#8217;s common stock were exercised prior to the completion of the IPO. </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In addition, in connection with the IPO,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">all shares of the Company&#8217;s then-outstanding convertible preferred stock were automatically converted into </span><span style="font-family:inherit;font-size:10pt;"><span>58,264,577</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock, and all then-outstanding warrants to purchase the Company&#8217;s convertible preferred stock were automatically converted into warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>7,636</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Follow-on Offering</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company completed an underwritten public offering, in which it issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>5,175,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of its common stock (including the exercise in full of the underwriters&#8217; over-allotment option to purchase&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>675,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;additional shares) at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$71.00</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company received net proceeds of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$349.7 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6854296800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (67,851)<span></span>
</td>
<td class="num">$ (84,263)<span></span>
</td>
<td class="num">$ (83,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">(7,800)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Guardant Health, Inc.</a></td>
<td class="num">(75,651)<span></span>
</td>
<td class="num">(85,063)<span></span>
</td>
<td class="num">(83,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend related to repurchase of convertible preferred stock</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to Guardant Health, Inc. common stockholders</a></td>
<td class="num">$ (75,651)<span></span>
</td>
<td class="num">$ (85,063)<span></span>
</td>
<td class="num">$ (88,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (2.80)<span></span>
</td>
<td class="num">$ (7.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)</a></td>
<td class="nump">90,597<span></span>
</td>
<td class="nump">30,403<span></span>
</td>
<td class="nump">12,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gh_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend related to repurchase of convertible preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (4,716)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gh_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend related to repurchase of convertible preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,058)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gh_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gh_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gh_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gh_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6858479600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition of Bellwether Bio - Future Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 6,890<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member', window );">Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2020</a></td>
<td class="nump">928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2024 and thereafter</a></td>
<td class="nump">3,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 6,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6854083792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Bellwether Bio - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability from business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Re-valuation of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member', window );">Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase consideration</a></td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid upon closing</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability from business acquisition</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identified intangible assets</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Re-valuation of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=gh_CommercializationMilestonesMember', window );">Commercialization Milestones | Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable', window );">Maximum contingent liability</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=gh_EarnOutConsiderationMember', window );">Earn-Out Consideration | Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable', window );">Maximum contingent liability</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability from business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability from business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_CovenantsNotToCompeteMember', window );">Covenants Not To Compete | Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identified intangible assets</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Maximum Amount Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_BusinessCombinationContingentConsiderationMaximumAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=gh_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=gh_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=gh_EarnOutConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=gh_EarnOutConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_CovenantsNotToCompeteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_CovenantsNotToCompeteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819001088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liability Maturities</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our future principal contractual obligations for operating lease commitments as of </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.57264957264957%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,582</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,534</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,684</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,892</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less:  Imputed Interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,396</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text">Total minimum lease payments as of <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.57264957264957%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,557</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,105</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,786</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,178</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608812352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except per share data)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(67,851</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84,263</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,221</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85,063</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,221</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deemed dividend related to repurchase of Series A convertible preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,716</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deemed dividend related to change in conversion rate of Series D convertible preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,058</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85,063</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(88,995</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,597</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,582</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:<div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible preferred stock (on an as if converted basis)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,818</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options issued and outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,179</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ESPP obligation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock warrants (on an as if converted basis)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock subject to repurchase</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,311</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,415</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6665572656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has patent license agreements with </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> different parties. Under these agreements, the Company has made one-time upfront and milestone payments, which it has capitalized and is amortizing to expense ratably over the useful life of the underlying patent right(s). Under some of these agreements, the Company is obligated to pay low single-digit percentage running royalties on net sales where the licensed patent right(s) are used in the product or service sold, subject to minimum annual royalties or fees in certain agreements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty expenses were included in cost of precision oncology testing on the accompanying consolidated statements of operations. The Company recognized royalty expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and  </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of precision oncology testing revenue in each period, for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, future minimum royalty payments are due as follows regardless of sales amounts:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,402</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,682</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,682</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,607</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total future minimum royalty payments   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,775</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: amount representing interest   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of future minimum royalty payments   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnification Agreements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into indemnification agreements with certain directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no such matters have arisen and the Company does not believe that the outcome of any claims under indemnification arrangements will have a material adverse effect on its financial positions, results of operations or cash flows. Accordingly, the Company has not recorded a liability related to such indemnifications as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Security Incidents</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with a former employee&#8217;s complaints alleging non-compliance with applicable provisions of the Health Insurance Portability and Accountability Act of 1996, the Company received requests for information from the Office for Civil Rights, or OCR, of the U.S. Department of Health and Human Services in August 2019. After the Company responded to these requests, the Company was informed by the OCR that it has closed this matter without further action. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Patent Disputes</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2016, Foundation Medicine, Inc. (&#8220;Foundation Medicine&#8221;) filed a lawsuit for patent infringement against the Company in the United States District Court for the Eastern District of Texas, alleging that the Company infringed Foundation Medicine&#8217;s patent relating to its tissue biopsy assay technology and seeking compensatory damages and attorneys&#8217; fees. The Company filed </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> petitions for inter partes review (&#8220;IPR&#8221;) with the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) at the U.S. Patent and Trademark Office, challenging the patentability of Foundation Medicine&#8217;s patent. In July 2018, the Company reached an agreement with Foundation Medicine to settle the lawsuit and resolve the IPRs. As part of the settlement agreement, which was accepted by the PTAB and the United States District Court, </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Company made a one-time payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to Foundation Medicine. The Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as litigation settlement expense, a component of general and administrative expenses, at December 31, 2017.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2017, the Company filed separate lawsuits against Foundation Medicine and Personal Genome Diagnostics, Inc. (&#8220;Personal Genome Diagnostics&#8221;) in the United States District Court for the District of Delaware, alleging that each of the </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> companies has infringed a patent relating to the Company&#8217;s digital sequencing technology. The Company subsequently amended its original complaints in each case to assert infringement of three additional patents relating to its digital sequencing technology. In each lawsuit, the Company is seeking compensatory damages, injunctive relief and attorneys&#8217; fees. Personal Genome Diagnostics and Foundation Medicine have each asserted counterclaims of patent invalidity and non-infringement. In March 2018, Personal Genome Diagnostics filed </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> petitions for post-grant review with the PTAB, challenging the patentability of </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> of the patents asserted by the Company. Prior to reaching a decision on the merits, the </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> post-grant review petitions were dismissed with prejudice in July 2018. Subsequently,&#160;Foundation Medicine filed </span><span style="font-family:inherit;font-size:10pt;"><span>six</span></span><span style="font-family:inherit;font-size:10pt;"> petitions for inter partes review with the PTAB, challenging the patentability of all four of the patents asserted by the Company, which actions are currently pending at the PTAB. The Company plans to vigorously defend its patent rights during such PTAB actions.&#160;At this time, the Company cannot reasonably ascertain the likelihood that any of the challenged patents will be found to be invalid or unenforceable.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License Dispute</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the Company filed a request for arbitration to the International Chamber of Commerce claiming that one of its licensors, KeyGene N.V. (&#8220;Licensor&#8221;), has breached its patent license agreement with the Company. In January 2019, Licensor responded with its answer and counterclaims and alleged that the Company has breached the patent license agreement. The Company subsequently followed up with supplemental claims, for which Licensor responded with its supplemental answer. The Company is seeking damages, declaratory relief and alternative forms of relief including recession and reformation to address Licensor&#8217;s alleged breaches of the patent license agreement. Licensor is seeking damages, recovery of costs and fees and declaratory relief in addition to the dismissal of the Company&#8217;s claims. The arbitration is in preliminary stages, and no date has been set for rendering a final decision. At this time, the Company cannot reasonably ascertain the likelihood that any of its claims or Licensor&#8217;s counterclaims will be heard by the arbitration panel or succeed on the merits.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Disputes</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2018, the Company settled a commercial dispute. In connection with the settlement, the Company received a payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.25 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was reported as other income in the consolidated statements of operations for the year ended December&#160;31, 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>305</ContextCount>
  <ElementCount>548</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>93</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001001 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004001 - Statement - Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Investment in Joint Venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/InvestmentInJointVenture</Role>
      <ShortName>Investment in Joint Venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Consolidated Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedBalanceSheetComponents</Role>
      <ShortName>Consolidated Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Fair Value Measurements. Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Acquisition of Bellwether Bio</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionOfBellwetherBio</Role>
      <ShortName>Acquisition of Bellwether Bio</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Patent License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/PatentLicenseAgreement</Role>
      <ShortName>Patent License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Senior Term Loan and Royalty Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreement</Role>
      <ShortName>Senior Term Loan and Royalty Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentAndGeographicInformation</Role>
      <ShortName>Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Consolidated Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsTables</Role>
      <ShortName>Consolidated Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/ConsolidatedBalanceSheetComponents</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Fair Value Measurements. Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Acquisition of Bellwether Bio (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionOfBellwetherBioTables</Role>
      <ShortName>Acquisition of Bellwether Bio (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/AcquisitionOfBellwetherBio</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/Tables</Role>
      <ShortName>(Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/StockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentAndGeographicInformationTables</Role>
      <ShortName>Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SegmentAndGeographicInformation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DescriptionOfBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/DescriptionOfBusiness</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Useful Life of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesUsefulLifeOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Useful Life of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesRemainingPerformanceObligationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Remaining Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Summary of Significant Accounting Policies - Adoption of ASC 606 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAsc606Details</Role>
      <ShortName>Summary of Significant Accounting Policies - Adoption of ASC 606 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Investment in Joint Venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/InvestmentInJointVentureDetails</Role>
      <ShortName>Investment in Joint Venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/InvestmentInJointVenture</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Consolidated Balance Sheet Components - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Consolidated Balance Sheet Components - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Consolidated Balance Sheet Components - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Consolidated Balance Sheet Components - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Consolidated Balance Sheet Components - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Consolidated Balance Sheet Components - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Fair Value Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements. Cash Equivalents and Marketable Securities - Fair Value Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements. Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Fair Value Measurements. Cash Equivalents and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Acquisition of Bellwether Bio - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionOfBellwetherBioNarrativeDetails</Role>
      <ShortName>Acquisition of Bellwether Bio - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Acquisition of Bellwether Bio - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionOfBellwetherBioAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisition of Bellwether Bio - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Acquisition of Bellwether Bio - Intangible Assets Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionOfBellwetherBioIntangibleAssetsAcquiredDetails</Role>
      <ShortName>Acquisition of Bellwether Bio - Intangible Assets Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2406405 - Disclosure - Acquisition of Bellwether Bio - Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionOfBellwetherBioOtherIntangibleAssetsDetails</Role>
      <ShortName>Acquisition of Bellwether Bio - Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2406406 - Disclosure - Acquisition of Bellwether Bio - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionOfBellwetherBioFutureAmortizationExpenseDetails</Role>
      <ShortName>Acquisition of Bellwether Bio - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Patent License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/PatentLicenseAgreementDetails</Role>
      <ShortName>Patent License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/PatentLicenseAgreement</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Senior Term Loan and Royalty Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreementDetails</Role>
      <ShortName>Senior Term Loan and Royalty Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SeniorTermLoanAndRoyaltyPurchaseAgreement</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesScheduleOfOperatingLiabilityMaturitiesDetails</Role>
      <ShortName>Leases - Schedule of Operating Liability Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Leases - Schedule of Future Minimal Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesScheduleOfFutureMinimalLeasePaymentsDetails</Role>
      <ShortName>Leases - Schedule of Future Minimal Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Commitments and Contingencies - Schedule of Future Royalty Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Royalty Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CommonStock</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2412401 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/Warrants</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/ConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/ConvertiblePreferredStock</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Stock-Based Compensation - Valuation of Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationValuationOfEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation of Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Income Taxes - Schedule of Loss Before Components of the Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxesScheduleOfLossBeforeComponentsOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Components of the Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Income Taxes - Schedule of Components of the Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of the Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2416404 - Disclosure - Income Taxes - Schedule of the Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of the Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Income Taxes - Reconciliation of the Balance of Total Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxesReconciliationOfBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Balance of Total Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2417401 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Segment and Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentAndGeographicInformationDetails</Role>
      <ShortName>Segment and Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SegmentAndGeographicInformationTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2419401 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/RelatedPartyTransactions</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="gh-12312019x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - gh-12312019x10k.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - gh-12312019x10k.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="gh-12312019x10k.htm">gh-12312019x10k.htm</File>
    <File>a10-kexhibit1021lanman.htm</File>
    <File>descriptionofregistran.htm</File>
    <File>exhibit211.htm</File>
    <File>exhibit231.htm</File>
    <File>exhibit311.htm</File>
    <File>exhibit312.htm</File>
    <File>exhibit321.htm</File>
    <File>exhibit322.htm</File>
    <File>gh-20191231.xsd</File>
    <File>gh-20191231_cal.xml</File>
    <File>gh-20191231_def.xml</File>
    <File>gh-20191231_lab.xml</File>
    <File>gh-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>graphic3.jpg</File>
    <File>guardantgraphic201910k.jpg</File>
    <File>marketopportunity.jpg</File>
    <File>slide1a01.jpg</File>
    <File>slide1a03.jpg</File>
    <File>stockchart.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6638526544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Bellwether Bio<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition of Bellwether Bio</a></td>
<td class="text">Acquisition of Bellwether Bio<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2019, the Company purchased of all of the outstanding shares of Bellwether Bio, Inc. (&#8220;Bellwether Bio&#8221;), a privately-held company developing a method for early blood-based cancer detection. The Company accounted for the acquisition as a business combination. The total purchase consideration was </span><span style="font-family:inherit;font-size:10pt;"><span>$8.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, which consisted of i)&#160;&#160;&#160;&#160; </span><span style="font-family:inherit;font-size:10pt;"><span>$7.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash paid upon closing; and ii) future contingent consideration liability with a fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the acquisition date. The contingent consideration is subject to the achievement of certain commercialization milestones with a maximum payout amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company will also pay additional earn-out consideration of up to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> subject to the achievement of certain commercialization milestones and&#160;the continued provision of services to the Company by certain former employees&#160;and consultants&#160;of Bellwether Bio. The contingent consideration and earn-out consideration may be paid, at the Company&#8217;s election, in cash or in the Company&#8217;s common stock. As of December&#160;31, 2019, the Company did not believe the earn-out consideration is probable to be achieved, and therefore, did not record any compensation expense. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The excess purchase consideration over the fair value of assets acquired and liabilities assumed was recorded as goodwill. Goodwill is attributable to future revenue opportunities that we expect to achieve from leveraging Bellwether Bio&#8217;s existing license and IPR&amp;D, as well as the assembled workforce. The valuation of the intangible assets acquired was determined using currently available information and reasonable assumptions. The following table summarizes the allocation of the total consideration to the estimated fair values of assets acquired and liabilities assumed:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>521</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identified intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net liabilities assumed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,802</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,708</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents details of the identified intangible assets acquired from the Bellwether Bio acquisition:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Useful Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired license</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">IPR&amp;D assets are not subject to amortization.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the acquisition of Bellwether Bio, the Company also entered into non-compete agreements with certain key individuals based on their experience and importance to the operation of Bellwether Bio. The Company accounted for the covenants not to compete as purchases of intangible assets separate from the business combination as these non-compete agreements were initiated by the Company to protect its interests. The fair value of acquired covenants not to compete was estimated to be </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is recorded within intangible assets on the consolidated balance sheet and will be amortized over an estimated useful life of </span><span style="font-family:inherit;font-size:10pt;"><span>6 years</span></span><span style="font-family:inherit;font-size:10pt;"> using the straight-line method.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents other intangible assets - net: </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Useful Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired license</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-compete agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,290</span></span></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,490</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>676</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,814</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no intangible assets as of December 31, 2018.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes estimated future amortization expense of finite-lived intangible assets&#8212;net:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:29%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,924</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration is measured at fair value on a quarterly basis based on additional information as it becomes available and change in estimated contingent consideration to be paid will be included in </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">operating expenses in the consolidated statements of operations. The fair value of acquisition-related contingent consideration is estimated using a multiple-outcome discounted cash flow valuation technique. Contingent consideration is classified within Level 3 of the fair value hierarchy, as it is based on a probability that includes significant unobservable inputs. The significant unobservable inputs include a probability-weighted estimate of achievement of certain commercialization milestones, continued services from certain former employees and consultants, resulting contingent payments, and discount rate to present value the expected payments. A significant change in any of these input factors in isolation could have a material impact to fair value measurement. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since initial valuation on the date of acquisition, contingent consideration liability increased by </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3</span></span><span style="font-family:inherit;font-size:10pt;"> million due to change in estimate relating to inputs used to determine the fair value of contingent consideration. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, contingent consideration liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded within other long-term liabilities on the consolidated balance sheet. </span></div><span style="font-family:inherit;font-size:10pt;">For the period ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company incurred acquisition-related transaction costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4</span></span> million which are included in general and administrative expenses in the consolidated statements of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6839400384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#8217; interests in the Joint Venture are shown in the consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company believes that its existing cash and cash equivalents and marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations,&#160;goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">JOBS Act Accounting Election</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective December 31, 2019, we are no longer an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Prior to losing our status as an emerging growth company, the JOBS Act allowed us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements were made applicable to private companies, and we had elected to use this extended transition period.&#160;We can no longer take advantage of this extended transition period. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#8217; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the consolidated statements of operations. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, foreign currency translation adjustment was immaterial. For the year ended December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company did not have foreign currency translation adjustment as the foreign subsidiaries were established in 2018.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company operates as one operating and reportable segment. The Company&#8217;s chief operating decision makers, the Chief Executive Officer, and the President and Chief Operating Officer, manage the Company&#8217;s operations on an aggregate basis for purposes of allocating resources.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments with original maturities at the time of purchase of three months or less.&#160;Cash equivalents include bank demand deposits and money market accounts that invest primarily in U.S. government-backed securities and treasuries. Cash equivalents are carried at cost, which approximates their fair value.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In fiscal 2017, restricted cash consists of deposits related to the Company&#8217;s corporate credit card. The Company did not have any restricted cash as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities consist primarily of high-grade corporate bonds, commercial papers and certificates of deposit with third parties. Marketable securities with original maturities at the time of purchase between three and twelve months from balance sheet dates are classified as short-term marketable securities and those with maturities over twelve months from balance sheet dates are classified as long-term marketable securities. The Company classifies all marketable securities as available-for-sale, which are recorded at fair value. Unrealized gains and losses are included in accumulated other comprehensive loss in stockholders&#8217; equity. Any premium or discount arising at purchase is amortized or accreted to interest income or expense. Realized gains and losses and declines in value, if any, judged to be other than temporary on available&#8209;for&#8209;sale securities are reported in other income (expense), net. When securities are sold, any associated unrealized gain or loss initially recorded as a separate component of stockholders&#8217; equity is reclassified out of stockholders&#8217; equity on a specific&#8209;identification basis and recorded in earnings for the period.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not that it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and management&#8217;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also invests in investment&#8209;grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after&#8209;tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective consolidated balance sheet date, are as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:39%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Accounts Receivable</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer A   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer B   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer C   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">less than 10%</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> allowance for doubtful accounts.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory consisted entirely of supplies, which are consumed when providing liquid biopsy tests, and therefore the Company does not maintain any finished goods inventory.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by the Company, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Amounts written-down due to unmarketable inventory are recorded in cost of precision oncology testing.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost. Depreciation is computed over estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The Company periodically reviews the depreciable lives assigned to property and equipment placed in service and changes the estimates of useful lives, if necessary. Maintenance and repairs are expensed as incurred.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated useful lives for property and equipment are as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:56%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Property and Equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated&#160;Useful&#160;Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3 &#8211; 5 years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7 years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer hardware and computer software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3 years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lesser of estimated useful life or remaining lease term</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company includes the results of operations of the businesses that are acquired as of the acquisition date. The Company allocates the purchase price of acquisitions to the assets acquired and liabilities assumed based on the estimated fair values. The excess of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition related costs are recognized separately from the business combination and are expensed as incurred.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Intangible Assets, net</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets related to in-process research and development costs (&#8220;IPR&amp;D&#8221;) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there has been&#160;no&#160;impairment of goodwill.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6-</span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Obligation Related to Royalty</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of the Company&#8217;s asset acquisitions involve the potential for future payment of consideration that is contingent upon the royalty payments due on future product net sales, subject to annual minimums. The fair value of such liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment for Long-Lived Assets</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition under ASC 606</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include companion diagnostic development, information solutions and laboratory services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, we adopted the new revenue recognition standard FASB ASC Topic 606,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">,&#160;or ASC 606. Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Precision oncology testing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Development services</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations. The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contracts with multiple performance obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated. For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contract assets</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable.&#160;Contract assets are presented under accounts receivable and other assets on the Company&#8217;s consolidated balance sheets. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had contract assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> is recorded in other assets in the consolidated balance sheet.  The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of contract assets as of January 1, 2019. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred revenue </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company&#8217;s performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the deferred revenue balance was </span><span style="font-family:inherit;font-size:10pt;"><span>$12.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$16.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which included </span><span style="font-family:inherit;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the&#160;twelve months ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">&#160;that was included in the deferred revenue balance as of January 1, 2019 was&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$15.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, which primarily represented revenue from&#160;provision of development services under the collaboration agreement with our biopharmaceutical companies.&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Transaction price allocated to the remaining performance obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next </span><span style="font-family:inherit;font-size:10pt;"><span>12 months</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition under ASC 605</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include the development of new platforms and information solutions, including companion diagnostic development and laboratory services. The Company currently receives payments from commercial third-party payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when all of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Criterion (i) is satisfied when the Company has an arrangement or contract in place. Criterion (ii) is satisfied when the Company delivers a test report corresponding to each sample, without further commercial obligations. Determination of criteria (iii) and (iv) are based on management&#8217;s judgments regarding whether the fee is fixed or determinable, and whether the collectability of the fee is reasonably assured. The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians, if criteria (i) through (iv) above are met. The Company recognizes revenue on a cash basis when it cannot conclude that criteria (iii) and (iv) have been met. Most of precision oncology tests requested by clinical customers are sold without a contracted engagement with a third-party payer; therefore, the Company experiences significant variability in collections and does not have sufficient history to establish a predictable pattern of payment. Because the price is not fixed or determinable and collectability is not reasonably assured, the Company recognizes revenue on a cash basis for sales of its liquid biopsy tests to clinical customers where collection depends on a third-party payer or the individual patient. The Company uses judgment in its assessment of whether the fee is fixed or determinable and whether collectability is reasonably assured in determining when to recognize revenue. Accordingly, the Company expects to recognize revenue on a cash basis for these clinical customers until it has sufficient history to reliably estimate payment patterns. The Company&#8217;s precision oncology information services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from sales of the Company&#8217;s tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume, data access or biopharmaceutical research and development services over a defined period. The Company recognizes revenue upon delivery of the test results, or over the period in which biopharmaceutical research and development services are provided, as appropriate.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple-element arrangements.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Contracts with biopharmaceutical customers are primarily analyzed as multiple-element arrangements given the nature of the service deliverables. For development services performed, the Company is compensated in various ways, including (i) through non-refundable regulatory and other developmental milestone payments; and (ii) through royalty and sales milestone payments. The Company performs development services as part of its normal activities. The Company records these payments as development services revenue in the consolidated statements of operations using a proportional performance model over the period which the unit of accounting is delivered or based on the level of effort expended to date over the total expected effort, whichever is considered the most appropriate measure of performance. For development of new products or services under these arrangements, costs incurred before technological feasibility is assured are included as research and development expenses in the Company&#8217;s consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services. The Company collaborates with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations the Company generates revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For revenue arrangements with multiple deliverables, the Company evaluates each deliverable to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has stand-alone value to the customer and whether a general right of return exists. In assessing whether an item has standalone value, the Company considers factors such as the research, development and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the other party in the arrangement can use the other deliverables for their intended purpose without the receipt of the remaining elements, whether the value of the deliverable is dependent on the undelivered items and whether there are other vendors that can provide the </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">undelivered elements. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The Company allocates the arrangement consideration following a hierarchy to determine the relative selling price to be used for allocating revenue to deliverables: (i) vendor-specific objective evidence of fair value (&#8220;VSOE&#8221;), (ii) third-party evidence of selling price (&#8220;TPE&#8221;), and (iii) best estimate of the selling price (&#8220;BESP&#8221;) if neither VSOE nor TPE is available. The Company typically uses BESP to estimate the selling price, since it generally does not have VSOE or TPE of selling price for its units of accounting under multiple-element arrangements. In developing the BESP for a unit of accounting, the Company considers applicable market conditions and estimated costs. The Company validates the BESP for units of accounting by evaluating whether changes in the key assumptions used to determine the BESP will have a significant effect on the allocation of arrangement consideration between multiple units of accounting. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. The Company uses judgment in identifying the deliverables in its arrangements, assessing whether each deliverable is a separate unit of accounting and in determining the best estimate of selling price for certain deliverables. The Company also uses judgment in determining the period over which the deliverables are recognized in certain of its arrangements. Any amounts received that do not meet the criteria for revenue recognition are recorded as deferred revenue until such criteria are met. The Company performed laboratory installation and maintenance services for one of its customers as part of a multiple-element arrangement entered into in 2017. The Company recognized certain revenue from its construction service deliverables in a multiple-element collaboration arrangement based on the completed-contract method. This method was used as the Company determined that it did not have the basis for estimating performance under the contract. Other construction service deliverables under that contract were recognized under the percentage-of-completion method due to the Company&#8217;s ability to make reasonably dependable estimates of the extent of progress toward contract completion. All construction services under this arrangement were completed in March 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestones</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes payments that are contingent upon achievement of a substantive milestone in their entirety in the period in which the milestone is achieved. Milestones are defined as events that can only be achieved based on the Company&#8217;s performance and there is substantive uncertainty about whether the event will be achieved at the inception of the arrangement. Events that are contingent only on the passage of time or only on counterparty performance are not considered substantive milestones. Further, the amounts received must relate solely to prior performance, be reasonable relative to all of the deliverables and payment terms within the agreement and commensurate with the Company&#8217;s performance to achieve the milestone after commencement of the agreement. Any contingent payment that becomes payable upon achievement of events that are not considered substantive milestones are allocated to the units of accounting previously identified at the inception of an arrangement when the contingent payment is received and revenue is recognized based on the revenue recognition criteria for each unit of accounting. Revenue from commercial milestone payments are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs of Precision Oncology Testing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Development Services</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of development service includes costs incurred for the performance of development services requested by the Company&#8217;s customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses are comprised of costs incurred to develop technology and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development expenses </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">also include costs related to activities performed under contracts with biopharmaceutical companies. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#8217;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expenses advertising costs as incurred. The Company incurred advertising costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Offering Costs</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred offering costs consist of fees and expenses incurred in connection with the anticipated sale of the Company&#8217;s common stock in the IPO, including the legal, accounting, printing and other IPO-related costs. In October 2018, upon completion of the IPO, the Company reclassified deferred offering costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> into additional paid-in capital as a reduction of the net proceeds received from the IPO. There were no deferred offering costs as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock&#8209;Based Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock&#8209;based compensation related to stock options granted to the Company&#8217;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, the Company accounted for stock options issued to nonemployees consultants based on the estimated fair value at the grant date and re-measured at each reporting period. Starting January 1, 2019, upon adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2018-07,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718)</span><span style="font-family:inherit;font-size:10pt;">,&#160;Improvements to Nonemployee Share-Based Payment Accounting,&#160;the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the Black&#8209;Scholes option&#8209;pricing model to estimate the fair value of its stock options and purchase rights under its 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Starting January 1, 2017, forfeitures are accounted for as they occur.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for restricted stock units issued to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in the Company&#8217;s consolidated statement of operations on a straight-line basis over the requisite vesting period.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes are recorded using an asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the closing of the Company&#8217;s IPO in October 2018 and the conversion of its convertible preferred stock into common stock, the Company calculated its basic and diluted net loss per share attributable to common stockholders of the Company in conformity with the two-class method required for companies with participating securities. The Company considered its convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on the Company&#8217;s common stock, holders of convertible preferred stock were entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock did not have a contractual obligation to share in the Company&#8217;s losses.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Adopted </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2014-09,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)&#160;and all related amendments (collectively, &#8220;ASC 606&#8221;)</span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2019 utilizing the modified retrospective method. The cumulative effect of applying the standard to all contracts that were not completed as of the date of initial application was recognized to beginning accumulated deficit as of January 1, 2019. The Company identified certain differences in accounting for revenue recognition as a result of the adoption of ASC 606 which have impacted its financial position and results of operations.  For precision oncology testing revenue with certain clinical customers, the Company historically deferred revenue recognition until cash receipt when the price pursuant to the underlying customer arrangement became fixed and determinable and collectability became reasonably assured. Under the new standard, this is considered variable consideration and revenue is recognized at the estimated transaction price upon delivery. This results in earlier revenue recognition under the new standard as compared to previous revenue recognition. For development services revenue with certain biopharmaceutical customers, the Company historically limited revenue recognition based on the right to invoice the customer. Under the new standard, for these arrangements, the Company constrains revenue such that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For arrangements with regulatory and other developmental milestone payments, this results in a change to the timing and pattern of revenue recognition under the new standard as compared to previous revenue recognition.  Comparative information from prior periods has not been restated and&#160;continues to be reported under the accounting standards in effect for those periods. The cumulative effect of changes made to the consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments due to ASC 606 </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of January 1, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,597</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(280,799</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(275,892</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC 606 requirements under the modified retrospective method of adoption, the impact of the adoption of ASC 606 on the Company&#8217;s consolidated statement of operations and consolidated balance sheet was as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the year ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported Under ASC 606</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology testing </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180,462</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Development services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported Under ASC 606</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,639</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(352,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(353,156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 606 did not have an aggregate impact on the Company&#8217;s net cash used in operating activities but resulted in offsetting changes in certain assets presented within net cash used in operating activities in the Company&#8217;s consolidated statement of cash flows, as reflected in the above table. The the Company&#8217;s revenue is generated primarily from the sale of precision oncology testing and development services. Precision oncology testing revenue is generated from sales of the Company&#8217;s current products to clinical and biopharmaceutical customers. Total precision oncology testing revenues from sales to clinical customers for the years ended December 31, 2019, 2018 and 2017 were </span><span style="font-family:inherit;font-size:10pt;">$94.2 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$43.7 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$24.5 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. Total precision oncology testing revenues from sales to biopharmaceutical customers for the years ended December 31, 2019, 2018 and 2017 were </span><span style="font-family:inherit;font-size:10pt;">$79.5 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$34.7 million</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$17.6 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. Development services revenue represent services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted&#160;ASC 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">,  and its related amendments which requires the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for operating leases on the consolidated balance sheet on January 1, 2019 using a modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases in place as of January 1, 2019. The Company also elected the practical expedient to not separate lease and non-lease components for its facility leases, and to not recognize ROU assets and operating lease liabilities for short-term leases.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 842, the Company determines if an arrangement contains a lease and the classification of that lease, if applicable, at inception or upon modification of a contract. The Company has elected to not recognize a lease liability or ROU asset for short-term leases (leases with a term of twelve months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise). The Company has elected to not allocate the contract consideration for operating lease contracts with lease and non-lease components, and account for the lease and non-lease components as a single lease component. ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at lease commencement date. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. An option to extend the lease </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The primary impact of adopting&#160;Topic 842&#160;was the recognition of ROU assets and lease liabilities for operating leases of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$14.5</span></span><span style="font-family:inherit;font-size:10pt;"> million and </span><span style="font-family:inherit;font-size:10pt;"><span>$22.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively, on January 1, 2019, which included reclassifying prepaid rent and deferred rent as a component of the ROU asset.&#160;Topic 842&#160;did not have a material impact on the Company's consolidated statements of operations and cash flows.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The short-term liabilities from the Company's operating leases are included in accrued expenses in the consolidated balance sheet. The Company's accounting for finance leases (formerly referred to as capital leases prior to the adoption of&#160;Topic 842) remains substantially unchanged. Finance leases are not material to the consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease expense for lease payments for the operating leases is recognized on a straight-line basis over the term of the lease.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718):</span><span style="font-family:inherit;font-size:10pt;"> Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, with certain exceptions. The Company early adopted this new guidance effective January 1, 2019. In accordance with the transition guidance, the Company assessed its outstanding nonemployee awards for which a measurement date had not been established. These outstanding awards were re-measured to fair value as of the January 1, 2019 adoption date. For nonemployee awards that contain performance condition, the measurement is based on the outcome that is probable as opposed to the lowest aggregate fair value within a range of possible outcomes. The adoption of ASU 2018-07 provided administrative relief by fixing the measurement date of nonemployee awards and eliminating the requirement of quarterly re-measurement. The Company adopted this standard on a modified retrospective basis and recorded a cumulative-effect adjustment of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;as an increase to accumulated deficit and an equal increase to additional paid-in capital as of January 1, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;), which contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December&#160;31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No.&#160;118,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Tax Accounting Implications of the Tax Cuts and Jobs Act</span><span style="font-family:inherit;font-size:10pt;">&#160;(&#8220;SAB 118&#8221;) to address the accounting implications of the enacted U.S. federal tax reform. SAB 118 allows companies&#160;to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and no measurement period adjustments were recognized due to the full valuation allowance on the Company&#8217;s deferred tax assets.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13,&#160;Financial Instruments - Credit Losses:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">the FASB issued ASU 2017-04</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:10pt;">Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment which eliminates Step 2 from the goodwill impairment test and instead requires entities to perform its annual or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount</span><span style="font-family:Arial;font-size:9pt;">. </span><span style="font-family:inherit;font-size:10pt;">The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements in ASC 820, Fair Value Measurement, as part of its disclosure framework project. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted. The amendments in ASU 2018-13 on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments in ASU 2018-13 should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cloud Computing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15&#8212;Intangibles-Goodwill and Other-Internal&#8212;Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC Topic 350, Intangibles&#8212;Goodwill and Other, to determine which implementation costs to capitalize as assets or expense as incurred.  The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB amended ASC 808 and ASC 606 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The guidance is effective for us beginning January 1, 2020 and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU 2019-12, Income Taxes - Topic 740, which simplifies the accounting for income taxes.&#160; Amendments include removal of certain exceptions to the general principles of ASC 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes,</span><span style="font-family:inherit;font-size:10pt;"> related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences.&#160;ASU 2019-12 also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning January 1, 2021, and early adoption is permitted.&#160; The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6858935552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 16,954<span></span>
</td>
<td class="nump">$ 6,851<span></span>
</td>
<td class="nump">$ 3,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember', window );">Precision oncology testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">512<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,907<span></span>
</td>
<td class="nump">1,684<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,716<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,468<span></span>
</td>
<td class="nump">$ 2,928<span></span>
</td>
<td class="nump">$ 2,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6862859872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Balance of Total Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits - Beginning of period</a></td>
<td class="nump">$ 3,427<span></span>
</td>
<td class="nump">$ 1,712<span></span>
</td>
<td class="nump">$ 884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year&#8217;s tax positions</a></td>
<td class="nump">3,116<span></span>
</td>
<td class="nump">1,635<span></span>
</td>
<td class="nump">828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior years&#8217; tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits - End of period</a></td>
<td class="nump">$ 6,543<span></span>
</td>
<td class="nump">$ 3,427<span></span>
</td>
<td class="nump">$ 1,712<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885936672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (67,851,000)<span></span>
</td>
<td class="num">$ (84,263,000)<span></span>
</td>
<td class="num">$ (83,221,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">11,411,000<span></span>
</td>
<td class="nump">7,136,000<span></span>
</td>
<td class="nump">5,206,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AmortizationOfRightOfUseAssets', window );">Amortization of ROU</a></td>
<td class="nump">2,198,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty', window );">Unrealized translation (gains) losses on obligation related to royalty</a></td>
<td class="num">(147,000)<span></span>
</td>
<td class="num">(357,000)<span></span>
</td>
<td class="nump">980,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Re-valuation of contingent consideration</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">16,954,000<span></span>
</td>
<td class="nump">6,851,000<span></span>
</td>
<td class="nump">3,670,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NoncashInterestExpensePaid', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
<td class="nump">685,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,075,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium (discount) on marketable securities</a></td>
<td class="num">(2,310,000)<span></span>
</td>
<td class="num">(412,000)<span></span>
</td>
<td class="nump">359,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Benefit from income tax differences</a></td>
<td class="num">(1,597,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,389,000)<span></span>
</td>
<td class="num">(22,903,000)<span></span>
</td>
<td class="num">(9,292,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(6,045,000)<span></span>
</td>
<td class="num">(1,849,000)<span></span>
</td>
<td class="num">(4,518,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(6,185,000)<span></span>
</td>
<td class="num">(3,663,000)<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(2,852,000)<span></span>
</td>
<td class="num">(451,000)<span></span>
</td>
<td class="num">(883,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,341,000<span></span>
</td>
<td class="nump">5,046,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">5,571,000<span></span>
</td>
<td class="nump">8,075,000<span></span>
</td>
<td class="nump">2,348,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,213,000<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
<td class="nump">4,657,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets', window );">Long-term operating lease liabilities net of ROU</a></td>
<td class="nump">1,039,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,307,000<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(3,861,000)<span></span>
</td>
<td class="nump">13,025,000<span></span>
</td>
<td class="nump">1,215,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">76,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(47,134,000)<span></span>
</td>
<td class="num">(72,185,000)<span></span>
</td>
<td class="num">(72,235,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(614,290,000)<span></span>
</td>
<td class="num">(287,450,000)<span></span>
</td>
<td class="num">(236,835,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturity of marketable securities</a></td>
<td class="nump">325,333,000<span></span>
</td>
<td class="nump">154,625,000<span></span>
</td>
<td class="nump">75,402,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisition, net of cash acquired</a></td>
<td class="num">(7,328,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(18,717,000)<span></span>
</td>
<td class="num">(20,203,000)<span></span>
</td>
<td class="num">(6,681,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets and capitalized license obligations</a></td>
<td class="num">(2,500,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_PaymentsInConnectionWithLicenseAgreements', window );">Payment in connection with a license agreement</a></td>
<td class="num">(68,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,302,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(317,570,000)<span></span>
</td>
<td class="num">(153,028,000)<span></span>
</td>
<td class="num">(170,416,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations', window );">Payment related to settlement of debt and buyout of royalty obligations</a></td>
<td class="num">(311,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,844,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments made on capital lease obligations</a></td>
<td class="num">(128,000)<span></span>
</td>
<td class="num">(443,000)<span></span>
</td>
<td class="num">(244,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">319,536,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">6,395,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">11,639,000<span></span>
</td>
<td class="nump">3,111,000<span></span>
</td>
<td class="nump">753,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of common stock upon the exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock', window );">Repurchase of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,335,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(172,000)<span></span>
</td>
<td class="num">(7,222,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offerings of common stock</a></td>
<td class="nump">350,432,000<span></span>
</td>
<td class="nump">254,006,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs related to public offerings of common stock</a></td>
<td class="num">(723,000)<span></span>
</td>
<td class="num">(4,386,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Net proceeds from issuance of equity interests in redeemable noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">367,304,000<span></span>
</td>
<td class="nump">293,161,000<span></span>
</td>
<td class="nump">281,656,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Net effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,684,000<span></span>
</td>
<td class="nump">67,948,000<span></span>
</td>
<td class="nump">39,005,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - Beginning of period</a></td>
<td class="nump">140,544,000<span></span>
</td>
<td class="nump">72,596,000<span></span>
</td>
<td class="nump">33,591,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - End of period</a></td>
<td class="nump">143,228,000<span></span>
</td>
<td class="nump">140,544,000<span></span>
</td>
<td class="nump">72,596,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="nump">16,714,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,181,000<span></span>
</td>
<td class="nump">1,251,000<span></span>
</td>
<td class="nump">1,339,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">298,000<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment', window );">Capitalized license fees financed through future royalty payment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,302,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid', window );">Increase in purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">3,296,000<span></span>
</td>
<td class="nump">897,000<span></span>
</td>
<td class="nump">591,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly', window );">Vesting of common stock exercised early</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Property and equipment acquired under capital leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ConversionofStockUponInitialPublicOffering', window );">Conversion of convertible preferred stock to common stock upon initial public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">499,974,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">1,065,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_OfferingCostsIncurredbutNotyetPaid', window );">Deferred offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement', window );">Issuance of Series D convertible preferred stock in exchange for a technology license agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,060,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly', window );">Vesting of common stock exercised early</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AmortizationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AmortizationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized License Fees Financed Through Future Royalty Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ConversionofStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock Upon Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ConversionofStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Capital Expenditures Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Operating Lease Liabilities Net Of Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NoncashInterestExpensePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Interest Expense Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NoncashInterestExpensePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_OfferingCostsIncurredbutNotyetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Incurred but Not yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_OfferingCostsIncurredbutNotyetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Related to Settlement of Debt and Buyout of Royalty Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PaymentsInConnectionWithLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments In Connection With License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PaymentsInConnectionWithLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Stock Options Exercised Early</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Translations Gain (Loss) On Obligation Related To Royalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value Of Convertible Preferred Stock Issued In Exchange For License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase during the period in capital lease obligations due to entering into new capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based compensation arrangement, excluding stock option exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6880275840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">6,311<span></span>
</td>
<td class="nump">51,707<span></span>
</td>
<td class="nump">50,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,898<span></span>
</td>
<td class="nump">44,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">5,976<span></span>
</td>
<td class="nump">7,527<span></span>
</td>
<td class="nump">5,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gh_EmployeeStockPurchasePlanObligationMember', window );">ESPP obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockCommonMember', window );">Common stock subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Convertible Preferred Stock | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gh_EmployeeStockPurchasePlanObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gh_EmployeeStockPurchasePlanObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6639062496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at the statutory federal rate</a></td>
<td class="num">$ (14,642)<span></span>
</td>
<td class="num">$ (17,690)<span></span>
</td>
<td class="num">$ (28,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other nondeductible items</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(33,042)<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">3,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(5,266)<span></span>
</td>
<td class="num">(1,726)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">59,049<span></span>
</td>
<td class="nump">22,516<span></span>
</td>
<td class="nump">5,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefits</a></td>
<td class="num">(8,253)<span></span>
</td>
<td class="num">(4,231)<span></span>
</td>
<td class="num">(1,868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rate due to Tax Act</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(605)<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="num">$ (1,872)<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6880818928">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromPrecisionOncologyTesting', window );">Precision oncology testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 180,462<span></span>
</td>
<td class="nump">$ 78,407<span></span>
</td>
<td class="nump">$ 42,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromDevelopmentServices', window );">Development services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">33,913<span></span>
</td>
<td class="nump">12,232<span></span>
</td>
<td class="nump">7,754<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">214,375<span></span>
</td>
<td class="nump">90,639<span></span>
</td>
<td class="nump">49,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CostsofPrecisionOncologyTesting', window );">Cost of precision oncology testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62,255<span></span>
</td>
<td class="nump">39,846<span></span>
</td>
<td class="nump">28,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CostofDevelopmentServices', window );">Cost of development services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,465<span></span>
</td>
<td class="nump">3,364<span></span>
</td>
<td class="nump">2,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,292<span></span>
</td>
<td class="nump">50,714<span></span>
</td>
<td class="nump">25,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78,335<span></span>
</td>
<td class="nump">53,465<span></span>
</td>
<td class="nump">32,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,399<span></span>
</td>
<td class="nump">36,192<span></span>
</td>
<td class="nump">36,777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">296,746<span></span>
</td>
<td class="nump">183,581<span></span>
</td>
<td class="nump">126,454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(82,371)<span></span>
</td>
<td class="num">(92,942)<span></span>
</td>
<td class="num">(76,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,741<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
<td class="nump">2,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,181)<span></span>
</td>
<td class="num">(1,251)<span></span>
</td>
<td class="num">(2,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,075)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">88<span></span>
</td>
<td class="nump">4,702<span></span>
</td>
<td class="num">(1,059)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before provision for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(69,723)<span></span>
</td>
<td class="num">(84,225)<span></span>
</td>
<td class="num">(83,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,872)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(67,851)<span></span>
</td>
<td class="num">(84,263)<span></span>
</td>
<td class="num">(83,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,800)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Guardant Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(75,651)<span></span>
</td>
<td class="num">(85,063)<span></span>
</td>
<td class="num">(83,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend related to repurchase of convertible preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to Guardant Health, Inc. common stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (75,651)<span></span>
</td>
<td class="num">$ (85,063)<span></span>
</td>
<td class="num">$ (88,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (2.80)<span></span>
</td>
<td class="num">$ (7.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,597<span></span>
</td>
<td class="nump">30,403<span></span>
</td>
<td class="nump">12,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gh_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend related to repurchase of convertible preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (4,716)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gh_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend related to repurchase of convertible preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,058)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Fiscal year 2018 and 2017 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostofDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Development Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostofDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostsofPrecisionOncologyTesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of Precision Oncology Testing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostsofPrecisionOncologyTesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RevenuefromDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Development Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RevenuefromDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RevenuefromPrecisionOncologyTesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Precision Oncology Testing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RevenuefromPrecisionOncologyTesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gh_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gh_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gh_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gh_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6859641296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Bellwether Bio - Other Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,890<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member', window );">Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,289<span></span>
</td>
<td class="nump">3,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_IntangibleAssetsGrossIncludingGoodwill', window );">Total intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member', window );">Bellweather Bio, Inc. | Acquired license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member', window );">Bellweather Bio, Inc. | Non-compete agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IntangibleAssetsGrossIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Gross (Including Goodwill)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IntangibleAssetsGrossIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6852840096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements. Cash Equivalents and Marketable Securities - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_MarketableSecuritiesMaturityPeriod', window );">Maturity period (years)</a></td>
<td class="text">1 year 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_MarketableSecuritiesMaturityPeriod', window );">Maturity period (years)</a></td>
<td class="text">1 year 9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_MarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_MarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M'WY78>>-W=M_;'P1E!W\N@OY!5!+ P04    "  +26)0F5R<(Q &  "<)P
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MQWG0VBA[*_&='?9)Y?OIHE0'TYW.['DS;-V'"Z//XV>):/HVLOH'4$L#!!0
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M$\"F1L#4^ O9DJ0=%:FS>RY;8D99)>HML6398<*,"9L; 7.S4ZECKZ'BX[]
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M8\<K:7^#W5DJ7O<L6DI-W[NQ;.QX[;[DJ$^#$Y(^(1D2$'F8D/8)Z6<"?IB
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MN01?*W'@?\'Y.GR[JG ;X=L_%/ZC_FZ58!<)=O]M<2WGHTJVF*D&4\=MLJ3
MOHV;O(C."WO#XYV\IX_;_E.86K:6G-#YFXWSKQ =>"G)E5^AQC^PV5%0N6!^
M]K89UVQT'';3"V+S,\[? %!+ P04    "  +26)08Z[P1[0!  #2 P  &0
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MC<>7C?VOC/& 4C97.$(-?K#9D%#Y</R,9SN.V6AXTTT_B,W?./\+4$L#!!0
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M_C=:._!2-E=^A#K_P69#0./"\8L_FVG,)L/I/OT@,G_C\B]02P,$%     @
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M;#$4U"X</_BSF<9L,ASV\P]BRS<N_@)02P,$%     @ "TEB4+.I-J"U 0
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M%%0N'/?^;,8Q&PV'W?2#V/R-\U]02P,$%     @ "TEB4!8?PTJW 0  T@,
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MRH7CWI_-.&:CX;";?A";OW'^!U!+ P04    "  +26)0:MN+U[,!  #2 P
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M]OGX2ZZE-&!3V=S87%K;Q<N"06W<]-;.U?26IX61_=RF9/E7%.]02P,$%
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MSK]L['^-Z,"GDESY$6K]!UL,!;4+QQM_-M.838;#?OY!;/G&Q3]02P,$%
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MLJC2@XJ3O/(N WM+XYN\PZ=I_\E,RY5%9^W\R\;^-UH[\*DD5WZ$.O_!%D-
MX\+QFS^;:<PFP^E^_D%D^<;E?U!+ P04    "  +26)0K*V1@W,#  #%#P
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M"X9'>A _4#((E.!!S4"0/Q(,V*U+[ ,2(XV"X5;#P2=* C<;#A\I"0!*QOS
M/8F!ADLF(Q)PQ^'H$]G"/8?C1[(%0,GP94=7W_V2BJ.=J=+)^*E2YO-Y9>WG
M]M(W<V-@7YEY;N?)NTQ[&?A!Q+&HI+/C2D\E.SL.G"NJ8_2>=#ES??_H#XP>
ME-G&>B_:(=P>%*^["P;J;SF+?U!+ P04    "  +26)0>E$$O!4"  #5!@
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M Z%K&P'2TJK:I$V*.FU[[< 1K-H<LYW0??N=#4%IQQOL.__O=P_8Q8CVU74
MGKT9W;N2=]X/6R%<W8&1[@8'Z.FD16ND)],>A1LLR"8&&2VR)/DDC%0]KXKH
MV]NJP)/7JH>]9>YDC+1_=Z!Q+'G*+XX7=>Q\<(BJ&.01?H#_.>PM66*A-,I
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M BZ9B!H;EC?MK[4Y-IP5?19!I4C?NFM6MM=S]T\4]6%X /0!, 2(VM<"O#[
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M&*>"HWLG7K"#.!D.#SG=<7D;B?NZ.QYU#YQ5_='/&<Z?B_]02P,$%     @
M"TEB4): $[,O @  RP8  !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&UL
MC57;CILP$/T5Q'O7Y@X106H25:W42JNMVCX[R22@-9C:3MC^?6U#$ %OFQ=\
MX9PS9\8PSCO&7T4)()VWFC9B[992MBN$Q*&$FH@GUD*CWIP8KXE42WY&HN5
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M23U-U)SW[;5?2-8.5P<:[Z_B+U!+ P04    "  +26)0M'KDQ_ !   (!0
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MX /?Z3?8SCLNWF0)H+SWFC5RXY=*M6N$Y*&$FLHGWD*CWYRXJ*G20W%&LA5
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M,^<*M&7PI+=?I9^-:<#@K$PWTWTQW)W#0/%N?!?0]#B5_P!02P,$%     @
M"TEB4/3<S2$# @  P 4  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL
M=93MCIP@%(9OQ7@!B^*(.G%,.MLT;=(FDVW:_F;T.)I%L<",V[LOH&N,LG_D
MZSWO<PX(^<C%JVP E/?6L5Z>_$:IX8B0+!OHJ'SB _1ZI>:BHTH/Q0W)00"M
M;%#'$ X"@CK:]GZ1V[F+*')^5ZSMX2(\>>\Z*OZ=@?'QY(?^^\1+>VN4F4!%
M/M ;_ 3U:[@(/4*+2]5VT,N6]YZ ^N1_"H_GS.BMX'<+HUSU/5/)E?-7,_A6
MG?S ) 0,2F4<J&X>\ R,&2.=QM_9TU^0)G#=?W?_8FO7M5RIA&?._K25:DY^
MZGL5U/3.U L?O\)<3^Q[<_'?X0%,RTTFFE%R)NW7*^]2\6YVT:ET]&UJV]ZV
MX[22D#G,'8#G +P$X*F6"60S_TP5+7+!1T],>S]0<\3A$>N]*<VDW0J[II.7
M>O91D#3*T<,8S9KSI,%K#8X7#=+^"P0[(=@:1"L#G'Y@$#D-(FMP6!L$FR0G
M26(EO94<@BQS0PY.R&$'(6&ZH4P:LJ+$.(G<E-A)B1V4;$.)]Y0H3MT4XJ20
M/66W8V1/B>/$34F<E,1!"3>49$<A8?#!X:=.2NJ@X TEW5'".$F)&Y,Y,=D.
M$Y+MEF7[GPR'R?9DT.KRF;?M!Q6WMI?>E2M]C^UMJSE7H!V#)WW6C7Y.EP&#
M6IENHOMB>E2F@>+#_%ZBY=$N_@-02P,$%     @ "TEB4-LS :39 @  #@P
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M^HRQXUPP*8?N9+,<Y.&\&^1L)]1M+._K]H3:#@2OS.G;Z_X"+/X#4$L#!!0
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MVG0,=Z_/0F@PCOC!'*K2=.YQP>&L[30U<]FWKWZA13NT9C1^'XJ_4$L#!!0
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MU9]<^T5CML.I/-C_-;#X#U!+ P04    "  +26)0?Z4V_?D"  "["P  &0
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M%   &0   'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6R56%USJS@,_2N9O&]
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M!Z)_&:$/[ OZP A]8(@^Q$Z%7'T((R:"4%(1$PK!L.W?F19W_^<@(K#+X,)
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M(S FOF BBMF8>9K-LIV7LL,(@_\'"DPUKB4!LB30)^"CDL1T DXFX'V":)1
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MIH]:M\HD#!>FVT\J.UQ/"G5LNT-ICNOA1<EPTNJS?0D47-]$K?\#4$L#!!0
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MF -HW"C 0CQ,!,ION@V!NM-TM(AS28S1U$;0FLM]S77=B/.F0%ZC4B".LZ9
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MUF-$FMQ"-F,(PG=41&"@D26(!@19DL $,4@06X+X)E.9DRD(,W&"A3!3)UH
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M#(.*;J5^S=0[[T[XW4"RMK^]!,,5:O$/4$L#!!0    (  M)8E#!V^\W, (
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MRV<^)I2$P9C]5W[FC98;$AUC(YK>_@:;4Z]$.WK1*&WU.CSKSCXOH_\W,]@
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MR=EMYL"Y FWJ/>EON-2GTSA@<%"FF^B^Z+?H?J!X.QP_9#P#BW]02P,$%
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MT-% JJ6Y2E;[- J#Z![T 7@*E(5?Z"VS.S( 38)7NDIKGBM?&CW$AZ0*$]6
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MHL(N*G)0;_!WB8H#TIAN]S61,K(^ME!C79C0F"NO$ 2/8LDJVR#SJ%+FQ:S
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M&30D23A&8[&@AQ/]+4RPI ZE=F6Q*@U,78\N9PM86UWNI3H]-KN 1YG#L',
M(VC*JAK@8-AE=/08=W2 L^J@E-@3)T6*E6P5ILIWT+!4#N.T/$94YB^]LT1*
MNX#W'RE5[T7'%. .%F(>-P%V7/Y+F1[\$BM$9"7M#8B24E)K^MF!4>"ZKG_
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M)6 MI[#\9E(L\V.K=<H^<M%;XG3-@'BGLGIH^]E=W+'!7"!(VCITDQT:V;0
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M(E9_X6K&_C8TJ<-JZHX-4CQ#.KF8PO_.AW/W)&,!W#1@MZ<7T6(T=0_4R=<
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M,RY*O %:1)@+3O[MQT__DFQW+UX''2$T/K&]Q2K,#T7Y"VRPIK.U##;0!T#
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M@2LK=XOP;C*3V,]@X$A!0](3VKCO<P-P,(<<;/MN0]UH&K>.H!/M8R='(8P
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M,]\0#L]B0(.1]%J("P7>E9?"^ 4O^G^ LTGC4!> Z_6%\(+G?P9&>:Y+D3Q
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ML\-^:]^%3QZ/7OT5XGS;"MTPB9O@MOI:VM_':X1Y>,R]BCWBFDWS,Z=WT=7
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M']>')UQTS.+-<'V2 WZPS%S0KMG+#?!G6/TPB- >=I<KJ@'AHD:8-.0KL/D
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M78C,W%(L?(/8O%G^Y=HH<+N'NK;J[HZK!(S=8?_FU^?3U&&[5!CM9?_&\#V
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MV<8,[T+1*\9VE<QFWMGBC>(7%,0K.$31_>ND,$3=91N6I/[YCHD6E*$TZHN
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MG==L.)3R')C WWH?>\6Z7B$TI2-*<O4.G[&-XL61U8R_[ZX;(ZX.Q07\B9U
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M@39O!$CY!R]Q^/P\G5C@;7YDR#DA"BP,@T[&#;(432>ZC_2C3F_E#'<5N=/
M$]@C&S_\(Y/K^=K#-?*R9\,&!9JZRG7NY:;!Z'OQP8RGS1'YX)G&1#043]T6
M*DT^ >#,VQU#GUD05^E6ZA1GLS3U]HV*QO]^W-K[-ZI%PAL' N:4X_6Z6I+.
MVW85O;44(6#P1$H*M91=Z ^UW:18*!NWH)(HQ4DOD<4X!">MF<VRA1D\U1VS
M7\(%R*FBU[O]GFI>EM6]F1@S+1?'^^*P.Y%';M]+[I0-1LXX!'Y@O#N%#A39
M5JD +SGG&W.C5T9!XQAJU*UY;S:)7G59+/'XHF=Y5V87\]4W4-;-]?I95BRU
MH%$S'19!(_IQM5JDM6S,'6ZD,N2XG>JH/. B^K)O#AN,,7,\.GSO_SE6^P.
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MM)_8%F=\Y:1*GZ<"?42.2#?:RC/ZZ,@$(^9*W;LV7\6_6MZ]4N*,X2/ TYB
M6YOW9O%O@:LQ_JWWD32Z%U ])IJ;I)I#D+N8!C [@$%OFK ^4WED@][BG,^E
MAS),34P22&^8FMB 03%]G4]LBE?J$I]:I:OMKTX56+0^-[4NB=;'!O388[=O
MJR- [^9VEX#51X?I0:4()U-^$2"<[+P5XG4=)W: G>Y)LF>3Y G(N:. %C-^
M^H?R5OHY%!V:3I)?=O6!N%^HLHIV>9HES41$?NX-1JUQE+='O"H@391"V0P@
MUAJ]_O,F-$?$IV>,)R4Q-U'0Y<?0^K47A.EOJ&B^3]\74([6\@W?+LJY@7Q>
MNLC@/TD"%[_15D[!(?[,9TX\Y9''^6N+6^8Y$;HIA",. ;[WR$]\#KJSE0J/
M]R#\(S-^G='S/[FWPI46WQ(),9JE28L-/:9)B\9/1#?IAE-,9^DGNU/0M<RL
MT'JXV;60T<BDDP87>@SL0DPZEA)K[1QD\<!.%# E&<@2AEXK\5'X?,0PUF$E
MDQ5B63ZQ\,$T!EVT7;/D8K'&$)*+Q0?X)+58/"T9:K'4.B=(Q4[L6L<I!AL3
M2K2*@&+I$;;/*2ZNR!&5H]V*1$H;)592SIQ@P\I_(,. =6(ZOZ>D1+NP(E17
M[SOM0+M4.H#W<X=9>J[HN-#/5W%\%[?0K5 *I79R)VJM6/RT"Q^89Y(0_G,8
M;$6!<F()T@QASUT@@.2( WNQPX!//[<T:8]  @X_G&V]9%T-JSKO"*?<Z&4'
M]O6:[?;J6V4L7'[M \*7FG7_L+N]!6I/F)$8HOL\GK#$-#Z&(*Q3,Z?XP<X9
MBL<-%NF48C#*MHY,RFSUQQJG&]WLH/)CDIT7:*^V6W"^VWB[?I147OF3+6^+
M? []9-9"R\>YR;W_M?B..DU]=O9^;B5":T\%U\1@D?) RL\?NJ.GZ1$6L]3$
M=6O+_+U5<_[ &_4]%*SX]"F/P#!HA53U$E[#/WJIKFUO1FGZV1%TX)S*YDV6
MZ0#<U7J-,LX\_LH8B8D*)69:P1M%A #7/,4N&F-:XGWYSC2[-/O\#\^<CK2A
MZKJ.=M2KVV3Q9]+CKZ#@/S*QFKD%[M'7#/?N97]1_/LOR $7 QQ%,.[H*_GJ
MX<L+5PML$H9_!P= !HK]V%S>5-7]_^N:II;?K4V[KEG;ZILMM?ENG6OQG &V
M<L5DI^',+WR $P32S7H@'MGPN&UMSGFW8Z?^I6D.__?_!U!+ P04    "  +
M26)0#M$C8I@"  !$$   #0   'AL+W-T>6QE<RYX;6S5F.MNVC 4QU_%,M-$
MI8DD=(6R$J2M4J5)VU2I?-BWRA '+/F2.0Z#OL[>9$\V7W(C&S 8G9HOC7V.
MS__\?,7N.%4;BA^6&"NP9I2G(5PJE;SSO'2^Q RE/9%@KCVQD PI794++TTD
M1E%J@ACU^KX_\!@B'$[&/&-W3*5@+C*N0C@J3<#%WXH(A_"Q^_I;)M3-*^"^
MG3>=CM_S'R]NFIYN[KJ P.E\C$(8#-Y"[^^%=\HV1*^.$>WY^W";TH,=TD5S
M*]:M:HWPX?[P6FPC\/I EW[^V#%0I>./(S4Z2K:W1[A)//2/G(3]T] <R6%P
MM/P!_6:"ODG@Y=M@,HX%KW;#)70&38 8!BM$0WB+*)E)8J)BQ C=.+.5F0LJ
M)%!Z&VI"2YX^.7?@:F:'YCJ,<"%M;I?!_9WES1N.HF8 ":4E8!\ZPV2<(*6P
MY'>Z8AM;XV\ND)>GFT03+B3:!/TK6 78CTXR$S+"LDP3P,(T&5,<&QQ)%DOS
M52+QC%,IP70A(F@A.+(,141>T+)S3.F#.;Z^QEO:ZQBX-F9*? @,15'4O<Z+
MU:S9->?5U9QV779PDBY(R$JH#YGN#K=ULWSPO<0Q6=OZ.BX!M#I*$KIY3\F"
M,^PZ<S!A<&+"R1@5><!22/*D]<Q2F6L#EA"LL%1D7K=\ERB9XK4JEM,Z/I6Y
MWT+F<X_S G,L$:U#Z[7_DD?Y/Q.;'_E_9K;'2I/XC)"7PY?/:"XV+8 <M &R
M%=-]W0;(40L@AV<X-9_]!&K%0 9M@.P_,Z27WREK%]>M:VMI!;.,4$5XCKLD
M480=CWDWA/"+>;C0K<MC=7O5\@K-])-^2U_'1CA&&57WIHO6&<*J_,F ZTMN
MT6I:2H2P*G_&$<F8??UYU?\-)K\ 4$L#!!0    (  M)8E"FPO:A,08   XX
M   /    >&PO=V]R:V)O;VLN>&ULQ9M=<],X%(;_BB97W8N2^CLPE!E*@>U.
M@4S2[5[NJ(Z2:+"EK"2WE%^/Y- BE^2=O3G-56O9L9[(EIYS).7UG39?;[3^
MRKZUC;*GH[5SFU?CL:W7HN7VA=X(Y<\LM6FY\X=F-;8;(_C"KH5P;3-.3T[*
M<<NE&KUY_7"OJ1G'!]J)VDFM?&$HN);BSOXZ'PX9]Q?<BBM^<SHZ&3'>.?U!
M-DZ8<^[$1Z.[C52KTU$R8DMIK)N'NOLK6ZED*[^+17]DU_KN3VWD=ZT<;^:U
MT4W3?RJ<Z#_D:["/)=?".%D/+G3\9L8]Z^FH//$WO)56WLA&NOO34?]_(T;^
M6XRCK]&WP\/?;2.^,O^G&?5R*6MQKNNN%<IMV]&()M2N[%IN[(@IWHK3T3M]
M*PR;\I4(V+Z6B\7V*SC?.+^XF'DE_0ESL4@"(R6/LKJ1"U_[@IWQAJM:L+YU
M;028 L#T8(#L:,HCR Q 9L\(.0\0X0.6Z27[LA$F@LP!9'XPR'>ZW420!8 L
M#@8Y$XNXTY0 LCP@Y+]I!%D!R.IPCYO;=00Y 9 36LAS86LC-Z$\@)UU5BIA
MXZ'G)8![20LW[]J6F_L -I<K)?W'N'+L;5WK3CD9#^ G: 0_H<6\4+?"NG 1
MDXK]I:7_Y]H?=6;@&"B9@UGFZ="3(-4DQ*[YP*5AU[SI!/LDN/4-V'>9%WV'
M8>]C3"2;A-@V;^O_.E_I8Z<137,GW-K'%6=2QY!(-@FQ;::^7O\B7OJKE17L
M[<J(OC5C/N29A%@T<Z&D-NQ*F)9=:JX85PLVT_>\<?=LVL68R#0)L6HN_7LH
MXO$P04I)R)W2MM)M/1+:R_=KYX-YH6HYA$1*28B=$B!]SY@[77^-F9!)$F*5
M_,.-\>X8Q-3(&2FQ,_R#NPT)DZ^538U8"F/Z*&'89"ER1DKLC![F^,R__HM>
M$GX8Z2^*^6!>0BR+S_Z^E]I:-O4#[WS-C1_DG#/RIO-Y9Q.K-T6R2(EE<:%J
MW0IVQ;\->FB*W) 2N^%]NVGTO1!>74HLI6-3'Q'$<$@,*;D85GTL%<:WCT*O
M#-^L9<TNU/9N,2820THLAEDH]%UCRHT7UI4?72SO)V8&3QG)(B66!0R?!UE2
MBG21$NL"8V8Q)C)(2FP0&$(/6C-#8LF(Q0)#Z"$FDDM&+!<80K.C&!,Y)B-V
MS#;Z8T=7P2CVCQ@+SG:13W>!,'#8>D@S&;%F=C4;,DM&;98]$<W/YQMC(K-D
MQ&:!@<VP"R.]9,1ZB0.;G3T$226CE@H*(H9MB*22$4MES_0;.SH7CLLFGK=&
M4LF)I8(5G<>82"HY=<8",8L8$TDE)Y8*QBQC3"29G%@R&+.*,>&B"K%D,.8D
MQD3NR8G= R:)0V^/,9%[\N=<6?DMRHV#\1RY)W_.M97?, <#$K)03CX3AC '
M Q*R4$YL(9PSQ ^]0!8J#IK:Q ^]0!8JB"V$,>.'7B +%<06PAG8<8R)+%0<
M<JUE$,@5R$(%L84PYJ +P<5]8@MAS$$70A8JB"V$,0=="%FH(+;0OB6VG^%[
MC(DL5)#G0F"E;=B%D(4*8@O]G&LY9I_#6DW8P?:0!@W2RA(IJ"16T"/CW-]L
MT37B88<1#_,O+,9$"BJ)%;03\T/7!YN?9#S37R(%E>1;R] T5JR@$BFH/.1L
MVZ#_E$A!)?GVLE_+KKM[#C)/26R>AP78W61P+QE]RK-O*?9)9E8BV934JSG[
M)B^W V:,B6134LMF/V8X%6,BV9346\OV8\Y\GA[O($2^J:@GWE!K#C<Z(M]4
M!]HJX#%#(A1C(M]4U!-O"'/8FL@W%;%O\/Q_G$M4R#<5L6\P9IQ+5$@\%?G$
M6[1,,8R( GV,B2Q4$5L(8#[9H5G!/<W/N>@SQ/3Y61P 5\A"%;&%GF"^7RY%
M_YN84,)F\8\6*F2ABMA"3S"?)CX1Y@19:$*^P7F .1.U]K%O([>#9[SC=8(L
M-"&VT,Y=33OCS0FRT(3:0G!I,A[>)\A"$V(+[=_?U#=IC(DL-"&VT-^J]C6O
MPN_4/.R%$VUX15?KXR3-DGZ+YR,FLM"DM]"XO]B^>;WP[X\2B\^^"NO+:][4
M4\/"GW"G),V+L)MUV37-.U_V15UJ'LK[>SS\%._-#U!+ P04    "  +26)0
MPFY\W9P"  "T,@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSQ=I!
M;MLP$(7AJQ@Z0&@.R2%3Q%EUDVW;"P@V;1FQ)4%4T>3V5;VI"B1Z71A/&PN&
MA>&_\0>!XM.W?*G'<]>6YMR7S=OUTI9=U8QC_\68LF_RM2X/79_;Z9=C-USK
M<?HZG$Q?[U_K4S:RW:H9YC.JYZ?YS,W+85<-+P=;;7[4PRF/N\J\7<RO;G@M
M3<YC,;>+?9@6F&YY[_/_+-\=C^=]_MKM?UYS.WY0\7>!RGP<),M!0@]RRT&.
M'N27@SP]*"P'!7J0+@<I/2@N!T5Z4%H.2O2@Q^6@1WJ0W0(9M_PDA#5?:PNX
MMGRO+0#;\L6V@&S+-]L"M"U?;0O8MGRW+8#;\N6V@&[+M]L"O"U?;P%Z"U]O
M 7K+"L_:Z&&;K[< O86OMP"]A:^W +V%K[< O86OMP"]A:^W +V%K[< O86O
MMP-Z.[[>#NCM^'H[H+=;8:\$;9;P]79 ;\?7VP&]'5]O!_1V?+T=T-OQ]79
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MULS@+N/[)=\_XS;UT_5G2H_3*MG</N_^%[]-_1-AYA7E^3=02P,$%     @
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M]J8=_I?DUSCN7^:+^;\3UW\ 4$L! A0#%     @ "TEB4!\CSP/     $P(
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M4$L! A0#%     @ "TEB4,8_O9QO @  V@@  !@              ( !MA$
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (  M)8E#,:%G
M[P0  "48   8              "  5L4  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    "  +26)01-^,!*("  !0"0  &
M@ & &0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ "TEB
M4)0LKJ5#!P  3RD  !@              ( !6!P  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    (  M)8E#_DD?'[0$  -P$   8
M      "  =$C  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M"  +26)0QPHE.= '  "\+P  &               @ 'T)0  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ "TEB4*0*<H2P 0  T@,  !@
M             ( !^BT  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    (  M)8E!CKO!'M $  -(#   9              "  > O  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ "TEB4";C9'JU 0
MT@,  !D              ( !RS$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    "  +26)0D/.^-[4!  #2 P  &0              @ &W
M,P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  M)8E!9
MYGF M0$  -(#   9              "  :,U  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ "TEB4.X1=)2U 0  T@,  !D
M     ( !CS<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M"  +26)03JCOL[8!  #2 P  &0              @ %[.0  >&PO=V]R:W-H
M965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  M)8E!"7RAGM $  -(#   9
M              "  6@[  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!
M A0#%     @ "TEB4,]H[7JT 0  T@,  !D              ( !4ST  'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  +26)04@_/K[8!
M  #2 P  &0              @ $^/P  >&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;%!+ 0(4 Q0    (  M)8E#JH'23M $  -(#   9              "
M 2M!  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ "TEB
M4/D"03&T 0  T@,  !D              ( !%D,  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    "  +26)00M_CC+8!  #2 P  &0
M        @ $!10  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   (  M)8E"SJ3:@M0$  -(#   9              "  >Y&  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ "TEB4!8?PTJW 0  T@,
M !D              ( !VD@  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    "  +26)0:MN+U[,!  #2 P  &0              @ '(2@
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  M)8E!FC%S(
MM0$  -(#   9              "  ;),  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ "TEB4%&=:XNV 0  T@,  !D
M ( !GDX  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  +
M26)0D^TD/;,!  #2 P  &0              @ &+4   >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  M)8E""9[U<"0,  .L-   9
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M970S,BYX;6Q02P$"% ,4    "  +26)04S#W(\0!   W!   &0
M    @ '+70  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M  M)8E E'+/@N@$  -(#   9              "  <9?  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ "TEB4 3C\MJV 0  T@,  !D
M             ( !MV$  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    "  +26)0:RE.\^\!  !F!0  &0              @ &D8P  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  M)8E 2K!!QP@$
M #<$   9              "  <IE  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ "TEB4/M$R&_M 0  9@4  !D              ( !
MPV<  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  +26)0
MO/M=3K8!  #2 P  &0              @ 'G:0  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    (  M)8E"LK9&#<P,  ,4/   9
M      "  =1K  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ "TEB4)K]&)FU P  M1$  !D              ( !?F\  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  +26)004-&4F4"  #Q"
M&0              @ %J<P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    (  M)8E!Z402\%0(  -4&   9              "  09V  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ "TEB4(=MXNBB
M 0  F0,  !D              ( !4G@  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    "  +26)0 &6.@U,#  "L#0  &0
M@ $K>@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (  M)
M8E @ T(L[P(  /$+   9              "  ;5]  !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ "TEB4%B0KSK* @  9@L  !D
M         ( !VX   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M    "  +26)0O'/OV_D!   -!0  &0              @ '<@P  >&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (  M)8E!-MHVC9P(  "T(
M   9              "  0R&  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL
M4$L! A0#%     @ "TEB4!8[&$O(!0   R4  !D              ( !JH@
M 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  +26)048H_
M6V4#  !6#P  &0              @ &IC@  >&PO=V]R:W-H965T<R]S:&5E
M=#4Q+GAM;%!+ 0(4 Q0    (  M)8E"M3940W@$  /H$   9
M  "  462  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M"TEB4-6Q]$U% P  BPX  !D              ( !6I0  'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    "  +26)0EH 3LR\"  #+!@  &0
M            @ '6EP  >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    (  M)8E"T>N3'\ $   @%   9              "  3R:  !X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ "TEB4#;NWN\F P
MA@T  !D              ( !8YP  'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    "  +26)04"G)21T"  "[!@  &0              @ '
MGP  >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (  M)8E ,
MTA)H(@,  +D-   9              "  12B  !X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ "TEB4$MUY%-& P  D0\  !D
M     ( !;:4  'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  M)8E#S.9U $@(  "L&   9              "
M 1FS  !X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ "TEB
M4)(,SPJ0 P  )A   !D              ( !8K4  'AL+W=O<FMS:&5E=',O
M<VAE970V-2YX;6Q02P$"% ,4    "  +26)0?Z4V_?D"  "["P  &0
M        @ $IN0  >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0
M   (  M)8E#V0*DS0P0  #T4   9              "  5F\  !X;"]W;W)K
M<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ "TEB4' 1%$S0 P  E1(
M !D              ( !T\   'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q0
M2P$"% ,4    "  +26)0T!F#TD $  !9$P  &0              @ ':Q
M>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (  M)8E PZ$^R
M90(  ,4'   9              "  5')  !X;"]W;W)K<VAE971S+W-H965T
M-S N>&UL4$L! A0#%     @ "TEB4+X$UOVI @  N0D  !D
M ( ![<L  'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    "  +
M26)0X/+<@IT"  #^"0  &0              @ '-S@  >&PO=V]R:W-H965T
M<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    (  M)8E"9'9JS80(  *((   9
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M970W-RYX;6Q02P$"% ,4    "  +26)0$;/77.D"   ]"P  &0
M    @ ';WP  >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    (
M  M)8E#M.#QKY0(  &X*   9              "  ?OB  !X;"]W;W)K<VAE
M971S+W-H965T-SDN>&UL4$L! A0#%     @ "TEB4&^J<,W+ @  (0H  !D
M             ( !%^8  'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"
M% ,4    "  +26)0CJ!MD48"  #D!@  &0              @ $9Z0  >&PO
M=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    (  M)8E#[.)'.^0$
M #\%   9              "  9;K  !X;"]W;W)K<VAE971S+W-H965T.#(N
M>&UL4$L! A0#%     @ "TEB4/4/O[:: @  +@D  !D              ( !
MQNT  'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    "  +26)0
MLEV?I,8"  !#"@  &0              @ &7\   >&PO=V]R:W-H965T<R]S
M:&5E=#@T+GAM;%!+ 0(4 Q0    (  M)8E!SCYY5&0(   \'   9
M      "  93S  !X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%
M  @ "TEB4-)W_^KOV0  96H# !0              ( !Y/4  'AL+W-H87)E
M9%-T<FEN9W,N>&UL4$L! A0#%     @ "TEB4 [1(V*8 @  1!    T
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52P4&     %X 7@#$&0  7]X!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6880932000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross', window );">Shares canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">508,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ReversalOfStockBasedCompensationExpense', window );">Reversal of stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,954<span></span>
</td>
<td class="nump">$ 6,851<span></span>
</td>
<td class="nump">$ 3,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CommonStockSubjecttoRepurchaseorCancellation', window );">Stock subject to repurchase (in shares)</a></td>
<td class="nump">44,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare', window );">Stock subject to repurchase, per share</a></td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Cash proceeds received for unvested shares</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercises in period, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,200<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, grants in period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.37<span></span>
</td>
<td class="nump">$ 5.17<span></span>
</td>
<td class="nump">$ 2.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock based compensation not recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock based compensation not recognized, restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock based compensation not recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Employee stock purchase plan, maximum employee subscription rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Employee stock purchase plan, purchase price of common stock (percent of stock value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,333<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gh_A2018EmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CommonStockSubjecttoRepurchaseorCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Subject to Repurchase or Cancellation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CommonStockSubjecttoRepurchaseorCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ReversalOfStockBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reversal Of Stock Based Compensation Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ReversalOfStockBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gh_A2018EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gh_A2018EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6862243312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Royalty Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 1,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2021</a></td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2022</a></td>
<td class="nump">1,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2023</a></td>
<td class="nump">1,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualObligationDueInFifthYearAndAfterFifthYear', window );">2024 and thereafter</a></td>
<td class="nump">5,607<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total future minimum royalty payments</a></td>
<td class="nump">11,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments', window );">Less: amount representing interest</a></td>
<td class="num">(4,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments', window );">Present value of future minimum royalty payments</a></td>
<td class="nump">$ 6,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualObligationDueInFifthYearAndAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, Due In Fifth Year And After Fifth Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualObligationDueInFifthYearAndAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, Future Minimum Payments, Interest Amount Included in Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, Future Minimum Payments, Present Value of Net Minimum Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871838608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense under Topic 840</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability', window );">Lease not yet commenced, liability</a></td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount', window );">Lease not yet commenced, imputed interest</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome', window );">Lease not yet commenced, sublease income</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Sublease Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Excess Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6845509280">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">174,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">(174,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">4,907,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 4,907,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6866888128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Useful Life of Property and Equipment, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gh_ComputerEquipmentandSoftwareMember', window );">Computer hardware and computer software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gh_ComputerEquipmentandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gh_ComputerEquipmentandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6861630656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet Components - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 65,591<span></span>
</td>
<td class="nump">$ 47,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(21,923)<span></span>
</td>
<td class="num">(16,634)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">43,668<span></span>
</td>
<td class="nump">31,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">29,119<span></span>
</td>
<td class="nump">23,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,296<span></span>
</td>
<td class="nump">4,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">21,031<span></span>
</td>
<td class="nump">13,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,354<span></span>
</td>
<td class="nump">$ 3,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6614507504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">Segment and Geographic Information<div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194,312</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,715</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,063</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>214,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,639</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">No single country outside of the United States accounted for more than 10% of total revenue during each of the years ended </span><span style="font-family:inherit;font-size:7.5pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:7.5pt;">, </span><span style="font-family:inherit;font-size:7.5pt;">2018</span><span style="font-family:inherit;font-size:7.5pt;"> and </span><span style="font-family:inherit;font-size:7.5pt;">2017</span><span style="font-family:inherit;font-size:7.5pt;">. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:24px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(2)    Fiscal years 2018 and 2017 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019. </span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>97%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span>, respectively, of the Company&#8217;s long-lived assets are located in the United States.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6614807616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2012 Stock Plan and 2018 Incentive Award Plan</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2012 and September 2018, the Company&#8217;s Board of Directors adopted and its stockholders approved the Company&#8217;s 2012 Stock Plan (as amended and restated, the &#8220;2012 Plan&#8221;) and the Company&#8217;s 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;), respectively, under which the Company may grant cash and equity incentive awards such as stock options, restricted shares, stock units and stock appreciation rights to its employees and non-employees. Stock options granted may be either incentive stock options or nonstatutory stock options. Shares issued under the 2018 Plan may be authorized but unissued shares, or shares purchased in the open market or treasury shares. Upon effectiveness of the 2018 Plan in connection with the IPO in October 2018, the 2012 Plan was terminated and </span><span style="font-family:inherit;font-size:10pt;"><span>508,847</span></span><span style="font-family:inherit;font-size:10pt;"> shares reserved under the 2012 Plan were forfeited. Any outstanding awards granted under the 2012 Plan remain outstanding, subject to the terms of the 2012 Plan and applicable award agreement, and further cancellation of awards granted under the 2012 Plan are not available for grant in the future. No further grants will be made under the 2012 Plan. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Activity</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:28%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Available for Grant&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Subject to Options Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Exercise Price&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Remaining Contractual Life (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,698,790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,391,052</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,658,602</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(508,847</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,088,639</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,088,639</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,007,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>795,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(883,899</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repurchase of early exercised shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,230</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,556,507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,588,405</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares authorized</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(324,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>324,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,999,419</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,636</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(418,676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repurchase of early exercised shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,244,564</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,494,889</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306,392</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and Exercisable as of December 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,908,216</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was </span><span style="font-family:inherit;font-size:10pt;"><span>$218.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted-average grant date fair value of options granted was </span><span style="font-family:inherit;font-size:10pt;"><span>$52.37</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.17</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.90</span></span><span style="font-family:inherit;font-size:10pt;"> per share for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future stock-based compensation for unvested options as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$26.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span><span style="font-family:inherit;font-size:10pt;"> years. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the Company modified one of the performance based awards issued to a nonemployee which resulted in reversal of expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> due to options not vested.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s restricted stock unit activity under the 2012 Plan and the 2018 Plan and related information   is as follows: </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Units Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49,086</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57.51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,131</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future stock-based compensation for unvested restricted stock units as of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$36.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>3.5</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock&#8209;Based Compensation Expense</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the effect of employee and non&#8209;employee related stock&#8209;based compensation expense:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>863</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>512</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and marketing expense   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,716</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,954</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,851</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Valuation of Stock Options</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Starting January 1, 2019, the Company adopted ASU 2018-07 which aligns the accounting treatment of nonemployee awards with employee awards, and the fair value of stock options issued to employees and nonemployee consultants are both determined as of the grant date.&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The grant date fair value of employee and nonemployee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 &#8211; 6.22</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.01 &#8211; 6.51</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.02 &#8211; 6.08</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63.2% &#8211; 68.7%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68.7% &#8211; 78.8%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74.1% &#8211; 75.1%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.6% &#8211; 2.7%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.5% &#8211; 3.0%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.9% &#8211; 2.2%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company&#8217;s common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Common Stock</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the IPO, the grant date fair value of the Company&#8217;s common stock was determined by the Company&#8217;s Board of Directors with the assistance of management and an independent third-party valuation specialist. The grant date fair value of the Company&#8217;s common stock was determined using valuation methodologies which utilizes certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of the Company&#8217;s </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">common stock, the methodologies used to estimate the enterprise value of the Company were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="font-family:inherit;font-size:10pt;">. Subsequent to the IPO, the fair value of the Company&#8217;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Term</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the commencement of trading of the Company&#8217;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company&#8217;s common stock. Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-Free Interest Rate</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Dividend Yield</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Employee Stock Purchase Plan</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company&#8217;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). A total of </span><span style="font-family:inherit;font-size:10pt;"><span>922,250</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock are initially reserved for issuance under the ESPP. The number of shares may be increased in accordance with the terms of the ESPP. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the fair market value of the Company&#8217;s common stock on the first or last day of the offering period, whichever is lower. The initial offering period ran from October&#160;2, 2018 to January 31, 2019, the second offering period ran from February 1, 2019 to July 31, 2019, and the third offering period began on August 1, 2019 and ran to November 14, 2019. On a going forward basis, the ESPP will provide for separate&#160;six-month offering periods beginning on May 15 and November 15 of each year.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>232,333</span></span><span style="font-family:inherit;font-size:10pt;"> shares were purchased under the ESPP. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> shares were purchased under the ESPP during the year ended December 31, 2018. The total compensation expense related to the ESPP for year ended&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP: </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.29 &#8211; 0.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.33</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58.8% &#8211; 60.3%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43.6%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.6% &#8211; 2.5%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.4%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future stock-based compensation under the ESPP as of</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 was</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:10pt;">which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities for Early Exercise of Employee Options</span></div><span style="font-family:inherit;font-size:10pt;">The Company allowed certain stock option holders to exercise unvested options to purchase shares of the Company&#8217;s common stock. Shares received from such early exercises are subject to repurchase in the event of the optionee&#8217;s employment termination, at the original issuance price, until the options are fully vested.  As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>23,981</span></span><span style="font-family:inherit;font-size:10pt;"> shares and </span><span style="font-family:inherit;font-size:10pt;"><span>44,268</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were subject to repurchase at weighted-average price of    </span><span style="font-family:inherit;font-size:10pt;"><span>$4.66</span></span><span style="font-family:inherit;font-size:10pt;"> per share. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the cash proceeds received for unvested shares of common stock of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2</span></span> million was recorded within other long-term liabilities on the consolidated balance sheet, respectively. The shares issued pursuant to unvested options have been included in shares issued and outstanding on the consolidated balance sheet and consolidated statement of redeemable noncontrolling interest and stockholders&#8217; equity as such shares are considered legally outstanding.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6603565248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Senior Term Loan and Royalty Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Senior Term Loan and Royalty Purchase Agreement</a></td>
<td class="text">Senior Term Loan and Royalty Purchase Agreement<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, the Company entered into a credit agreement with a financial institution for a senior term loan (the &#8220;Credit Agreement&#8221;). The Credit Agreement provided for up to </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in borrowing capacity. The Company borrowed </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the effective date of the Credit Agreement. The Credit Agreement provided for an interest rate equal to the greater of (i) three-month LIBOR or (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum plus </span><span style="font-family:inherit;font-size:10pt;"><span>8.75%</span></span><span style="font-family:inherit;font-size:10pt;"> on the outstanding balance of the term loan not exceeding </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Concurrent with the Credit Agreement, the Company also entered into a Royalty Purchase Agreement (the &#8220;Royalty Agreement&#8221;) with the same financial institution, which obligated the Company to make quarterly royalty payments of (i) </span><span style="font-family:inherit;font-size:10pt;"><span>1.5%</span></span><span style="font-family:inherit;font-size:10pt;"> applied to total Company fiscal year revenues of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> and (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>2.45%</span></span><span style="font-family:inherit;font-size:10pt;"> applied to fiscal year revenues in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Royalty Agreement included a buyout option, by which the Company had the right, exercisable in its sole discretion, to buy out the obligation to make future royalty payments. The price of this buyout option was calculated based on a table with axes of principal balance outstanding and time, less the cumulative sum of royalty payments at the time the buy-out option is exercised.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2017, the Company exercised its prepayment right under the Credit Agreement and repaid the outstanding principal balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:inherit;font-size:10pt;">  and accrued interest of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. The prepayment option also required the Company to pay a prepayment penalty of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. Concurrent with the prepayment of the senior term loan, the Company also excised its royalty buyout option for </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. The transaction was accounted for as a debt extinguishment. The net carrying amount of the debt and royalty liabilities immediately before the extinguishment was </span><span style="font-family:inherit;font-size:10pt;"><span>$20.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. As a result, the difference between the reacquisition price and the net carrying amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as loss on debt extinguishment in the accompanying consolidated statements of operations. As of December&#160;31, 2019 and 2018, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding balance under the senior term loan and its related royalty obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6852809360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Consolidated Balance Sheet Components</a></td>
<td class="text">Consolidated Balance Sheet Components<div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer hardware   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,962</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,522</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer software   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>829</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>643</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,354</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, gross   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,591</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,637</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,923</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,634</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,668</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense related to property and equipment was </span><span style="font-family:inherit;font-size:10pt;"><span>$9.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Expenses</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued royalty obligations   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,564</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued legal expenses   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued tax liabilities   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,050</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional services   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,791</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trials and studies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,029</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of property and equipment included in accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,424</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>343</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,986</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,817</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued expenses   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,178</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871739488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194,312</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,715</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,063</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>214,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,639</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">No single country outside of the United States accounted for more than 10% of total revenue during each of the years ended </span><span style="font-family:inherit;font-size:7.5pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:7.5pt;">, </span><span style="font-family:inherit;font-size:7.5pt;">2018</span><span style="font-family:inherit;font-size:7.5pt;"> and </span><span style="font-family:inherit;font-size:7.5pt;">2017</span><span style="font-family:inherit;font-size:7.5pt;">. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:24px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(2)    Fiscal years 2018 and 2017 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019. </span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8721-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6662212272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements. Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bonds   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>362,884</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>362,884</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term marketable securities   </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term marketable securities   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>648,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,365</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,365</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bonds   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,004</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,004</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term marketable securities   </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bonds   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,758</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,758</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term marketable securities   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,563</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,563</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355,980</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DebtSecuritiesTableTextBlock', window );">Debt Securities, Available-for-sale</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarizes the Company&#8217;s cash equivalents and marketable securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market fund   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bond   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,679</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>631,666</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>657,696</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,433</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659,090</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market fund   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bond   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(71</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>308,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>308,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency bonds................</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,014</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,004</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>381,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(317</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871668128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Stock by Class</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares underlying outstanding stock options   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,494,889</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,588,405</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares available for future stock option grants   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,726,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,556,507</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>689,917</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922,250</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,911,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,067,162</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6859533552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition of Bellwether Bio - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member', window );">Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,290<span></span>
</td>
<td class="nump">3,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Net liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,802)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885654080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements. Cash Equivalents and Marketable Securities - Fair Value Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">10,734<span></span>
</td>
<td class="nump">25,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">379,574<span></span>
</td>
<td class="nump">278,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">268,783<span></span>
</td>
<td class="nump">77,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">659,091<span></span>
</td>
<td class="nump">381,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">10,734<span></span>
</td>
<td class="nump">25,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">10,734<span></span>
</td>
<td class="nump">25,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">379,574<span></span>
</td>
<td class="nump">278,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">268,783<span></span>
</td>
<td class="nump">77,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">648,357<span></span>
</td>
<td class="nump">355,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">16,690<span></span>
</td>
<td class="nump">38,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds | Fair value, measurements, recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds | Fair value, measurements, recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">16,690<span></span>
</td>
<td class="nump">38,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds | Fair value, measurements, recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government debt securities | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">362,884<span></span>
</td>
<td class="nump">235,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">268,783<span></span>
</td>
<td class="nump">73,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government debt securities | Fair value, measurements, recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government debt securities | Fair value, measurements, recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">362,884<span></span>
</td>
<td class="nump">235,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">268,783<span></span>
</td>
<td class="nump">73,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government debt securities | Fair value, measurements, recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency bonds | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency bonds | Fair value, measurements, recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">10,734<span></span>
</td>
<td class="nump">25,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair value, measurements, recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">10,734<span></span>
</td>
<td class="nump">25,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair value, measurements, recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair value, measurements, recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6854187632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patent License Agreement (Details)<br> $ in Thousands, &#163; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">One-time upfront payment for finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Capitalized license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="nump">6,890<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Patent Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">One-time upfront payment for finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">&#163; 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LicenseAgreementMilestonePaymentUponAchievement', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_PaymentsforFutureRoyalties', window );">Future royalty payments | &#163;</a></td>
<td class="nump">&#163; 13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Capitalized license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gh_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock | Patent Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued during period for purchase of asset, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,774<span></span>
</td>
<td class="nump">141,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Fair value of stock issued for purchase of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt security, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LicenseAgreementMilestonePaymentUponAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Milestone, Payment Upon Achievement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LicenseAgreementMilestonePaymentUponAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PaymentsforFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PaymentsforFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gh_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gh_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6638396336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation of Employee Stock Purchase Plan (Details) - Employee Stock<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">3 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">58.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">60.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871739488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 214,375<span></span>
</td>
<td class="nump">$ 90,639<span></span>
</td>
<td class="nump">$ 49,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">194,312<span></span>
</td>
<td class="nump">77,916<span></span>
</td>
<td class="nump">43,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 20,063<span></span>
</td>
<td class="nump">$ 12,723<span></span>
</td>
<td class="nump">$ 6,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember', window );">Assets | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember', window );">Assets | Geographic Concentration Risk | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6837730016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of the Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(1,652)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(311)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(178)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="num">(2,141)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="num">$ (1,872)<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6881007072">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 143,228<span></span>
</td>
<td class="nump">$ 140,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">379,574<span></span>
</td>
<td class="nump">278,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,986<span></span>
</td>
<td class="nump">35,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,181<span></span>
</td>
<td class="nump">9,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,389<span></span>
</td>
<td class="nump">5,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">597,358<span></span>
</td>
<td class="nump">468,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">268,783<span></span>
</td>
<td class="nump">77,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,668<span></span>
</td>
<td class="nump">31,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,524<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Capitalized license fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,890<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,882<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">962,535<span></span>
</td>
<td class="nump">587,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,197<span></span>
</td>
<td class="nump">10,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,557<span></span>
</td>
<td class="nump">12,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,703<span></span>
</td>
<td class="nump">7,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,277<span></span>
</td>
<td class="nump">16,138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,734<span></span>
</td>
<td class="nump">46,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AccruedRoyaltiesNoncurrent', window );">Obligation related to royalty</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,880<span></span>
</td>
<td class="nump">7,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">114,542<span></span>
</td>
<td class="nump">62,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,600<span></span>
</td>
<td class="nump">41,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2019 and 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, par value of $0.00001 per share; 350,000,000 and 350,000,000 shares authorized as of December 31, 2019 and 2018, respectively; 94,261,414 and 85,832,454 shares issued and outstanding as of December 31, 2019 and 2018, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,150,090<span></span>
</td>
<td class="nump">764,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,111<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(352,809)<span></span>
</td>
<td class="num">(280,799)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">798,393<span></span>
</td>
<td class="nump">483,152<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 962,535<span></span>
</td>
<td class="nump">$ 587,403<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of&#160;<span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, includes&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$45.1 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$48.3 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#8220;VIE&#8221;) and VIE&#8217;s subsidiaries, and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$5.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of liabilities, respectively, of the consolidated VIE &#160;of liabilities of consolidated VIE and VIE&#8217;s subsidiaries for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investment in Joint Venture</span><span style="font-family:inherit;font-size:10pt;">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Fiscal 2018 does not reflect the impact of the adoption of the new revenue accounting and lease accounting standards in fiscal year 2019.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AccruedRoyaltiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalties, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AccruedRoyaltiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19512-108361<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20028-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6886194880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series D Convertible Preferred Stock</div></th>
<th class="th"><div>Series E Convertible Preferred Stock</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Redeemable Noncontrolling Interest</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series E Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A Convertible Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series A Convertible Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="nump">$ 79,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (86)<span></span>
</td>
<td class="num">$ (107,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,181,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,184,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,774<span></span>
</td>
<td class="nump">38,970,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="nump">$ 319,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="nump">$ 319,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common and convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(666,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(666,920)<span></span>
</td>
<td class="num">(1,719,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common and convertible preferred stock</a></td>
<td class="num">(7,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodSharesExerciseofWarrants', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueExerciseofWarrants', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions', window );">Vesting of common stock exercised early</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) gain, net of tax impact</a></td>
<td class="num">(446)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(446)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">(83,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,627,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,896,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="nump">308,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(532)<span></span>
</td>
<td class="num">(195,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering', window );">Conversion of convertible preferred stock to common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,627,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,264,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering', window );">Conversion of convertible preferred stock to common stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (499,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common and convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(666,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common and convertible preferred stock</a></td>
<td class="num">$ (172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">1,007,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">963,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 2,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod', window );">Issuance of common stock upon early exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodSharesExerciseofWarrants', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueExerciseofWarrants', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) gain, net of tax impact</a></td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">(84,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,832,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">483,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="num">(280,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of equity interests in redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering', window );">Conversion of convertible preferred stock to common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,264,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon follow-on offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon follow-on offering, net of offering costs of $723</a></td>
<td class="nump">$ 349,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">2,999,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,999,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 11,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod', window );">Issuance of common stock upon early exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly', window );">Issuance of common stock upon early exercise of stock options</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">6,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">(7,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) gain, net of tax impact</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">(67,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,261,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 798,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="num">$ (352,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Share-based Compensation For Early Exercised Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercises in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodSharesExerciseofWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodSharesExerciseofWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodValueExerciseofWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Exercise of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodValueExerciseofWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Stock Options Exercised Early</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850069056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet Components - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalty obligations</a></td>
<td class="nump">$ 1,564<span></span>
</td>
<td class="nump">$ 707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_EstimatedLitigationLiabilityLegalFeesCurrent', window );">Accrued legal expenses</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued tax liabilities</a></td>
<td class="nump">3,050<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">3,464<span></span>
</td>
<td class="nump">1,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AccruedClinicalTrialsandStudies', window );">Accrued clinical trials and studies</a></td>
<td class="nump">2,029<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AccruedExpensesPropertyandEquipmentCurrent', window );">Purchases of property and equipment included in accrued expenses</a></td>
<td class="nump">2,424<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">7,140<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,986<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 25,703<span></span>
</td>
<td class="nump">$ 7,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AccruedClinicalTrialsandStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trials and Studies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AccruedClinicalTrialsandStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AccruedExpensesPropertyandEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses, Property and Equipment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AccruedExpensesPropertyandEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EstimatedLitigationLiabilityLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Litigation Liability, Legal Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EstimatedLitigationLiabilityLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6884875664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract asset</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs related to initial public offering</a></td>
<td class="nump">723,000<span></span>
</td>
<td class="nump">4,386,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">12,300,000<span></span>
</td>
<td class="nump">16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue, revenue recognized</a></td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">29,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">40,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=gh_AccountingStandardsUpdate201807Member', window );">ASU 2018-07 adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=gh_AccountingStandardsUpdate201807Member', window );">ASU 2018-07 adoption | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=gh_AccountingStandardsUpdate201807Member', window );">ASU 2018-07 adoption | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,266,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract asset</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=gh_AccountingStandardsUpdate201807Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=gh_AccountingStandardsUpdate201807Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6881733312">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Adoption of ASC 606 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 47,986<span></span>
</td>
<td class="nump">$ 35,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(352,809)<span></span>
</td>
<td class="num">(280,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromPrecisionOncologyTesting', window );">Precision oncology testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">180,462<span></span>
</td>
<td class="nump">78,407<span></span>
</td>
<td class="nump">$ 42,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromDevelopmentServices', window );">Development services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">33,913<span></span>
</td>
<td class="nump">$ 12,232<span></span>
</td>
<td class="nump">$ 7,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Balances Without Adoption of ASC 606</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(353,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromPrecisionOncologyTesting', window );">Precision oncology testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">180,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromDevelopmentServices', window );">Development services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Topic 606 adoption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Topic 606 adoption | Effect of Change</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromPrecisionOncologyTesting', window );">Precision oncology testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromDevelopmentServices', window );">Development services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Fiscal year 2018 and 2017 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RevenuefromDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Development Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RevenuefromDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RevenuefromPrecisionOncologyTesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Precision Oncology Testing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RevenuefromPrecisionOncologyTesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6853974208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodSharesExerciseofWarrants', window );">Stock issued from exercise of warrants (in shares)</a></td>
<td class="nump">6,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,741<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gh_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gh_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodSharesExerciseofWarrants', window );">Stock issued from exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,289<span></span>
</td>
<td class="nump">89,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO', window );">Shares issued during period, exercise of warrants prior to IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,741<span></span>
</td>
<td class="nump">89,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodSharesExerciseofWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodSharesExerciseofWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise of Warrants Prior to IPO</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gh_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gh_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gh_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gh_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6681793408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimal Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">$ 4,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">5,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">5,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="nump">5,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="nump">6,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2024 and thereafter</a></td>
<td class="nump">15,786<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 42,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>gh-12312019x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:gh="http://guardanthealth.com/20191231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gh-20191231.xsd" xlink:type="simple"/>
    <context id="FD2019Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2020Q1Feb14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2020-02-14</instant>
        </period>
    </context>
    <context id="I2019Q2Jun28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">gh:AccountingStandardsUpdate201807Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">gh:AccountingStandardsUpdate201807Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">gh:AccountingStandardsUpdate201807Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="FI2016Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q2May31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="D2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-09</startDate>
            <endDate>2018-10-09</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2018-09-19</startDate>
            <endDate>2018-09-19</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-09</instant>
        </period>
    </context>
    <context id="I2018Q4Oct9_us-gaap_ClassOfWarrantOrRightAxis_gh_WarrantsPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gh:WarrantsPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-09</instant>
        </period>
    </context>
    <context id="D2019Q2May">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct9_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-09</instant>
        </period>
    </context>
    <context id="I2018Q2Apr30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="FI2018Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="D2019Q2May_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_gh_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-01-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2018Q4Oct31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gh_ComputerEquipmentandSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gh:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q2May01-May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="I2018Q2May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q2May31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="D2018Q2May01-May31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_ContingentConsiderationByTypeAxis_gh_CommercializationMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">gh:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gh_CovenantsNotToCompeteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:CovenantsNotToCompeteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_ContingentConsiderationByTypeAxis_gh_EarnOutConsiderationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">gh:EarnOutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gh_CovenantsNotToCompeteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:CovenantsNotToCompeteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-31</instant>
        </period>
    </context>
    <context id="D2019Q4Dec312019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q4Dec31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q3Aug01-Aug31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan31_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-31</instant>
        </period>
    </context>
    <context id="I2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="D2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-31</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="D2015Q4Jun01-Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="D2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierOneMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:RoyaltyAgreementbyPaymentTierAxis">gh:TierOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-31</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="I2017Q2Jun30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="I2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierTwoMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:RoyaltyAgreementbyPaymentTierAxis">gh:TierTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierOneMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:RoyaltyAgreementbyPaymentTierAxis">gh:TierOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="D2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierTwoMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:RoyaltyAgreementbyPaymentTierAxis">gh:TierTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-31</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:RoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2017Q4Nov01-Nov30_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="D2017Q4Dec31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="D2018Q3Jul01-Jul31_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="D2016Q2May01-May31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="D2018Q3Jul01-Jul31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2018-10-09</startDate>
            <endDate>2018-10-09</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep01-Sep30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct9_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-09</startDate>
            <endDate>2018-10-09</endDate>
        </period>
    </context>
    <context id="D2019Q2May_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct9_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-09</startDate>
            <endDate>2018-10-09</endDate>
        </period>
    </context>
    <context id="D2019Q2May_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_gh_SharesAvailableForFutureStockOptionGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_gh_SharesAvailableForFutureStockOptionGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2013Q3Sep30_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gh:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-09-30</instant>
        </period>
    </context>
    <context id="I2012Q4Dec31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="I2014Q4Oct31_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gh:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-10-31</instant>
        </period>
    </context>
    <context id="D2018Q4Oct01-Oct31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Oct01-Oct31_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="D2017Q3Aug01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="I2017Q4Oct31_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="D2017Q2Apr30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2017-04-30</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="D2017Q3Jul01-Jul31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="I2017Q2May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:SoftBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:SoftBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gh:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="D2017Q2May01-May31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2019Q4Dec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q4Dec31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:EmployeeStockPurchasePlanObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:EmployeeStockPurchasePlanObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:EmployeeStockPurchasePlanObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_AssetsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_AssetsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q3Jul01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="company">
        <measure>gh:company</measure>
    </unit>
    <unit id="petition">
        <measure>gh:petition</measure>
    </unit>
    <unit id="party">
        <measure>gh:party</measure>
    </unit>
    <unit id="patent">
        <measure>gh:patent</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2019Q4YTD"
      id="Fact-15972A11356727F6BB33A6258E3EB357-wk-Fact-15972A11356727F6BB33A6258E3EB357">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q4YTD"
      id="Fact-61ABC39C7305E9F7B0FEA6258E385316-wk-Fact-61ABC39C7305E9F7B0FEA6258E385316">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q4YTD"
      id="Fact-6DA9E62544E58D25B36BA6258E363422-wk-Fact-6DA9E62544E58D25B36BA6258E363422">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q4YTD"
      id="Fact-EA5A785CA08FF352020FA6258E39157E-wk-Fact-EA5A785CA08FF352020FA6258E39157E">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q4YTD"
      id="Fact-3CC2E13DA20ED7F4FA6BA6258E37863A-wk-Fact-3CC2E13DA20ED7F4FA6BA6258E37863A">0001576280</dei:EntityCentralIndexKey>
    <dei:TradingSymbol
      contextRef="FD2019Q4YTD"
      id="Fact-7140260DEDB4A34C6CF891F8BEE6B0AC-wk-Fact-7140260DEDB4A34C6CF891F8BEE6B0AC">GH</dei:TradingSymbol>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact-E263632CFEA0D88960DCA6258E81A39D-wk-Fact-E263632CFEA0D88960DCA6258E81A39D"
      unitRef="shares">0</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact-69A944AAC1A5119DC9B877FFE6C6FDBE-wk-Fact-69A944AAC1A5119DC9B877FFE6C6FDBE"
      unitRef="usd">883000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact-8109534AF13A6CE6EAFFA6258E5108FA-wk-Fact-8109534AF13A6CE6EAFFA6258E5108FA"
      unitRef="usd">4475000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact-EE448B6E75B27D334D08AA058AC509E2-wk-Fact-EE448B6E75B27D334D08AA058AC509E2"
      unitRef="usd">723000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="FI2018Q4"
      decimals="0"
      id="Fact-61DA4A35953FCCE88DA57821615A244A-wk-Fact-61DA4A35953FCCE88DA57821615A244A"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-AFDA1D8DA22E78D612F3A6258E459D3B-wk-Fact-AFDA1D8DA22E78D612F3A6258E459D3B"
      unitRef="usdPerShare">0.0000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-62A30F91F5DC63B38576A6258E387B8F-wk-Fact-62A30F91F5DC63B38576A6258E387B8F"
      unitRef="usdPerShare">0.0000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-1084DC70F6DD649CC7F1A6258E5ED9D4-wk-Fact-1084DC70F6DD649CC7F1A6258E5ED9D4"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-67BCF8868EF08722AA8AA6258E2AD45A-wk-Fact-67BCF8868EF08722AA8AA6258E2AD45A"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-B1CACAF7AB7A40AA5D18A6258E81B216-wk-Fact-B1CACAF7AB7A40AA5D18A6258E81B216"
      unitRef="shares">85832454</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-71CA52211AE2B777AB14A6258E485B19-wk-Fact-71CA52211AE2B777AB14A6258E485B19"
      unitRef="shares">94261414</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-504816C04F8D786A5D0BA6258E6AC44B-wk-Fact-504816C04F8D786A5D0BA6258E6AC44B"
      unitRef="shares">85832454</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-E2A5B57D6C844DC8B805A6258E66BFB3-wk-Fact-E2A5B57D6C844DC8B805A6258E66BFB3"
      unitRef="shares">94261414</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="Fact-B924B24942AF1C5207EEF27610AA5EE2-wk-Fact-B924B24942AF1C5207EEF27610AA5EE2"
      unitRef="usd">1300000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="Fact-76BBDE943DF797E827F978CEF6E6298F-wk-Fact-76BBDE943DF797E827F978CEF6E6298F"
      unitRef="usd">0</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="Fact-D9D618D4C164013EB56278CEE95DFD5C-wk-Fact-D9D618D4C164013EB56278CEE95DFD5C"
      unitRef="usd">0</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-52D9E9FDC269CCD67D88784BD183FCF7-wk-Fact-52D9E9FDC269CCD67D88784BD183FCF7">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember"
      decimals="INF"
      id="Fact-E0816C9E1CBB7AF2EDECF297D58799C5-wk-Fact-E0816C9E1CBB7AF2EDECF297D58799C5"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-EEEC6D0A1304391F8163A6258E72D989-wk-Fact-EEEC6D0A1304391F8163A6258E72D989"
      unitRef="usdPerShare">0.0000001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-236F7AF67DD8A90AE4B4A6258E997A11-wk-Fact-236F7AF67DD8A90AE4B4A6258E997A11"
      unitRef="usdPerShare">0.0000001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-6C2D8FE7FF0C7194B61DA6258E8BFF4F-wk-Fact-6C2D8FE7FF0C7194B61DA6258E8BFF4F"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-0AB6E7656457DC0D7E16A6258E43235B-wk-Fact-0AB6E7656457DC0D7E16A6258E43235B"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-10F2B33FCCD468961D6EA6258E3AA083-wk-Fact-10F2B33FCCD468961D6EA6258E3AA083"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-FA08BF4F310A2C2DED81A6258E4289A1-wk-Fact-FA08BF4F310A2C2DED81A6258E4289A1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-2E44BEAB699432CB8DBBA6258E6C9180-wk-Fact-2E44BEAB699432CB8DBBA6258E6C9180"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-9337DF82298BE0581FFAA6258EA62B21-wk-Fact-9337DF82298BE0581FFAA6258EA62B21"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      id="Fact-3A7669FDAFE69FB9463CA6258E80B579-wk-Fact-3A7669FDAFE69FB9463CA6258E80B579">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      id="Fact-A588C5498461F7CBB4FCA6258E7D5FC5-wk-Fact-A588C5498461F7CBB4FCA6258E7D5FC5">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gh_ComputerEquipmentandSoftwareMember"
      id="Fact-C41CC81AF102148FB148A6258E7E2E39-wk-Fact-C41CC81AF102148FB148A6258E7E2E39">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      id="Fact-14A8581EAB630E8727D6A6258E7E4212-wk-Fact-14A8581EAB630E8727D6A6258E7E4212">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RestrictedCash
      contextRef="FI2018Q4"
      decimals="0"
      id="Fact-C97BBE696C2ECAD63DE2781DCBA0F486-wk-Fact-C97BBE696C2ECAD63DE2781DCBA0F486"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="FI2019Q4"
      decimals="0"
      id="Fact-4082D3B7B2F7EEC6F4EB781DCB1C6DD1-wk-Fact-4082D3B7B2F7EEC6F4EB781DCB1C6DD1"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RevenueFromRelatedParties
      contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember"
      decimals="-5"
      id="Fact-D10DC2C1B94596BD67E791E862CB5D2B-wk-Fact-D10DC2C1B94596BD67E791E862CB5D2B"
      unitRef="usd">500000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="3"
      id="Fact-FF4F0CB7FFD0DBBD8802F3136FE23487-wk-Fact-FF4F0CB7FFD0DBBD8802F3136FE23487"
      unitRef="number">0.436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="3"
      id="Fact-049EB0A70061DE1C48C8F3131A7FD60C-wk-Fact-049EB0A70061DE1C48C8F3131A7FD60C"
      unitRef="number">0.603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="3"
      id="Fact-2A704D969DD185097282F3131A8D6DE8-wk-Fact-2A704D969DD185097282F3131A8D6DE8"
      unitRef="number">0.588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-E433AECEEB20DD00A83EA6258E4A7BB2-wk-Fact-E433AECEEB20DD00A83EA6258E4A7BB2"
      unitRef="number">0.751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-C9046FC0C16BB9A3EB52A6258E56DD00-wk-Fact-C9046FC0C16BB9A3EB52A6258E56DD00"
      unitRef="number">0.788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-1C8E045C08ACA664A5C0F3026D4FC8D5-wk-Fact-1C8E045C08ACA664A5C0F3026D4FC8D5"
      unitRef="number">0.687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-EF39EAEE666457747390A6258E701AE0-wk-Fact-EF39EAEE666457747390A6258E701AE0"
      unitRef="number">0.741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-C8B21F5DEB8BEF1BB4A3A6258E69C839-wk-Fact-C8B21F5DEB8BEF1BB4A3A6258E69C839"
      unitRef="number">0.687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-1610E9DA0054DED5BD06F3026C57B4F0-wk-Fact-1610E9DA0054DED5BD06F3026C57B4F0"
      unitRef="number">0.632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="3"
      id="Fact-4D5D8F2D138E1E6A5161F31386240401-wk-Fact-4D5D8F2D138E1E6A5161F31386240401"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="3"
      id="Fact-1292E8670200F89FB53AF3131A776860-wk-Fact-1292E8670200F89FB53AF3131A776860"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-4BB386B2AB8D9AE72373A6258E481402-wk-Fact-4BB386B2AB8D9AE72373A6258E481402"
      unitRef="number">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-E2835A45DE468419ED89A6258E4E2C89-wk-Fact-E2835A45DE468419ED89A6258E4E2C89"
      unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-077932B4BD59055E9E33F3026EF8CD79-wk-Fact-077932B4BD59055E9E33F3026EF8CD79"
      unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-9712D3BDE703B11A6173A6258E472A7B-wk-Fact-9712D3BDE703B11A6173A6258E472A7B"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-385A158D39B2D1ADFEBDA6258E754CA6-wk-Fact-385A158D39B2D1ADFEBDA6258E754CA6"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="Fact-5AAE0C6D5FE8045770B7F3026E030ED5-wk-Fact-5AAE0C6D5FE8045770B7F3026E030ED5"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-3A627B61BCADC08438A5A6258E5E4A52-wk-Fact-3A627B61BCADC08438A5A6258E5E4A52">P6Y1M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-0824CD1152BDD5DA97FDA6258E74E869-wk-Fact-0824CD1152BDD5DA97FDA6258E74E869">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-221E2A732549F077B5E9A6258E57C958-wk-Fact-221E2A732549F077B5E9A6258E57C958">P6Y6M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-23507DCF070D9524C008A6258E76C359-wk-Fact-23507DCF070D9524C008A6258E76C359">P5Y4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="Fact-053D95A092D93B039A7EF313575E35FB-wk-Fact-053D95A092D93B039A7EF313575E35FB">P3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="Fact-DCABCBB7B4D9CAA9AC2AF312041C16A5-wk-Fact-DCABCBB7B4D9CAA9AC2AF312041C16A5">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-4ABE8B486CF9D6589F8DF3026ACE6A41-wk-Fact-4ABE8B486CF9D6589F8DF3026ACE6A41">P6Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="Fact-51CF0AF71C00909F43EEF31202DE1B20-wk-Fact-51CF0AF71C00909F43EEF31202DE1B20">P3M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-56CE46D68CBF3ED802CCF3026903064E-wk-Fact-56CE46D68CBF3ED802CCF3026903064E">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentType
      contextRef="FD2019Q4YTD"
      id="d884e895-wk-Fact-2771A58601099553AAC5AB994851A54F">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="FD2019Q4YTD"
      id="d884e908-wk-Fact-69318997CBC21EE5D0AAAB99D2314F99">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q4YTD"
      id="d884e917-wk-Fact-A7F73014D07516ABC15DF36E7B13E456">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q4YTD"
      id="d884e927-wk-Fact-AA4FF2FC26BA47BAF72EAB9B0053B7B5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q4YTD"
      id="d884e939-wk-Fact-C7F2EB2D6EFA821A2A53AB9BF11B4B38">001-38683</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q4YTD"
      id="d884e948-wk-Fact-28771D4B956C1C40924CAB9CCA66166E">GUARDANT HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q4YTD"
      id="d884e973-wk-Fact-FE0B3E9ED1E56500DBA7ABA02507C561">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q4YTD"
      id="d884e983-wk-Fact-709CB4345A52F158AD85ABA146EFD3AE">45-4139254</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q4YTD"
      id="d884e1008-wk-Fact-48A643C6E6B5799907F97E890DE78B78">505 Penobscot Dr.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q4YTD"
      id="d884e1014-wk-Fact-07A5CFF40B59734A00BF7E8956767DD7">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q4YTD"
      id="d884e1019-wk-Fact-777F7C3DA48A5D752D737E8997FB09BD">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q4YTD"
      id="d884e1024-wk-Fact-3F52941B45D12F3C1F627E89E1B24350">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q4YTD"
      id="d884e1036-wk-Fact-3868DA39C17FFF7571F9AF3311E375F2">855</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q4YTD"
      id="d884e1041-wk-Fact-2EBDBADBE7E565D596AEAF34A7223033">698-8887</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q4YTD"
      id="d884e1083-wk-Fact-E53AA6DEE1BBC27FF902ABA2B54E4E3B">Common Stock, par value $0.00001</dei:Security12bTitle>
    <dei:SecurityExchangeName
      contextRef="FD2019Q4YTD"
      id="d884e1093-wk-Fact-FE24D33EE96896A47084ABA34114625F">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="FD2019Q4YTD"
      id="d884e1131-wk-Fact-312DF623356342D5A21777E65CA40AB4">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="FD2019Q4YTD"
      id="d884e1152-wk-Fact-86C002F60CEA10FBCA82AF36826CA423">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q4YTD"
      id="d884e1163-wk-Fact-F512ABE94C298A779434AF37BD58BBEC">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q4YTD"
      id="d884e1176-wk-Fact-DAF63E8436AF288DC055AF3944A302FD">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q4YTD"
      id="d884e1204-wk-Fact-8FD104E387DA432F8237AF3B4D1723B7">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q4YTD"
      id="d884e1261-wk-Fact-FA4EAE2934468FF36BD4AF3C8212BB23">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q4YTD"
      id="d884e1293-wk-Fact-06E9CA7FC82FBF9D4C60AF3CADBD73B8">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q4YTD"
      id="d884e1315-wk-Fact-7F3CB34B4D174D8DD15AAF44CED57D4E">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="I2019Q2Jun28"
      decimals="-8"
      id="d884e1328-wk-Fact-6A646C201020A1A8B3BE7E910E44CB51"
      unitRef="usd">3400000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q1Feb14"
      decimals="INF"
      id="d884e1339-wk-Fact-8FE44DA58FFC49881D7FEE41F0474686"
      unitRef="shares">94382681</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9683F8C212F5DCF7AF55AF4786F56093-0-wk-Fact-463736903FF57BAD9CA2AF47987E241C">&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Portions of the registrant&#x2019;s definitive proxy statement relating to its annual meeting of stockholders to be held in&#160;2020 (the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&#x201c;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020 Annual Meeting&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&#x201d;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;), to be filed with the Securities and Exchange Commission (the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&#x201c;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;SEC&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&#x201d;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates, are incorporated herein by reference where indicated. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, such proxy statement is not deemed to be filed as part hereof.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1068-wk-Fact-B3107E60B877A65B3F8DA6258E67A624"
      unitRef="usd">143228000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1087-wk-Fact-94C37B74DA89F5960565A6258E2E90F1"
      unitRef="usd">140544000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1102-wk-Fact-DBF6C13215DB00C0E06AA6258E6AEF42"
      unitRef="usd">379574000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1121-wk-Fact-4E6001699A1D52981298A6258E2C442E"
      unitRef="usd">278417000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1141-wk-Fact-932964D0A06B579D5FA9A6258E2C9EB4"
      unitRef="usd">47986000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1160-wk-Fact-458877E932D5EBD4BD8CA6258E614976"
      unitRef="usd">35690000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1180-wk-Fact-E190A32224F0C2ED41B1A6258E691196"
      unitRef="usd">15181000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1199-wk-Fact-73EB6DD4D040B8E58FA4A6258E681AB5"
      unitRef="usd">9136000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1219-wk-Fact-234F20EA2CCDC4F83668A6258E2C6FE7"
      unitRef="usd">11389000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1238-wk-Fact-C1404E0FA5DD1E13F78BA6258E33FB32"
      unitRef="usd">5204000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1258-wk-Fact-9CFF4FFE3BC02EA5FCFBA6258E6BEEAA"
      unitRef="usd">597358000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1277-wk-Fact-00E8A3950A32C9968A04A6258E63CD03"
      unitRef="usd">468991000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1297-wk-Fact-3B1FA43F8C9DF451E37FA6258E2CD4EC"
      unitRef="usd">268783000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1316-wk-Fact-53678F51D29428BDCD16A6258E2DAFA7"
      unitRef="usd">77563000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1337-wk-Fact-70D2EDBA0CE7622F37B1A6258E2A47FB"
      unitRef="usd">43668000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1356-wk-Fact-F2928BF2B06270B1745EA6258E2F72DD"
      unitRef="usd">31003000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1376-wk-Fact-8C80AF6CC4A8BCD0FCDCEE6D1A15FBBC"
      unitRef="usd">29140000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1415-wk-Fact-6D771168FBAEC197A7FCEE6DF63A7404"
      unitRef="usd">8524000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1434-wk-Fact-8F972AC5CAC336F5E358EE6DF64C2E3A"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1454-wk-Fact-FE97572C8D1B2F96ECD4EE6E1A0CCB3E"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1473-wk-Fact-978B05E7243D87CCF76BEE6E1A087B24"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1493-wk-Fact-7AB982A0A366416C7ECBA6258E6855F5"
      unitRef="usd">6890000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1512-wk-Fact-0ABDE53C90E7BD355E30A6258E6239CD"
      unitRef="usd">7800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1532-wk-Fact-4BD1C4130DFD0EAC3A4FA6258E310079"
      unitRef="usd">4882000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1551-wk-Fact-920DF56407E2DE37DC2CA6258E2AB586"
      unitRef="usd">2046000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1578-wk-Fact-4A43155C56BC426FCBE3A6258E2DF4E7"
      unitRef="usd">962535000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1597-wk-Fact-CCBF4B2DE891C350F87CA6258E343288"
      unitRef="usd">587403000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1699-wk-Fact-549F3227B6E38C4A3A53A6258E3057C0"
      unitRef="usd">16197000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1718-wk-Fact-88ABD59BB60B02643A89A6258E3737BA"
      unitRef="usd">10642000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1733-wk-Fact-A143034E4B9FB92D9FB3A6258E367FA7"
      unitRef="usd">18557000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1752-wk-Fact-0B82DFDAFDD85F4BC0FFA6258E63C82A"
      unitRef="usd">12986000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1773-wk-Fact-71CC6343C9567D0701CFA6258E2F8222"
      unitRef="usd">25703000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1792-wk-Fact-B215684635F57C2B1BB6A6258E5F1626"
      unitRef="usd">7178000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1812-wk-Fact-FC10FC77A02C712BEC01A6258E36079F"
      unitRef="usd">12277000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1831-wk-Fact-86E438AD1CC1914DEE39A6258E336EE4"
      unitRef="usd">16138000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1851-wk-Fact-38FB97B89C3C4B2E135FA6258E688B8C"
      unitRef="usd">72734000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1870-wk-Fact-C9BA75F77CC595F33FFCA6258E3466D9"
      unitRef="usd">46944000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1890-wk-Fact-6BDAA847E1388CB98902EE769A57661E"
      unitRef="usd">33256000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1929-wk-Fact-97090656F47F8E27C3F0A6258E2C2E87"
      unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1948-wk-Fact-61ECFFECABA92FA38684A6258E6A44EB"
      unitRef="usd">7844000</us-gaap:DeferredRentCreditNoncurrent>
    <gh:AccruedRoyaltiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e1968-wk-Fact-97AFDFA53C0512E74784A6258E367455"
      unitRef="usd">6880000</gh:AccruedRoyaltiesNoncurrent>
    <gh:AccruedRoyaltiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e1987-wk-Fact-1BCA6BB19220D4943D39A6258E663F8B"
      unitRef="usd">7338000</gh:AccruedRoyaltiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e2007-wk-Fact-3180396D5E94ED6882DCA6258E331915"
      unitRef="usd">1672000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e2026-wk-Fact-24C608AFFD17A2477C31A6258E605847"
      unitRef="usd">325000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e2048-wk-Fact-D9E58FA15C46A8F94757A6258E2ABF68"
      unitRef="usd">114542000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e2067-wk-Fact-787E9732FDA1620CF163A6258E2DEF38"
      unitRef="usd">62451000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d27497e2087-wk-Fact-8B7360B8EF33839A7C33A6258E697AC9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d27497e2105-wk-Fact-F78D811242E88740F26CA6258E69BB69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e2124-wk-Fact-ACD2A94D262935F8BC49A6258E33B156"
      unitRef="usd">49600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e2143-wk-Fact-650B8E998CF3863DCAA5A6258E3807ED"
      unitRef="usd">41800000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e2220-wk-Fact-6A7F35AE585C2C21ECAEA6258E60DD29"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e2239-wk-Fact-34424C986E7FFB80571BA6258E2BB23E"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e2259-wk-Fact-AC1D2E2EE2172E340DB2A6258E2FC305"
      unitRef="usd">1000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e2278-wk-Fact-F5C2C56EFBB695224069A6258E2A846A"
      unitRef="usd">1000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e2298-wk-Fact-F218BA73D777ACC507AAA6258E70EE86"
      unitRef="usd">1150090000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e2317-wk-Fact-030E0C34DEF5054693A2A6258E353F5E"
      unitRef="usd">764033000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e2337-wk-Fact-C14C877790BB8D9F4B75A6258E76EB22"
      unitRef="usd">1111000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e2356-wk-Fact-A935E69713932BF01599A6258E65463C"
      unitRef="usd">-83000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e2377-wk-Fact-BFC5FAAB703E313E049DA6258E318F4E"
      unitRef="usd">-352809000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e2397-wk-Fact-6BABCF1E83F5B56BEB09A6258E34C8AB"
      unitRef="usd">-280799000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e2418-wk-Fact-59A7633466DC3816626FA6258E32DB25"
      unitRef="usd">798393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e2437-wk-Fact-2158FF91CAAC625B3D80A6258E2EC32E"
      unitRef="usd">483152000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d27497e2462-wk-Fact-DABB7C98D261DC6E8FDBA6258E65EC6B"
      unitRef="usd">962535000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d27497e2481-wk-Fact-CB529FF0DC7487D23733A6258E310B12"
      unitRef="usd">587403000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets
      contextRef="FI2019Q4"
      decimals="-5"
      id="d27497e2501-wk-Fact-C9B30A4D96217FC20AEA7E6D5E733780"
      unitRef="usd">45100000</us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets>
    <us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets
      contextRef="FI2018Q4"
      decimals="-5"
      id="d27497e2505-wk-Fact-C94CABE66DBAD6C4DBB377E239F32181"
      unitRef="usd">48300000</us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets>
    <us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d27497e2509-wk-Fact-7D6DDEA18C7D528A30AA7E6D6D02DFBF"
      unitRef="usd">5700000</us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities>
    <us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d27497e2514-wk-Fact-E51091D4C563EE19EFA877F339E8CAC1"
      unitRef="usd">1200000</us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1184-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF"
      unitRef="usd">180462000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1203-wk-Fact-5B2DE63C41AB69886EC1A6258E3B0666"
      unitRef="usd">78407000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1223-wk-Fact-37278A89EE20DFC9B188A6258E33CABC"
      unitRef="usd">42088000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromDevelopmentServices
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1245-wk-Fact-8B6729A9D18284EECA68A6258E3316AE"
      unitRef="usd">33913000</gh:RevenuefromDevelopmentServices>
    <gh:RevenuefromDevelopmentServices
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1264-wk-Fact-E139CBAD9FD19C557986A6258E2D7893"
      unitRef="usd">12232000</gh:RevenuefromDevelopmentServices>
    <gh:RevenuefromDevelopmentServices
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1283-wk-Fact-4D2936D9D7A53B6DF502A6258E460D65"
      unitRef="usd">7754000</gh:RevenuefromDevelopmentServices>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1309-wk-Fact-4DE9547D7B5D2159A859A6258E3A1898"
      unitRef="usd">214375000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1328-wk-Fact-D1D5341DAF1488A2957EA6258E683A12"
      unitRef="usd">90639000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1347-wk-Fact-71C181FD76A4A1A34CB0A6258E9FCF29"
      unitRef="usd">49842000</us-gaap:Revenues>
    <gh:CostsofPrecisionOncologyTesting
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1440-wk-Fact-D776885A696B45EC18A7A6258E2FD195"
      unitRef="usd">62255000</gh:CostsofPrecisionOncologyTesting>
    <gh:CostsofPrecisionOncologyTesting
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1459-wk-Fact-FC5F2158414C80AA7DA4A6258E4283FB"
      unitRef="usd">39846000</gh:CostsofPrecisionOncologyTesting>
    <gh:CostsofPrecisionOncologyTesting
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1478-wk-Fact-B7EFBFBB082FE8085973A6258E301ECD"
      unitRef="usd">28883000</gh:CostsofPrecisionOncologyTesting>
    <gh:CostofDevelopmentServices
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1504-wk-Fact-624893A7D30D95177256A6258E39666F"
      unitRef="usd">8465000</gh:CostofDevelopmentServices>
    <gh:CostofDevelopmentServices
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1523-wk-Fact-22A4CDE99A64B5FC0099A6258E8705D7"
      unitRef="usd">3364000</gh:CostofDevelopmentServices>
    <gh:CostofDevelopmentServices
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1542-wk-Fact-71D6CFCE72A450B5C150A6258E676789"
      unitRef="usd">2735000</gh:CostofDevelopmentServices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1568-wk-Fact-E4F9389B4D6CBB291C84A6258E2D3A8B"
      unitRef="usd">86292000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1587-wk-Fact-F723EEEAA4F3220C47ACA6258E3FE220"
      unitRef="usd">50714000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1606-wk-Fact-66A294FA7328F9F4B953A6258E2EC23F"
      unitRef="usd">25562000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1633-wk-Fact-2C2223E877947D62403CA6258E3248D1"
      unitRef="usd">78335000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1652-wk-Fact-083DF7C4B235810094E7A6258E363A46"
      unitRef="usd">53465000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1671-wk-Fact-23B45AC22F4A6BFF5D6CA6258E34A620"
      unitRef="usd">32497000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1697-wk-Fact-F0C0B87D8E21F5313043A6258E2E5884"
      unitRef="usd">61399000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1716-wk-Fact-FD13D0A9D094DDCA3507A6258E32F402"
      unitRef="usd">36192000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1735-wk-Fact-1A94BC50A606749A1ADCA6258E2BC2C0"
      unitRef="usd">36777000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1761-wk-Fact-838BF008B4D0A88EB3A9A6258E40B668"
      unitRef="usd">296746000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1780-wk-Fact-F97427327B186CEC1349A6258E33EA92"
      unitRef="usd">183581000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1799-wk-Fact-292C6B080F1A4188053FA6258E8F7A3A"
      unitRef="usd">126454000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1825-wk-Fact-126EDB351B5B224FBB25A6258E34C500"
      unitRef="usd">-82371000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1845-wk-Fact-CFCEE5A46FE3701A17E0A6258EA6DE70"
      unitRef="usd">-92942000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1865-wk-Fact-AE2F748415B13DDE756FA6258E437681"
      unitRef="usd">-76612000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1892-wk-Fact-496CCEDD3A01D6AFD755A6258EA38C22"
      unitRef="usd">13741000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1911-wk-Fact-36A785827904CDC46D4FA6258E2F2C08"
      unitRef="usd">5266000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1930-wk-Fact-C0A655E0A6BD7D06BB66A6258E4977F0"
      unitRef="usd">2234000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e1956-wk-Fact-CCD8898096D567E0882FA6258E321E3E"
      unitRef="usd">1181000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e1976-wk-Fact-F17B8B9C6B72F3A3BD01A6258EA2CFB4"
      unitRef="usd">1251000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e1996-wk-Fact-C12A4C43DE5AE549875EA6258E47EA4E"
      unitRef="usd">2702000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e2023-wk-Fact-043D7BA11E1A4E1E6280A6258E45617B"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e2042-wk-Fact-136B8C09A698F74DEA31A6258E30FC6D"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e2061-wk-Fact-63487DDF114014865E64A6258E356BB1"
      unitRef="usd">-5075000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e2088-wk-Fact-2E6394D22E236EB7B233A6258EA4039F"
      unitRef="usd">88000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e2107-wk-Fact-B037EB1E746BDCD793D7A6258E543A62"
      unitRef="usd">4702000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e2126-wk-Fact-F68A726106C5DF3128E5A6258E59E89A"
      unitRef="usd">-1059000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e2153-wk-Fact-533D35D4131C9059CAE7A6258E46A63A"
      unitRef="usd">-69723000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e2173-wk-Fact-E8046E8FEE4F9385958AA6258E318575"
      unitRef="usd">-84225000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e2193-wk-Fact-129FBB53D2772B0CEB01A6258E337EF0"
      unitRef="usd">-83214000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e2220-wk-Fact-0169B057D253E86D735EA6258E55D708"
      unitRef="usd">-1872000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e2240-wk-Fact-E068EE171D06C4C2BD3DA6258E2D3C45"
      unitRef="usd">38000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e2259-wk-Fact-29DDE49B36BBF8FF706BA6258E39EA9B"
      unitRef="usd">7000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e2285-wk-Fact-DD9CA72B1BBB5CC40BD8A6258E32F7EC"
      unitRef="usd">-67851000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e2305-wk-Fact-4A8DB7FF4A717BAB2EA3A6258E443A47"
      unitRef="usd">-84263000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e2325-wk-Fact-FF90E30B64F2C7FBE5B5A6258EA91FF9"
      unitRef="usd">-83221000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e2353-wk-Fact-D077CEFD0B079FCF3D61A6258E2E6647"
      unitRef="usd">7800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e2373-wk-Fact-31CADB87CCF74DD2F2C1A6258E34EF14"
      unitRef="usd">800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e2393-wk-Fact-418F0527488BE40C35CDA6258E2FA7B8"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e2424-wk-Fact-0C6706E1876259798ED2A6258E385A17"
      unitRef="usd">-75651000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e2444-wk-Fact-DA7C32E8FAD7508D2E32A6258E8265E9"
      unitRef="usd">-85063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e2465-wk-Fact-AFCDBD0520C9E2C5AB33A6258E29D834"
      unitRef="usd">-83221000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="-3"
      id="d30009e2486-wk-Fact-E68A8C708E2097EC5946A6258E9E2226"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="-3"
      id="d30009e2505-wk-Fact-EBA109E0CAADBD273C7BA6258E32AF46"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="-3"
      id="d30009e2524-wk-Fact-1FF0D1ABEA05EF2C682AA6258E3BA553"
      unitRef="usd">4716000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember"
      decimals="-3"
      id="d30009e2551-wk-Fact-26F1F32EB6B9B7D7D5A6A6258E3AC275"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember"
      decimals="-3"
      id="d30009e2570-wk-Fact-E839DF2B5D3BDD98BBBDA6258E87AB93"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember"
      decimals="-3"
      id="d30009e2589-wk-Fact-A468E27BF4939F5E8D3EA6258E447BE2"
      unitRef="usd">1058000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e2621-wk-Fact-1535B29FF0DAB4B154A2A6258E365584"
      unitRef="usd">-75651000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e2641-wk-Fact-6133CF14439345C7338DA6258E9D2D95"
      unitRef="usd">-85063000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e2662-wk-Fact-28A37E9521F9874504E6A6258E35A77C"
      unitRef="usd">-88995000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d30009e2688-wk-Fact-431CA7CCFD12D7D5971FA6258E4536C1"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d30009e2708-wk-Fact-67E566506F83BC6276A1A6258E62F4F5"
      unitRef="usdPerShare">-2.80</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d30009e2729-wk-Fact-08CC3E0BCEE177D04CA6A6258E311A4A"
      unitRef="usdPerShare">-7.07</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30009e2750-wk-Fact-77260172BDC24CAE0417A6258E2DCB75"
      unitRef="shares">90597000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30009e2769-wk-Fact-C2FF126AE24D032B0278A6258E405B49"
      unitRef="shares">30403000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30009e2788-wk-Fact-F37245EBF17027238E7AA6258E393BCD"
      unitRef="shares">12582000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30310e1115-wk-Fact-DD9CA72B1BBB5CC40BD8A6258E32F7EC"
      unitRef="usd">-67851000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30310e1135-wk-Fact-4A8DB7FF4A717BAB2EA3A6258E443A47"
      unitRef="usd">-84263000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30310e1156-wk-Fact-FF90E30B64F2C7FBE5B5A6258EA91FF9"
      unitRef="usd">-83221000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30310e1244-wk-Fact-431720F5631AE9EC0AA3A6258E5DF56D"
      unitRef="usd">1110000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30310e1264-wk-Fact-9DDBB9CF92558B43AD3DA6258EA31002"
      unitRef="usd">449000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30310e1283-wk-Fact-6AF17876E717FD91DE78A6258EA80FE8"
      unitRef="usd">-446000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30310e1310-wk-Fact-E81D30CAB9FEB9A19AD5A6258E59CFB4"
      unitRef="usd">84000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30310e1329-wk-Fact-DDD8AED4C293E1923D8CA6258E9E4064"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30310e1348-wk-Fact-26E8492B95AC8A4AACF3A6258E7F8A3A"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30310e1374-wk-Fact-D825F1C00002D1476452A6258EA6AC45"
      unitRef="usd">1194000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30310e1394-wk-Fact-6032CF74833A27BB2656A6258EA10F0B"
      unitRef="usd">449000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30310e1414-wk-Fact-2645F570754ED8CF2FA3A6258EA89EEE"
      unitRef="usd">-446000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30310e1446-wk-Fact-70D9E087B0785AB188A5A6258E5B8236"
      unitRef="usd">-66657000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30310e1466-wk-Fact-E475CF877E4BE418F2EDA6258E492196"
      unitRef="usd">-83814000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30310e1487-wk-Fact-23B1FA79DA408B2DA907A6258E5B9B1E"
      unitRef="usd">-83667000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30310e1508-wk-Fact-632373B76C7D4F306A7CA6258E615967"
      unitRef="usd">7800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30310e1528-wk-Fact-B38BBC67C906DBBD5E09A6258E982ADB"
      unitRef="usd">800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30310e1548-wk-Fact-44357517AF31A11CBC26A6258EA01EC4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d30310e1579-wk-Fact-A01AA133C8DDDD269880A6258E96B77B"
      unitRef="usd">-74457000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d30310e1599-wk-Fact-30CA6E429CAC2B4C4DFCA6258E551015"
      unitRef="usd">-84614000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d30310e1620-wk-Fact-A9345E53687F4E4EF49BA6258E49ED20"
      unitRef="usd">-83667000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="d38105e1279-wk-Fact-844359596E5A81188057A6258E64C56C"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d38105e1293-wk-Fact-EC5B6CF88ED198FF1543A6258E5F6694"
      unitRef="shares">40181923</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d38105e1312-wk-Fact-99EFC2DD48BE27860015A6258E70DF87"
      unitRef="usd">179997000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e1327-wk-Fact-E3D4F63FB6C4CAF8F396A6258E57802D"
      unitRef="shares">13184214</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d38105e1346-wk-Fact-51A7E87E84947FE6BDC8A6258E56C5BA"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e1365-wk-Fact-1A3057BA00C1FDB92DBFA6258E49610E"
      unitRef="usd">7410000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d38105e1385-wk-Fact-841BD83A559BF48A12F8A6258E5E435C"
      unitRef="usd">-86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e1405-wk-Fact-387AECF7D9986CE3E2D1A6258E57F216"
      unitRef="usd">-107625000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4"
      decimals="-3"
      id="d38105e1425-wk-Fact-93D20B2CDD63F757F7D7A6258E5C0E0D"
      unitRef="usd">79696000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e1527-wk-Fact-883BD08D27B652702B72A650FAE9045A"
      unitRef="usd">174000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e1566-wk-Fact-ABF2382D144F73297812A6515D6E5367"
      unitRef="usd">-174000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2017Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member"
      decimals="-3"
      id="d38105e1586-wk-Fact-7C6968FAF086066164F0A65342EC458B"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d38105e1626-wk-Fact-91205F150B16F709D7ADA6258E909E9B"
      unitRef="shares">141774</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d38105e1640-wk-Fact-CDBDC115FD78CFDB806FA6258E4A5711"
      unitRef="usd">1060000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember"
      decimals="-3"
      id="d38105e1751-wk-Fact-2CCB1E39EC48142BE2EEA6258E85D953"
      unitRef="usd">1060000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d38105e1791-wk-Fact-B6044D557E81640823D6A669A94E924D"
      unitRef="shares">38970592</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d38105e1805-wk-Fact-6E7F37FAACB5B83F416FA66A80F3F8E5"
      unitRef="usd">319536000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember"
      decimals="-3"
      id="d38105e1916-wk-Fact-023408736869AEF995B5A66ADC294A90"
      unitRef="usd">319536000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d38105e1956-wk-Fact-1620020D7FE1E7D40ACCA66C3E81B6F7"
      unitRef="shares">666920</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d38105e1971-wk-Fact-C8B6786B36CF8837D421A66D3667032C"
      unitRef="usd">619000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e2064-wk-Fact-B2077C8A8666D6CFC49CA66EA1BFAF47"
      unitRef="usd">4716000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="-3"
      id="d38105e2084-wk-Fact-79F8BF82D03BF789CE2EA66EB3AB6CDF"
      unitRef="usd">5335000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e2159-wk-Fact-8B750B024F53AD6933E7A6258E739B0D"
      unitRef="shares">342946</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e2192-wk-Fact-F3A31CB39EBD5E2B9CA4A6258E68F385"
      unitRef="usd">753000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d38105e2250-wk-Fact-E76BABF6E56B3A3D959AA6258E4BDFA3"
      unitRef="usd">753000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <gh:StockIssuedDuringPeriodSharesExerciseofWarrants
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e2324-wk-Fact-E53379C9F058B6310E4BA6258E7733EF"
      unitRef="shares">89030</gh:StockIssuedDuringPeriodSharesExerciseofWarrants>
    <gh:StockIssuedDuringPeriodValueExerciseofWarrants
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e2357-wk-Fact-E1EAA2531418FA68EB13A6258E660D19"
      unitRef="usd">12000</gh:StockIssuedDuringPeriodValueExerciseofWarrants>
    <gh:StockIssuedDuringPeriodValueExerciseofWarrants
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d38105e2415-wk-Fact-B33913FA4DAA79C63A0EA6258E57F9A6"
      unitRef="usd">12000</gh:StockIssuedDuringPeriodValueExerciseofWarrants>
    <gh:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e2522-wk-Fact-7E3483D21BCDF6FE63A9A6258E66924B"
      unitRef="usd">103000</gh:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions>
    <gh:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d38105e2580-wk-Fact-62AA337F1165EE48764DA6258E50E9E3"
      unitRef="usd">103000</gh:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationForEarlyExercisedStockOptions>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e2654-wk-Fact-C0D77428FA4EE47EE729A6258E55A3B4"
      unitRef="shares">1719308</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e2688-wk-Fact-78F8E1AE90B2D5241002A6258E673330"
      unitRef="usd">7222000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d38105e2747-wk-Fact-DC4FE97CD4564A276D2AA6258E608E5D"
      unitRef="usd">7222000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e2856-wk-Fact-B069381EB3919FA61FE7A6258E543679"
      unitRef="usd">3670000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d38105e2914-wk-Fact-B717513E3231A67304DCA6258E4CB48E"
      unitRef="usd">3670000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d38105e3041-wk-Fact-3EBC7F2943EE49B511FDA6258E714197"
      unitRef="usd">-446000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d38105e3080-wk-Fact-2645F570754ED8CF2FA3A6258EA89EEE"
      unitRef="usd">-446000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e3227-wk-Fact-D0DFB23EA2E2C9444ED2A6258E6B0A19"
      unitRef="usd">-83221000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d38105e3247-wk-Fact-34CE2134FBEFD23EE8C1A6258E71CA36"
      unitRef="usd">-83221000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="d38105e3269-wk-Fact-26A55D8A79EFC5CDAFE3A6258E600EED"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d38105e3288-wk-Fact-1C9C92E8245CF509A918A6258E68A0A0"
      unitRef="shares">78627369</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d38105e3302-wk-Fact-EB182468A2F67BD0EFB5A6258E54906C"
      unitRef="usd">499974000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e3322-wk-Fact-C2E32A259D26C3F5FA0FA6258E4C294A"
      unitRef="shares">11896882</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d38105e3336-wk-Fact-0FDDB1FDA68140134EE0A6258E51BDF8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e3355-wk-Fact-6BB87F447B7F9082895FA6258E4A7420"
      unitRef="usd">4900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d38105e3375-wk-Fact-B41561B8858F7FB5E763A6258E5D2174"
      unitRef="usd">-532000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e3395-wk-Fact-E5B3E6C9202EEE11E893A6258E844559"
      unitRef="usd">-195736000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-3"
      id="d38105e3415-wk-Fact-AE041E9B471A7A5500CAA6258E8366F4"
      unitRef="usd">308606000</us-gaap:StockholdersEquity>
    <gh:StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d38105e3456-wk-Fact-D7AF0F049A77A03801C8A6258E589335"
      unitRef="shares">-78627369</gh:StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering>
    <gh:StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d38105e3471-wk-Fact-722158C7214C8BB48B9FA6258E58BC14"
      unitRef="usd">-499974000</gh:StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering>
    <gh:StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e3492-wk-Fact-B448638235D53B379AD3A6708D8F3FF0"
      unitRef="shares">58264577</gh:StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering>
    <gh:StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d38105e3506-wk-Fact-F1AEBBCB6ED198A6414DA67092164D2E"
      unitRef="usd">1000</gh:StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering>
    <gh:StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e3525-wk-Fact-53B5CF9E5EB9D781D439A671D866270C"
      unitRef="usd">499973000</gh:StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e3657-wk-Fact-AAEC892EEB6D5A46ABFDA67095A26E49"
      unitRef="shares">14375000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e3690-wk-Fact-96E3C9FDF6A59BE38CD2A671DB5AE9A7"
      unitRef="usd">249531000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember"
      decimals="-3"
      id="d38105e3748-wk-Fact-72C9B53C70E53E24DA9BA6258E8D4994"
      unitRef="usd">249531000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e3822-wk-Fact-9DF3038E96A65CECE02AA6258E685B6A"
      unitRef="shares">963119</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e3855-wk-Fact-24460FAA09CDC664E0C8A6258E5B0BE7"
      unitRef="usd">2905000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d38105e3913-wk-Fact-E9BDC192EDBE399C903AA6258E8E2CAC"
      unitRef="usd">2905000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e3987-wk-Fact-FAE829818E22E2491C3BAA1C6A61DC45"
      unitRef="shares">44268</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsEarlyExercisesinPeriod>
    <gh:StockIssuedDuringPeriodSharesExerciseofWarrants
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e4152-wk-Fact-A892D4CDF35028AB6E0CA6258E4E112A"
      unitRef="shares">320289</gh:StockIssuedDuringPeriodSharesExerciseofWarrants>
    <gh:StockIssuedDuringPeriodValueExerciseofWarrants
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e4185-wk-Fact-BC4532F950FE1A327B01A6258E59D412"
      unitRef="usd">45000</gh:StockIssuedDuringPeriodValueExerciseofWarrants>
    <gh:StockIssuedDuringPeriodValueExerciseofWarrants
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d38105e4243-wk-Fact-03EEFF6DFCDC76500CA1A6258E51B7B9"
      unitRef="usd">45000</gh:StockIssuedDuringPeriodValueExerciseofWarrants>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e4317-wk-Fact-5F712EAF4837136E3808A6258E67F9EF"
      unitRef="shares">31681</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e4351-wk-Fact-AF0A8D659B245F5E4277A6258E75B3E0"
      unitRef="usd">172000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d38105e4410-wk-Fact-CD7503101B1D97FE7B4DA6258E5EE9AC"
      unitRef="usd">172000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e4518-wk-Fact-68335CE4E8B46E32A99AA6258E8A7ADF"
      unitRef="usd">6851000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d38105e4576-wk-Fact-C53E2344CDD99C9DA233A6258E8DF9C2"
      unitRef="usd">6851000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="d38105e4598-wk-Fact-8065A33FE3BC9958E75EA680101F62E9"
      unitRef="usd">41000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="d38105e4765-wk-Fact-553DDC56FBF0AF164694A67F1FA4044B"
      unitRef="usd">-800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e4890-wk-Fact-FEEC64875C7F5EF75C2DA6810FD7B4AA"
      unitRef="usd">800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d38105e4910-wk-Fact-31CADB87CCF74DD2F2C1A6258E34EF14"
      unitRef="usd">800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d38105e5038-wk-Fact-619F4F9716FF443336C9A6258E571550"
      unitRef="usd">449000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d38105e5076-wk-Fact-6032CF74833A27BB2656A6258EA10F0B"
      unitRef="usd">449000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e5222-wk-Fact-0EEDA505BA1872D2C1DEA6258E718592"
      unitRef="usd">-84263000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d38105e5242-wk-Fact-368EB0132B0845EE0BB7A6258E609A48"
      unitRef="usd">-84263000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="d38105e5264-wk-Fact-784A6A47FC82D5112436A6258E4E73D5"
      unitRef="usd">41800000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d38105e5283-wk-Fact-481479906A5715583CFEA6258E6F49EA"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d38105e5297-wk-Fact-650ECFF3F15E7AE0D47EA6258E500B6F"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e5317-wk-Fact-65E087CD13D7333D1BB5A6258E5AE2B8"
      unitRef="shares">85832454</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d38105e5331-wk-Fact-07B2592A318983B625E6A6258E867DBF"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e5350-wk-Fact-9BDB2607EE37C81DBFD9A6258E678A4B"
      unitRef="usd">764033000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d38105e5370-wk-Fact-08B637DCD4DC1CFDB473A6258E6A5D60"
      unitRef="usd">-83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e5390-wk-Fact-8A4CBE8A184AFC9AB561A6258E7D298A"
      unitRef="usd">-280799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d38105e5410-wk-Fact-2158FF91CAAC625B3D80A6258E2EC32E"
      unitRef="usd">483152000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e5556-wk-Fact-CD7118FBB5EA8B711AF5A65AE9E58BAD"
      unitRef="usd">4907000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-3"
      id="d38105e5575-wk-Fact-754623305367FB8670D2A65AEDEC3D9A"
      unitRef="usd">4907000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e5682-wk-Fact-1F4029FAFCD0176E373EA659259A0188"
      unitRef="usd">1266000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e5721-wk-Fact-E771CE1D173C901BF9F1A6592EF355EB"
      unitRef="usd">-1266000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member"
      decimals="-3"
      id="d38105e5741-wk-Fact-C5F55928FFEE1BB7F11EA65932BCB594"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e5817-wk-Fact-D334E916D5ED370DD485A678AF937CAF"
      unitRef="shares">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e5851-wk-Fact-71103611F9819B68397AA67A589AA9C5"
      unitRef="usd">349709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d38105e5909-wk-Fact-D80DB7845EAEFC246118A67AA61D4D90"
      unitRef="usd">349709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e5983-wk-Fact-D0E866893B056217E1D1A6258E66948A"
      unitRef="shares">2999419</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e6016-wk-Fact-957E7A0D9BC623236B24A6258E8A0F22"
      unitRef="usd">11638000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d38105e6074-wk-Fact-958399E96E998909F666A6258E66306B"
      unitRef="usd">11638000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e6148-wk-Fact-6B8935B982091915B203EE9B7CC2DD25"
      unitRef="shares">22208</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e6346-wk-Fact-9511BE589CD72311C692EE92B5B07E4D"
      unitRef="usd">95000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d38105e6404-wk-Fact-2DF306F21BAA283704E5A6258E7E4D25"
      unitRef="usd">95000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e6479-wk-Fact-9ED3ED7A51B767BFA96FEE9FFA079A86"
      unitRef="shares">232333</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e6512-wk-Fact-00E045273C28358CC750EEA03E663580"
      unitRef="usd">6395000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d38105e6570-wk-Fact-B5F5E09DEE0A04900E1DEEA03E5D796A"
      unitRef="usd">6395000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e6677-wk-Fact-082023D26E2DFE75FFFFA6258E8996F6"
      unitRef="usd">16954000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d38105e6735-wk-Fact-5CF7741B94AE9AAFA946A6258E8F921B"
      unitRef="usd">16954000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="d38105e6756-wk-Fact-C0BBC3EE13E30CBD6160A6258E7137FD"
      unitRef="usd">-7800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e6881-wk-Fact-2F21490BC6438412F38CA6258E6ED04A"
      unitRef="usd">7800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d38105e6901-wk-Fact-D077CEFD0B079FCF3D61A6258E2E6647"
      unitRef="usd">7800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d38105e7029-wk-Fact-8943A091ED1540BBFD48A6258E80104C"
      unitRef="usd">1194000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d38105e7067-wk-Fact-D825F1C00002D1476452A6258EA6AC45"
      unitRef="usd">1194000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e7213-wk-Fact-9E797B007E634194BBFAA6258E4DDBF8"
      unitRef="usd">-67851000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d38105e7233-wk-Fact-329F61DE9C9E18698163A6258E4D1211"
      unitRef="usd">-67851000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_gh_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="d38105e7260-wk-Fact-96EC9E7A002824BC9591A6258E4F713F"
      unitRef="usd">49600000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d38105e7274-wk-Fact-534506779DFDA28AAC2AA6258E6D56B9"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d38105e7293-wk-Fact-5531DC2F54D9594B534AA6258E71A99F"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d38105e7308-wk-Fact-D1CCA7E55C89588405B9A6258E4C34E6"
      unitRef="shares">94261414</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d38105e7327-wk-Fact-53A8E7D91DDA2DA6CAF2A6258E83CCAA"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d38105e7346-wk-Fact-D86A2CD29D99DA7B9516A6258E750491"
      unitRef="usd">1150090000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d38105e7366-wk-Fact-638F26B618BA52D4D793A6258E48CC94"
      unitRef="usd">1111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d38105e7385-wk-Fact-4FCD1090338F4CC86BA4A6258E5CC293"
      unitRef="usd">-352809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d38105e7405-wk-Fact-59A7633466DC3816626FA6258E32DB25"
      unitRef="usd">798393000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1155-wk-Fact-DD9CA72B1BBB5CC40BD8A6258E32F7EC"
      unitRef="usd">-67851000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e1175-wk-Fact-4A8DB7FF4A717BAB2EA3A6258E443A47"
      unitRef="usd">-84263000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e1195-wk-Fact-FF90E30B64F2C7FBE5B5A6258EA91FF9"
      unitRef="usd">-83221000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1274-wk-Fact-B062B1261FFB69270A54A6258EA99214"
      unitRef="usd">11411000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e1293-wk-Fact-40E17ABB23FA741F33BFA6258E6C0A28"
      unitRef="usd">7136000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e1312-wk-Fact-CAD88392C12F20B538C6A6258E75105B"
      unitRef="usd">5206000</us-gaap:DepreciationDepletionAndAmortization>
    <gh:AmortizationOfRightOfUseAssets
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1333-wk-Fact-0B3BCC71E68BD5F32F1A78109DD1F67F"
      unitRef="usd">2198000</gh:AmortizationOfRightOfUseAssets>
    <gh:AmortizationOfRightOfUseAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e1352-wk-Fact-C5C1B42A526B522C49C078109DD9E088"
      unitRef="usd">0</gh:AmortizationOfRightOfUseAssets>
    <gh:AmortizationOfRightOfUseAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e1371-wk-Fact-2972B587F40F465D1C6D78109E9086DA"
      unitRef="usd">0</gh:AmortizationOfRightOfUseAssets>
    <gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1392-wk-Fact-86374F05F8E990E78695A6258E7D1013"
      unitRef="usd">147000</gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty>
    <gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e1412-wk-Fact-40A9A74353E7AE18F10FA6258E549B1B"
      unitRef="usd">357000</gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty>
    <gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e1432-wk-Fact-8BD476A52310851068DDA6258E7CF785"
      unitRef="usd">-980000</gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1453-wk-Fact-695859C2BE5BB8EA621AEEA6A0A443E2"
      unitRef="usd">300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e1472-wk-Fact-8BB9D959B78CF48BACD4EEA6A0A9B9A3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e1491-wk-Fact-5370DB297AF9F34F6E4EEEA6A0B0F3D9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1512-wk-Fact-FC7ECE6A56FC09C182ACA6258E831498"
      unitRef="usd">16954000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e1531-wk-Fact-527730141B1277FED241A6258E96C5EF"
      unitRef="usd">6851000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e1550-wk-Fact-C2C0DA4A45BAACB4C262A6258E6E8710"
      unitRef="usd">3670000</us-gaap:ShareBasedCompensation>
    <gh:NoncashInterestExpensePaid
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1572-wk-Fact-0CB62532CD6C5BA241DAA6258E3FCCAD"
      unitRef="usd">0</gh:NoncashInterestExpensePaid>
    <gh:NoncashInterestExpensePaid
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e1591-wk-Fact-4D1A9E807312EF139FC0A6258E68AF64"
      unitRef="usd">13000</gh:NoncashInterestExpensePaid>
    <gh:NoncashInterestExpensePaid
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e1611-wk-Fact-411719B4308F46D87844A6258E868D04"
      unitRef="usd">-685000</gh:NoncashInterestExpensePaid>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1632-wk-Fact-043D7BA11E1A4E1E6280A6258E45617B"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e1651-wk-Fact-136B8C09A698F74DEA31A6258E30FC6D"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e1670-wk-Fact-63487DDF114014865E64A6258E356BB1"
      unitRef="usd">-5075000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1691-wk-Fact-81EAE14B5C7B6F8026F0A6258E8B0E60"
      unitRef="usd">2310000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e1711-wk-Fact-956F0156A20189804BC4A6258E826A4E"
      unitRef="usd">412000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e1731-wk-Fact-84AF50A89D0884814503A6258E4150F9"
      unitRef="usd">-359000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1752-wk-Fact-EC17940722CD7D2CCE95EEA815E45409"
      unitRef="usd">-1597000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="FD2018Q4YTD"
      decimals="0"
      id="d42770e1772-wk-Fact-EC3A4084AFC1C09AC7C6EEA815C51D58"
      unitRef="usd">0</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="FD2017Q4YTD"
      decimals="0"
      id="d42770e1791-wk-Fact-48181F3FD7293B94A331EEA8163FF273"
      unitRef="usd">0</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1874-wk-Fact-BD724D67BB1D74DCFC05A6258E7D9A13"
      unitRef="usd">7389000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e1894-wk-Fact-E6C1C7437164DD97D89AA6258E46B590"
      unitRef="usd">22903000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e1914-wk-Fact-596C6979C26601F79712A6258E2CE5B2"
      unitRef="usd">9292000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1936-wk-Fact-68B5376A5DDABE50737EA6258E7E24B2"
      unitRef="usd">6045000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e1956-wk-Fact-00A9F8E342670D7EA588A6258E8CBE9B"
      unitRef="usd">1849000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e1976-wk-Fact-E8B8D0381436169FDB09A6258E2CD2C2"
      unitRef="usd">4518000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e1998-wk-Fact-13336E8061F2583A108CA6258E5479FE"
      unitRef="usd">6185000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2018-wk-Fact-06B1B732AE9F4644AA6BA6258E443FDA"
      unitRef="usd">3663000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2038-wk-Fact-27DD4DB22970BCE258E1A6258E47D822"
      unitRef="usd">-30000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2059-wk-Fact-B822674454A57012AA1AA6258E497E92"
      unitRef="usd">2852000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2079-wk-Fact-32ABBFA802FFCAB03689A6258EA9892D"
      unitRef="usd">451000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2099-wk-Fact-7B07C42F635C4D9045A2A6258E8431CD"
      unitRef="usd">883000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2121-wk-Fact-E90F3AA8BFA95A2195E8A6258E7FE4B0"
      unitRef="usd">4341000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2140-wk-Fact-AE1F388039D4B100EE00A6258E2B0371"
      unitRef="usd">5046000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2159-wk-Fact-16FF9C55E2B14233B960A6258E77904D"
      unitRef="usd">1250000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2180-wk-Fact-6A02953E27D10A17FB39A6258EA99831"
      unitRef="usd">5571000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2199-wk-Fact-E71096B42E8E297DC0B0A6258E999015"
      unitRef="usd">8075000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2218-wk-Fact-1668DED7F2EBCB14F71EA6258E74AEBC"
      unitRef="usd">2348000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2240-wk-Fact-AFB9950F937E81E83CBBA6258E45A65B"
      unitRef="usd">9213000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2259-wk-Fact-340276766C20FA9BF230A6258E8A3034"
      unitRef="usd">286000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2278-wk-Fact-C1A9ABE0A5BA0427CC40A6258E9D96D0"
      unitRef="usd">4657000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <gh:LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2299-wk-Fact-A55C716DDA3FB8642F12780F9DD28110"
      unitRef="usd">1039000</gh:LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets>
    <gh:LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2318-wk-Fact-E4DAB43EC3A33FF53F78780F9E75B3C5"
      unitRef="usd">0</gh:LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets>
    <gh:LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2337-wk-Fact-3409BD0946A5376D93E3780F9DD8D641"
      unitRef="usd">0</gh:LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2358-wk-Fact-EC4916E930B61507508CA6258E441B98"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2377-wk-Fact-F32490393809CC104A3AA6258E78F795"
      unitRef="usd">-1307000</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2396-wk-Fact-D7C5895A691EEC6DB3D9A6258E7389BE"
      unitRef="usd">-204000</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2417-wk-Fact-5799D84240BD9D651211A6258E69E034"
      unitRef="usd">-3861000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2437-wk-Fact-452C6E1983A6DD9D24DAA6258E2B71C1"
      unitRef="usd">13025000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2456-wk-Fact-999941ACCD8F64EBD397A6258E762177"
      unitRef="usd">1215000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2477-wk-Fact-C8AACBF5D48B3452C188EEAFE4AD111F"
      unitRef="usd">76000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2496-wk-Fact-AEB445FA8EA2483BF062EEAFE4EE5A6A"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2515-wk-Fact-0443D46A09D03CC89928EEAFE494F0E2"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2536-wk-Fact-0E5C3F5EA9B9988A74EFA6258E7E9EB3"
      unitRef="usd">-47134000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2556-wk-Fact-20C2084CBAC2D5ECD3A9A6258E5ABC01"
      unitRef="usd">-72185000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2576-wk-Fact-8DA04641D9F40BD79AE7A6258E79CEF3"
      unitRef="usd">-72235000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2722-wk-Fact-47C6BC2745BE353D99ECA6258E74CA75"
      unitRef="usd">614290000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2742-wk-Fact-6414296C0D4282375112A6258E6AFFC6"
      unitRef="usd">287450000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2762-wk-Fact-FA5A6F380F28BB143DB4A6258E72BCC9"
      unitRef="usd">236835000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2784-wk-Fact-F963FDC84A13C2386FC1A6258EA74692"
      unitRef="usd">325333000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2803-wk-Fact-D313BD034AF3E952FFDAA6258E865272"
      unitRef="usd">154625000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2822-wk-Fact-46BEF93CAAEEC73B275DA6258E909900"
      unitRef="usd">75402000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2843-wk-Fact-BF82F088BEAA78851BE1EECB5087CAC8"
      unitRef="usd">7328000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2863-wk-Fact-9AA2BAA5814C47532FECEECB508C44F6"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2882-wk-Fact-7E1D1546D2F1D1C8DCB1EECB5093CFD2"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2904-wk-Fact-43799ED6A01FAA7A9CB2A6258E6EE0C4"
      unitRef="usd">18717000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2924-wk-Fact-4825724AF3CE76175E8DA6258E70AB53"
      unitRef="usd">20203000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e2944-wk-Fact-9C0244D82DFBC6FCE01DA6258E9F3599"
      unitRef="usd">6681000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e2966-wk-Fact-8A32F24289B2A4A393EBEECBBBDC573A"
      unitRef="usd">2500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e2986-wk-Fact-9A8E8D724A0C38372EB6EECBBBE3E380"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3005-wk-Fact-0995C1C96C12279EC995EECBBBD77B32"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <gh:PaymentsInConnectionWithLicenseAgreements
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3026-wk-Fact-97C8CCA91535576E796FA6258E29D949"
      unitRef="usd">68000</gh:PaymentsInConnectionWithLicenseAgreements>
    <gh:PaymentsInConnectionWithLicenseAgreements
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3046-wk-Fact-B6B455A20F5BB55A3655A6258E7C087D"
      unitRef="usd">0</gh:PaymentsInConnectionWithLicenseAgreements>
    <gh:PaymentsInConnectionWithLicenseAgreements
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3065-wk-Fact-6E8B228FB63B6B308ACEA6258E976EB9"
      unitRef="usd">2302000</gh:PaymentsInConnectionWithLicenseAgreements>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3087-wk-Fact-327AAE6B25258AD57064A6258E761269"
      unitRef="usd">-317570000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3107-wk-Fact-444CC6E07F59D0173BE4A6258E712693"
      unitRef="usd">-153028000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3127-wk-Fact-C957C19A88AE82D33A7DA6258E692500"
      unitRef="usd">-170416000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3273-wk-Fact-364C680433E936E523B7A6258E91225D"
      unitRef="usd">311000</gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations>
    <gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3293-wk-Fact-BF5677E2461E53807183A6258E8CBFB0"
      unitRef="usd">0</gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations>
    <gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3312-wk-Fact-A65AB8B729EE78CCB916A6258E7737E6"
      unitRef="usd">25844000</gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3334-wk-Fact-4F7238D6DE482E85DF22A6258E84FA8E"
      unitRef="usd">128000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3354-wk-Fact-2CE49154B582C1D315E3A6258E8E814A"
      unitRef="usd">443000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3374-wk-Fact-A80BB693DA87D2500EABA6258E8136DA"
      unitRef="usd">244000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3396-wk-Fact-36BC709343FE2F62A35DA6258E46A74A"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3415-wk-Fact-322AE5F732A4DDF0CD63A6258E870DF9"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3434-wk-Fact-CBDA46C2C006472D6306A6258E83423A"
      unitRef="usd">319536000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3475-wk-Fact-66CC9DCC2725E6EE0D72EED222F1163C"
      unitRef="usd">6395000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3494-wk-Fact-21BE3C7D2442104A4144EED222904E2F"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3513-wk-Fact-F4D09867FE0F44CED433EED2226DE79D"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3534-wk-Fact-D5E294EDA3CAD38C5E2DA6258E6F291C"
      unitRef="usd">11639000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3553-wk-Fact-C9610AA671969BD70C57A6258E6CB0C7"
      unitRef="usd">3111000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3572-wk-Fact-98DA59601E9AB5CEE3D4A6258E6455FF"
      unitRef="usd">753000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3593-wk-Fact-48822D392392C6C75C00A6258E7A7255"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3612-wk-Fact-15B1DE2DED142F0EA092A6258E786734"
      unitRef="usd">45000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3631-wk-Fact-EE9A3E73CF4865C3DF1DA6258E80D532"
      unitRef="usd">12000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3652-wk-Fact-799468E3C03215130187A6258E88D309"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3671-wk-Fact-4BDECA21E4F6B47914ECA6258E79E565"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3690-wk-Fact-4D0755D9DCFCCD33CA32A6258E407DD3"
      unitRef="usd">5335000</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3712-wk-Fact-B8947F769C147625B299A6258E9060B9"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3731-wk-Fact-A7A02ABDE893288E8B81A6258E2979F1"
      unitRef="usd">172000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3751-wk-Fact-49A0F4DCDB910BB4A20BA6258E885C75"
      unitRef="usd">7222000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3773-wk-Fact-0E1F20ACF630A31A34A8EECFFD719DCB"
      unitRef="usd">350432000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3792-wk-Fact-C98D0721C8F2F31FD34AA6258E8DDF1A"
      unitRef="usd">254006000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3811-wk-Fact-F6DA493335109C59404BA6258E709B00"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3832-wk-Fact-D9EB8980E54E77B8771CEED0245AEDF4"
      unitRef="usd">723000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3852-wk-Fact-250821B5ADE1605E55B1A6258E31319B"
      unitRef="usd">4386000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3872-wk-Fact-9AAA0DF72545A22C0C9BA6258E8C3494"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3893-wk-Fact-F5DB2BC7D2979730E347A6258E6C43EF"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3912-wk-Fact-37642EDCB2E2680BA7B8A6258E64EE98"
      unitRef="usd">41000000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3931-wk-Fact-6C00D544842BF44D9FB6A6258E8975F1"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e3952-wk-Fact-7A19ED48037D49910E57A6258E7AE6BD"
      unitRef="usd">367304000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e3971-wk-Fact-8B90ADD0424CE4381980A6258E435DB5"
      unitRef="usd">293161000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e3990-wk-Fact-1B53BC142360F8BA19C8A6258E3A8C2D"
      unitRef="usd">281656000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e4011-wk-Fact-68A445988AC1B0CEA8E2EEDBB9034ED0"
      unitRef="usd">84000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e4030-wk-Fact-5724F477FA6BCEA5195EEEDBB887EDB4"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e4049-wk-Fact-D9E1D34F03294FFACB75EEDBB8ACB894"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e4070-wk-Fact-BACDB46B3A61CF8D88B7A6258E9EE8F1"
      unitRef="usd">2684000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e4089-wk-Fact-444550461EBB1F7975B0A6258E8BDB96"
      unitRef="usd">67948000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e4108-wk-Fact-D1E56F5CE9D53FDB0D80A6258E6B2A44"
      unitRef="usd">39005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d42770e4130-wk-Fact-4DFB52891D1C2A2BF3B6A6258E2BA807"
      unitRef="usd">140544000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d42770e4149-wk-Fact-2EA92269F4995E4107BDA6258E6D0295"
      unitRef="usd">72596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2016Q4"
      decimals="-3"
      id="d42770e4168-wk-Fact-01D1C015B3460FF565A4A6258E96B037"
      unitRef="usd">33591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d42770e4194-wk-Fact-E0E98295F85918915C83A6258E8552B4"
      unitRef="usd">143228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d42770e4213-wk-Fact-4DFB52891D1C2A2BF3B6A6258E2BA807"
      unitRef="usd">140544000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d42770e4232-wk-Fact-2EA92269F4995E4107BDA6258E6D0295"
      unitRef="usd">72596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e4315-wk-Fact-DE8F9DD13CC53A32D020780DC9666B9F"
      unitRef="usd">16714000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e4334-wk-Fact-CECC9DB95DB392D79A5E780DC977C264"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e4353-wk-Fact-BD2F9B865745932BA691780DC96B9B20"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e4374-wk-Fact-EBDA9ACC7D4A511633DDA6258E7541BF"
      unitRef="usd">1181000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e4393-wk-Fact-8B291B4FD288FEEA1C4CA6258E739680"
      unitRef="usd">1251000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e4412-wk-Fact-E07E556F81F890D4BDADA6258E48E1F3"
      unitRef="usd">1339000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e4433-wk-Fact-911858A5574499D7E879A6258E8ECD16"
      unitRef="usd">298000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e4452-wk-Fact-5BAE0DEAC219AC0A9E94A6258EA8557E"
      unitRef="usd">102000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e4471-wk-Fact-A49D5AAA74624769A7F4A6258E6E1418"
      unitRef="usd">26000</us-gaap:IncomeTaxesPaidNet>
    <gh:CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e4554-wk-Fact-0CB3785580E45D59B29BA6258E5D94CD"
      unitRef="usd">0</gh:CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment>
    <gh:CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e4573-wk-Fact-AF86E56277F0A7E21670A6258E7F4B77"
      unitRef="usd">0</gh:CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment>
    <gh:CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e4592-wk-Fact-58B5EEDDA726BAC8B741A6258E8FB03B"
      unitRef="usd">6302000</gh:CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment>
    <gh:ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      id="d42770e4613-wk-Fact-FF6217A3D0CAEA627C93A6258E6FD7F9"
      unitRef="usd">0</gh:ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement>
    <gh:ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      id="d42770e4632-wk-Fact-2974C3D2DBD5D57C4113A6258E6D22FF"
      unitRef="usd">0</gh:ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement>
    <gh:ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      id="d42770e4651-wk-Fact-1B429475A124591BB7B5A6258E6D5F3D"
      unitRef="usd">1060000</gh:ValueOfConvertiblePreferredStockIssuedInExchangeForLicenseAgreement>
    <gh:IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e4672-wk-Fact-6A1353FD0C7582C33455A6258E8B206E"
      unitRef="usd">3296000</gh:IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid>
    <gh:IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e4691-wk-Fact-6DD42BA88FBAEB9D097FA6258EA11A28"
      unitRef="usd">897000</gh:IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid>
    <gh:IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e4710-wk-Fact-3E4BCCDE23AB5F9B22F7A6258E880EA3"
      unitRef="usd">591000</gh:IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d42770e4731-wk-Fact-B70D11D0006DB0912E00A6258E8E6197"
      unitRef="usd">95000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d42770e4750-wk-Fact-5ED46B953A8D90E8D32EA6258E728452"
      unitRef="usd">0</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d42770e4769-wk-Fact-6049FA07A2AA1BB0B62BA6258E3D031A"
      unitRef="usd">103000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e4791-wk-Fact-5A937AF22FE1A08518ACA6258EA4D88C"
      unitRef="usd">0</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e4810-wk-Fact-448A23C1966023A8AF3DA6258EA74AA6"
      unitRef="usd">0</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e4829-wk-Fact-35854CB4A562CBD9391DA6258E8CFEA5"
      unitRef="usd">346000</us-gaap:CapitalLeaseObligationsIncurred>
    <gh:ConversionofStockUponInitialPublicOffering
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e4850-wk-Fact-DFC28B95A79F22FB2A34A6258E2BF2F9"
      unitRef="usd">0</gh:ConversionofStockUponInitialPublicOffering>
    <gh:ConversionofStockUponInitialPublicOffering
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e4869-wk-Fact-1A3D9852821976386641A6258E7B0A01"
      unitRef="usd">499974000</gh:ConversionofStockUponInitialPublicOffering>
    <gh:ConversionofStockUponInitialPublicOffering
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e4888-wk-Fact-4A3E7735E42D490B1A4EA6258E79F946"
      unitRef="usd">0</gh:ConversionofStockUponInitialPublicOffering>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d42770e4909-wk-Fact-3A3DA23C593B0141B1A4EEEDE8192884"
      unitRef="usd">1065000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4"
      decimals="-3"
      id="d42770e4928-wk-Fact-4FE428D8EA7AC7B7AE58EEEDE89F7AE7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2017Q4"
      decimals="-3"
      id="d42770e4947-wk-Fact-668D3026A3C296FCB53AEEEDE83E35D7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <gh:OfferingCostsIncurredbutNotyetPaid
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d42770e4968-wk-Fact-59DF0DBD277CEB7C7D6CA6258E8F3E30"
      unitRef="usd">0</gh:OfferingCostsIncurredbutNotyetPaid>
    <gh:OfferingCostsIncurredbutNotyetPaid
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d42770e4987-wk-Fact-38BFD28FFD4341E8AA92A6258E899F67"
      unitRef="usd">89000</gh:OfferingCostsIncurredbutNotyetPaid>
    <gh:OfferingCostsIncurredbutNotyetPaid
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d42770e5006-wk-Fact-D2D03B7FEE0503F33914A6258E8B9CF6"
      unitRef="usd">0</gh:OfferingCostsIncurredbutNotyetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-DBB1898643B7CE5D6759A6258EB4A5D6-0-wk-Fact-BB5AD0EA84DD4FAB7F0DA6258E6C1CCE">Description of Business&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Guardant Health, Inc. (the &#x201c;Company&#x201d;) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which it enables by a routine blood draw, or liquid biopsy. The Guardant Health Oncology Platform is designed to leverage the Company&#x2019;s capabilities in technology, clinical development, regulatory, reimbursement and commercial adoption to improve patient clinical outcomes, lower healthcare costs and accelerate biopharmaceutical drug development. In pursuit of its goal to manage cancer across all stages of the disease, the Company has launched its Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer patients, and is developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In April 2018, the Company established Guardant Health AMEA, Inc. (the &#x201c;Joint Venture&#x201d;) in the United States with an entity affiliated with SoftBank. Under the terms of the joint venture agreement, the Company held a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ownership interest in the Joint Venture. The Joint Venture has subsidiaries in Singapore and Japan (see Note 3,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Investment in Joint Venture&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) and the Company has a subsidiary in Switzerland which was incorporated in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2018, the Company&#x2019;s Board of Directors and its stockholders approved a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.7378&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-for-one reverse stock split of the Company&#x2019;s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the Company&#x2019;s initial public offering (the &#x201c;IPO&#x201d;).  All share and per share amounts in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Approval of Amended and Restated Certificate of Incorporation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September&#160;2018, the Company&#x2019;s Board of Directors and stockholders approved an amended and restated certificate of incorporation, which authorized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;350,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of preferred stock. The amended and restated certificate of incorporation became effective on October 9, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On October 9, 2018, the Company completed the IPO, in which it issued and sold &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,375,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a public offering price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. The Company received net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$249.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million after deducting underwriting discounts and commissions and offering expenses payable by the Company. All then-outstanding warrants to purchase the Company&#x2019;s common stock were exercised prior to the completion of the IPO. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;In addition, in connection with the IPO,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;all shares of the Company&#x2019;s then-outstanding convertible preferred stock were automatically converted into &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,264,577&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock, and all then-outstanding warrants to purchase the Company&#x2019;s convertible preferred stock were automatically converted into warrants to purchase &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,636&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Follow-on Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2019, the Company completed an underwritten public offering, in which it issued and sold&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,175,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of its common stock (including the exercise in full of the underwriters&#x2019; over-allotment option to purchase&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;675,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;additional shares) at a price of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$71.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share. The Company received net proceeds of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$349.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;after deducting underwriting discounts and commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2018Q2Apr30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="2"
      id="d43018e880-wk-Fact-71D9EEE1A0CD32387F70A6258E902245"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="D2018Q3Sep19"
      decimals="4"
      id="d43018e894-wk-Fact-ADE4A68992916C4D7D34A6258E8E969C"
      unitRef="number">0.7378</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q3"
      decimals="INF"
      id="d43018e904-wk-Fact-B6A5E87AA10E1E450EB587A865675956"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q3"
      decimals="INF"
      id="d43018e908-wk-Fact-A432DE2994BC4AD113D487A84B9CE174"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
      decimals="INF"
      id="d43018e918-wk-Fact-A4903E7BDC376AB5D527A6258E90BAEF"
      unitRef="shares">14375000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
      decimals="2"
      id="d43018e922-wk-Fact-6D513932D4FBBB2C60FBA6258E6A82E0"
      unitRef="usdPerShare">19.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="D2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
      decimals="-5"
      id="d43018e926-wk-Fact-05123C85F25836BFDC65A6258E8F0BDF"
      unitRef="usd">249500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="I2018Q4Oct9_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="d43018e936-wk-Fact-E2D0FF8793DD041F4F6FCF4496FAB72B"
      unitRef="shares">58264577</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="I2018Q4Oct9_us-gaap_ClassOfWarrantOrRightAxis_gh_WarrantsPreferredStockMember"
      decimals="INF"
      id="d43018e941-wk-Fact-C3CF7ED03157D5A518FFCF44DE8F2817"
      unitRef="shares">7636</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2019Q2May"
      decimals="INF"
      id="d43018e954-wk-Fact-24441838FD19FADE8E7EEF14FA2DAB4A"
      unitRef="shares">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2019Q2May_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="d43018e958-wk-Fact-5459A2E6D8D84FC4A772EF16003CAF22"
      unitRef="shares">675000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="I2019Q2May31"
      decimals="INF"
      id="d43018e962-wk-Fact-B100FE920B9098A1600CEF0EAEF7DD28"
      unitRef="usdPerShare">71.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="D2019Q2May"
      decimals="-5"
      id="d43018e966-wk-Fact-BFFF2C6D2159E772523EEF11FC1BD5AD"
      unitRef="usd">349700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-38F18625E00267BD0051A6258EB62A7E-0-wk-Fact-3A356495F14F6AE0DDD7A6258EA2A02A">Summary of Significant Accounting Policies&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#x2019; interests in the Joint Venture are shown in the consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company believes that its existing cash and cash equivalents and marketable securities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#x2019;s cost structure. If the Company&#x2019;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations,&#160;goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;JOBS Act Accounting Election&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective December 31, 2019, we are no longer an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Prior to losing our status as an emerging growth company, the JOBS Act allowed us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements were made applicable to private companies, and we had elected to use this extended transition period.&#160;We can no longer take advantage of this extended transition period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#x2019; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the consolidated statements of operations. For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, foreign currency translation adjustment was immaterial. For the year ended December&#160;31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company did not have foreign currency translation adjustment as the foreign subsidiaries were established in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company operates as one operating and reportable segment. The Company&#x2019;s chief operating decision makers, the Chief Executive Officer, and the President and Chief Operating Officer, manage the Company&#x2019;s operations on an aggregate basis for purposes of allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents consist of highly liquid investments with original maturities at the time of purchase of three months or less.&#160;Cash equivalents include bank demand deposits and money market accounts that invest primarily in U.S. government-backed securities and treasuries. Cash equivalents are carried at cost, which approximates their fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In fiscal 2017, restricted cash consists of deposits related to the Company&#x2019;s corporate credit card. The Company did not have any restricted cash as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities consist primarily of high-grade corporate bonds, commercial papers and certificates of deposit with third parties. Marketable securities with original maturities at the time of purchase between three and twelve months from balance sheet dates are classified as short-term marketable securities and those with maturities over twelve months from balance sheet dates are classified as long-term marketable securities. The Company classifies all marketable securities as available-for-sale, which are recorded at fair value. Unrealized gains and losses are included in accumulated other comprehensive loss in stockholders&#x2019; equity. Any premium or discount arising at purchase is amortized or accreted to interest income or expense. Realized gains and losses and declines in value, if any, judged to be other than temporary on available&#x2011;for&#x2011;sale securities are reported in other income (expense), net. When securities are sold, any associated unrealized gain or loss initially recorded as a separate component of stockholders&#x2019; equity is reclassified out of stockholders&#x2019; equity on a specific&#x2011;identification basis and recorded in earnings for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not that it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and management&#x2019;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#x2019;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company also invests in investment&#x2011;grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#x2019;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after&#x2011;tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#x2019;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#x2019;s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#x2019;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#x2019;s total accounts receivable balance, at the respective consolidated balance sheet date, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Customer A   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Customer B   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Customer C   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Customer D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;less than 10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable and provides for an allowance for potential credit losses based on management&#x2019;s best estimate of the amount of probable credit losses. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory consisted entirely of supplies, which are consumed when providing liquid biopsy tests, and therefore the Company does not maintain any finished goods inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by the Company, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Amounts written-down due to unmarketable inventory are recorded in cost of precision oncology testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are recorded at cost. Depreciation is computed over estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The Company periodically reviews the depreciable lives assigned to property and equipment placed in service and changes the estimates of useful lives, if necessary. Maintenance and repairs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:56%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;3 &#x2013; 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer hardware and computer software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lesser of estimated useful life or remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company includes the results of operations of the businesses that are acquired as of the acquisition date. The Company allocates the purchase price of acquisitions to the assets acquired and liabilities assumed based on the estimated fair values. The excess of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition related costs are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill and Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets related to in-process research and development costs (&#x201c;IPR&amp;amp;D&#x201d;) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there has been&#160;no&#160;impairment of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6-&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Obligation Related to Royalty&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain of the Company&#x2019;s asset acquisitions involve the potential for future payment of consideration that is contingent upon the royalty payments due on future product net sales, subject to annual minimums. The fair value of such liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment for Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#x2019;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#x2019;s platform. Development services include companion diagnostic development, information solutions and laboratory services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective January 1, 2019, we adopted the new revenue recognition standard FASB ASC Topic 606,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;or ASC 606. Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Precision oncology testing&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company&#x2019;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Development services&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations. The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#x2019;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#x2019;s consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contracts with multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated. For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable.&#160;Contract assets are presented under accounts receivable and other assets on the Company&#x2019;s consolidated balance sheets. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had contract assets of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is recorded in other assets in the consolidated balance sheet.  The Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of contract assets as of January 1, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Deferred revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company&#x2019;s performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the deferred revenue balance was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$16.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, which included &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the&#160;twelve months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;that was included in the deferred revenue balance as of January 1, 2019 was&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which primarily represented revenue from&#160;provision of development services under the collaboration agreement with our biopharmaceutical companies.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Transaction price allocated to the remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue Recognition under ASC 605&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#x2019;s platform. Development services include the development of new platforms and information solutions, including companion diagnostic development and laboratory services. The Company currently receives payments from commercial third-party payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue when all of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Criterion (i) is satisfied when the Company has an arrangement or contract in place. Criterion (ii) is satisfied when the Company delivers a test report corresponding to each sample, without further commercial obligations. Determination of criteria (iii) and (iv) are based on management&#x2019;s judgments regarding whether the fee is fixed or determinable, and whether the collectability of the fee is reasonably assured. The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians, if criteria (i) through (iv) above are met. The Company recognizes revenue on a cash basis when it cannot conclude that criteria (iii) and (iv) have been met. Most of precision oncology tests requested by clinical customers are sold without a contracted engagement with a third-party payer; therefore, the Company experiences significant variability in collections and does not have sufficient history to establish a predictable pattern of payment. Because the price is not fixed or determinable and collectability is not reasonably assured, the Company recognizes revenue on a cash basis for sales of its liquid biopsy tests to clinical customers where collection depends on a third-party payer or the individual patient. The Company uses judgment in its assessment of whether the fee is fixed or determinable and whether collectability is reasonably assured in determining when to recognize revenue. Accordingly, the Company expects to recognize revenue on a cash basis for these clinical customers until it has sufficient history to reliably estimate payment patterns. The Company&#x2019;s precision oncology information services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue from sales of the Company&#x2019;s tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume, data access or biopharmaceutical research and development services over a defined period. The Company recognizes revenue upon delivery of the test results, or over the period in which biopharmaceutical research and development services are provided, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Multiple-element arrangements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Contracts with biopharmaceutical customers are primarily analyzed as multiple-element arrangements given the nature of the service deliverables. For development services performed, the Company is compensated in various ways, including (i) through non-refundable regulatory and other developmental milestone payments; and (ii) through royalty and sales milestone payments. The Company performs development services as part of its normal activities. The Company records these payments as development services revenue in the consolidated statements of operations using a proportional performance model over the period which the unit of accounting is delivered or based on the level of effort expended to date over the total expected effort, whichever is considered the most appropriate measure of performance. For development of new products or services under these arrangements, costs incurred before technological feasibility is assured are included as research and development expenses in the Company&#x2019;s consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services. The Company collaborates with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#x2019;s liquid biopsy panels. Under these collaborations the Company generates revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For revenue arrangements with multiple deliverables, the Company evaluates each deliverable to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has stand-alone value to the customer and whether a general right of return exists. In assessing whether an item has standalone value, the Company considers factors such as the research, development and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the other party in the arrangement can use the other deliverables for their intended purpose without the receipt of the remaining elements, whether the value of the deliverable is dependent on the undelivered items and whether there are other vendors that can provide the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;undelivered elements. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The Company allocates the arrangement consideration following a hierarchy to determine the relative selling price to be used for allocating revenue to deliverables: (i) vendor-specific objective evidence of fair value (&#x201c;VSOE&#x201d;), (ii) third-party evidence of selling price (&#x201c;TPE&#x201d;), and (iii) best estimate of the selling price (&#x201c;BESP&#x201d;) if neither VSOE nor TPE is available. The Company typically uses BESP to estimate the selling price, since it generally does not have VSOE or TPE of selling price for its units of accounting under multiple-element arrangements. In developing the BESP for a unit of accounting, the Company considers applicable market conditions and estimated costs. The Company validates the BESP for units of accounting by evaluating whether changes in the key assumptions used to determine the BESP will have a significant effect on the allocation of arrangement consideration between multiple units of accounting. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. The Company uses judgment in identifying the deliverables in its arrangements, assessing whether each deliverable is a separate unit of accounting and in determining the best estimate of selling price for certain deliverables. The Company also uses judgment in determining the period over which the deliverables are recognized in certain of its arrangements. Any amounts received that do not meet the criteria for revenue recognition are recorded as deferred revenue until such criteria are met. The Company performed laboratory installation and maintenance services for one of its customers as part of a multiple-element arrangement entered into in 2017. The Company recognized certain revenue from its construction service deliverables in a multiple-element collaboration arrangement based on the completed-contract method. This method was used as the Company determined that it did not have the basis for estimating performance under the contract. Other construction service deliverables under that contract were recognized under the percentage-of-completion method due to the Company&#x2019;s ability to make reasonably dependable estimates of the extent of progress toward contract completion. All construction services under this arrangement were completed in March 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes payments that are contingent upon achievement of a substantive milestone in their entirety in the period in which the milestone is achieved. Milestones are defined as events that can only be achieved based on the Company&#x2019;s performance and there is substantive uncertainty about whether the event will be achieved at the inception of the arrangement. Events that are contingent only on the passage of time or only on counterparty performance are not considered substantive milestones. Further, the amounts received must relate solely to prior performance, be reasonable relative to all of the deliverables and payment terms within the agreement and commensurate with the Company&#x2019;s performance to achieve the milestone after commencement of the agreement. Any contingent payment that becomes payable upon achievement of events that are not considered substantive milestones are allocated to the units of accounting previously identified at the inception of an arrangement when the contingent payment is received and revenue is recognized based on the revenue recognition criteria for each unit of accounting. Revenue from commercial milestone payments are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Costs of Precision Oncology Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#x2019;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cost of Development Services&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of development service includes costs incurred for the performance of development services requested by the Company&#x2019;s customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses are comprised of costs incurred to develop technology and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;also include costs related to activities performed under contracts with biopharmaceutical companies. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#x2019;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company expenses advertising costs as incurred. The Company incurred advertising costs of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred offering costs consist of fees and expenses incurred in connection with the anticipated sale of the Company&#x2019;s common stock in the IPO, including the legal, accounting, printing and other IPO-related costs. In October 2018, upon completion of the IPO, the Company reclassified deferred offering costs of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; into additional paid-in capital as a reduction of the net proceeds received from the IPO. There were no deferred offering costs as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock&#x2011;Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock&#x2011;based compensation related to stock options granted to the Company&#x2019;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2018, the Company accounted for stock options issued to nonemployees consultants based on the estimated fair value at the grant date and re-measured at each reporting period. Starting January 1, 2019, upon adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-07,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;Improvements to Nonemployee Share-Based Payment Accounting,&#160;the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company uses the Black&#x2011;Scholes option&#x2011;pricing model to estimate the fair value of its stock options and purchase rights under its 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Starting January 1, 2017, forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for restricted stock units issued to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in the Company&#x2019;s consolidated statement of operations on a straight-line basis over the requisite vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income taxes are recorded using an asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prior to the closing of the Company&#x2019;s IPO in October 2018 and the conversion of its convertible preferred stock into common stock, the Company calculated its basic and diluted net loss per share attributable to common stockholders of the Company in conformity with the two-class method required for companies with participating securities. The Company considered its convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on the Company&#x2019;s common stock, holders of convertible preferred stock were entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock did not have a contractual obligation to share in the Company&#x2019;s losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company adopted ASU 2014-09,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&#160;and all related amendments (collectively, &#x201c;ASC 606&#x201d;)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on January 1, 2019 utilizing the modified retrospective method. The cumulative effect of applying the standard to all contracts that were not completed as of the date of initial application was recognized to beginning accumulated deficit as of January 1, 2019. The Company identified certain differences in accounting for revenue recognition as a result of the adoption of ASC 606 which have impacted its financial position and results of operations.  For precision oncology testing revenue with certain clinical customers, the Company historically deferred revenue recognition until cash receipt when the price pursuant to the underlying customer arrangement became fixed and determinable and collectability became reasonably assured. Under the new standard, this is considered variable consideration and revenue is recognized at the estimated transaction price upon delivery. This results in earlier revenue recognition under the new standard as compared to previous revenue recognition. For development services revenue with certain biopharmaceutical customers, the Company historically limited revenue recognition based on the right to invoice the customer. Under the new standard, for these arrangements, the Company constrains revenue such that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For arrangements with regulatory and other developmental milestone payments, this results in a change to the timing and pattern of revenue recognition under the new standard as compared to previous revenue recognition.  Comparative information from prior periods has not been restated and&#160;continues to be reported under the accounting standards in effect for those periods. The cumulative effect of changes made to the consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Adjustments due to ASC 606 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of January 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Equity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(280,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(275,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In accordance with ASC 606 requirements under the modified retrospective method of adoption, the impact of the adoption of ASC 606 on the Company&#x2019;s consolidated statement of operations and consolidated balance sheet was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;For the year ended December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As Reported Under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Effect of Change &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances Without Adoption of ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Precision oncology testing &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;180,462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;180,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Development services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As Reported Under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Effect of Change &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances Without Adoption of ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Equity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(352,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(353,156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASC 606 did not have an aggregate impact on the Company&#x2019;s net cash used in operating activities but resulted in offsetting changes in certain assets presented within net cash used in operating activities in the Company&#x2019;s consolidated statement of cash flows, as reflected in the above table. The the Company&#x2019;s revenue is generated primarily from the sale of precision oncology testing and development services. Precision oncology testing revenue is generated from sales of the Company&#x2019;s current products to clinical and biopharmaceutical customers. Total precision oncology testing revenues from sales to clinical customers for the years ended December 31, 2019, 2018 and 2017 were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$94.2 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$43.7 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$24.5 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Total precision oncology testing revenues from sales to biopharmaceutical customers for the years ended December 31, 2019, 2018 and 2017 were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$79.5 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$34.7 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$17.6 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Development services revenue represent services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company adopted&#160;ASC 842, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,  and its related amendments which requires the recognition of right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities for operating leases on the consolidated balance sheet on January 1, 2019 using a modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases in place as of January 1, 2019. The Company also elected the practical expedient to not separate lease and non-lease components for its facility leases, and to not recognize ROU assets and operating lease liabilities for short-term leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under ASC 842, the Company determines if an arrangement contains a lease and the classification of that lease, if applicable, at inception or upon modification of a contract. The Company has elected to not recognize a lease liability or ROU asset for short-term leases (leases with a term of twelve months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise). The Company has elected to not allocate the contract consideration for operating lease contracts with lease and non-lease components, and account for the lease and non-lease components as a single lease component. ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at lease commencement date. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. An option to extend the lease &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The primary impact of adopting&#160;Topic 842&#160;was the recognition of ROU assets and lease liabilities for operating leases of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$22.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; respectively, on January 1, 2019, which included reclassifying prepaid rent and deferred rent as a component of the ROU asset.&#160;Topic 842&#160;did not have a material impact on the Company's consolidated statements of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The short-term liabilities from the Company's operating leases are included in accrued expenses in the consolidated balance sheet. The Company's accounting for finance leases (formerly referred to as capital leases prior to the adoption of&#160;Topic 842) remains substantially unchanged. Finance leases are not material to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lease expense for lease payments for the operating leases is recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2018, the FASB issued ASU 2018-07,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation&#x2014;Stock Compensation (Topic 718):&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, with certain exceptions. The Company early adopted this new guidance effective January 1, 2019. In accordance with the transition guidance, the Company assessed its outstanding nonemployee awards for which a measurement date had not been established. These outstanding awards were re-measured to fair value as of the January 1, 2019 adoption date. For nonemployee awards that contain performance condition, the measurement is based on the outcome that is probable as opposed to the lowest aggregate fair value within a range of possible outcomes. The adoption of ASU 2018-07 provided administrative relief by fixing the measurement date of nonemployee awards and eliminating the requirement of quarterly re-measurement. The Company adopted this standard on a modified retrospective basis and recorded a cumulative-effect adjustment of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;as an increase to accumulated deficit and an equal increase to additional paid-in capital as of January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December&#160;22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act (the &#x201c;Tax Act&#x201d;), which contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December&#160;31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No.&#160;118,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Tax Accounting Implications of the Tax Cuts and Jobs Act&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;(&#x201c;SAB 118&#x201d;) to address the accounting implications of the enacted U.S. federal tax reform. SAB 118 allows companies&#160;to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and no measurement period adjustments were recognized due to the full valuation allowance on the Company&#x2019;s deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;Financial Instruments - Credit Losses:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2017,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the FASB issued ASU 2017-04&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment which eliminates Step 2 from the goodwill impairment test and instead requires entities to perform its annual or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;"&gt;. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements in ASC 820, Fair Value Measurement, as part of its disclosure framework project. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted. The amendments in ASU 2018-13 on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments in ASU 2018-13 should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cloud Computing&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued ASU 2018-15&#x2014;Intangibles-Goodwill and Other-Internal&#x2014;Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC Topic 350, Intangibles&#x2014;Goodwill and Other, to determine which implementation costs to capitalize as assets or expense as incurred.  The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB amended ASC 808 and ASC 606 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The guidance is effective for us beginning January 1, 2020 and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes - Topic 740, which simplifies the accounting for income taxes.&#160; Amendments include removal of certain exceptions to the general principles of ASC 740, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences.&#160;ASU 2019-12 also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning January 1, 2021, and early adoption is permitted.&#160; The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-25435946BBC3D479B38FA6258EB4C960-0-wk-Fact-36D3157E3F089B77229CA6258EA595A1">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#x2019; interests in the Joint Venture are shown in the consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company believes that its existing cash and cash equivalents and marketable securities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#x2019;s cost structure. If the Company&#x2019;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q4YTD"
      id="TextSelection-ABF1DB6225C983D0ABF5A6258EB67068-0-wk-Fact-4D389012F41CD1A4724BA6258E9545CF">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations,&#160;goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <gh:JOBSActAccountingElectionPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-FFC6327D42FFF21A80DCA6258EB523B7-0-wk-Fact-7F90C03F4D3331669FFFA6258E9C4E66">&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;JOBS Act Accounting Election&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective December 31, 2019, we are no longer an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Prior to losing our status as an emerging growth company, the JOBS Act allowed us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements were made applicable to private companies, and we had elected to use this extended transition period.&#160;We can no longer take advantage of this extended transition period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</gh:JOBSActAccountingElectionPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D3152085D246544562EDA6258EB453AF-0-wk-Fact-B3BBFC398DEAE1B25BEEA6258EA30FCE">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#x2019; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the consolidated statements of operations. For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;, foreign currency translation adjustment was immaterial. </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B0FB0113A8286071EB11A6258EB48F4E-0-wk-Fact-70D87E20E84BBEB7CCE7A6258E942306">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company operates as one operating and reportable segment. The Company&#x2019;s chief operating decision makers, the Chief Executive Officer, and the President and Chief Operating Officer, manage the Company&#x2019;s operations on an aggregate basis for purposes of allocating resources.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-50290207811D8392D546A6258EB5880B-0-wk-Fact-5AAE5A4A22BF6DE9E12DA6258EA1A58F">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents consist of highly liquid investments with original maturities at the time of purchase of three months or less.&#160;Cash equivalents include bank demand deposits and money market accounts that invest primarily in U.S. government-backed securities and treasuries. Cash equivalents are carried at cost, which approximates their fair value.&lt;/span&gt;&lt;/div&gt;In fiscal 2017, restricted cash consists of deposits related to the Company&#x2019;s corporate credit card.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-7AA20F4AA6A01F35596FA6258EB7C0D5-0-wk-Fact-CAF885DC7B77C194C7F9A6258E994572">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities consist primarily of high-grade corporate bonds, commercial papers and certificates of deposit with third parties. Marketable securities with original maturities at the time of purchase between three and twelve months from balance sheet dates are classified as short-term marketable securities and those with maturities over twelve months from balance sheet dates are classified as long-term marketable securities. The Company classifies all marketable securities as available-for-sale, which are recorded at fair value. Unrealized gains and losses are included in accumulated other comprehensive loss in stockholders&#x2019; equity. Any premium or discount arising at purchase is amortized or accreted to interest income or expense. Realized gains and losses and declines in value, if any, judged to be other than temporary on available&#x2011;for&#x2011;sale securities are reported in other income (expense), net. When securities are sold, any associated unrealized gain or loss initially recorded as a separate component of stockholders&#x2019; equity is reclassified out of stockholders&#x2019; equity on a specific&#x2011;identification basis and recorded in earnings for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not that it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and management&#x2019;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="FD2019Q4YTD"
      id="TextSelection-458811539D1E0AA903E1A6258EB6AC5D-0-wk-Fact-F6822369679C11FF56A3A6258EA08AFC">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#x2019;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company also invests in investment&#x2011;grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#x2019;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after&#x2011;tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#x2019;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BFC253F18F7406671915A6258EB66166-0-wk-Fact-5D8A5889367A3CED68CFA6258EA7523A">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#x2019;s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#x2019;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#x2019;s total accounts receivable balance, at the respective consolidated balance sheet date, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Customer A   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Customer B   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Customer C   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Customer D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;less than 10%&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_gh_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d46357e1377-wk-Fact-DAA0F8E88A8486A32675A6258E8A24B5"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d46357e1422-wk-Fact-0DA4B97C077E6E6DEDBFEF246E98DB68"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d46357e1437-wk-Fact-FF3AC7BA5638D1E40650A6258E899A23"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d46357e1452-wk-Fact-AE23964FA90CF67F44E6AA387E66ADC1"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d46357e1467-wk-Fact-78320D385AE888A5740C781C6AFE258C"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_gh_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d46357e1483-wk-Fact-FF23F2397F29CB98C44CA6258E8C49F0"
      unitRef="number">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d46357e1541-wk-Fact-BBEDAC7B2E5B07C11B8CEF25661E7C18"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_gh_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d46357e1572-wk-Fact-FDA4BC74556D1126C68391CD066CA193"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EAB0ED0129DEF5180BA7A6258EB5D42E-0-wk-Fact-53C8F2F4B5AD5A67F820A6258EA72B71">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable and provides for an allowance for potential credit losses based on management&#x2019;s best estimate of the amount of probable credit losses.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="FI2019Q4"
      decimals="INF"
      id="d46357e1664-wk-Fact-4B1F04EC0A27BDA65F92A6258EA7A876"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-498052C4C09176AA8A64A6258EB7F9CB-0-wk-Fact-B413DAE7EFBC65B03051A6258EA8617D">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory consisted entirely of supplies, which are consumed when providing liquid biopsy tests, and therefore the Company does not maintain any finished goods inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by the Company, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Amounts written-down due to unmarketable inventory are recorded in cost of precision oncology testing.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4268DE8F01DB20E2157AA6258EB72BC1-0-wk-Fact-F3B7E9A3CE8210058924A6258E967D4B">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are recorded at cost. Depreciation is computed over estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The Company periodically reviews the depreciable lives assigned to property and equipment placed in service and changes the estimates of useful lives, if necessary. Maintenance and repairs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-64DFF5E6BD39A6BC70E0A6258EB5D05C-0-wk-Fact-8506191ED15D4E85BC1FA6258E91F782">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:56%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;3 &#x2013; 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer hardware and computer software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lesser of estimated useful life or remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer hardware   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,962&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,522&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer software   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;643&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Construction in progress   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, gross   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation and amortization   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(21,923&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16,634&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,003&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-FD68FCA0AB7CFFE96B35EF38AA0B4E31-0-wk-Fact-8F10849A834E574279A0EF3971169D3F">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company includes the results of operations of the businesses that are acquired as of the acquisition date. The Company allocates the purchase price of acquisitions to the assets acquired and liabilities assumed based on the estimated fair values. The excess of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition related costs are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1107D69A7CFDBC6DFFD5EF39BE6AE556-0-wk-Fact-647C3FEDE7F1A0391814EF3A6C529912">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill and Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets related to in-process research and development costs (&#x201c;IPR&amp;amp;D&#x201d;) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there has been&#160;no&#160;impairment of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6-&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10 years&lt;/span&gt;&lt;/span&gt;.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="d46357e1854-wk-Fact-2DC399A5A549CC34F9F3EF3D4378DC5F">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <gh:ObligationRelatedtoRoyaltyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4C79470F2DA3A2EE10E9A6258EB6F2C4-0-wk-Fact-38BE6A9F0C2F99D291C5A6258E99B163">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Obligation Related to Royalty&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain of the Company&#x2019;s asset acquisitions involve the potential for future payment of consideration that is contingent upon the royalty payments due on future product net sales, subject to annual minimums. The fair value of such liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows.&lt;/span&gt;&lt;/div&gt;</gh:ObligationRelatedtoRoyaltyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F43F9EF791C11130E338A6258EB57F8F-0-wk-Fact-B302DE4C92B78911B6B7A6258E9BA1FD">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment for Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-A6E20FAF8E4F440E437C784CA0CEDB7F-0-wk-Fact-8E3B69F259C0B4BF341F784CF02CE585">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#x2019;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7E6334ECD450BEE940B3A6258EB65E6D-0-wk-Fact-B8C76FA7F19A9E4B4A59A6258E997A5E">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#x2019;s platform. Development services include companion diagnostic development, information solutions and laboratory services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective January 1, 2019, we adopted the new revenue recognition standard FASB ASC Topic 606,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;or ASC 606. Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Precision oncology testing&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company&#x2019;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Development services&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations. The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#x2019;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#x2019;s consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contracts with multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated. For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable.&#160;Contract assets are presented under accounts receivable and other assets on the Company&#x2019;s consolidated balance sheets. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had contract assets of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is recorded in other assets in the consolidated balance sheet.  The Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of contract assets as of January 1, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Deferred revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company&#x2019;s performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the deferred revenue balance was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$16.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, which included &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the&#160;twelve months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;that was included in the deferred revenue balance as of January 1, 2019 was&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which primarily represented revenue from&#160;provision of development services under the collaboration agreement with our biopharmaceutical companies.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Transaction price allocated to the remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d46357e1960-wk-Fact-2F1263100D85C236F7F0784F8E62FB0C"
      unitRef="usd">6200000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember"
      decimals="-5"
      id="d46357e1964-wk-Fact-521C42450508B3BB0CD2784FD96F4D41"
      unitRef="usd">1000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="I2019Q1Jan1"
      decimals="-5"
      id="d46357e1968-wk-Fact-9525492D58552333B8E77850FEBCEDDB"
      unitRef="usd">4900000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4"
      decimals="-5"
      id="d46357e1992-wk-Fact-4CC8DCB50DBCFA2CF78BA6258E9DECD6"
      unitRef="usd">12300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4"
      decimals="-5"
      id="d46357e1996-wk-Fact-7B451599D3639134B38AA6258EA4983B"
      unitRef="usd">16100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d46357e2000-wk-Fact-A5CAA86878EF6C31B11AA6258E96EBB3"
      unitRef="usd">4800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d46357e2005-wk-Fact-60419A91375B78193646A6258EA8AB24"
      unitRef="usd">10500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d46357e2013-wk-Fact-1E630130A5494378B71DEF5C99F22B33"
      unitRef="usd">15200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration
      contextRef="FI2019Q4_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-01-01"
      id="d46357e2028-wk-Fact-2A9E293824A505C50FCF7854B9267D91">P12M</us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration>
    <gh:CostsofPrecisionOncologyTestingPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-26A4C6EB9917A93AD619A6258EB538E2-0-wk-Fact-7A347F07F774283E9EE5A6258EA314D4">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Costs of Precision Oncology Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#x2019;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.&lt;/span&gt;&lt;/div&gt;</gh:CostsofPrecisionOncologyTestingPolicyTextBlock>
    <gh:CostofDevelopmentServicesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-72D73ED5151CF3D8F9AFA6258EB5E181-0-wk-Fact-EBDF08374808E7FCC123A6258E9C6E41">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cost of Development Services&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of development service includes costs incurred for the performance of development services requested by the Company&#x2019;s customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.&lt;/span&gt;&lt;/div&gt;</gh:CostofDevelopmentServicesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-0CB5436E0F1FEDB3F7CDA6258EB7EB7B-0-wk-Fact-D80E2A8F3952EF166DE1A6258E9EF73B">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses are comprised of costs incurred to develop technology and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;also include costs related to activities performed under contracts with biopharmaceutical companies. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#x2019;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-679E083033BBAA341A12A6258EB5FC0B-0-wk-Fact-F08CDB65B47F7115FDC8A6258EA8B91A">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Advertising&lt;/span&gt;&lt;/div&gt;The Company expenses advertising costs as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d46357e2152-wk-Fact-FF447140591007E81626A6258E95A48B"
      unitRef="usd">1300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d46357e2156-wk-Fact-6854C5E6363933A89AEBA6258E9B6ED2"
      unitRef="usd">200000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d46357e2160-wk-Fact-BD61C9ACCA11202D7941A6258E91C488"
      unitRef="usd">300000</us-gaap:AdvertisingExpense>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7D99061816A04DF0038FA6258EB6ED0B-0-wk-Fact-29CE08ED0806B4D4D445A6258EA9CE46">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/div&gt;Deferred offering costs consist of fees and expenses incurred in connection with the anticipated sale of the Company&#x2019;s common stock in the IPO, including the legal, accounting, printing and other IPO-related costs.</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="I2018Q4Oct31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d46357e2188-wk-Fact-6D3D12B968B75764DFC9A6258EA9CB02"
      unitRef="usd">4500000</us-gaap:DeferredOfferingCosts>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-BCA558D8919E80E6F25FA6258EB56644-0-wk-Fact-6143684B7852FD01825CA6258EA297FF">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock&#x2011;Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock&#x2011;based compensation related to stock options granted to the Company&#x2019;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2018, the Company accounted for stock options issued to nonemployees consultants based on the estimated fair value at the grant date and re-measured at each reporting period. Starting January 1, 2019, upon adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-07,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;Improvements to Nonemployee Share-Based Payment Accounting,&#160;the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company uses the Black&#x2011;Scholes option&#x2011;pricing model to estimate the fair value of its stock options and purchase rights under its 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Starting January 1, 2017, forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for restricted stock units issued to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in the Company&#x2019;s consolidated statement of operations on a straight-line basis over the requisite vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-590DB43CA205803F0E38A6258EB67EFE-0-wk-Fact-C9381ADDC3220418D364A6258E9F1ADC">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income taxes are recorded using an asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-16FBB4235DBB5751E9D1A6258EB5C70A-0-wk-Fact-7E5F235B4C5942862AE9A6258E971A44">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prior to the closing of the Company&#x2019;s IPO in October 2018 and the conversion of its convertible preferred stock into common stock, the Company calculated its basic and diluted net loss per share attributable to common stockholders of the Company in conformity with the two-class method required for companies with participating securities. The Company considered its convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on the Company&#x2019;s common stock, holders of convertible preferred stock were entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock did not have a contractual obligation to share in the Company&#x2019;s losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9DA0AF7B64619413413EA6258EB63D1C-0-wk-Fact-C4157E84F500185022E0A6258EA5A6E9">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company adopted ASU 2014-09,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&#160;and all related amendments (collectively, &#x201c;ASC 606&#x201d;)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on January 1, 2019 utilizing the modified retrospective method. The cumulative effect of applying the standard to all contracts that were not completed as of the date of initial application was recognized to beginning accumulated deficit as of January 1, 2019. The Company identified certain differences in accounting for revenue recognition as a result of the adoption of ASC 606 which have impacted its financial position and results of operations.  For precision oncology testing revenue with certain clinical customers, the Company historically deferred revenue recognition until cash receipt when the price pursuant to the underlying customer arrangement became fixed and determinable and collectability became reasonably assured. Under the new standard, this is considered variable consideration and revenue is recognized at the estimated transaction price upon delivery. This results in earlier revenue recognition under the new standard as compared to previous revenue recognition. For development services revenue with certain biopharmaceutical customers, the Company historically limited revenue recognition based on the right to invoice the customer. Under the new standard, for these arrangements, the Company constrains revenue such that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For arrangements with regulatory and other developmental milestone payments, this results in a change to the timing and pattern of revenue recognition under the new standard as compared to previous revenue recognition.  Comparative information from prior periods has not been restated and&#160;continues to be reported under the accounting standards in effect for those periods. The cumulative effect of changes made to the consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Adjustments due to ASC 606 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of January 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Equity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(280,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(275,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In accordance with ASC 606 requirements under the modified retrospective method of adoption, the impact of the adoption of ASC 606 on the Company&#x2019;s consolidated statement of operations and consolidated balance sheet was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;For the year ended December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As Reported Under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Effect of Change &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances Without Adoption of ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Precision oncology testing &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;180,462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;180,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Development services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As Reported Under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Effect of Change &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances Without Adoption of ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Equity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(352,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(353,156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASC 606 did not have an aggregate impact on the Company&#x2019;s net cash used in operating activities but resulted in offsetting changes in certain assets presented within net cash used in operating activities in the Company&#x2019;s consolidated statement of cash flows, as reflected in the above table. The the Company&#x2019;s revenue is generated primarily from the sale of precision oncology testing and development services. Precision oncology testing revenue is generated from sales of the Company&#x2019;s current products to clinical and biopharmaceutical customers. Total precision oncology testing revenues from sales to clinical customers for the years ended December 31, 2019, 2018 and 2017 were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$94.2 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$43.7 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$24.5 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Total precision oncology testing revenues from sales to biopharmaceutical customers for the years ended December 31, 2019, 2018 and 2017 were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$79.5 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$34.7 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$17.6 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Development services revenue represent services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company adopted&#160;ASC 842, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,  and its related amendments which requires the recognition of right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities for operating leases on the consolidated balance sheet on January 1, 2019 using a modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases in place as of January 1, 2019. The Company also elected the practical expedient to not separate lease and non-lease components for its facility leases, and to not recognize ROU assets and operating lease liabilities for short-term leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under ASC 842, the Company determines if an arrangement contains a lease and the classification of that lease, if applicable, at inception or upon modification of a contract. The Company has elected to not recognize a lease liability or ROU asset for short-term leases (leases with a term of twelve months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise). The Company has elected to not allocate the contract consideration for operating lease contracts with lease and non-lease components, and account for the lease and non-lease components as a single lease component. ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at lease commencement date. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. An option to extend the lease &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The primary impact of adopting&#160;Topic 842&#160;was the recognition of ROU assets and lease liabilities for operating leases of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$22.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; respectively, on January 1, 2019, which included reclassifying prepaid rent and deferred rent as a component of the ROU asset.&#160;Topic 842&#160;did not have a material impact on the Company's consolidated statements of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The short-term liabilities from the Company's operating leases are included in accrued expenses in the consolidated balance sheet. The Company's accounting for finance leases (formerly referred to as capital leases prior to the adoption of&#160;Topic 842) remains substantially unchanged. Finance leases are not material to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lease expense for lease payments for the operating leases is recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2018, the FASB issued ASU 2018-07,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation&#x2014;Stock Compensation (Topic 718):&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, with certain exceptions. The Company early adopted this new guidance effective January 1, 2019. In accordance with the transition guidance, the Company assessed its outstanding nonemployee awards for which a measurement date had not been established. These outstanding awards were re-measured to fair value as of the January 1, 2019 adoption date. For nonemployee awards that contain performance condition, the measurement is based on the outcome that is probable as opposed to the lowest aggregate fair value within a range of possible outcomes. The adoption of ASU 2018-07 provided administrative relief by fixing the measurement date of nonemployee awards and eliminating the requirement of quarterly re-measurement. The Company adopted this standard on a modified retrospective basis and recorded a cumulative-effect adjustment of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;as an increase to accumulated deficit and an equal increase to additional paid-in capital as of January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December&#160;22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act (the &#x201c;Tax Act&#x201d;), which contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December&#160;31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No.&#160;118,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Tax Accounting Implications of the Tax Cuts and Jobs Act&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;(&#x201c;SAB 118&#x201d;) to address the accounting implications of the enacted U.S. federal tax reform. SAB 118 allows companies&#160;to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and no measurement period adjustments were recognized due to the full valuation allowance on the Company&#x2019;s deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;Financial Instruments - Credit Losses:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2017,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the FASB issued ASU 2017-04&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment which eliminates Step 2 from the goodwill impairment test and instead requires entities to perform its annual or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;"&gt;. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements in ASC 820, Fair Value Measurement, as part of its disclosure framework project. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted. The amendments in ASU 2018-13 on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments in ASU 2018-13 should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cloud Computing&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued ASU 2018-15&#x2014;Intangibles-Goodwill and Other-Internal&#x2014;Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC Topic 350, Intangibles&#x2014;Goodwill and Other, to determine which implementation costs to capitalize as assets or expense as incurred.  The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB amended ASC 808 and ASC 606 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The guidance is effective for us beginning January 1, 2020 and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes - Topic 740, which simplifies the accounting for income taxes.&#160; Amendments include removal of certain exceptions to the general principles of ASC 740, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences.&#160;ASU 2019-12 also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning January 1, 2021, and early adoption is permitted.&#160; The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-55C49623009BA29C67DBF1F8CAE5E3B9-0-wk-Fact-23A0191C29D9CC148576F1FAD87DF06A">The cumulative effect of changes made to the consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Adjustments due to ASC 606 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of January 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Equity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(280,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(275,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In accordance with ASC 606 requirements under the modified retrospective method of adoption, the impact of the adoption of ASC 606 on the Company&#x2019;s consolidated statement of operations and consolidated balance sheet was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;For the year ended December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As Reported Under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Effect of Change &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances Without Adoption of ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Precision oncology testing &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;180,462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;180,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Development services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As Reported Under ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Effect of Change &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances Without Adoption of ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Equity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(352,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(353,156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d46357e2465-wk-Fact-458877E932D5EBD4BD8CA6258E614976"
      unitRef="usd">35690000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-3"
      id="d46357e2479-wk-Fact-21C4766D75BA87333B62F1FD981A765E"
      unitRef="usd">4907000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="I2019Q1Jan1"
      decimals="-3"
      id="d46357e2493-wk-Fact-5B3B135E1C0581457D83F1FD986A2547"
      unitRef="usd">40597000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d46357e2564-wk-Fact-6BABCF1E83F5B56BEB09A6258E34C8AB"
      unitRef="usd">-280799000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-3"
      id="d46357e2579-wk-Fact-120E4A1004C58F5480C4F1FE09E87E55"
      unitRef="usd">4907000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I2019Q1Jan1"
      decimals="-3"
      id="d46357e2593-wk-Fact-AC015DFCD394626F2E4AF1FE0A8616B9"
      unitRef="usd">-275892000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d46357e2840-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF"
      unitRef="usd">180462000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"
      decimals="-3"
      id="d46357e2854-wk-Fact-481AE1D70CF3C2A3683AF20ECBDB8D28"
      unitRef="usd">-347000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="FD2019Q4YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"
      decimals="-3"
      id="d46357e2869-wk-Fact-D38896642B4E797B2ECAF20ECBBA34D0"
      unitRef="usd">180115000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromDevelopmentServices
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d46357e2889-wk-Fact-8B6729A9D18284EECA68A6258E3316AE"
      unitRef="usd">33913000</gh:RevenuefromDevelopmentServices>
    <gh:RevenuefromDevelopmentServices
      contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"
      decimals="-3"
      id="d46357e2903-wk-Fact-ABE309BC28661FD410CFF20F160C908E"
      unitRef="usd">0</gh:RevenuefromDevelopmentServices>
    <gh:RevenuefromDevelopmentServices
      contextRef="FD2019Q4YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"
      decimals="-3"
      id="d46357e2917-wk-Fact-28D0F15716DF909D3CE7F20F15FF66DB"
      unitRef="usd">33913000</gh:RevenuefromDevelopmentServices>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d46357e3160-wk-Fact-932964D0A06B579D5FA9A6258E2C9EB4"
      unitRef="usd">47986000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-3"
      id="d46357e3174-wk-Fact-4E2CC39A2D75A32C2020F26AA60FB8A3"
      unitRef="usd">-347000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"
      decimals="-3"
      id="d46357e3189-wk-Fact-5AAB289FB1273A355E80F26AA84BA3DD"
      unitRef="usd">47639000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-3"
      id="d46357e3260-wk-Fact-BFC5FAAB703E313E049DA6258E318F4E"
      unitRef="usd">-352809000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-3"
      id="d46357e3275-wk-Fact-8BD49ABF515A94853454F26AAB03880E"
      unitRef="usd">-347000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"
      decimals="-3"
      id="d46357e3290-wk-Fact-6CC9122B7F3514E4E1DDF26AAC384919"
      unitRef="usd">-353156000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan1"
      decimals="-5"
      id="d46357e3357-wk-Fact-DE8847CD24AE38E25259785C5E7C7888"
      unitRef="usd">14500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="I2019Q1Jan1"
      decimals="-5"
      id="d46357e3361-wk-Fact-DA726A1F20C742EE27DD785CF6D0BCEB"
      unitRef="usd">22400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_gh_AccountingStandardsUpdate201807Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d46357e3390-wk-Fact-D32D5958E516C669488FF2724486FA8A"
      unitRef="usd">-1300000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9A1DD23329CFFB0848D2A6258EB72347-0-wk-Fact-F552699B878982C62121A6258E85A76D">Investment in Joint Venture&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Variable Interest Entity (&#x201c;VIE&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with SoftBank&#x2019;s purchase of its Series E convertible preferred stock, the Company entered into a joint venture agreement with an entity affiliated with SoftBank, a related party. In May 2018, the Company and SoftBank formed and capitalized Guardant Health AMEA, Inc. (the &#x201c;Joint Venture&#x201d;) for the sale, marketing and distribution of the Company&#x2019;s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the joint venture agreement, the Company paid &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$41.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, or the other &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ownership interest, of the Joint Venture. Neither party has the obligation to provide additional financial support to the Joint Venture. Each party holds two seats on the board of the Joint Venture and has to cast through its representatives on the board at least one vote for any board resolution of the Joint Venture to pass. The representatives of the Company on the Joint Venture&#x2019;s board of directors have the right to appoint and remove a chief executive officer and a legal representative for the Joint Venture, in each case, subject to the approval of the full Joint Venture board of directors. The Joint Venture&#x2019;s board of directors has the right to appoint and remove all other members of the Joint Venture&#x2019;s senior management reporting to its chief executive officer and to approve the compensation of all foregoing individuals, including the compensation of the chief executive officer and legal representative.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At the inception of the arrangement and at the end of each reporting period, the Company assesses whether the Joint Venture is a variable interest entity (&#x201c;VIE&#x201d;), and if so, who is the primary beneficiary of the VIE. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company and SoftBank had equal ownership interests and equal voting rights in the Joint Venture, and the Joint Venture&#x2019;s board consisted of an equal number of directors representing the interest of the Company and SoftBank, respectively. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Joint Venture&#x2019;s board had the right to vote on all critical matters that most significantly impact the Joint Venture&#x2019;s economic performance, except that the Company had the unilateral right to make pricing decisions. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had responsibility for the Joint Venture&#x2019;s daily operations, while SoftBank served as a financing partner. The Company also entered into various ancillary agreements with the Joint Venture necessary to operate its business. The Joint Venture is deemed to be a VIE, and considering the power and benefits criterion, the Company and SoftBank, collectively as a related party group, has the characteristics of the primary beneficiary of the Joint Venture, as the related party group has the power to direct the activities of the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;VIE that most significantly impact the VIE&#x2019;s economic performance and has the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Because the Company is most closely associated with the Joint Venture within the related party group, it has been identified as the VIE&#x2019;s primary beneficiary.  As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation. The Company concluded the Joint Venture did not meet the definition of a business upon consolidation as it lacked the processes required to generate outputs. Upon consolidation no liabilities were assumed and other than cash, and any identifiable assets were related to intellectual property rights that the Company transferred to the Joint Venture shortly before it became its primary beneficiary and therefore such transfer was treated as a common control transaction.  Upon initial consolidation, the non-controlling interest of the affiliate of SoftBank was recorded at its estimated fair value of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$41.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is equal to the original investment made by the affiliate of SoftBank. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Joint Venture had total assets of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$45.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was primarily comprised of cash and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company&#x2019;s general credit or assets.&#160; Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Put-call arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the &#x201c;put right&#x201d;), and the Company has a right to purchase all such shares (the &#x201c;call right&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If the Company&#x2019;s business model were to change such that the sale, marketing and distribution of its tests in the territory covered by the joint venture agreement was no longer economical, SoftBank would have the right to cause the Company to purchase, or the Company would have the right to purchase, all of the shares of the Joint Venture held by SoftBank and its affiliates. In this instance, the Company would be required to repurchase the shares at an aggregate purchase price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$41.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the original purchase price paid by SoftBank to the Joint Venture for the shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additionally, each of the Company and SoftBank may exercise its respective put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#x2019;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of the Company&#x2019;s initial public offering, a change in control of the Company, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#x2019;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank&#x2019;s interests in the Joint Venture being determined to be materially different from what has been recorded in the Company&#x2019;s consolidated financial statements including those included elsewhere in this Annual Report on Form 10-K. As a result of the IPO, the put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank are exercisable on each subsequent anniversary of the IPO by the Company or SoftBank.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the event the Company exercises its call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the fair value of the Company, the Company will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the Company&#x2019;s fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its capital stock (which may be a non-voting security with senior preferences to all other classes of its equity or, if its common stock is publicly &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;traded on a national exchange, its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company&#x2019;s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the IPO and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the fair value of the redeemable noncontrolling interest held by SoftBank was determined using the combination of the income approach and the market approach. Determining the fair value of the redeemable noncontrolling interest requires judgment and the use of significant estimates and assumptions. Such estimates and assumptions include future revenue growth rates, gross profit margins, EBITDA margins, future capital expenditures, weighted average costs of capital and future market conditions, among others. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy. The change in the value of the redeemable noncontrolling interest consists of net loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and increase in fair value adjustment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="D2018Q2May01-May31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="-5"
      id="d43300e881-wk-Fact-8C26BBE8F0E3CBAD6438A6258E827D10"
      unitRef="usd">9000000.0</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <gh:EquityMethodInvestmentSharesPurchased
      contextRef="D2018Q2May01-May31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="INF"
      id="d43300e885-wk-Fact-D06192E4D1F1B8852F1CA6258E85544D"
      unitRef="shares">40000</gh:EquityMethodInvestmentSharesPurchased>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2018Q2May31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="2"
      id="d43300e889-wk-Fact-B2EF8B21EE0B433FCF0CA6258E7F9FF0"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue
      contextRef="I2018Q2May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="-5"
      id="d43300e893-wk-Fact-E40488D1537F276C8113A6258E7FFCC2"
      unitRef="usd">41000000.0</us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue>
    <gh:EquityMethodInvestmentSharesPurchased
      contextRef="D2018Q2May01-May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="INF"
      id="d43300e897-wk-Fact-7167E8B87C6540D682BBA6258E84B939"
      unitRef="shares">40000</gh:EquityMethodInvestmentSharesPurchased>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2018Q2May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="2"
      id="d43300e902-wk-Fact-690C01940D851E2F6EC3A6258E817F00"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="-5"
      id="d43300e924-wk-Fact-86B0F528337762C7E702A6258E84C93C"
      unitRef="usd">41000000.0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets
      contextRef="FI2019Q4"
      decimals="-5"
      id="d43300e935-wk-Fact-C9B30A4D96217FC20AEA7E6D5E733780"
      unitRef="usd">45100000</us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="D2018Q2May01-May31_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="-5"
      id="d43300e952-wk-Fact-D779310F226C8637F547A6258E805193"
      unitRef="usd">41000000.0</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <gh:VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      id="d43300e959-wk-Fact-FA20312C610461BE4A15A6258E82ED6E">P20D</gh:VariableInterestEntityThresholdPeriodForUnremediedMaterialBreachoftheJointVentureAgreementByTheOtherParty>
    <gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="INF"
      id="d43300e967-wk-Fact-63575D82AADF30660B02A6258E83496F"
      unitRef="number">0.20</gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn>
    <gh:VariableInterestEntityThresholdPercentageofFairValue
      contextRef="FD2019Q4YTD_dei_LegalEntityAxis_gh_SoftBankMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="INF"
      id="d43300e974-wk-Fact-E0D29BA9909D45704FD7A6258E80A25A"
      unitRef="number">0.40</gh:VariableInterestEntityThresholdPercentageofFairValue>
    <gh:VariableInterestEntityPercentageoftheProduct
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_gh_GuardantHealthAMEAIncMember"
      decimals="INF"
      id="d43300e978-wk-Fact-E0A72FF5D485E73CA2A0A6258E8345D5"
      unitRef="number">0.40</gh:VariableInterestEntityPercentageoftheProduct>
    <us-gaap:NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d43300e998-wk-Fact-2C79E32DE5F23D21248E91DCF662B62E"
      unitRef="usd">-3900000</us-gaap:NoncontrollingInterestInNetIncomeLossJointVenturePartnersRedeemable>
    <gh:RedeemableNoncontrollingInterestFairValueAdjustment
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d43300e1002-wk-Fact-1CC866EBE92622FEDF2591DFDB50C639"
      unitRef="usd">11700000</gh:RedeemableNoncontrollingInterestFairValueAdjustment>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BDD1E3D0403BB854D123A6258EB8E730-0-wk-Fact-F2CFF77A8024B4D85FD2A6258E704F39">Consolidated Balance Sheet Components&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer hardware   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,962&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,522&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer software   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;643&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Construction in progress   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, gross   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation and amortization   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(21,923&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16,634&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,003&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization expense related to property and equipment was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued royalty obligations   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;707&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued legal expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued tax liabilities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,050&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,470&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional services   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical trials and studies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,029&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Purchases of property and equipment included in accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;343&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,817&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accrued expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      decimals="-3"
      id="d47727e1071-wk-Fact-52D54E66E81C1441C5F5A6258E5D6077"
      unitRef="usd">29119000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      decimals="-3"
      id="d47727e1090-wk-Fact-115FB2A8AA00E62EDD36A6258E610A22"
      unitRef="usd">23440000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="d47727e1105-wk-Fact-F711530F834B36F48856A6258E62CE05"
      unitRef="usd">6296000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="d47727e1124-wk-Fact-44706A748E19E7A87FE4A6258E4C1BBE"
      unitRef="usd">4949000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d47727e1144-wk-Fact-2B01B4B25D662CC8964BA6258E6816D2"
      unitRef="usd">21031000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d47727e1163-wk-Fact-38CA83213AF601F25C3CA6258E4AA4DE"
      unitRef="usd">13965000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d47727e1183-wk-Fact-B7F464BFB2AAD744578BA6258E5C8FA6"
      unitRef="usd">1962000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d47727e1202-wk-Fact-64C1DDDC2C9DC13891B4A6258E5A615A"
      unitRef="usd">1522000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="d47727e1222-wk-Fact-90D21C93AA1DF503E312A6258E5FA3AC"
      unitRef="usd">829000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="d47727e1241-wk-Fact-4712F28D05EBAA5E7AE3A6258E5C85AB"
      unitRef="usd">643000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d47727e1261-wk-Fact-72C0F336C062F9C18994A6258E55174A"
      unitRef="usd">6354000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d47727e1280-wk-Fact-41D083013DB3817A6EACA6258E5A2090"
      unitRef="usd">3118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1300-wk-Fact-F230E8CD3E5D2A9B6559A6258E60022A"
      unitRef="usd">65591000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1319-wk-Fact-55629F1389A054638E9AA6258E5E8A3B"
      unitRef="usd">47637000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1340-wk-Fact-E839D4CEDDC51DD9A3F5A6258E5F1B4B"
      unitRef="usd">21923000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1360-wk-Fact-A3FDD2D982F93E24CE15A6258E5A66C0"
      unitRef="usd">16634000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1386-wk-Fact-70D2EDBA0CE7622F37B1A6258E2A47FB"
      unitRef="usd">43668000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1405-wk-Fact-F2928BF2B06270B1745EA6258E2F72DD"
      unitRef="usd">31003000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d47727e1417-wk-Fact-5EAE97E511CD0E1B5FABA6258E8956B9"
      unitRef="usd">9300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d47727e1421-wk-Fact-25F6266F40468F52641AA6258E8241FF"
      unitRef="usd">6100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d47727e1425-wk-Fact-0F2A3C67E3D78BA79D7DA6258EA79485"
      unitRef="usd">4200000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EBD91A698FB77568D764A6258EB87142-0-wk-Fact-4BF089C4EDE02292C7D4A6258E86F976">&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued royalty obligations   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;707&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued legal expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued tax liabilities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,050&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,470&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional services   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical trials and studies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,029&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Purchases of property and equipment included in accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;343&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,817&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accrued expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1641-wk-Fact-5CC1574E79AA1DD6CDB0A6258E4BA54A"
      unitRef="usd">1564000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1660-wk-Fact-BBD4DA70CA1AD667E84FA6258E39D829"
      unitRef="usd">707000</us-gaap:AccruedRoyaltiesCurrent>
    <gh:EstimatedLitigationLiabilityLegalFeesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1675-wk-Fact-2A0893F7049639B3E9D7A6258E6DE3C8"
      unitRef="usd">1046000</gh:EstimatedLitigationLiabilityLegalFeesCurrent>
    <gh:EstimatedLitigationLiabilityLegalFeesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1694-wk-Fact-4EF6D7FC5D6878531270A6258E9A2B5C"
      unitRef="usd">814000</gh:EstimatedLitigationLiabilityLegalFeesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1714-wk-Fact-55E66D800C11ED2E9CB9A6258E990A95"
      unitRef="usd">3050000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1733-wk-Fact-2466EFC06958272EBF30A6258E995832"
      unitRef="usd">1470000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1753-wk-Fact-851301F17DCF4F5B1313A6258E92A60F"
      unitRef="usd">3464000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1772-wk-Fact-37207F5BDA967F66B36FA6258E8D17AE"
      unitRef="usd">1791000</us-gaap:AccruedProfessionalFeesCurrent>
    <gh:AccruedClinicalTrialsandStudies
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1792-wk-Fact-35DBE7E39C1C8CC48D177865EA77FE89"
      unitRef="usd">2029000</gh:AccruedClinicalTrialsandStudies>
    <gh:AccruedClinicalTrialsandStudies
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1811-wk-Fact-7BB3265439D5592E22477865EA727D6C"
      unitRef="usd">236000</gh:AccruedClinicalTrialsandStudies>
    <gh:AccruedExpensesPropertyandEquipmentCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1831-wk-Fact-59E37DA604328A434D4BA6258E845813"
      unitRef="usd">2424000</gh:AccruedExpensesPropertyandEquipmentCurrent>
    <gh:AccruedExpensesPropertyandEquipmentCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1850-wk-Fact-0C9887E8F147A0536405A6258E91291C"
      unitRef="usd">343000</gh:AccruedExpensesPropertyandEquipmentCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1870-wk-Fact-FF8E6088F12AD6FD2D3F7866343D9311"
      unitRef="usd">7140000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1889-wk-Fact-796558F200135C29D4C37866335DC6B9"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1910-wk-Fact-848C671FF5A12406BF83A6258E9A515B"
      unitRef="usd">4986000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1929-wk-Fact-5C7059992575A367C8EBA6258E6D208F"
      unitRef="usd">1817000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d47727e1954-wk-Fact-71CC6343C9567D0701CFA6258E2F8222"
      unitRef="usd">25703000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d47727e1973-wk-Fact-B215684635F57C2B1BB6A6258E5F1626"
      unitRef="usd">7178000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B031BDC2A7A97D739FE9A6258EB8A6C1-0-wk-Fact-3D42AE7156F168E2858CA6258EA55D44">Fair Value Measurements, Cash Equivalents and Marketable Securities&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Financial instruments consist of cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#x2019;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;362,884&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;362,884&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;379,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;379,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;268,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;268,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;268,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;268,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;659,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;648,357&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,004&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,004&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;278,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;278,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,758&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,758&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,563&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,563&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381,776&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;355,980&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Corporate bonds, U.S. government debt securities and U.S. government agency bonds are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on  the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's contingent consideration was valued using the discounted cash flow method. Significant unobservable inputs used in the fair value measurement of the Company&#x2019;s contingent consideration liability include the estimated amount and timing of projected cash flows, and the risk-adjusted discount rate used to present value the cash flows. The change in discount rate has an inverse relationship to the overall valuation of the contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The use of different inputs in the valuation of the contingent consideration liability could result in materially different fair value estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables summarizes the Company&#x2019;s cash equivalents and marketable securities&#x2019; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate bond   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;630,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;631,666&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;657,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;659,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate bond   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42,202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;308,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;308,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government agency bonds................&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5,004&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;381,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381,776&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company&#x2019;s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The maturities of the Company&#x2019;s long-term marketable securities range from&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.04&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;to&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.75&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-84C3E739ECA52D29FE6AA6258EB82078-0-wk-Fact-F359620A5FDABCE5295FA6258E64EE9D">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;362,884&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;362,884&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;379,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;379,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;268,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;268,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;268,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;268,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;659,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;648,357&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,004&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,004&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;278,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;278,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,758&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,758&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,563&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,563&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381,776&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;355,980&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1341-wk-Fact-5FDE4566ED302958C89BA6258E9CFBBC"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1360-wk-Fact-695890ADCCAEB47E875FA6258E38124E"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1379-wk-Fact-8F5C52372BCD15E76044A6258E9B7511"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1399-wk-Fact-ACE53A88E3E08C24481DA6258E63C808"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1419-wk-Fact-54324F1796CE5431DB7AA6258E3A54BE"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1438-wk-Fact-2A1EA75C39E35D1543B2A6258E3BC9C5"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1457-wk-Fact-1B93B01EE1F44A8C8966A6258EA19BCE"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1477-wk-Fact-FFD3447266770304BE61A6258E493FD1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1579-wk-Fact-8219E78A61C9C0F73CB9A6258E9A5ED4"
      unitRef="usd">16690000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1593-wk-Fact-73B22957B3288FE70C94A6258E3F65AD"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1617-wk-Fact-C4B705CBB1E57B02340BA6258E9CC1B9"
      unitRef="usd">16690000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1632-wk-Fact-54567EF0AC14D808FB09A6258E5BFD31"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1652-wk-Fact-0D606E7F360093B1C2DFA6258E3D28CC"
      unitRef="usd">362884000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1671-wk-Fact-3708C9AADA9CEDEEF4A4A6258E4DF262"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1690-wk-Fact-D5222568BEBF82F440E0A6258E553098"
      unitRef="usd">362884000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1710-wk-Fact-5F8C8581753526B7E7F5A6258E9AD5F3"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1735-wk-Fact-1E42CA33F0DEA22E31B5A6258E4A701F"
      unitRef="usd">379574000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1754-wk-Fact-90A447B969B018AB55F3A6258EA6D3B3"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1773-wk-Fact-0F855BCCAE4E2AEC624EA6258E40A129"
      unitRef="usd">379574000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1793-wk-Fact-26D3A160D33A35DE451FA6258E9A7BEC"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1896-wk-Fact-35D00E555F1463691ABFA6258E432C3F"
      unitRef="usd">268783000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1910-wk-Fact-4303D814EB481C5E8FBBA6258EA58363"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1934-wk-Fact-95DC9BDDE03EAB584CFCA6258E641717"
      unitRef="usd">268783000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e1949-wk-Fact-6E78C1C5B0275787EBF1A6258E340219"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1969-wk-Fact-A95C2FA8C683E166B552A6258E4E4591"
      unitRef="usd">268783000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e1988-wk-Fact-4BBDD2371514F5C75E39A6258E46D53E"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2007-wk-Fact-EB72A9473A9E0E3B3061A6258E4BCB73"
      unitRef="usd">268783000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2027-wk-Fact-78A0C112C223D9E9E71CA6258E511F3A"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2052-wk-Fact-1A58A435DC345B7B8C19A6258E47482B"
      unitRef="usd">659091000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2071-wk-Fact-C766AA606F511FB1ECD1A6258E3C92C7"
      unitRef="usd">10734000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2090-wk-Fact-31B80E38E6BF22AF0C0AA6258E99A621"
      unitRef="usd">648357000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2110-wk-Fact-2D5C39D61C3B4F68D107A6258EA49D6D"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2294-wk-Fact-E837135145F568A3198CF27CECA7D7B7"
      unitRef="usd">1365000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2308-wk-Fact-31217D07D044E6BE3B40F27CECD24A68"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2327-wk-Fact-7BC5FF0C39CAFCA2EDD4F27CECFE45A6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2352-wk-Fact-00DF04757C5656D0261AF27CECB0F636"
      unitRef="usd">1365000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2372-wk-Fact-54FBE21D48EC6CAFA9F3F27A965AE6C2"
      unitRef="usd">1365000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2391-wk-Fact-23D0D28A7923B26E5714F27A96675F06"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2410-wk-Fact-A6C3114C1DD853C66D02F27A965633BD"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2430-wk-Fact-C672075260B2DE9ADD91F27A965FD7C9"
      unitRef="usd">1365000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2883-wk-Fact-4E004E536BD3989C6646A6258E815F75"
      unitRef="usd">25796000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2902-wk-Fact-364307160ACFE121D855A6258E5EB3F4"
      unitRef="usd">25796000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2921-wk-Fact-78336598781D732D2B4DA6258E3C6ACD"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2941-wk-Fact-1E209741A88526E41339A6258E417ADD"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2961-wk-Fact-73FDED3F6891F2A79786A6258E935B8F"
      unitRef="usd">25796000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2980-wk-Fact-FF053F08F4B6FA16A3ABA6258E413FF1"
      unitRef="usd">25796000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e2999-wk-Fact-8338EC7FC92B736D4F94A6258EA6F4F9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3019-wk-Fact-05EE7F61ECB01B362E90A6258E6E7DE7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3121-wk-Fact-748EF9CC968EA75D3FABA6258E90E496"
      unitRef="usd">38397000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3140-wk-Fact-7ABD543A369EE1537A5CA6258E35601F"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3159-wk-Fact-148A8EF3AF6D8AD887B4A6258E3B367D"
      unitRef="usd">38397000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3179-wk-Fact-E61F44B0ABCA4E9F9999A6258EA671CF"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3194-wk-Fact-F74C3C0995BEC4F8E667A6258E3AB35C"
      unitRef="usd">235016000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3213-wk-Fact-C26F04FBA487311506FDA6258E9F9653"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3232-wk-Fact-0AC0803268A5E8F7B9B2A6258E3A1DBC"
      unitRef="usd">235016000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3252-wk-Fact-E4D9E1A771A2611A5511A6258EA9D418"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3272-wk-Fact-62ADCE60EECD55529741AACD1338F0DA"
      unitRef="usd">5004000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3311-wk-Fact-6FB0A6261B84A1292F1CAACD1F360B60"
      unitRef="usd">5004000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3358-wk-Fact-1728BF5046D0D6C5A78AA6258E3B4969"
      unitRef="usd">278417000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3377-wk-Fact-94E0875163298A1A3681A6258E700F42"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3396-wk-Fact-459BCCC9B00A4DE5D36CA6258E78EFE0"
      unitRef="usd">278417000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3416-wk-Fact-1853E9B484E1365D243AA6258E30EE6D"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3518-wk-Fact-124DC59E9188223C1FE8A6258E5AF4B7"
      unitRef="usd">3805000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3537-wk-Fact-F72DE1D47E33FDCA88EBA6258E4D8231"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3556-wk-Fact-3F93E08C6AB50DD1DE74A6258E301E82"
      unitRef="usd">3805000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3576-wk-Fact-E749CF19F24947CEE40BA6258E9C456F"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3591-wk-Fact-27D67F8278EAEABE1659A6258E2FCC92"
      unitRef="usd">73758000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3610-wk-Fact-D9D59285BDC08488B772A6258E94A3DB"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3629-wk-Fact-80200FE38C3ECAC1336DA6258E39D67D"
      unitRef="usd">73758000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="d54325e3649-wk-Fact-80BBA46E6A7E56D51463A6258E3E042C"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3674-wk-Fact-33B7F53BD83C58F43BC3A6258E98B4A0"
      unitRef="usd">77563000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3693-wk-Fact-2E08D02AE1EBD1253937A6258E76182C"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3712-wk-Fact-72D6E850883BA7B2E1F2A6258E418CF6"
      unitRef="usd">77563000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3732-wk-Fact-559EFF8BE02C0A563869A6258E46FC3B"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3752-wk-Fact-9F779335831D23274CD1A6258E6FBCB7"
      unitRef="usd">381776000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3771-wk-Fact-DC7A3E77B62BC8DF9E76A6258E91ACE1"
      unitRef="usd">25796000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3790-wk-Fact-7EB49472586F6F0DD166A6258E52CEE0"
      unitRef="usd">355980000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d54325e3810-wk-Fact-C6D39F28205536244908A6258EA497F7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <gh:DebtSecuritiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-91A9300D95C3A58A943DA6258EB8DAB9-0-wk-Fact-5103A419498E6EE004ECA6258E803EF2">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables summarizes the Company&#x2019;s cash equivalents and marketable securities&#x2019; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate bond   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;630,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;631,666&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;657,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;659,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate bond   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42,202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government debt securities &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;308,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;308,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government agency bonds................&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5,004&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;381,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381,776&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</gh:DebtSecuritiesTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d54325e4204-wk-Fact-E0C30020ECE5EE6E6B83A6258E727E84"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d54325e4262-wk-Fact-72871018D9DA32A6B3EFA6258E9C3AE8"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e4277-wk-Fact-F61024AEB724DD91D03DA6258E427D7F"
      unitRef="usd">16679000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e4296-wk-Fact-921481AEC20EDEFB6BB6A6258E379A45"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e4315-wk-Fact-9D9C8CBF587295F0C4A5A6258E79AB0B"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e4335-wk-Fact-2131B05296ECE2B19F80A6258E721C3C"
      unitRef="usd">16690000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d54325e4355-wk-Fact-2D2B4CC95E369B68FBF4A6258E9F9B36"
      unitRef="usd">630283000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d54325e4374-wk-Fact-61F220C4009A69E72450A6258EA123F3"
      unitRef="usd">1422000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d54325e4393-wk-Fact-8693BCC71AD7B5C868D8A6258E747635"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d54325e4414-wk-Fact-C3FA759084FF703B841AA6258E9FF9E9"
      unitRef="usd">631666000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost
      contextRef="FI2019Q4"
      decimals="-3"
      id="d54325e4439-wk-Fact-13247A7BC6986311BF0BA6258E8495F4"
      unitRef="usd">657696000</gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d54325e4458-wk-Fact-4764552C1891DC110518A6258E85B35E"
      unitRef="usd">1433000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d54325e4477-wk-Fact-29D4A04F0FD588A00EA1A6258E400C34"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <gh:CashCashEquivalentsandDebtSecuritiesFairValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d54325e4498-wk-Fact-91991EC1E12BFA12D261A6258E88E487"
      unitRef="usd">659090000</gh:CashCashEquivalentsandDebtSecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d54325e4868-wk-Fact-ED9C6356056B40D14124A6258E8A74FD"
      unitRef="usd">25796000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d54325e4926-wk-Fact-77E4E5823C167F1A71C3A6258E30E4DC"
      unitRef="usd">25796000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e4941-wk-Fact-CDEC56DAB4B43C5BE703A6258E8A62FB"
      unitRef="usd">42273000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e4960-wk-Fact-5F8BBE8B529583277AD1A6258E2B9502"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e4979-wk-Fact-6D3A476A1F87EE5AE561A6258E37A663"
      unitRef="usd">71000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d54325e5000-wk-Fact-645E4F2FBB07C6D4E10EA6258E8B3333"
      unitRef="usd">42202000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d54325e5020-wk-Fact-9998E24FDF83884AE047A6258E3CF379"
      unitRef="usd">308775000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d54325e5039-wk-Fact-42701DFABF9BDB4BCD72A6258E3C709C"
      unitRef="usd">235000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d54325e5058-wk-Fact-E10DA2264E34171D61C2A6258E356E6D"
      unitRef="usd">236000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d54325e5079-wk-Fact-A8BC26DE57CF45F8403EA6258E3415DE"
      unitRef="usd">308774000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d54325e5099-wk-Fact-BF03DF1D47B3F7D4EA48AAD0D27EE6E7"
      unitRef="usd">5014000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d54325e5118-wk-Fact-E041D09997E99A9B54A4AAD0D62A1C80"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d54325e5137-wk-Fact-CA87E448A4493EADF99EAAD0D919A2EA"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d54325e5158-wk-Fact-16F8BBF3517B2F6D0A02AAD0DBEDBBD3"
      unitRef="usd">5004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost
      contextRef="FI2018Q4"
      decimals="-3"
      id="d54325e5183-wk-Fact-8A01D01700230EB517EDA6258E3579A3"
      unitRef="usd">381858000</gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d54325e5202-wk-Fact-9049BB35EF9B8E9A36C6A6258E88FC69"
      unitRef="usd">235000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d54325e5221-wk-Fact-F653F0508C8C777674E1A6258E8E995D"
      unitRef="usd">317000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <gh:CashCashEquivalentsandDebtSecuritiesFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d54325e5242-wk-Fact-4AA6C026B4DB89BD75B0A6258E3B7ED2"
      unitRef="usd">381776000</gh:CashCashEquivalentsandDebtSecuritiesFairValue>
    <gh:MarketableSecuritiesMaturityPeriod
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="d54325e5262-wk-Fact-CC1C182141095C66DAD9A6258E6F111D">P1Y14D</gh:MarketableSecuritiesMaturityPeriod>
    <gh:MarketableSecuritiesMaturityPeriod
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="d54325e5266-wk-Fact-457182361D9E0A3F8B4EA6258EA16B26">P1Y9M</gh:MarketableSecuritiesMaturityPeriod>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F3D8B63B0E85E95ED4A6F2840A0FF93B-0-wk-Fact-F7F9ABE1B11AC48578A1F2842751A62E">Acquisition of Bellwether Bio&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April 2019, the Company purchased of all of the outstanding shares of Bellwether Bio, Inc. (&#x201c;Bellwether Bio&#x201d;), a privately-held company developing a method for early blood-based cancer detection. The Company accounted for the acquisition as a business combination. The total purchase consideration was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which consisted of i)&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash paid upon closing; and ii) future contingent consideration liability with a fair value of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the acquisition date. The contingent consideration is subject to the achievement of certain commercialization milestones with a maximum payout amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company will also pay additional earn-out consideration of up to&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; subject to the achievement of certain commercialization milestones and&#160;the continued provision of services to the Company by certain former employees&#160;and consultants&#160;of Bellwether Bio. The contingent consideration and earn-out consideration may be paid, at the Company&#x2019;s election, in cash or in the Company&#x2019;s common stock. As of December&#160;31, 2019, the Company did not believe the earn-out consideration is probable to be achieved, and therefore, did not record any compensation expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The excess purchase consideration over the fair value of assets acquired and liabilities assumed was recorded as goodwill. Goodwill is attributable to future revenue opportunities that we expect to achieve from leveraging Bellwether Bio&#x2019;s existing license and IPR&amp;amp;D, as well as the assembled workforce. The valuation of the intangible assets acquired was determined using currently available information and reasonable assumptions. The following table summarizes the allocation of the total consideration to the estimated fair values of assets acquired and liabilities assumed:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identified intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,708&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents details of the identified intangible assets acquired from the Bellwether Bio acquisition:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquired license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;IPR&amp;amp;D assets are not subject to amortization.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with the acquisition of Bellwether Bio, the Company also entered into non-compete agreements with certain key individuals based on their experience and importance to the operation of Bellwether Bio. The Company accounted for the covenants not to compete as purchases of intangible assets separate from the business combination as these non-compete agreements were initiated by the Company to protect its interests. The fair value of acquired covenants not to compete was estimated to be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is recorded within intangible assets on the consolidated balance sheet and will be amortized over an estimated useful life of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; using the straight-line method.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents other intangible assets - net: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Useful Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquired license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-compete agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;676&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,924&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total intangible assets &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;676&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There were no intangible assets as of December 31, 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes estimated future amortization expense of finite-lived intangible assets&#x2014;net:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,924&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquisition-related contingent consideration is measured at fair value on a quarterly basis based on additional information as it becomes available and change in estimated contingent consideration to be paid will be included in &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;operating expenses in the consolidated statements of operations. The fair value of acquisition-related contingent consideration is estimated using a multiple-outcome discounted cash flow valuation technique. Contingent consideration is classified within Level 3 of the fair value hierarchy, as it is based on a probability that includes significant unobservable inputs. The significant unobservable inputs include a probability-weighted estimate of achievement of certain commercialization milestones, continued services from certain former employees and consultants, resulting contingent payments, and discount rate to present value the expected payments. A significant change in any of these input factors in isolation could have a material impact to fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Since initial valuation on the date of acquisition, contingent consideration liability increased by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million due to change in estimate relating to inputs used to determine the fair value of contingent consideration. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, contingent consideration liability of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was recorded within other long-term liabilities on the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company incurred acquisition-related transaction costs of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4&lt;/span&gt;&lt;/span&gt; million which are included in general and administrative expenses in the consolidated statements of operations.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-5"
      id="d51364e874-wk-Fact-C1502677C50D96646BFCF2852FBCE9F0"
      unitRef="usd">8700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-5"
      id="d51364e880-wk-Fact-4B0E5F15CCA141FD0422F28561F7EAF1"
      unitRef="usd">7600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-5"
      id="d51364e884-wk-Fact-A2D8A99CFA7ADA3C8534F2859E1264B8"
      unitRef="usd">1100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <gh:BusinessCombinationContingentConsiderationMaximumAmountPayable
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_ContingentConsiderationByTypeAxis_gh_CommercializationMilestonesMember"
      decimals="-5"
      id="d51364e888-wk-Fact-E180F44349FCC1CB1333F285D15A47B4"
      unitRef="usd">10000000.0</gh:BusinessCombinationContingentConsiderationMaximumAmountPayable>
    <gh:BusinessCombinationContingentConsiderationMaximumAmountPayable
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_ContingentConsiderationByTypeAxis_gh_EarnOutConsiderationMember"
      decimals="-5"
      id="d51364e892-wk-Fact-F4C8D8761DBA71B2CD81F28608125EAA"
      unitRef="usd">10000000.0</gh:BusinessCombinationContingentConsiderationMaximumAmountPayable>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-53EB3CB458C4C5F773F7F286D58F72A4-0-wk-Fact-4DA66A29ACF0A0CD66C1F286E59AD778">The following table summarizes the allocation of the total consideration to the estimated fair values of assets acquired and liabilities assumed:&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identified intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,708&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e984-wk-Fact-E996561590CD7F738C36F287FCCCB4A4"
      unitRef="usd">521000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1004-wk-Fact-96C37527A045B9FE51D6F28A5ADBEA52"
      unitRef="usd">6700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1029-wk-Fact-1EDAE73F9077AAEBCE21F288015A01E4"
      unitRef="usd">3289000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1054-wk-Fact-DC5AF06F6F7BAFBC24A2F288032158E6"
      unitRef="usd">1802000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1085-wk-Fact-E3A5D6739C58FE7958DBF28804E94921"
      unitRef="usd">8708000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C9AE7AC11A3B94DFD373F2871F120237-0-wk-Fact-4F8BC51626BBF364736EF28734F0ACF7">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents details of the identified intangible assets acquired from the Bellwether Bio acquisition:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquired license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;IPR&amp;amp;D assets are not subject to amortization.&lt;/span&gt;&lt;/div&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1201-wk-Fact-123F807A326367F66AFAF28A55C4DC7F"
      unitRef="usd">5100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      id="d51364e1215-wk-Fact-670887BC7775CDD44A9B5ABBBC5C8134">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1231-wk-Fact-23C22089F8D5C5AD85DAF28A58AC8E9D"
      unitRef="usd">1600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1271-wk-Fact-96C37527A045B9FE51D6F28A5ADBEA52"
      unitRef="usd">6700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2019Q2Apr30_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gh_CovenantsNotToCompeteMember"
      decimals="-5"
      id="d51364e1298-wk-Fact-35CD9D0C8230E7C24D09F28BE9D8D19F"
      unitRef="usd">2500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="D2019Q2Apr_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gh_CovenantsNotToCompeteMember"
      id="d51364e1302-wk-Fact-F001B1F6E8F257E41D70F28C2229A0BC">P6Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-19EAD41277D51B6B414A5AB8A55B4AC6-0-wk-Fact-D4F391E15E30FF11D9935AB930E408B0">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents other intangible assets - net: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Useful Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquired license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-compete agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;676&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,924&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total intangible assets &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;676&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember"
      id="d51364e1576-wk-Fact-9146FC59F51913201EE15AB2D51C414D">P9Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d51364e1591-wk-Fact-CF7634AF8A8EC576C02D5AB3527CAB25"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d51364e1610-wk-Fact-9E3C8B1123736E958F345AB37ACEA885"
      unitRef="usd">373000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d51364e1630-wk-Fact-1091955DDB6B0C2621805AB39E30B9E2"
      unitRef="usd">4727000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember"
      id="d51364e1650-wk-Fact-7A79770BE3F6871C27A55AB2D523E68F">P5Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember"
      decimals="-3"
      id="d51364e1660-wk-Fact-243F168C2DCBDA1AE74C5AB3528A214B"
      unitRef="usd">2500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember"
      decimals="-3"
      id="d51364e1679-wk-Fact-C49166042AA2CAC809C75AB37A6D0561"
      unitRef="usd">303000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember"
      decimals="-3"
      id="d51364e1699-wk-Fact-CFFCA65119F641C4EBE35AB39DB25CBD"
      unitRef="usd">2197000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1739-wk-Fact-D3FD8B509F52276BE6455AB352812DCA"
      unitRef="usd">7600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1753-wk-Fact-BA6CA4CB0346BB1C85B35AB37A52F748"
      unitRef="usd">676000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1778-wk-Fact-2DC6157EF74A36F3BE2B5AB39DD1F0AF"
      unitRef="usd">6924000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1890-wk-Fact-41F0ADCC00F7FDCC59975AB3D96E2A41"
      unitRef="usd">1600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1929-wk-Fact-41F0ADCC00F7FDCC59975AB3D96E2A41"
      unitRef="usd">1600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1959-wk-Fact-5D382625C755DDDD26485AB409737FD1"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e1998-wk-Fact-5D382625C755DDDD26485AB409737FD1"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <gh:IntangibleAssetsGrossIncludingGoodwill
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e2038-wk-Fact-104BA2843BDFFE6F97C55AB5626DBAAA"
      unitRef="usd">12490000</gh:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e2057-wk-Fact-BA6CA4CB0346BB1C85B35AB37A52F748"
      unitRef="usd">676000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e2077-wk-Fact-4EB51FE98AD220A757925AB45C58EF8F"
      unitRef="usd">11814000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8A790E949E50EB4F994F5AA82AD02163-0-wk-Fact-AE5C1BFFE1DAD61F1CC65AA8839BEBAB">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes estimated future amortization expense of finite-lived intangible assets&#x2014;net:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,924&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e2158-wk-Fact-29134B8A119AB6FD14385AAD6B0859C1"
      unitRef="usd">928000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e2173-wk-Fact-8B834E49C670730882495AAD9F6AFAB4"
      unitRef="usd">928000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e2193-wk-Fact-5560EDE0A2B4BE5579115AADE9C89574"
      unitRef="usd">928000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e2213-wk-Fact-03F53D9D516182CF6FEA5AAE124CDE35"
      unitRef="usd">928000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e2233-wk-Fact-B6DD73864B239E1A7C475AAE4EE77EF3"
      unitRef="usd">3212000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-3"
      id="d51364e2258-wk-Fact-2DC6157EF74A36F3BE2B5AB39DD1F0AF"
      unitRef="usd">6924000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-5"
      id="d51364e2276-wk-Fact-4EED99E2748C781EFD14F28E1E8BA1A8"
      unitRef="usd">300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-5"
      id="d51364e2284-wk-Fact-2F4C76650FBB2136C20D786E37E8B717"
      unitRef="usd">1400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_gh_BellweatherBioInc.Member"
      decimals="-5"
      id="d51364e2295-wk-Fact-E397901871C88EABF94FF28D13EED02F"
      unitRef="usd">400000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B234509F7B5DBE76E82FA6258EB88BA6-0-wk-Fact-5EAC17FD7264F978451DA6258E667586">Patent License Agreement&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the Company entered into a license agreement with a biotechnology company for an exclusive, non-transferable right to use proprietary technology related to high-throughput screening and identification of mutations in targeted gene sequences. The payment terms of the license agreement included (i) a one-time upfront payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x20ac;1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;; (ii) issuance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;141,774&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s Series D convertible preferred stock; (iii) a milestone payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x20ac;1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with the achievement of a specified milestone event; and (iv) future royalty payments at the minimum of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x20ac;13.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the aggregate based on annual net sales in which the licensed technology are used. The Company made a one-time upfront payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in January 2017 and a milestone payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in August 2017 upon achievement of the specified milestone event. The Series D convertible preferred stock issued under the license agreement had a fair value of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the date of issuance. The transaction was treated as an acquisition of an asset and the Company capitalized the upfront payment, milestone payments and fair value of Series D convertible preferred stock in addition to license fees of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to the future minimum royalty payments discounted to the present value. The Company recorded the obligation at the estimated present value of the future payments using a discount rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company&#x2019;s estimate of its effective borrowing rate for similar obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, unamortized capitalized license fees plus one-time upfront and milestone payments totaled &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, which will be amortized over the remaining useful life of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years, respectively. Amortization of capitalized license fees plus one-time upfront and milestone payments totaled &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-5"
      id="d54431e875-wk-Fact-15D7C009945783D64BDBA6258E6489DD"
      unitRef="gbp">1000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      id="d54431e879-wk-Fact-332A3EF2BB1C098D7F84A6258E63259C"
      unitRef="shares">141774</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <gh:LicenseAgreementMilestonePaymentUponAchievement
      contextRef="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-5"
      id="d54431e883-wk-Fact-1928F01DED1B914C0B58A6258E616F8F"
      unitRef="gbp">1000000.0</gh:LicenseAgreementMilestonePaymentUponAchievement>
    <gh:PaymentsforFutureRoyalties
      contextRef="D2019Q4Dec312019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-5"
      id="d54431e887-wk-Fact-BD11A21AD9D6963947C4A6258E60BAC6"
      unitRef="gbp">13400000</gh:PaymentsforFutureRoyalties>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-5"
      id="d54431e891-wk-Fact-B071CA0061686FC499F7A6258E61A1CE"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <gh:LicenseAgreementMilestonePaymentUponAchievement
      contextRef="D2017Q3Aug01-Aug31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-5"
      id="d54431e896-wk-Fact-9AA53D45963C88D6686EA6258E650899"
      unitRef="usd">1200000</gh:LicenseAgreementMilestonePaymentUponAchievement>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="D2017Q1Jan01-Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember"
      decimals="-5"
      id="d54431e900-wk-Fact-2AD53EE00F74BBAD2C71A6258E632CC5"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="I2018Q1Jan31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-5"
      id="d54431e904-wk-Fact-C24A642A9254C2F10DECA6258E622D56"
      unitRef="usd">6300000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="I2018Q1Jan31_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="2"
      id="d54431e908-wk-Fact-C35E48B756427C1CF55DA6258E649E6F"
      unitRef="number">0.15</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-5"
      id="d54431e923-wk-Fact-DD68403CCE95177EA7DBA6258E650107"
      unitRef="usd">6900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-5"
      id="d54431e927-wk-Fact-371B9B676139BBF8E5A0A6258E62B6F0"
      unitRef="usd">7800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="D2019Q4Dec312019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      id="d54431e931-wk-Fact-B433439426327D3DF8F0A6258E648F46">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="D2018Q4Dec31_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      id="d54431e936-wk-Fact-6D52F56935119238FFE9A6258E62AF1D">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-5"
      id="d54431e940-wk-Fact-B84287E7FC50804C00CCA6258E643FD5"
      unitRef="usd">1000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q4QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-5"
      id="d54431e944-wk-Fact-9C9A3818673C88289CAFA6258E6097E3"
      unitRef="usd">900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-362BC4A6CE9523FE4E6BA6258EB887A7-0-wk-Fact-C78D27BAAE100907D6B0A6258E651597">Senior Term Loan and Royalty Purchase Agreement&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2015, the Company entered into a credit agreement with a financial institution for a senior term loan (the &#x201c;Credit Agreement&#x201d;). The Credit Agreement provided for up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in borrowing capacity. The Company borrowed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the effective date of the Credit Agreement. The Credit Agreement provided for an interest rate equal to the greater of (i) three-month LIBOR or (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per annum plus &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the outstanding balance of the term loan not exceeding &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Concurrent with the Credit Agreement, the Company also entered into a Royalty Purchase Agreement (the &#x201c;Royalty Agreement&#x201d;) with the same financial institution, which obligated the Company to make quarterly royalty payments of (i) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; applied to total Company fiscal year revenues of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; applied to fiscal year revenues in excess of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Royalty Agreement included a buyout option, by which the Company had the right, exercisable in its sole discretion, to buy out the obligation to make future royalty payments. The price of this buyout option was calculated based on a table with axes of principal balance outstanding and time, less the cumulative sum of royalty payments at the time the buy-out option is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2017, the Company exercised its prepayment right under the Credit Agreement and repaid the outstanding principal balance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;  and accrued interest of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The prepayment option also required the Company to pay a prepayment penalty of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Concurrent with the prepayment of the senior term loan, the Company also excised its royalty buyout option for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The transaction was accounted for as a debt extinguishment. The net carrying amount of the debt and royalty liabilities immediately before the extinguishment was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As a result, the difference between the reacquisition price and the net carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was recorded as loss on debt extinguishment in the accompanying consolidated statements of operations. As of December&#160;31, 2019 and 2018, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; outstanding balance under the senior term loan and its related royalty obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="I2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember"
      decimals="INF"
      id="d54558e875-wk-Fact-83C7EBF893B0D2251CFAA6258E927528"
      unitRef="usd">40000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="D2015Q4Jun01-Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember"
      decimals="-5"
      id="d54558e879-wk-Fact-260EB182D3A360398D32A6258E9BA758"
      unitRef="usd">20000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <gh:DebtInstrumentVariableRateBasisBaseRate
      contextRef="I2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember"
      decimals="2"
      id="d54558e883-wk-Fact-6E73027CF634E02AA38EA6258E947E86"
      unitRef="number">0.01</gh:DebtInstrumentVariableRateBasisBaseRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember"
      decimals="INF"
      id="d54558e887-wk-Fact-002E1FCA0A64D835882EA6258E99F825"
      unitRef="number">0.0875</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="I2015Q4Dec31_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember"
      decimals="-5"
      id="d54558e891-wk-Fact-EB62A24435DDBC9FA67FA6258E65391F"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <gh:RoyaltyPaymentsPercentageofRevenue
      contextRef="D2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierOneMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember"
      decimals="3"
      id="d54558e898-wk-Fact-F2B236E3434C9673912CA6258E61730D"
      unitRef="number">0.015</gh:RoyaltyPaymentsPercentageofRevenue>
    <gh:RoyaltyAgreementPaymentTierThreshold
      contextRef="I2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierOneMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember"
      decimals="-6"
      id="d54558e902-wk-Fact-F8CCB5C59BB50D7BCC9AA6258E6533DD"
      unitRef="usd">50000000</gh:RoyaltyAgreementPaymentTierThreshold>
    <gh:RoyaltyPaymentsPercentageofRevenue
      contextRef="D2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierTwoMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember"
      decimals="4"
      id="d54558e906-wk-Fact-437554D12857FCA6366BA6258E611746"
      unitRef="number">0.0245</gh:RoyaltyPaymentsPercentageofRevenue>
    <gh:RoyaltyAgreementPaymentTierThreshold
      contextRef="I2015Q4Dec31_gh_RoyaltyAgreementbyPaymentTierAxis_gh_TierTwoMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember"
      decimals="-6"
      id="d54558e910-wk-Fact-D19C75002A5BD61F7A52A6258E97492C"
      unitRef="usd">50000000</gh:RoyaltyAgreementPaymentTierThreshold>
    <us-gaap:RepaymentsOfDebt
      contextRef="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember"
      decimals="-5"
      id="d54558e917-wk-Fact-4900BD8ECDA93AC6B5DDA6258E6389F7"
      unitRef="usd">19800000</us-gaap:RepaymentsOfDebt>
    <gh:PaymentofAccruedInterestDebt
      contextRef="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember"
      decimals="-5"
      id="d54558e921-wk-Fact-8858AE3378C4935BB0FBA6258E9397DB"
      unitRef="usd">700000</gh:PaymentofAccruedInterestDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_CreditAgreementMember"
      decimals="-5"
      id="d54558e925-wk-Fact-618B317CEDEDEB9ADEC1A6258E96CBC8"
      unitRef="usd">1500000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="D2017Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember"
      decimals="-5"
      id="d54558e929-wk-Fact-EEBF1A79994CC8C9BABEA6258E6527E5"
      unitRef="usd">4500000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="I2017Q2Jun30"
      decimals="-5"
      id="d54558e933-wk-Fact-D92FC2FBFF677EA518C9A6258E973BCA"
      unitRef="usd">20700000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d54558e938-wk-Fact-C4D4A0C2B8919F027465A6258E9BFBE0"
      unitRef="usd">-5100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_SeniorLoansMember_us-gaap_DebtInstrumentAxis_gh_RoyaltyAgreementMember"
      decimals="INF"
      id="d54558e942-wk-Fact-6268321BE3C2941A8C4DA6258E96B28F"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C02E51550F9A15757DFCF298FE7E3FB8-0-wk-Fact-B744833B42CD60954E7FF299A03031D7">Leases&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has&#160;entered into various operating lease agreements for office space,&#160;with remaining terms ranging from 1 year to 8 years some of which include one or more options to renew.  As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether we will renew the lease, as such, we do not include renewal options in our lease terms for calculating our lease liability, as the renewal options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these renewal options at the time of the lease commencement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease expense for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; which includes both lease and non-lease components (primarily common area maintenance charges and property taxes).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Rent expense for the facility leases was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended December&#160;31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the weighted-average remaining lease term and weighted-average discount rate for operating leases is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.4 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.77%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our future principal contractual obligations for operating lease commitments as of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.57264957264957%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,534&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,816&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less:  Imputed Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11,496&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,396&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has additional future minimum lease payments relating to a facility agreement had not yet commenced amounting to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (imputed interest of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) net of sublease income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance leases are not material to the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;ASC 840 Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The Company elected&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;modified retrospective transition approach and is required to present previously disclosed information under the prior accounting standards for leases. Total minimum lease payments as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.57264957264957%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,557&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42,178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d55254e882-wk-Fact-C93D5D7DB21104C226857E99085C2787"
      unitRef="usd">4400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d55254e889-wk-Fact-6D745D6F6B7836EF2C99A6258E94D8C1"
      unitRef="usd">4600000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d55254e893-wk-Fact-ABD98A708A2256DA0A05A6258E4137EF"
      unitRef="usd">1800000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q4"
      id="d55254e912-wk-Fact-D24531DBF6068DF3F947787468CE4FD1">P6Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q4"
      decimals="4"
      id="d55254e916-wk-Fact-83A7B31BA08DDD5160017874D71F3C4A"
      unitRef="number">0.0777</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4A58E19D2F9E55D9D6E55A85EEBB9D91-0-wk-Fact-31836988BFA398424C075A860A4A7E74">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our future principal contractual obligations for operating lease commitments as of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.57264957264957%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,534&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,816&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less:  Imputed Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11,496&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,396&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="FI2019Q4"
      decimals="-3"
      id="d55254e996-wk-Fact-0E28E7299195E7C936349841277D13D2"
      unitRef="usd">7582000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q4"
      decimals="-3"
      id="d55254e1011-wk-Fact-D4DDE1CC1C7C6452F5D0984127853353"
      unitRef="usd">7534000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q4"
      decimals="-3"
      id="d55254e1031-wk-Fact-06FFBF6B3137991077A798412775FFD4"
      unitRef="usd">7684000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q4"
      decimals="-3"
      id="d55254e1051-wk-Fact-351600B3087615CFF05B984127489FAB"
      unitRef="usd">8276000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q4"
      decimals="-3"
      id="d55254e1071-wk-Fact-46A4642330C6527A1AFA984127950AE6"
      unitRef="usd">20816000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d55254e1096-wk-Fact-897179A39FD3B5E6A6F29841278D1A6E"
      unitRef="usd">51892000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q4"
      decimals="-3"
      id="d55254e1111-wk-Fact-686F874BBEAD8AE881C19841276CAB23"
      unitRef="usd">11496000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d55254e1137-wk-Fact-93B195EFFEDB975235D398412764C7EE"
      unitRef="usd">40396000</us-gaap:OperatingLeaseLiability>
    <gh:LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability
      contextRef="FI2019Q4"
      decimals="-5"
      id="d55254e1152-wk-Fact-FF6BF00D10702DB3492E7889B6E7CACE"
      unitRef="usd">13700000</gh:LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability>
    <gh:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount
      contextRef="FI2019Q4"
      decimals="-5"
      id="d55254e1156-wk-Fact-BE4F102108E46B600541788B09A0C5D7"
      unitRef="usd">3400000</gh:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedExcessAmount>
    <gh:LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome
      contextRef="FI2019Q4"
      decimals="-5"
      id="d55254e1160-wk-Fact-B0673ACF9D44530A1684788D0579B38F"
      unitRef="usd">100000</gh:LesseeOperatingLeaseLeaseNotYetCommencedSubleaseIncome>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1A8E40CC2D55919BDFB55A8685613CF8-0-wk-Fact-C5ADDF34168AD6341CFE5A86A4A5D656">Total minimum lease payments as of &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.57264957264957%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,557&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42,178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d55254e1251-wk-Fact-C79621EA0041B93E80985A8DB26F312C"
      unitRef="usd">4099000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="FI2018Q4"
      decimals="-3"
      id="d55254e1266-wk-Fact-408647E97376652067C95A8DD82793D8"
      unitRef="usd">5273000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="FI2018Q4"
      decimals="-3"
      id="d55254e1286-wk-Fact-111A610D43D8369BB5DA5A8E0199D994"
      unitRef="usd">5358000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="FI2018Q4"
      decimals="-3"
      id="d55254e1306-wk-Fact-BE1B4607EDAAEE9322D55A8E2E074077"
      unitRef="usd">5557000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="FI2018Q4"
      decimals="-3"
      id="d55254e1326-wk-Fact-46C5DC37EDEFA07426325A8E5868DB41"
      unitRef="usd">6105000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="FI2018Q4"
      decimals="-3"
      id="d55254e1346-wk-Fact-99CAE67ED6985FDB1CCD5A8E80BE468E"
      unitRef="usd">15786000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d55254e1371-wk-Fact-DCF96958530CFD37ADB35A8EA8148B3D"
      unitRef="usd">42178000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7C3B71F77517B8628BACA6258EB8D3E5-0-wk-Fact-B09938E3CF36D194AE2CA6258E9FA8BF">Commitments and Contingencies &lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has patent license agreements with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; different parties. Under these agreements, the Company has made one-time upfront and milestone payments, which it has capitalized and is amortizing to expense ratably over the useful life of the underlying patent right(s). Under some of these agreements, the Company is obligated to pay low single-digit percentage running royalties on net sales where the licensed patent right(s) are used in the product or service sold, subject to minimum annual royalties or fees in certain agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Royalty expenses were included in cost of precision oncology testing on the accompanying consolidated statements of operations. The Company recognized royalty expenses of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and  &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of precision oncology testing revenue in each period, for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, future minimum royalty payments are due as follows regardless of sales amounts:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,607&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total future minimum royalty payments   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: amount representing interest   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Present value of future minimum royalty payments   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Indemnification Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has entered into indemnification agreements with certain directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no such matters have arisen and the Company does not believe that the outcome of any claims under indemnification arrangements will have a material adverse effect on its financial positions, results of operations or cash flows. Accordingly, the Company has not recorded a liability related to such indemnifications as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Security Incidents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with a former employee&#x2019;s complaints alleging non-compliance with applicable provisions of the Health Insurance Portability and Accountability Act of 1996, the Company received requests for information from the Office for Civil Rights, or OCR, of the U.S. Department of Health and Human Services in August 2019. After the Company responded to these requests, the Company was informed by the OCR that it has closed this matter without further action. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Patent Disputes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2016, Foundation Medicine, Inc. (&#x201c;Foundation Medicine&#x201d;) filed a lawsuit for patent infringement against the Company in the United States District Court for the Eastern District of Texas, alleging that the Company infringed Foundation Medicine&#x2019;s patent relating to its tissue biopsy assay technology and seeking compensatory damages and attorneys&#x2019; fees. The Company filed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; petitions for inter partes review (&#x201c;IPR&#x201d;) with the Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) at the U.S. Patent and Trademark Office, challenging the patentability of Foundation Medicine&#x2019;s patent. In July 2018, the Company reached an agreement with Foundation Medicine to settle the lawsuit and resolve the IPRs. As part of the settlement agreement, which was accepted by the PTAB and the United States District Court, &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the Company made a one-time payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to Foundation Medicine. The Company recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as litigation settlement expense, a component of general and administrative expenses, at December 31, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2017, the Company filed separate lawsuits against Foundation Medicine and Personal Genome Diagnostics, Inc. (&#x201c;Personal Genome Diagnostics&#x201d;) in the United States District Court for the District of Delaware, alleging that each of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; companies has infringed a patent relating to the Company&#x2019;s digital sequencing technology. The Company subsequently amended its original complaints in each case to assert infringement of three additional patents relating to its digital sequencing technology. In each lawsuit, the Company is seeking compensatory damages, injunctive relief and attorneys&#x2019; fees. Personal Genome Diagnostics and Foundation Medicine have each asserted counterclaims of patent invalidity and non-infringement. In March 2018, Personal Genome Diagnostics filed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; petitions for post-grant review with the PTAB, challenging the patentability of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the patents asserted by the Company. Prior to reaching a decision on the merits, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; post-grant review petitions were dismissed with prejudice in July 2018. Subsequently,&#160;Foundation Medicine filed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; petitions for inter partes review with the PTAB, challenging the patentability of all four of the patents asserted by the Company, which actions are currently pending at the PTAB. The Company plans to vigorously defend its patent rights during such PTAB actions.&#160;At this time, the Company cannot reasonably ascertain the likelihood that any of the challenged patents will be found to be invalid or unenforceable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;License Dispute&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the Company filed a request for arbitration to the International Chamber of Commerce claiming that one of its licensors, KeyGene N.V. (&#x201c;Licensor&#x201d;), has breached its patent license agreement with the Company. In January 2019, Licensor responded with its answer and counterclaims and alleged that the Company has breached the patent license agreement. The Company subsequently followed up with supplemental claims, for which Licensor responded with its supplemental answer. The Company is seeking damages, declaratory relief and alternative forms of relief including recession and reformation to address Licensor&#x2019;s alleged breaches of the patent license agreement. Licensor is seeking damages, recovery of costs and fees and declaratory relief in addition to the dismissal of the Company&#x2019;s claims. The arbitration is in preliminary stages, and no date has been set for rendering a final decision. At this time, the Company cannot reasonably ascertain the likelihood that any of its claims or Licensor&#x2019;s counterclaims will be heard by the arbitration panel or succeed on the merits.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other Disputes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the first quarter of 2018, the Company settled a commercial dispute. In connection with the settlement, the Company received a payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.25 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was reported as other income in the consolidated statements of operations for the year ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <gh:NumberofPartiesWithPatentLicenseAgreement
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d56022e889-wk-Fact-3CDE37C6ECE0569A3EB2A6258E42C53C"
      unitRef="party">4</gh:NumberofPartiesWithPatentLicenseAgreement>
    <us-gaap:RoyaltyExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d56022e896-wk-Fact-8BB6924A58929DE4E01BA6258E36F332"
      unitRef="usd">4400000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d56022e900-wk-Fact-D0A2B97CF3B68326B885A6258EA07279"
      unitRef="usd">1400000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d56022e904-wk-Fact-84BC5CDD1740120076DFA6258E386245"
      unitRef="usd">1100000</us-gaap:RoyaltyExpense>
    <gh:RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d56022e908-wk-Fact-AC59761931AE5D39FE1DA6258E43F8AA"
      unitRef="number">0.02</gh:RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue>
    <gh:RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d56022e912-wk-Fact-8B641E9B913DDD437C69A6258E99763A"
      unitRef="number">0.02</gh:RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue>
    <gh:RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d56022e917-wk-Fact-2D2810C119BAB7719BF2A6258E45C820"
      unitRef="number">0.02</gh:RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue>
    <us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6D60B49139E78A262681F2A48FF71533-0-wk-Fact-9592D554F51464064E9BF2A4A158A857">As of &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, future minimum royalty payments are due as follows regardless of sales amounts:&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,607&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total future minimum royalty payments   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: amount representing interest   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Present value of future minimum royalty payments   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="FI2019Q4"
      decimals="-3"
      id="d56022e1008-wk-Fact-0160EB6A282421F139B6A6258E44BE7D"
      unitRef="usd">1402000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="FI2019Q4"
      decimals="-3"
      id="d56022e1023-wk-Fact-65C32A1B1AC48FB1BCF5A6258E3D1FF3"
      unitRef="usd">1402000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="FI2019Q4"
      decimals="-3"
      id="d56022e1043-wk-Fact-20F11A80B7E701AF6408A6258E38D1B6"
      unitRef="usd">1682000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="FI2019Q4"
      decimals="-3"
      id="d56022e1063-wk-Fact-FD491ACCDA5DE078ACDCA6258E3CFEF8"
      unitRef="usd">1682000</us-gaap:ContractualObligationDueInFourthYear>
    <gh:ContractualObligationDueInFifthYearAndAfterFifthYear
      contextRef="FI2019Q4"
      decimals="-3"
      id="d56022e1083-wk-Fact-1FBEC5268F94C073E751A6258E45BB9C"
      unitRef="usd">5607000</gh:ContractualObligationDueInFifthYearAndAfterFifthYear>
    <us-gaap:ContractualObligation
      contextRef="FI2019Q4"
      decimals="-3"
      id="d56022e1103-wk-Fact-3BA602FF9746286C5040A6258E3B1613"
      unitRef="usd">11775000</us-gaap:ContractualObligation>
    <gh:ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments
      contextRef="FI2019Q4"
      decimals="-3"
      id="d56022e1123-wk-Fact-8F8F536DE9A646721F26A6258E39707F"
      unitRef="usd">4895000</gh:ContractualObligationFutureMinimumPaymentsInterestAmountIncludedinPayments>
    <gh:ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments
      contextRef="FI2019Q4"
      decimals="-3"
      id="d56022e1149-wk-Fact-118BD7BB49B67C5D0DB1A6258E428997"
      unitRef="usd">6880000</gh:ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments>
    <gh:NumberofPetitionsFiled
      contextRef="D2016Q2May01-May31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member"
      decimals="INF"
      id="d56022e1188-wk-Fact-BCA997D036EB0B362250A6258E3F2BA0"
      unitRef="patent">3</gh:NumberofPetitionsFiled>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="D2018Q3Jul01-Jul31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member"
      decimals="-5"
      id="d56022e1195-wk-Fact-CF983E1DD007041EE190A6258E3284A2"
      unitRef="usd">3000000.0</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationSettlementExpense
      contextRef="D2017Q4Dec31_srt_LitigationCaseAxis_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="d56022e1199-wk-Fact-90C0E48ACCE95196B72DA6258E926D34"
      unitRef="usd">3000000.0</us-gaap:LitigationSettlementExpense>
    <gh:NumberofCompaniesthatInfringedonaPatent
      contextRef="D2017Q4Nov01-Nov30_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member"
      decimals="INF"
      id="d56022e1206-wk-Fact-62742564CC4FBA21466AA6258E98D81F"
      unitRef="company">2</gh:NumberofCompaniesthatInfringedonaPatent>
    <gh:NumberofPetitionsFiled
      contextRef="D2017Q4Nov01-Nov30_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member"
      decimals="INF"
      id="d56022e1210-wk-Fact-0FE4EF63802AAB84963AA6258E9D3FA1"
      unitRef="petition">2</gh:NumberofPetitionsFiled>
    <gh:NumberofAssertedPatents
      contextRef="D2017Q4Nov01-Nov30_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member"
      decimals="INF"
      id="d56022e1214-wk-Fact-91421785F17B6BAC8B2AA6258E9E18F7"
      unitRef="patent">2</gh:NumberofAssertedPatents>
    <gh:NumberofPetitionsFiled
      contextRef="D2017Q4Nov01-Nov30_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member"
      decimals="INF"
      id="d56022e1218-wk-Fact-0FE4EF63802AAB84963AA6258E9D3FA1"
      unitRef="petition">2</gh:NumberofPetitionsFiled>
    <gh:NumberofPetitionsFiled
      contextRef="D2018Q3Jul01-Jul31_srt_LitigationCaseAxis_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member"
      decimals="INF"
      id="d56022e1222-wk-Fact-F7F781115B71AC2B8AAEA6258E4388C4"
      unitRef="petition">6</gh:NumberofPetitionsFiled>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherIncomeMember"
      decimals="-4"
      id="d56022e1238-wk-Fact-72CBA5AD8DBDA0C67DC6A6258E44D944"
      unitRef="usd">4250000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-39B4F28548148354383BA6258EB9FFFF-0-wk-Fact-322386941A47CEE3FF05A6258E4F9176">Common Stock&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s common stockholders are entitled to dividends if and when declared by the Company&#x2019;s Board of Directors (the &#x201c;Board of Directors&#x201d;). As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, no dividends on the Company&#x2019;s common stock had been declared by the Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s common stock has been reserved for the following potential future issuances:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares underlying outstanding stock options   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4,494,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,588,405&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares available for future stock option grants   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,726,225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,556,507&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares available for issuance under the 2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;689,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,911,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,067,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2018, the Board of Directors and its stockholders approved a&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.7378&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-for-one reverse stock split of the Company&#x2019;s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the IPO. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On October 9, 2018, the Company completed the IPO, in which it issued and sold&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,375,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of its common stock at a price of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share. The Company received net proceeds of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$249.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;after deducting underwriting discounts and commissions and offering expenses payable by the Company. All then-outstanding warrants to purchase the Company&#x2019;s common stock were exercised prior to the completion of the IPO.&#160;In addition, in connection with the IPO,&#160;all shares of the Company&#x2019;s then-outstanding convertible preferred stock were automatically converted into&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,264,577&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of its common stock, and all then-outstanding warrants to purchase the Company&#x2019;s convertible preferred stock were automatically converted into warrants to purchase&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,636&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Follow-on Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2019, the Company completed an underwritten public offering, in which it issued and sold&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,175,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of its common stock at a price of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$71.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share. The Company received net proceeds of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$349.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;after deducting underwriting discounts and commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;Warrants&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with a bank loan agreement with a financial institution in September 2013, the Company issued warrants to purchase &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,386&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of Series A convertible preferred stock at an exercise price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.93&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. In October 2014, the Company issued additional warrants to the same financial institution to purchase &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,965&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of Series B convertible preferred stock at an exercise price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.16&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. These preferred stock warrants were converted to warrants to purchase common stock upon the consummation of the IPO and were net exercised into &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,548&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock in October 2018. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;No&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; warrants remained outstanding as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2012, the Company issued to certain investors warrants to purchase&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;495,775&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock. The exercise price of the warrants is&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.14&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share and the warrants have a contractual term through September 2023.  For the year ended&#160;December&#160;31, 2018&#160;and&#160;2017,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;313,741&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89,030&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares, respectively,&#160;were issued upon the exercise of these warrants. As of&#160;December&#160;31, 2017, warrants to purchase&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;313,741&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock were outstanding, and these warrants were fully exercised prior to the consummation of the IPO in October 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-FB058028885B58EFF601A6258EB936C2-0-wk-Fact-C349C02373953CF012ACA6258E53E1BB">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s common stock has been reserved for the following potential future issuances:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares underlying outstanding stock options   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4,494,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,588,405&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares available for future stock option grants   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,726,225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,556,507&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares available for issuance under the 2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;689,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,911,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,067,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d55622e961-wk-Fact-185DBAA426AE4FF343CCF2AC2D659D66"
      unitRef="shares">4494889</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d55622e975-wk-Fact-00698694BCDBE0E3A250A6258E3EFAD8"
      unitRef="shares">7588405</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_gh_SharesAvailableForFutureStockOptionGrantsMember"
      decimals="INF"
      id="d55622e986-wk-Fact-7C1953D0C05D7DB5789BF2AC2D512C49"
      unitRef="shares">2726225</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_gh_SharesAvailableForFutureStockOptionGrantsMember"
      decimals="INF"
      id="d55622e1000-wk-Fact-A5F533B9A5A00391DDF2A6258E3D50C1"
      unitRef="shares">3556507</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d55622e1011-wk-Fact-67E9E290E5A5A3C7BF6D5ACABBBCDE68"
      unitRef="shares">689917</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d55622e1025-wk-Fact-7840158B91889CEA32E65ACABF4C9AE1"
      unitRef="shares">922250</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2019Q4"
      decimals="INF"
      id="d55622e1036-wk-Fact-5343D12B2071A7DBAA06A6258E2D0232"
      unitRef="shares">7911031</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2018Q4"
      decimals="INF"
      id="d55622e1050-wk-Fact-EC281575EAB8E7AF6E06A6258E3D3DC4"
      unitRef="shares">12067162</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="D2018Q3Sep01-Sep30"
      decimals="INF"
      id="d55622e1063-wk-Fact-66B2F4323D6BD6FFE53BF2B2FEB63B25"
      unitRef="number">0.7378</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
      decimals="INF"
      id="d55622e1082-wk-Fact-62ADFC804E8296F676A5F2B33A4FCB14"
      unitRef="shares">14375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I2018Q4Oct9_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
      decimals="2"
      id="d55622e1086-wk-Fact-6D513932D4FBBB2C60FBA6258E6A82E0"
      unitRef="usdPerShare">19.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="D2018Q4Oct9"
      decimals="-5"
      id="d55622e1090-wk-Fact-BA0280F25241ED78C2F1F2B3A82C35B6"
      unitRef="usd">249500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="D2018Q4Oct9_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d55622e1094-wk-Fact-753899F125885BECC4ECF2B3E5AA13CB"
      unitRef="shares">58264577</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="D2018Q4Oct9_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d55622e1098-wk-Fact-B13F866F794BE51D627CF2B42DE714B8"
      unitRef="shares">7636</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2019Q2May_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d55622e1112-wk-Fact-1301C8E4E7E524C306B3F2B46A15C403"
      unitRef="shares">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="I2019Q2May31"
      decimals="2"
      id="d55622e1116-wk-Fact-F06F402A4E13A768B030F2B4DAB273DD"
      unitRef="usdPerShare">71.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="D2019Q2May_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d55622e1120-wk-Fact-D464BB361B62C516613DF2B511F5A70E"
      unitRef="usd">349700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="I2013Q3Sep30_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="d56154e875-wk-Fact-0EC1AFAC94857AEE6E09A6258E95B9E7"
      unitRef="shares">5386</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I2013Q3Sep30_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="d56154e879-wk-Fact-34FDBACD8EF1C1EA3994A6258E95A11F"
      unitRef="usdPerShare">0.93</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="I2014Q4Oct31_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="d56154e883-wk-Fact-775B4FBD10F5A384BAB0A6258E979811"
      unitRef="shares">4965</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I2014Q4Oct31_us-gaap_ClassOfWarrantOrRightAxis_gh_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="d56154e887-wk-Fact-332916907DF7E134E82EA6258E969675"
      unitRef="usdPerShare">3.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gh:StockIssuedDuringPeriodSharesExerciseofWarrants
      contextRef="D2018Q4Oct01-Oct31"
      decimals="INF"
      id="d56154e891-wk-Fact-C7083C5A034715F3A6C4A6258E95079C"
      unitRef="shares">6548</gh:StockIssuedDuringPeriodSharesExerciseofWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="d56154e896-wk-Fact-9717F86972FA0E75F170A6258E993B08"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="I2012Q4Dec31"
      decimals="INF"
      id="d56154e907-wk-Fact-3C3B6EDD32248B2B3329F2C0074C6118"
      unitRef="shares">495775</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I2012Q4Dec31"
      decimals="INF"
      id="d56154e911-wk-Fact-ECD3B8293DFE3C8BDA71F2C09092204D"
      unitRef="usdPerShare">0.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gh:StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d56154e915-wk-Fact-D44CD555569EB47868C8F2C1181D3F6A"
      unitRef="shares">313741</gh:StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO>
    <gh:StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d56154e919-wk-Fact-F14074B09A9B1A615F51F2C12F056CA5"
      unitRef="shares">89030</gh:StockIssuedDuringPeriodSharesExerciseofWarrantsPriortoIPO>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="FI2017Q4"
      decimals="INF"
      id="d56154e923-wk-Fact-6EFC8C5A08CEDEB1F44AF2CA95976E13"
      unitRef="shares">313741</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:PreferredStockTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-091DE5FB7AD0018EA8B1A6258EB942C7-0-wk-Fact-D677A8DF0369CD7432A3A6258E629D66">Convertible Preferred Stock&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company previously issued convertible preferred stock in one or more series, each with such designations, rights, qualifications, limitations, and restrictions as set forth in the Company&#x2019;s certificate of incorporation, as in effect prior to the IPO. Immediately prior to the completion of the IPO, as described in Note 1,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Description of Business&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, all shares of convertible preferred stock then outstanding were automatically converted to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,264,577&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock at the respective conversion ratios in October 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2017, the Company entered into the Series E convertible preferred stock purchase agreement with SoftBank and certain of the Company&#x2019;s existing stockholders. Pursuant to the purchase agreement, the Company issued and sold an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,174,246&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of Series E convertible preferred stock at a purchase price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.3936&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, for an aggregate purchase price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$320.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The purchase agreement also provided that the Company would issue additional shares of Series E convertible preferred stock to the Series E investors in such an amount as to cause SoftBank&#x2019;s equity ownership in the Company to equal &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the Company&#x2019;s outstanding fully-diluted capital stock measured &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days after the initial closing. This gross-up was intended to enable the Company to engage in various repurchases of its equity from existing stockholders and still maintain SoftBank&#x2019;s equity ownership at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&#160;As a result, in July 2017, the Company repurchased an aggregate of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,588,065&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock from certain of its directors and executive officers for a purchase price of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.23887&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share, which represented a price equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the original price per shares for the Series E convertible preferred stock, as adjusted to reflect the&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.7378&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-for-one reverse stock split of the Company&#x2019;s common stock effected on September 19, 2018. The Company also engaged in a tender offer pursuant to which it repurchased&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;131,243&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock from certain employees at the same per share price paid for the Series E convertible preferred stock as adjusted to reflect the&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.7378&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-for-one reverse stock split of the Company&#x2019;s common stock effected on September 19, 2018, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;666,920&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of Series A convertible preferred stock from existing stockholders at a purchase price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share of Series A convertible preferred stock. Following these repurchases, in October 2017, the Company issued an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;796,346&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of Series E convertible preferred stock to the Series E investors for a purchase price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.00001&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share pursuant to the terms of the gross up provision. The conversion price of Series E convertible preferred stock was adjusted as a result of the dilutive issuance of Series E convertible preferred stock under the gross up provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2017, in accordance with its certificate of incorporation then in effect, the Company adjusted the conversion price of Series D convertible preferred stock from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.1338&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.8329&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. The Company accounted for the transaction as a modification. A deemed dividend of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, calculated as the additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;253,361&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock to be received upon the conversion of the Series D convertible preferred stock after the conversion ratio adjustment, multiplied by the then current fair value of the Company&#x2019;s common stock, was reported as an increase to net loss attributable to common stockholders for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Repurchase of Series A Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the year ended December 31, 2017, the Company repurchased&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;666,920&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of outstanding Series A convertible preferred stock at a price of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share for a total consideration of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The difference between the repurchase amount and the carrying value of these shares of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;was recorded as a deemed dividend in accumulated deficit on the accompanying consolidated statements of stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
    <gh:StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d56267e879-wk-Fact-1CF4CE1BEE8AE5801550AF7C04BAFEDC"
      unitRef="shares">58264577</gh:StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember"
      decimals="INF"
      id="d56267e890-wk-Fact-609BF8B2EC518E03972FA6258E50F012"
      unitRef="shares">38174246</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I2017Q2May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember"
      decimals="INF"
      id="d56267e894-wk-Fact-E43B29BE3936C33B8BE3A6258E51B5C3"
      unitRef="usdPerShare">8.3936</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember"
      decimals="-5"
      id="d56267e898-wk-Fact-04460944FA670E5BD3B7A6258E62703E"
      unitRef="usd">320400000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <gh:ThresholdPercentageofNewSharesIssued
      contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember"
      decimals="INF"
      id="d56267e902-wk-Fact-4A5C2537694FCF7DFD80A6258E6EF97E"
      unitRef="number">0.35</gh:ThresholdPercentageofNewSharesIssued>
    <gh:ThresholdPeriodAfterInitialClosingtoIssueNewShares
      contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember"
      id="d56267e906-wk-Fact-FCE220F8398CFB595620A6258E4B5FE6">P70Y</gh:ThresholdPeriodAfterInitialClosingtoIssueNewShares>
    <gh:ThresholdPercentageofNewSharesIssued
      contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_gh_SoftBankMember_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember"
      decimals="INF"
      id="d56267e911-wk-Fact-4A5C2537694FCF7DFD80A6258E6EF97E"
      unitRef="number">0.35</gh:ThresholdPercentageofNewSharesIssued>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="D2017Q3Jul01-Jul31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d56267e915-wk-Fact-B1FD96DE59E91446F626A6258E605914"
      unitRef="shares">1588065</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="D2017Q3Jul01-Jul31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="5"
      id="d56267e919-wk-Fact-187C53FA06B4AEFABBCCA6258E623271"
      unitRef="usdPerShare">10.23887</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <gh:PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock
      contextRef="D2017Q3Jul01-Jul31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d56267e923-wk-Fact-E96893E4800EFD420309A6258E634923"
      unitRef="number">0.90</gh:PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="D2018Q3Sep19"
      decimals="INF"
      id="d56267e927-wk-Fact-F00D389237F914004969A6258E6A529E"
      unitRef="number">0.7378</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="D2017Q3Aug01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d56267e931-wk-Fact-DF1107AF5C3C2F92A428A6258E5E8376"
      unitRef="shares">131243</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="D2018Q3Sep19"
      decimals="INF"
      id="d56267e936-wk-Fact-F00D389237F914004969A6258E6A529E"
      unitRef="number">0.7378</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="d56267e940-wk-Fact-C962A0B82E54C63AFD72A6258E5EB61F"
      unitRef="shares">666920</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="2"
      id="d56267e944-wk-Fact-69676FBA403CC02D9BC3A6258E6F206A"
      unitRef="usdPerShare">8.00</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="D2017Q4Oct01-Oct31_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember"
      decimals="INF"
      id="d56267e948-wk-Fact-1756DBA8DC3F7224A13CA6258E5C5AEC"
      unitRef="shares">796346</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="I2017Q4Oct31_us-gaap_StatementClassOfStockAxis_gh_SeriesEConvertiblePreferredStockMember"
      decimals="5"
      id="d56267e952-wk-Fact-FA8C4F792E233B3E730EA6258E50D4F3"
      unitRef="usdPerShare">0.00001</us-gaap:SharesIssuedPricePerShare>
    <gh:ConvertiblePreferredStockConversionPrice
      contextRef="D2017Q2Apr30"
      decimals="INF"
      id="d56267e959-wk-Fact-5C4A9F6B5FC59093646CA6258E56B84A"
      unitRef="usdPerShare">10.1338</gh:ConvertiblePreferredStockConversionPrice>
    <gh:ConvertiblePreferredStockConversionPrice
      contextRef="D2017Q2May01-May31"
      decimals="INF"
      id="d56267e963-wk-Fact-09B02A4261E4597F2624A6258E6C0D11"
      unitRef="usdPerShare">9.8329</gh:ConvertiblePreferredStockConversionPrice>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d56267e967-wk-Fact-50C0567FC5367E4EA3ECA6258E661B35"
      unitRef="usd">1100000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsShares
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d56267e971-wk-Fact-84DB369356091935B2EBA6258E58C9A0"
      unitRef="shares">253361</us-gaap:PreferredStockDividendsShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="d56267e985-wk-Fact-87BCCBD138266C4F7015F2D31B5E1BAC"
      unitRef="shares">666920</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="2"
      id="d56267e989-wk-Fact-2A7A7011EEC4F038AE9BF2D3708BFA27"
      unitRef="usdPerShare">8.00</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="-5"
      id="d56267e993-wk-Fact-0B8E6D8301748E7BF121F2D43280EE5F"
      unitRef="usd">5300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="-5"
      id="d56267e997-wk-Fact-818EFA0EDF4CDEAA4DBCF2D4B47F2A8F"
      unitRef="usd">4700000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-907E8A30B5E54A4B050AA6258EBA3AA5-0-wk-Fact-1E0C7E22D9846A1889DFA6258E564CF5">Stock-Based Compensation&lt;div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2012 Stock Plan and 2018 Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2012 and September 2018, the Company&#x2019;s Board of Directors adopted and its stockholders approved the Company&#x2019;s 2012 Stock Plan (as amended and restated, the &#x201c;2012 Plan&#x201d;) and the Company&#x2019;s 2018 Incentive Award Plan (the &#x201c;2018 Plan&#x201d;), respectively, under which the Company may grant cash and equity incentive awards such as stock options, restricted shares, stock units and stock appreciation rights to its employees and non-employees. Stock options granted may be either incentive stock options or nonstatutory stock options. Shares issued under the 2018 Plan may be authorized but unissued shares, or shares purchased in the open market or treasury shares. Upon effectiveness of the 2018 Plan in connection with the IPO in October 2018, the 2012 Plan was terminated and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;508,847&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares reserved under the 2012 Plan were forfeited. Any outstanding awards granted under the 2012 Plan remain outstanding, subject to the terms of the 2012 Plan and applicable award agreement, and further cancellation of awards granted under the 2012 Plan are not available for grant in the future. No further grants will be made under the 2012 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of the Company&#x2019;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Available for Grant&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares Subject to Options Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,698,790&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,391,052&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;padding-left:2px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,658,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(508,847&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,088,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,088,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,007,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;795,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(883,899&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Repurchase of early exercised shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,556,507&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,588,405&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;padding-left:2px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;250,495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(324,579&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;324,579&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,999,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(418,676&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Repurchase of early exercised shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,244,564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,494,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;306,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and Exercisable as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,908,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;139,337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$218.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The weighted-average grant date fair value of options granted was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$52.37&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.17&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future stock-based compensation for unvested options as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$26.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2019, the Company modified one of the performance based awards issued to a nonemployee which resulted in reversal of expense of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; due to options not vested.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of the Company&#x2019;s restricted stock unit activity under the 2012 Plan and the 2018 Plan and related information   is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;567,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(22,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47.78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(49,086&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;496,131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:14px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:14px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:14px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:14px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future stock-based compensation for unvested restricted stock units as of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$36.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized over a weighted-average period of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock&#x2011;Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the effect of employee and non&#x2011;employee related stock&#x2011;based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of precision oncology testing   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;512&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;507&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales and marketing expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,716&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,954&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,670&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Valuation of Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Starting January 1, 2019, the Company adopted ASU 2018-07 which aligns the accounting treatment of nonemployee awards with employee awards, and the fair value of stock options issued to employees and nonemployee consultants are both determined as of the grant date.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The grant date fair value of employee and nonemployee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.50 &#x2013; 6.22&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.01 &#x2013; 6.51&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;6.02 &#x2013; 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;63.2% &#x2013; 68.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;68.7% &#x2013; 78.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;74.1% &#x2013; 75.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.6% &#x2013; 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.5% &#x2013; 3.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.9% &#x2013; 2.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company&#x2019;s common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prior to the IPO, the grant date fair value of the Company&#x2019;s common stock was determined by the Company&#x2019;s Board of Directors with the assistance of management and an independent third-party valuation specialist. The grant date fair value of the Company&#x2019;s common stock was determined using valuation methodologies which utilizes certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;common stock, the methodologies used to estimate the enterprise value of the Company were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Subsequent to the IPO, the fair value of the Company&#x2019;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Expected Term&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Expected Volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prior to the commencement of trading of the Company&#x2019;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company&#x2019;s common stock. Due to limited historical data for the trading of the Company&#x2019;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;zero&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2018, the Company&#x2019;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). A total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922,250&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock are initially reserved for issuance under the ESPP. The number of shares may be increased in accordance with the terms of the ESPP. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;of their earnings for the purchase of the Company&#x2019;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;of the fair market value of the Company&#x2019;s common stock on the first or last day of the offering period, whichever is lower. The initial offering period ran from October&#160;2, 2018 to January 31, 2019, the second offering period ran from February 1, 2019 to July 31, 2019, and the third offering period began on August 1, 2019 and ran to November 14, 2019. On a going forward basis, the ESPP will provide for separate&#160;six-month offering periods beginning on May 15 and November 15 of each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;232,333&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares were purchased under the ESPP. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;No&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares were purchased under the ESPP during the year ended December 31, 2018. The total compensation expense related to the ESPP for year ended&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.29 &#x2013; 0.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.33&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;58.8% &#x2013; 60.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;43.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.6% &#x2013; 2.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future stock-based compensation under the ESPP as of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019 was&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liabilities for Early Exercise of Employee Options&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company allowed certain stock option holders to exercise unvested options to purchase shares of the Company&#x2019;s common stock. Shares received from such early exercises are subject to repurchase in the event of the optionee&#x2019;s employment termination, at the original issuance price, until the options are fully vested.  As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,981&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,268&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were subject to repurchase at weighted-average price of    &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.66&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the cash proceeds received for unvested shares of common stock of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2&lt;/span&gt;&lt;/span&gt; million was recorded within other long-term liabilities on the consolidated balance sheet, respectively. The shares issued pursuant to unvested options have been included in shares issued and outstanding on the consolidated balance sheet and consolidated statement of redeemable noncontrolling interest and stockholders&#x2019; equity as such shares are considered legally outstanding.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross
      contextRef="D2018Q4Oct01-Oct31"
      decimals="INF"
      id="d61512e878-wk-Fact-2698E141E89E352BBA1F789BC55C3C23"
      unitRef="shares">508847</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1237CF052B25A7DA5450A6258EBAA0FF-0-wk-Fact-699891A9F7F78899FA67A6258E58CACC">&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of the Company&#x2019;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Available for Grant&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares Subject to Options Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,698,790&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,391,052&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;padding-left:2px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,658,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(508,847&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,088,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,088,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,007,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;795,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(883,899&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Repurchase of early exercised shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,556,507&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,588,405&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;padding-left:2px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;250,495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(324,579&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;324,579&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,999,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(418,676&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Repurchase of early exercised shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,244,564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,494,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;306,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and Exercisable as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,908,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;139,337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2017Q4"
      decimals="INF"
      id="d61512e1252-wk-Fact-32339A7F1B0D1B539C41A6258E43517B"
      unitRef="shares">1698790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2017Q4"
      decimals="INF"
      id="d61512e1266-wk-Fact-EE72805FE1A89A9E899CA6258E44114A"
      unitRef="shares">7391052</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2017Q4"
      decimals="2"
      id="d61512e1285-wk-Fact-664359953086E5BA1FCFA6258EA38310"
      unitRef="usdPerShare">3.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2017Q4YTD"
      id="d61512e1300-wk-Fact-700E092FA0570D60F488A6258E91F04F">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d61512e1315-wk-Fact-A4F0AFD91904AA36107EA6258E455822"
      unitRef="usd">3325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d61512e1330-wk-Fact-190B103497FB59635A98A6258E928084"
      unitRef="shares">3658602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d61512e1410-wk-Fact-493E36020F48967BB2F7AF61C0E5F3BD"
      unitRef="shares">508847</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d61512e1491-wk-Fact-3DF7DDCEEC995EBF9E92A6258E41FFB0"
      unitRef="shares">2088639</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d61512e1506-wk-Fact-C02161AA2946C69E231FA6258E3E731E"
      unitRef="shares">2088639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d61512e1520-wk-Fact-3996820A5217681C704EA6258EA3F981"
      unitRef="usdPerShare">7.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d61512e1571-wk-Fact-7C4B7234CE8D520BB438AF67F3B74EE9"
      unitRef="shares">0</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d61512e1585-wk-Fact-FFEF43FE62B6E7F07529A6258EA79728"
      unitRef="shares">1007387</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d61512e1600-wk-Fact-D61EE7F872BF2566795BA6258E3C585B"
      unitRef="usdPerShare">3.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d61512e1651-wk-Fact-06AD82A31CB1558C2436A6258E4303D1"
      unitRef="shares">795371</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d61512e1665-wk-Fact-FD895EE10C8C6A0034B4A6258EA01EF5"
      unitRef="shares">883899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d61512e1680-wk-Fact-5281B11E50C88227BF90A6258E3F5828"
      unitRef="usdPerShare">4.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d61512e1731-wk-Fact-09AFA3AF4B8CD2F95A2BAF68DAAD7C97"
      unitRef="shares">1230</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2018Q4"
      decimals="INF"
      id="d61512e1812-wk-Fact-1F9C9555A99E00D8784BA6258EA2F955"
      unitRef="shares">3556507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q4"
      decimals="INF"
      id="d61512e1826-wk-Fact-8B30EE4A348B5293AE8CA6258E2A7197"
      unitRef="shares">7588405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q4"
      decimals="2"
      id="d61512e1845-wk-Fact-9FB10817AF46E99A023BA6258E9C39A8"
      unitRef="usdPerShare">4.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD"
      id="d61512e1860-wk-Fact-FC00A8D3F487ACA23C04A6258E421D5A">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d61512e1870-wk-Fact-4E5C350C939500AEEE94A6258E43E2BD"
      unitRef="usd">250495000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d61512e1890-wk-Fact-23EA3F1E547057B77979A6258E40EC93"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d61512e1970-wk-Fact-1747F80411D923907574A6258E4B8513"
      unitRef="shares">0</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d61512e2050-wk-Fact-2294A855D745208B9570A6258E9F39A7"
      unitRef="shares">324579</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d61512e2065-wk-Fact-AB58A2276F83627210D1A6258EA890DF"
      unitRef="shares">324579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d61512e2079-wk-Fact-F6C7A3E1416569BA0AD4A6258EA1E823"
      unitRef="usdPerShare">88.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d61512e2130-wk-Fact-BA88507F0AFF7D883CA8AF688D1171B8"
      unitRef="shares">0</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantExercisedinPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d61512e2144-wk-Fact-E1660D3408341BCD3F21A6258E40B6AE"
      unitRef="shares">2999419</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d61512e2159-wk-Fact-C7937BD4156EC8809635A6258E3FA894"
      unitRef="usdPerShare">3.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d61512e2210-wk-Fact-7CFD27023140FCAEC72CA6258E94C608"
      unitRef="shares">12636</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d61512e2224-wk-Fact-9799F33F128332B19D57A6258E9E33ED"
      unitRef="shares">418676</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d61512e2239-wk-Fact-CF9FC9790CB676E1B57BA6258E2A6B97"
      unitRef="usdPerShare">6.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d61512e2290-wk-Fact-33A852BBBD00EA628175A6258E45EC67"
      unitRef="shares">0</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q4"
      decimals="INF"
      id="d61512e2370-wk-Fact-83C3AF72C8487BE15D12A6258E98640C"
      unitRef="shares">3244564</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4"
      decimals="INF"
      id="d61512e2384-wk-Fact-663A610EC22F88449182A6258E3EC19E"
      unitRef="shares">4494889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d61512e2403-wk-Fact-55C7B3C2046A1732EEBFA6258E3B190C"
      unitRef="usdPerShare">10.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2019Q4YTD"
      id="d61512e2418-wk-Fact-7399E8930D32E9556498A6258E4094F4">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d61512e2433-wk-Fact-04F1680A81A274CAD11BA6258E2A7A20"
      unitRef="usd">306392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="FI2019Q4"
      decimals="INF"
      id="d61512e2463-wk-Fact-7584C6B29E3F0EDCDF25A6258E421447"
      unitRef="shares">1908216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d61512e2482-wk-Fact-D6D7B6A161830880879FA6258E3F6228"
      unitRef="usdPerShare">5.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q4YTD"
      id="d61512e2497-wk-Fact-65973B1803D33EFE2802A6258E91F1E7">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="FI2019Q4"
      decimals="-3"
      id="d61512e2512-wk-Fact-6005C09258959E0D9F4BA6258E9ACE54"
      unitRef="usd">139337000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d61512e2524-wk-Fact-408531BF56E5C560A671A6258E527D30"
      unitRef="usd">218200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d61512e2528-wk-Fact-441D3DF9C7851F2CA9FFA6258E4D7DC9"
      unitRef="usd">8400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d61512e2532-wk-Fact-951BBD4B96D32F45C829A6258E4E8192"
      unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d61512e2552-wk-Fact-761C6B71AC7596A8311CA6258E55FE60"
      unitRef="usdPerShare">52.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d61512e2556-wk-Fact-64ABDD3EBE55E884F5C2A6258E5F7FC3"
      unitRef="usdPerShare">5.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d61512e2560-wk-Fact-B7F7F454C7C7099E4743A6258E596116"
      unitRef="usdPerShare">2.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d61512e2584-wk-Fact-E2AC45143992C94DCB02A6258E593E21"
      unitRef="usd">26000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d61512e2588-wk-Fact-D14E51B362696236CD3CA6258E4C0E69">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <gh:ReversalOfStockBasedCompensationExpense
      contextRef="D2019Q4Dec"
      decimals="-5"
      id="d61512e2595-wk-Fact-9EDCF03C8057AC444D4378A06F50380E"
      unitRef="usd">1000000.0</gh:ReversalOfStockBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E59AD59F857DE810548FF2DA944D9F56-0-wk-Fact-B75C4CD9FA87B527E58CF2DAC88BF773">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of the Company&#x2019;s restricted stock unit activity under the 2012 Plan and the 2018 Plan and related information   is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;567,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(22,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47.78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(49,086&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;496,131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:14px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:14px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:14px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:14px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d61512e2706-wk-Fact-E5C6422323F578581722F2E79C6D9203"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d61512e2725-wk-Fact-56FB989A468AA7428235F2E79E5451E9"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d61512e2740-wk-Fact-933EA7D2392FA12493B57E9A9874D785"
      unitRef="shares">567425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d61512e2754-wk-Fact-D961FDED1AF43909B748F2E7A193AD86"
      unitRef="usdPerShare">78.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d61512e2774-wk-Fact-E481F5B87E12EB53EB17F2E7A2F102C6"
      unitRef="shares">22208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d61512e2789-wk-Fact-CC58DD7068623337C82EF2E7A55622E0"
      unitRef="usdPerShare">47.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d61512e2809-wk-Fact-A5C94CE29D4AD57149E77E9A987D14B9"
      unitRef="shares">49086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d61512e2824-wk-Fact-D45B0C2E21E92295A6ECF2E7A8016FA5"
      unitRef="usdPerShare">57.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d61512e2844-wk-Fact-C0563BDA5A06C77A0A1AF2E7A8C63938"
      unitRef="shares">496131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d61512e2863-wk-Fact-225EFD4FD8E938E2155CF2E7A9E3099B"
      unitRef="usdPerShare">82.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d61512e2916-wk-Fact-83BABE1758EF5BF3926EF2F9CAC38019"
      unitRef="usd">36500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d61512e2920-wk-Fact-EA64A3CFA7053C176DE4F2FB91E43C2D">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9E228F75D6C541CDE480A6258EBA0BAD-0-wk-Fact-C2D50DEF208FD27A0628A6258E73CD44">&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the effect of employee and non&#x2011;employee related stock&#x2011;based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of precision oncology testing   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;512&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;507&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales and marketing expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,716&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,954&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,670&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember"
      decimals="-3"
      id="d61512e3214-wk-Fact-4FE09771B9BE5EBD17AFA6258E77546C"
      unitRef="usd">863000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember"
      decimals="-3"
      id="d61512e3233-wk-Fact-397F7D70F83CF2C7B493A6258E870297"
      unitRef="usd">512000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_gh_PrecisionOncologyTestingMember"
      decimals="-3"
      id="d61512e3252-wk-Fact-334FAE2A5F9BF2D01D87A6258E77745F"
      unitRef="usd">162000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d61512e3268-wk-Fact-830812F0A6471074EF67A6258E8C8F0F"
      unitRef="usd">5907000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d61512e3287-wk-Fact-D3AE418DDF1F46701067A6258E783DDC"
      unitRef="usd">1684000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d61512e3306-wk-Fact-BB696C90052F1D431942A6258E6B95F2"
      unitRef="usd">507000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="d61512e3327-wk-Fact-DB861C124E9F5B969FBFA6258E8C8E4C"
      unitRef="usd">4716000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="d61512e3346-wk-Fact-EA19E802EB7A329F9A5BA6258E756ECD"
      unitRef="usd">1727000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="d61512e3365-wk-Fact-AA8C115C9B1413D24789A6258E86168A"
      unitRef="usd">80000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d61512e3386-wk-Fact-442B1011B7CDD77ABBE0A6258E896D8A"
      unitRef="usd">5468000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d61512e3405-wk-Fact-5E3FAD61FA3E8BDB550EA6258E857106"
      unitRef="usd">2928000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d61512e3424-wk-Fact-5C019454E9C59E70B521A6258E772DC3"
      unitRef="usd">2921000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d61512e3450-wk-Fact-C6C1619F66C53495E91BA6258E8ED626"
      unitRef="usd">16954000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d61512e3469-wk-Fact-9874A7596968C66EB931A6258E8693AB"
      unitRef="usd">6851000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d61512e3488-wk-Fact-1F479EFDF42FA1FEFAA6A6258E9311FB"
      unitRef="usd">3670000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-A3F8CC4F7D247A30B610A6258EB90DDA-0-wk-Fact-CC46C772C6AE792264B5A6258E5AF305">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The grant date fair value of employee and nonemployee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.50 &#x2013; 6.22&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.01 &#x2013; 6.51&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;6.02 &#x2013; 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;63.2% &#x2013; 68.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;68.7% &#x2013; 78.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;74.1% &#x2013; 75.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.6% &#x2013; 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.5% &#x2013; 3.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.9% &#x2013; 2.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d61512e3756-wk-Fact-0CF356A38BD7E01D9FE2A6258E594991"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d61512e3766-wk-Fact-D03B1DDD4BA510B37404884DEEC55D63"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d61512e3776-wk-Fact-956C1320747A057FA031884E00A7536F"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d61512e3826-wk-Fact-0CF356A38BD7E01D9FE2A6258E594991"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="d61512e3840-wk-Fact-E95928C1BAAE5D2762FCA6258E55AA85"
      unitRef="shares">922250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d61512e3847-wk-Fact-9EE279C031A1DA097D7CF34AC676446E"
      unitRef="number">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d61512e3851-wk-Fact-A426AF1B3DE406E5CF49F34B09705DA8"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d61512e3862-wk-Fact-85EFBF03B988BDF96480F309DAFC9846"
      unitRef="shares">232333</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d61512e3866-wk-Fact-68CDA95A0B77A4D9ED06F349392875DB"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d61512e3879-wk-Fact-FCD12B99A6871CC5CE4CF30842B06218"
      unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_gh_A2018EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d61512e3883-wk-Fact-E6B8A1B4910532C168ABA6258E535A7C"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1A0C193E689C3BCADC07F2DF991D5B2A-0-wk-Fact-EF16A07782C5C05BB775F2DFB572D8C2">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP: &lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.29 &#x2013; 0.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.33&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;58.8% &#x2013; 60.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;43.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.6% &#x2013; 2.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d61512e4106-wk-Fact-5125433A8B7400AAA5F0884F08E588A0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d61512e4116-wk-Fact-4AA21D2F0C0D137B553B884F17D54257"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="-5"
      id="d61512e4136-wk-Fact-A1F525057EA060EC7870F31AA4C7BDC7"
      unitRef="usd">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d61512e4142-wk-Fact-14F7869118B228979EE2F31AE3B1D93F">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <gh:CommonStockSubjecttoRepurchaseorCancellation
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d61512e4160-wk-Fact-5FA851AB369FD45882ACF31BD5AC6BCE"
      unitRef="shares">23981</gh:CommonStockSubjecttoRepurchaseorCancellation>
    <gh:CommonStockSubjecttoRepurchaseorCancellation
      contextRef="D2018Q4Dec31"
      decimals="INF"
      id="d61512e4164-wk-Fact-C39E887E577F396D53B0A6258E52A389"
      unitRef="shares">44268</gh:CommonStockSubjecttoRepurchaseorCancellation>
    <gh:WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare
      contextRef="FI2018Q4"
      decimals="2"
      id="d61512e4168-wk-Fact-DB353BD528BE51A01D4DA6258E540256"
      unitRef="usdPerShare">4.66</gh:WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d61512e4181-wk-Fact-26BBCCD31354E033B8A4F31E355BD2A4"
      unitRef="usd">100000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d61512e4185-wk-Fact-930EBED188B237767E3BF34838EECEC4"
      unitRef="usd">200000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EE144B3EE32AC293DDC9A6258EBA515F-0-wk-Fact-60ED24339D1217751650A6258E6CF805">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(67,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(84,263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Adjustment of redeemable noncontrolling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to Guardant Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(75,651&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(85,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deemed dividend related to repurchase of Series A convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,716&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deemed dividend related to change in conversion rate of Series D convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(75,651&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(85,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(88,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock (on an as if converted basis)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,976&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,527&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ESPP obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Preferred stock warrants (on an as if converted basis)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock subject to repurchase&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51,707&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-748C48DDC853CD5D3B3AA6258EBA660A-0-wk-Fact-2B93B30838EC17A09AFDA6258E6B8A06">&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(67,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(84,263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Adjustment of redeemable noncontrolling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to Guardant Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(75,651&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(85,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deemed dividend related to repurchase of Series A convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,716&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deemed dividend related to change in conversion rate of Series D convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(75,651&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(85,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(88,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d58146e1159-wk-Fact-DD9CA72B1BBB5CC40BD8A6258E32F7EC"
      unitRef="usd">-67851000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d58146e1179-wk-Fact-4A8DB7FF4A717BAB2EA3A6258E443A47"
      unitRef="usd">-84263000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d58146e1199-wk-Fact-FF90E30B64F2C7FBE5B5A6258EA91FF9"
      unitRef="usd">-83221000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d58146e1216-wk-Fact-D077CEFD0B079FCF3D61A6258E2E6647"
      unitRef="usd">7800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d58146e1236-wk-Fact-31CADB87CCF74DD2F2C1A6258E34EF14"
      unitRef="usd">800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d58146e1256-wk-Fact-418F0527488BE40C35CDA6258E2FA7B8"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d58146e1277-wk-Fact-0C6706E1876259798ED2A6258E385A17"
      unitRef="usd">-75651000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d58146e1297-wk-Fact-DA7C32E8FAD7508D2E32A6258E8265E9"
      unitRef="usd">-85063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d58146e1317-wk-Fact-AFCDBD0520C9E2C5AB33A6258E29D834"
      unitRef="usd">-83221000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="-3"
      id="d58146e1339-wk-Fact-E68A8C708E2097EC5946A6258E9E2226"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="-3"
      id="d58146e1358-wk-Fact-EBA109E0CAADBD273C7BA6258E32AF46"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesAConvertiblePreferredStockMember"
      decimals="-3"
      id="d58146e1377-wk-Fact-1FF0D1ABEA05EF2C682AA6258E3BA553"
      unitRef="usd">4716000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember"
      decimals="-3"
      id="d58146e1399-wk-Fact-26F1F32EB6B9B7D7D5A6A6258E3AC275"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember"
      decimals="-3"
      id="d58146e1418-wk-Fact-E839DF2B5D3BDD98BBBDA6258E87AB93"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_gh_SeriesDConvertiblePreferredStockMember"
      decimals="-3"
      id="d58146e1437-wk-Fact-A468E27BF4939F5E8D3EA6258E447BE2"
      unitRef="usd">1058000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d58146e1464-wk-Fact-1535B29FF0DAB4B154A2A6258E365584"
      unitRef="usd">-75651000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d58146e1484-wk-Fact-6133CF14439345C7338DA6258E9D2D95"
      unitRef="usd">-85063000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d58146e1504-wk-Fact-28A37E9521F9874504E6A6258E35A77C"
      unitRef="usd">-88995000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d58146e1526-wk-Fact-431CA7CCFD12D7D5971FA6258E4536C1"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d58146e1546-wk-Fact-67E566506F83BC6276A1A6258E62F4F5"
      unitRef="usdPerShare">-2.80</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d58146e1566-wk-Fact-08CC3E0BCEE177D04CA6A6258E311A4A"
      unitRef="usdPerShare">-7.07</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d58146e1584-wk-Fact-77260172BDC24CAE0417A6258E2DCB75"
      unitRef="shares">90597000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d58146e1603-wk-Fact-C2FF126AE24D032B0278A6258E405B49"
      unitRef="shares">30403000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d58146e1622-wk-Fact-F37245EBF17027238E7AA6258E393BCD"
      unitRef="shares">12582000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9A06CAEDB8471CC725FFA6258EBADDD1-0-wk-Fact-25B27759EB637076E0C7A6258E46970F">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock (on an as if converted basis)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,976&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,527&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ESPP obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Preferred stock warrants (on an as if converted basis)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock subject to repurchase&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51,707&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      id="d58146e1853-wk-Fact-88A66F16EFEC6F0EB52BA6258E7B224A"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      id="d58146e1867-wk-Fact-39DD5FB2BC9FD042074AA6258E7B3E4E"
      unitRef="shares">43898000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember"
      decimals="-3"
      id="d58146e1881-wk-Fact-FF6CF5FD501A49D5D07DA6258E750C22"
      unitRef="shares">44818000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d58146e1896-wk-Fact-7D11D7765B47A6FBFAD6A6258E775F9D"
      unitRef="shares">5976000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d58146e1910-wk-Fact-1EF5130E5AC501C62A47A6258E7E6359"
      unitRef="shares">7527000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d58146e1924-wk-Fact-D560DFAF49ECA821884FA6258E792E16"
      unitRef="shares">5179000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember"
      decimals="-3"
      id="d58146e1939-wk-Fact-0B512BB2B2F038A67C93A6258E8140BA"
      unitRef="shares">52000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember"
      decimals="-3"
      id="d58146e1953-wk-Fact-67AE1003AC3ADF9211E4A6258E7C06C7"
      unitRef="shares">22000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gh_EmployeeStockPurchasePlanObligationMember"
      decimals="-3"
      id="d58146e1967-wk-Fact-A0288CBABCA622C4AC3BA6258E7B31D5"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d58146e1982-wk-Fact-BFCB2A9D8A2E6BDD2506A6258E7645B9"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d58146e1996-wk-Fact-5D0DF66A78B90423E2B2A6258E7EA46B"
      unitRef="shares">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d58146e2010-wk-Fact-B0703BF47A93C9A4943FA6258E7C787A"
      unitRef="shares">8000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d58146e2025-wk-Fact-361B61D2AE0CD51A59B7A6258E7A92E7"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d58146e2039-wk-Fact-AEF73A0E6D398C0E2FFFA6258E7B7FC8"
      unitRef="shares">208000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d58146e2053-wk-Fact-408620BF81A6E27CEDCAA6258E7A486E"
      unitRef="shares">382000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d58146e2068-wk-Fact-E09C8BEADA143836BA75F3242E5355EC"
      unitRef="shares">252000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d58146e2082-wk-Fact-8612A650F57E21D6314EF3242E4A5643"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d58146e2096-wk-Fact-BAEBB45E797A34756D9D88514C7388EB"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="d58146e2111-wk-Fact-EBDD8B82FFE9C27F7E63A6258E7842BF"
      unitRef="shares">31000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="d58146e2125-wk-Fact-8EC54D059B80054A3665A6258E7B5477"
      unitRef="shares">46000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="d58146e2139-wk-Fact-350F30B88EF95FE237C7A6258E77BE9B"
      unitRef="shares">28000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d58146e2155-wk-Fact-82C3F8620404D6F4210BA6258E7C511A"
      unitRef="shares">6311000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d58146e2169-wk-Fact-BA875E69B9AD16EFEFB8A6258E85352A"
      unitRef="shares">51707000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d58146e2183-wk-Fact-7CFEE43E8546E70BF872A6258E78CEB6"
      unitRef="shares">50415000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BB803EEE40D9AFD4E286A6258EBB5F6A-0-wk-Fact-C284B1D80C6F5A900000A6258E9F5913">Income Taxes&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of loss before provision for income taxes were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(69,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(84,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(69,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(84,225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of the provision for income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total current tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Federal &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,652&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,872&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net operating losses carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90,534&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accruals and reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,936&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;210&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;134,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Section 481 (a) adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,363&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrealized gain/loss on investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(125,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(66,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents a reconciliation of the income tax expense computed at the statutory federal rate and the Company&#x2019;s income tax expense for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Tax at the statutory federal rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14,642&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(28,293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other nondeductible items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;887&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(33,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,049&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State taxes, net of federal benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8,253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in tax rate due to Tax Act&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;343&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total provision for (benefit from) income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,872&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s actual tax expense differed from the statutory federal income tax expense using a tax rate of 21% for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; primarily due to state and foreign income taxes, nondeductible expenses, research and development tax credits, the acquisition of Bellwether Bio, and the change in valuation allowance.  The Company&#x2019;s actual tax expense differed from the statutory federal income tax expense using a tax rate of 21% and 34% for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, primarily due to state income taxes, nondeductible expenses, research and development tax credits, and the change in valuation allowance.  The benefit from income taxes for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; included a release of a valuation allowance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with nondeductible intangible assets recorded as a result of the acquisition of Bellwether Bio.  In connection with the acquisition of Bellwether Bio, a deferred tax liability was established for the book-tax basis differences related to the non-goodwill intangible assets.  The net deferred tax liability from this acquisition creates an additional source of income to offset the Company&#x2019;s deferred tax assets. The benefit from income taxes for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; also included a benefit of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with the utilization of tax losses from continuing operations against other comprehensive income gains in accordance with intra-period tax allocation under ASC Topic 740.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had a net operating loss carryforwards of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$365.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;152.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for federal purposes, respectively, and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;223.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for state and local purposes, respectively, which may be subject to limitations as described below. If not utilized, these carryforwards will begin to expire in 2031 for federal, and 2020 for state and local purposes. Under the newly enacted federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the newly enacted federal income tax law.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had research and development tax credit carryforwards for federal tax purposes of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and state research and development tax credit carryforwards of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. The federal research and development tax credit carryforwards will expire at various dates beginning in the year 2032. The Company&#x2019;s state research and development tax credit carryforwards do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Utilization of the net operating loss (&#x201c;NOL&#x201d;) carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. Current laws impose substantial restrictions on the utilization of NOL carryforwards and credits in the event of an &#x201c;ownership change&#x201d; within a three-year period as defined by the Internal Revenue Code Section 382 (&#x201c;Section 382&#x201d;). If there should be an ownership change, the Company&#x2019;s ability to utilize its NOL carryforwards and credits could be limited. The Company has not performed a Section 382 analysis. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Realization of the future tax benefits is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the carryforward period. Due to the Company&#x2019;s history of U.S. operating losses, the Company believes that the recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not more likely than not to be realized and, accordingly, have provided a full valuation allowance against net U.S. deferred tax assets. The net change in total valuation allowance was an increase of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$59.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and an increase of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$22.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The SEC staff issued SAB 118 on December 23, 2017 regarding application of the Tax Act.  It provides a &#x201c;measurement period,&#x201d; lasting through December 22, 2018, to allow registrants time to obtain, prepare and analyze information to complete the accounting required under ASC 740, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  The Company completed its analysis during the measurement period and there were no measurement period adjustments recognized during &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has not recorded a provision for deferred U.S. tax expense that could result from the remittance of foreign undistributed earnings since the Company intends to reinvest the earnings in its foreign subsidiaries indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has made an accounting policy election to treat Global Intangible Low-Taxed Income ("GILTI") taxes as a current period expense rather than including these amounts in the measurement of deferred taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company records unrecognized tax benefits, where appropriate, for all uncertain income tax positions. The Company recorded unrecognized tax benefits for uncertain tax positions of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, none of which would impact the Company&#x2019;s effective tax rate if recognized, because the benefit would be offset by an increase in the valuation allowance. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the beginning and ending balance of total unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrecognized tax benefits - Beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,427&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;884&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Increases related to current year&#x2019;s tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Increases related to prior years&#x2019; tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrecognized tax benefits - End of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,427&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. During the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized no interest and penalties associated with unrecognized tax benefits. There are no tax positions for which it is reasonably possible that &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.&lt;/span&gt;&lt;/div&gt;Due to the net operating loss carryforwards, all years remain open for income tax examination by tax authorities in the United States, various states and foreign tax jurisdictions in which the Company files tax returns.</us-gaap:IncomeTaxDisclosureTextBlock>
    <gh:ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3BDDD8D29B781A08D001A6258EBAFBF5-0-wk-Fact-6D05D647819F0D9472DAA6258E98FFB9">&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of loss before provision for income taxes were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(69,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(84,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(69,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(84,225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</gh:ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock>
    <gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e1157-wk-Fact-094B10E9853787CDBAC9A6258E94DAF4"
      unitRef="usd">-69930000</gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest>
    <gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e1177-wk-Fact-86C23967F91E6226163FA6258E8BF5C3"
      unitRef="usd">-84313000</gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest>
    <gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e1197-wk-Fact-38065CA8E88DF1AC1843A6258E7B8EB6"
      unitRef="usd">-83214000</gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest>
    <gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e1214-wk-Fact-5744A2E0CBE407B8139E885251F0386B"
      unitRef="usd">207000</gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest>
    <gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e1233-wk-Fact-715F5C49FEE34B7C1A0AA6258E934F20"
      unitRef="usd">88000</gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest>
    <gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e1252-wk-Fact-5B5DE80F8A81E4001A9DA6258E4A09CD"
      unitRef="usd">0</gh:IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e1278-wk-Fact-533D35D4131C9059CAE7A6258E46A63A"
      unitRef="usd">-69723000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e1298-wk-Fact-E8046E8FEE4F9385958AA6258E318575"
      unitRef="usd">-84225000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e1318-wk-Fact-129FBB53D2772B0CEB01A6258E337EF0"
      unitRef="usd">-83214000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-90EA7E357A2B31F8CDFDA6258EBA76E1-0-wk-Fact-A2CABD8EAD0BFD91C43DA6258EA54027">&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of the provision for income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total current tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Federal &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,652&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,872&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e1676-wk-Fact-8E1A219854B409D43717A6258E766136"
      unitRef="usd">3000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e1695-wk-Fact-A4E4C4808CAB5466A2B1A6258E79EA7A"
      unitRef="usd">4000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e1714-wk-Fact-1D83A40C28D0D43EEBCFA6258E99D368"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e1730-wk-Fact-50B864E0A4E002D598C9A6258E7199C6"
      unitRef="usd">266000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e1749-wk-Fact-3CDBA8B46A59A5CE6AE6A6258E95D4B0"
      unitRef="usd">34000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e1768-wk-Fact-924450592E573B5AE2AFA6258E8F0905"
      unitRef="usd">7000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e1794-wk-Fact-7180FA45AD20D10D5A5778AF9AC3F203"
      unitRef="usd">269000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e1813-wk-Fact-BDC215B13A616FB08D4D78AF9AC76B23"
      unitRef="usd">38000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e1832-wk-Fact-A9F8A0FC538AF082A24F78AF9B8D99AC"
      unitRef="usd">7000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e1915-wk-Fact-CF7FA2C22474B3A695B978B175C8B639"
      unitRef="usd">-1652000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e1935-wk-Fact-9224CBB86D689799F29778B175C0D308"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e1954-wk-Fact-AFB9E184F42284E7303B7E7B3958A598"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e1970-wk-Fact-155E83265833D498911978B1D7C9D8B4"
      unitRef="usd">-311000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e1990-wk-Fact-1305B910200FBAA98DAB78B1D7925800"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e2009-wk-Fact-683CF273D0AA00886B427E7B395FA2DB"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e2031-wk-Fact-65996545CE759E983D2E7E7BBFA9E371"
      unitRef="usd">-178000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e2051-wk-Fact-9E14B7920B1022957B497E7BBFB2C06A"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e2070-wk-Fact-D02170DBF3D22F7E45007E7BBF2F9BAF"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e2096-wk-Fact-507ECC115A80FEBCFE7E78B2335E3BCF"
      unitRef="usd">-2141000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e2116-wk-Fact-A92AE0C819AC1AC7403178B233561813"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e2135-wk-Fact-EE963EE1308DD8CF1BCD78B2335149C7"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e2156-wk-Fact-0169B057D253E86D735EA6258E55D708"
      unitRef="usd">-1872000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e2176-wk-Fact-E068EE171D06C4C2BD3DA6258E2D3C45"
      unitRef="usd">38000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e2195-wk-Fact-29DDE49B36BBF8FF706BA6258E39EA9B"
      unitRef="usd">7000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-64ECFD5030EF89AC3717A6258EBBE0A4-0-wk-Fact-F8F2A702BA84A9A33E5CA6258E94E3D6">Significant components of the Company&#x2019;s deferred tax assets are as follows:&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net operating losses carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90,534&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accruals and reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,936&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;210&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;134,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Section 481 (a) adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,363&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrealized gain/loss on investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(125,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(66,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2443-wk-Fact-6EB7F72E6D0F675EB954A6258E803B41"
      unitRef="usd">90534000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2462-wk-Fact-8B8F240683694FCB558AA6258E72206F"
      unitRef="usd">36783000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2477-wk-Fact-B66C9F1C099FE6658F57A6258E7954D9"
      unitRef="usd">14165000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2496-wk-Fact-25B214E7195360061CC8A6258E7C7FC9"
      unitRef="usd">17107000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2516-wk-Fact-4C419B8BE9BD4228F0E2A6258E847806"
      unitRef="usd">4936000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2535-wk-Fact-0698849B28734B1CB3D7A6258E8101C3"
      unitRef="usd">5127000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2555-wk-Fact-3A8BE15D1EB34D71035EA6258E484E25"
      unitRef="usd">11031000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2574-wk-Fact-2FF1CC406D0D9ADA7656A6258E74F3BB"
      unitRef="usd">5753000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2594-wk-Fact-D00DA4A172E9C86CA045A6258E7F95F0"
      unitRef="usd">3143000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2613-wk-Fact-E7F2E16A1CF9450CD300A6258E7972A0"
      unitRef="usd">1289000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <gh:DeferredTaxAssetsLeaseLiabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2633-wk-Fact-7D70FC7152D0F1A0587478B7EF15C499"
      unitRef="usd">10195000</gh:DeferredTaxAssetsLeaseLiabilities>
    <gh:DeferredTaxAssetsLeaseLiabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2652-wk-Fact-6DE5BEB550931014075778B7EF11B6CC"
      unitRef="usd">0</gh:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2673-wk-Fact-F8C42848A434AB06E0DDA6258E89A3CB"
      unitRef="usd">160000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2692-wk-Fact-C3F0617DDD2DF5FD941BA6258E7EACE3"
      unitRef="usd">210000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2717-wk-Fact-68508137C4F7DB73E8F2A6258E53B96E"
      unitRef="usd">134164000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2736-wk-Fact-3453CCE80E02E5AF7064A6258E497073"
      unitRef="usd">66269000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2797-wk-Fact-BF6ECD0550E650B56788A6258E4A2932"
      unitRef="usd">119000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2817-wk-Fact-8CA38608A4AF075DC32EA6258E803C18"
      unitRef="usd">73000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <gh:DeferredTaxLiabilitiesSection481aAdjustment
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2833-wk-Fact-89557B1C3C5432A1E5E078B91F33B458"
      unitRef="usd">914000</gh:DeferredTaxLiabilitiesSection481aAdjustment>
    <gh:DeferredTaxLiabilitiesSection481aAdjustment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2853-wk-Fact-68F489F2C723BF0F7AA678B91F3844ED"
      unitRef="usd">0</gh:DeferredTaxLiabilitiesSection481aAdjustment>
    <gh:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2873-wk-Fact-A272C54FF37F5E9AD14278B9A9369683"
      unitRef="usd">7363000</gh:DeferredTaxLiabilitiesRightOfUseAssets>
    <gh:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2893-wk-Fact-1CDE9030DED035BCC13278B9A93B2DE6"
      unitRef="usd">0</gh:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2913-wk-Fact-FCF17067007869E3C79778BA4B00233B"
      unitRef="usd">346000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2933-wk-Fact-00AF5F59C9F68E05681778BA4B04D580"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2953-wk-Fact-0A44FBA5B737C0B5A305A6258E8CCE07"
      unitRef="usd">125245000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e2973-wk-Fact-51E868CFF51C7E896CA6A6258E7D5F4C"
      unitRef="usd">66196000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e2999-wk-Fact-0954F0696EC2C2BBC636A6258E7B7C99"
      unitRef="usd">177000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e3018-wk-Fact-9DCA76308D33D27386EFA6258E4C0BE7"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-00119CC80BDB5F1E06D7A6258EBA2F14-0-wk-Fact-F33ACB006FF8568BDAD3A6258E9D0872">&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents a reconciliation of the income tax expense computed at the statutory federal rate and the Company&#x2019;s income tax expense for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Tax at the statutory federal rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14,642&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(28,293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other nondeductible items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;887&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(33,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,049&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State taxes, net of federal benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8,253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in tax rate due to Tax Act&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;343&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total provision for (benefit from) income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,872&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e3312-wk-Fact-65EEF7F6F552662C7968A6258E883819"
      unitRef="usd">-14642000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e3332-wk-Fact-2368588343F70C95ED1CA6258E855CB5"
      unitRef="usd">-17690000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e3352-wk-Fact-96193225834255A0683EA6258E7DE555"
      unitRef="usd">-28293000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e3369-wk-Fact-EE43C5F7D86B59F2548DA6258E7D3974"
      unitRef="usd">887000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e3388-wk-Fact-BB8DC0A5C674C8D138E0A6258E89B0EC"
      unitRef="usd">329000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e3407-wk-Fact-29DD65E8F7D3CE81A32AA6258E86E749"
      unitRef="usd">371000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e3428-wk-Fact-656C64B94BDF356AE0D4A6258E86A7DA"
      unitRef="usd">-33042000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e3448-wk-Fact-F086AE66D4D552C22BFBA6258E7BCD02"
      unitRef="usd">497000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e3467-wk-Fact-FD29CAD0D20A887688C2A6258E7AB74F"
      unitRef="usd">3819000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e3488-wk-Fact-FBD26BB32384609EB2B4A6258E8781FD"
      unitRef="usd">5266000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e3508-wk-Fact-87C3799CBC53C23CB08DA6258E7CD3AB"
      unitRef="usd">1726000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e3528-wk-Fact-76AE62184BE5373DC134A6258E82FDC8"
      unitRef="usd">714000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e3550-wk-Fact-D172FCE180DCA2B5A2A7A6258E8C6D1E"
      unitRef="usd">59049000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e3569-wk-Fact-95D93E181AF87F834EE4A6258E716403"
      unitRef="usd">22516000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e3588-wk-Fact-456496FB51CCB6266916A6258E9250B3"
      unitRef="usd">5415000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e3609-wk-Fact-16B08C11B7DB0FBE7A8DA6258E80F948"
      unitRef="usd">-8253000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e3629-wk-Fact-9D83B7CA391B1C9A598AA6258E81B05D"
      unitRef="usd">-4231000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e3649-wk-Fact-7FCBA5D11106B20A61D1A6258E88E2FA"
      unitRef="usd">-1868000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e3671-wk-Fact-417A25FB8F2536E03556A6258E878AFD"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e3690-wk-Fact-1803CFBBC6C8152B2912A6258E724CB1"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e3709-wk-Fact-253FABA05360AACBFF9AA6258E86FC22"
      unitRef="usd">21346000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e3731-wk-Fact-4F45FBA17B2D07EFA339A6258E74ECDC"
      unitRef="usd">-605000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e3751-wk-Fact-4644064BBD81ABCF2496A6258E94CFD9"
      unitRef="usd">343000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e3770-wk-Fact-E59F2F1BC28E4181964FA6258E7DF80E"
      unitRef="usd">-69000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e3797-wk-Fact-0169B057D253E86D735EA6258E55D708"
      unitRef="usd">-1872000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e3817-wk-Fact-E068EE171D06C4C2BD3DA6258E2D3C45"
      unitRef="usd">38000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e3836-wk-Fact-29DDE49B36BBF8FF706BA6258E39EA9B"
      unitRef="usd">7000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d65609e3865-wk-Fact-B525FBF4712C88E29A4378C23F9345B5"
      unitRef="usd">-1600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d65609e3874-wk-Fact-78888B25FBB238F95A869843AA29189B"
      unitRef="usd">400000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="d65609e3892-wk-Fact-7583165C9B4B84F19C7EA6258EA296BE"
      unitRef="usd">365300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="d65609e3896-wk-Fact-B98A84B7676871CDBCB5A6258E9D6629"
      unitRef="usd">152300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="d65609e3900-wk-Fact-A98118EF36D7AC23619478C8B6EA88CF"
      unitRef="usd">223200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="d65609e3905-wk-Fact-7F992EDCD7AE2D9B2B9678C8C9A82599"
      unitRef="usd">73200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="d65609e3920-wk-Fact-75C45ABC684B3F6D311EA6258EA4D3B9"
      unitRef="usd">6800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="d65609e3924-wk-Fact-1E5EE8BE9BADE443AE9F78C996D4D5AA"
      unitRef="usd">3500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="d65609e3928-wk-Fact-EE51105E0465E7DBA9B3A6258EA05A18"
      unitRef="usd">5300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="d65609e3933-wk-Fact-F9F36027EB64B21684BA78C9B9CDE4DE"
      unitRef="usd">2900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d65609e3943-wk-Fact-A4A8F43B6455DE1B7E9BA6258E9AF97A"
      unitRef="usd">59000000.0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d65609e3947-wk-Fact-5F806FB0367CD4E9594278CA74506A62"
      unitRef="usd">22500000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4"
      decimals="-5"
      id="d65609e3982-wk-Fact-3A641797B4FFDC6755E3A6258EA06016"
      unitRef="usd">6500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-5"
      id="d65609e3986-wk-Fact-635F750577B11A1FE41478CAF5BCFA77"
      unitRef="usd">3400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-13D863AA82A7AB66B23BA6258EBA93D7-0-wk-Fact-FBCC64A04C81757B95A4A6258E9AD2AC">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the beginning and ending balance of total unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrecognized tax benefits - Beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,427&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;884&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Increases related to current year&#x2019;s tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Increases related to prior years&#x2019; tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrecognized tax benefits - End of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,427&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e4283-wk-Fact-9E7D88DAA12579DDE467A6258E955F45"
      unitRef="usd">3427000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-3"
      id="d65609e4302-wk-Fact-DAD949776C6CB25E1689A6258E9542A8"
      unitRef="usd">1712000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2016Q4"
      decimals="-3"
      id="d65609e4321-wk-Fact-6CEAF32A104AC0677A3DA6258E9CF131"
      unitRef="usd">884000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e4337-wk-Fact-793F476162E8F20E2B1FA6258E9D6EB8"
      unitRef="usd">3116000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e4356-wk-Fact-118D90BB9BA0CB32306FA6258E9E761D"
      unitRef="usd">1635000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e4375-wk-Fact-0AEFFE5FF73E22E17DE7A6258E9BE5EE"
      unitRef="usd">828000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d65609e4396-wk-Fact-D32A3660BE65918760C6A6258E9B1972"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d65609e4415-wk-Fact-3510187359E3E1CD7982A6258E9930BD"
      unitRef="usd">80000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d65609e4434-wk-Fact-C6D1B59EDE6AC55C9AB1A6258E995DF3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4"
      decimals="-3"
      id="d65609e4460-wk-Fact-BDB89330966926D6A6A0A6258E96EC3D"
      unitRef="usd">6543000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-3"
      id="d65609e4479-wk-Fact-9E7D88DAA12579DDE467A6258E955F45"
      unitRef="usd">3427000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-3"
      id="d65609e4498-wk-Fact-DAD949776C6CB25E1689A6258E9542A8"
      unitRef="usd">1712000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1AD9893B6FC4324EB371A6258EBB6A84-0-wk-Fact-9D270926AA9905CF49B4A6258E99335C">Employee Benefit Plan&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company sponsors a 401(k) plan, and pursuant to its terms, eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of eligible compensation on a pre-tax basis. For the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company contributed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt; to match employee contributions as permitted by the plan. For the years ended December 31, 2018 and 2017, the Company did not elect to match employee contributions as permitted by the plan. The Company pays the administrative costs for the plan.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d65532e875-wk-Fact-12558B18F2DD647FBF66A6258EA01CE4"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d65532e883-wk-Fact-05CA6421C7E481C2C563F32AEDB62059"
      unitRef="usd">300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-74D169856C31CDD13E59A6258EBB82EC-0-wk-Fact-1604C86EB1790017E38DA6258E45AC0A">Segment and Geographic Information&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the Company&#x2019;s revenue by geographic areas based on the customers&#x2019; locations:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;United States &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;194,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;International&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;214,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;No single country outside of the United States accounted for more than 10% of total revenue during each of the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:24px;text-indent:-24px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;(2)    Fiscal years 2018 and 2017 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;97%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;, respectively, of the Company&#x2019;s long-lived assets are located in the United States.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E150EFFEFFA2A46D1F1DA6258EBBF7D9-0-wk-Fact-FA4CAEBCA137B7A6E1F6A6258E470B84">&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the Company&#x2019;s revenue by geographic areas based on the customers&#x2019; locations:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;United States &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;194,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;International&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;214,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;No single country outside of the United States accounted for more than 10% of total revenue during each of the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:24px;text-indent:-24px;font-size:7.5pt;"&gt;&lt;span style="font-family:inherit;font-size:7.5pt;"&gt;(2)    Fiscal years 2018 and 2017 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019. &lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d66415e1159-wk-Fact-2DE8F73B9564A760CC76A6258E717869"
      unitRef="usd">194312000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d66415e1178-wk-Fact-2B085F1AE228B69DF701A6258E86B388"
      unitRef="usd">77916000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d66415e1197-wk-Fact-9C3491BECB8297B3D4A3AB6DB9A7C16E"
      unitRef="usd">43715000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-3"
      id="d66415e1219-wk-Fact-EDDE9BBC277C6333A5AEA6258E7EDBB5"
      unitRef="usd">20063000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-3"
      id="d66415e1238-wk-Fact-F7335247DEFCDC6BE3DEA6258E820F0E"
      unitRef="usd">12723000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-3"
      id="d66415e1257-wk-Fact-F5786265061FA6AEBE19AB6DB9B06563"
      unitRef="usd">6127000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d66415e1283-wk-Fact-4DE9547D7B5D2159A859A6258E3A1898"
      unitRef="usd">214375000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d66415e1302-wk-Fact-D1D5341DAF1488A2957EA6258E683A12"
      unitRef="usd">90639000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d66415e1321-wk-Fact-71C181FD76A4A1A34CB0A6258E9FCF29"
      unitRef="usd">49842000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_AssetsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="2"
      id="d66415e1365-wk-Fact-7F704507EFDA2E13E8B491E4D5CDDB2A"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_AssetsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="2"
      id="d66415e1369-wk-Fact-5513AB697022AF9010B291E4D61C1924"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-06542193A9644BDBC5E0A6258EBBEABD-0-wk-Fact-7C8CD47F3B565F0A4CE6A6258EA369CC">Related Party Transactions&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As discussed in Note 3, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Investment in Joint Venture&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and Note 13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, in connection with Softbank&#x2019;s purchase of its Series E convertible preferred stock in 2017, the Company entered into a joint venture agreement with an entity affiliated with SoftBank. In May 2018, the Company and SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As discussed in Note 11, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, in July and August 2017, the Company repurchased an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,640,901&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of outstanding common stock from certain executive officers for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$16.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The difference between the repurchase amount and the fair value of repurchased shares of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were recorded as cash-based compensation expense in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For each of the years ended December&#160;31, 2019 and 2017, the Company recognized revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million from an entity affiliated with a member of the Company&#x2019;s Board of Directors, who serves on the board of both the aforementioned entity and the Company. This individual was appointed to the Company&#x2019;s board in January 2017. There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; revenue recognized by the Company from that entity for the year ended December 31, 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="D2018Q3Jul01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember"
      decimals="INF"
      id="d65814e890-wk-Fact-76E79E0F81A8FBFAAC1FA6258EA25CAE"
      unitRef="shares">1640901</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="D2018Q3Jul01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember"
      decimals="-5"
      id="d65814e894-wk-Fact-67344EE60838DEE07AF4A6258EA2340D"
      unitRef="usd">16900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <gh:CommonStockCompensationExpense
      contextRef="D2018Q3Jul01-Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember"
      decimals="-5"
      id="d65814e898-wk-Fact-31A39A4BC1533C0553EAA6258EA16EB9"
      unitRef="usd">10000000.0</gh:CommonStockCompensationExpense>
    <us-gaap:RevenueFromRelatedParties
      contextRef="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember"
      decimals="-5"
      id="d65814e905-wk-Fact-BC2ED7A09B15F230BF1DF32EEC6E8DAC"
      unitRef="usd">500000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember"
      decimals="-5"
      id="d65814e909-wk-Fact-40F17908BE3982D5005B91E7F2023059"
      unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#d30009e1223-wk-Fact-37278A89EE20DFC9B188A6258E33CABC"
          xlink:label="d30009e1223-wk-Fact-37278A89EE20DFC9B188A6258E33CABC"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl" xlink:label="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Fiscal year 2018 and 2017 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d30009e1223-wk-Fact-37278A89EE20DFC9B188A6258E33CABC"
          xlink:to="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d27497e1578-wk-Fact-4A43155C56BC426FCBE3A6258E2DF4E7"
          xlink:label="d27497e1578-wk-Fact-4A43155C56BC426FCBE3A6258E2DF4E7"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6357B93E950236AB9E87A6258EB47973-0-wk-Footnote-6357B93E950236AB9E87A6258EB47973_lbl" xlink:label="TextSelection-6357B93E950236AB9E87A6258EB47973-0-wk-Footnote-6357B93E950236AB9E87A6258EB47973_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"> As of&#160;<xhtml:span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;">2018</xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;">, includes&#160;</xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:span>$45.1 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:span>$48.3 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#x201c;VIE&#x201d;) and VIE&#x2019;s subsidiaries, and&#160;</xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:span>$5.7 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;"> and&#160;</xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;"><xhtml:span>$1.2 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;">&#160;of liabilities, respectively, of the consolidated VIE &#160;of liabilities of consolidated VIE and VIE&#x2019;s subsidiaries for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, </xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;font-style:italic;">Investment in Joint Venture</xhtml:span><xhtml:span style="font-family:inherit;font-size:10pt;">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d27497e1578-wk-Fact-4A43155C56BC426FCBE3A6258E2DF4E7"
          xlink:to="TextSelection-6357B93E950236AB9E87A6258EB47973-0-wk-Footnote-6357B93E950236AB9E87A6258EB47973_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-8658C3672FC3B51B14F877E26D4F91C5-0-wk-Footnote-8658C3672FC3B51B14F877E26D4F91C5_lbl" xlink:label="TextSelection-8658C3672FC3B51B14F877E26D4F91C5-0-wk-Footnote-8658C3672FC3B51B14F877E26D4F91C5_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Fiscal 2018 does not reflect the impact of the adoption of the new revenue accounting and lease accounting standards in fiscal year 2019.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d27497e1578-wk-Fact-4A43155C56BC426FCBE3A6258E2DF4E7"
          xlink:to="TextSelection-8658C3672FC3B51B14F877E26D4F91C5-0-wk-Footnote-8658C3672FC3B51B14F877E26D4F91C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d30009e1283-wk-Fact-4D2936D9D7A53B6DF502A6258E460D65"
          xlink:label="d30009e1283-wk-Fact-4D2936D9D7A53B6DF502A6258E460D65"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d30009e1283-wk-Fact-4D2936D9D7A53B6DF502A6258E460D65"
          xlink:to="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d30009e1203-wk-Fact-5B2DE63C41AB69886EC1A6258E3B0666"
          xlink:label="d30009e1203-wk-Fact-5B2DE63C41AB69886EC1A6258E3B0666"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d30009e1203-wk-Fact-5B2DE63C41AB69886EC1A6258E3B0666"
          xlink:to="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d27497e2067-wk-Fact-787E9732FDA1620CF163A6258E2DEF38"
          xlink:label="d27497e2067-wk-Fact-787E9732FDA1620CF163A6258E2DEF38"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d27497e2067-wk-Fact-787E9732FDA1620CF163A6258E2DEF38"
          xlink:to="TextSelection-6357B93E950236AB9E87A6258EB47973-0-wk-Footnote-6357B93E950236AB9E87A6258EB47973_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d27497e2067-wk-Fact-787E9732FDA1620CF163A6258E2DEF38"
          xlink:to="TextSelection-8658C3672FC3B51B14F877E26D4F91C5-0-wk-Footnote-8658C3672FC3B51B14F877E26D4F91C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d30009e1245-wk-Fact-8B6729A9D18284EECA68A6258E3316AE"
          xlink:label="d30009e1245-wk-Fact-8B6729A9D18284EECA68A6258E3316AE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d46357e2889-wk-Fact-8B6729A9D18284EECA68A6258E3316AE"
          xlink:label="d46357e2889-wk-Fact-8B6729A9D18284EECA68A6258E3316AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d30009e1245-wk-Fact-8B6729A9D18284EECA68A6258E3316AE"
          xlink:to="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d46357e2889-wk-Fact-8B6729A9D18284EECA68A6258E3316AE"
          xlink:to="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d30009e1184-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF"
          xlink:label="d30009e1184-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d46357e2840-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF"
          xlink:label="d46357e2840-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d30009e1184-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF"
          xlink:to="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d46357e2840-wk-Fact-92E5C8648F3C87C32668A6258E6FF3DF"
          xlink:to="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d27497e1597-wk-Fact-CCBF4B2DE891C350F87CA6258E343288"
          xlink:label="d27497e1597-wk-Fact-CCBF4B2DE891C350F87CA6258E343288"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d27497e1597-wk-Fact-CCBF4B2DE891C350F87CA6258E343288"
          xlink:to="TextSelection-6357B93E950236AB9E87A6258EB47973-0-wk-Footnote-6357B93E950236AB9E87A6258EB47973_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d27497e1597-wk-Fact-CCBF4B2DE891C350F87CA6258E343288"
          xlink:to="TextSelection-8658C3672FC3B51B14F877E26D4F91C5-0-wk-Footnote-8658C3672FC3B51B14F877E26D4F91C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d27497e2048-wk-Fact-D9E58FA15C46A8F94757A6258E2ABF68"
          xlink:label="d27497e2048-wk-Fact-D9E58FA15C46A8F94757A6258E2ABF68"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d27497e2048-wk-Fact-D9E58FA15C46A8F94757A6258E2ABF68"
          xlink:to="TextSelection-6357B93E950236AB9E87A6258EB47973-0-wk-Footnote-6357B93E950236AB9E87A6258EB47973_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d27497e2048-wk-Fact-D9E58FA15C46A8F94757A6258E2ABF68"
          xlink:to="TextSelection-8658C3672FC3B51B14F877E26D4F91C5-0-wk-Footnote-8658C3672FC3B51B14F877E26D4F91C5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d30009e1264-wk-Fact-E139CBAD9FD19C557986A6258E2D7893"
          xlink:label="d30009e1264-wk-Fact-E139CBAD9FD19C557986A6258E2D7893"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d30009e1264-wk-Fact-E139CBAD9FD19C557986A6258E2D7893"
          xlink:to="TextSelection-C420DE61D3CB86A789A877F94D0ABC11-0-wk-Footnote-C420DE61D3CB86A789A877F94D0ABC11_lbl"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6836955440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of loss before provision for income taxes were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,214</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the provision for income taxes are as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal </span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,652</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(178</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total provision for income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets are as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating losses carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,534</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,783</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals and reserves</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,936</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,289</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax asset</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Section 481 (a) adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(914</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain/loss on investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(346</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(125,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents a reconciliation of the income tax expense computed at the statutory federal rate and the Company&#8217;s income tax expense for the periods presented:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax at the statutory federal rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,642</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,690</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other nondeductible items</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>887</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>497</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,266</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,726</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(714</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,049</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,516</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State taxes, net of federal benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,253</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,231</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,868</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in tax rate due to Tax Act</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,346</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(605</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>343</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s actual tax expense differed from the statutory federal income tax expense using a tax rate of 21% for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> primarily due to state and foreign income taxes, nondeductible expenses, research and development tax credits, the acquisition of Bellwether Bio, and the change in valuation allowance.  The Company&#8217;s actual tax expense differed from the statutory federal income tax expense using a tax rate of 21% and 34% for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, primarily due to state income taxes, nondeductible expenses, research and development tax credits, and the change in valuation allowance.  The benefit from income taxes for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> included a release of a valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with nondeductible intangible assets recorded as a result of the acquisition of Bellwether Bio.  In connection with the acquisition of Bellwether Bio, a deferred tax liability was established for the book-tax basis differences related to the non-goodwill intangible assets.  The net deferred tax liability from this acquisition creates an additional source of income to offset the Company&#8217;s deferred tax assets. The benefit from income taxes for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> also included a benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the utilization of tax losses from continuing operations against other comprehensive income gains in accordance with intra-period tax allocation under ASC Topic 740.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had a net operating loss carryforwards of </span><span style="font-family:inherit;font-size:10pt;"><span>$365.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>152.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for federal purposes, respectively, and $</span><span style="font-family:inherit;font-size:10pt;"><span>223.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>73.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for state and local purposes, respectively, which may be subject to limitations as described below. If not utilized, these carryforwards will begin to expire in 2031 for federal, and 2020 for state and local purposes. Under the newly enacted federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the newly enacted federal income tax law.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had research and development tax credit carryforwards for federal tax purposes of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and state research and development tax credit carryforwards of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>2.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The federal research and development tax credit carryforwards will expire at various dates beginning in the year 2032. The Company&#8217;s state research and development tax credit carryforwards do not expire.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Utilization of the net operating loss (&#8220;NOL&#8221;) carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. Current laws impose substantial restrictions on the utilization of NOL carryforwards and credits in the event of an &#8220;ownership change&#8221; within a three-year period as defined by the Internal Revenue Code Section 382 (&#8220;Section 382&#8221;). If there should be an ownership change, the Company&#8217;s ability to utilize its NOL carryforwards and credits could be limited. The Company has not performed a Section 382 analysis. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Due to the Company&#8217;s history of U.S. operating losses, the Company believes that the recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not more likely than not to be realized and, accordingly, have provided a full valuation allowance against net U.S. deferred tax assets. The net change in total valuation allowance was an increase of </span><span style="font-family:inherit;font-size:10pt;"><span>$59.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and an increase of </span><span style="font-family:inherit;font-size:10pt;"><span>$22.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The SEC staff issued SAB 118 on December 23, 2017 regarding application of the Tax Act.  It provides a &#8220;measurement period,&#8221; lasting through December 22, 2018, to allow registrants time to obtain, prepare and analyze information to complete the accounting required under ASC 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;">.  The Company completed its analysis during the measurement period and there were no measurement period adjustments recognized during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has not recorded a provision for deferred U.S. tax expense that could result from the remittance of foreign undistributed earnings since the Company intends to reinvest the earnings in its foreign subsidiaries indefinitely.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has made an accounting policy election to treat Global Intangible Low-Taxed Income ("GILTI") taxes as a current period expense rather than including these amounts in the measurement of deferred taxes.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Uncertain Tax Positions</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records unrecognized tax benefits, where appropriate, for all uncertain income tax positions. The Company recorded unrecognized tax benefits for uncertain tax positions of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, none of which would impact the Company&#8217;s effective tax rate if recognized, because the benefit would be offset by an increase in the valuation allowance. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balance of total unrecognized tax benefits is as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits - Beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>884</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to current year&#8217;s tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,635</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to prior years&#8217; tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits - End of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,543</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,427</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. During the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized no interest and penalties associated with unrecognized tax benefits. There are no tax positions for which it is reasonably possible that </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.</span></div>Due to the net operating loss carryforwards, all years remain open for income tax examination by tax authorities in the United States, various states and foreign tax jurisdictions in which the Company files tax returns.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6591998480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Warrants</a></td>
<td class="text">Common Stock<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors (the &#8220;Board of Directors&#8221;). As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, no dividends on the Company&#8217;s common stock had been declared by the Board of Directors.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares underlying outstanding stock options   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,494,889</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,588,405</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares available for future stock option grants   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,726,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,556,507</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>689,917</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922,250</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,911,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,067,162</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Board of Directors and its stockholders approved a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>0.7378</span></span><span style="font-family:inherit;font-size:10pt;">-for-one reverse stock split of the Company&#8217;s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the IPO. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 9, 2018, the Company completed the IPO, in which it issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>14,375,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of its common stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$19.00</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company received net proceeds of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$249.5 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;after deducting underwriting discounts and commissions and offering expenses payable by the Company. All then-outstanding warrants to purchase the Company&#8217;s common stock were exercised prior to the completion of the IPO.&#160;In addition, in connection with the IPO,&#160;all shares of the Company&#8217;s then-outstanding convertible preferred stock were automatically converted into&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>58,264,577</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of its common stock, and all then-outstanding warrants to purchase the Company&#8217;s convertible preferred stock were automatically converted into warrants to purchase&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>7,636</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of the Company&#8217;s common stock.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Follow-on Offering</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company completed an underwritten public offering, in which it issued and sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>5,175,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of its common stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$71.00</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The Company received net proceeds of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$349.7 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div>Warrants<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with a bank loan agreement with a financial institution in September 2013, the Company issued warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>5,386</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series A convertible preferred stock at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.93</span></span><span style="font-family:inherit;font-size:10pt;"> per share. In October 2014, the Company issued additional warrants to the same financial institution to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>4,965</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series B convertible preferred stock at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.16</span></span><span style="font-family:inherit;font-size:10pt;"> per share. These preferred stock warrants were converted to warrants to purchase common stock upon the consummation of the IPO and were net exercised into </span><span style="font-family:inherit;font-size:10pt;"><span>6,548</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in October 2018. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> warrants remained outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2012, the Company issued to certain investors warrants to purchase&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>495,775</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock. The exercise price of the warrants is&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$0.14</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share and the warrants have a contractual term through September 2023.  For the year ended&#160;December&#160;31, 2018&#160;and&#160;2017,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>313,741</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>89,030</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares, respectively,&#160;were issued upon the exercise of these warrants. As of&#160;December&#160;31, 2017, warrants to purchase&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>313,741</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock were outstanding, and these warrants were fully exercised prior to the consummation of the IPO in October 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6859823680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#8217; interests in the Joint Venture are shown in the consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company believes that its existing cash and cash equivalents and marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations,&#160;goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_JOBSActAccountingElectionPolicyTextBlock', window );">JOBS Act Accounting Election</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">JOBS Act Accounting Election</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective December 31, 2019, we are no longer an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Prior to losing our status as an emerging growth company, the JOBS Act allowed us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements were made applicable to private companies, and we had elected to use this extended transition period.&#160;We can no longer take advantage of this extended transition period. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translations</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</span></div><span style="font-family:inherit;font-size:10pt;">The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#8217; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the consolidated statements of operations. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span>, foreign currency translation adjustment was immaterial. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company operates as one operating and reportable segment. The Company&#8217;s chief operating decision makers, the Chief Executive Officer, and the President and Chief Operating Officer, manage the Company&#8217;s operations on an aggregate basis for purposes of allocating resources.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments with original maturities at the time of purchase of three months or less.&#160;Cash equivalents include bank demand deposits and money market accounts that invest primarily in U.S. government-backed securities and treasuries. Cash equivalents are carried at cost, which approximates their fair value.</span></div>In fiscal 2017, restricted cash consists of deposits related to the Company&#8217;s corporate credit card.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities consist primarily of high-grade corporate bonds, commercial papers and certificates of deposit with third parties. Marketable securities with original maturities at the time of purchase between three and twelve months from balance sheet dates are classified as short-term marketable securities and those with maturities over twelve months from balance sheet dates are classified as long-term marketable securities. The Company classifies all marketable securities as available-for-sale, which are recorded at fair value. Unrealized gains and losses are included in accumulated other comprehensive loss in stockholders&#8217; equity. Any premium or discount arising at purchase is amortized or accreted to interest income or expense. Realized gains and losses and declines in value, if any, judged to be other than temporary on available&#8209;for&#8209;sale securities are reported in other income (expense), net. When securities are sold, any associated unrealized gain or loss initially recorded as a separate component of stockholders&#8217; equity is reclassified out of stockholders&#8217; equity on a specific&#8209;identification basis and recorded in earnings for the period.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not that it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and management&#8217;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also invests in investment&#8209;grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after&#8209;tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</span></div>Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory consisted entirely of supplies, which are consumed when providing liquid biopsy tests, and therefore the Company does not maintain any finished goods inventory.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by the Company, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Amounts written-down due to unmarketable inventory are recorded in cost of precision oncology testing.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost. Depreciation is computed over estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The Company periodically reviews the depreciable lives assigned to property and equipment placed in service and changes the estimates of useful lives, if necessary. Maintenance and repairs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company includes the results of operations of the businesses that are acquired as of the acquisition date. The Company allocates the purchase price of acquisitions to the assets acquired and liabilities assumed based on the estimated fair values. The excess of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition related costs are recognized separately from the business combination and are expensed as incurred.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, net</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Intangible Assets, net</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets related to in-process research and development costs (&#8220;IPR&amp;D&#8221;) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there has been&#160;no&#160;impairment of goodwill.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6-</span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ObligationRelatedtoRoyaltyPolicyTextBlock', window );">Obligation Related to Royalty</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Obligation Related to Royalty</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of the Company&#8217;s asset acquisitions involve the potential for future payment of consideration that is contingent upon the royalty payments due on future product net sales, subject to annual minimums. The fair value of such liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment for Long-Lived Assets</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment for Long-Lived Assets</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition under ASC 606</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include companion diagnostic development, information solutions and laboratory services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, we adopted the new revenue recognition standard FASB ASC Topic 606,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">,&#160;or ASC 606. Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Precision oncology testing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Development services</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations. The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contracts with multiple performance obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated. For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contract assets</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable.&#160;Contract assets are presented under accounts receivable and other assets on the Company&#8217;s consolidated balance sheets. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had contract assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> is recorded in other assets in the consolidated balance sheet.  The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of contract assets as of January 1, 2019. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred revenue </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company&#8217;s performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the deferred revenue balance was </span><span style="font-family:inherit;font-size:10pt;"><span>$12.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$16.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which included </span><span style="font-family:inherit;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the&#160;twelve months ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">&#160;that was included in the deferred revenue balance as of January 1, 2019 was&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$15.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, which primarily represented revenue from&#160;provision of development services under the collaboration agreement with our biopharmaceutical companies.&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Transaction price allocated to the remaining performance obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next </span><span style="font-family:inherit;font-size:10pt;"><span>12 months</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CostsofPrecisionOncologyTestingPolicyTextBlock', window );">Costs of Precision Oncology Testing</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs of Precision Oncology Testing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CostofDevelopmentServicesPolicyTextBlock', window );">Cost of Development Services</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Development Services</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of development service includes costs incurred for the performance of development services requested by the Company&#8217;s customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses are comprised of costs incurred to develop technology and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development expenses </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">also include costs related to activities performed under contracts with biopharmaceutical companies. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#8217;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising</span></div>The Company expenses advertising costs as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Offering Costs</span></div>Deferred offering costs consist of fees and expenses incurred in connection with the anticipated sale of the Company&#8217;s common stock in the IPO, including the legal, accounting, printing and other IPO-related costs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock&#8209;Based Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock&#8209;based compensation related to stock options granted to the Company&#8217;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, the Company accounted for stock options issued to nonemployees consultants based on the estimated fair value at the grant date and re-measured at each reporting period. Starting January 1, 2019, upon adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2018-07,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718)</span><span style="font-family:inherit;font-size:10pt;">,&#160;Improvements to Nonemployee Share-Based Payment Accounting,&#160;the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the Black&#8209;Scholes option&#8209;pricing model to estimate the fair value of its stock options and purchase rights under its 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Starting January 1, 2017, forfeitures are accounted for as they occur.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for restricted stock units issued to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in the Company&#8217;s consolidated statement of operations on a straight-line basis over the requisite vesting period.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes are recorded using an asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the closing of the Company&#8217;s IPO in October 2018 and the conversion of its convertible preferred stock into common stock, the Company calculated its basic and diluted net loss per share attributable to common stockholders of the Company in conformity with the two-class method required for companies with participating securities. The Company considered its convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on the Company&#8217;s common stock, holders of convertible preferred stock were entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock did not have a contractual obligation to share in the Company&#8217;s losses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Adopted </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2014-09,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)&#160;and all related amendments (collectively, &#8220;ASC 606&#8221;)</span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2019 utilizing the modified retrospective method. The cumulative effect of applying the standard to all contracts that were not completed as of the date of initial application was recognized to beginning accumulated deficit as of January 1, 2019. The Company identified certain differences in accounting for revenue recognition as a result of the adoption of ASC 606 which have impacted its financial position and results of operations.  For precision oncology testing revenue with certain clinical customers, the Company historically deferred revenue recognition until cash receipt when the price pursuant to the underlying customer arrangement became fixed and determinable and collectability became reasonably assured. Under the new standard, this is considered variable consideration and revenue is recognized at the estimated transaction price upon delivery. This results in earlier revenue recognition under the new standard as compared to previous revenue recognition. For development services revenue with certain biopharmaceutical customers, the Company historically limited revenue recognition based on the right to invoice the customer. Under the new standard, for these arrangements, the Company constrains revenue such that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For arrangements with regulatory and other developmental milestone payments, this results in a change to the timing and pattern of revenue recognition under the new standard as compared to previous revenue recognition.  Comparative information from prior periods has not been restated and&#160;continues to be reported under the accounting standards in effect for those periods. The cumulative effect of changes made to the consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments due to ASC 606 </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of January 1, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,597</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(280,799</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(275,892</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC 606 requirements under the modified retrospective method of adoption, the impact of the adoption of ASC 606 on the Company&#8217;s consolidated statement of operations and consolidated balance sheet was as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the year ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported Under ASC 606</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology testing </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180,462</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Development services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported Under ASC 606</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,639</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(352,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(353,156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 606 did not have an aggregate impact on the Company&#8217;s net cash used in operating activities but resulted in offsetting changes in certain assets presented within net cash used in operating activities in the Company&#8217;s consolidated statement of cash flows, as reflected in the above table. The the Company&#8217;s revenue is generated primarily from the sale of precision oncology testing and development services. Precision oncology testing revenue is generated from sales of the Company&#8217;s current products to clinical and biopharmaceutical customers. Total precision oncology testing revenues from sales to clinical customers for the years ended December 31, 2019, 2018 and 2017 were </span><span style="font-family:inherit;font-size:10pt;">$94.2 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$43.7 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$24.5 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. Total precision oncology testing revenues from sales to biopharmaceutical customers for the years ended December 31, 2019, 2018 and 2017 were </span><span style="font-family:inherit;font-size:10pt;">$79.5 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$34.7 million</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$17.6 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. Development services revenue represent services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted&#160;ASC 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">,  and its related amendments which requires the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for operating leases on the consolidated balance sheet on January 1, 2019 using a modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases in place as of January 1, 2019. The Company also elected the practical expedient to not separate lease and non-lease components for its facility leases, and to not recognize ROU assets and operating lease liabilities for short-term leases.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 842, the Company determines if an arrangement contains a lease and the classification of that lease, if applicable, at inception or upon modification of a contract. The Company has elected to not recognize a lease liability or ROU asset for short-term leases (leases with a term of twelve months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise). The Company has elected to not allocate the contract consideration for operating lease contracts with lease and non-lease components, and account for the lease and non-lease components as a single lease component. ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at lease commencement date. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. An option to extend the lease </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The primary impact of adopting&#160;Topic 842&#160;was the recognition of ROU assets and lease liabilities for operating leases of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$14.5</span></span><span style="font-family:inherit;font-size:10pt;"> million and </span><span style="font-family:inherit;font-size:10pt;"><span>$22.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively, on January 1, 2019, which included reclassifying prepaid rent and deferred rent as a component of the ROU asset.&#160;Topic 842&#160;did not have a material impact on the Company's consolidated statements of operations and cash flows.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The short-term liabilities from the Company's operating leases are included in accrued expenses in the consolidated balance sheet. The Company's accounting for finance leases (formerly referred to as capital leases prior to the adoption of&#160;Topic 842) remains substantially unchanged. Finance leases are not material to the consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease expense for lease payments for the operating leases is recognized on a straight-line basis over the term of the lease.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718):</span><span style="font-family:inherit;font-size:10pt;"> Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, with certain exceptions. The Company early adopted this new guidance effective January 1, 2019. In accordance with the transition guidance, the Company assessed its outstanding nonemployee awards for which a measurement date had not been established. These outstanding awards were re-measured to fair value as of the January 1, 2019 adoption date. For nonemployee awards that contain performance condition, the measurement is based on the outcome that is probable as opposed to the lowest aggregate fair value within a range of possible outcomes. The adoption of ASU 2018-07 provided administrative relief by fixing the measurement date of nonemployee awards and eliminating the requirement of quarterly re-measurement. The Company adopted this standard on a modified retrospective basis and recorded a cumulative-effect adjustment of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;as an increase to accumulated deficit and an equal increase to additional paid-in capital as of January 1, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;), which contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December&#160;31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No.&#160;118,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Tax Accounting Implications of the Tax Cuts and Jobs Act</span><span style="font-family:inherit;font-size:10pt;">&#160;(&#8220;SAB 118&#8221;) to address the accounting implications of the enacted U.S. federal tax reform. SAB 118 allows companies&#160;to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and no measurement period adjustments were recognized due to the full valuation allowance on the Company&#8217;s deferred tax assets.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13,&#160;Financial Instruments - Credit Losses:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">the FASB issued ASU 2017-04</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:10pt;">Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment which eliminates Step 2 from the goodwill impairment test and instead requires entities to perform its annual or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount</span><span style="font-family:Arial;font-size:9pt;">. </span><span style="font-family:inherit;font-size:10pt;">The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements in ASC 820, Fair Value Measurement, as part of its disclosure framework project. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted. The amendments in ASU 2018-13 on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments in ASU 2018-13 should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cloud Computing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15&#8212;Intangibles-Goodwill and Other-Internal&#8212;Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC Topic 350, Intangibles&#8212;Goodwill and Other, to determine which implementation costs to capitalize as assets or expense as incurred.  The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB amended ASC 808 and ASC 606 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The guidance is effective for us beginning January 1, 2020 and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU 2019-12, Income Taxes - Topic 740, which simplifies the accounting for income taxes.&#160; Amendments include removal of certain exceptions to the general principles of ASC 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes,</span><span style="font-family:inherit;font-size:10pt;"> related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences.&#160;ASU 2019-12 also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning January 1, 2021, and early adoption is permitted.&#160; The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostofDevelopmentServicesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Development Services [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostofDevelopmentServicesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostsofPrecisionOncologyTestingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of Precision Oncology Testing [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostsofPrecisionOncologyTestingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_JOBSActAccountingElectionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>JOBS Act Accounting Election [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_JOBSActAccountingElectionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ObligationRelatedtoRoyaltyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligation Related to Royalty [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ObligationRelatedtoRoyaltyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159346&amp;loc=d3e8275-108329<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054294&amp;loc=d3e8384-108330<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e4975-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6882203440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 09, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 19, 2018</div></th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering and follow on offering | $</a></td>
<td class="nump">$ 249,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,911,031<span></span>
</td>
<td class="nump">12,067,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon follow-on offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price of stock issued (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon follow-on offering, net of offering costs of $723 | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">14,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price (usd per share) | $ / shares</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering and follow on offering | $</a></td>
<td class="nump">$ 249,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon follow-on offering, net of offering costs (in shares)</a></td>
<td class="nump">14,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon follow-on offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">58,264,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gh_WarrantsPreferredStockMember', window );">Warrants, Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">7,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gh_WarrantsPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gh_WarrantsPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6661462096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Remaining Performance Obligation (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration', window );">Remaining performance obligation, expected recognition period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining duration of performance obligation for which optional exemption was applied not to disclose amount of transaction price allocated to and timing of revenue recognition for remaining performance obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130558-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6847038000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheet Components - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885934224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 09, 2018 </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 19, 2018</div></th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price of stock issued (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ConvertiblePreferredStockConversionPrice', window );">Preferred stock, convertible, conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.1338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.8329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend related to repurchase of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Incremental common shares attributable to dilutive effect of conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 7,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,243<span></span>
</td>
<td class="nump">1,588,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.23887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock', window );">Percentage of the original price per share of Series E convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gh_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price of stock issued (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gh_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,920<span></span>
</td>
<td class="nump">666,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend related to repurchase of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering', window );">Conversion of convertible preferred stock to common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,264,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,681<span></span>
</td>
<td class="nump">1,719,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="nump">7,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gh_SoftBankMember', window );">SoftBank | Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares purchased in joint venture (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,174,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.3936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ThresholdPercentageofNewSharesIssued', window );">Threshold percentage of new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares', window );">Threshold period after initial closing to issue new shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">70 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Original Price per Share of the Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PercentageoftheOriginalPriceperShareoftheConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodSharesConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ThresholdPercentageofNewSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold Percentage of New Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ThresholdPercentageofNewSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold Period After Initial Closing to Issue New Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ThresholdPeriodAfterInitialClosingtoIssueNewShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gh_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gh_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gh_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gh_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gh_SoftBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gh_SoftBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6854278544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($) </div>
<div>petition</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>company </div>
<div>petition </div>
<div>patent</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>patent</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>party</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberofPartiesWithPatentLicenseAgreement', window );">Number of parties with patent license agreement | party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue', window );">Percentage of precision oncology testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember', window );">Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Amount awarded from other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gh_FoundationMedicineInc.vs.GuardantHealthInc.Member', window );">Foundation Medicine, Inc. vs. Guardant Health, Inc..</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberofPetitionsFiled', window );">Number of petitions filed | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gh_FoundationMedicineInc.vs.GuardantHealthInc.Member', window );">Foundation Medicine, Inc. vs. Guardant Health, Inc.. | General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement, expense</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member', window );">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberofPetitionsFiled', window );">Number of petitions filed | petition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberofCompaniesthatInfringedonaPatent', window );">Number of companies that infringed on a patent | company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberofAssertedPatents', window );">Number of asserted patents | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberofAssertedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Asserted Patents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberofAssertedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberofCompaniesthatInfringedonaPatent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Companies that Infringed on a Patent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberofCompaniesthatInfringedonaPatent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberofPartiesWithPatentLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Parties With Patent License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberofPartiesWithPatentLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberofPetitionsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Petitions Filed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberofPetitionsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Expense, Percentage of Precision Oncology Testing Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gh_FoundationMedicineInc.vs.GuardantHealthInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gh_FoundationMedicineInc.vs.GuardantHealthInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6637864656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective consolidated balance sheet date, are as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:39%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Accounts Receivable</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer A   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer B   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer C   </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">less than 10%</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated useful lives for property and equipment are as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:56%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Property and Equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated&#160;Useful&#160;Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3 &#8211; 5 years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7 years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer hardware and computer software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3 years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lesser of estimated useful life or remaining lease term</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer hardware   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,962</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,522</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer software   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>829</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>643</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,354</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, gross   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,591</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,637</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,923</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,634</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,668</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of Impact of Adoption of ASC 606</a></td>
<td class="text">The cumulative effect of changes made to the consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments due to ASC 606 </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of January 1, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,597</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(280,799</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(275,892</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC 606 requirements under the modified retrospective method of adoption, the impact of the adoption of ASC 606 on the Company&#8217;s consolidated statement of operations and consolidated balance sheet was as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the year ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported Under ASC 606</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Precision oncology testing </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180,462</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Development services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported Under ASC 606</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,639</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(352,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(353,156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22580-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e725-108305<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6735041664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<span style="font-family:inherit;font-size:10pt;">The Company sponsors a 401(k) plan, and pursuant to its terms, eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of eligible compensation on a pre-tax basis. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company contributed </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span> to match employee contributions as permitted by the plan. For the years ended December 31, 2018 and 2017, the Company did not elect to match employee contributions as permitted by the plan. The Company pays the administrative costs for the plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6669488240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">Convertible Preferred Stock<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company previously issued convertible preferred stock in one or more series, each with such designations, rights, qualifications, limitations, and restrictions as set forth in the Company&#8217;s certificate of incorporation, as in effect prior to the IPO. Immediately prior to the completion of the IPO, as described in Note 1,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Description of Business</span><span style="font-family:inherit;font-size:10pt;">, all shares of convertible preferred stock then outstanding were automatically converted to </span><span style="font-family:inherit;font-size:10pt;"><span>58,264,577</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at the respective conversion ratios in October 2018.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, the Company entered into the Series E convertible preferred stock purchase agreement with SoftBank and certain of the Company&#8217;s existing stockholders. Pursuant to the purchase agreement, the Company issued and sold an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>38,174,246</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series E convertible preferred stock at a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.3936</span></span><span style="font-family:inherit;font-size:10pt;"> per share, for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$320.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. The purchase agreement also provided that the Company would issue additional shares of Series E convertible preferred stock to the Series E investors in such an amount as to cause SoftBank&#8217;s equity ownership in the Company to equal </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s outstanding fully-diluted capital stock measured </span><span style="font-family:inherit;font-size:10pt;"><span>70</span></span><span style="font-family:inherit;font-size:10pt;"> days after the initial closing. This gross-up was intended to enable the Company to engage in various repurchases of its equity from existing stockholders and still maintain SoftBank&#8217;s equity ownership at </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;">.&#160;As a result, in July 2017, the Company repurchased an aggregate of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>1,588,065</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock from certain of its directors and executive officers for a purchase price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$10.23887</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share, which represented a price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span><span style="font-family:inherit;font-size:10pt;"> of the original price per shares for the Series E convertible preferred stock, as adjusted to reflect the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>0.7378</span></span><span style="font-family:inherit;font-size:10pt;">-for-one reverse stock split of the Company&#8217;s common stock effected on September 19, 2018. The Company also engaged in a tender offer pursuant to which it repurchased&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>131,243</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock from certain employees at the same per share price paid for the Series E convertible preferred stock as adjusted to reflect the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>0.7378</span></span><span style="font-family:inherit;font-size:10pt;">-for-one reverse stock split of the Company&#8217;s common stock effected on September 19, 2018, and </span><span style="font-family:inherit;font-size:10pt;"><span>666,920</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series A convertible preferred stock from existing stockholders at a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share of Series A convertible preferred stock. Following these repurchases, in October 2017, the Company issued an additional </span><span style="font-family:inherit;font-size:10pt;"><span>796,346</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Series E convertible preferred stock to the Series E investors for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.00001</span></span><span style="font-family:inherit;font-size:10pt;"> per share pursuant to the terms of the gross up provision. The conversion price of Series E convertible preferred stock was adjusted as a result of the dilutive issuance of Series E convertible preferred stock under the gross up provision.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, in accordance with its certificate of incorporation then in effect, the Company adjusted the conversion price of Series D convertible preferred stock from </span><span style="font-family:inherit;font-size:10pt;"><span>$10.1338</span></span><span style="font-family:inherit;font-size:10pt;"> per share to </span><span style="font-family:inherit;font-size:10pt;"><span>$9.8329</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The Company accounted for the transaction as a modification. A deemed dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, calculated as the additional </span><span style="font-family:inherit;font-size:10pt;"><span>253,361</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock to be received upon the conversion of the Series D convertible preferred stock after the conversion ratio adjustment, multiplied by the then current fair value of the Company&#8217;s common stock, was reported as an increase to net loss attributable to common stockholders for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Repurchase of Series A Convertible Preferred Stock</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2017, the Company repurchased&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>666,920</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of outstanding Series A convertible preferred stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$8.00</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share for a total consideration of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. The difference between the repurchase amount and the carrying value of these shares of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;was recorded as a deemed dividend in accumulated deficit on the accompanying consolidated statements of stockholders&#8217; equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6642486000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has&#160;entered into various operating lease agreements for office space,&#160;with remaining terms ranging from 1 year to 8 years some of which include one or more options to renew.  As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether we will renew the lease, as such, we do not include renewal options in our lease terms for calculating our lease liability, as the renewal options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these renewal options at the time of the lease commencement. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease expense for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> which includes both lease and non-lease components (primarily common area maintenance charges and property taxes).</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rent expense for the facility leases was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the weighted-average remaining lease term and weighted-average discount rate for operating leases is </span><span style="font-family:inherit;font-size:10pt;"><span>6.4 years</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>7.77%</span></span><span style="font-family:inherit;font-size:10pt;"> respectively. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our future principal contractual obligations for operating lease commitments as of </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.57264957264957%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,582</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,534</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,684</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,892</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less:  Imputed Interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,396</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has additional future minimum lease payments relating to a facility agreement had not yet commenced amounting to </span><span style="font-family:inherit;font-size:10pt;"><span>$13.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> (imputed interest of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;">) net of sublease income of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases are not material to the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">ASC 840 Disclosures</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">The Company elected</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">modified retrospective transition approach and is required to present previously disclosed information under the prior accounting standards for leases. Total minimum lease payments as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.57264957264957%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,557</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,105</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,786</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,178</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6637799328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements. Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements. Cash Equivalents and Marketable Securities</a></td>
<td class="text">Fair Value Measurements, Cash Equivalents and Marketable Securities<div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments consist of cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bonds   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>362,884</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>362,884</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term marketable securities   </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term marketable securities   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>648,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,365</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,365</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bonds   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,004</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,004</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term marketable securities   </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bonds   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,758</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,758</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term marketable securities   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,563</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,563</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355,980</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Corporate bonds, U.S. government debt securities and U.S. government agency bonds are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on  the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's contingent consideration was valued using the discounted cash flow method. Significant unobservable inputs used in the fair value measurement of the Company&#8217;s contingent consideration liability include the estimated amount and timing of projected cash flows, and the risk-adjusted discount rate used to present value the cash flows. The change in discount rate has an inverse relationship to the overall valuation of the contingent consideration.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The use of different inputs in the valuation of the contingent consideration liability could result in materially different fair value estimates.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarizes the Company&#8217;s cash equivalents and marketable securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market fund   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bond   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,679</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>631,666</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>657,696</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,433</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659,090</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market fund   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,796</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate bond   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(71</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government debt securities </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>308,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>308,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency bonds................</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,014</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,004</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>381,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(317</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company&#8217;s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. The maturities of the Company&#8217;s long-term marketable securities range from&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>1.04</span></span><span style="font-family:inherit;font-size:10pt;">&#160;to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>1.75</span></span><span style="font-family:inherit;font-size:10pt;"> years from </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871793184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated useful lives for property and equipment are as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:56%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Property and Equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated&#160;Useful&#160;Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3 &#8211; 5 years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7 years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer hardware and computer software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3 years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lesser of estimated useful life or remaining lease term</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer hardware   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,962</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,522</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer software   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>829</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>643</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,354</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, gross   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,591</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,637</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,923</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,634</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,668</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued royalty obligations   </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,564</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued legal expenses   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued tax liabilities   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,050</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional services   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,791</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trials and studies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,029</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of property and equipment included in accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,424</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>343</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other   </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,986</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,817</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued expenses   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,178</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6661908048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Future Minimum Royalty Payments</a></td>
<td class="text">As of <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, future minimum royalty payments are due as follows regardless of sales amounts:</span><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,402</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,682</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,682</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,607</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total future minimum royalty payments   </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,775</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: amount representing interest   </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of future minimum royalty payments   </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph a<br> -Subparagraph 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6728722288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of loss before provision for income taxes</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of loss before provision for income taxes were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,214</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(84,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of the provision for income taxes</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the provision for income taxes are as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal </span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,652</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(178</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total provision for income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of the components of deferred tax assets and liabilities</a></td>
<td class="text">Significant components of the Company&#8217;s deferred tax assets are as follows:<div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating losses carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,534</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,783</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accruals and reserves</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,936</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,289</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax asset</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Section 481 (a) adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(914</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain/loss on investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(346</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(125,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Effective tax rate reconciliation</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents a reconciliation of the income tax expense computed at the statutory federal rate and the Company&#8217;s income tax expense for the periods presented:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax at the statutory federal rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,642</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,690</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other nondeductible items</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>887</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>497</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,266</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,726</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(714</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,049</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,516</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State taxes, net of federal benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,253</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,231</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,868</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in tax rate due to Tax Act</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,346</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(605</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>343</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the balance of total gross unrecognized tax benefits</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balance of total unrecognized tax benefits is as follows:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits - Beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>884</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to current year&#8217;s tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,635</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to prior years&#8217; tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits - End of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,543</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,427</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Components Before Income Tax Expense Benefit [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ScheduleOfComponentsBeforeIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=109238393&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6881344608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Senior Term Loan and Royalty Purchase Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_CreditAgreementMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_PaymentofAccruedInterestDebt', window );">Payment of accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_CreditAgreementMember', window );">Credit Agreement | Senior Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity (up to)</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DebtInstrumentVariableRateBasisBaseRate', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (percent)</a></td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_RoyaltyAgreementMember', window );">Royalty Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_RoyaltyAgreementMember', window );">Royalty Agreement | Senior Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RoyaltyAgreementbyPaymentTierAxis=gh_TierOneMember', window );">Tier One | Royalty Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RoyaltyAgreementPaymentTierThreshold', window );">Royalty agreement payment tier threshold</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RoyaltyPaymentsPercentageofRevenue', window );">Quarterly royalty payments, percentage of revenue</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RoyaltyAgreementbyPaymentTierAxis=gh_TierTwoMember', window );">Tier Two | Royalty Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RoyaltyAgreementPaymentTierThreshold', window );">Royalty agreement payment tier threshold</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RoyaltyPaymentsPercentageofRevenue', window );">Quarterly royalty payments, percentage of revenue</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentVariableRateBasisBaseRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate Basis, Base Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentVariableRateBasisBaseRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PaymentofAccruedInterestDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Accrued Interest, Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PaymentofAccruedInterestDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RoyaltyAgreementPaymentTierThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement Payment Tier Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RoyaltyAgreementPaymentTierThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RoyaltyPaymentsPercentageofRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Payments, Percentage of Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RoyaltyPaymentsPercentageofRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SeniorLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SeniorLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gh_RoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gh_RoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RoyaltyAgreementbyPaymentTierAxis=gh_TierOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RoyaltyAgreementbyPaymentTierAxis=gh_TierOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RoyaltyAgreementbyPaymentTierAxis=gh_TierTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RoyaltyAgreementbyPaymentTierAxis=gh_TierTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6855535072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Bellwether Bio - Intangible Assets Acquired (Details) - Bellweather Bio, Inc.<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired license</a></td>
<td class="nump">$ 5,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">IPR&amp;D</a></td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identified intangible assets</a></td>
<td class="nump">$ 6,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6882679712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements. Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 143,228<span></span>
</td>
<td class="nump">$ 140,544<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost', window );">Amortized cost, cash and cash equivalents and debt securities available-for-sale</a></td>
<td class="nump">657,696<span></span>
</td>
<td class="nump">381,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">1,433<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CashCashEquivalentsandDebtSecuritiesFairValue', window );">Estimated Fair Value, Cash, Cash Equivalents and Debt Securities</a></td>
<td class="nump">659,090<span></span>
</td>
<td class="nump">381,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">10,734<span></span>
</td>
<td class="nump">25,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value, Cash and Cash Equivalents</a></td>
<td class="nump">10,734<span></span>
</td>
<td class="nump">25,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost, debt securities, available-for-sale</a></td>
<td class="nump">16,679<span></span>
</td>
<td class="nump">42,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value, Debt Securities</a></td>
<td class="nump">16,690<span></span>
</td>
<td class="nump">42,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost, debt securities, available-for-sale</a></td>
<td class="nump">630,283<span></span>
</td>
<td class="nump">308,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value, Debt Securities</a></td>
<td class="nump">$ 631,666<span></span>
</td>
<td class="nump">308,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost, debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value, Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CashCashEquivalentsandDebtSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents and Debt Securities, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CashCashEquivalentsandDebtSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6881165456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0000001<span></span>
</td>
<td class="nump">$ 0.0000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0000001<span></span>
</td>
<td class="nump">$ 0.0000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">94,261,414<span></span>
</td>
<td class="nump">85,832,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">94,261,414<span></span>
</td>
<td class="nump">85,832,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets', window );">Variable interest entity, assets</a></td>
<td class="nump">$ 45.1<span></span>
</td>
<td class="nump">$ 48.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities', window );">Variable interest entity, liabilities</a></td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the consolidated Variable Interest Entity's assets included in the reporting entity's statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=108788376&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the consolidated Variable Interest Entity's liabilities included in the reporting entity's statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=108788376&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6858943424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 723<span></span>
</td>
<td class="nump">$ 4,475<span></span>
</td>
<td class="nump">$ 883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6837574960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation of Stock Options (Details) - Stock option<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">63.20%<span></span>
</td>
<td class="nump">68.70%<span></span>
</td>
<td class="nump">74.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">68.70%<span></span>
</td>
<td class="nump">78.80%<span></span>
</td>
<td class="nump">75.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 4 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 2 months 19 days<span></span>
</td>
<td class="text">6 years 6 months 2 days<span></span>
</td>
<td class="text">6 years 1 month<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6728743408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan, maximum annual employee contributions per employee, percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, employer contributions</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6816617856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Components of the Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest', window );">United States</a></td>
<td class="num">$ (69,930)<span></span>
</td>
<td class="num">$ (84,313)<span></span>
</td>
<td class="num">$ (83,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest', window );">Foreign</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (69,723)<span></span>
</td>
<td class="num">$ (84,225)<span></span>
</td>
<td class="num">$ (83,214)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Continuing Operations before Equity Method Investments, Federal, Income Taxes, Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Continuing Operations before Equity Method Investments, Foreign, Income Taxes, Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
